-DOCSTART- -X- -X- O

Famotidine	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
delirium	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Famotidine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
histamine	NN	I-NP	O
H2	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
inpatient	NN	B-NP	O
settings	NNS	I-NP	O
for	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
stress	NN	B-NP	O
ulcers	NNS	I-NP	B
and	CC	O	O
is	VBZ	B-VP	O
showing	VBG	I-VP	O
increasing	VBG	B-NP	O
popularity	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
low	JJ	I-NP	O
cost	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
all	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
currently	RB	I-NP	O
available	JJ	I-NP	O
H2	NN	I-NP	O
-	HYPH	B-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
the	DT	B-NP	O
propensity	NN	I-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
delirium	NN	B-NP	B
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
famotidine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
famotidine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
delirium	NN	I-NP	B
in	IN	B-PP	O
hospitalized	VBN	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
cleared	VBD	B-VP	O
completely	RB	B-ADVP	O
upon	IN	B-PP	O
removal	NN	B-NP	O
of	IN	B-PP	O
famotidine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacokinetics	NNS	I-NP	O
of	IN	B-PP	O
famotidine	NN	B-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
elderly	JJ	I-NP	O
population	NN	I-NP	O
seen	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
using	VBG	B-VP	O
famotidine	NN	B-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
persons	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Indomethacin	NN	B-NP	O
induced	VBD	B-VP	O
hypotension	NN	B-NP	B
in	IN	B-PP	O
sodium	NN	B-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
depleted	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
indomethacin	NN	I-NP	O
(	(	O	O
IDM	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
sodium	NN	B-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
depleted	VBD	B-VP	O
rats	NNS	B-NP	O
plasma	NN	I-NP	O
renin	NN	I-NP	O
activity	NN	I-NP	O
(	(	O	O
PRA	NN	B-NP	O
)	)	O	O
and	CC	O	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
fell	VBD	B-VP	O
significantly	RB	B-ADVP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
sodium	NN	B-NP	O
repleted	VBN	B-VP	O
animals	NNS	B-NP	O
indomethacin	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
although	IN	B-SBAR	O
plasma	NN	B-NP	O
renin	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
indomethacin	NN	B-NP	O
by	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthesis	NN	I-NP	O
may	MD	B-VP	O
diminish	VB	I-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
maintaining	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
stimulated	VBN	I-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
sodium	NN	B-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
depletion	NN	I-NP	O
.	.	O	O

Late	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
scleroderma	NN	I-NP	B
renal	JJ	I-NP	I
crisis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
tacrolimus	NN	B-NP	O
and	CC	I-NP	O
prednisolone	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Scleroderma	NN	B-NP	B
renal	JJ	I-NP	I
crisis	NN	I-NP	I
(	(	O	O
SRC	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	B
sclerosis	NN	I-NP	I
(	(	O	O
SSc	NN	B-NP	B
)	)	O	O
but	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
severe	JJ	B-ADJP	O
enough	RB	I-ADJP	O
to	TO	B-VP	O
require	VB	I-VP	O
temporary	JJ	B-NP	O
or	CC	I-NP	O
permanent	JJ	I-NP	O
renal	JJ	I-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Moderate	JJ	B-ADJP	O
to	TO	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
corticosteroid	NN	I-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
recognized	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
major	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
SRC	NN	B-NP	B
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reports	NNS	B-NP	O
of	IN	B-PP	O
thrombotic	JJ	B-NP	B
microangiopathy	NN	I-NP	I
precipitated	VBN	B-VP	O
by	IN	B-PP	O
cyclosporine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SSc	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
article	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
SRC	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
tacrolimus	NN	B-NP	O
and	CC	I-NP	O
corticosteroids	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
work	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
call	VB	I-VP	O
attention	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SSc	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
and	CC	O	O
associated	VBN	B-VP	O
factors	NNS	B-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
psychosis	NN	I-NP	B
in	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
Malaysia	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
lifetime	NN	B-NP	O
and	CC	O	O
current	JJ	B-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
methamphetamine	NN	B-NP	O
dependence	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
psychiatric	JJ	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
was	VBD	B-VP	O
also	RB	I-VP	O
studied	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
study	NN	I-NP	O
conducted	VBN	B-VP	O
concurrently	RB	B-ADVP	O
at	IN	B-PP	O
a	DT	B-NP	O
teaching	NN	I-NP	O
hospital	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
drug	NN	I-NP	O
rehabilitation	NN	I-NP	O
center	NN	I-NP	O
in	IN	B-PP	O
Malaysia	NNP	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
based	VBN	B-VP	O
on	IN	B-PP	O
DSM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Mini	NNP	I-NP	O
International	NNP	I-NP	O
Neuropsychiatric	NNP	I-NP	O
Interview	NNP	I-NP	O
(	(	O	O
M.I.N.I.	NNP	B-NP	O
)	)	O	O
for	IN	B-PP	O
methamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
and	CC	O	O
other	JJ	B-NP	O
Axis	NN	I-NP	O
num	CD	I-NP	O
psychiatric	JJ	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
information	NN	I-NP	O
on	IN	B-PP	O
sociodemographic	JJ	B-NP	O
background	NN	I-NP	O
and	CC	I-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
history	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
interview	NN	B-NP	O
or	CC	O	O
medical	JJ	B-NP	O
records	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
past	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
psychotic	JJ	B-NP	B
symptoms	NNS	I-NP	I
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
having	VBG	I-VP	O
current	JJ	B-NP	O
psychotic	JJ	I-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
morbid	JJ	I-NP	O
major	JJ	I-NP	O
depressive	JJ	I-NP	B
disorder	NN	I-NP	I
,	,	O	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
,	,	O	O
antisocial	JJ	B-NP	B
personality	NN	I-NP	I
disorder	NN	I-NP	I
and	CC	O	O
heavy	JJ	B-NP	O
methamphetamine	NN	I-NP	O
uses	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
lifetime	NN	B-NP	O
methamphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychosis	NN	I-NP	B
after	IN	B-SBAR	O
adjusted	VBN	B-VP	O
for	IN	B-PP	O
other	JJ	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Major	JJ	B-NP	B
depressive	JJ	I-NP	I
disorder	NN	I-NP	I
and	CC	O	O
antisocial	JJ	B-NP	B
personality	NN	I-NP	I
disorder	NN	I-NP	I
were	VBD	B-VP	O
the	DT	B-NP	O
only	JJ	I-NP	O
factors	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
current	JJ	B-NP	O
psychosis	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
psychosis	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
methamphetamine	NN	B-NP	O
dependence	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
morbid	NN	I-NP	O
affective	JJ	I-NP	B
disorder	NN	I-NP	I
,	,	O	O
antisocial	JJ	B-NP	B
personality	NN	I-NP	I
,	,	O	O
and	CC	O	O
heavy	JJ	B-NP	O
methamphetamine	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
that	IN	B-SBAR	O
all	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
dependence	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
screened	VBN	I-VP	O
for	IN	B-PP	O
psychotic	JJ	B-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Cerebellar	JJ	B-NP	O
sensory	JJ	I-NP	O
processing	NN	I-NP	O
alterations	NNS	I-NP	O
impact	VBP	B-VP	O
motor	NN	B-NP	O
cortical	JJ	I-NP	O
plasticity	NN	I-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
:	:	O	O
clues	NNS	B-NP	O
from	IN	B-PP	O
dyskinetic	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
plasticity	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
motor	NN	I-NP	O
cortex	NN	I-NP	O
(	(	O	O
M1	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
and	CC	O	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
(	(	O	O
LIDs	NNS	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
severely	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
.	.	O	O

We	PRP	B-NP	O
recently	RB	B-ADVP	O
reported	VBD	B-VP	O
in	IN	B-PP	O
young	JJ	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
that	IN	B-NP	O
inhibitory	JJ	B-NP	O
cerebellar	JJ	I-NP	O
stimulation	NN	I-NP	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
sensorimotor	NN	I-NP	O
plasticity	NN	I-NP	O
of	IN	B-PP	O
M1	NN	B-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
paired	JJ	B-NP	O
associative	JJ	I-NP	O
stimulation	NN	I-NP	O
(	(	O	O
PAS	NN	B-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
deficient	JJ	I-NP	O
sensorimotor	NN	I-NP	O
M1	NN	I-NP	O
plasticity	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
LIDs	NNS	B-NP	B
could	MD	B-VP	O
be	VB	I-VP	O
reinstated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
session	NN	I-NP	O
of	IN	B-PP	O
real	JJ	B-NP	O
inhibitory	JJ	I-NP	O
cerebellar	JJ	I-NP	O
stimulation	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
sham	NN	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
evident	JJ	B-ADJP	O
only	RB	B-ADVP	O
when	WRB	B-ADVP	O
a	DT	B-NP	O
sensory	JJ	I-NP	O
component	NN	I-NP	O
was	VBD	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
plasticity	NN	B-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
cerebellar	JJ	B-NP	O
sensory	JJ	I-NP	O
processing	NN	I-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
resurgence	NN	I-NP	O
of	IN	B-PP	O
M1	NN	B-NP	O
plasticity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
benefit	NN	I-NP	O
of	IN	B-PP	O
inhibitory	JJ	B-NP	O
cerebellar	JJ	I-NP	O
stimulation	NN	I-NP	O
on	IN	B-PP	O
LIDs	NNS	B-NP	B
is	VBZ	B-VP	O
known	VBN	I-VP	O
.	.	O	O

To	TO	B-VP	O
explore	VB	I-VP	O
whether	IN	B-SBAR	O
this	DT	B-NP	O
benefit	NN	I-NP	O
is	VBZ	B-VP	O
linked	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
sensorimotor	NN	B-NP	O
plasticity	NN	I-NP	O
of	IN	B-PP	O
M1	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
study	NN	I-NP	O
looking	VBG	B-VP	O
at	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
LIDs	NNS	B-NP	B
and	CC	I-NP	O
PAS	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
plasticity	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
sessions	NNS	I-NP	O
of	IN	B-PP	O
either	CC	B-NP	O
bilateral	JJ	I-NP	O
,	,	I-NP	O
real	JJ	I-NP	O
inhibitory	JJ	I-NP	O
cerebellar	JJ	I-NP	O
stimulation	NN	I-NP	O
or	CC	I-NP	O
sham	NN	I-NP	O
stimulation	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
real	JJ	I-NP	O
and	CC	I-NP	O
not	RB	I-NP	O
sham	NN	B-NP	O
stimulation	NN	I-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
antidyskinetic	JJ	I-NP	O
effect	NN	I-NP	O
and	CC	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
paralleled	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
resurgence	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
sensorimotor	NN	I-NP	O
plasticity	NN	I-NP	O
of	IN	B-PP	O
M1	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
cerebellar	JJ	B-NP	O
sensory	JJ	I-NP	O
processing	NN	I-NP	O
function	NN	I-NP	O
,	,	O	O
occurring	VBG	B-VP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
abnormal	JJ	B-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
signals	NNS	I-NP	O
reaching	VBG	B-VP	O
it	PRP	B-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
element	NN	I-NP	O
contributing	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
maladaptive	JJ	I-NP	O
sensorimotor	NN	I-NP	O
plasticity	NN	I-NP	O
of	IN	B-PP	O
M1	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
emergence	NN	I-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	B
involuntary	JJ	I-NP	I
movements	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
P2X3	NN	B-NP	O
receptor	NN	I-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
on	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
P2X3	NN	B-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptors	NNS	I-NP	O
antagonists	NNS	I-NP	O
on	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
female	JJ	I-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
intraperitoneally	RB	B-ADVP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
injected	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
saline	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
model	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
i.p.	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
;	:	O	O
and	CC	O	O
the	DT	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intervention	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
i.p.	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
with	IN	B-PP	O
subsequently	RB	B-NP	O
perfusion	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
with	IN	B-PP	O
P2X3	NN	B-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptors	NNS	I-NP	O
s	VBZ	B-VP	O
antagonists	NNS	B-NP	O
,	,	O	O
Suramin	NN	B-NP	O
and	CC	O	O
GR	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Spontaneous	JJ	B-NP	O
pain	NN	I-NP	B
behaviors	NNS	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
CYP	NN	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Urodynamic	JJ	B-NP	O
parameters	NNS	I-NP	O
,	,	O	O
bladder	NN	B-NP	O
pressure	NN	I-NP	O
-	HYPH	B-NP	O
volume	NN	I-NP	O
curve	NN	I-NP	O
,	,	O	O
maximum	JJ	B-NP	O
voiding	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MVP	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
maximum	JJ	B-NP	O
cystometric	JJ	I-NP	O
capacity	NN	I-NP	O
(	(	O	O
MCC	NN	B-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Pathological	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
tissue	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Immunofluorescence	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
detect	VB	I-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P2X3	NN	B-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
.	.	O	O

Cyclophosphamide	NN	B-NP	O
treatment	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
pain	NN	I-NP	B
behaviors	NN	I-NP	O
scores	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
instability	NN	I-NP	O
during	IN	B-PP	O
urine	NN	B-NP	O
storage	NN	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
model	NN	B-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
intervention	NN	B-NP	O
group	NN	I-NP	O
and	CC	O	O
control	NN	B-NP	O
group	NN	I-NP	O
.	.	O	O

MCC	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
model	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
and	CC	I-NP	O
intervention	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Histological	JJ	B-NP	O
changes	NNS	I-NP	O
evident	JJ	B-ADJP	O
in	IN	B-PP	O
model	NN	B-NP	O
and	CC	I-NP	O
intervention	NN	I-NP	O
groups	NNS	I-NP	O
rats	NNS	I-NP	O
s	NNS	I-NP	O
bladder	NN	I-NP	O
included	VBD	B-VP	O
edema	NN	B-NP	B
,	,	O	O
vasodilation	NN	B-NP	O
,	,	O	O
and	CC	O	O
infiltration	NN	B-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
model	NN	B-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P2X3	NN	B-NP	O
receptor	NN	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
urothelium	NN	B-NP	O
and	CC	I-NP	O
suburothelium	NN	I-NP	O
,	,	O	O
and	CC	O	O
NK1	NN	B-NP	O
receptor	NN	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
suburothelium	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
in	IN	B-PP	O
intervention	NN	B-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
CYP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
P2X3	NN	B-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptors	NNS	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
urothelium	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
suburothelium	NN	B-NP	O
.	.	O	O

Perfusion	NN	B-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
with	IN	B-PP	O
P2X3	NN	B-NP	O
and	CC	I-NP	O
NK1	NN	I-NP	O
receptors	NNS	I-NP	O
antagonists	NNS	I-NP	O
ameliorated	VBD	B-VP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
function	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
clopidogrel	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
recognition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
responsible	JJ	I-NP	O
drug	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
difficult	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
clopidogrel	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
acute	JJ	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
is	VBZ	B-VP	O
strongly	RB	I-VP	O
suggested	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
accurate	JJ	I-NP	O
medical	JJ	I-NP	O
history	NN	I-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
.	.	O	O

Reports	NNS	B-NP	O
about	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
clopidogrel	NN	B-NP	O
are	VBP	B-VP	O
increasing	VBG	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
few	JJ	I-NP	O
years	NNS	I-NP	O
,	,	O	O
after	IN	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
believe	VBP	B-VP	O
that	IN	B-SBAR	O
physicians	NNS	B-NP	O
should	MD	B-VP	O
carefully	RB	I-VP	O
consider	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
when	WRB	B-ADVP	O
clopidogrel	NN	B-NP	O
is	VBZ	B-VP	O
prescribed	VBN	I-VP	O
.	.	O	O

Bortezomib	NN	B-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
as	IN	B-PP	O
salvage	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	JJ	I-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
:	:	O	O
analysis	NN	B-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
clinical	JJ	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

Bortezomib	NN	B-NP	O
(	(	O	O
bort	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
dexamethasone	NN	B-NP	O
(	(	O	O
dex	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	NN	I-NP	O
(	(	O	O
R	NN	B-NP	O
/	SYM	B-NP	O
R	NN	I-NP	O
)	)	I-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
(	(	O	O
MM	NN	B-NP	B
)	)	O	O
.	.	O	O

This	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
bort	NN	B-NP	O
and	CC	I-NP	O
dex	NN	I-NP	O
as	IN	B-PP	O
salvage	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
R	NN	B-NP	O
/	SYM	B-NP	O
R	NN	I-NP	O
MM	NN	I-NP	B
after	IN	B-PP	O
prior	JJ	B-NP	O
autologous	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
or	CC	O	O
conventional	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
lines	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
immunomodulatory	JJ	B-NP	O
drugs	NNS	I-NP	O
included	VBN	B-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
line	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
before	IN	B-PP	O
bort	NN	B-NP	O
-	HYPH	B-NP	O
dex	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
bort	NN	B-NP	O
-	HYPH	I-NP	O
dex	NN	I-NP	O
cycles	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
up	IN	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
maximum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
an	DT	B-NP	O
intention	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
treat	NN	I-NP	O
basis	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
achieved	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
CR	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
achieved	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
very	RB	I-NP	O
good	JJ	I-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
durations	NNS	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
,	,	O	O
time	NN	B-NP	O
to	TO	B-PP	O
next	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
interval	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
relevant	JJ	I-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
was	VBD	B-VP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
grade	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
grade	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
led	VBD	B-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
discontinuation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
progression	NN	B-NP	O
,	,	O	O
progression	NN	B-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survival	NN	I-NP	O
(	(	O	O
PFS	NN	B-NP	O
)	)	O	O
and	CC	O	O
overall	JJ	B-NP	O
survival	NN	I-NP	O
(	(	O	O
OS	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Prolonged	JJ	B-NP	O
PFS	NN	I-NP	O
and	CC	I-NP	O
OS	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
achieving	VBG	B-VP	O
CR	NN	B-NP	O
and	CC	O	O
receiving	VBG	B-VP	O
bort	NN	B-NP	O
-	HYPH	I-NP	O
dex	NN	I-NP	O
a	DT	B-NP	O
single	JJ	I-NP	O
line	NN	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Bort	NN	B-NP	O
-	HYPH	I-NP	O
dex	NN	I-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
salvage	NN	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
MM	NN	B-NP	B
patients	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
for	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
first	JJ	B-NP	O
relapse	NN	I-NP	O
.	.	O	O

Pubertal	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
Bisphenol	NN	B-NP	O
A	NN	I-NP	O
increases	VBZ	B-VP	O
anxiety	NN	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
behavior	NN	I-NP	O
and	CC	O	O
decreases	VBZ	B-VP	O
acetylcholinesterase	NN	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
hippocampus	NN	B-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
negative	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Bisphenol	NN	B-NP	O
A	NN	I-NP	O
(	(	O	O
BPA	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
neurodevelopment	NN	B-NP	O
and	CC	I-NP	O
behaviors	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
well	RB	I-VP	O
established	VBN	I-VP	O
.	.	O	O

Acetylcholinesterase	NN	B-NP	O
(	(	O	O
AChE	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
regulatory	JJ	I-NP	O
enzyme	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
anxiety	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
behavior	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
behavioral	JJ	B-NP	O
phenotypes	NNS	I-NP	O
and	CC	O	O
AChE	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
mice	NNS	I-NP	O
following	VBG	B-PP	O
BPA	NN	B-NP	O
exposure	NN	I-NP	O
during	IN	B-PP	O
puberty	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
postnatal	JJ	B-NP	O
day	NN	I-NP	O
(	(	O	O
PND	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
male	JJ	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
BPA	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
diet	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
PND71	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
behavioral	JJ	I-NP	O
assay	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
elevated	JJ	I-NP	O
plus	CC	O	O
maze	NN	B-NP	O
(	(	O	O
EPM	NN	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
light	NN	I-NP	O
/	SYM	B-NP	O
dark	JJ	I-NP	O
test	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
AChE	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	I-NP	O
hypothalamus	NN	I-NP	O
,	,	I-NP	O
cerebellum	NN	I-NP	O
and	CC	I-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
from	IN	B-PP	O
our	PRP$	B-NP	O
behavioral	JJ	I-NP	O
phenotyping	NN	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
anxiety	NN	B-NP	B
-	HYPH	B-VP	O
like	JJ	B-NP	O
behavior	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
BPA	NN	B-NP	O
.	.	O	O

AChE	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
BPA	NN	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
control	NN	B-NP	O
mice	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
no	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	I-NP	O
hypothalamus	NN	I-NP	O
and	CC	I-NP	O
cerebellum	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
pubertal	JJ	B-NP	O
BPA	NN	I-NP	O
exposure	NN	I-NP	O
increased	VBD	B-VP	O
anxiety	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
behavior	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
decreased	VBN	B-NP	O
AChE	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
male	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
cholinergic	JJ	I-NP	O
signaling	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
in	IN	B-PP	O
PBE	NN	B-NP	O
induced	VBD	B-VP	O
anxiety	NN	B-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
behaviors	NNS	I-NP	O
.	.	O	O

Biochemical	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Solidago	NNP	B-NP	O
virgaurea	NNP	I-NP	O
extract	NN	I-NP	O
on	IN	B-PP	O
experimental	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Cardiovascular	JJ	B-NP	B
diseases	NNS	I-NP	I
(	(	O	O
CVDs	NNS	B-NP	B
)	)	O	O
are	VBP	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
health	NN	I-NP	O
problem	NN	I-NP	O
of	IN	B-PP	O
advanced	VBN	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
developing	VBG	B-NP	O
countries	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
world	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Solidago	NNP	I-NP	O
virgaurea	NNP	I-NP	O
extract	NN	I-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
subcutaneous	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
into	IN	B-PP	O
rats	NNS	B-NP	O
twice	RB	B-ADVP	O
at	IN	B-PP	O
an	DT	B-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
,	,	O	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
lactate	NN	I-NP	O
dehydrogenase	NN	I-NP	O
,	,	O	O
creatine	NN	B-NP	O
phosphokinase	NN	I-NP	O
,	,	O	O
alanine	NN	B-NP	O
transaminase	NN	I-NP	O
,	,	O	O
aspartate	NN	B-NP	O
transaminase	NN	I-NP	O
,	,	O	O
and	CC	O	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
activities	NNS	I-NP	O
,	,	O	O
total	JJ	B-NP	O
cholesterol	NN	I-NP	O
,	,	O	O
triglycerides	NNS	B-NP	O
,	,	O	O
free	JJ	B-NP	O
serum	NN	I-NP	O
fatty	JJ	I-NP	O
acid	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
tissue	NN	I-NP	O
malondialdehyde	NN	I-NP	O
(	(	O	O
MDA	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
glutathione	NN	B-NP	O
and	CC	I-NP	O
superoxide	NN	I-NP	O
dismutase	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
tissue	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
with	IN	B-PP	O
S.	NNP	B-NP	O
virgaurea	NNP	I-NP	O
extract	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
injection	NN	I-NP	O
significantly	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
observed	VBN	I-NP	O
alterations	NNS	I-NP	O
.	.	O	O

Captopril	NNP	B-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
used	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
standard	JJ	I-NP	O
cardioprotective	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
control	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
S.	NNP	B-NP	O
virgaurea	NNP	I-NP	O
extract	NN	I-NP	O
exerts	VBZ	B-VP	O
its	PRP$	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
by	IN	B-PP	O
decreasing	VBG	B-VP	O
MDA	NN	B-NP	O
level	NN	I-NP	O
and	CC	O	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
antioxidant	JJ	I-NP	O
status	NN	I-NP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
S.	NNP	B-NP	O
virgaurea	NNP	I-NP	O
extract	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
cardioprotective	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Real	JJ	B-NP	O
-	HYPH	I-NP	O
world	NN	I-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
lenalidomide	NN	B-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	JJ	I-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
clinical	JJ	I-NP	O
practice	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Greek	NNP	I-NP	O
Myeloma	NNP	I-NP	B
Study	NNP	I-NP	O
Group	NNP	I-NP	O
.	.	O	O

Lenalidomide	NN	B-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
(	(	O	O
RD	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
standard	NN	I-NP	O
of	IN	B-PP	O
care	NN	B-NP	O
for	IN	B-PP	O
relapsed	VBN	B-NP	O
/	SYM	I-NP	O
refractory	JJ	I-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
(	(	O	O
RRMM	NN	B-NP	B
)	)	O	O
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
published	VBN	B-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
its	PRP$	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
real	JJ	I-NP	O
world	NN	I-NP	O
(	(	O	O
RW	NN	B-NP	O
)	)	O	O
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
International	NNP	I-NP	O
Society	NNP	I-NP	O
of	IN	B-PP	O
Pharmacoeconomics	NNP	B-NP	O
and	CC	I-NP	O
Outcomes	NNP	I-NP	O
Research	NNP	I-NP	O
definition	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
RRMM	NN	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
RD	NN	B-NP	O
in	IN	B-PP	O
RW	NN	B-NP	O
.	.	O	O

Objective	JJ	B-NP	O
response	NN	I-NP	O
(	(	O	O
>	SYM	B-NP	O
PR	NN	I-NP	O
(	(	O	O
partial	JJ	B-NP	O
response	NN	I-NP	O
)	)	O	O
)	)	O	O
rate	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
complete	JJ	B-NP	O
response	NN	I-NP	O
(	(	O	O
CR	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
and	CC	I-NP	O
best	JJS	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
CR	NN	B-NP	O
when	WRB	B-ADVP	O
RD	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
as	IN	B-PP	O
num	CD	B-NP	O
or	CC	O	O
>	SYM	O	O
num	CD	B-NP	O
(	(	O	O
nd	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Quality	NN	B-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
was	VBD	B-VP	O
independent	JJ	B-ADJP	O
of	IN	B-PP	O
previous	JJ	B-NP	O
lines	NNS	I-NP	O
of	IN	B-PP	O
therapies	NNS	B-NP	O
or	CC	O	O
previous	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
thalidomide	NN	B-NP	O
or	CC	I-NP	O
bortezomib	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
RD	NN	B-NP	O
until	IN	B-PP	O
progression	NN	B-NP	O
.	.	O	O

Improvement	NN	B-NP	O
of	IN	B-PP	O
humoral	JJ	B-NP	O
immunity	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
responders	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
achieved	VBD	B-VP	O
stable	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
(	(	O	O
myelosuppression	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
needed	VBD	B-VP	O
hospitalization	NN	B-NP	O
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
deep	JJ	B-NP	B
vein	NN	I-NP	I
thrombosis	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
reductions	NNS	I-NP	O
were	VBD	B-VP	O
needed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
permanent	JJ	B-NP	O
discontinuation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
discontinuation	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Performance	NN	B-NP	O
status	NN	I-NP	O
(	(	O	O
PS	NN	B-NP	O
)	)	O	O
and	CC	O	O
initial	JJ	B-NP	O
lenalidomide	NN	I-NP	O
dose	NN	I-NP	O
predicted	VBN	B-VP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

Extra	AFX	B-NP	O
-	HYPH	I-NP	O
medullary	JJ	I-NP	O
relapses	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
study	NN	I-NP	O
confirms	VBZ	B-VP	O
that	IN	B-SBAR	O
RD	NN	B-NP	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
and	CC	I-ADJP	O
safe	JJ	I-ADJP	O
in	IN	B-PP	O
RRMM	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
RW	NN	I-NP	O
;	:	O	O
it	PRP	B-NP	O
produces	VBZ	B-VP	O
durable	JJ	B-NP	O
responses	NNS	I-NP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
continue	VBP	B-VP	O
on	IN	B-PP	O
treatment	NN	B-NP	O
till	NN	I-NP	O
progression	NN	I-NP	O
and	CC	O	O
improves	VBZ	B-VP	O
humoral	JJ	B-NP	O
immunity	NN	I-NP	O
even	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cytogenetic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
,	,	O	O
mesna	NN	B-NP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
combination	NN	I-NP	O
on	IN	B-PP	O
peripheral	JJ	B-NP	O
rabbit	NN	I-NP	O
lymphocytes	NNS	I-NP	O
:	:	O	O
an	DT	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
/	SYM	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
cytogenetic	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Ifosfamide	NN	B-NP	O
(	(	O	O
IFO	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
alkylating	VBG	I-NP	O
nitrogen	NN	I-NP	O
mustard	NN	I-NP	O
,	,	O	O
administrated	VBN	B-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
antineoplasmic	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
intense	JJ	I-NP	O
urotoxic	JJ	I-NP	O
action	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
IFO	NN	B-NP	O
raises	VBZ	B-VP	O
the	DT	B-NP	O
requirement	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
sulfanylethanesulfonate	NN	I-NP	O
(	(	O	O
Mesna	NN	B-NP	O
)	)	O	O
aiming	VBG	B-VP	O
to	TO	I-VP	O
avoid	VB	I-VP	O
or	CC	I-VP	O
minimize	VB	I-VP	O
this	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

IFO	NNP	B-NP	O
and	CC	I-NP	O
Mesna	NNP	I-NP	O
were	VBD	B-VP	O
administrated	VBN	I-VP	O
separately	RB	B-ADVP	O
on	IN	B-PP	O
rabbit	NN	B-NP	O
s	VBZ	B-VP	O
lymphocytes	NNS	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
later	RB	I-VP	O
developed	VBN	I-VP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

Cytogenetic	JJ	B-NP	O
markers	NNS	I-NP	O
for	IN	B-PP	O
sister	NN	B-NP	O
chromatid	NN	I-NP	O
exchanges	NNS	I-NP	O
(	(	O	O
SCEs	NNS	B-NP	O
)	)	O	O
,	,	O	O
proliferation	NN	B-NP	O
rate	NN	I-NP	O
index	NN	I-NP	O
(	(	O	O
PRI	NN	B-NP	O
)	)	O	O
and	CC	O	O
Mitotic	JJ	B-NP	O
Index	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Mesna	NNP	B-NP	O
s	VBZ	B-VP	O
action	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
IFO	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
SCEs	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
SCEs	NNS	I-NP	O
recordings	NNS	I-NP	O
obtained	VBN	B-VP	O
when	WRB	B-ADVP	O
IFO	NNP	B-NP	O
is	VBZ	B-VP	O
administered	VBN	I-VP	O
alone	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
,	,	O	O
when	WRB	B-ADVP	O
high	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
Mesna	NNP	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
alone	RB	B-NP	O
significant	JJ	I-NP	O
reductions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
PRI	NN	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
,	,	O	O
than	IN	B-PP	O
with	IN	B-PP	O
IFO	NN	B-NP	O
acting	VBG	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
concentration	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
lymphocytes	NNS	I-NP	O
.	.	O	O

Mesna	NNP	B-NP	O
significantly	RB	B-ADVP	O
reduces	VBZ	B-VP	O
IFO	NN	B-NP	O
s	NNS	I-NP	O
genotoxicity	NN	I-NP	B
,	,	O	O
while	IN	B-SBAR	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
in	IN	B-PP	O
high	JJ	B-NP	O
concentrations	NNS	I-NP	O
it	PRP	B-NP	O
acts	VBZ	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
inhibitory	JJ	I-NP	O
fashion	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cytostatic	JJ	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
factors	NNS	I-NP	O
and	CC	O	O
predictors	NNS	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
among	IN	B-PP	O
multiethnic	JJ	B-NP	O
Malaysians	NNPS	I-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Chronic	JJ	B-NP	O
pulsatile	JJ	I-NP	O
levodopa	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
fluctuations	NNS	I-NP	O
and	CC	O	O
dyskinesia	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
and	CC	I-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
among	IN	B-PP	O
multiethnic	JJ	B-NP	O
Malaysian	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
study	NN	I-NP	O
involving	VBG	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
on	IN	B-PP	O
uninterrupted	JJ	B-NP	O
levodopa	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
instrument	NN	I-NP	O
used	VBN	B-VP	O
was	VBD	B-VP	O
the	DT	B-NP	O
UPDRS	NNP	I-NP	O
questionnaires	VBZ	B-VP	O
.	.	O	O

The	DT	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
dyskinesia	NN	B-NP	B
were	VBD	B-VP	O
determined	VBN	I-VP	O
using	VBG	B-VP	O
multivariate	JJ	B-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
onset	NN	I-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
disease	NN	I-NP	O
duration	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Dyskinesia	NNP	B-NP	B
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
median	JJ	B-NP	O
levodopa	NN	I-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
Chinese	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
Malays	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
Indians	NNPS	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
ethnic	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
dyskinesia	NN	B-NP	B
had	VBD	B-VP	O
clinical	JJ	B-NP	O
fluctuations	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
dyskinesia	NN	B-NP	B
had	VBD	B-VP	O
lower	JJR	B-NP	O
onset	NN	I-NP	O
age	NN	I-NP	O
,	,	O	O
longer	JJR	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
longer	JJR	B-NP	O
disease	NN	I-NP	O
duration	NN	I-NP	O
,	,	O	O
higher	JJR	B-NP	O
total	JJ	I-NP	O
daily	JJ	I-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
,	,	O	O
and	CC	O	O
higher	JJR	B-NP	O
total	JJ	I-NP	O
UPDRS	NN	I-NP	O
scores	NNS	I-NP	O
than	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
dyskinesia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
significant	JJ	I-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
dyskinesia	NN	B-NP	B
were	VBD	B-VP	O
duration	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
onset	NN	B-NP	O
age	NN	I-NP	O
,	,	O	O
and	CC	O	O
total	JJ	B-NP	O
daily	JJ	I-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesia	NN	I-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
significant	JJ	I-NP	O
predictors	NNS	I-NP	O
were	VBD	B-VP	O
duration	NN	B-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
daily	JJ	I-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
,	,	O	O
and	CC	O	O
onset	NN	B-NP	O
age	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
unexpected	JJ	I-NP	O
diagnosis	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
renal	JJ	I-NP	O
-	HYPH	I-NP	O
transplant	NN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
proteinuria	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
everolimus	NN	B-NP	O
:	:	O	O
AL	JJ	B-NP	B
amyloidosis	NN	I-NP	B
.	.	O	O

Proteinuria	NNP	B-NP	B
is	VBZ	B-VP	O
an	DT	B-NP	O
expected	JJ	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
transplant	NN	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
mammalian	JJ	B-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
rapamycin	NN	B-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
mTOR	NN	B-NP	O
-	HYPH	O	O
i	NN	B-NP	O
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
clinical	JJ	B-NP	O
suspicion	NN	I-NP	O
should	MD	B-VP	O
always	RB	I-VP	O
be	VB	I-VP	O
supported	VBN	I-VP	O
by	IN	B-PP	O
histological	JJ	B-NP	O
evidence	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
potential	JJ	B-NP	O
alternate	JJ	I-NP	O
diagnoses	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
acute	JJ	B-NP	O
or	CC	I-NP	O
chronic	JJ	I-NP	O
rejection	NN	I-NP	O
,	,	O	O
interstitial	JJ	B-NP	O
fibrosis	NN	I-NP	B
and	CC	O	O
tubular	JJ	B-NP	O
atrophy	NN	I-NP	B
,	,	O	O
or	CC	O	O
recurrent	JJ	B-NP	O
or	CC	I-NP	O
de	FW	I-NP	O
novo	FW	I-NP	O
glomerulopathy	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
we	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
unexpected	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
amyloidosis	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
renal	JJ	I-NP	O
-	HYPH	I-NP	O
transplant	NN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
transplant	NN	I-NP	O
monoclonal	JJ	I-NP	O
gammapathy	NN	I-NP	O
of	IN	B-PP	O
undetermined	JJ	B-NP	O
significance	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
proteinuria	NN	B-NP	B
after	IN	B-PP	O
conversion	NN	B-NP	O
from	IN	B-PP	O
tacrolimus	NN	B-NP	O
to	TO	B-PP	O
everolimus	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
investigation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
HIV	NN	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
persons	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-VP	O
tenofovir	VB	I-VP	O
disoproxil	NN	B-NP	O
fumarate	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
large	JJ	I-NP	O
population	NN	I-NP	O
database	NN	I-NP	O
(	(	O	O
MHRA	NN	B-NP	O
database	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
tenofovir	NN	B-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
syndromes	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
established	VBN	I-VP	O
from	IN	B-PP	O
mechanistic	JJ	O	O
and	CC	O	O
randomised	VBD	B-VP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
exact	JJ	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
involvement	NN	I-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
uncertain	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
undertook	VBD	B-VP	O
a	DT	B-NP	O
descriptive	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
Yellow	NNP	B-NP	O
Card	NNP	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
HIV	NN	I-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
persons	NNS	I-NP	O
taking	VBG	B-VP	O
tenofovir	NN	B-NP	O
disoproxil	NN	I-NP	O
fumarate	NN	I-NP	O
(	(	O	O
TDF	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
antiretroviral	JJ	I-NP	O
therapy	NN	I-NP	O
regimen	NN	I-NP	O
and	CC	O	O
submitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Medicines	NNP	I-NP	O
and	CC	O	O
Healthcare	NNP	B-NP	O
Products	NNP	I-NP	O
Regulatory	NNP	I-NP	O
Agency	NNP	I-NP	O
(	(	O	O
MHRA	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
suspected	VBN	B-NP	O
kidney	NN	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Reports	NNS	B-NP	O
that	WDT	B-NP	O
satisfy	VBP	B-VP	O
defined	VBN	B-NP	O
criteria	NNS	I-NP	O
were	VBD	B-VP	O
classified	VBN	I-VP	O
as	IN	B-PP	O
acute	JJ	B-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
,	,	O	O
kidney	NN	B-NP	B
tubular	JJ	I-NP	I
dysfunction	NN	I-NP	I
and	CC	O	O
Fanconi	NNP	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
Yellow	NNP	I-NP	O
Card	NNP	I-NP	O
records	NNS	I-NP	O
analysed	VBD	B-VP	O
,	,	O	O
num	CD	B-NP	O
satisfied	JJ	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
TDF	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
kidney	NN	I-NP	B
disease	NN	I-NP	I
,	,	O	O
of	IN	B-PP	O
which	WDT	B-NP	O
num	CD	B-NP	O
had	VBD	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	B
tubular	JJ	I-NP	I
dysfunction	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
Fanconi	NNP	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
TDF	NN	I-NP	O
exposure	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
(	(	O	O
interquartile	JJ	B-NP	O
range	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
hospitalisation	NN	B-NP	O
for	IN	B-PP	O
TDF	NN	B-NP	O
kidney	NN	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
was	VBD	B-VP	O
high	JJ	B-ADJP	O
,	,	O	O
particularly	RB	B-ADVP	O
amongst	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
features	NNS	B-NP	O
of	IN	B-PP	O
Fanconi	NNP	B-NP	B
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
syndromes	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
series	NN	I-NP	O
mirrors	NNS	I-NP	O
that	WDT	B-NP	O
reported	VBD	B-VP	O
in	IN	B-PP	O
randomised	VBN	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

Cessation	NN	B-NP	O
of	IN	B-PP	O
TDF	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
complete	JJ	B-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
up	RP	B-PRT	O
half	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
is	VBZ	B-VP	O
high	JJ	B-ADJP	O
even	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
without	IN	B-PP	O
known	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Postoperative	JJ	B-NP	B
delirium	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
recognized	VBN	I-NP	O
complication	NN	I-NP	O
in	IN	B-PP	O
populations	NNS	B-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
postoperative	JJ	I-NP	B
delirium	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
without	IN	B-PP	O
known	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
ICU	NN	I-NP	O
for	IN	B-PP	O
postoperative	JJ	B-NP	O
monitoring	NN	I-NP	O
after	IN	B-PP	O
elective	JJ	B-NP	O
major	JJ	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
secondary	JJ	I-NP	O
outcome	NN	I-NP	O
investigated	VBN	B-VP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
eventual	JJ	B-NP	O
independent	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
among	IN	B-PP	O
demographic	JJ	B-NP	O
data	NNS	I-NP	O
and	CC	O	O
anesthetic	JJ	B-NP	O
drugs	NNS	I-NP	O
used	VBN	B-VP	O
.	.	O	O

An	DT	B-NP	O
observational	JJ	I-NP	O
,	,	I-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
consecutive	JJ	I-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
ICU	NN	I-NP	O
within	IN	B-PP	O
and	CC	B-PP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
major	JJ	B-NP	O
surgical	JJ	I-NP	O
procedures	NNS	I-NP	O
.	.	O	O

Exclusion	NN	B-NP	O
criteria	NNS	I-NP	O
were	VBD	B-VP	O
any	DT	B-NP	O
preexisting	JJ	I-NP	O
predisposing	VBG	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
delirium	NN	B-NP	B
or	CC	O	O
other	JJ	B-ADJP	O
potentially	RB	B-VP	O
confounding	VBG	I-VP	O
neurological	JJ	B-NP	B
dysfunctions	NNS	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
daily	RB	B-ADVP	O
using	VBG	B-VP	O
the	DT	B-NP	O
confusion	NN	I-NP	B
assessment	NN	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
ICU	NN	I-NP	O
scale	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
surgical	JJ	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

Early	RB	B-NP	O
postoperative	JJ	I-NP	B
delirium	NN	I-NP	I
incidence	NN	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
assessed	VBN	I-VP	O
through	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
multiple	JJ	I-NP	O
regression	NN	I-NP	O
models	NNS	I-NP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
confusion	NN	I-NP	O
assessment	NN	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
ICU	NN	I-NP	O
scale	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
early	JJ	B-NP	O
postoperative	JJ	I-NP	B
delirium	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
thiopentone	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	RB	I-NP	O
-	HYPH	I-NP	O
higher	JJR	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
delirium	NN	B-NP	B
compared	VBN	B-VP	O
to	TO	B-PP	O
propofol	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
early	JJ	B-NP	O
postoperative	JJ	I-NP	B
delirium	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
very	RB	I-NP	O
common	JJ	I-NP	O
complication	NN	I-NP	O
after	IN	B-PP	O
major	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
without	IN	B-PP	O
known	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Thiopentone	NN	B-NP	O
was	VBD	B-VP	O
independently	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
its	PRP$	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
neurotoxic	JJ	I-NP	B
dose	NN	I-NP	O
of	IN	B-PP	O
methamphetamine	NN	B-NP	O
induces	VBZ	B-VP	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
lasting	VBG	B-VP	O
depressive	JJ	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
behaviour	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Methamphetamine	NN	B-NP	O
(	(	O	O
METH	NN	B-NP	O
)	)	O	O
triggers	VBZ	B-VP	O
a	DT	B-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
monoaminergic	JJ	I-NP	O
system	NN	I-NP	O
and	CC	I-NP	O
METH	NN	I-NP	O
abuse	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
negative	JJ	B-NP	O
emotional	JJ	I-NP	O
states	NNS	I-NP	O
including	VBG	B-PP	O
depressive	JJ	B-NP	B
symptoms	NNS	I-NP	I
during	IN	B-PP	O
drug	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
currently	RB	B-ADJP	O
unknown	JJ	I-ADJP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
acute	JJ	I-NP	O
toxic	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
also	RB	B-ADVP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
lasting	VBG	B-VP	O
depressive	JJ	B-NP	B
phenotype	NN	I-NP	O
and	CC	O	O
persistent	JJ	B-NP	O
monoaminergic	JJ	I-NP	O
deficits	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
now	RB	B-ADVP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
depressive	JJ	I-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
behaviour	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
at	IN	B-PP	O
early	JJ	B-NP	O
and	CC	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
periods	NNS	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
high	JJ	I-NP	O
METH	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

METH	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
motor	NN	I-NP	O
function	NN	I-NP	O
and	CC	O	O
procedural	JJ	B-NP	O
memory	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
as	IN	B-SBAR	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
swimming	VBG	B-VP	O
speed	NN	B-NP	O
and	CC	I-NP	O
escape	NN	I-NP	O
latency	NN	I-NP	O
to	TO	B-VP	O
find	VB	I-VP	O
the	DT	B-NP	O
platform	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
cued	VBN	I-NP	O
version	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
task	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
METH	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
immobility	NN	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
tail	NN	I-NP	O
suspension	NN	I-NP	O
test	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
depressive	JJ	I-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
profile	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
METH	NN	B-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
frontostriatal	JJ	B-NP	O
dopaminergic	JJ	I-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
neurotransmission	NN	I-NP	O
,	,	O	O
indicated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
,	,	O	O
DOPAC	NN	B-NP	O
and	CC	I-NP	O
HVA	NN	I-NP	O
,	,	O	O
tyrosine	NN	B-NP	O
hydroxylase	NN	I-NP	O
and	CC	I-NP	O
serotonin	NN	I-NP	O
,	,	O	O
observed	VBN	B-VP	O
at	IN	B-PP	O
both	CC	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
parallel	NN	B-NP	O
,	,	O	O
another	DT	B-NP	O
neurochemical	JJ	I-NP	O
feature	NN	I-NP	O
of	IN	B-PP	O
depression	NN	B-NP	B
-	HYPH	O	O
-	HYPH	O	O
astroglial	JJ	B-NP	O
dysfunction	NN	I-NP	O
-	HYPH	O	O
-	SYM	B-NP	O
was	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
cortex	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
striatal	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
astrocytic	JJ	I-NP	O
protein	NN	I-NP	O
marker	NN	I-NP	O
,	,	O	O
glial	JJ	B-NP	O
fibrillary	JJ	I-NP	O
acidic	JJ	I-NP	O
protein	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
only	RB	I-VP	O
transiently	RB	I-VP	O
increased	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
that	IN	B-ADVP	O
a	DT	B-NP	O
single	JJ	I-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
METH	NN	B-NP	O
induces	VBZ	B-VP	O
long	RB	B-ADVP	O
-	HYPH	O	O
lasting	VBG	B-VP	O
depressive	JJ	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
behaviour	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
persistent	JJ	I-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
frontostriatal	JJ	B-NP	O
dopaminergic	JJ	I-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
homoeostasis	NN	I-NP	O
.	.	O	O

Linezolid	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Many	JJ	B-NP	O
systemic	JJ	I-NP	O
antimicrobials	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
ocular	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
especially	RB	B-ADJP	O
relevant	JJ	I-ADJP	O
in	IN	B-PP	O
multidrug	JJ	B-NP	O
therapy	NN	I-NP	O
where	WRB	B-ADVP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
drug	NN	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
ocular	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
linezolid	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
multiple	JJ	B-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
anti	AFX	O	O
-	HYPH	O	O
tuberculous	JJ	B-NP	O
drugs	NNS	I-NP	O
including	VBG	B-PP	O
linezolid	NN	B-NP	O
and	CC	I-NP	O
ethambutol	NN	I-NP	O
for	IN	B-PP	O
extensively	RB	B-NP	B
drug	NN	I-NP	I
-	HYPH	B-NP	I
resistant	JJ	I-NP	I
tuberculosis	NN	I-NP	I
(	(	O	O
XDR	NN	B-NP	B
-	HYPH	B-NP	I
TB	NN	I-NP	I
)	)	O	O
presented	VBN	B-VP	O
to	TO	B-PP	O
us	PRP	B-NP	O
with	IN	B-PP	O
painless	JJ	B-NP	O
progressive	JJ	I-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Color	NN	B-NP	O
vision	NN	I-NP	O
was	VBD	B-VP	O
defective	JJ	B-NP	O
and	CC	I-NP	O
fundus	NN	I-NP	O
examination	NN	I-NP	O
revealed	VBD	B-VP	O
optic	JJ	B-NP	B
disc	NN	I-NP	I
edema	NN	I-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Ethambutol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
toxic	JJ	I-NP	B
optic	JJ	I-NP	I
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
suspected	VBN	I-VP	O
and	CC	O	O
tablet	NN	B-NP	O
ethambutol	NN	I-NP	O
was	VBD	B-VP	O
withdrawn	VBN	I-VP	O
.	.	O	O

Deterioration	NN	B-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
occurred	VBD	B-VP	O
despite	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
.	.	O	O

Discontinuation	NN	B-NP	O
of	IN	B-PP	O
linezolid	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
marked	JJ	B-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
vision	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
report	NN	I-NP	O
emphasizes	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
monitoring	NN	B-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
linezolid	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Resuscitation	NN	B-NP	O
with	IN	B-PP	O
lipid	NN	B-NP	O
,	,	O	O
epinephrine	NN	B-NP	O
,	,	O	O
or	CC	O	O
both	CC	O	O
in	IN	B-PP	O
levobupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
in	IN	B-PP	O
newborn	JJ	B-NP	O
piglets	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
optimal	JJ	I-NP	O
dosing	NN	I-NP	O
regimens	NNS	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
emulsion	NN	I-NP	O
,	,	O	O
epinephrine	NN	B-NP	O
,	,	O	O
or	CC	O	O
both	DT	O	O
are	VBP	B-VP	O
not	RB	I-VP	O
yet	RB	I-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
neonates	NNS	B-NP	O
in	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anaesthetic	JJ	I-NP	O
systemic	JJ	I-NP	O
toxicity	NN	I-NP	B
(	(	O	O
LAST	NN	B-NP	O
)	)	O	O
.	.	O	O

Newborn	JJ	B-NP	O
piglets	NNS	I-NP	O
received	VBD	B-VP	O
levobupivacaine	NN	B-NP	O
until	IN	B-PP	O
cardiovascular	JJ	B-NP	B
collapse	NN	I-NP	I
occurred	VBD	B-VP	O
.	.	O	O

Standard	JJ	B-NP	O
cardiopulmonary	JJ	I-NP	O
resuscitation	NN	I-NP	O
was	VBD	B-VP	O
started	VBN	I-VP	O
and	CC	O	O
electrocardiogram	NN	B-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
,	,	O	O
fibrillation	NN	B-NP	B
,	,	O	O
or	CC	O	O
QRS	NN	B-NP	O
prolongation	NN	I-NP	O
.	.	O	O

Piglets	NNS	B-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
control	NN	B-NP	O
(	(	O	O
saline	NN	B-NP	O
)	)	O	O
,	,	O	O
Intralipid	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
epinephrine	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
or	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
Intralipd	NNP	B-NP	O
plus	CC	O	O
epinephrine	NN	B-NP	O
.	.	O	O

Resuscitation	NN	B-NP	O
continued	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
or	CC	B-PP	O
until	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
return	NN	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
circulation	NN	I-NP	O
(	(	O	O
ROSC	NN	B-NP	O
)	)	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
at	IN	B-PP	O
or	CC	O	O
superior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
normal	JJ	B-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

ROSC	NN	B-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
piglets	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treated	VBN	I-NP	O
piglets	NNS	I-NP	O
.	.	O	O

Mortality	NN	B-NP	O
was	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
ECG	NN	B-NP	O
abnormalities	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Intralipid	NN	I-NP	O
only	RB	B-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
respectively	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
epinephrine	NN	I-NP	O
and	CC	I-NP	O
epinephrine	NN	I-NP	O
plus	CC	I-NP	O
lipid	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Lipid	NN	B-NP	O
emulsion	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
epinephrine	NN	B-NP	O
,	,	O	O
or	CC	O	O
epinephrine	NN	B-NP	O
alone	RB	B-ADVP	O
were	VBD	B-VP	O
equally	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
achieving	VBG	B-VP	O
a	DT	B-NP	O
return	NN	I-NP	O
to	TO	B-PP	O
spontaneous	JJ	B-NP	O
circulation	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
LAST	NN	B-NP	O
.	.	O	O

Epinephrine	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
lipid	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
ECG	NN	B-NP	O
abnormalities	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
lipid	NN	B-NP	O
emulsion	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
and	CC	O	O
postoperative	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
platelet	NN	B-NP	O
count	NN	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
graft	NN	I-NP	O
recipients	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
cohort	JJ	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Thrombocytopenia	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
disorder	NN	I-NP	O
caused	VBD	B-VP	O
mainly	RB	B-ADVP	O
by	IN	B-PP	O
portal	JJ	B-NP	B
hypertension	NN	I-NP	I
,	,	O	O
low	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
thrombopoetin	NN	B-NP	O
,	,	O	O
and	CC	O	O
endotoxemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
immune	JJ	B-NP	O
-	HYPH	I-NP	O
mediated	VBN	I-NP	O
heparin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
thrombocytopenia	NN	I-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
(	(	O	O
HIT	NN	B-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
)	)	O	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
thrombocytopenia	NN	B-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
yet	RB	I-VP	O
understood	VBN	I-VP	O
,	,	O	O
with	IN	B-SBAR	O
few	JJ	B-NP	O
literature	NN	I-NP	O
citations	NNS	I-NP	O
reporting	VBG	B-VP	O
contradictory	JJ	B-NP	O
results	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
demonstrate	VB	I-VP	O
the	DT	B-NP	O
perioperative	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
thrombocytopenia	NN	B-NP	B
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
and	CC	O	O
determine	VB	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
HIT	NN	I-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
.	.	O	O

We	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
full	JJ	B-NP	O
-	HYPH	I-NP	O
size	NN	I-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
between	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
December	NNP	B-NP	O
num	CD	I-NP	O
due	IN	B-ADVP	O
to	TO	B-VP	O
end	VB	I-VP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
or	CC	O	I
malignant	JJ	B-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Preoperative	JJ	B-NP	O
platelet	NN	I-NP	O
count	NN	I-NP	O
,	,	O	O
postoperative	JJ	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
platelets	NNS	B-NP	O
,	,	O	O
and	CC	O	O
clinical	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
thrombocytopenia	NN	B-NP	B
before	IN	B-PP	O
transplantation	NN	B-NP	O
,	,	O	O
significantly	RB	B-VP	O
influenced	VBN	I-VP	O
by	IN	B-PP	O
Model	NN	B-NP	O
of	IN	B-PP	O
End	NN	B-NP	B
-	HYPH	B-NP	I
Stage	NN	I-NP	I
Liver	NN	I-NP	I
Disease	NN	I-NP	I
score	NN	I-NP	O
and	CC	O	O
liver	NN	B-NP	B
cirrhosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
platelet	NN	I-NP	O
count	NN	I-NP	O
exceeded	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
uL	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
medium	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
.	.	O	O

Regarding	VBG	B-VP	O
HIT	NN	B-NP	B
num	CD	I-NP	I
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
background	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
end	NN	B-NP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
is	VBZ	B-VP	O
,	,	O	O
with	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
rare	JJ	B-ADJP	O
.	.	O	O

For	IN	B-PP	O
further	JJR	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
type	NN	I-NP	I
num	CD	I-NP	I
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
heparin	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
anticoagulation	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
molecular	JJ	I-NP	O
-	HYPH	I-NP	O
weight	NN	I-NP	O
heparin	NN	I-NP	O
after	IN	B-PP	O
normalization	NN	B-NP	O
of	IN	B-PP	O
platelet	NN	B-NP	O
count	NN	I-NP	O
.	.	O	O

Takotsubo	NN	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
or	CC	O	O
apical	JJ	B-NP	B
ballooning	NN	I-NP	I
syndrome	NN	I-NP	I
)	)	O	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
Zolmitriptan	NNP	B-NP	O
.	.	O	O

Takotsubo	NN	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
TS	NN	B-NP	B
)	)	O	O
,	,	O	O
also	RB	B-VP	O
known	VBN	I-VP	O
as	IN	B-PP	O
broken	JJ	B-NP	B
heart	NN	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
left	JJ	B-NP	O
ventricle	NN	I-NP	O
apical	JJ	I-NP	O
ballooning	NN	I-NP	O
with	IN	B-PP	O
elevated	JJ	B-NP	O
cardiac	JJ	I-NP	O
biomarkers	NNS	I-NP	O
and	CC	O	O
electrocardiographic	JJ	B-NP	O
changes	NNS	I-NP	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	B
coronary	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
ie	FW	B-NP	O
,	,	O	O
ST	NN	B-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
,	,	O	O
T	NN	B-NP	O
wave	NN	I-NP	O
inversions	NNS	I-NP	O
,	,	O	O
and	CC	O	O
pathologic	JJ	B-NP	O
Q	NN	I-NP	O
waves	NNS	I-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
medical	JJ	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
mitral	JJ	B-NP	B
valve	NN	I-NP	I
prolapse	NN	I-NP	I
and	CC	I-NP	O
migraines	NNS	I-NP	B
,	,	O	O
who	WP	B-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
substernal	JJ	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
and	CC	I-NP	O
electrocardiogram	NN	I-NP	O
demonstrated	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
ST	NN	I-NP	O
-	HYPH	B-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
leads	NNS	B-NP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
aVF	NN	B-NP	O
,	,	O	O
V5	NN	B-NP	O
,	,	O	O
and	CC	O	O
V6	NN	B-NP	O
and	CC	O	O
positive	JJ	B-NP	O
troponin	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

Emergent	JJ	B-NP	O
coronary	JJ	I-NP	O
angiogram	NN	I-NP	O
revealed	VBD	B-VP	O
normal	JJ	B-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
with	IN	B-PP	O
moderately	RB	B-NP	O
reduced	VBN	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
with	IN	B-PP	O
wall	NN	B-NP	O
motion	NN	I-NP	O
abnormalities	NNS	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
TS	NN	B-NP	B
.	.	O	O

Detailed	JJ	B-NP	O
history	NN	I-NP	O
obtained	VBN	B-VP	O
retrospectively	RB	B-ADVP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
took	VBD	B-VP	O
zolmitriptan	NN	B-NP	O
sparingly	RB	B-ADVP	O
only	RB	O	O
when	WRB	B-ADVP	O
she	PRP	B-NP	O
had	VBD	B-VP	O
migraines	NNS	B-NP	B
.	.	O	O

But	CC	O	O
before	IN	B-SBAR	O
this	DT	B-NP	O
event	NN	I-NP	O
,	,	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
zolmitriptan	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
daily	RB	I-NP	O
for	IN	B-PP	O
several	JJ	B-NP	O
days	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
persistent	JJ	I-NP	O
migraine	NN	I-NP	B
headache	NN	I-NP	I
.	.	O	O

She	PRP	B-NP	O
otherwise	RB	B-ADVP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
she	PRP	B-NP	O
is	VBZ	B-VP	O
quite	RB	B-ADJP	O
active	JJ	I-ADJP	O
,	,	O	O
rides	NNS	B-NP	O
horses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
does	VBZ	B-VP	O
show	VB	I-VP	O
jumping	VBG	B-VP	O
without	IN	B-PP	O
any	DT	B-NP	O
limitations	NNS	I-NP	O
in	IN	B-PP	O
her	PRP$	B-NP	O
physical	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
recent	JJ	I-NP	O
stress	NN	I-NP	O
or	CC	I-NP	O
status	NN	I-NP	B
migrainosus	NN	I-NP	I
.	.	O	O

Extensive	JJ	B-NP	O
literature	NN	I-NP	O
search	NN	I-NP	O
revealed	VBD	B-VP	O
multiple	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
vasospasm	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
zolmitriptan	NN	B-NP	O
,	,	O	O
but	CC	O	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
TS	NN	B-NP	B
.	.	O	O

Depression	NN	B-NP	B
,	,	O	O
impulsiveness	NN	B-NP	B
,	,	O	O
sleep	NN	B-NP	O
,	,	O	O
and	CC	O	O
memory	NN	B-NP	O
in	IN	B-PP	O
past	JJ	B-NP	O
and	CC	I-NP	O
present	JJ	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylenedioxymethamphetamine	NN	I-NP	O
(	(	O	O
MDMA	NN	B-NP	O
,	,	O	O
ecstasy	JJ	B-ADJP	O
)	)	O	O
.	.	O	O

Ecstasy	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methylenedioxymethamphetamine	NN	I-NP	O
,	,	I-NP	O
MDMA	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
worldwide	RB	I-NP	O
recreational	JJ	I-NP	O
drug	NN	I-NP	O
of	IN	B-PP	O
abuse	NN	B-NP	O
.	.	O	O

Unfortunately	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
from	IN	B-PP	O
human	JJ	B-NP	O
research	NN	I-NP	O
investigating	VBG	B-VP	O
its	PRP$	B-NP	O
psychological	JJ	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
inconsistent	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
largest	JJS	I-NP	O
to	TO	B-PP	O
date	NN	B-NP	O
in	IN	B-PP	O
sample	NN	B-NP	O
size	NN	I-NP	O
and	CC	I-NP	O
5HT	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
behaviors	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
to	TO	B-VP	O
compare	VB	I-VP	O
present	JJ	B-NP	O
ecstasy	JJ	I-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
past	JJ	B-NP	O
users	NNS	I-NP	O
after	IN	B-PP	O
an	DT	B-NP	O
abstinence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
to	TO	B-VP	O
include	VB	I-VP	O
robust	JJ	B-NP	O
controls	NNS	I-NP	O
for	IN	B-PP	O
other	JJ	B-NP	O
recreational	JJ	I-NP	O
substances	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
sample	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
participants	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
male	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
recruited	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
non	AFX	O	O
-	HYPH	O	O
drug	NN	B-NP	O
(	(	O	O
ND	NN	B-NP	O
)	)	O	O
,	,	O	O
alcohol	NN	B-NP	O
/	SYM	O	O
nicotine	NN	B-NP	O
(	(	O	O
AN	NN	B-NP	O
)	)	O	O
,	,	O	O
cannabis	NN	B-NP	O
/	SYM	I-NP	O
alcohol	NN	I-NP	O
/	SYM	O	O
nicotine	NN	B-NP	O
(	(	O	O
CAN	NN	B-NP	O
)	)	O	O
,	,	O	O
non	AFX	O	O
-	HYPH	O	O
ecstasy	JJ	B-NP	O
polydrug	NN	I-NP	O
(	(	O	O
PD	NN	B-NP	O
)	)	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
ecstasy	JJ	I-NP	O
polydrug	NN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
present	JJ	B-ADJP	O
(	(	O	O
MDMA	NN	B-NP	O
)	)	O	O
and	CC	O	O
past	JJ	B-NP	O
users	NNS	I-NP	O
(	(	O	O
EX	NN	B-NP	O
-	HYPH	O	O
MDMA	NN	B-NP	O
)	)	O	O
.	.	O	O

Participants	NNS	B-NP	O
completed	VBD	B-VP	O
a	DT	B-NP	O
drug	NN	I-NP	O
history	NN	I-NP	O
questionnaire	NN	I-NP	O
,	,	O	O
Beck	NNP	B-NP	O
Depression	NNP	I-NP	B
Inventory	NNP	I-NP	O
,	,	O	O
Barratt	NNP	B-NP	O
Impulsiveness	NNP	I-NP	B
Scale	NNP	I-NP	O
,	,	O	O
Pittsburgh	NNP	B-NP	O
Sleep	NNP	I-NP	O
Quality	NNP	I-NP	O
Index	NNP	I-NP	O
,	,	O	O
and	CC	O	O
Wechsler	NNP	B-NP	O
Memory	NNP	I-NP	O
Scale	NNP	I-NP	O
-	HYPH	O	O
Revised	VBN	B-VP	O
which	WDT	B-NP	O
,	,	O	O
in	IN	B-PP	O
total	NN	B-NP	O
,	,	O	O
provided	VBN	B-PP	O
num	CD	B-NP	O
psychometric	JJ	I-NP	O
measures	NNS	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
CAN	NN	I-NP	O
and	CC	I-NP	O
PD	NN	I-NP	O
groups	NNS	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
record	VB	I-VP	O
greater	JJR	B-NP	O
deficits	NNS	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
controls	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
MDMA	NN	I-NP	O
and	CC	I-NP	O
EX	NN	I-NP	O
-	HYPH	I-NP	O
MDMA	NN	I-NP	O
groups	NNS	I-NP	O
recorded	VBD	B-VP	O
greater	JJR	B-NP	O
deficits	NNS	I-NP	O
than	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
psychometric	JJ	I-NP	O
measures	NNS	I-NP	O
.	.	O	O

Strikingly	RB	B-ADVP	O
,	,	O	O
despite	IN	B-PP	O
prolonged	JJ	B-NP	O
abstinence	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
;	:	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
,	,	O	O
past	IN	B-PP	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
showed	VBD	B-VP	O
few	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
recovery	NN	B-NP	O
.	.	O	O

Compared	VBN	B-PP	O
with	IN	B-PP	O
present	JJ	B-NP	O
ecstasy	JJ	I-NP	O
users	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
past	JJ	I-NP	O
users	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
measures	NNS	I-NP	O
,	,	O	O
increased	VBN	B-NP	O
impairment	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
measures	NNS	I-NP	O
,	,	O	O
and	CC	O	O
improvement	NN	B-NP	O
on	IN	B-PP	O
just	RB	B-NP	O
num	CD	I-NP	O
measure	NN	I-NP	O
.	.	O	O

Given	VBN	B-PP	O
this	DT	B-NP	O
record	NN	I-NP	O
of	IN	B-PP	O
impaired	JJ	B-NP	B
memory	NN	I-NP	I
and	CC	O	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
depression	NN	B-NP	B
,	,	O	O
impulsiveness	NN	B-NP	B
,	,	O	O
and	CC	O	O
sleep	NN	B-NP	B
disturbance	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
prognosis	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
generation	NN	I-NP	O
of	IN	B-PP	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
cause	NN	I-NP	O
for	IN	B-PP	O
concern	NN	B-NP	O
.	.	O	O

Association	NN	B-NP	O
of	IN	B-PP	O
common	JJ	B-NP	O
genetic	JJ	I-NP	O
variants	NNS	I-NP	O
of	IN	B-PP	O
HOMER1	NN	B-NP	O
gene	NN	I-NP	O
with	IN	B-PP	O
levodopa	NN	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

Levodopa	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
effective	JJ	I-NP	O
symptomatic	JJ	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
chronic	JJ	I-NP	O
use	NN	I-NP	O
could	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
adverse	JJ	I-NP	O
outcomes	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
motor	NN	B-NP	O
fluctuations	NNS	I-NP	O
,	,	O	O
dyskinesia	NN	B-NP	B
and	CC	O	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
.	.	O	O

HOMER1	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
protein	NN	I-NP	O
with	IN	B-PP	O
pivotal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
glutamate	NN	B-NP	O
transmission	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigates	VBZ	B-VP	O
whether	IN	B-SBAR	O
polymorphisms	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
HOMER1	NN	I-NP	O
gene	NN	I-NP	O
promoter	NN	I-NP	O
region	NN	I-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
Parkinson	NNP	I-NP	I
s	NNS	I-NP	I
disease	NN	I-NP	I
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
genotyped	VBN	I-VP	O
for	IN	B-PP	O
rs4704559	NN	B-NP	O
,	,	I-NP	O
rs10942891	NN	I-NP	O
and	CC	I-NP	O
rs4704560	NN	I-NP	O
by	IN	B-PP	O
allelic	JJ	B-NP	O
discrimination	NN	I-NP	O
with	IN	B-PP	O
Taqman	NN	B-NP	O
assays	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rs4704559	NN	I-NP	O
G	NN	I-NP	O
allele	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
dyskinesia	NN	B-NP	B
(	(	O	O
prevalence	NN	B-NP	O
ratio	NN	I-NP	O
(	(	O	O
PR	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
and	CC	O	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
HOMER1	NN	B-NP	O
rs4704559	NN	I-NP	O
G	NN	I-NP	O
allele	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Crocin	NN	B-NP	O
improves	VBZ	B-VP	O
lipid	NN	B-NP	O
dysregulation	NN	I-NP	O
in	IN	B-PP	O
subacute	JJ	B-NP	O
diazinon	NN	I-NP	O
exposure	NN	I-NP	O
through	IN	B-PP	O
ERK1	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
pathway	NN	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
liver	NN	I-NP	O
.	.	O	O

Diazinon	NNP	B-NP	O
Yis	NNP	I-NP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
broadly	RB	I-NP	O
used	VBN	I-NP	O
organophosphorus	NN	I-NP	O
insecticides	NNS	I-NP	O
in	IN	B-PP	O
agriculture	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
exposure	NN	B-NP	O
to	TO	B-PP	O
diazinon	NN	B-NP	O
may	MD	B-VP	O
interfere	VB	I-VP	O
with	IN	B-PP	O
lipid	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
hypolipidemic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
crocin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
established	VBN	I-VP	O
.	.	O	O

Earlier	JJR	B-NP	O
studies	NNS	I-NP	O
revealed	VBD	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Extracellular	JJ	B-NP	O
signal	NN	I-NP	O
-	HYPH	B-NP	O
regulated	VBN	I-NP	O
kinase	NN	I-NP	O
(	(	O	O
ERK	NN	B-NP	O
)	)	O	O
pathways	NNS	B-NP	O
in	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
LDLr	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
metabolism	NN	I-NP	O
,	,	O	O
ERK	NN	B-NP	O
and	CC	O	O
LDLr	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
subacute	JJ	B-NP	O
diazinon	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
ameliorating	VBG	B-VP	O
effect	NN	B-NP	O
of	IN	B-PP	O
crocin	NN	B-NP	O
on	IN	B-PP	O
diazinon	NN	B-NP	O
induced	VBD	B-VP	O
disturbed	JJ	B-NP	O
cholesterol	NN	I-NP	O
homeostasis	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
Rats	NNS	I-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
and	CC	O	O
received	VBD	B-VP	O
following	VBG	B-PP	O
treatments	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
;	:	O	O
Corn	NN	B-NP	O
oil	NN	I-NP	O
(	(	O	O
control	NN	B-NP	O
)	)	O	O
,	,	O	O
diazinon	NN	B-NP	O
and	CC	I-NP	O
crocin	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
diazinon	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
cholesterol	NN	B-NP	O
,	,	O	O
triglyceride	NN	B-NP	O
and	CC	I-NP	O
LDL	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

Moreover	RB	B-ADVP	O
mRNA	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
LDLr	NN	B-NP	O
and	CC	I-NP	O
ERK1	NN	I-NP	O
/	SYM	O	O
num	CD	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
protein	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
and	CC	I-NP	O
activated	JJ	I-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
ERK1	NN	B-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
liver	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
Western	JJ	B-NP	O
blotting	NN	I-NP	O
and	CC	O	O
quantitative	JJ	B-NP	O
real	JJ	I-NP	O
time	NN	I-NP	O
polymerase	NN	I-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
subacute	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-VP	O
diazinon	VB	I-VP	O
significantly	RB	B-NP	O
increased	VBN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
cholesterol	NN	B-NP	O
,	,	O	O
triglyceride	NN	B-NP	O
and	CC	I-NP	O
LDL	NN	I-NP	O
.	.	O	O

Moreover	RB	B-NP	O
diazinon	NN	I-NP	O
decreased	VBD	B-VP	O
ERK1	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
protein	NN	I-NP	O
phosphorylation	NN	I-NP	O
and	CC	O	O
LDLr	NN	B-NP	O
transcript	NN	I-NP	O
.	.	O	O

Crocin	NN	B-NP	O
reduced	VBD	B-VP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
ERK	NN	B-NP	O
activation	NN	I-NP	O
and	CC	O	O
diazinon	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperlipemia	NN	I-NP	B
and	CC	O	O
increased	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
LDLr	NN	B-NP	O
transcript	NN	I-NP	O
.	.	O	O

Crocin	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
protective	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
diazinon	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperlipemia	NN	I-NP	B
through	IN	B-PP	O
modulating	NN	B-NP	O
of	IN	B-PP	O
ERK	NN	B-NP	O
pathway	NN	I-NP	O
and	CC	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
LDLr	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

GEM	NN	B-NP	O
-	HYPH	I-NP	O
P	NN	I-NP	O
chemotherapy	NN	I-NP	O
is	VBZ	B-VP	O
active	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
relapsed	VBN	B-NP	O
Hodgkin	NN	I-NP	B
lymphoma	NN	I-NP	I
.	.	O	O

Hodgkin	NN	B-NP	B
lymphoma	NN	I-NP	I
(	(	O	O
HL	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
chemosensitive	JJ	I-NP	O
malignancy	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
relapse	NN	B-NP	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
chemotherapy	NN	I-NP	O
with	IN	B-PP	O
autologous	JJ	B-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplant	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
which	WDT	B-NP	O
relies	VBZ	B-VP	O
on	IN	B-PP	O
adequate	JJ	B-NP	O
disease	NN	I-NP	O
control	NN	I-NP	O
with	IN	B-PP	O
salvage	NN	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Regimens	NNS	B-NP	O
commonly	RB	B-VP	O
used	VBN	I-VP	O
often	RB	B-ADVP	O
require	VBP	B-VP	O
inpatient	NN	B-NP	O
administration	NN	I-NP	O
and	CC	O	O
can	MD	B-VP	O
be	VB	I-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
deliver	VB	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

Gemcitabine	NN	B-NP	O
and	CC	I-NP	O
cisplatin	NN	I-NP	O
have	VBP	B-VP	O
activity	NN	B-NP	O
in	IN	B-PP	O
HL	NN	B-NP	B
,	,	O	O
non	AFX	O	O
-	HYPH	O	O
overlapping	VBG	B-VP	O
toxicity	NN	B-NP	B
with	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
chemotherapeutics	NNS	I-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
delivered	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
setting	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
retrospective	JJ	I-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
centre	NN	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
relapsed	JJ	B-NP	O
or	CC	I-NP	O
refractory	JJ	I-NP	O
HL	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
gemcitabine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m	NN	B-NP	O
day	NN	I-NP	O
(	(	O	O
D	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
D8	NN	I-NP	O
and	CC	I-NP	O
D15	NN	I-NP	O
;	:	O	O
methylprednisolone	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
D1	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
;	:	O	O
and	CC	O	O
cisplatin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
D15	NN	I-NP	O
,	,	O	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
(	(	O	O
GEM	NN	B-NP	O
-	HYPH	I-NP	O
P	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

Demographic	JJ	B-NP	O
,	,	I-NP	O
survival	NN	I-NP	O
,	,	I-NP	O
response	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
data	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
eligible	JJ	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
:	:	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
GEM	NN	B-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
total	NN	B-NP	O
(	(	O	O
median	NN	B-NP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
;	:	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
GEM	NN	B-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
as	IN	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
treatment	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
as	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Overall	JJ	B-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
ORR	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
GEM	NN	B-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
cohort	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
complete	JJ	B-NP	O
response	NN	I-NP	O
(	(	O	O
CR	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
partial	JJ	B-NP	O
response	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
with	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
CR	NN	I-NP	O
confirmed	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
metabolic	JJ	I-NP	O
CR	NN	I-NP	O
on	IN	B-PP	O
PET	NN	B-NP	O
and	CC	I-NP	O
ORR	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
haematological	JJ	B-ADJP	O
:	:	O	O
neutropenia	NN	B-NP	B
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
from	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
GEM	NN	B-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
GEM	NN	B-NP	O
-	HYPH	I-NP	O
P	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
progression	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
(	(	O	O
CI	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
overall	JJ	I-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
proceeded	VBD	B-VP	O
directly	RB	B-ADVP	O
to	TO	B-PP	O
autologous	JJ	B-NP	O
transplant	NN	I-NP	O
.	.	O	O

GEM	NN	B-NP	O
-	HYPH	I-NP	O
P	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
salvage	NN	I-NP	O
chemotherapy	NN	I-NP	O
with	IN	B-PP	O
relatively	RB	B-NP	O
high	JJ	I-NP	O
response	NN	I-NP	O
rates	NNS	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
successful	JJ	B-NP	O
transplantation	NN	I-NP	O
in	IN	B-PP	O
appropriate	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
relapsed	JJ	B-NP	O
or	CC	I-NP	O
refractory	JJ	I-NP	O
HL	NN	I-NP	B
.	.	O	O

Basal	JJ	B-NP	O
functioning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypothalamic	JJ	I-NP	O
-	HYPH	I-NP	O
pituitary	JJ	I-NP	O
-	HYPH	I-NP	O
adrenal	JJ	I-NP	O
(	(	O	O
HPA	JJ	B-ADJP	O
)	)	O	O
axis	NN	B-NP	O
and	CC	O	O
psychological	JJ	B-NP	O
distress	NN	I-NP	O
in	IN	B-PP	O
recreational	JJ	B-NP	O
ecstasy	JJ	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

Ecstasy	NN	B-NP	O
(	(	O	O
MDMA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
psychostimulant	JJ	I-NP	O
drug	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
increasingly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
psychobiological	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

While	IN	B-SBAR	O
some	DT	B-NP	O
recent	JJ	I-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
acute	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
neuroendocrine	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
less	JJR	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
about	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
HPA	NN	B-NP	O
functionality	NN	I-NP	O
in	IN	B-PP	O
recreational	JJ	B-NP	O
users	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ecstasy	JJ	B-NP	O
-	HYPH	I-NP	O
polydrug	NN	I-NP	O
use	NN	I-NP	O
on	IN	B-PP	O
psychological	JJ	B-NP	O
distress	NN	I-NP	O
and	CC	O	O
basal	JJ	B-NP	O
functioning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
HPA	JJ	I-NP	O
axis	NN	I-NP	O
through	IN	B-PP	O
assessing	VBG	B-VP	O
the	DT	B-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
cortisol	NN	B-NP	O
across	IN	B-PP	O
the	DT	B-NP	O
diurnal	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
participants	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
nonusers	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
light	JJ	I-NP	O
ecstasy	JJ	I-NP	O
-	HYPH	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
heavy	JJ	I-NP	O
ecstasy	JJ	I-NP	O
-	HYPH	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
)	)	O	O
completed	VBD	B-VP	O
a	DT	B-NP	O
substance	NN	I-NP	O
use	NN	I-NP	O
inventory	NN	I-NP	O
and	CC	I-NP	O
measures	NNS	I-NP	O
of	IN	B-PP	O
psychological	JJ	B-NP	O
distress	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
then	RB	O	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
cortisol	NN	B-NP	O
sampling	NN	I-NP	O
(	(	O	O
on	IN	B-PP	O
awakening	VBG	B-VP	O
,	,	O	O
num	CD	B-NP	O
min	NN	I-NP	O
post	NN	I-NP	O
awakening	NN	I-NP	O
,	,	O	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
and	CC	O	O
pre	JJ	B-NP	O
bedtime	NN	I-NP	O
)	)	O	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	B-NP	O
participants	NNS	I-NP	O
also	RB	B-ADVP	O
attended	VBD	B-VP	O
the	DT	B-NP	O
laboratory	NN	I-NP	O
to	TO	B-VP	O
complete	VB	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
multitasking	JJ	I-NP	O
stressor	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
user	NN	I-NP	O
groups	NNS	I-NP	O
exhibited	VBD	B-VP	O
significantly	RB	B-NP	O
greater	JJR	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
anxiety	NN	B-NP	B
and	CC	I-NP	O
depression	NN	I-NP	B
than	IN	B-PP	O
nonusers	NNS	B-NP	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
all	DT	B-NP	O
participants	NNS	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
cortisol	NN	I-NP	O
profile	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
light	JJ	B-NP	O
users	NNS	I-NP	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
elevated	JJ	I-NP	O
levels	NNS	I-NP	O
pre	AFX	O	O
-	HYPH	O	O
bed	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
heavy	JJ	I-NP	O
users	NNS	I-NP	O
demonstrated	VBD	B-VP	O
elevated	JJ	B-NP	O
levels	NNS	I-NP	O
upon	IN	B-PP	O
awakening	VBG	B-VP	O
and	CC	O	O
all	DT	B-NP	O
ecstasy	JJ	I-NP	O
-	HYPH	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
demonstrated	VBD	B-VP	O
elevated	VBN	I-VP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
bed	NN	I-NP	O
levels	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
users	NNS	I-NP	O
.	.	O	O

Significant	JJ	B-ADJP	O
between	IN	B-PP	O
group	NN	B-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
afternoon	NN	B-NP	O
cortisol	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
overall	JJ	B-NP	O
cortisol	NN	I-NP	O
secretion	NN	I-NP	O
across	IN	B-PP	O
the	DT	B-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
anxiety	NN	B-NP	B
and	CC	I-NP	O
depression	NN	I-NP	B
are	VBP	B-VP	O
in	IN	B-PP	O
line	NN	B-NP	O
with	IN	B-PP	O
previous	JJ	B-NP	O
observations	NNS	I-NP	O
in	IN	B-PP	O
recreational	JJ	B-NP	O
ecstasy	JJ	I-NP	O
-	HYPH	I-NP	O
polydrug	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

Dysregulated	VBN	B-NP	O
diurnal	JJ	I-NP	O
cortisol	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
inappropriate	JJ	B-NP	O
anticipation	NN	I-NP	O
of	IN	B-PP	O
forthcoming	JJ	B-NP	O
demands	NNS	I-NP	O
and	CC	I-NP	O
hypersecretion	NN	I-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
psychological	JJ	I-NP	O
and	CC	I-NP	O
physical	JJ	I-NP	O
morbidity	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
heavy	JJ	B-NP	O
recreational	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
ecstasy	NN	B-NP	O
.	.	O	O

Ifosfamide	NN	B-NP	O
related	JJ	I-NP	O
encephalopathy	NN	I-NP	B
:	:	O	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
timely	JJ	I-NP	O
EEG	NN	I-NP	O
evaluation	NN	I-NP	O
.	.	O	O

Ifosfamide	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
alkylating	VBG	I-NP	O
agent	NN	I-NP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
cancers	NNS	B-NP	B
including	VBG	B-PP	O
sarcomas	NNS	B-NP	B
,	,	O	O
lymphoma	NN	B-NP	B
,	,	O	O
gynecologic	JJ	B-NP	B
and	CC	I-NP	I
testicular	JJ	I-NP	I
cancers	NNS	I-NP	I
.	.	O	O

Encephalopathy	NN	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
ifosfamide	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
highlight	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
electroencephalogram	NN	B-NP	O
(	(	O	O
EEG	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
detection	NN	I-NP	O
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
related	JJ	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

Retrospective	JJ	B-NP	O
chart	NN	I-NP	O
review	NN	I-NP	O
including	VBG	B-PP	O
clinical	JJ	B-NP	O
data	NNS	I-NP	O
and	CC	I-NP	O
EEG	NN	I-NP	O
recordings	NNS	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
MD	NNP	B-NP	O
Anderson	NNP	I-NP	O
Cancer	NNP	I-NP	B
Center	NNP	I-NP	O
between	IN	B-PP	O
years	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
ifosfamide	NN	B-NP	O
related	JJ	I-NP	O
acute	JJ	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
encephalopathy	NN	B-NP	B
soon	RB	B-ADVP	O
after	IN	B-SBAR	O
(	(	O	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
receiving	VBG	B-VP	O
ifosfamide	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
generalized	VBN	B-NP	O
convulsions	NNS	I-NP	B
while	IN	B-SBAR	O
num	CD	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
continuous	JJ	B-NP	O
non	AFX	I-NP	B
-	HYPH	I-NP	I
convulsive	JJ	I-NP	I
status	NN	I-NP	I
epilepticus	NN	I-NP	I
(	(	O	O
NCSE	NN	B-NP	B
)	)	O	O
that	WDT	B-NP	O
required	VBD	B-VP	O
ICU	NN	B-NP	O
admission	NN	I-NP	O
and	CC	I-NP	O
intubation	NN	I-NP	O
.	.	O	O

Initial	JJ	B-NP	O
EEG	NN	I-NP	O
showed	VBD	B-VP	O
epileptiform	NN	B-NP	O
discharges	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
run	NN	B-NP	O
of	IN	B-PP	O
triphasic	JJ	B-NP	O
waves	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
moderate	JJ	B-NP	O
degree	NN	I-NP	O
diffuse	JJ	B-ADJP	O
generalized	VBN	B-VP	O
slowing	VBG	B-VP	O
.	.	O	O

Mixed	VBN	B-NP	O
pattern	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
sharps	NNS	I-NP	O
and	CC	O	O
triphasic	JJ	B-NP	O
waves	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
noted	VBN	I-VP	O
.	.	O	O

Repeat	NN	B-NP	O
EEGs	NNS	I-NP	O
within	IN	B-PP	O
24_h	NN	B-NP	O
of	IN	B-PP	O
symptom	NN	B-NP	O
onset	NN	I-NP	O
showed	VBD	B-VP	O
marked	JJ	B-NP	O
improvement	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
improvement	NN	I-NP	O
.	.	O	O

Severity	NN	B-NP	O
of	IN	B-PP	O
ifosfamide	NN	B-NP	O
related	JJ	I-NP	O
encephalopathy	NN	I-NP	B
correlates	VBZ	B-VP	O
with	IN	B-PP	O
EEG	NN	B-NP	O
changes	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
timely	JJ	I-NP	O
EEG	NN	I-NP	O
evaluation	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
ifosfamide	NN	B-NP	O
who	WP	B-NP	O
develop	VBP	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
encephalopathy	NN	B-NP	B
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
hospitalised	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
and	CC	O	O
possible	JJ	B-NP	O
factors	NNS	I-NP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
contrast	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephropathy	NN	I-NP	B
(	(	O	O
CIN	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
hospitalised	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
were	VBD	B-VP	O
excluded	VBN	I-VP	O
.	.	O	O

Blood	NN	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
the	DT	B-NP	O
day	NN	I-NP	O
before	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	O	O
enhanced	VBN	B-VP	O
computed	VBN	B-NP	O
tomography	NN	I-NP	O
(	(	O	O
CT	NN	B-NP	O
)	)	O	O
and	CC	O	O
serially	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
thereafter	RB	B-ADVP	O
.	.	O	O

CIN	NN	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
(	(	O	O
Cr	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
,	,	O	O
or	CC	O	O
elevation	NN	B-NP	O
of	IN	B-PP	O
Cr	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
over	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Relationships	NNS	B-NP	O
between	IN	B-PP	O
CIN	NN	B-NP	O
and	CC	O	O
possible	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

CIN	NN	B-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

CIN	NN	B-NP	O
developed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
chemotherapy	NN	B-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
.	.	O	O

CIN	NN	B-NP	O
more	RBR	B-VP	O
frequently	RB	I-VP	O
developed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
CT	NN	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
chemotherapy	NN	I-NP	O
;	:	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
an	DT	B-NP	O
independent	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
.	.	O	O

CIN	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	JJR	I-ADJP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
bevacizumab	NN	B-NP	O
/	SYM	B-NP	O
irinotecan	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
CIN	NN	B-NP	O
after	IN	B-PP	O
CT	NN	B-NP	O
in	IN	B-PP	O
hospitalised	JJ	B-NP	O
oncological	JJ	I-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

CIN	NN	B-NP	O
developed	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	O	O
times	NNS	B-NP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cancer	NN	B-NP	B
who	WP	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
recent	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
bevacizumab	NN	B-NP	O
/	SYM	O	O
irinotecan	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
additional	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
CIN	NN	B-NP	O
development	NN	I-NP	O
.	.	O	O

.	.	O	O

Contrast	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
nephropathy	NN	I-NP	B
(	(	O	O
CIN	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
concern	NN	I-NP	O
for	IN	B-PP	O
oncological	JJ	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
CT.	NNP	B-NP	O
.	.	O	O

CIN	NN	B-NP	O
occurs	VBZ	B-VP	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
when	WRB	B-ADVP	O
CT	NN	B-NP	O
is	VBZ	B-VP	O
performed	VBN	I-VP	O
<	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
chemotherapy.	NN	B-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
and	CC	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
bevacizumab	NN	B-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
additional	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Syndrome	NN	B-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
antidiuretic	JJ	I-NP	I
hormone	NN	I-NP	I
secretion	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
desvenlafaxine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
syndrome	NN	B-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
anti	AFX	I-NP	I
-	HYPH	I-NP	I
diuretic	JJ	I-NP	I
hormone	NN	I-NP	I
(	(	O	O
SIADH	NN	B-NP	B
)	)	O	O
secretion	NN	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
desvenlafaxine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
female	NN	I-NP	O
with	IN	B-PP	O
hyponatraemia	NN	B-NP	B
.	.	O	O

Her	PRP$	B-NP	O
medications	NNS	I-NP	O
included	VBD	B-VP	O
desvenlafaxine	NN	B-NP	O
,	,	O	O
and	CC	O	O
symptoms	NNS	B-NP	O
included	VBD	B-VP	O
nausea	NN	B-NP	B
,	,	I-NP	O
anxiety	NN	I-NP	B
and	CC	I-NP	O
confusion	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
sodium	NN	I-NP	O
at	IN	B-PP	O
this	DT	B-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
osmolality	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mosmol	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
,	,	O	O
urine	NN	B-NP	O
osmolality	NN	I-NP	O
num	CD	I-NP	O
mosmol	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
sodium	NN	I-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
SIADH	NN	B-NP	B
.	.	O	O

Desvenlafaxine	NN	B-NP	O
was	VBD	B-VP	O
ceased	VBN	I-VP	O
and	CC	O	O
fluid	NN	B-NP	O
restriction	NN	I-NP	O
implemented	VBD	B-VP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
the	DT	B-NP	O
sodium	NN	I-NP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mmol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
and	CC	I-NP	O
fluid	NN	I-NP	O
restriction	NN	I-NP	O
was	VBD	B-VP	O
relaxed	VBN	I-VP	O
.	.	O	O

During	IN	B-PP	O
her	PRP$	B-NP	O
further	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
inpatient	JJ	I-NP	O
admission	NN	I-NP	O
the	DT	B-NP	O
serum	NN	I-NP	O
sodium	NN	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
mirtazapine	NN	B-NP	O
.	.	O	O

SIADH	NN	B-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
widely	RB	I-VP	O
reported	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
antidepressants	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
desvenlafaxine	NN	B-NP	O
might	MD	B-VP	O
cause	VB	I-VP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
hyponatremia	NN	I-NP	B
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
antidepressants	NNS	B-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
hyponatremia	NN	B-NP	B
,	,	O	O
and	CC	O	O
take	VB	B-VP	O
appropriate	JJ	B-NP	O
corrective	JJ	I-NP	O
action	NN	I-NP	O
where	WRB	B-ADVP	O
necessary	JJ	B-ADJP	O
.	.	O	O

Oxidative	JJ	B-NP	O
stress	NN	I-NP	O
on	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
single	JJ	B-NP	O
and	CC	I-NP	O
multiple	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
remains	VBZ	B-VP	O
controversial	JJ	B-ADJP	O
.	.	O	O

Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
DOX	NN	B-NP	O
injections	NNS	I-NP	O
intraperitoneally	RB	B-ADVP	O
and	CC	O	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
experimental	JJ	I-NP	O
protocols	NNS	I-NP	O
:	:	O	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
before	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
DOX	NN	I-NP	O
acute	JJ	I-NP	O
effect	NN	I-NP	O
and	CC	I-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
and	CC	O	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
injection	NN	I-NP	O
(	(	O	O
M0	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
week	NN	I-NP	O
after	IN	B-SBAR	O
each	DT	B-NP	O
injection	NN	I-NP	O
(	(	O	O
M1	NN	B-NP	O
,	,	O	O
M2	NN	B-NP	O
,	,	O	O
M3	NN	B-NP	O
,	,	O	O
and	CC	O	O
M4	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
chronological	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
used	VBN	B-VP	O
at	IN	B-PP	O
M0	NN	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
used	VBN	I-VP	O
at	IN	B-PP	O
moment	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
total	JJ	I-NP	O
antioxidant	JJ	I-NP	O
performance	NN	I-NP	O
(	(	O	O
TAP	NN	B-NP	O
)	)	O	O
,	,	O	O
DNA	NN	B-NP	O
damage	NN	I-NP	O
,	,	O	O
and	CC	O	O
morphology	NN	B-NP	O
analyses	NNS	I-NP	O
were	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
at	IN	B-PP	O
each	DT	B-NP	O
time	NN	I-NP	O
point	NN	I-NP	O
.	.	O	O

Single	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
cardiac	JJ	I-NP	B
disarrangement	NN	I-NP	I
,	,	O	O
necrosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
DNA	NN	B-NP	O
damage	NN	I-NP	O
(	(	O	O
strand	NN	B-NP	O
breaks	NNS	I-NP	O
(	(	O	O
SBs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
oxidized	VBN	B-NP	O
pyrimidines	NNS	I-NP	O
)	)	O	O
and	CC	O	O
decreased	VBN	B-NP	O
TAP	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
chronological	JJ	I-NP	O
study	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
on	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
necrosis	NN	B-NP	B
,	,	O	O
TAP	NN	B-NP	O
,	,	O	O
and	CC	O	O
DNA	NN	B-NP	O
SBs	NNS	I-NP	O
.	.	O	O

DNA	NN	B-NP	O
SBs	NNS	I-NP	O
damage	NN	I-NP	O
was	VBD	B-VP	O
negatively	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
TAP	NN	B-NP	O
,	,	O	O
and	CC	O	O
necrosis	NN	B-NP	B
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

Increased	VBN	B-NP	O
resistance	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
is	VBZ	B-VP	O
plausible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
different	JJ	B-NP	O
mechanisms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
toxicity	NN	I-NP	B
versus	IN	B-PP	O
chronic	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Tacrolimus	NN	B-NP	O
-	HYPH	B-PP	O
related	VBN	B-NP	O
seizure	NN	I-NP	B
after	IN	B-PP	O
pediatric	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
-	HYPH	B-VP	O
-	:	O	O
a	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
center	NN	I-NP	O
experience	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
new	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
seizures	NNS	I-NP	B
after	IN	B-PP	O
pediatric	JJ	B-NP	O
LT	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
assess	VB	I-VP	O
their	PRP$	B-NP	O
clinical	JJ	I-NP	O
implications	NNS	I-NP	O
and	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
prognosis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
data	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
children	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
LT	NNP	B-NP	O
from	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
center	NN	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
retrospectively	RB	B-ADVP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
seizures	NNS	B-NP	B
group	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
seizures	NNS	I-NP	B
group	NN	I-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	B-ADJP	O
,	,	O	O
intra	AFX	O	O
-	HYPH	O	O
operative	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	B-NP	O
data	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
.	.	O	O

Seizures	NNS	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
exhibited	VBD	B-VP	O
generalized	VBN	I-VP	O
tonic	JJ	B-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizures	NNS	I-NP	I
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
wk	NN	I-NP	O
after	IN	B-PP	O
LT	NN	B-NP	O
.	.	O	O

Univariate	JJ	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
seizures	NNS	B-NP	B
after	IN	B-PP	O
pediatric	JJ	B-NP	O
LT	NN	I-NP	O
included	VBD	B-VP	O
gender	NN	B-NP	O
,	,	O	O
pediatric	JJ	B-NP	O
end	NN	I-NP	B
-	HYPH	O	I
stage	NN	B-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
score	NN	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
Child	NNP	B-NP	O
-	HYPH	I-NP	O
Pugh	NNP	I-NP	O
score	NN	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
total	JJ	I-NP	O
bilirubin	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
,	,	O	O
and	CC	O	O
trough	NN	B-NP	O
TAC	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
trough	NN	B-NP	O
TAC	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
independent	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

All	DT	B-NP	O
children	NNS	I-NP	O
who	WP	B-NP	O
experienced	VBD	B-VP	O
seizures	NNS	B-NP	B
survived	VBN	B-VP	O
with	IN	B-PP	O
good	JJ	B-NP	O
graft	NN	I-NP	O
function	NN	I-NP	O
and	CC	O	O
remained	VBD	B-VP	O
seizure	NN	B-NP	B
-	HYPH	B-ADJP	O
free	JJ	I-ADJP	O
without	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
epileptic	JJ	I-NP	B
drugs	NNS	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
trough	NN	I-NP	O
TAC	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
predominant	JJ	I-NP	O
factor	NN	I-NP	O
that	WDT	B-NP	O
contributed	VBD	B-VP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
period	NN	I-NP	O
after	IN	B-PP	O
pediatric	JJ	B-NP	O
LT	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
PELD	NN	I-NP	O
and	CC	O	O
Child	NNP	B-NP	O
-	HYPH	I-NP	O
Pugh	NNP	I-NP	O
scores	NNS	I-NP	O
before	IN	B-PP	O
LT	NN	B-NP	O
and	CC	O	O
high	JJ	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
serum	NN	I-NP	O
Tbil	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
contributory	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
TAC	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
flavonoid	JJ	I-NP	O
apigenin	NN	I-NP	O
delays	VBZ	B-VP	O
forgetting	NN	B-NP	O
of	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
conditioning	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
experiments	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
flavonoid	NN	I-NP	O
apigenin	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
intraperitoneally	RB	B-ADVP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
h	NN	I-NP	O
before	IN	B-PP	O
acquisition	NN	B-NP	O
)	)	O	O
,	,	O	O
on	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
retention	NN	I-NP	O
performance	NN	I-NP	O
and	CC	O	O
forgetting	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
step	NN	I-NP	O
-	HYPH	B-VP	O
through	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
young	JJ	B-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
apigenin	NN	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
retention	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
apigenin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
amnesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
saline	NN	I-NP	O
-	HYPH	B-ADVP	O
and	CC	I-ADVP	O
apigenin	NN	I-ADVP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
step	VB	I-VP	O
through	RP	B-PRT	O
into	IN	B-PP	O
the	DT	B-NP	O
dark	JJ	I-NP	O
compartment	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
cut	VB	I-NP	O
-	HYPH	B-VP	O
off	RP	B-PRT	O
time	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
s	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
retested	VBN	I-VP	O
weekly	RB	B-ADVP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
treated	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
significant	JJ	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
and	CC	O	O
complete	JJ	B-NP	O
memory	NN	I-NP	B
loss	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
acquisition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
period	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
apigenin	NN	B-NP	O
still	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
step	VB	I-VP	O
through	IN	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
)	)	O	O
apigenin	NN	B-NP	O
delays	VBZ	B-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
forgetting	NN	I-NP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
modulate	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
retention	NN	I-NP	O
of	IN	B-PP	O
fear	NN	B-NP	O
memory	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
the	DT	B-NP	O
obtained	VBN	I-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
apigenin	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
conditioning	NN	I-NP	O
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
mechanisms	NNS	B-NP	O
that	WDT	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
implicate	VB	I-VP	O
its	PRP$	B-NP	O
action	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
muscarinic	JJ	I-NP	O
cholinergic	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Cholecystokinin	NN	B-NP	O
-	HYPH	I-NP	O
octapeptide	NN	I-NP	O
restored	VBD	B-VP	O
morphine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hippocampal	JJ	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
potentiation	NN	I-NP	O
impairment	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Cholecystokinin	NN	B-NP	O
-	HYPH	O	O
octapeptide	NN	B-NP	O
(	(	O	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
brain	NN	I-NP	O
-	HYPH	I-NP	O
gut	NN	I-NP	O
peptide	NN	I-NP	O
,	,	O	O
exerts	VBZ	B-VP	O
a	DT	B-NP	O
wide	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
biological	JJ	B-NP	O
activities	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
previously	RB	I-VP	O
reported	VBN	I-VP	O
that	IN	B-SBAR	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
significantly	RB	I-NP	O
alleviated	VBN	I-NP	O
morphine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
amnesia	NN	I-NP	B
and	CC	O	O
reversed	VBD	B-VP	O
spine	NN	B-NP	O
density	NN	I-NP	O
decreases	VBZ	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
CA1	NN	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
in	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
potentiation	NN	I-NP	O
(	(	O	O
LTP	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
perforant	JJ	I-NP	O
path	NN	I-NP	O
(	(	O	O
LPP	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
synapse	NN	I-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
(	(	O	O
DG	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
acute	JJ	B-NP	O
saline	NN	I-NP	O
or	CC	I-NP	O
morphine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Population	NN	B-NP	O
spikes	NNS	I-NP	O
(	(	O	O
PS	NNS	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
evoked	VBN	I-VP	O
by	IN	B-PP	O
stimulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LPP	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
DG	NN	I-NP	O
region	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
morphine	NN	I-NP	O
treatment	NN	I-NP	O
significantly	RB	B-ADVP	O
attenuated	VBD	B-VP	O
hippocampal	JJ	B-NP	O
LTP	NN	I-NP	O
and	CC	I-NP	O
CCK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
1ug	NN	B-NP	O
,	,	O	O
i.c.v.	JJ	B-ADJP	O
)	)	O	O
restored	VBD	B-VP	O
the	DT	B-NP	O
amplitude	NN	I-NP	O
of	IN	B-PP	O
PS	NNP	B-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
,	,	O	O
i.c.v.	JJ	B-ADJP	O
)	)	O	O
also	RB	B-ADVP	O
significantly	RB	B-ADVP	O
augmented	VBD	B-VP	O
hippocampal	JJ	B-NP	O
LTP	NN	I-NP	O
in	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
CCK2	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
L	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
,	,	O	O
i.c.v	JJ	B-ADJP	O
)	)	O	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
but	CC	O	O
the	DT	B-NP	O
CCK1	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
L	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
,	,	O	O
i.c.v	JJ	B-ADJP	O
)	)	O	O
did	VBD	B-VP	O
not	RB	O	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
attenuates	VBZ	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
on	IN	B-PP	O
hippocampal	JJ	B-NP	O
LTP	NN	I-NP	O
through	IN	B-PP	O
CCK2	NN	B-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
suggest	VBP	B-VP	O
an	DT	B-NP	O
ameliorative	JJ	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
memory	NN	I-NP	B
impairment	NN	I-NP	I
.	.	O	O

Glial	JJ	B-NP	O
activation	NN	I-NP	O
and	CC	O	O
post	AFX	O	O
-	HYPH	O	O
synaptic	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
:	:	O	O
the	DT	B-NP	O
key	JJ	I-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
Streptozotocin	NN	B-NP	O
(	(	O	O
ICV	NN	B-NP	O
)	)	O	O
induced	VBD	B-VP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
glial	JJ	B-NP	O
activation	NN	I-NP	O
and	CC	O	O
post	NN	B-NP	O
synaptic	JJ	I-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
ICV	NN	B-NP	O
Streptozotocin	NN	I-NP	O
(	(	O	O
STZ	NN	B-NP	O
)	)	O	O
induced	VBD	B-VP	O
memory	NN	B-NP	B
impaired	JJ	I-NP	I
rats	NNS	I-NP	O
was	VBD	B-VP	O
explored	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
experiment	NN	B-NP	O
set	VBN	B-VP	O
up	RP	B-PRT	O
num	CD	B-NP	O
:	:	O	O
Memory	NN	B-NP	B
deficit	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
Morris	NNP	B-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
test	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
STZ	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

STZ	NN	B-NP	O
causes	VBZ	B-VP	O
increased	VBN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
GFAP	NN	B-NP	O
,	,	I-NP	O
CD11b	NN	I-NP	O
and	CC	I-NP	O
TNF	NN	I-NP	O
-	:	O	O
a	DT	B-NP	O
indicating	VBG	I-NP	O
glial	JJ	I-NP	O
activation	NN	I-NP	O
and	CC	I-NP	O
neuroinflammation	NN	I-NP	B
.	.	O	O

STZ	NN	B-NP	O
also	RB	B-ADVP	O
significantly	RB	B-VP	O
increased	VBD	I-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
ROS	NN	B-NP	O
,	,	O	O
nitrite	NN	B-NP	O
,	,	O	O
Ca	NN	B-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
mitochondrial	JJ	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
synaptosomal	JJ	B-NP	O
preparation	NN	I-NP	O
illustrating	VBG	B-VP	O
free	JJ	B-NP	O
radical	NN	I-NP	O
generation	NN	I-NP	O
and	CC	I-NP	O
excitotoxicity	NN	I-NP	B
.	.	O	O

Increased	VBN	B-VP	O
expression	NN	B-NP	O
and	CC	O	O
activity	NN	B-NP	O
of	IN	B-PP	O
Caspase	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
STZ	NN	B-NP	O
treated	JJ	I-NP	O
rat	NN	I-NP	O
which	WDT	B-NP	O
specify	VBP	B-VP	O
apoptotic	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
hippocampus	NN	B-NP	O
and	CC	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

STZ	NN	B-NP	O
treatment	NN	I-NP	O
showed	VBD	B-VP	O
decrease	NN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
post	JJ	B-NP	O
synaptic	JJ	I-NP	O
markers	NNS	I-NP	O
CaMKIIa	NN	I-NP	O
and	CC	I-NP	O
PSD	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
while	NN	I-NP	O
,	,	O	O
expression	NN	B-NP	O
of	IN	B-PP	O
pre	JJ	B-NP	O
synaptic	JJ	I-NP	O
markers	NNS	I-NP	O
(	(	O	O
synaptophysin	NN	B-NP	O
and	CC	I-NP	O
SNAP	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
remains	VBZ	B-VP	O
unaltered	JJ	B-NP	O
indicating	VBG	I-NP	O
selective	JJ	I-NP	O
post	NN	I-NP	O
synaptic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Oral	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
Memantine	NN	B-NP	O
and	CC	I-NP	O
Ibuprofen	NN	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
attenuated	VBD	B-VP	O
STZ	NN	B-NP	O
induced	JJ	I-NP	O
glial	JJ	I-NP	O
activation	NN	I-NP	O
,	,	O	O
apoptotic	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
and	CC	O	O
post	NN	B-NP	O
synaptic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
rat	NN	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Further	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
experiment	NN	B-NP	O
set	VBN	B-VP	O
up	RP	B-PRT	O
num	CD	B-NP	O
:	:	O	O
where	WRB	B-ADVP	O
memory	NN	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
i.e.	FW	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
STZ	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
GFAP	NN	B-NP	O
,	,	O	O
CD11b	NN	B-NP	O
,	,	O	O
TNF	NN	B-NP	O
-	HYPH	I-NP	O
a	NN	I-NP	O
,	,	I-NP	O
ROS	NN	I-NP	O
and	CC	I-NP	O
nitrite	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
apoptotic	JJ	B-NP	O
marker	NN	I-NP	O
,	,	O	O
synaptic	JJ	B-NP	O
markers	NNS	I-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	I-NP	O
Ca	NN	I-NP	O
levels	NNS	I-NP	O
remained	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
.	.	O	O

Collective	JJ	B-NP	O
data	NNS	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
neuroinflammatory	JJ	B-NP	B
process	NN	I-NP	O
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
occurs	VBZ	B-VP	O
earlier	JJR	B-ADVP	O
to	TO	B-PP	O
apoptosis	NN	B-NP	O
and	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
memory	NN	B-NP	O
function	NN	I-NP	O
.	.	O	O

Present	JJ	B-NP	O
study	NN	I-NP	O
clearly	RB	B-ADVP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
glial	JJ	B-NP	O
activation	NN	I-NP	O
and	CC	O	O
post	NN	B-NP	O
synaptic	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
are	VBP	B-VP	O
the	DT	B-NP	O
key	JJ	I-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
STZ	NN	B-NP	O
induced	VBD	B-VP	O
memory	NN	B-NP	B
impairment	NN	I-NP	I
and	CC	O	O
neuronal	JJ	B-NP	O
cell	NN	I-NP	O
death	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
with	IN	B-PP	O
diltiazem	NN	B-NP	O
in	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
contrast	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Contrast	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
nephropathy	NN	I-NP	B
(	(	O	O
CIN	NN	B-NP	O
)	)	O	O
significantly	RB	B-VP	O
increases	VBZ	I-VP	O
the	DT	B-NP	O
morbidity	NN	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
and	CC	I-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
infusion	NN	I-NP	O
and	CC	O	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
diltiazem	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
CIN	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
study	NN	I-NP	O
included	VBD	B-VP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
iodinated	VBN	B-NP	O
contrast	NN	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
angiography	NN	I-NP	O
(	(	O	O
PCAG	NN	B-NP	O
)	)	O	O
,	,	O	O
all	DT	B-NP	O
with	IN	B-PP	O
creatinine	NN	B-NP	O
values	NNS	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
and	CC	O	O
each	DT	B-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
a	DT	B-NP	O
solution	NN	I-NP	O
that	IN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
dextrose	NN	I-NP	O
and	CC	I-NP	O
sodium	NN	I-NP	O
bicarbonate	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
third	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
contrast	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
third	JJ	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
diltiazem	NN	B-NP	O
the	DT	B-NP	O
day	NN	I-NP	O
before	IN	B-PP	O
and	CC	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
contrast	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
plasma	NN	B-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
(	(	O	O
BUN	NN	B-NP	O
)	)	O	O
and	CC	O	O
creatinine	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
and	CC	I-NP	O
seventh	JJ	I-NP	O
day	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
contrast	NN	I-NP	O
material	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
basal	JJ	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
included	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ARF	NN	B-NP	B
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
contrast	NN	B-NP	O
material	NN	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
ARF	NN	B-NP	B
on	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
day	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
injection	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
and	CC	O	O
the	DT	B-NP	O
third	JJ	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
,	,	O	O
sodium	NN	B-NP	O
bicarbonate	NN	I-NP	O
and	CC	O	O
isotonic	JJ	B-NP	O
sodium	NN	I-NP	O
chloride	NN	I-NP	O
with	IN	B-PP	O
diltiazem	NN	B-NP	O
application	NN	I-NP	O
in	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
CIN	NN	B-NP	O
.	.	O	O

Neurocognitive	JJ	B-NP	O
and	CC	I-NP	O
neuroradiologic	JJ	I-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
late	JJ	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
treated	VBN	B-VP	O
on	IN	B-PP	O
Pediatric	NNP	B-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
(	(	O	O
POG	NN	B-NP	O
)	)	O	O
P9605	NN	B-NP	O
(	(	O	O
standard	JJ	B-NP	O
risk	NN	I-NP	O
)	)	O	O
and	CC	O	O
P9201	NN	B-NP	O
(	(	O	O
lesser	JJR	B-NP	O
risk	NN	I-NP	O
)	)	I-NP	O
acute	JJ	I-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
protocols	NNS	I-NP	O
(	(	O	O
ACCL0131	NN	B-NP	O
)	)	O	O
:	:	O	O
a	DT	B-NP	O
methotrexate	NN	I-NP	O
consequence	NN	I-NP	O
?	.	O	O
A	NN	B-NP	O
report	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Oncology	NNP	B-NP	O
Group	NNP	I-NP	O
.	.	O	O

Concerns	NNS	B-NP	O
about	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
methotrexate	NN	I-NP	O
(	(	O	O
MTX	NN	B-NP	O
)	)	O	O
neurotoxicity	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
1990s	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
modifications	NNS	B-NP	O
in	IN	B-PP	O
intrathecal	JJ	O	O
(	(	O	O
IT	JJ	B-ADJP	O
)	)	O	O
therapy	NN	B-NP	O
,	,	O	O
leucovorin	NN	B-NP	O
rescue	NN	I-NP	O
,	,	O	O
and	CC	O	O
frequency	NN	B-NP	O
of	IN	B-PP	O
systemic	JJ	B-NP	O
MTX	NN	I-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
neurocognitive	JJ	B-NP	O
outcomes	NNS	I-NP	O
and	CC	O	O
neuroradiologic	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
leukoencephalopathy	NN	B-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
intense	JJ	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
directed	VBN	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
P9605	NN	B-NP	O
)	)	O	O
versus	IN	B-PP	O
those	DT	B-NP	O
receiving	VBG	B-VP	O
fewer	JJR	B-NP	O
CNS	NN	I-NP	O
-	HYPH	O	O
directed	VBN	B-NP	O
treatment	NN	I-NP	O
days	NNS	I-NP	O
during	IN	B-PP	O
intensive	JJ	B-NP	O
consolidation	NN	I-NP	O
(	(	O	O
P9201	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
Pediatric	NNP	I-NP	O
Oncology	NNP	I-NP	O
Group	NNP	I-NP	O
institutions	NNS	I-NP	O
with	IN	B-PP	O
standard	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
acute	JJ	I-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
at	IN	B-PP	O
diagnosis	NN	B-NP	O
,	,	O	O
without	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
CNS	NN	B-NP	O
leukemia	NN	I-NP	B
at	IN	B-PP	O
diagnosis	NN	B-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
on	IN	B-PP	O
ACCL0131	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
from	IN	B-PP	O
P9201	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
from	IN	B-PP	O
P9605	NN	B-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
scans	NNS	I-NP	O
and	CC	O	O
standard	JJ	B-NP	O
neuropsychological	JJ	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
>	SYM	B-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Significantly	RB	B-NP	O
more	JJR	I-NP	O
P9605	NN	I-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
leukoencephalopathy	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
P9201	NN	B-NP	O
patients	NNS	I-NP	O
identified	VBN	B-VP	O
as	IN	B-PP	O
late	RB	B-ADVP	O
as	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
scored	VBD	B-VP	O
<	SYM	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
either	DT	B-NP	O
Verbal	NNP	I-NP	O
or	CC	I-NP	O
Performance	NNP	I-NP	O
IQ	NNP	I-NP	O
.	.	O	O

Children	NNS	B-NP	O
on	IN	B-PP	O
both	DT	B-NP	O
studies	NNS	I-NP	O
had	VBD	B-VP	O
significant	JJ	B-NP	O
attention	NN	I-NP	B
problems	NNS	I-NP	I
,	,	O	O
but	CC	O	O
P9605	NN	B-NP	O
children	NNS	I-NP	O
scored	VBN	B-VP	O
below	IN	B-PP	O
average	NN	B-NP	O
on	IN	B-PP	O
more	RBR	B-NP	O
neurocognitive	JJ	I-NP	O
measures	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
treated	VBN	B-VP	O
on	IN	B-PP	O
P9201	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
measures	NNS	I-NP	O
vs.	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
measures	NNS	I-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
supports	VBZ	B-VP	O
ongoing	JJ	B-NP	O
concerns	NNS	I-NP	O
about	IN	B-PP	O
intensive	JJ	B-NP	O
MTX	NN	I-NP	O
exposure	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
major	JJ	I-NP	O
contributor	NN	I-NP	O
to	TO	B-PP	O
CNS	NN	B-NP	O
late	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
overdosage	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
generalized	VBN	I-NP	O
seizure	NN	I-NP	B
in	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
lady	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
kidney	NN	I-NP	I
disease	NN	I-NP	I
stage	NN	I-NP	O
num	CD	I-NP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
chronic	JJ	B-NP	O
tubulointerstial	JJ	I-NP	B
disease	NN	I-NP	I
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
center	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
anemia	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
menorrhagia	NN	B-NP	B
and	CC	I-NP	O
deterioration	NN	I-NP	B
of	IN	B-PP	I
renal	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
num	CD	B-NP	O
units	NNS	I-NP	O
of	IN	B-PP	O
packed	JJ	B-NP	O
cells	NNS	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
session	NN	I-NP	O
of	IN	B-PP	O
hemodialysis	NN	B-NP	O
.	.	O	O

Tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
TNA	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
g	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hourly	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
her	PRP	B-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
bleeding	VBG	I-VP	B
per	IN	B-PP	O
vaginum	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
sixth	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
TNA	NN	B-NP	O
,	,	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
generalized	VBN	B-NP	O
tonic	JJ	I-NP	B
clonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
.	.	O	O

TNA	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Investigations	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
biochemical	JJ	I-NP	O
or	CC	I-NP	O
structural	JJ	I-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	B
system	NN	I-NP	I
abnormalities	NNS	I-NP	I
that	WDT	B-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
provoked	VBN	I-VP	O
the	DT	B-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

She	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
any	DT	B-NP	O
further	JJ	I-NP	O
dialytic	JJ	I-NP	O
support	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
further	JJ	I-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
convulsion	NN	B-NP	B
till	IN	B-PP	O
dis	NN	B-NP	O
-	HYPH	I-NP	O
charge	NN	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
precipitating	VBG	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
was	VBD	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
overdose	NN	I-NP	B
of	IN	B-PP	O
TNA	NN	B-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiovascular	JJ	I-NP	B
depression	NN	I-NP	I
using	VBG	B-VP	O
different	JJ	B-NP	O
lipid	NN	I-NP	O
formulations	NNS	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
lipid	NN	B-NP	O
emulsions	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
lethal	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
lipid	NN	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
may	MD	B-VP	O
alleviate	VB	I-VP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
in	IN	B-PP	O
intralipid	NN	B-NP	O
or	CC	I-NP	O
medialipid	NN	I-NP	O
emulsions	NNS	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
anaesthetised	VBN	I-VP	O
with	IN	B-PP	O
ketamine	NN	B-NP	O
and	CC	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
propofol	NN	I-NP	O
in	IN	B-PP	O
intralipid	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
P	NN	I-NP	O
)	)	O	O
,	,	O	O
propofol	NN	B-NP	O
in	IN	B-PP	O
medialipid	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
saline	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
C	NN	I-NP	O
)	)	O	O
over	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

Thereafter	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	O	O
min	NN	B-NP	O
bupivacaine	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
recorded	VBD	B-VP	O
time	NN	B-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
dysrhythmia	NN	I-NP	B
occurrence	NN	I-NP	O
,	,	O	O
respective	JJ	B-NP	O
times	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
and	CC	O	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
time	NN	B-NP	O
to	TO	B-PP	O
asystole	NN	B-NP	B
and	CC	O	O
total	JJ	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
consumption	NN	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
and	CC	I-NP	O
tissue	NN	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
following	VBG	B-PP	O
asystole	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
dysrhythmia	NN	I-NP	B
occurrence	NN	I-NP	O
,	,	O	O
time	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
HR	NN	B-NP	O
,	,	O	O
and	CC	O	O
time	NN	B-NP	O
to	TO	B-PP	O
asystole	NN	B-NP	B
were	VBD	B-VP	O
longer	JJR	B-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
P	NN	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
bupivacaine	NN	I-NP	O
dose	NN	I-NP	O
given	VBN	B-VP	O
at	IN	B-PP	O
those	DT	B-NP	O
time	NN	I-NP	O
points	NNS	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
P	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
bupivacaine	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
P	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Group	NN	B-NP	O
C	NN	I-NP	O
.	.	O	O

Bupivacaine	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
P	NN	I-NP	O
and	CC	I-NP	O
Group	NN	I-NP	O
L	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Group	NN	B-NP	O
C	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
in	IN	B-PP	O
intralipid	NN	B-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
propofol	NN	B-NP	O
in	IN	B-PP	O
medialipid	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
,	,	O	O
delayed	VBD	B-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
reduced	VBN	B-NP	O
plasma	NN	I-NP	O
bupivacaine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
explore	VB	I-VP	O
tissue	NN	B-NP	O
bupivacaine	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
in	IN	B-PP	O
medialipid	NN	B-NP	O
and	CC	O	O
adapt	VB	B-VP	O
these	DT	B-NP	O
results	NNS	I-NP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	B
-	HYPH	B-VP	I
Induced	VBN	B-NP	I
Acute	JJ	I-NP	I
Liver	NN	I-NP	I
Injury	NN	I-NP	I
Within	IN	B-PP	O
num	CD	B-NP	O
Hours	NNS	I-NP	O
After	IN	B-PP	O
Fluvastatin	NN	B-NP	O
Therapy	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
statins	NNS	B-NP	O
are	VBP	B-VP	O
generally	RB	B-ADVP	O
well	RB	B-ADVP	O
-	HYPH	B-NP	O
tolerated	VBN	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
recent	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	B
-	HYPH	O	I
induced	VBN	B-NP	I
liver	NN	I-NP	I
injury	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
their	PRP$	B-NP	O
use	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Chinese	JJ	I-NP	O
man	NN	I-NP	O
reported	VBN	B-VP	O
with	IN	B-PP	O
liver	NN	B-NP	B
damage	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
appeared	VBD	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
beginning	VBG	B-VP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
fluvastatin	NN	B-NP	O
.	.	O	O

Patient	NN	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
complaints	NNS	B-NP	O
of	IN	B-PP	O
increasing	VBG	B-VP	O
nausea	NN	B-NP	B
,	,	O	O
anorexia	NN	B-NP	B
,	,	O	O
and	CC	O	O
upper	JJ	B-NP	O
abdominal	JJ	I-NP	B
pain	NN	I-NP	I
.	.	O	O

His	PRP$	B-NP	O
laboratory	NN	I-NP	O
values	NNS	I-NP	O
showed	VBD	B-VP	O
elevated	JJ	B-NP	O
creatine	NN	I-NP	O
kinase	NN	I-NP	O
and	CC	I-NP	O
transaminases	NNS	I-NP	O
.	.	O	O

Testing	VBG	B-VP	O
for	IN	B-PP	O
autoantibodies	NNS	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
negative	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
liver	NN	I-NP	O
biochemistries	NNS	I-NP	O
eventually	RB	B-ADVP	O
normalized	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
fluvastatin	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
when	WRB	B-ADVP	O
prescribing	VBG	B-NP	O
statins	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
damage	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
taken	VBN	I-VP	O
into	IN	B-PP	O
account	NN	B-NP	O
.	.	O	O

Fluconazole	NN	B-NP	O
associated	VBN	I-NP	O
agranulocytosis	NN	I-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
second	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
associated	VBN	I-NP	O
agranulocytosis	NN	I-NP	B
with	IN	B-PP	O
thrombocytopenia	NN	B-NP	B
and	CC	I-NP	O
recovery	NN	I-NP	O
upon	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
began	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
white	JJ	B-NP	O
blood	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
platelets	NNS	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
and	CC	O	O
began	VBD	B-VP	O
to	TO	I-VP	O
recover	VB	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
discontinuation	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
highlights	VBZ	B-VP	O
that	IN	B-SBAR	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
blood	NN	I-NP	B
dyscrasias	NNS	I-NP	I
can	MD	B-VP	O
occur	VB	I-VP	O
unexpectedly	RB	B-ADVP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
drug	NN	I-NP	O
thought	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
Naranjo	NNP	B-NP	O
s	NNS	I-NP	O
algorithm	VBP	B-VP	O
the	DT	B-NP	O
likelihood	NN	I-NP	O
that	IN	B-SBAR	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
agranulocytosis	NN	B-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
occurred	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
fluconazole	NN	B-NP	O
is	VBZ	B-VP	O
probable	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
points	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
feel	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
evidence	NN	I-NP	O
is	VBZ	B-VP	O
strong	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-ADJP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
bone	NN	B-NP	B
marrow	NN	I-NP	I
suppression	NN	I-NP	I
to	TO	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
fluconazole	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
abatement	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
that	WDT	B-NP	O
rapidly	RB	B-ADVP	O
reversed	VBD	B-VP	O
immediately	RB	I-VP	O
following	VBG	I-VP	O
discontinuation	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
dimensional	JJ	I-NP	O
speckle	NN	I-NP	O
tracking	VBG	B-VP	O
echocardiography	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
sensitive	JJ	I-NP	O
cardiac	JJ	I-NP	O
troponin	NN	I-NP	O
T	NN	I-NP	O
in	IN	B-PP	O
early	JJ	B-NP	O
detection	NN	I-NP	O
and	CC	O	O
prediction	NN	B-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
during	IN	B-PP	O
epirubicine	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
alterations	NNS	B-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
strain	NN	I-NP	I
and	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
sensitive	JJ	I-NP	O
cardiac	JJ	I-NP	O
troponin	NN	I-NP	O
T	NN	I-NP	O
(	(	O	O
cTnT	NN	B-NP	O
)	)	O	O
could	MD	B-VP	O
predict	VB	I-VP	O
future	JJ	B-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
after	IN	B-PP	O
epirubicin	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
non	AFX	B-NP	B
-	HYPH	I-NP	I
Hodgkin	NN	I-NP	I
lymphoma	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
epirubicin	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

Blood	NN	B-NP	O
collection	NN	I-NP	O
and	CC	I-NP	O
echocardiography	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
cycle	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
completion	NN	B-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
using	VBG	B-VP	O
echocardiography	NN	B-NP	O
during	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

Global	JJ	B-NP	O
longitudinal	JJ	I-NP	O
(	(	O	O
GLS	NN	B-NP	O
)	)	O	O
,	,	O	O
circumferential	JJ	B-ADJP	O
(	(	O	O
GCS	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
radial	JJ	B-NP	O
strain	NN	I-NP	O
(	(	O	O
GRS	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
calculated	VBN	I-VP	O
using	VBG	B-VP	O
speckle	NN	B-NP	O
tracking	NN	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
was	VBD	B-VP	O
analysed	VBN	I-VP	O
by	IN	B-PP	O
real	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
3D	NN	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Cardiotoxicity	NN	B-NP	B
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LVEF	NN	I-NP	O
of	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
<	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
or	CC	O	O
an	DT	B-NP	O
asymptomatic	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LVEF	NN	I-NP	O
of	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
<	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
cardiotoxicity	NN	B-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

GLS	NN	B-NP	O
,	,	O	O
GCS	NN	B-NP	O
,	,	O	O
and	CC	O	O
GRS	NNS	B-NP	O
were	VBD	B-VP	O
markedly	RB	I-VP	O
reduced	VBN	I-VP	O
and	CC	O	O
cTnT	NN	B-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
+	SYM	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
baseline	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
>	SYM	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
GLS	NN	B-NP	O
[	(	O	O
sensitivity	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
specificity	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
area	NN	B-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
curve	NN	I-NP	O
(	(	O	O
AUC	NN	B-NP	O
)	)	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
;	:	O	O
P	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
]	)	O	O
and	CC	O	O
a	DT	B-NP	O
>	JJR	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
cTnT	NN	B-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
cycle	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
predicted	VBD	B-VP	O
later	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
GLS	NN	B-NP	O
remained	VBD	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
independent	JJ	I-NP	O
predictor	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
.	.	O	O

GLS	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
cTnT	NN	B-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
a	DT	B-NP	O
reliable	JJ	I-NP	O
and	CC	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
invasive	JJ	I-NP	O
method	NN	I-NP	O
to	TO	B-VP	O
predict	VB	I-VP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
anthracycline	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Prevention	NN	B-NP	O
of	IN	B-PP	O
etomidate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myoclonus	NN	I-NP	B
:	:	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
superior	JJ	B-ADJP	O
:	:	O	O
Fentanyl	NN	B-NP	O
,	,	O	O
midazolam	NN	B-NP	O
,	,	O	O
or	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
?	.	O	O
A	DT	B-NP	O
Retrospective	JJ	I-NP	O
comparative	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
retrospective	JJ	I-NP	O
comparative	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
,	,	O	O
midazolam	NN	B-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
and	CC	I-NP	O
midazolam	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
etomidate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myoclonus	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
based	VBN	B-PP	O
on	IN	B-PP	O
anesthesia	NN	B-NP	O
records	NNS	I-NP	O
.	.	O	O

Depending	VBG	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
anesthesia	NN	B-NP	O
with	IN	B-PP	O
etomidate	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
separated	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
no	DT	B-NP	O
pretreatment	NN	I-NP	O
(	(	O	O
Group	NN	B-NP	O
NP	NN	I-NP	O
)	)	O	O
,	,	O	O
fentanyl	NN	B-NP	O
num	CD	I-NP	O
ug.kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
Group	NN	B-NP	O
F	NN	I-NP	O
)	)	O	O
,	,	O	O
midazolam	NN	B-NP	O
num	CD	I-NP	O
mg.kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
Group	NN	B-NP	O
M	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
midazolam	NN	B-NP	O
num	CD	I-NP	O
mg.kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
+	SYM	I-NP	O
fentanyl	NN	I-NP	O
num	CD	I-NP	O
ug.kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
Group	NN	B-NP	O
FM	NN	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
anesthetic	JJ	I-NP	O
procedure	NN	I-NP	O
were	VBD	B-VP	O
selected	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
intravenous	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pretreatment	NN	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
anesthesia	NN	B-NP	O
is	VBZ	B-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg.kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
etomidate	NN	I-NP	O
injected	VBN	B-VP	O
intravenously	RB	B-ADVP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
seconds	NNS	I-NP	O
.	.	O	O

Myoclonic	JJ	B-NP	B
movements	NNS	I-NP	I
are	VBP	B-VP	O
evaluated	VBN	I-VP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
and	CC	I-VP	O
graded	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
severity	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
etomidate	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-VP	O
etomidate	VB	I-VP	O
injection	NN	B-NP	O
,	,	O	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
and	CC	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Study	NN	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
myoclonus	NN	B-NP	B
incidence	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
Group	NNP	B-NP	O
NP	NNP	I-NP	O
,	,	O	O
Group	NNP	B-NP	O
F	NNP	I-NP	O
,	,	O	O
Group	NNP	B-NP	O
M	NNP	I-NP	O
,	,	O	O
and	CC	O	O
Group	NNP	B-NP	O
FM	NNP	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
Group	NN	B-NP	O
F	NN	I-NP	O
and	CC	O	O
Group	NN	B-NP	O
FM	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
fentanyl	NN	B-NP	O
or	CC	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
and	CC	I-NP	O
midazolam	NN	I-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
etomidate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myoclonus	NN	I-NP	B
.	.	O	O

Cholestatic	JJ	B-NP	B
presentation	NN	I-NP	O
of	IN	B-PP	O
yellow	JJ	B-NP	O
phosphorus	NN	I-NP	O
poisoning	NN	I-NP	B
.	.	O	O

Yellow	JJ	B-NP	O
phosphorus	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
certain	JJ	B-NP	O
pesticide	NN	I-NP	O
pastes	NNS	I-NP	O
and	CC	I-NP	O
fireworks	NNS	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
hepatotoxicity	NN	B-NP	B
.	.	O	O

Poisoning	VBG	B-VP	B
with	IN	B-PP	O
yellow	JJ	B-NP	O
phosphorus	NN	I-NP	O
classically	RB	B-ADVP	O
manifests	VBZ	B-VP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
hepatitis	NN	I-NP	I
leading	VBG	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
which	WDT	B-NP	O
may	MD	B-VP	O
need	VB	I-VP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
yellow	JJ	B-NP	O
phosphorus	NN	I-NP	O
poisoning	NN	I-NP	B
in	IN	B-PP	O
which	WDT	B-NP	O
a	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
florid	JJ	B-NP	O
clinical	JJ	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
cholestasis	NN	B-NP	B
highlighting	VBG	B-VP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
cholestasis	NN	B-NP	B
can	MD	B-VP	O
rarely	RB	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
presenting	VBG	I-NP	O
feature	NN	I-NP	O
of	IN	B-PP	O
yellow	JJ	B-NP	O
phosphorus	NN	I-NP	O
hepatotoxicity	NN	I-NP	B
.	.	O	O

Vasovagal	JJ	B-NP	B
syncope	NN	I-NP	I
and	CC	O	O
severe	JJ	B-NP	O
bradycardia	NN	I-NP	B
following	VBG	B-PP	O
intranasal	JJ	B-NP	O
dexmedetomidine	NN	I-NP	O
for	IN	B-PP	O
pediatric	JJ	B-NP	O
procedural	JJ	I-NP	O
sedation	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
syncope	NN	B-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
girl	NN	I-NP	O
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
intranasal	JJ	B-NP	O
dexmedetomidine	NN	I-NP	O
for	IN	B-PP	O
sedation	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
voiding	VBG	I-NP	O
cystourethrogram	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
successful	JJ	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
VCUG	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
recovery	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
level	NN	B-NP	O
of	IN	B-PP	O
consciousness	NN	B-NP	O
and	CC	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
presedation	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

Upon	IN	B-PP	O
leaving	VBG	B-VP	O
the	DT	B-NP	O
sedation	NN	I-NP	O
area	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
collapsed	VBD	B-VP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
apparent	JJ	I-NP	O
inciting	VBG	I-NP	O
event	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
quickly	RB	B-ADVP	O
regained	VBD	B-VP	O
consciousness	NN	B-NP	O
and	CC	O	O
no	DT	B-NP	O
injury	NN	I-NP	O
occurred	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
abnormality	NN	I-NP	O
found	VBN	B-VP	O
was	VBD	B-VP	O
persistent	JJ	B-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
and	CC	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
telemetric	JJ	B-NP	O
observation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
bradycardia	NN	I-NP	B
lasted	VBD	B-VP	O
~	RB	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
,	,	O	O
and	CC	O	O
further	JJ	B-NP	O
cardiac	JJ	I-NP	O
workup	NN	I-NP	O
revealed	VBD	B-VP	O
no	DT	B-NP	O
underlying	VBG	I-NP	O
abnormality	NN	I-NP	O
.	.	O	O

Unanticipated	JJ	B-ADJP	O
and	CC	O	O
previously	RB	B-NP	O
unreported	JJ	I-NP	O
outcomes	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
witnessed	VBN	I-VP	O
as	IN	B-SBAR	O
we	PRP	B-NP	O
expand	VBP	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
certain	JJ	B-NP	O
sedatives	NNS	I-NP	O
to	TO	B-PP	O
alternative	JJ	B-NP	O
routes	NNS	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
.	.	O	O

Paradoxical	JJ	B-NP	O
severe	JJ	I-NP	O
agitation	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
add	NN	B-NP	O
-	HYPH	B-ADVP	O
on	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
doses	NNS	I-NP	O
quetiapine	NN	I-NP	O
in	IN	B-PP	O
schizo	AFX	B-NP	B
-	HYPH	I-NP	I
affective	JJ	I-NP	I
disorder	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
schizo	AFX	B-NP	B
-	HYPH	I-NP	I
affective	JJ	I-NP	I
disorder	NN	I-NP	I
since	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
treated	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
antipsychotics	NNS	I-NP	O
,	,	O	O
zuclopenthixol	NN	B-NP	O
and	CC	I-NP	O
lithium	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
associated	VBN	I-NP	O
personality	NN	I-NP	B
disorder	NN	I-NP	I
(	(	O	O
particularly	RB	B-NP	O
no	DT	I-NP	O
antisocial	JJ	I-NP	B
disorder	NN	I-NP	I
)	)	O	O
and	CC	O	O
no	DT	B-NP	O
substance	NN	I-NP	B
abuse	NN	I-NP	I
disorder	NN	I-NP	I
.	.	O	O

Within	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
gradual	JJ	I-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
quetiapine	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
severe	JJ	B-NP	O
agitation	NN	I-NP	B
without	IN	B-PP	O
an	DT	B-NP	O
environmental	JJ	I-NP	O
explanation	NN	I-NP	O
,	,	O	O
contrasting	VBG	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
aggressiveness	NN	B-NP	B
or	CC	I-NP	O
personality	NN	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
diagnoses	NNS	I-NP	O
of	IN	B-PP	O
manic	JJ	B-NP	B
shift	NN	I-NP	O
and	CC	I-NP	O
akathisia	NN	I-NP	B
were	VBD	B-VP	O
dismissed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
withdrawal	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
gradual	JJ	I-NP	O
reintroduction	NN	I-NP	O
of	IN	B-PP	O
quetiapine	NN	B-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
which	WDT	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
another	DT	B-NP	O
severe	JJ	I-NP	O
agitation	NN	I-NP	B
,	,	O	O
enabled	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
attribute	VB	I-VP	O
the	DT	B-NP	O
agitation	NN	I-NP	B
specifically	RB	B-ADVP	O
to	TO	B-PP	O
quetiapine	NN	B-NP	O
.	.	O	O

Antioxidant	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
bovine	JJ	B-NP	O
lactoferrin	NN	I-NP	O
on	IN	B-PP	O
dexamethasone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
rat	NN	B-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
-	HYPH	O	O
(	(	O	O
Dex	NN	B-NP	O
-	SYM	O	O
)	)	O	O
induced	VBN	B-NP	O
hypertension	NN	I-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
enhanced	VBN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

Lactoferrin	NN	B-NP	O
(	(	O	O
LF	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
iron	NN	I-NP	O
-	HYPH	O	O
binding	VBG	B-VP	O
glycoprotein	NN	B-NP	O
with	IN	B-PP	O
antihypertensive	JJ	B-NP	O
properties	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
LF	NN	B-NP	O
on	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
hypertension	NN	I-NP	B
upon	IN	B-PP	O
Dex	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
by	IN	B-PP	O
Dex	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
bovine	JJ	I-NP	O
LF	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
from	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
reversal	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
prevention	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
rats	NNS	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
LF	NN	B-NP	O
treatment	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
Dex	NN	B-NP	O
and	CC	O	O
continued	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SBP	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
tail	NN	B-NP	O
-	HYPH	I-NP	O
cuff	NN	I-NP	O
method	NN	I-NP	O
.	.	O	O

Thymus	NN	B-NP	O
weight	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
glucocorticoid	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
hydrogen	NN	I-NP	O
peroxide	NN	I-NP	O
(	(	O	O
H2O2	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
and	CC	O	O
ferric	JJ	B-ADJP	O
reducing	VBG	B-VP	O
antioxidant	JJ	B-NP	O
power	NN	I-NP	O
(	(	O	O
FRAP	NN	B-NP	O
)	)	O	O
value	NN	B-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
SBP	NN	B-NP	O
and	CC	O	O
plasma	NN	B-NP	O
H2O2	NN	I-NP	O
level	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
thymus	NN	B-NP	O
and	CC	I-NP	O
body	NN	I-NP	O
weights	NNS	I-NP	O
.	.	O	O

LF	NN	B-NP	O
lowered	VBD	B-VP	O
and	CC	O	O
dose	NN	B-NP	O
dependently	RB	B-ADVP	O
prevented	VBD	B-VP	O
Dex	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

LF	NN	B-NP	O
prevented	VBD	B-VP	O
body	NN	B-NP	O
weight	NN	I-NP	B
loss	NN	I-NP	I
and	CC	O	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	O
the	DT	B-NP	O
elevated	VBN	I-NP	O
plasma	NN	I-NP	O
H2O2	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
FRAP	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
LF	NN	B-NP	O
strongly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
ROS	NN	B-NP	O
and	CC	O	O
improved	VBN	B-NP	O
antioxidant	JJ	I-NP	O
capacity	NN	I-NP	O
in	IN	B-PP	O
Dex	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
as	IN	B-PP	O
another	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
antihypertensive	JJ	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
LF	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
and	CC	O	O
convulsive	JJ	B-NP	B
seizures	NNS	I-NP	B
after	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
multivariate	JJ	I-NP	O
analysis	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
contemporary	JJ	B-NP	O
data	NNS	I-NP	O
regarding	VBG	B-VP	O
seizures	NNS	B-NP	B
after	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
undertook	VBD	B-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
prospectively	RB	B-NP	O
collected	VBN	I-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
cardiopulmonary	JJ	B-NP	O
bypass	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
from	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

A	DT	B-NP	O
convulsive	JJ	I-NP	B
seizure	NN	I-NP	B
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
disturbed	JJ	B-NP	O
brain	NN	I-NP	O
function	NN	I-NP	O
characterised	VBN	B-VP	O
by	IN	B-PP	O
abnormal	JJ	B-NP	B
involuntary	JJ	I-NP	I
motor	NN	I-NP	I
movements	NNS	I-NP	I
.	.	O	O

Multivariate	JJ	B-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	I-VP	O
identify	VB	I-VP	O
independent	JJ	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
postoperative	JJ	B-NP	O
convulsive	JJ	I-NP	B
seizures	NNS	I-NP	B
.	.	O	O

Generalised	VBN	B-NP	B
and	CC	I-NP	I
focal	JJ	I-NP	I
seizures	NNS	I-NP	I
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
(	(	O	O
IQR	NN	B-NP	O
[	(	O	O
range	NN	B-NP	O
]	)	O	O
)	)	O	O
time	NN	B-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
seizure	NN	I-NP	B
occurred	VBD	B-VP	O
was	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Epileptiform	JJ	B-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
electroencephalography	NN	B-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Independent	JJ	B-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
seizures	NNS	I-NP	B
included	VBD	B-VP	O
age	NN	B-NP	O
,	,	O	O
female	JJ	B-NP	O
sex	NN	I-NP	O
,	,	O	O
redo	VBP	B-VP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
,	,	O	O
calcification	NN	B-NP	O
of	IN	B-PP	O
ascending	VBG	B-VP	O
aorta	NN	B-NP	O
,	,	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
deep	JJ	B-NP	O
hypothermic	JJ	I-NP	B
circulatory	JJ	I-NP	O
arrest	NN	I-NP	O
,	,	O	O
duration	NN	B-NP	O
of	IN	B-PP	O
aortic	JJ	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
clamp	NN	I-NP	O
and	CC	O	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
tested	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
multivariate	JJ	I-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
independent	JJ	I-NP	O
predictor	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
convulsive	JJ	B-NP	B
seizures	NNS	I-NP	B
had	VBD	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
higher	JJR	B-ADVP	O
in	IN	B-PP	O
-	HYPH	B-NP	O
hospital	NN	I-NP	O
mortality	NN	I-NP	O
rates	NNS	I-NP	O
and	CC	O	O
twice	RB	B-NP	O
the	DT	I-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
hospital	NN	B-NP	O
stay	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
convulsive	JJ	B-NP	B
seizures	NNS	I-NP	B
.	.	O	O

Mean	NN	B-NP	O
(	(	O	O
IQR	NN	B-NP	O
[	(	O	O
range	NN	B-NP	O
]	)	O	O
)	)	O	O
length	NN	B-NP	O
of	IN	B-PP	O
stay	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
convulsive	JJ	B-NP	B
seizures	NNS	I-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Convulsive	JJ	B-NP	B
seizures	NNS	I-NP	B
are	VBP	B-VP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
postoperative	JJ	I-NP	B
complication	NN	I-NP	I
after	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
modifiable	JJ	I-NP	O
factor	NN	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
administration	NN	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
exceeding	VBG	B-VP	O
num	CD	B-NP	O
mg.kg	NN	I-NP	O
,	,	O	O
should	MD	B-VP	O
be	VB	I-VP	O
weighed	VBN	I-VP	O
against	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Dysfunctional	JJ	B-NP	B
overnight	JJ	I-NP	I
memory	NN	I-NP	I
consolidation	NN	I-NP	O
in	IN	B-PP	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
.	.	O	O

Sleep	NN	B-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
consolidation	NN	I-NP	O
and	CC	I-NP	O
integration	NN	I-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
process	NN	I-NP	O
called	VBN	B-VP	O
overnight	JJ	B-NP	O
memory	NN	I-NP	O
consolidation	NN	I-NP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
have	VBP	B-VP	O
marked	VBN	I-VP	O
and	CC	O	O
persistent	JJ	B-NP	O
neurocognitive	JJ	I-NP	O
and	CC	I-NP	O
sleep	NN	I-NP	B
-	HYPH	B-NP	I
related	VBN	I-NP	I
impairments	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
extend	VBP	B-VP	O
past	JJ	B-NP	O
research	NN	I-NP	O
by	IN	B-PP	O
examining	VBG	B-VP	O
overnight	JJ	B-NP	O
memory	NN	I-NP	O
consolidation	NN	I-NP	O
among	IN	B-PP	O
regular	JJ	B-NP	O
ecstasy	JJ	I-NP	O
users	NNS	I-NP	O
and	CC	O	O
drug	NN	B-NP	O
naive	JJ	I-NP	O
healthy	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

Memory	NN	B-NP	O
recall	NN	I-NP	O
of	IN	B-PP	O
word	NN	B-NP	O
pairs	NNS	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
sleep	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
interference	NN	B-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
testing	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
neurocognitive	JJ	B-NP	O
performances	NNS	I-NP	O
across	IN	B-PP	O
tasks	NNS	B-NP	O
of	IN	B-PP	O
learning	NN	B-NP	O
,	,	O	O
memory	NN	B-NP	O
and	CC	O	O
executive	NN	B-NP	O
functioning	NN	I-NP	O
.	.	O	O

Ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
demonstrated	VBD	B-VP	O
impaired	JJ	B-NP	B
overnight	JJ	I-NP	I
memory	NN	I-NP	I
consolidation	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
finding	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
following	VBG	B-PP	O
associative	JJ	B-NP	O
interference	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
ecstasy	JJ	B-NP	O
users	NNS	I-NP	O
demonstrated	VBD	B-VP	O
impairments	NNS	B-NP	O
on	IN	B-PP	O
tasks	NNS	B-NP	O
recruiting	VBG	B-VP	O
frontostriatal	JJ	B-NP	O
and	CC	I-NP	O
hippocampal	JJ	I-NP	O
neural	JJ	I-NP	O
circuitry	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
domains	NNS	I-NP	O
of	IN	B-PP	O
proactive	JJ	B-NP	O
interference	NN	I-NP	O
memory	NN	I-NP	O
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
memory	NN	I-NP	O
,	,	O	O
encoding	VBG	B-VP	O
,	,	O	O
working	VBG	B-VP	O
memory	NN	B-NP	O
and	CC	O	O
complex	JJ	B-NP	O
planning	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
ecstasy	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
dysfunction	NN	I-NP	O
in	IN	B-PP	O
fronto	AFX	B-NP	O
-	HYPH	I-NP	O
temporal	JJ	I-NP	O
circuitry	NN	I-NP	O
may	MD	B-VP	O
underlie	VB	I-VP	O
overnight	JJ	B-NP	O
consolidation	NN	I-NP	O
memory	NN	I-NP	B
impairments	NNS	I-NP	I
in	IN	B-PP	O
regular	JJ	B-NP	O
ecstasy	JJ	I-NP	O
users	NNS	I-NP	O
.	.	O	O

Normoammonemic	JJ	B-NP	O
encephalopathy	NN	I-NP	B
:	:	O	O
solely	RB	B-NP	O
valproate	NN	I-NP	O
induced	JJ	I-NP	O
or	CC	I-NP	O
multiple	JJ	I-NP	O
mechanisms	NNS	I-NP	O
?	.	O	O
A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
subacute	JJ	B-NP	O
onset	NN	I-NP	O
progressive	JJ	I-NP	O
confusion	NN	I-NP	B
,	,	O	O
aggression	NN	B-NP	B
,	,	O	O
auditory	JJ	B-NP	B
hallucinations	NNS	I-NP	I
and	CC	I-NP	O
delusions	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
preceding	VBG	I-NP	O
months	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
admissions	NNS	B-NP	O
with	IN	B-PP	O
transient	JJ	B-NP	O
unilateral	JJ	I-NP	O
hemiparesis	NN	I-NP	B
with	IN	B-PP	O
facial	JJ	B-NP	O
droop	NN	I-NP	O
,	,	O	O
and	CC	O	O
had	VBD	B-VP	O
been	VBN	I-VP	O
started	VBN	I-VP	O
on	IN	B-PP	O
valproate	NN	B-NP	O
for	IN	B-PP	O
presumed	VBN	B-NP	O
hemiplegic	JJ	I-NP	B
migraine	NN	I-NP	I
.	.	O	O

Valproate	NN	B-NP	O
was	VBD	B-VP	O
withdrawn	VBN	I-VP	O
soon	RB	B-ADVP	O
after	IN	B-PP	O
admission	NN	B-NP	O
and	CC	O	O
her	PRP$	B-NP	O
cognitive	JJ	I-NP	O
abilities	NNS	I-NP	O
have	VBP	B-VP	O
gradually	RB	I-VP	O
improved	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

Valproate	NN	B-NP	O
levels	NNS	I-NP	O
taken	VBN	B-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
withdrawal	NN	B-NP	O
were	VBD	B-VP	O
subtherapeutic	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
normoammonaemic	JJ	B-ADJP	O
.	.	O	O

EEG	NN	B-NP	O
undertaken	VBN	B-VP	O
during	IN	B-PP	O
inpatient	NN	B-NP	O
stay	NN	I-NP	O
showed	VBD	B-VP	O
changes	NNS	B-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
encephalopathy	NN	B-NP	B
,	,	O	O
and	CC	O	O
low	JJ	B-NP	O
titre	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
antibodies	NNS	I-NP	O
were	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
aetiologies	NNS	I-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
and	CC	I-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
encephalitis	NN	I-NP	B
present	VBP	B-VP	O
a	DT	B-NP	O
diagnostic	JJ	I-NP	O
dilemma	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
putative	JJ	I-NP	O
combinatorial	JJ	I-NP	O
hypothesis	NN	I-NP	O
to	TO	B-VP	O
explain	VB	I-VP	O
this	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Cerebellar	NN	B-NP	B
and	CC	I-NP	I
oculomotor	NN	I-NP	I
dysfunction	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
rapid	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
pethidine	NN	B-NP	O
.	.	O	O

Pethidine	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
opioid	NN	I-NP	O
that	WDT	B-NP	O
gains	VBZ	B-VP	O
its	PRP$	B-NP	O
popularity	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
effective	JJ	I-NP	O
pain	NN	I-NP	B
control	NN	I-NP	O
through	IN	B-PP	O
acting	VBG	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
opioid	JJ	I-NP	O
-	HYPH	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
rapid	JJ	B-NP	O
pain	NN	I-NP	B
relief	NN	I-NP	O
sometimes	RB	B-ADVP	O
brings	VBZ	B-VP	O
about	IN	B-PP	O
unfavourable	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
that	WDT	B-NP	O
largely	RB	B-ADVP	O
limit	VBP	B-VP	O
its	PRP$	B-NP	O
clinical	JJ	I-NP	O
utility	NN	I-NP	O
.	.	O	O

Common	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
include	VBP	B-VP	O
nausea	NN	B-NP	B
,	,	I-NP	O
vomiting	NN	I-NP	B
and	CC	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
impaired	JJ	B-NP	B
renal	JJ	I-NP	I
and	CC	I-NP	I
liver	NN	I-NP	I
function	NN	I-NP	I
,	,	O	O
and	CC	O	O
those	DT	B-NP	O
who	WP	B-NP	O
need	VBP	B-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
pain	NN	I-NP	B
control	NN	I-NP	O
,	,	O	O
pethidine	NN	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
excitatory	JJ	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
effects	NNS	B-NP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
neurotoxic	JJ	I-NP	B
metabolite	NN	I-NP	O
,	,	O	O
norpethidine	NN	B-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
irritability	NN	B-NP	B
and	CC	I-NP	O
seizure	NN	I-NP	B
attack	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
not	RB	O	O
clinically	RB	B-ADJP	O
apparent	JJ	I-ADJP	O
,	,	O	O
pethidine	NN	B-NP	O
potentially	RB	B-ADVP	O
causes	VBZ	B-VP	O
inhibitory	JJ	B-NP	O
impacts	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
CNS	NN	I-NP	O
and	CC	O	O
impairs	VBZ	B-VP	O
normal	JJ	B-NP	O
cerebellar	NN	I-NP	O
and	CC	I-NP	O
oculomotor	NN	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
short	JJ	I-NP	O
term	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
highlight	VBP	B-VP	O
opioid	JJ	B-NP	O
s	NNS	I-NP	O
inhibitory	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cerebellar	JJ	I-NP	O
structure	NN	I-NP	O
that	WDT	B-NP	O
causes	VBZ	B-VP	O
dysmetria	NN	B-NP	B
,	,	O	O
dysarthria	NN	B-NP	B
,	,	O	O
reduced	VBD	B-VP	O
smooth	JJ	B-NP	O
pursuit	NN	I-NP	O
gain	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
saccadic	JJ	B-NP	O
velocity	NN	I-NP	O
.	.	O	O

Baboon	NN	B-NP	B
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
ketoconazole	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
maculopapular	JJ	I-NP	B
eruption	NN	I-NP	I
on	IN	B-PP	O
the	DT	B-NP	O
flexural	JJ	I-NP	O
areas	NNS	I-NP	O
and	CC	I-NP	O
buttocks	NNS	I-NP	O
after	IN	B-PP	O
using	VBG	B-VP	O
oral	JJ	B-NP	O
ketoconazole	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
baboon	NN	I-NP	B
syndrome	NN	I-NP	I
based	VBN	B-VP	O
on	IN	B-PP	O
his	PRP$	B-NP	O
history	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
included	VBD	B-VP	O
prior	JJ	B-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
topical	JJ	B-NP	O
ketoconazole	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
physical	JJ	I-NP	O
examination	NN	I-NP	O
,	,	O	O
and	CC	O	O
histopathological	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Baboon	NN	B-NP	B
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-VP	O
or	CC	O	O
contact	NN	B-NP	O
allergen	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
maculopapular	JJ	I-NP	B
eruption	NN	I-NP	I
that	WDT	B-NP	O
typically	RB	B-ADVP	O
involves	VBZ	B-VP	O
the	DT	B-NP	O
flexural	JJ	I-NP	O
and	CC	I-NP	O
gluteal	JJ	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

To	TO	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
ketoconazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
baboon	NN	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
English	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
Case	NNP	I-NP	O
of	IN	B-PP	O
Sudden	NNP	B-NP	B
Cardiac	NNP	I-NP	I
Death	NNP	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
Pilsicainide	NN	B-NP	O
-	HYPH	O	O
Induced	VBN	B-VP	O
Torsades	NNP	B-NP	B
de	IN	I-NP	I
Pointes	NNP	I-NP	I
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
male	JJ	I-NP	O
received	VBN	I-NP	O
oral	JJ	I-NP	O
pilsicainide	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
pure	JJ	I-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
with	IN	B-PP	O
slow	JJ	B-NP	O
recovery	NN	I-NP	O
kinetics	NNS	I-NP	O
,	,	O	O
to	TO	B-VP	O
convert	VB	I-VP	O
his	PRP$	B-NP	O
paroxysmal	JJ	I-NP	O
atrial	JJ	I-NP	B
fibrillation	NN	I-NP	I
to	TO	B-PP	O
a	DT	B-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
sudden	JJ	B-NP	B
cardiac	JJ	I-NP	I
death	NN	I-NP	I
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
Holter	NNP	I-NP	O
electrocardiogram	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
worn	VBN	I-VP	O
by	IN	B-PP	O
chance	NN	B-NP	O
,	,	O	O
revealed	VBD	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
with	IN	B-PP	O
gradually	RB	B-NP	O
prolonged	VBN	I-NP	O
QT	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
rapidly	RB	I-VP	O
absorbed	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
gastrointestinal	JJ	I-NP	O
tract	NN	I-NP	O
,	,	O	O
and	CC	O	O
most	JJS	B-NP	O
of	IN	B-PP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
excreted	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
highly	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
and	CC	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pilsicainide	NN	B-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
pilsicainide	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
high	JJ	B-ADJP	O
,	,	O	O
which	WDT	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
torsades	NNS	B-NP	B
de	IN	I-NP	I
pointes	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
octogenarian	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
oral	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
class	NN	B-NP	O
IC	NN	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
pilsicainide	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
to	TO	B-VP	O
terminate	VB	I-VP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
,	,	O	O
careful	JJ	B-NP	O
consideration	NN	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
taken	VBN	I-VP	O
before	IN	B-PP	O
giving	VBG	B-VP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
to	TO	B-PP	O
octogenarians	NNS	B-NP	O
.	.	O	O

All	DT	B-NP	O
-	HYPH	I-NP	O
trans	NN	I-NP	O
retinoic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
inflammatory	JJ	I-NP	O
myositis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
-	HYPH	I-NP	O
trans	NN	I-NP	O
retinoic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
ATRA	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
standard	JJ	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
APL	NN	B-NP	B
)	)	O	O
,	,	O	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
potentially	RB	B-NP	O
serious	JJ	I-NP	O
but	CC	I-NP	O
treatable	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
involving	VBG	B-VP	O
numerous	JJ	B-NP	O
organ	NN	I-NP	O
systems	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
rare	JJ	B-NP	O
skeletal	JJ	I-NP	O
muscle	NN	I-NP	O
involvement	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
a	DT	I-NP	O
handful	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
ATRA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myositis	NN	I-NP	B
in	IN	B-PP	O
children	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
,	,	O	O
and	CC	O	O
none	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
radiology	NN	I-NP	O
literature	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
such	PDT	B-NP	O
a	DT	I-NP	O
case	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
with	IN	B-PP	O
APL	NN	B-NP	B
,	,	O	O
where	WRB	B-ADVP	O
recognition	NN	B-NP	O
of	IN	B-PP	O
imaging	VBG	B-NP	O
findings	NNS	I-NP	O
played	VBD	B-VP	O
a	DT	B-NP	O
crucial	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
making	VBG	B-VP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
and	CC	O	O
facilitated	VBD	B-VP	O
prompt	JJ	B-NP	O
,	,	I-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Tolerability	NN	B-NP	O
of	IN	B-PP	O
lomustine	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
lymphoma	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
describes	VBZ	B-VP	O
toxicity	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
protocol	NN	I-NP	O
of	IN	B-PP	O
lomustine	NN	B-NP	O
(	(	O	O
CCNU	NN	B-NP	O
)	)	O	O
and	CC	O	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CTX	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
lymphoma	NN	B-NP	B
.	.	O	O

CCNU	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
per	IN	B-PP	O
os	NNS	B-NP	O
(	(	O	O
PO	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
a	DT	B-NP	O
targeted	VBN	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
body	NN	I-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
CTX	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
PO	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
targeted	VBN	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
divided	VBN	B-VP	O
over	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
all	DT	B-NP	O
dogs	NNS	I-NP	O
received	VBD	B-VP	O
prophylactic	JJ	B-NP	O
antibiotics	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
included	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Neutropenia	NNP	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
principal	JJ	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
overall	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
CCNU	NN	B-NP	O
/	SYM	B-NP	O
CTX	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
dogs	NNS	B-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
develop	VB	I-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
dog	NN	I-NP	O
developed	VBD	B-VP	O
hematologic	JJ	B-NP	O
changes	NNS	I-NP	O
suggestive	JJ	B-ADJP	O
of	IN	B-PP	O
hepatotoxicity	NN	B-NP	B
.	.	O	O

No	DT	B-NP	O
dogs	NNS	I-NP	O
had	VBD	B-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
either	CC	B-NP	O
renal	JJ	I-NP	B
toxicity	NN	I-NP	I
or	CC	O	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
.	.	O	O

Adverse	JJ	B-NP	O
gastrointestinal	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
uncommon	JJ	B-ADJP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
findings	NNS	I-NP	O
reported	VBN	B-VP	O
herein	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
of	IN	B-PP	O
CCNU	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
of	IN	B-PP	O
CTX	NN	B-NP	O
(	(	O	O
divided	VBN	B-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
q	NN	B-NP	O
num	CD	I-NP	O
wk	NN	I-NP	O
is	VBZ	B-VP	O
tolerable	JJ	B-ADJP	O
in	IN	B-PP	O
tumor	NN	B-NP	B
-	HYPH	O	O
bearing	VBG	B-VP	O
dogs	NNS	B-NP	O
.	.	O	O

Nelarabine	NN	B-NP	O
neurotoxicity	NN	I-NP	B
with	IN	B-PP	O
concurrent	JJ	B-NP	O
intrathecal	JJ	I-NP	O
chemotherapy	NN	I-NP	O
:	:	O	O
Case	NN	B-NP	O
report	NN	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
literature	NN	B-NP	O
.	.	O	O

Severe	JJ	B-NP	O
nelarabine	NN	I-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
concurrent	JJ	B-NP	O
intrathecal	JJ	I-NP	O
(	(	O	O
IT	JJ	B-ADJP	O
)	)	O	O
chemotherapy	NN	B-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Caucasian	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
T	NN	B-NP	B
-	HYPH	I-NP	I
cell	NN	I-NP	I
lymphoblastic	JJ	I-NP	I
lymphoma	NN	I-NP	I
was	VBD	B-VP	O
admitted	VBN	I-VP	O
for	IN	B-PP	O
relapsed	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
originally	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
induction	NN	B-NP	O
chemotherapy	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
autologous	JJ	I-NP	O
transplant	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
developed	VBD	B-VP	O
relapsed	VBN	I-VP	O
disease	NN	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
with	IN	B-PP	O
leukemic	JJ	B-NP	B
involvement	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
re	AFX	B-ADJP	O
-	HYPH	O	O
induced	VBN	B-VP	O
with	IN	B-PP	O
nelarabine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
IT	NN	B-NP	O
cytarabine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
as	IN	B-PP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
prophylaxis	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
continuous	JJ	B-NP	O
renal	JJ	I-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-VP	O
sequelae	VB	I-VP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
lysis	NN	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
TLS	NN	B-NP	B
)	)	O	O
.	.	O	O

She	PRP	B-NP	O
tolerated	VBD	B-VP	O
therapy	NN	B-NP	O
well	RB	B-ADVP	O
,	,	O	O
entered	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
remission	NN	I-NP	O
,	,	O	O
and	CC	O	O
recovered	VBD	B-VP	O
her	PRP$	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
second	JJ	I-NP	O
cycle	NN	I-NP	O
of	IN	B-PP	O
nelarabine	NN	B-NP	O
without	IN	B-PP	O
additional	JJ	B-NP	O
IT	NN	I-NP	O
prophylaxis	NN	I-NP	O
num	CD	B-NP	O
month	NN	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
week	NN	I-NP	O
after	IN	B-PP	O
this	DT	B-NP	O
second	JJ	I-NP	O
cycle	NN	I-NP	O
,	,	O	O
she	PRP	B-NP	O
noted	VBD	B-VP	O
numbness	NN	B-NP	O
in	IN	B-PP	O
her	PRP$	B-NP	O
lower	JJR	I-NP	O
extremities	NNS	I-NP	O
.	.	O	O

Predominantly	RB	B-ADJP	O
sensory	JJ	I-ADJP	O
,	,	O	O
though	IN	B-SBAR	O
also	RB	B-ADVP	O
motor	NN	B-NP	O
and	CC	O	O
autonomic	JJ	B-NP	O
,	,	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
started	VBN	B-VP	O
in	IN	B-PP	O
her	PRP$	B-NP	O
feet	NNS	I-NP	O
,	,	O	O
ascended	VBD	B-VP	O
proximally	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
mid	NN	I-NP	O
-	HYPH	B-NP	O
thoracic	JJ	I-NP	O
region	NN	I-NP	O
,	,	O	O
and	CC	O	O
eventually	RB	B-VP	O
included	VBD	I-VP	O
her	PRP	B-NP	O
distal	JJ	I-NP	O
upper	JJ	I-NP	O
extremities	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
her	PRP$	B-NP	O
spine	NN	I-NP	O
demonstrated	VBD	B-VP	O
changes	NNS	B-NP	O
from	IN	B-PP	O
C2	NN	B-NP	O
to	TO	B-PP	O
C6	NN	B-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
subacute	JJ	B-NP	O
combined	VBN	I-NP	O
degeneration	NN	I-NP	O
.	.	O	O

Nelarabine	NN	B-NP	O
was	VBD	B-VP	O
felt	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Her	PRP$	B-NP	O
neuropathy	NN	I-NP	B
stabilized	VBD	B-VP	O
and	CC	I-VP	O
showed	VBD	I-VP	O
slight	JJ	B-NP	O
improvement	NN	I-NP	O
and	CC	O	O
ultimately	RB	B-VP	O
received	VBD	I-VP	O
an	DT	B-NP	O
unrelated	JJ	I-NP	O
,	,	I-NP	O
reduced	VBN	I-NP	O
-	HYPH	I-NP	O
intensity	NN	I-NP	O
allogeneic	JJ	I-NP	O
transplant	NN	I-NP	O
while	IN	B-SBAR	O
in	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
,	,	O	O
but	CC	O	O
relapsed	VBD	B-VP	O
disease	NN	B-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

She	PRP	B-NP	O
is	VBZ	B-VP	O
currently	RB	I-VP	O
being	VBG	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
best	JJS	B-NP	O
supportive	JJ	I-NP	O
care	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
published	VBN	I-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
nelarabine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
concurrent	JJ	B-NP	O
IT	NN	I-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Valproate	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperammonemic	JJ	I-NP	B
encephalopathy	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
renal	JJ	I-NP	O
transplanted	VBN	I-NP	O
patient	NN	I-NP	O
.	.	O	O

Neurological	JJ	B-NP	B
complications	NNS	I-NP	I
after	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
constitute	VBP	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
morbidity	NN	B-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
.	.	O	O

Their	PRP$	B-NP	O
differential	JJ	I-NP	O
diagnosis	NN	I-NP	O
is	VBZ	B-VP	O
difficult	JJ	B-ADJP	O
and	CC	I-ADJP	O
essential	JJ	I-ADJP	O
for	IN	B-PP	O
subsequent	JJ	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
management	NN	B-NP	O
.	.	O	O

Valproate	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperammonemic	JJ	I-NP	B
encephalopathy	NN	I-NP	B
is	VBZ	B-VP	O
an	DT	B-NP	O
uncommon	JJ	I-NP	O
but	CC	I-NP	O
serious	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
valproate	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
epilepsy	NN	B-NP	B
and	CC	O	O
revealed	VBD	B-VP	O
impaired	JJ	B-NP	B
consciousness	NN	I-NP	I
with	IN	B-PP	O
hyperammonemia	NN	B-NP	B
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
renal	JJ	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
withdraw	NN	B-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
s	VBZ	B-VP	O
symptoms	NNS	B-NP	O
resolved	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
increase	VB	I-VP	O
their	PRP$	B-NP	O
awareness	NN	I-NP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
valproate	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
transplanted	VBN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Necrotising	VBG	B-VP	B
fasciitis	NN	B-NP	I
after	IN	B-PP	O
bortezomib	NN	B-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimen	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
patient	NN	I-NP	O
of	IN	B-PP	O
Waldenstrom	NNP	B-NP	B
macroglobulinaemia	NN	I-NP	I
.	.	O	O

Bortezomib	NN	B-NP	O
and	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
dexamethasone	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimens	NNS	B-NP	O
are	VBP	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
generally	RB	B-ADJP	O
tolerable	JJ	I-ADJP	O
with	IN	B-PP	O
few	JJ	B-NP	O
severe	JJ	I-NP	O
bacterial	JJ	I-NP	B
infections	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
B	NN	B-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
malignancies	NNS	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
information	NN	B-NP	O
is	VBZ	B-VP	O
limited	VBN	I-VP	O
concerning	VBG	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
regimen	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
Waldenstrom	NNP	B-NP	B
macroglobulinaemia	NN	I-NP	I
who	WP	B-NP	O
suffered	VBD	B-VP	O
necrotising	VBG	I-VP	B
fasciitis	NN	B-NP	I
without	IN	B-PP	O
neutropenia	NN	B-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
bortezomib	NN	B-NP	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
dexamethasone	NN	I-NP	O
and	CC	I-NP	O
rituximab	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
immediate	JJ	B-NP	O
intravenous	JJ	I-NP	O
antimicrobial	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
succumbed	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
should	MD	B-VP	O
recognise	VB	I-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
bacterial	JJ	I-NP	B
infections	NNS	I-NP	I
related	VBN	B-VP	O
to	TO	B-VP	O
bortezomib	VB	I-VP	O
plus	CC	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
dexamethasone	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
we	PRP	B-NP	O
believe	VBP	B-VP	O
this	DT	B-NP	O
case	NN	I-NP	O
warrants	VBZ	B-VP	O
further	JJ	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
integrated	VBN	I-NP	O
characterization	NN	I-NP	O
of	IN	B-PP	O
serological	JJ	B-NP	O
,	,	I-NP	O
pathological	JJ	I-NP	O
,	,	O	O
and	CC	O	O
functional	JJ	B-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Many	JJ	B-NP	O
efficacious	JJ	I-NP	O
cancer	NN	I-NP	B
treatments	NNS	I-NP	O
cause	VBP	B-VP	O
significant	JJ	B-NP	O
cardiac	JJ	I-NP	O
morbidity	NN	I-NP	O
,	,	O	O
yet	CC	O	O
biomarkers	NNS	B-NP	O
or	CC	O	O
functional	JJ	B-NP	O
indices	NNS	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
damage	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
would	MD	B-VP	O
allow	VB	I-VP	O
monitoring	NN	B-NP	O
and	CC	I-NP	O
intervention	NN	I-NP	O
,	,	O	O
are	VBP	B-VP	O
lacking	VBG	I-VP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
utilized	VBN	I-VP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
,	,	O	O
applying	VBG	B-VP	O
multiple	JJ	B-NP	O
approaches	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
cardiac	JJ	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
,	,	O	O
to	TO	B-VP	O
provide	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
comprehensive	JJ	I-NP	O
characterization	NN	I-NP	O
to	TO	B-PP	O
date	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
timecourse	NN	I-NP	O
of	IN	B-PP	O
serological	JJ	B-NP	O
,	,	I-NP	O
pathological	JJ	I-NP	O
,	,	O	O
and	CC	O	O
functional	JJ	B-NP	O
events	NNS	I-NP	O
underlying	VBG	B-VP	O
this	DT	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Hannover	NNP	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
dosed	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
DOX	NN	I-NP	O
weekly	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
week	NN	I-NP	O
off	RB	B-ADVP	O
-	HYPH	B-NP	O
dosing	NN	I-NP	O
recovery	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Electron	NN	B-NP	O
microscopy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
revealed	VBD	B-VP	O
subcellular	JJ	B-NP	B
degeneration	NN	I-NP	I
and	CC	O	O
marked	JJ	B-NP	O
mitochondrial	JJ	I-NP	O
changes	NNS	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
progressive	JJ	B-NP	O
cardiomyocyte	NN	I-NP	B
degeneration	NN	I-NP	I
,	,	O	O
hypertrophy	NN	B-NP	B
/	SYM	B-NP	O
cytomegaly	NN	I-NP	O
,	,	O	O
and	CC	O	O
extensive	JJ	B-NP	O
vacuolation	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Extensive	JJ	B-NP	O
replacement	NN	I-NP	O
fibrosis	NN	I-NP	B
(	(	O	O
quantified	VBN	B-VP	O
by	IN	B-PP	O
Sirius	NNP	B-NP	O
red	JJ	I-NP	O
staining	NN	I-NP	O
)	)	O	O
developed	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
off	RB	I-NP	O
-	HYPH	I-NP	O
dosing	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Functional	JJ	B-NP	O
indices	NNS	I-NP	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
cardiac	JJ	B-NP	O
MRI	NN	I-NP	O
(	(	O	O
including	VBG	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
(	(	O	O
LVEF	NN	B-NP	O
)	)	O	O
,	,	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
,	,	O	O
and	CC	O	O
E	NN	B-NP	O
/	SYM	O	O
A	NN	B-NP	O
ratio	NN	I-NP	O
)	)	O	O
declined	VBD	B-VP	O
progressively	RB	B-ADVP	O
,	,	O	O
reaching	VBG	B-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
and	CC	O	O
culminating	VBG	B-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
LV	NN	I-NP	B
dysfunction	NN	I-NP	I
by	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
peak	NN	B-NP	O
myocardial	JJ	I-NP	O
contrast	NN	I-NP	O
enhancement	NN	I-NP	O
and	CC	O	O
serological	JJ	B-NP	O
cardiac	JJ	I-NP	O
troponin	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
cTnI	NN	B-NP	O
)	)	O	O
emerged	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
importantly	RB	B-VP	O
preceding	VBG	I-VP	O
the	DT	B-NP	O
LVEF	NN	I-NP	O
decline	NN	I-NP	O
to	TO	B-PP	O
<	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Troponin	NN	B-NP	O
num	CD	I-NP	O
levels	NNS	I-NP	O
positively	RB	B-ADVP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
delayed	VBN	B-NP	O
and	CC	I-NP	O
peak	JJ	I-NP	O
gadolinium	NN	I-NP	O
contrast	NN	I-NP	O
enhancement	NN	I-NP	O
,	,	O	O
histopathological	JJ	B-NP	O
grading	NN	I-NP	O
,	,	O	O
and	CC	O	O
diastolic	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
subcellular	JJ	B-NP	O
cardiomyocyte	NN	I-NP	B
degeneration	NN	I-NP	I
was	VBD	B-VP	O
the	DT	B-NP	O
earliest	JJS	I-NP	O
marker	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
progressive	JJ	B-NP	O
functional	JJ	I-NP	O
decline	NN	I-NP	O
and	CC	O	O
histopathological	JJ	B-NP	O
manifestations	NNS	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
contrast	NN	I-NP	O
enhancement	NN	I-NP	O
and	CC	O	O
elevations	NNS	B-NP	O
in	IN	B-PP	O
cTnI	NN	B-NP	O
occurred	VBD	B-VP	O
later	RB	B-ADVP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
all	DT	B-NP	O
indices	NNS	I-NP	O
predated	VBD	B-VP	O
clinical	JJ	B-NP	O
LV	NN	I-NP	B
dysfunction	NN	I-NP	I
and	CC	O	O
thus	RB	B-NP	O
warrant	JJ	I-NP	O
further	JJ	I-NP	O
evaluation	NN	I-NP	O
as	IN	B-PP	O
predictive	JJ	B-NP	O
biomarkers	NNS	I-NP	O
.	.	O	O

Intradermal	JJ	B-NP	O
glutamate	NN	I-NP	O
and	CC	I-NP	O
capsaicin	NN	I-NP	O
injections	NNS	I-NP	O
:	:	O	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
interindividual	JJ	I-NP	O
variability	NN	I-NP	O
of	IN	B-PP	O
provoked	JJ	B-NP	O
hyperalgesia	NN	I-NP	B
and	CC	I-NP	O
allodynia	NN	I-NP	B
.	.	O	O

Intradermal	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
capsaicin	NN	I-NP	O
are	VBP	B-VP	O
attractive	JJ	B-ADJP	O
to	TO	B-VP	O
use	VB	I-VP	O
in	IN	B-PP	O
human	JJ	B-NP	O
experimental	JJ	I-NP	O
pain	NN	I-NP	B
models	NNS	I-NP	O
because	IN	B-SBAR	O
hyperalgesia	NN	B-NP	B
and	CC	I-NP	O
allodynia	NN	I-NP	B
mimic	VBP	B-VP	O
isolated	VBN	I-VP	O
aspects	NNS	B-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
pain	NN	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
reproducibility	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
models	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
male	JJ	I-NP	O
volunteers	NNS	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
received	VBD	B-VP	O
intradermal	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
glutamate	NN	B-NP	O
and	CC	I-NP	O
capsaicin	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
volar	JJ	I-NP	O
forearm	NN	I-NP	O
.	.	O	O

Magnitudes	NNS	B-NP	O
of	IN	B-PP	O
secondary	JJ	B-NP	O
pinprick	NN	I-NP	O
hyperalgesia	NN	I-NP	B
and	CC	I-NP	O
brush	NN	I-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
allodynia	NN	I-NP	B
were	VBD	B-VP	O
investigated	VBN	I-VP	O
using	VBG	B-VP	O
von	NNP	B-NP	O
Frey	NNP	I-NP	O
filaments	NNS	I-NP	O
(	(	O	O
gauges	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
and	CC	O	O
brush	JJ	B-NP	O
strokes	NNS	I-NP	O
.	.	O	O

Areas	NNS	B-NP	O
of	IN	B-PP	O
secondary	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
and	CC	I-NP	O
allodynia	NN	I-NP	B
were	VBD	B-VP	O
quantified	VBN	I-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
injection	NN	B-NP	O
and	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
identical	JJ	I-NP	O
experiments	NNS	I-NP	O
separated	VBN	B-VP	O
by	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

Reproducibility	NN	B-NP	O
across	IN	B-PP	O
and	CC	I-PP	O
within	IN	I-PP	O
volunteers	NNS	B-NP	O
(	(	O	O
inter	NN	B-NP	O
-	HYPH	B-ADJP	O
and	CC	O	O
intra	AFX	O	O
-	HYPH	O	O
individual	JJ	B-NP	O
variation	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
intraclass	JJ	B-NP	O
correlation	NN	I-NP	O
coefficient	NN	I-NP	O
(	(	O	O
ICC	NN	B-NP	O
)	)	O	O
and	CC	O	O
coefficient	JJ	B-ADJP	O
of	IN	B-PP	O
variation	NN	B-NP	O
(	(	O	O
CV	NN	B-NP	O
)	)	O	O
.	.	O	O

Secondary	JJ	B-NP	O
pinprick	NN	I-NP	O
hyperalgesia	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
visual	JJ	I-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
(	(	O	O
VAS	NN	B-NP	O
)	)	O	O
response	NN	B-NP	O
to	TO	B-PP	O
von	NNP	B-NP	O
Frey	NNP	I-NP	O
gauges	VBZ	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
after	IN	B-PP	O
glutamate	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
capsaicin	NN	B-NP	O
,	,	O	O
secondary	JJ	B-NP	O
pinprick	NN	I-NP	O
hyperalgesia	NN	I-NP	B
was	VBD	B-VP	O
detected	VBN	I-VP	O
with	IN	B-PP	O
all	DT	B-NP	O
von	NNP	I-NP	O
Frey	NNP	I-NP	O
gauges	NNS	I-NP	O
.	.	O	O

Glutamate	NN	B-NP	O
evoked	VBD	B-VP	O
reproducible	JJ	B-NP	O
VAS	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
all	DT	B-NP	O
von	NNP	I-NP	O
Frey	NNP	I-NP	O
gauges	NNS	I-NP	O
and	CC	O	O
brush	JJ	B-NP	O
strokes	NNS	I-NP	O
.	.	O	O

Capsaicin	NN	B-NP	O
injection	NN	I-NP	O
was	VBD	B-VP	O
reproducible	JJ	B-ADJP	O
for	IN	B-PP	O
secondary	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
and	CC	I-NP	O
allodynia	NN	I-NP	B
.	.	O	O

Intra	AFX	B-NP	O
-	HYPH	I-NP	O
individual	JJ	I-NP	O
variability	NN	I-NP	O
was	VBD	B-VP	O
generally	RB	B-ADJP	O
lower	JJR	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
VAS	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
von	NNP	B-NP	O
Frey	NNP	I-NP	O
and	CC	O	O
brush	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
areas	NNS	B-NP	O
of	IN	B-PP	O
secondary	JJ	B-NP	B
hyperalgesia	NN	I-NP	I
and	CC	I-NP	O
allodynia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
glutamate	NN	B-NP	O
and	CC	O	O
capsaicin	NN	B-NP	O
yield	NN	I-NP	O
reproducible	JJ	B-NP	O
hyperalgesic	JJ	I-NP	B
and	CC	I-NP	O
allodynic	JJ	I-NP	B
responses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
present	JJ	I-NP	O
model	NN	I-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
suited	VBN	I-VP	O
for	IN	B-PP	O
basic	JJ	B-NP	O
research	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
for	IN	B-PP	O
assessing	VBG	B-VP	O
the	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
phenomena	NNS	I-NP	O
.	.	O	O

Ocular	JJ	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
ER	NN	I-NP	O
stress	NN	I-NP	O
reduction	NN	I-NP	O
rescues	VBZ	B-VP	O
glaucoma	NN	B-NP	B
in	IN	B-PP	O
murine	JJ	B-NP	O
glucocorticoid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
glaucoma	NN	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
glucocorticoids	NNS	B-NP	O
induces	VBZ	B-VP	O
ocular	JJ	B-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

If	IN	B-SBAR	O
untreated	JJ	B-ADJP	O
,	,	O	O
these	DT	B-NP	O
patients	NNS	I-NP	O
can	MD	B-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
secondary	JJ	I-NP	O
glaucoma	NN	I-NP	B
that	WDT	B-NP	O
resembles	VBZ	B-VP	O
primary	JJ	B-NP	B
open	JJ	I-NP	I
-	HYPH	I-NP	I
angle	NN	I-NP	I
glaucoma	NN	I-NP	I
(	(	O	O
POAG	NN	B-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
underlying	VBG	I-NP	O
pathology	NN	I-NP	O
of	IN	B-PP	O
glucocorticoid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
glaucoma	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
fully	RB	I-VP	O
understood	VBN	I-VP	O
,	,	O	O
due	JJ	B-ADJP	O
in	IN	B-PP	O
part	NN	B-NP	O
to	TO	B-PP	O
lack	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
appropriate	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
murine	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
glucocorticoid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
glaucoma	NN	I-NP	B
that	WDT	B-NP	O
exhibits	VBZ	B-VP	O
glaucoma	NN	B-NP	B
features	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
with	IN	B-PP	O
topical	JJ	B-NP	O
ocular	JJ	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
dexamethasone	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
elevation	NN	B-NP	O
of	IN	B-PP	O
intraocular	JJ	B-NP	O
pressure	NN	I-NP	O
(	(	O	O
IOP	NN	B-NP	O
)	)	O	O
,	,	O	O
functional	JJ	B-NP	O
and	CC	I-NP	O
structural	JJ	I-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
retinal	JJ	B-NP	B
ganglion	NN	I-NP	I
cells	NNS	I-NP	O
,	,	O	O
and	CC	O	O
axonal	JJ	B-NP	B
degeneration	NN	I-NP	I
,	,	O	O
resembling	VBG	B-VP	O
glucocorticoid	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
glaucoma	NN	I-NP	B
in	IN	B-PP	O
human	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
hypertension	NN	I-NP	I
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
ER	NN	I-NP	O
stress	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
trabecular	JJ	I-NP	O
meshwork	NN	I-NP	O
(	(	O	O
TM	NN	B-NP	O
)	)	O	O
.	.	O	O

Similar	JJ	B-ADJP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
dexamethasone	NN	B-NP	O
treatment	NN	I-NP	O
reduced	VBD	B-VP	O
elevated	JJ	B-NP	O
IOP	NN	I-NP	O
and	CC	I-NP	O
ER	NN	I-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Dexamethasone	NN	B-NP	O
induced	VBD	B-VP	O
the	DT	B-NP	O
transcriptional	JJ	I-NP	O
factor	NN	I-NP	O
CHOP	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
marker	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	O
ER	NN	I-NP	O
stress	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
segment	NN	I-NP	O
tissues	NNS	I-NP	O
,	,	O	O
and	CC	O	O
Chop	NN	B-NP	O
deletion	NN	I-NP	O
reduced	VBD	B-VP	O
ER	NN	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
tissues	NNS	I-NP	O
and	CC	O	O
prevented	VBD	B-VP	O
dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
hypertension	NN	I-NP	I
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
reduction	NN	B-NP	O
of	IN	B-PP	O
ER	NN	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
TM	NN	I-NP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenylbutyrate	NN	I-NP	O
prevented	VBD	B-VP	O
dexamethasone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
ER	NN	B-NP	O
stress	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
glucocorticoid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ocular	JJ	I-NP	B
hypertension	NN	I-NP	I
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
reducing	VBG	B-VP	O
ER	NN	B-NP	O
stress	NN	I-NP	O
has	VBZ	B-VP	O
potential	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
strategy	NN	I-NP	O
for	IN	B-PP	O
treating	VBG	B-VP	O
glucocorticoid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
glaucoma	NN	I-NP	B
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
ginsenosides	NNS	B-NP	O
on	IN	B-PP	O
opioid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperalgesia	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Opioid	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
hyperalgesia	NN	I-NP	B
(	(	O	O
OIH	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
nociceptive	JJ	B-NP	O
sensitization	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
cessation	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
opioid	JJ	I-NP	O
use	NN	I-NP	O
.	.	O	O

OIH	NN	B-NP	B
can	MD	B-VP	O
limit	VB	I-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
opioid	JJ	B-NP	O
analgesics	NNS	I-NP	O
and	CC	O	O
complicate	VBP	B-VP	O
withdrawal	NN	B-NP	O
from	IN	B-PP	O
opioid	JJ	B-NP	B
addiction	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Re	NN	B-NP	O
,	,	O	O
Rg1	NN	B-NP	O
,	,	O	O
and	CC	O	O
Rb1	NN	B-NP	O
ginsenosides	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
bioactive	JJ	I-NP	O
components	NNS	I-NP	O
of	IN	B-PP	O
ginseng	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
OIH	NN	B-NP	B
.	.	O	O

OIH	NN	B-NP	B
was	VBD	B-VP	O
achieved	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
after	IN	B-PP	O
subcutaneous	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
withdrawal	NN	B-NP	O
(	(	O	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
these	DT	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
Re	NN	B-NP	O
,	,	O	O
Rg1	NN	B-NP	O
,	,	O	O
or	CC	O	O
Rb1	NN	B-NP	O
intragastrically	RB	B-ADVP	O
num	CD	B-NP	O
times	NNS	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
day	NN	I-NP	O
(	(	O	O
day	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
thermal	JJ	I-NP	O
sensitivity	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
acetic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
writhing	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Re	NN	B-NP	O
inhibited	VBD	B-VP	O
OIH	NN	B-NP	B
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
thermal	JJ	I-NP	O
sensitivity	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
acetic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
writhing	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
Rg1	NN	I-NP	O
and	CC	I-NP	O
Rb1	NN	I-NP	O
ginsenosides	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
prevent	VB	I-VP	O
OIH	NN	B-NP	B
in	IN	B-PP	O
either	DT	B-NP	O
test	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
Rg1	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
tendency	NN	I-NP	O
to	TO	B-VP	O
aggravate	VB	I-VP	O
OIH	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
acetic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
writhing	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
ginsenoside	NN	I-NP	O
Re	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
Rg1	NN	B-NP	O
or	CC	O	O
Rb1	NN	B-NP	O
,	,	O	O
may	MD	B-VP	O
contribute	VB	I-VP	O
toward	IN	B-PP	O
reversal	NN	B-NP	O
of	IN	B-PP	O
OIH	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
disturbances	NNS	I-NP	O
between	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
and	CC	I-NP	O
propofol	NN	I-NP	O
for	IN	B-PP	O
sedation	NN	B-NP	O
in	IN	B-PP	O
neurocritical	JJ	B-NP	O
care	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Dexmedetomidine	NN	B-NP	O
and	CC	I-NP	O
propofol	NN	I-NP	O
are	VBP	B-VP	O
commonly	RB	I-VP	O
used	VBN	I-VP	O
sedatives	NNS	B-NP	O
in	IN	B-PP	O
neurocritical	JJ	B-NP	O
care	NN	I-NP	O
as	IN	B-SBAR	O
they	PRP	B-NP	O
allow	VBP	B-VP	O
for	IN	B-PP	O
frequent	JJ	B-NP	O
neurologic	JJ	I-NP	O
examinations	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
both	DT	B-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
neurocritical	JJ	B-NP	O
care	NN	I-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
dexmedetomidine	NN	B-NP	O
and	CC	I-NP	O
propofol	NN	I-NP	O
.	.	O	O

Multicenter	JJ	B-NP	O
,	,	I-NP	O
retrospective	JJ	I-NP	O
,	,	I-NP	O
propensity	NN	I-NP	O
-	HYPH	I-NP	O
matched	VBN	B-VP	O
cohort	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

Neurocritical	JJ	B-NP	O
care	NN	I-NP	O
units	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
academic	JJ	I-NP	O
medical	JJ	I-NP	O
centers	NNS	I-NP	O
with	IN	B-PP	O
dedicated	VBN	B-NP	O
neurocritical	JJ	I-NP	O
care	NN	I-NP	O
teams	NNS	I-NP	O
and	CC	I-NP	O
board	NN	I-NP	O
-	HYPH	B-NP	O
certified	VBN	I-NP	O
neurointensivists	NNS	I-NP	O
.	.	O	O

Neurocritical	JJ	B-NP	O
care	NN	I-NP	O
patients	NNS	I-NP	O
admitted	VBN	B-VP	O
between	IN	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
September	NNP	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
and	CC	O	O
then	RB	O	O
matched	VBD	B-VP	O
num	CD	B-NP	O
:	SYM	I-NP	O
num	CD	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
propensity	NN	B-NP	O
scoring	NN	I-NP	O
of	IN	B-PP	O
baseline	NN	B-NP	O
characteristics	NNS	I-NP	O
.	.	O	O

Continuous	JJ	B-NP	O
sedation	NN	I-NP	O
with	IN	B-PP	O
dexmedetomidine	NN	B-NP	O
or	CC	I-NP	O
propofol	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
dexmedetomidine	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
propofol	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
matched	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
)	)	O	O
by	IN	B-PP	O
propensity	NN	B-NP	O
score	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
outcome	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
composite	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
during	IN	B-PP	O
sedative	JJ	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
composite	JJ	I-NP	O
outcome	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
unmatched	JJ	I-NP	O
or	CC	I-NP	O
matched	JJ	I-NP	O
cohorts	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
found	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
analyzed	VBN	B-VP	O
separately	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
differences	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
or	CC	I-NP	O
bradycardia	NN	I-NP	B
in	IN	B-PP	O
either	CC	O	O
the	DT	B-NP	O
unmatched	JJ	I-NP	O
or	CC	I-NP	O
matched	JJ	I-NP	O
cohorts	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
occur	VBP	B-VP	O
at	IN	B-PP	O
similar	JJ	B-NP	O
prevalence	NN	I-NP	O
in	IN	B-PP	O
neurocritical	JJ	B-NP	O
care	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
receive	VBP	B-VP	O
dexmedetomidine	NN	B-NP	O
or	CC	I-NP	O
propofol	NN	I-NP	O
.	.	O	O

Providers	NNS	B-NP	O
should	MD	B-VP	O
similarly	RB	I-VP	O
consider	VB	I-VP	O
the	DT	B-NP	O
likelihood	NN	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
or	CC	I-NP	O
bradycardia	NN	I-NP	B
before	IN	B-PP	O
starting	VBG	B-VP	O
either	CC	O	O
sedative	JJ	B-ADJP	O
.	.	O	O

Hydroxytyrosol	NN	B-NP	O
ameliorates	VBZ	B-VP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

Oxidative	JJ	B-NP	O
stress	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
several	JJ	B-NP	O
processes	NNS	I-NP	O
including	VBG	B-PP	O
cancer	NN	B-NP	B
,	,	I-NP	O
aging	NN	I-NP	O
and	CC	I-NP	O
cardiovascular	JJ	I-NP	B
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
potentiate	VB	I-VP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
causes	VBZ	B-VP	O
significant	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
characterized	VBN	B-VP	O
by	IN	B-PP	O
marked	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Herein	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
investigate	VBP	B-VP	O
whether	IN	B-SBAR	O
doxorubicin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
chronic	JJ	B-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
can	MD	B-VP	O
be	VB	I-VP	O
ameliorated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
antioxidant	JJ	I-NP	O
hydroxytyrosol	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
bearing	VBG	B-VP	O
breast	NN	B-NP	B
tumors	NNS	I-NP	I
induced	VBN	B-VP	O
chemically	RB	B-ADVP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
control	NN	B-NP	O
,	,	O	O
hydroxytyrosol	NN	B-NP	O
,	,	O	O
doxorubicin	NN	B-NP	O
,	,	O	O
and	CC	O	O
doxorubicin	NN	B-NP	O
plus	CC	I-NP	O
hydroxytyrosol	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	B
disturbances	NNS	I-NP	I
at	IN	B-PP	O
the	DT	B-NP	O
cellular	JJ	I-NP	O
and	CC	I-NP	O
mitochondrial	JJ	I-NP	O
level	NN	I-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
electron	NN	I-NP	O
transport	NN	I-NP	O
chain	NN	I-NP	O
complexes	NNS	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
apoptosis	NN	I-NP	O
-	HYPH	O	O
inducing	VBG	B-VP	O
factor	NN	B-NP	O
,	,	O	O
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
markers	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

Hydroxytyrosol	NN	B-NP	O
improved	VBD	B-VP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	B
disturbances	NNS	I-NP	I
enhanced	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
by	IN	B-PP	O
significantly	RB	B-VP	O
reducing	VBG	I-VP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
altered	VBN	B-NP	O
mitochondria	NNS	I-NP	O
and	CC	O	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
hydroxytyrosol	NN	B-NP	O
improve	VBP	B-VP	O
the	DT	B-NP	O
mitochondrial	JJ	I-NP	O
electron	NN	I-NP	O
transport	NN	I-NP	O
chain	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
hydroxytyrosol	NN	B-NP	O
protect	NN	I-NP	O
rat	NN	I-NP	O
heart	NN	I-NP	B
damage	NN	I-NP	I
provoked	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
decreasing	VBG	B-VP	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
and	CC	O	O
mitochondrial	JJ	B-NP	O
alterations	NNS	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myxoedema	NN	I-NP	B
coma	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
bradycardia	NN	B-NP	B
,	,	O	O
hypothermia	NN	B-NP	B
and	CC	O	O
respiratory	JJ	B-NP	B
failure	NN	I-NP	I
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Thyroid	NN	B-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
hormone	NN	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
uIU	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	B-NP	O
(	(	O	O
nl.	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
uIU	NN	I-NP	O
/	SYM	I-NP	O
mL	NN	I-NP	O
)	)	O	O
and	CC	O	O
free	JJ	B-NP	O
thyroxine	NN	I-NP	O
(	(	O	O
FT4	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
<	SYM	B-ADJP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	B-NP	O
(	(	O	O
nl.	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
)	)	O	O
.	.	O	O

He	PRP	B-NP	O
received	VBD	B-VP	O
intravenous	JJ	B-NP	O
fluids	NNS	I-NP	O
,	,	O	O
vasopressor	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
stress	NN	B-NP	O
dose	NN	I-NP	O
steroids	NNS	I-NP	O
;	:	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
intubated	VBN	I-VP	O
and	CC	O	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
ug	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
levothyroxine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
ug	NN	I-NP	O
intravenous	JJ	B-ADJP	O
daily	RB	B-ADVP	O
thereafter	RB	I-ADVP	O
.	.	O	O

Haemodynamic	JJ	B-NP	O
improvement	NN	I-NP	O
,	,	O	O
along	IN	B-PP	O
with	IN	B-PP	O
complete	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
,	,	O	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
FT4	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
on	IN	B-PP	O
levothyroxine	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
g	NN	B-NP	O
POorally	RB	B-ADVP	O
daily	RB	I-ADVP	O
.	.	O	O

A	DT	B-NP	O
thyroid	JJ	I-NP	O
ultrasound	NN	I-NP	O
showed	VBD	B-VP	O
diffuse	JJ	B-NP	O
heterogeneity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
iodine	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
mcg	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
(	(	O	O
mcg	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
only	JJ	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myxoedema	NN	I-NP	B
coma	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
report	NN	I-NP	O
patient	NN	I-NP	O
death	NN	I-NP	O
despite	IN	B-PP	O
supportive	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	I-NP	O
thyroid	NN	I-NP	O
hormone	NN	I-NP	O
replacement	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
represents	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
thoroughly	RB	I-NP	O
investigated	VBN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myxoedema	NN	I-NP	B
coma	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
significant	JJ	B-ADJP	O
for	IN	B-PP	O
subclinical	JJ	B-NP	O
thyroid	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
argatroban	NN	B-NP	O
and	CC	I-NP	O
catheter	NN	I-NP	O
-	HYPH	O	O
directed	VBN	B-NP	O
thrombolysis	NN	I-NP	B
with	IN	B-PP	O
alteplase	NN	B-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
oncology	NN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
with	IN	B-PP	O
thrombosis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
oncology	NN	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
with	IN	B-PP	O
thrombosis	NN	B-NP	B
(	(	O	O
HITT	NN	B-NP	B
)	)	O	O
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
argatroban	NN	B-NP	O
plus	CC	I-NP	O
catheter	NN	I-NP	O
-	HYPH	O	O
directed	VBN	B-VP	O
thrombolysis	NN	B-NP	B
(	(	O	O
CDT	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
alteplase	NN	B-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Caucasian	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	O
amyloidosis	NN	I-NP	B
undergoing	VBG	B-VP	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
collection	NN	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
autologous	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplant	NN	I-NP	O
developed	VBD	B-VP	O
extensive	JJ	B-NP	O
bilateral	JJ	I-NP	O
upper	JJ	I-NP	B
-	HYPH	I-NP	I
extremity	NN	I-NP	I
deep	JJ	I-NP	I
venous	JJ	I-NP	I
thrombosis	NN	I-NP	I
(	(	O	O
DVT	NN	B-NP	B
)	)	O	O
and	CC	O	O
pulmonary	JJ	B-NP	B
embolism	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
continuous	JJ	I-NP	O
i.v.	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
argatroban	NN	B-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
managed	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
general	JJ	I-NP	O
medical	JJ	I-NP	O
floor	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
transferred	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
with	IN	B-PP	O
cardiopulmonary	JJ	B-NP	O
compromise	NN	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
superior	JJ	B-NP	B
vena	NN	I-NP	I
cava	NN	I-NP	I
(	(	O	I
SVC	NN	B-NP	I
)	)	O	I
syndrome	NN	B-NP	I
.	.	O	O

A	DT	B-NP	O
percutaneous	JJ	I-NP	O
mechanical	JJ	I-NP	O
thrombectomy	NN	I-NP	O
and	CC	I-NP	O
CDT	NN	I-NP	O
with	IN	B-PP	O
alteplase	NN	B-NP	O
were	VBD	B-VP	O
attempted	VBN	I-VP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
procedure	NN	I-NP	O
was	VBD	B-VP	O
aborted	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
epistaxis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
epistaxis	NN	I-NP	B
resolved	VBD	B-VP	O
the	DT	B-NP	O
next	JJ	I-NP	O
day	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
restarted	VBN	I-VP	O
on	IN	B-PP	O
argatroban	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
second	JJ	I-NP	O
percutaneous	JJ	I-NP	O
mechanical	JJ	I-NP	O
thrombectomy	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
and	CC	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
partial	JJ	B-NP	O
revascularization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
SVC	NN	I-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
veins	NNS	I-NP	O
.	.	O	O

Postthrombectomy	JJ	B-NP	O
continuous	JJ	I-NP	O
CDT	NN	I-NP	O
with	IN	B-PP	O
alteplase	NN	B-NP	O
was	VBD	B-VP	O
commenced	VBN	I-VP	O
while	IN	B-SBAR	O
argatroban	NN	B-NP	O
was	VBD	B-VP	O
withheld	VBN	I-VP	O
,	,	O	O
and	CC	O	O
complete	JJ	B-NP	O
patency	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
SVC	NN	I-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
veins	NNS	I-NP	O
was	VBD	B-VP	O
achieved	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Alteplase	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
reinitiated	VBN	I-VP	O
on	IN	B-PP	O
argatroban	NN	B-NP	O
;	:	O	O
ultimately	RB	B-ADVP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
transitioned	VBN	I-VP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
for	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
anticoagulation	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
,	,	O	O
he	PRP	B-NP	O
experienced	VBD	B-VP	O
permanent	JJ	B-NP	O
vision	NN	I-NP	B
and	CC	I-NP	I
hearing	NN	I-NP	I
loss	NN	I-NP	I
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	O
amyloidosis	NN	I-NP	B
and	CC	I-NP	O
SVC	NN	I-NP	B
syndrome	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
HITT	NN	B-NP	B
was	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
argatroban	NN	B-NP	O
and	CC	I-NP	O
CDT	NN	I-NP	O
with	IN	B-PP	O
alteplase	NN	B-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
dehydroepiandrosterone	NN	B-NP	O
in	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
schizophrenia	NN	I-NP	B
models	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dehydroepiandrosterone	NN	B-NP	O
(	(	O	O
DHEA	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
Swiss	JJ	I-NP	O
albino	NN	I-NP	O
female	JJ	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
amphetamine	NN	B-NP	O
-	HYPH	O	O
free	JJ	O	O
(	(	O	O
control	NN	B-NP	O
)	)	O	O
,	,	O	O
amphetamine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
DHEA	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
DHEA	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
(	(	O	O
ip	RB	B-ADVP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Amphetamine	NN	B-NP	O
induced	VBD	B-VP	O
hyper	NN	B-NP	B
locomotion	NN	I-NP	O
,	,	O	O
apomorphine	NN	B-NP	O
induced	VBD	B-VP	O
climbing	VBG	I-VP	O
,	,	O	O
and	CC	O	O
haloperidol	NN	B-NP	O
induced	VBD	B-VP	O
catalepsy	NN	B-NP	B
tests	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
animal	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
Animal	NNP	I-NP	O
Experiment	NNP	I-NP	O
Laboratories	NNP	I-NP	O
,	,	O	O
Department	NNP	B-NP	O
of	IN	B-PP	O
Pharmacology	NNP	B-NP	O
,	,	O	O
Medical	NNP	B-NP	O
School	NNP	I-NP	O
,	,	O	O
Eskisehir	NNP	B-NP	O
Osmangazi	NNP	I-NP	O
University	NNP	I-NP	O
,	,	O	O
Eskisehir	NNP	B-NP	O
,	,	O	O
Turkey	NNP	B-NP	O
between	IN	B-PP	O
March	NNP	B-NP	O
and	CC	O	O
May	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Statistical	JJ	B-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
using	VBG	B-VP	O
Kruskal	NNP	B-NP	O
-	HYPH	I-NP	O
Wallis	NNP	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
hyper	NN	B-NP	B
locomotion	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
way	NN	I-NP	O
ANOVA	NN	I-NP	O
for	IN	B-PP	O
climbing	NN	B-NP	O
and	CC	I-NP	O
catalepsy	NN	I-NP	B
tests	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotion	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
movements	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
group	NN	I-NP	O
.	.	O	O

Both	CC	O	O
DHEA	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	O
all	DT	B-NP	O
movements	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotion	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
test	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
climbing	NN	I-NP	O
time	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
apomorphine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
climbing	VBG	I-NP	O
test	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
that	IN	B-SBAR	O
DHEA	NN	B-NP	O
reduced	VBD	B-VP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
catalepsy	NN	I-NP	B
at	IN	B-PP	O
both	DT	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
it	PRP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
climbing	VBG	B-VP	O
behavior	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
DHEA	NN	B-NP	O
displays	VBZ	B-VP	O
typical	JJ	B-NP	O
neuroleptic	JJ	I-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Availability	NN	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
induced	VBN	I-NP	O
pluripotent	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
-	HYPH	B-NP	O
derived	VBN	I-NP	O
cardiomyocytes	NNS	I-NP	O
in	IN	B-PP	O
assessment	NN	B-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
.	.	O	O

Field	JJ	B-NP	O
potential	JJ	I-NP	O
duration	NN	I-NP	O
(	(	O	O
FPD	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
human	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
pluripotent	JJ	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
-	HYPH	B-NP	O
derived	VBN	I-NP	O
cardiomyocytes	NNS	I-NP	O
(	(	O	O
hiPS	NN	B-NP	O
-	HYPH	B-NP	O
CMs	NNS	I-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
can	MD	B-VP	O
express	VB	I-VP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
electrocardiogram	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
tool	NN	I-NP	O
to	TO	B-VP	O
predict	VB	I-VP	O
K	NN	B-NP	O
channel	NN	I-NP	O
and	CC	O	O
Ca	NN	B-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
report	NN	I-NP	O
showing	VBG	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
technique	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
predict	VB	I-VP	O
multichannel	JJ	B-NP	O
blocker	NN	I-NP	O
potential	NN	I-NP	O
for	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
show	VB	I-VP	O
that	IN	B-SBAR	O
FPD	NN	B-NP	O
from	IN	B-PP	O
MEA	NN	B-NP	O
(	(	O	O
Multielectrode	NN	B-NP	O
array	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
hiPS	NN	B-NP	O
-	HYPH	O	O
CMs	NNS	B-NP	O
can	MD	B-VP	O
detect	VB	I-VP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
multichannel	JJ	B-NP	O
blockers.	NN	I-NP	O
hiPS	NN	I-NP	O
-	HYPH	B-NP	O
CMs	NNS	I-NP	O
were	VBD	B-VP	O
seeded	VBN	I-VP	O
onto	IN	B-PP	O
MEA	NN	B-NP	O
and	CC	I-NP	O
FPD	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
for	IN	B-PP	O
2min	NN	B-NP	O
every	DT	B-NP	O
10min	NN	I-NP	O
for	IN	B-PP	O
30min	NN	B-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
exposure	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
and	CC	O	O
each	DT	B-NP	O
drug	NN	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

IKr	NN	B-NP	O
and	CC	I-NP	O
IKs	NN	I-NP	O
blockers	NNS	I-NP	O
concentration	NN	I-NP	O
-	HYPH	O	O
dependently	RB	B-ADVP	O
prolonged	VBD	B-VP	O
corrected	VBN	I-VP	O
FPD	NN	B-NP	O
(	(	O	O
FPDc	NN	B-NP	O
)	)	O	O
,	,	O	O
whereas	IN	O	O
Ca	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
concentration	NN	I-NP	O
-	HYPH	O	O
dependently	RB	B-ADVP	O
shortened	VBD	B-VP	O
FPDc	NN	B-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
multichannel	JJ	I-NP	O
blockers	NNS	I-NP	O
Amiodarone	NN	I-NP	O
,	,	O	O
Paroxetine	NN	B-NP	O
,	,	O	O
Terfenadine	NN	B-NP	O
and	CC	I-NP	O
Citalopram	NN	I-NP	O
prolonged	VBD	B-VP	O
FPDc	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
concentration	NN	I-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
IKr	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
Terfenadine	NN	B-NP	O
and	CC	I-NP	O
Citalopram	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
Torsade	NNP	B-NP	B
de	IN	I-NP	I
Pointes	NNP	I-NP	I
(	(	O	O
TdP	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
,	,	O	O
produced	VBD	B-VP	O
early	JJ	B-NP	O
afterdepolarization	NN	I-NP	O
(	(	O	O
EAD	NN	B-NP	O
)	)	O	O
.	.	O	O
hiPS	NN	B-NP	O
-	HYPH	O	O
CMs	NNS	B-NP	O
using	VBG	B-VP	O
MEA	NN	B-NP	O
system	NN	I-NP	O
and	CC	I-NP	O
FPDc	NN	I-NP	O
can	MD	B-VP	O
predict	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
candidates	NNS	I-NP	O
on	IN	B-PP	O
QT	NN	B-NP	O
interval	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
also	RB	B-ADVP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
assay	NN	I-NP	O
can	MD	B-VP	O
help	VB	I-VP	O
detect	VB	I-VP	O
EAD	NN	B-NP	O
for	IN	B-PP	O
drugs	NNS	B-NP	O
with	IN	B-PP	O
TdP	NN	B-NP	B
potential	NN	I-NP	O
.	.	O	O

Dermal	JJ	B-NP	O
developmental	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
phenylimide	NN	I-NP	O
herbicides	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

S	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
S	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
are	VBP	B-VP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
phenylimide	NN	I-NP	O
herbicides	NNS	I-NP	O
and	CC	O	O
produced	VBD	B-VP	O
embryolethality	NN	B-NP	B
,	,	O	O
teratogenicity	NN	B-NP	B
(	(	O	O
mainly	RB	B-NP	O
ventricular	JJ	I-NP	B
septal	JJ	I-NP	I
defects	NNS	I-NP	I
and	CC	O	O
wavy	NN	B-NP	O
ribs	NNS	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
growth	NN	B-NP	B
retardation	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
in	IN	B-PP	O
conventional	JJ	B-NP	O
oral	JJ	I-NP	O
developmental	JJ	I-NP	O
toxicity	NN	I-NP	B
studies	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
objective	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
compounds	NNS	I-NP	O
induce	VBP	B-VP	O
developmental	JJ	B-NP	O
toxicity	NN	I-NP	B
via	IN	B-PP	O
the	DT	B-NP	O
dermal	JJ	I-NP	O
route	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
relevant	JJ	I-ADJP	O
to	TO	B-PP	O
occupational	JJ	B-NP	O
exposure	NN	I-NP	O
,	,	O	O
hence	RB	B-ADJP	O
better	JJR	I-ADJP	O
addressing	VBG	B-VP	O
human	JJ	B-NP	O
health	NN	I-NP	O
risks	NNS	I-NP	O
.	.	O	O

S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
dermally	RB	B-ADVP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
during	IN	B-PP	O
organogenesis	NN	B-NP	O
,	,	O	O
and	CC	O	O
S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	O	O
the	DT	B-NP	O
maximum	NN	I-NP	O
applicable	JJ	I-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
)	)	O	O
.	.	O	O

Fetuses	NNS	B-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
Cesarean	JJ	I-NP	O
section	NN	I-NP	O
and	CC	O	O
examined	VBN	B-VP	O
for	IN	B-PP	O
external	JJ	B-NP	O
,	,	I-NP	O
visceral	JJ	I-NP	O
,	,	O	O
and	CC	O	O
skeletal	JJ	B-NP	O
alterations	NNS	I-NP	O
.	.	O	O

Dermal	JJ	B-NP	O
exposure	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
to	TO	B-PP	O
S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
produced	VBN	B-VP	O
patterns	NNS	B-NP	O
of	IN	B-PP	O
developmental	JJ	B-NP	O
toxicity	NN	I-NP	B
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
resulting	VBG	B-VP	O
from	IN	B-PP	O
oral	JJ	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

Toxicity	NN	B-NP	B
included	VBD	B-VP	O
embryolethality	NN	B-NP	B
,	,	O	O
teratogenicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
growth	NN	B-NP	B
retardation	NN	I-NP	I
.	.	O	O

Dermal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
embryonic	JJ	B-NP	B
death	NN	I-NP	I
and	CC	O	O
ventricular	JJ	B-NP	B
septal	JJ	I-NP	I
defect	NN	I-NP	I
,	,	O	O
but	CC	O	O
retarded	VBD	B-VP	O
fetal	JJ	B-NP	O
growth	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
as	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
following	VBG	I-VP	O
oral	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
,	,	O	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	B-NP	O
were	VBD	B-VP	O
teratogenic	JJ	B-ADJP	B
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
dermally	RB	B-ADVP	O
to	TO	B-PP	O
pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
as	IN	B-SBAR	O
were	VBD	B-VP	O
the	DT	B-NP	O
compounds	NNS	I-NP	O
administered	VBN	B-VP	O
orally	RB	B-ADVP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
investigation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
human	JJ	I-NP	O
relevancy	NN	I-NP	O
become	VBP	B-VP	O
more	RBR	B-ADJP	O
important	JJ	I-ADJP	O
.	.	O	O

Rates	NNS	B-NP	O
of	IN	B-PP	O
Renal	JJ	B-NP	B
Toxicity	NN	I-NP	I
in	IN	B-PP	O
Cancer	NNP	B-NP	B
Patients	NNP	I-NP	O
Receiving	NNP	I-NP	O
Cisplatin	NNP	I-NP	O
With	IN	B-PP	O
and	CC	I-PP	O
Without	IN	I-PP	O
Mannitol	NNP	B-NP	O
.	.	O	O

Cisplatin	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
antineoplastic	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
many	JJ	B-NP	O
strategies	NNS	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
this	DT	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
nephroprotectant	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
hydration	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
agent	NN	I-NP	O
cisplatin	NN	I-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
mannitol	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
center	NN	I-NP	O
retrospective	JJ	I-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
quasi	JJ	I-NP	O
experiment	NN	I-NP	O
created	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
national	JJ	I-NP	O
mannitol	NN	I-NP	O
shortage	NN	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
on	IN	B-PP	O
adult	JJ	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
agent	NN	I-NP	O
cisplatin	NN	I-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
from	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
September	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
acute	JJ	B-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
(	(	O	O
AKI	NN	B-NP	B
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
single	JJ	B-NP	O
-	HYPH	I-NP	O
agent	NN	I-NP	O
cisplatin	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
head	NN	B-NP	B
and	CC	I-NP	I
neck	NN	I-NP	I
cancer	NN	I-NP	I
as	IN	B-PP	O
their	PRP$	B-NP	O
primary	JJ	I-NP	O
malignancy	NN	I-NP	B
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
receive	VB	I-VP	O
mannitol	NN	B-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
develop	VB	I-VP	O
nephrotoxicity	NN	B-NP	B
:	:	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
[	(	O	O
OR	NN	B-NP	O
]	)	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m	NN	I-NP	O
dosing	NN	I-NP	O
and	CC	O	O
patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
also	RB	B-ADVP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
likelihood	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
nephrotoxicity	NN	B-NP	B
:	:	O	O
OR	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
and	CC	O	O
OR	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

When	WRB	B-ADVP	O
limited	JJ	B-NP	O
quantities	NNS	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
,	,	O	O
it	PRP	B-NP	O
should	MD	B-VP	O
preferentially	RB	I-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
particularly	RB	B-NP	O
high	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

Our	PRP$	B-NP	O
analysis	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
those	DT	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
dosing	NN	I-NP	O
schedule	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
cisplatin	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
those	DT	B-NP	O
with	IN	B-PP	O
hypertension	NN	B-NP	B
are	VBP	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
and	CC	O	O
would	MD	B-VP	O
benefit	VB	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
mannitol	NN	B-NP	O
.	.	O	O

Metformin	NN	B-NP	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
learning	NN	B-NP	B
and	CC	I-NP	I
memory	NN	I-NP	I
impairments	NNS	I-NP	I
and	CC	O	O
oxidative	JJ	B-NP	O
damage	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
pentylenetetrazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
kindling	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
and	CC	I-NP	O
severe	JJ	I-NP	O
comorbidity	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
,	,	O	O
greatly	RB	B-VP	O
diminishes	VBZ	I-VP	O
the	DT	B-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
current	JJ	B-NP	O
therapeutic	JJ	I-NP	O
interventions	NNS	I-NP	O
for	IN	B-PP	O
epilepsy	NN	B-NP	B
can	MD	B-VP	O
also	RB	I-VP	O
cause	VB	I-VP	O
untoward	JJ	B-NP	O
cognitive	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
urgent	JJ	I-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
new	JJ	B-NP	O
kinds	NNS	I-NP	O
of	IN	B-PP	O
agents	NNS	B-NP	O
targeting	VBG	B-VP	O
both	DT	B-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
cognition	NN	I-NP	B
deficits	NNS	I-NP	I
.	.	O	O

Oxidative	JJ	B-NP	O
stress	NN	I-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
epileptogenesis	NN	B-NP	O
and	CC	O	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
,	,	O	O
and	CC	O	O
antioxidants	NNS	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
putative	JJ	I-NP	O
antiepileptic	JJ	I-NP	O
potential	NN	I-NP	O
.	.	O	O

Metformin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
commonly	RB	I-NP	O
prescribed	VBN	I-NP	O
antidiabetic	JJ	I-NP	O
oral	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
antioxidant	JJ	B-NP	O
properties	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
ameliorative	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
on	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
and	CC	O	O
brain	NN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
markers	NNS	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
pentylenetetrazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
kindling	NN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
C57BL	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
with	IN	B-PP	O
subconvulsive	JJ	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pentylenetetrazole	NN	B-NP	O
every	DT	B-NP	O
other	JJ	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
injections	NNS	I-NP	O
.	.	O	O

Metformin	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
in	IN	B-PP	O
dose	NN	B-NP	O
of	IN	B-PP	O
200mg	NN	B-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
alternate	JJ	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
PTZ	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
metformin	NN	B-NP	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
kindling	NN	B-NP	O
,	,	O	O
ameliorated	VBD	B-VP	O
the	DT	B-NP	O
cognitive	JJ	I-NP	B
impairment	NN	I-NP	I
and	CC	O	O
decreased	VBD	B-VP	O
brain	NN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
concluded	VBD	B-VP	O
that	IN	B-SBAR	O
metformin	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
potential	JJ	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
medicine	NN	I-NP	O
against	IN	B-PP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

P53	NN	B-NP	O
inhibition	NN	I-NP	O
exacerbates	VBZ	B-VP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
stage	NN	I-NP	O
anthracycline	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Doxorubicin	NN	B-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
cancer	NN	I-NP	B
therapeutic	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
both	CC	B-NP	O
acute	JJ	I-NP	O
and	CC	I-NP	O
late	JJ	I-NP	O
-	HYPH	I-NP	O
stage	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Children	NNS	B-NP	O
are	VBP	B-VP	O
particularly	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
DOX	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
impact	NN	I-NP	O
of	IN	B-PP	O
p53	NN	B-NP	O
inhibition	NN	I-NP	O
on	IN	B-PP	O
acute	JJ	B-NP	O
vs.	IN	B-PP	O
late	JJ	B-NP	O
-	HYPH	I-NP	O
stage	NN	I-NP	O
DOX	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
juvenile	JJ	I-NP	O
model	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
MHC	NN	I-NP	O
-	HYPH	B-NP	O
CB7	NN	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
which	WDT	B-NP	O
express	VBP	B-VP	O
dominant	JJ	B-ADJP	O
-	HYPH	O	O
interfering	VBG	B-VP	O
p53	NN	B-NP	O
in	IN	B-PP	O
cardiomyocytes	NNS	B-NP	O
)	)	O	O
and	CC	O	O
their	PRP$	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
transgenic	JJ	I-NP	O
(	(	O	O
NON	NN	B-NP	O
-	HYPH	B-NP	O
TXG	NN	I-NP	O
)	)	O	O
littermates	NNS	B-NP	O
received	VBD	B-VP	O
weekly	JJ	B-NP	O
DOX	NN	I-NP	O
injections	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
week	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
DOX	NN	I-NP	O
treatment	NN	I-NP	O
(	(	O	O
acute	JJ	B-NP	O
stage	NN	I-NP	O
)	)	O	O
,	,	O	O
MHC	NN	B-NP	O
-	HYPH	B-NP	O
CB7	NN	I-NP	O
mice	NNS	I-NP	O
exhibited	VBD	B-VP	O
improved	JJ	B-NP	O
cardiac	JJ	I-NP	O
function	NN	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
apoptosis	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
NON	NN	I-NP	O
-	HYPH	B-NP	O
TXG	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Surprisingly	RB	B-ADVP	O
,	,	O	O
by	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
following	VBG	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
DOX	NN	I-NP	O
treatment	NN	I-NP	O
(	(	O	O
late	JJ	B-NP	O
stage	NN	I-NP	O
)	)	O	O
,	,	O	O
MHC	NN	B-NP	O
-	HYPH	B-NP	O
CB7	NN	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
apoptosis	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
NON	NN	B-NP	O
-	HYPH	I-NP	O
TXG	NN	I-NP	O
mice.	NN	I-NP	O
p53	NN	I-NP	O
inhibition	NN	I-NP	O
blocked	VBD	B-VP	O
transient	JJ	B-NP	O
DOX	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
STAT3	NN	I-NP	O
activation	NN	I-NP	O
in	IN	B-PP	O
MHC	NN	B-NP	O
-	HYPH	B-NP	O
CB7	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
enhanced	VBN	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DNA	NN	I-NP	O
repair	NN	I-NP	O
proteins	NNS	I-NP	O
Ku70	NN	I-NP	O
and	CC	I-NP	O
Ku80	NN	I-NP	O
.	.	O	O

Mice	NNS	B-NP	O
with	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
-	HYPH	B-NP	O
restricted	VBN	I-NP	O
deletion	NN	I-NP	O
of	IN	B-PP	O
STAT3	NN	B-NP	O
exhibited	VBD	B-VP	O
worse	JJR	B-NP	O
cardiac	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
higher	JJR	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
apoptosis	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
greater	JJR	I-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
Ku70	NN	B-NP	O
and	CC	I-NP	O
Ku80	NN	I-NP	O
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
DOX	NN	B-NP	O
treatment	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
stage	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
support	VBP	B-VP	O
a	DT	B-NP	O
model	NN	I-NP	O
wherein	IN	B-PP	O
a	DT	B-NP	O
p53	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
cardioprotective	JJ	I-NP	O
pathway	NN	I-NP	O
,	,	O	O
mediated	VBN	B-VP	O
via	IN	B-PP	O
STAT3	NN	B-NP	O
activation	NN	I-NP	O
,	,	O	O
mitigates	VBZ	B-VP	O
DOX	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	O
stress	NN	I-NP	O
during	IN	B-PP	O
drug	NN	B-NP	O
delivery	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
an	DT	B-NP	O
explanation	NN	I-NP	O
as	IN	B-PP	O
to	TO	B-PP	O
how	WRB	B-ADVP	O
p53	NN	B-NP	O
inhibition	NN	I-NP	O
can	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
cardioprotection	NN	B-NP	O
during	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
,	,	O	O
paradoxically	RB	B-ADVP	O
,	,	O	O
enhanced	VBN	B-NP	O
cardiotoxicity	NN	I-NP	B
long	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
cessation	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Metronidazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
:	:	O	O
an	DT	B-NP	O
uncommon	JJ	I-NP	O
scenario	NN	I-NP	O
.	.	O	O

Metronidazole	NN	B-NP	O
can	MD	B-VP	O
produce	VB	I-VP	O
neurological	JJ	B-NP	O
complications	NNS	I-NP	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
scenario	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
where	WRB	B-ADVP	O
a	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
features	NNS	B-NP	O
of	IN	B-PP	O
encephalopathy	NN	B-NP	B
following	VBG	B-PP	O
prolonged	JJ	B-NP	O
metronidazole	NN	I-NP	O
intake	NN	I-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
brain	NN	B-NP	O
showed	VBD	B-VP	O
abnormal	JJ	B-NP	O
signal	NN	I-NP	O
intensity	NN	I-NP	O
involving	VBG	B-VP	O
both	CC	O	O
dentate	VBP	B-VP	O
nuclei	NNS	B-NP	O
of	IN	B-PP	O
cerebellum	NN	B-NP	O
and	CC	I-NP	O
splenium	NN	I-NP	O
of	IN	B-PP	O
corpus	NN	B-NP	O
callosum	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
metronidazole	NN	B-NP	O
toxicity	NN	I-NP	B
was	VBD	B-VP	O
made	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
MRI	NN	I-NP	O
findings	NNS	I-NP	O
and	CC	O	O
supported	VBN	B-VP	O
clinically	RB	B-ADVP	O
.	.	O	O

Aconitine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Ca2	NN	I-NP	O
+	SYM	O	O
overload	NN	B-NP	O
causes	VBZ	B-VP	O
arrhythmia	NN	B-NP	B
and	CC	O	O
triggers	VBZ	B-VP	O
apoptosis	NN	B-NP	O
through	IN	B-PP	O
p38	NN	B-NP	O
MAPK	NN	I-NP	O
signaling	NN	I-NP	O
pathway	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Aconitine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
bioactive	JJ	I-NP	O
diterpenoid	NN	I-NP	O
alkaloid	JJ	B-ADJP	O
with	IN	B-PP	O
high	JJ	B-NP	O
content	NN	I-NP	O
derived	VBN	B-VP	O
from	IN	B-PP	O
herbal	JJ	B-NP	O
aconitum	NN	I-NP	O
plants	NNS	I-NP	O
.	.	O	O

Emerging	VBG	B-NP	O
evidence	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
voltage	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
Na	NN	I-NP	O
channels	NNS	I-NP	O
have	VBP	B-VP	O
pivotal	JJ	B-NP	O
roles	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
aconitine	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
reports	NNS	I-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
in	IN	B-PP	O
aconitine	NN	B-NP	O
poisoning	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
explored	VBD	B-VP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
pathological	JJ	B-NP	O
Ca	NN	I-NP	O
signaling	NN	I-NP	O
in	IN	B-PP	O
aconitine	NN	B-NP	O
poisoning	NN	I-NP	B
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
Ca	NN	B-NP	O
overload	NN	I-NP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
accelerated	VBN	B-NP	O
beating	VBG	I-NP	O
rhythm	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
rat	NN	I-NP	O
ventricular	JJ	I-NP	O
myocytes	NNS	I-NP	O
and	CC	O	O
caused	VBD	B-VP	O
arrhythmia	NN	B-NP	B
in	IN	B-PP	O
conscious	JJ	B-ADJP	O
freely	RB	B-VP	O
moving	VBG	I-VP	O
rats	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
aconitine	NN	B-NP	O
on	IN	B-PP	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
cytotoxicity	NN	B-NP	B
assay	NN	I-NP	O
in	IN	B-PP	O
neonatal	JJ	B-NP	O
rat	NN	I-NP	O
ventricular	JJ	I-NP	O
myocytes	NNS	I-NP	O
(	(	O	O
NRVMs	NNS	B-NP	O
)	)	O	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
measured	VBN	B-NP	O
lactate	NN	I-NP	O
dehydrogenase	NN	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
culture	NN	I-NP	O
medium	NN	I-NP	O
of	IN	B-PP	O
NRVMs	NNS	B-NP	O
and	CC	I-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
cardiac	JJ	I-NP	O
enzymes	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
aconitine	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	B
injury	NN	I-NP	I
and	CC	O	O
reduced	VBN	B-NP	O
NRVMs	NNS	I-NP	O
viability	NN	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-VP	O
dependently	RB	B-ADVP	O
.	.	O	O

To	TO	B-VP	O
confirm	VB	I-VP	O
the	DT	B-NP	O
pro	AFX	I-NP	O
-	HYPH	I-NP	O
apoptotic	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
flow	NN	B-NP	O
cytometric	JJ	I-NP	O
detection	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
histology	NN	I-NP	O
,	,	O	O
transmission	NN	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
and	CC	O	O
terminal	JJ	B-NP	O
deoxynucleotidyl	NN	I-NP	O
transferase	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
dUTP	NN	I-NP	O
-	HYPH	B-NP	O
biotin	NN	I-NP	O
nick	NN	I-NP	O
end	NN	I-NP	O
labeling	NN	I-NP	O
assay	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
aconitine	NN	B-NP	O
stimulated	VBD	B-VP	O
apoptosis	NN	B-NP	O
time	NN	I-NP	O
-	HYPH	B-VP	O
dependently	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
handling	NN	I-NP	O
proteins	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
aconitine	NN	B-NP	O
promoted	VBD	B-VP	O
Ca	NN	B-NP	O
overload	RB	B-ADVP	O
through	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
Ca	NN	B-NP	O
handling	VBG	B-VP	O
proteins	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
apoptosis	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
proteins	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
pro	AFX	B-NP	O
-	HYPH	I-NP	O
apoptotic	JJ	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
upregulated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
apoptotic	JJ	I-NP	O
protein	NN	I-NP	O
BCL	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
downregulated	VBN	I-VP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
increased	VBN	B-NP	O
phosphorylation	NN	I-NP	O
of	IN	B-PP	O
MAPK	NN	B-NP	O
family	NN	I-NP	O
members	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
the	DT	B-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P38	NN	I-NP	O
/	SYM	B-NP	O
P38	NN	I-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
tissues	NNS	I-NP	O
.	.	O	O

Hence	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
aconitine	NN	B-NP	O
significantly	RB	B-VP	O
aggravates	VBZ	I-VP	O
Ca	NN	B-NP	O
overload	NN	I-NP	O
and	CC	O	O
causes	VBZ	B-VP	O
arrhythmia	NN	B-NP	B
and	CC	O	O
finally	RB	B-VP	O
promotes	VBZ	I-VP	O
apoptotic	JJ	B-NP	O
development	NN	I-NP	O
via	IN	B-PP	O
phosphorylation	NN	B-NP	O
of	IN	B-PP	O
P38	NN	B-NP	O
mitogen	NN	I-NP	O
-	HYPH	B-VP	O
activated	VBN	B-NP	O
protein	NN	I-NP	O
kinase	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
suppresses	VBZ	B-VP	O
toll	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
receptor	NN	I-NP	O
num	CD	I-NP	O
signaling	NN	I-NP	O
and	CC	O	O
attenuates	VBZ	B-VP	O
left	JJ	B-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
following	VBG	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
by	IN	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
responses	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
activation	NN	B-NP	O
of	IN	B-PP	O
AMP	NN	B-NP	O
-	HYPH	B-NP	O
activated	VBN	I-NP	O
protein	NN	I-NP	O
kinase	NN	I-NP	O
(	(	O	O
AMPK	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
toll	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
receptor	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
TLR4	NN	B-NP	O
)	)	O	O
activities	NNS	B-NP	O
following	VBG	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
and	CC	O	O
their	PRP$	B-NP	O
relation	NN	I-NP	O
with	IN	B-PP	O
AMPK	NN	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
normal	JJ	B-NP	O
control	NN	I-NP	O
and	CC	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
isoproterenol	NN	B-NP	O
after	IN	B-PP	O
chronic	JJ	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
subcutaneously	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
13th	JJ	I-NP	O
and	CC	I-NP	O
14th	JJ	I-NP	O
days	NNS	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
.	.	O	O

Isoproterenol	NN	B-NP	O
alone	RB	B-ADVP	O
decreased	VBD	B-VP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
systolic	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
myocardial	JJ	B-NP	O
contractility	NN	I-NP	O
indexed	VBN	B-VP	O
as	IN	B-PP	O
LVdp	NN	B-NP	O
/	SYM	B-VP	O
dtmax	NN	B-NP	O
and	CC	I-NP	O
LVdp	NN	I-NP	O
/	SYM	B-NP	O
dtmin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
.	.	O	O

Metfromin	NN	B-NP	O
markedly	RB	B-ADVP	O
lowered	VBD	B-VP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
elevation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
TLR4	NN	B-NP	O
mRNA	NN	I-NP	O
,	,	O	O
myeloid	JJ	B-NP	O
differentiation	NN	I-NP	O
protein	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
MyD88	NN	B-NP	O
)	)	O	O
,	,	O	O
tumor	NN	B-NP	B
necrosis	NN	I-NP	B
factor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
(	(	O	O
TNF	NN	B-NP	O
-	HYPH	O	O
a	DT	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
interleukin	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
tissues	NNS	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
TNF	NN	B-NP	O
-	HYPH	O	O
a	DT	B-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
lower	JJR	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
effective	JJ	I-ADJP	O
than	IN	B-PP	O
100mg	NN	B-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Phosphorylated	VBN	B-NP	O
AMPKa	NN	I-NP	O
(	(	O	O
p	NN	B-NP	O
-	HYPH	B-NP	O
AMPK	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
elevated	VBN	I-VP	O
by	IN	B-PP	O
25mg	NN	B-NP	O
/	SYM	O	O
kg	NN	B-NP	O
of	IN	B-PP	O
metformin	NN	B-NP	O
,	,	O	O
slightly	RB	B-ADVP	O
by	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	I-PP	O
by	IN	B-PP	O
100mg	NN	B-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

Chronic	JJ	O	O
pre	AFX	O	O
-	HYPH	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
reduces	VBZ	B-VP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
cardiac	JJ	I-NP	O
dysfunction	NN	I-NP	O
and	CC	O	O
suppresses	VBZ	B-VP	O
inflammatory	JJ	B-NP	O
responses	NNS	I-NP	O
,	,	O	O
possibly	RB	B-ADVP	O
through	IN	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
TLR4	NN	B-NP	O
activities	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
mechanism	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
target	NN	I-NP	O
to	TO	B-VP	O
protect	VB	I-VP	O
infarcted	JJ	B-NP	O
myocardium	NN	I-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
tetrabenazine	NN	B-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
Japanese	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
Huntington	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
at	IN	B-PP	O
the	DT	B-NP	O
terminal	JJ	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
recurrent	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
herein	RB	B-ADVP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Japanese	JJ	I-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
that	WDT	B-NP	O
occurred	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
tiapride	NN	B-NP	O
and	CC	I-NP	O
tetrabenazine	NN	I-NP	O
for	IN	B-PP	O
Huntington	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
tiapride	NN	B-NP	O
or	CC	I-NP	O
tetrabenazine	NN	I-NP	O
alone	RB	B-ADVP	O
without	IN	B-PP	O
any	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
also	RB	B-ADVP	O
had	VBD	B-VP	O
advanced	VBN	I-VP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
when	WRB	B-ADVP	O
the	DT	B-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
.	.	O	O

To	TO	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
tetrabenazine	NN	B-NP	O
and	CC	I-NP	O
tiapride	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Tetrabenazine	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
very	RB	B-ADVP	O
carefully	RB	I-ADVP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
neuroleptic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
worsening	VBG	I-NP	O
general	JJ	I-NP	O
condition	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
metoprolol	NN	I-NP	O
-	HYPH	I-NP	O
terbinafine	NN	I-NP	O
combination	NN	I-NP	O
induced	VBD	B-VP	O
bradycardia	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
sinus	NN	I-NP	B
bradycardia	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
metoprolol	NN	B-NP	O
and	CC	I-NP	O
terbinafine	NN	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
management	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Caucasian	JJ	I-NP	O
man	NN	I-NP	O
on	IN	B-PP	O
metoprolol	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
stable	JJ	B-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
was	VBD	B-VP	O
prescribed	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
terbinafine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
onychomycosis	NN	B-NP	B
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
49th	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
terbinafine	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
brought	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
room	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
his	PRP$	B-NP	O
global	JJ	I-NP	O
health	NN	I-NP	O
status	NN	I-NP	O
,	,	O	O
confusion	NN	B-NP	B
and	CC	I-NP	O
falls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
electrocardiogram	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
sinus	NN	I-NP	B
bradycardia	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
adverse	JJ	I-NP	B
drug	NN	I-NP	I
reaction	NN	I-NP	I
probability	NN	I-NP	O
scale	NN	I-NP	O
indicates	VBZ	B-VP	O
a	DT	B-NP	O
probable	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
sinus	NN	I-NP	B
bradycardia	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
metoprolol	NN	B-NP	O
and	CC	I-NP	O
terbinafine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
ameliorated	VBN	B-VP	O
first	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
metoprolol	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
subsequently	RB	I-VP	O
changed	VBN	I-VP	O
to	TO	B-PP	O
bisoprolol	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
remained	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

By	IN	B-PP	O
inhibiting	VBG	B-VP	O
the	DT	B-NP	O
cytochrome	NN	I-NP	O
P450	NN	I-NP	O
2D6	NN	I-NP	O
,	,	O	O
terbinafine	NN	B-NP	O
had	VBD	B-VP	O
decreased	VBN	I-VP	O
metoprolol	NN	B-NP	O
s	NNS	I-NP	O
clearance	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
in	IN	B-PP	O
metoprolol	NN	B-NP	O
accumulation	NN	I-NP	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
resulted	VBN	I-VP	O
in	IN	B-PP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
sinus	NN	I-NP	B
bradycardia	NN	I-NP	I
.	.	O	O

Optochiasmatic	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
ethambutol	NN	B-NP	O
overtreatment	NN	I-NP	O
.	.	O	O

Ethambutol	NN	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
and	CC	O	O
,	,	O	O
more	RBR	B-ADVP	O
rarely	RB	I-ADVP	O
,	,	O	O
axonal	JJ	B-NP	O
polyneuropathy	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
characterize	VBP	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
,	,	I-NP	O
neurophysiological	JJ	I-NP	O
,	,	O	O
and	CC	O	O
neuroimaging	NN	B-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
visual	JJ	B-NP	B
loss	NN	I-NP	I
and	CC	I-NP	O
paresthesias	NNS	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
supratherapeutic	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ethambutol	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
demonstrates	VBZ	B-VP	O
the	DT	B-NP	O
selective	JJ	I-NP	O
vulnerability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anterior	JJ	I-NP	O
visual	JJ	I-NP	O
pathways	NNS	I-NP	O
and	CC	O	O
peripheral	JJ	B-NP	O
nerves	NNS	I-NP	O
to	TO	B-PP	O
ethambutol	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Testosterone	NN	B-NP	O
ameliorates	VBZ	B-VP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
memory	NN	I-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
testosterone	NN	B-NP	O
on	IN	B-PP	O
streptozotocin	NN	B-NP	O
(	(	O	O
STZ	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
memory	NN	I-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Adult	JJ	B-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
intracerebroventricularly	RB	B-ADVP	O
(	(	O	O
icv	NN	B-NP	O
)	)	O	O
infused	VBN	B-VP	O
with	IN	B-PP	O
STZ	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
ug	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
d	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
d	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
a	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
STZ	NN	B-NP	O
.	.	O	O

Castration	NN	B-NP	O
surgery	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
another	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
operation	NN	I-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
androgen	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
flutamide	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
estrogen	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
tamoxifen	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
aromatase	NN	I-NP	O
inhibitor	NN	I-NP	O
letrozole	NN	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
d	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
STZ	NN	B-NP	O
.	.	O	O

STZ	NN	B-NP	O
administration	NN	I-NP	O
and	CC	O	O
castration	NN	B-NP	O
markedly	RB	B-ADVP	O
decreased	VBD	B-VP	O
both	CC	O	O
STL1	NN	B-NP	O
(	(	O	O
the	DT	B-NP	O
short	JJ	I-NP	O
memory	NN	I-NP	O
)	)	O	O
and	CC	O	O
STL2	NN	B-NP	O
(	(	O	O
the	DT	B-NP	O
long	JJ	I-NP	O
memory	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

Testosterone	NN	B-NP	O
replacement	NN	I-NP	O
almost	RB	B-ADVP	O
restored	VBD	B-VP	O
the	DT	B-NP	O
STL1	NN	I-NP	O
and	CC	I-NP	O
STL2	NN	I-NP	O
in	IN	B-PP	O
castrated	VBN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
and	CC	O	O
significantly	RB	B-VP	O
prolonged	VBD	I-VP	O
the	DT	B-NP	O
STL1	NN	I-NP	O
and	CC	I-NP	O
STL2	NN	I-NP	O
in	IN	B-PP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
flutamide	NN	B-NP	O
,	,	O	O
letrozole	NN	B-NP	O
or	CC	O	O
tamoxifen	NN	B-NP	O
significantly	RB	B-ADVP	O
impaired	VBD	B-VP	B
the	DT	B-NP	I
memory	NN	I-NP	I
in	IN	B-PP	O
intact	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
and	CC	O	O
significantly	RB	B-VP	O
attenuated	VBD	I-VP	O
the	DT	B-NP	O
testosterone	NN	I-NP	O
replacement	NN	I-NP	O
in	IN	B-PP	O
improving	VBG	B-VP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
castration	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
memory	NN	I-NP	B
impairment	NN	I-NP	I
.	.	O	O

Testosterone	NN	B-NP	O
administration	NN	I-NP	O
ameliorates	VBZ	B-VP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
castration	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
memory	NN	I-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Behavioral	JJ	B-NP	O
and	CC	I-NP	O
neurochemical	JJ	I-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
garcinielliptone	NN	B-NP	O
FC	NN	I-NP	O
in	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Garcinielliptone	NN	B-NP	O
FC	NN	I-NP	O
(	(	O	O
GFC	NN	B-NP	O
)	)	O	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
hexanic	JJ	B-NP	O
fraction	NN	I-NP	O
seed	NN	I-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
species	NNS	B-NP	O
Platonia	NNP	B-NP	O
insignis	VBZ	B-VP	O
Mart	NNP	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
folk	NN	B-NP	O
medicine	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
skin	NN	B-NP	B
diseases	NNS	I-NP	I
in	IN	B-PP	O
both	CC	B-NP	O
humans	NNS	I-NP	O
and	CC	I-NP	O
animals	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
seed	NN	I-NP	O
decoction	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	I-VP	O
treat	VB	I-VP	O
diarrheas	NNS	B-NP	B
and	CC	O	O
inflammatory	JJ	B-NP	B
diseases	NNS	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
research	NN	I-NP	O
on	IN	B-PP	O
GFC	NN	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
of	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
GFC	NN	I-NP	O
effects	NNS	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
on	IN	B-PP	O
seizure	NN	B-NP	B
parameters	NNS	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
their	PRP$	B-NP	O
anticonvulsant	JJ	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
amino	NN	B-NP	O
acid	NN	I-NP	O
(	(	O	O
r	NN	B-NP	O
-	HYPH	O	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
)	)	O	O
,	,	O	O
glutamine	NN	B-NP	O
,	,	O	O
aspartate	NN	B-NP	O
and	CC	O	O
glutathione	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
on	IN	B-PP	O
acetylcholinesterase	NN	B-NP	O
(	(	O	O
AChE	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
hippocampus	NN	I-NP	O
after	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

GFC	NN	B-NP	O
produced	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
latency	NN	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
seizure	NN	I-NP	B
,	,	O	O
at	IN	B-PP	O
doses	NNS	B-NP	O
25mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
seized	VBN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
GABA	NN	B-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
hippocampus	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
GFC75	NN	B-NP	O
plus	CC	I-NP	O
P400	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
seized	VBN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
aspartate	NN	B-NP	O
,	,	O	O
glutamine	NN	B-NP	O
and	CC	I-NP	O
glutamate	NN	I-NP	O
levels	NNS	I-NP	O
detected	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
hippocampus	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
GFC75	NN	B-NP	O
plus	CC	I-NP	O
P400	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
seized	VBN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Hippocampus	NN	B-NP	O
mice	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
GFC75	NN	B-NP	O
plus	CC	I-NP	O
P400	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
AChE	NN	B-NP	O
activity	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
seized	VBN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
GFC	NN	B-NP	O
can	MD	B-VP	O
exert	VB	I-VP	O
anticonvulsant	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
reduce	VB	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
installation	NN	B-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
,	,	O	O
as	IN	B-SBAR	O
demonstrated	VBN	B-VP	O
by	IN	B-PP	O
increase	NN	B-NP	O
in	IN	B-PP	O
latency	NN	B-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
seizure	NN	I-NP	B
and	CC	O	O
decrease	NN	B-NP	O
in	IN	B-PP	O
mortality	NN	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
GFC	NN	B-NP	O
may	MD	B-VP	O
influence	VB	I-VP	O
in	IN	B-PP	O
epileptogenesis	NN	B-NP	O
and	CC	O	O
promote	VB	B-VP	O
anticonvulsant	JJ	B-NP	O
actions	NNS	I-NP	O
in	IN	B-PP	O
pilocarpine	NN	B-NP	O
model	NN	I-NP	O
by	IN	B-PP	O
modulating	VBG	B-VP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
and	CC	I-NP	O
glutamate	NN	I-NP	O
contents	NNS	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
AChE	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
seized	VBN	B-NP	O
mice	NNS	I-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
compound	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
to	TO	B-VP	O
produce	VB	I-VP	O
neuronal	JJ	B-NP	O
protection	NN	I-NP	O
and	CC	O	O
it	PRP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
anticonvulsant	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Standard	JJ	B-NP	O
operating	NN	I-NP	O
procedures	NNS	I-NP	O
for	IN	B-PP	O
antibiotic	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
clinical	JJ	I-NP	O
,	,	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
interventional	JJ	I-NP	O
,	,	I-NP	O
observational	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
(	(	O	O
AKI	NN	B-NP	B
)	)	O	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
hospitalized	VBN	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Intensive	JJ	B-NP	O
Care	NNP	I-NP	O
Unit	NNP	I-NP	O
(	(	O	O
ICU	NN	B-NP	O
)	)	O	O
patients	NNS	B-NP	O
.	.	O	O

It	PRP	B-NP	O
increases	VBZ	B-VP	O
mortality	NN	B-NP	O
,	,	O	O
hospital	NN	B-NP	O
length	NN	I-NP	O
of	IN	B-PP	O
stay	NN	B-NP	O
,	,	O	O
and	CC	O	O
costs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	I-VP	O
investigate	VB	I-VP	O
,	,	O	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
adherence	NN	B-NP	O
to	TO	B-PP	O
guidelines	NNS	B-NP	O
(	(	O	O
standard	JJ	B-NP	O
operating	NN	I-NP	O
procedures	NNS	I-NP	O
(	(	O	O
SOP	NN	B-NP	O
)	)	O	O
)	)	O	O
for	IN	B-PP	O
potentially	RB	B-NP	O
nephrotoxic	JJ	I-NP	B
antibiotics	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
AKI	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
as	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
clinical	JJ	I-NP	O
,	,	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
interventional	JJ	I-NP	O
,	,	I-NP	O
observational	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Data	NN	B-NP	O
collection	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
ICUs	NNS	I-NP	O
at	IN	B-PP	O
Charite	NNP	B-NP	O
-	HYPH	O	O
Universitaetsmedizin	NNP	B-NP	O
Berlin	NNP	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
;	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
had	VBD	B-VP	O
therapy	NN	B-NP	O
with	IN	B-PP	O
vancomycin	NN	B-NP	O
,	,	O	O
gentamicin	NN	B-NP	O
,	,	O	O
or	CC	O	O
tobramycin	NN	B-NP	O
;	:	O	O
were	VBD	B-VP	O
>	SYM	B-ADJP	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
and	CC	O	O
treated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
ICU	NN	I-NP	O
for	IN	B-PP	O
>	SYM	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
adherence	NN	I-NP	O
to	TO	B-PP	O
SOP	NN	B-NP	O
>	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
classified	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
adherence	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
HAG	NN	B-NP	O
)	)	O	O
and	CC	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
adherence	NN	I-NP	O
of	IN	B-PP	O
<	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
adherence	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
LAG	NN	B-NP	O
)	)	O	O
.	.	O	O

AKI	NN	B-NP	B
was	VBD	B-VP	O
defined	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
RIFLE	NN	B-NP	O
criteria	NNS	I-NP	O
.	.	O	O

Adherence	NN	B-NP	O
to	TO	B-PP	O
SOPs	NNS	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
retrospective	JJ	B-NP	O
expert	NN	I-NP	O
audit	NN	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
AKI	NN	B-NP	B
was	VBD	B-VP	O
compared	VBN	I-VP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
with	IN	B-PP	O
exact	JJ	B-NP	O
Chi2	NN	I-NP	O
-	HYPH	B-NP	O
test	NN	I-NP	O
and	CC	O	O
multivariate	JJ	B-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

LAG	NN	B-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
HAG	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

AKI	NN	B-NP	B
occurred	VBD	B-VP	O
significantly	RB	B-ADVP	O
more	RBR	I-ADVP	O
often	RB	I-ADVP	O
in	IN	B-PP	O
LAG	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
HAG	NN	B-NP	O
.	.	O	O

Basic	JJ	B-NP	O
characteristics	NNS	I-NP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
,	,	O	O
except	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
soft	JJ	B-NP	O
tissue	NN	I-NP	O
infections	NNS	I-NP	B
in	IN	B-PP	O
LAG	NN	B-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
an	DT	B-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
for	IN	B-PP	O
LAG	NN	B-NP	O
to	TO	B-VP	O
develop	VB	I-VP	O
AKI	NN	B-NP	B
compared	VBN	B-PP	O
with	IN	B-PP	O
HAG	NN	B-NP	O
.	.	O	O

Low	JJ	B-NP	O
adherence	NN	I-NP	O
to	TO	B-PP	O
SOPs	NNS	B-NP	O
for	IN	B-PP	O
potentially	RB	B-NP	O
nephrotoxic	JJ	I-NP	B
antibiotics	NNS	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
AKI	NN	B-NP	B
.	.	O	O

Current	JJ	B-NP	O
Controlled	JJ	I-NP	O
Trials	NNS	I-NP	O
ISRCTN54598675	NN	I-NP	O
.	.	O	O

Registered	VBN	B-NP	O
num	CD	I-NP	O
August	NNP	I-NP	O
num	CD	I-NP	O
.	.	O	O

Rhabdomyolysis	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
hepatitis	NN	I-NP	B
C	NN	I-NP	I
virus	NN	I-NP	I
infected	JJ	I-NP	I
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
telaprevir	NN	B-NP	O
and	CC	I-NP	O
simvastatin	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
chronic	JJ	I-NP	O
hepatitis	NN	I-NP	B
C	NN	I-NP	I
virus	NN	I-NP	I
infection	NN	I-NP	I
received	VBD	B-VP	O
triple	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
ribavirin	NN	B-NP	O
,	,	O	O
pegylated	VBN	B-NP	O
interferon	NN	I-NP	O
and	CC	I-NP	O
telaprevir	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
simvastatin	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
month	NN	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
the	DT	B-NP	O
antiviral	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
because	IN	B-SBAR	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
rhabdomyolysis	NN	B-NP	B
.	.	O	O

At	IN	B-PP	O
admission	NN	B-NP	O
simvastatin	NN	I-NP	O
and	CC	O	O
all	DT	B-NP	O
antiviral	JJ	I-NP	O
drugs	NNS	I-NP	O
were	VBD	B-VP	O
discontinued	VBN	I-VP	O
because	IN	B-SBAR	O
toxicity	NN	B-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
creatine	NN	I-NP	O
kinase	NN	I-NP	O
peaked	VBD	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
remained	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
hospitalization	NN	B-NP	O
,	,	O	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
level	NN	I-NP	O
had	VBD	B-VP	O
returned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
IU	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
discharged	VBN	I-VP	O
.	.	O	O

Telaprevir	NN	B-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
the	DT	B-NP	O
probable	JJ	I-NP	O
causative	JJ	I-NP	O
agent	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
interaction	NN	I-NP	O
with	IN	B-PP	O
simvastatin	NN	B-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
Drug	NNP	I-NP	O
Interaction	NNP	I-NP	O
Probability	NNP	I-NP	O
Scale	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
interaction	NN	I-NP	O
is	VBZ	B-VP	O
due	IN	B-PP	O
to	TO	I-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
CYP3A4	NN	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
simvastatin	NN	I-NP	O
clearance	NN	I-NP	O
.	.	O	O

Simvastatin	NN	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
increased	VBD	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
and	CC	I-NP	O
statin	NN	I-NP	O
induced	VBD	B-VP	O
muscle	NN	B-NP	B
toxicity	NN	I-NP	I
is	VBZ	B-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
statin	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
we	PRP	B-NP	O
illustrate	VBP	B-VP	O
that	IN	B-SBAR	O
telaprevir	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
statins	NNS	B-NP	O
are	VBP	B-VP	O
susceptible	JJ	B-ADJP	O
to	TO	B-PP	O
clinical	JJ	B-NP	O
relevant	JJ	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
.	.	O	O

Combination	NN	B-NP	O
of	IN	B-PP	O
bortezomib	NN	B-NP	O
,	,	O	O
thalidomide	NN	B-NP	O
,	,	O	O
and	CC	O	O
dexamethasone	NN	B-NP	O
(	(	O	O
VTD	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
a	DT	B-NP	O
consolidation	NN	I-NP	O
therapy	NN	I-NP	O
after	IN	B-PP	O
autologous	JJ	B-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
symptomatic	JJ	B-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
in	IN	B-PP	O
Japanese	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Consolidation	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
multiple	JJ	B-NP	B
myeloma	NN	I-NP	I
(	(	O	O
MM	NN	B-NP	B
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
widely	RB	I-VP	O
adopted	VBN	I-VP	O
to	TO	I-VP	O
improve	VB	I-VP	O
treatment	NN	B-NP	O
response	NN	I-NP	O
following	VBG	B-PP	O
autologous	JJ	B-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
analyzed	VBD	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
regimen	NN	I-NP	O
of	IN	B-PP	O
bortezomib	NN	B-NP	O
,	,	O	O
thalidomide	NN	B-NP	O
,	,	O	O
and	CC	O	O
dexamethasone	NN	B-NP	O
(	(	O	O
VTD	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
consolidation	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
Japanese	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
newly	RB	B-NP	O
diagnosed	VBN	I-NP	O
MM	NN	I-NP	B
.	.	O	O

VTD	NN	B-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
bortezomib	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
cycle	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
daily	JJ	B-NP	O
oral	JJ	I-NP	O
thalidomide	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Grade	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
were	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
drug	NN	B-NP	O
dose	NN	I-NP	O
reduction	NN	I-NP	O
due	IN	B-PP	O
to	TO	B-PP	O
cytopenia	NN	B-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
required	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
case	NN	I-NP	O
.	.	O	O

Peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
common	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
severe	JJ	B-NP	O
grade	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
peripheral	JJ	I-NP	B
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
.	.	O	O

Very	RB	B-NP	O
good	JJ	I-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
or	CC	O	O
better	JJR	B-NP	O
response	NN	I-NP	O
(	(	O	O
>	SYM	B-NP	O
VGPR	NN	I-NP	O
)	)	O	O
rates	NNS	B-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
consolidation	NN	B-NP	O
therapy	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Patients	NNS	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
probability	NN	I-NP	O
of	IN	B-PP	O
improving	VBG	B-VP	O
from	IN	B-PP	O
<	JJR	B-NP	O
VGPR	NN	I-NP	O
before	IN	B-PP	O
consolidation	NN	B-NP	O
therapy	NN	I-NP	O
to	TO	B-PP	O
>	JJR	B-NP	O
VGPR	NN	I-NP	O
after	IN	B-PP	O
consolidation	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
VTD	NN	I-NP	O
regimen	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
and	CC	I-ADJP	O
effective	JJ	I-ADJP	O
as	IN	B-PP	O
a	DT	B-NP	O
consolidation	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
MM	NN	B-NP	O
in	IN	B-PP	O
Japanese	JJ	B-NP	O
population	NN	I-NP	O
.	.	O	O

Conversion	NN	B-NP	O
to	TO	B-PP	O
sirolimus	NN	B-NP	O
ameliorates	VBZ	B-VP	O
cyclosporine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
:	:	O	O
focus	NN	B-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
,	,	O	O
urine	NN	B-NP	O
,	,	O	O
gene	NN	B-NP	O
,	,	O	O
and	CC	O	O
protein	NN	B-NP	O
renal	JJ	I-NP	O
expression	NN	I-NP	O
biomarkers	NNS	I-NP	O
.	.	O	O

Protocols	NNS	B-NP	O
of	IN	B-PP	O
conversion	NN	B-NP	O
from	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
(	(	O	O
CsA	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
sirolimus	NN	B-NP	O
(	(	O	O
SRL	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
immunotherapy	NN	B-NP	O
after	IN	B-PP	O
transplantation	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
CsA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
underlying	VBG	B-VP	O
these	DT	B-NP	O
protocols	NNS	I-NP	O
remain	VBP	B-VP	O
nuclear	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
pathways	NNS	I-NP	O
and	CC	O	O
putative	JJ	B-NP	O
biomarkers	NNS	I-NP	O
of	IN	B-PP	O
CsA	NN	B-NP	O
-	HYPH	B-ADVP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
SRL	NN	I-NP	O
conversion	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
animal	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
:	:	O	O
control	NN	B-NP	O
,	,	O	O
CsA	NN	B-NP	O
,	,	O	O
SRL	NN	B-NP	O
,	,	O	O
and	CC	O	O
conversion	NN	B-NP	O
(	(	O	O
CsA	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
SRL	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
.	.	O	O

Classical	JJ	B-NP	O
and	CC	I-NP	O
emergent	JJ	I-NP	O
serum	NN	I-NP	O
,	,	O	O
urinary	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
kidney	NN	B-NP	O
tissue	NN	I-NP	O
(	(	O	O
gene	NN	B-NP	O
and	CC	O	O
protein	NN	B-NP	O
expression	NN	I-NP	O
)	)	O	O
markers	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

Renal	JJ	B-NP	B
lesions	NNS	I-NP	I
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
in	IN	B-PP	O
hematoxylin	NN	B-NP	O
and	CC	I-NP	O
eosin	NN	I-NP	O
,	,	O	O
periodic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
Schiff	NNP	B-NP	O
,	,	O	O
and	CC	O	O
Masson	NNP	B-NP	O
s	VBZ	B-VP	O
trichrome	NN	B-NP	O
stains	NNS	I-NP	O
.	.	O	O

SRL	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
presented	VBD	B-VP	O
proteinuria	NN	B-NP	B
and	CC	I-NP	O
NGAL	NN	I-NP	O
(	(	O	O
serum	NN	B-NP	O
and	CC	O	O
urinary	JJ	B-ADJP	O
)	)	O	O
as	IN	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
markers	NNS	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
.	.	O	O

Short	JJ	B-NP	O
CsA	NN	I-NP	O
treatment	NN	I-NP	O
presented	VBD	B-VP	O
slight	JJ	B-NP	O
or	CC	I-NP	O
even	RB	I-NP	O
absent	JJ	I-NP	O
kidney	NN	I-NP	B
lesions	NNS	I-NP	I
and	CC	O	O
TGF	NN	B-NP	O
-	HYPH	I-NP	O
b	NN	B-NP	O
,	,	O	O
NF	NN	B-NP	O
-	HYPH	O	O
kb	NN	B-NP	O
,	,	O	O
mTOR	NN	B-NP	O
,	,	O	O
PCNA	NN	B-NP	O
,	,	O	O
TP53	NN	B-NP	O
,	,	O	O
KIM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
CTGF	NN	I-NP	O
as	IN	B-PP	O
relevant	JJ	B-NP	O
gene	NN	I-NP	O
and	CC	I-NP	O
protein	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

Prolonged	VBN	B-NP	O
CsA	NN	I-NP	O
exposure	NN	I-NP	O
aggravated	VBD	B-VP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
,	,	O	O
without	IN	B-PP	O
clear	JJ	B-NP	O
changes	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
traditional	JJ	I-NP	O
markers	NNS	I-NP	O
,	,	O	O
but	CC	O	O
with	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
serums	NNS	B-NP	O
TGF	NN	I-NP	O
-	HYPH	B-NP	O
b	NN	I-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
TBARs	NNS	I-NP	O
clearance	NN	I-NP	O
,	,	O	O
and	CC	O	O
kidney	NN	B-NP	O
TGF	NN	I-NP	O
-	HYPH	B-NP	O
b	NN	I-NP	O
and	CC	I-NP	O
mTOR	NN	I-NP	O
.	.	O	O

Conversion	NN	B-NP	O
to	TO	B-PP	O
SRL	NN	B-NP	O
prevented	VBD	B-VP	O
CsA	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
evolution	NN	I-NP	O
(	(	O	O
absent	JJ	B-NP	O
/	SYM	I-NP	O
mild	JJ	I-NP	O
grade	NN	I-NP	O
lesions	NNS	I-NP	O
)	)	O	O
,	,	O	O
while	IN	B-SBAR	O
NGAL	NN	B-NP	O
(	(	O	O
serum	NN	B-NP	O
versus	IN	B-PP	O
urine	NN	B-NP	O
)	)	O	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
feasible	JJ	I-NP	O
biomarker	NN	I-NP	O
of	IN	B-PP	O
CsA	NN	B-NP	O
replacement	NN	I-NP	O
to	TO	B-PP	O
SRL	NN	B-NP	O
.	.	O	O

Kinin	NN	B-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
deletion	NN	I-NP	O
and	CC	I-NP	O
blockage	NN	I-NP	O
ameliorates	VBZ	B-VP	O
cisplatin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
injury	NN	I-NP	I
.	.	O	O

Cisplatin	NN	B-NP	O
treatment	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
adopted	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
chemotherapies	NNS	I-NP	O
;	:	O	O
however	RB	O	O
,	,	O	O
this	DT	B-NP	O
drug	NN	I-NP	O
can	MD	B-VP	O
induce	VB	I-VP	O
acute	JJ	B-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
due	IN	B-PP	O
its	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
negatively	RB	I-VP	O
affect	VB	I-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
augment	NN	B-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
creatinine	NN	B-NP	O
and	CC	I-NP	O
urea	NN	I-NP	O
,	,	O	O
increase	VBP	B-VP	O
the	DT	B-NP	O
acute	JJ	I-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
score	NN	I-NP	O
and	CC	O	O
up	RB	B-VP	O
-	HYPH	I-VP	O
regulate	VB	I-VP	O
cytokines	NNS	B-NP	O
(	(	O	O
e.g.	FW	B-NP	O
,	,	O	O
IL	NN	B-NP	O
-	HYPH	I-NP	O
1b	NN	I-NP	O
and	CC	I-NP	O
TNF	NN	I-NP	O
-	HYPH	O	O
a	DT	O	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
kinin	NN	I-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
inflammation	NN	I-NP	B
process	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
cytokine	NN	B-NP	O
expression	NN	I-NP	O
,	,	O	O
and	CC	O	O
its	PRP$	B-NP	O
deletion	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
status	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
in	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
,	,	O	O
kinin	NN	B-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
knockout	NN	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
challenged	VBN	I-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
after	IN	B-PP	O
cisplatin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

B2	NN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-NP	O
deficient	JJ	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
less	RBR	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
WT	JJ	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
shown	VBN	B-VP	O
by	IN	B-PP	O
reduced	VBN	B-NP	O
weight	NN	I-NP	B
loss	NN	I-NP	I
,	,	O	O
better	JJR	B-NP	O
preservation	NN	I-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	O
function	NN	I-NP	O
,	,	O	O
down	RB	B-ADVP	O
regulation	NN	B-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
cytokines	NNS	I-NP	O
and	CC	O	O
less	RBR	B-NP	O
acute	JJ	I-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
effectively	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
and	CC	I-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
after	IN	B-PP	O
cisplatin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
by	IN	B-PP	O
mediating	VBG	B-VP	O
the	DT	B-NP	O
necrotic	JJ	I-NP	B
process	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
cytokines	NNS	I-NP	O
,	,	O	O
thus	RB	B-ADVP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
declined	VBN	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
highlight	VBP	B-VP	O
the	DT	B-NP	O
kinin	NN	I-NP	O
B2	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
amelioration	NN	B-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
cisplatin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Safety	NN	B-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
fluocinolone	NN	B-NP	O
acetonide	NN	I-NP	O
intravitreal	JJ	I-NP	O
implant	NN	I-NP	O
in	IN	B-PP	O
birdshot	NN	B-NP	B
retinochoroidopathy	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fluocinolone	NN	I-NP	O
acetonide	NN	I-NP	O
intravitreal	JJ	I-NP	O
implant	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
birdshot	NN	B-NP	B
retinochoroidopathy	NN	I-NP	I
whose	WP$	B-NP	O
disease	NN	I-NP	O
is	VBZ	B-VP	O
refractory	JJ	B-ADJP	O
or	CC	I-ADJP	O
intolerant	JJ	I-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
immunomodulatory	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
retrospective	JJ	I-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
involving	VBG	B-VP	O
num	CD	B-NP	O
birdshot	NN	I-NP	B
retinochoroidopathy	NN	I-NP	I
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
eyes	NNS	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
eyes	NNS	I-NP	O
)	)	O	O
underwent	VBD	B-VP	O
surgery	NN	B-NP	O
for	IN	B-PP	O
fluocinolone	NN	B-NP	O
acetonide	NN	I-NP	O
implant	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
interest	NN	B-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
before	IN	B-PP	O
fluocinolone	NN	B-NP	O
acetonide	NN	I-NP	O
implant	NN	I-NP	O
,	,	O	O
and	CC	O	O
then	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
beyond	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Disease	NN	B-NP	O
activity	NN	I-NP	O
markers	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	O
inflammation	NN	I-NP	B
,	,	O	O
evidence	NN	B-NP	O
of	IN	B-PP	O
retinal	JJ	B-NP	B
vasculitis	NN	I-NP	I
,	,	O	O
Swedish	JJ	B-NP	O
interactive	JJ	I-NP	O
threshold	NN	I-NP	O
algorithm	NN	I-NP	O
-	HYPH	B-NP	O
short	JJ	I-NP	O
wavelength	NN	I-NP	O
automated	VBD	B-VP	O
perimetry	NN	B-NP	O
Humphrey	NNP	I-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
analysis	NN	I-NP	O
,	,	O	O
electroretinographic	JJ	B-NP	O
parameters	NNS	I-NP	O
,	,	O	O
and	CC	O	O
optical	JJ	B-NP	O
coherence	NN	I-NP	O
tomography	NN	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
occurrence	NN	B-NP	O
of	IN	B-PP	O
cataract	NN	B-NP	B
and	CC	O	O
raised	VBD	B-VP	B
intraocular	JJ	B-NP	I
pressure	NN	I-NP	I
were	VBD	B-VP	O
collected	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
eyes	NNS	I-NP	O
.	.	O	O

Intraocular	JJ	B-NP	O
inflammation	NN	I-NP	B
was	VBD	B-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
beyond	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
the	DT	B-NP	O
implant	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Active	JJ	B-NP	O
vasculitis	NN	I-NP	B
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

More	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
central	JJ	B-NP	O
retinal	JJ	I-NP	O
thickness	NN	I-NP	O
was	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cystoid	JJ	B-NP	B
macular	JJ	I-NP	I
edema	NN	I-NP	I
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
postimplant	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
on	IN	B-PP	O
immunomodulatory	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
percentage	NN	I-NP	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
postimplant	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Adverse	JJ	B-NP	O
events	NNS	I-NP	O
included	VBD	B-VP	O
increased	VBN	B-NP	B
intraocular	JJ	I-NP	I
pressure	NN	I-NP	I
and	CC	I-NP	O
cataract	NN	I-NP	B
formation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
fluocinolone	NN	B-NP	O
acetonide	NN	I-NP	O
implant	NN	I-NP	O
helps	VBZ	B-VP	O
to	TO	I-VP	O
control	VB	I-VP	O
inflammation	NN	B-NP	B
in	IN	B-PP	O
otherwise	RB	B-NP	O
treatment	NN	I-NP	O
-	HYPH	B-NP	O
refractory	JJ	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
birdshot	NN	B-NP	B
retinochoroidopathy	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cataract	NN	B-NP	B
and	CC	O	O
ocular	JJ	B-NP	B
hypertension	NN	I-NP	I
requiring	VBG	B-VP	O
treatment	NN	B-NP	O
.	.	O	O

Optimal	JJ	B-NP	O
precurarizing	VBG	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
to	TO	B-VP	O
decrease	VB	I-VP	O
fasciculation	NN	B-NP	B
and	CC	I-NP	O
myalgia	NN	I-NP	B
following	VBG	B-PP	O
succinylcholine	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Succinylcholine	NN	B-NP	O
commonly	RB	B-ADVP	O
produces	VBZ	B-VP	O
frequent	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
muscle	NN	B-NP	B
fasciculation	NN	I-NP	I
and	CC	I-NP	O
myalgia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
identified	VBD	B-VP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
succinylcholine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
fasciculation	NN	I-NP	B
and	CC	I-NP	O
myalgia	NN	I-NP	B
and	CC	O	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
speed	NN	I-NP	O
of	IN	B-PP	O
onset	NN	B-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
succinylcholine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blinded	VBN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
randomly	RB	B-VP	O
allocated	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
each	DT	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
rocuronium	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
precurarizing	VBG	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Neuromuscular	JJ	B-NP	O
monitoring	NN	I-NP	O
after	IN	B-SBAR	O
each	DT	B-NP	O
precurarizing	VBG	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
adductor	NN	I-NP	O
pollicis	NN	I-NP	O
muscle	NN	I-NP	O
using	VBG	B-VP	O
acceleromyography	NN	B-NP	O
with	IN	B-PP	O
train	NN	B-NP	O
-	HYPH	B-NP	O
of	IN	B-PP	O
-	SYM	B-NP	O
num	CD	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ulnar	JJ	I-NP	O
nerve	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
succinylcholine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
precurarization	NN	I-NP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
fasciculations	NNS	B-NP	B
,	,	O	O
while	IN	B-SBAR	O
myalgia	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
visible	JJ	B-NP	O
muscle	NN	I-NP	B
fasciculation	NN	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
with	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
precurarizing	VBG	B-VP	O
dose	NN	B-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
.	.	O	O

Those	DT	B-NP	O
of	IN	B-PP	O
myalgia	NN	B-NP	B
tend	VBP	B-VP	O
to	TO	I-VP	O
decrease	VB	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
precurarizing	VBG	B-VP	O
dose	NN	B-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
onset	NN	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
longer	RBR	I-ADJP	O
with	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
precurarizing	VBG	B-VP	O
dose	NN	B-NP	O
of	IN	B-PP	O
rocuronium	NN	B-NP	O
.	.	O	O

Precurarization	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
rocuronium	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
dose	NN	I-NP	O
considering	VBG	B-VP	O
the	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
fasciculation	NN	B-NP	B
and	CC	I-NP	O
myalgia	NN	I-NP	B
with	IN	B-PP	O
acceptable	JJ	B-NP	O
onset	NN	I-NP	O
time	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
safe	JJ	I-NP	O
and	CC	I-NP	O
effective	JJ	I-NP	O
precurarization	NN	I-NP	O
.	.	O	O

Absence	NN	B-NP	O
of	IN	B-PP	O
PKC	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
attenuates	VBZ	B-VP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
.	.	O	O

Lithium	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
effective	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
,	,	O	O
induces	VBZ	B-VP	O
nephrogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
(	(	O	O
NDI	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
decreased	VBN	I-NP	O
capacity	NN	I-NP	O
to	TO	B-VP	O
concentrate	VB	I-VP	O
urine	NN	B-NP	O
is	VBZ	B-VP	O
likely	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
lithium	NN	B-NP	O
acutely	RB	B-VP	O
disrupting	VBG	I-VP	O
the	DT	B-NP	O
cAMP	NN	I-NP	O
pathway	NN	I-NP	O
and	CC	O	O
chronically	RB	B-VP	O
reducing	VBG	I-VP	O
urea	NN	B-NP	O
transporter	NN	I-NP	O
(	(	O	O
UT	NN	B-NP	O
-	HYPH	B-NP	O
A1	NN	I-NP	O
)	)	O	O
and	CC	O	O
water	NN	B-NP	O
channel	NN	I-NP	O
(	(	O	O
AQP2	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
medulla	NN	I-NP	O
.	.	O	O

Targeting	VBG	B-VP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
signaling	NN	I-NP	O
pathway	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
PKC	NN	B-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
signaling	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
treating	VBG	B-VP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
polyuria	NN	I-NP	B
.	.	O	O

PKC	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
null	NN	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
PKCa	NN	B-NP	O
KO	NN	I-NP	O
)	)	O	O
and	CC	O	O
strain	NN	B-NP	O
-	HYPH	O	O
matched	VBN	B-VP	O
wild	JJ	B-NP	O
type	NN	I-NP	O
(	(	O	O
WT	NN	B-NP	O
)	)	O	O
controls	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

WT	JJ	B-NP	O
mice	NNS	I-NP	O
had	VBD	B-VP	O
increased	VBN	I-VP	O
urine	NN	B-NP	O
output	NN	I-NP	O
and	CC	O	O
lowered	VBD	B-VP	O
urine	NN	B-NP	O
osmolality	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
whereas	IN	B-PP	O
PKCa	NN	B-NP	O
KO	NN	I-NP	O
mice	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
urine	NN	B-NP	O
output	NN	I-NP	O
or	CC	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

Western	NN	B-NP	O
blot	NN	I-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
AQP2	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
medullary	JJ	B-NP	O
tissues	NNS	I-NP	O
was	VBD	B-VP	O
lowered	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
AQP2	NN	B-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
in	IN	B-PP	O
PKCa	NN	B-NP	O
KO	NN	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
UT	NN	B-NP	O
-	HYPH	O	O
A1	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fold	RB	I-NP	O
increased	VBN	I-NP	O
urine	NN	I-NP	O
output	NN	I-NP	O
whereas	IN	B-PP	O
treated	VBN	B-NP	O
PKCa	NN	I-NP	O
KO	NN	I-NP	O
animals	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
output	NN	B-NP	O
.	.	O	O

AQP2	NN	B-NP	O
and	CC	I-NP	O
UT	NN	I-NP	O
-	HYPH	O	O
A1	NN	B-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
lowered	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
lithium	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
WT	JJ	B-NP	O
animals	NNS	I-NP	O
whereas	IN	B-ADVP	O
in	IN	B-PP	O
treated	VBN	B-NP	O
PKCa	NN	I-NP	O
KO	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
AQP2	NN	B-NP	O
was	VBD	B-VP	O
only	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
and	CC	O	O
UT	NN	B-NP	O
-	HYPH	O	O
A1	NN	B-NP	O
expression	NN	I-NP	O
was	VBD	B-VP	O
unaffected	JJ	B-ADJP	O
.	.	O	O

Urinary	JJ	B-NP	O
sodium	NN	I-NP	O
,	,	I-NP	O
potassium	NN	I-NP	O
and	CC	I-NP	O
calcium	NN	I-NP	O
were	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
fed	VBN	B-NP	O
WT	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
fed	VBN	I-NP	O
PKCa	NN	I-NP	O
KO	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
ablation	NN	B-NP	O
of	IN	B-PP	O
PKCa	NN	B-NP	O
preserves	VBZ	B-VP	O
AQP2	NN	B-NP	O
and	CC	I-NP	O
UT	NN	I-NP	O
-	HYPH	B-NP	O
A1	NN	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
localization	NN	B-NP	O
in	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
NDI	NN	I-NP	B
,	,	O	O
and	CC	O	O
prevents	VBZ	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
severe	JJ	I-NP	O
polyuria	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Is	VBZ	O	O
Dysguesia	NNP	B-NP	B
Going	NNP	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
Rare	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
Common	JJ	I-NP	O
Side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
Amlodipine	NN	B-NP	O
?	.	O	O
A	NN	B-NP	O
very	RB	I-NP	O
rare	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amlodipine	NN	B-NP	O
is	VBZ	B-VP	O
dysguesia	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
produced	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
case	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
about	IN	B-PP	O
a	DT	B-NP	O
female	NN	I-NP	O
with	IN	B-PP	O
essential	JJ	B-NP	O
hypertension	NN	I-NP	B
on	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
amlodipine	NN	B-NP	O
developed	VBD	B-VP	O
loss	NN	B-NP	B
of	IN	B-PP	I
taste	NN	B-NP	I
sensation	NN	I-NP	I
.	.	O	O

Condition	NN	B-NP	O
moderately	RB	B-VP	O
improved	VBN	I-VP	O
on	IN	B-PP	O
stoppage	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
amlodipine	NN	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
dysguesia	NN	B-NP	B
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
presentation	NN	I-NP	O
and	CC	O	O
review	VB	B-VP	O
the	DT	B-NP	O
relevant	JJ	I-NP	O
literature	NN	I-NP	O
on	IN	B-PP	O
amlodipine	NN	B-NP	O
and	CC	I-NP	O
dysguesia	NN	I-NP	B
.	.	O	O

Rhabdomyolysis	NN	B-NP	B
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
simvastatin	NN	B-NP	O
and	CC	I-NP	O
dosage	NN	I-NP	O
increment	NN	I-NP	O
in	IN	B-PP	O
clarithromycin	NN	B-NP	O
.	.	O	O

Clarithromycin	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
documented	VBN	I-NP	O
cytochrome	NN	I-NP	O
P450	NN	I-NP	O
3A4	NN	I-NP	O
(	(	O	O
CYP3A4	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
an	DT	B-NP	O
adverse	JJ	I-NP	O
interaction	NN	I-NP	O
with	IN	B-PP	O
simvastatin	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
particular	JJ	I-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
interest	NN	B-NP	O
as	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
only	RB	B-ADVP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clarithromycin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
raised	VBN	I-VP	O
cardiac	JJ	B-NP	O
biomarkers	NNS	I-NP	O
without	IN	B-PP	O
any	DT	B-NP	O
obvious	JJ	I-NP	O
cardiac	JJ	I-NP	O
issues	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
phenomenon	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
linked	VBN	I-VP	O
to	TO	B-PP	O
rhabdomyolysis	NN	B-NP	B
previously	RB	B-ADVP	O
.	.	O	O

To	TO	B-PP	O
date	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
no	DT	B-NP	O
reported	VBN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
on	IN	B-PP	O
the	DT	B-NP	O
structure	NN	I-NP	O
and	CC	I-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
muscle	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
prescribing	VBG	B-VP	O
concomitant	JJ	B-NP	O
medications	NNS	I-NP	O
that	WDT	B-NP	O
increase	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
myopathy	NN	B-NP	B
or	CC	O	O
inhibit	VB	B-VP	O
the	DT	B-NP	O
CYP3A4	NN	I-NP	O
enzyme	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
case	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
troponin	NN	B-NP	O
elevation	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
statin	NN	B-NP	O
induced	VBD	B-VP	O
rhabdomyolysis	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
warrant	VB	I-VP	O
further	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Characterization	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
BCHE	NN	I-NP	O
silent	JJ	I-NP	O
allele	NN	I-NP	O
:	:	O	O
point	NN	B-NP	O
mutation	NN	I-NP	O
(	(	O	O
p.Val204Asp	NN	B-NP	O
)	)	O	O
causes	VBZ	B-VP	O
loss	NN	B-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
and	CC	O	O
prolonged	JJ	B-NP	O
apnea	NN	I-NP	B
with	IN	B-PP	O
suxamethonium	NN	B-NP	O
.	.	O	O

Butyrylcholinesterase	NN	B-NP	B
deficiency	NN	I-NP	I
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
prolonged	VBN	B-NP	O
apnea	NN	I-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	O
relaxants	NNS	I-NP	O
(	(	O	O
suxamethonium	NN	B-NP	O
or	CC	O	O
mivacurium	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
mutations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BCHE	NN	I-NP	O
gene	NN	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
prolonged	JJ	B-NP	O
neuromuscular	JJ	I-NP	O
block	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
discovery	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
BCHE	NN	I-NP	O
variant	NN	I-NP	O
.	.	O	O

Inhibition	NN	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
kinetic	JJ	B-NP	O
analysis	NN	I-NP	O
and	CC	O	O
molecular	JJ	B-NP	O
dynamics	NNS	I-NP	O
were	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
understand	VB	I-VP	O
how	WRB	B-ADVP	O
this	DT	B-NP	O
mutation	NN	I-NP	O
disrupts	VBZ	B-VP	O
the	DT	B-NP	O
catalytic	JJ	I-NP	O
triad	NN	I-NP	O
and	CC	O	O
determines	VBZ	B-VP	O
a	DT	B-NP	O
silent	JJ	I-NP	O
phenotype	NN	I-NP	O
.	.	O	O

Low	JJ	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
patient	NN	B-NP	O
plasma	NN	I-NP	O
butyrylcholinesterase	NN	I-NP	O
with	IN	B-PP	O
butyrylthiocholine	NN	B-NP	O
(	(	O	O
BTC	NN	B-NP	O
)	)	O	O
and	CC	O	O
benzoylcholine	NN	B-NP	O
,	,	O	O
and	CC	O	O
values	NNS	B-NP	O
of	IN	B-PP	O
dibucaine	NN	B-NP	O
and	CC	I-NP	O
fluoride	NN	I-NP	O
numbers	NNS	I-NP	O
fit	VBP	B-VP	O
with	IN	B-PP	O
heterozygous	JJ	B-NP	O
atypical	JJ	I-NP	O
silent	JJ	I-NP	O
genotype	NN	I-NP	O
.	.	O	O

Electrophoretic	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
BChE	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
proband	NN	I-NP	O
and	CC	O	O
his	PRP$	B-NP	O
mother	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
patient	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
tetrameric	JJ	B-NP	O
enzyme	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
and	CC	O	O
that	IN	B-SBAR	O
minor	JJ	B-NP	O
fast	JJ	I-NP	O
-	HYPH	I-NP	O
moving	VBG	I-NP	O
BChE	NN	I-NP	O
components	NNS	I-NP	O
:	:	O	O
monomer	NN	B-NP	O
,	,	O	O
dimer	NN	B-NP	O
,	,	O	O
and	CC	O	O
monomer	NN	B-NP	O
-	HYPH	I-NP	O
albumin	NN	I-NP	O
conjugate	NN	I-NP	O
are	VBP	B-VP	O
missing	VBG	I-VP	O
.	.	O	O

Kinetic	JJ	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
p.Val204Asp	NN	I-NP	O
/	SYM	B-NP	O
p.Asp70Gly	NN	I-NP	O
-	HYPH	B-NP	O
p.Ala539Thr	NN	I-NP	O
BChE	NN	I-NP	O
displays	VBZ	B-VP	O
a	DT	B-NP	O
pure	JJ	I-NP	O
Michaelian	JJ	I-NP	O
behavior	NN	I-NP	O
with	IN	B-PP	O
BTC	NN	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
substrate	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
catalytic	JJ	I-NP	O
parameters	NNS	I-NP	O
Km	NN	I-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
uM	NN	I-NP	O
for	IN	B-PP	O
BTC	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
higher	JJR	B-ADVP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
atypical	JJ	I-NP	O
enzyme	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
low	JJ	I-NP	O
Vmax	NN	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
against	IN	B-PP	O
suxamethonium	NN	B-NP	O
.	.	O	O

Molecular	JJ	B-NP	O
dynamic	JJ	I-NP	O
(	(	O	O
MD	NN	B-NP	O
)	)	O	O
simulations	NNS	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
overall	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mutation	NN	I-NP	O
p.Val204Asp	NN	I-NP	O
is	VBZ	B-VP	O
disruption	NN	B-NP	O
of	IN	B-PP	O
hydrogen	NN	B-NP	O
bonding	NN	I-NP	O
between	IN	B-PP	O
Gln223	NN	B-NP	O
and	CC	I-NP	O
Glu441	NN	I-NP	O
,	,	O	O
leading	VBG	B-NP	O
Ser198	NN	I-NP	O
and	CC	I-NP	O
His438	NN	I-NP	O
to	TO	B-VP	O
move	VB	I-VP	O
away	RB	B-ADVP	O
from	IN	B-PP	O
each	DT	B-NP	O
other	JJ	I-NP	O
with	IN	B-PP	O
subsequent	JJ	B-NP	O
disruption	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
catalytic	JJ	I-NP	O
triad	NN	I-NP	O
functionality	NN	I-NP	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
substrate	NN	B-NP	O
.	.	O	O

MD	NN	B-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
enzyme	NN	I-NP	O
volume	NN	I-NP	O
is	VBZ	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
suggesting	VBG	B-VP	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
denaturation	NN	I-NP	O
state	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
fits	VBZ	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
reduced	VBN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
p.Ala204Asp	NN	B-NP	O
/	SYM	B-NP	O
p.Asp70Gly	NN	I-NP	O
-	HYPH	B-NP	O
p.Ala539Thr	NN	I-NP	O
tetrameric	JJ	I-NP	O
enzyme	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
detectable	JJ	B-ADJP	O
fast	RB	B-VP	O
moving	VBG	I-VP	O
-	HYPH	B-NP	O
bands	NNS	I-NP	O
on	IN	B-PP	O
electrophoresis	NN	B-NP	O
gels	NNS	I-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
anemia	NN	I-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
injectable	JJ	B-NP	O
artesunate	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Democratic	JJ	I-NP	O
Republic	NNP	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Congo	NNP	I-NP	O
:	:	O	O
a	DT	B-NP	O
manageable	JJ	I-NP	O
issue	NN	I-NP	O
.	.	O	O

Cases	NNS	B-NP	O
of	IN	B-PP	O
delayed	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
injectable	JJ	B-NP	O
artesunate	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
current	JJ	I-NP	O
World	NNP	I-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
(	(	O	O
WHO	WP	B-NP	O
)	)	O	O
-	HYPH	O	O
recommended	VBN	B-NP	O
first	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
malaria	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
injectable	JJ	B-NP	O
artesunate	NN	I-NP	O
for	IN	B-PP	O
severe	JJ	B-NP	O
malaria	NN	I-NP	B
in	IN	B-PP	O
hospitals	NNS	B-NP	O
and	CC	I-NP	O
health	NN	I-NP	O
centers	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Democratic	JJ	I-NP	O
Republic	NNP	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Congo	NNP	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
hemoglobin	NN	B-NP	O
(	(	O	O
Hb	NN	B-NP	O
)	)	O	O
measurements	NNS	B-NP	O
were	VBD	B-VP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
Hb	NN	B-NP	O
levels	NNS	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	I-NP	O
dL	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
.	.	O	O

For	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
Hb	NN	B-NP	O
levels	NNS	I-NP	O
decreased	VBD	B-VP	O
below	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
during	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
visit	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
delayed	VBN	B-NP	O
anemia	NN	I-NP	B
were	VBD	B-VP	O
clinically	RB	B-ADJP	O
manageable	JJ	I-ADJP	O
and	CC	O	O
resolved	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
.	.	O	O

Regulation	NN	B-NP	O
of	IN	B-PP	O
signal	NN	B-NP	O
transducer	NN	I-NP	O
and	CC	I-NP	O
activator	NN	I-NP	O
of	IN	B-PP	O
transcription	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
apoptotic	JJ	B-NP	O
pathways	NNS	I-NP	O
by	IN	B-PP	O
betaine	NN	B-NP	O
attenuates	VBZ	B-VP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
cardioprotective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
betaine	NN	B-NP	O
on	IN	B-PP	O
acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
induced	VBN	B-VP	O
experimentally	RB	B-ADVP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
focusing	VBG	B-VP	O
on	IN	B-PP	O
regulation	NN	B-NP	O
of	IN	B-PP	O
signal	NN	B-NP	O
transducer	NN	I-NP	O
and	CC	I-NP	O
activator	NN	I-NP	O
of	IN	B-PP	O
transcription	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
STAT3	NN	B-NP	O
)	)	O	O
and	CC	O	O
apoptotic	JJ	B-NP	O
pathways	NNS	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
mechanism	NN	I-NP	O
underlying	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Male	NNP	B-NP	O
Sprague	NNP	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
betaine	NN	B-NP	O
orally	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
ischemic	JJ	I-NP	I
injury	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
subcutaneous	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
cardiac	JJ	I-NP	O
marker	NN	I-NP	O
enzyme	NN	I-NP	O
,	,	O	O
histopathological	JJ	B-NP	O
variables	NNS	I-NP	O
and	CC	O	O
expression	NN	B-NP	O
of	IN	B-PP	O
protein	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
betaine	NN	B-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
marker	NN	I-NP	O
enzyme	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
and	CC	O	O
prevented	VBD	B-VP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	B
remodeling	NN	I-NP	I
.	.	O	O

Western	NN	B-NP	O
blot	NN	I-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
phosphorylation	NN	I-NP	O
of	IN	B-PP	O
STAT3	NN	B-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
or	CC	O	O
further	RBR	B-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
betaine	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
myocardium	NN	B-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
betaine	NN	B-NP	O
treatment	NN	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
Bcl	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
Bax	NN	B-NP	O
,	,	O	O
therefore	RB	B-ADVP	O
causing	VBG	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
Bcl	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
Bax	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
betaine	NN	B-NP	O
on	IN	B-PP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
further	RBR	I-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
histopathological	JJ	B-NP	O
examination	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
betaine	NN	B-NP	O
pretreatment	NN	I-NP	O
attenuated	VBD	B-VP	O
isoproterenol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
via	IN	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
STAT3	NN	B-NP	O
and	CC	O	O
apoptotic	JJ	B-NP	O
pathways	NNS	I-NP	O
.	.	O	O

Quetiapine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
neutropenia	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
bipolar	JJ	I-NP	B
patient	NN	I-NP	O
with	IN	B-PP	O
hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

Quetiapine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
dibenzothiazepine	NN	I-NP	O
derivative	NN	I-NP	O
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
clozapine	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
causing	VBG	B-VP	O
blood	NN	B-NP	B
dyscrasias	NNS	I-NP	I
,	,	O	O
especially	RB	B-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
some	DT	B-NP	O
case	NN	I-NP	O
reports	VBZ	B-VP	O
about	IN	B-PP	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
quetiapine	NN	B-NP	O
,	,	O	O
but	CC	O	O
possible	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
are	VBP	B-VP	O
seldom	RB	I-VP	O
discussed	VBN	I-VP	O
and	CC	I-VP	O
identified	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
that	WDT	B-NP	O
developed	VBD	B-VP	O
neutropenia	NN	B-NP	B
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
here	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
Taiwanese	JJ	I-NP	O
widow	NN	I-NP	O
with	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
at	IN	B-PP	O
age	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

She	PRP	B-NP	O
developed	VBD	B-VP	O
leucopenia	NN	B-NP	B
after	IN	B-PP	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
quetiapine	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
quetiapine	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
,	,	O	O
her	PRP$	B-NP	O
white	JJ	I-NP	O
blood	NN	I-NP	O
cell	NN	I-NP	O
count	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
neutropenia	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
quetiapine	NN	B-NP	O
,	,	O	O
physicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
cautious	JJ	B-ADJP	O
about	IN	B-PP	O
its	PRP$	B-NP	O
presentation	NN	I-NP	O
and	CC	I-NP	O
associated	VBN	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Hepatic	JJ	B-NP	B
dysfunction	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
,	,	O	O
and	CC	O	O
concomitant	JJ	B-NP	O
fever	NN	I-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
diagnostic	JJ	I-NP	O
marker	NN	I-NP	O
for	IN	B-PP	O
adverse	JJ	B-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
quetiapine	NN	B-NP	O
.	.	O	O

Lateral	JJ	B-NP	O
antebrachial	JJ	I-NP	O
cutaneous	JJ	I-NP	O
neuropathy	NN	I-NP	B
after	IN	B-PP	O
steroid	NN	B-NP	O
injection	NN	I-NP	O
at	IN	B-PP	O
lateral	JJ	B-NP	O
epicondyle	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
aimed	VBN	B-VP	O
to	TO	B-VP	O
present	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
lateral	JJ	B-NP	O
antebrachial	JJ	I-NP	O
cutaneous	JJ	I-NP	O
neuropathy	NN	I-NP	B
(	(	O	O
LACNP	NN	B-NP	O
)	)	O	O
that	WDT	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
steroid	NN	I-NP	O
injection	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
epicondyle	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
lateral	JJ	B-NP	B
epicondylitis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
decreased	VBN	B-NP	O
sensation	NN	I-NP	O
and	CC	I-NP	O
paresthesia	NN	I-NP	B
over	IN	B-PP	O
her	PRP$	B-NP	O
right	JJ	I-NP	O
lateral	JJ	I-NP	O
forearm	NN	I-NP	O
;	:	O	O
the	DT	B-NP	O
paresthesia	NN	I-NP	B
had	VBD	B-VP	O
occurred	VBN	I-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
steroid	NN	I-NP	O
injection	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
lateral	JJ	I-NP	O
epicondyle	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
before	RB	B-ADVP	O
.	.	O	O

Her	PRP$	B-NP	O
sensation	NN	I-NP	O
of	IN	B-PP	O
light	JJ	B-NP	O
touch	NN	I-NP	O
and	CC	I-NP	O
pain	NN	I-NP	B
was	VBD	B-VP	O
diminished	VBN	I-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
side	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
forearm	NN	I-NP	O
and	CC	I-NP	O
wrist	NN	I-NP	O
area	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
sensory	JJ	I-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
amplitude	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
lateral	JJ	I-NP	O
antebrachial	JJ	I-NP	O
cutaneous	JJ	I-NP	O
nerve	NN	I-NP	O
(	(	O	O
LACN	NN	B-NP	O
)	)	O	O
(	(	O	O
num	CD	B-NP	O
uV	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
uV	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
difference	NN	I-NP	O
of	IN	B-PP	O
amplitude	NN	B-NP	O
between	IN	B-PP	O
both	DT	B-NP	O
sides	NNS	I-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
because	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
more	JJR	B-NP	O
than	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reduction	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
right	JJ	B-NP	O
LACNP	NN	I-NP	O
(	(	O	O
mainly	RB	B-NP	O
axonal	JJ	I-NP	O
involvement	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
manifestation	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
electrodiagnostic	JJ	I-NP	O
findings	NNS	I-NP	O
.	.	O	O

Her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
improved	VBN	B-VP	O
through	IN	B-PP	O
physical	JJ	B-NP	O
therapy	NN	I-NP	O
but	CC	O	O
persisted	VBD	B-VP	O
to	TO	B-PP	O
some	DT	B-NP	O
degree	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
LACNP	NN	B-NP	O
that	WDT	B-NP	O
developed	VBD	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
steroid	NN	I-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
lateral	JJ	B-NP	B
epicondylitis	NN	I-NP	I
.	.	O	O

An	DT	B-NP	O
electrodiagnostic	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
a	DT	B-NP	O
nerve	NN	I-NP	O
conduction	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LACN	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
helpful	JJ	B-ADJP	O
to	TO	B-VP	O
diagnose	VB	I-VP	O
right	JJ	B-NP	O
LACNP	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
find	VB	I-VP	O
the	DT	B-NP	O
passage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LACN	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
epicondyle	NN	I-NP	O
.	.	O	O

Curcumin	NN	B-NP	O
prevents	VBZ	B-VP	O
maleate	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
:	:	O	O
relation	NN	B-NP	O
to	TO	B-PP	O
hemodynamic	JJ	B-NP	O
alterations	NNS	I-NP	O
,	,	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
,	,	O	O
mitochondrial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
and	CC	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	O
complex	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
potential	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dietary	JJ	I-NP	O
antioxidant	JJ	I-NP	O
curcumin	NN	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	B
injury	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
maleate	NN	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Tubular	JJ	B-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
maleate	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Maleate	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
injury	NN	I-NP	I
included	VBD	B-VP	O
increase	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
protein	NN	I-NP	O
,	,	O	O
glucose	NN	B-NP	O
,	,	O	O
sodium	NN	B-NP	O
,	,	O	O
neutrophil	NN	B-NP	O
gelatinase	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
lipocalin	NN	B-NP	O
(	(	O	O
NGAL	NN	B-NP	O
)	)	O	O
and	CC	O	O
N	NN	B-NP	O
-	HYPH	O	O
acetyl	NN	B-NP	O
b	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
(	(	O	O
NAG	NN	B-NP	O
)	)	O	O
,	,	O	O
upregulation	NN	B-NP	O
of	IN	B-PP	O
kidney	NN	B-NP	B
injury	NN	I-NP	I
molecule	NN	I-NP	O
(	(	O	O
KIM	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
num	CD	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
and	CC	I-NP	O
claudin	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
expression	NN	I-NP	O
besides	IN	B-PP	O
of	IN	B-PP	O
necrosis	NN	B-NP	B
and	CC	I-NP	O
apoptosis	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
cells	NNS	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Oxidative	JJ	B-NP	O
stress	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
oxidation	NN	I-NP	O
of	IN	B-PP	O
lipids	NNS	B-NP	O
and	CC	I-NP	O
proteins	NNS	I-NP	O
and	CC	O	O
diminution	NN	B-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
Nrf2	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
epithelial	JJ	I-NP	O
LLC	NN	I-NP	O
-	HYPH	I-NP	O
PK1	NN	I-NP	O
cells	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
mitochondria	NNS	B-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
kidneys	NNS	B-NP	O
of	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
experimental	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Maleate	NN	B-NP	O
induced	VBD	B-VP	O
cell	NN	B-NP	O
damage	NN	I-NP	O
and	CC	O	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
(	(	O	O
ROS	NN	B-NP	O
)	)	O	O
production	NN	B-NP	O
in	IN	B-PP	O
LLC	NN	B-NP	O
-	HYPH	I-NP	O
PK1	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
culture	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
maleate	NN	B-NP	O
treatment	NN	I-NP	O
reduced	VBD	B-VP	O
oxygen	NN	B-NP	O
consumption	NN	I-NP	O
in	IN	B-PP	O
ADP	NN	B-NP	O
-	HYPH	B-NP	O
stimulated	VBN	I-NP	O
mitochondria	NNS	I-NP	O
and	CC	O	O
diminished	VBN	B-VP	O
respiratory	JJ	B-NP	O
control	NN	I-NP	O
index	NN	I-NP	O
when	WRB	B-ADVP	O
using	VBG	B-VP	O
malate	NN	B-NP	O
/	SYM	B-NP	O
glutamate	NN	I-NP	O
as	IN	B-PP	O
substrate	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
both	CC	O	O
complex	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
aconitase	NN	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
diminished	VBN	I-VP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
above	RB	I-NP	O
-	HYPH	I-NP	O
described	VBN	I-NP	O
alterations	NNS	I-NP	O
were	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
curcumin	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
curcumin	NN	B-NP	O
is	VBZ	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
attenuate	VB	I-VP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
maleate	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephropathy	NN	I-NP	B
and	CC	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
cell	NN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
protection	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	I-NP	O
preservation	NN	I-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
and	CC	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
respiratory	JJ	B-NP	O
complex	NN	I-NP	O
I	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
protection	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
ROS	NN	B-NP	O
production	NN	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
solid	JJ	B-NP	O
tumours	NNS	I-NP	B
among	IN	B-PP	O
pesticide	NN	B-NP	O
applicators	NNS	I-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
organophosphate	NN	I-NP	O
insecticide	NN	I-NP	O
diazinon	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Agricultural	NNP	I-NP	O
Health	NNP	I-NP	O
Study	NNP	I-NP	O
:	:	O	O
an	DT	B-NP	O
updated	VBN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Diazinon	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
common	JJ	I-NP	O
organophosphate	NN	I-NP	O
insecticide	NN	I-NP	O
with	IN	B-PP	O
genotoxic	JJ	B-NP	O
properties	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
previously	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
lung	NN	B-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
Agricultural	NNP	I-NP	O
Health	NNP	I-NP	O
Study	NNP	I-NP	O
(	(	O	O
AHS	NNP	B-NP	O
)	)	O	O
cohort	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
few	JJ	B-NP	O
other	JJ	I-NP	O
epidemiological	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
examined	VBN	I-VP	O
diazinon	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
cancer	NN	I-NP	B
risk	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
updated	VBN	B-NP	O
diazinon	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
cancer	NN	B-NP	B
incidence	NN	I-NP	O
information	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
solid	JJ	B-NP	O
tumour	NN	I-NP	B
risk	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
AHS	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
pesticide	NN	I-NP	O
applicators	NNS	I-NP	O
in	IN	B-PP	O
Iowa	NNP	B-NP	O
and	CC	O	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
reported	VBD	B-VP	O
lifetime	NN	B-NP	O
diazinon	NN	I-NP	O
use	NN	I-NP	O
at	IN	B-PP	O
enrolment	NN	B-NP	O
and	CC	O	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
;	:	O	O
cancer	NN	B-NP	B
incidence	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
through	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
)	)	O	O
/	SYM	B-NP	O
num	CD	I-NP	O
(	(	O	O
Iowa	NN	B-NP	O
)	)	O	O
.	.	O	O

Among	IN	B-PP	O
applicators	NNS	B-NP	O
with	IN	B-PP	O
usage	NN	B-NP	O
information	NN	I-NP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
exposure	NN	B-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
patterns	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
used	VBD	B-VP	O
Poisson	NN	B-NP	O
regression	NN	I-NP	O
to	TO	B-VP	O
estimate	VB	I-VP	O
adjusted	VBN	B-NP	O
rate	NN	I-NP	O
ratios	NNS	I-NP	O
(	(	O	O
RRs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
for	IN	B-PP	O
cancer	NN	B-NP	B
sites	NNS	I-NP	O
with	IN	B-PP	O
>	SYM	B-NP	O
num	CD	I-NP	O
exposed	VBN	I-NP	O
cases	NNS	I-NP	O
for	IN	B-PP	O
both	CC	O	O
lifetime	NN	B-NP	O
(	(	O	O
LT	NN	B-NP	O
)	)	O	O
exposure	NN	B-NP	O
days	NNS	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
(	(	O	O
IW	NN	B-NP	O
)	)	O	O
lifetime	NN	B-NP	O
exposure	NN	I-NP	O
days	NNS	I-NP	O
(	(	O	O
accounting	NN	B-NP	O
for	IN	B-PP	O
factors	NNS	B-NP	O
impacting	VBG	B-VP	O
exposure	NN	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
elevated	JJ	B-NP	O
lung	NN	I-NP	B
cancer	NN	I-NP	I
risks	NNS	I-NP	O
among	IN	B-PP	O
applicators	NNS	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
LT	NN	B-NP	O
and	CC	I-NP	O
IW	NN	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
diazinon	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Kidney	NN	B-NP	B
cancer	NN	I-NP	I
risks	NNS	I-NP	O
were	VBD	B-VP	O
non	AFX	O	O
-	HYPH	O	O
significantly	RB	B-VP	O
elevated	VBN	I-VP	O
,	,	O	O
as	IN	B-SBAR	O
were	VBD	B-VP	O
risks	NNS	B-NP	O
for	IN	B-PP	O
aggressive	JJ	B-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
updated	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
diazinon	NN	B-NP	O
provides	VBZ	B-VP	O
additional	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
lung	NN	B-NP	B
cancer	NN	I-NP	I
risk	NN	I-NP	O
.	.	O	O

Newly	RB	B-NP	O
identified	VBN	I-NP	O
links	NNS	I-NP	O
to	TO	B-PP	O
kidney	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
associations	NNS	B-NP	O
with	IN	B-PP	O
aggressive	JJ	B-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
require	VBP	B-VP	O
further	JJR	B-NP	O
evaluation	NN	I-NP	O
.	.	O	O

Associations	NNS	B-NP	O
of	IN	B-PP	O
Ozone	NN	B-NP	O
and	CC	I-NP	O
PM2.5	NN	I-NP	O
Concentrations	NNS	I-NP	O
With	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Among	NNP	I-NP	O
Participants	NNPS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Agricultural	NNP	I-NP	O
Health	NNP	I-NP	O
Study	NNP	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
describes	VBZ	B-VP	O
associations	NNS	B-NP	O
of	IN	B-PP	O
ozone	NN	B-NP	O
and	CC	O	O
fine	JJ	B-NP	O
particulate	JJ	I-NP	O
matter	NN	I-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
observed	VBN	B-VP	O
among	IN	B-PP	O
farmers	NNS	B-NP	O
in	IN	B-PP	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
and	CC	I-NP	O
Iowa	NNP	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
logistic	JJ	B-NP	O
regression	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
associations	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
pollutants	NNS	I-NP	O
with	IN	B-PP	O
self	NN	B-NP	O
-	HYPH	O	O
reported	VBN	B-VP	O
,	,	O	O
doctor	NN	B-NP	O
-	HYPH	B-VP	O
diagnosed	VBN	B-NP	O
Parkinson	NN	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Daily	NNP	B-NP	O
predicted	VBD	B-VP	O
pollutant	JJ	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
derive	VB	I-VP	O
surrogates	NNS	B-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
link	VB	B-VP	O
them	PRP	B-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
participants	NNS	B-NP	O
s	NNS	B-NP	O
geocoded	VBN	B-VP	O
addresses	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
observed	VBD	B-VP	O
positive	JJ	B-NP	O
associations	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
with	IN	B-PP	O
ozone	NN	B-NP	O
and	CC	O	O
fine	JJ	B-NP	O
particulate	JJ	I-NP	O
matter	NN	I-NP	O
in	IN	B-PP	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
Iowa	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
plausibility	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ambient	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
pollutants	NNS	I-NP	O
on	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
risk	NN	I-NP	O
is	VBZ	B-VP	O
supported	VBN	I-VP	O
by	IN	B-PP	O
experimental	JJ	B-NP	O
data	NNS	I-NP	O
demonstrating	VBG	B-VP	O
damage	NN	B-NP	O
to	TO	B-PP	O
dopaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
at	IN	B-PP	O
relevant	JJ	B-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
address	VB	I-VP	O
uncertainties	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
confounding	VBG	B-VP	O
and	CC	O	O
to	TO	B-VP	O
examine	VB	I-VP	O
temporal	JJ	B-NP	O
aspects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
associations	NNS	I-NP	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
.	.	O	O

Low	JJ	B-NP	O
functional	JJ	I-NP	O
programming	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
AT2R	NN	I-NP	O
mediates	VBZ	B-VP	O
the	DT	B-NP	O
developmental	JJ	I-NP	O
origin	NN	I-NP	O
of	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
in	IN	B-PP	O
adult	JJ	B-NP	O
offspring	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
prenatal	JJ	B-NP	O
caffeine	NN	I-NP	O
exposure	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
previous	JJ	I-NP	O
study	NN	I-NP	O
has	VBZ	B-VP	O
indicated	VBN	I-VP	O
that	IN	B-SBAR	O
prenatal	JJ	B-NP	O
caffeine	NN	I-NP	O
exposure	NN	I-NP	O
(	(	O	O
PCE	NN	B-NP	O
)	)	O	O
could	MD	B-VP	O
induce	VB	I-VP	O
intrauterine	JJ	B-NP	B
growth	NN	I-NP	I
retardation	NN	I-NP	I
(	(	O	O
IUGR	NN	B-NP	B
)	)	O	O
of	IN	B-PP	O
offspring	NN	B-NP	O
.	.	O	O

Recent	JJ	B-NP	O
research	NN	I-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
IUGR	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
whether	IN	B-SBAR	O
PCE	NN	B-NP	O
could	MD	B-VP	O
induce	VB	I-VP	O
glomerulosclerosis	NN	B-NP	B
and	CC	O	O
its	PRP$	B-NP	O
underlying	JJ	I-NP	O
mechanisms	NNS	I-NP	O
remain	VBP	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
demonstrate	VB	I-VP	O
the	DT	B-NP	O
induction	NN	I-NP	O
to	TO	B-PP	O
glomerulosclerosis	NN	B-NP	B
in	IN	B-PP	O
adult	JJ	B-NP	O
offspring	NN	I-NP	O
by	IN	B-PP	O
PCE	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
intrauterine	JJ	I-NP	O
programming	NN	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
IUGR	NN	B-NP	B
was	VBD	B-VP	O
established	VBN	I-VP	O
by	IN	B-PP	O
PCE	NN	B-NP	O
,	,	O	O
male	JJ	B-NP	O
fetuses	NNS	I-NP	O
and	CC	O	O
adult	JJ	B-NP	O
offspring	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
postnatal	JJ	B-NP	O
week	NN	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
euthanized	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
adult	JJ	I-NP	O
offspring	NN	I-NP	O
kidneys	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PCE	NN	I-NP	O
group	NN	I-NP	O
exhibited	VBD	B-VP	O
glomerulosclerosis	NN	B-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
interstitial	JJ	B-NP	B
fibrosis	NN	I-NP	I
,	,	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
elevated	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
and	CC	O	O
urine	NN	B-NP	O
protein	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
AT2R	NN	B-NP	O
)	)	O	O
gene	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
offspring	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
PCE	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
renal	JJ	I-NP	O
angiotensin	NN	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
type	NN	I-NP	O
1a	NN	I-NP	O
(	(	O	O
AT1aR	NN	B-NP	O
)	)	O	O
/	SYM	O	O
AT2R	NN	B-NP	O
expression	NN	I-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
fetal	JJ	I-NP	O
kidneys	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PCE	NN	I-NP	O
group	NN	I-NP	O
displayed	VBD	B-VP	O
an	DT	B-NP	O
enlarged	JJ	I-NP	O
Bowman	NNP	I-NP	O
s	NNS	I-NP	O
space	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
shrunken	JJ	I-NP	O
glomerular	JJ	I-NP	O
tuft	NN	I-NP	O
,	,	O	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
cortex	NN	I-NP	O
width	NN	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
nephrogenic	JJ	I-NP	O
zone	NN	I-NP	O
/	SYM	B-NP	O
cortical	JJ	I-NP	O
zone	NN	I-NP	O
ratio	NN	I-NP	O
.	.	O	O

Observation	NN	B-NP	O
by	IN	B-PP	O
electronic	JJ	B-NP	O
microscope	NN	I-NP	O
revealed	VBD	B-VP	O
structural	JJ	B-NP	O
damage	NN	I-NP	O
of	IN	B-PP	O
podocytes	NNS	B-NP	O
;	:	O	O
the	DT	B-NP	O
reduced	VBN	I-NP	O
expression	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
podocyte	NN	B-NP	O
marker	NN	I-NP	O
genes	NNS	I-NP	O
,	,	O	O
nephrin	NN	B-NP	O
and	CC	O	O
podocin	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
detected	VBN	I-VP	O
by	IN	B-PP	O
q	NN	B-NP	O
-	HYPH	B-NP	O
PCR	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
AT2R	NN	B-NP	O
gene	NN	I-NP	O
and	CC	O	O
protein	NN	B-NP	O
expressions	NNS	I-NP	O
in	IN	B-PP	O
fetal	JJ	B-NP	O
kidneys	NNS	I-NP	O
were	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
PCE	NN	B-NP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
repression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
glial	JJ	B-NP	O
-	HYPH	I-NP	O
cell	NN	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
-	HYPH	O	O
derived	VBN	B-VP	O
neurotrophic	JJ	B-NP	O
factor	NN	I-NP	O
(	(	O	O
GDNF	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
tyrosine	NN	I-NP	O
kinase	NN	I-NP	O
receptor	NN	I-NP	O
(	(	O	O
c	NN	B-NP	O
-	HYPH	I-NP	O
Ret	NN	I-NP	O
)	)	O	O
signaling	NN	B-NP	O
pathway	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
PCE	NN	B-NP	O
could	MD	B-VP	O
induce	VB	I-VP	O
dysplasia	NN	B-NP	B
of	IN	B-PP	I
fetal	JJ	B-NP	I
kidneys	NNS	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
glomerulosclerosis	NN	B-NP	B
of	IN	B-PP	O
adult	JJ	B-NP	O
offspring	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
low	JJ	I-NP	O
functional	JJ	I-NP	O
programming	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
AT2R	NN	I-NP	O
might	MD	B-VP	O
mediate	VB	I-VP	O
the	DT	B-NP	O
developmental	JJ	I-NP	O
origin	NN	I-NP	O
of	IN	B-PP	O
adult	JJ	B-NP	O
glomerulosclerosis	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
Butadiene	NN	I-NP	O
,	,	O	O
CML	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
t	NN	I-NP	O
translocation	NN	I-NP	O
:	:	O	O
A	DT	B-NP	O
reality	NN	I-NP	O
check	NN	I-NP	O
.	.	O	O

Epidemiological	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
butadiene	NN	I-NP	O
have	VBP	B-VP	O
suggest	VBP	I-VP	O
that	IN	B-SBAR	O
exposures	NNS	B-NP	O
to	TO	B-PP	O
humans	NNS	B-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
myeloid	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
CML	NN	B-NP	B
)	)	O	O
.	.	O	O

CML	NN	B-NP	B
has	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
documented	VBN	I-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
ionizing	VBG	B-VP	O
radiation	NN	B-NP	O
,	,	O	O
but	CC	O	O
reports	NNS	B-NP	O
of	IN	B-PP	O
associations	NNS	B-NP	O
with	IN	B-PP	O
chemical	JJ	B-NP	O
exposures	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
questioned	VBN	I-VP	O
.	.	O	O

Ionizing	VBG	B-VP	O
radiation	NN	B-NP	O
is	VBZ	B-VP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
inducing	VBG	B-VP	O
the	DT	B-NP	O
requisite	JJ	I-NP	O
CML	NN	I-NP	B
-	HYPH	B-VP	O
associated	VBN	B-NP	O
t	NN	I-NP	O
translocation	NN	I-NP	O
(	(	O	O
Philadelphia	NN	B-NP	B
chromosome	NN	I-NP	I
)	)	O	O
in	IN	B-PP	O
appropriate	JJ	B-NP	O
cells	NNS	I-NP	O
in	FW	B-PP	O
vitro	FW	B-NP	O
but	CC	O	O
,	,	O	O
thus	RB	B-ADVP	O
far	RB	I-ADVP	O
,	,	O	O
chemicals	NNS	B-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
shown	VBN	I-VP	O
this	DT	B-NP	O
capacity	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
butadiene	NN	I-NP	O
metabolites	NNS	I-NP	O
be	VB	B-VP	O
so	RB	I-VP	O
tested	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
reality	NN	I-NP	O
check	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
epidemiological	JJ	I-NP	O
reports	NNS	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
conduct	VB	I-VP	O
reliable	JJ	B-NP	O
testing	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
regard	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
positive	JJ	I-NP	O
control	NN	I-NP	O
for	IN	B-PP	O
induction	NN	B-NP	O
be	VB	B-VP	O
available	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
used	VBN	I-VP	O
ionizing	VBG	I-VP	O
radiation	NN	B-NP	O
to	TO	B-VP	O
develop	VB	I-VP	O
such	PDT	B-NP	O
a	DT	I-NP	O
control	NN	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
described	VBN	B-VP	O
here	RB	B-ADVP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
agent	NN	I-NP	O
does	VBZ	B-VP	O
in	IN	B-PP	O
fact	NN	B-NP	O
induce	VBP	B-VP	O
pathogenic	JJ	B-NP	O
t	NN	I-NP	O
translocations	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
human	JJ	I-NP	O
myeloid	JJ	I-NP	O
cell	NN	I-NP	O
line	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
but	CC	O	O
does	VBZ	B-VP	O
so	RB	B-ADVP	O
at	IN	B-PP	O
low	JJ	B-NP	O
frequencies	NNS	I-NP	O
.	.	O	O

Conditions	NNS	B-NP	O
that	WDT	B-NP	O
will	MD	B-VP	O
be	VB	I-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
studies	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
butadiene	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Cancer	NN	B-NP	B
incidence	NN	I-NP	O
and	CC	I-NP	O
metolachlor	NN	I-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Agricultural	NNP	I-NP	O
Health	NNP	I-NP	O
Study	NNP	I-NP	O
:	:	O	O
An	DT	B-NP	O
update	NN	I-NP	O
.	.	O	O

Metolachlor	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
herbicide	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
classified	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
Group	NN	I-NP	O
C	NN	I-NP	O
carcinogen	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
U.S	NNP	I-NP	O
.	.	O	O

Environmental	NNP	B-NP	O
Protection	NNP	I-NP	O
Agency	NNP	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
increased	VBN	B-NP	O
liver	NN	I-NP	B
neoplasms	NNS	I-NP	I
in	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Epidemiologic	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
health	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
metolachlor	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
limited	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
Agricultural	NNP	I-NP	O
Health	NNP	I-NP	O
Study	NNP	I-NP	O
(	(	O	O
AHS	NNP	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
including	VBG	B-PP	O
licensed	VBN	B-NP	O
private	JJ	I-NP	O
and	CC	I-NP	O
commercial	JJ	I-NP	O
pesticide	NN	I-NP	O
applicators	NNS	I-NP	O
in	IN	B-PP	O
Iowa	NNP	B-NP	O
and	CC	O	O
North	NNP	B-NP	O
Carolina	NNP	I-NP	O
enrolled	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
cancer	NN	B-NP	B
incidence	NN	I-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
(	(	O	O
NC	NN	B-NP	O
/	SYM	B-NP	O
IA	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
applicators	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
reported	VBD	B-VP	O
ever	RB	I-VP	O
using	VBG	I-VP	O
metolachlor	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
Poisson	NN	B-NP	O
regression	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
relations	NNS	B-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
metrics	NNS	I-NP	O
of	IN	B-PP	O
metolachlor	NN	B-NP	O
use	NN	I-NP	O
(	(	O	O
lifetime	NN	B-NP	O
days	NNS	I-NP	O
,	,	O	O
intensity	NN	B-NP	O
-	HYPH	B-VP	O
weighted	VBN	B-NP	O
lifetime	NN	I-NP	O
days	NNS	I-NP	O
)	)	O	O
and	CC	O	O
cancer	NN	B-NP	B
incidence	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
saw	VBD	B-VP	O
no	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
metolachlor	NN	B-NP	O
use	NN	I-NP	O
and	CC	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
cancers	NNS	I-NP	B
combined	VBN	B-VP	O
or	CC	O	O
most	JJS	B-NP	O
site	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
cancers	NNS	I-NP	B
.	.	O	O

For	IN	B-PP	O
liver	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
in	IN	B-PP	O
analyses	NNS	B-NP	O
restricted	VBN	B-VP	O
to	TO	B-PP	O
exposed	VBN	B-NP	O
workers	NNS	I-NP	O
,	,	O	O
elevations	NNS	B-NP	O
observed	VBN	B-VP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
categories	NNS	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
were	VBD	B-VP	O
not	RB	O	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
trends	NNS	B-NP	O
for	IN	B-PP	O
both	CC	O	O
lifetime	NN	B-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
-	HYPH	O	O
weighted	VBN	B-NP	O
lifetime	NN	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
metolachor	NN	B-NP	O
use	NN	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
and	CC	O	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
with	IN	B-PP	O
an	DT	B-NP	O
unexposed	JJ	I-NP	O
reference	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
similar	JJ	I-NP	O
pattern	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
follicular	JJ	B-NP	B
cell	NN	I-NP	I
lymphoma	NN	I-NP	I
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
other	JJ	I-NP	O
lymphoma	NN	I-NP	B
subtypes	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
earlier	JJR	I-NP	O
suggestion	NN	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
lung	NN	I-NP	B
cancer	NN	I-NP	I
risk	NN	I-NP	O
at	IN	B-PP	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
metolachlor	NN	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
cohort	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
confirmed	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
update	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
suggestion	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
metolachlor	NN	B-NP	O
and	CC	O	O
liver	NN	B-NP	B
cancer	NN	I-NP	I
among	IN	B-PP	O
pesticide	NN	B-NP	O
applicators	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
finding	NN	I-NP	O
and	CC	O	O
echoes	VBZ	B-VP	O
observation	NN	B-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
liver	NN	I-NP	B
neoplasms	NNS	I-NP	I
in	IN	B-PP	O
some	DT	B-NP	O
animal	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
our	PRP$	B-NP	O
findings	NNS	I-NP	O
for	IN	B-PP	O
both	CC	O	O
liver	NN	B-NP	B
cancer	NN	I-NP	I
and	CC	O	O
follicular	JJ	B-NP	O
cell	NN	I-NP	O
lymphoma	NN	I-NP	B
warrant	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
to	TO	B-VP	O
better	RBR	I-VP	O
differentiate	VB	I-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
metolachlor	NN	B-NP	O
use	NN	I-NP	O
from	IN	B-PP	O
other	JJ	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Mechanisms	NNS	B-NP	O
Underlying	VBG	B-VP	O
Latent	JJ	B-NP	O
Disease	NN	I-NP	O
Risk	NN	I-NP	O
Associated	VBN	B-VP	O
with	IN	B-PP	O
Early	JJ	B-NP	O
-	HYPH	I-NP	O
Life	NN	I-NP	O
Arsenic	JJ	I-NP	O
Exposure	NN	I-NP	O
:	:	O	O
Current	NNP	B-NP	O
Research	NNP	I-NP	O
Trends	NNP	I-NP	O
and	CC	O	O
Scientific	NNP	B-NP	O
Gaps	NNP	I-NP	O
.	.	O	O

Millions	NNS	B-NP	O
of	IN	B-PP	O
individuals	NNS	B-NP	O
worldwide	RB	B-ADVP	O
,	,	O	O
particularly	RB	B-ADVP	O
those	DT	B-NP	O
living	VBG	B-VP	O
in	IN	B-PP	O
rural	JJ	B-NP	O
and	CC	I-NP	O
developing	VBG	I-NP	O
areas	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
harmful	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
inorganic	JJ	B-NP	O
arsenic	JJ	I-NP	O
(	(	O	O
iAs	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
their	PRP$	B-NP	O
drinking	NN	I-NP	O
water	NN	I-NP	O
.	.	O	O

Inorganic	JJ	B-ADJP	O
As	IN	B-PP	O
exposure	NN	B-NP	O
during	IN	B-PP	O
key	JJ	B-NP	O
developmental	JJ	I-NP	O
periods	NNS	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
health	NN	I-NP	O
effects	NNS	I-NP	O
including	VBG	B-PP	O
those	DT	B-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
evident	JJ	B-ADJP	O
in	IN	B-PP	O
adulthood	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
considerable	JJ	B-NP	O
interest	NN	I-NP	O
in	IN	B-PP	O
identifying	VBG	B-VP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
that	WDT	B-NP	O
relate	VBP	B-VP	O
early	JJ	B-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
iAs	NNS	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
latent	JJ	I-NP	O
diseases	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
relationship	NN	B-NP	O
to	TO	B-PP	O
cancer	NN	B-NP	B
.	.	O	O

This	DT	B-NP	O
work	NN	I-NP	O
summarizes	VBZ	B-VP	O
research	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
molecular	JJ	I-NP	O
mechanisms	NNS	I-NP	O
that	WDT	B-NP	O
underlie	VBP	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
cancer	NN	B-NP	B
development	NN	I-NP	O
in	IN	B-PP	O
adulthood	NN	B-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
early	JJ	B-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
iAs	NNS	I-NP	O
exposure	NN	I-NP	O
.	.	O	O

Epigenetic	JJ	B-NP	O
reprogramming	NN	I-NP	O
that	WDT	B-NP	O
imparts	VBZ	B-VP	O
functional	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
gene	NN	B-NP	O
expression	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cancer	NN	B-NP	B
stem	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
and	CC	O	O
immunomodulation	NN	B-NP	O
are	VBP	B-VP	O
plausible	JJ	B-NP	O
underlying	VBG	I-NP	O
mechanisms	NNS	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
early	JJ	B-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
iAs	NNS	I-NP	O
exposure	NN	I-NP	O
elicits	VBZ	B-VP	O
latent	JJ	B-NP	O
carcinogenic	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
is	VBZ	B-VP	O
mounting	VBG	I-VP	O
that	DT	B-NP	O
relates	VBZ	B-VP	O
early	JJ	B-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
iAs	NNS	I-NP	O
exposure	NN	I-NP	O
and	CC	I-NP	O
cancer	NN	I-NP	B
development	NN	I-NP	O
later	RB	B-ADVP	O
in	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

Future	JJ	B-NP	O
research	NN	I-NP	O
should	MD	B-VP	O
include	VB	I-VP	O
animal	NN	B-NP	O
studies	NNS	I-NP	O
that	WDT	B-NP	O
address	VBP	B-VP	O
mechanistic	JJ	B-NP	O
hypotheses	NNS	I-NP	O
and	CC	I-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
populations	NNS	I-NP	O
that	WDT	B-NP	O
integrate	VBP	B-VP	O
early	JJ	B-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
molecular	JJ	B-NP	O
alterations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
latent	JJ	B-NP	O
disease	NN	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
antiarrhythmic	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
substituted	VBN	I-NP	O
piperazine	NN	I-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
trans	AFX	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
amino	JJ	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydroanaphthalene	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
antiarrhythmic	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
compound	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	O	O
(	(	O	O
trans	AFX	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
naphthyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
oxo	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methylpropyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
piperazine	NN	I-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
referred	VBN	B-VP	O
to	TO	B-PP	O
as	IN	B-PP	O
P11	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
studied	VBN	I-VP	O
on	IN	B-PP	O
anaesthesized	VBN	B-NP	O
cats	NNS	I-NP	O
and	CC	O	O
Wistar	NNP	B-NP	O
albino	NNP	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
on	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
anaesthesized	VBN	I-NP	O
rabbits	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
arrhythmia	NN	I-NP	B
are	VBP	B-VP	O
used	VBN	I-VP	O
-	SYM	B-NP	O
-	HYPH	B-ADJP	O
with	IN	B-PP	O
BaCl2	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
chloroform	NN	B-NP	O
-	HYPH	B-NP	O
adrenaline	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
strophantine	JJ	B-NP	O
G	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
aconitine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
compound	NN	I-NP	O
P11	NN	I-NP	O
is	VBZ	B-VP	O
introduced	VBN	I-VP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
intravenously	RB	B-ADVP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
orally	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
compound	NN	I-NP	O
manifests	VBZ	B-VP	O
antiarrhythmic	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
arrhythmia	NN	I-NP	B
used	VBN	B-VP	O
,	,	O	O
causing	VBG	B-VP	O
greatest	JJS	B-NP	O
inhibition	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
chloroform	NN	B-NP	O
-	HYPH	B-NP	O
adrenaline	NN	I-NP	O
(	(	O	O
in	IN	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
)	)	O	O
and	CC	O	O
with	IN	B-PP	O
BaCl2	NN	B-NP	O
(	(	O	O
in	IN	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoblocking	VBG	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
membrane	NN	I-NP	O
-	HYPH	O	O
stabilizing	VBG	B-VP	O
action	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
compound	NN	I-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
progressive	JJ	I-NP	O
muscular	JJ	I-NP	B
dystrophy	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
anabolizing	VBG	B-VP	O
agents	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
are	VBP	B-VP	O
still	RB	B-ADVP	O
a	DT	B-NP	O
long	JJ	I-NP	O
way	NN	I-NP	O
from	IN	B-PP	O
discovering	VBG	B-VP	O
an	DT	B-NP	O
unequivocal	JJ	I-NP	O
pathogenetic	JJ	I-NP	O
interpretation	NN	I-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
muscular	JJ	I-NP	B
dystrophy	NN	I-NP	I
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Noteworthy	JJ	B-NP	O
efforts	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
made	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
field	NN	I-NP	O
;	:	O	O
a	DT	B-NP	O
recessive	JJ	I-NP	O
autosomic	JJ	I-NP	O
form	NN	I-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mouse	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
bear	VB	I-VP	O
the	DT	B-NP	O
closest	JJS	I-NP	O
resemblance	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
form	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
genetic	JJ	I-NP	O
point	NN	I-NP	O
of	IN	B-PP	O
view	NN	B-NP	O
.	.	O	O

Myopathy	NN	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
lack	NN	B-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
and	CC	I-NP	O
myopathy	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
certain	JJ	B-NP	O
viruses	NNS	I-NP	O
have	VBP	B-VP	O
much	JJ	B-NP	O
in	IN	B-PP	O
common	JJ	B-ADJP	O
anatomically	RB	B-ADVP	O
and	CC	I-ADVP	O
pathologically	RB	I-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
form	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
induced	VBD	B-VP	O
myodystrophy	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
by	IN	B-PP	O
giving	VBG	B-VP	O
it	PRP	B-NP	O
a	DT	B-NP	O
diet	NN	I-NP	O
lacking	VBG	B-VP	O
in	IN	B-PP	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacological	JJ	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
degenerative	JJ	I-NP	O
changes	NNS	I-NP	O
brought	VBD	B-VP	O
about	RP	B-PRT	O
by	IN	B-PP	O
its	PRP$	B-NP	O
deficiency	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
muscles	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
illustrated	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
thus	RB	I-VP	O
confirmed	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
histological	JJ	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
myopathic	JJ	B-NP	B
rat	NN	I-NP	O
muscle	NN	I-NP	O
induced	VBN	B-VP	O
experimentally	RB	B-ADVP	O
are	VBP	B-VP	O
extraordinarily	RB	B-ADJP	O
similar	JJ	I-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
myopathy	NN	I-NP	B
as	IN	B-SBAR	O
confirmed	VBN	B-VP	O
during	IN	B-PP	O
biopsies	NNS	B-NP	O
performed	VBN	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
Orthopaedic	NNP	I-NP	O
Traumatological	NNP	I-NP	O
Centre	NNP	I-NP	O
,	,	O	O
Florence	NNP	B-NP	O
.	.	O	O

The	DT	B-NP	O
encouraging	JJ	I-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
in	IN	B-PP	O
various	JJ	B-NP	O
authoratative	JJ	I-NP	O
departments	NNS	I-NP	O
in	IN	B-PP	O
myopathic	JJ	B-NP	B
patients	NNS	I-NP	O
by	IN	B-PP	O
using	VBG	B-VP	O
anabolizing	VBG	B-NP	O
steroids	NNS	I-NP	O
have	VBP	B-VP	O
encouraged	VBN	I-VP	O
the	DT	B-NP	O
authors	NNS	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
anabolizing	VBG	B-VP	O
agent	NN	B-NP	O
(	(	O	O
Dianabol	NN	B-NP	O
,	,	O	O
CIBA	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
rendered	VBN	B-VP	O
myopathic	JJ	B-ADJP	B
by	IN	B-PP	O
a	DT	B-NP	O
diet	NN	I-NP	O
deficient	JJ	B-ADJP	O
in	IN	B-PP	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
way	NN	I-NP	O
they	PRP	B-NP	O
obtained	VBD	B-VP	O
appreciable	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
but	CC	O	O
most	JJS	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
they	PRP	B-NP	O
found	VBD	B-VP	O
histological	JJ	B-NP	O
changes	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
regenerative	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
tissue	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
however	RB	B-ADVP	O
maintained	VBD	B-VP	O
its	PRP$	B-NP	O
myopathic	JJ	I-NP	B
characteristics	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
anabolizing	VBG	I-NP	O
agent	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
conclude	VBP	B-VP	O
by	IN	B-PP	O
affirming	VBG	B-VP	O
the	DT	B-NP	O
undoubted	JJ	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anabolizing	VBG	I-NP	O
steroids	NNS	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
myopathic	JJ	I-NP	B
disease	NN	I-NP	I
,	,	O	O
but	CC	O	O
they	PRP	B-NP	O
have	VBP	B-VP	O
reservations	NNS	B-NP	O
as	IN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
transfer	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
field	NN	I-NP	O
,	,	O	O
where	WRB	B-ADVP	O
high	JJ	B-NP	O
dosage	NN	I-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
continuously	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
on	IN	B-PP	O
virility	NN	B-NP	O
;	:	O	O
because	IN	B-SBAR	O
the	DT	B-NP	O
tissue	NN	I-NP	O
injury	NN	I-NP	O
too	RB	B-ADVP	O
often	RB	I-ADVP	O
occurs	VBZ	B-VP	O
at	IN	B-PP	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
stage	NN	I-NP	O
vis	NNS	I-NP	O
-	:	O	O
a	DT	B-NP	O
-	:	O	O
vis	IN	B-PP	O
the	DT	B-NP	O
regeneration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
muscle	NN	I-NP	O
tissue	NN	I-NP	O
;	:	O	O
and	CC	O	O
finally	RB	B-ADVP	O
because	IN	B-SBAR	O
the	DT	B-NP	O
dystrophic	JJ	I-NP	O
injurious	JJ	I-NP	O
agent	NN	I-NP	O
is	VBZ	B-VP	O
certainly	RB	B-ADVP	O
not	RB	O	O
the	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
E	NN	I-NP	O
but	CC	O	O
something	NN	B-NP	O
as	RB	B-ADJP	O
yet	RB	I-ADJP	O
unknown	JJ	I-ADJP	O
.	.	O	O

Fetal	JJ	B-NP	O
risks	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
therapy	NN	I-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
mothers	NNS	I-NP	O
with	IN	B-PP	O
heart	NN	B-NP	O
valve	NN	I-NP	O
prosthesis	NN	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
a	DT	B-NP	O
caesarean	JJ	I-NP	O
section	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
num	CD	B-NP	O
week	NN	I-NP	O
after	IN	B-PP	O
replacement	NN	B-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
with	IN	B-PP	O
heparin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
baby	NN	I-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
and	CC	I-NP	I
pulmonary	JJ	I-NP	I
hemorrhage	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
mother	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
male	JJ	I-NP	O
infant	NN	I-NP	O
by	IN	B-PP	O
caesarean	JJ	B-NP	O
section	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
baby	NN	I-NP	O
showed	VBD	B-VP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
embryopathy	NN	I-NP	B
with	IN	B-PP	O
nasal	JJ	B-NP	B
hypoplasia	NN	I-NP	I
and	CC	O	O
stippled	VBN	B-NP	B
epiphyses	NNS	I-NP	I
(	(	O	O
chondrodysplasia	NN	B-NP	B
punctata	NN	I-NP	I
)	)	O	O
.	.	O	O

Nasal	JJ	B-NP	B
hypoplasia	NN	I-NP	I
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
stippled	VBN	B-NP	B
epiphyses	NNS	I-NP	I
has	VBZ	B-VP	O
now	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
infants	NNS	I-NP	O
born	VBN	B-VP	O
to	TO	B-PP	O
mothers	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
warfarin	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
trimester	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
causal	JJ	I-NP	O
association	NN	I-NP	O
is	VBZ	B-VP	O
probable	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
view	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
risks	NNS	I-NP	O
to	TO	B-PP	O
both	CC	O	O
mother	NN	B-NP	O
and	CC	I-NP	O
fetus	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
prosthetic	JJ	B-NP	O
cardiac	JJ	I-NP	O
valves	NNS	I-NP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
that	IN	B-SBAR	O
therapeutic	JJ	B-NP	O
abortion	NN	I-NP	O
be	VB	B-VP	O
advised	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
alternative	NN	I-NP	O
.	.	O	O

Isradipine	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
in	IN	B-PP	O
general	JJ	B-NP	O
practice	NN	I-NP	O
in	IN	B-PP	O
Hong	NNP	B-NP	O
Kong	NNP	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
open	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
isradipine	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
general	JJ	B-NP	O
practice	NN	I-NP	O
in	IN	B-PP	O
Hong	NNP	B-NP	O
Kong.	NNP	I-NP	O
num	CD	I-NP	O
Chinese	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
mild	JJ	B-ADJP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
hypertension	NN	I-NP	B
entered	VBD	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
caused	VBD	B-VP	O
withdrawal	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
side	NN	I-NP	O
-	HYPH	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
headache	NN	B-NP	B
,	,	I-NP	O
dizziness	NN	I-NP	B
,	,	I-NP	O
palpitation	NN	I-NP	B
and	CC	I-NP	O
flushing	NN	I-NP	B
and	CC	O	O
these	DT	B-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
more	RBR	I-ADJP	O
frequent	JJ	I-ADJP	O
than	IN	B-SBAR	O
reported	VBN	B-VP	O
in	IN	B-PP	O
other	JJ	B-NP	O
studies	NNS	I-NP	O
with	IN	B-PP	O
isradipine	NN	B-NP	O
or	CC	B-PP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

Supine	NN	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
respectively	RB	B-ADVP	O
in	IN	B-PP	O
evaluable	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
reductions	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
standing	VBG	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
postural	JJ	B-NP	B
hypotension	NN	I-NP	I
.	.	O	O

Normalization	NN	B-NP	O
and	CC	I-NP	O
responder	NN	I-NP	O
rates	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

Dosage	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
b.d.	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
b.d.	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
further	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
remaining	VBG	B-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
b.d	NN	I-NP	O
.	.	O	O

Tachyphylaxis	NN	B-NP	O
to	TO	B-PP	O
systemic	JJ	B-ADJP	O
but	CC	I-ADJP	O
not	RB	I-ADJP	O
to	TO	B-PP	O
airway	NN	B-NP	O
responses	NNS	I-NP	O
during	IN	B-PP	O
prolonged	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
inhaled	VBD	B-VP	O
salbutamol	NN	B-NP	O
in	IN	B-PP	O
asthmatics	NNS	B-NP	B
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
inhaled	VBN	B-NP	O
salbutamol	NN	I-NP	O
produce	VBP	B-VP	O
substantial	JJ	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
airway	NN	B-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
asthma	NN	B-NP	B
,	,	O	O
and	CC	O	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
systemic	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
tachyphylaxis	NN	B-NP	O
occurs	VBZ	B-VP	O
during	IN	B-PP	O
prolonged	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
inhaled	VBD	B-VP	O
salbutamol	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
asthmatic	JJ	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
requiring	VBG	B-VP	O
only	RB	B-NP	O
occasional	JJ	I-NP	O
inhaled	VBD	B-VP	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
agonists	NNS	B-NP	O
as	IN	B-PP	O
their	PRP$	B-NP	O
sole	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
dose	NN	I-NP	O
inhaled	VBD	B-VP	O
salbutamol	NN	B-NP	O
(	(	O	O
HDS	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
daily	JJ	I-NP	O
,	,	I-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
inhaled	VBD	B-VP	O
salbutamol	NN	B-NP	O
(	(	O	O
LDS	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
daily	RB	B-ADVP	O
,	,	O	O
or	CC	O	O
placebo	NN	B-NP	O
(	(	O	O
PI	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
metered	VBN	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
inhaler	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
crossover	NN	I-NP	O
design	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
run	VB	B-VP	O
-	HYPH	B-NP	O
in	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
washout	NN	B-NP	O
periods	NNS	I-NP	O
,	,	O	O
inhaled	VBD	B-VP	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
agonists	NNS	B-NP	O
were	VBD	B-VP	O
withheld	VBN	I-VP	O
and	CC	O	O
ipratropium	NN	B-NP	O
bromide	NN	I-NP	O
was	VBD	B-VP	O
substituted	VBN	I-VP	O
for	IN	B-PP	O
rescue	NN	B-NP	O
purposes	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
response	NN	B-NP	O
curve	NN	I-NP	O
(	(	O	O
DRC	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
airway	NN	B-NP	O
(	(	O	O
FEV1	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
chronotropic	JJ	O	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
,	,	O	O
tremor	NN	B-NP	B
,	,	O	O
and	CC	O	O
metabolic	JJ	B-ADJP	O
(	(	O	O
K	NN	B-NP	O
,	,	O	O
Glu	NN	B-NP	O
)	)	O	O
responses	NNS	B-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
each	DT	B-NP	O
step	NN	I-NP	O
(	(	O	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
)	)	O	O
.	.	O	O

Treatment	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
baseline	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
FEV1	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
HDS	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
displace	VB	I-VP	O
the	DT	B-NP	O
DRC	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
right	NN	I-NP	O
.	.	O	O

DRC	NN	B-NP	O
for	IN	B-PP	O
HR	NN	B-NP	O
,	,	O	O
K	NN	B-NP	O
,	,	O	O
and	CC	O	O
Glu	NN	B-NP	O
were	VBD	B-VP	O
attenuated	VBN	I-VP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
HDS	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
PI	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
differences	NNS	B-NP	O
between	IN	B-PP	O
HDS	NN	B-NP	O
and	CC	I-NP	O
LDS	NN	I-NP	O
for	IN	B-PP	O
HR	NN	B-NP	O
and	CC	I-NP	O
Glu	NN	I-NP	O
responses	NNS	I-NP	O
.	.	O	O

Frequency	NN	B-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
subjective	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
reduced	VBN	I-VP	O
after	IN	B-PP	O
HDS	NN	B-NP	O
:	:	O	O
tremor	NN	B-NP	B
,	,	O	O
palpitations	NNS	B-NP	B
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
anxiogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
panic	NN	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
on	IN	B-PP	O
behavioral	JJ	B-NP	O
ratings	NNS	I-NP	O
,	,	O	O
somatic	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
plasma	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxyphenethyleneglycol	NN	I-NP	O
(	(	O	O
MHPG	NN	B-NP	O
)	)	O	O
and	CC	O	O
cortisol	NN	B-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
meeting	VBG	B-VP	O
DSM	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
agoraphobia	NN	B-NP	B
with	IN	B-PP	O
panic	JJ	B-NP	B
attacks	NNS	I-NP	I
or	CC	O	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

Caffeine	NN	B-NP	O
produced	VBD	B-VP	O
significantly	RB	B-NP	O
greater	JJR	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
subject	NN	B-NP	O
-	HYPH	B-PP	O
rated	VBN	B-NP	O
anxiety	NN	I-NP	B
,	,	O	O
nervousness	NN	B-NP	O
,	,	O	O
fear	NN	B-NP	O
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
palpitations	NNS	B-NP	B
,	,	O	O
restlessness	NN	B-NP	B
,	,	O	O
and	CC	O	O
tremors	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
the	DT	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
,	,	O	O
these	DT	B-NP	O
symptoms	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
plasma	NN	B-NP	O
caffeine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
experienced	VBN	B-VP	O
during	IN	B-PP	O
panic	NN	B-NP	B
attacks	NNS	I-NP	I
.	.	O	O

Caffeine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
plasma	NN	B-NP	O
MHPG	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
either	CC	O	O
the	DT	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
or	CC	O	O
patients	NNS	B-NP	O
.	.	O	O

Caffeine	NN	B-NP	O
increased	VBD	B-VP	O
plasma	NN	B-NP	O
cortisol	NN	I-NP	O
levels	NNS	I-NP	O
equally	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
and	CC	O	O
healthy	JJ	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
caffeine	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
these	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
some	DT	B-NP	O
panic	JJ	I-NP	B
disorder	NN	I-NP	I
patients	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
abnormalities	NNS	B-NP	B
in	IN	B-PP	I
neuronal	JJ	B-NP	I
systems	NNS	I-NP	I
involving	VBG	B-VP	O
adenosine	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
anxiety	NN	B-NP	B
disorders	NNS	I-NP	I
may	MD	B-VP	O
benefit	VB	I-VP	O
by	IN	B-PP	O
avoiding	VBG	B-VP	O
caffeine	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
foods	NNS	B-NP	O
and	CC	I-NP	O
beverages	NNS	I-NP	O
.	.	O	O

Human	JJ	B-NP	O
and	CC	I-NP	O
canine	JJ	I-NP	O
ventricular	JJ	I-NP	O
vasoactive	JJ	I-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
:	:	O	O
decrease	NN	B-NP	O
with	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Vasoactive	JJ	B-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
(	(	O	O
VIP	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
systemic	JJ	I-NP	O
and	CC	I-NP	O
coronary	JJ	I-NP	O
vasodilator	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
positive	JJ	B-NP	O
inotropic	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
VIP	NN	B-NP	O
were	VBD	B-VP	O
assayed	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
canine	JJ	I-NP	O
models	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
,	,	I-NP	O
cobalt	NN	I-NP	O
cardiomyopathy	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
;	:	O	O
VIP	NN	B-NP	O
(	(	O	O
by	IN	B-PP	O
radioimmunoassay	NN	B-NP	O
)	)	O	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	O	O
mg	NN	B-NP	O
protein	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
SD	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
pg	NN	I-NP	O
/	SYM	I-NP	O
mg	NN	I-NP	O
protein	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
,	,	O	O
VIP	NN	B-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
pg	NN	I-NP	O
/	SYM	I-NP	O
mg	NN	I-NP	O
protein	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
VIP	NN	B-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
muscle	NN	I-NP	O
of	IN	B-PP	O
resected	VBN	B-NP	O
failing	VBG	I-NP	O
hearts	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
heart	NN	I-NP	O
transplant	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
papillary	JJ	I-NP	O
muscles	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
rheumatic	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
myxomatous	JJ	B-NP	B
degeneration	NN	I-NP	I
)	)	O	O
receiving	VBG	B-VP	O
mitral	JJ	B-NP	O
valve	NN	I-NP	O
prostheses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
lowest	JJS	I-NP	O
myocardial	JJ	I-NP	O
VIP	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hearts	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
disease	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
transplant	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
receiving	VBG	I-NP	O
mitral	JJ	I-NP	O
prostheses	NNS	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
transplantation	NN	B-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
average	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
VIP	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	O	O
mg	NN	B-NP	O
protein	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hearts	NNS	I-NP	O
without	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
had	VBD	B-VP	O
a	DT	B-NP	O
VIP	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
mg	NN	I-NP	O
protein	NN	I-NP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
hearts	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
disease	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
hearts	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
transplant	NN	I-NP	O
.	.	O	O

Myocardial	JJ	B-NP	O
catecholamines	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
;	:	O	O
a	DT	B-NP	O
weak	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
tissue	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
VIP	NN	B-NP	O
and	CC	I-NP	O
norepinephrine	NN	I-NP	O
was	VBD	B-VP	O
noted.	RB	B-ADVP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Interstrain	NN	B-NP	O
variation	NN	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
toxic	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
caffeine	NN	B-NP	O
among	IN	B-PP	O
inbred	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
toxic	JJ	I-NP	O
dosage	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
behavioral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
males	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
inbred	JJ	I-NP	O
mouse	NN	I-NP	O
strains	NNS	I-NP	O
(	(	O	O
A	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
,	,	O	O
BALB	NN	B-NP	O
/	SYM	I-NP	O
cJ	NN	I-NP	O
,	,	O	O
CBA	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
,	,	O	O
C3H	NN	B-NP	O
/	SYM	I-NP	O
HeJ	NN	I-NP	O
,	,	O	O
C57BL	NN	B-NP	O
/	SYM	I-NP	O
6J	NN	I-NP	O
,	,	O	O
DBA	NN	B-NP	O
/	SYM	I-NP	O
2J	NN	I-NP	O
,	,	O	O
SWR	NN	B-NP	O
/	SYM	I-NP	O
J	NN	I-NP	O
)	)	O	O
.	.	O	O

C57BL	NN	B-NP	O
/	SYM	I-NP	O
6J	NN	I-NP	O
,	,	O	O
chosen	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
prototypic	JJ	I-NP	O
mouse	NN	I-NP	O
strain	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
behavioral	JJ	B-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
broad	JJ	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
caffeine	NN	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
phenotypic	JJ	I-NP	O
characteristics	NNS	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
righting	NN	B-NP	O
ability	NN	I-NP	O
,	,	O	O
clonic	JJ	B-NP	B
seizure	NN	I-NP	I
induction	NN	I-NP	O
,	,	O	O
stress	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lethality	NN	I-NP	O
,	,	O	O
death	NN	B-NP	O
without	IN	B-PP	O
external	JJ	B-NP	O
stress	NN	I-NP	O
-	HYPH	B-NP	O
-	SYM	B-NP	O
were	VBD	B-VP	O
scored	VBN	I-VP	O
at	IN	B-PP	O
various	JJ	B-NP	O
caffeine	NN	I-NP	O
doses	NNS	I-NP	O
in	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
naive	JJ	I-NP	O
animals	NNS	I-NP	O
under	IN	B-PP	O
empirically	RB	B-NP	O
optimized	VBN	B-VP	O
,	,	O	O
rigidly	RB	B-NP	O
constant	JJ	I-NP	O
experimental	JJ	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Mice	NNS	B-NP	O
received	VBD	B-VP	O
single	JJ	B-NP	O
IP	NN	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
volume	NN	I-NP	O
/	SYM	I-NP	O
g	NN	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
of	IN	B-PP	O
physiological	JJ	B-NP	O
saline	NN	I-NP	O
carrier	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
caffeine	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

Loss	NN	B-NP	O
of	IN	B-PP	O
righting	NN	B-NP	O
ability	NN	I-NP	O
was	VBD	B-VP	O
scored	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
post	NN	I-NP	O
dosing	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
intervals	NNS	I-NP	O
thereafter	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
animals	NNS	I-NP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
clonic	JJ	B-NP	B
seizures	NNS	I-NP	I
was	VBD	B-VP	O
scored	VBN	I-VP	O
as	IN	B-PP	O
to	TO	B-PP	O
time	NN	B-NP	O
of	IN	B-PP	O
onset	NN	B-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
these	DT	B-NP	O
proceeded	VBD	B-VP	O
to	TO	B-PP	O
tonic	JJ	B-NP	B
seizures	NNS	I-NP	I
,	,	O	O
death	NN	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
surviving	VBG	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
were	VBD	B-VP	O
immediately	RB	I-VP	O
stressed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
swim	NN	I-NP	O
test	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
C	NN	I-NP	O
water	NN	I-NP	O
,	,	O	O
and	CC	O	O
death	NN	B-NP	O
-	HYPH	O	O
producing	VBG	B-VP	O
tonic	JJ	B-NP	B
seizures	NNS	I-NP	I
were	VBD	B-VP	O
scored	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
other	JJ	B-NP	O
animals	NNS	I-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
caffeine	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
any	DT	B-NP	O
single	JJ	I-NP	O
behavioral	JJ	I-NP	O
criterion	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
criteria	NNS	I-NP	O
,	,	O	O
marked	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
toxic	JJ	B-NP	O
caffeine	NN	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
strains	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
behavioral	JJ	B-NP	O
toxicity	NN	I-NP	B
testing	NN	I-NP	O
of	IN	B-PP	O
alkylxanthines	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
mouse	NN	I-NP	O
strain	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
misleading	JJ	B-ADJP	O
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
toxic	JJ	B-NP	O
responses	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
compounds	NNS	B-NP	O
are	VBP	B-VP	O
genetically	RB	I-VP	O
influenced	VBN	I-VP	O
in	IN	B-PP	O
mammals	NNS	B-NP	O
.	.	O	O

Invasive	JJ	B-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
pelvis	NN	I-NP	I
following	VBG	B-PP	O
cyclophosphamide	NN	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
nonmalignant	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
right	JJ	B-NP	O
hydroureteronephrosis	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
ureterovesical	JJ	B-NP	O
junction	NN	I-NP	O
obstruction	NN	I-NP	O
had	VBD	B-VP	O
gross	JJ	B-NP	O
hematuria	NN	I-NP	B
after	IN	B-PP	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
wtih	VBP	B-VP	O
cyclophosphamide	NN	B-NP	O
for	IN	B-PP	O
cerebral	JJ	B-NP	B
vasculitis	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
right	JJ	I-NP	O
nephroureterectomy	NN	I-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
for	IN	B-PP	O
control	NN	B-NP	O
of	IN	B-PP	O
bleeding	VBG	B-NP	B
.	.	O	O

The	DT	B-NP	O
pathology	NN	I-NP	O
specimen	NN	I-NP	O
contained	VBD	B-VP	O
clinically	RB	B-NP	O
occult	JJ	I-NP	O
invasive	JJ	I-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
pelvis	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
to	TO	B-VP	O
cause	VB	I-VP	O
hemorrhagic	JJ	B-NP	B
cystitis	NN	I-NP	I
and	CC	O	O
urine	NN	B-NP	O
cytologic	JJ	I-NP	O
abnormalities	NNS	I-NP	O
indistinguishable	JJ	B-ADJP	O
from	IN	B-PP	O
high	JJ	B-NP	O
grade	NN	I-NP	O
carcinoma	NN	I-NP	B
is	VBZ	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
less	RBR	I-VP	O
widely	RB	I-VP	O
appreciated	VBN	I-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
also	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
carcinoma	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
urinary	JJ	I-NP	I
tract	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
carcinomas	NNS	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
urinary	JJ	I-NP	I
bladder	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
prostate	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
pelvis	NN	I-NP	I
reported	VBN	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
third	JJ	I-NP	O
urinary	JJ	I-NP	B
tract	NN	I-NP	I
cancer	NN	I-NP	I
reported	VBN	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
nonmalignant	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumor	NN	I-NP	B
with	IN	B-PP	O
preexisting	VBG	B-VP	O
hydroureteronephrosis	NN	B-NP	B
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
stasis	NN	B-NP	O
prolonged	VBD	B-VP	O
and	CC	I-VP	O
intensified	VBD	I-VP	O
exposure	NN	B-NP	O
of	IN	B-PP	O
upper	JJ	B-NP	O
urinary	JJ	I-NP	O
tract	NN	I-NP	O
epithelium	NN	I-NP	O
to	TO	B-PP	O
cyclophosphamide	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
candidates	NNS	B-NP	O
for	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
cyclophosphamide	NN	I-NP	O
treatment	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
routinely	RB	I-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
obstructive	JJ	B-NP	B
uropathy	NN	I-NP	I
.	.	O	O

Ascending	VBG	B-VP	O
dose	NN	B-NP	O
tolerance	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
intramuscular	JJ	B-NP	O
carbetocin	NN	I-NP	O
administered	VBN	B-VP	O
after	IN	B-PP	O
normal	JJ	B-NP	O
vaginal	JJ	I-NP	O
birth	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
maximum	NN	I-NP	O
tolerated	VBN	I-NP	O
dose	NN	I-NP	O
(	(	O	O
MTD	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
carbetocin	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
synthetic	JJ	B-NP	O
analogue	NN	I-NP	O
of	IN	B-PP	O
oxytocin	NN	B-NP	O
)	)	O	O
,	,	O	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
vaginal	JJ	B-NP	O
delivery	NN	I-NP	O
at	IN	B-PP	O
term	NN	B-NP	O
.	.	O	O

Carbetocin	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
intramuscular	JJ	I-NP	O
injection	NN	I-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
birth	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infant	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
singleton	JJ	I-NP	O
pregnancies	NNS	I-NP	O
who	WP	B-NP	O
delivered	VBD	B-VP	O
vaginally	RB	B-ADVP	O
at	IN	B-PP	O
term	NN	B-NP	O
.	.	O	O

Dosage	NN	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
carbetocin	NN	I-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
blocks	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
continual	JJ	I-NP	O
reassessment	NN	I-NP	O
method	NN	I-NP	O
(	(	O	O
CRM	NN	B-NP	O
)	)	O	O
.	.	O	O

All	DT	B-NP	O
dosage	NN	I-NP	O
groups	NNS	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
,	,	O	O
except	IN	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
microg	NN	I-NP	O
.	.	O	O

Recorded	VBN	B-VP	O
were	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
:	:	O	O
hyper	NN	B-NP	B
-	HYPH	B-NP	I
or	CC	O	I
hypotension	NN	B-NP	I
(	(	O	O
num	CD	B-NP	O
)	)	O	O
,	,	O	O
severe	JJ	B-NP	O
abdominal	JJ	I-NP	B
pain	NN	I-NP	I
,	,	O	O
vomiting	NN	B-NP	B
and	CC	O	O
retained	VBN	B-NP	B
placenta	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Serious	JJ	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
blood	NN	B-NP	B
loss	NN	I-NP	I
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
ml	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
manual	JJ	B-NP	O
placenta	NN	I-NP	O
removal	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
additional	JJ	B-NP	O
oxytocics	NNS	I-NP	O
administration	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
transfusion	NN	I-NP	O
.	.	O	O

Maximum	JJ	B-NP	O
blood	NN	I-NP	B
loss	NN	I-NP	I
was	VBD	B-VP	O
greatest	JJS	B-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
upper	JJ	I-NP	O
and	CC	I-NP	O
lower	JJR	I-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
and	CC	O	O
lowest	JJS	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
dose	NN	I-NP	O
range	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
with	IN	B-PP	O
blood	NN	B-NP	B
loss	NN	I-NP	I
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
ml	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
additional	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
oxytocics	NNS	B-NP	O
and	CC	O	O
blood	NN	B-NP	O
transfusion	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
retained	VBN	I-NP	O
placentae	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
MTD	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
carbetocin	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Chest	JJS	B-NP	B
pain	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
poses	VBZ	B-VP	O
a	DT	B-NP	O
diagnostic	JJ	I-NP	O
dilemma	NN	I-NP	O
.	.	O	O

Dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
(	(	O	O
DSE	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
widely	RB	I-NP	O
available	JJ	I-NP	O
and	CC	I-NP	O
sensitive	JJ	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
evaluating	VBG	B-VP	O
cardiac	JJ	B-NP	O
ischemia	NN	I-NP	B
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
theoretical	JJ	I-NP	O
concern	NN	I-NP	O
regarding	VBG	B-VP	O
administration	NN	B-NP	O
of	IN	B-PP	O
dobutamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
pilot	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
DSE	NN	B-NP	O
in	IN	B-PP	O
emergency	NN	B-NP	O
department	NN	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
diagnostic	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
unit	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ED	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
urban	JJ	I-NP	O
tertiary	NN	I-NP	O
-	HYPH	B-NP	O
care	NN	I-NP	O
teaching	NN	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
eligible	JJ	B-ADJP	O
for	IN	B-PP	O
DSE	NN	B-NP	O
if	IN	B-SBAR	O
they	PRP	B-NP	O
had	VBD	B-VP	O
used	VBN	I-VP	O
cocaine	NN	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
preceding	VBG	B-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
and	CC	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
ECG	NN	I-NP	O
and	CC	I-NP	O
tropinin	NN	I-NP	O
num	CD	I-NP	O
level	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
exhibiting	VBG	B-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
continuing	VBG	B-NP	O
cocaine	NN	I-NP	O
toxicity	NN	I-NP	B
were	VBD	B-VP	O
excluded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
serial	JJ	B-NP	O
testing	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
DSE	NN	I-NP	O
testing	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intensive	JJ	I-NP	O
diagnostic	NN	I-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
unit	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
inadequate	JJ	B-NP	O
resting	VBG	I-NP	O
images	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
DSE	NN	I-NP	O
was	VBD	B-VP	O
terminated	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
inferior	JJ	B-NP	O
hypokinesis	NN	I-NP	B
,	,	O	O
another	DT	B-NP	O
DSE	NN	I-NP	O
was	VBD	B-VP	O
terminated	VBN	I-VP	O
because	RB	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
rate	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
atrial	JJ	I-NP	O
conduction	NN	I-NP	O
deficit	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patient	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
the	DT	B-NP	O
target	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
completed	VBD	B-VP	O
a	DT	B-NP	O
DSE	NN	I-NP	O
and	CC	O	O
reached	VBD	B-VP	O
their	PRP$	B-NP	O
target	NN	I-NP	O
heart	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
exaggerated	JJ	B-NP	O
adrenergic	JJ	I-NP	O
response	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
of	IN	B-PP	O
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
tachydysrhythmias	NNS	B-NP	B
(	(	O	O
excluding	VBG	B-VP	O
sinus	NN	B-NP	B
tachycardia	NN	I-NP	I
)	)	O	O
.	.	O	O

Further	RB	B-ADVP	O
suggesting	VBG	B-VP	O
lack	NN	B-NP	O
of	IN	B-PP	O
exaggerated	JJ	B-NP	O
adrenergic	JJ	I-NP	O
response	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
required	VBD	B-VP	O
supplemental	JJ	B-NP	O
atropine	NN	I-NP	O
to	TO	B-VP	O
reach	VB	I-VP	O
their	PRP$	B-NP	O
target	NN	I-NP	O
heart	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
exaggerated	JJ	I-NP	O
adrenergic	JJ	I-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
when	WRB	B-ADVP	O
dobutamine	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Amiodarone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
during	IN	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
:	:	O	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
presentation	NN	I-NP	O
-	HYPH	B-NP	O
-	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
early	JJ	B-ADVP	O
(	(	O	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
development	NN	B-NP	O
of	IN	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TdP	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
oral	JJ	B-NP	O
amiodarone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Consistent	JJ	B-ADJP	O
with	IN	B-PP	O
other	JJ	B-NP	O
reports	NNS	I-NP	O
this	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
TdP	NN	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
context	NN	I-NP	O
of	IN	B-PP	O
multiple	JJ	B-NP	O
exacerbating	JJ	I-NP	O
factors	NNS	I-NP	O
including	VBG	B-PP	O
hypokalemia	NN	B-NP	B
and	CC	I-NP	O
digoxin	NN	I-NP	O
excess	NN	I-NP	O
.	.	O	O

Transient	JJ	B-NP	O
prolongation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
QT	NN	I-NP	O
during	IN	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
prompted	VBD	B-VP	O
the	DT	B-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
TdP	NN	B-NP	B
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
that	IN	B-SBAR	O
bradycardia	NN	B-NP	B
exacerbates	NNS	I-NP	O
acquired	VBN	B-VP	O
TdP	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
speculate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
increased	VBN	I-NP	O
vagal	JJ	I-NP	O
tone	NN	I-NP	O
during	IN	B-PP	O
bladder	NN	B-NP	O
irrigation	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
vagal	JJ	I-NP	O
maneuver	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
context	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
therapy	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
proarrhythmia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
second	JJ	I-NP	O
bladder	NN	I-NP	O
irrigation	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
TdP	NN	B-NP	B
despite	IN	B-PP	O
hypokalemia	NN	B-NP	B
and	CC	I-NP	O
hypomagnesemia	NN	I-NP	B
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
melphalan	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
systemic	JJ	I-NP	I
amyloidosis	NN	I-NP	I
during	IN	B-PP	O
stem	NN	B-NP	O
cell	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	B
systemic	JJ	I-NP	I
amyloidosis	NN	I-NP	I
(	(	O	O
AL	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
prognosis	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
survival	NN	I-NP	O
time	NN	I-NP	O
from	IN	B-PP	O
standard	JJ	B-NP	O
treatments	NNS	I-NP	O
is	VBZ	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
melphalan	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
peripheral	JJ	B-NP	O
blood	NN	I-NP	O
stem	NN	I-NP	O
cell	NN	I-NP	O
transplant	NN	I-NP	O
(	(	O	O
PBSCT	NN	B-NP	O
)	)	O	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
promising	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
but	CC	O	O
treatment	NN	B-NP	O
mortality	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
high	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
have	VBP	B-VP	O
noted	VBN	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
immediately	RB	B-ADVP	O
after	IN	B-PP	O
melphalan	NN	B-NP	O
conditioning	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
further	RB	I-VP	O
examine	VB	I-VP	O
its	PRP$	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
and	CC	O	O
impact	NN	B-NP	O
on	IN	B-PP	O
posttransplant	NN	B-NP	O
mortality	NN	I-NP	O
.	.	O	O

Consecutive	JJ	B-NP	O
AL	NN	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
PBSCT	NNS	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
retrospectively	RB	B-ADVP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
insufficiency	NN	I-NP	I
(	(	O	O
ARI	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
melphalan	NN	I-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
minimum	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
level	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
baseline	NN	B-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
conditioning	VBG	B-VP	O
.	.	O	O

Urine	NN	B-NP	O
sediment	NN	I-NP	O
score	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
sum	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
individual	JJ	I-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
sediment	NN	B-NP	O
identified	VBN	B-VP	O
on	IN	B-PP	O
urine	NN	B-NP	O
microscopy	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
studied	VBN	B-VP	O
,	,	O	O
ARI	NN	B-NP	B
developed	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
melphalan	NN	I-NP	O
.	.	O	O

Univariate	JJ	B-NP	O
analysis	NN	I-NP	O
identified	VBD	B-VP	O
age	NN	B-NP	O
,	,	O	O
hypoalbuminemia	NN	B-NP	B
,	,	O	O
heavy	JJ	B-NP	O
proteinuria	NN	I-NP	B
,	,	O	O
diuretic	JJ	B-NP	O
use	NN	I-NP	O
,	,	O	O
and	CC	O	O
urine	NN	B-NP	O
sediment	NN	I-NP	O
score	NN	I-NP	O
as	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Age	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
sediment	NN	I-NP	O
score	NN	I-NP	O
remained	VBD	B-VP	O
independently	RB	B-NP	O
significant	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
multivariate	JJ	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
ARI	NN	B-NP	B
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
melphalan	NN	I-NP	O
underwent	VBD	B-VP	O
dialysis	NN	B-NP	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
,	,	O	O
and	CC	O	O
had	VBD	B-VP	O
a	DT	B-NP	O
worse	JJR	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
survival	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
timing	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
strongly	RB	B-ADVP	O
suggests	VBZ	B-VP	O
melphalan	NN	B-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
causative	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

Ongoing	VBG	B-VP	O
tubular	JJ	B-NP	B
injury	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
prerequisite	NN	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
by	IN	B-PP	O
melphalan	NN	B-NP	O
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
active	JJ	I-NP	O
urinary	JJ	I-NP	O
sediment	NN	I-NP	O
.	.	O	O

Development	NN	B-NP	O
of	IN	B-PP	O
ARI	NN	B-NP	B
adversely	RB	B-VP	O
affected	VBD	I-VP	O
the	DT	B-NP	O
outcome	NN	I-NP	O
after	IN	B-PP	O
PBSCT	NN	B-NP	O
.	.	O	O

Effective	JJ	B-NP	O
preventive	JJ	I-NP	O
measures	NNS	I-NP	O
may	MD	B-VP	O
help	VB	I-VP	O
decrease	VB	I-VP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
mortality	NN	I-NP	O
of	IN	B-PP	O
PBSCT	NN	B-NP	O
in	IN	B-PP	O
AL	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Impaired	JJ	B-NP	B
fear	NN	I-NP	I
recognition	NN	I-NP	I
in	IN	B-PP	O
regular	JJ	B-NP	O
recreational	JJ	I-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
read	VB	I-VP	O
facial	JJ	B-NP	O
expressions	NNS	I-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
normal	JJ	B-NP	O
human	JJ	I-NP	O
social	JJ	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
conduct	VB	I-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
investigation	NN	I-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	O
expression	NN	I-NP	O
recognition	NN	I-NP	O
performance	NN	I-NP	O
in	IN	B-PP	O
recreational	JJ	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
comprised	VBN	B-VP	O
of	IN	B-PP	O
num	CD	B-NP	O
cocaine	NN	I-NP	O
naive	JJ	I-NP	O
participants	NNS	I-NP	O
(	(	O	O
CN	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
occasional	JJ	I-NP	O
cocaine	NN	I-NP	O
(	(	O	O
OC	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
regular	JJ	I-NP	O
recreational	JJ	I-NP	O
cocaine	NN	I-NP	O
(	(	O	O
RC	NN	B-NP	O
)	)	O	O
users	NNS	B-NP	O
,	,	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
emotional	JJ	I-NP	O
facial	JJ	I-NP	O
expression	NN	I-NP	O
(	(	O	O
EFE	NN	B-NP	O
)	)	O	O
task	NN	B-NP	O
consisting	VBG	B-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
face	NN	I-NP	O
expressing	VBG	B-VP	O
num	CD	B-NP	O
basic	JJ	I-NP	O
emotions	NNS	I-NP	O
(	(	O	O
happiness	NN	B-NP	O
,	,	O	O
surprise	NN	B-NP	O
,	,	O	O
sadness	NN	B-NP	O
,	,	O	O
anger	NN	B-NP	O
,	,	O	O
fear	NN	B-NP	O
,	,	O	O
and	CC	O	O
disgust	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Mean	JJ	B-NP	O
percent	NN	I-NP	O
accuracy	NN	I-NP	O
and	CC	O	O
latencies	NNS	B-NP	O
for	IN	B-PP	O
correct	JJ	B-NP	O
responses	NNS	I-NP	O
across	IN	B-PP	O
num	CD	B-NP	O
presentations	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
basic	JJ	I-NP	O
emotion	NN	I-NP	O
were	VBD	B-VP	O
derived	VBN	I-VP	O
.	.	O	O

Participants	NNS	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
assessed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Eyes	NNP	I-NP	O
task	NN	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
their	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
recognize	VB	I-VP	O
more	RBR	B-NP	O
complex	JJ	I-NP	O
emotional	JJ	I-NP	O
states	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Symptom	NNP	I-NP	O
CheckList	NNP	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	B-VP	O
Revised	VBN	I-VP	O
to	TO	I-VP	O
measure	VB	I-VP	O
psychopathology	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
group	NN	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
psychopathology	NN	B-NP	O
or	CC	O	O
eyes	VBZ	B-VP	O
task	NN	B-NP	O
performance	NN	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
RC	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
otherwise	RB	B-ADVP	O
had	VBD	B-VP	O
similar	JJ	B-NP	O
illicit	JJ	I-NP	O
substance	NN	I-NP	O
use	NN	I-NP	O
histories	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
OC	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
exhibited	VBD	B-VP	O
impaired	JJ	B-NP	B
fear	NN	I-NP	I
recognition	NN	I-NP	I
accuracy	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
OC	NN	I-NP	O
and	CC	I-NP	O
CN	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
RC	NNP	I-NP	O
group	NN	I-NP	O
also	RB	B-ADVP	O
correctly	RB	B-VP	O
identified	VBN	I-VP	O
anger	NN	B-NP	O
,	,	O	O
fear	NN	B-NP	O
,	,	O	O
happiness	NN	B-NP	O
,	,	O	O
and	CC	O	O
surprise	NN	B-NP	O
,	,	O	O
more	RBR	B-ADVP	O
slowly	RB	I-ADVP	O
than	IN	B-PP	O
CN	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
OC	NN	B-NP	O
participants	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
OC	NNP	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
slower	JJR	B-ADJP	O
than	IN	B-PP	O
CN	NN	B-NP	O
when	WRB	B-ADVP	O
correctly	RB	B-ADVP	O
identifying	VBG	B-VP	O
disgust	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
selective	JJ	I-NP	O
deficit	NN	I-NP	B
in	IN	B-PP	I
fear	NN	B-NP	I
recognition	NN	I-NP	I
accuracy	NN	I-NP	O
manifested	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
RC	NN	I-NP	O
group	NN	I-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
subacute	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
or	CC	O	O
ecstasy	NN	B-NP	O
,	,	O	O
because	IN	B-SBAR	O
recent	JJ	B-NP	O
and	CC	I-NP	O
less	RBR	I-NP	O
recent	JJ	I-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
within	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
similarly	RB	B-ADJP	O
impaired	JJ	I-ADJP	O
.	.	O	O

Possible	JJ	B-NP	O
parallels	NNS	I-NP	O
between	IN	B-PP	O
RC	NN	B-NP	O
users	NNS	I-NP	O
and	CC	I-NP	O
psychopaths	NNS	I-NP	B
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
impaired	JJ	B-NP	B
fear	NN	I-NP	I
recognition	NN	I-NP	I
,	,	O	O
amygdala	NN	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
and	CC	O	O
etiology	NN	B-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Corneal	JJ	B-NP	B
ulcers	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
aerosolized	VBN	B-NP	O
crack	NN	I-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
corneal	JJ	B-NP	B
ulcers	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
drug	NN	B-NP	B
abuse	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
ulcers	NNS	I-NP	B
and	CC	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Review	NN	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
corneal	JJ	B-NP	B
ulcers	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
drug	NN	B-NP	B
abuse	NN	I-NP	I
seen	VBN	B-VP	O
at	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
from	IN	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
corneal	JJ	B-NP	B
ulcers	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
corneal	JJ	I-NP	B
ulcers	NNS	I-NP	I
were	VBD	B-VP	O
cultured	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
intensive	JJ	B-NP	O
topical	JJ	I-NP	O
antibiotic	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Each	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
comprehensive	JJ	B-NP	O
health	NN	I-NP	O
care	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
medical	JJ	B-NP	O
and	CC	I-NP	O
substance	NN	I-NP	B
abuse	NN	I-NP	I
consultations	NNS	I-NP	O
.	.	O	O

Streptococcal	JJ	B-NP	O
organisms	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
and	CC	O	O
Capnocytophaga	NNP	B-NP	O
and	CC	I-NP	O
Brevibacterium	NNP	I-NP	O
casei	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
infections	NNS	I-NP	B
responded	VBD	B-VP	O
to	TO	B-PP	O
antibiotic	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
needed	VBD	B-VP	O
a	DT	B-NP	O
lateral	JJ	I-NP	O
tarsorrhaphy	NN	I-NP	O
for	IN	B-PP	O
persistent	JJ	B-NP	O
epithelial	JJ	I-NP	B
defects	NNS	I-NP	I
.	.	O	O

Aerosolized	VBN	B-NP	O
crack	NN	I-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
corneal	JJ	B-NP	B
ulcers	NNS	I-NP	I
.	.	O	O

Drug	NN	B-NP	B
abuse	NN	I-NP	I
provides	VBZ	B-VP	O
additional	JJ	B-NP	O
challenges	NNS	I-NP	O
for	IN	B-PP	O
management	NN	B-NP	O
.	.	O	O

Not	RB	B-CONJP	O
only	RB	I-CONJP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
infections	NNS	I-NP	B
but	CC	B-CONJP	O
also	RB	I-CONJP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
poor	JJ	I-NP	O
health	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
noncompliance	NN	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
addressed	VBN	I-VP	O
.	.	O	O

Comprehensive	JJ	B-NP	O
care	NN	I-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
the	DT	B-NP	O
opportunity	NN	I-NP	O
to	TO	B-VP	O
discontinue	VB	I-VP	O
their	PRP$	B-NP	O
substance	NN	I-NP	B
abuse	NN	I-NP	I
,	,	O	O
improve	VB	B-VP	O
their	PRP$	B-NP	O
overall	JJ	I-NP	O
health	NN	I-NP	O
,	,	O	O
and	CC	O	O
prevent	VB	B-VP	O
future	JJ	B-NP	O
corneal	JJ	I-NP	O
complications	NNS	I-NP	O
.	.	O	O

Levetiracetam	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
adjunct	NN	I-NP	O
to	TO	B-PP	O
phenobarbital	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
with	IN	B-PP	O
suspected	VBN	B-NP	O
idiopathic	JJ	I-NP	B
epilepsy	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
pharmacokinetics	NNS	B-NP	O
,	,	O	O
efficacy	NN	B-NP	O
,	,	O	O
and	CC	O	O
tolerability	NN	B-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
levetiracetam	NN	I-NP	O
administered	VBN	B-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
adjunct	NN	I-NP	O
to	TO	B-PP	O
phenobarbital	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
with	IN	B-PP	O
poorly	RB	B-NP	O
controlled	VBN	I-NP	O
suspected	VBN	I-NP	O
idiopathic	JJ	I-NP	B
epilepsy	NN	I-NP	I
.	.	O	O

DESIGN	NN	B-NP	O
-	HYPH	I-NP	O
Open	NN	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
,	,	O	O
noncomparative	JJ	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cats	NNS	I-NP	O
suspected	VBN	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
idiopathic	JJ	B-NP	B
epilepsy	NN	I-NP	I
that	WDT	B-NP	O
was	VBD	B-VP	O
poorly	RB	I-VP	O
controlled	VBN	I-VP	O
with	IN	B-PP	O
phenobarbital	NN	B-NP	O
or	CC	O	O
that	WDT	B-NP	O
had	VBD	B-VP	O
unacceptable	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
when	WRB	B-ADVP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
phenobarbital	NN	B-NP	O
.	.	O	O

Cats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
levetiracetam	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
serum	NN	B-NP	O
levetiracetam	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
before	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
and	CC	O	O
maximum	NN	B-NP	O
and	CC	I-NP	O
minimum	NN	I-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
elimination	NN	B-NP	O
half	NN	I-NP	O
-	HYPH	B-NP	O
life	NN	I-NP	O
were	VBD	B-VP	O
calculated	VBN	I-VP	O
.	.	O	O

Seizure	NN	B-NP	B
frequencies	NNS	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
levetiracetam	NN	B-NP	O
treatment	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
,	,	O	O
and	CC	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Median	JJ	B-NP	O
maximum	JJ	I-NP	O
serum	NN	I-NP	O
levetiracetam	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
,	,	O	O
median	JJ	B-NP	O
minimum	JJ	I-NP	O
serum	NN	I-NP	O
levetiracetam	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
,	,	O	O
and	CC	O	O
median	JJ	B-NP	O
elimination	NN	I-NP	O
half	NN	I-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
seizure	NN	I-NP	B
frequency	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
levetiracetam	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
seizures	NNS	I-NP	B
/	SYM	B-NP	O
mo	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
median	JJ	B-NP	O
seizure	NN	I-NP	B
frequency	NN	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
levetiracetam	NN	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
seizures	NNS	I-NP	B
/	SYM	B-NP	O
mo	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cats	NNS	I-NP	O
were	VBD	B-VP	O
classified	VBN	I-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
responded	VBN	I-VP	O
to	TO	B-PP	O
levetiracetam	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
cats	NNS	I-NP	O
had	VBD	B-VP	O
transient	JJ	B-NP	O
lethargy	NN	I-NP	B
and	CC	I-NP	O
inappetence	NN	I-NP	B
.	.	O	O

Results	NNS	B-NP	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
levetiracetam	NN	B-NP	O
is	VBZ	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
and	CC	O	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
as	IN	B-PP	O
an	DT	B-NP	O
adjunct	NN	I-NP	O
to	TO	B-PP	O
phenobarbital	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
epilepsy	NN	I-NP	I
.	.	O	O

Bilateral	JJ	B-NP	O
haemorrhagic	JJ	I-NP	B
infarction	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
globus	NN	I-NP	I
pallidus	NN	I-NP	I
after	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
alcohol	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
both	CC	B-NP	O
ischemic	JJ	I-NP	B
and	CC	I-NP	I
haemorrhagic	JJ	I-NP	I
stroke	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
bilateral	JJ	B-NP	O
ischemia	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
globus	NN	I-NP	I
pallidus	NN	I-NP	I
after	IN	B-PP	O
excessive	JJ	B-NP	O
alcohol	NN	I-NP	O
and	CC	O	O
intranasal	JJ	B-NP	O
cocaine	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	I-NP	O
related	VBN	I-NP	O
globus	NN	I-NP	B
pallidus	NN	I-NP	I
infarctions	NNS	I-NP	I
are	VBP	B-VP	O
most	RBS	I-VP	O
often	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
heroin	NN	B-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
basal	JJ	I-NP	B
ganglia	NNS	I-NP	I
infarcts	NNS	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
without	IN	B-PP	O
concurrent	JJ	B-NP	O
heroin	NN	I-NP	O
use	NN	I-NP	O
,	,	O	O
have	VBP	B-VP	O
never	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
,	,	O	O
transient	JJ	B-NP	O
cardiac	JJ	I-NP	B
arrhythmia	NN	I-NP	I
or	CC	O	O
respiratory	JJ	B-NP	B
dysfunction	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
ethanol	NN	B-NP	O
use	NN	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
likely	JJ	I-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	B
hypoperfusion	NN	I-NP	I
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methotrexate	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
ileostomy	NN	B-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methotrexate	NN	I-NP	O
(	(	O	O
HD	NN	B-NP	O
-	HYPH	B-NP	O
MTX	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
Burkitt	NN	B-NP	B
lymphoma	NN	I-NP	I
,	,	O	O
but	CC	O	O
can	MD	B-VP	O
cause	VB	I-VP	O
hepatic	JJ	B-NP	B
and	CC	I-NP	I
renal	JJ	I-NP	I
toxicity	NN	I-NP	I
when	WRB	B-ADVP	O
its	PRP$	B-NP	O
clearance	NN	I-NP	O
is	VBZ	B-VP	O
delayed	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
HD	NN	B-NP	O
-	HYPH	B-NP	O
MTX	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
ileostomy	NN	B-NP	O
,	,	O	O
The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
boy	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
a	DT	B-NP	O
living	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
congenital	JJ	B-NP	O
biliary	JJ	I-NP	B
atresia	NN	I-NP	I
.	.	O	O

At	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
transplantation	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
PTLD	NN	B-NP	B
(	(	O	O
post	AFX	B-NP	B
-	HYPH	I-NP	I
transplantation	NN	I-NP	I
lymphoproliferative	JJ	I-NP	I
disorder	NN	I-NP	I
,	,	O	O
Burkitt	NN	B-NP	B
-	HYPH	I-NP	I
type	NN	I-NP	I
malignant	JJ	I-NP	I
lymphoma	NN	I-NP	I
)	)	O	O
.	.	O	O

During	IN	B-PP	O
induction	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
suffered	VBD	B-VP	O
ileal	JJ	B-NP	O
perforation	NN	I-NP	O
and	CC	I-NP	O
ileostomy	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

Subsequent	JJ	B-NP	O
HD	NN	I-NP	O
-	HYPH	I-NP	O
MTX	NN	I-NP	O
therapy	NN	I-NP	O
caused	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
that	WDT	B-NP	O
required	VBD	B-VP	O
continuous	JJ	B-NP	O
hemodialysis	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
supposed	VBD	B-VP	O
that	IN	B-SBAR	O
intravascular	JJ	B-NP	O
hypovolemia	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
substantial	JJ	B-NP	O
drainage	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
ileostoma	NN	I-NP	O
caused	VBD	B-VP	O
acute	JJ	B-NP	B
prerenal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
recovery	NN	B-NP	O
of	IN	B-PP	O
his	PRP$	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
could	MD	B-VP	O
safely	RB	I-VP	O
treat	VB	I-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
HD	NN	B-NP	O
-	HYPH	I-NP	O
MTX	NN	I-NP	O
therapy	NN	I-NP	O
by	IN	B-PP	O
controlling	VBG	B-VP	O
drainage	NN	B-NP	O
from	IN	B-PP	O
ileostoma	NN	B-NP	O
with	IN	B-PP	O
total	JJ	B-NP	O
parenteral	JJ	I-NP	O
nutrition	NN	I-NP	O
.	.	O	O

Antithrombotic	JJ	B-NP	O
drug	NN	I-NP	O
use	NN	I-NP	O
,	,	O	O
cerebral	JJ	B-NP	B
microbleeds	NNS	I-NP	I
,	,	O	O
and	CC	O	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
systematic	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
published	VBN	B-NP	O
and	CC	I-NP	O
unpublished	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	B
microbleeds	NNS	I-NP	I
(	(	O	O
MB	NN	B-NP	B
)	)	O	O
are	VBP	B-VP	O
potential	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
(	(	O	O
ICH	NN	B-NP	B
)	)	O	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
if	IN	B-SBAR	O
they	PRP	B-NP	O
are	VBP	B-VP	O
a	DT	B-NP	O
contraindication	NN	I-NP	O
to	TO	B-PP	O
using	VBG	B-VP	O
antithrombotic	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Insights	NNS	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
gained	VBN	I-VP	O
by	IN	B-PP	O
pooling	VBG	B-VP	O
data	NNS	B-NP	O
on	IN	B-PP	O
MB	NN	B-NP	B
frequency	NN	I-NP	O
stratified	VBN	B-VP	O
by	IN	B-PP	O
antithrombotic	JJ	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
cohorts	NNS	B-NP	O
with	IN	B-PP	O
ICH	NN	B-NP	B
and	CC	O	O
ischemic	JJ	B-NP	B
stroke	NN	I-NP	I
(	(	O	O
IS	NN	B-NP	B
)	)	O	O
/	SYM	B-NP	O
transient	JJ	I-NP	B
ischemic	JJ	I-NP	I
attack	NN	I-NP	I
(	(	O	O
TIA	NN	B-NP	B
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
systematic	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
published	VBN	B-NP	O
and	CC	I-NP	O
unpublished	JJ	I-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
cohorts	NNS	B-NP	O
with	IN	B-PP	O
stroke	NN	B-NP	B
or	CC	I-NP	O
TIA	NN	I-NP	B
to	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
MB	NN	B-NP	B
in	IN	B-PP	O
:	:	O	O
antithrombotic	JJ	B-NP	O
users	NNS	I-NP	O
vs	IN	B-PP	O
nonantithrombotic	JJ	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
ICH	NN	B-NP	B
;	:	O	O
antithrombotic	JJ	B-NP	O
users	NNS	I-NP	O
vs	IN	B-PP	O
nonusers	NNS	B-NP	O
with	IN	B-PP	O
IS	NN	B-NP	B
/	SYM	B-NP	O
TIA	NN	I-NP	B
;	:	O	O
and	CC	O	O
ICH	NN	B-NP	B
vs	IN	B-PP	O
ischemic	JJ	B-NP	B
events	NNS	I-NP	O
stratified	VBN	B-VP	O
by	IN	B-PP	O
antithrombotic	JJ	B-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
analyzed	VBD	B-VP	O
published	VBN	B-VP	O
and	CC	O	O
unpublished	JJ	B-VP	O
follow	VB	I-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
data	NNS	B-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ICH	NN	B-NP	B
in	IN	B-PP	O
antithrombotic	JJ	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
MB	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
pooled	JJ	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ICH	NN	I-NP	B
and	CC	I-NP	O
num	CD	I-NP	O
IS	NN	I-NP	B
/	SYM	I-NP	O
TIA	NN	I-NP	B
,	,	O	O
MB	NN	B-NP	B
were	VBD	B-VP	O
more	RBR	B-ADJP	O
frequent	JJ	I-ADJP	O
in	IN	B-PP	O
ICH	NN	B-NP	B
vs	IN	B-PP	O
IS	NN	B-NP	B
/	SYM	B-NP	O
TIA	NN	I-NP	B
in	IN	B-PP	O
all	DT	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
excess	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
;	:	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
nonantithrombotic	JJ	B-NP	O
users	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
antiplatelet	JJ	B-NP	O
users	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
warfarin	NN	B-NP	O
users	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
an	DT	B-NP	O
excess	NN	I-NP	O
of	IN	B-PP	O
MB	NN	B-NP	B
in	IN	B-PP	O
warfarin	NN	B-NP	O
users	NNS	I-NP	O
vs	IN	B-PP	O
nonusers	NNS	B-NP	O
with	IN	B-PP	O
ICH	NN	B-NP	B
but	CC	O	O
none	NN	B-NP	O
in	IN	B-PP	O
warfarin	NN	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
IS	NN	B-NP	B
/	SYM	I-NP	O
TIA	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
smaller	JJR	I-NP	O
excess	NN	I-NP	O
of	IN	B-PP	O
MB	NN	B-NP	B
in	IN	B-PP	O
antiplatelet	JJ	B-NP	O
users	NNS	I-NP	O
vs	IN	B-PP	O
nonusers	NNS	B-NP	O
with	IN	B-PP	O
ICH	NN	B-NP	B
,	,	O	O
but	CC	O	O
findings	NNS	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-PP	O
antiplatelet	JJ	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
IS	NN	B-NP	B
/	SYM	I-NP	O
TIA	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
pooled	VBN	B-VP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
data	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
antithrombotic	JJ	I-NP	O
users	NNS	I-NP	O
,	,	O	O
presence	NN	B-NP	O
of	IN	B-PP	O
MB	NN	B-NP	B
at	IN	B-PP	O
baseline	NN	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
substantially	RB	I-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
subsequent	JJ	B-NP	O
ICH	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
excess	NN	I-NP	O
of	IN	B-PP	O
MB	NN	B-NP	B
in	IN	B-PP	O
warfarin	NN	B-NP	O
users	NNS	I-NP	O
with	IN	B-PP	O
ICH	NN	B-NP	B
compared	VBN	B-VP	O
to	TO	B-PP	O
other	JJ	B-NP	O
groups	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
MB	NN	B-NP	B
increase	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
ICH	NN	I-NP	B
.	.	O	O

Limited	VBN	B-NP	O
prospective	JJ	I-NP	O
data	NNS	I-NP	O
corroborate	VBP	B-VP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
,	,	O	O
but	CC	O	O
larger	JJR	B-NP	O
prospective	JJ	I-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
urgently	RB	I-VP	O
required	VBN	I-VP	O
.	.	O	O

Verapamil	NN	B-NP	O
stimulation	NN	I-NP	O
test	NN	I-NP	O
in	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
:	:	O	O
loss	NN	B-NP	O
of	IN	B-PP	O
prolactin	NN	B-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
anatomic	JJ	B-NP	O
or	CC	I-NP	O
functional	JJ	I-NP	O
stalk	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
stimulation	NN	I-NP	O
test	NN	I-NP	O
was	VBD	B-VP	O
previously	RB	I-VP	O
investigated	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
tool	NN	I-NP	O
for	IN	B-PP	O
differential	JJ	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
,	,	O	O
but	CC	O	O
with	IN	B-PP	O
conflicting	VBG	B-VP	O
results	NNS	B-NP	O
.	.	O	O

Macroprolactinemia	NNP	B-NP	B
was	VBD	B-VP	O
never	RB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
previous	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
re	VB	I-VP	O
-	HYPH	O	O
investigate	VB	B-VP	O
the	DT	B-NP	O
diagnostic	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
verapamil	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
population	NN	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
all	DT	O	O
screened	VBN	B-VP	O
for	IN	B-PP	O
macroprolactinemia	NN	B-NP	B
.	.	O	O

Prolactin	NN	B-NP	O
responses	NNS	I-NP	O
to	TO	B-VP	O
verapamil	VB	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
were	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
descriptive	JJ	I-NP	O
,	,	I-NP	O
matched	VBN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
p.o.	FW	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
,	,	O	O
and	CC	O	O
then	RB	O	O
PRL	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
8th	JJ	B-NP	O
and	CC	I-NP	O
16th	JJ	I-NP	O
hours	NNS	I-NP	O
,	,	O	O
by	IN	B-PP	O
immunometric	JJ	B-NP	O
chemiluminescence	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
responsiveness	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
peak	NN	B-NP	O
percent	NN	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
basal	JJ	B-NP	O
prolactin	NN	I-NP	O
levels	NNS	I-NP	O
(	(	O	O
PRL	NN	B-NP	O
)	)	O	O
.	.	O	O

Verapamil	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
PRL	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
controls	NNS	I-NP	O
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
macroprolactinoma	NN	B-NP	B
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
microprolactinoma	NN	B-NP	B
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
macroprolactinemia	NN	B-NP	B
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
pseudoprolactinoma	NN	B-NP	B
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
risperidone	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperprolactinemia	NN	I-NP	B
(	(	O	O
N.	NNP	B-NP	O
num	CD	I-NP	O
PRL	NNP	I-NP	O
:	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

ROC	NN	B-NP	O
curve	NN	I-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
unresponsiveness	NN	B-NP	O
to	TO	B-PP	O
verapamil	NN	B-NP	O
defined	VBN	B-VP	O
as	IN	B-PP	O
PRL	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
discriminated	VBN	B-VP	O
anatomical	JJ	B-NP	O
or	CC	I-NP	O
functional	JJ	I-NP	O
stalk	NN	I-NP	O
effect	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
pseudoprolactinoma	NN	B-NP	B
or	CC	I-NP	O
risperidone	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Verapamil	NN	B-NP	O
responsiveness	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
reliable	JJ	I-NP	O
finding	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
differential	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
verapamil	NN	B-NP	O
unresponsiveness	NN	I-NP	O
discriminates	VBZ	B-VP	O
stalk	NN	B-NP	O
effect	NN	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
,	,	O	O
anatomically	RB	B-ADVP	O
or	CC	I-ADVP	O
functionally	RB	I-VP	O
inhibited	VBD	I-VP	O
dopaminergic	JJ	B-NP	O
tonus	NN	I-NP	O
)	)	O	O
from	IN	B-PP	O
other	JJ	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
with	IN	B-PP	O
varying	VBG	B-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
responsiveness	NN	B-NP	O
.	.	O	O

Central	JJ	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
narcotic	JJ	B-NP	O
analgesics	NNS	I-NP	O
.	.	O	O

Part	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Noradrenergic	JJ	B-NP	O
influences	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
analgesics	NNS	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	I-NP	O
naphazoline	NN	I-NP	O
and	CC	I-NP	O
xylometazoline	NN	I-NP	O
on	IN	B-PP	O
analgesia	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
,	,	I-NP	O
codeine	NN	I-NP	O
,	,	I-NP	O
fentanyl	NN	I-NP	O
and	CC	I-NP	O
pentazocine	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
on	IN	B-PP	O
cataleptic	JJ	B-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
,	,	I-NP	O
codine	NN	I-NP	O
and	CC	I-NP	O
fentanyl	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
biochemical	JJ	I-NP	O
assays	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
analgesics	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
concentration	NN	I-NP	O
and	CC	I-NP	O
turnover	NN	I-NP	O
of	IN	B-PP	O
noradrenaline	NN	B-NP	O
(	(	O	O
NA	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
also	RB	I-VP	O
performed	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
drugs	NNS	I-NP	O
stimulating	VBG	B-VP	O
central	JJ	B-NP	O
NA	NN	I-NP	O
receptors	NNS	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
the	DT	B-NP	O
analgesic	JJ	I-NP	O
ED50	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
antinociceptive	JJ	I-NP	O
agents	NNS	I-NP	O
and	CC	O	O
they	PRP	B-NP	O
enhanced	VBD	B-VP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	I-NP	O
fentanyl	NN	I-NP	O
.	.	O	O

Codeine	NN	B-NP	O
catalepsy	NN	I-NP	B
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	O	O
decreased	VBN	B-VP	O
by	IN	B-PP	O
naphazoline	NN	B-NP	O
and	CC	I-NP	O
xylometazoline	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
brain	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
NA	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
changed	VBN	I-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	I-NP	O
fentanyl	NN	I-NP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
codeine	NN	B-NP	O
slightly	RB	B-ADVP	O
enhanced	VBD	B-VP	O
it	PRP	B-NP	O
.	.	O	O

Pentazocine	NN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependently	RB	B-ADVP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
brain	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
NA	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
NA	NN	B-NP	O
turnover	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
altered	VBN	I-VP	O
by	IN	B-PP	O
analgesics	NNS	B-NP	O
except	IN	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
fentanyl	NN	B-NP	O
following	VBG	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
NA	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
was	VBD	B-VP	O
diminished	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
light	NN	I-NP	O
of	IN	B-PP	O
various	JJ	B-NP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
uniform	JJ	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
rats	NNS	B-NP	O
the	DT	B-NP	O
brain	NN	I-NP	O
NA	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
less	RBR	I-NP	O
important	JJ	I-NP	O
function	NN	I-NP	O
than	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
monoamines	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
behavioural	JJ	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
potent	JJ	B-NP	O
analgesics	NNS	I-NP	O
.	.	O	O

Modification	NN	B-NP	O
by	IN	B-PP	O
propranolol	NN	B-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
induced	VBN	B-NP	O
hypoglycaemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
hypoglycaemia	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
and	CC	O	O
without	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
blockade	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
men	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
received	VBD	B-VP	O
insulin	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
original	JJ	I-NP	O
insulin	NN	I-NP	O
-	HYPH	B-NP	O
only	RB	I-NP	O
group	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
insulin	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
insulin	NN	I-NP	O
-	HYPH	I-NP	O
group	NN	I-NP	O
the	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
hypoglycaemia	NN	B-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
-	HYPH	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
-	HYPH	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
propranolol	NN	I-NP	O
-	HYPH	B-NP	O
insulin	NN	I-NP	O
group	NN	I-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
-	HYPH	B-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
diastolic	JJ	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Typical	JJ	B-NP	O
S	NN	I-NP	O
-	HYPH	I-NP	O
T	NN	I-NP	O
/	SYM	I-NP	O
T	NN	I-NP	O
changes	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
insulin	NN	I-NP	O
-	HYPH	I-NP	O
group	NN	I-NP	O
but	CC	B-PP	O
in	IN	B-PP	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
propranolol	NN	I-NP	O
-	HYPH	I-NP	O
insulin	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
in	IN	B-PP	O
diabetics	NNS	B-NP	B
prone	JJ	B-ADJP	O
to	TO	B-PP	O
hypoglycaemia	NN	B-NP	B
attacks	NNS	I-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
blockers	NNS	B-NP	O
because	IN	B-SBAR	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
a	DT	B-NP	O
sharp	JJ	I-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
-	HYPH	B-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
such	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Prevention	NN	B-NP	O
and	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
climacteric	JJ	B-NP	O
women	NNS	I-NP	O
receiving	VBG	B-VP	O
oestrogen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
treatment	NN	I-NP	O
regimens	NNS	I-NP	O
are	VBP	B-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
endometrial	JJ	B-NP	B
disease	NN	I-NP	I
among	IN	B-PP	O
num	CD	B-NP	O
climacteric	JJ	I-NP	O
women	NNS	I-NP	O
receiving	VBG	B-VP	O
oestrogen	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Cystic	JJ	B-NP	O
hyperplasia	NN	I-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
unopposed	JJ	B-NP	O
oestrogen	NN	I-NP	O
therapy	NN	I-NP	O
without	IN	B-PP	O
progestagen	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
courses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
norethisterone	NN	I-NP	O
daily	RB	B-ADVP	O
caused	VBD	B-VP	O
reversion	NN	B-NP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cystic	JJ	B-NP	O
hyperplasia	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
atypical	JJ	B-NP	O
hyperplasia	NN	I-NP	B
.	.	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
carcinoma	NN	I-NP	I
referred	VBN	B-VP	O
from	IN	B-PP	O
elsewhere	RB	B-NP	O
demonstrated	VBD	B-VP	O
the	DT	B-NP	O
problems	NNS	I-NP	O
of	IN	B-PP	O
inappropriate	JJ	B-NP	O
and	CC	I-NP	O
unsupervised	JJ	I-NP	O
unopposed	JJ	I-NP	O
oestrogen	NN	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
difficulty	NN	I-NP	O
in	IN	B-PP	O
distinguishing	VBG	B-VP	O
severe	JJ	B-NP	O
hyperplasia	NN	I-NP	B
from	IN	B-PP	O
malignancy	NN	B-NP	B
.	.	O	O

Cyclical	JJ	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
oestrogen	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
progestagen	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	B
hyperplasia	NN	I-NP	I
or	CC	I-NP	O
carcinoma	NN	I-NP	B
.	.	O	O

Pure	NN	B-NP	B
red	JJ	I-NP	I
cell	NN	I-NP	I
aplasia	NN	I-NP	I
,	,	O	O
toxic	JJ	B-NP	B
dermatitis	NN	I-NP	I
and	CC	I-NP	O
lymphadenopathy	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
taking	VBG	B-VP	O
diphenylhydantoin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
taking	VBG	B-VP	O
diphenylhydantoin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
skin	NN	I-NP	B
rash	NN	I-NP	I
,	,	O	O
lymphadenopathy	NN	B-NP	B
and	CC	O	O
pure	JJ	B-NP	B
red	JJ	I-NP	I
cell	NN	I-NP	I
aplasia	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pharmacon	NN	I-NP	O
all	DT	B-NP	O
symptoms	NNS	I-NP	O
disappeared	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
.	.	O	O

Skin	NN	B-NP	B
rash	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
diphenylhydantoin	NN	B-NP	O
treatment	NN	I-NP	O
as	IN	B-SBAR	O
is	VBZ	B-VP	O
benign	JJ	B-NP	O
and	CC	I-NP	O
malignant	JJ	I-NP	O
lymphadenopathy	NN	I-NP	B
.	.	O	O

Pure	NN	B-NP	B
red	JJ	I-NP	I
cell	NN	I-NP	I
aplasia	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
diphenylhydantoin	NN	B-NP	O
medication	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
exact	JJ	I-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
diphenylhydantoin	NN	B-NP	O
exerts	VBZ	B-VP	O
its	PRP$	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
the	DT	B-NP	O
time	NN	I-NP	O
relation	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
ingestion	NN	I-NP	O
of	IN	B-PP	O
diphenylhydantoin	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
skin	NN	I-NP	B
rash	NN	I-NP	I
,	,	O	O
lymphadenopathy	NN	B-NP	B
and	CC	O	O
pure	JJ	B-NP	B
red	JJ	I-NP	I
cell	NN	I-NP	I
aplasia	NN	I-NP	I
is	VBZ	B-VP	O
very	RB	B-ADJP	O
suggestive	JJ	I-ADJP	O
of	IN	B-PP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
connection	NN	I-NP	O
.	.	O	O

Continuous	JJ	B-NP	O
infusion	NN	I-NP	O
tobramycin	NN	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
carbenicillin	NN	B-NP	O
for	IN	B-PP	O
infections	NNS	B-NP	B
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
cure	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
infections	NNS	B-NP	B
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
is	VBZ	B-VP	O
adversely	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
neutropenia	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
neutropenia	NN	I-NP	B
have	VBP	B-VP	O
shown	VBN	I-VP	O
a	DT	B-NP	O
poor	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
antibiotics	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
overcome	VB	I-VP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
neutropenia	NN	B-NP	B
,	,	O	O
tobramycin	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
by	IN	B-PP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
intermittent	JJ	B-NP	O
carbenicillin	NN	I-NP	O
.	.	O	O

Tobramycin	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
total	JJ	I-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
and	CC	I-NP	O
carbenicillin	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
gm	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
infectious	JJ	I-NP	O
episodes	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
myelosuppressive	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
cure	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Pneumonia	NN	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
infection	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
were	VBD	B-VP	O
cured	VBN	I-VP	O
.	.	O	O

Gram	NN	B-NP	O
-	HYPH	I-NP	O
negative	JJ	I-NP	O
bacilli	NNS	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
causative	JJ	I-NP	O
organisms	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
infections	NNS	I-NP	B
were	VBD	B-VP	O
cured	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
pathogen	NN	I-NP	O
was	VBD	B-VP	O
Klebsiella	NNP	B-NP	O
pneumoniae	NNP	I-NP	B
and	CC	O	O
this	DT	B-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
Escherichia	FW	B-NP	O
coli	FW	I-NP	O
and	CC	O	O
Pseudomonas	NNP	B-NP	O
aeruginosa	NN	I-NP	O
,	,	O	O
accounted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
gram	NN	I-NP	B
-	HYPH	B-NP	I
negative	JJ	I-NP	I
bacillary	JJ	I-NP	I
infections	NNS	I-NP	I
.	.	O	O

Response	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
influenced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
neutrophil	NN	I-NP	O
count	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
cure	NN	I-NP	O
rate	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
neutropenia	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
failure	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neutrophil	NN	I-NP	O
count	NN	I-NP	O
to	TO	B-VP	O
increase	VB	I-VP	O
during	IN	B-PP	O
therapy	NN	B-NP	O
adversely	RB	B-VP	O
affected	VBD	I-VP	O
response	NN	B-NP	O
.	.	O	O

Azotemia	NN	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
recognized	VBD	B-VP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
episodes	NNS	B-NP	O
.	.	O	O

Major	JJ	B-NP	O
azotemia	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Azotemia	NN	B-NP	B
was	VBD	B-VP	O
not	RB	O	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
duration	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
or	CC	I-NP	O
serum	NN	I-NP	O
tobramycin	NN	I-NP	O
concentration	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
antibiotic	JJ	I-NP	O
regimen	NN	I-NP	O
showed	VBD	B-VP	O
both	CC	O	O
therapeutic	JJ	B-NP	O
efficacy	NN	I-NP	O
and	CC	O	O
acceptable	JJ	B-NP	O
renal	JJ	I-NP	B
toxicity	NN	I-NP	I
for	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Recurrent	JJ	B-NP	O
subarachnoid	JJ	I-NP	B
hemorrhage	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
aminocaproic	JJ	B-NP	O
acid	NN	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
artery	NN	I-NP	I
thrombosis	NN	I-NP	I
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

Epsilon	NN	B-NP	O
aminocaproic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
EACA	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
rebleeding	VBG	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
(	(	O	O
SAH	NN	B-NP	B
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
agent	NN	I-NP	O
does	VBZ	B-VP	O
decrease	VB	I-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
rebleeding	VBG	B-VP	O
,	,	O	O
several	JJ	B-NP	O
reports	NNS	I-NP	O
have	VBP	B-VP	O
described	VBN	I-VP	O
thrombotic	JJ	B-NP	B
complications	NNS	I-NP	O
of	IN	B-PP	O
EACA	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
complications	NNS	I-NP	O
have	VBP	B-VP	O
included	VBN	I-VP	O
clinical	JJ	B-NP	O
deterioration	NN	I-NP	O
and	CC	O	O
intracranial	JJ	B-NP	B
vascular	JJ	I-NP	I
thrombosis	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SAH	NN	B-NP	B
,	,	O	O
arteriolar	JJ	B-NP	O
and	CC	I-NP	O
capillary	JJ	I-NP	O
fibrin	NN	I-NP	O
thrombi	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
fibrinolytic	JJ	B-NP	O
syndromes	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
EACA	NN	B-NP	O
,	,	O	O
or	CC	O	O
other	JJ	B-NP	O
thromboembolic	JJ	I-NP	B
phenomena	NNS	I-NP	I
.	.	O	O

Since	IN	B-SBAR	O
intravascular	JJ	B-NP	O
fibrin	NN	I-NP	O
thrombi	NN	I-NP	B
are	VBP	B-VP	O
often	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
fibrinolytic	JJ	B-NP	O
disorders	NNS	I-NP	O
,	,	O	O
EACA	NN	B-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
fibrin	NN	B-NP	O
thrombi	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
disseminated	VBN	B-NP	B
intravascular	JJ	I-NP	I
coagulation	NN	I-NP	I
or	CC	O	O
other	JJ	B-NP	O
consumption	NN	I-NP	B
coagulopathies	NNS	I-NP	I
.	.	O	O
This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
subtotal	JJ	B-NP	O
infarction	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
thrombosis	NN	B-NP	B
of	IN	B-PP	I
a	DT	B-NP	I
normal	JJ	I-NP	I
renal	JJ	I-NP	I
artery	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
occlusion	NN	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
EACA	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
SAH	NN	B-NP	B
and	CC	O	O
histopathological	JJ	B-NP	O
documentation	NN	I-NP	O
of	IN	B-PP	O
recurrent	JJ	B-NP	O
SAH	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
corresponding	VBG	I-NP	O
clinical	JJ	I-NP	O
event	NN	I-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
marked	JJ	B-NP	O
hypertension	NN	I-NP	B
and	CC	O	O
abrupt	JJ	B-NP	O
neurological	JJ	I-NP	O
deterioration	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
propranolol	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
pregnancy	NN	B-NP	O
:	:	O	O
maternal	JJ	B-NP	O
and	CC	I-NP	O
fetal	JJ	I-NP	O
outcome	NN	I-NP	O
.	.	O	O

Propranolol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
agent	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
found	VBN	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
position	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
practice	NN	I-NP	O
of	IN	B-PP	O
medicine	NN	B-NP	O
.	.	O	O

Its	PRP$	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
pregnancy	NN	B-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
open	JJ	I-NP	O
question	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
detrimental	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
fetus	NN	I-NP	O
and	CC	I-NP	O
neonate	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
pregnancies	NNS	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
where	WRB	B-ADVP	O
chronic	JJ	B-NP	O
propranolol	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
administered	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
serial	JJ	B-NP	O
pregnancies	NNS	I-NP	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
propranolol	NN	B-NP	O
therapy	NN	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
examined	VBN	I-VP	O
.	.	O	O

Maternal	JJ	B-NP	O
,	,	I-NP	O
fetal	JJ	I-NP	O
,	,	O	O
and	CC	O	O
neonatal	JJ	B-NP	O
complications	NNS	I-NP	O
are	VBP	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
attempt	NN	I-NP	O
is	VBZ	B-VP	O
made	VBN	I-VP	O
to	TO	I-VP	O
differentiate	VB	I-VP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
complications	NNS	I-NP	O
from	IN	B-PP	O
maternal	JJ	B-NP	O
disease	NN	I-NP	O
-	HYPH	B-NP	O
-	HYPH	I-NP	O
related	VBN	I-NP	O
complications	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
previously	RB	B-NP	O
reported	VBN	I-NP	O
hypoglycemia	NN	I-NP	B
,	,	O	O
hyperbilirubinemia	NN	B-NP	B
,	,	O	O
polycythemia	NN	B-NP	B
,	,	O	O
neonatal	JJ	B-NP	B
apnea	NN	I-NP	I
,	,	O	O
and	CC	O	O
bradycardia	NN	B-NP	B
are	VBP	B-VP	O
not	RB	O	O
invariable	JJ	B-ADJP	O
and	CC	O	O
can	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
statistically	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
propranolol	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Growth	NN	B-NP	B
retardation	NN	I-NP	I
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
significant	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
series	NN	I-NP	O
.	.	O	O

Use	NN	B-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
idiopathic	JJ	B-NP	B
orthostatic	JJ	I-NP	I
hypotension	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
idiopathic	JJ	B-NP	B
orthostatic	JJ	I-NP	I
hypotension	NN	I-NP	I
who	WP	B-NP	O
had	VBD	B-VP	O
physiologic	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
autonomic	JJ	I-NP	O
dysfunction	NN	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
all	DT	O	O
exhibited	VBD	B-VP	O
markedly	RB	B-NP	O
reduced	VBN	I-NP	O
plasma	NN	I-NP	O
catecholamines	NNS	I-NP	O
and	CC	O	O
plasma	NN	B-NP	O
renin	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
recumbent	JJ	I-NP	O
and	CC	I-NP	O
upright	JJ	I-NP	O
positions	NNS	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
marked	VBN	I-VP	O
hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
infused	VBN	B-NP	O
norepinephrine	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
propanolol	NN	B-NP	O
administered	VBN	B-VP	O
intravenously	RB	B-NP	O
produced	VBN	I-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
supine	NN	B-NP	O
and	CC	O	O
upright	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
individuals	NNS	I-NP	O
with	IN	B-PP	O
rises	NNS	B-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mmHg	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
oral	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
also	RB	B-ADVP	O
elevated	VBD	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
individuals	NNS	I-NP	O
with	IN	B-PP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
order	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mmg	NN	I-NP	O
being	VBG	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
marked	JJ	B-NP	O
hypertension	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
had	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
withdrawn	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
otherwise	RB	B-ADVP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
no	DT	B-NP	O
important	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Treatment	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
continued	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
individuals	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
with	IN	B-PP	O
persistence	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
there	EX	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
some	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
with	IN	B-PP	O
time	NN	B-NP	O
.	.	O	O

Hemodynamic	JJ	B-NP	O
measurements	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
demonstrated	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
total	JJ	B-NP	O
peripheral	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
essentially	RB	B-NP	O
no	DT	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
following	VBG	B-PP	O
propranolol	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
propranolol	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
selected	VBN	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
idiopathic	JJ	I-NP	B
orthostatic	JJ	I-NP	I
hypotension	NN	I-NP	I
.	.	O	O

Total	JJ	B-NP	O
intravenous	JJ	I-NP	O
anesthesia	NN	I-NP	O
with	IN	B-PP	O
etomidate	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
.	.	O	O

Some	DT	B-NP	O
observations	NNS	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
.	.	O	O

An	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
etomidate	NN	B-NP	O
required	VBN	B-VP	O
to	TO	I-VP	O
maintain	VB	I-VP	O
sleep	NN	B-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
undergoing	VBG	B-VP	O
surgery	NN	B-NP	O
under	IN	B-PP	O
regional	JJ	B-NP	O
local	JJ	I-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Premedication	NN	B-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
atropine	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
,	,	O	O
and	CC	O	O
sleep	NN	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
and	CC	I-VP	O
maintained	VBN	I-VP	O
by	IN	B-PP	O
intermittent	JJ	B-NP	O
intravenous	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
etomidate	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
given	VBN	B-PP	O
whenever	WRB	B-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
would	MD	B-VP	O
open	VB	I-VP	O
his	PRP$	B-NP	O
eyes	NNS	I-NP	O
on	IN	B-PP	O
request	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
mean	JJ	I-NP	O
overall	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
etomidate	NN	B-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min.	NN	I-NP	O
was	VBD	B-VP	O
required	VBN	I-VP	O
to	TO	I-VP	O
maintain	VB	I-VP	O
sleep	NN	B-NP	O
,	,	O	O
but	CC	O	O
great	JJ	B-NP	O
individual	JJ	I-NP	O
variation	NN	I-NP	O
occurred	VBD	B-VP	O
,	,	O	O
with	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
requiring	VBG	B-VP	O
less	JJR	B-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
,	,	O	O
particularly	RB	B-NP	O
pain	NN	I-NP	B
and	CC	I-NP	O
myoclonia	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
caused	VBD	B-VP	O
the	DT	B-NP	O
technique	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
abandoned	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
considered	VBN	I-VP	O
unlikely	JJ	B-ADJP	O
that	IN	B-SBAR	O
etomidate	NN	B-NP	O
will	MD	B-VP	O
prove	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
hypnotic	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
totally	RB	I-NP	O
intravenous	JJ	I-NP	O
anesthetic	JJ	I-NP	O
technique	NN	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
myoclonia	NN	B-NP	B
after	IN	B-SBAR	O
prolonged	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
several	JJ	B-NP	O
patients	NNS	I-NP	O
uncontrollable	JJ	B-NP	O
muscle	NN	I-NP	O
movements	NNS	I-NP	O
persisted	VBD	B-VP	O
for	IN	B-PP	O
many	JJ	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
complete	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
consciousness	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
tocolytic	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
mimetics	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
method	NN	I-NP	O
permitting	VBG	B-VP	O
measurement	NN	B-NP	O
of	IN	B-PP	O
finger	NN	B-NP	O
tremor	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
displacement	NN	I-NP	O
-	HYPH	O	O
time	NN	B-NP	O
curve	NN	I-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
,	,	O	O
using	VBG	B-VP	O
a	DT	B-NP	O
test	NN	I-NP	O
system	NN	I-NP	O
with	IN	B-PP	O
simple	JJ	B-NP	O
amplitude	NN	I-NP	O
calibration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
coordinates	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
inversion	NN	I-NP	O
points	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
displacement	NN	I-NP	O
-	HYPH	O	O
time	NN	B-NP	O
curves	NNS	I-NP	O
were	VBD	B-VP	O
transferred	VBN	I-VP	O
through	IN	B-PP	O
graphical	JJ	B-NP	O
input	NN	I-NP	O
equipment	NN	I-NP	O
to	TO	B-PP	O
punched	VBN	B-NP	O
tape	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
computer	NN	I-NP	O
program	NN	I-NP	O
,	,	O	O
periods	NNS	B-NP	O
and	CC	I-NP	O
amplitudes	NNS	I-NP	O
of	IN	B-PP	O
tremor	NN	B-NP	B
oscillations	NNS	I-NP	O
were	VBD	B-VP	O
calculated	VBN	I-VP	O
and	CC	O	O
classified	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
event	NN	I-NP	O
frequency	NN	I-NP	O
for	IN	B-PP	O
each	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
periods	NNS	B-NP	O
and	CC	I-NP	O
amplitudes	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
fenoterol	NN	B-NP	O
-	HYPH	B-NP	O
hydrobromide	NN	I-NP	O
,	,	O	O
ritodrin	NN	B-NP	O
-	HYPH	B-NP	O
HCl	NN	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
given	VBN	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
by	IN	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
crossover	NN	I-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
by	IN	B-PP	O
this	DT	B-NP	O
method	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
therapeutic	JJ	B-NP	O
doses	NNS	I-NP	O
both	DT	B-NP	O
substances	NNS	I-NP	O
raised	VBD	B-VP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
tremor	NN	I-NP	B
amplitude	NN	I-NP	O
to	TO	B-PP	O
about	IN	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
control	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
period	NN	I-NP	O
within	IN	B-PP	O
each	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
amplitudes	NNS	B-NP	O
shortened	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
ms	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
periods	NNS	I-NP	O
calculated	VBN	B-VP	O
from	IN	B-PP	O
all	DT	B-NP	O
oscillations	NNS	I-NP	O
together	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
significantly	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
fenoterol	NN	B-NP	O
-	HYPH	B-NP	O
hydrobromide	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
tremor	NN	B-NP	B
amplitudes	NNS	I-NP	O
decreased	VBD	B-VP	O
significantly	RB	B-ADJP	O
faster	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
following	VBG	I-NP	O
ritodrin	NN	I-NP	O
-	HYPH	B-NP	O
HCl	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
retinal	JJ	I-NP	B
artery	NN	I-NP	I
and	CC	I-NP	I
choriocapillaris	NN	I-NP	I
occlusion	NN	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
corticosteroid	NN	I-NP	O
suspensions	NNS	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
:	:	O	O
I	LS	B-LST	O
.	.	O	O

Clinical	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
documented	VBN	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
retinal	JJ	I-NP	B
artery	NN	I-NP	I
and	CC	I-NP	I
choriocapillaris	NN	I-NP	I
occlusions	NNS	I-NP	I
with	IN	B-PP	O
blindness	NN	B-NP	B
following	VBG	B-PP	O
head	NN	B-NP	O
and	CC	O	O
neck	NN	B-NP	O
soft	JJ	I-NP	O
-	HYPH	I-NP	O
tissue	NN	I-NP	O
injection	NN	I-NP	O
with	IN	B-PP	O
methylprednisolone	NN	B-NP	O
acetate	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
lidocaine	NN	B-NP	O
,	,	O	O
epinephrine	NN	B-NP	O
,	,	O	O
or	CC	O	O
penicillin	NN	B-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
case	NN	I-NP	O
had	VBD	B-VP	O
only	RB	B-NP	O
a	DT	I-NP	O
unilateral	JJ	I-NP	O
injection	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
acute	JJ	I-NP	O
observations	NNS	I-NP	O
included	VBD	B-VP	O
hazy	JJ	B-NP	O
sensorium	NN	I-NP	O
,	,	O	O
superior	JJ	B-NP	O
gaze	NN	I-NP	O
palsy	NN	I-NP	B
,	,	O	O
pupillary	JJ	B-NP	B
abnormalities	NNS	I-NP	I
,	,	O	O
and	CC	O	O
conjunctival	JJ	B-NP	O
hemorrhages	NNS	I-NP	B
with	IN	B-PP	O
edema	NN	B-NP	B
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
changes	NNS	B-NP	O
showed	VBD	B-VP	O
marked	JJ	B-NP	O
visual	JJ	I-NP	B
loss	NN	I-NP	I
,	,	O	O
constricted	VBN	B-VP	O
visual	JJ	B-NP	O
fields	NNS	I-NP	O
,	,	O	O
optic	JJ	B-NP	O
nerve	NN	I-NP	O
pallor	NN	I-NP	O
,	,	O	O
vascular	JJ	B-NP	O
attenuation	NN	I-NP	O
,	,	O	O
and	CC	O	O
chorioretinal	JJ	B-NP	B
atrophy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
literature	NN	I-NP	O
is	VBZ	B-VP	O
reviewed	VBN	I-VP	O
,	,	O	O
and	CC	O	O
possible	JJ	B-NP	O
causes	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Cephalothin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
developed	VBD	B-VP	O
Coombs	NNP	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
cephalothin	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
cephalothin	NN	I-NP	O
IgG	NN	I-NP	O
antibody	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NNS	I-NP	O
serum	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
eluates	NNS	I-NP	O
from	IN	B-PP	O
her	PRP$	B-NP	O
erythrocytes	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
nonimmunologic	JJ	B-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
and	CC	I-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
serum	NN	B-NP	O
proteins	NNS	I-NP	O
to	TO	B-PP	O
her	PRP$	B-NP	O
own	JJ	I-NP	O
and	CC	I-NP	O
cephalothin	NN	I-NP	O
-	HYPH	B-VP	O
coated	VBN	B-NP	O
normal	JJ	I-NP	O
red	JJ	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
.	.	O	O

Skin	NN	B-NP	O
tests	NNS	I-NP	O
and	CC	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
lymphocyte	NN	I-NP	O
stimulation	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
sensitized	VBN	I-VP	O
to	TO	B-PP	O
cephalothin	NN	B-NP	O
and	CC	O	O
also	RB	B-ADVP	O
to	TO	B-PP	O
ampicillin	NN	B-NP	O
.	.	O	O

Careful	JJ	B-NP	O
investigation	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolytic	JJ	I-NP	B
anemias	NNS	I-NP	I
reveals	VBZ	B-VP	O
the	DT	B-NP	O
complexity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
immune	JJ	I-NP	O
mechanisms	NNS	I-NP	O
involved	VBN	B-VP	O
.	.	O	O

Kaliuretic	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Hypokalemia	NN	B-NP	B
,	,	O	O
sometimes	RB	B-ADJP	O
severe	JJ	I-ADJP	O
,	,	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
dopa	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hypokalemia	NN	B-NP	B
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
normokalemic	JJ	I-NP	O
patients	NNS	I-NP	O
by	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
plasma	NN	I-NP	O
flow	NN	I-NP	O
,	,	O	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
and	CC	I-NP	O
sodium	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
urinary	JJ	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
,	,	I-NP	O
sodium	NN	I-NP	O
and	CC	I-NP	O
aldosterone	NN	I-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	I-NP	O
Dopa	NN	I-NP	O
intake	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
potassium	NN	B-NP	O
,	,	O	O
and	CC	O	O
sometimes	RB	B-ADVP	O
also	RB	B-ADVP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
hypokalemic	JJ	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
normokalemic	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
prohibited	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
peripheral	JJ	I-NP	O
dopa	NN	I-NP	O
decarbodylase	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
known	VBN	I-VP	O
why	WRB	B-ADVP	O
this	DT	B-NP	O
effect	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
some	DT	B-NP	O
individuals	NNS	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
others	NNS	B-NP	O
,	,	O	O
but	CC	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
aldosterone	NN	B-NP	O
production	NN	I-NP	O
and	CC	O	O
this	DT	B-NP	O
renal	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	I-NP	O
dopa	NN	B-NP	O
.	.	O	O

Phenytoin	NN	B-NP	O
encephalopathy	NN	I-NP	B
as	IN	B-PP	O
probable	JJ	B-NP	O
idiosyncratic	JJ	I-NP	O
reaction	NN	I-NP	O
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
(	(	O	O
DPH	NN	B-NP	O
)	)	O	O
encephalopathy	NN	B-NP	B
with	IN	B-PP	O
increasing	VBG	B-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
EEG	NN	I-NP	O
and	CC	I-NP	O
mental	JJ	I-NP	O
changes	NNS	I-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Despite	IN	B-PP	O
adequate	JJ	B-NP	O
oral	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
DPH	NN	B-NP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
very	RB	B-ADJP	O
low	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
encephalopathy	NN	I-NP	B
was	VBD	B-VP	O
probably	RB	B-ADVP	O
an	DT	B-NP	O
idiosyncratic	JJ	I-NP	O
and	CC	I-NP	O
not	RB	I-NP	O
toxic	JJ	I-NP	O
or	CC	I-NP	O
allergic	JJ	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
fact	NN	B-NP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
DPH	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
presented	VBD	B-VP	O
a	DT	B-NP	O
retarded	VBN	I-NP	O
morbilliform	NN	I-NP	O
rash	NN	I-NP	B
during	IN	B-PP	O
DPH	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
protidogram	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
an	DT	B-NP	O
intradermic	JJ	I-NP	O
DPH	NN	I-NP	O
injection	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
local	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
starting	VBG	B-VP	O
DPH	NN	B-NP	O
treatment	NN	I-NP	O
an	DT	B-NP	O
unexpected	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
with	IN	B-PP	O
EEG	NN	B-NP	O
and	CC	O	O
mental	JJ	B-NP	O
changes	NNS	I-NP	O
occurring	VBG	B-VP	O
simultaneously	RB	B-ADVP	O
,	,	O	O
should	MD	B-VP	O
alert	VB	I-VP	O
the	DT	B-NP	O
physician	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
eliminating	VBG	B-VP	O
DPH	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
regimen	NN	I-NP	O
,	,	O	O
even	RB	B-SBAR	O
if	IN	I-SBAR	O
plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
are	VBP	B-VP	O
low	JJ	B-ADJP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
exercise	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
exercise	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
male	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
exercise	NN	I-NP	O
-	HYPH	O	O
isoproterenol	NN	B-NP	O
(	(	O	O
E	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
exercise	NN	B-NP	O
control	NN	I-NP	O
(	(	O	O
EC	NN	B-NP	O
)	)	O	O
groups	NNS	B-NP	O
exercised	VBN	B-VP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
treadmill	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mph	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
grade	NN	I-NP	O
while	IN	B-SBAR	O
animals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
sedentary	JJ	I-NP	O
-	HYPH	I-NP	O
isoproterenol	NN	I-NP	O
(	(	O	O
S	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
)	)	O	O
group	NN	B-NP	O
remained	VBD	B-VP	O
sedentary	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
sedentary	JJ	I-NP	O
control	NN	I-NP	O
(	(	O	O
SC	NN	B-NP	O
)	)	O	O
group	NN	B-NP	O
which	WDT	B-NP	O
remained	VBD	B-VP	O
sedentary	JJ	B-ADJP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
final	JJ	I-NP	O
exercise	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
S	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
and	CC	I-NP	O
E	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
animals	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
subcutaneous	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
group	NN	I-NP	O
exhibited	VBD	B-VP	O
significantly	RB	B-NP	O
greater	JJR	I-NP	O
mortality	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
than	IN	B-PP	O
animals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
E	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
CPK	NN	I-NP	O
activity	NN	I-NP	O
for	IN	B-PP	O
E	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
animals	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
than	IN	B-PP	O
for	IN	B-PP	O
animals	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
EC	NNP	B-NP	O
groups	NNS	I-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
following	VBG	B-PP	O
isoproterenol	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
isoproterenol	NN	I-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
for	IN	B-PP	O
severity	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
induced	VBN	I-NP	O
lesions	NNS	I-NP	O
,	,	O	O
changes	NNS	B-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
weight	NN	I-NP	O
,	,	O	O
or	CC	O	O
heart	NN	B-NP	O
weight	NN	I-NP	O
to	TO	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
ratios	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
exercise	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
mortality	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
large	JJ	B-NP	O
dosages	NNS	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
but	CC	O	O
had	VBD	B-VP	O
little	JJ	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infarction	NN	I-NP	B
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	O	O
Glucarates	NNS	B-NP	O
on	IN	B-PP	O
basic	JJ	B-NP	O
antibiotic	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Dehydrated	VBN	B-NP	B
rats	NNS	I-NP	O
regularly	RB	B-ADVP	O
develop	VBP	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
single	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
antibiotics	NNS	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
dextran	NN	B-NP	O
or	CC	B-PP	O
of	IN	B-PP	O
antibiotics	NNS	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

Oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
di	AFX	O	O
-	HYPH	B-NP	O
O	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
glucaro	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dilactone	NN	I-NP	O
protected	VBD	B-VP	O
rats	NNS	B-NP	O
against	IN	B-PP	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
kanamycin	NN	B-NP	O
-	HYPH	B-NP	O
dextran	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
prevalent	JJ	B-ADJP	O
among	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
glucarates	NNS	I-NP	O
,	,	O	O
and	CC	O	O
also	RB	B-ADVP	O
to	TO	B-PP	O
other	JJ	B-NP	O
saccharic	JJ	I-NP	O
acid	NN	I-NP	O
,	,	O	O
hexauronic	JJ	B-NP	O
acids	NNS	I-NP	O
and	CC	O	O
hexaaldonic	JJ	B-NP	O
acids	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
to	TO	B-PP	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
degree	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
to	TO	B-PP	O
a	DT	B-NP	O
hexaaldose	NN	I-NP	O
,	,	O	O
sugar	NN	B-NP	O
alcohols	NNS	I-NP	O
,	,	O	O
substances	NNS	B-NP	O
inthe	VBP	B-VP	O
TCA	NN	B-NP	O
cycle	NN	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
acidic	JJ	I-NP	O
compounds	NNS	I-NP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
Glucarates	NNS	I-NP	O
were	VBD	B-VP	O
effective	JJ	B-ADJP	O
against	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
peptide	NN	B-NP	O
antibiotics	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
various	JJ	B-NP	O
aminoglycoside	NN	I-NP	O
antibitocis	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
Glucarates	NNS	I-NP	O
.	.	O	O

With	IN	B-PP	O
a	DT	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
glucarate	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
dose	NN	B-NP	O
,	,	O	O
approximately	RB	B-NP	O
the	DT	I-NP	O
same	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
protection	NN	B-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
against	IN	B-PP	O
renal	JJ	B-NP	B
damages	NNS	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
different	JJ	B-NP	O
basic	JJ	I-NP	O
antibiotics	NNS	I-NP	O
despite	IN	B-PP	O
large	JJ	B-NP	O
disparities	NNS	I-NP	O
in	IN	B-PP	O
administration	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
antibiotics	NNS	I-NP	O
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
Glucarates	NNS	I-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
but	CC	O	O
not	RB	O	O
to	TO	B-VP	O
cure	VB	I-VP	O
it	PRP	B-NP	O
.	.	O	O

Rats	NNS	B-NP	O
excreted	VBD	B-VP	O
acidic	JJ	B-NP	O
urine	NN	I-NP	O
when	WRB	B-ADVP	O
they	PRP	B-NP	O
were	VBD	B-VP	O
spared	VBN	I-VP	O
from	IN	B-PP	O
renal	JJ	B-NP	B
lesions	NNS	I-NP	I
by	IN	B-PP	O
monosaccharides	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
reduction	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
glucarates	NNS	B-NP	O
against	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
of	IN	B-PP	O
basic	JJ	B-NP	O
antibiotics	NNS	I-NP	O
was	VBD	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Paraplegia	NNP	B-NP	B
following	VBG	B-PP	O
intrathecal	JJ	B-NP	O
methotrexate	NN	I-NP	O
:	:	O	O
report	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
case	NN	I-NP	O
and	CC	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
paraplegia	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
intrathecal	JJ	I-NP	O
instillation	NN	I-NP	O
of	IN	B-PP	O
methotrexate	NN	B-NP	O
is	VBZ	B-VP	O
discribed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
unusual	JJ	I-NP	O
complication	NN	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
following	VBG	I-NP	O
factors	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
predispose	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
:	:	O	O
abnormal	JJ	B-NP	O
cerebrospinal	JJ	I-NP	O
dynamics	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
leukemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
epidural	JJ	B-NP	O
cerebrospinal	JJ	I-NP	O
leakage	NN	I-NP	O
;	:	O	O
elevated	VBN	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
methothexate	NN	I-NP	O
concentration	NN	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
abnormal	JJ	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
dynamics	NNS	I-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
inappropriately	RB	B-NP	O
high	JJ	I-NP	O
methotrexate	NN	I-NP	O
doses	NNS	I-NP	O
based	VBN	B-VP	O
on	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
calculations	NNS	I-NP	O
in	IN	B-PP	O
older	JJR	B-NP	O
children	NNS	I-NP	O
and	CC	I-NP	O
adults	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
neurotoxic	JJ	B-NP	B
preservatives	NNS	I-NP	O
in	IN	B-PP	O
commercially	RB	B-NP	O
available	JJ	I-NP	O
methotrexate	NN	I-NP	O
preparations	NNS	I-NP	O
and	CC	I-NP	O
diluents	NNS	I-NP	O
;	:	O	O
and	CC	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
methotrexate	NN	B-NP	O
diluents	NNS	I-NP	O
of	IN	B-PP	O
unphysiologic	JJ	B-NP	O
pH	NN	I-NP	O
,	,	O	O
ionic	JJ	B-NP	O
content	NN	I-NP	O
and	CC	I-NP	O
osmolarity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
methotrexate	NN	B-NP	O
contaminants	NNS	I-NP	O
,	,	O	O
local	JJ	B-NP	O
folate	JJ	I-NP	B
deficiency	NN	I-NP	I
,	,	O	O
and	CC	O	O
cranial	JJ	B-NP	O
irradiation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
methotrexate	NN	I-NP	O
toxicity	NN	I-NP	B
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
employing	VBG	B-VP	O
lower	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
methotrexate	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
leukemia	NN	I-NP	I
,	,	O	O
in	IN	B-PP	O
older	JJR	B-NP	O
children	NNS	I-NP	O
and	CC	I-NP	O
adults	NNS	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
epidural	JJ	B-NP	O
leakage	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
preservative	JJ	I-NP	O
-	HYPH	I-NP	O
free	JJ	I-NP	O
methotrexate	NN	I-NP	O
in	IN	B-PP	O
Elliott	NNP	B-NP	O
s	NN	I-NP	O
B	NN	I-NP	O
Solution	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
not	RB	B-NP	O
more	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
intrathecal	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Periodic	JJ	B-NP	O
monitoring	NN	I-NP	O
of	IN	B-PP	O
cerebruspinal	JJ	B-NP	O
fluid	NN	I-NP	O
methotrexate	NN	I-NP	O
levels	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
predictive	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

Centrally	RB	B-NP	O
mediated	VBN	I-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
intracisternal	JJ	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
carbachol	NN	B-NP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
pressor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
intracisternal	JJ	I-NP	O
(	(	O	O
i.c.	JJ	B-ADJP	O
)	)	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
carbachol	NN	B-NP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
(	(	O	O
i.v.	JJ	B-ADJP	O
)	)	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
guanethidine	NN	B-NP	O
,	,	I-NP	O
hexamethonium	NN	I-NP	O
or	CC	I-NP	O
phentolamine	NN	I-NP	O
,	,	O	O
and	CC	O	O
conversely	RB	B-ADVP	O
,	,	O	O
potentiated	VBN	B-VP	O
by	IN	B-PP	O
i.v.	JJ	B-NP	O
desmethylimipramine	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
propranolol	NN	B-NP	O
i.v.	NN	I-NP	O
selectively	RB	B-ADVP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
enlargement	NN	I-NP	B
of	IN	B-PP	I
pulse	NN	B-NP	I
pressure	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
tachycardia	NN	I-NP	B
following	VBG	B-PP	O
i.c.	JJ	B-NP	O
carbachol	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
pressor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
i.c.	JJ	B-NP	O
carbachol	NN	I-NP	O
was	VBD	B-VP	O
almost	RB	I-VP	O
completely	RB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
i.c.	JJ	B-NP	O
atropine	NN	I-NP	O
or	CC	I-NP	O
hexamethonium	NN	I-NP	O
,	,	O	O
and	CC	O	O
significantly	RB	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
i.c.	JJ	B-NP	O
chlorpromazine	NN	I-NP	O
but	CC	O	O
significantly	RB	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
i.c.	JJ	B-NP	O
desmethylimipramine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pressor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
i.c.	JJ	B-NP	O
carbachol	NN	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
after	IN	B-PP	O
sectioning	VBG	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
bilateral	JJ	I-NP	O
cervical	JJ	I-NP	O
vagal	JJ	I-NP	O
nerves	NNS	I-NP	O
but	CC	O	O
disappeared	VBD	B-VP	O
after	IN	B-PP	O
sectioning	VBG	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
(	(	O	O
C7	NN	B-NP	O
-	HYPH	B-NP	O
C8	NN	I-NP	O
)	)	O	O
.	.	O	O

From	IN	B-PP	O
the	DT	B-NP	O
above	JJ	I-NP	O
result	NN	I-NP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
pressor	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
i.c.	JJ	B-NP	O
carbachol	NN	I-NP	O
ortral	JJ	I-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
adrenergic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
sympathetic	JJ	I-NP	O
trunk	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Hyperglycemic	JJ	B-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
amino	JJ	B-NP	O
compounds	NNS	I-NP	O
structurally	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-VP	O
caproate	VB	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
chronic	JJ	I-NP	O
feeding	NN	I-NP	O
of	IN	B-PP	O
small	JJ	B-NP	O
amounts	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
diet	NN	B-NP	O
weight	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
certain	JJ	B-NP	O
amino	NN	I-NP	O
derivatives	NNS	I-NP	O
of	IN	B-PP	O
caproate	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
hyperglycemia	NN	B-NP	B
,	,	O	O
an	DT	B-NP	O
elevated	JJ	I-NP	O
glucose	NN	I-NP	O
tolerance	NN	I-NP	O
curve	NN	I-NP	O
and	CC	O	O
,	,	O	O
occasionally	RB	B-ADVP	O
,	,	O	O
glucosuria	NN	B-NP	B
.	.	O	O

Effective	JJ	B-NP	O
compounds	NNS	I-NP	O
included	VBD	B-VP	O
norleucine	NN	B-NP	O
,	,	O	O
norvaline	NN	B-NP	O
,	,	O	O
glutamate	NN	B-NP	O
,	,	O	O
epsilon	NN	B-NP	O
-	HYPH	O	O
aminocaproate	NN	B-NP	O
,	,	O	O
methionine	NN	B-NP	O
,	,	O	O
and	CC	O	O
leucine	NN	B-NP	O
.	.	O	O

Fatty	JJ	B-NP	B
liver	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
tetracycline	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
response	NN	I-NP	O
relationships	NNS	I-NP	O
and	CC	O	O
effect	NN	B-NP	O
of	IN	B-PP	O
sex	NN	B-NP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
response	NN	I-NP	O
relationships	NNS	I-NP	O
,	,	O	O
biochemical	JJ	B-NP	O
mechanisms	NNS	I-NP	O
,	,	O	O
and	CC	O	O
sex	NN	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
experimental	JJ	I-NP	O
fatty	JJ	I-NP	B
liver	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
tetracycline	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
rat	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
perfused	VBN	I-NP	O
rat	NN	I-NP	O
liver	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
male	JJ	I-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
rat	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
direct	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
dose	NN	B-NP	O
of	IN	B-PP	O
tetracycline	NN	B-NP	O
and	CC	O	O
hepatic	JJ	B-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
provision	NN	B-NP	O
of	IN	B-PP	O
adequate	JJ	B-NP	O
oleic	JJ	I-NP	O
acid	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
substrate	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
isolated	VBN	I-NP	O
perfused	VBN	I-NP	O
liver	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
direct	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
dose	NN	B-NP	O
of	IN	B-PP	O
tetracycline	NN	B-NP	O
and	CC	O	O
both	CC	O	O
accumulation	NN	B-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	I-NP	O
depression	NN	I-NP	B
of	IN	B-PP	O
output	NN	B-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
by	IN	B-PP	O
livers	NNS	B-NP	O
from	IN	B-PP	O
male	JJ	B-NP	O
and	CC	I-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Marked	JJ	B-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
female	JJ	B-NP	O
and	CC	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
base	NN	B-NP	O
line	NN	I-NP	O
(	(	O	O
control	NN	B-NP	O
)	)	O	O
hepatic	JJ	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
and	CC	I-NP	O
output	NN	I-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
.	.	O	O

Accumulation	NN	B-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
triglyceride	NN	I-NP	O
,	,	O	O
as	IN	B-PP	O
a	DT	O	O
per	IN	B-PP	O
cent	NN	B-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
graded	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
tetracycline	NN	B-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
between	IN	B-PP	O
male	JJ	B-NP	O
,	,	I-NP	O
female	JJ	I-NP	O
and	CC	I-NP	O
pregnant	JJ	I-NP	O
rat	NN	I-NP	O
livers	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
livers	NNS	B-NP	O
from	IN	B-PP	O
female	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
especially	RB	B-NP	O
pregnant	JJ	I-NP	O
female	JJ	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
strikingly	RB	B-ADJP	O
resistant	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
tetracycline	NN	B-NP	O
on	IN	B-PP	O
depression	NN	B-NP	B
of	IN	B-PP	O
output	NN	B-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
under	IN	B-PP	O
these	DT	B-NP	O
experimental	JJ	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
sexes	NNS	I-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
altered	JJ	B-NP	O
disposition	NN	I-NP	O
of	IN	B-PP	O
tetracycline	NN	B-NP	O
or	CC	O	O
altered	JJ	B-NP	O
uptake	NN	I-NP	O
of	IN	B-PP	O
oleic	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

Depressed	VBN	B-NP	O
hepatic	JJ	I-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
accounted	VBD	B-VP	O
only	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
accumulated	VBN	B-NP	O
hepatic	JJ	I-NP	O
triglyceride	NN	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
additional	JJ	B-NP	O
mechanisms	NNS	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
production	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
triglyceride	NN	I-NP	O
-	HYPH	B-NP	O
rich	JJ	I-NP	O
fatty	JJ	I-NP	B
liver	NN	I-NP	I
in	IN	B-PP	O
response	NN	I-PP	O
to	TO	I-PP	O
tetracycline	NN	B-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
myeloencephalopathy	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
intrathecal	JJ	B-NP	O
vincristine	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

Vincristine	NN	B-NP	O
was	VBD	B-VP	O
accidentally	RB	I-VP	O
given	VBN	I-VP	O
intrathecally	RB	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
with	IN	B-PP	O
leukaemia	NN	B-NP	B
,	,	O	O
producing	VBG	B-VP	O
sensory	NN	B-NP	B
and	CC	I-NP	I
motor	NN	I-NP	I
dysfunction	NN	I-NP	I
followed	VBN	B-VP	O
by	IN	B-PP	O
encephalopathy	NN	B-NP	B
and	CC	I-NP	O
death	NN	I-NP	O
.	.	O	O

Separate	JJ	B-NP	O
times	NNS	I-NP	O
for	IN	B-PP	O
administering	VBG	B-VP	O
vincristine	NN	B-NP	O
and	CC	O	O
intrathecal	JJ	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

Progesterone	NN	B-NP	O
potentiation	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
arrhythmogenicity	NN	I-NP	O
in	IN	B-PP	O
pentobarbital	NN	B-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
rats	NNS	I-NP	O
and	CC	O	O
beating	VBG	B-VP	O
rat	NN	B-NP	O
heart	NN	I-NP	O
cell	NN	I-NP	O
cultures	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
progesterone	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
arrhythmogenicity	NN	I-NP	O
in	IN	B-PP	O
beating	VBG	B-VP	O
rat	NN	B-NP	O
heart	NN	I-NP	O
myocyte	NN	I-NP	O
cultures	NNS	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
anesthetized	VBN	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
determining	VBG	B-VP	O
the	DT	B-NP	O
bupivacaine	NN	I-NP	O
AD50	NN	I-NP	O
(	(	O	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
that	WDT	B-NP	O
caused	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
beating	VBG	I-NP	O
rat	NN	I-NP	O
heart	NN	I-NP	O
myocyte	NN	I-NP	O
cultures	NNS	I-NP	O
to	TO	B-VP	O
become	VB	I-VP	O
arrhythmic	JJ	B-ADJP	B
)	)	O	O
,	,	O	O
we	PRP	B-NP	O
determined	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
progesterone	NN	I-NP	O
HCl	NN	I-NP	O
exposure	NN	I-NP	O
on	IN	B-PP	O
myocyte	NN	B-NP	O
contractile	JJ	I-NP	O
rhythm	NN	I-NP	O
.	.	O	O

Each	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
progesterone	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	I-NP	O
ml	NN	I-NP	O
)	)	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
and	CC	I-NP	O
concentration	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
AD50	NN	I-NP	O
for	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

Estradiol	NN	B-NP	O
treatment	NN	I-NP	O
also	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
arrhythmogenicity	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
in	IN	B-PP	O
myocyte	NN	B-NP	O
cultures	NNS	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
fourth	JJ	I-NP	O
as	IN	B-PP	O
potent	JJ	B-ADJP	O
as	IN	B-PP	O
progesterone	NN	B-NP	O
.	.	O	O

Neither	CC	O	O
progesterone	NN	B-NP	O
nor	CC	O	O
estradiol	NN	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
bupivacaine	NN	B-NP	O
arrhythmogenicity	NN	I-NP	O
were	VBD	B-VP	O
potentiated	VBN	I-VP	O
by	IN	B-PP	O
epinephrine	NN	B-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
progesterone	NN	I-NP	O
pretreatment	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
bupivacaine	NN	B-NP	O
arrhythmogenicity	NN	I-NP	O
in	IN	B-PP	O
intact	JJ	B-NP	O
pentobarbital	NN	I-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
arrhythmia	NN	B-NP	B
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
nonprogesterone	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
progesterone	NN	B-NP	O
can	MD	B-VP	O
potentiate	VB	I-VP	O
bupivacaine	NN	B-NP	O
arrhythmogenicity	NN	I-NP	O
both	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
.	.	O	O

Potentiation	NN	B-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
arrhythmia	NN	I-NP	B
in	IN	B-PP	O
myocyte	NN	B-NP	O
cultures	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
partly	RB	B-VP	O
mediated	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
myocyte	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
occurring	VBG	B-VP	O
during	IN	B-PP	O
intravenous	JJ	B-NP	O
desferrioxamine	NN	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
recovery	NN	B-NP	O
after	IN	B-PP	O
haemodialysis	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
transfusion	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
thalassemia	NN	I-NP	B
was	VBD	B-VP	O
undergoing	VBG	I-VP	O
home	NN	B-NP	O
intravenous	JJ	I-NP	O
desferrioxamine	NN	I-NP	O
(	(	O	O
DFX	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
totally	RB	I-NP	O
implanted	VBN	I-NP	O
system	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
his	PRP$	B-NP	O
poor	JJ	I-NP	O
compliance	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
nightly	RB	I-NP	O
subcutaneous	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Due	JJ	B-PP	O
to	TO	B-PP	O
an	DT	B-NP	O
accidental	JJ	I-NP	O
malfunctioning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
pump	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
inadvertently	RB	I-VP	O
administered	VBN	I-VP	O
a	DT	B-NP	O
toxic	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
which	WDT	B-NP	O
caused	VBD	B-VP	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
progressive	JJ	I-NP	O
deterioration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
laboratory	NN	I-NP	O
values	NNS	I-NP	O
,	,	O	O
despite	IN	B-PP	O
adequate	JJ	B-NP	O
medical	JJ	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
decision	NN	I-NP	O
was	VBD	B-VP	O
made	VBN	I-VP	O
to	TO	B-VP	O
introduce	VB	I-VP	O
haemodialytical	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
remove	VB	I-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	I-NP	O
therapy	NN	I-NP	O
reduce	VBP	B-VP	O
the	DT	B-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

From	IN	B-PP	O
the	DT	B-NP	O
results	NNS	I-NP	O
obtained	VBN	B-VP	O
,	,	O	O
haemodialysis	NN	B-NP	O
can	MD	B-VP	O
therefore	RB	I-VP	O
be	VB	I-VP	O
suggested	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
rare	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
desferrioxamine	NN	B-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
associated	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
.	.	O	O

Can	MD	O	O
it	PRP	B-NP	O
be	VB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
bromocriptine	NN	B-NP	O
?	.	O	O
num	CD	B-NP	O
stable	JJ	I-NP	O
psychiatric	JJ	I-NP	O
outpatients	NNS	I-NP	O
with	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
and	CC	I-NP	O
amenorrhea	NN	I-NP	B
/	SYM	B-NP	O
oligomenorrhea	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
their	PRP$	B-NP	O
neuroleptic	JJ	I-NP	O
medications	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
bromocriptine	NN	B-NP	O
.	.	O	O

Daily	JJ	B-NP	O
dosages	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
corrected	VBD	B-VP	O
the	DT	B-NP	O
hyperprolactinemia	NN	I-NP	B
and	CC	O	O
restored	VBD	B-VP	O
menstruation	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
woman	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
developed	VBN	B-VP	O
worsened	VBD	B-VP	O
psychiatric	JJ	B-NP	B
symptoms	NNS	I-NP	I
while	IN	B-SBAR	O
taking	VBG	B-VP	O
bromocriptine	NN	B-NP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
their	PRP$	B-NP	O
menstrual	JJ	I-NP	O
irregularity	NN	I-NP	O
successfully	RB	B-VP	O
corrected	VBN	I-VP	O
with	IN	B-PP	O
bromocriptine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
bromocriptine	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
further	RBR	B-ADJP	O
evaluated	VBN	I-ADJP	O
as	IN	B-PP	O
potential	JJ	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
associated	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
and	CC	I-NP	O
amenorrhea	NN	I-NP	B
/	SYM	B-NP	O
galactorrhea	NN	I-NP	B
.	.	O	O

Ethacrynic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
and	CC	I-NP	O
brain	NN	I-NP	O
neurotransmitters	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Intracerebroventricular	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
ethacrynic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
convulsive	JJ	I-NP	B
dose	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
mouse	NN	I-NP	O
)	)	O	O
accelerated	VBD	B-VP	O
the	DT	B-NP	O
synthesis	NN	I-NP	O
/	SYM	B-NP	O
turnover	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptamine	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
but	CC	O	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
synthesis	NN	I-NP	O
of	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
aminobutyric	JJ	I-NP	O
acid	NN	I-NP	O
and	CC	I-NP	O
acetylcholine	NN	I-NP	O
in	IN	B-PP	O
mouse	NN	B-NP	O
brain	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
completely	RB	I-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
glutamate	NN	I-NP	O
/	SYM	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartate	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
aminophosphonovaleric	JJ	B-NP	O
acid	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
ethacrynic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
,	,	O	O
these	DT	B-NP	O
neurotransmitter	NN	I-NP	O
systems	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
differentially	RB	I-VP	O
modulated	VBN	I-VP	O
,	,	O	O
probably	RB	B-ADVP	O
through	IN	B-PP	O
activation	NN	B-NP	O
of	IN	B-PP	O
glutaminergic	JJ	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Pharmacology	NN	B-NP	O
of	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
aminobutyric	JJ	I-NP	O
acidA	NN	I-NP	O
receptor	NN	I-NP	O
complex	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
anxioselective	JJ	I-NP	O
and	CC	I-NP	O
anticonvulsant	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
carboline	NN	I-NP	O
derivative	NN	I-NP	O
abecarnil	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
rodents	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
carboline	NN	I-NP	O
derivative	JJ	I-NP	O
isopropyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
benzyloxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
methoxymethyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
carboline	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxylate	NN	I-NP	O
(	(	O	O
abecarrnil	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
ligand	NN	I-NP	O
for	IN	B-PP	O
benzodiazepine	NN	B-NP	O
receptors	NNS	I-NP	O
possessing	VBG	B-VP	O
anxiolytic	JJ	B-NP	O
and	CC	I-NP	O
anticonvulsant	JJ	I-NP	O
properties	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
)	)	O	O
A	NN	B-NP	O
receptor	NN	I-NP	O
complex	NN	I-NP	O
,	,	O	O
both	CC	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Added	VBN	B-VP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
to	TO	B-PP	O
rat	NN	B-NP	O
cortical	JJ	I-NP	O
membrane	NN	I-NP	O
preparation	NN	I-NP	O
,	,	O	O
abecarnil	NN	B-NP	O
increased	VBD	B-VP	O
[	(	O	O
3H	NN	B-NP	O
]	)	I-NP	O
GABA	NN	I-NP	O
binding	NN	I-NP	O
,	,	O	O
enhanced	VBD	B-VP	O
muscimol	NN	B-NP	O
-	HYPH	O	O
stimulated	VBN	B-NP	O
36Cl	NN	I-NP	O
-	HYPH	I-NP	O
uptake	NN	I-NP	O
and	CC	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
t	NN	B-NP	O
-	HYPH	B-NP	O
[	(	I-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
butylbicyclophosphorothionate	JJ	I-NP	O
(	(	O	O
[	(	O	O
35S	NN	B-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
diazepam	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
partial	JJ	I-NP	O
agonist	NN	I-NP	O
Ro	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
(	(	O	O
tert	NN	B-NP	O
-	HYPH	B-NP	O
butyl	NN	I-NP	O
-	HYPH	O	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
bromo	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydro	AFX	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
oxo	NN	I-NP	O
-	HYPH	B-NP	O
9H	NN	I-NP	O
-	HYPH	I-NP	O
imidazo	NN	I-NP	O
[	(	O	O
num	CD	B-NP	O
-	HYPH	O	O
a	DT	B-NP	O
]	)	I-NP	O
-	HYPH	I-NP	O
pyrrolo	AFX	I-NP	O
-	HYPH	I-NP	O
[	(	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
c	NN	I-NP	O
]	)	O	O
[	(	O	O
num	CD	O	O
]	)	O	O
benzodiazepine	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxylate	NN	I-NP	O
)	)	O	O
showed	VBD	B-VP	O
very	RB	B-NP	O
weak	JJ	I-NP	O
efficacy	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
biochemical	JJ	I-NP	O
tests	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
i.p.	JJ	B-NP	O
injection	NN	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
abecarnil	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
decreased	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
manner	NN	I-NP	O
[	(	I-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
measured	VBN	B-VP	O
ex	FW	B-ADVP	O
vivo	FW	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebral	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
antagonized	VBD	B-VP	O
completely	RB	B-ADVP	O
the	DT	B-NP	O
convulsant	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
[	(	B-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
isoniazide	NN	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
[	(	B-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
foot	NN	B-NP	O
-	HYPH	I-NP	O
shock	NN	I-NP	O
stress	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
better	RBR	I-VP	O
correlate	VB	I-VP	O
the	DT	B-NP	O
biochemical	JJ	I-NP	O
and	CC	O	O
the	DT	B-NP	O
pharmacological	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
abecarnil	NN	B-NP	O
on	IN	B-PP	O
[	(	B-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
,	,	O	O
exploratory	JJ	B-NP	O
motility	NN	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
isoniazid	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
biochemical	JJ	I-NP	O
and	CC	I-NP	O
pharmacological	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
abecarnil	NN	B-NP	O
produced	VBD	B-VP	O
a	DT	B-NP	O
paralleled	VBN	I-NP	O
dose	NN	I-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
both	CC	O	O
motor	NN	B-NP	O
behavior	NN	I-NP	O
and	CC	O	O
cortical	JJ	B-NP	O
[	(	I-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
carboline	NN	I-NP	O
reduced	VBD	B-VP	O
markedly	RB	B-ADVP	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
[	(	B-NP	O
35S	NN	I-NP	O
]	)	I-NP	O
TBPS	NN	I-NP	O
binding	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
convulsions	NNS	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
isoniazid	NN	B-NP	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Recurrent	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
postpartum	NN	I-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
bromocriptine	NN	B-NP	O
.	.	O	O

Myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
puerperium	NN	B-NP	O
is	VBZ	B-VP	O
infrequently	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Spasm	NN	B-NP	B
,	,	O	O
coronary	JJ	B-NP	O
dissection	NN	I-NP	O
,	,	O	O
or	CC	O	O
atheromatous	JJ	B-NP	O
etiology	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
.	.	O	O

Bromocriptine	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
several	JJ	B-NP	O
previous	JJ	I-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
puerperium	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
case	NN	I-NP	O
(	(	O	O
including	VBG	B-PP	O
an	DT	B-NP	O
inadvertent	JJ	I-NP	O
rechallenge	NN	I-NP	O
)	)	O	O
suggests	VBZ	B-VP	O
such	PDT	B-NP	O
a	DT	I-NP	O
relationship	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
generally	RB	B-ADVP	O
regarded	VBN	B-VP	O
as	IN	B-PP	O
safe	JJ	B-NP	O
,	,	I-NP	O
possible	JJ	I-NP	O
serious	JJ	I-NP	O
cardiac	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
bromocriptine	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
acknowledged	VBN	I-VP	O
.	.	O	O

Asterixis	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
carbamazepine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
very	RB	B-NP	O
few	JJ	I-NP	O
reports	NNS	I-NP	O
about	IN	B-PP	O
asterixis	NN	B-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
psychopharmacologic	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
we	PRP	B-NP	O
present	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
psychotropic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
whom	WP	B-NP	O
asterixis	NN	B-NP	B
was	VBD	B-VP	O
triggered	VBN	I-VP	O
either	CC	O	O
by	IN	B-PP	O
adding	VBG	B-VP	O
carbamazepine	NN	B-NP	O
(	(	O	O
CBZ	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
a	DT	B-NP	O
treatment	NN	I-NP	O
regimen	NN	I-NP	O
,	,	O	O
or	CC	O	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
its	PRP$	B-NP	O
dosage	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
dosage	NN	B-NP	O
nor	CC	I-NP	O
serum	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
CBZ	NN	B-NP	O
were	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
range	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
consider	VBP	B-VP	O
asterixis	NN	B-NP	B
to	TO	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
easily	RB	I-NP	O
overlooked	VBN	I-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
occur	VB	I-VP	O
even	RB	B-ADVP	O
at	IN	B-PP	O
low	JJ	B-NP	O
or	CC	I-NP	O
moderate	JJ	I-NP	O
dosage	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
if	IN	B-SBAR	O
certain	JJ	B-NP	O
drugs	NNS	I-NP	O
as	IN	B-PP	O
lithium	NN	B-NP	O
or	CC	I-NP	O
clozapine	NN	I-NP	O
are	VBP	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
CBZ	NN	B-NP	O
.	.	O	O

Pharmacodynamics	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.v.	JJ	B-NP	O
levodopa	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
parkinsonian	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	O
and	CC	I-NP	O
fluctuating	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
levodopa	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
was	VBD	B-VP	O
concentration	NN	B-NP	O
dependent	JJ	B-ADJP	O
and	CC	O	O
was	VBD	B-VP	O
fit	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
Emax	NN	I-NP	O
model	NN	I-NP	O
in	IN	B-PP	O
fluctuating	VBG	B-VP	O
responders	NNS	B-NP	O
.	.	O	O

Stable	JJ	B-NP	O
responders	NNS	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
small	JJ	I-NP	O
hypotensive	JJ	I-NP	B
response	NN	I-NP	O
.	.	O	O

Baseline	NN	B-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
fluctuating	VBG	B-VP	O
patients	NNS	B-NP	O
;	:	O	O
a	DT	B-NP	O
higher	JJR	I-NP	O
baseline	NN	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
greater	JJR	B-NP	O
hypotensive	JJ	I-NP	B
effects	NNS	I-NP	O
.	.	O	O

Antiparkinsonian	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
temporally	RB	B-ADVP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

Phenylalanine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
large	JJ	I-NP	O
neutral	JJ	I-NP	O
amino	NN	I-NP	O
acid	NN	I-NP	O
(	(	O	O
LNAA	NN	B-NP	O
)	)	O	O
competing	VBG	B-VP	O
with	IN	B-PP	O
levodopa	NN	B-NP	O
for	IN	B-PP	O
transport	NN	B-NP	O
across	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
,	,	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
hypotensive	JJ	I-NP	B
and	CC	I-NP	O
antiparkinsonian	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
levodopa	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
central	JJ	I-NP	O
hypotensive	JJ	I-NP	B
action	NN	I-NP	O
that	WDT	B-NP	O
parallels	VBZ	B-VP	O
the	DT	B-NP	O
motor	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
fluctuating	VBG	B-VP	O
patients	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
hypotensive	JJ	I-NP	B
effect	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
baseline	NN	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
in	IN	B-PP	O
fluctuating	VBG	B-VP	O
patients	NNS	B-NP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
stable	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Syndrome	NN	B-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
secretion	NN	I-NP	I
of	IN	B-PP	I
antidiuretic	JJ	B-NP	I
hormone	NN	I-NP	I
after	IN	B-PP	O
infusional	JJ	B-NP	O
vincristine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
refractory	JJ	B-NP	O
multiple	JJ	I-NP	B
myeloma	NN	I-NP	I
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
continuous	JJ	I-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
dexamethasone	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
her	PRP$	B-NP	O
second	JJ	I-NP	O
cycle	NN	I-NP	O
she	PRP	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
lethargy	NN	B-NP	B
and	CC	I-NP	O
weakness	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
hyponatremia	NN	B-NP	B
.	.	O	O

Evaluation	NN	B-NP	O
revealed	VBD	B-VP	O
the	DT	B-NP	O
syndrome	NN	I-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
secretion	NN	I-NP	I
of	IN	B-PP	I
antidiuretic	JJ	B-NP	I
hormone	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
vincristine	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
normal	JJ	B-NP	O
serum	NN	I-NP	O
sodium	NN	I-NP	O
levels	NNS	I-NP	O
returned	VBD	B-VP	O
,	,	O	O
further	JJ	B-NP	O
doxorubicin	NN	I-NP	O
and	CC	I-NP	O
dexamethasone	NN	I-NP	O
chemotherapy	NN	I-NP	O
without	IN	B-PP	O
vincristine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

Heart	NN	B-NP	B
failure	NN	I-NP	I
:	:	O	O
to	TO	B-VP	O
digitalise	VB	I-VP	O
or	CC	O	O
not	RB	O	O
?	.	O	O
The	DT	B-NP	O
view	NN	I-NP	O
against	IN	B-PP	O
.	.	O	O

Despite	IN	B-PP	O
extensive	JJ	B-NP	O
clinical	JJ	I-NP	O
experience	NN	I-NP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
digoxin	NN	B-NP	O
is	VBZ	B-VP	O
still	RB	B-ADVP	O
not	RB	O	O
well	RB	B-ADJP	O
defined	VBN	I-ADJP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
digoxin	NN	I-NP	O
is	VBZ	B-VP	O
beneficial	JJ	B-ADJP	O
for	IN	B-PP	O
ventricular	JJ	B-NP	O
rate	NN	I-NP	O
control	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
sinus	NN	B-NP	O
rhythm	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	B
failure	VBP	B-VP	I
the	DT	B-NP	O
situation	NN	I-NP	O
is	VBZ	B-VP	O
less	RBR	B-ADJP	O
clear	JJ	I-ADJP	O
.	.	O	O

Digoxin	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
narrow	JJ	I-NP	O
therapeutic	JJ	I-NP	O
:	:	O	O
toxic	JJ	B-NP	O
ratio	NN	I-NP	O
and	CC	I-NP	O
concentrations	NNS	I-NP	O
are	VBP	B-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
digoxin	NN	B-NP	O
has	VBZ	B-VP	O
undesirable	JJ	B-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
increasing	VBG	B-VP	O
peripheral	JJ	B-NP	O
resistance	NN	I-NP	O
and	CC	I-NP	O
myocardial	JJ	I-NP	O
demands	NNS	I-NP	O
,	,	O	O
and	CC	O	O
causing	VBG	B-VP	O
arrhythmias	NNS	B-NP	B
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
paucity	NN	I-NP	O
of	IN	B-PP	O
data	NN	B-NP	O
from	IN	B-PP	O
well	RB	B-NP	O
-	HYPH	I-NP	O
designed	VBN	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
trials	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
available	JJ	B-ADJP	O
are	VBP	B-VP	O
generally	RB	B-ADJP	O
small	JJ	I-ADJP	O
with	IN	B-PP	O
limitations	NNS	B-NP	O
in	IN	B-PP	O
design	NN	B-NP	O
and	CC	O	O
these	DT	B-NP	O
show	NN	I-NP	O
variation	NN	I-NP	O
in	IN	B-PP	O
patient	NN	B-NP	O
benefit	NN	I-NP	O
.	.	O	O

More	RBR	B-NP	O
convincing	JJ	I-NP	O
evidence	NN	I-NP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
showing	VBG	I-VP	O
that	IN	B-SBAR	O
digoxin	NN	B-NP	O
improves	VBZ	B-VP	O
symptoms	NNS	B-NP	O
or	CC	O	O
exercise	NN	B-NP	O
capacity	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
trial	NN	I-NP	O
has	VBZ	B-VP	O
had	VBN	I-VP	O
sufficient	JJ	B-NP	O
power	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
mortality	NN	B-NP	O
.	.	O	O

Pooled	VBN	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
inotropic	JJ	I-NP	O
drugs	NNS	I-NP	O
shows	VBZ	B-VP	O
an	DT	B-NP	O
excess	JJ	I-NP	O
mortality	NN	I-NP	O
and	CC	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
digoxin	NN	B-NP	O
may	MD	B-VP	O
increase	VB	I-VP	O
mortality	NN	B-NP	O
after	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
.	.	O	O

Angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
first	RB	B-ADVP	O
as	IN	B-SBAR	O
they	PRP	B-NP	O
are	VBP	B-VP	O
safer	JJR	B-ADJP	O
,	,	O	O
do	VBP	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
blood	NN	B-NP	O
level	NN	I-NP	O
monitoring	NN	I-NP	O
,	,	O	O
modify	VBP	B-VP	O
progression	NN	B-NP	O
of	IN	B-PP	O
disease	NN	B-NP	O
,	,	O	O
relieve	VB	B-VP	O
symptoms	NNS	B-NP	O
,	,	O	O
improve	VB	B-VP	O
exercise	NN	B-NP	O
tolerance	NN	I-NP	O
and	CC	O	O
reduce	VB	B-VP	O
mortality	NN	B-NP	O
.	.	O	O

Caution	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
exercised	VBN	I-VP	O
in	IN	B-PP	O
using	VBG	B-VP	O
digoxin	NN	B-NP	O
until	IN	B-SBAR	O
large	JJ	B-NP	O
mortality	NN	I-NP	O
trials	NNS	I-NP	O
are	VBP	B-VP	O
completed	VBN	I-VP	O
showing	VBG	I-VP	O
either	CC	O	O
benefit	NN	B-NP	O
or	CC	I-NP	O
harm	NN	I-NP	O
.	.	O	O

Until	IN	B-PP	O
then	RB	B-NP	O
digoxin	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
a	DT	B-NP	O
third	JJ	I-NP	O
-	HYPH	I-NP	O
line	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Intravascular	JJ	B-NP	O
hemolysis	NN	I-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
intermittent	JJ	B-NP	O
rifampin	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
failure	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
rifampin	NN	B-NP	O
.	.	O	O

Intravascular	JJ	B-NP	O
hemolysis	NN	I-NP	B
leading	VBG	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
rifampin	NN	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
extremely	RB	B-ADJP	O
rare	JJ	I-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
leprosy	NN	B-NP	B
who	WP	B-NP	O
developed	VBD	B-VP	O
hemolysis	NN	B-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
rifampin	NN	B-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Zidovudine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
zidovudine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
AIDS	NN	B-NP	B
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
whereby	WRB	B-ADVP	O
the	DT	B-NP	O
hepatitis	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
is	VBZ	B-VP	O
not	RB	O	O
known	VBN	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
tolerated	VBD	B-VP	O
well	RB	B-ADVP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
reverse	JJ	I-NP	O
transcriptase	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
dideoxyinosine	NN	I-NP	O
.	.	O	O

Physicians	NNS	B-NP	O
caring	VBG	B-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
AIDS	NN	B-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
hitherto	NN	I-NP	O
rarely	RB	B-ADVP	O
reported	VBD	B-VP	O
complication	NN	B-NP	O
.	.	O	O

Thoracic	JJ	B-NP	B
hematomyelia	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
coumadin	NN	B-NP	O
anticoagulant	JJ	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
thoracic	JJ	B-NP	B
hematomyelia	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
anticoagulant	JJ	B-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

Clinical	JJ	B-NP	O
features	NNS	I-NP	O
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
other	JJ	I-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
high	JJ	I-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
suspicion	NN	B-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
quick	JJ	I-NP	O
diagnostic	JJ	I-NP	O
procedure	NN	I-NP	O
and	CC	O	O
successful	JJ	B-NP	O
decompressive	JJ	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

Mania	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
adolescents	NNS	B-NP	O
.	.	O	O

Fluoxetine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
gaining	VBG	I-VP	O
increased	VBN	B-NP	O
acceptance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
adolescent	JJ	B-NP	O
depression	NN	I-NP	B
.	.	O	O

Generally	RB	B-ADJP	O
safe	JJ	I-ADJP	O
and	CC	O	O
well	RB	B-VP	O
tolerated	VBN	I-VP	O
by	IN	B-PP	O
adults	NNS	B-NP	O
,	,	O	O
fluoxetine	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
induce	VB	I-VP	O
mania	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
depressed	JJ	I-NP	B
adolescents	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
mania	NN	B-NP	B
during	IN	B-PP	O
pharmacotherapy	NN	B-NP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
,	,	O	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
here	RB	B-ADVP	O
.	.	O	O

Apparent	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
mania	NN	B-NP	B
or	CC	I-NP	O
hypomania	NN	I-NP	B
during	IN	B-PP	O
fluoxetine	NN	B-NP	O
pharmacotherapy	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
attention	NN	B-NP	B
-	HYPH	I-NP	I
deficit	NN	I-NP	I
hyperactivity	NN	I-NP	I
disorder	NN	I-NP	I
and	CC	O	O
affective	JJ	B-NP	O
instability	NN	I-NP	O
;	:	O	O
major	JJ	B-NP	O
depression	NN	I-NP	B
with	IN	B-PP	O
psychotic	JJ	B-NP	B
features	NNS	I-NP	O
;	:	O	O
a	DT	B-NP	O
family	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
affective	JJ	B-NP	B
disorder	NN	I-NP	I
,	,	O	O
especially	RB	B-NP	O
bipolar	JJ	I-NP	B
disorder	NN	I-NP	I
;	:	O	O
and	CC	O	O
a	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

Further	JJ	B-NP	O
study	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
optimal	JJ	I-NP	O
dosage	NN	I-NP	O
and	CC	O	O
to	TO	B-VP	O
identify	VB	I-VP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
that	WDT	B-NP	O
increase	VBP	B-VP	O
individual	JJ	B-NP	O
vulnerability	NN	I-NP	O
to	TO	B-PP	O
fluoxetine	NN	B-NP	O
induced	VBD	B-VP	O
mania	NN	B-NP	B
in	IN	B-PP	O
adolescents	NNS	B-NP	O
.	.	O	O

Gemfibrozil	NN	B-NP	O
-	HYPH	I-NP	O
lovastatin	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
primary	JJ	B-NP	O
hyperlipoproteinemias	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
specific	JJ	I-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
retrospective	JJ	I-NP	O
,	,	I-NP	O
observational	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
safety	NN	B-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
/	SYM	B-NP	O
patient	NN	I-NP	O
)	)	O	O
,	,	O	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
,	,	O	O
gemfibrozil	NN	B-NP	O
-	HYPH	B-NP	O
lovastatin	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
primary	JJ	B-NP	O
mixed	JJ	I-NP	O
hyperlipidemia	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
atherosclerotic	JJ	B-NP	B
vascular	JJ	I-NP	I
disease	NN	I-NP	I
)	)	O	O
.	.	O	O

Because	IN	B-SBAR	O
ideal	JJ	B-NP	O
lipid	NN	I-NP	O
targets	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
reached	VBN	I-VP	O
(	(	O	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
(	(	O	O
LDL	NN	B-NP	O
)	)	O	O
cholesterol	NN	B-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
dl	NN	I-NP	O
,	,	O	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
density	NN	I-NP	O
lipoprotein	NN	I-NP	O
with	IN	B-PP	O
diet	NN	B-NP	O
plus	CC	O	O
a	DT	B-NP	O
single	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
gemfibrozil	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
lovastatin	NN	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
.	.	O	O

Follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
visits	NNS	B-NP	O
were	VBD	B-VP	O
scheduled	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
visits	NNS	I-NP	O
per	IN	B-PP	O
patient	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
batteries	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
creatine	NN	I-NP	O
phosphokinase	NN	I-NP	O
levels	NNS	I-NP	O
measured	VBN	B-VP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
gamma	NN	I-NP	O
glutamyl	NN	I-NP	O
transferase	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
normal	JJ	I-NP	O
limit	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
creatine	NN	I-NP	O
phosphokinase	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
high	JJ	B-ADJP	O
;	:	O	O
only	RB	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
normal	JJ	I-NP	O
limit	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
total	JJ	I-NP	O
cholesterol	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
dl	NN	I-NP	O
,	,	O	O
triglyceride	NN	B-NP	O
levels	NNS	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
dl	NN	I-NP	O
,	,	O	O
LDL	NN	B-NP	O
cholesterol	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
dl	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
cholesterol	NN	I-NP	O
/	SYM	B-VP	O
HDL	NN	B-NP	O
cholesterol	NN	I-NP	O
ratio	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
,	,	O	O
all	DT	B-NP	O
p	NN	I-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Myositis	NN	B-NP	B
,	,	O	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
combination	NN	I-NP	O
and	CC	O	O
symptomatic	JJ	B-ADJP	O
enough	RB	I-ADJP	O
to	TO	B-VP	O
discontinue	VB	I-VP	O
it	PRP	B-NP	O
,	,	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
concurrent	JJ	B-NP	O
high	JJ	I-NP	O
creatine	NN	I-NP	O
phosphokinase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
liter	NN	I-NP	O
)	)	O	O
;	:	O	O
no	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
rhabdomyolysis	NN	B-NP	B
or	CC	I-NP	O
myoglobinuria	NN	I-NP	B
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Hepatocellular	JJ	B-NP	B
carcinoma	NN	I-NP	I
in	IN	B-PP	O
Fanconi	NNP	B-NP	B
s	NN	I-NP	I
anemia	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
androgen	NN	B-NP	O
and	CC	I-NP	O
corticosteroid	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
who	WP	B-NP	O
was	VBD	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
Fanconi	NNP	B-NP	B
s	NNS	I-NP	I
anemia	NN	I-NP	I
for	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
androgens	NNS	B-NP	O
,	,	I-NP	O
corticosteroids	NNS	I-NP	O
and	CC	I-NP	O
transfusions	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
before	IN	B-PP	O
his	PRP$	B-NP	O
death	NN	I-NP	O
he	PRP	B-NP	O
was	VBD	B-VP	O
readmitted	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
aplastic	JJ	B-NP	O
crisis	NN	I-NP	O
with	IN	B-PP	O
septicemia	NN	B-NP	B
and	CC	O	O
marked	JJ	B-NP	O
abnormalities	NNS	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
function	NN	I-NP	O
and	CC	O	O
died	VBD	B-VP	O
of	IN	B-PP	O
hemorrhagic	JJ	B-NP	B
bronchopneumonia	NN	I-NP	I
.	.	O	O

At	IN	B-PP	O
autopsy	NN	B-NP	O
peliosis	NN	I-NP	B
and	CC	O	O
multiple	JJ	B-NP	O
hepatic	JJ	I-NP	B
tumors	NNS	I-NP	I
were	VBD	B-VP	O
found	VBN	I-VP	O
which	WDT	B-NP	O
histologically	RB	B-ADVP	O
proved	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
well	RB	B-ADJP	O
-	HYPH	I-ADJP	O
differentiated	VBN	B-NP	O
hepatocellular	JJ	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
previous	JJ	I-NP	O
observations	NNS	I-NP	O
that	IN	B-NP	O
non	AFX	O	O
-	HYPH	O	O
metastasizing	VBG	B-VP	O
hepatic	JJ	B-NP	B
neoplasms	NNS	I-NP	I
and	CC	I-NP	O
peliosis	NN	I-NP	B
can	MD	B-VP	O
develop	VB	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
androgen	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
corticosteroid	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
Fanconi	NNP	I-NP	B
s	JJ	I-NP	I
anemia	NN	I-NP	I
.	.	O	O

Chronic	JJ	B-NP	O
lesion	NN	I-NP	O
of	IN	B-PP	O
rostral	JJ	B-NP	O
ventrolateral	JJ	I-NP	O
medulla	NN	I-NP	O
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
selective	JJ	I-NP	O
neuronal	JJ	I-NP	O
lesion	NN	I-NP	O
of	IN	B-PP	O
rostral	JJ	B-NP	O
ventrolateral	JJ	I-NP	O
medulla	NN	I-NP	O
on	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
and	CC	O	O
neurogenic	JJ	B-NP	O
tone	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
,	,	I-NP	O
unrestrained	JJ	I-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
lesions	NNS	I-NP	O
were	VBD	B-VP	O
placed	VBN	I-VP	O
via	IN	B-PP	O
bilateral	JJ	B-NP	O
microinjections	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
nmol	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
nl	NN	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	B-NP	O
aspartic	JJ	I-NP	O
acid	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
restimulation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
area	NN	I-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartic	JJ	B-NP	O
acid	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
postlesion	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
produce	VB	I-VP	O
a	DT	B-NP	O
pressor	NN	I-NP	O
response	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
day	NN	I-NP	O
postlesion	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
resting	VBG	I-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
decreased	VBN	I-VP	O
in	IN	B-PP	O
lesioned	VBN	B-NP	O
rats	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
sham	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
lesioned	VBN	I-NP	O
group	NN	I-NP	O
still	RB	B-ADVP	O
showed	VBD	B-VP	O
values	NNS	B-NP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
sham	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
sham	NN	I-NP	O
and	CC	O	O
lesioned	VBD	B-VP	O
groups	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
ganglionic	JJ	I-NP	O
blocker	NN	I-NP	O
trimethaphan	NN	I-NP	O
caused	VBD	B-VP	O
similar	JJ	B-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
lesioned	VBN	I-NP	O
and	CC	I-NP	O
sham	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
trimethaphan	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
bradycardia	NN	I-NP	B
in	IN	B-PP	O
lesioned	VBN	B-NP	O
rats	NNS	I-NP	O
but	CC	O	O
a	DT	B-NP	O
tachycardia	NN	I-NP	B
in	IN	B-PP	O
sham	NN	B-NP	O
rats	NNS	I-NP	O
num	CD	B-NP	O
day	NN	I-NP	O
postlesion	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
rostral	JJ	B-NP	O
ventrolateral	JJ	I-NP	O
medulla	NN	I-NP	O
neurons	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
play	VB	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
maintaining	VBG	B-VP	O
hypertension	NN	B-NP	B
in	IN	B-PP	O
conscious	JJ	B-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

Spinal	JJ	B-NP	O
or	CC	I-NP	O
suprabulbar	JJ	I-NP	O
structures	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
gradual	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
lesioned	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Damage	NN	B-NP	B
of	IN	B-PP	I
substantia	NN	B-NP	I
nigra	NN	I-NP	I
pars	NNS	I-NP	I
reticulata	VBP	B-VP	I
during	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
:	:	O	O
immunohistochemical	JJ	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
neurons	NNS	B-NP	O
,	,	O	O
astrocytes	NNS	B-NP	O
and	CC	O	O
serum	NN	B-NP	O
-	HYPH	I-NP	O
protein	NN	I-NP	O
extravasation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
gating	VBG	I-NP	O
function	NN	I-NP	O
controlling	VBG	B-VP	O
the	DT	B-NP	O
spread	NN	I-NP	O
of	IN	B-PP	O
epileptic	JJ	B-NP	B
seizure	NN	I-NP	I
activity	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
models	NNS	B-NP	O
of	IN	B-PP	O
prolonged	JJ	B-NP	B
status	NN	I-NP	I
epilepticus	NN	I-NP	I
the	DT	B-NP	O
pars	NNS	I-NP	O
reticulata	NNS	I-NP	O
of	IN	B-PP	O
substantia	NN	B-NP	O
nigra	NN	I-NP	O
(	(	O	O
SNR	NN	B-NP	O
)	)	O	O
suffers	VBZ	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
massive	JJ	I-NP	O
lesion	NN	I-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
arise	VB	I-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
massive	JJ	I-NP	O
metabolic	JJ	I-NP	B
derangement	NN	I-NP	I
and	CC	I-NP	O
hyperexcitation	NN	I-NP	O
developing	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
activated	VBN	I-NP	O
SNR	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
systemic	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
neuropathology	NN	I-NP	O
of	IN	B-PP	O
SNR	NN	B-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
using	VBG	B-VP	O
immunohistochemical	JJ	B-NP	O
techniques	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
major	JJ	I-NP	O
emphasis	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
and	CC	I-NP	O
astrocytes	NNS	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
surviving	VBG	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
were	VBD	B-VP	O
perfusion	NN	B-NP	O
-	HYPH	O	O
fixed	VBN	B-VP	O
,	,	O	O
and	CC	O	O
brains	NNS	B-NP	O
processed	VBN	B-VP	O
for	IN	B-PP	O
immunohistochemical	JJ	B-NP	O
staining	NN	I-NP	O
of	IN	B-PP	O
SNR	NN	B-NP	O
.	.	O	O

Nissl	NN	B-NP	O
-	HYPH	I-NP	O
staining	NN	I-NP	O
and	CC	I-NP	O
antibodies	NNS	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
neuron	NN	I-NP	O
-	HYPH	O	O
specific	JJ	B-NP	O
calcium	NN	I-NP	O
-	HYPH	B-PP	O
binding	VBG	B-NP	O
protein	NN	I-NP	O
,	,	O	O
parvalbumin	NN	B-NP	O
,	,	O	O
served	VBD	B-VP	O
to	TO	I-VP	O
detect	VB	I-VP	O
neuronal	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
SNR	NN	B-NP	O
.	.	O	O

Antibodies	NNS	B-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
astroglia	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
cytoskeletal	JJ	I-NP	O
protein	NN	I-NP	O
,	,	O	O
glial	JJ	B-NP	O
fibrillary	JJ	I-NP	O
acidic	JJ	I-NP	O
protein	NN	I-NP	O
(	(	O	O
GFAP	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
against	IN	B-PP	O
the	DT	B-NP	O
glial	JJ	I-NP	O
calcium	NN	I-NP	O
-	HYPH	B-PP	O
binding	VBG	B-NP	O
protein	NN	I-NP	O
,	,	O	O
S	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
protein	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
status	NN	I-NP	O
of	IN	B-PP	O
astrocytes	NNS	B-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
staining	NN	I-NP	O
for	IN	B-PP	O
serum	NN	B-NP	O
-	HYPH	B-NP	O
albumin	NN	I-NP	O
and	CC	I-NP	O
immunoglobulins	NNS	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
tissue	NN	I-NP	O
was	VBD	B-VP	O
taken	VBN	I-VP	O
as	IN	B-PP	O
indicator	NN	B-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
disturbances	NNS	I-NP	O
and	CC	O	O
vasogenic	JJ	B-NP	B
edema	NN	I-NP	I
formation	NN	I-NP	O
.	.	O	O

Immunohistochemical	JJ	B-NP	O
staining	NN	I-NP	O
indicated	VBD	B-VP	O
loss	NN	B-NP	O
of	IN	B-PP	O
GFAP	NN	B-NP	O
-	HYPH	O	O
staining	VBG	B-VP	O
already	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
oval	NN	I-NP	O
focus	NN	I-NP	O
situated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
center	NN	I-NP	O
of	IN	B-PP	O
SNR	NN	B-NP	O
while	IN	B-SBAR	O
sparing	VBG	B-VP	O
medial	JJ	B-NP	O
and	CC	I-NP	O
lateral	JJ	I-NP	O
aspects	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
additional	JJ	B-NP	O
vacuolation	NN	I-NP	O
in	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
protein	NN	I-NP	O
staining	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
,	,	O	O
parvalbumin	NN	B-NP	O
-	HYPH	I-NP	O
staining	NN	I-NP	O
changed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
SNR	NN	I-NP	O
indicating	VBG	B-VP	O
neuronal	JJ	B-NP	B
damage	NN	I-NP	I
,	,	O	O
and	CC	O	O
Nissl	NN	B-NP	O
-	HYPH	B-VP	O
staining	VBG	I-VP	O
visualized	VBN	I-VP	O
some	DT	B-NP	O
neuronal	JJ	I-NP	O
distortion	NN	I-NP	O
.	.	O	O

Staining	VBG	B-VP	O
for	IN	B-PP	O
serum	NN	B-NP	O
-	HYPH	I-NP	O
proteins	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patchy	JJ	I-NP	O
manner	NN	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
forebrain	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
hours	NNS	I-NP	O
.	.	O	O

By	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
vasogenic	JJ	B-NP	B
edema	NN	I-NP	I
covered	VBD	B-VP	O
the	DT	B-NP	O
lesioned	VBN	I-NP	B
SNR	NN	I-NP	I
.	.	O	O

By	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
glial	JJ	B-NP	O
and	CC	I-NP	O
neuronal	JJ	I-NP	O
markers	NNS	I-NP	O
indicated	VBD	B-VP	O
a	DT	B-NP	O
massive	JJ	I-NP	O
lesion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
center	NN	I-NP	O
of	IN	B-PP	O
SNR	NN	B-NP	O
.	.	O	O

By	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
,	,	O	O
astrocytes	NNS	B-NP	O
surrounding	VBG	B-VP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
increased	VBD	B-VP	O
in	IN	B-PP	O
size	NN	B-NP	O
,	,	O	O
and	CC	O	O
polymorphic	JJ	B-NP	O
phagocytotic	JJ	I-NP	O
cells	NNS	I-NP	O
invaded	VBD	B-VP	O
the	DT	B-NP	O
damaged	VBN	I-NP	O
area	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
further	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
surviving	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
,	,	O	O
conventional	JJ	B-NP	O
paraffin	NN	I-NP	O
-	HYPH	B-NP	O
sections	NNS	I-NP	O
confirmed	VBD	B-VP	O
the	DT	B-NP	O
neuronal	JJ	I-NP	O
and	CC	I-NP	O
glial	JJ	I-NP	O
damage	NN	I-NP	B
of	IN	B-PP	I
SNR	NN	B-NP	I
.	.	O	O

Additional	JJ	B-NP	O
pathology	NN	I-NP	O
of	IN	B-PP	O
similar	JJ	B-NP	O
quality	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
globus	NN	I-NP	O
pallidus	NN	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
astrocytes	NNS	B-NP	O
were	VBD	B-VP	O
always	RB	I-VP	O
damaged	VBN	I-VP	O
in	IN	B-PP	O
parallel	NN	B-NP	O
with	IN	B-PP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
SNR	NN	B-NP	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
anatomical	JJ	I-NP	O
and	CC	I-NP	O
functional	JJ	I-NP	O
interrelationship	NN	I-NP	O
between	IN	B-PP	O
neurons	NNS	B-NP	O
and	CC	I-NP	O
astrocytes	NNS	I-NP	O
is	VBZ	B-VP	O
particularly	RB	B-ADJP	O
tight	JJ	I-ADJP	O
in	IN	B-PP	O
SNR	NN	B-NP	O
.	.	O	O

Both	DT	B-NP	O
cell	NN	I-NP	O
elements	NNS	I-NP	O
may	MD	B-VP	O
suffer	VB	I-VP	O
in	IN	B-PP	O
common	JJ	B-ADJP	O
from	IN	B-PP	O
metabolic	JJ	B-NP	O
disturbance	NN	I-NP	O
and	CC	I-NP	O
neurotransmitter	NN	I-NP	B
dysfunction	NN	I-NP	I
as	IN	B-PP	O
occur	NN	B-NP	O
during	IN	B-PP	O
massive	JJ	B-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Reduced	VBN	B-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
given	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxypropyl	NN	I-NP	O
)	)	O	O
methacrylamide	NN	B-NP	O
conjugates	NNS	I-NP	O
:	:	O	O
and	CC	O	O
experimental	JJ	B-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
general	JJ	I-NP	O
acute	JJ	I-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
late	JJ	I-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
given	VBN	B-VP	O
either	CC	O	O
as	IN	B-PP	O
free	JJ	B-NP	O
drug	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
N	NN	I-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxypropyl	NN	I-NP	O
)	)	O	O
methacrylamide	NN	B-NP	O
(	(	O	O
HPMA	NN	B-NP	O
)	)	O	O
copolymer	NN	B-NP	O
conjugates	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
HPMA	NN	I-NP	O
copolymers	NNS	I-NP	O
,	,	O	O
DOX	NN	B-NP	O
was	VBD	B-VP	O
covalently	RB	I-VP	O
bound	VBN	I-VP	O
via	IN	B-PP	O
peptide	NN	B-NP	O
linkages	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
either	CC	O	O
non	AFX	B-ADJP	O
-	HYPH	I-ADJP	O
biodegradable	JJ	I-ADJP	O
(	(	O	O
Gly	NN	B-NP	O
-	HYPH	B-NP	O
Gly	NN	I-NP	O
)	)	O	O
or	CC	O	O
degradable	JJ	B-ADJP	O
by	IN	B-PP	O
lysosomal	JJ	B-NP	O
proteinases	NNS	I-NP	O
(	(	O	O
Gly	NN	B-NP	O
-	HYPH	B-NP	O
Phe	NN	I-NP	O
-	HYPH	B-NP	O
Leu	NN	I-NP	O
-	HYPH	I-NP	O
Gly	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
biodegradable	JJ	I-NP	O
conjugate	NN	I-NP	O
containing	VBG	B-VP	O
galactosamine	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
;	:	O	O
this	DT	B-NP	O
residue	NN	I-NP	O
was	VBD	B-VP	O
targeted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
.	.	O	O

Over	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
i.v.	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
and	CC	I-NP	O
polymer	NN	I-NP	O
-	HYPH	O	O
bound	VBN	B-NP	O
DOX	NN	I-NP	O
,	,	O	O
all	DT	B-NP	O
animals	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
maximal	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
polymer	NN	B-NP	O
-	HYPH	O	O
bound	VBN	B-NP	O
DOX	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
those	DT	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
unmodified	JJ	I-NP	O
parent	NN	I-NP	O
HPMA	NN	I-NP	O
copolymer	NN	I-NP	O
and	CC	O	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
.	.	O	O

Throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
,	,	O	O
deaths	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
cardiotoxicity	NN	B-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
either	CC	O	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
HPMA	NN	B-NP	O
copolymer	NN	I-NP	O
and	CC	O	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
;	:	O	O
in	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
histological	JJ	B-NP	O
investigations	NNS	I-NP	O
revealed	VBD	B-VP	O
marked	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
DOX	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Sequential	JJ	B-NP	O
measurements	NNS	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
in	IN	B-PP	O
surviving	VBG	B-VP	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
either	CC	O	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
HPMA	NN	B-NP	O
copolymer	NN	I-NP	O
and	CC	O	O
free	JJ	B-NP	O
DOX	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
function	NN	B-NP	O
beginning	VBG	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
4th	JJ	I-NP	O
week	NN	I-NP	O
after	IN	B-SBAR	O
drug	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
was	VBD	B-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
measured	VBN	B-VP	O
in	IN	B-PP	O
age	NN	B-NP	O
-	HYPH	O	O
matched	VBN	B-NP	O
control	NN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
the	DT	B-NP	O
HPMA	NN	I-NP	O
copolymer	NN	I-NP	O
conjugates	NNS	I-NP	O
containing	VBG	B-VP	O
DOX	NN	B-NP	O
exhibited	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
significant	JJ	I-NP	O
histological	JJ	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
DOX	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
HPMA	NN	B-NP	O
copolymer	NN	I-NP	O
conjugates	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
animals	NNS	I-NP	O
had	VBD	B-VP	O
shown	VBN	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
beginning	VBG	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-SBAR	O
drug	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Topical	JJ	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
capsaicin	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
post	AFX	I-NP	B
-	HYPH	I-NP	I
herpetic	JJ	I-NP	I
neuralgia	NN	I-NP	I
:	:	O	O
efficacy	NN	B-NP	O
,	,	O	O
predictors	NNS	B-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
and	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
course	NN	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
,	,	O	O
time	NN	B-NP	O
-	HYPH	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
and	CC	I-NP	O
predictors	NNS	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
topical	JJ	B-NP	O
capsaicin	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
post	AFX	I-NP	B
-	HYPH	I-NP	I
herpetic	JJ	I-NP	I
neuralgia	NN	I-NP	I
(	(	O	O
PHN	NN	B-NP	B
)	)	O	O
,	,	O	O
median	JJ	B-NP	O
duration	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
capsaicin	NN	I-NP	O
cream	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
therapy	NN	B-NP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
rated	VBD	B-VP	O
their	PRP$	B-NP	O
pain	NN	I-NP	B
on	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
(	(	O	O
VAS	NN	B-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
verbal	JJ	I-NP	O
outcome	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
investigation	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
study	NN	B-NP	O
onset	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
improved	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
substantially	RB	B-VP	O
improved	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
trial	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
discontinued	VBN	I-NP	O
therapy	NN	I-NP	O
due	IN	B-PP	O
to	TO	B-PP	O
side	NN	B-NP	O
-	HYPH	I-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
intolerable	JJ	B-NP	O
capsaicin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
burning	NN	I-NP	O
sensations	NNS	I-NP	O
or	CC	I-NP	O
mastitis	NN	I-NP	B
;	:	O	O
num	CD	B-NP	O
reported	VBD	B-VP	O
no	DT	B-NP	O
benefit	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
VAS	NN	B-NP	O
ratings	NNS	I-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
application	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
responders	NNS	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
still	RB	I-VP	O
improved	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
;	:	O	O
only	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
third	JJ	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
had	VBD	B-VP	O
continued	VBN	I-VP	O
application	NN	B-NP	O
irregularly	RB	B-ADVP	O
.	.	O	O

Treatment	NN	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
patient	NN	B-NP	O
s	NNS	I-NP	O
age	NN	I-NP	O
,	,	I-NP	O
duration	NN	I-NP	O
or	CC	I-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
PHN	NN	B-NP	B
(	(	O	O
trigeminal	JJ	B-NP	O
involvement	NN	I-NP	O
was	VBD	B-VP	O
excluded	VBN	I-VP	O
)	)	O	O
,	,	O	O
sensory	JJ	B-NP	B
disturbance	NN	I-NP	I
or	CC	I-NP	O
pain	NN	I-NP	B
character	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
,	,	O	O
time	NN	B-NP	O
-	HYPH	B-NP	O
course	NN	I-NP	O
or	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
burning	NN	I-NP	O
.	.	O	O

If	IN	B-SBAR	O
confirmed	VBN	B-VP	O
in	IN	B-PP	O
controlled	JJ	B-NP	O
trials	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
open	JJ	I-NP	O
,	,	O	O
non	AFX	O	O
-	HYPH	O	O
randomized	VBN	B-NP	O
study	NN	I-NP	O
might	MD	B-VP	O
indicate	VB	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
analgesic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
capsaicin	NN	B-NP	O
in	IN	B-PP	O
PHN	NN	B-NP	B
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
both	CC	O	O
interference	NN	B-NP	O
with	IN	B-PP	O
neuropeptide	NN	B-NP	O
metabolism	NN	I-NP	O
and	CC	O	O
morphological	JJ	B-NP	O
changes	NNS	I-NP	O
(	(	O	O
perhaps	RB	B-NP	O
degeneration	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
nociceptive	JJ	B-NP	O
afferents	NNS	I-NP	O
.	.	O	O

Serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
paranoia	NN	B-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
.	.	O	O

Antidepressants	NNS	B-NP	O
have	VBP	B-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
paranoid	JJ	B-NP	B
reactions	NNS	I-NP	O
in	IN	B-PP	O
psychiatric	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
paranoid	JJ	B-NP	B
exacerbation	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
fluoxetine	NN	I-NP	O
and	CC	I-NP	O
amitriptyline	NN	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
here	RB	B-ADVP	O
.	.	O	O

Elements	NNS	B-NP	O
common	JJ	B-ADJP	O
to	TO	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
included	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
paranoid	JJ	B-NP	B
symptomatology	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
depressive	JJ	B-NP	B
and	CC	I-NP	I
psychotic	JJ	I-NP	I
symptoms	NNS	I-NP	I
.	.	O	O

Complicated	VBN	B-NP	O
depressive	JJ	I-NP	B
disorders	NNS	I-NP	I
(	(	O	O
including	VBG	B-PP	O
atypicality	NN	B-NP	O
of	IN	B-PP	O
course	NN	B-NP	O
and	CC	I-NP	O
symptomatology	NN	I-NP	O
,	,	O	O
chronicity	NN	B-NP	O
,	,	O	O
psychosis	NN	B-NP	B
,	,	O	O
bipolarity	NN	B-NP	O
,	,	O	O
and	CC	O	O
secondary	JJ	B-NP	O
onset	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
primary	JJ	I-NP	O
psychosis	NN	I-NP	B
)	)	O	O
may	MD	B-VP	O
present	VB	I-VP	O
particular	JJ	B-NP	O
vulnerability	NN	I-NP	O
to	TO	B-PP	O
paranoid	JJ	B-NP	B
exacerbations	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
pharmacology	NN	I-NP	O
and	CC	I-NP	O
neurobiology	NN	I-NP	O
of	IN	B-PP	O
paranoia	NN	B-NP	B
remain	VBP	B-VP	O
cryptic	JJ	B-ADJP	O
,	,	O	O
several	JJ	B-NP	O
mechanisms	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
5HT3	NN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
dopamine	NN	I-NP	O
release	NN	I-NP	O
,	,	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
noradrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
downregulation	NN	I-NP	O
,	,	O	O
or	CC	O	O
GABAB	NN	B-NP	O
receptor	NN	I-NP	O
upregulation	NN	I-NP	O
acting	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
vicinity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventral	JJ	I-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
(	(	O	O
possibly	RB	B-ADVP	O
in	IN	B-PP	O
lateral	JJ	B-NP	O
orbitofrontal	JJ	I-NP	O
or	CC	I-NP	O
anterior	JJ	I-NP	O
cingulate	JJ	I-NP	O
circuits	NNS	I-NP	O
)	)	O	O
,	,	O	O
might	MD	B-VP	O
apply	VB	I-VP	O
to	TO	B-PP	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
cases	NNS	I-NP	O
call	VBP	B-VP	O
attention	NN	B-NP	O
to	TO	B-PP	O
possible	JJ	B-NP	O
paranoid	JJ	I-NP	B
exacerbations	NNS	I-NP	O
with	IN	B-PP	O
serotonin	NN	B-NP	O
reuptake	NN	I-NP	O
blockers	NNS	I-NP	O
in	IN	B-PP	O
select	JJ	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
raise	VB	B-VP	O
neurobiological	JJ	B-NP	O
considerations	NNS	I-NP	O
regarding	VBG	B-VP	O
paranoia	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
encephalitis	NN	B-NP	B
during	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
loiasis	NN	B-NP	B
with	IN	B-PP	O
diethylcarbamazine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
encephalitis	NN	B-NP	B
following	VBG	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
diethylcarbamazine	NN	B-NP	O
(	(	O	O
DEC	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
Congolese	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Loa	NN	B-NP	O
loa	NN	I-NP	O
filariasis	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
fatal	JJ	I-NP	O
outcome	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
sequelae	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
notable	JJ	I-NP	O
fact	NN	I-NP	O
was	VBD	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
complication	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
hospitalized	VBN	B-VP	O
before	IN	B-PP	O
treatment	NN	B-NP	O
began	VBD	B-VP	O
,	,	O	O
with	IN	B-PP	O
whom	WP	B-NP	O
particularly	RB	B-ADVP	O
strict	VBP	B-VP	O
therapeutic	JJ	B-NP	O
precautions	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
,	,	O	O
i.e.	FW	O	O
,	,	O	O
initial	JJ	B-NP	O
dose	NN	I-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
DEC	NNP	B-NP	O
,	,	O	O
very	RB	B-NP	O
gradual	JJ	I-NP	O
dose	NN	I-NP	O
increases	NNS	I-NP	O
,	,	O	O
and	CC	O	O
associated	VBN	B-VP	O
anti	AFX	O	O
-	HYPH	B-NP	O
allergic	JJ	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
complication	NN	I-NP	O
may	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
that	RB	B-ADJP	O
uncommon	JJ	I-ADJP	O
in	IN	B-PP	O
highly	RB	B-NP	O
endemic	JJ	I-NP	O
regions	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
occurs	VBZ	B-VP	O
primarily	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
not	RB	B-ADVP	O
exclusively	RB	I-ADVP	O
,	,	O	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
presenting	VBG	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
microfilarial	JJ	I-NP	O
load	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
encephalitis	NN	B-NP	B
and	CC	O	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
microfilaremia	NN	B-NP	B
is	VBZ	B-VP	O
evident	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
pathophysiological	JJ	I-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
light	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
observations	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
few	JJ	I-NP	O
other	JJ	I-NP	O
comments	NNS	I-NP	O
on	IN	B-PP	O
this	DT	B-NP	O
subject	NN	I-NP	O
published	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Delirium	NN	B-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
elderly	JJ	I-NP	O
woman	NN	I-NP	O
possibly	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
.	.	O	O

Misoprostol	NNP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
gastrointestinal	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
gynecologic	JJ	B-NP	O
problems	NNS	I-NP	O
,	,	O	O
and	CC	O	O
headache	NN	B-NP	B
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
care	NN	I-NP	O
facility	NN	I-NP	O
became	VBD	B-VP	O
confused	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
change	NN	B-NP	O
in	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
was	VBD	B-VP	O
first	RB	I-VP	O
reported	VBN	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

Her	PRP$	B-NP	O
delirium	NN	I-NP	B
significantly	RB	B-VP	O
improved	VBD	I-VP	O
after	IN	B-SBAR	O
misoprostol	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
her	PRP$	B-NP	O
mental	JJ	I-NP	O
status	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
within	IN	B-PP	O
a	DT	B-NP	O
week	NN	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
no	DT	B-NP	O
other	JJ	I-NP	O
factors	NNS	I-NP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
changed	VBD	B-VP	O
significantly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
delirium	NN	I-NP	B
experienced	VBN	B-VP	O
by	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
possibly	RB	B-ADVP	O
resulted	VBD	B-VP	O
from	IN	B-PP	O
misoprostol	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Hepatocellular	JJ	B-NP	O
oxidant	JJ	I-NP	O
stress	NN	I-NP	O
following	VBG	B-PP	O
intestinal	JJ	B-NP	O
ischemia	NN	I-NP	B
-	HYPH	I-NP	O
reperfusion	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Reperfusion	NN	B-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
intestine	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
liver	NN	I-NP	B
dysfunction	NN	I-NP	I
characterized	VBN	B-VP	O
by	IN	B-PP	O
hepatocellular	JJ	B-NP	O
enzyme	NN	I-NP	O
release	NN	I-NP	O
into	IN	B-PP	O
plasma	NN	B-NP	O
,	,	O	O
reduction	NN	B-NP	O
in	IN	B-PP	O
bile	NN	B-NP	O
flow	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
and	CC	O	O
neutrophil	NN	B-NP	O
sequestration	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pathophysiology	NN	I-NP	O
underlying	VBG	B-VP	O
this	DT	B-NP	O
acute	JJ	I-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
is	VBZ	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
oxidants	NNS	B-NP	O
are	VBP	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
and	CC	O	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
indirect	JJ	I-NP	O
methods	NNS	I-NP	O
of	IN	B-PP	O
assessing	VBG	B-VP	O
oxidant	JJ	B-NP	O
exposure	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
standardized	JJ	I-NP	O
intestinal	JJ	I-NP	O
ischemia	NN	I-NP	B
-	HYPH	B-NP	O
reperfusion	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Hepatic	JJ	B-NP	O
tissue	NN	I-NP	O
was	VBD	B-VP	O
assayed	VBN	I-VP	O
for	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
products	NNS	I-NP	O
and	CC	O	O
oxidized	VBN	B-VP	O
and	CC	O	O
reduced	VBN	B-NP	O
glutathione	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
hepatic	JJ	B-NP	O
tissue	NN	I-NP	O
total	JJ	I-NP	O
glutathione	NN	I-NP	O
following	VBG	B-PP	O
intestinal	JJ	B-NP	O
ischemia	NN	I-NP	B
-	HYPH	I-NP	O
reperfusion	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Oxidized	VBN	B-NP	O
glutathione	NN	I-NP	O
(	(	O	O
GSSG	NN	B-NP	O
)	)	O	O
increased	VBD	B-VP	O
significantly	RB	I-VP	O
following	VBG	I-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
reperfusion	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
products	NNS	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
injury	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
GSSG	NN	B-NP	O
within	IN	B-PP	O
hepatic	JJ	B-NP	O
tissue	NN	I-NP	O
during	IN	B-PP	O
intestinal	JJ	B-NP	O
reperfusion	NN	I-NP	O
suggests	VBZ	B-VP	O
exposure	NN	B-NP	O
of	IN	B-PP	O
hepatocytes	NNS	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
oxidant	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
products	NNS	B-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
oxidant	JJ	I-NP	O
stress	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
insufficient	JJ	B-NP	O
magnitude	NN	I-NP	O
to	TO	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
irreversible	JJ	B-NP	O
injury	NN	I-NP	O
to	TO	B-PP	O
hepatocyte	NN	B-NP	O
cell	NN	I-NP	O
membranes	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
also	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
tissue	NN	B-NP	O
GSSG	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
sensitive	JJ	I-NP	O
indicator	NN	I-NP	O
of	IN	B-PP	O
oxidant	JJ	B-NP	O
stress	NN	I-NP	O
than	IN	B-PP	O
measurement	NN	B-NP	O
of	IN	B-PP	O
products	NNS	B-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxidation	NN	I-NP	O
.	.	O	O

Diphenhydramine	NN	B-NP	O
prevents	VBZ	B-VP	O
the	DT	B-NP	O
haemodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
in	IN	B-PP	O
ICU	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Cimetidine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
histamine	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
H2	NN	B-NP	O
)	)	O	O
antagonist	NN	B-NP	O
,	,	O	O
produces	VBZ	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
vasodilatation	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
critically	RB	B-NP	O
ill	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
because	IN	B-SBAR	O
cimetidine	NN	B-NP	O
acts	VBZ	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
histamine	NN	I-NP	O
agonist	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
histamine	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
H1	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
antagonist	NN	I-NP	O
,	,	O	O
diphenhydramine	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
haemodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
observed	VBN	B-VP	O
after	IN	B-PP	O
cimetidine	NN	B-NP	O
in	IN	B-PP	O
ICU	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Each	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
separate	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
random	JJ	I-NP	O
fashion	NN	I-NP	O
,	,	O	O
they	PRP	B-NP	O
received	VBD	B-VP	O
cimetidine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
iv	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
,	,	O	O
and	CC	O	O
on	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
,	,	O	O
a	DT	B-NP	O
pretreatment	NN	I-NP	O
of	IN	B-PP	O
diphenhydramine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
iv	NN	I-NP	O
with	IN	B-PP	O
cimetidine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
iv	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
pretreatment	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
cimetidine	NN	B-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
(	(	O	O
SVR	NN	B-NP	O
)	)	O	O
decreased	VBD	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	NN	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
pretreatment	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
little	JJ	B-NP	O
haemodynamic	JJ	I-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
H1	NN	I-NP	O
antagonist	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
hypotension	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
iv	NN	B-NP	O
cimetidine	NN	I-NP	O
,	,	O	O
since	IN	B-SBAR	O
the	DT	B-NP	O
vasodilating	VBG	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
cimetidine	NN	B-NP	O
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
,	,	O	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
through	IN	B-PP	O
the	DT	B-NP	O
H1	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
rifampicin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
bacteriologically	RB	B-NP	O
proven	VBN	I-NP	O
pulmonary	JJ	I-NP	B
tuberculosis	NN	I-NP	I
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
various	JJ	I-NP	O
regimens	NNS	I-NP	O
of	IN	B-PP	O
antituberculosis	JJ	B-NP	O
drugs	NNS	I-NP	O
for	IN	B-PP	O
nearly	RB	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Rifampicin	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
thrice	NN	B-NP	O
as	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
drug	NN	I-NP	O
regimen	NN	I-NP	O
and	CC	O	O
each	DT	B-NP	O
time	NN	I-NP	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
untoward	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
like	IN	B-PP	O
nausea	NN	B-NP	B
,	,	O	O
vomiting	NN	B-NP	B
and	CC	O	O
fever	NN	B-NP	B
with	IN	B-PP	O
chills	NNS	B-NP	O
and	CC	I-NP	O
rigors	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
last	JJ	I-NP	O
such	JJ	I-NP	O
episode	NN	I-NP	O
was	VBD	B-VP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
renal	JJ	I-NP	O
failure	NN	I-NP	O
at	IN	B-PP	O
which	WDT	B-NP	O
stage	NN	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
seen	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
authors	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
made	VBD	B-VP	O
a	DT	B-NP	O
full	JJ	I-NP	O
recovery	NN	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
polyneuropathy	NN	I-NP	B
and	CC	I-NP	O
motor	NN	I-NP	O
loss	NN	I-NP	O
after	IN	B-PP	O
intrathecal	JJ	B-NP	O
thiotepa	NN	I-NP	O
combination	NN	I-NP	O
chemotherapy	NN	I-NP	O
:	:	O	O
description	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
delayed	VBN	I-NP	O
neurologic	JJ	I-NP	B
toxicity	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	O	O
(	(	O	O
IT	JJ	B-ADJP	O
)	)	O	O
combination	NN	B-NP	O
chemotherapy	NN	I-NP	O
including	VBG	B-PP	O
thiotepa	NN	B-NP	O
(	(	O	O
TSPA	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

Both	DT	B-NP	O
cases	NNS	I-NP	O
developed	VBD	B-VP	O
axonal	JJ	B-NP	B
neuropathy	NN	I-NP	I
with	IN	B-PP	O
motor	NN	B-NP	O
predominance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
extremities	NNS	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
IT	NN	B-NP	O
chemotherapy	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

Neurologic	JJ	B-NP	B
toxicities	NNS	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
with	IN	B-PP	O
IT	NN	B-NP	O
-	HYPH	I-NP	O
methotrexate	NN	I-NP	O
,	,	O	O
IT	NN	B-NP	O
-	HYPH	I-NP	O
cytosine	NN	I-NP	O
arabinoside	NN	I-NP	O
and	CC	I-NP	O
IT	NN	I-NP	O
-	HYPH	B-NP	O
TSPA	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
axonal	JJ	B-NP	B
neuropathy	NN	I-NP	I
following	VBG	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
agents	NNS	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
described	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
TSPA	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
IT	NN	I-NP	O
agent	NN	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
combination	NN	I-NP	O
with	IN	B-PP	O
MTX	NN	B-NP	O
,	,	O	O
ara	AFX	B-NP	O
-	HYPH	I-NP	O
C	NN	I-NP	O
and	CC	I-NP	O
radiotherapy	NN	I-NP	O
could	MD	B-VP	O
cause	VB	I-VP	O
severe	JJ	B-NP	O
neurotoxicity	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
unexpected	JJ	I-NP	O
complication	NN	I-NP	O
indicates	VBZ	B-VP	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
further	JJ	B-NP	O
toxicology	NN	I-NP	O
research	NN	I-NP	O
on	IN	B-PP	O
IT	NN	B-NP	O
-	HYPH	I-NP	O
TSPA	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
cromakalim	NN	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
on	IN	B-PP	O
large	JJ	B-NP	O
epicardial	JJ	I-NP	O
and	CC	I-NP	O
small	JJ	I-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
i.v.	JJ	B-NP	O
bolus	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cromakalim	NN	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
on	IN	B-PP	O
large	JJ	B-NP	O
(	(	I-NP	O
circumflex	NN	I-NP	O
artery	NN	I-NP	O
)	)	O	O
and	CC	O	O
small	JJ	B-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
systemic	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
chronically	RB	B-NP	O
instrumented	VBN	I-NP	O
conscious	JJ	I-NP	O
dogs	NNS	I-NP	O
and	CC	O	O
compared	VBN	B-VP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
nitroglycerin	NN	B-NP	O
.	.	O	O

Nitroglycerin	NN	B-NP	O
,	,	O	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
selectively	RB	B-ADVP	O
increased	VBD	B-VP	O
circumflex	NN	B-NP	O
artery	NN	I-NP	O
diameter	NN	I-NP	O
(	(	O	O
CxAD	NN	B-NP	O
)	)	O	O
without	IN	B-PP	O
simultaneously	RB	B-ADVP	O
affecting	VBG	B-VP	O
any	DT	B-NP	O
other	JJ	I-NP	O
cardiac	JJ	I-NP	O
or	CC	I-NP	O
systemic	JJ	I-NP	O
hemodynamic	JJ	I-NP	O
parameter	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
cromakalim	NN	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
at	IN	B-PP	O
all	DT	B-NP	O
doses	NNS	I-NP	O
and	CC	I-NP	O
nitroglycerin	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
simultaneously	RB	B-ADVP	O
and	CC	O	O
dose	NN	B-NP	O
-	HYPH	B-VP	O
dependently	RB	B-NP	O
increased	VBN	I-NP	O
CxAD	NN	I-NP	O
,	,	O	O
coronary	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
coronary	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
aortic	JJ	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Cromakalim	NN	B-NP	O
was	VBD	B-VP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADJP	O
more	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
pinacidil	NN	B-NP	O
in	IN	B-PP	O
increasing	VBG	B-VP	O
CxAD	NN	B-NP	O
.	.	O	O

Vasodilation	NN	B-NP	O
of	IN	B-PP	O
large	JJ	B-NP	O
and	CC	I-NP	O
small	JJ	I-NP	O
coronary	JJ	I-NP	O
vessels	NNS	I-NP	O
and	CC	I-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
cromakalim	NN	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
prior	JJ	B-NP	O
combined	JJ	I-NP	O
beta	NN	I-NP	O
adrenergic	JJ	I-NP	O
and	CC	I-NP	O
muscarinic	JJ	I-NP	O
receptors	NNS	I-NP	O
blockade	NN	I-NP	O
but	CC	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
was	VBD	B-VP	O
abolished	VBN	I-VP	O
.	.	O	O

When	WRB	B-ADVP	O
circumflex	JJ	B-NP	O
artery	NN	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
constant	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
CxAD	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
cromakalim	NN	B-NP	O
,	,	I-NP	O
pinacidil	NN	I-NP	O
and	CC	I-NP	O
nitroglycerin	NN	I-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
-	SYM	B-ADJP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
whereas	IN	O	O
nitroglycerin	NN	B-NP	O
preferentially	RB	B-ADVP	O
and	CC	O	O
flow	NN	B-NP	O
-	HYPH	B-NP	O
independently	RB	B-ADVP	O
dilates	VBZ	B-VP	O
large	JJ	B-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
,	,	O	O
cromakalim	NN	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
dilate	VBP	B-VP	O
both	CC	O	O
large	JJ	B-NP	O
and	CC	I-NP	O
small	JJ	I-NP	O
coronary	JJ	I-NP	O
arteries	NNS	I-NP	O
and	CC	O	O
this	DT	B-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
dependent	JJ	B-ADJP	O
upon	IN	B-PP	O
the	DT	B-NP	O
simultaneous	JJ	I-NP	O
beta	NN	I-NP	O
adrenoceptors	NNS	I-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
rise	NN	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	O
metabolic	JJ	I-NP	O
demand	NN	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mechanisms	NNS	I-NP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
,	,	O	O
direct	JJ	B-NP	O
vasodilation	NN	I-NP	O
and	CC	I-NP	O
flow	NN	I-NP	O
dependency	NN	I-NP	O
,	,	O	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cromakalim	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
pinacidil	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
CxAD	NN	B-NP	O
.	.	O	O

Mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neutropenia	NN	I-NP	B
and	CC	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
elderly	JJ	B-NP	O
females	NNS	I-NP	O
with	IN	B-PP	O
hypothyroidism	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
non	AFX	B-ADVP	O
-	HYPH	B-NP	O
oliguric	JJ	I-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
and	CC	O	O
severe	JJ	B-NP	O
neutropenia	NN	I-NP	B
occurring	VBG	B-VP	O
simultaneously	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
elderly	JJ	I-NP	O
females	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
neutropenia	NN	I-NP	B
was	VBD	B-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
maturation	NN	B-NP	O
arrest	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myeloid	JJ	I-NP	O
series	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
hypothyroid	JJ	B-ADJP	B
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
clear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
this	DT	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
predisposing	VBG	I-NP	O
factor	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
would	MD	B-VP	O
seem	VB	I-VP	O
prudent	JJ	B-ADJP	O
not	RB	O	O
to	TO	B-VP	O
use	VB	I-VP	O
mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
hypothyroid	JJ	B-NP	B
patients	NNS	I-NP	O
until	IN	B-PP	O
the	DT	B-NP	O
hypothyroidism	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
corrected	VBN	I-VP	O
.	.	O	O

Etiology	NN	B-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
in	IN	B-PP	O
hemodialysis	NN	B-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
calcium	NN	B-NP	O
carbonate	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dialysis	NN	I-NP	O
patients	NNS	I-NP	O
became	VBD	B-VP	O
hypercalcemic	JJ	B-ADJP	B
after	IN	B-PP	O
switching	VBG	B-VP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
carbonate	NN	I-NP	O
as	IN	B-PP	O
their	PRP$	B-NP	O
principal	JJ	I-NP	O
phosphate	NN	I-NP	O
binder	NN	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
identify	VB	I-VP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
,	,	O	O
indirect	JJ	B-NP	O
parameters	NNS	I-NP	O
of	IN	B-PP	O
intestinal	JJ	B-NP	O
calcium	NN	I-NP	O
reabsorption	NN	I-NP	O
and	CC	I-NP	O
bone	NN	I-NP	O
turnover	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
results	NNS	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
eucalcemic	JJ	I-NP	O
patients	NNS	I-NP	O
matched	VBN	B-VP	O
for	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
length	NN	B-NP	O
of	IN	B-PP	O
time	NN	B-NP	O
on	IN	B-PP	O
dialysis	NN	B-NP	O
,	,	O	O
and	CC	O	O
etiology	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
experiencing	VBG	B-VP	O
hypercalcemic	JJ	B-NP	B
episodes	NNS	I-NP	O
with	IN	B-PP	O
peak	JJ	B-NP	O
calcium	NN	I-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mmol	NN	I-NP	O
/	SYM	O	O
L	NN	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hypercalcemic	JJ	I-NP	B
group	NN	I-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
calcium	NN	I-NP	O
concentration	NN	I-NP	O
obtained	VBN	B-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
before	IN	B-SBAR	O
the	DT	B-NP	O
switch	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
mean	JJ	I-NP	O
value	NN	I-NP	O
obtained	VBN	B-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
observation	NN	B-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
switch	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
eucalcemic	JJ	B-NP	O
patients	NNS	I-NP	O
exhibited	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
calcium	NN	I-NP	O
values	NNS	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

CaCO3	NN	B-NP	O
dosage	NN	I-NP	O
,	,	O	O
calculated	VBN	B-VP	O
dietary	JJ	B-NP	O
calcium	NN	I-NP	O
intake	NN	I-NP	O
,	,	O	O
and	CC	O	O
circulating	VBG	B-VP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
vitamin	NN	B-NP	O
D	NN	I-NP	O
metabolites	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

Physical	JJ	B-NP	O
activity	NN	I-NP	O
index	NN	I-NP	O
and	CC	O	O
predialysis	NN	B-NP	O
serum	NN	I-NP	O
bicarbonate	NN	I-NP	O
levels	NNS	I-NP	O
also	RB	B-ADVP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
parameters	NNS	B-NP	O
reflecting	VBG	B-VP	O
bone	NN	B-NP	O
turnover	NN	I-NP	O
rates	NNS	I-NP	O
between	IN	B-PP	O
groups.	NN	B-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Methyldopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
presenting	NN	I-NP	O
as	IN	B-SBAR	O
near	JJ	B-NP	O
-	HYPH	I-NP	O
syncope	NN	I-NP	B
.	.	O	O

Methyldopa	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antihypertensive	JJ	I-NP	O
medication	NN	I-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
available	JJ	B-ADJP	O
generically	RB	B-ADVP	O
and	CC	O	O
under	IN	B-PP	O
the	DT	B-NP	O
trade	NN	I-NP	O
name	NN	I-NP	O
Aldomet	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
prescribed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
adult	JJ	I-NP	O
population	NN	I-NP	O
and	CC	O	O
infrequently	RB	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

Methyldopa	NN	B-NP	O
causes	VBZ	B-VP	O
an	DT	B-NP	O
autoimmune	JJ	I-NP	B
hemolytic	JJ	I-NP	I
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
small	JJ	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
take	VBP	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
methyldopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
boy	NN	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	B
department	NN	I-NP	I
with	IN	B-PP	O
near	JJ	B-NP	O
-	HYPH	I-NP	O
syncope	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
boy	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
methyldopa	NN	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
trauma	NN	I-NP	B
admission	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
presentation	NN	B-NP	O
.	.	O	O

Evaluation	NN	B-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
hemoglobin	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
grams	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	I-NP	O
Coombs	NNS	I-NP	O
s	VBZ	B-VP	O
test	NN	B-NP	O
with	IN	B-PP	O
polyspecific	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
human	JJ	I-NP	O
globulin	NN	I-NP	O
and	CC	I-NP	O
monospecific	JJ	I-NP	O
IgG	NN	I-NP	O
reagents	NNS	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
warm	JJ	I-NP	O
reacting	VBG	I-NP	O
autoantibody	NN	I-NP	O
.	.	O	O

Transfusion	NN	B-NP	O
and	CC	I-NP	O
corticosteroid	NN	I-NP	O
therapy	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Emergency	NN	B-NP	O
physicians	NNS	I-NP	O
treating	VBG	B-VP	O
children	NNS	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
diagnose	VB	I-VP	O
and	CC	I-VP	O
treat	VB	I-VP	O
it	PRP	B-NP	O
correctly	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
brief	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
autoimmune	JJ	B-NP	O
and	CC	I-NP	O
drug	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hemolytic	JJ	I-NP	B
anemias	NNS	I-NP	I
is	VBZ	B-VP	O
provided	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
danazol	NN	B-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
hereditary	JJ	B-NP	B
angioedema	NN	I-NP	I
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
short	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
danazol	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
established	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
settings	NNS	B-NP	O
,	,	O	O
no	DT	B-NP	O
information	NN	I-NP	O
exists	VBZ	B-VP	O
as	IN	B-SBAR	O
to	TO	B-PP	O
its	PRP$	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
safety	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
danazol	NN	B-NP	O
by	IN	B-PP	O
performing	VBG	B-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
chart	NN	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hereditary	JJ	B-NP	B
angioedema	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
danazol	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
or	CC	O	O
longer	JJR	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Virtually	RB	B-ADVP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
.	.	O	O

Menstrual	JJ	B-NP	B
abnormalities	NNS	I-NP	I
,	,	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
,	,	O	O
muscle	NN	B-NP	B
cramps	NNS	I-NP	I
/	SYM	B-NP	O
myalgias	NNS	I-NP	B
,	,	O	O
and	CC	O	O
transaminase	NN	B-NP	O
elevations	NNS	I-NP	O
were	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
patient	NN	I-NP	O
has	VBZ	B-VP	O
died	VBN	I-VP	O
or	CC	I-VP	O
suffered	VBN	I-VP	O
any	DT	B-NP	O
apparent	JJ	I-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
sequelae	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
directly	RB	B-ADJP	O
attributable	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
despite	IN	B-PP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
,	,	O	O
danazol	NN	B-NP	O
has	VBZ	B-VP	O
proven	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
remarkably	RB	B-ADJP	O
safe	JJ	I-ADJP	O
over	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Patient	NN	B-NP	O
tolerance	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
topical	JJ	B-NP	O
chlorhexidine	NN	I-NP	O
diphosphanilate	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
topical	JJ	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
burns	NNS	B-NP	B
.	.	O	O

Effective	JJ	B-NP	O
topical	JJ	I-NP	O
antimicrobial	JJ	I-NP	O
agents	NNS	I-NP	O
decrease	VBP	B-VP	O
infection	NN	B-NP	B
and	CC	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
burn	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Chlorhexidine	NN	B-NP	O
phosphanilate	NN	I-NP	O
(	(	O	O
CHP	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
broad	JJ	I-NP	O
-	HYPH	I-NP	O
spectrum	NN	I-NP	O
antimicrobial	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
evaluated	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
topical	JJ	I-NP	O
burn	NN	I-NP	B
wound	NN	I-NP	O
dressing	VBG	B-VP	O
in	IN	B-PP	O
cream	NN	B-NP	O
form	NN	I-NP	O
,	,	O	O
but	CC	O	O
preliminary	JJ	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
painful	JJ	B-ADJP	O
upon	IN	B-PP	O
application	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
compared	VBD	B-VP	O
various	JJ	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
CHP	NN	B-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
a	DT	B-NP	O
tolerable	JJ	I-NP	O
concentration	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
identified	VBN	I-VP	O
with	IN	B-PP	O
retention	NN	B-NP	O
of	IN	B-PP	O
antimicrobial	JJ	B-NP	O
efficacy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
burn	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
each	DT	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
similar	JJ	I-NP	O
burns	NNS	I-NP	B
which	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
separately	RB	I-VP	O
treated	VBN	I-VP	O
,	,	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
pairs	NNS	B-NP	O
of	IN	B-PP	O
treatments	NNS	B-NP	O
at	IN	B-PP	O
successive	JJ	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
intervals	NNS	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
burn	NN	I-NP	B
site	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
each	DT	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
CHP	NN	I-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
,	,	O	O
their	PRP$	B-NP	O
vehicle	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
silver	NN	I-NP	O
sulphadiazine	NN	I-NP	O
(	(	O	O
AgSD	NN	B-NP	O
)	)	O	O
cream	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
antimicrobial	JJ	I-NP	O
agent	NN	I-NP	O
frequently	RB	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
topical	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
burn	NN	B-NP	B
wounds	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
site	NN	I-NP	O
was	VBD	B-VP	O
always	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
AgSD	NN	B-NP	O
cream	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
CHP	NN	B-NP	O
concentration	NN	I-NP	O
and	CC	O	O
patients	NNS	B-NP	O
s	VBZ	B-VP	O
ratings	NNS	B-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
on	IN	B-PP	O
an	DT	B-NP	O
analogue	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
CHP	NN	I-NP	O
cream	NN	I-NP	O
was	VBD	B-VP	O
closest	RB	B-ADVP	O
to	TO	B-PP	O
AgSD	NN	B-NP	O
in	IN	B-PP	O
pain	NN	B-NP	B
tolerance	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatments	NNS	I-NP	O
differed	VBD	B-VP	O
statistically	RB	B-ADVP	O
from	IN	B-PP	O
AgSD	NN	B-NP	O
or	CC	B-PP	O
from	IN	B-PP	O
each	DT	B-NP	O
other	JJ	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
ease	NN	B-NP	O
of	IN	B-PP	O
application	NN	B-NP	O
of	IN	B-PP	O
CHP	NN	B-NP	O
creams	NNS	I-NP	O
was	VBD	B-VP	O
less	RBR	B-ADJP	O
satisfactory	JJ	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
AgSD	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
formulations	NNS	B-NP	O
at	IN	B-PP	O
or	CC	I-PP	O
below	IN	I-PP	O
num	CD	B-NP	O
per	IN	B-PP	O
cent	NN	B-NP	O
CHP	NN	I-NP	O
may	MD	B-VP	O
prove	VB	I-VP	O
acceptable	JJ	B-ADJP	O
for	IN	B-PP	O
wound	NN	B-NP	O
care	NN	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
vehicle	NN	I-NP	O
system	NN	I-NP	O
needs	VBZ	B-VP	O
pharmaceutical	JJ	B-NP	O
improvement	NN	I-NP	O
to	TO	B-VP	O
render	VB	I-VP	O
it	PRP	B-NP	O
more	RBR	B-ADJP	O
tolerable	JJ	I-ADJP	O
and	CC	O	O
easier	JJR	B-ADJP	O
to	TO	B-VP	O
use	VB	I-VP	O
.	.	O	O

Dose	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
busulfan	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
:	:	O	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
pharmacological	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Busulfan	NNP	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
neurotoxic	JJ	B-ADJP	B
in	IN	B-PP	O
animals	NNS	B-NP	O
and	CC	I-NP	O
humans	NNS	I-NP	O
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
acute	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
remains	VBZ	B-VP	O
poorly	RB	B-VP	O
characterized	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
here	RB	B-ADVP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
(	(	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
receiving	VBG	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
busulfan	NN	I-NP	O
in	IN	B-PP	O
combined	VBN	B-NP	O
chemotherapy	NN	I-NP	O
before	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
malignant	JJ	B-NP	O
solid	JJ	I-NP	O
tumors	NNS	I-NP	B
,	,	O	O
brain	NN	B-NP	B
tumors	NNS	I-NP	I
excluded	VBD	B-VP	O
.	.	O	O

Busulfan	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
p.o.	FW	B-NP	O
,	,	O	O
every	DT	B-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
total	JJ	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
consecutively	RB	I-VP	O
used	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
then	RB	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
calculation	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
children	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
given	VBN	I-VP	O
anticonvulsive	JJ	B-NP	O
prophylaxis	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
developed	VBN	I-NP	O
seizures	NNS	I-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
busulfan	NN	I-NP	O
course	NN	I-NP	O
or	CC	B-PP	O
within	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
dosing	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
the	DT	B-NP	O
total	JJ	I-NP	O
busulfan	NN	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
taken	VBN	I-VP	O
into	IN	B-PP	O
account	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
neurotoxicity	NN	B-NP	B
incidence	NN	I-NP	O
among	IN	B-PP	O
patients	NNS	B-NP	O
under	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
patients	NNS	B-NP	O
under	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
busulfan	NN	I-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
with	IN	B-PP	O
continuous	JJ	B-NP	O
i.v.	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
clonazepam	NN	B-NP	O
;	:	O	O
none	NN	B-NP	O
had	VBD	B-VP	O
any	DT	B-NP	O
neurological	JJ	I-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

Busulfan	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
gas	NN	I-NP	O
chromatographic	JJ	I-NP	O
-	HYPH	I-NP	O
mass	NN	I-NP	O
spectrometry	NN	I-NP	O
assay	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
plasma	NN	I-NP	O
and	CC	I-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
without	IN	B-PP	O
central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
disease	NN	I-NP	I
under	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
busulfan	NN	I-NP	O
with	IN	B-PP	O
clonazepam	NN	B-NP	O
:	:	O	O
busulfan	NN	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
:	:	O	O
plasma	NN	B-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
the	DT	B-NP	O
cerebrospinal	JJ	I-NP	O
fluid	NN	I-NP	O
:	:	O	O
plasma	NN	B-NP	O
ratio	NN	I-NP	O
previously	RB	B-VP	O
defined	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
busulfan	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
busulfan	NN	B-NP	O
neurotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
dose	NN	B-NP	O
-	HYPH	O	O
dependent	JJ	B-ADJP	O
in	IN	B-PP	O
children	NNS	B-NP	O
and	CC	O	O
efficiently	RB	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
clonazepam	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
busulfan	JJ	I-NP	O
dose	NN	I-NP	O
calculated	VBN	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
children	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
increased	VBN	B-NP	O
neurotoxicity	NN	I-NP	B
,	,	O	O
close	RB	B-ADVP	O
to	TO	B-PP	O
neurotoxicity	NN	B-NP	B
incidence	NN	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
.	.	O	O

Since	IN	B-SBAR	O
plasma	NN	B-NP	O
pharmacokinetic	JJ	I-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
faster	JJR	I-NP	O
busulfan	NN	I-NP	O
clearance	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
,	,	O	O
this	DT	B-NP	O
new	JJ	I-NP	O
dose	NN	I-NP	O
may	MD	B-VP	O
approximate	VB	I-VP	O
more	RBR	B-ADVP	O
closely	RB	I-ADVP	O
the	DT	B-NP	O
adult	JJ	I-NP	O
systemic	JJ	I-NP	O
exposure	NN	I-NP	O
obtained	VBN	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
usual	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
potential	JJ	B-NP	O
inferences	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
anticancer	JJ	B-NP	O
or	CC	I-NP	O
myeloablative	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
busulfan	NN	I-NP	O
dose	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
and	CC	I-NP	O
infants	NNS	I-NP	O
undergoing	VBG	B-VP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
reconsidered	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
pharmacokinetic	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Histamine	NN	B-NP	O
antagonists	NNS	I-NP	O
and	CC	O	O
d	NN	B-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
cardiac	JJ	B-NP	O
surgical	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Hemodynamic	JJ	B-NP	O
effects	NNS	I-NP	O
and	CC	O	O
histamine	NN	B-NP	O
release	NN	I-NP	O
by	IN	B-PP	O
bolus	NN	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

H1	NN	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
H2	NN	I-NP	O
-	HYPH	I-NP	O
histamine	NN	I-NP	O
antagonists	NNS	I-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
before	IN	B-PP	O
dosing	NN	B-NP	O
with	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
fashion	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
-	HYPH	I-NP	O
placebo	NN	I-NP	O
;	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
-	HYPH	I-NP	O
cimetidine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
plus	CC	O	O
placebo	NN	B-NP	O
;	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
-	HYPH	I-NP	O
chlorpheniramine	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
plus	CC	O	O
placebo	NN	B-NP	O
;	:	O	O
and	CC	O	O
group	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
-	HYPH	I-NP	O
cimetidine	NN	I-NP	O
plus	CC	I-NP	O
chlorpheniramine	NN	I-NP	O
.	.	O	O

Histamine	NN	B-NP	O
release	NN	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
highest	JJS	I-NP	O
level	NN	I-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
dosing	NN	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
negative	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
plasma	NN	B-NP	O
histamine	NN	I-NP	O
change	NN	I-NP	O
and	CC	O	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
not	RB	B-ADJP	O
present	JJ	I-ADJP	O
in	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Prior	JJ	B-NP	O
dosing	NN	I-NP	O
with	IN	B-PP	O
antagonists	NNS	B-NP	O
partially	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
hemodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	I-NP	O
tubocurarine	NN	I-NP	O
dosing	NN	I-NP	O
are	VBP	B-VP	O
only	RB	I-VP	O
partially	RB	I-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
histamine	NN	B-NP	O
release	NN	I-NP	O
.	.	O	O

Thus	RB	B-NP	O
prior	JJ	I-NP	O
dosing	NN	I-NP	O
with	IN	B-PP	O
H1	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
H2	NN	I-NP	O
-	HYPH	I-NP	O
antagonists	NNS	I-NP	O
provides	VBZ	B-VP	O
only	RB	B-NP	O
partial	JJ	I-NP	O
protection	NN	I-NP	O
.	.	O	O

Convulsant	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
and	CC	I-NP	O
regional	JJ	I-NP	O
brain	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
and	CC	I-NP	O
dopamine	NN	I-NP	O
.	.	O	O

Lindane	NN	B-NP	O
(	(	O	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
hexachlorocyclohexane	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
organochlorine	NN	I-NP	O
insecticide	NN	I-NP	O
with	IN	B-PP	O
known	JJ	B-NP	O
neurotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
.	.	O	O

Its	PRP$	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
action	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
well	RB	B-VP	O
understood	VBN	I-VP	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
proposed	VBN	I-VP	O
that	IN	B-SBAR	O
lindane	NN	B-NP	O
acts	VBZ	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
competitive	JJ	I-NP	O
antagonist	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
A	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
GABAergic	JJ	I-NP	O
and	CC	I-NP	O
dopaminergic	JJ	I-NP	O
systems	NNS	I-NP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
,	,	O	O
dopamine	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
brain	NN	I-NP	O
areas	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

All	DT	B-NP	O
animals	NNS	I-NP	O
suffered	VBD	B-VP	O
tonic	JJ	B-NP	O
convulsions	NNS	I-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
lindane	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
was	VBD	B-VP	O
only	RB	I-VP	O
slightly	RB	I-VP	O
but	CC	I-VP	O
significantly	RB	I-VP	O
decreased	VBD	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
colliculi	NNS	I-NP	O
without	IN	B-PP	O
modifications	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
areas	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mesencephalon	NN	I-NP	O
and	CC	O	O
that	DT	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
metabolite	NN	I-NP	O
DOPAC	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mesencephalon	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

Unusual	JJ	B-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
and	CC	O	O
review	NN	B-NP	O
of	IN	B-PP	O
literature	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
acute	JJ	B-NP	O
hepatitis	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
methimazole	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
hepatocellular	JJ	B-NP	B
necrosis	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
lupus	NN	I-NP	B
-	HYPH	B-NP	I
like	JJ	I-NP	I
syndrome	NN	I-NP	I
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
literature	NN	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
antithyroid	JJ	B-NP	O
drug	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
occurrence	NN	I-NP	O
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
complications	NNS	I-NP	O
of	IN	B-PP	O
thyroidectomy	NN	B-NP	O
and	CC	I-NP	O
radioiodine	NN	I-NP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
most	JJS	B-NP	O
circumstances	NNS	I-NP	O
131I	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
for	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
.	.	O	O

Anticonvulsant	JJ	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

MK	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
noncompetitive	JJ	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
(	(	O	O
NMDA	NN	B-NP	O
)	)	O	O
receptor	NN	B-NP	O
antagonist	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
anticonvulsant	JJ	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
seizure	NN	I-NP	B
models	NNS	I-NP	O
,	,	O	O
coadministration	NN	B-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
and	CC	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
major	JJ	I-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

First	RB	B-ADVP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
produced	VBD	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
anticonvulsant	JJ	I-NP	O
action	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
with	IN	I-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
different	JJ	B-NP	O
biochemical	JJ	I-NP	O
mechanisms	NNS	I-NP	O
control	VBP	B-VP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
models	NNS	I-NP	O
.	.	O	O

Second	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
anticonvulsant	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
only	RB	B-ADVP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
initial	JJ	B-NP	O
periods	NNS	I-NP	O
of	IN	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
observation	NN	I-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
demonstration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
conclusion	NN	I-NP	O
derived	VBN	B-VP	O
from	IN	B-PP	O
in	FW	B-NP	O
vitro	FW	I-NP	O
experiments	NNS	I-NP	O
that	IN	B-SBAR	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
binding	NN	I-NP	O
requires	VBZ	B-VP	O
agonist	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
opening	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
channel	NN	I-NP	O
sites	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Third	RB	B-ADVP	O
,	,	O	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
relatively	RB	B-ADJP	O
easy	JJ	I-ADJP	O
to	TO	B-VP	O
block	VB	I-VP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
by	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
anticonvulsants	NNS	B-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
difficult	JJ	I-ADJP	O
to	TO	B-VP	O
terminate	VB	I-VP	O
ongoing	JJ	B-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
and	CC	O	O
block	VB	B-VP	O
the	DT	B-NP	O
lethality	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
i.e.	FW	B-NP	O
,	,	O	O
during	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
,	,	O	O
gradually	RB	B-ADVP	O
reduced	VBD	B-VP	O
electrical	JJ	B-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
seizure	NN	I-NP	B
activity	NN	I-NP	O
and	CC	O	O
greatly	RB	B-VP	O
enhanced	VBD	I-VP	O
the	DT	B-NP	O
survival	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
receptors	NNS	I-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
and	CC	I-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
further	RB	I-VP	O
supported	VBN	I-VP	O
by	IN	B-PP	O
results	NNS	B-NP	O
showing	VBG	B-VP	O
that	IN	B-SBAR	O
nonconvulsive	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
NMDA	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
were	VBD	B-VP	O
synergistic	JJ	B-ADJP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
and	CC	O	O
subsequent	JJ	B-NP	O
mortality	NN	I-NP	O
.	.	O	O

Nifedipine	NN	B-NP	O
induced	VBD	B-VP	O
bradycardia	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
autonomic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
diabetic	JJ	I-NP	B
male	NN	I-NP	O
with	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
and	CC	I-NP	I
autonomic	JJ	I-NP	I
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
admitted	VBN	I-VP	O
with	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
at	IN	B-PP	O
a	DT	B-NP	O
ventricular	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
which	WDT	B-NP	O
slowed	VBD	B-VP	O
down	RB	B-ADVP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
when	WRB	B-ADVP	O
nifedipine	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
divided	VBN	I-NP	O
doses	NNS	I-NP	O
,	,	O	O
during	IN	B-PP	O
which	WDT	B-NP	O
he	PRP	B-NP	O
was	VBD	B-VP	O
paced	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
inconsistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
established	VBN	I-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
nifedipine	NN	B-NP	O
induces	VBZ	B-VP	O
tachycardia	NN	B-NP	B
in	IN	B-PP	O
normally	RB	B-NP	O
innervated	VBN	I-NP	O
hearts	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
hearts	NNS	B-NP	O
deprived	VBN	B-VP	O
of	IN	B-PP	O
compensatory	JJ	B-NP	O
sympathetic	JJ	I-NP	O
drive	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
bradycardia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
pretreatment	NN	I-NP	O
in	IN	B-PP	O
preventing	VBG	B-VP	O
the	DT	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
,	,	O	O
toxic	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
intraperitoneal	JJ	O	O
(	(	O	O
i.p.	JJ	B-ADJP	O
)	)	O	O
injection	NN	B-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
death	NN	I-NP	O
rate	NN	I-NP	O
)	)	O	O
or	CC	O	O
cocaine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
death	NN	I-NP	O
rate	NN	I-NP	O
)	)	O	O
.	.	O	O

Haloperidol	NN	B-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
prevent	VB	I-VP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
lower	JJR	B-ADVP	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
at	IN	B-PP	O
most	JJS	B-NP	O
doses	NNS	I-NP	O
tested	VBN	B-VP	O
.	.	O	O

Haloperidol	NN	B-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
highest	JJS	I-NP	O
doses	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
lowering	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mortality	NN	I-NP	O
rate	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
dose	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
dopamine	NN	I-NP	O
blocker	NN	I-NP	O
haloperidol	NN	I-NP	O
against	IN	B-PP	O
death	NN	B-NP	O
from	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
amphetamine	NN	I-NP	O
exposure	NN	I-NP	O
without	IN	B-PP	O
reducing	VBG	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
haloperidol	NN	B-NP	O
demonstrated	VBD	B-VP	O
an	DT	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
reduce	VB	I-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
without	IN	B-PP	O
significantly	RB	B-VP	O
reducing	VBG	I-VP	O
mortality	NN	B-NP	O
.	.	O	O

Autoradiographic	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
in	IN	B-PP	O
nuclei	NNS	B-NP	O
of	IN	B-PP	O
diethylstilbesterol	NN	B-NP	O
induced	VBD	B-VP	O
hamster	NN	B-NP	O
renal	JJ	I-NP	B
carcinomas	NNS	I-NP	I
.	.	O	O

Estrogen	NN	B-NP	O
binding	NN	I-NP	O
sites	NNS	I-NP	O
were	VBD	B-VP	O
demonstrated	VBN	I-VP	O
by	IN	B-PP	O
autoradiography	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
transplantable	JJ	I-NP	O
and	CC	O	O
num	CD	B-NP	O
primary	JJ	I-NP	O
diethylstilbesterol	NN	I-NP	O
induced	VBD	B-VP	O
renal	JJ	B-NP	B
carcinomas	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
hamsters	NNS	I-NP	O
.	.	O	O

Radiolabelling	NN	B-NP	O
,	,	O	O
following	VBG	B-PP	O
the	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
3H	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
beta	SYM	I-NP	O
estradiol	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
only	RB	B-ADVP	O
over	IN	B-PP	O
the	DT	B-NP	O
nuclei	NNS	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
cells	NNS	I-NP	O
;	:	O	O
stereologic	JJ	B-NP	O
analysis	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	B-NP	O
times	NNS	I-NP	O
higher	JJR	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
reduced	VBN	B-NP	O
silver	NN	I-NP	O
grains	NNS	I-NP	O
over	IN	B-PP	O
nuclei	NNS	B-NP	O
than	IN	B-PP	O
cytoplasm	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
rapid	JJ	B-NP	O
tubular	JJ	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
estradiol	NN	B-NP	O
which	WDT	B-NP	O
peaked	VBD	B-VP	O
in	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
normal	JJ	I-NP	O
cells	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
bind	VB	I-VP	O
the	DT	B-NP	O
ligand	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
published	VBN	I-NP	O
report	NN	I-NP	O
documenting	VBG	B-VP	O
the	DT	B-NP	O
preferential	JJ	I-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
binding	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
to	TO	B-PP	O
nuclei	NNS	B-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
in	IN	B-PP	O
estrogen	NN	B-NP	O
induced	VBD	B-VP	O
hamster	NN	B-NP	O
renal	JJ	I-NP	B
carcinomas	NNS	I-NP	I
.	.	O	O

Bradycardia	NNP	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-VP	O
biperiden	VB	I-VP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
postzosteric	JJ	I-NP	B
trigeminal	JJ	I-NP	B
neuralgia	NN	I-NP	I
,	,	O	O
intravenous	JJ	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
biperiden	JJ	I-NP	O
lactate	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
lasting	VBG	B-VP	O
paradoxical	JJ	B-NP	O
reaction	NN	I-NP	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
considerable	JJ	B-NP	O
bradycardia	NN	I-NP	B
,	,	O	O
dysarthria	NN	B-NP	B
,	,	O	O
and	CC	O	O
dysphagia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
back	RB	B-ADVP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
upon	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
orciprenaline	NN	B-NP	O
under	IN	B-PP	O
cardiac	JJ	B-NP	O
monitoring	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
.	.	O	O

Bradycardia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
biperiden	NN	B-NP	O
is	VBZ	B-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
speed	NN	I-NP	O
of	IN	B-PP	O
injection	NN	B-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
dual	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
atropine	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
muscarine	NN	B-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
labetalol	NN	B-NP	O
with	IN	B-PP	O
halothane	NN	B-NP	O
,	,	I-NP	O
enflurane	NN	I-NP	O
or	CC	I-NP	O
isoflurane	NN	I-NP	O
for	IN	B-PP	O
middle	JJ	B-NP	O
-	HYPH	I-NP	O
ear	NN	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
feasibility	NN	I-NP	O
of	IN	B-PP	O
using	VBG	B-VP	O
labetalol	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
and	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
blocking	VBG	I-NP	O
agent	NN	I-NP	O
,	,	O	O
as	IN	B-PP	O
a	DT	B-NP	O
hypotensive	JJ	I-NP	B
agent	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
inhalation	NN	B-NP	O
anaesthetics	NNS	I-NP	O
(	(	O	O
halothane	NN	B-NP	O
,	,	O	O
enflurane	NN	B-NP	O
or	CC	O	O
isoflurane	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
middle	JJ	B-NP	O
-	HYPH	I-NP	O
ear	NN	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
s.e.	NN	B-NP	O
mean	NN	I-NP	O
)	)	O	O
mmHg	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
min	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
halothane	NN	I-NP	O
(	(	O	O
H	NN	B-NP	O
)	)	O	O
group	NN	B-NP	O
,	,	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
min	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
enflurane	NN	I-NP	O
(	(	O	O
E	NN	B-NP	O
)	)	O	O
group	NN	B-NP	O
,	,	B-PP	O
and	CC	I-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
min	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
isoflurane	NN	I-NP	O
(	(	O	O
I	NN	B-NP	O
)	)	O	O
group	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
H	NN	I-NP	O
concentration	NN	I-NP	O
during	IN	B-PP	O
hypotension	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
inspiratory	JJ	I-NP	O
gas	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
vol	NN	I-NP	O
%	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
E	NN	I-NP	O
concentration	NN	I-NP	O
num	CD	I-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
vol	NN	I-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
num	CD	I-NP	O
concentration	NN	I-NP	O
num	CD	B-NP	O
+	SYM	I-NP	O
/	SYM	B-NP	O
-	SYM	B-VP	O
num	CD	B-NP	O
vol	NN	I-NP	O
%	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
fentanyl	NN	B-NP	O
and	CC	I-NP	O
d	NN	I-NP	O
-	HYPH	B-NP	O
tubocurarine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
initial	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
labetalol	NN	B-NP	O
for	IN	B-PP	O
lowering	VBG	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
stable	JJ	B-ADJP	O
without	IN	B-PP	O
tachy	JJ	B-NP	B
-	HYPH	I-NP	I
or	CC	I-NP	I
bradycardia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
operating	NN	I-NP	O
conditions	NNS	I-NP	O
regarding	VBG	B-VP	O
bleeding	NN	B-NP	B
were	VBD	B-VP	O
estimated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
concentration	NN	I-NP	O
rose	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
all	DT	B-NP	O
groups	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
values	NNS	I-NP	O
before	IN	B-PP	O
hypotension	NN	B-NP	B
and	CC	O	O
returned	VBD	B-VP	O
postoperatively	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
except	IN	B-PP	O
the	DT	B-NP	O
isoflurane	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
hypotension	NN	B-NP	B
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
rebound	NN	I-NP	O
phenomenon	NN	I-NP	O
in	IN	B-PP	O
either	CC	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
or	CC	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
labetalol	NN	B-NP	O
induces	VBZ	B-VP	O
easily	RB	B-NP	O
adjustable	JJ	I-NP	O
hypotension	NN	I-NP	B
without	IN	B-PP	O
compensatory	JJ	B-NP	O
tachycardia	NN	I-NP	B
and	CC	O	O
rebound	VB	B-VP	O
hypertension	NN	B-NP	B
.	.	O	O

Convulsion	NN	B-NP	B
following	VBG	B-PP	O
intravenous	JJ	B-NP	O
fluorescein	NN	I-NP	O
angiography	NN	I-NP	O
.	.	O	O

Tonic	JJ	B-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizures	NNS	I-NP	I
followed	VBD	B-VP	O
intravenous	JJ	B-NP	O
fluorescein	NN	I-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
fundus	NN	B-NP	O
angiography	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
precautions	NNS	B-NP	O
this	DT	B-NP	O
adverse	JJ	I-NP	O
reaction	NN	I-NP	O
recurred	VBD	B-VP	O
on	IN	B-PP	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
intravenous	JJ	B-NP	O
fluorescein	NN	I-NP	O
.	.	O	O

Pharmacology	NN	B-NP	O
of	IN	B-PP	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
phenytoin	NN	B-NP	O
prodrug	NN	I-NP	O
)	)	O	O
.	.	O	O

ACC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
the	DT	B-NP	O
disodium	NN	I-NP	O
phosphate	NN	I-NP	O
ester	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxymethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
diphenylhydantoin	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
prodrug	NN	I-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
with	IN	B-PP	O
advantageous	JJ	B-NP	O
physicochemical	JJ	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

ACC	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
is	VBZ	B-VP	O
rapidly	RB	I-VP	O
converted	VBN	I-VP	O
enzymatically	RB	B-ADVP	O
to	TO	B-PP	O
phenytoin	NN	B-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

ACC	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
have	VBP	B-VP	O
equivalent	JJ	B-NP	O
anticonvulsant	JJ	I-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
maximal	JJ	B-NP	O
electroshock	NN	I-NP	O
(	(	O	O
MES	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
mice	NNS	B-NP	O
following	VBG	B-PP	O
i.p.	JJ	B-NP	O
,	,	I-NP	O
oral	JJ	I-NP	O
,	,	O	O
or	CC	O	O
i.v.	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ED50	NN	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
i.v.	JJ	B-NP	O
ACC	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
for	IN	B-PP	O
i.v.	JJ	B-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
.	.	O	O

ACC	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
have	VBP	B-VP	O
similar	JJ	B-NP	O
antiarrhythmic	JJ	I-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
ouabain	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
total	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
or	CC	O	O
phenytoin	NN	B-NP	O
sodium	NN	I-NP	O
necessary	JJ	B-ADJP	O
to	TO	B-VP	O
convert	VB	I-VP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
to	TO	B-PP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Only	RB	B-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
displayed	VBD	B-VP	O
in	FW	B-NP	O
vitro	FW	I-NP	O
antiarrhythmic	JJ	I-NP	O
activity	NN	I-NP	O
against	IN	B-PP	O
strophanthidin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
arrhythmias	NNS	I-NP	B
in	IN	B-PP	O
guinea	NN	B-NP	O
pig	NN	I-NP	O
right	JJ	I-NP	O
atria	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
anesthetized	VBN	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
infused	VBN	I-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
equimolar	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
phenytoin	NN	B-NP	O
sodium	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ACC	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
treatments	NNS	I-NP	O
produced	VBD	B-VP	O
similar	JJ	B-NP	O
marked	JJ	I-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
contractile	JJ	B-NP	O
force	NN	I-NP	O
(	(	O	O
LVdP	NN	B-NP	O
/	SYM	O	O
dt	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
treatment	NN	I-NP	O
occurred	VBD	B-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
maximum	NN	B-NP	O
phenytoin	NN	I-NP	O
sodium	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
toxicity	NN	I-NP	B
studies	NNS	I-NP	O
of	IN	B-PP	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
phenytoin	NN	B-NP	O
sodium	NN	I-NP	O
were	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
rats	NNS	B-NP	O
,	,	O	O
rabbits	NNS	B-NP	O
,	,	O	O
and	CC	O	O
dogs	NNS	B-NP	O
by	IN	B-PP	O
i.v.	JJ	B-NP	O
,	,	I-NP	O
i.m.	JJ	I-NP	O
,	,	O	O
and	CC	O	O
i.p.	JJ	B-NP	O
routes	NNS	I-NP	O
of	IN	B-PP	O
administration	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
systemic	JJ	I-NP	O
toxic	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
agents	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
and	CC	O	O
occurred	VBD	B-VP	O
at	IN	B-PP	O
approximately	RB	B-NP	O
equivalent	JJ	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

Importantly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
local	JJ	I-NP	O
irritation	NN	I-NP	O
of	IN	B-PP	O
ACC	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
markedly	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
phenytoin	NN	B-NP	O
sodium	NN	I-NP	O
following	VBG	B-PP	O
i.m.	JJ	B-NP	O
administration.	NN	I-NP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Phenytoin	NN	B-NP	O
induced	VBD	B-VP	O
fatal	JJ	B-NP	O
hepatic	JJ	I-NP	B
injury	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
old	JJ	I-NP	O
female	NN	I-NP	O
developed	VBD	B-VP	O
fatal	JJ	B-NP	O
hepatic	JJ	I-NP	B
failure	NN	I-NP	I
after	IN	B-PP	O
phenytoin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
typical	JJ	I-NP	O
multisystem	JJ	I-NP	O
clinical	JJ	I-NP	O
pattern	NN	I-NP	O
precedes	VBZ	B-VP	O
the	DT	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	B
injury	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
hematologic	JJ	I-NP	O
,	,	I-NP	O
biochemical	JJ	I-NP	O
and	CC	I-NP	O
pathologic	JJ	I-NP	O
features	NNS	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
mixed	JJ	I-NP	O
hepatocellular	JJ	I-NP	B
damage	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
drug	NN	B-NP	B
hypersensitivity	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
phenytoin	NN	B-NP	O
who	WP	B-NP	O
presents	VBZ	B-VP	O
a	DT	B-NP	O
viral	JJ	I-NP	O
-	HYPH	I-NP	O
like	JJ	I-NP	O
illness	NN	I-NP	O
,	,	O	O
early	JJ	B-NP	O
recognition	NN	I-NP	O
and	CC	O	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
are	VBP	B-VP	O
mandatory	JJ	B-ADJP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
lethal	JJ	B-NP	O
pertussis	NN	I-NP	O
vaccine	NN	I-NP	O
reaction	NN	I-NP	O
with	IN	B-PP	O
histamine	NN	B-NP	O
H1	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
mortality	NN	B-NP	O
after	IN	B-PP	O
pertussis	NN	B-NP	B
immunization	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mouse	NN	I-NP	O
.	.	O	O

Without	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
animals	NNS	I-NP	O
died	VBD	B-VP	O
after	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
bovine	JJ	B-NP	O
serum	NN	I-NP	O
albumin	NN	I-NP	O
(	(	O	O
BSA	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
day	NN	B-NP	O
+	SYM	O	O
num	CD	B-NP	O
of	IN	B-PP	O
pertussis	NN	B-NP	B
immunization	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
cyproheptadine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
mianserin	NN	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
chlorpheniramine	NN	I-NP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
animals	NNS	I-NP	O
died	VBD	B-VP	O
after	IN	B-PP	O
receiving	VBG	B-VP	O
BSA	NN	B-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
+	SYM	B-ADVP	O
num	CD	B-NP	O
.	.	O	O

Blockade	NN	B-NP	O
of	IN	B-PP	O
histamine	NN	B-NP	O
H1	NN	I-NP	O
receptors	NNS	I-NP	O
may	MD	B-VP	O
reduce	VB	I-VP	O
mortality	NN	B-NP	O
in	IN	B-PP	O
pertussis	NN	B-NP	B
immunization	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Support	NN	B-NP	O
for	IN	B-PP	O
adrenaline	NN	B-NP	O
-	HYPH	I-NP	O
hypertension	NN	I-NP	B
hypothesis	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
hour	NN	I-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
adrenaline	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
crossover	JJ	I-NP	O
study	NN	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
infusions	NNS	I-NP	O
of	IN	B-PP	O
adrenaline	NN	B-NP	O
,	,	O	O
noradrenaline	NN	B-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
dextrose	NN	I-NP	O
solution	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
ml	NN	I-NP	O
/	SYM	B-NP	O
h	NN	I-NP	O
)	)	O	O
,	,	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
in	IN	B-PP	O
random	JJ	B-NP	O
order	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
apart	RB	B-ADVP	O
.	.	O	O

By	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
arterial	JJ	I-NP	O
ambulatory	JJ	I-NP	O
monitoring	NN	I-NP	O
the	DT	B-NP	O
haemodynamic	JJ	I-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
infusions	NNS	I-NP	O
were	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Adrenaline	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
noradrenaline	NN	B-NP	O
,	,	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
and	CC	O	O
protracted	VBD	B-VP	O
pressor	NN	B-NP	O
effect	NN	I-NP	O
.	.	O	O

Over	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
postinfusion	NN	I-NP	O
period	NN	I-NP	O
systolic	JJ	I-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
SEM	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
%	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
after	IN	B-PP	O
dextrose	NN	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
stress	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
adrenaline	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
pg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
cause	VBD	B-VP	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
and	CC	I-NP	O
protracted	VBN	I-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
strong	JJ	B-NP	O
support	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
adrenaline	NN	I-NP	O
-	HYPH	B-NP	O
hypertension	NN	I-NP	B
hypothesis	NN	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
alkylxanthines	NNS	B-NP	O
on	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Adenosine	NN	B-NP	O
antagonists	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
benefit	NN	B-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
ischaemic	JJ	I-NP	B
and	CC	I-NP	O
nephrotoxic	JJ	I-NP	B
models	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ARF	NN	B-NP	B
)	)	O	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
alkylxanthines	NNS	I-NP	O
with	IN	B-PP	O
different	JJ	B-NP	O
potencies	NNS	I-NP	O
as	IN	B-PP	O
adenosine	NN	B-NP	O
antagonists	NNS	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
phenyltheophylline	NN	I-NP	O
,	,	I-NP	O
theophylline	NN	I-NP	O
and	CC	I-NP	O
enprofylline	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
developing	VBG	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
daily	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
.	.	O	O

Renal	JJ	B-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
biochemical	JJ	B-NP	O
(	(	O	O
plasma	NN	B-NP	O
urea	NN	I-NP	O
and	CC	O	O
creatinine	NN	B-NP	O
)	)	O	O
,	,	O	O
functional	JJ	B-ADJP	O
(	(	O	O
urine	NN	B-NP	O
analysis	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
3H	NN	I-NP	O
]	)	I-NP	O
inulin	NN	I-NP	O
and	CC	O	O
[	(	B-NP	O
14C	NN	I-NP	O
]	)	I-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
aminohippuric	JJ	I-NP	O
acid	NN	I-NP	O
clearances	NNS	I-NP	O
)	)	O	O
and	CC	O	O
morphological	JJ	B-NP	O
(	(	O	O
degree	NN	B-NP	O
of	IN	B-PP	O
necrosis	NN	B-NP	B
)	)	O	O
indices	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
various	JJ	I-NP	O
drug	NN	I-NP	O
treatments	NNS	I-NP	O
produced	VBD	B-VP	O
improvements	NNS	B-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	B-NP	O
all	DT	I-NP	O
,	,	O	O
measurements	NNS	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
any	DT	B-NP	O
improvement	NN	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
largely	RB	B-ADVP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
beneficial	JJ	I-NP	O
effect	NN	I-NP	O
exerted	VBN	B-VP	O
by	IN	B-PP	O
its	PRP$	B-NP	O
vehicle	NN	I-NP	O
(	(	O	O
polyethylene	NN	B-NP	O
glycol	NN	I-NP	O
and	CC	O	O
NaOH	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
consistent	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
noted	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
alkylxanthines	NNS	I-NP	O
tested	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
adenosine	NN	B-NP	O
plays	VBZ	B-VP	O
little	JJ	O	O
,	,	O	O
if	IN	B-SBAR	O
any	DT	B-NP	O
,	,	O	O
pathophysiological	JJ	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ARF	NN	I-NP	B
.	.	O	O

Adverse	JJ	B-NP	O
ocular	JJ	I-NP	O
reactions	NNS	I-NP	O
possibly	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
isotretinoin	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
adverse	JJ	I-NP	O
ocular	JJ	I-NP	O
reactions	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
isotretinoin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
cystic	JJ	I-NP	O
acne	NN	I-NP	B
.	.	O	O

Blepharoconjunctivitis	NN	B-NP	B
,	,	O	O
subjective	JJ	B-NP	O
complaints	NNS	I-NP	O
of	IN	B-PP	O
dry	JJ	B-NP	B
eyes	NNS	I-NP	I
,	,	O	O
blurred	VBD	B-VP	B
vision	NN	B-NP	I
,	,	O	O
contact	NN	B-NP	O
lens	NN	I-NP	O
intolerance	NN	I-NP	O
,	,	O	O
and	CC	O	O
photodermatitis	NN	B-NP	B
are	VBP	B-VP	O
reversible	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

More	RBR	B-NP	O
serious	JJ	I-NP	O
ocular	JJ	I-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
include	VBP	B-VP	O
papilledema	NN	B-NP	B
,	,	O	O
pseudotumor	NN	B-NP	B
cerebri	NN	I-NP	I
,	,	O	O
and	CC	O	O
white	JJ	B-NP	O
or	CC	I-NP	O
gray	JJ	I-NP	O
subepithelial	JJ	I-NP	O
corneal	JJ	I-NP	B
opacities	NNS	I-NP	I
;	:	O	O
all	DT	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
are	VBP	B-VP	O
reversible	JJ	B-ADJP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
discontinued	VBN	I-VP	O
.	.	O	O

Reported	VBN	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
decreased	VBN	B-NP	O
dark	JJ	I-NP	O
adaptation	NN	I-NP	O
are	VBP	B-VP	O
under	IN	B-PP	O
investigation	NN	B-NP	O
.	.	O	O

Isotretinoin	NN	B-NP	O
is	VBZ	B-VP	O
contraindicated	VBN	I-VP	O
in	IN	B-PP	O
pregnancy	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
many	JJ	I-NP	O
reported	VBD	B-VP	O
congenital	JJ	B-NP	B
abnormalities	NNS	I-NP	I
after	IN	B-PP	O
maternal	JJ	B-NP	O
use	NN	I-NP	O
(	(	O	O
including	VBG	B-PP	O
microphthalmos	NNS	B-NP	B
,	,	O	O
orbital	JJ	B-NP	O
hypertelorism	NN	I-NP	B
,	,	O	O
and	CC	O	O
optic	JJ	B-NP	B
nerve	NN	I-NP	I
hypoplasia	NN	I-NP	I
)	)	O	O
.	.	O	O

Procaterol	NN	B-NP	O
and	CC	I-NP	O
terbutaline	NN	I-NP	O
in	IN	B-PP	O
bronchial	JJ	B-NP	B
asthma	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
over	IN	B-PP	O
study	NN	B-NP	O
.	.	O	O

Procaterol	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adrenoceptor	NN	I-NP	O
stimulant	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
over	IN	B-PP	O
trial	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
bronchial	JJ	B-NP	B
asthma	NN	I-NP	I
.	.	O	O

Oral	JJ	B-NP	O
procaterol	NN	I-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
b.d.	NN	I-NP	O
,	,	O	O
procaterol	NN	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
b.d.	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
terbutaline	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
t.i.d.	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
randomly	RB	B-ADVP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
treatment	NN	I-NP	O
periods	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
best	RBS	I-NP	O
clinical	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
with	IN	B-PP	O
terbutaline	NN	B-NP	O
.	.	O	O

Both	CC	O	O
anti	AFX	O	O
-	HYPH	B-NP	O
asthmatic	JJ	I-NP	B
and	CC	I-NP	O
tremorgenic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
procaterol	NN	B-NP	O
were	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADJP	O
related	VBN	I-ADJP	O
.	.	O	O

Procaterol	NNP	B-NP	O
appeared	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
tested	VBN	B-VP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
twice	RB	I-NP	O
daily	JJ	I-NP	O
regimen	NN	I-NP	O
would	MD	B-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
suitable	JJ	B-ADJP	O
with	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Subacute	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
B	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
rat	NN	I-NP	O
heart	NN	I-NP	B
hypertrophy	NN	I-NP	I
in	IN	B-PP	O
correlation	NN	B-NP	O
with	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
beta	SYM	B-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
B	NN	B-NP	O
num	CD	I-NP	O
/	SYM	O	O
num	CD	B-NP	O
i.e.	FW	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dichlorophenoxy	NN	I-NP	O
)	)	O	O
-	SYM	B-NP	O
num	CD	I-NP	O
[	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dimethoxyphenyl	NN	I-NP	O
)	)	O	O
ethanolamino	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
prop	NN	I-NP	O
an	DT	B-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
ol	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
blocking	NN	I-NP	O
and	CC	O	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
stimulating	VBG	B-VP	O
properties	NNS	B-NP	O
with	IN	B-PP	O
propranolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
heart	NN	I-NP	B
hypertrophy	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
correlation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
neither	DT	B-NP	O
found	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
nor	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
suppress	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
hypertrophy	NN	I-NP	I
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
blockers	NNS	I-NP	O
.	.	O	O

Both	CC	O	O
beta	SYM	B-NP	O
-	HYPH	O	O
blockers	NNS	B-NP	O
influenced	VBD	B-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
hypertrophy	NN	B-NP	B
to	TO	B-PP	O
a	DT	B-NP	O
different	JJ	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
reproducible	JJ	B-NP	O
extent	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
possible	JJ	B-ADJP	O
to	TO	B-VP	O
suppress	VB	I-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
ornithine	NN	I-NP	O
decarboxylase	NN	I-NP	O
activity	NN	I-NP	O
with	IN	B-PP	O
both	CC	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
blockers	NNS	I-NP	O
in	IN	B-PP	O
hypertrophied	JJ	B-NP	B
hearts	NNS	I-NP	I
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
mass	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
propranolol	NN	B-NP	O
nor	CC	O	O
B	NN	B-NP	O
num	CD	I-NP	O
/	SYM	O	O
num	CD	B-NP	O
could	MD	B-VP	O
stop	VB	I-VP	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
characteristic	JJ	I-NP	O
myosin	NN	I-NP	O
isoenzyme	NN	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hypertrophied	JJ	I-NP	B
rat	NN	I-NP	O
heart	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
investigations	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
provide	VB	I-VP	O
any	DT	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
blockers	NNS	I-NP	O
propranolol	NN	I-NP	O
and	CC	I-NP	O
B	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
have	VBP	B-VP	O
the	DT	B-NP	O
potency	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
isoproterenol	NN	B-NP	O
from	IN	B-PP	O
producing	VBG	B-VP	O
heart	NN	B-NP	B
hypertrophy	NN	I-NP	I
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
oxitropium	NN	B-NP	O
bromide	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
slow	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
theophylline	NN	I-NP	O
on	IN	B-PP	O
nocturnal	JJ	B-NP	O
asthma	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
inhaled	JJ	I-NP	O
antimuscarinic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
oxitropium	NN	B-NP	O
bromide	NN	I-NP	O
,	,	O	O
and	CC	O	O
of	IN	B-PP	O
a	DT	B-NP	O
slow	JJ	I-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
theophylline	NN	I-NP	O
preparation	NN	I-NP	O
upon	IN	B-PP	O
nocturnal	JJ	B-NP	O
asthma	NN	I-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
oxitropium	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
or	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
t.i.d.	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
)	)	O	O
whereas	IN	O	O
num	CD	B-NP	O
received	VBD	B-VP	O
theophylline	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
b.i.d	NN	I-NP	O
.	.	O	O

Morning	VBG	B-NP	O
dipping	NN	I-NP	O
,	,	O	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
peak	NN	B-NP	O
flow	NN	I-NP	O
overnight	RB	B-ADVP	O
,	,	O	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
periods	NNS	I-NP	O
when	WRB	B-ADVP	O
either	CC	O	O
active	JJ	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
taken	VBN	I-VP	O
,	,	O	O
whereas	IN	O	O
no	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
noticed	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
placebo	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
noticed	VBN	I-VP	O
between	IN	B-PP	O
results	NNS	B-NP	O
obtained	VBN	B-VP	O
with	IN	B-PP	O
either	CC	B-NP	O
active	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
with	IN	B-PP	O
either	CC	O	O
dosage	NN	B-NP	O
of	IN	B-PP	O
oxitropium	NN	B-NP	O
.	.	O	O

No	DT	B-NP	O
subject	NN	I-NP	O
reported	VBD	B-VP	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oxitropium	NN	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
subjects	NNS	I-NP	O
reporting	VBG	B-VP	O
nausea	NN	B-NP	B
,	,	I-NP	O
vomiting	NN	I-NP	B
and	CC	I-NP	O
tremors	NNS	I-NP	B
after	IN	B-PP	O
theophylline	NN	B-NP	O
.	.	O	O

Oxitropium	NN	B-NP	O
proves	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
valuable	JJ	I-NP	O
alternative	NN	I-NP	O
to	TO	B-PP	O
theophylline	NN	B-NP	O
in	IN	B-PP	O
nocturnal	JJ	B-NP	O
asthma	NN	I-NP	B
,	,	O	O
since	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
equally	RB	B-ADJP	O
potent	JJ	I-ADJP	O
,	,	O	O
safer	JJR	B-ADJP	O
and	CC	O	O
does	VBZ	B-VP	O
not	RB	I-VP	O
require	VB	I-VP	O
the	DT	B-NP	O
titration	NN	I-NP	O
of	IN	B-PP	O
dosage	NN	B-NP	O
.	.	O	O

Penicillin	NN	B-NP	O
anaphylaxis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
penicillin	NN	I-NP	O
anaphylaxis	NN	I-NP	B
is	VBZ	B-VP	O
described	VBN	I-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
terminology	NN	I-NP	O
,	,	O	O
occurrence	NN	B-NP	O
,	,	O	O
clinical	JJ	B-NP	O
manifestations	NNS	I-NP	O
,	,	O	O
pathogenesis	NN	B-NP	O
,	,	O	O
prevention	NN	B-NP	O
,	,	O	O
and	CC	O	O
treatment	NN	B-NP	O
of	IN	B-PP	O
anaphylaxis	NN	B-NP	B
are	VBP	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Emergency	NN	B-NP	O
physicians	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
penicillin	NN	I-NP	O
anaphylaxis	NN	I-NP	B
in	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
prevent	VB	I-VP	O
its	PRP$	B-NP	O
occurrence	NN	I-NP	O
by	IN	B-PP	O
prescribing	VBG	B-VP	O
the	DT	B-NP	O
antibiotic	JJ	I-NP	O
judiciously	RB	B-ADVP	O
and	CC	I-ADVP	O
knowledgeably	RB	I-ADVP	O
and	CC	O	O
to	TO	B-VP	O
offer	VB	I-VP	O
optimal	JJ	B-NP	O
medical	JJ	I-NP	O
therapy	NN	I-NP	O
once	RB	O	O
this	DT	B-NP	O
life	NN	I-NP	O
-	HYPH	B-VP	O
threatening	VBG	I-VP	O
reaction	NN	B-NP	O
has	VBZ	B-VP	O
begun	VBN	I-VP	O
.	.	O	O

Reversible	JJ	B-NP	O
valproic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dementia	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Reversible	JJ	B-NP	O
valproic	JJ	I-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dementia	NN	I-NP	B
was	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
epilepsy	NN	B-NP	B
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
insidious	JJ	B-NP	O
progressive	JJ	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
global	JJ	B-NP	O
cognitive	JJ	I-NP	O
abilities	NNS	I-NP	O
documented	VBN	B-VP	O
by	IN	B-PP	O
serial	JJ	B-NP	O
neuropsychological	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

Repeat	NN	B-NP	O
neuropsychological	JJ	I-NP	O
testing	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
revealed	VBD	B-VP	O
dramatic	JJ	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
IQ	NN	B-NP	O
,	,	O	O
memory	NN	B-NP	O
,	,	O	O
naming	NN	B-NP	O
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
tasks	NNS	I-NP	O
commensurate	VBP	B-VP	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
recovery	NN	I-NP	O
in	IN	B-PP	O
his	PRP$	B-NP	O
intellectual	JJ	I-NP	O
capacity	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
pathophysiological	JJ	I-NP	O
mechanisms	NNS	I-NP	O
which	WDT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
operative	JJ	B-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
include	VBP	B-VP	O
:	:	O	O
a	DT	B-NP	O
direct	JJ	I-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
toxic	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
;	:	O	O
a	DT	B-NP	O
paradoxical	JJ	I-NP	O
epileptogenic	JJ	I-NP	O
effect	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
;	:	O	O
and	CC	O	O
an	DT	B-NP	O
indirect	JJ	I-NP	O
CNS	NN	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
mediated	VBN	B-VP	O
through	IN	B-PP	O
valproic	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperammonemia	NN	I-NP	B
.	.	O	O

Reversal	NN	B-NP	O
of	IN	B-PP	O
scopolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
of	IN	B-PP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
by	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
training	NN	I-NP	O
naloxone	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
experiments	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
modulating	VBG	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
retention	NN	I-NP	B
deficit	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
paradigm	NN	I-NP	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Scopolamine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
methyl	NN	B-NP	O
scopolamine	NN	I-NP	O
,	,	O	O
induced	VBD	B-VP	O
an	DT	B-NP	O
amnesia	NN	I-NP	B
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
latency	NN	B-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
parameters	NNS	I-NP	O
.	.	O	O

Naloxone	NN	B-NP	O
injected	VBN	B-VP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
training	NN	B-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
retention	NN	I-NP	B
deficit	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
peak	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
antagonized	VBN	I-VP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
,	,	O	O
demonstrating	VBG	B-VP	O
the	DT	B-NP	O
opioid	JJ	I-NP	O
specificity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
naloxone	NN	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Post	AFX	B-NP	O
-	HYPH	I-NP	O
training	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
or	CC	O	O
as	IN	B-PP	O
a	DT	B-NP	O
split	JJ	I-NP	O
dose	NN	I-NP	O
also	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
.	.	O	O

Control	NN	B-NP	O
experiments	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
neither	CC	B-NP	O
an	DT	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
pain	NN	B-NP	B
sensitivity	NN	I-NP	O
(	(	O	O
pre	AFX	O	O
-	HYPH	O	O
training	NN	B-NP	O
naloxone	NN	I-NP	O
)	)	O	O
nor	CC	O	O
an	DT	B-NP	O
induced	VBN	I-NP	O
aversive	JJ	I-NP	O
state	NN	I-NP	O
(	(	O	O
post	AFX	O	O
-	HYPH	O	O
training	NN	B-NP	O
naloxone	NN	I-NP	O
)	)	O	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
responsible	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
naloxone	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
retention	NN	I-NP	B
deficit	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
extend	VBP	B-VP	O
previous	JJ	B-NP	O
findings	NNS	I-NP	O
implicating	VBG	B-VP	O
a	DT	B-NP	O
cholinergic	JJ	I-NP	O
-	HYPH	I-NP	O
opioid	JJ	I-NP	O
interaction	NN	I-NP	O
in	IN	B-PP	O
memory	NN	B-NP	O
processes	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
possible	JJ	I-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
interaction	NN	I-NP	O
involving	VBG	B-VP	O
the	DT	B-NP	O
septo	AFX	I-NP	O
-	HYPH	I-NP	O
hippocampal	JJ	I-NP	O
cholinergic	JJ	I-NP	O
pathway	NN	I-NP	O
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Electron	NN	B-NP	O
microscopic	JJ	I-NP	O
investigations	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
lesions	NNS	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
urinary	JJ	I-NP	I
bladder	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
prevention	NN	I-NP	O
by	IN	B-PP	O
mesna	NN	B-NP	O
.	.	O	O

Fully	RB	B-NP	O
developed	VBN	I-NP	O
cyclophosphamide	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
nearly	RB	B-NP	O
complete	JJ	I-NP	O
detachment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
urothelium	NN	I-NP	O
,	,	O	O
severe	JJ	B-NP	O
submucosal	JJ	I-NP	O
edema	NN	I-NP	B
owing	VBG	B-VP	O
to	TO	I-VP	O
damage	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
microvascular	JJ	I-NP	O
bed	NN	I-NP	O
and	CC	O	O
focal	JJ	B-NP	O
muscle	NN	I-NP	O
necroses	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
initial	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
attack	NN	I-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
cyclophosphamide	NN	I-NP	O
metabolites	NNS	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
fragmentation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
luminal	JJ	I-NP	O
membrane	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
damages	VBZ	B-VP	O
the	DT	B-NP	O
cellular	JJ	I-NP	O
barrier	NN	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
hypertonic	JJ	I-NP	O
urine	NN	I-NP	O
.	.	O	O

Subsequent	JJ	B-NP	O
breaks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
cell	NN	I-NP	O
membranes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
superficial	JJ	I-NP	O
cells	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
plasma	NN	I-NP	O
membranes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intermediate	JJ	I-NP	O
and	CC	I-NP	O
basal	JJ	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
intercellular	JJ	B-NP	O
and	CC	I-NP	O
intracellular	JJ	I-NP	O
edema	NN	I-NP	B
and	CC	I-NP	O
disintegration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
desmosomes	NNS	I-NP	O
and	CC	I-NP	O
hemidesmosomes	NNS	I-NP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
progressive	JJ	B-NP	O
degeneration	NN	I-NP	O
and	CC	I-NP	O
detachment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
epithelial	JJ	I-NP	O
cells	NNS	I-NP	O
with	IN	B-PP	O
exposure	NN	B-NP	O
and	CC	I-NP	O
splitting	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
membrane	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
become	VBP	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
later	JJ	I-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
experiment	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
vessels	NNS	I-NP	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
diameter	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
location	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
damage	NN	I-NP	O
indicate	VBP	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
mediator	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
permeability	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
morphological	JJ	I-NP	O
correlate	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
gaps	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
interendothelial	JJ	I-NP	O
cell	NN	I-NP	O
connections	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
venules	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
effectively	RB	I-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
mesna	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
only	JJ	I-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
involvement	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
specific	JJ	B-NP	O
granules	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
presumed	JJ	I-NP	O
lysosomal	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
superficial	JJ	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

Increase	NN	B-NP	O
in	IN	B-PP	O
intragastric	JJ	B-NP	O
pressure	NN	I-NP	O
during	IN	B-PP	O
suxamethonium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
fasciculations	NNS	I-NP	I
in	IN	B-PP	O
children	NNS	B-NP	O
:	:	O	O
inhibition	NN	B-NP	O
by	IN	B-PP	O
alfentanil	NN	B-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
intragastric	JJ	B-NP	O
pressure	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.v.	JJ	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
(	(	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	I-NP	O
yr	NN	I-NP	O
)	)	O	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
either	CC	B-NP	O
physiological	JJ	I-NP	O
saline	NN	I-NP	O
or	CC	I-NP	O
alfentanil	NN	I-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

Anaesthesia	NN	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
thiopentone	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
kg	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	B
fasciculations	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
suxamethonium	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
alfentanil	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
intragastric	JJ	I-NP	O
pressure	NN	I-NP	O
during	IN	B-PP	O
muscle	NN	B-NP	B
fasciculations	NNS	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
SEM	NN	B-NP	O
)	)	O	O
cm	NN	B-NP	O
H2O	NN	I-NP	O
)	)	O	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
alfentanil	NN	I-NP	O
group	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
SEM	NN	B-NP	O
)	)	O	O
cm	NN	B-NP	O
H2O	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
intragastric	JJ	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
directly	RB	B-ADJP	O
related	VBN	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	B
fasciculations	NNS	I-NP	I
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
intragastric	JJ	B-NP	O
pressure	NN	I-NP	O
increases	VBZ	B-VP	O
significantly	RB	B-ADVP	O
during	IN	B-PP	O
muscle	NN	B-NP	B
fasciculations	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
suxamethonium	NN	B-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
children	NNS	I-NP	O
.	.	O	O

Alfentanil	NNP	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
effectively	RB	B-ADVP	O
inhibits	VBZ	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
muscle	NN	I-NP	B
fasciculations	NNS	I-NP	I
;	:	O	O
moreover	RB	B-ADVP	O
,	,	O	O
intragastric	JJ	B-NP	O
pressure	NN	I-NP	O
remains	VBZ	B-VP	O
at	IN	B-PP	O
its	PRP$	B-NP	O
control	NN	I-NP	O
value	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
insulin	NN	I-NP	O
treatment	NN	I-NP	O
normalizes	VBZ	B-VP	O
the	DT	B-NP	O
resistance	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
cardiotoxic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
in	IN	B-PP	O
streptozotocin	NN	B-NP	O
diabetic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
morphometric	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	O
fibrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
acute	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
earlier	JJR	I-NP	O
reported	VBD	B-VP	O
protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
streptozotocin	NN	B-NP	O
diabetes	NNS	I-NP	B
against	IN	B-PP	O
the	DT	B-NP	O
cardiotoxic	JJ	I-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
(	(	O	O
ISO	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
crystalline	NN	B-NP	O
insulin	NN	I-NP	O
,	,	O	O
ISO	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
subcutaneously	RB	B-ADVP	O
and	CC	O	O
when	WRB	B-ADVP	O
ISO	NN	B-NP	O
induced	VBD	B-VP	O
fibrosis	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
was	VBD	B-VP	O
morphometrically	RB	I-VP	O
analyzed	VBN	I-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
highly	RB	I-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
slope	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
glucose	NN	I-NP	O
after	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
appeared	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
myocardial	JJ	I-NP	O
content	NN	I-NP	O
of	IN	B-PP	O
catecholamines	NNS	B-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
day	NN	I-NP	O
diabetic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
norepinephrine	NN	I-NP	O
content	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
while	IN	B-SBAR	O
epinephrine	NN	B-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

An	DT	B-NP	O
enhanced	VBN	I-NP	O
sympathetic	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
activity	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
consequent	JJ	I-NP	O
down	JJ	I-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	B-NP	O
receptors	NNS	I-NP	O
could	MD	B-VP	O
,	,	O	O
therefore	RB	B-ADVP	O
,	,	O	O
explain	VB	B-VP	O
this	DT	B-NP	O
catecholamine	NN	I-NP	O
resistance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rapid	JJ	I-NP	O
reversion	NN	I-NP	O
after	IN	B-PP	O
insulin	NN	B-NP	O
treatment	NN	I-NP	O
excludes	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
streptozotocin	NN	B-NP	O
in	IN	B-PP	O
itself	PRP	B-NP	O
causes	VBZ	B-VP	O
the	DT	B-NP	O
ISO	NN	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
points	NNS	B-NP	O
towards	IN	B-PP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
insulin	NN	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
myocardial	JJ	B-NP	O
catecholamine	NN	I-NP	O
sensitivity	NN	I-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
phenomenon	NN	I-NP	O
described	VBN	B-VP	O
might	MD	B-VP	O
elucidate	VB	I-VP	O
pathogenetic	JJ	B-NP	O
mechanisms	NNS	I-NP	O
behind	IN	B-PP	O
toxic	JJ	B-NP	O
myocardial	JJ	I-NP	O
cell	NN	I-NP	O
degeneration	NN	I-NP	O
and	CC	O	O
may	MD	B-VP	O
possibly	RB	I-VP	O
have	VB	I-VP	O
relevance	NN	B-NP	O
for	IN	B-PP	O
acute	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
complications	NNS	I-NP	O
in	IN	B-PP	O
diabetic	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Differential	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
on	IN	B-PP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
muscarinic	JJ	I-NP	O
cholinergic	JJ	I-NP	O
agonist	NN	I-NP	O
pilocarpine	NN	I-NP	O
induces	VBZ	B-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
followed	VBN	B-VP	O
by	IN	B-PP	O
widespread	JJ	B-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
forebrain	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
sodium	NN	B-NP	O
salicylate	NN	I-NP	O
,	,	O	O
phenylbutazone	NN	B-NP	O
,	,	O	O
indomethacin	NN	B-NP	O
,	,	O	O
ibuprofen	NN	B-NP	O
and	CC	O	O
mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
salicylate	NN	I-NP	O
,	,	O	O
ED50	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
and	CC	O	O
phenylbutazone	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
converted	VBD	B-VP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
convulsant	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
to	TO	B-PP	O
a	DT	B-NP	O
convulsant	JJ	I-NP	O
num	CD	I-NP	O
.	.	O	O

Indomethacin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
and	CC	O	O
ibuprofen	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
modulate	VB	I-VP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

Mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
prevented	VBD	B-VP	O
seizures	NNS	B-NP	B
and	CC	O	O
protected	JJ	B-NP	O
rats	NNS	I-NP	O
from	IN	B-PP	O
seizure	NN	B-NP	B
-	HYPH	B-PP	O
related	VBN	B-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
differentially	RB	B-ADVP	O
modulate	VBP	B-VP	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Acute	JJ	B-NP	B
neurologic	JJ	I-NP	I
dysfunction	NN	I-NP	I
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
etoposide	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
malignant	JJ	B-NP	B
glioma	NN	I-NP	I
.	.	O	O

Etoposide	NN	B-NP	O
(	(	O	O
VP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
many	JJ	B-NP	O
solid	JJ	I-NP	O
tumors	NNS	I-NP	B
and	CC	O	O
hematologic	JJ	B-NP	B
malignancies	NNS	I-NP	I
.	.	O	O

When	WRB	B-ADVP	O
used	VBN	B-VP	O
in	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
conjunction	NN	B-NP	O
with	IN	B-PP	O
autologous	JJ	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
agent	NN	I-NP	O
has	VBZ	B-VP	O
activity	NN	B-NP	O
against	IN	B-PP	O
several	JJ	B-NP	O
treatment	NN	I-NP	O
-	HYPH	I-NP	O
resistant	JJ	I-NP	O
cancers	NNS	I-NP	B
including	VBG	B-PP	O
malignant	JJ	B-NP	B
glioma	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
we	PRP	B-NP	O
treated	VBD	B-VP	O
for	IN	B-PP	O
recurrent	JJ	B-NP	O
or	CC	I-NP	O
resistant	JJ	I-NP	O
glioma	NN	I-NP	B
,	,	O	O
sudden	JJ	B-NP	O
severe	JJ	I-NP	O
neurologic	JJ	I-NP	B
deterioration	NN	I-NP	I
occurred	VBD	B-VP	O
.	.	O	O

This	DT	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
etoposide	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
clinical	JJ	I-NP	O
manifestations	NNS	I-NP	O
have	VBP	B-VP	O
included	VBN	I-VP	O
confusion	NN	B-NP	B
,	,	O	O
papilledema	NN	B-NP	B
,	,	O	O
somnolence	NN	B-NP	B
,	,	O	O
exacerbation	NN	B-NP	O
of	IN	B-PP	O
motor	NN	B-NP	B
deficits	NNS	I-NP	I
,	,	O	O
and	CC	O	O
sharp	JJ	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
activity	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
abnormalities	NNS	I-NP	O
resolved	VBD	B-VP	O
rapidly	RB	B-ADVP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
dexamethasone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
computerized	VBD	B-VP	O
tomographic	JJ	B-NP	O
(	(	O	O
CT	NN	B-NP	O
)	)	O	O
brain	NN	B-NP	O
scans	NNS	I-NP	O
demonstrated	VBD	B-VP	O
stability	NN	B-NP	O
in	IN	B-PP	O
tumor	NN	B-NP	B
size	NN	I-NP	O
and	CC	I-NP	O
peritumor	NN	I-NP	O
edema	NN	I-NP	B
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
pretransplant	NN	B-NP	O
scans	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
complication	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
represent	VB	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
new	JJ	I-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
etoposide	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
malignant	JJ	B-NP	B
glioma	NN	I-NP	I
.	.	O	O

Progressive	JJ	B-NP	O
bile	NN	I-NP	B
duct	NN	I-NP	I
injury	NN	I-NP	I
after	IN	B-PP	O
thiabendazole	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
developed	VBD	B-VP	O
jaundice	NN	B-NP	B
num	CD	I-NP	O
wk	NN	I-NP	O
after	IN	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
thiabendazole	NN	B-NP	O
.	.	O	O

Cholestasis	NN	B-NP	B
persisted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
yr	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
which	WDT	B-NP	O
time	NN	I-NP	O
a	DT	B-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
liver	NN	I-NP	O
biopsy	NN	I-NP	O
specimens	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
hepatectomy	NN	I-NP	O
specimen	NN	I-NP	O
were	VBD	B-VP	O
remarkable	JJ	B-ADJP	O
for	IN	B-PP	O
almost	RB	B-NP	O
complete	JJ	I-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
interlobular	JJ	B-NP	O
bile	NN	I-NP	O
ducts	NNS	I-NP	O
.	.	O	O

Prominent	JJ	B-NP	O
fibrosis	NN	I-NP	B
and	CC	O	O
hepatocellular	JJ	B-NP	O
regeneration	NN	I-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
present	JJ	B-ADJP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
lobular	JJ	I-NP	O
architecture	NN	I-NP	O
was	VBD	B-VP	O
preserved	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
represents	VBZ	B-VP	O
an	DT	B-NP	O
example	NN	I-NP	O
of	IN	B-PP	O
idiosyncratic	JJ	B-NP	O
drug	NN	I-NP	B
-	HYPH	B-VP	I
induced	VBN	B-NP	I
liver	NN	I-NP	I
damage	NN	I-NP	I
in	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
injury	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
bile	NN	I-NP	O
duct	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
autoimmune	JJ	I-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bile	NN	I-NP	B
duct	NN	I-NP	I
destruction	NN	I-NP	I
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
.	.	O	O

Differential	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydropyridine	NN	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
:	:	O	O
therapeutic	JJ	B-NP	O
implications	NNS	I-NP	O
.	.	O	O

Increasing	VBG	B-VP	O
recognition	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
has	VBZ	B-VP	O
stimulated	VBN	I-VP	O
research	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blocking	VBG	B-VP	O
agents	NNS	B-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
diseases	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
favorable	JJ	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
profiles	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
make	VBP	B-VP	O
them	PRP	B-NP	O
attractive	JJ	B-NP	O
therapeutic	JJ	I-NP	O
modalities	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
applications	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
parallel	VBP	B-VP	O
their	PRP$	B-NP	O
tissue	NN	I-NP	O
selectivity	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
verapamil	NN	B-NP	O
and	CC	I-NP	O
diltiazem	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
are	VBP	B-VP	O
roughly	RB	B-ADJP	O
equipotent	JJ	I-ADJP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
actions	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
and	CC	O	O
vascular	JJ	B-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
dihydropyridine	NN	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
are	VBP	B-VP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
potent	JJ	B-NP	O
peripheral	JJ	I-NP	O
vasodilator	NN	I-NP	O
agents	NNS	I-NP	O
that	WDT	B-NP	O
exert	VBP	B-VP	O
minimal	JJ	B-NP	O
electrophysiologic	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
nodal	NN	I-NP	O
or	CC	I-NP	O
conduction	NN	I-NP	O
tissue	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
dihydropyridine	NN	I-NP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
,	,	O	O
nifedipine	NN	B-NP	O
controls	VBZ	B-VP	O
angina	NN	B-NP	B
and	CC	I-NP	O
hypertension	NN	I-NP	B
with	IN	B-PP	O
minimal	JJ	B-NP	O
depression	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Additional	JJ	B-NP	O
members	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
studied	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
indications	NNS	B-NP	O
for	IN	B-PP	O
which	WDT	B-NP	O
they	PRP	B-NP	O
may	MD	B-VP	O
offer	VB	I-VP	O
advantages	NNS	B-NP	O
over	IN	B-PP	O
current	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Once	RB	B-ADVP	O
or	CC	O	O
twice	RB	B-NP	O
daily	RB	I-NP	O
dosage	NN	I-NP	O
possible	JJ	B-ADJP	O
with	IN	B-PP	O
nitrendipine	NN	B-NP	O
and	CC	I-NP	O
nisoldipine	NN	I-NP	O
offers	VBZ	B-VP	O
a	DT	B-NP	O
convenient	JJ	I-NP	O
administration	NN	I-NP	O
schedule	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
encourages	VBZ	B-VP	O
patient	NN	B-NP	O
compliance	NN	I-NP	O
in	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
coronary	JJ	I-NP	O
vasodilating	VBG	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
nisoldipine	NN	B-NP	O
have	VBP	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
investigation	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
use	NN	B-NP	O
in	IN	B-PP	O
angina	NN	B-NP	B
.	.	O	O

Selectivity	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
cerebrovascular	JJ	I-NP	O
bed	NN	I-NP	O
makes	VBZ	B-VP	O
nimodipine	NN	B-NP	O
potentially	RB	B-ADJP	O
useful	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
subarachnoid	JJ	B-NP	B
hemorrhage	NN	I-NP	I
,	,	O	O
migraine	NN	B-NP	B
headache	NN	I-NP	I
,	,	O	O
dementia	NN	B-NP	B
,	,	O	O
and	CC	O	O
stroke	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
general	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
dihydropyridine	NN	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
are	VBP	B-VP	O
usually	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
headache	NN	B-NP	B
,	,	O	O
facial	JJ	B-NP	O
flushing	NN	I-NP	B
,	,	O	O
palpitations	NNS	B-NP	B
,	,	O	O
edema	NN	B-NP	B
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
anorexia	NN	B-NP	B
,	,	O	O
and	CC	O	O
dizziness	NN	B-NP	B
being	VBG	B-VP	O
the	DT	B-NP	O
more	RBR	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
aminonucleoside	NN	B-NP	O
nephrosis	NN	I-NP	B
by	IN	B-PP	O
the	DT	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
protamine	NN	B-NP	O
.	.	O	O

An	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
focal	JJ	B-NP	B
segmental	JJ	I-NP	I
glomerular	JJ	I-NP	I
sclerosis	NN	I-NP	I
(	(	O	O
FSGS	NN	B-NP	B
)	)	O	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
puromycin	NN	B-NP	O
-	HYPH	O	O
aminonucleoside	NN	B-NP	O
(	(	O	O
AMNS	NN	B-NP	O
)	)	O	O
and	CC	O	O
protamine	NN	B-NP	O
sulfate	NN	I-NP	O
(	(	O	O
PS	NN	B-NP	O
)	)	O	O
.	.	O	O

Male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
uninephrectomized	JJ	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
before	RB	B-ADVP	O
,	,	O	O
received	VBD	B-VP	O
daily	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
subcutaneous	JJ	B-NP	O
AMNS	NN	I-NP	O
and	CC	O	O
intravenous	JJ	B-NP	O
PS	NNP	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
injections	NNS	B-NP	O
were	VBD	B-VP	O
repeated	VBN	I-VP	O
another	DT	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
.	.	O	O

They	PRP	B-NP	O
developed	VBD	B-VP	O
nephrotic	JJ	B-NP	B
syndrome	NN	I-NP	I
and	CC	O	O
finally	RB	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	B-NP	O
course	NN	I-NP	O
curve	NN	I-NP	O
of	IN	B-PP	O
creatinine	NN	B-NP	O
clearance	NN	I-NP	O
dropped	VBD	B-VP	O
and	CC	I-VP	O
showed	VBD	I-VP	O
significant	JJ	B-NP	O
difference	NN	I-NP	O
from	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
,	,	O	O
AMNS	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
PS	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
saline	NN	B-NP	O
injected	VBN	B-VP	O
.	.	O	O

Their	PRP$	B-NP	O
glomeruli	NNS	I-NP	O
showed	VBD	B-VP	O
changes	NNS	B-NP	O
of	IN	B-PP	O
progressive	JJ	B-NP	O
FSGS	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
ultrastructural	JJ	I-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
stage	NN	I-NP	O
revealed	VBD	B-VP	O
significant	JJ	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
particles	NNS	B-NP	O
of	IN	B-PP	O
perfused	VBN	B-NP	O
ruthenium	NN	I-NP	O
red	VBD	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
lamina	NN	I-NP	O
rara	NN	I-NP	O
externa	NN	I-NP	O
and	CC	O	O
marked	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
epithelial	JJ	B-NP	O
cell	NN	I-NP	O
cytoplasm	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
PS	NNP	B-NP	O
enhances	VBZ	B-VP	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
AMNS	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
glomerulus	NN	I-NP	O
and	CC	O	O
readily	RB	B-VP	O
produces	VBZ	I-VP	O
progressive	JJ	B-NP	O
FSGS	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
end	NN	I-NP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Theophylline	NN	B-NP	O
neurotoxicity	NN	I-NP	B
in	IN	B-PP	O
pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
neurotoxicity	NN	I-NP	B
of	IN	B-PP	O
theophylline	NN	B-NP	O
is	VBZ	B-VP	O
altered	VBN	I-VP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
pregnancy	NN	I-NP	O
.	.	O	O

Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
that	WDT	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
pregnant	JJ	B-NP	O
and	CC	I-NP	O
nonpregnant	JJ	I-NP	O
rats	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
age	NN	I-NP	O
and	CC	I-NP	O
strain	NN	I-NP	O
received	VBD	B-VP	O
infusions	NNS	B-NP	O
of	IN	B-PP	O
aminophylline	NN	B-NP	O
until	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
maximal	JJ	B-NP	O
seizures	NNS	I-NP	B
which	WDT	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

Theophylline	NN	B-NP	O
concentrations	NNS	I-NP	O
at	IN	B-PP	O
this	DT	B-NP	O
endpoint	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
(	(	O	O
total	NN	B-NP	O
)	)	O	O
and	CC	O	O
CSF	NN	B-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
but	CC	O	O
serum	NN	B-NP	O
(	(	O	O
free	JJ	B-ADJP	O
)	)	O	O
and	CC	O	O
brain	NN	B-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
slightly	RB	B-ADJP	O
different	JJ	I-ADJP	O
in	IN	B-PP	O
pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Theophylline	NN	B-NP	O
serum	NN	I-NP	O
protein	NN	I-NP	O
binding	NN	I-NP	O
determined	VBN	B-VP	O
by	IN	B-PP	O
equilibrium	NN	B-NP	O
dialysis	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
pregnant	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Fetal	JJ	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
at	IN	B-PP	O
onset	NN	B-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
mother	NN	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
maternal	JJ	B-NP	O
brain	NN	I-NP	O
and	CC	I-NP	O
CSF	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
correlated	VBD	B-VP	O
significantly	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
former	JJ	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
advanced	VBN	B-NP	O
pregnancy	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
negligible	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
neurotoxic	JJ	I-NP	B
response	NN	I-NP	O
to	TO	B-PP	O
theophylline	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Hyperkalemia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
indomethacin	NN	B-NP	O
and	CC	I-NP	O
naproxen	NN	I-NP	O
and	CC	O	O
reversed	VBN	B-VP	O
by	IN	B-PP	O
fludrocortisone	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
described	VBN	I-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
rheumatoid	JJ	I-NP	B
arthritis	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
mefenamic	JJ	B-NP	O
acid	NN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
whom	WP	B-NP	O
hyperkalemia	NN	B-NP	B
and	CC	O	O
inappropriate	JJ	B-NP	O
hypoaldosteronism	NN	I-NP	B
were	VBD	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
both	CC	O	O
indomethacin	NN	B-NP	O
and	CC	I-NP	O
naproxen	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
major	JJ	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
that	IN	B-SBAR	O
preexisting	VBG	B-VP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
predisposed	VBD	B-VP	O
this	DT	B-NP	O
patient	NN	I-NP	O
to	TO	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
renal	JJ	I-NP	I
tubular	JJ	I-NP	I
acidosis	NN	I-NP	I
with	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthetase	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
he	PRP	B-NP	O
was	VBD	B-VP	O
unable	JJ	B-ADJP	O
to	TO	B-VP	O
discontinue	VB	I-VP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
fludrocortisone	NN	B-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
,	,	O	O
correcting	VBG	B-VP	O
the	DT	B-NP	O
hyperkalemia	NN	I-NP	B
and	CC	O	O
allowing	VBG	B-VP	O
indomethacin	NN	B-NP	O
therapy	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
continued	VBN	I-VP	O
safely	RB	B-ADVP	O
.	.	O	O

Hypotension	NN	B-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
cisplatin	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
hypotension	NN	B-NP	B
,	,	O	O
developed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
colorectal	JJ	I-NP	B
carcinoma	NN	I-NP	I
while	IN	B-SBAR	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
cisplatin	NN	B-NP	O
(	(	O	O
CDDP	NN	B-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
hypotension	NN	B-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
required	VBD	B-VP	O
therapy	NN	B-NP	O
discontinuation	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
enzymes	NNS	I-NP	O
remained	VBD	B-VP	O
normal	JJ	B-ADJP	O
despite	IN	B-PP	O
transient	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
(	(	O	O
EKG	NN	B-NP	O
)	)	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
presentation	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
evaluation	NN	I-NP	O
(	(	O	O
hemodynamic	JJ	B-ADJP	O
,	,	O	O
echocardiographic	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
scintigraphic	JJ	B-ADJP	O
)	)	O	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
suggest	VBP	B-VP	O
new	JJ	B-NP	O
manifestations	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
influenced	VBN	I-VP	O
by	IN	B-PP	O
CDDP	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
pathophysiologic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
epileptic	JJ	I-NP	B
woman	NN	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

Despite	IN	B-PP	O
concerns	NNS	B-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
bone	NN	I-NP	B
marrow	NN	I-NP	I
toxicity	NN	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
only	RB	B-NP	O
the	DT	I-NP	O
fourth	JJ	I-NP	O
documented	VBN	I-NP	O
and	CC	I-NP	O
published	VBN	I-NP	O
report	NN	I-NP	O
.	.	O	O

Carbamazepine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
but	CC	O	O
physicians	NNS	B-NP	O
and	CC	I-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
exceedingly	RB	I-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
potentially	RB	I-NP	O
fatal	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
better	RBR	B-ADJP	O
prevented	VBN	I-ADJP	O
by	IN	B-PP	O
clinical	JJ	B-ADJP	O
than	IN	B-PP	O
by	IN	B-PP	O
laboratory	NN	B-NP	O
monitoring	NN	I-NP	O
.	.	O	O

Participation	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
bulbospinal	JJ	I-NP	O
serotonergic	JJ	I-NP	O
pathway	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
brain	NN	I-NP	O
in	IN	B-PP	O
clonidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
microliter	NN	I-NP	O
)	)	O	O
into	IN	B-PP	O
a	DT	B-NP	O
region	NN	I-NP	O
adjacent	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
ventrolateral	JJ	I-NP	O
surface	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
oblongata	NN	I-NP	O
on	IN	B-PP	O
cardiovascular	JJ	B-NP	O
function	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
urethane	NN	B-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Intramedullary	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
saline	NN	B-NP	O
vehicle	NN	I-NP	O
,	,	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
the	DT	I-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
clonidine	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
prior	JJ	B-NP	O
spinal	JJ	I-NP	O
transection	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
bilateral	JJ	B-NP	O
vagotomy	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
clonidine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
antagonized	VBN	I-VP	O
by	IN	B-PP	O
prior	JJ	B-NP	O
bilateral	JJ	I-NP	O
vagotomy	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
spinal	JJ	B-NP	O
transection	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
selective	JJ	B-NP	O
destruction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
nerves	NNS	I-NP	O
,	,	O	O
produced	VBN	B-VP	O
by	IN	B-PP	O
bilateral	JJ	B-NP	O
spinal	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydroxytryptamine	NN	I-NP	O
,	,	O	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
vasodepressor	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
bradycardiac	JJ	I-NP	B
responses	NNS	I-NP	O
to	TO	B-PP	O
clonidine	NN	B-NP	O
microinjected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
area	NN	I-NP	O
near	IN	B-PP	O
the	DT	B-NP	O
ventrolateral	JJ	I-NP	O
surface	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medulla	NN	I-NP	O
oblongata	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
bulbospinal	JJ	I-NP	O
serotonergic	JJ	I-NP	O
pathway	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
bradycardia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
is	VBZ	B-VP	O
brought	VBN	I-VP	O
about	RP	B-PRT	O
by	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
sympathetic	JJ	B-NP	O
efferent	JJ	I-NP	O
activity	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
induced	VBN	I-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
vagal	JJ	B-NP	O
efferent	JJ	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
in	IN	B-PP	O
neuroblastoma	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
imipramine	NN	B-NP	O
.	.	O	O

Hypertension	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
finding	NN	I-NP	O
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
neuroblastoma	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
Imipramine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
(	(	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
girl	NN	I-NP	O
with	IN	B-PP	O
neuroblastoma	NN	B-NP	B
who	WP	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
Imipramine	NN	B-NP	O
to	TO	B-VP	O
control	VB	I-VP	O
a	DT	B-NP	O
behavior	NN	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
later	RB	B-ADVP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
patient	NN	I-NP	O
s	NNS	I-NP	O
tumor	NN	I-NP	B
was	VBD	B-VP	O
recurring	VBG	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
hypertensive	JJ	I-NP	B
episode	NN	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
she	PRP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
elevation	NN	I-NP	O
at	IN	B-PP	O
initial	JJ	B-NP	O
diagnosis	NN	I-NP	O
and	CC	O	O
none	NN	B-NP	O
following	VBG	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Imipramine	NN	I-NP	O
(	(	O	O
when	WRB	B-ADVP	O
she	PRP	B-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
florid	JJ	B-NP	O
relapse	NN	I-NP	O
)	)	O	O
,	,	O	O
we	PRP	B-NP	O
believe	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
drug	NN	I-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
her	PRP$	B-NP	O
underlying	VBG	I-NP	O
disease	NN	I-NP	O
alone	RB	B-ADVP	O
caused	VBD	B-VP	O
her	PRP$	B-NP	O
hypertension	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
mechanism	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
is	VBZ	B-VP	O
believed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
increased	VBN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
vasoactive	JJ	B-NP	O
catecholamines	NNS	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
interference	NN	B-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
physiologic	JJ	I-NP	O
inactivation	NN	I-NP	O
by	IN	B-PP	O
Imipramine	NN	B-NP	O
.	.	O	O

From	IN	B-PP	O
this	DT	B-NP	O
experience	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
urge	VBP	B-VP	O
extreme	JJ	B-NP	O
caution	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
tricyclic	JJ	B-NP	O
antidepressants	NNS	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
active	JJ	B-NP	O
neuroblastoma	NN	I-NP	B
.	.	O	O

Rechallenge	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
oral	JJ	B-NP	B
candidiasis	NN	I-NP	I
or	CC	I-NP	O
hoarseness	NN	I-NP	B
with	IN	B-PP	O
beclomethasone	NN	B-NP	O
dipropionate	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
asthmatic	JJ	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
placed	VBN	I-VP	O
on	IN	B-PP	O
inhaled	VBN	B-NP	O
beclomethasone	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
developed	VBD	B-VP	O
either	CC	O	O
hoarseness	NN	B-NP	B
,	,	O	O
oral	JJ	B-NP	O
thrush	NN	I-NP	B
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
.	.	O	O

When	WRB	B-ADVP	O
their	PRP$	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
subsided	VBD	B-VP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
rechallenged	VBN	I-VP	O
with	IN	B-PP	O
inhaled	VBN	B-NP	O
beclomethasone	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
hoarseness	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
Candidiasis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
both	DT	B-NP	O
.	.	O	O

Oral	JJ	B-NP	O
thrush	NN	I-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
recur	VB	I-VP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hoarseness	NN	B-NP	B
had	VBD	B-VP	O
recurrence	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
restarted	VBN	I-VP	O
on	IN	B-PP	O
inhaled	VBN	B-NP	O
beclomethasone	NN	I-NP	O
when	WRB	B-ADVP	O
clinically	RB	B-ADVP	O
indicated	VBN	B-VP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
recurrence	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
patients	NNS	B-NP	O
who	WP	B-NP	O
develop	VBP	B-VP	O
hoarseness	NN	B-NP	B
should	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
re	AFX	B-ADJP	O
-	HYPH	I-ADJP	O
challenged	VBN	B-VP	O
.	.	O	O

Concomitant	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
prednisone	NN	I-NP	O
and	CC	O	O
topical	JJ	B-NP	O
beclomethasone	NN	I-NP	O
may	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
hoarseness	NN	B-NP	B
or	CC	I-NP	O
candidiasis	NN	I-NP	B
.	.	O	O

Cyclophosphamide	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
:	:	O	O
an	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
dosing	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
undergo	VBP	B-VP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
transplantation	NN	I-NP	O
are	VBP	B-VP	O
generally	RB	I-VP	O
immunosuppressed	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYA	NN	B-NP	O
)	)	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
usually	RB	I-VP	O
calculated	VBN	I-VP	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
weight	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
these	DT	B-NP	O
high	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
CYA	NN	B-NP	O
,	,	O	O
serious	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
,	,	O	O
but	CC	O	O
definitive	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
.	.	O	O

Since	IN	B-SBAR	O
chemotherapeutic	JJ	B-NP	O
agent	NN	I-NP	O
toxicity	NN	I-NP	B
generally	RB	B-ADVP	O
correlates	VBZ	B-VP	O
with	IN	B-PP	O
dose	NN	B-NP	O
per	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
calculated	VBD	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
CYA	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
transplanted	VBN	B-VP	O
at	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
CYA	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
correlated	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
per	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
CYA	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
as	IN	B-PP	O
preparation	NN	B-NP	O
for	IN	B-PP	O
marrow	NN	B-NP	O
grafting	NN	I-NP	O
underwent	VBD	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
transplants	NNS	I-NP	O
for	IN	B-PP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
,	,	O	O
Wiskott	NNP	B-NP	B
-	HYPH	I-NP	I
Aldrich	NNP	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
or	CC	O	O
severe	JJ	B-NP	B
combined	JJ	I-NP	I
immunodeficiency	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
symptoms	NNS	B-NP	O
and	CC	I-NP	O
signs	NNS	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
CYA	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
CYA	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
with	IN	B-PP	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
CYA	NN	B-NP	O
per	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
for	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
daily	JJ	B-NP	O
CYA	NN	I-NP	O
dose	NN	I-NP	O
:	:	O	O
Group	NN	B-NP	O
num	CD	I-NP	O
CYA	NN	I-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
or	CC	O	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
;	:	O	O
Group	NN	B-NP	O
num	CD	I-NP	O
CYA	NN	I-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
.	.	O	O

Cardiotoxicity	NN	B-NP	B
that	WDT	B-NP	O
was	VBD	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
CYA	NN	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
caused	VBD	B-VP	O
or	CC	I-VP	O
contributed	VBD	I-VP	O
to	TO	B-PP	O
death	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
v	NN	I-NP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
Group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
engraftment	NN	B-NP	O
of	IN	B-PP	O
evaluable	JJ	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
P	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
CYA	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
correlates	VBZ	B-VP	O
with	IN	B-PP	O
CYA	NN	B-NP	O
dosage	NN	I-NP	O
as	IN	B-SBAR	O
calculated	VBN	B-VP	O
by	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
with	IN	B-PP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
and	CC	I-NP	O
immunodeficiencies	NNS	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
effectively	RB	I-VP	O
prepared	VBN	I-VP	O
for	IN	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
grafting	VBG	B-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
CYA	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
than	IN	B-PP	O
patients	NNS	B-NP	O
whose	WP$	B-NP	O
CYA	NN	I-NP	O
dosage	NN	I-NP	O
is	VBZ	B-VP	O
calculated	VBN	I-VP	O
based	VBN	B-PP	O
on	IN	B-PP	O
weight	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
reaffirms	VBZ	B-VP	O
the	DT	B-NP	O
principle	NN	I-NP	O
that	IN	B-SBAR	O
drug	NN	B-NP	O
toxicity	NN	I-NP	B
correlates	VBZ	B-VP	O
with	IN	B-PP	O
dose	NN	B-NP	O
per	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
area	NN	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
aminoglycoside	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
epidemiology	NN	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
not	RB	I-VP	O
fully	RB	I-VP	O
understood	VBN	I-VP	O
.	.	O	O

Experimental	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
human	JJ	I-NP	O
volunteers	NNS	I-NP	O
indicate	VBP	B-VP	O
aminoglycosides	NNS	B-NP	O
cause	VBP	B-VP	O
proximal	JJ	B-NP	O
tubular	JJ	I-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
rarely	RB	B-ADVP	O
,	,	O	O
if	IN	B-SBAR	O
ever	RB	B-ADVP	O
,	,	O	O
cause	VBP	B-VP	O
glomerular	JJ	B-NP	B
or	CC	I-NP	I
tubular	JJ	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

Clinical	JJ	B-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
aminoglycosides	NNS	B-NP	O
in	IN	B-PP	O
seriously	RB	B-NP	O
ill	JJ	I-NP	O
patients	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
developing	VBG	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
during	IN	B-PP	O
therapy	NN	B-NP	O
ranges	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
attributable	JJ	I-NP	O
risk	NN	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
data	NNS	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
plasma	NN	B-NP	O
aminoglycoside	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
liver	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
advanced	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
high	JJ	B-NP	O
initial	JJ	I-NP	O
estimated	VBN	I-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
and	CC	O	O
,	,	O	O
possibly	RB	B-ADVP	O
,	,	O	O
female	JJ	B-NP	O
gender	NN	I-NP	O
all	DT	O	O
increase	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

Other	JJ	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
shock	NN	B-NP	B
,	,	O	O
appear	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
additive	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Predictive	JJ	B-NP	O
models	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
developed	VBN	I-VP	O
from	IN	B-PP	O
these	DT	B-NP	O
analyses	NNS	I-NP	O
that	WDT	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
identifying	VBG	B-VP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
high	JJ	B-NP	O
risk	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
models	NNS	I-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
developing	VBG	B-VP	O
insights	NNS	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

Flurothyl	NN	B-NP	O
seizure	NN	I-NP	B
thresholds	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
neonatally	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
monosodium	NN	B-NP	O
glutamate	NN	I-NP	O
(	(	O	O
MSG	NN	B-NP	O
)	)	O	O
:	:	O	O
evaluation	NN	B-NP	O
of	IN	B-PP	O
experimental	JJ	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
flurothyl	NN	B-NP	O
seizure	NN	I-NP	B
testing	NN	I-NP	O
.	.	O	O

Monosodium	NN	B-NP	O
glutamate	NN	I-NP	O
(	(	O	O
MSG	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
to	TO	B-PP	O
neonatal	JJ	B-NP	O
rodents	NNS	I-NP	O
produces	VBZ	B-VP	O
convulsions	NNS	B-NP	B
and	CC	O	O
results	VBZ	B-VP	O
in	IN	B-PP	O
numerous	JJ	B-NP	O
biochemical	JJ	I-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
deficits	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
neonatal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
MSG	NN	B-NP	O
produced	VBD	B-VP	O
permanent	JJ	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
,	,	O	O
since	IN	B-SBAR	O
previous	JJ	B-NP	O
investigations	NNS	I-NP	O
were	VBD	B-VP	O
inconclusive	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
flurothyl	NN	I-NP	O
ether	NN	I-NP	O
seizure	NN	I-NP	B
screening	NN	I-NP	O
technique	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
neonatal	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
MSG	NN	B-NP	O
.	.	O	O

MSG	NN	B-NP	O
treatment	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
significant	JJ	B-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
whole	JJ	B-NP	O
brain	NN	I-NP	O
weight	NN	I-NP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
seizure	NN	B-NP	B
threshold	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
naloxone	NN	I-NP	O
challenge	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
ineffective	JJ	B-ADJP	O
in	IN	B-PP	O
altering	VBG	B-VP	O
the	DT	B-NP	O
seizure	NN	I-NP	B
thresholds	NNS	I-NP	O
of	IN	B-PP	O
either	CC	O	O
control	NN	B-NP	O
of	IN	B-PP	O
MSG	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Flurothyl	NN	B-NP	O
ether	NN	I-NP	O
produced	VBD	B-VP	O
hypothermia	NN	B-NP	B
which	WDT	B-NP	O
was	VBD	B-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
flurothyl	NN	B-NP	O
exposure	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
hypothermia	NN	B-NP	B
to	TO	B-PP	O
seizure	NN	B-NP	B
induction	NN	I-NP	O
was	VBD	B-VP	O
unclear	JJ	B-ADJP	O
.	.	O	O

Flurothyl	NN	B-NP	O
seizure	NN	I-NP	B
testing	NN	I-NP	O
proved	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
and	CC	I-NP	O
reliable	JJ	I-NP	O
technique	NN	I-NP	O
with	IN	B-PP	O
which	WDT	B-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
seizure	NN	B-NP	B
susceptibility	NN	I-NP	O
.	.	O	O

Susceptibility	NN	B-NP	O
to	TO	B-PP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
after	IN	B-PP	O
microinjection	NN	B-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
or	CC	O	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
vinyl	NN	I-NP	O
-	HYPH	B-NP	O
GABA	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
.	.	O	O

Pilocarpine	NN	B-NP	O
,	,	O	O
given	VBN	B-VP	O
intraperitoneally	RB	B-ADVP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
reproduces	VBZ	B-VP	O
the	DT	B-NP	O
neuropathological	JJ	I-NP	O
sequelae	NNS	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
and	CC	O	O
provides	VBZ	B-VP	O
a	DT	B-NP	O
relevant	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
studying	VBG	B-VP	O
mechanisms	NNS	B-NP	O
of	IN	B-PP	O
buildup	NN	B-NP	O
of	IN	B-PP	O
convulsive	JJ	B-NP	B
activity	NN	I-NP	O
and	CC	O	O
pathways	NNS	B-NP	O
operative	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
generalization	NN	I-NP	O
and	CC	I-NP	O
propagation	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
within	IN	B-PP	O
the	DT	B-NP	O
forebrain	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
manipulating	VBG	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
GABA	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
mediated	VBN	B-NP	O
synaptic	JJ	I-NP	O
inhibition	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
on	IN	B-PP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
animals	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
microinjections	NNS	B-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
-	HYPH	O	O
synthesizing	VBG	B-VP	O
enzyme	NN	B-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
glutamic	JJ	I-NP	O
acid	NN	I-NP	O
decarboxylase	NN	I-NP	O
,	,	O	O
into	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
pars	NNS	I-NP	O
reticulata	NN	I-NP	O
(	(	O	O
SNR	NN	B-NP	O
)	)	O	O
,	,	O	O
bilaterally	RB	B-ADVP	O
,	,	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
convulsant	NN	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
motor	NN	I-NP	O
limbic	JJ	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Electroencephalographic	JJ	B-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
monitoring	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
profound	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

Morphological	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
frontal	JJ	B-NP	O
forebrain	NN	I-NP	O
sections	NNS	I-NP	O
with	IN	B-PP	O
light	JJ	B-NP	O
microscopy	NN	I-NP	O
revealed	VBD	B-VP	O
seizure	NN	B-NP	B
-	HYPH	B-NP	O
related	VBN	I-NP	O
damage	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
formation	NN	I-NP	O
,	,	O	O
thalamus	NN	B-NP	O
,	,	O	O
amygdala	NN	B-NP	O
,	,	O	O
olfactory	JJ	B-NP	O
cortex	NN	I-NP	O
,	,	O	O
substantia	NN	B-NP	O
nigra	NN	I-NP	O
and	CC	I-NP	O
neocortex	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
typically	RB	I-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
exceeding	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
intrastriatal	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
isoniazid	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
augment	VB	I-VP	O
seizures	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Application	NN	B-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
irreversible	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
transaminase	NN	I-NP	O
,	,	O	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
vinyl	NN	I-NP	O
-	HYPH	O	O
GABA	NN	B-NP	O
(	(	O	O
D	NN	B-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
amino	JJ	I-NP	O
-	HYPH	I-NP	O
hex	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
enoic	JJ	I-NP	O
acid	NN	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
,	,	O	O
into	IN	B-PP	O
the	DT	B-NP	O
SNR	NN	I-NP	O
,	,	O	O
bilaterally	RB	B-ADVP	O
,	,	O	O
suppressed	VBD	B-VP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
electrographic	JJ	B-NP	O
and	CC	I-NP	O
behavioral	JJ	I-NP	O
seizures	NNS	I-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
protect	VB	I-VP	O
animals	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	B
damage	NN	I-NP	I
.	.	O	O

Microinjections	NNS	B-NP	O
of	IN	B-PP	O
gamma	SYM	B-NP	O
-	HYPH	B-NP	O
vinyl	NN	I-NP	O
-	HYPH	I-NP	O
GABA	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
,	,	O	O
into	IN	B-PP	O
the	DT	B-NP	O
dorsal	JJ	I-NP	O
striatum	NN	I-NP	O
,	,	O	O
bilaterally	RB	B-ADVP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
convulsions	NNS	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
threshold	NN	I-NP	O
for	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
is	VBZ	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GABA	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
synaptic	JJ	I-NP	O
inhibition	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
.	.	O	O

Non	AFX	B-NP	O
-	HYPH	I-NP	O
invasive	JJ	I-NP	O
detection	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
by	IN	B-PP	O
body	NN	B-NP	O
surface	NN	I-NP	O
electrocardiographic	JJ	I-NP	O
mapping	NN	I-NP	O
after	IN	B-PP	O
dipyridamole	NN	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

Electrocardiographic	JJ	B-NP	O
changes	NNS	I-NP	O
after	IN	B-PP	O
dipyridamole	NN	B-NP	O
infusion	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
and	CC	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
after	IN	B-PP	O
submaximal	JJ	B-NP	O
treadmill	NN	I-NP	O
exercise	NN	I-NP	O
by	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
body	NN	I-NP	O
surface	NN	I-NP	O
mapping	NN	I-NP	O
technique	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
MI	NN	I-NP	B
group	NN	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
anterior	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
ANT	NN	B-NP	B
-	HYPH	B-NP	I
MI	NN	I-NP	I
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
inferior	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
INF	NN	B-NP	B
-	HYPH	B-NP	I
MI	NN	I-NP	I
)	)	O	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
unipolar	JJ	I-NP	O
electrocardiograms	NNS	I-NP	O
(	(	O	O
ECGs	NNS	B-NP	O
)	)	O	O
distributed	VBN	B-VP	O
over	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
thoracic	JJ	I-NP	O
surface	NN	I-NP	O
were	VBD	B-VP	O
simultaneously	RB	I-VP	O
recorded	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
dipyridamole	NN	B-NP	O
,	,	O	O
ischemic	JJ	B-NP	B
ST	NN	I-NP	O
-	HYPH	B-NP	O
segment	NN	I-NP	O
depression	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
mV	NN	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
)	)	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
MI	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ANT	NN	I-NP	B
-	HYPH	I-NP	I
MI	NN	I-NP	I
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
INF	NN	I-NP	B
-	HYPH	I-NP	I
MI	NN	I-NP	I
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
population	NN	I-NP	O
.	.	O	O

Exercise	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ST	NN	I-NP	O
depression	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
MI	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ANT	NN	I-NP	B
-	HYPH	I-NP	I
MI	NN	I-NP	I
group	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
INF	NN	I-NP	B
-	HYPH	I-NP	I
MI	NN	I-NP	I
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
total	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
individual	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
obvious	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
body	NN	I-NP	O
surface	NN	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
ST	JJ	B-NP	O
depression	NN	I-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
tests	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
pressure	NN	B-NP	O
rate	NN	I-NP	O
product	NN	I-NP	O
after	IN	B-PP	O
dipyridamole	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
treadmill	NN	I-NP	O
exercise	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
dipyridamole	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
is	VBZ	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
inhomogenous	JJ	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
dipyridamole	NN	I-NP	O
ECG	NN	I-NP	O
test	NN	I-NP	O
is	VBZ	B-VP	O
as	RB	B-ADJP	O
useful	JJ	I-ADJP	O
as	IN	B-PP	O
the	DT	B-NP	O
exercise	NN	I-NP	O
ECG	NN	I-NP	O
test	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Bradycardia	NNP	B-NP	B
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
intravenous	JJ	I-NP	O
methylprednisolone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
who	WP	B-NP	O
received	VBD	B-VP	O
intravenous	JJ	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methylprednisolone	NN	I-NP	O
(	(	O	O
MP	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
pulse	NN	B-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
most	RBS	B-ADJP	O
pronounced	JJ	I-ADJP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
the	DT	B-NP	O
bradycardia	NN	I-NP	B
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
complaints	NNS	B-NP	O
of	IN	B-PP	O
substernal	JJ	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Reversal	NN	B-NP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Electrocardiographic	JJ	B-NP	O
registrations	NNS	I-NP	O
showed	VBD	B-VP	O
sinus	NN	B-NP	B
bradycardia	NN	I-NP	I
in	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
electrolytes	NNS	B-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Careful	JJ	B-NP	O
observation	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
MP	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
MP	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
contraindicated	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
known	VBN	B-NP	O
heart	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
downbeat	JJ	B-NP	B
nystagmus	NN	I-NP	I
and	CC	I-NP	O
oscillopsia	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
carbamazepine	NN	B-NP	O
.	.	O	O

Downbeat	NN	B-NP	B
nystagmus	NN	I-NP	I
is	VBZ	B-VP	O
often	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
structural	JJ	B-NP	O
lesions	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
craniocervical	JJ	I-NP	O
junction	NN	I-NP	O
,	,	O	O
but	CC	O	O
has	VBZ	B-VP	O
occasionally	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
manifestation	NN	I-NP	O
of	IN	B-PP	O
metabolic	JJ	B-NP	O
imbalance	NN	I-NP	O
or	CC	I-NP	O
drug	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
recorded	VBD	B-VP	O
the	DT	B-NP	O
eye	NN	I-NP	O
movements	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
reversible	JJ	B-NP	O
downbeat	JJ	I-NP	B
nystagmus	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
nystagmus	NN	I-NP	B
of	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	I-NP	O
resolved	VBN	B-VP	O
after	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
carbamazepine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Neuroradiologic	JJ	B-NP	O
investigations	NNS	I-NP	O
including	VBG	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
scans	NNS	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
intracranial	JJ	B-NP	O
abnormality	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
downbeat	JJ	B-NP	B
nystagmus	NN	I-NP	I
who	WP	B-NP	O
are	VBP	B-VP	O
taking	VBG	I-VP	O
anticonvulsant	JJ	B-NP	O
medications	NNS	I-NP	O
,	,	O	O
consideration	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
dose	NN	B-NP	O
before	IN	B-PP	O
further	JJ	B-NP	O
investigation	NN	I-NP	O
is	VBZ	B-VP	O
undertaken	VBN	I-VP	O
.	.	O	O

Improvement	NN	B-NP	O
by	IN	B-PP	O
denopamine	NN	B-NP	O
(	(	O	O
TA	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
of	IN	B-PP	O
pentobarbital	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
dog	NN	I-NP	O
heart	NN	I-NP	O
-	HYPH	B-NP	O
lung	NN	I-NP	O
preparation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
denopamine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
orally	RB	I-NP	O
active	JJ	I-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
improving	VBG	B-VP	O
cardiac	JJ	B-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
dog	NN	B-NP	O
heart	NN	I-NP	O
-	HYPH	B-NP	O
lung	NN	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
functions	NNS	I-NP	O
depressed	VBN	B-VP	O
by	IN	B-PP	O
pentobarbital	NN	B-NP	O
such	JJ	B-NP	O
that	IN	I-NP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
and	CC	O	O
maximum	JJ	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
rise	NN	B-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
LV	NN	B-NP	O
dP	NN	I-NP	O
/	SYM	B-NP	O
dt	NN	I-NP	O
max	NN	I-NP	O
)	)	O	O
had	VBD	B-VP	O
been	VBN	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
respective	JJ	I-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
improved	VBN	I-VP	O
by	IN	B-PP	O
denopamine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
denopamine	NN	I-NP	O
,	,	O	O
almost	RB	B-NP	O
complete	JJ	I-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
performance	NN	I-NP	O
was	VBD	B-VP	O
attained	VBN	I-VP	O
,	,	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
slight	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
arrhythmias	NNS	I-NP	B
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
these	DT	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
denopamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
warrant	VBP	B-VP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
denopamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
failure	NN	I-NP	I
.	.	O	O

Clonazepam	NN	B-NP	O
monotherapy	NN	I-NP	O
for	IN	B-PP	O
epilepsy	NN	B-NP	B
in	IN	B-PP	O
childhood	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
age	NN	B-NP	O
-	HYPH	B-NP	O
range	NN	I-NP	O
num	CD	B-NP	O
month	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
other	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
than	IN	B-PP	O
infantile	JJ	B-NP	B
spasms	NNS	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
clonazepam	NN	B-NP	O
.	.	O	O

Disappearance	NN	B-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
and	CC	O	O
normalization	NN	B-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
EEG	NN	I-NP	O
with	IN	B-PP	O
disappearance	NN	B-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
were	VBD	B-VP	O
recognized	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Seizures	NNS	B-NP	B
disappeared	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
generalized	VBN	B-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
partial	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Improvement	NN	B-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
EEG	NN	I-NP	O
was	VBD	B-VP	O
noticed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
diffuse	JJ	B-NP	O
paroxysms	NNS	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
focal	JJ	B-NP	O
paroxysms	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
excellent	JJ	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
mean	JJ	B-NP	O
effective	JJ	I-NP	O
dosages	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
in	IN	B-PP	O
infants	NNS	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
in	IN	B-PP	O
schoolchildren	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
drowsiness	NN	B-NP	B
and	CC	I-NP	O
ataxia	NN	I-NP	B
was	VBD	B-VP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

Postmarketing	VBG	B-VP	O
study	NN	B-NP	O
of	IN	B-PP	O
timolol	NN	B-NP	O
-	HYPH	B-NP	O
hydrochlorothiazide	NN	I-NP	O
antihypertensive	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
postmarketing	VBG	I-NP	O
surveillance	NN	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
-	HYPH	I-NP	O
ratio	NN	I-NP	O
combination	NN	I-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
timolol	NN	B-NP	O
maleate	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
hydrochlorothiazide	NN	B-NP	O
,	,	O	O
administered	VBN	B-VP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
to	TO	B-PP	O
hypertensive	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
collected	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
participating	VBG	I-NP	O
physicians	NNS	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
and	CC	O	O
mean	JJ	B-NP	O
diastolic	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
declined	VBD	B-VP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
of	IN	B-PP	O
timolol	NN	B-NP	O
-	HYPH	B-NP	O
hydrochlorothiazide	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Age	NN	B-NP	O
,	,	O	O
race	NN	B-NP	O
,	,	O	O
and	CC	O	O
sex	NN	B-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
no	DT	B-NP	O
influence	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
antihypertensive	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
more	RBR	B-NP	O
severe	JJ	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
being	VBG	I-NP	O
fatigue	NN	I-NP	B
,	,	O	O
dizziness	NN	B-NP	B
,	,	O	O
and	CC	O	O
weakness	NN	B-NP	B
.	.	O	O

Treatment	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
.	.	O	O

Salicylate	NN	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
Gunn	NNP	I-NP	O
rat	NN	I-NP	O
:	:	O	O
potential	JJ	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
prostaglandins	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
prostaglandins	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
analgesic	JJ	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
Gunn	NNP	I-NP	O
strain	NN	I-NP	O
of	IN	B-PP	O
rat	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
homozygous	JJ	I-NP	O
Gunn	NNP	I-NP	O
rats	NNS	I-NP	O
have	VBP	B-VP	O
unconjugated	VBN	I-VP	O
hyperbilirubinemia	NN	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
glucuronyl	NN	B-NP	O
transferase	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
marked	JJ	B-NP	O
bilirubin	NN	I-NP	O
deposition	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
medulla	NN	I-NP	O
and	CC	I-NP	O
papilla	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
rats	NNS	I-NP	O
are	VBP	B-VP	O
also	RB	B-ADVP	O
highly	RB	B-ADJP	O
susceptible	JJ	I-ADJP	O
to	TO	B-VP	O
develop	VB	I-VP	O
papillary	JJ	B-NP	B
necrosis	NN	I-NP	I
with	IN	B-PP	O
analgesic	JJ	B-NP	O
administration	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
homozygous	JJ	B-ADJP	O
(	(	O	O
jj	NN	B-NP	O
)	)	O	O
and	CC	O	O
phenotypically	RB	B-NP	O
normal	JJ	I-NP	O
heterozygous	JJ	I-NP	O
(	(	O	O
jJ	NN	B-NP	O
)	)	O	O
animals	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
:	:	O	O
jj	NN	B-NP	O
and	CC	I-NP	O
jJ	NN	I-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
either	CC	B-PP	O
with	IN	I-PP	O
aspirin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
every	DT	B-NP	O
other	JJ	I-NP	O
day	NN	I-NP	O
or	CC	I-NP	O
sham	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	B-VP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
,	,	O	O
slices	NNS	B-NP	O
of	IN	B-PP	O
cortex	NN	B-NP	O
,	,	O	O
outer	JJ	B-NP	O
and	CC	I-NP	O
inner	JJ	I-NP	O
medulla	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
kidney	NN	I-NP	O
were	VBD	B-VP	O
incubated	VBN	I-VP	O
in	IN	B-PP	O
buffer	NN	B-NP	O
and	CC	I-NP	O
prostaglandin	NN	I-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
radioimmunoassay	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
other	JJ	I-NP	O
kidney	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
histologically	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
marked	JJ	I-NP	O
corticomedullary	JJ	I-NP	O
gradient	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

PGE2	NN	B-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
outer	JJ	B-NP	O
medulla	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
cortex	NN	B-NP	O
or	CC	O	O
inner	JJ	B-NP	O
medulla	NN	I-NP	O
,	,	O	O
of	IN	B-PP	O
jj	NN	B-NP	O
than	IN	B-PP	O
jJ	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Aspirin	NN	B-NP	O
treatment	NN	I-NP	O
reduced	VBD	B-VP	O
PGE2	NN	B-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
all	DT	B-NP	O
regions	NNS	I-NP	O
,	,	O	O
but	CC	O	O
outer	JJ	B-NP	O
medullary	JJ	I-NP	O
PGE2	NN	I-NP	O
remained	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
jj	NN	B-NP	O
than	IN	B-PP	O
jJ	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

PGF2	NN	B-NP	O
alpha	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
outer	JJ	I-NP	O
medulla	NN	I-NP	O
of	IN	B-PP	O
jj	NN	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
aspirin	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
prostaglandin	NN	I-NP	O
synthesis	NN	I-NP	O
were	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
aspirin	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
jj	NN	I-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
jJ	NN	B-NP	O
rats	NNS	I-NP	O
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
:	:	O	O
increased	VBN	B-NP	O
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
hematuria	NN	B-NP	B
;	:	O	O
increased	VBN	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
;	:	O	O
and	CC	O	O
increase	VB	B-VP	O
in	IN	B-PP	O
outer	JJ	B-NP	O
medullary	JJ	I-NP	O
histopathologic	JJ	I-NP	O
lesions	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
enhanced	VBN	B-NP	O
prostaglandin	NN	I-NP	O
synthesis	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
maintenance	NN	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
morphological	JJ	B-NP	O
integrity	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthesis	NN	I-NP	O
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
pathological	JJ	B-NP	B
renal	JJ	I-NP	I
medullary	JJ	I-NP	I
lesions	NNS	I-NP	I
and	CC	O	O
deterioration	NN	B-NP	B
of	IN	B-PP	I
renal	JJ	B-NP	I
function	NN	I-NP	I
.	.	O	O

Prophylactic	JJ	B-NP	O
lidocaine	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
suspected	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
suspected	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
seen	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
entered	VBD	B-VP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
randomized	VBN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
vs	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
or	CC	O	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
low	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Lidocaine	NNP	B-NP	O
,	,	O	O
given	VBN	B-PP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
dose	NN	I-NP	O
intramuscularly	RB	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
intravenously	RB	B-ADVP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
,	,	O	O
although	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
warning	VBG	B-VP	O
arrhythmias	NNS	B-NP	B
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
plasma	NN	I-NP	O
lidocaine	NN	I-NP	O
level	NN	I-NP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
infarction	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
plasma	NN	I-NP	O
lidocaine	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
on	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-PP	O
blocking	VBG	B-NP	O
agents	NNS	I-NP	O
was	VBD	B-VP	O
no	RB	B-ADJP	O
different	JJ	I-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
not	RB	O	O
on	IN	B-PP	O
beta	NN	B-NP	O
blocking	VBG	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
study	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
lidocaine	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
hypotension	NN	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
lidocaine	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
from	IN	B-PP	O
asystole	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
had	VBD	B-VP	O
had	VBN	I-VP	O
lidocaine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
advocate	VB	I-VP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
prophylactically	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
suspected	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

Evidence	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
cholinergic	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

Experiments	NNS	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
tested	VBN	B-VP	O
previous	JJ	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
cholinergic	JJ	B-NP	O
systems	NNS	I-NP	O
promotes	VBZ	B-VP	O
catalepsy	NN	B-NP	B
and	CC	O	O
that	IN	B-SBAR	O
cholinergic	JJ	B-NP	O
mechanisms	NNS	I-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
intact	JJ	B-ADJP	O
for	IN	B-PP	O
full	JJ	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
neuroleptic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

Large	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cholinomimetic	JJ	I-NP	O
,	,	I-NP	O
pilocarpine	NN	I-NP	O
,	,	O	O
could	MD	B-VP	O
induce	VB	I-VP	O
catalepsy	NN	B-NP	B
when	WRB	B-ADVP	O
peripheral	JJ	B-NP	O
cholinergic	JJ	I-NP	O
receptors	NNS	I-NP	O
were	VBD	B-VP	O
blocked	VBN	I-VP	O
.	.	O	O

Low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
pronounced	JJ	I-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
that	WDT	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
haloperidol	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
muscarinic	JJ	I-NP	O
receptor	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
atropine	NN	B-NP	O
,	,	O	O
disrupted	VBD	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

Intracranial	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
acetylcholine	NN	I-NP	O
-	HYPH	I-NP	O
synthesis	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
hemicholinium	NN	B-NP	O
,	,	O	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
that	WDT	B-NP	O
is	VBZ	B-VP	O
usually	RB	I-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
catalepsy	NN	I-NP	B
that	WDT	B-NP	O
is	VBZ	B-VP	O
produced	VBN	I-VP	O
by	IN	B-PP	O
neuroleptics	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
haloperidol	NN	B-NP	O
is	VBZ	B-VP	O
actually	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
intrinsic	JJ	B-NP	O
central	JJ	I-NP	O
cholinergic	JJ	I-NP	O
systems	NNS	I-NP	O
.	.	O	O

Alternatively	RB	B-ADVP	O
,	,	O	O
activation	NN	B-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
cholinergic	JJ	I-NP	O
systems	NNS	I-NP	O
could	MD	B-VP	O
promote	VB	I-VP	O
catalepsy	NN	B-NP	B
by	IN	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
systems	NNS	I-NP	O
.	.	O	O

Cardiovascular	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
hypersensitivity	NN	I-NP	B
to	TO	B-PP	O
sodium	NN	B-NP	O
pentobarbital	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
barium	NN	I-NP	O
chloride	NN	I-NP	O
ingestion	NN	I-NP	O
.	.	O	O

Barium	NN	B-NP	O
-	HYPH	O	O
supplemented	VBN	B-VP	O
Long	NNP	B-NP	O
-	HYPH	O	O
Evans	NNP	B-NP	O
hooded	VBD	B-VP	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
persistent	JJ	I-NP	O
hypertension	NN	I-NP	B
that	WDT	B-NP	O
was	VBD	B-VP	O
evident	JJ	B-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
of	IN	B-PP	O
barium	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
mineral	NN	I-NP	O
fortified	VBN	B-VP	O
water	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
myocardial	JJ	I-NP	O
excitability	NN	I-NP	O
,	,	O	O
contractility	NN	B-NP	O
,	,	O	O
and	CC	O	O
metabolic	JJ	B-NP	O
characteristics	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
revealed	VBD	B-VP	O
other	JJ	B-NP	O
significant	JJ	I-NP	O
barium	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
disturbances	NNS	I-NP	B
within	IN	B-PP	I
the	DT	B-NP	I
cardiovascular	JJ	I-NP	I
system	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
distinctive	JJ	I-NP	O
aspect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
barium	NN	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
demonstrated	VBN	I-NP	O
hypersensitivity	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
sodium	NN	B-NP	O
pentobarbital	NN	I-NP	O
.	.	O	O

Under	IN	B-PP	O
barbiturate	NN	B-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
virtually	RB	B-NP	O
all	DT	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
contractile	JJ	I-NP	O
indices	NNS	I-NP	O
were	VBD	B-VP	O
depressed	VBN	I-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
barium	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
rats	NNS	I-NP	O
relative	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
corresponding	VBG	I-NP	O
control	NN	I-NP	O
-	HYPH	B-NP	O
fed	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
ketamine	NN	B-NP	O
and	CC	I-NP	O
xylazine	NN	I-NP	O
anesthesia	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
pentobarbital	NN	I-NP	O
in	IN	B-PP	O
barium	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
linked	VBN	I-VP	O
specifically	RB	B-ADVP	O
to	TO	B-PP	O
this	DT	B-NP	O
anesthetic	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
not	RB	O	O
representative	JJ	B-ADJP	O
of	IN	B-PP	O
a	DT	B-NP	O
generalized	VBN	I-NP	O
anesthetic	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

Other	JJ	B-NP	O
myocardial	JJ	I-NP	O
pathophysiologic	JJ	I-NP	O
and	CC	I-NP	O
metabolic	JJ	I-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
barium	NN	B-NP	O
were	VBD	B-VP	O
manifest	JJ	B-ADJP	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
employed	VBN	B-VP	O
.	.	O	O

The	DT	B-NP	O
contractile	JJ	I-NP	O
element	NN	I-NP	O
shortening	VBG	B-VP	O
velocity	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
muscle	NN	I-NP	O
fibers	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
slower	JJR	I-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
barium	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
relative	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
significant	JJ	B-NP	O
disturbances	NNS	I-NP	O
in	IN	B-PP	O
myocardial	JJ	B-NP	O
energy	NN	I-NP	O
metabolism	NN	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
barium	NN	I-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
rats	NNS	I-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
reduced	VBN	I-NP	O
contractile	JJ	I-NP	O
element	NN	I-NP	O
shortening	VBG	B-VP	O
velocity	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
excitability	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
conduction	NN	I-NP	O
system	NN	I-NP	O
was	VBD	B-VP	O
depressed	VBN	I-VP	O
preferentially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
atrioventricular	JJ	I-NP	O
nodal	JJ	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
hearts	NNS	B-NP	O
from	IN	B-PP	O
barium	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
altered	VBN	I-NP	O
cardiac	JJ	I-NP	O
contractility	NN	I-NP	O
and	CC	I-NP	O
excitability	NN	I-NP	O
characteristics	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
metabolic	JJ	I-NP	B
disturbances	NNS	I-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
hypersensitivity	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
system	NN	I-NP	O
to	TO	B-PP	O
sodium	NN	B-NP	O
pentobarbital	NN	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
existence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
heretofore	RB	I-NP	O
undescribed	JJ	I-NP	O
cardiomyopathic	JJ	I-NP	B
disorder	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
chronic	JJ	B-NP	O
barium	NN	I-NP	O
exposure	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
experimental	JJ	I-NP	O
findings	NNS	I-NP	O
represent	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
indication	NN	I-NP	O
that	IN	B-NP	O
life	NN	B-NP	O
-	HYPH	B-NP	O
long	JJ	I-NP	O
barium	NN	I-NP	O
ingestion	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
significant	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
mammalian	JJ	I-NP	O
cardiovascular	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Propranolol	NN	B-NP	O
antagonism	NN	I-NP	O
of	IN	B-PP	O
phenylpropanolamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Phenylpropanolamine	NN	B-NP	O
(	(	O	O
PPA	NN	B-NP	O
)	)	O	O
overdose	NN	B-NP	B
can	MD	B-VP	O
cause	VB	I-VP	O
severe	JJ	B-NP	O
hypertension	NN	I-NP	B
,	,	O	O
intracerebral	JJ	B-NP	B
hemorrhage	NN	I-NP	I
,	,	O	O
and	CC	O	O
death	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Subjects	NNS	B-NP	O
received	VBD	B-VP	O
propranolol	NN	B-NP	O
either	CC	B-PP	O
by	IN	B-PP	O
mouth	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
before	IN	B-PP	O
PPA	NN	B-NP	O
or	CC	B-PP	O
as	IN	B-PP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
after	IN	B-PP	O
PPA	NN	B-NP	O
.	.	O	O

PPA	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
alone	RB	B-ADVP	O
,	,	O	O
increased	VBN	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
propranolol	NN	B-NP	O
pretreatment	NN	I-NP	O
antagonized	VBD	B-VP	O
this	DT	B-NP	O
increase	NN	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
propranolol	NN	I-NP	O
after	IN	B-PP	O
PPA	NN	B-NP	O
also	RB	B-ADVP	O
decreased	VBD	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
(	(	O	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
echocardiography	NN	B-NP	O
)	)	O	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
PPA	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
stroke	NN	I-NP	B
volume	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
propranolol	NN	I-NP	O
reversed	VBD	B-VP	O
these	DT	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
PPA	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
further	RBR	I-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
propranolol	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
PPA	NN	B-NP	O
increases	VBZ	B-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
systemic	JJ	B-NP	O
vascular	JJ	I-NP	O
resistance	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
propranolol	NN	B-NP	O
antagonizes	VBZ	B-VP	O
this	DT	B-NP	O
increase	NN	I-NP	O
by	IN	B-PP	O
reversing	VBG	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
.	.	O	O

That	DT	B-NP	O
propranolol	NN	I-NP	O
antagonizes	VBZ	B-VP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
PPA	NN	B-NP	O
is	VBZ	B-VP	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
propranolol	NN	B-NP	O
enhances	VBZ	B-VP	O
the	DT	B-NP	O
pressor	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
norepinephrine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
probably	RB	B-ADVP	O
because	IN	B-SBAR	O
PPA	NN	B-NP	O
has	VBZ	B-VP	O
less	JJR	B-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
activity	NN	I-NP	O
than	IN	B-SBAR	O
does	VBZ	O	O
norepinephrine	NN	B-NP	O
.	.	O	O

Mesangial	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
aminonucleoside	NN	B-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
possible	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
mesangial	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
model	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
repeated	VBN	I-VP	O
subcutaneous	JJ	B-NP	O
PAN	NN	I-NP	O
injections	NNS	I-NP	O
;	:	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
received	VBD	B-VP	O
saline	NN	B-NP	O
only	RB	B-ADVP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
severely	RB	B-ADJP	O
proteinuric	JJ	I-ADJP	B
,	,	O	O
and	CC	O	O
all	DT	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
colloidal	JJ	B-NP	O
carbon	NN	I-NP	O
(	(	O	O
CC	NN	B-NP	O
)	)	O	O
intravenously	RB	B-ADVP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
glomeruli	NN	I-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
rats	NNS	I-NP	O
;	:	O	O
glomeruli	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
.	.	O	O

Glomeruli	NNS	B-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
rats	NNS	I-NP	O
contained	VBD	B-VP	O
significantly	RB	B-NP	O
more	JJR	I-NP	O
CC	NN	I-NP	O
than	IN	B-PP	O
glomeruli	NNS	B-NP	O
of	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Glomeruli	NNS	B-NP	O
with	IN	B-PP	O
sclerosis	NN	B-NP	B
contained	VBD	B-VP	O
significantly	RB	B-NP	O
more	JJR	I-NP	O
CC	NN	I-NP	O
than	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
sclerotic	JJ	I-NP	O
glomeruli	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
kidneys	NNS	I-NP	O
.	.	O	O

CC	NN	B-NP	O
was	VBD	B-VP	O
preferentially	RB	I-VP	O
localized	VBN	I-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
sclerotic	JJ	I-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
affected	VBN	I-NP	O
glomeruli	NNS	I-NP	O
.	.	O	O

Since	IN	B-SBAR	O
mesangial	JJ	B-NP	O
CC	NN	I-NP	O
clearance	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
mesangium	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
during	IN	B-PP	O
chronic	JJ	B-NP	O
PAN	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
preferential	JJ	I-NP	O
CC	NN	I-NP	O
localization	NN	I-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
lesions	NNS	I-NP	O
is	VBZ	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
CC	NN	I-NP	O
uptake	NN	I-NP	O
shortly	RB	B-ADVP	O
after	IN	B-PP	O
injection	NN	B-NP	O
in	IN	B-PP	O
apparent	JJ	B-NP	O
vulnerable	JJ	I-NP	O
areas	NNS	I-NP	O
where	WRB	B-ADVP	O
sclerosis	NN	B-NP	B
will	MD	B-VP	O
develop	VB	I-VP	O
subsequently	RB	B-ADVP	O
.	.	O	O

Cluster	NN	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
random	JJ	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
lesions	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
glomeruli	NN	I-NP	O
in	IN	B-PP	O
concordance	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
random	JJ	I-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
mesangial	JJ	B-NP	O
areas	NNS	I-NP	O
with	IN	B-PP	O
dysfunction	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
.	.	O	O

Similar	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
remnant	NN	I-NP	O
kidney	NN	I-NP	O
model	NN	I-NP	O
in	IN	B-PP	O
PAN	NN	B-NP	O
nephrosis	NN	I-NP	B
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
sclerosis	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
mesangial	JJ	B-NP	O
overloading.	NN	I-NP	O
.	.	O	O

Relationship	NN	B-NP	O
between	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
hippocampal	JJ	B-NP	O
nicotinic	JJ	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
controversy	NN	I-NP	O
has	VBZ	B-VP	O
existed	VBN	I-VP	O
for	IN	B-PP	O
several	JJ	B-NP	O
years	NNS	I-NP	O
concerning	VBG	B-VP	O
the	DT	B-NP	O
physiological	JJ	I-NP	O
relevance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nicotinic	JJ	I-NP	O
receptor	NN	I-NP	O
measured	VBN	B-VP	O
by	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
bungarotoxin	NN	I-NP	O
binding	NN	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
mice	NNS	B-NP	O
derived	VBN	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
classical	JJ	I-NP	O
F2	NN	I-NP	O
and	CC	O	O
backcross	RB	B-NP	O
genetic	JJ	I-NP	O
design	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
nicotine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
alpha	SYM	B-NP	O
-	HYPH	B-NP	O
bungarotoxin	NN	I-NP	O
nicotinic	JJ	I-NP	O
receptor	NN	I-NP	O
concentration	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

Mice	NNS	B-NP	O
sensitive	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
convulsant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
had	VBD	B-VP	O
greater	JJR	B-NP	O
alpha	SYM	I-NP	O
-	HYPH	I-NP	O
bungarotoxin	NN	I-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
than	IN	B-PP	O
seizure	NN	B-NP	B
insensitive	JJ	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
binding	VBG	I-NP	O
sites	NNS	I-NP	O
from	IN	B-PP	O
seizure	NN	B-NP	B
sensitive	JJ	I-NP	O
and	CC	I-NP	O
resistant	JJ	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
equally	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
dithiothreitol	NN	B-NP	O
,	,	I-NP	O
trypsin	NN	I-NP	O
or	CC	I-NP	O
heat	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
it	PRP	B-NP	O
appears	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
seizure	NN	B-NP	B
sensitive	JJ	I-NP	O
and	CC	I-NP	O
insensitive	JJ	I-NP	O
animals	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
hippocampal	JJ	B-NP	O
nicotinic	JJ	I-NP	O
receptor	NN	I-NP	O
concentration	NN	I-NP	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
with	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	I-NP	O
bungarotoxin	NN	I-NP	O
binding	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
p	NN	B-NP	O
-	HYPH	B-NP	O
aminophenol	NN	I-NP	O
in	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
:	:	O	O
effect	NN	B-NP	O
of	IN	B-PP	O
bis	NN	B-NP	O
(	(	O	O
p	NN	B-NP	O
-	HYPH	B-NP	O
nitrophenyl	NN	I-NP	O
)	)	O	O
phosphate	NN	B-NP	O
on	IN	B-PP	O
acetaminophen	NN	B-NP	O
and	CC	I-NP	O
p	NN	I-NP	O
-	HYPH	B-NP	O
aminophenol	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	I-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
Fischer	NNP	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Acetaminophen	NN	B-NP	O
(	(	O	O
APAP	NN	B-NP	O
)	)	O	O
produces	VBZ	B-VP	O
proximal	JJ	B-NP	O
tubular	JJ	I-NP	B
necrosis	NN	I-NP	I
in	IN	B-PP	O
Fischer	NNP	B-NP	O
num	CD	I-NP	O
(	(	O	O
F344	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
p	NN	B-NP	O
-	HYPH	O	O
aminophenol	NN	B-NP	O
(	(	O	O
PAP	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
known	JJ	I-NP	O
potent	JJ	I-NP	O
nephrotoxicant	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
identified	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
APAP	NN	B-NP	O
in	IN	B-PP	O
F344	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
PAP	NN	B-NP	O
formation	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
requisite	JJ	I-NP	O
step	NN	I-NP	O
in	IN	B-PP	O
APAP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
bis	NN	B-NP	O
(	(	O	O
p	NN	B-NP	O
-	HYPH	B-NP	O
nitrophenyl	NN	I-NP	O
)	)	O	O
phosphate	NN	B-NP	O
(	(	O	O
BNPP	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
acylamidase	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
APAP	NN	B-NP	O
and	CC	I-NP	O
PAP	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	I-NP	O
metabolism	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

BNPP	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mM	NN	I-NP	O
)	)	O	O
reduced	VBD	B-VP	O
APAP	NN	B-NP	O
deacetylation	NN	I-NP	O
and	CC	O	O
covalent	JJ	B-NP	O
binding	NN	I-NP	O
in	IN	B-PP	O
F344	NN	B-NP	O
renal	JJ	I-NP	O
cortical	JJ	I-NP	O
homogenates	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
concentration	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

Pretreatment	NN	B-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
with	IN	B-PP	O
BNPP	NN	B-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
APAP	NN	B-NP	O
or	CC	I-NP	O
PAP	NN	I-NP	O
administration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
marked	JJ	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
APAP	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
but	CC	B-NP	O
not	RB	I-NP	O
PAP	NN	B-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
result	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
altered	JJ	B-NP	O
disposition	NN	I-NP	O
of	IN	B-PP	O
either	CC	O	O
APAP	NN	B-NP	O
or	CC	O	O
acetylated	VBN	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
or	CC	O	O
renal	JJ	B-NP	O
cortical	JJ	I-NP	O
and	CC	I-NP	O
hepatic	JJ	I-NP	O
tissue	NN	I-NP	O
.	.	O	O

Rather	RB	B-ADVP	O
,	,	O	O
BNPP	NN	B-NP	O
pretreatment	NN	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
fraction	NN	I-NP	O
of	IN	B-PP	O
APAP	NN	B-NP	O
excreted	VBN	B-VP	O
as	IN	B-PP	O
PAP	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
APAP	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

BNPP	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
the	DT	B-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
APAP	NN	B-NP	O
or	CC	O	O
any	DT	B-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
deacetylated	VBN	I-NP	O
metabolites	NNS	I-NP	O
nor	CC	O	O
did	VBD	B-VP	O
BNPP	NN	B-NP	O
alter	NN	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
PAP	NN	B-NP	O
or	CC	O	O
its	PRP$	B-NP	O
metabolites	NNS	I-NP	O
after	IN	B-PP	O
PAP	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
BNPP	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
APAP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
APAP	NN	B-NP	O
deacetylation	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
PAP	NN	B-NP	O
formation	NN	I-NP	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
accounts	NNS	B-NP	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
part	NN	B-NP	O
,	,	O	O
for	IN	B-PP	O
APAP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
.	.	O	O

Morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
newborn	JJ	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
neonates	NNS	I-NP	O
suffered	VBN	B-VP	O
from	IN	B-PP	O
generalized	VBN	B-NP	O
seizures	NNS	I-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
morphine	NN	I-NP	O
sulfate	NN	I-NP	O
for	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
analgesia	NN	I-NP	O
.	.	O	O

They	PRP	B-NP	O
received	VBD	B-VP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
hr	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
hr	NN	I-NP	O
larger	JJR	B-ADJP	O
than	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
neonates	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
hr	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
neonates	NNS	I-NP	O
was	VBD	B-VP	O
excessive	JJ	B-ADJP	O
.	.	O	O

Other	JJ	B-NP	O
known	JJ	I-NP	O
reasons	NNS	I-NP	O
for	IN	B-PP	O
seizures	NNS	B-NP	B
were	VBD	B-VP	O
ruled	VBN	I-VP	O
out	RP	B-PRT	O
and	CC	O	O
the	DT	B-NP	O
convulsions	NNS	I-NP	B
stopped	VBD	B-VP	O
a	DT	B-NP	O
few	JJ	I-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
reoccur	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
subsequent	JJ	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
intravenous	JJ	I-NP	O
morphine	NN	I-NP	O
should	MD	B-VP	O
not	RB	I-VP	O
exceed	VB	I-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
in	IN	B-PP	O
neonates	NNS	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
sulfate	NN	I-NP	O
on	IN	B-PP	O
Pseudomonas	NNP	B-NP	B
infections	NNS	I-NP	I
in	IN	B-PP	O
monkeys	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
rhesus	NN	B-NP	O
monkeys	NNS	I-NP	O
,	,	O	O
intravenous	JJ	B-NP	O
challenge	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
Pseudomonas	NN	I-NP	O
aeruginosa	NN	I-NP	O
organisms	NNS	I-NP	O
caused	VBD	B-VP	O
acute	JJ	B-NP	O
illness	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
s	VBZ	B-VP	O
duration	NN	B-NP	O
with	IN	B-PP	O
spontaneous	JJ	B-NP	O
recovery	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
monkeys	NNS	I-NP	O
;	:	O	O
blood	NN	B-NP	O
cultures	NNS	I-NP	O
became	VBD	B-VP	O
negative	JJ	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
challenge	NN	B-NP	O
.	.	O	O

Leukocytosis	NN	B-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
monkeys	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
or	CC	I-NP	O
intratracheal	JJ	I-NP	O
inoculation	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
sulfate	NN	I-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
leukopenia	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

Intravenous	JJ	B-NP	O
inoculation	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
pyocin	NN	I-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
Pseudomonas	NNP	I-NP	O
organisms	NNS	I-NP	O
in	IN	B-PP	O
monkeys	NNS	B-NP	O
given	VBN	B-VP	O
vincristine	NN	B-NP	O
sulfate	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
previously	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
fatal	JJ	B-NP	O
infection	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
monkeys	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
none	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
receiving	VBG	B-VP	O
Pseudomonas	NNP	B-NP	O
alone	RB	B-ADVP	O
died	VBD	B-VP	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
an	DT	B-NP	O
antimetabolite	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
leukopenia	NN	I-NP	B
predisposes	VBZ	B-VP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
Pseudomonas	NN	I-NP	O
sepsis	NN	I-NP	B
and	CC	O	O
that	IN	B-SBAR	O
such	JJ	B-NP	O
monkeys	NNS	I-NP	O
may	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
biological	JJ	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
study	NN	B-NP	O
of	IN	B-PP	O
comparative	JJ	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
antimicrobial	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

Central	JJ	B-NP	O
excitatory	JJ	I-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
flurazepam	NN	B-NP	O
.	.	O	O

Toxic	JJ	B-NP	O
actions	NNS	I-NP	O
of	IN	B-PP	O
flurazepam	NN	B-NP	O
(	(	O	O
FZP	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
cats	NNS	B-NP	O
,	,	I-NP	O
mice	NNS	I-NP	O
and	CC	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
doses	NNS	I-NP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
apparent	JJ	I-NP	O
central	JJ	I-NP	O
excitation	NN	I-NP	O
,	,	O	O
most	RBS	B-VP	O
clearly	RB	I-VP	O
seen	VBN	I-VP	O
as	IN	B-PP	O
clonic	JJ	B-NP	O
convulsions	NNS	I-NP	B
,	,	O	O
superimposed	VBN	B-VP	O
on	IN	B-PP	O
general	JJ	B-NP	O
depression	NN	I-NP	B
.	.	O	O

Following	VBG	B-PP	O
a	DT	B-NP	O
lethal	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
death	NN	B-NP	O
was	VBD	B-VP	O
always	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
convulsions	NNS	B-NP	B
.	.	O	O

Comparing	VBG	B-VP	O
the	DT	B-NP	O
relative	JJ	I-NP	O
sensitivity	NN	I-NP	O
to	TO	B-PP	O
central	JJ	B-NP	O
depression	NN	I-NP	B
and	CC	I-NP	O
excitation	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
rats	NNS	B-NP	O
were	VBD	B-VP	O
least	RBS	B-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
convulsions	NNS	B-NP	B
at	IN	B-PP	O
doses	NNS	B-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	B-NP	O
first	JJ	I-NP	O
cause	NN	I-NP	O
loss	NN	I-NP	B
of	IN	B-PP	I
consciousness	NN	B-NP	I
,	,	O	O
while	IN	B-SBAR	O
cats	NNS	B-NP	O
most	RBS	B-ADVP	O
clearly	RB	I-ADVP	O
showed	VBD	B-VP	O
marked	JJ	B-NP	O
central	JJ	I-NP	O
excitatory	JJ	I-NP	O
actions	NNS	I-NP	O
.	.	O	O

Signs	NNS	B-NP	O
of	IN	B-PP	O
FZP	NN	B-NP	O
toxocity	NN	I-NP	B
in	IN	B-PP	O
cats	NNS	B-NP	O
included	VBD	B-VP	O
excessive	JJ	B-NP	O
salivation	NN	I-NP	B
,	,	O	O
extreme	JJ	B-NP	O
apprehensive	JJ	I-NP	O
behavior	NN	I-NP	O
,	,	O	O
retching	NN	B-NP	O
,	,	O	O
muscle	NN	B-NP	B
tremors	NNS	I-NP	I
and	CC	I-NP	O
convulsions	NNS	I-NP	B
.	.	O	O

An	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
FZP	NN	B-NP	O
and	CC	O	O
pentylenetetrazol	NN	B-NP	O
(	(	O	O
PTZ	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
by	IN	B-PP	O
pretreating	VBG	B-VP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
FZP	NN	B-NP	O
before	IN	B-PP	O
PTZ	NN	B-NP	O
challenge	NN	I-NP	O
.	.	O	O

As	IN	B-PP	O
a	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
dose	NN	B-NP	O
,	,	O	O
FZP	NN	B-NP	O
first	RB	B-ADVP	O
protected	VBD	B-VP	O
against	IN	B-PP	O
convulsions	NNS	B-NP	B
and	CC	O	O
death	NN	B-NP	O
.	.	O	O

At	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
convulsions	NNS	B-NP	B
again	RB	B-ADVP	O
emerged	VBD	B-VP	O
.	.	O	O

These	DT	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
FZP	NN	B-NP	O
were	VBD	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
that	WDT	B-NP	O
would	MD	B-VP	O
alone	RB	I-VP	O
cause	VB	I-VP	O
convulsions	NNS	B-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
relevant	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
FZP	NN	B-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
situations	NNS	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
increased	VBN	I-VP	O
neural	JJ	B-NP	O
excitability	NN	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
epilepsy	NN	B-NP	B
or	CC	O	O
sedative	JJ	B-NP	O
-	HYPH	I-NP	O
hypnotic	JJ	I-NP	O
drug	NN	I-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
for	IN	B-PP	O
cardiac	JJ	B-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
adrenoceptors	NNS	I-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
single	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
atenolol	NN	I-NP	O
(	(	O	O
cardioselective	JJ	B-ADVP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
propranolol	NN	I-NP	O
(	(	O	O
nonselective	JJ	B-ADVP	O
)	)	O	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
on	IN	B-PP	O
both	CC	O	O
exercise	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
tachycardia	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
experiments	NNS	I-NP	O
involving	VBG	B-VP	O
num	CD	B-NP	O
normal	JJ	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
exercise	NN	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
SEM	NN	B-NP	O
)	)	O	O
after	IN	B-PP	O
placebo	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
bpm	NN	I-NP	O
after	IN	B-PP	O
atenolol	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
bpm	NN	I-NP	O
after	IN	B-PP	O
propranolol	NN	B-NP	O
,	,	O	O
but	CC	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
tachycardia	NN	I-NP	B
were	VBD	B-VP	O
determined	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
atropine	NN	B-NP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
sensitivity	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
dose	NN	I-NP	O
that	WDT	B-NP	O
increased	VBD	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
bpm	NN	I-NP	O
(	(	O	O
CD25	NN	B-NP	O
)	)	O	O
and	CC	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
after	IN	B-PP	O
placebo	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
after	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
after	IN	B-PP	O
atenolol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
.	.	O	O

After	IN	B-PP	O
atropine	NN	B-NP	O
the	DT	B-NP	O
CD25	NN	I-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
after	IN	B-SBAR	O
placebo	NN	B-NP	O
and	CC	I-NP	O
atenolol	NN	I-NP	O
;	:	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
after	IN	B-PP	O
propranolol	NN	B-NP	O
,	,	O	O
but	CC	O	O
remained	VBD	B-VP	O
different	JJ	B-ADJP	O
from	IN	B-PP	O
atenolol	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
change	NN	I-NP	O
with	IN	B-PP	O
propranolol	NN	B-NP	O
sensitivity	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
apparent	JJ	I-NP	O
Ka	NNP	I-NP	O
,	,	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
by	IN	B-PP	O
atropine	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
exercise	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
results	NNS	I-NP	O
largely	RB	B-ADVP	O
from	IN	B-PP	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
activation	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
both	CC	B-NP	O
cardioselective	JJ	I-NP	O
and	CC	I-NP	O
nonselective	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
isoproterenol	NN	B-NP	O
activates	VBZ	B-VP	O
both	CC	O	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	B-ADJP	O
and	CC	O	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
receptors	NNS	I-NP	O
so	IN	B-SBAR	O
that	IN	I-SBAR	O
after	IN	B-PP	O
cardioselective	JJ	B-NP	O
blockade	NN	I-NP	O
there	EX	B-NP	O
remains	VBZ	B-VP	O
a	DT	B-NP	O
beta	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
component	NN	I-NP	O
that	WDT	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
blocked	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
nonselective	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
there	EX	B-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
beta	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
human	JJ	I-NP	O
heart	NN	I-NP	O
,	,	O	O
their	PRP$	B-NP	O
physiologic	JJ	I-NP	O
or	CC	I-NP	O
pathologic	JJ	I-NP	O
roles	NNS	I-NP	O
remain	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
defined	VBN	I-VP	O
.	.	O	O

Hormones	NNS	B-NP	O
and	CC	O	O
risk	NN	B-NP	O
of	IN	B-PP	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
reports	VBZ	B-VP	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
menopausal	JJ	I-NP	O
women	NNS	I-NP	O
receiving	VBG	B-VP	O
hormonal	JJ	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
had	VBD	B-VP	O
surgical	JJ	B-NP	O
menopause	NN	I-NP	O
;	:	O	O
their	PRP$	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
hypothesized	VBN	I-VP	O
that	IN	B-SBAR	O
progestins	NNS	B-NP	O
could	MD	B-VP	O
equilibrate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
estrogenic	JJ	I-NP	O
stimulation	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
mammary	JJ	I-NP	O
and	CC	I-NP	O
endometrial	JJ	I-NP	O
target	NN	I-NP	O
tissues	NNS	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
on	IN	B-PP	O
hormonal	JJ	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
treatment	NN	I-NP	O
schedule	NN	I-NP	O
consisted	VBD	B-VP	O
of	IN	B-PP	O
conjugated	VBN	B-NP	O
estrogens	NNS	I-NP	O
(	(	O	O
Premarin	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
and	CC	O	O
Medroxyprogesterone	NN	B-NP	O
acetate	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
month	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
period	NN	B-NP	O
,	,	O	O
attention	NN	B-NP	O
was	VBD	B-VP	O
paid	VBN	I-VP	O
to	TO	B-PP	O
breast	NN	B-NP	O
modifications	NNS	I-NP	O
as	IN	B-SBAR	O
evidenced	VBN	B-VP	O
by	IN	B-PP	O
symptomatology	NN	B-NP	O
,	,	O	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
,	,	O	O
and	CC	O	O
plate	NN	B-NP	O
thermography	NN	I-NP	O
.	.	O	O

Mastodynia	NNP	B-NP	B
was	VBD	B-VP	O
reported	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
light	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
breast	NN	B-NP	O
firmness	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
breast	NN	B-NP	O
nodularity	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Themography	NN	B-NP	O
confirmed	VBD	B-VP	O
the	DT	B-NP	O
existence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
excessive	JJ	I-NP	O
breast	NN	I-NP	O
stimulation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
moderate	JJ	B-NP	O
mastodynia	NN	I-NP	B
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
mastodynia	NN	I-NP	B
.	.	O	O

Normalization	NN	B-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
by	IN	B-PP	O
halving	VBG	B-VP	O
the	DT	B-NP	O
estrogen	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
hormonal	JJ	B-NP	O
replacement	NN	I-NP	O
therapy	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
safely	RB	I-VP	O
prescribed	VBN	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
following	VBG	I-NP	O
criteria	NNS	I-NP	O
are	VBP	B-VP	O
satisfied	VBN	I-VP	O
:	:	O	O
num	CD	B-NP	O
)	)	I-NP	O
preliminary	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
,	,	I-NP	O
metabolic	JJ	I-NP	O
,	,	I-NP	O
cytologic	JJ	I-NP	O
,	,	O	O
and	CC	O	O
mammographic	JJ	B-NP	O
perspective	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
)	)	I-NP	O
cyclic	JJ	I-NP	O
treatment	NN	I-NP	O
schedule	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
progestative	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
periodic	JJ	B-NP	O
complete	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
with	IN	B-PP	O
accurate	JJ	B-NP	O
thermographic	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
breast	NN	I-NP	O
target	NN	I-NP	O
tissues	NNS	I-NP	O
.	.	O	O

Early	JJ	B-NP	O
infections	NNS	I-NP	B
in	IN	B-PP	O
kidney	NN	B-NP	O
,	,	O	O
heart	NN	B-NP	O
,	,	O	O
and	CC	O	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
recipients	NNS	I-NP	O
on	IN	B-PP	O
cyclosporine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
renal	JJ	I-NP	O
,	,	I-NP	O
seventeen	JJ	I-NP	O
heart	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
for	IN	B-PP	O
infection	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
renal	JJ	I-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
azathioprine	NN	B-NP	O
(	(	O	O
Aza	NN	B-NP	O
)	)	O	O
and	CC	O	O
prednisone	NN	B-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
immunosuppression	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
cyclosporine	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
-	HYPH	I-NP	O
prednisone	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
others	NNS	I-NP	O
received	VBD	B-VP	O
cyclosporine	NN	B-NP	O
and	CC	I-NP	O
prednisone	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
randomized	VBN	I-NP	O
Aza	NN	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
more	RBR	B-NP	O
overall	JJ	I-NP	O
infections	NNS	I-NP	B
and	CC	O	O
more	RBR	B-NP	O
nonviral	JJ	I-NP	O
infections	NNS	I-NP	B
than	IN	B-PP	O
the	DT	B-NP	O
randomized	VBN	I-NP	O
cyclosporine	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Heart	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
more	JJR	B-NP	O
infections	NNS	I-NP	B
than	IN	B-PP	O
cyclosporine	NN	B-NP	O
renal	JJ	I-NP	O
patients	NNS	I-NP	O
but	CC	O	O
fewer	JJR	B-NP	O
infections	NNS	I-NP	B
than	IN	B-PP	O
the	DT	B-NP	O
Aza	NNP	I-NP	O
renal	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
infectious	JJ	I-NP	O
deaths	NNS	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
transplant	NN	I-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
cyclosporine	NN	B-NP	O
or	CC	I-NP	O
Aza	NN	I-NP	O
,	,	O	O
but	CC	O	O
infection	NN	B-NP	B
played	VBD	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
cardiac	JJ	I-NP	O
transplant	NN	I-NP	O
deaths	NNS	I-NP	O
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
deaths	NNS	I-NP	O
.	.	O	O

Renal	JJ	B-NP	O
patients	NNS	I-NP	O
on	IN	B-PP	O
cyclosporine	NN	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
fewest	JJS	I-NP	O
bacteremias	NNS	I-NP	B
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
site	NN	B-NP	O
of	IN	B-PP	O
infection	NN	B-NP	B
showed	VBD	B-VP	O
a	DT	B-NP	O
preponderance	NN	I-NP	O
of	IN	B-PP	O
abdominal	JJ	B-NP	B
infections	NNS	I-NP	I
in	IN	B-PP	O
liver	NN	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
intrathoracic	JJ	B-NP	O
infections	NNS	I-NP	B
in	IN	B-PP	O
heart	NN	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
urinary	JJ	B-NP	B
tract	NN	I-NP	I
infections	NNS	I-NP	I
in	IN	B-PP	O
renal	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Pulmonary	JJ	B-NP	O
infections	NNS	I-NP	B
were	VBD	B-VP	O
less	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
cyclosporine	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
renal	JJ	B-NP	O
patients	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
Aza	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Aza	NN	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
significantly	RB	B-NP	O
more	JJR	I-NP	O
staphylococcal	JJ	I-NP	B
infections	NNS	I-NP	I
than	IN	B-PP	O
all	DT	B-NP	O
other	JJ	I-NP	O
transplant	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
and	CC	O	O
systemic	JJ	B-NP	O
fungal	JJ	I-NP	B
infections	NNS	I-NP	I
occurred	VBD	B-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Cytomegalovirus	NN	B-NP	O
(	(	O	O
CMV	NN	B-NP	O
)	)	O	O
shedding	NN	B-NP	O
or	CC	O	O
serological	JJ	B-NP	O
rises	NNS	I-NP	O
in	IN	B-PP	O
antibody	NN	B-NP	O
titer	NN	I-NP	O
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
cyclosporine	NN	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
Aza	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
cyclosporine	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
symptoms	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
CMV	NN	B-NP	B
infection	NN	I-NP	I
.	.	O	O

Serological	JJ	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
Epstein	NNP	B-NP	B
Barr	NNP	I-NP	I
Virus	NNP	I-NP	I
infection	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cyclosporine	NN	I-NP	O
patients	NNS	I-NP	O
studied	VBN	B-VP	O
.	.	O	O

num	CD	B-NP	O
had	VBD	B-VP	O
associated	VBN	I-VP	O
symptoms	NNS	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
lymphoma	NN	I-NP	B
.	.	O	O

Structure	NN	B-NP	O
-	HYPH	I-NP	O
activity	NN	I-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
relationships	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antagonism	NN	I-NP	O
of	IN	B-PP	O
picrotoxin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
by	IN	B-PP	O
cholecystokinin	NN	B-NP	O
,	,	O	O
fragments	NNS	B-NP	O
and	CC	I-NP	O
analogues	NNS	I-NP	O
of	IN	B-PP	O
cholecystokinin	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Intraperitoneal	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
cholecystokinin	NN	B-NP	O
octapeptide	NN	I-NP	O
sulphate	NN	I-NP	O
ester	NN	I-NP	O
(	(	O	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
)	)	O	O
and	CC	O	O
nonsulphated	JJ	B-NP	O
cholecystokinin	NN	I-NP	O
octapeptide	NN	I-NP	O
(	(	O	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
NS	NN	I-NP	O
)	)	O	O
enhanced	VBD	B-VP	O
the	DT	B-NP	O
latency	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
picrotoxin	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Experiments	NNS	B-NP	O
with	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
C	NN	I-NP	O
-	HYPH	B-NP	O
terminal	JJ	I-NP	O
fragments	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
C	NN	I-NP	O
-	HYPH	B-NP	O
terminal	JJ	I-NP	O
tetrapeptide	NN	I-NP	O
(	(	O	O
CCK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
was	VBD	B-VP	O
the	DT	B-NP	O
active	JJ	I-NP	O
centre	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
CCK	NN	I-NP	O
octapeptide	NN	I-NP	O
molecule	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
analogues	NNS	I-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
and	CC	I-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
NS	NN	I-NP	O
and	CC	I-NP	O
caerulein	NN	I-NP	O
dose	NN	I-NP	O
range	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
)	)	O	O
showed	VBD	B-VP	O
bell	NN	B-NP	O
-	HYPH	O	O
shaped	VBN	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
effect	NN	I-NP	O
curves	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
greatest	JJS	I-NP	O
maximum	JJ	I-NP	O
inhibition	NN	I-NP	O
for	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
NS	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
peptide	NN	I-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
had	VBD	B-VP	O
weak	JJ	B-NP	O
anticonvulsant	JJ	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
octapeptides	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
mumol	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
and	CC	O	O
larger	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
reference	NN	I-NP	O
drug	NN	I-NP	O
,	,	O	O
diazepam	NN	B-NP	O
,	,	O	O
totally	RB	B-ADVP	O
prevented	VBD	B-VP	O
picrotoxin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	I-NP	O
mortality	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
peptides	NNS	I-NP	O
tested	VBN	B-VP	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
.	.	O	O

Experiments	NNS	B-NP	O
with	IN	B-PP	O
analogues	NNS	B-NP	O
and	CC	I-NP	O
derivatives	NNS	I-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
alanyl	NN	I-NP	O
derivatives	NNS	I-NP	O
of	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
enhanced	VBN	I-VP	O
and	CC	O	O
that	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
equipotent	JJ	B-ADJP	O
with	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
analogues	NNS	I-NP	O
,	,	O	O
Ser	NN	B-NP	O
(	(	O	O
SO3H	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Ac	NN	I-NP	O
-	HYPH	B-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
and	CC	I-NP	O
Thr	NN	I-NP	O
(	(	O	O
SO3H	NN	B-NP	O
)	)	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Ac	NN	I-NP	O
-	HYPH	B-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
and	CC	I-NP	O
Hyp	NN	I-NP	O
(	(	O	O
SO3H	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
Ac	NN	I-NP	O
-	HYPH	B-NP	O
CCK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
were	VBD	B-VP	O
slightly	RB	B-ADJP	O
more	RBR	I-ADJP	O
active	JJ	I-ADJP	O
than	IN	B-PP	O
CCK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
SE	NN	I-NP	O
.	.	O	O

Vasopressin	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
contributor	NN	I-NP	O
to	TO	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
pressor	NN	I-NP	O
agent	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypertensive	JJ	I-NP	B
process	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
.	.	O	O

Vasopressin	NN	B-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
DOCA	NN	B-NP	O
-	HYPH	B-NP	O
salt	NN	I-NP	O
hypertension	NN	I-NP	B
,	,	O	O
since	IN	B-SBAR	O
the	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
substantial	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
diabetes	NN	I-NP	B
insipidus	NN	I-NP	I
after	IN	B-PP	O
DOCA	NN	B-NP	O
-	HYPH	B-NP	O
salt	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
DDAVP	NN	B-NP	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
antidiuretic	JJ	B-NP	O
action	NN	I-NP	O
but	CC	O	O
minimal	JJ	B-NP	O
vasopressor	NN	I-NP	O
effect	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
increase	VB	I-VP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
observed	VBN	B-VP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
pressor	NN	I-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
since	IN	B-SBAR	O
the	DT	B-NP	O
enhanced	VBN	I-NP	O
pressor	NN	I-NP	O
responsiveness	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hormone	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
stage	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

Increased	VBN	B-NP	O
secretion	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
from	IN	B-PP	O
neurohypophysis	NN	B-NP	O
also	RB	B-ADVP	O
promotes	VBZ	B-VP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hormone	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
pathogenetic	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

An	DT	B-NP	O
unproportional	JJ	I-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
plasma	NN	B-NP	O
osmolality	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
adjusting	VBG	I-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
forming	VBG	I-NP	O
and	CC	I-NP	O
receptor	NN	I-NP	O
binding	NN	I-NP	O
capacity	NN	I-NP	O
for	IN	B-PP	O
sodium	NN	B-NP	O
balance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
vasopressin	NN	B-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
human	JJ	B-NP	O
essential	JJ	I-NP	O
hypertension	NN	I-NP	B
.	.	O	O

Toxic	JJ	B-NP	B
hepatitis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
disulfiram	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
alcoholic	JJ	I-NP	O
.	.	O	O

A	DT	B-NP	O
reversible	JJ	I-NP	O
toxic	JJ	I-NP	B
liver	NN	I-NP	I
damage	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
alcoholic	JJ	I-NP	O
woman	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
disulfiram	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
causative	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
proven	VBN	I-VP	O
by	IN	B-PP	O
challenge	NN	B-NP	O
.	.	O	O

Atrial	JJ	B-NP	B
thrombosis	NN	I-NP	I
involving	VBG	B-VP	O
the	DT	B-NP	O
heart	NN	I-NP	O
of	IN	B-PP	O
F	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
rats	NNS	I-NP	O
ingesting	VBG	B-VP	O
quinacrine	NN	B-NP	O
hydrochloride	NN	I-NP	O
.	.	O	O

Quinacrine	JJ	B-NP	O
hydrochloride	NN	I-NP	O
is	VBZ	B-VP	O
toxic	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
of	IN	B-PP	O
F	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
ppm	NN	I-NP	O
quinacrine	NN	I-NP	O
hydrochloride	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
diet	NN	I-NP	O
all	DT	O	O
developed	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
atrial	JJ	I-NP	B
thrombosis	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
lesion	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
cardiac	JJ	B-NP	B
hypertrophy	NN	I-NP	I
and	CC	I-NP	O
dilatation	NN	I-NP	O
and	CC	O	O
focal	JJ	B-NP	O
myocardial	JJ	I-NP	B
degeneration	NN	I-NP	I
.	.	O	O

Rats	NNS	B-NP	O
died	VBD	B-VP	O
from	IN	B-PP	O
cardiac	JJ	B-NP	B
hypertrophy	NN	I-NP	I
with	IN	B-PP	O
severe	JJ	B-NP	O
acute	JJ	I-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
congestion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lungs	NNS	I-NP	O
,	,	O	O
liver	NN	B-NP	O
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
organs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-VP	O
num	CD	B-NP	O
ppm	NN	I-NP	O
quinacrine	NN	I-NP	O
hydrochloride	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
ppm	NN	I-NP	O
sodium	NN	I-NP	O
nitrite	NN	I-NP	O
simultaneously	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
diet	NN	I-NP	O
had	VBD	B-VP	O
thrombosis	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
atria	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
untreated	JJ	B-NP	O
control	NN	I-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
laboratory	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
atrial	JJ	B-NP	B
thrombosis	NN	I-NP	I
.	.	O	O

Sodium	NN	B-NP	O
nitrite	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
quinacrine	NN	B-NP	O
hydrochloride	NN	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
no	DT	B-NP	O
additional	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Alternating	VBG	B-VP	B
sinus	NN	B-NP	I
rhythm	NN	I-NP	I
and	CC	O	O
intermittent	JJ	B-NP	O
sinoatrial	JJ	I-NP	B
block	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
propranolol	NN	B-NP	O
.	.	O	O

Alternating	VBG	B-VP	B
sinus	NN	B-NP	I
rhythm	NN	I-NP	I
and	CC	O	O
intermittent	JJ	B-NP	O
sinoatrial	JJ	I-NP	B
(	(	O	I
S	NN	B-NP	I
-	HYPH	B-NP	I
A	NN	I-NP	I
)	)	O	I
block	NN	B-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
,	,	O	O
under	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
angina	NN	B-NP	B
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
propranolol	NN	I-NP	O
daily	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
electrocardiogram	NN	I-NP	O
showed	VBD	B-VP	O
alternation	NN	B-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
and	CC	I-NP	O
short	JJ	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
intervals	NNS	I-NP	O
and	CC	O	O
occasional	JJ	B-NP	O
pauses	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
pauses	NNS	I-NP	O
were	VBD	B-VP	O
always	RB	I-VP	O
preceded	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
short	JJ	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
intervals	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
usually	RB	I-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
P	NN	I-NP	O
-	HYPH	I-NP	O
P	NN	I-NP	O
intervals	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
representing	VBG	B-VP	O
the	DT	B-NP	O
basic	JJ	I-NP	O
sinus	NN	I-NP	O
cycle	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
these	DT	B-NP	O
basic	JJ	I-NP	O
sinus	NN	I-NP	O
cycles	NNS	I-NP	O
,	,	O	O
alternating	VBG	B-VP	B
rhythm	NN	B-NP	I
started	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
longer	JJR	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
interval	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
long	JJ	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
intervals	NNS	I-NP	O
ranged	VBD	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
short	JJ	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
intervals	NNS	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pauses	NNS	I-NP	O
were	VBD	B-VP	O
equal	JJ	B-ADJP	O
or	CC	O	O
almost	RB	B-ADJP	O
equal	JJ	I-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
short	JJ	I-NP	O
plus	CC	O	O
num	CD	B-NP	O
long	JJ	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
interval	NN	I-NP	O
or	CC	O	O
to	TO	B-VP	O
twice	VB	I-VP	O
the	DT	B-NP	O
basic	JJ	I-NP	O
sinus	NN	I-NP	O
cycle	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
recording	VBG	B-VP	O
a	DT	B-NP	O
short	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
regular	JJ	B-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
with	IN	B-PP	O
intermittent	JJ	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
S	NN	I-NP	B
-	HYPH	I-NP	I
A	NN	I-NP	I
block	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
short	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
sinus	NN	B-NP	O
rhythm	NN	I-NP	O
was	VBD	B-VP	O
interrupted	VBN	I-VP	O
by	IN	B-PP	O
sudden	JJ	B-NP	O
prolongation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
interval	NN	I-NP	O
starting	VBG	B-VP	O
the	DT	B-NP	O
alternative	JJ	I-NP	O
rhythm	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
small	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
shape	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
P	NN	I-NP	O
waves	NNS	I-NP	O
and	CC	O	O
P	NN	B-NP	O
-	HYPH	I-NP	O
R	NN	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

S	NN	B-NP	O
-	HYPH	I-NP	O
A	NN	I-NP	O
conduction	NN	I-NP	O
through	IN	B-PP	O
num	CD	B-NP	O
pathways	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
block	VBP	B-VP	O
the	DT	B-NP	O
second	JJ	I-NP	O
having	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
longer	JJR	B-NP	O
conduction	NN	I-NP	O
time	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
occasional	JJ	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
block	NN	I-NP	O
was	VBD	B-VP	O
proposed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
explanation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
alternating	VBG	I-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
P	NN	I-NP	O
interval	NN	I-NP	O
and	CC	O	O
other	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
features	NNS	I-NP	O
seen	VBN	B-VP	O
.	.	O	O

Atropine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
given	VBN	B-VP	O
intravenously	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
shortening	NN	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
P	NN	I-NP	O
-	HYPH	O	O
P	NN	B-NP	O
intervals	NNS	I-NP	O
without	IN	B-PP	O
changing	VBG	B-VP	O
the	DT	B-NP	O
rhythm	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
abnormal	JJ	I-NP	O
rhythm	NN	I-NP	O
disappeared	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	O	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
restarted	VBN	I-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
S	NN	I-NP	B
-	HYPH	I-NP	I
A	NN	I-NP	I
block	NN	I-NP	I
was	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
accepted	VBN	I-VP	O
as	IN	B-PP	O
evidence	NN	B-NP	O
for	IN	B-PP	O
propranolol	NN	B-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
conduction	NN	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

Antitumor	JJ	B-NP	O
effect	NN	I-NP	O
,	,	O	O
cardiotoxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
nephrotoxicity	NN	B-NP	B
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
IgM	NN	I-NP	O
solid	JJ	I-NP	O
immunocytoma	NN	I-NP	B
-	HYPH	O	O
bearing	VBG	B-VP	O
LOU	NN	B-NP	O
/	SYM	B-NP	O
M	NN	I-NP	O
/	SYM	I-NP	O
WSL	NN	I-NP	O
rat	NN	I-NP	O
.	.	O	O

Antitumor	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
cardiotoxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
nephrotoxicity	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
LOU	NN	B-NP	O
/	SYM	B-NP	O
M	NN	I-NP	O
/	SYM	B-NP	O
WSL	NN	I-NP	O
inbred	JJ	I-NP	O
rats	NNS	I-NP	O
each	DT	B-NP	O
bearing	VBG	B-VP	O
a	DT	B-NP	O
transplantable	JJ	I-NP	O
solid	JJ	I-NP	O
IgM	NN	I-NP	O
immunocytoma	NN	I-NP	B
.	.	O	O

Animals	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
tumor	NN	I-NP	B
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
iv	NN	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
weekly	JJ	I-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Tumor	NN	B-NP	B
regression	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
doxorubicin	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Complete	JJ	B-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tumor	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
doxorubicin	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Histologic	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
scored	VBN	B-VP	O
as	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
only	RB	I-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
doxorubicin	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Light	NN	B-NP	O
microscopic	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
seen	VBN	I-VP	O
above	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
doxorubicin	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
albuminuria	NN	B-NP	B
and	CC	O	O
very	RB	B-NP	O
low	JJ	I-NP	O
serum	NN	I-NP	O
albumin	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
group	NN	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
doxorubicin	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
albumin	NN	I-NP	O
level	NN	I-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
liter	NN	I-NP	O
.	.	O	O

Ascites	NN	B-NP	B
and	CC	I-NP	O
hydrothorax	NN	I-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
same	JJ	I-NP	O
experiments	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
tumor	NN	I-NP	B
-	HYPH	O	O
bearing	VBG	B-VP	O
rats	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
which	WDT	B-NP	O
no	DT	B-NP	O
major	JJ	I-NP	O
differences	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
,	,	O	O
cardiotoxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
nephrotoxicity	NN	B-NP	B
were	VBD	B-VP	O
studied	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
LOU	NN	I-NP	O
/	SYM	B-NP	O
M	NN	I-NP	O
/	SYM	I-NP	O
WSL	NN	I-NP	O
rat	NN	I-NP	O
.	.	O	O

Albuminuria	NNP	B-NP	B
due	IN	B-PP	O
to	TO	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
led	VBD	B-VP	O
to	TO	B-PP	O
extremely	RB	B-NP	O
low	JJ	I-NP	O
serum	NN	I-NP	O
albumin	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
so	IN	O	O
ascites	NNS	B-NP	B
and	CC	I-NP	O
hydrothorax	NN	I-NP	B
were	VBD	B-VP	O
not	RB	O	O
necessarily	RB	B-ADVP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
observed	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Intraoperative	JJ	B-NP	O
bradycardia	NN	I-NP	B
and	CC	I-NP	O
hypotension	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
timolol	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
eye	NN	I-NP	O
drops	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
was	VBD	B-VP	O
concurrently	RB	I-VP	O
being	VBG	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
nitrate	NN	I-NP	O
and	CC	O	O
timolol	NN	B-NP	O
maleate	NN	I-NP	O
eye	NN	I-NP	O
drops	NNS	I-NP	O
,	,	O	O
developed	VBD	B-VP	O
a	DT	B-NP	O
bradycardia	NN	I-NP	B
and	CC	O	O
became	VBD	B-VP	O
hypotensive	JJ	B-ADJP	B
during	IN	B-PP	O
halothane	NN	B-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Both	CC	O	O
timolol	NN	B-NP	O
and	CC	I-NP	O
pilocarpine	NN	I-NP	O
were	VBD	B-VP	O
subsequently	RB	I-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
collection	NN	I-NP	O
of	IN	B-PP	O
urine	NN	B-NP	O
.	.	O	O

Timolol	NN	B-NP	O
(	(	O	O
but	CC	O	O
not	RB	O	O
pilocarpine	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
sample	NN	I-NP	O
of	IN	B-PP	O
plasma	NN	B-NP	O
removed	VBN	B-VP	O
during	IN	B-PP	O
surgery	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
timolol	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
ng	NN	I-NP	O
ml	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
was	VBD	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
partial	JJ	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
blockade	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
postulated	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
action	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
enhanced	VBN	I-VP	O
during	IN	B-PP	O
halothane	NN	B-NP	O
anaesthesia	NN	I-NP	O
with	IN	B-PP	O
resultant	JJ	B-NP	O
bradycardia	NN	I-NP	B
and	CC	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Pilocarpine	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
had	VBD	I-VP	O
a	DT	B-NP	O
contributory	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Succinylcholine	NN	B-NP	O
apnoea	NN	I-NP	B
:	:	O	O
attempted	VBN	B-NP	O
reversal	NN	I-NP	O
with	IN	B-PP	O
anticholinesterases	NNS	B-NP	O
.	.	O	O

Anticholinesterases	NNS	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
attempt	NN	I-NP	O
to	TO	B-VP	O
antagonize	VB	I-VP	O
prolonged	JJ	B-NP	O
neuromuscular	JJ	I-NP	B
blockade	NN	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
succinylcholine	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
later	RB	B-ADVP	O
found	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
homozygous	JJ	B-ADJP	O
for	IN	B-PP	O
atypical	JJ	B-NP	O
plasma	NN	I-NP	O
cholinesterase	NN	I-NP	O
.	.	O	O

Edrophonium	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
given	VBN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
,	,	O	O
when	WRB	B-ADVP	O
train	NN	B-NP	O
-	HYPH	B-NP	O
of	IN	B-PP	O
-	SYM	B-NP	O
num	CD	I-NP	O
stimulation	NN	I-NP	O
was	VBD	B-VP	O
characteristic	JJ	B-ADJP	O
of	IN	B-PP	O
phase	NN	B-NP	O
num	CD	I-NP	O
block	NN	I-NP	O
,	,	O	O
produced	VBD	B-VP	O
partial	JJ	B-NP	O
antagonism	NN	I-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
sustained	VBN	I-VP	O
.	.	O	O

Repeated	VBN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
edrophonium	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
neostigmine	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
antagonize	VB	I-VP	O
or	CC	I-VP	O
augment	VB	I-VP	O
the	DT	B-NP	O
block	NN	I-NP	O
.	.	O	O

Spontaneous	JJ	B-NP	O
respiration	NN	I-NP	O
recommenced	VBD	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
succinylcholine	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
anticholinesterases	NNS	B-NP	O
are	VBP	B-VP	O
only	RB	B-ADVP	O
partially	RB	B-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
restoring	VBG	B-VP	O
neuromuscular	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
succinylcholine	NN	B-NP	O
apnoea	NN	I-NP	B
despite	IN	B-PP	O
muscle	NN	B-NP	O
twitch	NN	I-NP	O
activity	NN	I-NP	O
typical	JJ	B-ADJP	O
of	IN	B-PP	O
phase	NN	B-NP	O
num	CD	I-NP	O
block	NN	I-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
on	IN	B-PP	O
[	(	O	O
omega	SYM	O	O
-	HYPH	B-NP	O
I	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	I-NP	O
heptadecanoic	JJ	I-NP	O
acid	NN	I-NP	O
myocardial	JJ	I-NP	O
scintigraphy	NN	I-NP	O
and	CC	I-NP	O
echocardiography	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
serial	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
on	IN	B-PP	O
dynamic	JJ	B-NP	O
myocardial	JJ	I-NP	O
scintigraphy	NN	I-NP	O
with	IN	B-PP	O
[	(	O	O
omega	SYM	O	O
-	HYPH	B-NP	O
I	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	I-NP	O
heptadecanoic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
I	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
HA	NN	I-NP	O
)	)	O	O
,	,	B-PP	O
and	CC	I-PP	O
on	IN	B-PP	O
global	JJ	B-NP	O
left	JJ	I-NP	O
-	HYPH	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
determined	VBN	B-VP	O
echocardiographically	RB	B-ADVP	O
,	,	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mongrel	NN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

Total	JJ	B-NP	O
extractable	JJ	I-NP	O
myocardial	JJ	I-NP	O
lipid	NN	I-NP	O
was	VBD	B-VP	O
compared	VBN	I-VP	O
postmortem	JJ	B-ADJP	O
between	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
dogs	NNS	I-NP	O
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
and	CC	O	O
then	RB	B-ADVP	O
progressive	JJ	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
global	JJ	B-NP	O
LV	NN	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
cumulative	JJ	I-NP	O
doxorubicin	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
t1	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
I	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
HA	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
only	RB	B-ADVP	O
at	IN	B-PP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
significant	JJ	I-NP	O
alteration	NN	I-NP	O
in	IN	B-PP	O
total	JJ	B-NP	O
extractable	JJ	I-NP	O
myocardial	JJ	I-NP	O
lipids	NNS	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
control	NN	B-NP	O
dogs	NNS	I-NP	O
and	CC	O	O
those	DT	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
changes	NNS	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
alteration	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	O
dynamic	JJ	I-NP	O
imaging	NN	I-NP	O
with	IN	B-PP	O
I	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
HA	NN	I-NP	O
are	VBP	B-VP	O
not	RB	O	O
the	DT	B-NP	O
initiating	VBG	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
doxorubicin	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

Hemodynamics	NNS	B-NP	O
and	CC	O	O
myocardial	JJ	B-NP	O
metabolism	NN	I-NP	O
under	IN	B-PP	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

An	DT	B-NP	O
experimental	JJ	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

Coronary	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
work	NN	I-NP	O
and	CC	I-NP	O
metabolism	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
under	IN	B-PP	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
(	(	O	O
SNP	NN	B-NP	O
)	)	O	O
and	CC	O	O
trimetaphan	NN	B-NP	O
(	(	O	O
TMP	NN	B-NP	O
)	)	O	O
deliberate	JJ	B-NP	O
hypotension	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
mean	JJ	I-NP	O
pressure	NN	I-NP	O
decrease	NN	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
)	)	O	O
.	.	O	O

Regarding	VBG	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
on	IN	B-PP	O
coronary	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
,	,	O	O
aortic	JJ	B-NP	O
and	CC	I-NP	O
coronary	JJ	I-NP	O
sinus	NN	I-NP	O
metabolic	JJ	I-NP	O
data	NNS	I-NP	O
(	(	O	O
pH	NN	B-NP	O
,	,	O	O
pO2	NN	B-NP	O
,	,	O	O
pCO2	NN	B-NP	O
)	)	O	O
we	PRP	B-NP	O
could	MD	B-VP	O
confirm	VB	I-VP	O
that	IN	B-SBAR	O
nitroprusside	NN	B-NP	O
hypotension	NN	I-NP	B
could	MD	B-VP	O
be	VB	I-VP	O
safely	RB	I-VP	O
used	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
mean	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
decrease	NN	I-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
,	,	O	O
trimetaphan	NN	B-NP	O
hypotension	NN	I-NP	B
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
mean	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
decrease	NN	I-NP	O
.	.	O	O

Cardiac	JJ	B-NP	O
work	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
during	IN	B-PP	O
SNP	NN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Myocardial	JJ	B-NP	O
O2	NN	I-NP	O
consumption	NN	I-NP	O
and	CC	O	O
O2	NN	B-NP	O
availability	NN	I-NP	O
were	VBD	B-VP	O
directly	RB	B-ADJP	O
dependent	JJ	I-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
coronary	JJ	I-NP	O
perfusion	NN	I-NP	O
.	.	O	O

Careful	JJ	B-NP	O
invasive	JJ	I-NP	O
monitoring	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
blood	NN	B-NP	O
gases	NNS	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
ECG	NN	I-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
T	NN	I-NP	O
segment	NN	I-NP	O
is	VBZ	B-VP	O
mandatory	JJ	B-ADJP	O
.	.	O	O

Evidence	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
brain	NN	I-NP	O
noradrenergic	JJ	I-NP	O
involvement	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
locomotor	JJ	I-NP	O
stimulant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
noradrenaline	NN	I-NP	O
neurotoxin	NN	I-NP	O
DSP4	NN	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hyperactivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
amphetamine	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
DSP4	NN	B-NP	O
pretreatment	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
increased	VBN	I-NP	O
rearings	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
amphetamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
stereotypies	NNS	I-NP	B
were	VBD	B-VP	O
not	RB	I-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
DSP4	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
hyperactivity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
DSP4	NN	B-NP	O
was	VBD	B-VP	O
blocked	VBN	I-VP	O
by	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
noradrenaline	NN	I-NP	O
-	HYPH	O	O
uptake	NN	B-NP	O
blocking	VBG	B-VP	O
agent	NN	B-NP	O
,	,	O	O
desipramine	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
prevents	VBZ	B-VP	O
the	DT	B-NP	O
neurotoxic	JJ	I-NP	B
action	NN	I-NP	O
of	IN	B-PP	O
DSP4	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
noradrenergic	JJ	I-NP	O
neurones	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
locomotor	NN	I-NP	O
stimulant	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Accelerated	VBN	B-NP	B
junctional	JJ	I-NP	I
rhythms	NNS	I-NP	I
during	IN	B-PP	O
oral	JJ	B-NP	O
verapamil	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
atrioventricular	JJ	B-NP	O
(	(	O	O
AV	NN	B-NP	O
)	)	O	O
dissociation	NN	B-NP	O
and	CC	O	O
accelerated	VBD	B-VP	B
junctional	JJ	B-NP	I
rhythms	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
oral	JJ	B-NP	O
verapamil	NN	I-NP	O
.	.	O	O

Accelerated	VBN	B-NP	B
junctional	JJ	I-NP	I
rhythms	NNS	I-NP	I
and	CC	O	O
AV	NN	B-NP	O
dissociation	NN	I-NP	O
were	VBD	B-VP	O
frequent	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
supraventricular	JJ	B-NP	B
tachyarrhythmias	NNS	I-NP	I
,	,	O	O
particularly	RB	B-ADVP	O
AV	NN	B-NP	O
nodal	JJ	I-NP	O
reentry	NN	I-NP	O
.	.	O	O

Verapamil	NN	B-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
asymptomatic	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
activity	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
junctional	JJ	I-NP	O
pacemakers	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
various	JJ	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
syndromes	NNS	I-NP	O
,	,	O	O
verapamil	NN	B-NP	O
neither	CC	O	O
increased	VBD	B-VP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
junctional	JJ	B-NP	O
rhythms	NNS	I-NP	O
nor	CC	O	O
suppressed	VBD	B-VP	O
their	PRP$	B-NP	O
role	NN	I-NP	O
as	IN	B-PP	O
escape	NN	B-NP	O
rhythms	NNS	I-NP	O
under	IN	B-PP	O
physiologically	RB	B-NP	O
appropriate	JJ	I-NP	O
circumstances	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
ovarian	JJ	B-NP	B
cancer	NN	I-NP	I
with	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cis	NN	B-NP	O
-	HYPH	I-NP	O
platinum	NN	I-NP	O
,	,	I-NP	O
adriamycin	NN	I-NP	O
,	,	I-NP	O
cyclophosphamide	NN	I-NP	O
and	CC	I-NP	O
hexamethylmelamine	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
ovarian	JJ	B-NP	B
cancer	NN	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cisplatinum	NN	B-NP	O
(	(	O	O
CPDD	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m2	NN	B-NP	O
,	,	O	O
adriamycin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m2	NN	B-NP	O
,	,	O	O
cyclophosphamide	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m2	NN	B-NP	O
,	,	O	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
and	CC	O	O
hexamethylmelamine	NN	B-NP	O
(	(	O	O
HMM	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
daily	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Each	DT	B-NP	O
course	NN	I-NP	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
monthly.	NN	B-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
stage	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
stage	NN	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
stage	NN	I-NP	O
num	CD	B-NP	O
disease.	NN	I-NP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
previously	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
chemotherapy	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
radiation	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
both	CC	O	O
chemotherapy	NN	B-NP	O
and	CC	I-NP	O
radiation	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
any	DT	B-NP	O
treatment	NN	I-NP	O
before	IN	B-PP	O
CPDD	NN	B-NP	O
combination.	NN	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
demonstrated	VBD	B-VP	O
objective	JJ	B-NP	O
responses	NNS	I-NP	O
lasting	VBG	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
.	.	O	O

These	DT	B-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
partial	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	O	O
complete	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Hematologic	JJ	B-NP	B
toxicity	NN	I-NP	I
was	VBD	B-VP	O
moderate	JJ	B-ADJP	O
and	CC	O	O
with	IN	B-PP	O
reversible	JJ	B-NP	O
anemia	NN	I-NP	B
developing	VBG	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Gastrointestinal	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
from	IN	B-PP	O
CPDD	NN	B-NP	O
were	VBD	B-VP	O
universal	JJ	B-ADJP	O
.	.	O	O

HMM	NN	B-NP	O
gastrointestinal	JJ	I-NP	B
toxicity	NN	I-NP	I
necessitated	VBD	B-VP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Severe	JJ	B-NP	O
nephrotoxicity	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
but	CC	O	O
was	VBD	B-VP	O
reversible	JJ	B-ADJP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
deaths	NNS	I-NP	O
.	.	O	O

Nontraumatic	JJ	B-NP	O
dissecting	VBG	I-NP	B
aneurysm	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
basilar	JJ	I-NP	O
artery	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
nontraumatic	JJ	B-NP	O
dissecting	VBG	I-NP	B
aneurysm	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
basilar	JJ	I-NP	O
artery	NN	I-NP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
smoke	NN	B-NP	O
,	,	O	O
and	CC	O	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
young	JJ	I-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
locked	VBN	I-NP	B
-	HYPH	I-NP	I
in	IN	B-PP	I
syndrome	NN	B-NP	I
.	.	O	O

Propylthiouracil	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hepatic	JJ	I-NP	B
damage	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
propylthiouracil	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
damage	NN	I-NP	I
have	VBP	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
of	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
,	,	O	O
proven	VBN	B-VP	O
by	IN	B-PP	O
rechallenge	NN	B-NP	O
;	:	O	O
the	DT	B-NP	O
second	JJ	I-NP	O
presents	VBZ	B-VP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
histologic	JJ	I-NP	O
picture	NN	I-NP	O
resembling	VBG	B-VP	O
chronic	JJ	B-NP	B
active	JJ	I-NP	I
hepatitis	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
spontaneous	JJ	B-NP	O
remission	NN	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bradycardia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
bepridil	NN	B-NP	O
.	.	O	O

Bepridil	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
novel	JJ	I-NP	O
active	JJ	I-NP	O
compound	NN	I-NP	O
for	IN	B-PP	O
prophylactic	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
anginal	JJ	B-NP	B
attacks	NNS	I-NP	I
,	,	O	O
induced	VBD	B-VP	O
persistent	JJ	B-NP	O
bradycardia	NN	I-NP	B
and	CC	O	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
tachycardial	JJ	I-NP	B
effect	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
investigated	VBN	I-VP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

In	FW	B-NP	O
vitro	FW	I-NP	O
perfusion	NN	I-NP	O
of	IN	B-PP	O
bepridil	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
life	NN	I-NP	O
-	HYPH	I-NP	O
support	NN	I-NP	O
medium	NN	I-NP	O
for	IN	B-PP	O
isolated	VBN	B-NP	O
sino	AFX	I-NP	O
-	HYPH	I-NP	O
atrial	JJ	I-NP	O
tissue	NN	I-NP	O
from	IN	B-PP	O
rabbit	NN	B-NP	O
heart	NN	I-NP	O
,	,	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
action	NN	B-NP	O
potential	NN	I-NP	O
(	(	O	O
AP	NN	B-NP	O
)	)	O	O
spike	NN	B-NP	O
frequency	NN	I-NP	O
(	(	O	O
recorded	VBN	B-VP	O
by	IN	B-PP	O
KCl	NN	B-NP	O
microelectrodes	NNS	I-NP	O
)	)	O	O
starting	VBG	B-VP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
X	SYM	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADJP	O
dependent	JJ	I-ADJP	O
up	IN	B-PP	O
to	TO	B-PP	O
concentrations	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
X	SYM	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
,	,	O	O
whereupon	IN	B-PP	O
blockade	NN	B-NP	O
of	IN	B-PP	O
sinus	NN	B-NP	O
activity	NN	I-NP	O
set	VBN	B-VP	O
in	IN	B-PP	O
.	.	O	O

Bepridil	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
X	SYM	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
,	,	O	O
induced	VBD	B-VP	O
a	DT	B-NP	O
concomitant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
AP	NN	B-NP	O
amplitude	NN	I-NP	O
,	,	O	O
maximum	JJ	B-NP	O
systolic	JJ	I-NP	O
depolarization	NN	I-NP	O
velocity	NN	I-NP	O
(	(	O	O
phase	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
which	WDT	B-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-VP	O
/	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
V	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
V	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
maximum	NN	B-NP	O
diastolic	JJ	I-NP	O
depolarization	NN	I-NP	O
velocity	NN	I-NP	O
(	(	O	O
phase	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
which	WDT	B-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mV	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mV	NN	I-NP	O
/	SYM	I-NP	O
s	NN	I-NP	O
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
bepridil	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
(	(	O	O
i.v.	JJ	B-ADJP	O
)	)	O	O
into	IN	B-PP	O
num	CD	B-NP	O
anaesthetized	VBN	I-NP	O
dogs	NNS	I-NP	O
which	WDT	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
ablation	NN	B-NP	O
of	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
extrinsic	JJ	I-NP	O
cardiac	JJ	I-NP	O
afferent	JJ	I-NP	O
nerve	NN	I-NP	O
supply	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
bilateral	JJ	I-NP	O
medullo	AFX	I-NP	O
-	HYPH	I-NP	O
adrenalectomy	NN	I-NP	O
,	,	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
which	WDT	B-NP	O
fell	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
sustained	VBN	B-VP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
bepridil	NN	B-NP	O
reduces	VBZ	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
by	IN	B-PP	O
acting	VBG	B-VP	O
directly	RB	B-ADVP	O
on	IN	B-PP	O
the	DT	B-NP	O
sinus	NN	I-NP	O
node	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
flattening	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
and	CC	O	O
phase	NN	B-NP	O
num	CD	I-NP	O
slope	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
longer	JJR	I-NP	O
AP	NN	I-NP	O
duration	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
constants	NNS	I-NP	O
of	IN	B-PP	O
slow	JJ	B-NP	O
inward	JJ	I-NP	O
ionic	JJ	I-NP	O
currents	NNS	I-NP	O
(	(	O	O
already	RB	B-VP	O
demonstrated	VBN	I-VP	O
elsewhere	RB	B-ADVP	O
)	)	O	O
,	,	O	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
to	TO	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
time	NN	I-NP	O
constant	NN	I-NP	O
for	IN	B-PP	O
deactivation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
outward	JJ	I-NP	O
potassium	NN	I-NP	O
current	NN	I-NP	O
(	(	O	O
Ip	NN	B-NP	O
)	)	O	O
.	.	O	O

Hepatitis	NN	B-NP	B
and	CC	I-NP	O
renal	JJ	I-NP	B
tubular	JJ	I-NP	I
acidosis	NN	I-NP	I
after	IN	B-PP	O
anesthesia	NN	B-NP	O
with	IN	B-PP	O
methoxyflurane	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
operated	VBN	B-VP	O
for	IN	B-PP	O
acute	JJ	B-NP	B
cholecystitis	NN	I-NP	I
under	IN	B-PP	O
methoxyflurane	NN	B-NP	O
anesthesia	NN	I-NP	O
developed	VBD	B-VP	O
postoperatively	RB	B-ADVP	O
a	DT	B-NP	O
hepatic	JJ	I-NP	B
insufficiency	NN	I-NP	I
syndrome	NN	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
tubular	JJ	I-NP	I
acidosis	NN	I-NP	I
.	.	O	O

Massive	JJ	B-NP	O
bleeding	NN	I-NP	B
appeared	VBD	B-VP	O
during	IN	B-PP	O
surgery	NN	B-NP	O
which	WDT	B-NP	O
lasted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Postoperative	JJ	B-NP	O
evolution	NN	I-NP	O
under	IN	B-PP	O
supportive	JJ	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
favourable	JJ	B-ADJP	O
.	.	O	O

Complete	JJ	B-NP	O
recovery	NN	I-NP	O
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
repeated	VBN	B-NP	O
controls	NNS	I-NP	O
performed	VBN	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

Pituitary	JJ	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
luteinizing	VBG	B-VP	O
hormone	NN	B-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
during	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
prolactin	NN	I-NP	O
and	CC	O	O
luteinizing	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
LH	NN	B-NP	O
)	)	O	O
levels	NNS	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
male	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
the	DT	B-NP	O
infusions	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pituitary	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
LH	NN	B-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
LH	NN	B-NP	O
-	HYPH	B-NP	O
RH	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
.	.	O	O

Control	NN	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
infusions	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
NaCl	NN	I-NP	O
solution	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
infusions	NNS	I-NP	O
,	,	O	O
significant	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
an	DT	B-NP	O
abolished	VBN	I-NP	O
pituitary	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
LH	NN	B-NP	O
-	HYPH	O	O
RH	NN	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
responses	NNS	B-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Antirifampicin	NN	B-NP	O
antibodies	NNS	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
rifampicin	NN	I-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
.	.	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
thrombopenia	NN	B-NP	B
and	CC	I-NP	O
hemolysis	NN	I-NP	B
)	)	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
reintroduction	NN	I-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
are	VBP	B-VP	O
described	VBN	I-VP	O
.	.	O	O

No	DT	B-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
manifestations	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
taken	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
but	CC	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
,	,	O	O
antirifampicin	NN	B-NP	O
antibodies	NNS	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
.	.	O	O

Antibodies	NNS	B-NP	O
suggested	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
IgM	NN	I-NP	O
class	NN	I-NP	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hematological	JJ	B-NP	B
disorders	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
acute	JJ	I-NP	B
tubular	JJ	I-NP	I
necrosis	NN	I-NP	I
found	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
biopsied	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
indistinguishable	JJ	B-ADJP	O
from	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	O
origin	NN	I-NP	O
,	,	O	O
raised	VBD	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
vascular	JJ	I-NP	O
-	HYPH	I-NP	O
mediated	VBN	I-NP	O
damage	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
triggering	VBG	I-NP	O
immunoallergic	JJ	I-NP	O
mechanism	NN	I-NP	O
is	VBZ	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Cardiovascular	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
hypotension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
adenosine	NN	B-NP	O
triphosphate	NN	I-NP	O
and	CC	O	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
on	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
denervated	VBN	B-NP	O
hearts	NNS	I-NP	O
.	.	O	O

Adenosine	NN	B-NP	O
triphosphate	NN	I-NP	O
(	(	O	O
ATP	NN	B-NP	O
)	)	O	O
and	CC	O	O
sodium	NN	B-NP	O
nitroprusside	NN	I-NP	O
(	(	O	O
SNP	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
and	CC	I-VP	O
control	VB	I-VP	O
hypotension	NN	B-NP	B
during	IN	B-PP	O
anesthesia	NN	B-NP	O
.	.	O	O

SNP	NN	B-NP	O
is	VBZ	B-VP	O
authorized	VBN	I-VP	O
for	IN	B-PP	O
clinical	JJ	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
USA	NNP	B-NP	O
and	CC	I-NP	O
UK	NNP	I-NP	O
,	,	O	O
and	CC	O	O
ATP	NN	B-NP	O
is	VBZ	B-VP	O
clinically	RB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
other	JJ	B-NP	O
countries	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
Japan	NNP	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
how	WRB	B-ADVP	O
these	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
act	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
systems	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
whose	WP$	B-NP	O
hearts	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
denervated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
procedure	NN	I-NP	O
we	PRP	B-NP	O
had	VBD	B-VP	O
devised	VBN	I-VP	O
.	.	O	O

ATP	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
)	)	O	O
or	CC	O	O
SNP	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
)	)	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	I-VP	O
reduce	VB	I-VP	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
.	.	O	O

Before	IN	B-ADVP	O
,	,	O	O
during	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
induced	VBN	B-NP	O
hypotension	NN	I-NP	B
,	,	O	O
we	PRP	B-NP	O
measured	VBD	B-VP	O
major	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
parameters	NNS	I-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
ATP	NN	B-NP	O
was	VBD	B-VP	O
accompanied	VBN	I-VP	O
by	IN	B-PP	O
significant	JJ	B-NP	O
decreases	NNS	I-NP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
pulmonary	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
central	JJ	B-NP	O
venous	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
peripheral	JJ	I-NP	O
resistance	NN	I-NP	O
,	,	O	O
rate	NN	B-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
body	NN	I-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
,	,	O	O
and	CC	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
;	:	O	O
all	PDT	B-NP	O
these	DT	I-NP	O
variables	NNS	I-NP	O
returned	VBD	B-VP	O
normal	JJ	B-ADJP	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
ATP	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Cardiac	JJ	B-NP	O
output	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
.	.	O	O

During	IN	B-PP	O
hypotension	NN	B-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
SNP	NN	B-NP	O
similar	JJ	I-NP	O
decreases	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
mean	JJ	B-NP	O
pulmonary	JJ	I-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
central	JJ	B-NP	O
venous	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
total	JJ	B-NP	O
peripheral	JJ	I-NP	O
resistance	NN	I-NP	O
,	,	O	O
rate	NN	B-NP	O
pressure	NN	I-NP	O
product	NN	I-NP	O
,	,	O	O
and	CC	O	O
oxygen	NN	B-NP	O
content	NN	I-NP	O
difference	NN	I-NP	O
between	IN	B-PP	O
arterial	JJ	B-NP	O
and	CC	I-NP	O
mixed	JJ	I-NP	O
venous	JJ	I-NP	O
blood	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
output	NN	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
.	.	O	O

Recoveries	NNS	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
shown	VBN	I-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-SBAR	O
SNP	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Both	CC	O	O
ATP	NN	B-NP	O
and	CC	I-NP	O
SNP	NN	I-NP	O
should	MD	B-VP	O
act	VB	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
pacemaker	NN	I-NP	O
tissue	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

Comparative	JJ	B-NP	O
study	NN	I-NP	O
:	:	O	O
Endografine	NN	B-NP	O
(	(	O	O
diatrizoate	NN	B-NP	O
)	)	O	O
,	,	O	O
Vasurix	NN	B-NP	O
polyvidone	NN	I-NP	O
(	(	O	O
acetrizoate	NN	B-NP	O
)	)	O	O
,	,	O	O
Dimer	NN	B-NP	O
-	HYPH	O	O
X	NN	B-NP	O
(	(	O	O
iocarmate	NN	B-NP	O
)	)	O	O
and	CC	O	O
Hexabrix	NN	B-NP	O
(	(	O	O
ioxaglate	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
hysterosalpingography	NN	B-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
hysterosalpingography	NN	B-NP	O
with	IN	B-PP	O
Dimer	NN	B-NP	O
-	HYPH	I-NP	O
X	NN	I-NP	O
,	,	O	O
Hexabrix	NNP	B-NP	O
,	,	O	O
Vasurix	NNP	B-NP	O
polyvidone	NN	I-NP	O
and	CC	I-NP	O
Endografine	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
receiving	VBG	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
tested	VBN	I-NP	O
media	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
from	IN	B-PP	O
replies	NNS	B-NP	O
to	TO	B-PP	O
postal	JJ	B-NP	O
questionnaires	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
Dimer	NN	I-NP	O
-	HYPH	I-NP	O
X	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
nausea	NN	B-NP	B
and	CC	I-NP	O
dizziness	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
Endografine	NNP	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
differences	NNS	I-NP	O
occur	VBP	B-VP	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
groups	NNS	I-NP	O
under	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Hexabrix	NNP	B-NP	O
and	CC	I-NP	O
Vasurix	NNP	I-NP	O
polyvidone	NN	I-NP	O
are	VBP	B-VP	O
considered	VBN	I-VP	O
the	DT	B-NP	O
best	JJS	I-NP	O
contrast	NN	I-NP	O
media	NNS	I-NP	O
for	IN	B-PP	O
hysterosalpingography	NN	B-NP	O
and	CC	O	O
perhaps	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
low	JJ	I-NP	O
toxicity	NN	I-NP	B
Hexabrix	NNP	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
preferred	VBN	I-VP	O
.	.	O	O

Post	AFX	B-NP	O
-	HYPH	I-NP	O
suxamethonium	NN	I-NP	O
pains	NNS	I-NP	B
in	IN	B-PP	O
Nigerian	JJ	B-NP	O
surgical	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Contrary	JJ	B-ADVP	O
to	TO	B-PP	O
an	DT	B-NP	O
earlier	JJR	I-NP	O
report	NN	I-NP	O
by	IN	B-PP	O
Coxon	NNP	B-NP	O
,	,	O	O
scoline	NN	B-NP	O
pain	NN	I-NP	B
occurs	VBZ	B-VP	O
in	IN	B-PP	O
African	JJ	B-NP	O
negroes	NNS	I-NP	O
.	.	O	O

Its	PRP$	B-NP	O
incidence	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
involving	VBG	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
Nigerian	JJ	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
out	RP	B-PRT	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

About	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
out	RB	I-NP	O
-	HYPH	O	O
patients	NNS	B-NP	O
developed	VBD	B-VP	O
scoline	NN	B-NP	O
pain	NN	I-NP	B
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
among	IN	B-PP	O
the	DT	B-NP	O
in	IN	B-PP	O
-	HYPH	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
abolition	NN	I-NP	O
of	IN	B-PP	O
muscle	NN	B-NP	O
fasciculations	NNS	I-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
scoline	NN	B-NP	O
pain	NN	I-NP	B
.	.	O	O

Neither	CC	O	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
induction	NN	B-NP	O
agent	NN	I-NP	O
(	(	O	O
Althesin	NN	B-NP	O
or	CC	O	O
Thiopentone	NN	B-NP	O
)	)	O	O
nor	CC	O	O
the	DT	B-NP	O
salt	NN	I-NP	O
preparation	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
used	VBN	B-VP	O
(	(	O	O
chloride	NN	B-NP	O
or	CC	O	O
bromide	NN	B-NP	O
)	)	O	O
,	,	O	O
affected	VBD	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
scoline	NN	B-NP	O
pain	NN	I-NP	B
.	.	O	O

Medial	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
arterial	JJ	B-NP	O
spasm	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
norepinephrine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
media	NNS	I-NP	O
of	IN	B-PP	O
small	JJ	B-NP	O
arteries	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
in	IN	B-PP	O
diameter	NN	B-NP	O
)	)	O	O
previously	RB	B-ADVP	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
contain	VB	I-VP	O
intracellular	JJ	B-NP	O
vacuoles	NNS	I-NP	O
,	,	O	O
identified	VBN	B-VP	O
ultrastructurally	RB	B-ADVP	O
as	IN	B-PP	O
herniations	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
cell	NN	I-NP	O
into	IN	B-PP	O
another	DT	B-NP	O
.	.	O	O

The	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
intense	JJ	B-NP	O
vasoconstriction	NN	I-NP	O
would	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
such	JJ	B-NP	O
vacuoles	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
tested	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
media	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
saphenous	JJ	I-NP	O
artery	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
distal	JJ	I-NP	O
branch	NN	I-NP	O
,	,	O	O
vasoconstriction	NN	B-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
norepinephrine	NN	B-NP	O
produced	VBD	B-VP	O
many	JJ	B-NP	O
cell	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
hernias	NNS	I-NP	B
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
their	PRP$	B-NP	O
number	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
about	IN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
original	JJ	I-NP	O
number	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
the	DT	B-NP	O
vessel	NN	I-NP	O
was	VBD	B-VP	O
almost	RB	I-VP	O
restored	VBN	I-VP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
.	.	O	O

Triple	JJ	B-NP	O
stimulation	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
day	NN	I-NP	O
induced	VBD	B-VP	O
more	RBR	B-NP	O
severe	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
media	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
smooth	JJ	B-NP	O
muscle	NN	I-NP	O
cells	NNS	I-NP	O
are	VBP	B-VP	O
susceptible	JJ	B-ADJP	O
to	TO	B-VP	O
damage	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
specific	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
experimental	JJ	I-NP	O
data	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
medial	JJ	B-NP	O
changes	NNS	I-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
other	JJ	B-NP	O
instances	NNS	I-NP	O
of	IN	B-PP	O
arterial	JJ	B-NP	O
spasm	NN	I-NP	B
.	.	O	O

Endothelial	JJ	B-NP	O
changes	NNS	I-NP	O
that	WDT	B-NP	O
developed	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
were	VBD	B-VP	O
described	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
paper	NN	I-NP	O
.	.	O	O

Abnormalities	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pupil	NN	I-NP	O
and	CC	I-NP	O
visual	JJ	I-NP	O
-	HYPH	I-NP	O
evoked	JJ	I-NP	O
potential	NN	I-NP	O
in	IN	B-PP	O
quinine	NN	B-NP	O
amblyopia	NN	I-NP	B
.	.	O	O

Total	JJ	B-NP	O
blindness	NN	I-NP	B
with	IN	B-PP	O
a	DT	B-NP	O
transient	JJ	I-NP	O
tonic	JJ	I-NP	B
pupillary	JJ	I-NP	I
response	NN	I-NP	O
,	,	O	O
denervation	NN	B-NP	O
supersensitivity	NN	I-NP	O
,	,	O	O
and	CC	O	O
abnormal	JJ	B-NP	O
visual	JJ	I-NP	O
-	HYPH	I-NP	O
evoked	VBN	I-NP	O
potentials	NNS	I-NP	O
developed	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
sulfate	NN	I-NP	O
for	IN	B-PP	O
leg	NN	B-NP	B
cramps	NNS	I-NP	I
.	.	O	O

He	PRP	B-NP	O
later	RB	B-ADVP	O
recovered	VBD	B-VP	O
normal	JJ	B-NP	O
visual	JJ	I-NP	O
acuity	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
transient	JJ	I-NP	O
tonic	JJ	I-NP	B
pupillary	JJ	I-NP	I
response	NN	I-NP	O
,	,	O	O
denervation	NN	B-NP	O
supersensitivity	NN	I-NP	O
,	,	O	O
and	CC	O	O
abnormal	JJ	B-NP	O
visual	JJ	I-NP	O
-	HYPH	I-NP	O
evoked	VBN	I-NP	O
potentials	NNS	I-NP	O
in	IN	B-PP	O
quinine	NN	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
to	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Suxamethonium	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
jaw	NN	I-NP	B
stiffness	NN	I-NP	I
and	CC	I-NP	O
myalgia	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
atypical	JJ	B-NP	O
cholinesterase	NN	I-NP	O
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
boy	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
halothane	NN	B-NP	O
,	,	O	O
nitrous	JJ	B-NP	O
oxide	NN	I-NP	O
and	CC	I-NP	O
oxygen	NN	I-NP	O
,	,	O	O
pancuronium	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
suxamethonium	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
for	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
anaesthesia	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
a	DT	I-NP	O
marked	JJ	I-NP	O
jaw	NN	I-NP	B
stiffness	NN	I-NP	I
occurred	VBD	B-VP	O
which	WDT	B-NP	O
lasted	VBD	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
anaesthesia	NN	I-NP	O
were	VBD	B-VP	O
terminated	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
apnoea	NN	B-NP	B
ensued	VBD	B-VP	O
and	CC	O	O
he	PRP	B-NP	O
suffered	VBD	B-VP	O
generalized	VBN	I-VP	O
severe	JJ	B-NP	O
myalgia	NN	I-NP	B
lasting	VBG	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
atypical	JJ	B-NP	O
plasma	NN	I-NP	O
cholinesterase	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
dibucaine	NN	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
indicating	VBG	I-NP	O
homozygocity	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
was	VBD	B-VP	O
verified	VBN	I-VP	O
by	IN	B-PP	O
study	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
family	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
prolonged	JJ	B-NP	B
jaw	NN	I-NP	I
rigidity	NN	I-NP	I
and	CC	I-NP	O
myalgia	NN	I-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
after	IN	B-PP	O
suxamethonium	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
atypical	JJ	B-NP	O
cholinesterase	NN	I-NP	O
despite	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
pancuronium	NN	B-NP	O
.	.	O	O

Indomethacin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
hyperkalemia	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
gouty	NN	B-NP	B
arthritis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
severe	JJ	B-NP	O
,	,	I-NP	O
life	NN	I-NP	O
-	HYPH	I-NP	O
threatening	VBG	B-VP	O
hyperkalemia	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	B
insufficiency	NN	I-NP	I
developed	VBN	B-VP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
gouty	NN	I-NP	B
arthritis	NN	I-NP	I
with	IN	B-PP	O
indomethacin	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
complication	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
an	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
prostaglandin	NN	B-NP	O
synthesis	NN	I-NP	O
and	CC	O	O
consequent	JJ	B-NP	O
hyporeninemic	JJ	I-NP	B
hypoaidosteronism	NN	I-NP	I
.	.	O	O

Careful	JJ	B-NP	O
attention	NN	I-NP	O
to	TO	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
potassium	NN	I-NP	O
balance	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
indomethacin	NN	B-NP	O
or	CC	O	O
other	JJ	B-NP	O
nonsteroidal	JJ	I-NP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
those	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
or	CC	O	O
preexisting	JJ	B-NP	O
renal	JJ	I-NP	B
disease	NN	I-NP	I
,	,	O	O
will	MD	B-VP	O
help	VB	I-VP	O
prevent	VB	I-VP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
serious	JJ	I-NP	O
complication	NN	I-NP	O
.	.	O	O

Etomidate	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
foreshortened	VBN	I-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
clinical	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
etomidate	NN	B-NP	O
for	IN	B-PP	O
outpatient	NN	B-NP	O
cystoscopy	NN	I-NP	O
was	VBD	B-VP	O
embarked	VBN	I-VP	O
upon	IN	B-PP	O
.	.	O	O

Unpremedicated	JJ	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
fentanyl	NN	B-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
etomidate	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

Anaesthesia	NN	B-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
with	IN	B-PP	O
intermittent	JJ	B-NP	O
etomidate	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
interviewed	VBN	I-VP	O
personally	RB	B-ADVP	O
later	RB	B-NP	O
the	DT	I-NP	O
same	JJ	I-NP	O
day	NN	I-NP	O
,	,	O	O
and	CC	O	O
by	IN	B-PP	O
questionnaire	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
trial	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
an	DT	B-NP	O
unacceptable	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Venous	JJ	B-NP	O
pain	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
redness	NN	B-NP	O
,	,	O	O
pain	NN	B-NP	B
or	CC	O	O
swelling	VBG	B-VP	B
related	VBN	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
site	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
some	DT	B-NP	O
cases	NNS	I-NP	O
lasting	VBG	B-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
anaesthesia	NN	B-NP	O
.	.	O	O

Skeletal	JJ	B-NP	O
movements	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
experienced	JJ	I-NP	O
respiratory	JJ	I-NP	B
upset	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
sufficiently	RB	B-ADJP	O
severe	JJ	I-ADJP	O
to	TO	B-VP	O
necessitate	VB	I-VP	O
abandoning	VBG	I-VP	O
the	DT	B-NP	O
technique	NN	I-NP	O
.	.	O	O

Nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
disturbing	JJ	B-NP	O
emergence	NN	I-NP	O
psychoses	NNS	I-NP	B
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
are	VBP	B-VP	O
improved	VBN	I-VP	O
by	IN	B-PP	O
fluoxetine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	B
disability	NN	I-NP	I
and	CC	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
levodopa	NN	I-NP	O
-	HYPH	O	O
responsive	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
after	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
challenge	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
mixed	JJ	I-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
apomorphine	NN	B-NP	O
,	,	O	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
fluoxetine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
fluoxetine	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
without	IN	B-PP	O
modification	NN	B-NP	O
of	IN	B-PP	O
parkinsonian	JJ	B-NP	B
motor	NN	I-NP	B
disability	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
dyskinesias	NNS	I-NP	B
were	VBD	B-VP	O
reduced	VBN	I-VP	O
predominantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
limbs	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
and	CC	I-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
dystonic	JJ	B-NP	B
dyskinesias	NNS	I-NP	I
(	(	O	O
onset	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
end	NN	I-NP	O
-	HYPH	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
dyskinesias	NNS	I-NP	B
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
upper	JJ	I-NP	O
limbs	NNS	I-NP	O
during	IN	B-PP	O
choreic	JJ	B-NP	B
mid	JJ	I-NP	I
-	HYPH	I-NP	I
dose	NN	I-NP	I
dyskinesias	NNS	I-NP	I
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
increased	VBN	B-NP	O
brain	NN	I-NP	O
serotoninergic	JJ	I-NP	O
transmission	NN	I-NP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
may	MD	B-VP	O
reduce	VB	I-VP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
or	CC	O	O
dopamine	NN	B-NP	O
agonist	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
without	IN	B-PP	O
aggravating	VBG	B-VP	O
parkinsonian	JJ	B-NP	B
motor	NN	I-NP	B
disability	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
large	JJ	I-NP	O
population	NN	I-NP	O
-	HYPH	B-VP	O
based	VBN	I-VP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
study	NN	B-NP	O
of	IN	B-PP	O
trimethoprim	NN	B-NP	O
-	HYPH	O	O
sulfamethoxazole	NN	B-NP	O
,	,	O	O
trimethoprim	NN	B-NP	O
,	,	O	O
and	CC	O	O
cephalexin	NN	B-NP	O
for	IN	B-PP	O
uncommon	JJ	B-NP	O
serious	JJ	I-NP	O
drug	NN	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
population	NN	I-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
study	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
people	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
prescribed	VBN	I-VP	O
trimethoprim	AFX	O	O
-	HYPH	O	O
sulfamethoxazole	NN	B-NP	O
(	(	O	O
TMP	NN	B-NP	O
-	HYPH	B-NP	O
SMZ	NN	I-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
prescribed	VBN	I-NP	O
trimethoprim	NN	I-NP	O
alone	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
prescribed	VBN	I-NP	O
cephalexin	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
serious	JJ	B-NP	O
liver	NN	I-NP	B
,	,	O	I
blood	NN	B-NP	I
,	,	O	I
skin	NN	B-NP	I
,	,	O	I
and	CC	O	I
renal	JJ	B-NP	I
disorders	NNS	I-NP	I
resulting	VBG	B-VP	O
in	IN	B-PP	O
referral	NN	B-NP	O
or	CC	I-NP	O
hospitalization	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
based	VBN	I-VP	O
on	IN	B-PP	O
information	NN	B-NP	O
recorded	VBN	B-VP	O
on	IN	B-PP	O
office	NN	B-NP	O
computers	NNS	I-NP	O
by	IN	B-PP	O
selected	VBN	B-NP	O
general	JJ	I-NP	O
practitioners	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
Kingdom	NNP	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
records	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
clinically	RB	B-NP	O
important	JJ	I-NP	O
idiopathic	JJ	I-NP	O
liver	NN	I-NP	B
disease	NN	I-NP	I
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
for	IN	B-SBAR	O
persons	NNS	B-NP	O
prescribed	VBD	B-VP	O
TMP	NN	B-NP	O
-	HYPH	B-NP	O
SMZ	NN	I-NP	O
and	CC	O	O
those	DT	B-NP	O
prescribed	VBN	I-NP	O
trimethoprim	NN	I-NP	O
alone	RB	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
those	DT	B-NP	O
prescribed	VBN	I-NP	O
cephalexin	NN	I-NP	O
was	VBD	B-VP	O
somewhat	RB	B-ADJP	O
lower	JJR	I-ADJP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
blood	NN	B-NP	O
disorders	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
was	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
TMP	NN	B-NP	O
-	HYPH	B-NP	O
SMZ	NN	I-NP	O
;	:	O	O
of	IN	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
erythema	NN	B-NP	B
multiforme	JJ	I-NP	I
and	CC	I-NP	O
Stevens	NNP	I-NP	B
-	HYPH	I-NP	I
Johnson	NNP	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
TMP	NN	B-NP	O
-	HYPH	B-NP	O
SMZ	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
toxic	JJ	B-NP	B
epidermal	JJ	I-NP	I
necrolysis	NN	I-NP	I
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
took	VBD	B-VP	O
cephalexin	NN	B-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
only	RB	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
parenchymal	JJ	I-NP	O
renal	JJ	I-NP	B
disease	NN	I-NP	I
occurred	VBD	B-VP	O
,	,	O	O
none	NN	B-NP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
study	NN	I-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
serious	JJ	I-NP	O
diseases	NNS	I-NP	O
studied	VBN	B-VP	O
is	VBZ	B-VP	O
small	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
and	CC	O	O
compares	VBZ	B-VP	O
reasonably	RB	B-ADVP	O
with	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
many	JJ	B-NP	O
other	JJ	I-NP	O
antibiotics	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
.	.	O	O

A	DT	B-NP	O
retrospective	JJ	I-NP	O
,	,	I-NP	O
multicenter	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
university	NN	I-NP	O
,	,	O	O
university	NN	B-NP	O
-	HYPH	B-VP	O
affiliated	VBN	I-VP	O
,	,	O	O
or	CC	O	O
community	NN	B-NP	O
hospitals	NNS	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
(	(	O	O
total	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cumulative	JJ	I-NP	O
hospital	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
MI	NN	I-NP	B
who	WP	B-NP	O
received	VBD	B-VP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
setting	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
MI	NN	I-NP	B
,	,	O	O
no	DT	B-NP	O
patient	NN	I-NP	O
died	VBD	B-VP	O
;	:	O	O
exhibited	VBN	B-NP	O
bradydysrhythmias	NNS	I-NP	B
,	,	O	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
,	,	O	O
or	CC	O	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
;	:	O	O
or	CC	O	O
experienced	JJ	B-NP	O
seizures	NNS	I-NP	B
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Despite	IN	B-PP	O
theoretical	JJ	B-NP	O
concerns	NNS	I-NP	O
that	IN	B-NP	O
lidocaine	NN	B-NP	O
may	MD	B-VP	O
enhance	VB	I-VP	O
cocaine	NN	B-NP	O
toxicity	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
lidocaine	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
MI	NN	I-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
cardiovascular	JJ	I-NP	B
or	CC	I-NP	I
central	JJ	I-NP	I
nervous	JJ	I-NP	I
system	NN	I-NP	I
toxicity	NN	I-NP	I
.	.	O	O

Paclitaxel	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
given	VBN	B-VP	O
alone	RB	B-ADVP	O
and	CC	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
carboplatin	NN	B-NP	O
:	:	O	O
preliminary	JJ	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
escalation	NN	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
(	(	O	O
Taxol	NN	B-NP	O
;	:	O	O
Bristol	NNP	B-NP	O
-	:	O	O
Myers	NNP	B-NP	O
Squibb	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
combined	VBN	I-VP	O
with	IN	B-PP	O
carboplatin	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
directed	VBN	B-VP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
non	AFX	O	B
-	HYPH	O	I
small	JJ	B-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
.	.	O	O

Carboplatin	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
fixed	VBN	I-NP	O
target	NN	I-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
-	HYPH	B-NP	O
time	NN	I-NP	O
curve	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
Calvert	NNP	I-NP	O
formula	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
paclitaxel	NN	B-NP	O
was	VBD	B-VP	O
escalated	VBN	I-VP	O
in	IN	B-PP	O
patient	NN	B-NP	O
cohorts	NNS	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
(	(	I-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
to	TO	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m2	NN	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
expanded	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
since	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
level	NN	I-NP	O
achieved	VBN	B-VP	O
required	VBD	B-VP	O
modification	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
nonhematologic	JJ	B-NP	O
toxicities	NNS	I-NP	B
(	(	O	O
arthralgia	NN	B-NP	B
and	CC	O	O
sensory	JJ	B-NP	B
neuropathy	NN	I-NP	I
)	)	O	O
.	.	O	O

Therapeutic	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
at	IN	B-PP	O
all	DT	B-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
objective	JJ	B-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
complete	JJ	I-NP	O
and	CC	O	O
num	CD	B-NP	O
partial	JJ	I-NP	O
regressions	NNS	I-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
previously	RB	I-NP	O
untreated	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Toxicities	NNS	B-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
alone	RB	B-ADVP	O
at	IN	B-PP	O
identical	JJ	B-NP	O
dose	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Carboplatin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
add	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hematologic	JJ	I-NP	B
toxicities	NNS	I-NP	I
observed	VBN	B-VP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
paclitaxel	NN	I-NP	O
/	SYM	B-VP	O
carboplatin	NN	B-NP	O
combination	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
dosed	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
on	IN	B-PP	O
indomethacin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
well	RB	B-NP	O
compensated	VBN	I-NP	O
cirrhosis	NN	I-NP	B
.	.	O	O

Misoprostol	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
acutely	RB	I-VP	O
counteract	VB	I-VP	O
the	DT	B-NP	O
indomethacin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
well	RB	B-NP	O
compensated	VBN	I-NP	O
cirrhotic	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
prophylactic	JJ	I-NP	O
value	NN	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
was	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-ADJP	O
dependent	JJ	I-ADJP	O
.	.	O	O

Parameters	NNS	B-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
and	CC	O	O
tubular	JJ	B-NP	O
sodium	NN	I-NP	O
and	CC	O	O
water	NN	B-NP	O
handling	NN	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
clearance	NN	B-NP	O
techniques	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
well	RB	I-NP	O
compensated	VBN	I-NP	O
cirrhotic	JJ	I-NP	B
patients	NNS	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
an	DT	B-NP	O
oral	JJ	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
indomethacin	NN	B-NP	O
and	CC	O	O
various	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
able	JJ	B-ADJP	O
to	TO	B-VP	O
totally	RB	I-VP	O
abolish	VB	I-VP	O
the	DT	B-NP	O
deleterious	JJ	I-NP	O
renal	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
indomethacin	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
dose	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
significant	JJ	B-NP	O
worsening	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
and	CC	O	O
sodium	NN	B-NP	O
retention	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
were	VBD	B-VP	O
maximal	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
hour	NN	I-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
medications	NNS	B-NP	O
and	CC	O	O
slowly	RB	B-VP	O
returned	VBD	I-VP	O
toward	IN	B-PP	O
base	NN	B-NP	O
-	HYPH	B-NP	O
line	NN	I-NP	O
levels	NNS	I-NP	O
thereafter	RB	B-ADVP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
renal	JJ	I-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
is	VBZ	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-PP	O
dependent	JJ	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
until	IN	B-PP	O
this	DT	B-NP	O
apparent	JJ	I-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
of	IN	B-PP	O
misoprostol	NN	B-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
indomethacin	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
confirmed	VBN	I-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
frequent	JJ	I-NP	O
dosing	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
prudent	JJ	B-ADJP	O
to	TO	B-VP	O
avoid	VB	I-VP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cirrhosis	NN	B-NP	B
.	.	O	O

Increased	VBN	B-NP	O
frequency	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
angio	AFX	B-NP	B
-	HYPH	I-NP	I
oedema	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
drugs	NNS	B-NP	O
are	VBP	B-VP	O
well	RB	I-VP	O
recognized	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
or	CC	I-NP	O
chronic	JJ	I-NP	O
urticaria	NN	I-NP	B
,	,	O	O
and	CC	O	O
angio	AFX	B-NP	B
-	HYPH	I-NP	I
oedema	NN	I-NP	I
.	.	O	O

Angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
,	,	O	O
used	VBN	B-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
hypertension	NN	B-NP	B
and	CC	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
introduced	VBN	I-VP	O
in	IN	B-PP	O
Europe	NNP	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
middle	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
eighties	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
has	VBZ	B-VP	O
increased	VBN	I-VP	O
progressively	RB	B-ADVP	O
.	.	O	O

Soon	RB	B-PP	O
after	IN	I-PP	O
the	DT	B-NP	O
introduction	NN	I-NP	O
of	IN	B-PP	O
ACE	NN	B-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
acute	JJ	B-NP	O
bouts	NNS	I-NP	O
of	IN	B-PP	O
angio	AFX	B-NP	B
-	HYPH	I-NP	I
oedema	NN	I-NP	I
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
wish	VBP	B-VP	O
to	TO	I-VP	O
draw	VB	I-VP	O
attention	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-VP	O
ACE	VB	I-VP	O
inhibitors	NNS	B-NP	O
after	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	B-PP	O
existing	VBG	B-NP	O
angio	AFX	I-NP	B
-	HYPH	I-NP	I
oedema	NN	I-NP	I
.	.	O	O

Myoclonus	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
lorazepam	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
very	RB	B-NP	O
-	HYPH	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
birth	NN	I-NP	O
-	HYPH	I-NP	O
weight	NN	I-NP	O
infants	NNS	I-NP	O
.	.	O	O

Lorazepam	NNP	B-NP	O
is	VBZ	B-VP	O
being	VBG	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
frequency	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
sedative	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
newborn	JJ	I-NP	O
and	CC	O	O
the	DT	B-NP	O
young	JJ	I-NP	O
infant	NN	I-NP	O
.	.	O	O

Concern	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
raised	VBN	I-VP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
lorazepam	NN	B-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
age	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
very	RB	B-NP	O
-	HYPH	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
birth	NN	I-NP	O
-	HYPH	I-NP	O
weight	NN	I-NP	O
infants	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
young	JJ	I-NP	O
infants	NNS	I-NP	O
,	,	O	O
all	DT	B-NP	O
of	IN	B-PP	O
birth	NN	B-NP	O
weight	NN	I-NP	O
<	SYM	O	O
num	CD	B-NP	O
g	NN	I-NP	O
,	,	O	O
experienced	VBD	B-VP	O
myoclonus	NN	B-NP	B
following	VBG	B-PP	O
the	DT	B-NP	O
intravenous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
lorazepam	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
potential	JJ	I-NP	O
neurotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
(	(	O	O
and	CC	O	O
its	PRP$	B-NP	O
vehicle	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
this	DT	B-NP	O
population	NN	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Injectable	JJ	B-NP	O
lorazepam	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
with	IN	B-PP	O
caution	NN	B-NP	O
in	IN	B-PP	O
VLBW	NN	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

Transvenous	JJ	B-NP	O
right	JJ	I-NP	O
ventricular	JJ	I-NP	O
pacing	NN	I-NP	O
during	IN	B-PP	O
cardiopulmonary	JJ	B-NP	O
resuscitation	NN	I-NP	O
of	IN	B-PP	O
pediatric	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
cardiopulmonary	JJ	I-NP	O
resuscitation	NN	I-NP	O
efforts	NNS	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
circulatory	JJ	I-NP	B
failure	NN	I-NP	I
from	IN	B-PP	O
myocardial	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
acute	JJ	B-NP	O
viral	JJ	I-NP	O
myocarditis	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
carbamazepine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
eosinophilic	JJ	I-NP	B
myocarditis	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
cardiac	JJ	B-NP	O
hemosiderosis	NN	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
cardiogenic	JJ	I-NP	B
shock	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
continuously	RB	I-VP	O
monitored	VBN	I-VP	O
with	IN	B-PP	O
central	JJ	B-NP	O
venous	JJ	I-NP	O
and	CC	I-NP	O
arterial	JJ	I-NP	O
catheters	NNS	I-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
routine	JJ	B-NP	O
noninvasive	JJ	I-NP	O
monitoring	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
introducer	NN	I-NP	O
sheath	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
pacemaker	NN	I-NP	O
,	,	O	O
and	CC	O	O
sterile	JJ	B-NP	O
pacing	NN	I-NP	O
wires	NNS	I-NP	O
were	VBD	B-VP	O
made	VBN	I-VP	O
readily	RB	B-ADJP	O
available	JJ	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
should	MD	O	O
the	DT	B-NP	O
need	NN	I-NP	O
arise	VBP	B-VP	O
to	TO	I-VP	O
terminate	VB	I-VP	O
resistant	JJ	B-NP	O
cardiac	JJ	I-NP	O
dysrhythmias	NNS	I-NP	B
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
cardiocirculatory	JJ	B-NP	O
arrest	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
extreme	JJ	B-NP	O
hypotension	NN	I-NP	B
and	CC	I-NP	O
dysrhythmias	NNS	I-NP	B
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
admission	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
pediatric	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
(	(	O	O
PICU	NN	B-NP	O
)	)	O	O
.	.	O	O

Right	RB	B-NP	O
ventricular	JJ	I-NP	O
pacemaker	NN	I-NP	O
wires	NNS	I-NP	O
were	VBD	B-VP	O
inserted	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
during	IN	B-PP	O
cardiopulmonary	JJ	B-NP	O
resuscitation	NN	I-NP	O
(	(	O	O
CPR	NN	B-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
pacing	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
temporary	JJ	I-NP	O
captured	JJ	I-NP	O
rhythm	NN	I-NP	O
and	CC	I-NP	O
restoration	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
cardiac	JJ	I-NP	O
output	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
second	JJ	I-NP	O
event	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
death	NN	B-NP	O
,	,	O	O
within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	O
pacing	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
used	VBN	I-VP	O
,	,	O	O
because	IN	B-SBAR	O
he	PRP	B-NP	O
converted	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
by	IN	B-PP	O
electrical	JJ	B-NP	O
defibrillation	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
of	IN	B-PP	O
initiating	VBG	B-VP	O
CPR	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
cardiac	JJ	B-NP	O
pacing	NN	I-NP	O
during	IN	B-PP	O
resuscitative	JJ	B-NP	O
efforts	NNS	I-NP	O
in	IN	B-PP	O
pediatric	JJ	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
acute	JJ	B-NP	O
myocardial	JJ	I-NP	B
dysfunction	NN	I-NP	I
may	MD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
value	NN	I-NP	O
in	IN	B-PP	O
and	CC	I-PP	O
of	IN	I-PP	O
itself	PRP	B-NP	O
;	:	O	O
however	RB	O	O
,	,	O	O
if	IN	B-SBAR	O
temporary	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
stability	NN	I-NP	O
is	VBZ	B-VP	O
achieved	VBN	I-VP	O
by	IN	B-PP	O
this	DT	B-NP	O
procedure	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
additional	JJ	B-NP	O
time	NN	I-NP	O
needed	VBN	B-VP	O
to	TO	B-VP	O
institute	VB	I-VP	O
other	JJ	B-NP	O
therapeutic	JJ	I-NP	O
modalities	NNS	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
granisetron	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
selective	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxytryptamine	NN	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cisplatin	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
antiemetic	JJ	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
safety	NN	B-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
granisetron	NN	B-NP	O
(	(	O	O
Kytril	NNP	B-NP	O
;	:	O	O
SmithKline	NNP	B-NP	O
Beecham	NNP	I-NP	O
Pharmaceuticals	NNPS	I-NP	O
,	,	O	O
Philadelphia	NNP	B-NP	O
,	,	O	O
PA	NNP	B-NP	O
)	)	O	O
when	WRB	B-ADVP	O
administered	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
intravenous	JJ	I-NP	O
(	(	O	O
num	CD	O	O
)	)	O	O
dose	NN	B-NP	O
for	IN	B-PP	O
prophylaxis	NN	B-NP	O
of	IN	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nausea	NN	I-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
chemotherapy	NN	I-NP	O
-	HYPH	O	O
naive	JJ	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
cisplatin	NN	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
granisetron	NN	I-NP	O
doses	NNS	I-NP	O
administered	VBN	B-VP	O
before	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
on	IN	B-PP	O
an	DT	B-NP	O
inpatient	JJ	I-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
,	,	O	O
and	CC	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
,	,	O	O
nausea	NN	B-NP	B
,	,	O	O
vomiting	NN	B-NP	B
,	,	O	O
retching	NN	B-NP	O
,	,	O	O
and	CC	O	O
appetite	NN	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
.	.	O	O

Safety	NN	B-NP	O
analyses	NNS	I-NP	O
included	VBD	B-VP	O
incidence	NN	B-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
experiences	NNS	I-NP	O
and	CC	O	O
laboratory	NN	B-NP	O
parameter	NN	I-NP	O
changes	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
granisetron	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
major	JJ	I-NP	O
response	NN	I-NP	O
(	(	O	O
<	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
vomiting	VBG	B-VP	B
or	CC	I-VP	O
retching	VBG	I-VP	O
episodes	NNS	B-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
antiemetic	JJ	I-NP	O
rescue	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
complete	JJ	I-NP	O
response	NN	I-NP	O
(	(	O	O
no	DT	B-NP	O
vomiting	NN	I-NP	B
or	CC	I-NP	O
retching	NN	I-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
antiemetic	JJ	I-NP	O
rescue	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
longer	JJR	I-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
nausea	NN	B-NP	B
and	CC	I-NP	O
vomiting	NN	I-NP	B
,	,	O	O
and	CC	O	O
fewer	JJR	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
additional	JJ	B-NP	O
antiemetic	JJ	I-NP	O
medication	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
dosing	NN	I-NP	O
groups	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
dosing	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
granisetron	NN	B-NP	O
dose	NN	I-NP	O
increased	VBD	B-VP	O
,	,	O	O
appetite	JJ	B-NP	O
return	NN	I-NP	O
increased	VBD	B-VP	O
.	.	O	O

Headache	PRP	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequently	RB	I-NP	O
reported	VBN	I-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
granisetron	NN	B-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
controlling	VBG	B-VP	O
vomiting	VBG	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
cisplatin	NN	B-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
and	CC	O	O
totally	RB	B-VP	O
prevented	VBD	I-VP	O
vomiting	VBG	I-VP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
efficacy	NN	B-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
dose	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Granisetron	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
at	IN	B-PP	O
all	DT	B-NP	O
doses	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
adverse	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
atrioventricular	JJ	B-NP	B
(	(	O	I
AV	NN	B-NP	I
)	)	O	I
block	NN	B-NP	I
in	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	B-NP	O
and	CC	O	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
hyperaldosteronism	NN	B-NP	B
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
verapamil	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	B-NP	O
and	CC	I-NP	O
spironolactone	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
minimal	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
,	,	O	O
she	PRP	B-NP	O
developed	VBD	B-VP	O
complete	JJ	B-NP	O
AV	NN	I-NP	B
block	NN	I-NP	I
and	CC	O	O
severe	JJ	B-NP	O
hypotension	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
upon	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
medications	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
extended	VBN	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
verapamil	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
d	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
addition	NN	I-NP	O
of	IN	B-PP	O
clonidine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
bid	RB	B-ADVP	O
she	PRP	B-NP	O
developed	VBD	B-VP	O
complete	JJ	B-NP	O
AV	NN	I-NP	B
block	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
resolved	VBD	B-VP	O
after	IN	B-PP	O
all	DT	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
adverse	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
clonidine	NN	B-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
previously	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
such	JJ	I-NP	O
cases	NNS	I-NP	O
and	CC	O	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
various	JJ	I-NP	O
mechanisms	NNS	I-NP	O
that	WDT	B-NP	O
might	MD	B-VP	O
cause	VB	I-VP	O
such	PDT	B-NP	O
an	DT	I-NP	O
interaction	NN	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
acquainted	VBN	I-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
possibly	RB	I-NP	O
fatal	JJ	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
antihypertensive	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Caution	NN	B-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
in	IN	B-PP	O
combining	VBG	B-VP	O
clonidine	NN	B-NP	O
and	CC	I-NP	O
verapamil	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
sinus	NN	B-NP	O
or	CC	I-NP	O
AV	NN	I-NP	O
node	NN	I-NP	O
dysfunction	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
may	MD	B-VP	O
act	VB	I-VP	O
synergistically	RB	B-ADVP	O
on	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
AV	NN	I-NP	O
node	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
peripheral	JJ	I-NP	O
circulation	NN	I-NP	O
.	.	O	O

Pharmacological	JJ	B-NP	O
studies	NNS	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
dihydrothienopyridine	NN	I-NP	O
calcium	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
d.	NN	I-NP	O
5th	JJ	I-NP	O
communication	NN	I-NP	O
:	:	O	O
anticonvulsant	JJ	B-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
S	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
d	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
l	NN	I-NP	O
,	,	O	O
L	NN	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
antagonists	NNS	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
anticonvulsant	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
audiogenic	JJ	I-NP	B
tonic	JJ	I-NP	I
convulsions	NNS	I-NP	I
in	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
;	:	O	O
and	CC	O	O
their	PRP$	B-NP	O
ED50	NN	I-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
p.o.	FW	B-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
p.o.	FW	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
that	DT	B-NP	O
of	IN	B-PP	O
flunarizine	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
,	,	O	O
p.o	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
moderate	JJ	B-NP	O
anticonvulsant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
d	NN	I-NP	O
in	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
against	IN	B-PP	O
the	DT	B-NP	O
clonic	JJ	I-NP	O
convulsions	NNS	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
pentylenetetrazole	NN	B-NP	O
or	CC	I-NP	O
bemegride	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
convulsions	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
N	NN	B-NP	O
-	HYPH	B-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
D	NN	I-NP	O
-	HYPH	O	O
aspartate	NN	B-NP	O
,	,	O	O
picrotoxin	NN	B-NP	O
,	,	O	O
or	CC	O	O
electroshock	NN	B-NP	O
in	IN	B-PP	O
Slc	NN	B-NP	O
:	:	O	O
ddY	NN	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
d	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
therapy	NN	I-NP	O
of	IN	B-PP	O
certain	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
epilepsy	NN	I-NP	B
.	.	O	O

Transmural	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
with	IN	B-PP	O
sumatriptan	NN	B-NP	O
.	.	O	O

For	IN	B-PP	O
sumatriptan	NN	B-NP	O
,	,	O	O
tightness	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
chest	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
unknown	JJ	I-NP	O
mechanism	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
users	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
sumatriptan	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
subcutaneously	RB	B-ADVP	O
for	IN	B-PP	O
cluster	NN	B-NP	B
headache	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
underlying	VBG	B-VP	O
ischaemic	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
or	CC	O	O
Prinzmetal	JJ	B-NP	B
s	NNS	I-NP	I
angina	NN	I-NP	I
.	.	O	O

She	PRP	B-NP	O
recovered	VBD	B-VP	O
without	IN	B-PP	O
complications	NNS	B-NP	O
.	.	O	O

Flumazenil	NNP	B-NP	O
induces	VBZ	B-VP	O
seizures	NNS	B-NP	B
and	CC	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
mixed	VBN	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
diazepam	NN	I-NP	O
intoxications	NNS	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
benzodiazepine	NN	I-NP	O
antagonist	NN	I-NP	O
flumazenil	NN	I-NP	O
may	MD	B-VP	O
unmask	VB	I-VP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
mixed	VBN	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
benzodiazepine	NN	I-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
cocaine	NN	I-NP	O
IP	NN	I-NP	O
alone	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
diazepam	NN	I-NP	O
alone	RB	B-ADVP	O
,	,	O	O
or	CC	O	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	I-NP	O
cocaine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
minutes	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
groups	NNS	B-NP	O
were	VBD	B-VP	O
challenged	VBN	I-VP	O
with	IN	B-PP	O
vehicle	NN	B-NP	O
or	CC	I-NP	O
flumazenil	NN	I-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
IP	NN	I-NP	O
.	.	O	O

Animal	JJ	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
seizures	NNS	B-NP	B
(	(	O	O
time	NN	B-NP	O
to	TO	B-PP	O
and	CC	O	O
incidence	NN	B-NP	O
)	)	O	O
,	,	O	O
death	NN	B-NP	O
(	(	O	O
time	NN	B-NP	O
to	TO	B-PP	O
and	CC	O	O
incidence	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
cortical	JJ	B-NP	O
EEG	NN	I-NP	O
tracings	NNS	I-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
flumazenil	NN	B-NP	O
to	TO	B-PP	O
animals	NNS	B-NP	O
after	IN	B-SBAR	O
they	PRP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
a	DT	B-NP	O
combination	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
num	CD	B-NP	O
animals	NNS	I-NP	O
received	VBD	B-VP	O
cocaine	NN	B-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
vehicle	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
developing	VBG	B-VP	O
seizures	NNS	B-NP	B
and	CC	I-NP	O
death	NN	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
diazepam	NN	B-NP	O
alone	RB	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
vehicle	NN	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
became	VBD	B-VP	O
somnolent	JJ	B-ADJP	O
and	CC	O	O
none	NN	B-NP	O
died	VBD	B-VP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
diazepam	NN	B-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
flumazenil	NN	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
became	VBD	B-VP	O
somnolent	JJ	B-ADJP	O
after	IN	B-PP	O
diazepam	NN	B-NP	O
and	CC	O	O
then	RB	B-ADJP	O
active	JJ	I-ADJP	O
after	IN	B-SBAR	O
flumazenil	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
no	DT	B-NP	O
overt	JJ	I-NP	O
or	CC	I-NP	O
EEG	NN	I-NP	O
-	HYPH	B-NP	O
detectable	JJ	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
,	,	O	O
followed	VBD	B-VP	O
later	RB	B-ADVP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
flumazenil	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
death	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Group	NN	B-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
diazepam	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
flumazenil	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
also	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
death	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
group	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Flumazenil	NN	B-NP	O
can	MD	B-VP	O
unmask	VB	I-VP	O
seizures	NNS	B-NP	B
and	CC	O	O
increase	VB	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
death	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
combined	VBN	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
diazepam	NN	I-NP	O
intoxications	NNS	I-NP	O
.	.	O	O

Mechanisms	NNS	B-NP	O
for	IN	B-PP	O
protective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
radical	NN	I-NP	O
scavengers	NNS	I-NP	O
on	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Studies	NNS	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
radical	NN	I-NP	O
scavengers	NNS	I-NP	O
on	IN	B-PP	O
gentamicin	NN	B-NP	O
(	(	O	O
GM	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
mediated	VBN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
GM	NNP	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
sc	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
(	(	O	O
RBF	NN	B-NP	O
)	)	O	O
and	CC	O	O
inulin	NN	B-NP	O
clearance	NN	I-NP	O
(	(	O	O
CIn	NN	B-NP	O
)	)	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
marked	JJ	B-NP	O
tubular	JJ	I-NP	B
damage	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
guanosine	NN	I-NP	O
num	CD	I-NP	O
'	SYM	B-NP	O
,	,	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
cyclic	JJ	I-NP	O
monophosphate	NN	I-NP	O
(	(	O	O
cGMP	NN	B-NP	O
)	)	O	O
excretion	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
cortical	JJ	I-NP	O
renin	NN	I-NP	O
and	CC	I-NP	O
endothelin	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
contents	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
GM	NNP	B-NP	O
-	HYPH	B-NP	B
mediated	VBN	I-NP	O
nephropathy	NN	I-NP	O
.	.	O	O

Superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
(	(	O	O
SOD	NN	B-NP	O
)	)	O	O
or	CC	O	O
dimethylthiourea	NN	B-NP	O
(	(	O	O
DMTU	NN	B-NP	O
)	)	O	O
significantly	RB	B-VP	O
lessened	VBD	I-VP	O
the	DT	B-NP	O
GM	NNP	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
decrement	NN	I-NP	O
in	IN	B-PP	O
CIn	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
SOD	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
RBF	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
urinary	JJ	B-NP	O
cGMP	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
renin	NN	I-NP	O
and	CC	I-NP	O
endothelin	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
content	NN	I-NP	O
.	.	O	O

SOD	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
attenuate	VB	I-VP	O
the	DT	B-NP	O
tubular	JJ	I-NP	B
damage	NN	I-NP	I
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
DMTU	NN	B-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
tubular	JJ	I-NP	B
damage	NN	I-NP	I
and	CC	I-NP	O
lipid	NN	I-NP	O
peroxidation	NN	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
renal	JJ	B-NP	O
hemodynamics	NNS	I-NP	O
and	CC	O	O
vasoactive	JJ	B-NP	O
substances	NNS	I-NP	O
.	.	O	O

Neither	CC	O	O
SOD	NN	B-NP	O
nor	CC	I-NP	O
DMTU	NN	I-NP	O
affected	VBD	B-VP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortical	JJ	I-NP	O
GM	NNP	I-NP	O
content	NN	I-NP	O
in	IN	B-PP	O
GM	NNP	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
)	)	O	O
both	CC	O	O
SOD	NN	B-NP	O
and	CC	I-NP	O
DMTU	NN	I-NP	O
have	VBP	B-VP	O
protective	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
GM	NNP	B-NP	O
-	HYPH	B-NP	O
mediated	VBN	I-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
num	CD	B-NP	O
)	)	O	O
the	DT	B-NP	O
mechanisms	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
protective	JJ	I-NP	O
effects	NNS	I-NP	O
differ	VBP	B-VP	O
for	IN	B-PP	O
SOD	NN	B-NP	O
and	CC	I-NP	O
DMTU	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
superoxide	NN	B-NP	O
anions	NNS	I-NP	O
play	VBP	B-VP	O
a	DT	B-NP	O
critical	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
GM	NNP	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
renal	JJ	I-NP	O
vasoconstriction	NN	I-NP	O
.	.	O	O

Assessment	NN	B-NP	O
of	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
DNA	NN	I-NP	O
synthesis	NN	I-NP	O
during	IN	B-PP	O
hypertrophy	NN	B-NP	B
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
cardiomyocytes	NNS	B-NP	O
to	TO	B-VP	O
synthesize	VB	I-VP	O
DNA	NN	B-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
hypertrophy	NN	I-NP	I
was	VBD	B-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Isoproterenol	NN	B-NP	O
delivered	VBN	B-VP	O
by	IN	B-PP	O
osmotic	JJ	B-NP	O
minipump	NN	I-NP	O
implantation	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
C3Heb	NN	I-NP	O
/	SYM	B-VP	O
FeJ	NN	B-NP	O
mice	NNS	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
weight	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
area	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
DNA	NN	I-NP	O
synthesis	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
autoradiographic	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
isolated	VBN	B-NP	O
cardiomyocytes	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
control	NN	B-NP	O
or	CC	O	O
hypertrophic	JJ	B-NP	B
hearts	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
survey	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
independent	JJ	I-NP	O
inbred	JJ	I-NP	O
strains	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
ventricular	JJ	B-NP	O
cardiomyocyte	NN	I-NP	O
nuclear	JJ	I-NP	O
number	NN	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
mononucleate	NN	I-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
cardiomyocyte	NN	B-NP	O
terminal	JJ	I-NP	O
differentiation	NN	I-NP	O
is	VBZ	B-VP	O
influenced	VBN	I-VP	O
directly	RB	B-ADVP	O
or	CC	B-ADVP	O
indirectly	RB	B-ADVP	O
by	IN	B-PP	O
genetic	JJ	B-NP	O
background	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
capacity	NN	I-NP	O
for	IN	B-PP	O
reactive	JJ	B-NP	O
DNA	NN	I-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
subject	JJ	B-ADJP	O
to	TO	B-PP	O
genetic	JJ	B-NP	O
regulation	NN	I-NP	O
,	,	O	O
cardiac	JJ	B-NP	B
hypertrophy	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
strains	NNS	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
comprising	VBG	B-VP	O
the	DT	B-NP	O
extremes	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nuclear	JJ	I-NP	O
number	NN	I-NP	O
survey	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
adult	JJ	B-NP	O
mouse	NN	I-NP	O
atrial	JJ	I-NP	O
and	CC	I-NP	O
ventricular	JJ	I-NP	O
cardiomyocytes	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
synthesize	VB	I-VP	O
DNA	NN	B-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
hypertrophy	NN	I-NP	I
.	.	O	O

Central	JJ	B-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
and	CC	I-NP	O
ANP	NN	I-NP	O
in	IN	B-PP	O
normotensive	JJ	B-NP	O
and	CC	I-NP	O
spontaneously	RB	I-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
influence	NN	B-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
arginine	NN	I-NP	O
vasopressin	NN	I-NP	O
(	(	O	O
AVP	NN	B-NP	O
)	)	O	O
and	CC	O	O
of	IN	B-PP	O
atrial	JJ	B-NP	O
natriuretic	JJ	I-NP	O
peptide	NN	I-NP	O
(	(	O	O
ANP	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
control	NN	B-NP	O
of	IN	B-PP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
and	CC	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
normotensive	JJ	B-NP	O
(	(	O	O
WKY	NN	B-NP	O
)	)	O	O
and	CC	O	O
spontaneously	RB	B-ADJP	O
hypertensive	JJ	I-ADJP	B
(	(	O	O
SHR	NN	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
experiments	NNS	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
WKY	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
SHR	NN	I-NP	O
,	,	O	O
chronically	RB	B-VP	O
instrumented	VBN	I-VP	O
with	IN	B-PP	O
guide	NN	B-NP	O
tubes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
ventricle	NN	I-NP	O
(	(	O	O
LV	NN	B-NP	O
)	)	O	O
and	CC	O	O
arterial	JJ	B-NP	O
and	CC	I-NP	O
venous	JJ	I-NP	O
catheters	NNS	I-NP	O
.	.	O	O

MAP	NN	B-NP	O
and	CC	I-NP	O
HR	NN	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
i.v.	JJ	B-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
either	CC	O	O
vehicle	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
of	IN	B-PP	O
ANP	NN	B-NP	O
.	.	O	O

Sensitivity	NN	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
component	NN	I-NP	O
of	IN	B-PP	O
baroreflex	NN	B-NP	O
(	(	O	O
CCB	NN	B-NP	O
)	)	O	O
,	,	O	O
expressed	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
slope	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
regression	NN	I-NP	O
line	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
from	IN	B-PP	O
relationships	NNS	B-NP	O
between	IN	B-PP	O
systolic	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
SAP	NN	B-NP	O
)	)	O	O
and	CC	O	O
HR	NN	B-NP	O
period	NN	I-NP	O
(	(	O	O
HRp	NN	B-NP	O
)	)	O	O
during	IN	B-PP	O
phenylephrine	NN	B-NP	O
(	(	O	O
Phe	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
and	CC	I-NP	O
sodium	NN	I-NP	O
nitroprusside	NN	I-NP	O
(	(	O	O
SN	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

CCB	NN	B-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
either	DT	B-NP	O
vehicle	NN	I-NP	O
,	,	O	O
AVP	NN	B-NP	O
,	,	O	O
ANP	NN	B-NP	O
,	,	O	O
or	CC	O	O
both	DT	B-NP	O
peptides	NNS	I-NP	O
together	RB	B-ADVP	O
.	.	O	O

Increases	NNS	B-NP	O
of	IN	B-PP	O
MAP	NN	B-NP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
LV	NN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
in	IN	B-PP	O
WKY	NN	B-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
ng	NN	I-NP	O
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

ANP	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
cause	VB	I-VP	O
significant	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
MAP	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
strains	NNS	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
vehicle	NN	B-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
abolished	VBD	B-VP	O
AVP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
MAP	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
WKY	NN	B-NP	O
and	CC	I-NP	O
SHR	NN	I-NP	O
.	.	O	O

CCB	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
WKY	NN	B-NP	O
and	CC	I-NP	O
SHR	NN	I-NP	O
after	IN	B-PP	O
LV	NN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
AVP	NN	B-NP	O
during	IN	B-PP	O
SN	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
SHR	NN	B-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
WKY	NN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ANP	NN	B-NP	O
,	,	I-NP	O
AVP	NN	I-NP	O
and	CC	I-NP	O
ANP	NN	I-NP	O
+	SYM	B-NP	O
AVP	NN	I-NP	O
decreased	VBD	B-VP	O
CCB	NN	B-NP	O
during	IN	B-PP	O
Phe	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
MAP	NN	I-NP	O
elevation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
centrally	RB	B-NP	O
applied	VBN	I-NP	O
AVP	NN	I-NP	O
and	CC	I-NP	O
ANP	NN	I-NP	O
exert	VBP	B-VP	O
differential	JJ	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
baroreflex	NN	B-NP	O
control	NN	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
WKY	NN	B-NP	O
and	CC	I-NP	O
SHR	NN	I-NP	O
and	CC	O	O
suggest	VBP	B-VP	O
interaction	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
peptides	NNS	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
regulation	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

Cutaneous	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
anticoagulant	NN	I-NP	O
causing	VBG	B-VP	O
an	DT	B-NP	O
intracerebral	JJ	I-NP	B
hemorrhage	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
intercerebral	JJ	B-NP	O
hematoma	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
warfarin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
coagulopathy	NN	I-NP	B
is	VBZ	B-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
had	VBD	B-VP	O
spread	VBN	I-VP	O
a	DT	B-NP	O
warfarin	NN	I-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
rat	NN	I-NP	O
poison	NN	I-NP	O
around	IN	B-PP	O
her	PRP$	B-NP	O
house	NN	I-NP	O
weekly	RB	B-VP	O
using	VBG	I-VP	O
her	PRP$	B-NP	O
bare	JJ	I-NP	O
hands	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
washing	VBG	I-NP	O
post	NN	I-NP	O
application	NN	I-NP	O
.	.	O	O

Percutaneous	JJ	B-NP	O
absorption	NN	I-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
causing	VBG	B-VP	O
coagulopathy	NN	B-NP	B
,	,	O	O
reported	VBD	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
past	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
risk	NN	I-NP	O
if	IN	B-SBAR	O
protective	JJ	B-NP	O
measures	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
gloves	NNS	B-NP	O
,	,	O	O
are	VBP	B-VP	O
not	RB	I-VP	O
used	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
with	IN	B-PP	O
piroxicam	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
she	PRP	B-NP	O
took	VBD	B-VP	O
occasionally	RB	B-ADVP	O
,	,	O	O
may	MD	B-VP	O
have	VB	I-VP	O
exacerbated	VBN	I-VP	O
the	DT	B-NP	O
coagulopathy	NN	I-NP	B
.	.	O	O

Pediatric	JJ	B-NP	O
heart	NN	I-NP	O
transplantation	NN	I-NP	O
without	IN	B-PP	O
chronic	JJ	B-NP	O
maintenance	NN	I-NP	O
steroids	NNS	I-NP	O
.	.	O	O

From	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
February	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
children	NNS	I-NP	O
aged	VBN	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
underwent	VBD	B-VP	O
heart	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Indications	NNS	B-NP	O
for	IN	B-PP	O
transplantation	NN	B-NP	O
were	VBD	B-VP	O
idiopathic	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
,	,	O	O
congenital	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
prior	JJ	B-NP	O
repair	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
,	,	O	O
hypertrophic	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
,	,	O	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
doxorubicin	NN	B-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
managed	VBN	I-VP	O
with	IN	B-PP	O
cyclosporine	NN	B-NP	O
and	CC	I-NP	O
azathioprine	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
prophylaxis	NN	I-NP	O
with	IN	B-PP	O
antilymphocyte	NN	B-NP	O
globulin	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

Steroids	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
for	IN	B-PP	O
refractory	JJ	B-NP	O
rejection	NN	I-NP	O
,	,	O	O
but	CC	O	O
weaning	NN	B-NP	O
was	VBD	B-VP	O
always	RB	I-VP	O
attempted	VBN	I-VP	O
and	CC	O	O
generally	RB	B-ADJP	O
successful	JJ	I-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
maintenance	NN	B-NP	O
steroids	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
perioperative	JJ	I-NP	O
period	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
died	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

There	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
no	DT	B-NP	O
deaths	NNS	I-NP	O
related	VBN	B-ADJP	O
to	TO	B-PP	O
rejection	NN	B-NP	O
or	CC	I-NP	O
infection	NN	I-NP	B
.	.	O	O

Average	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

Cumulative	JJ	B-NP	O
survival	NN	I-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
rejection	NN	B-NP	O
was	VBD	B-VP	O
monitored	VBN	I-VP	O
noninvasively	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
postoperative	JJ	I-NP	O
month	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
rejection	NN	B-NP	O
.	.	O	O

Freedom	NN	B-NP	O
from	IN	B-PP	O
serious	JJ	B-NP	O
infections	NNS	I-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
.	.	O	O

Cytomegalovirus	NN	B-NP	B
infections	NNS	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
successfully	RB	B-ADVP	O
with	IN	B-PP	O
ganciclovir	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
growth	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
who	WP	B-NP	O
underwent	VBD	B-VP	O
transplantation	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
population	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
have	VBP	B-VP	O
undergone	VBN	I-VP	O
annual	JJ	B-NP	O
catheterizations	NNS	I-NP	O
and	CC	O	O
no	DT	B-NP	O
sign	NN	I-NP	O
of	IN	B-PP	O
graft	NN	B-NP	O
atherosclerosis	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
.	.	O	O

Seizures	NNS	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	I-NP	O
hypertension	NN	I-NP	B
was	VBD	B-VP	O
treated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
disabled	JJ	B-ADJP	O
and	CC	O	O
no	DT	B-NP	O
lymphoproliferative	JJ	I-NP	B
disorder	NN	I-NP	I
was	VBD	B-VP	O
observed.	VBN	I-VP	O
(	(	O	O
ABSTRACT	NN	B-NP	O
TRUNCATED	VBN	B-VP	O
AT	IN	B-PP	O
num	CD	B-NP	O
WORDS	NNS	I-NP	O
.	.	O	O

Delirium	NN	B-NP	B
during	IN	B-PP	O
fluoxetine	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
high	JJ	B-NP	O
serum	NN	I-NP	O
tricyclic	JJ	I-NP	O
antidepressant	NN	I-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
central	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
well	RB	I-VP	O
established	VBN	I-VP	O
.	.	O	O

Only	RB	B-NP	O
a	DT	I-NP	O
few	JJ	I-NP	O
reports	NNS	I-NP	O
exist	VBP	B-VP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
on	IN	B-PP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
selective	JJ	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
SSRIs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
their	PRP$	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
some	DT	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
citalopram	NN	B-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
somnolence	NN	I-NP	B
and	CC	I-NP	O
movement	NN	I-NP	B
difficulties	NNS	I-NP	I
.	.	O	O

Widespread	JJ	B-NP	O
cognitive	JJ	I-NP	B
disorders	NNS	I-NP	I
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
delirium	NN	B-NP	B
,	,	O	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
linked	VBN	I-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
blood	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
SSRIs	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
report	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	O
hyperkinetic	JJ	I-NP	B
delirium	NN	I-NP	B
connected	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
total	JJ	I-NP	O
fluoxetine	NN	I-NP	O
(	(	O	O
fluoxetine	NN	B-NP	O
plus	CC	O	O
desmethylfluoxetine	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
.	.	O	O

Pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
and	CC	I-NP	O
shock	NN	I-NP	B
after	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
aracytine	NN	I-NP	O
-	HYPH	B-NP	O
C	NN	I-NP	O
for	IN	B-PP	O
lymphoma	NN	B-NP	B
;	:	O	O
possible	JJ	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
TNF	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
and	CC	O	O
PAF	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
Ara	NN	I-NP	O
-	HYPH	B-NP	O
C	NN	I-NP	O
for	IN	B-PP	O
lymphomas	NNS	B-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
institution	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
strikingly	RB	I-NP	O
similar	JJ	I-NP	O
syndrome	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
perfusion	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
fever	NN	B-NP	B
,	,	O	O
diarrhea	NN	B-NP	B
,	,	O	O
shock	NN	B-NP	B
,	,	O	O
pulmonary	JJ	B-NP	B
edema	NN	I-NP	I
,	,	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
metabolic	JJ	B-NP	B
acidosis	NN	I-NP	I
,	,	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
and	CC	I-NP	O
leukocytosis	NN	I-NP	B
.	.	O	O

Thorough	IN	B-PP	O
bacteriological	JJ	B-NP	O
screening	NN	I-NP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
provide	VB	I-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
infection	NN	B-NP	B
.	.	O	O

Sequential	JJ	B-NP	O
biological	JJ	I-NP	O
assays	NNS	I-NP	O
of	IN	B-PP	O
IL	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
IL	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
TNF	NN	I-NP	O
and	CC	I-NP	O
PAF	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
during	IN	B-PP	O
Ara	NN	B-NP	O
-	HYPH	I-NP	O
C	NN	I-NP	O
infusion	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

TNF	NN	B-NP	O
and	CC	I-NP	O
PAF	NN	I-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
of	IN	B-PP	O
respectively	RB	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
TNF	NN	B-NP	O
and	CC	I-NP	O
PAF	NN	I-NP	O
are	VBP	B-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
septic	JJ	B-NP	O
shock	NN	I-NP	B
and	CC	O	O
adult	JJ	B-NP	B
respiratory	JJ	I-NP	I
distress	NN	I-NP	I
syndrome	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
hypothesize	VBP	B-VP	O
that	IN	B-SBAR	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
Ara	NN	I-NP	O
-	HYPH	O	O
C	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
cytokine	NN	B-NP	O
release	NN	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
clentiazem	NN	B-NP	O
against	IN	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
clentiazem	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
benzothiazepine	NN	I-NP	O
calcium	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiomyopathy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

With	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
chronic	JJ	I-NP	O
epinephrine	NN	I-NP	O
infusion	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
died	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
and	CC	O	O
severe	JJ	B-NP	O
ischemic	JJ	I-NP	B
lesions	NNS	I-NP	I
and	CC	O	O
fibrosis	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricles	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
left	VBD	B-VP	O
atrial	JJ	B-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
papillary	JJ	I-NP	O
muscle	NN	I-NP	O
contractile	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
,	,	O	O
but	CC	O	O
responses	NNS	B-NP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
or	CC	O	O
enhanced	VBN	B-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Left	VBN	B-NP	O
ventricular	JJ	I-NP	O
alpha	NN	I-NP	O
and	CC	O	O
beta	NN	B-NP	O
adrenoceptor	NN	I-NP	O
densities	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
reduced	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
clentiazem	NN	B-NP	O
prevented	VBD	B-VP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
death	NN	I-NP	O
,	,	O	O
and	CC	O	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	O
ischemic	JJ	I-NP	B
lesions	NNS	I-NP	I
and	CC	O	O
fibrosis	NN	B-NP	B
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

Left	VBN	B-NP	O
atrial	JJ	I-NP	O
and	CC	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
papillary	JJ	I-NP	O
muscle	NN	I-NP	O
contractile	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
were	VBD	B-VP	O
reduced	VBN	I-VP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
in	IN	B-PP	O
groups	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
clentiazem	NN	B-NP	O
alone	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
combined	VBN	B-VP	O
with	IN	B-PP	O
epinephrine	NN	B-NP	O
,	,	O	O
clentiazem	NN	B-NP	O
restored	VBD	B-VP	O
left	JJ	B-NP	O
atrial	JJ	I-NP	O
responses	NNS	I-NP	O
and	CC	O	O
enhanced	VBN	B-VP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
papillary	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
clentiazem	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
epinephrine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
down	RB	B-ADVP	O
-	HYPH	B-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
alpha	NN	B-NP	O
and	CC	O	O
beta	NN	B-NP	O
adrenoceptors	NNS	I-NP	O
.	.	O	O

Interestingly	RB	B-ADVP	O
,	,	O	O
clentiazem	NN	B-NP	O
,	,	O	O
infused	VBN	B-VP	O
alone	RB	B-ADVP	O
,	,	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
decreased	VBN	B-NP	O
adrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
densities	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricle	NN	I-NP	O
.	.	O	O

Clentiazem	NNP	B-NP	O
also	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
enhanced	VBN	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
epinephrine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
high	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
clentiazem	NN	B-NP	O
partially	RB	B-ADVP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
maximal	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
calcium	NN	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
epinephrine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
clentiazem	NN	B-NP	O
attenuated	VBD	B-VP	O
epinephrine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
injury	NN	I-NP	I
,	,	O	O
possibly	RB	B-ADVP	O
through	IN	B-PP	O
its	PRP$	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
adrenergic	JJ	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
ischemia	NN	I-NP	B
probably	RB	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
spasm	NN	I-NP	I
was	VBD	B-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
nitroglycerin	NN	B-NP	O
and	CC	O	O
calcium	NN	B-NP	O
blocking	NN	I-NP	O
agents	NNS	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
monitored	VBN	B-VP	O
by	IN	B-PP	O
ECG	NN	B-NP	O
in	IN	B-PP	O
freely	RB	B-ADVP	O
moving	VBG	B-VP	O
mice	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
new	JJ	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
test	VB	I-VP	O
potential	JJ	B-NP	O
protectors	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
laboratory	NN	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
histology	NN	B-NP	O
is	VBZ	B-VP	O
most	RBS	B-ADJP	O
commonly	RB	I-ADJP	O
used	VBN	I-ADJP	O
to	TO	B-VP	O
study	VB	I-VP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
for	IN	B-PP	O
monitoring	VBG	B-VP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
large	JJ	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
.	.	O	O

Recently	RB	B-ADVP	O
we	PRP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
method	NN	I-NP	O
to	TO	B-VP	O
measure	VB	I-VP	O
ECG	NN	B-NP	O
values	NNS	I-NP	O
in	IN	B-PP	O
freely	RB	B-ADVP	O
moving	VBG	B-VP	O
mice	NNS	B-NP	O
by	IN	B-PP	O
telemetry	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
this	DT	B-NP	O
model	NN	I-NP	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
doxorubicin	NN	I-NP	O
administration	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
ECG	NN	I-NP	O
of	IN	B-PP	O
freely	RB	B-VP	O
moving	VBG	I-VP	O
BALB	NN	B-NP	O
/	SYM	B-VP	O
c	NN	B-NP	O
mice	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
ICRF	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
protective	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ST	NN	I-NP	O
interval	NN	I-NP	O
significantly	RB	B-ADVP	O
widened	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
ms	NNS	I-NP	O
in	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
ECG	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
sacrifice	NN	B-NP	O
the	DT	B-NP	O
hearts	NNS	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
enlarged	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
atria	NN	I-NP	O
were	VBD	B-VP	O
hypertrophic	JJ	B-ADJP	B
.	.	O	O

As	IN	B-SBAR	O
this	DT	B-NP	O
schedule	NN	I-NP	O
exerted	VBD	B-VP	O
more	JJR	B-NP	O
toxicity	NN	I-NP	B
than	IN	B-SBAR	O
needed	VBN	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
protective	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
protection	NN	I-NP	O
of	IN	B-PP	O
ICRF	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
schedule	NN	I-NP	O
with	IN	B-PP	O
lower	JJR	B-NP	O
general	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

On	IN	B-PP	O
this	DT	B-NP	O
schedule	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
animals	NNS	I-NP	O
s	NNS	I-NP	O
hearts	NNS	I-NP	O
appeared	VBD	B-VP	O
normal	JJ	B-ADJP	O
after	IN	B-PP	O
sacrifice	NN	B-NP	O
and	CC	I-NP	O
ICRF	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
provided	VBD	B-VP	O
almost	RB	B-NP	O
full	JJ	I-NP	O
protection	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
histology	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
new	JJ	I-NP	O
model	NN	I-NP	O
is	VBZ	B-VP	O
very	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
and	CC	O	O
enables	VBZ	B-VP	O
monitoring	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
cardiotoxicity	NN	B-NP	B
with	IN	B-PP	O
time	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
result	VBP	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
that	WDT	B-NP	O
allows	VBZ	B-VP	O
the	DT	B-NP	O
testing	NN	I-NP	O
of	IN	B-PP	O
protectors	NNS	B-NP	O
against	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
as	IN	B-SBAR	O
demonstrated	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
protection	NN	I-NP	O
provided	VBN	B-VP	O
by	IN	B-PP	O
ICRF	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

Epinephrine	NN	B-NP	O
dysrhythmogenicity	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
subtoxic	JJ	B-NP	O
bupivacaine	NN	I-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
.	.	O	O

Since	IN	B-SBAR	O
bupivacaine	NN	B-NP	O
and	CC	I-NP	O
epinephrine	NN	I-NP	O
may	MD	B-VP	O
both	DT	O	O
precipitate	VB	B-VP	O
dysrhythmias	NNS	B-NP	B
,	,	O	O
circulating	VBG	B-VP	O
bupivacaine	NN	B-NP	O
during	IN	B-PP	O
regional	JJ	B-NP	O
anesthesia	NN	I-NP	O
could	MD	B-VP	O
potentiate	VB	I-VP	O
dysrhythmogenic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
examined	VBD	B-VP	O
whether	IN	B-SBAR	O
bupivacaine	NN	B-NP	O
alters	VBZ	B-VP	O
the	DT	B-NP	O
dysrhythmogenicity	NN	I-NP	O
of	IN	B-PP	O
subsequent	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
epinephrine	NN	B-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
,	,	I-NP	O
healthy	JJ	I-NP	O
dogs	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
conscious	JJ	I-NP	O
dogs	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
micrograms.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
animals	NNS	I-NP	O
responded	VBD	B-VP	O
with	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
(	(	O	O
VT	NN	B-NP	B
)	)	O	O
within	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
,	,	O	O
these	DT	B-NP	O
responders	NNS	I-NP	O
randomly	RB	B-ADVP	O
received	VBD	B-VP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
bupivacaine	NN	I-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
micrograms.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
bupivacaine	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
epinephrine	NN	B-NP	O
caused	VBD	B-VP	O
fewer	JJR	B-NP	O
prodysrhythmic	JJ	I-NP	O
effects	NNS	I-NP	O
than	IN	B-PP	O
without	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

VT	NN	B-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
fewer	JJR	B-NP	O
dogs	NNS	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
a	DT	B-NP	O
later	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
and	CC	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
more	RBR	B-NP	O
sinoatrial	JJ	I-NP	O
beats	NNS	I-NP	O
and	CC	O	O
less	JJR	B-NP	O
ectopies	NNS	I-NP	O
.	.	O	O

Epinephrine	NN	B-NP	O
shortened	VBD	B-VP	O
QT	NN	B-NP	O
less	JJR	B-ADVP	O
after	IN	B-PP	O
bupivacaine	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
control	NN	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
day	NN	I-NP	O
after	IN	B-PP	O
experimental	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
additional	JJ	I-NP	O
halothane	NN	I-NP	O
-	HYPH	B-NP	O
anesthetized	VBN	I-NP	O
dogs	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
micrograms.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
epinephrine	NN	I-NP	O
until	IN	B-SBAR	O
VT	NN	B-NP	B
appeared	VBD	B-VP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
bupivacaine	NN	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
over	IN	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
,	,	O	O
again	RB	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
micrograms.kg	NN	I-NP	O
-	HYPH	B-NP	O
1.min	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
these	DT	B-NP	O
dogs	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
prodysrhythmic	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
epinephrine	NN	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
mitigated	VBN	I-VP	O
by	IN	B-PP	O
preceding	VBG	B-VP	O
bupivacaine	NN	B-NP	O
.	.	O	O

Bupivacaine	NN	B-NP	O
antagonizes	VBZ	B-VP	O
epinephrine	NN	B-NP	O
dysrhythmogenicity	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
dogs	NNS	I-NP	O
susceptible	JJ	B-ADJP	O
to	TO	B-PP	O
VT	NN	B-NP	B
and	CC	O	O
in	IN	B-PP	O
anesthetized	VBN	B-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
spontaneous	JJ	B-NP	O
postinfarct	JJ	I-NP	O
dysrhythmias	NNS	I-NP	B
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
evidence	NN	I-NP	O
that	IN	B-SBAR	O
systemic	JJ	B-NP	O
subtoxic	JJ	I-NP	O
bupivacaine	NN	I-NP	O
administration	NN	I-NP	O
enhances	VBZ	B-VP	O
the	DT	B-NP	O
dysrhythmogenicity	NN	I-NP	O
of	IN	B-PP	O
subsequent	JJ	B-NP	O
epinephrine	NN	I-NP	O
.	.	O	O

Milk	NN	B-NP	B
-	HYPH	I-NP	I
alkali	NN	I-NP	I
syndrome	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
OH	NN	B-NP	O
)	)	O	O
2D	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
hypoparathyroidism	NN	B-NP	B
.	.	O	O

Milk	NN	B-NP	B
-	HYPH	I-NP	I
alkali	NN	I-NP	I
syndrome	NN	I-NP	I
was	VBD	B-VP	O
first	RB	I-VP	O
described	VBN	I-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
ago	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
context	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
peptic	JJ	B-NP	B
ulcer	NN	I-NP	I
disease	NN	I-NP	I
with	IN	B-PP	O
large	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
calcium	NN	B-NP	O
and	CC	I-NP	O
alkali	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
with	IN	B-PP	O
current	JJ	B-NP	O
ulcer	NN	I-NP	B
therapy	NN	I-NP	O
(	(	O	O
H	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
blockers	NNS	I-NP	O
,	,	O	O
omeprazole	NN	B-NP	O
,	,	O	O
and	CC	O	O
sucralfate	NN	B-NP	O
)	)	O	O
,	,	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
milk	NN	B-NP	B
-	HYPH	B-NP	I
alkali	NN	I-NP	I
syndrome	NN	I-NP	I
has	VBZ	B-VP	O
decreased	VBN	I-VP	O
significantly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
classic	JJ	I-NP	O
triad	NN	I-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
,	,	O	O
alkalosis	NN	B-NP	B
,	,	O	O
and	CC	O	O
renal	JJ	B-NP	B
impairment	NN	I-NP	I
remains	VBZ	B-VP	O
the	DT	B-NP	O
hallmark	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

Milk	NN	B-NP	B
-	HYPH	I-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
can	MD	B-VP	O
present	VB	I-VP	O
serious	JJ	B-ADJP	O
and	CC	O	O
occasionally	RB	B-ADVP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
illness	NN	B-NP	O
unless	IN	B-SBAR	O
diagnosed	VBN	B-VP	O
and	CC	O	O
treated	VBN	B-VP	O
appropriately	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
article	NN	I-NP	O
presents	VBZ	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
hypoparathyroidism	NN	B-NP	B
who	WP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
calcium	NN	B-NP	O
carbonate	NN	I-NP	O
and	CC	I-NP	O
calcitriol	NN	I-NP	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
admissions	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
milk	NN	B-NP	B
-	HYPH	B-NP	I
alkali	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
pamidronate	NN	I-NP	O
on	IN	B-PP	O
his	PRP$	B-NP	O
first	JJ	I-NP	O
admission	NN	I-NP	O
and	CC	B-PP	O
with	IN	B-PP	O
hydrocortisone	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
second	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
illustrates	VBZ	B-VP	O
intravenous	JJ	B-NP	O
pamidronate	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
valuable	JJ	I-NP	O
therapeutic	JJ	I-NP	O
tool	NN	I-NP	O
when	WRB	B-ADVP	O
milk	NN	B-NP	B
-	HYPH	I-NP	I
alkali	NN	I-NP	I
syndrome	NN	I-NP	I
presents	VBZ	B-VP	O
as	IN	B-PP	O
hypercalcemic	JJ	B-NP	B
emergency	NN	I-NP	I
.	.	O	O

Encephalopathy	NN	B-NP	B
during	IN	B-PP	O
amitriptyline	NN	B-NP	O
therapy	NN	I-NP	O
:	:	O	O
are	VBP	B-VP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
serotonin	NN	I-NP	B
syndrome	NN	I-NP	I
spectrum	NN	I-NP	O
disorders	NNS	I-NP	O
?	.	O	O
This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
encephalopathy	NN	B-NP	B
developed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
amitriptyline	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
during	IN	B-PP	O
a	DT	B-NP	O
remission	NN	I-NP	O
of	IN	B-PP	O
unipolar	JJ	B-NP	B
depression	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
patient	NN	I-NP	O
could	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
having	VBG	B-VP	O
either	CC	O	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
NMS	NN	B-NP	B
)	)	O	O
or	CC	O	O
serotonin	NN	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
SS	NN	B-NP	B
)	)	O	O
.	.	O	O

The	DT	B-NP	O
major	JJ	I-NP	O
determinant	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
dopamine	NN	B-NP	O
/	SYM	O	O
serotonin	NN	B-NP	O
imbalance	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
NMS	NN	I-NP	B
-	HYPH	B-NP	O
like	JJ	I-NP	O
encephalopathy	NN	I-NP	B
that	WDT	B-NP	O
develops	VBZ	B-VP	O
in	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antidepressants	NNS	B-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
NMS	NN	B-NP	B
and	CC	I-NP	O
SS	NN	I-NP	B
are	VBP	B-VP	O
spectrum	NN	B-NP	O
disorders	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
drugs	NNS	B-NP	O
with	IN	B-PP	O
both	CC	B-NP	O
antidopaminergic	JJ	I-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Genetic	JJ	B-NP	O
separation	NN	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
growth	NN	I-NP	O
and	CC	O	O
hemorrhagic	JJ	B-NP	B
phenotypes	NNS	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
estrogen	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tumor	NN	I-NP	B
.	.	O	O

Chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
estrogen	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
Fischer	NNP	I-NP	O
num	CD	I-NP	O
(	(	O	O
F344	NN	B-NP	O
)	)	O	O
rat	NN	B-NP	O
induces	VBZ	B-VP	O
growth	NN	B-NP	O
of	IN	B-PP	O
large	JJ	B-NP	O
,	,	I-NP	O
hemorrhagic	JJ	I-NP	B
pituitary	JJ	I-NP	B
tumors	NNS	I-NP	I
.	.	O	O

num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
diethylstilbestrol	NN	B-NP	O
(	(	O	O
DES	NN	B-NP	O
)	)	O	O
treatment	NN	B-NP	O
caused	VBD	B-VP	O
female	JJ	B-NP	O
F344	NN	I-NP	O
rat	NN	I-NP	O
pituitaries	NNS	I-NP	O
to	TO	B-VP	O
grow	VB	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SE	NN	I-NP	O
)	)	O	O
versus	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
for	IN	B-PP	O
untreated	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
become	VB	I-VP	O
highly	RB	B-ADJP	O
hemorrhagic	JJ	I-ADJP	B
.	.	O	O

The	DT	B-NP	O
same	JJ	I-NP	O
DES	NNP	I-NP	O
treatment	NN	I-NP	O
produced	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
growth	NN	I-NP	O
or	CC	I-NP	O
morphological	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
Brown	NNP	B-NP	O
Norway	NNP	I-NP	O
(	(	O	O
BN	NN	B-NP	O
)	)	O	O
rat	NN	B-NP	O
pituitaries	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
F1	NN	I-NP	O
hybrid	NN	I-NP	O
of	IN	B-PP	O
F344	NN	B-NP	O
and	CC	I-NP	O
BN	NN	I-NP	O
exhibited	VBD	B-VP	O
significant	JJ	B-NP	O
pituitary	JJ	I-NP	O
growth	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
DES	NNP	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
average	JJ	I-NP	O
mass	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
for	IN	B-PP	O
untreated	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Surprisingly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
F1	NN	I-NP	O
hybrid	JJ	I-NP	O
tumors	NNS	I-NP	B
were	VBD	B-VP	O
not	RB	O	O
hemorrhagic	JJ	B-ADJP	B
and	CC	O	O
had	VBD	B-VP	O
hemoglobin	NN	B-NP	O
content	NN	I-NP	O
and	CC	O	O
outward	RB	B-ADVP	O
appearance	NN	B-NP	O
identical	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
BN	NN	B-NP	O
.	.	O	O

Expression	NN	B-NP	O
of	IN	B-PP	O
both	CC	O	O
growth	NN	B-NP	O
and	CC	O	O
morphological	JJ	B-NP	O
changes	NNS	I-NP	O
is	VBZ	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
multiple	JJ	B-NP	O
genes	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
DES	NNP	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
pituitary	JJ	I-NP	O
growth	NN	I-NP	O
exhibited	VBD	B-VP	O
quantitative	JJ	B-NP	O
,	,	I-NP	O
additive	JJ	I-NP	O
inheritance	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
phenotype	NN	I-NP	O
exhibited	VBD	B-VP	O
recessive	JJ	B-NP	O
,	,	I-NP	O
epistatic	JJ	I-NP	O
inheritance	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
F2	NN	I-NP	O
pituitaries	NNS	I-NP	O
exhibited	VBD	B-VP	O
the	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
phenotype	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
F2	NN	I-NP	O
pituitaries	NNS	I-NP	O
were	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
F344	NN	I-NP	O
range	NN	I-NP	O
of	IN	B-PP	O
mass	NN	B-NP	O
,	,	O	O
but	CC	O	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
were	VBD	B-VP	O
not	RB	O	O
hemorrhagic	JJ	B-ADJP	B
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
phenotype	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
merely	RB	B-ADVP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
extensive	JJ	B-NP	O
growth	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hemorrhagic	JJ	I-NP	B
F2	NN	I-NP	O
pituitaries	NNS	I-NP	O
were	VBD	B-VP	O
all	DT	O	O
among	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
massive	JJ	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
genes	NNS	I-NP	O
regulate	VBP	B-VP	O
both	DT	B-NP	O
phenotypes	NNS	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
neuronal	JJ	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
in	IN	B-PP	O
bladder	NN	B-NP	O
afferent	JJ	I-NP	O
pathways	NNS	I-NP	O
following	VBG	B-PP	O
chronic	JJ	B-NP	O
bladder	NN	I-NP	B
irritation	NN	I-NP	I
.	.	O	O

Immunocytochemical	JJ	B-NP	O
techniques	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
examine	VB	I-VP	O
alterations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
neuronal	JJ	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
NOS	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
bladder	NN	B-NP	O
pathways	NNS	I-NP	O
following	VBG	B-PP	O
acute	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
irritation	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
urinary	JJ	I-NP	I
tract	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Chemical	JJ	B-NP	O
cystitis	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
metabolized	VBN	I-VP	O
to	TO	B-PP	O
acrolein	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
irritant	JJ	I-NP	O
eliminated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
urine	NN	I-NP	O
.	.	O	O

Injection	NN	B-NP	O
of	IN	B-PP	O
CYP	NN	B-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
perfusion	NN	B-NP	O
(	(	O	O
acute	JJ	B-NP	O
treatment	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
increased	VBD	B-VP	O
Fos	NN	B-NP	O
-	HYPH	O	O
immunoreactivity	NN	B-NP	O
(	(	O	O
IR	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dorsal	JJ	I-NP	O
commissure	NN	I-NP	O
,	,	O	O
dorsal	JJ	B-NP	O
horn	NN	I-NP	O
,	,	O	O
and	CC	O	O
autonomic	JJ	B-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
segments	NNS	I-NP	O
(	(	O	O
L1	NN	B-NP	O
-	HYPH	I-NP	O
L2	NN	I-NP	O
and	CC	I-NP	O
L6	NN	I-NP	O
-	HYPH	B-NP	O
S1	NN	I-NP	O
)	)	O	O
which	WDT	B-NP	O
receive	VBP	B-VP	O
afferent	JJ	B-NP	O
inputs	NNS	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
,	,	O	O
urethra	NN	B-NP	O
,	,	O	O
and	CC	O	O
ureter	NN	B-NP	O
.	.	O	O

Fos	NN	B-NP	O
-	HYPH	I-NP	O
IR	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
changed	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
receiving	VBG	B-VP	O
chronic	JJ	B-NP	O
CYP	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
control	NN	B-NP	O
animals	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
acutely	RB	B-ADVP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
,	,	O	O
only	RB	B-NP	O
small	JJ	I-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
NOS	NN	B-NP	O
-	HYPH	I-NP	O
IR	NN	I-NP	O
cells	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
cell	NN	I-NP	O
profiles	NNS	I-NP	O
/	SYM	B-NP	O
sections	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
L6	NN	I-NP	O
-	HYPH	B-NP	O
S1	NN	I-NP	O
dorsal	JJ	I-NP	O
root	NN	I-NP	O
ganglia	NNS	I-NP	O
(	(	O	O
DRG	NN	B-NP	O
)	)	O	O
.	.	O	O

Chronic	JJ	B-NP	O
CYP	NN	I-NP	O
administration	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
bladder	NN	B-NP	O
weight	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
increased	VBN	B-VP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
)	)	O	O
the	DT	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
NOS	NN	B-NP	O
-	HYPH	B-NP	O
immunoreactive	JJ	I-NP	O
(	(	O	O
IR	NN	B-NP	O
)	)	O	O
afferent	JJ	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
L6	NN	I-NP	O
-	HYPH	B-NP	O
S1	NN	I-NP	O
DRG	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
small	JJ	I-NP	O
increase	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
)	)	O	O
also	RB	B-ADVP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
L1	NN	I-NP	O
DRG	NN	I-NP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
change	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
L2	NN	I-NP	O
and	CC	I-NP	O
L5	NN	I-NP	O
DRG	NN	I-NP	O
.	.	O	O

Bladder	NN	B-NP	O
afferent	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
L6	NN	I-NP	O
-	HYPH	B-NP	O
S1	NN	I-NP	O
DRG	NN	I-NP	O
labeled	VBN	B-VP	O
by	IN	B-PP	O
Fluorogold	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
microliters	NNS	I-NP	O
)	)	O	O
injected	VBN	B-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
wall	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
exhibit	VB	I-VP	O
NOS	NN	B-NP	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
animals	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
following	VBG	B-PP	O
chronic	JJ	B-NP	O
CYP	NN	I-NP	O
administration	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	O
afferent	JJ	I-NP	O
neurons	NNS	I-NP	O
were	VBD	B-VP	O
NOS	NN	B-NP	O
-	HYPH	O	O
IR	NN	B-NP	O
:	:	O	O
L6	NN	B-NP	O
and	CC	I-NP	O
S1	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
neuronal	JJ	B-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
visceral	JJ	B-NP	O
sensory	JJ	I-NP	O
pathways	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
upregulated	VBN	I-VP	O
by	IN	B-PP	O
chemical	JJ	B-NP	O
irritation	NN	I-NP	O
of	IN	B-PP	O
afferent	JJ	B-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
tract	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
that	IN	B-SBAR	O
pathological	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
tract	NN	I-NP	O
can	MD	B-VP	O
initiate	VB	I-VP	O
chemical	JJ	B-NP	O
signals	NNS	I-NP	O
that	WDT	B-NP	O
alter	VBP	B-VP	O
the	DT	B-NP	O
chemical	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
visceral	JJ	B-NP	O
afferent	JJ	I-NP	O
neurons	NNS	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
calcium	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
CD	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
in	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
partial	JJ	B-NP	O
coronary	JJ	I-NP	B
stenosis	NN	I-NP	I
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
CD	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
(	(	O	O
ISO	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
were	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
with	IN	B-PP	O
partial	JJ	B-NP	O
coronary	JJ	I-NP	B
stenosis	NN	I-NP	I
of	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
circumflex	NN	I-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
and	CC	I-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
for	IN	B-PP	O
nifedipine	NN	B-NP	O
or	CC	I-NP	O
diltiazem	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
stenosis	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
periods	NNS	I-NP	O
of	IN	B-PP	O
intracoronary	JJ	B-NP	O
ISO	NN	I-NP	O
infusion	NN	I-NP	O
increased	VBD	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
and	CC	O	O
maximal	JJ	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
pressure	NN	I-NP	O
rise	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
percentage	NN	B-NP	O
segmental	JJ	I-NP	O
shortening	NN	I-NP	O
and	CC	I-NP	O
ST	NN	I-NP	O
-	HYPH	I-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
epicardial	JJ	I-NP	O
electrocardiogram	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
ISO	NN	I-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
stenosis	NN	B-NP	B
was	VBD	B-VP	O
performed	VBN	I-VP	O
,	,	O	O
equihypotensive	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
CD	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
nifedipine	NN	I-NP	O
or	CC	I-NP	O
diltiazem	NN	I-NP	O
were	VBD	B-VP	O
infused	VBN	I-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
and	CC	I-NP	O
third	JJ	I-NP	O
ISO	NN	I-NP	O
infusion	NN	I-NP	O
.	.	O	O

Both	CC	O	O
CD	NNP	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
diltiazem	NN	I-NP	O
,	,	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
nifedipine	NN	B-NP	O
,	,	O	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
ISO	NN	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
nifedipine	NN	B-NP	O
,	,	O	O
CD	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
percentage	NN	B-NP	O
segmental	JJ	I-NP	O
shortening	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
value	NN	I-NP	O
and	CC	I-NP	O
ST	NN	I-NP	O
-	HYPH	B-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mV	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mV	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
ISO	NN	B-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
stenosis	NN	B-NP	B
.	.	O	O

Diltiazem	NNP	B-NP	O
also	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
percentage	NN	B-NP	O
segmental	JJ	I-NP	O
shortening	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
value	NN	I-NP	O
and	CC	I-NP	O
ST	NN	I-NP	O
-	HYPH	B-NP	O
segment	NN	I-NP	O
elevation	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mV	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mV	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
after	IN	B-PP	O
ISO	NN	B-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
stenosis	NN	B-NP	B
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
CD	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
improves	VBZ	B-VP	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
during	IN	B-PP	O
ISO	NN	B-NP	O
infusion	NN	I-NP	O
with	IN	B-PP	O
stenosis	NN	B-NP	B
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
negative	JJ	I-NP	O
chronotropic	JJ	I-NP	O
property	NN	I-NP	O
of	IN	B-PP	O
CD	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
beneficial	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
CD	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
recombinant	JJ	B-NP	O
human	JJ	I-NP	O
insulin	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
on	IN	B-PP	O
chronic	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
recently	RB	B-ADVP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
recombinant	JJ	B-NP	O
hGH	NN	I-NP	O
exacerbates	VBZ	B-VP	O
renal	JJ	B-NP	O
functional	JJ	I-NP	O
and	CC	I-NP	O
structural	JJ	I-NP	O
injury	NN	I-NP	O
in	IN	B-PP	O
chronic	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
nephropathy	NN	B-NP	B
,	,	O	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
whether	IN	B-SBAR	O
recombinant	JJ	B-NP	O
human	JJ	I-NP	O
(	(	O	O
rh	JJ	B-ADJP	O
)	)	O	O
IGF	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
safer	JJR	I-NP	O
alternative	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
growth	NN	B-NP	B
failure	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
PAN	NN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
glomerulopathy	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
serial	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
wk	NN	I-NP	O
.	.	O	O

Experimental	JJ	B-NP	O
animals	NNS	I-NP	O
received	VBD	B-VP	O
rhIGF	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
/	SYM	O	O
d	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
control	NN	B-NP	O
rats	NNS	I-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
vehicle.	NN	I-NP	O
rhIGF	NN	I-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
improved	VBD	B-VP	O
weight	NN	B-NP	O
gain	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
altering	VBG	B-VP	O
hematocrit	NN	B-NP	O
or	CC	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Urinary	JJ	B-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
was	VBD	B-VP	O
unaltered	JJ	B-ADJP	O
by	IN	B-PP	O
rhIGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
PAN	NN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
wk	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
inulin	NN	I-NP	O
clearance	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
rhIGF	NN	B-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mL	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
in	IN	B-PP	O
untreated	JJ	B-NP	O
PAN	NN	I-NP	O
nephropathy	NN	I-NP	B
animals	NNS	I-NP	O
,	,	O	O
p	NN	B-NP	O
<	SYM	B-VP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
improvement	NN	I-NP	O
in	IN	B-PP	O
GFR	NN	B-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
enhanced	VBN	B-NP	O
glomerular	JJ	I-NP	B
hypertrophy	NN	I-NP	I
or	CC	O	O
increased	VBN	B-NP	O
segmental	JJ	I-NP	O
glomerulosclerosis	NN	I-NP	B
,	,	O	O
tubulointerstitial	JJ	B-NP	B
injury	NN	I-NP	I
,	,	O	O
or	CC	O	O
renal	JJ	B-NP	O
cortical	JJ	I-NP	O
malondialdehyde	NN	I-NP	O
content	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
PAN	NN	B-NP	O
nephropathy	NN	I-NP	B
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
rhIGF	NN	B-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
increased	VBD	B-VP	O
IGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
and	CC	I-NP	O
GH	NN	I-NP	O
receptor	NN	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
,	,	O	O
without	IN	B-PP	O
altering	VBG	B-VP	O
the	DT	B-NP	O
steady	JJ	I-NP	O
state	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
IGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
receptor	NN	I-NP	O
mRNA	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
intact	JJ	B-NP	O
kidneys	NNS	I-NP	O
,	,	O	O
rhIGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
administration	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
alter	VB	I-VP	O
weight	NN	B-NP	O
gain	NN	I-NP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
proteinuria	NN	B-NP	B
,	,	O	O
GFR	NN	B-NP	O
,	,	O	O
glomerular	JJ	B-NP	O
planar	JJ	I-NP	O
area	NN	I-NP	O
,	,	O	O
renal	JJ	B-NP	O
cortical	JJ	I-NP	O
malondialdehyde	NN	I-NP	O
content	NN	I-NP	O
,	,	O	O
or	CC	O	O
glomerular	JJ	B-NP	O
or	CC	I-NP	O
tubulointerstitial	JJ	I-NP	B
damage	NN	I-NP	I
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
untreated	JJ	B-NP	O
animals	NNS	I-NP	O
.	.	O	O
rhIGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
treatment	NN	I-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
steady	JJ	I-NP	O
state	NN	I-NP	O
renal	JJ	I-NP	O
IGF	NN	I-NP	O
-	HYPH	B-NP	O
I	NN	I-NP	O
mRNA	NN	I-NP	O
level	NN	I-NP	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
modify	VB	I-VP	O
gene	NN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
IGF	NN	I-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
or	CC	I-NP	O
GH	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
:	:	O	O
num	CD	B-NP	O
)	)	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
rhIGF	NN	B-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
improves	VBZ	B-VP	O
growth	NN	B-NP	O
and	CC	I-NP	O
GFR	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
PAN	NN	I-NP	O
nephropathy	NN	I-NP	B
and	CC	O	O
num	CD	B-NP	O
)	)	O	O
unlike	IN	B-PP	O
rhGH	NN	B-NP	O
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
rhIGF	NN	B-NP	O
-	HYPH	O	O
I	PRP	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
worsen	VBN	I-VP	O
renal	JJ	B-NP	O
functional	JJ	I-NP	O
and	CC	I-NP	O
structural	JJ	I-NP	O
injury	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
disease	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

Nefiracetam	NN	B-NP	O
(	(	O	O
DM	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
reverses	VBZ	B-VP	O
apomorphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
amnesia	NN	I-NP	B
of	IN	B-PP	O
a	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
response	NN	I-NP	O
:	:	O	O
delayed	VBN	B-NP	O
emergence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
memory	NN	I-NP	O
retention	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Nefiracetam	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
pyrrolidone	NN	I-NP	O
derivative	NN	I-NP	O
which	WDT	B-NP	O
attenuates	VBZ	B-VP	O
scopolamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
learning	NN	I-NP	B
and	CC	O	I
post	AFX	O	I
-	HYPH	O	I
training	VBG	B-VP	I
consolidation	NN	B-NP	I
deficits	NNS	I-NP	I
.	.	O	O

Given	VBN	B-VP	O
that	IN	B-SBAR	O
apomorphine	NN	B-NP	O
inhibits	VBZ	B-VP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
retention	NN	I-NP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
during	IN	B-PP	O
training	NN	B-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
a	DT	B-NP	O
defined	VBN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
training	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
nefiracetam	NN	B-NP	O
to	TO	B-VP	O
attenuate	VB	I-VP	O
amnesia	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
dopaminergic	JJ	B-NP	O
agonism	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
step	NN	I-NP	O
-	HYPH	B-VP	O
down	RB	B-ADVP	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
paradigm	NN	I-NP	O
was	VBD	B-VP	O
employed	VBN	I-VP	O
and	CC	O	O
nefiracetam	NN	B-NP	O
and	CC	I-NP	O
apomorphine	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
during	IN	B-PP	O
training	NN	B-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
training	NN	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
consolidation	NN	B-NP	O
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	B-NP	O
of	IN	B-PP	O
nefiracetam	NN	B-NP	O
and	CC	I-NP	O
apomorphine	NN	I-NP	O
during	IN	B-PP	O
training	NN	B-NP	O
or	CC	I-NP	O
10h	NN	I-NP	O
thereafter	RB	B-VP	O
produced	VBN	I-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
amnesic	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
nefiracetam	NN	B-NP	O
during	IN	B-PP	O
training	NN	B-NP	O
completely	RB	B-ADVP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
amnesia	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
apomorphine	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
training	NN	I-NP	O
time	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
converse	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
true	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
dopaminergic	JJ	I-NP	O
mechanism	NN	I-NP	O
as	IN	B-PP	O
nefiracetam	NN	B-NP	O
,	,	O	O
at	IN	B-PP	O
millimolar	JJ	B-NP	O
concentrations	NNS	I-NP	O
,	,	O	O
failed	VBD	B-VP	O
to	TO	I-VP	O
displace	VB	I-VP	O
either	CC	O	O
[	(	O	O
3H	NN	B-NP	O
]	)	O	O
SCH	NN	B-NP	O
num	CD	I-NP	O
or	CC	O	O
[	(	O	O
3H	NN	B-NP	O
]	)	I-NP	O
spiperone	NN	I-NP	O
binding	NN	I-NP	O
from	IN	B-PP	O
D1	NN	B-NP	O
or	CC	I-NP	O
D2	NN	I-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
subtypes	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
nefiracetam	NN	B-NP	O
augments	VBZ	B-VP	O
molecular	JJ	B-NP	O
processes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
stages	NNS	I-NP	O
of	IN	B-PP	O
events	NNS	B-NP	O
which	WDT	B-NP	O
ultimately	RB	B-ADVP	O
lead	VBP	B-VP	O
to	TO	B-PP	O
consolidation	NN	B-NP	O
of	IN	B-PP	O
memory	NN	B-NP	O
.	.	O	O

Human	JJ	B-NP	O
corticotropin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
and	CC	I-NP	O
thyrotropin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
modulate	VBP	B-VP	O
the	DT	B-NP	O
hypercapnic	JJ	I-NP	B
ventilatory	JJ	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Human	JJ	B-NP	O
corticotropin	NN	I-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
hCRH	NN	B-NP	O
)	)	O	O
and	CC	O	O
thyrotropin	NN	B-NP	O
-	HYPH	O	O
releasing	VBG	B-VP	O
hormone	NN	B-NP	O
(	(	O	O
TRH	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
stimulate	VB	I-VP	O
ventilation	NN	B-NP	O
after	IN	B-SBAR	O
i.v.	JJ	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
,	,	I-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
clarify	VB	I-VP	O
if	IN	B-SBAR	O
both	DT	B-NP	O
peptides	NNS	I-NP	O
act	VBP	B-VP	O
by	IN	B-PP	O
altering	VBG	B-VP	O
central	JJ	B-NP	O
chemosensitivity	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
subsequent	JJ	I-NP	O
CO2	NN	I-NP	O
-	HYPH	B-VP	O
rebreathing	VBG	B-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
young	JJ	I-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
test	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
NaCl	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
i.v.	JJ	B-ADJP	O
;	:	O	O
during	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
test	NN	I-NP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
of	IN	B-PP	O
hCRH	NN	B-NP	O
or	CC	O	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
of	IN	B-PP	O
TRH	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
i.v.	JJ	B-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
NaCl	NN	I-NP	O
i.v.	JJ	B-ADJP	O
during	IN	B-PP	O
both	CC	O	O
rebreathing	VBG	B-VP	O
manoeuvres	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
CO2	NN	I-NP	O
-	HYPH	O	O
response	NN	B-NP	O
curves	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
tests	NNS	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
subject	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
hCRH	NN	I-NP	O
group	NN	I-NP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
parallel	JJ	I-NP	O
shift	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
CO2	NN	I-NP	O
-	HYPH	B-NP	O
response	NN	I-NP	O
curve	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
left	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
hCRH	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
same	JJ	I-NP	O
effect	NN	I-NP	O
occurred	VBD	B-VP	O
following	VBG	I-VP	O
TRH	NN	B-NP	O
but	CC	O	O
was	VBD	B-VP	O
less	RBR	B-ADJP	O
striking	JJ	I-ADJP	O
.	.	O	O
hCRH	NN	B-NP	O
and	CC	I-NP	O
TRH	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CO2	NN	I-NP	O
threshold	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
CO2	NN	I-NP	O
-	HYPH	O	O
response	NN	B-NP	O
curves	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
nearly	RB	B-ADJP	O
identical	JJ	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
an	DT	B-NP	O
additive	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
releasing	VBG	I-NP	O
hormones	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
hypercapnic	JJ	I-NP	B
ventilatory	JJ	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
,	,	O	O
presumably	RB	B-ADJP	O
independent	JJ	I-ADJP	O
of	IN	B-PP	O
central	JJ	B-NP	O
chemosensitivity	NN	I-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
suppressing	VBG	B-VP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
DNA	NN	I-NP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
hepatitis	NN	I-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
carriers	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
num	CD	I-NP	O
'	SYM	I-NP	O
,	,	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
dideoxy	NN	I-NP	O
cytosine	NN	I-NP	O
analogue	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
potent	JJ	B-NP	O
inhibitory	JJ	I-NP	O
effects	NNS	I-NP	B
on	IN	B-PP	I
hepatitis	NN	B-NP	O
B	NN	I-NP	O
virus	NN	I-NP	O
replication	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
assess	VB	I-VP	O
its	PRP$	B-NP	O
effectiveness	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
hepatitis	NN	I-NP	O
B	NN	I-NP	O
surface	NN	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
HBsAg	NN	B-NP	O
)	)	O	O
carriers	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
Chinese	JJ	I-NP	O
HBsAg	NN	I-NP	O
carriers	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	I-VP	O
receive	VB	I-VP	O
placebo	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
or	CC	O	O
lamivudine	NN	B-NP	O
orally	RB	B-ADVP	O
in	IN	B-PP	O
dosages	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
daily	JJ	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
for	IN	B-PP	O
each	DT	B-NP	O
dosage	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
closely	RB	I-VP	O
monitored	VBN	I-VP	O
clinically	RB	B-ADVP	O
,	,	O	O
biochemically	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
serologically	RB	B-ADVP	O
up	IN	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
drug	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
lamivudine	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
DNA	NN	B-NP	O
values	NNS	I-NP	O
of	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
was	VBD	B-VP	O
slightly	RB	B-ADJP	O
less	RBR	I-ADJP	O
effective	JJ	I-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
still	RB	B-ADVP	O
induced	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
suppression	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
DNA	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
fourth	JJ	I-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

HBV	NN	B-NP	O
DNA	NN	I-NP	O
values	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
pretreatment	NN	B-NP	O
levels	NNS	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
e	NN	I-NP	O
antigen	NN	I-NP	O
status	NN	I-NP	O
or	CC	B-PP	O
in	IN	B-PP	O
aminotransferase	NN	B-NP	O
levels	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
lamivudine	NN	B-NP	O
was	VBD	B-VP	O
safe	JJ	B-ADJP	O
and	CC	I-ADJP	O
effective	JJ	I-ADJP	O
in	IN	B-PP	O
suppression	NN	B-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
DNA	NN	I-NP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
HBsAg	NN	I-NP	O
carriers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
suppression	NN	I-NP	O
was	VBD	B-VP	O
>	SYM	B-ADJP	O
num	CD	B-NP	O
%	NN	I-NP	O
but	CC	O	O
reversible	JJ	B-ADJP	O
.	.	O	O

Studies	NNS	B-NP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lamivudine	NN	I-NP	O
administration	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
performed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
prolonged	JJ	B-NP	O
suppression	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
DNA	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
achieved	VBN	I-VP	O
.	.	O	O

Population	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
study	NN	B-NP	O
of	IN	B-PP	O
risk	NN	B-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
various	JJ	B-NP	O
oral	JJ	I-NP	O
contraceptives	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
studies	NNS	I-NP	O
published	VBN	B-VP	O
since	IN	B-PP	O
December	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
reported	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
(	(	O	O
VTE	NN	B-NP	B
)	)	O	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
women	NNS	B-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
oral	JJ	B-NP	O
contraceptives	NNS	I-NP	O
(	(	O	O
OCs	NNS	B-NP	O
)	)	O	O
containing	VBG	B-VP	O
the	DT	B-NP	O
third	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
progestagens	NNS	I-NP	O
gestodene	NN	I-NP	O
or	CC	I-NP	O
desogestrel	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
OCs	NNS	B-NP	O
containing	VBG	B-VP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
progestagens	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
confounding	VBG	B-NP	O
and	CC	I-NP	O
bias	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
design	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
affected	VBN	I-VP	O
the	DT	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
re	VB	I-VP	O
-	HYPH	O	O
examine	VB	B-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
risk	NN	B-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
and	CC	I-NP	O
OC	NN	I-NP	O
use	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
different	JJ	I-NP	O
study	NN	I-NP	O
design	NN	I-NP	O
and	CC	O	O
analysis	NN	B-NP	O
to	TO	B-VP	O
avoid	VB	I-VP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bias	NN	I-NP	O
and	CC	O	O
confounding	VBG	B-VP	O
of	IN	B-PP	O
the	DT	B-NP	O
earlier	JJR	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
computer	NN	B-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
general	JJ	I-NP	O
practices	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
UK	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
based	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
of	IN	B-PP	O
about	IN	B-NP	O
num	CD	I-NP	O
women	NNS	I-NP	O
born	VBN	B-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

All	DT	B-NP	O
women	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
recorded	VBN	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
deep	JJ	B-NP	B
-	HYPH	I-NP	I
vein	NN	I-NP	I
thrombosis	NN	I-NP	I
,	,	O	O
venous	JJ	B-NP	B
thrombosis	NN	I-NP	I
not	RB	B-VP	O
otherwise	RB	I-VP	O
specified	VBN	I-VP	O
,	,	O	O
or	CC	O	O
pulmonary	JJ	B-NP	O
embolus	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
and	CC	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
anticoagulant	NN	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
as	IN	B-PP	O
potential	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
did	VBD	B-VP	O
a	DT	B-NP	O
cohort	JJ	I-NP	O
analysis	NN	I-NP	O
to	TO	B-VP	O
estimate	VB	I-VP	O
and	CC	I-VP	O
compare	VB	I-VP	O
incidence	NN	B-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
main	JJ	I-NP	O
OC	NN	I-NP	O
preparations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
nested	VBN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
calculate	VB	I-VP	O
the	DT	B-NP	O
odds	NNS	I-NP	O
ratios	NNS	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
different	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
OC	NN	B-NP	O
,	,	O	O
after	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
confounding	VBG	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
matched	VBD	B-VP	O
cases	NNS	B-NP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
by	IN	B-PP	O
exact	JJ	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
birth	NN	B-NP	O
,	,	O	O
practice	NN	B-NP	O
,	,	O	O
and	CC	O	O
current	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
OCs	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
a	DT	B-NP	O
multiple	JJ	I-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
model	NN	I-NP	O
that	WDT	B-NP	O
included	VBD	B-VP	O
body	NN	B-NP	O
-	HYPH	B-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
,	,	O	O
number	NN	B-NP	O
of	IN	B-PP	O
cycles	NNS	B-NP	O
,	,	O	O
change	NN	B-NP	O
in	IN	B-PP	O
type	NN	B-NP	O
of	IN	B-PP	O
OC	NN	B-NP	O
prescribed	VBN	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
event	NN	I-NP	O
,	,	O	O
previous	JJ	B-NP	O
pregnancy	NN	I-NP	O
,	,	O	O
and	CC	O	O
concurrent	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
women	NNS	I-NP	O
met	VBD	B-VP	O
the	DT	B-NP	O
inclusion	NN	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
VTE	NNP	B-NP	B
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
users	NNS	B-NP	O
of	IN	B-PP	O
progestagen	NN	B-NP	O
-	HYPH	O	O
only	JJ	B-NP	O
OCs	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
combined	JJ	B-NP	O
OCs	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
as	IN	B-PP	O
deep	JJ	B-NP	B
-	HYPH	I-NP	I
vein	NN	I-NP	I
thrombosis	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
as	IN	B-PP	O
pulmonary	JJ	B-NP	O
thrombosis	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
as	IN	B-SBAR	O
venous	JJ	B-NP	B
thrombosis	NN	I-NP	I
not	RB	B-VP	O
otherwise	RB	I-VP	O
specified	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
crude	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
per	IN	B-PP	O
num	CD	B-NP	O
woman	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
in	IN	B-PP	O
current	JJ	B-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
OC	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
OCs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
adjustment	NN	B-NP	O
for	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
rate	NN	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
OCs	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Logistic	JJ	B-NP	O
regression	NN	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
between	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
and	CC	I-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
OCs	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
progestagens	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VTE	NN	B-NP	B
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
desogestrel	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
ethinyloestradiol	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
gestodene	NN	B-NP	O
or	CC	I-NP	O
desogestrel	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
ethinyloestradiol	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
all	DT	B-NP	O
second	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
OCs	NNS	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
reference	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
odds	NNS	I-NP	O
ratios	NNS	I-NP	O
for	IN	B-PP	O
VTE	NNP	B-NP	B
were	VBD	B-VP	O
num	CD	B-NP	O
for	IN	B-PP	O
desogestrel	NN	B-NP	O
plus	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
ethinyloestradiol	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
third	JJ	I-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
progestagens	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
previously	RB	I-NP	O
reported	VBN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
third	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
OCs	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
second	JJ	B-NP	O
-	HYPH	I-NP	O
generation	NN	I-NP	O
products	NNS	I-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
residual	JJ	B-NP	O
confounding	NN	I-NP	O
by	IN	B-PP	O
age	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
increased	VBN	I-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
products	NNS	B-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
micrograms	NNS	I-NP	O
ethinyloestradiol	NN	I-NP	O
and	CC	I-NP	O
desogestrel	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
micrograms	NNS	I-NP	O
product	NN	I-NP	O
is	VBZ	B-VP	O
biologically	RB	B-ADJP	O
implausible	JJ	I-ADJP	O
,	,	O	O
and	CC	O	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
preferential	JJ	B-NP	O
prescribing	NN	I-NP	O
and	CC	O	O
,	,	O	O
thus	RB	B-ADVP	O
,	,	O	O
confounding	VBG	B-VP	O
.	.	O	O

MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
augments	NNS	I-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
electrographic	JJ	I-NP	O
seizure	NN	I-NP	B
but	CC	O	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
brain	NN	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rats.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
anticonvulsant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
MK	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
model	NN	I-NP	O
.	.	O	O

Intraperitoneal	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
induced	VBD	B-VP	O
tonic	JJ	B-NP	B
and	CC	I-NP	I
clonic	JJ	I-NP	I
seizure	NN	I-NP	I
.	.	O	O

Scopolamine	NN	B-NP	O
and	CC	I-NP	O
pentobarbital	NN	I-NP	O
prevented	VBD	B-VP	O
development	NN	B-NP	O
of	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
behavioral	JJ	I-NP	O
seizure	NN	I-NP	B
but	CC	I-NP	O
MK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
did	VBD	B-VP	O
not.	RB	B-NP	O
num	CD	I-NP	O
.	.	O	O

An	DT	B-NP	O
electrical	JJ	I-NP	O
seizure	NN	I-NP	B
measured	VBN	B-VP	O
with	IN	B-PP	O
hippocampal	JJ	B-NP	O
EEG	NN	I-NP	O
appeared	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Scopolamine	NN	B-NP	O
and	CC	I-NP	O
pentobarbital	NN	I-NP	O
blocked	VBD	B-VP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
electrographic	JJ	I-NP	O
seizure	NN	I-NP	B
,	,	O	O
MK	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
treatment	NN	I-NP	O
augmented	VBD	B-VP	O
the	DT	B-NP	O
electrographic	JJ	I-NP	O
seizure	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Brain	NN	B-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
examining	VBG	B-VP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
microscopically	RB	B-ADVP	O
.	.	O	O

Pilocarpine	NN	B-NP	O
produced	VBD	B-VP	O
neuronal	JJ	B-NP	B
death	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
showed	VBD	B-VP	O
pyknotic	JJ	B-NP	O
changes	NNS	I-NP	O
.	.	O	O

Pentobarbital	NN	B-NP	O
,	,	I-NP	O
scopolamine	NN	I-NP	O
and	CC	I-NP	O
MK	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
protected	VBD	B-VP	O
the	DT	B-NP	O
brain	NN	I-NP	B
damage	NN	I-NP	I
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
,	,	O	O
though	IN	B-SBAR	O
in	IN	B-PP	O
the	DT	B-NP	O
MK	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
pyramidal	JJ	I-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
hippocampus	NN	B-NP	O
appeared	VBD	B-VP	O
darker	RBR	B-ADVP	O
than	IN	B-PP	O
normal	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
treatments	NNS	I-NP	O
,	,	O	O
granule	JJ	B-NP	O
cells	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
affected.	RB	B-ADVP	O
num	CD	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
is	VBZ	B-VP	O
initiated	VBN	I-VP	O
by	IN	B-PP	O
cholinergic	JJ	B-NP	O
overstimulation	NN	I-NP	O
and	CC	O	O
propagated	VBN	B-VP	O
by	IN	B-PP	O
glutamatergic	JJ	B-NP	O
transmission	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
elevation	NN	I-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
brain	NN	B-NP	B
damage	NN	I-NP	I
through	IN	B-PP	O
an	DT	B-NP	O
excitatory	JJ	I-NP	O
NMDA	NN	I-NP	O
receptor	NN	I-NP	O
-	HYPH	B-VP	O
mediated	VBN	B-NP	O
mechanism	NN	I-NP	O
.	.	O	O

Paclitaxel	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
,	,	O	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
:	:	O	O
BRE	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial.	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
Fluorouracil	NN	I-NP	O
plus	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
and	CC	O	O
paclitaxel	NN	B-NP	O
(	(	O	O
Taxol	NN	B-NP	O
;	:	O	O
Bristol	NNP	B-NP	O
-	:	O	O
Myers	NNP	B-NP	O
Squibb	NNP	I-NP	O
Company	NNP	I-NP	O
,	,	O	O
Princeton	NNP	B-NP	O
,	,	O	O
NJ	NNP	B-NP	O
)	)	O	O
are	VBP	B-VP	O
effective	JJ	B-NP	O
salvage	NN	I-NP	O
therapies	NNS	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

Paclitaxel	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
have	VBP	B-VP	O
additive	JJ	B-NP	O
cytotoxicity	NN	I-NP	B
in	IN	B-PP	O
MCF	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
cell	NN	I-NP	O
lines	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
hour	NN	I-NP	O
before	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m2	NN	I-NP	O
on	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
every	DT	B-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
(	(	O	O
TFL	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Analysis	NN	B-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
who	WP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
of	IN	B-PP	O
TFL	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
requiring	VBG	I-NP	O
hospitalization	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
cycles	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
required	VBD	B-VP	O
granulocyte	NN	B-NP	O
colony	NN	I-NP	O
-	HYPH	O	O
stimulating	VBG	B-VP	O
factor	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
neutropenia	NN	B-NP	B
;	:	O	O
no	DT	B-NP	O
patient	NN	I-NP	O
required	VBD	B-VP	O
platelet	NN	B-NP	O
transfusions	NNS	I-NP	O
.	.	O	O

Grade	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
nonhematologic	JJ	I-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
uncommon	JJ	B-ADJP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
complete	JJ	I-NP	O
responses	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
partial	JJ	I-NP	O
responses	NNS	I-NP	O
for	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
evaluable	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
prior	JJ	B-NP	O
doxorubicin	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
responded	VBD	B-VP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
without	IN	B-PP	O
prior	JJ	B-NP	O
doxorubicin	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
paclitaxel	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
completion	NN	I-NP	O
of	IN	B-PP	O
paclitaxel	NN	B-NP	O
infusion	NN	I-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

TFL	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
active	JJ	I-NP	O
,	,	I-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
tolerated	VBN	I-NP	O
regimen	NN	I-NP	O
in	IN	B-PP	O
metastatic	JJ	B-NP	O
breast	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Efficacy	NN	B-NP	O
and	CC	I-NP	O
proarrhythmia	NN	I-NP	B
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
for	IN	B-PP	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachyarrhythmias	NNS	I-NP	I
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
efficacy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
presumable	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
for	IN	B-PP	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachyarrhythmias	NNS	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
dilated	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
)	)	O	O
with	IN	B-PP	O
inducible	JJ	B-NP	O
sustained	JJ	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
or	CC	O	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
received	VBD	B-VP	O
oral	JJ	B-NP	O
d	NN	I-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
induction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	B
tachyarrhythmia	NN	I-NP	I
.	.	O	O

During	IN	B-PP	O
oral	JJ	B-NP	O
loading	NN	I-NP	O
with	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
sotalol	NN	I-NP	O
,	,	O	O
continuous	JJ	B-NP	O
electrocardiographic	JJ	I-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
monitoring	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

Those	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
prevented	VBD	B-VP	O
induction	NN	B-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
or	CC	O	O
ventricular	JJ	B-NP	B
fibrillation	NN	I-NP	I
were	VBD	B-VP	O
discharged	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
followed	VBD	B-VP	O
up	RP	B-PRT	O
on	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
basis	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	B
tachyarrhythmia	NN	I-NP	I
was	VBD	B-VP	O
prevented	VBN	I-VP	O
by	IN	B-PP	O
oral	JJ	B-NP	O
d	NN	I-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
ventricular	JJ	I-NP	B
tachyarrhythmia	NN	I-NP	I
remained	VBD	B-VP	O
inducible	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
;	:	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
even	RB	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
sotalol	NN	I-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
from	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
during	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
oral	JJ	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
sotalol	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
ECG	NN	B-NP	O
[	(	O	O
sinus	NN	B-NP	O
-	HYPH	O	O
cycle	NN	B-NP	O
length	NN	I-NP	O
(	(	O	O
SCL	NN	B-NP	O
)	)	O	O
,	,	O	O
QT	NN	B-NP	O
or	CC	O	O
QTc	NN	B-NP	O
interval	NN	I-NP	O
,	,	O	O
or	CC	O	O
U	NN	B-NP	O
wave	NN	I-NP	O
]	)	O	O
nor	CC	O	O
clinical	JJ	B-NP	O
parameters	NNS	I-NP	O
identified	VBD	B-VP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
.	.	O	O

Risk	NN	B-NP	O
factors	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	I-NP	I
pointes	NNS	I-NP	I
were	VBD	B-VP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
U	NN	I-NP	O
wave	NN	I-NP	O
,	,	O	O
female	JJ	B-NP	O
gender	NN	I-NP	O
,	,	O	O
and	CC	O	O
significant	JJ	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
corrected	VBN	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
SCL	NN	B-NP	O
,	,	O	O
QT	NN	B-NP	O
interval	NN	I-NP	O
,	,	O	O
and	CC	O	O
QTc	NN	B-NP	O
interval	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
nonfatal	JJ	I-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
recurrence	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
suddenly	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	O
cardiac	JJ	I-NP	B
disease	NN	I-NP	I
had	VBD	B-VP	O
recurrent	JJ	B-NP	O
torsades	NNS	I-NP	B
de	IN	I-NP	I
pointes	NNS	I-NP	I
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
successful	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
sotalol	NN	I-NP	O
.	.	O	O

Torsades	NNP	B-NP	B
de	IN	I-NP	I
pointes	NNS	I-NP	I
occurred	VBD	B-VP	O
early	RB	B-ADVP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
even	RB	B-ADVP	O
with	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
d	NN	I-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	I-NP	O
sotalol	NN	I-NP	O
.	.	O	O

Pronounced	VBN	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
surface	NN	I-NP	O
ECG	NN	I-NP	O
(	(	O	O
cycle	NN	B-NP	O
length	NN	I-NP	O
,	,	O	O
QT	NN	B-NP	O
,	,	O	O
and	CC	O	O
QTc	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
d	NN	I-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
might	MD	B-VP	O
identify	VB	I-VP	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
.	.	O	O

Other	JJ	B-NP	O
ECG	NN	I-NP	O
parameters	NNS	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
identify	VB	I-VP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
.	.	O	O

Recurrence	NN	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
ventricular	JJ	B-NP	B
tachyarrhythmias	NNS	I-NP	I
are	VBP	B-VP	O
high	JJ	B-ADJP	O
despite	IN	B-PP	O
complete	JJ	B-NP	O
suppression	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arrhythmia	NN	I-NP	B
during	IN	B-PP	O
programmed	VBN	B-NP	O
stimulation	NN	I-NP	O
.	.	O	O

Therefore	RB	B-NP	O
programmed	VBN	I-NP	O
electrical	JJ	I-NP	O
stimulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
,	,	O	O
l	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
limited	JJ	B-NP	O
prognostic	JJ	I-NP	O
value	NN	I-NP	O
.	.	O	O

Chronic	JJ	B-NP	O
hyperprolactinemia	NN	I-NP	B
and	CC	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
dopamine	NN	B-NP	O
neurons	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
tuberoinfundibular	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
(	(	O	O
TIDA	NN	B-NP	O
)	)	O	O
system	NN	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
prolactin	NN	B-NP	O
(	(	O	O
PRL	NN	B-NP	O
)	)	O	O
secretion	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
young	JJ	B-NP	O
animals	NNS	I-NP	O
this	DT	B-NP	O
system	NN	I-NP	O
responds	VBZ	B-VP	O
to	TO	B-PP	O
acute	JJ	B-NP	O
elevations	NNS	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
PRL	NN	I-NP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
its	PRP$	B-NP	O
activity	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
this	DT	B-NP	O
responsiveness	NN	I-NP	O
is	VBZ	B-VP	O
lost	VBN	I-VP	O
in	IN	B-PP	O
aging	VBG	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
chronically	RB	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
PRL	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
induce	VB	I-VP	O
hyperprolactinemia	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
for	IN	B-PP	O
extended	VBN	B-NP	O
periods	NNS	I-NP	O
of	IN	B-PP	O
time	NN	B-NP	O
and	CC	O	O
examine	VB	B-VP	O
its	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
dopaminergic	JJ	B-NP	O
systems	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

Hyperprolactinemia	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
and	CC	O	O
Palkovits	VBZ	B-VP	O
s	NN	B-NP	O
microdissection	NN	I-NP	O
technique	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
performance	NN	I-NP	O
liquid	NN	I-NP	O
chromatography	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
measure	VB	I-VP	O
neurotransmitter	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
several	JJ	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
,	,	O	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
concentrations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
median	NN	I-NP	O
eminence	NN	I-NP	O
(	(	O	O
ME	NN	B-NP	O
)	)	O	O
increased	VBD	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
produced	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
DA	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ME	NN	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
DA	NN	B-NP	O
response	NN	I-NP	O
was	VBD	B-VP	O
lost	VBN	I-VP	O
if	IN	B-SBAR	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
long	JJ	I-NP	O
haloperidol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperprolactinemia	NN	I-NP	B
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
month	NN	I-NP	O
-	HYPH	O	O
long	RB	B-NP	O
extremely	RB	I-NP	O
high	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
PRL	NN	I-NP	O
levels	NNS	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
implantation	NN	B-NP	O
of	IN	B-PP	O
MMQ	NN	B-NP	O
cells	NNS	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
capsule	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
DA	NN	B-NP	O
,	,	O	O
norepinephrine	NN	B-NP	O
(	(	O	O
NE	NN	B-NP	O
)	)	O	O
,	,	O	O
serotonin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
)	)	O	O
,	,	O	O
or	CC	O	O
their	PRP$	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
arcuate	JJ	I-NP	O
nucleus	NN	I-NP	O
(	(	O	O
AN	NN	B-NP	O
)	)	O	O
,	,	O	O
medial	JJ	B-NP	O
preoptic	JJ	I-NP	O
area	NN	I-NP	O
(	(	O	O
MPA	NN	B-NP	O
)	)	O	O
,	,	O	O
caudate	JJ	B-NP	O
putamen	NNS	I-NP	O
(	(	O	O
CP	NN	B-NP	O
)	)	O	O
,	,	O	O
substantia	NN	B-NP	O
nigra	NN	I-NP	O
(	(	O	O
SN	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
zona	NN	B-NP	O
incerta	NN	I-NP	O
(	(	O	O
ZI	NN	B-NP	O
)	)	O	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxyindoleacetic	JJ	I-NP	O
acid	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HIAA	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
AN	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
DA	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
AN	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
hyperprolactinemia	NN	B-NP	B
specifically	RB	B-ADVP	O
affects	VBZ	B-VP	O
TIDA	NN	B-NP	O
neurons	NNS	I-NP	O
and	CC	O	O
these	DT	B-NP	O
effects	NNS	I-NP	O
vary	VBP	B-VP	O
,	,	O	O
depending	VBG	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
and	CC	I-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
hyperprolactinemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
age	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hypothalamic	JJ	B-NP	O
dopamine	NN	I-NP	O
function	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
PRL	NN	B-NP	O
secretion	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-VP	O
disseminated	VBN	I-VP	O
necrotizing	VBG	B-VP	O
leukoencephalopathy	NN	B-NP	B
with	IN	B-PP	O
characteristic	JJ	B-NP	O
contrast	NN	I-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
describes	VBZ	B-VP	O
unique	JJ	B-NP	O
contrast	NN	I-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
on	IN	B-PP	O
T1	NN	B-NP	O
-	HYPH	O	O
weighted	VBN	B-VP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
images	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
disseminated	VBN	B-NP	O
necrotizing	VBG	I-NP	O
leukoencephalopathy	NN	I-NP	B
,	,	O	O
which	WDT	B-NP	O
developed	VBD	B-VP	O
from	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
methotrexate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
enhancement	NN	I-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
near	IN	B-PP	O
the	DT	B-NP	O
base	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
than	IN	B-PP	O
at	IN	B-PP	O
the	DT	B-NP	O
vertex	NN	I-NP	O
.	.	O	O

Necropsy	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
revealed	VBD	B-VP	O
loss	NN	B-NP	B
of	IN	B-PP	I
myelination	NN	B-NP	I
and	CC	I-NP	O
necrosis	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
.	.	O	O

Possible	JJ	B-NP	O
mechanisms	NNS	I-NP	O
causing	VBG	B-VP	O
such	JJ	B-NP	O
a	DT	I-NP	O
leukoencephalopathy	NN	I-NP	B
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Thrombotic	JJ	B-NP	B
complications	NNS	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
during	IN	B-PP	O
all	DT	B-NP	O
-	HYPH	I-NP	O
trans	AFX	I-NP	O
-	HYPH	I-NP	O
retinoic	JJ	B-NP	O
acid	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
,	,	O	O
due	IN	B-PP	O
to	TO	I-PP	O
occlusion	NN	B-NP	B
of	IN	B-PP	I
renal	JJ	B-NP	I
vessels	NNS	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
promyelocytic	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
APL	NN	B-NP	B
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
all	DT	B-NP	O
-	HYPH	I-NP	O
trans	AFX	I-NP	O
-	HYPH	I-NP	O
retinoic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
ATRA	NN	B-NP	O
)	)	O	O
and	CC	O	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
recently	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
in	IN	B-PP	O
an	DT	B-NP	O
APL	NN	I-NP	B
patient	NN	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ATRA	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
further	RBR	B-ADVP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
concern	NN	I-NP	O
about	IN	B-PP	O
thromboembolic	JJ	B-NP	B
complications	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
ATRA	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
APL	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
,	,	O	O
presented	VBD	B-VP	O
all	PDT	B-NP	O
the	DT	I-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
APL	NN	B-NP	B
and	CC	O	O
was	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
treatment	NN	I-NP	O
protocol	NN	I-NP	O
with	IN	B-PP	O
ATRA	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
that	WDT	B-NP	O
was	VBD	B-VP	O
completely	RB	B-ADJP	O
reversible	JJ	I-ADJP	O
after	IN	B-PP	O
complete	JJ	B-NP	O
remission	NN	I-NP	O
of	IN	B-PP	O
APL	NN	B-NP	B
was	VBD	B-VP	O
achieved	VBN	I-VP	O
and	CC	O	O
therapy	NN	B-NP	O
discontinued	VBN	B-VP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
ATRA	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
valid	JJ	I-NP	O
therapeutic	JJ	I-NP	O
choice	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
APL	NN	B-NP	B
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
procoagulant	JJ	I-NP	O
tendency	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
completely	RB	B-ADJP	O
corrected	VBN	I-ADJP	O
.	.	O	O

Thrombotic	JJ	B-NP	B
events	NNS	I-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
could	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
by	IN	B-PP	O
using	VBG	B-VP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
heparin	NN	I-NP	O
.	.	O	O

Pupillary	JJ	B-NP	O
changes	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
stimulant	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mania	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
subject	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
study	NN	I-NP	O
evaluating	VBG	B-VP	O
the	DT	B-NP	O
anticraving	VBG	I-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
stimulant	JJ	I-NP	O
medication	NN	I-NP	O
diethylpropion	NN	I-NP	O
(	(	O	O
DEP	NN	B-NP	O
)	)	O	O
became	VBD	B-VP	O
manic	JJ	B-ADJP	B
during	IN	B-PP	O
his	PRP$	B-NP	O
second	JJ	I-NP	O
week	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
drug	NN	I-NP	O
.	.	O	O

Pupillometric	JJ	B-NP	O
changes	NNS	I-NP	O
while	IN	B-SBAR	O
on	IN	B-PP	O
DEP	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
power	NN	I-NP	O
of	IN	B-PP	O
pupillary	JJ	B-NP	B
oscillation	NN	I-NP	I
,	,	O	O
were	VBD	B-VP	O
dramatically	RB	B-ADJP	O
different	JJ	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
observed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
other	JJ	I-NP	O
study	NN	I-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
become	VB	I-VP	O
manic	JJ	B-ADJP	B
.	.	O	O

The	DT	B-NP	O
large	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
total	JJ	B-NP	O
power	NN	I-NP	O
of	IN	B-PP	O
pupillary	JJ	B-NP	B
oscillation	NN	I-NP	I
occurred	VBD	B-VP	O
a	DT	B-NP	O
few	JJ	I-NP	O
days	NNS	I-NP	O
before	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
became	VBD	B-VP	O
fully	RB	B-ADJP	O
manic	JJ	I-ADJP	B
.	.	O	O

Such	JJ	B-NP	O
medication	NN	I-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
total	JJ	I-NP	O
power	NN	I-NP	O
of	IN	B-PP	O
pupillary	JJ	B-NP	B
oscillation	NN	I-NP	I
might	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
utility	NN	B-NP	O
in	IN	B-PP	O
identifying	VBG	B-VP	O
persons	NNS	B-NP	O
at	IN	B-PP	O
risk	NN	B-NP	O
for	IN	B-PP	O
manic	JJ	B-NP	B
-	HYPH	I-NP	O
like	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
psychomotor	NN	B-NP	O
stimulants	NNS	I-NP	O
or	CC	O	O
sympathomimetic	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
negative	JJ	I-NP	O
mucosal	JJ	I-NP	O
potential	NN	I-NP	O
:	:	O	O
separating	VBG	B-VP	O
central	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
NSAIDs	NNS	B-NP	O
in	IN	B-PP	O
man	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
wanted	VBD	B-VP	O
to	TO	I-VP	O
test	VB	I-VP	O
whether	IN	B-SBAR	O
assessment	NN	B-NP	O
of	IN	B-PP	O
both	CC	O	O
a	DT	B-NP	O
central	JJ	I-NP	O
pain	NN	I-NP	B
-	HYPH	B-VP	O
related	VBN	B-NP	O
signal	NN	I-NP	O
(	(	O	O
chemo	AFX	B-NP	O
-	HYPH	I-NP	O
somatosensory	JJ	I-NP	O
evoked	VBN	I-NP	O
potential	NN	I-NP	O
,	,	I-NP	O
CSSEP	NN	I-NP	O
)	)	O	O
and	CC	O	O
a	DT	B-NP	O
concomitantly	RB	I-NP	O
recorded	VBN	I-NP	O
peripheral	JJ	I-NP	O
signal	NN	I-NP	O
(	(	O	O
negative	JJ	B-NP	O
mucosal	JJ	I-NP	O
potential	NN	I-NP	O
,	,	O	O
NMP	NN	B-NP	O
)	)	O	O
allows	VBZ	B-VP	O
for	IN	B-PP	O
separation	NN	B-NP	O
of	IN	B-PP	O
central	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
NSAIDs	NNS	B-NP	O
.	.	O	O

For	IN	B-PP	O
this	DT	B-NP	O
purpose	NN	I-NP	O
,	,	O	O
experimental	JJ	B-NP	O
conditions	NNS	I-NP	O
were	VBD	B-VP	O
created	VBN	I-VP	O
in	IN	B-PP	O
which	WDT	B-NP	O
NSAIDs	NNS	B-NP	O
had	VBD	B-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
to	TO	B-VP	O
produce	VB	I-VP	O
effects	NNS	B-NP	O
on	IN	B-PP	O
phasic	JJ	B-NP	O
and	CC	I-NP	O
tonic	JJ	I-NP	O
pain	NN	I-NP	B
by	IN	B-PP	O
either	CC	B-NP	O
central	JJ	I-NP	O
or	CC	I-NP	O
peripheral	JJ	I-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	O	O
randomised	VBN	B-VP	O
,	,	O	O
controlled	VBN	B-VP	O
,	,	O	O
threefold	RB	B-ADVP	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
over	IN	B-PP	O
design	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
males	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
females	NNS	I-NP	O
;	:	O	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
received	VBD	B-VP	O
either	CC	O	O
placebo	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
ibuprofen	NN	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
ibuprofen	NN	I-NP	O
.	.	O	O

Phasic	JJ	B-NP	O
pain	NN	I-NP	B
was	VBD	B-VP	O
applied	VBN	I-VP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
short	JJ	B-NP	O
pulses	NNS	I-NP	O
of	IN	B-PP	O
CO2	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
nasal	JJ	I-NP	O
mucosa	NN	I-NP	O
(	(	O	O
stimulus	NN	B-NP	O
duration	NN	I-NP	O
num	CD	B-NP	O
ms	NN	I-NP	O
,	,	O	O
interval	NN	B-NP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
tonic	JJ	B-NP	O
pain	NN	I-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
nasal	JJ	I-NP	O
cavity	NN	I-NP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
dry	JJ	B-NP	O
air	NN	I-NP	O
of	IN	B-PP	O
controlled	VBN	B-NP	O
temperature	NN	I-NP	O
,	,	I-NP	O
humidity	NN	I-NP	O
and	CC	I-NP	O
flow	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
C	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
relative	JJ	I-NP	O
humidity	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
ml.s	NNS	I-NP	O
-	SYM	O	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Both	DT	B-NP	O
CSSEPs	NNS	I-NP	O
as	IN	B-PP	O
central	JJ	B-ADJP	O
and	CC	O	O
NMPs	NNS	B-NP	O
as	IN	B-PP	O
peripheral	JJ	B-NP	O
correlates	NNS	I-NP	O
of	IN	B-PP	O
pain	NN	B-NP	B
were	VBD	B-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
CO2	NN	I-NP	O
stimuli	NNS	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
rated	VBD	B-VP	O
the	DT	B-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
both	CC	B-NP	O
phasic	JJ	I-NP	O
and	CC	I-NP	O
tonic	JJ	I-NP	O
pain	NN	I-NP	B
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
analogue	NN	I-NP	O
scales	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
described	VBN	B-VP	O
earlier	RBR	B-ADVP	O
,	,	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
ibuprofen	NN	B-NP	O
was	VBD	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
tonic	JJ	B-NP	O
pain	NN	I-NP	B
but	CC	O	O
-	HYPH	B-NP	O
relative	JJ	B-ADVP	O
to	TO	B-PP	O
placebo	AFX	O	O
-	HYPH	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
correlates	NNS	B-NP	O
of	IN	B-PP	O
phasic	JJ	B-NP	O
pain	NN	I-NP	B
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ibuprofen	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
pain	NN	I-NP	B
stimuli	NNS	I-NP	O
under	IN	B-PP	O
these	DT	B-NP	O
special	JJ	I-NP	O
experimental	JJ	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
similar	JJ	I-NP	O
behaviour	NN	I-NP	O
of	IN	B-PP	O
CSSEP	NN	B-NP	O
and	CC	I-NP	O
NMP	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
pharmacological	JJ	I-NP	O
process	NN	I-NP	O
underlying	VBG	B-VP	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
was	VBD	B-VP	O
localised	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
periphery	NN	I-NP	O
.	.	O	O

By	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
simultaneous	JJ	I-NP	O
recording	NN	I-NP	O
of	IN	B-PP	O
interrelated	JJ	B-NP	O
peripheral	JJ	I-NP	O
and	CC	I-NP	O
central	JJ	I-NP	O
electrophysiologic	JJ	I-NP	O
correlates	NNS	I-NP	O
of	IN	B-PP	O
nociception	NN	B-NP	O
,	,	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
possible	JJ	B-ADJP	O
to	TO	B-VP	O
separate	VB	I-VP	O
central	JJ	B-NP	O
and	CC	I-NP	O
peripheral	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
NSAID	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
major	JJ	I-NP	O
advantage	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
pain	NN	I-NP	B
model	NN	I-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
obtaining	VBG	B-VP	O
peripheral	JJ	B-NP	O
pain	NN	I-NP	B
-	HYPH	B-VP	O
related	VBN	B-NP	O
activity	NN	I-NP	O
directly	RB	B-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
invasive	JJ	I-NP	O
technique	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

Acute	JJ	B-NP	O
severe	JJ	I-NP	O
depression	NN	I-NP	B
following	VBG	B-PP	O
peri	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
ondansetron	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	B
nausea	NN	I-NP	I
and	CC	I-NP	I
vomiting	NN	I-NP	I
presented	VBN	B-VP	O
for	IN	B-PP	O
abdominal	JJ	B-NP	O
hysterectomy	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
anaesthetic	NN	I-NP	O
where	WRB	B-ADVP	O
ondansetron	NN	B-NP	O
prophylaxis	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
developed	VBN	I-VP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
acute	JJ	I-NP	O
major	JJ	I-NP	B
depression	NN	I-NP	I
disorder	NN	I-NP	I
almost	RB	B-ADVP	O
immediately	RB	I-ADVP	O
thereafter	RB	I-ADVP	O
,	,	O	O
possibly	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
serotonin	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
years	NNS	I-NP	O
before	IN	B-SBAR	O
she	PRP	B-NP	O
had	VBD	B-VP	O
experienced	VBN	I-VP	O
a	DT	B-NP	O
self	NN	I-NP	O
-	HYPH	B-VP	O
limited	VBN	B-NP	O
puerperal	JJ	I-NP	O
depressive	JJ	I-NP	B
episode	NN	I-NP	I
.	.	O	O

Anaesthesia	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
propofol	NN	I-NP	O
infusion	NN	I-NP	O
and	CC	I-NP	O
avoidance	NN	I-NP	O
of	IN	B-PP	O
serotonin	NN	B-NP	O
antagonists	NNS	I-NP	O
provided	VBD	B-VP	O
a	DT	B-NP	O
nausea	NN	I-NP	B
-	HYPH	O	O
free	JJ	B-NP	O
postoperative	JJ	I-NP	O
course	NN	I-NP	O
without	IN	B-PP	O
exacerbation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
depression	NN	I-NP	B
disorder	NN	I-NP	I
.	.	O	O

Hypertensive	JJ	B-NP	B
response	NN	I-NP	O
during	IN	B-PP	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
num	CD	B-NP	O
dobutamine	NN	I-NP	O
stress	NN	I-NP	O
echocardiographic	JJ	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
hypertensive	JJ	I-NP	B
response	NN	I-NP	O
,	,	O	O
defined	VBN	B-VP	O
as	IN	B-PP	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
diastolic	JJ	B-NP	O
BP	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
response	NN	I-NP	O
more	RBR	B-ADVP	O
often	RB	I-ADVP	O
had	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
and	CC	O	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
resting	VBG	I-NP	O
systolic	JJ	I-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
BP	NN	I-NP	O
before	IN	B-PP	O
dobutamine	NN	B-NP	O
infusion	NN	I-NP	O
.	.	O	O

Continuously	RB	B-NP	O
nebulized	VBN	I-NP	O
albuterol	NN	I-NP	O
in	IN	B-PP	O
severe	JJ	B-NP	O
exacerbations	NNS	I-NP	O
of	IN	B-PP	O
asthma	NN	B-NP	B
in	IN	B-PP	O
adults	NNS	B-NP	O
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
retrospective	JJ	I-NP	O
,	,	I-NP	O
case	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
analysis	NN	B-NP	O
comparing	VBG	B-VP	O
patients	NNS	B-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
medical	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
exacerbations	NNS	I-NP	O
of	IN	B-PP	O
asthma	NN	B-NP	B
who	WP	B-NP	O
received	VBD	B-VP	O
continuously	RB	I-VP	O
nebulized	VBN	I-VP	O
albuterol	NN	B-NP	O
(	(	O	O
CNA	NN	B-NP	O
)	)	O	O
versus	IN	B-PP	O
intermittent	JJ	B-NP	O
albuterol	NN	I-NP	O
(	(	O	O
INA	NN	B-NP	O
)	)	O	O
treatments	NNS	B-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
matched	VBN	I-NP	O
pairs	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
asthma	NN	B-NP	B
are	VBP	B-VP	O
compared	VBN	I-VP	O
.	.	O	O

CNA	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
hr	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
dysrhythmias	NNS	I-NP	I
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
between	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

Symptomatic	JJ	B-NP	O
hypokalemia	NN	I-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
occur	VB	I-VP	O
.	.	O	O

CNA	NN	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
heart	NN	I-NP	O
rates	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
reflect	VB	I-VP	O
severity	NN	B-NP	O
of	IN	B-PP	O
illness	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
intubation	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
CNA	NN	B-NP	O
and	CC	I-NP	O
INA	NN	I-NP	O
demonstrated	VBD	B-VP	O
similar	JJ	B-NP	O
profiles	NNS	I-NP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
safety	NN	B-NP	O
,	,	O	O
morbidity	NN	B-NP	O
,	,	O	O
and	CC	O	O
mortality	NN	B-NP	O
.	.	O	O

Hyperosmolar	JJ	B-NP	B
nonketotic	JJ	I-NP	I
coma	NN	I-NP	I
precipitated	VBN	B-VP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrogenic	JJ	I-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
manic	JJ	B-NP	B
depression	NN	I-NP	I
treated	VBN	B-VP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
with	IN	B-PP	O
hyperosmolar	JJ	B-NP	B
,	,	I-NP	I
nonketotic	JJ	I-NP	I
coma	NN	I-NP	I
.	.	O	O

He	PRP	B-NP	O
gave	VBD	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
polyuria	NN	B-NP	B
and	CC	I-NP	O
polydipsia	NN	I-NP	B
,	,	O	O
during	IN	B-PP	O
which	WDT	B-NP	O
time	NN	B-NP	O
urinalysis	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
negative	JJ	B-ADJP	O
for	IN	B-PP	O
glucose	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
recovery	NN	B-NP	O
from	IN	B-PP	O
hyperglycaemia	NN	B-NP	B
,	,	O	O
he	PRP	B-NP	O
remained	VBD	B-VP	O
polyuric	JJ	B-ADJP	B
despite	IN	B-PP	O
normal	JJ	B-NP	O
blood	NN	I-NP	O
glucose	NN	I-NP	O
concentrations	NNS	I-NP	O
;	:	O	O
water	NN	B-NP	O
deprivation	NN	I-NP	O
testing	NN	I-NP	O
indicated	VBD	B-VP	O
nephrogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
,	,	O	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
lithium	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
.	.	O	O

We	PRP	B-NP	O
hypothesize	VBP	B-VP	O
that	IN	B-SBAR	O
when	WRB	B-ADVP	O
this	DT	B-NP	O
man	NN	I-NP	O
developed	VBD	B-VP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
,	,	O	O
chronic	JJ	B-NP	O
polyuria	NNS	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
nephrogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
was	VBD	B-VP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
precipitate	VB	I-VP	O
hyperosmolar	JJ	B-NP	O
dehydration	NN	I-NP	B
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
intracoronary	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
on	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
systolic	JJ	I-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
dogs	NNS	B-NP	O
,	,	O	O
a	DT	B-NP	O
large	JJ	I-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
cocaine	NN	I-NP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
profound	JJ	I-NP	O
deterioration	NN	I-NP	B
of	IN	B-PP	I
left	JJ	B-NP	I
ventricular	JJ	I-NP	I
(	(	O	I
LV	NN	B-NP	I
)	)	I-NP	I
systolic	JJ	I-NP	I
function	NN	I-NP	I
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
LV	NN	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
intracoronary	JJ	I-NP	O
cocaine	NN	I-NP	O
concentration	NN	I-NP	O
on	IN	B-PP	O
LV	NN	B-NP	O
systolic	JJ	I-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
humans	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
referred	VBN	B-VP	O
for	IN	B-PP	O
cardiac	JJ	B-NP	O
catheterization	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
measured	VBD	B-VP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
systemic	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
LV	NN	B-NP	O
pressure	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
first	JJ	I-NP	O
derivative	NN	I-NP	O
(	(	O	O
dP	NN	B-NP	O
/	SYM	O	O
dt	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
LV	NN	B-NP	O
volumes	NNS	I-NP	O
and	CC	O	O
ejection	NN	B-NP	O
fraction	NN	I-NP	O
before	IN	B-PP	O
and	CC	I-PP	O
during	IN	I-PP	O
the	DT	B-NP	O
final	JJ	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
minute	JJ	I-NP	O
intracoronary	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
saline	NN	B-NP	O
or	CC	I-NP	O
cocaine	NN	I-NP	O
hydrochloride	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
variable	JJ	I-NP	O
changed	VBD	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
.	.	O	O

With	IN	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
drug	NN	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
obtained	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
coronary	JJ	I-NP	O
sinus	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
mean	NN	B-NP	O
+	SYM	O	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
mg	NN	B-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
,	,	O	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
magnitude	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
cocaine	NN	I-NP	O
concentration	NN	I-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
abusers	NNS	B-NP	O
dying	VBG	B-VP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
intoxication	NN	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
induced	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
LV	NN	B-NP	O
dP	NN	I-NP	O
/	SYM	B-NP	O
dt	NN	I-NP	O
(	(	O	O
positive	JJ	B-ADJP	O
or	CC	I-ADJP	O
negative	JJ	I-ADJP	O
)	)	O	O
,	,	O	O
or	CC	O	O
LV	NN	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
volume	NN	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
caused	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
systolic	JJ	B-NP	O
and	CC	I-NP	O
mean	JJ	I-NP	O
arterial	JJ	I-NP	O
pressures	NNS	I-NP	O
,	,	O	O
LV	NN	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
and	CC	O	O
LV	NN	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
systolic	JJ	I-NP	O
volume	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
LV	NN	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
humans	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
intracoronary	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
sufficient	JJ	B-ADJP	O
in	IN	B-PP	O
amount	NN	B-NP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
drug	NN	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
coronary	JJ	B-NP	O
sinus	NN	I-NP	O
blood	NN	I-NP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
deterioration	NN	I-NP	B
of	IN	B-PP	I
LV	NN	B-NP	I
systolic	JJ	I-NP	I
and	CC	I-NP	I
diastolic	JJ	I-NP	I
performance	NN	I-NP	I
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
,	,	O	O
paradoxical	JJ	B-NP	O
thromboembolism	NN	I-NP	B
,	,	O	O
and	CC	O	O
other	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
several	JJ	B-NP	O
new	JJ	I-NP	O
anticoagulant	JJ	I-NP	O
drugs	NNS	I-NP	O
are	VBP	B-VP	O
in	IN	B-PP	O
development	NN	B-NP	O
,	,	O	O
heparin	NN	B-NP	O
remains	VBZ	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
for	IN	B-PP	O
most	JJS	B-NP	O
anticoagulation	NN	I-NP	O
needs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
are	VBP	B-VP	O
meritorious	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
side	NN	B-NP	O
effects	NNS	I-NP	O
do	VBP	B-VP	O
exist	VB	I-VP	O
.	.	O	O

Important	JJ	B-NP	O
untoward	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
including	VBG	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
,	,	O	O
heparin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
osteoporosis	NN	B-NP	B
,	,	O	O
eosinophilia	NN	B-NP	B
,	,	O	O
skin	NN	B-NP	B
reactions	NNS	I-NP	I
,	,	O	O
allergic	JJ	B-NP	B
reactions	NNS	I-NP	I
other	JJ	B-ADJP	O
than	IN	B-PP	O
thrombocytopenia	NN	B-NP	B
and	CC	I-NP	O
alopecia	NN	I-NP	B
will	MD	B-VP	O
be	VB	I-VP	O
discussed	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
article	NN	I-NP	O
.	.	O	O

Nonopaque	JJ	B-NP	O
crystal	JJ	I-NP	O
deposition	NN	I-NP	O
causing	VBG	B-VP	O
ureteric	JJ	B-NP	B
obstruction	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
undergoing	VBG	B-VP	O
indinavir	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
unique	JJ	I-NP	O
CT	NN	I-NP	O
features	NNS	I-NP	O
of	IN	B-PP	O
ureteric	JJ	B-NP	B
calculi	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
HIV	NN	I-NP	B
-	HYPH	B-NP	I
infected	VBN	I-NP	I
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
indinavir	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
most	RBS	I-NP	O
commonly	RB	I-NP	O
used	VBN	I-NP	O
HIV	NN	I-NP	O
protease	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
urolithiasis	NN	B-NP	B
.	.	O	O

Ureteric	JJ	B-NP	B
obstruction	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
precipitated	VBN	B-NP	O
indinavir	NN	I-NP	O
crystals	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
difficult	JJ	B-ADJP	O
to	TO	B-VP	O
diagnose	VB	I-VP	O
with	IN	B-PP	O
unenhanced	JJ	B-NP	O
CT	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
calculi	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	O	O
opaque	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
secondary	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
obstruction	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
absent	JJ	B-ADJP	O
or	CC	I-ADJP	O
minimal	JJ	I-ADJP	O
and	CC	O	O
should	MD	B-VP	O
be	VB	I-VP	O
sought	VBN	I-VP	O
carefully	RB	B-ADVP	O
.	.	O	O

Images	NNS	B-NP	O
may	MD	B-VP	O
need	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
obtained	VBN	I-VP	O
using	VBG	B-VP	O
i.v.	JJ	B-NP	O
contrast	NN	I-NP	O
material	NN	I-NP	O
to	TO	B-VP	O
enable	VB	I-VP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
ureteric	JJ	B-NP	B
stones	NNS	I-NP	I
or	CC	O	I
obstruction	NN	B-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	B
infection	NN	I-NP	I
who	WP	B-NP	O
receive	VBP	B-VP	O
indinavir	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Ischemic	JJ	B-NP	B
colitis	NN	I-NP	I
and	CC	I-NP	O
sumatriptan	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

Sumatriptan	NNP	B-NP	O
succinate	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
serotonin	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxytryptamine	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
antimigraine	JJ	I-NP	O
drug	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
act	VB	I-VP	O
by	IN	B-PP	O
selectively	RB	B-VP	O
constricting	VBG	I-VP	O
intracranial	JJ	B-NP	O
arteries	NNS	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
vasopressor	NN	B-NP	O
responses	NNS	I-NP	O
that	WDT	B-NP	O
are	VBP	B-VP	O
distinct	JJ	B-ADJP	O
from	IN	B-PP	O
the	DT	B-NP	O
cranial	JJ	I-NP	O
circulation	NN	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
demonstrated	VBN	I-VP	O
to	TO	I-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
systemic	JJ	I-NP	O
,	,	I-NP	O
pulmonary	JJ	I-NP	O
,	,	O	O
and	CC	O	O
coronary	JJ	B-NP	O
circulations	NNS	I-NP	O
.	.	O	O

Cases	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
published	VBN	I-VP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
vasospasm	NN	I-NP	I
,	,	O	O
myocardial	JJ	B-NP	B
ischemia	NN	I-NP	I
,	,	O	O
and	CC	O	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
occurring	VBG	B-VP	O
after	IN	B-PP	O
sumatriptan	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
serious	JJ	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ischemic	JJ	B-NP	B
colitis	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
migraine	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
sumatriptan	NN	B-NP	O
.	.	O	O

Pallidotomy	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
gamma	NN	I-NP	O
knife	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
positive	JJ	I-NP	O
experience.	NN	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
medically	RB	B-NP	O
refractory	JJ	I-NP	O
Parkinson	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
underwent	VBD	B-VP	O
stereotactic	JJ	B-NP	O
posteromedial	JJ	I-NP	O
pallidotomy	NN	I-NP	O
between	IN	B-PP	O
August	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
February	NNP	B-NP	O
num	CD	I-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
bradykinesia	NN	B-NP	B
,	,	O	O
rigidity	NN	B-NP	B
,	,	O	O
and	CC	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
pallidotomies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Leksell	NNP	I-NP	O
Gamma	NNP	I-NP	O
Knife	NNP	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
num	CD	B-NP	O
they	PRP	B-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
radiofrequency	NN	I-NP	O
(	(	O	O
RF	NN	B-NP	O
)	)	O	O
method	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
assessment	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
blinded	JJ	B-NP	O
ratings	NNS	I-NP	O
of	IN	B-PP	O
Unified	NNP	B-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
UPDRS	NNP	B-NP	O
)	)	O	O
scores	NNS	B-NP	O
were	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
pre	AFX	O	O
-	HYPH	O	O
and	CC	O	O
postoperatively	RB	B-ADVP	O
.	.	O	O

Mean	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
time	NN	B-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
all	DT	B-NP	O
except	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
followed	VBN	I-VP	O
more	RBR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
year.	NN	I-NP	O
num	CD	B-NP	O
percent	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
dyskinesias	NNS	B-NP	B
were	VBD	B-VP	O
relieved	VBN	I-VP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
,	,	O	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
pallidotomies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Gamma	NN	I-NP	O
Knife	NN	I-NP	O
or	CC	I-NP	O
radiofrequency	NN	I-NP	O
methods	NNS	I-NP	O
.	.	O	O

About	IN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
both	CC	O	O
Gamma	NN	B-NP	O
Knife	NN	I-NP	O
and	CC	I-NP	O
radiofrequency	NN	I-NP	O
groups	NNS	I-NP	O
showed	VBD	B-VP	O
improvements	NNS	B-NP	O
in	IN	B-PP	O
bradykinesia	NN	B-NP	B
and	CC	I-NP	O
rigidity	NN	I-NP	B
,	,	O	O
although	IN	B-SBAR	O
when	WRB	B-ADVP	O
considered	VBN	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
neither	CC	O	O
the	DT	B-NP	O
Gamma	NNP	I-NP	O
Knife	NNP	I-NP	O
nor	CC	O	O
the	DT	B-NP	O
radiofrequency	NN	I-NP	O
group	NN	I-NP	O
showed	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
UPDRS	NN	B-NP	O
scores	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Gamma	NN	I-NP	O
Knife	NN	I-NP	O
group	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
homonymous	JJ	I-NP	B
hemianopsia	NN	I-NP	I
num	CD	B-NP	O
months	NNS	I-NP	O
following	VBG	B-PP	O
treatment	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
radiofrequency	NN	I-NP	O
group	NN	I-NP	O
became	VBD	B-VP	O
transiently	RB	B-ADJP	O
confused	VBN	I-ADJP	O
postoperatively	RB	B-ADVP	O
.	.	O	O

No	DT	B-NP	O
other	JJ	I-NP	O
complications	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

Gamma	NN	B-NP	O
Knife	NN	I-NP	O
pallidotomy	NN	I-NP	O
is	VBZ	B-VP	O
as	RB	B-ADJP	O
effective	JJ	I-ADJP	O
as	IN	B-PP	O
radiofrequency	NN	B-NP	O
pallidotomy	NN	I-NP	O
in	IN	B-PP	O
controlling	VBG	B-VP	O
certain	JJ	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
practical	JJ	I-NP	O
technique	NN	I-NP	O
available	JJ	B-ADJP	O
in	IN	B-PP	O
certain	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
those	DT	B-NP	O
who	WP	B-NP	O
take	VBP	B-VP	O
anticoagulants	NNS	B-NP	O
,	,	O	O
have	VBP	B-VP	O
bleeding	VBG	I-VP	B
diatheses	NNS	B-NP	O
or	CC	O	O
serious	JJ	B-NP	O
systemic	JJ	I-NP	O
medical	JJ	I-NP	O
illnesses	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
viable	JJ	I-NP	O
option	NN	I-NP	O
for	IN	B-PP	O
other	JJ	B-NP	O
patients	NNS	I-NP	O
as	RB	B-ADVP	O
well	RB	I-ADVP	O
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
methylphenidate	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	JJ	I-NP	O
presented	VBN	B-VP	O
with	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
probably	RB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
methylphenidate	NN	B-NP	O
.	.	O	O

She	PRP	B-NP	O
had	VBD	B-VP	O
defects	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
supratentorial	JJ	I-NP	O
brain	NN	I-NP	O
including	VBG	B-PP	O
the	DT	B-NP	O
basal	JJ	I-NP	O
ganglia	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
striatum	NN	I-NP	O
(	(	O	O
multicystic	JJ	B-NP	B
encephalomalacia	NN	I-NP	I
)	)	O	O
due	JJ	B-ADJP	O
to	TO	B-VP	O
severe	VB	I-VP	O
perinatal	JJ	B-NP	O
hypoxic	JJ	I-NP	B
-	HYPH	I-NP	I
ischemic	JJ	I-NP	I
encephalopathy	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
predisposing	VBG	I-NP	O
factor	NN	I-NP	O
causing	VBG	B-VP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
dopaminergic	JJ	I-NP	O
blockade	NN	I-NP	O
mechanism	NN	I-NP	O
generally	RB	B-ADVP	O
is	VBZ	B-VP	O
accepted	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
methylphenidate	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
uptake	NN	B-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
,	,	O	O
and	CC	O	O
therefore	RB	B-ADVP	O
dopaminergic	JJ	B-NP	O
systems	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brainstem	NN	I-NP	O
(	(	O	O
mainly	RB	B-ADVP	O
the	DT	B-NP	O
midbrain	NN	I-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
spinal	JJ	I-NP	O
cord	NN	I-NP	O
were	VBD	B-VP	O
unlikely	JJ	B-ADJP	O
to	TO	B-VP	O
participate	VB	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
relative	JJ	I-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
ergic	JJ	I-NP	O
deficiency	NN	I-NP	O
might	MD	B-VP	O
occur	VB	I-VP	O
because	IN	B-SBAR	O
diazepam	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
gamma	SYM	I-NP	O
-	HYPH	I-NP	O
aminobutyric	JJ	B-NP	O
acid	NN	I-NP	O
-	HYPH	B-NP	O
mimetic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
strikingly	RB	B-ADJP	O
effective	JJ	I-ADJP	O
.	.	O	O

This	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
reported	VBN	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
probably	RB	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
methylphenidate	NN	B-NP	O
.	.	O	O

Differential	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
17alpha	NN	B-NP	O
-	HYPH	B-NP	O
ethinylestradiol	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
neutral	JJ	I-NP	O
and	CC	I-NP	O
acidic	JJ	I-NP	O
pathways	NNS	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	O
salt	NN	I-NP	O
synthesis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
17alpha	NN	B-NP	O
-	HYPH	O	O
ethinylestradiol	NN	B-NP	O
(	(	O	O
EE	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
the	DT	B-NP	O
neutral	JJ	I-NP	O
and	CC	I-NP	O
acidic	JJ	I-NP	O
biosynthetic	JJ	I-NP	O
pathways	NNS	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	O
salt	NN	I-NP	O
(	(	O	O
BS	NN	B-NP	O
)	)	O	O
synthesis	NN	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
intact	JJ	I-NP	O
enterohepatic	JJ	I-NP	O
circulation	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
bile	NN	I-NP	O
diversion	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
BS	NN	B-NP	O
synthesis	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
this	DT	B-NP	O
purpose	NN	I-NP	O
,	,	O	O
bile	NN	B-NP	O
salt	NN	I-NP	O
pool	NN	I-NP	O
composition	NN	I-NP	O
,	,	O	O
synthesis	NN	B-NP	O
of	IN	B-PP	O
individual	JJ	B-NP	O
BS	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
,	,	O	O
hepatic	JJ	B-NP	O
activities	NNS	I-NP	O
,	,	O	O
and	CC	O	O
expression	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
cholesterol	NN	B-NP	O
7alpha	NN	I-NP	O
-	HYPH	O	O
hydroxylase	NN	B-NP	O
(	(	O	O
CYP7A	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
sterol	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hydroxylase	NN	I-NP	O
(	(	O	O
CYP27	NN	B-NP	O
)	)	O	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
of	IN	B-PP	O
other	JJ	B-NP	O
enzymes	NNS	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
BS	NN	B-NP	O
synthesis	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
EE	NN	B-NP	O
or	CC	O	O
its	PRP$	B-NP	O
vehicle	NN	I-NP	O
.	.	O	O

BS	NN	B-NP	O
pool	NN	I-NP	O
size	NN	I-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
but	CC	O	O
total	JJ	B-NP	O
BS	NN	I-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
EE	NN	B-NP	O
in	IN	B-PP	O
intact	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Synthesis	NN	B-NP	O
of	IN	B-PP	O
cholate	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
EE	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
that	DT	B-NP	O
of	IN	B-PP	O
chenodeoxycholate	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
recently	RB	I-NP	O
identified	VBN	I-NP	O
Delta22	NN	I-NP	O
-	HYPH	I-NP	O
isomer	NN	I-NP	O
of	IN	B-PP	O
beta	SYM	O	O
-	HYPH	O	O
muricholate	NN	B-NP	O
contributed	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
pool	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
and	CC	I-NP	O
EE	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
but	CC	O	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
bile	NN	B-NP	O
after	IN	B-PP	O
exhaustion	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pool	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
clear	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
BS	NN	B-NP	O
synthesis	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
bile	NN	B-NP	O
-	HYPH	B-NP	O
diverted	VBN	I-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
EE	NN	B-NP	O
,	,	O	O
yet	RB	B-NP	O
biliary	JJ	I-NP	O
BS	NNP	I-NP	O
composition	NN	I-NP	O
was	VBD	B-VP	O
only	RB	I-VP	O
minimally	RB	I-VP	O
affected	VBN	I-VP	O
.	.	O	O

Activity	NN	B-NP	O
of	IN	B-PP	O
CYP7A	NN	B-NP	O
was	VBD	B-VP	O
decreased	VBN	I-VP	O
by	IN	B-PP	O
EE	NN	B-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
intact	JJ	I-NP	O
and	CC	I-NP	O
bile	NN	I-NP	O
-	HYPH	B-NP	O
diverted	VBN	I-NP	O
rats	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
CYP27	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
.	.	O	O

Hepatic	JJ	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
CYP7A	NN	B-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
EE	NN	B-NP	O
in	IN	B-PP	O
bile	NN	B-NP	O
-	HYPH	B-NP	O
diverted	VBN	I-NP	O
rats	NNS	I-NP	O
only	RB	B-ADVP	O
;	:	O	O
CYP27	NN	B-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
EE	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
mRNA	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
sterol	NN	B-NP	O
12alpha	NN	I-NP	O
-	HYPH	B-NP	O
hydroxylase	NN	I-NP	O
and	CC	I-NP	O
lithocholate	NN	I-NP	O
6beta	NN	I-NP	O
-	HYPH	B-NP	O
hydroxylase	NN	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
bile	NN	B-NP	O
diversion	NN	I-NP	O
and	CC	O	O
suppressed	VBN	B-VP	O
by	IN	B-PP	O
EE	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
17alpha	NN	B-NP	O
-	HYPH	O	O
ethinylestradiol	NN	B-NP	O
(	(	O	O
EE	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
intrahepatic	JJ	I-NP	B
cholestasis	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
selective	JJ	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
neutral	JJ	I-NP	O
pathway	NN	I-NP	O
of	IN	B-PP	O
bile	NN	B-NP	O
salt	NN	I-NP	O
(	(	O	O
BS	NN	B-NP	O
)	)	O	O
synthesis	NN	B-NP	O
.	.	O	O

Simultaneous	JJ	B-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
enzymes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
BS	NNP	I-NP	O
biosynthetic	JJ	I-NP	O
pathways	NNS	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
overall	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
EE	NN	B-NP	O
on	IN	B-PP	O
BS	NN	B-NP	O
synthesis	NN	I-NP	O
.	.	O	O

Glibenclamide	NN	B-NP	O
-	HYPH	I-NP	O
sensitive	JJ	I-NP	O
hypotension	NN	I-NP	B
produced	VBN	B-VP	O
by	IN	B-PP	O
helodermin	NN	B-NP	O
assessed	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
helodermin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
basic	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
amino	NN	I-NP	O
acid	NN	I-NP	O
peptide	NN	I-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
venom	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
lizard	NN	I-NP	O
salivary	JJ	I-NP	O
gland	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
,	,	O	O
focusing	VBG	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
ATP	NN	B-NP	O
sensitive	JJ	I-NP	O
K	NN	I-NP	O
+	SYM	B-NP	O
(	(	O	O
K	NN	B-NP	O
(	(	O	O
ATP	NN	B-NP	O
)	)	O	O
)	)	O	O
channels	NNS	B-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
responses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
vasoactive	JJ	B-NP	O
intestinal	JJ	I-NP	O
polypeptide	NN	I-NP	O
(	(	O	O
VIP	NN	B-NP	O
)	)	O	O
.	.	O	O

Helodermin	NN	B-NP	O
produced	VBD	B-VP	O
hypotension	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
with	IN	B-PP	O
approximately	RB	B-NP	O
similar	JJ	I-NP	O
potency	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
to	TO	B-PP	O
VIP	NN	B-NP	O
.	.	O	O

Hypotension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
both	DT	B-NP	O
peptides	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBN	I-VP	O
by	IN	B-PP	O
glibenclamide	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
abolished	VBD	B-VP	O
a	DT	B-NP	O
levcromakalim	NN	I-NP	O
-	HYPH	O	O
produced	VBN	B-VP	O
decrease	NN	B-NP	O
in	IN	B-PP	O
arterial	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
.	.	O	O

Oxyhemoglobin	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
helodermin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypotension	NN	I-NP	B
,	,	O	O
whereas	IN	O	O
it	PRP	B-NP	O
shortened	VBD	B-VP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
acetylcholine	NN	B-NP	O
(	(	O	O
ACh	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
produced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
helodermin	NN	B-NP	O
-	HYPH	B-VP	O
produced	VBN	B-NP	O
hypotension	NN	I-NP	B
is	VBZ	B-VP	O
partly	RB	B-ADJP	O
attributable	JJ	I-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
activation	NN	I-NP	O
of	IN	B-PP	O
glibenclamide	NN	B-NP	O
-	HYPH	B-NP	O
sensitive	JJ	I-NP	O
K	NN	I-NP	O
+	SYM	O	O
channels	NNS	B-NP	O
(	(	O	O
K	NN	B-NP	O
(	(	O	O
ATP	NN	B-NP	O
)	)	O	O
channels	NNS	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
presumably	RB	B-ADVP	O
exist	VBP	B-VP	O
on	IN	B-PP	O
arterial	JJ	B-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
cells	NNS	I-NP	O
.	.	O	O

EDRF	NN	B-NP	O
(	(	O	O
endothelium	NN	B-NP	O
-	HYPH	O	O
derived	VBN	B-NP	O
relaxing	NN	I-NP	O
factor	NN	I-NP	O
)	)	O	O
/	SYM	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
peptide	NN	I-NP	O
-	HYPH	B-VP	O
produced	VBN	B-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
efficacy	NN	I-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
event	NN	I-NP	O
of	IN	B-PP	O
nifedipine	NN	B-NP	O
sustained	JJ	I-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
tablets	NNS	I-NP	O
for	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
psoriasis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
psoriatic	JJ	I-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
hypertension	NN	B-NP	B
during	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
therapy	NN	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
calcium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
sustained	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
nifedipine	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
antihypertensive	JJ	I-NP	O
effects	NNS	I-NP	O
and	CC	O	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
exhibited	VBN	I-VP	O
a	DT	B-NP	O
subclinical	JJ	I-NP	O
hypertensive	JJ	I-NP	B
state	NN	I-NP	O
before	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Both	CC	O	O
systolic	JJ	B-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
significantly	RB	B-ADVP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
nifedipine	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
range	NN	I-NP	O
thereafter	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
during	IN	B-PP	O
combined	JJ	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
and	CC	I-NP	O
nifedipine	NN	I-NP	O
included	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
blood	NN	B-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
and	CC	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
gingival	JJ	B-NP	B
hyperplasia	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
sustained	JJ	B-NP	O
-	HYPH	I-NP	O
release	NN	I-NP	O
nifedipine	NN	I-NP	O
is	VBZ	B-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
hypertensive	JJ	B-NP	B
psoriatic	JJ	I-NP	B
patients	NNS	I-NP	O
under	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
cyclosporin	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
but	CC	O	O
that	IN	B-SBAR	O
these	DT	B-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
gingival	JJ	B-NP	B
hyperplasia	NN	I-NP	I
.	.	O	O

Torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
during	IN	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
intermittent	JJ	I-NP	O
dobutamine	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
dilated	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
and	CC	O	O
congestive	JJ	B-NP	B
heart	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
,	,	I-NP	O
severe	JJ	I-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
dilated	VBN	B-NP	B
cardiomyopathy	NN	I-NP	I
and	CC	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
ventricular	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
and	CC	O	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
during	IN	B-PP	O
num	CD	B-NP	O
cycle	NN	I-NP	O
of	IN	B-PP	O
intermittent	JJ	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
dobutamine	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
during	IN	B-PP	O
intermittent	JJ	B-NP	O
dobutamine	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
unpredictable	JJ	B-NP	O
fatal	JJ	I-NP	O
arrhythmias	NNS	I-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
even	RB	B-ADVP	O
with	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
significant	JJ	B-NP	O
rhythm	NN	I-NP	O
disturbances	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
proarrhythmic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Dubutamine	NN	B-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Positive	JJ	B-NP	O
skin	NN	I-NP	O
tests	NNS	I-NP	O
in	IN	B-PP	O
late	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
radiographic	JJ	B-NP	O
contrast	NN	I-NP	O
media	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
few	JJ	I-NP	O
years	NNS	I-NP	O
delayed	VBD	B-VP	O
reactions	NNS	B-NP	O
several	JJ	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
radiographic	JJ	B-NP	O
and	CC	I-NP	O
contrast	NN	I-NP	O
materials	NNS	I-NP	O
(	(	O	O
PRC	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
frequency	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
observations	NNS	I-NP	O
on	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
delayed	VBN	B-NP	O
reactions	NNS	I-NP	O
in	IN	B-PP	O
whom	WP	B-NP	O
intradermoreactions	NNS	B-NP	O
(	(	O	O
IDR	NN	B-NP	O
)	)	O	O
and	CC	O	O
patch	NN	B-NP	O
tests	NNS	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
ionic	JJ	B-NP	O
and	CC	I-NP	O
non	JJ	I-NP	O
ionic	JJ	I-NP	O
PRC	NN	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
angiography	NN	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
venous	JJ	I-NP	O
route	NN	I-NP	O
in	IN	B-PP	O
patient	NN	B-NP	O
n	NN	I-NP	O
degree	NN	I-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
biphasic	JJ	I-NP	O
reaction	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
immediate	JJ	I-NP	O
reaction	NN	I-NP	O
(	(	O	O
dyspnea	NN	B-NP	B
,	,	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
consciousness	NN	B-NP	I
)	)	O	O
and	CC	O	O
delayed	VBN	B-VP	O
macro	AFX	O	B
-	HYPH	O	I
papular	JJ	B-NP	I
rash	NN	I-NP	I
appeared	VBD	B-VP	O
,	,	O	O
whilst	IN	B-PP	O
patient	NN	B-NP	O
n	NN	I-NP	O
degree	NN	I-NP	O
num	CD	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
generalised	VBN	I-NP	O
sensation	NN	I-NP	O
of	IN	B-PP	O
heat	NN	B-NP	O
,	,	O	O
persistent	JJ	B-NP	O
pain	NN	I-NP	B
at	IN	B-PP	O
the	DT	B-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
injection	NN	B-NP	O
immediately	RB	B-ADVP	O
and	CC	O	O
a	DT	B-NP	O
generalised	VBN	I-NP	O
macro	AFX	I-NP	O
-	HYPH	I-NP	O
papular	JJ	I-NP	O
reaction	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
skin	NN	I-NP	O
tests	NNS	I-NP	O
revealed	VBD	B-VP	O
positive	JJ	B-NP	O
delayed	VBN	I-NP	O
reactions	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
by	IN	B-PP	O
IDR	NN	B-NP	O
and	CC	I-NP	O
patch	NN	I-NP	O
tests	NNS	I-NP	O
to	TO	B-PP	O
only	RB	B-NP	O
some	DT	I-NP	O
PRC	NN	I-NP	O
with	IN	B-PP	O
common	JJ	B-NP	O
chains	NNS	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
structures	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
positive	JJ	I-NP	O
skin	NN	I-NP	O
tests	NNS	I-NP	O
are	VBP	B-VP	O
in	IN	B-PP	O
favour	NN	B-NP	O
of	IN	B-PP	O
immunological	JJ	B-NP	O
reactions	NNS	I-NP	O
and	CC	O	O
may	MD	B-VP	O
help	VB	I-VP	O
in	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
allergy	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
hyperammonemic	JJ	I-NP	B
encephalopathy	NN	I-NP	I
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
dehydration	NN	B-NP	B
and	CC	I-NP	O
infection	NN	I-NP	B
.	.	O	O

From	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
cancer	NN	I-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
hyperammonemic	JJ	I-NP	B
encephalopathy	NN	I-NP	I
related	VBN	B-VP	O
to	TO	B-PP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
decompensated	VBN	I-VP	O
liver	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Onset	NN	B-NP	O
of	IN	B-PP	O
hyperammonemic	JJ	B-NP	B
encephalopathy	NN	I-NP	I
varied	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

Plasma	NN	B-NP	O
ammonium	NN	I-NP	O
level	NN	I-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
%	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
episodes	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
various	JJ	B-NP	O
degrees	NNS	I-NP	O
of	IN	B-PP	O
azotemia	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
occurred	VBD	B-VP	O
during	IN	B-PP	O
bacterial	JJ	B-NP	B
infections	NNS	I-NP	I
and	CC	O	O
num	CD	B-NP	O
without	IN	B-PP	O
infection	NN	B-NP	B
occurred	VBD	B-VP	O
during	IN	B-PP	O
periods	NNS	B-NP	O
of	IN	B-PP	O
dehydration	NN	B-NP	B
.	.	O	O

Higher	JJR	B-NP	O
plasma	NN	I-NP	O
ammonium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
more	RBR	B-NP	O
rapid	JJ	I-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
hyperammonemia	NN	B-NP	B
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
bacterial	JJ	B-NP	B
infections	NNS	I-NP	I
and	CC	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
high	JJ	B-NP	O
daily	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
out	IN	I-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
episodes	NNS	I-NP	O
,	,	O	O
plasma	NN	B-NP	O
ammonium	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
mental	JJ	B-NP	O
status	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
adequate	JJ	B-NP	O
management	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
hyperammonemic	JJ	B-NP	B
encephalopathy	NN	I-NP	I
can	MD	B-VP	O
occur	VB	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

Azotemia	NN	B-NP	B
,	,	O	O
body	NN	B-NP	O
fluid	NN	I-NP	O
insufficiency	NN	I-NP	O
and	CC	O	O
bacterial	JJ	B-NP	B
infections	NNS	I-NP	I
were	VBD	B-VP	O
frequently	RB	I-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
therefore	RB	B-ADVP	O
important	JJ	B-ADJP	O
to	TO	B-VP	O
recognize	VB	I-VP	O
this	DT	B-NP	O
condition	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
continuous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
on	IN	B-PP	O
conditioned	VBN	B-NP	O
place	NN	I-NP	O
preference	NN	I-NP	O
and	CC	O	O
changes	NNS	B-NP	O
in	IN	B-PP	O
motor	NN	B-NP	O
activity	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
rats.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
unselective	JJ	I-NP	O
potassium	NN	I-NP	O
(	(	O	O
K	NN	B-NP	O
-	HYPH	O	O
)	)	O	O
channel	NN	B-NP	O
blockers	NNS	I-NP	O
,	,	O	O
quinine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
conditioned	VBN	B-NP	O
place	NN	I-NP	O
preference	NN	I-NP	O
and	CC	O	O
biphasic	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
motor	NN	B-NP	O
activity	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
morphine	NN	B-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
Wistar	NNP	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Quinine	NN	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
voltage	NN	B-NP	O
-	HYPH	B-ADVP	O
,	,	O	O
calcium	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
ATP	NN	I-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
channels	NNS	I-NP	O
while	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
block	VB	I-VP	O
voltage	NN	B-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
K	NN	I-NP	O
-	HYPH	O	O
channels.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
counterbalanced	JJ	I-NP	O
method	NN	I-NP	O
,	,	O	O
quinine	NN	B-NP	O
attenuated	VBD	B-VP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
place	NN	I-NP	O
preference	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
was	VBD	B-VP	O
ineffective	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
motor	NN	I-NP	O
activity	NN	I-NP	O
test	NN	I-NP	O
measured	VBN	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
Animex	NNP	I-NP	O
-	HYPH	I-NP	O
activity	NN	I-NP	O
meter	NN	I-NP	O
neither	CC	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
affected	VBD	B-VP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypoactivity	NN	I-NP	B
,	,	O	O
but	CC	O	O
both	CC	O	O
K	NN	B-NP	O
-	HYPH	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
prevented	VBD	B-VP	O
morphine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
secondary	JJ	I-NP	O
hyperactivity	NN	I-NP	B
.	.	I-NP	O
num	CD	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
-	HYPH	O	O
sensitive	JJ	B-ADJP	O
but	CC	O	O
not	RB	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
channels	NNS	I-NP	O
in	IN	B-PP	O
morphine	NN	B-NP	O
reward	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
also	RB	I-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
K	NN	B-NP	O
-	HYPH	B-NP	O
channels	NNS	I-NP	O
sensitive	JJ	B-ADJP	O
to	TO	B-PP	O
these	DT	B-NP	O
blockers	NNS	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypoactivity	NN	I-NP	B
whereas	IN	B-PP	O
morphine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
connected	VBN	I-VP	O
to	TO	B-PP	O
both	CC	O	O
quinine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
aminopyridine	NN	I-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
channels	NNS	I-NP	O
.	.	O	O

Nociceptin	NN	B-NP	O
/	SYM	I-NP	O
orphanin	NN	I-NP	O
FQ	NN	I-NP	O
and	CC	I-NP	O
nocistatin	NN	I-NP	O
on	IN	B-PP	O
learning	NN	B-NP	B
and	CC	I-NP	I
memory	NN	I-NP	I
impairment	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
in	IN	B-PP	O
mice.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Nociceptin	NN	B-NP	O
,	,	O	O
also	RB	B-VP	O
known	VBN	I-VP	O
as	IN	B-PP	O
orphanin	NN	B-NP	O
FQ	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
endogenous	JJ	I-NP	O
ligand	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
orphan	NN	I-NP	O
opioid	JJ	I-NP	O
receptor	NN	I-NP	O
-	HYPH	B-NP	O
like	JJ	I-NP	O
receptor	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
ORL1	NN	B-NP	O
)	)	O	O
and	CC	O	O
involves	VBZ	B-VP	O
in	IN	B-PP	O
various	JJ	B-NP	O
functions	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
nocistatin	NN	B-NP	O
is	VBZ	B-VP	O
recently	RB	I-VP	O
isolated	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
precursor	NN	I-NP	O
as	IN	B-PP	O
nociceptin	NN	B-NP	O
and	CC	O	O
blocks	VBZ	B-VP	O
nociceptin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
allodynia	NN	I-NP	B
and	CC	I-NP	O
hyperalgesia	NN	I-NP	B
.	.	O	O
num	CD	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
ORL1	NN	B-NP	O
receptors	NNS	I-NP	O
which	WDT	B-NP	O
display	VBP	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
sequence	NN	B-NP	O
homology	NN	I-NP	O
with	IN	B-PP	O
classical	JJ	B-NP	O
opioid	JJ	I-NP	O
receptors	NNS	I-NP	O
are	VBP	B-VP	O
abundant	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
,	,	O	O
little	JJ	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
regarding	VBG	I-VP	O
their	PRP$	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
learning	NN	B-NP	O
and	CC	O	O
memory.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
whether	IN	B-SBAR	O
nociceptin	NN	B-NP	O
/	SYM	I-NP	O
orphanin	NN	I-NP	O
FQ	NN	I-NP	O
and	CC	I-NP	O
nocistatin	NN	I-NP	O
could	MD	B-VP	O
modulate	VB	I-VP	O
impairment	NN	B-NP	B
of	IN	B-PP	I
learning	NN	B-NP	I
and	CC	I-NP	I
memory	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
muscarinic	JJ	I-NP	O
cholinergic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
of	IN	B-PP	O
Y	NN	B-NP	O
-	HYPH	I-NP	O
maze	NN	I-NP	O
and	CC	I-NP	O
step	NN	I-NP	O
-	HYPH	B-VP	O
down	RP	B-PRT	O
type	NN	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
tasks	NNS	I-NP	O
in	IN	B-PP	O
mice.	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
nocistatin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
nmol	NN	I-NP	O
mouse	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.c.v.	LS	B-LST	O
)	)	O	O
administered	VBN	B-VP	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
performance	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
training	NN	I-NP	O
session	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
,	,	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
or	CC	O	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
behaviours	NNS	I-NP	O
,	,	O	O
a	DT	O	O
lower	JJR	O	O
per	IN	B-PP	O
cent	NN	B-NP	O
alternation	NN	I-NP	O
and	CC	O	O
shorter	JJR	B-NP	O
median	JJ	I-NP	O
step	NN	I-NP	O
-	HYPH	B-VP	O
down	RP	B-PRT	O
latency	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
retention	NN	I-NP	O
test	NN	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
nociceptin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
nmol	NN	I-NP	O
mouse	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.c.v.	LS	B-LST	O
)	)	O	O
-	HYPH	O	O
treated	VBN	B-NP	O
normal	JJ	I-NP	O
mice.	NNS	I-NP	O
num	CD	B-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
nocistatin	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
nmol	NN	I-NP	O
mouse	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
i.c.v.	NN	I-NP	O
)	)	O	O
num	CD	B-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
performance	NN	I-NP	O
or	CC	O	O
the	DT	B-NP	O
training	NN	I-NP	O
session	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
passive	JJ	I-NP	O
avoidance	NN	I-NP	O
task	NN	I-NP	O
,	,	O	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
scopolamine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
and	CC	O	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
behaviours.	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
nocistatin	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
biologically	RB	I-NP	O
active	JJ	I-NP	O
peptide	NN	I-NP	O
,	,	O	O
ameliorates	VBZ	B-VP	O
impairments	NNS	B-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
alternation	NN	I-NP	O
and	CC	O	O
passive	JJ	B-NP	O
avoidance	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
scopolamine	NN	B-NP	O
,	,	O	O
and	CC	O	O
suggested	VBD	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
peptides	NNS	I-NP	O
play	VBP	B-VP	O
opposite	JJ	B-NP	O
roles	NNS	I-NP	O
in	IN	B-PP	O
learning	NN	B-NP	O
and	CC	I-NP	O
memory	NN	I-NP	O
.	.	O	O

Meloxicam	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
liver	NN	I-NP	B
toxicity	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
rheumatoid	JJ	B-NP	B
arthritis	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	O
cytolytic	JJ	I-NP	O
hepatitis	NN	I-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
meloxicam	NN	B-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
introduced	VBN	B-VP	O
in	IN	B-PP	O
Belgium	NN	B-NP	O
,	,	O	O
meloxicam	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
nonsteroidal	JJ	I-NP	O
antiinflammatory	JJ	I-NP	O
drug	NN	I-NP	O
with	IN	B-PP	O
selective	JJ	B-NP	O
action	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
inducible	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
cyclooxygenase	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
acute	JJ	I-NP	O
cytolytic	JJ	I-NP	O
hepatitis	NN	I-NP	B
occurred	VBD	B-VP	O
rapidly	RB	B-ADVP	O
after	IN	B-SBAR	O
meloxicam	NN	B-NP	O
administration	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
antinuclear	JJ	B-NP	O
antibodies	NNS	I-NP	O
suggesting	VBG	B-VP	O
a	DT	B-NP	O
hypersensitivity	NN	I-NP	B
mechanism	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
first	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
meloxicam	NN	B-NP	O
related	JJ	I-NP	O
liver	NN	I-NP	B
toxicity	NN	I-NP	I
demonstrates	VBZ	B-VP	O
the	DT	B-NP	O
potential	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
drug	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
hepatic	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
apoptosis	NN	B-NP	O
by	IN	B-PP	O
remoxipride	NN	B-NP	O
metabolites	NNS	I-NP	O
in	IN	B-PP	O
HL60	NN	B-NP	O
and	CC	I-NP	O
CD34	NN	I-NP	O
+	SYM	B-NP	O
/	SYM	B-NP	O
CD19	NN	I-NP	O
-	HYPH	B-NP	O
human	JJ	I-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
progenitor	NN	I-NP	O
cells	NNS	I-NP	O
:	:	O	O
potential	JJ	B-NP	O
relevance	NN	I-NP	O
to	TO	B-PP	O
remoxipride	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
antipsychotic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
remoxipride	NN	B-NP	O
[	(	O	O
(	(	O	O
S	NN	B-NP	O
)	)	O	O
-	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
bromo	AFX	O	O
-	HYPH	B-NP	O
N	NN	I-NP	O
-	HYPH	O	O
[	(	O	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
ethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
pyrrolidinyl	NN	I-NP	O
)	)	O	O
methyl	NN	B-NP	O
]	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dimethoxybenz	NN	I-NP	O
amide	NN	I-NP	O
]	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
acquired	VBN	B-NP	O
aplastic	JJ	I-NP	B
anemia	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
examined	VBN	I-VP	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
remoxipride	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
pyrrolidine	NN	I-NP	O
ring	NN	I-NP	O
metabolites	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
aromatic	JJ	I-NP	O
ring	NN	I-NP	O
metabolites	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
parent	NN	I-NP	O
compound	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
apoptosis	NN	B-NP	O
in	IN	B-PP	O
HL60	NN	B-NP	O
cells	NNS	I-NP	O
and	CC	O	O
human	JJ	B-NP	O
bone	NN	I-NP	O
marrow	NN	I-NP	O
progenitor	NN	I-NP	O
(	(	O	O
HBMP	NN	B-NP	O
)	)	O	O
cells	NNS	B-NP	O
.	.	O	O

Cells	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
with	IN	B-PP	O
each	DT	B-NP	O
compound	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microM	NN	I-NP	O
)	)	O	O
.	.	O	O

Apoptosis	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
fluorescence	NN	B-NP	O
microscopy	NN	I-NP	O
in	IN	B-PP	O
Hoechst	NNP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
propidium	NN	I-NP	O
iodide	NN	I-NP	O
stained	VBD	B-VP	O
cell	NN	B-NP	O
samples	NNS	I-NP	O
.	.	O	O

Results	NNS	B-NP	O
were	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
determination	NN	B-NP	O
of	IN	B-PP	O
internucleosomal	JJ	B-NP	O
DNA	NN	I-NP	O
fragmentation	NN	I-NP	O
using	VBG	B-VP	O
gel	NN	B-NP	O
electrophoresis	NN	I-NP	O
for	IN	B-PP	O
HL60	NN	B-NP	O
cell	NN	I-NP	O
samples	NNS	I-NP	O
and	CC	O	O
terminal	JJ	B-NP	O
deoxynucleotidyl	NN	I-NP	O
transferase	NN	I-NP	O
assay	NN	I-NP	O
in	IN	B-PP	O
HBMP	NN	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
catechol	NN	I-NP	O
and	CC	I-NP	O
hydroquinone	NN	I-NP	O
metabolites	NNS	I-NP	O
,	,	O	O
NCQ436	NN	B-NP	O
and	CC	I-NP	O
NCQ344	NN	I-NP	O
,	,	O	O
induced	VBD	B-VP	O
apoptosis	NN	B-NP	O
in	IN	B-PP	O
HL60	NN	B-NP	O
and	CC	I-NP	O
HBMP	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
time	NN	I-NP	O
-	HYPH	O	O
and	CC	O	O
concentration	NN	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
phenols	NNS	I-NP	O
,	,	O	O
NCR181	NN	B-NP	O
,	,	O	O
FLA873	NN	B-NP	O
,	,	O	O
and	CC	O	O
FLA797	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
derivatives	NNS	I-NP	O
formed	VBN	B-VP	O
by	IN	B-PP	O
oxidation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pyrrolidine	NN	I-NP	O
ring	NN	I-NP	O
,	,	O	O
FLA838	NN	B-NP	O
,	,	O	O
NCM001	NN	B-NP	O
,	,	O	O
and	CC	O	O
NCL118	NN	B-NP	O
,	,	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
necrosis	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
cells	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
NCQ436	NN	B-NP	O
but	CC	O	O
NCQ344	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
biphasic	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
cell	NN	I-NP	O
types	NNS	I-NP	O
,	,	O	O
inducing	VBG	B-VP	O
apoptosis	NN	B-NP	O
at	IN	B-PP	O
lower	JJR	B-NP	O
concentrations	NNS	I-NP	O
and	CC	O	O
necrosis	NN	B-NP	B
at	IN	B-PP	O
higher	JJR	B-NP	O
concentrations	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
catechol	NN	I-NP	O
and	CC	I-NP	O
hydroquinone	NN	I-NP	O
metabolites	NNS	I-NP	O
of	IN	B-PP	O
remoxipride	NN	B-NP	O
have	VBP	B-VP	O
direct	JJ	B-NP	O
toxic	JJ	I-NP	O
effects	NNS	I-NP	O
in	IN	B-PP	O
HL60	NN	B-NP	O
and	CC	I-NP	O
HBMP	NN	I-NP	O
cells	NNS	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
apoptosis	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
the	DT	B-NP	O
phenol	NN	I-NP	O
metabolites	NNS	I-NP	O
were	VBD	B-VP	O
inactive	JJ	B-ADJP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
benzene	NN	B-NP	O
-	HYPH	B-NP	O
derived	VBN	I-NP	O
catechol	NN	I-NP	O
and	CC	I-NP	O
hydroquinone	NN	I-NP	O
,	,	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
phenol	NN	B-NP	O
,	,	O	O
induce	VBP	B-VP	O
apoptosis	NN	B-NP	O
in	IN	B-PP	O
HBMP	NN	B-NP	O
cells	NNS	I-NP	O
[	(	O	O
Moran	NNP	B-NP	O
et	FW	I-NP	O
al.	FW	I-NP	O
,	,	O	O
Mol	NNP	B-NP	O
.	.	O	O

Pharmacol.	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	O	O
.	.	O	O

We	PRP	B-NP	O
propose	VBP	B-VP	O
that	IN	B-SBAR	O
remoxipride	NN	B-NP	O
and	CC	I-NP	O
benzene	NN	I-NP	O
may	MD	B-VP	O
induce	VB	I-VP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
via	IN	B-PP	O
production	NN	B-NP	O
of	IN	B-PP	O
similar	JJ	B-NP	O
reactive	JJ	I-NP	O
metabolites	NNS	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
ability	NN	I-NP	O
of	IN	B-PP	O
NCQ436	NN	B-NP	O
and	CC	I-NP	O
NCQ344	NN	I-NP	O
to	TO	B-VP	O
induce	VB	I-VP	O
apoptosis	NN	B-NP	O
in	IN	B-PP	O
HBMP	NN	B-NP	O
cells	NNS	I-NP	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
underlying	VBG	B-VP	O
acquired	VBN	I-VP	O
aplastic	JJ	B-NP	B
anemia	NN	I-NP	I
that	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
remoxipride	NN	B-NP	O
.	.	O	O

Synthesis	NN	B-NP	O
and	CC	O	O
preliminary	JJ	B-NP	O
pharmacological	JJ	I-NP	O
investigations	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydro	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
acenaphthylenyl	NN	I-NP	O
)	)	O	O
piperazine	NN	B-NP	O
derivatives	NNS	I-NP	O
as	IN	B-PP	O
potential	JJ	B-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
research	NN	B-NP	O
towards	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
strategy	NN	I-NP	O
is	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
system	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
modulated	VBN	I-VP	O
through	IN	B-PP	O
manipulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
serotonergic	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
synthesis	NN	I-NP	O
and	CC	I-NP	O
preliminary	JJ	I-NP	O
pharmacological	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
potential	JJ	B-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
agents	NNS	I-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
structure	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dihydro	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
acenaphthylenyl	NN	I-NP	O
)	)	O	O
piperazine	NN	B-NP	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Compound	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
{	SYM	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
[	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
(	(	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihydro	AFX	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
acenaphthylenyl	NN	I-NP	O
)	)	O	O
piperazinyl	NN	B-NP	O
]	)	O	O
ethyl	NN	B-NP	O
}	AFX	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
dihy	JJ	I-NP	O
dro	AFX	I-NP	O
-	HYPH	I-NP	O
1H	NN	I-NP	O
-	HYPH	I-NP	O
indol	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
,	,	O	O
from	IN	B-PP	O
this	DT	B-NP	O
series	NN	I-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
affinities	NNS	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT1A	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT2A	NN	I-NP	O
receptors	NNS	I-NP	O
and	CC	O	O
moderate	JJ	B-NP	O
affinity	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
D2	NN	I-NP	O
receptor.	NN	I-NP	O
7e	NN	I-NP	O
exhibits	VBZ	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
indicating	VBG	B-VP	O
its	PRP$	B-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
nature	NN	I-NP	O
.	.	O	O

Sub	NN	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
-	HYPH	I-NP	O
oxide	NN	I-NP	O
synthesis	NN	I-NP	O
modifies	VBZ	B-VP	O
haloperidol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
catalepsy	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
NADPH	NN	B-NP	O
-	HYPH	B-NP	O
diaphorase	NN	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

NG	NN	B-NP	O
-	HYPH	I-NP	O
nitro	NN	I-NP	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
(	(	O	O
L	NN	B-NP	O
-	HYPH	O	O
NOARG	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
-	HYPH	I-NP	O
oxide	NN	I-NP	O
synthase	NN	I-NP	O
(	(	O	O
NOS	NN	B-NP	O
)	)	O	O
,	,	O	O
induces	VBZ	B-VP	O
catalepsy	NN	B-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
undergoes	VBZ	B-VP	O
rapid	JJ	B-NP	O
tolerance	NN	I-NP	O
,	,	O	O
showing	VBG	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
chronic	JJ	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
NOARG	NN	I-NP	O
treatment	NN	I-NP	O
.	.	O	O

Nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
influence	VB	I-VP	O
dopaminergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
striatum	NN	I-NP	O
.	.	O	O

Neuroleptic	JJ	B-NP	O
drugs	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
haloperidol	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
block	VBP	B-VP	O
dopamine	NN	B-NP	O
receptors	NNS	I-NP	O
,	,	O	O
also	RB	B-ADVP	O
cause	VBP	B-VP	O
catalepsy	NN	B-NP	B
in	IN	B-PP	O
rodents	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
subchronic	JJ	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
NOARG	NN	I-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
NOS	NN	B-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
areas	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
motor	NN	B-NP	O
control	NN	I-NP	O
.	.	O	O

Male	JJ	B-NP	O
albino	NN	I-NP	O
Swiss	JJ	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
sub	AFX	O	O
-	HYPH	O	O
chronically	RB	B-ADVP	O
(	(	O	O
twice	RB	B-NP	O
a	DT	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NOARG	NN	I-NP	O
or	CC	I-NP	O
haloperidol	NN	I-NP	O
.	.	O	O

Catalepsy	NN	B-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
end	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatments	NNS	I-NP	O
.	.	O	O

Reduced	VBN	B-NP	O
nicotinamide	NN	I-NP	O
adenine	NN	I-NP	O
dinucleotide	NN	I-NP	O
phosphate	NN	I-NP	O
-	HYPH	B-NP	O
diaphorase	NN	I-NP	O
(	(	O	O
NADPH	NN	B-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
)	)	O	O
histochemistry	NN	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
employed	VBN	I-VP	O
to	TO	I-VP	O
visualize	VB	I-VP	O
NOS	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
index	NN	I-NP	O
of	IN	B-PP	O
enzyme	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
brain	NN	I-NP	O
regions	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
motor	NN	B-NP	O
control	NN	I-NP	O
.	.	O	O

L	NN	B-NP	O
-	HYPH	I-NP	O
NOARG	NN	I-NP	O
sub	AFX	O	O
-	HYPH	O	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
produced	VBD	B-VP	O
tolerance	NN	B-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NOARG	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

It	PRP	B-NP	O
also	RB	B-ADVP	O
induced	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
NADPH	NN	B-NP	O
-	HYPH	I-NP	O
d	NN	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
dorsal	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
caudate	NN	I-NP	O
and	CC	O	O
accumbens	VBZ	B-VP	O
nuclei	NNS	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
haloperidol	NN	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
pedunculopontine	JJ	I-NP	O
tegmental	JJ	I-NP	O
nucleus	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
saline	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
NADPH	NN	B-NP	O
-	HYPH	B-NP	O
d	JJ	I-NP	O
neuron	NN	I-NP	O
number	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
substantia	NN	I-NP	O
nigra	NN	I-NP	O
,	,	O	O
pars	NNS	B-NP	O
compacta	VBP	B-VP	O
in	IN	B-PP	O
both	CC	O	O
haloperidol	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	B-VP	O
and	CC	O	O
L	NN	B-NP	O
-	HYPH	B-NP	O
NOARG	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
give	VBP	B-VP	O
further	JJ	B-NP	O
support	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
NO	NN	B-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
motor	NN	B-NP	O
behavior	NN	I-NP	O
control	VBP	B-VP	O
and	CC	I-VP	O
suggest	VBP	I-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
take	VB	I-VP	O
part	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
synaptic	JJ	I-NP	O
changes	NNS	I-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
antipsychotic	JJ	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Prolonged	VBN	B-VP	O
left	VBD	B-VP	B
ventricular	JJ	B-NP	I
dysfunction	NN	I-NP	I
occurs	VBZ	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
after	IN	B-SBAR	O
both	CC	O	O
dobutamine	NN	B-NP	O
and	CC	O	O
exercise	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	B
ischaemia	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
pharmacological	JJ	B-NP	O
stress	NN	I-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
prolonged	JJ	B-NP	O
but	CC	I-NP	O
reversible	JJ	I-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
seen	VBN	B-VP	O
after	IN	B-PP	O
exercise	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
randomised	VBN	I-NP	O
crossover	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
recovery	NN	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
systolic	JJ	B-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
after	IN	B-PP	O
exercise	NN	B-NP	O
and	CC	I-NP	O
dobutamine	NN	I-NP	O
induced	VBD	B-VP	O
ischaemia	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	B
angina	NN	I-NP	I
,	,	O	O
angiographically	RB	B-NP	O
proven	VBN	I-NP	O
coronary	JJ	I-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
and	CC	O	O
normal	JJ	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

Treadmill	NN	B-NP	O
exercise	NN	I-NP	O
and	CC	O	O
dobutamine	NN	B-NP	O
stress	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
different	JJ	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Quantitative	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
systolic	JJ	B-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
using	VBG	B-VP	O
transthoracic	JJ	B-NP	O
echocardiography	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	B-PP	O
at	IN	B-PP	O
regular	JJ	B-NP	O
intervals	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
test	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
stress	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
prolonged	JJ	B-NP	O
but	CC	I-NP	O
reversible	JJ	I-NP	O
systolic	JJ	I-NP	O
and	CC	I-NP	O
diastolic	JJ	I-NP	O
dysfunction	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
maximum	NN	I-NP	O
double	JJ	I-NP	O
product	NN	I-NP	O
or	CC	I-NP	O
ST	NN	I-NP	O
depression	NN	I-NP	B
with	IN	B-PP	O
either	CC	O	O
form	NN	B-NP	O
of	IN	B-PP	O
stress	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
exercise	NN	B-NP	O
,	,	O	O
ejection	NN	B-NP	O
fraction	NN	I-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
baseline	NN	B-NP	O
(	(	O	O
mean	NN	B-NP	O
,	,	O	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
dobutamine	NN	B-NP	O
.	.	O	O

Regional	JJ	B-NP	O
analysis	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
worst	JJS	I-NP	O
affected	VBN	I-NP	O
segment	NN	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
exercise	NN	B-NP	O
,	,	O	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
dobutamine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
isovolumic	JJ	I-NP	O
relaxation	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
prolonged	JJ	B-ADJP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
stress	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
dobutamine	NN	B-NP	O
induced	VBD	B-VP	O
ischaemia	NN	B-NP	B
results	VBZ	B-VP	O
in	IN	B-PP	O
prolonged	VBN	B-NP	O
reversible	JJ	I-NP	O
left	JJ	I-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
,	,	O	O
presumed	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
myocardial	JJ	B-ADJP	B
stunning	JJ	B-ADJP	I
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
seen	VBN	B-VP	O
after	IN	B-PP	O
exercise	NN	B-NP	O
.	.	O	O

Dobutamine	NN	B-NP	O
induced	VBD	B-VP	O
ischaemia	NN	B-NP	B
could	MD	B-VP	O
therefore	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
pathophysiology	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
phenomenon	NN	I-NP	O
further	RBR	B-ADVP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Anorexigens	NNS	B-NP	O
and	CC	O	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
:	:	O	O
results	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
surveillance	NN	I-NP	O
of	IN	B-PP	O
North	JJ	B-NP	O
American	JJ	I-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
appetite	JJ	B-NP	O
suppressants	NNS	I-NP	O
in	IN	B-PP	O
Europe	NNP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	B
pulmonary	JJ	I-NP	I
hypertension	NN	I-NP	I
(	(	O	O
PPH	NN	B-NP	B
)	)	O	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
fenfluramine	NN	B-NP	O
appetite	NN	I-NP	O
suppressants	NNS	I-NP	O
became	VBD	B-VP	O
widely	RB	B-ADJP	O
used	VBN	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
but	CC	O	O
were	VBD	B-VP	O
withdrawn	VBN	I-VP	O
in	IN	B-PP	O
September	NNP	B-NP	O
num	CD	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
concerns	NNS	B-NP	O
over	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
surveillance	NN	I-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
patients	NNS	B-NP	O
diagnosed	VBN	B-VP	O
with	IN	B-PP	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
at	IN	B-PP	O
num	CD	B-NP	O
large	JJ	I-NP	O
referral	JJ	I-NP	O
centers	NNS	I-NP	O
in	IN	B-PP	O
North	NNP	B-NP	O
America	NNP	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
collected	VBN	B-VP	O
on	IN	B-PP	O
patients	NNS	B-NP	O
seen	VBN	B-VP	O
from	IN	B-PP	O
September	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
to	TO	B-PP	O
December	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
included	VBD	B-VP	O
the	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
severity	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
identifiable	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
were	VBD	B-VP	O
classed	VBN	I-VP	O
as	IN	B-PP	O
PPH	NN	B-NP	B
.	.	O	O

A	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
exposure	NN	I-NP	O
also	RB	B-ADVP	O
was	VBD	B-VP	O
taken	VBN	I-VP	O
with	IN	B-PP	O
special	JJ	B-NP	O
attention	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antidepressants	NNS	B-NP	O
,	,	O	O
anorexigens	NNS	B-NP	O
,	,	O	O
and	CC	O	O
amphetamines	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
PPH	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
from	IN	B-PP	O
other	JJ	B-NP	O
causes	NNS	I-NP	O
(	(	O	O
secondary	JJ	B-NP	O
pulmonary	JJ	I-NP	B
hypertension	NN	I-NP	I
[	(	O	O
SPH	NN	B-NP	O
]	)	O	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
anorexigens	NNS	B-NP	O
was	VBD	B-VP	O
common	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
of	IN	B-PP	O
the	DT	B-NP	O
medications	NNS	I-NP	O
surveyed	VBN	B-VP	O
,	,	O	O
only	RB	B-NP	O
the	DT	I-NP	O
fenfluramines	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
preferential	JJ	I-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
PPH	NN	B-NP	B
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
SPH	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
was	VBD	B-VP	O
stronger	JJR	B-ADJP	O
with	IN	B-PP	O
longer	JJR	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
shorter	JJR	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
pronounced	JJ	I-ADJP	O
in	IN	B-PP	O
recent	JJ	B-NP	O
users	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
remote	JJ	B-NP	O
users	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
unexpectedly	RB	I-NP	O
high	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SPH	NN	B-NP	O
had	VBD	B-VP	O
used	VBN	I-VP	O
anorexigens	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
PPH	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
association	NN	B-NP	O
with	IN	B-PP	O
increasing	VBG	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
specificity	NN	I-NP	O
for	IN	B-PP	O
fenfluramines	NNS	B-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
previous	JJ	B-NP	O
studies	NNS	I-NP	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
fenfluramines	NNS	B-NP	O
are	VBP	B-VP	O
causally	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
PPH	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
high	JJ	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
anorexigen	NN	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
SPH	NN	B-NP	O
also	RB	B-ADVP	O
raises	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
drugs	NNS	I-NP	O
precipitate	VBP	B-VP	O
pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
underlying	VBG	B-VP	O
conditions	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
SPH	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
aspects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
and	CC	I-NP	O
thrombosis	NN	I-NP	B
and	CC	O	O
other	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Heparin	NN	B-NP	O
,	,	O	O
first	RB	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
the	DT	B-NP	O
clotting	NN	I-NP	O
of	IN	B-PP	O
blood	NN	B-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
clinically	RB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
treat	VB	I-VP	O
thrombosis	NN	B-NP	B
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
several	JJ	B-NP	O
new	JJ	I-NP	O
anticoagulant	JJ	I-NP	O
drugs	NNS	I-NP	O
are	VBP	B-VP	O
in	IN	B-PP	O
development	NN	B-NP	O
,	,	O	O
heparin	NN	B-NP	O
remains	VBZ	B-VP	O
the	DT	B-NP	O
anticoagulant	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
acute	JJ	B-NP	O
thrombotic	JJ	I-NP	B
episodes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
are	VBP	B-VP	O
meritorious	JJ	B-ADJP	O
,	,	O	O
but	CC	O	O
side	NN	B-NP	O
effects	NNS	I-NP	O
do	VBP	B-VP	O
exist	VB	I-VP	O
.	.	O	O

Bleeding	NN	B-NP	B
is	VBZ	B-VP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
untoward	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
.	.	O	O

Major	JJ	B-NP	O
bleeding	NN	I-NP	B
is	VBZ	B-VP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
concern	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
additional	JJ	B-NP	O
important	JJ	I-NP	O
untoward	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
therapy	NN	I-NP	O
include	VBP	B-VP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
,	,	O	O
heparin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
osteoporosis	NN	B-NP	B
,	,	O	O
eosinophilia	NN	B-NP	B
,	,	O	O
skin	NN	B-NP	B
reactions	NNS	I-NP	I
,	,	O	O
allergic	JJ	B-NP	B
reactions	NNS	I-NP	I
other	JJ	B-ADJP	O
than	IN	B-PP	O
thrombocytopenia	NN	B-NP	B
,	,	O	O
alopecia	NN	B-NP	B
,	,	O	O
transaminasemia	NN	B-NP	O
,	,	O	O
hyperkalemia	NN	B-NP	B
,	,	O	O
hypoaldosteronism	NN	B-NP	B
,	,	O	O
and	CC	O	O
priapism	NN	B-NP	B
.	.	O	O

These	DT	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
relatively	RB	B-ADJP	O
rare	JJ	I-ADJP	O
in	IN	B-PP	O
a	DT	B-NP	O
given	VBN	I-NP	O
individual	NN	I-NP	O
,	,	O	O
but	CC	O	O
given	VBN	B-PP	O
the	DT	B-NP	O
extremely	RB	I-NP	O
widespread	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
,	,	O	O
some	DT	B-NP	O
are	VBP	B-VP	O
quite	RB	B-ADJP	O
common	JJ	I-ADJP	O
,	,	O	O
particularly	RB	B-NP	O
HITT	NN	I-NP	B
and	CC	I-NP	O
osteoporosis	NN	I-NP	B
.	.	O	O

Although	IN	B-SBAR	O
reasonable	JJ	B-NP	O
incidences	NNS	I-NP	O
of	IN	B-PP	O
many	JJ	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
softly	RB	I-VP	O
deduced	VBN	I-VP	O
from	IN	B-PP	O
current	JJ	B-NP	O
reports	NNS	I-NP	O
dealing	VBG	B-VP	O
with	IN	B-PP	O
unfractionated	JJ	B-NP	O
heparin	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
present	JJ	B-ADJP	O
the	DT	B-NP	O
incidences	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
with	IN	B-PP	O
newer	JJR	B-NP	O
low	JJ	I-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
heparins	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
much	RB	B-ADJP	O
less	RBR	I-ADJP	O
common	JJ	I-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
only	RB	B-NP	O
longer	JJR	I-NP	O
experience	NN	I-NP	O
will	MD	B-VP	O
more	RBR	I-VP	O
clearly	RB	I-VP	O
define	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
molecular	JJ	I-NP	O
weight	NN	I-NP	O
preparations	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
on	IN	B-PP	O
tacrolimus	NN	B-NP	O
(	(	O	O
FK506	NN	B-NP	O
)	)	O	O
therapy	NN	B-NP	O
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
(	(	O	O
FK	NN	B-NP	O
num	CD	I-NP	O
Prograf	NNP	I-NP	O
;	:	O	O
Fujisawa	NNP	B-NP	O
USA	NNP	I-NP	O
,	,	O	O
Inc	NNP	B-NP	O
,	,	O	O
Deerfield	NNP	B-NP	O
,	,	O	O
Illinois	NNP	B-NP	O
)	)	O	O
for	IN	B-PP	O
immunosuppression	NN	B-NP	O
after	IN	B-PP	O
orthotropic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
receiving	VBG	B-VP	O
tacrolimus	NN	B-NP	O
after	IN	B-PP	O
orthotropic	JJ	B-NP	O
liver	NN	I-NP	O
transplantation	NN	I-NP	O
,	,	O	O
serial	JJ	B-NP	O
neuro	AFX	I-NP	O
-	HYPH	I-NP	O
ophthalmologic	JJ	I-NP	O
examinations	NNS	I-NP	O
and	CC	O	O
laboratory	NN	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
episodic	JJ	B-NP	O
deterioration	NN	I-NP	O
of	IN	B-PP	O
vision	NN	B-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
eyes	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
clinical	JJ	B-NP	O
features	NNS	I-NP	O
resembling	VBG	B-VP	O
ischemic	JJ	B-NP	B
optic	JJ	I-NP	I
neuropathies	NNS	I-NP	I
.	.	O	O

Deterioration	NN	B-NP	B
of	IN	B-PP	I
vision	NN	B-NP	I
occurred	VBD	B-VP	O
despite	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
tacrolimus	NN	I-NP	O
.	.	O	O

Tacrolimus	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
immunosuppressive	JJ	I-NP	O
agents	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
optic	JJ	B-NP	B
nerve	NN	I-NP	I
toxicity	NN	I-NP	I
.	.	O	O

Hypercalcemia	NN	B-NP	B
,	,	O	O
arrhythmia	NN	B-NP	B
,	,	O	O
and	CC	O	O
mood	NN	B-NP	O
stabilizers	NNS	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
bipolar	JJ	I-NP	B
patient	NN	I-NP	O
receiving	VBG	B-VP	O
maintenance	NN	B-NP	O
lithium	NN	I-NP	O
therapy	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
hypercalcemia	NN	B-NP	B
and	CC	O	O
severe	JJ	B-NP	O
bradyarrhythmia	NN	I-NP	B
prompted	VBD	B-VP	O
the	DT	B-NP	O
authors	NNS	I-NP	O
to	TO	B-VP	O
conduct	VB	I-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
bipolar	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
hypercalcemia	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
printout	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hypercalcemia	NN	B-NP	B
that	WDT	B-NP	O
presented	VBD	B-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
generated	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
eliminating	VBG	B-VP	O
spurious	JJ	B-NP	O
hypercalcemias	NNS	I-NP	B
or	CC	O	O
those	DT	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
fluids	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
authors	NNS	I-NP	O
identified	VBD	B-VP	O
num	CD	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
lithium	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hypercalcemias	NNS	B-NP	B
related	VBN	B-VP	O
to	TO	B-PP	O
malignancies	NNS	B-NP	B
and	CC	O	O
other	JJ	B-NP	O
medical	JJ	I-NP	O
conditions	NNS	I-NP	O
(	(	O	O
group	NN	B-NP	O
A	NN	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
hypercalcemia	NN	I-NP	B
(	(	O	O
group	NN	B-NP	O
B	NN	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
were	VBD	B-VP	O
not	RB	O	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
the	DT	B-NP	O
latter	JJ	I-NP	O
were	VBD	B-VP	O
medically	RB	I-VP	O
compromised	VBN	I-VP	O
and	CC	O	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
multiple	JJ	B-NP	O
pharmacotherapies	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
generated	VBN	I-VP	O
:	:	O	O
group	NN	B-NP	O
C1	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
included	VBD	B-VP	O
age	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
sex	NN	B-NP	O
-	HYPH	O	O
comparable	JJ	B-NP	O
lithium	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
bipolar	JJ	B-NP	B
normocalcemic	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
group	NN	B-NP	O
C2	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
included	VBD	B-VP	O
bipolar	JJ	B-NP	B
normocalcemic	JJ	I-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
anticonvulsant	JJ	B-NP	O
mood	NN	I-NP	O
stabilizers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
electrocardiographic	JJ	I-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
findings	NNS	B-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
B	NN	I-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
in	IN	B-PP	O
groups	NNS	B-NP	O
C1	NN	I-NP	O
and	CC	I-NP	O
C2	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
groups	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
overall	JJ	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
ECG	NN	B-NP	O
abnormalities	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
significant	JJ	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
conduction	NN	B-NP	O
defects	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
hypercalcemia	NN	B-NP	B
resulting	VBG	B-VP	O
from	IN	B-PP	O
medical	JJ	B-NP	O
diseases	NNS	I-NP	O
and	CC	O	O
bipolar	JJ	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
hypercalcemia	NN	I-NP	B
had	VBD	B-VP	O
significantly	RB	B-NP	O
higher	JJR	I-NP	O
frequencies	NNS	I-NP	O
of	IN	B-PP	O
conduction	NN	B-NP	O
defects	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
group	NN	B-NP	O
A	NN	I-NP	O
had	VBD	B-VP	O
significant	JJ	B-NP	O
mortality	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
in	IN	B-PP	O
contrast	NN	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Attenuation	NN	B-NP	O
of	IN	B-PP	O
nephrotoxicity	NN	B-NP	B
by	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
lipid	NN	I-NP	O
nanosphere	NN	I-NP	O
(	(	O	O
NS	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
)	)	O	O
incorporating	VBG	B-VP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
.	.	O	O

NS	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
lipid	NN	I-NP	O
nanosphere	NN	I-NP	O
incorporating	VBG	B-VP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
against	IN	B-PP	O
pathogenic	JJ	B-NP	O
fungi	NNS	I-NP	O
and	CC	O	O
has	VBZ	B-VP	O
low	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
Fungizone	NN	B-NP	O
(	(	O	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
sodium	NN	I-NP	O
deoxycholate	NN	I-NP	O
;	:	O	O
D	NN	B-NP	O
-	HYPH	O	O
AmB	NN	B-NP	O
)	)	O	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
using	VBG	B-VP	O
renal	JJ	B-NP	O
cell	NN	I-NP	O
cultures	NNS	I-NP	O
and	CC	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
by	IN	B-PP	O
biochemical	JJ	B-NP	O
analysis	NN	I-NP	O
,	,	O	O
histopathological	JJ	B-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
and	CC	I-NP	O
pharmacokinetic	JJ	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
following	VBG	B-PP	O
intravenous	JJ	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
formulation	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Incubation	NN	B-NP	O
with	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
significantly	RB	B-NP	O
less	JJR	I-NP	O
damage	NN	I-NP	O
of	IN	B-PP	O
cultured	VBN	B-NP	O
human	JJ	I-NP	O
renal	JJ	I-NP	O
proximal	JJ	I-NP	O
tubular	JJ	I-NP	O
epithelial	JJ	I-NP	O
cells	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	I-NP	O
AmB	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
and	CC	I-NP	O
creatinine	NN	I-NP	O
concentrations	NNS	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
given	VBN	B-PP	O
an	DT	B-NP	O
iv	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
AmB	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-VP	O
kg	NN	B-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
those	DT	B-NP	O
given	VBN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
showed	VBD	B-VP	O
tubular	JJ	B-NP	B
necrosis	NN	I-NP	I
in	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
AmB	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
but	CC	O	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Amphotericin	NN	B-NP	O
B	NN	I-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
in	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
D	NN	B-NP	O
-	HYPH	B-NP	O
AmB	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
in	FW	I-NP	O
vitro	FW	I-NP	O
and	CC	O	O
in	FW	B-NP	O
vivo	FW	I-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
incorporation	NN	B-NP	O
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
into	IN	B-PP	O
lipid	NN	B-NP	O
nanospheres	NNS	I-NP	O
of	IN	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
attenuates	VBZ	B-VP	O
the	DT	B-NP	O
nephrotoxicity	NN	I-NP	B
of	IN	B-PP	O
amphotericin	NN	B-NP	O
B	NN	I-NP	O
.	.	O	O

Patterns	NNS	B-NP	O
of	IN	B-PP	O
sulfadiazine	NN	B-NP	O
acute	JJ	I-NP	B
nephrotoxicity	NN	I-NP	I
.	.	O	O

Sulfadiazine	NN	B-NP	O
acute	JJ	I-NP	B
nephrotoxicity	NN	I-NP	I
is	VBZ	B-VP	O
reviving	VBG	I-VP	O
specially	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
in	IN	B-PP	O
toxoplasmosis	NN	B-NP	B
in	IN	B-PP	O
HIV	NN	B-NP	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
person	NN	I-NP	O
.	.	O	O

Under	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
sulfadiazine	NN	B-NP	O
they	PRP	B-NP	O
developed	VBD	B-VP	O
oliguria	NN	B-NP	B
,	,	O	O
abdominal	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
and	CC	O	O
showed	VBD	B-VP	O
multiple	JJ	B-NP	O
radiolucent	JJ	I-NP	O
renal	JJ	I-NP	B
calculi	NNS	I-NP	I
in	IN	B-PP	O
echography	NN	B-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
their	PRP$	B-NP	O
previous	JJ	I-NP	O
normal	JJ	I-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
after	IN	B-PP	O
adequate	JJ	B-NP	O
hydration	NN	I-NP	O
and	CC	I-NP	O
alcalinization	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
nephrostomy	NN	I-NP	O
tube	NN	I-NP	O
had	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
placed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
for	IN	B-PP	O
ureteral	JJ	B-NP	B
lithiasis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
functional	JJ	I-NP	O
kidney	NN	I-NP	O
.	.	O	O

None	NN	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
needed	VBD	B-VP	O
dialysis	NN	B-NP	O
or	CC	O	O
a	DT	B-NP	O
renal	JJ	I-NP	O
biopsy	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
benign	JJ	I-NP	O
course	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
sulfadiazine	NN	B-NP	O
requires	VBZ	B-VP	O
exquisite	NN	B-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
water	NN	B-NP	O
ingestion	NN	I-NP	O
and	CC	O	O
possibly	RB	B-ADVP	O
the	DT	B-NP	O
alcalinization	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
urine	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
communicate	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
person	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
fact	NN	I-NP	O
not	RB	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
recent	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

Probably	RB	B-NP	O
many	JJ	I-NP	O
more	JJR	I-NP	O
cases	NNS	I-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
detected	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
think	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
.	.	O	O

Downbeat	NN	B-NP	B
nystagmus	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
intravenous	JJ	B-NP	O
patient	NN	I-NP	O
-	HYPH	B-VP	O
controlled	VBN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
documents	VBZ	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
dizziness	NN	B-NP	B
with	IN	B-PP	O
downbeating	VBG	B-VP	B
nystagmus	NN	B-NP	I
while	IN	B-SBAR	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
large	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
analgesia	NN	I-NP	O
morphine	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
there	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
case	NN	B-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
epidural	JJ	B-NP	O
morphine	NN	I-NP	O
with	IN	B-PP	O
these	DT	B-NP	O
symptoms	NNS	I-NP	O
and	CC	I-NP	O
signs	NNS	I-NP	O
,	,	O	O
this	DT	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
previously	RB	I-VP	O
documented	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
or	CC	O	O
patient	NN	B-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
analgesia	NN	I-NP	O
morphine	NN	I-NP	O
.	.	O	O

Hemodynamic	JJ	B-NP	O
and	CC	I-NP	O
antiadrenergic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dronedarone	NN	B-NP	O
and	CC	I-NP	O
amiodarone	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
healed	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
hemodynamic	JJ	I-NP	O
and	CC	I-NP	O
antiadrenergic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dronedarone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
noniodinated	JJ	I-NP	O
compound	NN	I-NP	O
structurally	RB	B-ADJP	O
related	JJ	I-ADJP	O
to	TO	B-PP	O
amiodarone	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
after	IN	B-PP	O
prolonged	JJ	B-NP	O
oral	JJ	I-NP	O
administration	NN	I-NP	O
,	,	O	O
both	CC	B-PP	O
at	IN	I-PP	O
rest	NN	B-NP	O
and	CC	O	O
during	IN	B-PP	O
sympathetic	JJ	B-NP	O
stimulation	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
dogs	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
healed	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

All	DT	B-NP	O
dogs	NNS	I-NP	O
randomly	RB	B-VP	O
received	VBD	I-VP	O
orally	RB	B-NP	O
dronedarone	NN	I-NP	O
,	,	O	O
amiodarone	NN	B-NP	O
,	,	O	O
and	CC	O	O
placebo	NN	B-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
washout	NN	I-NP	O
between	IN	B-PP	O
consecutive	JJ	B-NP	O
treatments	NNS	I-NP	O
.	.	O	O

Heart	NN	B-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
,	,	O	O
mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MBP	NN	B-NP	O
)	)	O	O
,	,	O	O
positive	JJ	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
increase	NN	B-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
+LVdP	NN	B-NP	O
/	SYM	O	O
dt	NN	B-NP	O
)	)	O	O
,	,	O	O
echocardiographically	RB	B-VP	O
assessed	VBN	I-VP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
(	(	O	O
LVEF	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
fractional	JJ	B-NP	O
shortening	NN	I-NP	O
(	(	O	O
FS	NN	B-NP	O
)	)	O	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
chronotropic	JJ	B-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
isoproterenol	NN	B-NP	O
and	CC	I-NP	O
exercise	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
sympathetic	JJ	I-NP	O
stimulation	NN	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
under	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	I-NP	O
posttreatment	NN	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Resting	VBG	B-VP	O
values	NNS	B-NP	O
of	IN	B-PP	O
LVEF	NN	B-NP	O
,	,	O	O
FS	NN	B-NP	O
,	,	O	O
+	SYM	B-NP	O
LVdP	NN	I-NP	O
/	SYM	B-NP	O
dt	NN	I-NP	O
,	,	O	O
and	CC	O	O
MBP	NN	B-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
whatever	WDT	B-NP	O
the	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
dosing	NN	I-NP	O
regimen	NN	I-NP	O
,	,	O	O
whereas	IN	B-PP	O
resting	VBG	B-NP	O
HR	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADVP	O
and	CC	O	O
dose	NN	B-NP	O
-	HYPH	O	O
dependently	RB	B-VP	O
lowered	VBN	I-VP	O
after	IN	B-PP	O
dronedarone	NN	B-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
lesser	JJR	I-NP	O
extent	NN	I-NP	O
after	IN	B-PP	O
amiodarone	NN	B-NP	O
.	.	O	O

Both	CC	O	O
dronedarone	NN	B-NP	O
and	CC	I-NP	O
amiodarone	NN	I-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
exercise	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
tachycardia	NN	I-NP	B
and	CC	O	O
,	,	O	O
at	IN	B-PP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
dose	NN	I-NP	O
,	,	O	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
tachycardia	NN	I-NP	B
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
dronedarone	NN	B-NP	O
and	CC	I-NP	O
amiodarone	NN	I-NP	O
displayed	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
antiadrenergic	JJ	B-NP	O
effect	NN	I-NP	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
impair	VB	I-VP	O
the	DT	B-NP	O
resting	NN	I-NP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Consequently	RB	B-ADVP	O
,	,	O	O
dronedarone	NN	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
particularly	RB	B-ADJP	O
suitable	JJ	I-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
various	JJ	B-NP	O
clinical	JJ	I-NP	O
arrhythmias	NNS	I-NP	B
,	,	O	O
without	IN	B-PP	O
compromising	VBG	B-VP	O
the	DT	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
in	IN	B-PP	O
platinum	NN	B-NP	O
/	SYM	B-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	B-NP	O
refractory	JJ	I-NP	O
ovarian	JJ	I-NP	B
and	CC	I-NP	I
fallopian	JJ	I-NP	I
tube	NN	I-NP	I
cancers	NNS	I-NP	I
and	CC	O	O
primary	JJ	B-NP	O
carcinoma	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
peritoneum	NN	I-NP	I
.	.	O	O

Several	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
Doxil	NN	B-NP	O
)	)	O	O
to	TO	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
active	JJ	I-NP	O
antineoplastic	JJ	I-NP	O
agent	NN	I-NP	O
in	IN	B-PP	O
platinum	NN	B-NP	O
-	HYPH	B-NP	O
resistant	JJ	I-NP	O
ovarian	JJ	I-NP	B
cancer	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
dose	NN	B-NP	O
limiting	VBG	B-VP	O
toxicity	NN	B-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
dosing	NN	I-NP	O
regimen	NN	I-NP	O
being	VBG	B-VP	O
severe	JJ	B-NP	O
erythrodysesthesia	NN	I-NP	B
(	(	O	O
hand	NN	B-NP	B
-	HYPH	B-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
)	)	O	O
and	CC	O	O
stomatitis	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
wished	VBD	B-VP	O
to	TO	I-VP	O
develop	VB	I-VP	O
a	DT	B-NP	O
more	RBR	I-NP	O
tolerable	JJ	I-NP	O
liposomal	JJ	I-NP	O
doxorubicin	NN	I-NP	O
treatment	NN	I-NP	O
regimen	NN	I-NP	O
and	CC	O	O
document	VB	B-VP	O
its	PRP$	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
defined	VBN	I-NP	O
patient	NN	I-NP	O
population	NN	I-NP	O
with	IN	B-PP	O
platinum	NN	B-NP	O
/	SYM	B-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	B-NP	O
refractory	JJ	I-NP	O
disease	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
ovarian	JJ	B-NP	B
or	CC	I-NP	I
fallopian	JJ	I-NP	I
tube	NN	I-NP	I
cancers	NNS	I-NP	I
or	CC	O	O
primary	JJ	B-NP	O
peritoneal	JJ	I-NP	B
carcinoma	NN	I-NP	I
with	IN	B-PP	O
platinum	NN	B-NP	O
/	SYM	B-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	B-NP	O
refractory	JJ	I-NP	O
disease	NN	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
m	NN	B-NP	O
q	NN	I-NP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
;	:	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
entered	VBD	B-VP	O
this	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
trial	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
regimens	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
hand	NN	I-NP	B
-	HYPH	I-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
and	CC	I-NP	O
stomatitis	NN	I-NP	B
,	,	O	O
respectively	RB	B-ADVP	O
(	(	O	O
no	DT	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
grade	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
grade	NN	B-NP	O
num	CD	I-NP	O
diarrhea	NN	I-NP	B
requiring	VBG	B-VP	O
hospitalization	NN	B-NP	O
for	IN	B-PP	O
hydration	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
individuals	NNS	I-NP	O
required	VBD	B-VP	O
dose	NN	B-NP	O
reductions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
courses	NNS	B-NP	O
of	IN	B-PP	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
administered	VBN	B-VP	O
on	IN	B-PP	O
this	DT	B-NP	O
protocol	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
exhibited	VBD	B-VP	O
objective	JJ	B-NP	O
and	CC	I-NP	O
subjective	JJ	I-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
antineoplastic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
modified	VBN	I-NP	O
liposomal	JJ	I-NP	O
doxorubicin	NN	I-NP	O
regimen	NN	I-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
less	JJR	B-NP	O
toxicity	NN	I-NP	B
(	(	O	O
stomatitis	NN	B-NP	B
,	,	O	O
hand	NN	B-NP	B
-	HYPH	B-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
)	)	O	O
than	IN	B-PP	O
the	DT	B-NP	O
standard	JJ	I-NP	O
FDA	NN	I-NP	O
-	HYPH	B-VP	O
approved	VBN	B-NP	O
dose	NN	I-NP	O
schedule	NN	I-NP	O
.	.	O	O

Definite	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
limited	JJ	B-NP	O
,	,	I-NP	O
antineoplastic	JJ	I-NP	O
activity	NN	I-NP	O
is	VBZ	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
well	RB	B-ADVP	O
-	HYPH	I-ADVP	O
defined	VBN	B-NP	O
platinum	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
paclitaxel	NN	I-NP	O
-	HYPH	I-NP	O
refractory	JJ	I-NP	O
ovarian	JJ	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

Efficacy	NN	B-NP	O
of	IN	B-PP	O
olanzapine	NN	B-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
bipolar	JJ	I-NP	B
mania	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
Olanzipine	NNP	I-NP	O
HGGW	NNP	I-NP	O
Study	NNP	I-NP	O
Group	NNP	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
olanzapine	NN	B-NP	O
vs	CC	I-NP	O
placebo	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
bipolar	JJ	I-NP	B
mania	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
parallel	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
DSM	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
,	,	O	O
manic	JJ	B-ADJP	B
or	CC	I-ADJP	O
mixed	JJ	I-ADJP	O
,	,	O	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-PP	O
olanzapine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
d	NN	I-NP	O
,	,	O	O
or	CC	O	O
placebo	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
primary	JJ	I-NP	O
efficacy	NN	I-NP	O
measure	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
Young	NNP	I-NP	O
-	HYPH	I-NP	O
Mania	NNP	I-NP	B
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
(	(	O	O
Y	NN	B-NP	O
-	HYPH	I-NP	O
MRS	NN	I-NP	O
)	)	I-NP	O
total	JJ	I-NP	O
score	NN	I-NP	O
.	.	O	O

Response	NN	B-NP	O
and	CC	I-NP	O
euthymia	NN	I-NP	O
were	VBD	B-VP	O
defined	VBN	I-VP	O
,	,	O	O
a	DT	B-NP	O
priori	NNS	I-NP	O
,	,	O	O
as	IN	B-PP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
improvement	NN	I-NP	O
from	IN	B-PP	O
baseline	NN	B-NP	O
to	TO	B-VP	O
end	VB	I-VP	O
point	NN	B-NP	O
and	CC	B-PP	O
as	IN	B-PP	O
a	DT	B-NP	O
score	NN	I-NP	O
of	IN	B-PP	O
no	DT	B-NP	O
less	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
end	NN	B-NP	O
point	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Y	NN	I-NP	O
-	HYPH	B-NP	O
MRS	NN	I-NP	O
total	JJ	I-NP	O
score	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Safety	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
,	,	O	O
Extrapyramidal	NNP	B-NP	B
Symptom	NNP	I-NP	I
(	(	O	O
EPS	NNP	O	B
)	)	O	O
rating	NN	B-NP	O
scales	NNS	I-NP	O
,	,	O	O
laboratory	NN	B-NP	O
values	NNS	I-NP	O
,	,	O	O
electrocardiograms	NNS	B-NP	O
,	,	O	O
vital	JJ	B-NP	O
signs	NNS	I-NP	O
,	,	O	O
and	CC	O	O
weight	NN	B-NP	O
change	NN	I-NP	O
.	.	O	O

Olanzapine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
greater	JJR	I-NP	O
mean	NN	I-NP	O
(	(	O	O
+	SYM	B-NP	O
/	SYM	O	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
improvement	NN	B-NP	O
in	IN	B-PP	O
Y	NN	B-NP	O
-	HYPH	B-NP	O
MRS	NN	I-NP	O
total	JJ	I-NP	O
score	NN	I-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
evident	JJ	B-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
postbaseline	NN	I-NP	O
observation	NN	I-NP	O
num	CD	I-NP	O
week	NN	I-NP	O
after	IN	B-PP	O
randomization	NN	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
maintained	VBN	I-VP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
(	(	O	O
last	JJ	B-NP	O
observation	NN	I-NP	O
carried	VBD	B-VP	O
forward	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Olanzapine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
and	CC	I-NP	O
euthymia	NN	I-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
EPSs	NNS	B-NP	B
between	IN	B-PP	O
groups	NNS	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
olanzapine	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
greater	JJR	I-NP	O
mean	NN	I-NP	O
(	(	O	O
+	SYM	B-NP	O
/	SYM	O	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
)	)	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
than	IN	B-PP	O
placebo	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
and	CC	O	O
also	RB	B-ADVP	O
experienced	VBD	B-VP	O
more	JJR	B-NP	O
treatment	NN	I-NP	O
-	HYPH	O	O
emergent	NN	B-NP	O
somnolence	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
]	)	O	O
vs	IN	B-PP	O
num	CD	B-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
]	)	O	O
,	,	O	O
respectively	RB	B-ADVP	O
)	)	O	O
.	.	O	O

Olanzapine	NN	B-NP	O
demonstrated	VBD	B-VP	O
greater	JJR	B-NP	O
efficacy	NN	I-NP	O
than	IN	B-PP	O
placebo	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
bipolar	JJ	I-NP	B
mania	NN	I-NP	I
and	CC	O	O
was	VBD	B-VP	O
generally	RB	I-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
pupil	NN	B-NP	B
dilation	NN	I-NP	I
with	IN	B-PP	O
tropicamide	NN	B-NP	O
on	IN	B-PP	O
vision	NN	B-NP	O
and	CC	O	O
driving	VBG	B-VP	O
simulator	NN	B-NP	O
performance	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
pupil	NN	B-NP	B
dilation	NN	I-NP	I
on	IN	B-PP	O
vision	NN	B-NP	O
and	CC	O	O
driving	VBG	B-VP	O
ability	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
series	NN	I-NP	O
of	IN	B-PP	O
tests	NNS	B-NP	O
on	IN	B-PP	O
various	JJ	B-NP	O
parameters	NNS	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
driving	VBG	B-VP	O
simulator	NN	B-NP	O
performance	NN	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
drivers	NNS	I-NP	O
,	,	O	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
pupil	NN	B-NP	B
dilation	NN	I-NP	I
using	VBG	B-VP	O
guttae	NNS	B-NP	O
tropicamide	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
driving	VBG	I-NP	O
simulator	NN	I-NP	O
(	(	O	O
Transport	NNP	B-NP	O
Research	NNP	I-NP	O
Laboratory	NNP	I-NP	O
)	)	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
measure	VB	I-VP	O
reaction	NN	B-NP	O
time	NN	I-NP	O
(	(	O	O
RT	NN	B-NP	O
)	)	O	O
,	,	O	O
speed	NN	B-NP	O
maintenance	NN	I-NP	O
and	CC	I-NP	O
steering	NN	I-NP	O
accuracy	NN	I-NP	O
.	.	O	O

Tests	NNS	B-NP	O
of	IN	B-PP	O
basic	JJ	B-NP	O
visual	JJ	I-NP	O
function	NN	I-NP	O
included	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
contrast	NN	I-NP	O
visual	JJ	I-NP	O
acuity	NN	I-NP	O
(	(	O	O
HCVA	NN	B-NP	O
and	CC	O	O
LCVA	NN	B-NP	O
)	)	O	O
,	,	O	O
Pelli	NNP	B-NP	O
-	HYPH	I-NP	O
Robson	NNP	I-NP	O
contrast	NN	I-NP	O
threshold	NN	I-NP	O
(	(	O	O
CT	NN	B-NP	O
)	)	O	O
and	CC	O	O
Goldmann	NNP	B-NP	O
perimetry	NN	I-NP	O
(	(	O	O
FIELDS	NN	B-NP	O
)	)	O	O
.	.	O	O

Useful	NNP	B-NP	O
Field	NNP	I-NP	O
of	IN	B-PP	O
View	NNP	B-NP	O
(	(	O	O
UFOV	NN	B-NP	O
-	HYPH	B-ADJP	O
-	:	O	O
a	DT	B-NP	O
test	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
attention	NN	I-NP	O
)	)	O	O
was	VBD	B-VP	O
also	RB	I-VP	O
undertaken	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
dilatation	NN	I-NP	O
measurements	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
level	NN	I-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
tail	NN	I-NP	O
paired	JJ	I-NP	O
t	NN	I-NP	O
-	HYPH	B-NP	O
tests	NNS	I-NP	O
.	.	O	O

Pupillary	JJ	B-NP	B
dilation	NN	I-NP	I
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
deterioration	NN	I-NP	O
in	IN	B-PP	O
CT	NN	B-NP	O
and	CC	I-NP	O
HCVA	NN	I-NP	O
only	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
drivers	NNS	I-NP	O
also	RB	B-ADVP	O
exhibited	VBD	B-VP	O
deterioration	NN	B-NP	O
in	IN	B-PP	O
LCVA	NN	B-NP	O
,	,	I-NP	O
CT	NN	I-NP	O
and	CC	I-NP	O
RT	NN	I-NP	O
.	.	O	O

Little	JJ	B-NP	O
evidence	NN	I-NP	O
emerged	VBD	B-VP	O
for	IN	B-PP	O
deterioration	NN	B-NP	O
in	IN	B-PP	O
FIELDS	NN	B-NP	O
and	CC	I-NP	O
UFOV	NN	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
drivers	NNS	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
adjust	VB	I-VP	O
their	PRP$	B-NP	O
driving	NN	I-NP	O
behaviour	NN	I-NP	O
by	IN	B-PP	O
reducing	VBG	B-VP	O
their	PRP$	B-NP	O
speed	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
driving	VBG	I-NP	O
simulator	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
improved	VBN	B-NP	O
steering	NN	I-NP	O
accuracy	NN	I-NP	O
.	.	O	O

Pupillary	JJ	B-NP	B
dilation	NN	I-NP	I
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
vision	NN	B-NP	O
and	CC	I-NP	O
daylight	NN	I-NP	O
driving	VBG	B-VP	O
performance	NN	B-NP	O
in	IN	B-PP	O
young	JJ	B-NP	O
people	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
larger	JJR	I-NP	O
study	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
a	DT	B-NP	O
broader	JJR	I-NP	O
spectrum	NN	I-NP	O
of	IN	B-PP	O
subjects	NNS	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
before	IN	B-SBAR	O
guidelines	NNS	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
recommended	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
isotretinoin	NN	B-NP	B
embryopathy	NN	I-NP	I
with	IN	B-PP	O
bilateral	JJ	B-NP	O
anotia	NN	I-NP	B
and	CC	I-NP	O
Taussig	NN	I-NP	B
-	HYPH	O	I
Bing	VBG	B-VP	I
malformation	NN	B-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
newborn	JJ	I-NP	O
infant	NN	I-NP	O
with	IN	B-PP	O
multiple	JJ	B-NP	O
congenital	JJ	I-NP	O
anomalies	NNS	I-NP	O
(	(	O	O
anotia	NN	B-NP	B
and	CC	I-NP	O
Taussig	NN	I-NP	B
-	HYPH	O	I
Bing	VBG	B-VP	I
malformation	NN	B-NP	I
)	)	O	O
due	IN	B-PP	O
to	TO	B-PP	O
exposure	NN	B-NP	O
to	TO	B-PP	O
isotretinoin	NN	B-NP	O
within	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
trimester	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
paper	NN	I-NP	O
we	PRP	B-NP	O
aim	VBP	B-VP	O
to	TO	I-VP	O
draw	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
fact	NN	I-NP	O
that	IN	B-SBAR	O
caution	NN	B-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
when	WRB	B-ADVP	O
prescribing	VBG	B-VP	O
vitamin	NN	B-NP	O
A	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
drugs	NNS	B-NP	O
to	TO	B-PP	O
women	NNS	B-NP	O
of	IN	B-PP	O
childbearing	VBG	B-VP	O
years	NNS	B-NP	O
.	.	O	O

Effect	NN	B-NP	O
of	IN	B-PP	O
methoxamine	NN	B-NP	O
on	IN	B-PP	O
maximum	JJ	B-NP	O
urethral	JJ	I-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
genuine	JJ	B-NP	O
stress	NN	I-NP	B
incontinence	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
placebo	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-VP	O
,	,	O	O
double	JJ	B-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
crossover	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
alpha1	NN	I-NP	O
-	HYPH	B-NP	O
adrenoceptor	NN	I-NP	O
agonist	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
urinary	JJ	B-NP	B
stress	NN	I-NP	I
incontinence	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
randomised	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
crossover	NN	B-NP	O
study	NN	I-NP	O
design	NN	I-NP	O
was	VBD	B-VP	O
employed	VBN	I-VP	O
.	.	O	O

Half	NN	B-NP	O
log	NN	I-NP	O
incremental	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
methoxamine	NN	I-NP	O
or	CC	O	O
placebo	NN	B-NP	O
(	(	O	O
saline	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
genuine	JJ	B-NP	O
stress	NN	I-NP	B
incontinence	NN	I-NP	I
while	IN	B-SBAR	O
measuring	VBG	B-VP	O
maximum	JJ	B-NP	O
urethral	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
MUP	NN	B-NP	O
)	)	O	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
and	CC	O	O
symptomatic	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Methoxamine	NN	B-NP	O
evoked	VBD	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
MUP	NN	B-NP	O
and	CC	O	O
diastolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
but	CC	O	O
caused	VBD	B-VP	O
a	DT	B-NP	B
significant	JJ	I-NP	I
rise	NN	I-NP	I
in	IN	B-PP	I
systolic	JJ	B-NP	I
blood	NN	I-NP	I
pressure	NN	I-NP	I
and	CC	O	O
significant	JJ	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
at	IN	B-PP	O
maximum	JJ	B-NP	O
dosage	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
including	VBG	B-PP	O
piloerection	NN	B-NP	O
,	,	O	O
headache	NN	B-NP	B
,	,	O	O
and	CC	O	O
cold	JJ	B-NP	O
extremities	NNS	I-NP	O
were	VBD	B-VP	O
experienced	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
usefulness	NN	I-NP	O
of	IN	B-PP	O
direct	JJ	B-NP	O
,	,	O	O
peripherally	RB	B-VP	O
acting	VBG	I-VP	O
sub	AFX	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
alpha1	NN	I-NP	O
-	HYPH	O	O
adrenoceptor	NN	B-NP	O
agonists	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
stress	NN	B-NP	B
incontinence	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
limited	VBN	I-VP	O
by	IN	B-PP	O
associated	VBN	B-NP	O
piloerection	NN	I-NP	O
and	CC	O	O
cardiovascular	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Toleration	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitors	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
:	:	O	O
results	NNS	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
ATLAS	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
Assessment	NN	I-NP	O
of	IN	B-PP	O
Treatment	NN	B-NP	O
with	IN	B-PP	O
Lisinopril	NNP	B-NP	O
and	CC	O	O
Survival	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
angiotensin	NN	B-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitors	NNS	B-NP	O
reduces	VBZ	B-VP	O
mortality	NN	B-NP	O
and	CC	I-NP	O
morbidity	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
(	(	O	O
CHF	NN	B-NP	B
)	)	O	O
,	,	O	O
but	CC	O	O
most	JJS	B-VP	O
affected	VBN	I-VP	O
patients	NNS	B-NP	O
are	VBP	B-VP	O
not	RB	I-VP	O
receiving	VBG	I-VP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
or	CC	O	O
are	VBP	B-VP	O
being	VBG	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
doses	NNS	B-NP	O
lower	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
found	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
efficacious	JJ	B-ADJP	O
in	IN	B-PP	O
trials	NNS	B-NP	O
,	,	O	O
primarily	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
concerns	NNS	B-NP	O
about	IN	B-PP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
at	IN	B-PP	O
the	DT	B-NP	O
recommended	VBN	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
examines	VBZ	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
lisinopril	NN	I-NP	O
in	IN	B-PP	O
CHF	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
Assessment	NNP	I-NP	O
of	IN	B-PP	O
Lisinopril	NNP	B-NP	O
and	CC	O	O
Survival	NN	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trial	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
previous	JJ	B-NP	O
ACE	NN	I-NP	O
inhibitor	NN	I-NP	O
treatment	NN	I-NP	O
were	VBD	B-VP	O
stabilized	VBN	I-VP	O
receiving	VBG	B-VP	O
medium	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
lisinopril	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
then	RB	B-VP	O
randomized	VBD	I-VP	O
to	TO	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
or	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
New	NNP	B-NP	O
York	NNP	I-NP	O
Heart	NNP	I-NP	O
Association	NNP	I-NP	O
classes	NNS	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
CHF	NN	I-NP	B
and	CC	O	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
ejection	NN	I-NP	O
fractions	NNS	I-NP	O
of	IN	B-PP	O
no	DT	B-NP	O
greater	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
and	CC	O	O
followed	VBN	B-VP	O
up	RP	B-PRT	O
for	IN	B-PP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
discontinuation	NN	B-NP	O
and	CC	I-NP	O
dose	NN	I-NP	O
reduction	NN	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
focus	NN	I-NP	O
on	IN	B-PP	O
hypotension	NN	B-NP	B
and	CC	O	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
not	RB	O	O
previously	RB	B-VP	O
receiving	VBG	I-VP	O
an	DT	B-NP	O
ACE	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
doses	VBZ	B-VP	O
in	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
could	MD	B-VP	O
not	RB	I-VP	O
be	VB	I-VP	O
titrated	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
medium	NN	I-NP	O
doses	NNS	I-NP	O
required	VBN	B-VP	O
for	IN	B-PP	O
randomization	NN	B-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
symptoms	NNS	B-NP	O
possibly	RB	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
hypotension	NN	B-NP	B
or	CC	O	O
because	IN	B-PP	O
of	IN	I-PP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
or	CC	I-NP	O
hyperkalemia	NN	I-NP	B
.	.	O	O

Doses	NNS	B-NP	O
in	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
randomized	VBN	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
titrated	VBN	I-VP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
assigned	VBN	I-NP	O
target	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
blinded	JJ	B-NP	O
medication	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
remained	VBD	B-VP	O
similar	JJ	B-ADJP	O
throughout	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Withdrawals	NNS	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Subgroups	NNS	B-NP	O
presumed	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
at	IN	B-PP	O
higher	JJR	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
ACE	NN	B-NP	O
inhibitor	NN	I-NP	O
intolerance	NN	I-NP	O
generally	RB	B-ADVP	O
tolerated	VBD	B-VP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
strategy	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
ACE	NN	B-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
most	JJS	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
CHF	NN	B-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
successfully	RB	I-VP	O
titrated	VBN	I-VP	O
to	TO	B-PP	O
and	CC	O	O
maintained	VBN	B-VP	O
at	IN	B-PP	O
high	JJ	B-NP	O
doses	NNS	I-NP	O
,	,	O	O
and	CC	O	O
that	IN	B-SBAR	O
more	RBR	B-NP	O
aggressive	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Cocaine	NN	B-NP	O
,	,	O	O
ethanol	NN	B-NP	O
,	,	O	O
and	CC	O	O
cocaethylene	NN	B-NP	O
cardiotoxity	NN	I-NP	B
in	IN	B-PP	O
an	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
and	CC	I-NP	I
ethanol	NN	I-NP	I
abuse	NN	I-NP	I
.	.	O	O

Simultaneous	JJ	B-NP	O
abuse	NN	I-NP	B
of	IN	B-PP	I
cocaine	NN	B-NP	I
and	CC	I-NP	I
ethanol	NN	I-NP	I
affects	VBZ	B-VP	O
num	CD	B-NP	O
num	CD	I-NP	O
Americans	NNPS	I-NP	O
annually	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
combination	NN	B-NP	O
,	,	O	O
these	DT	B-NP	O
substances	NNS	I-NP	O
are	VBP	B-VP	O
substantially	RB	B-ADJP	O
more	RBR	I-ADJP	O
toxic	JJ	I-ADJP	O
than	IN	B-PP	O
either	DT	B-NP	O
drug	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Their	PRP$	B-NP	O
combined	JJ	I-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
independent	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
drug	NN	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
they	PRP	B-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
cocaethylene	NN	B-NP	O
(	(	O	O
CE	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
cocaine	NN	I-NP	O
metabolite	NN	I-NP	O
formed	VBN	B-VP	O
only	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
ethanol	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
delineate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
CE	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
combined	JJ	I-NP	O
cardiotoxicity	NN	I-NP	B
of	IN	B-PP	O
cocaine	NN	B-NP	O
and	CC	I-NP	O
ethanol	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
simulating	VBG	B-VP	O
their	PRP$	B-NP	O
abuse	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	O	O
num	CD	B-NP	O
)	)	O	O
num	CD	B-NP	O
intravenous	JJ	I-NP	O
num	CD	I-NP	O
cocaine	NN	I-NP	O
boluses	NNS	I-NP	O
only	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
ethanol	NN	B-NP	O
infusion	NN	I-NP	O
only	RB	B-ADVP	O
,	,	O	O
or	CC	O	O
num	CD	O	O
)	)	O	O
placebo	NN	B-NP	O
boluses	NNS	I-NP	O
and	CC	O	O
infusion	NN	B-NP	O
.	.	O	O

Hemodynamic	JJ	B-NP	O
measurements	NNS	I-NP	O
,	,	O	O
electrocardiograms	NNS	B-NP	O
,	,	O	O
and	CC	O	O
serum	NN	B-NP	O
drug	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
and	CC	O	O
then	RB	B-ADVP	O
at	IN	B-PP	O
fixed	VBN	B-NP	O
time	NN	I-NP	O
intervals	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
drug	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
dogs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
C+E	NN	I-NP	O
group	NN	I-NP	O
experienced	VBD	B-VP	O
cardiovascular	JJ	B-NP	B
collapse	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
dramatic	JJ	I-NP	O
hemodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
occurred	VBD	B-VP	O
after	IN	B-SBAR	O
each	DT	B-NP	O
cocaine	NN	I-NP	O
bolus	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
C+E	NN	I-NP	O
and	CC	I-NP	O
C	NN	I-NP	O
only	JJ	I-NP	O
groups	NNS	I-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
persistent	JJ	B-NP	O
hemodynamic	JJ	I-NP	O
changes	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
C+E	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Peak	JJ	B-NP	O
CE	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	B
in	IN	B-PP	I
cardiac	JJ	B-NP	I
output	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
dP	NN	B-NP	O
/	SYM	O	O
dt	NN	B-NP	O
(	(	O	O
max	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
SVO	NN	B-NP	O
.	.	O	O

Ventricular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
were	VBD	B-VP	O
primarily	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
C+E	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
which	WDT	B-NP	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
dogs	NNS	I-NP	O
experienced	VBD	B-VP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

Cocaine	NN	B-NP	O
and	CC	I-NP	O
ethanol	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
were	VBD	B-VP	O
more	RBR	B-ADJP	O
toxic	JJ	I-ADJP	O
than	IN	B-PP	O
either	DT	B-NP	O
substance	NN	I-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
prolonged	JJ	B-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
and	CC	O	O
was	VBD	B-VP	O
dysrhythmogenic	JJ	B-ADJP	O
.	.	O	O

Peak	JJ	B-NP	O
serum	NN	I-NP	O
cocaethylene	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
prolonged	JJ	B-NP	O
myocardial	JJ	I-NP	B
depression	NN	I-NP	I
.	.	O	O

Worsening	NN	B-NP	O
of	IN	B-PP	O
Parkinsonism	NNP	B-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
veralipride	NN	B-NP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
menopause	NN	B-NP	O
:	:	O	O
case	NN	B-NP	O
report	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
female	JJ	I-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
stable	JJ	B-NP	O
Parkinson	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
who	WP	B-NP	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
worsening	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
motor	NN	I-NP	O
functions	NNS	I-NP	O
following	VBG	B-PP	O
therapy	NN	B-NP	O
of	IN	B-PP	O
menopause	NN	B-NP	O
related	VBN	B-VP	O
symptoms	NNS	B-NP	O
with	IN	B-PP	O
veralipride	NN	B-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
improvement	NN	I-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
symptoms	NNS	I-NP	O
back	RB	B-ADVP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
emphasize	VBP	B-VP	O
the	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
dopaminergic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
veralipride	NN	B-NP	O
.	.	O	O

Viracept	JJ	B-NP	O
and	CC	I-NP	O
irregular	JJ	I-NP	B
heartbeat	NN	I-NP	I
warning	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
doctors	NNS	B-NP	O
in	IN	B-PP	O
Boston	NNP	B-NP	O
warn	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
protease	NN	I-NP	O
inhibitor	NN	I-NP	O
Viracept	NN	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
an	DT	B-NP	O
irregular	JJ	I-NP	B
heart	NN	I-NP	I
beat	NN	I-NP	I
,	,	O	O
known	VBN	B-VP	O
as	IN	B-PP	O
bradycardia	NN	B-NP	B
,	,	O	O
in	IN	B-PP	O
people	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
.	.	O	O

Bradycardia	NNP	B-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
was	VBD	B-VP	O
Viracept	VBN	I-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
HIV	NN	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
symptoms	NNS	I-NP	O
ceased	VBD	B-VP	O
after	IN	B-PP	O
switching	VBG	B-VP	O
to	TO	B-PP	O
another	DT	B-NP	O
drug	NN	I-NP	O
combination	NN	I-NP	O
.	.	O	O

Frequency	NN	B-NP	O
of	IN	B-PP	O
appearance	NN	B-NP	O
of	IN	B-PP	O
myeloperoxidase	NN	B-NP	O
-	HYPH	B-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
antibody	NN	I-NP	O
(	(	O	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
Graves	NN	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
propylthiouracil	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
manifestations	NNS	I-NP	O
.	.	O	O

Myeloperoxidase	NN	B-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
antibody	NN	I-NP	O
(	(	O	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
positive	JJ	I-NP	O
vasculitis	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Graves	NN	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
propylthiouracil	NN	B-NP	O
(	(	O	O
PTU	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
cases	NNS	I-NP	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
of	IN	B-PP	O
being	VBG	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
PTU	NN	B-NP	O
because	IN	B-SBAR	O
the	DT	B-NP	O
titres	NNS	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
decreased	VBD	B-VP	O
when	WRB	B-ADVP	O
PTU	NN	B-NP	O
was	VBD	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

Nevertheless	RB	B-ADVP	O
,	,	O	O
there	EX	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
no	DT	B-NP	O
studies	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
and	CC	I-NP	O
vasculitis	NN	I-NP	B
during	IN	B-PP	O
PTU	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
or	CC	O	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
in	IN	B-PP	O
untreated	JJ	B-NP	O
Graves	NN	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
address	VB	I-VP	O
these	DT	B-NP	O
parameters	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Graves	NN	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
investigated	VBD	B-VP	O
num	CD	B-NP	O
untreated	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
due	JJ	B-ADJP	O
to	TO	B-PP	O
Graves	NN	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
for	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
,	,	O	O
and	CC	O	O
for	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
vasculitis	NN	I-NP	B
after	IN	B-PP	O
starting	VBG	B-VP	O
PTU	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
were	VBD	B-VP	O
later	RB	I-VP	O
excluded	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
PTU	NN	B-NP	O
or	CC	O	O
because	IN	B-SBAR	O
the	DT	B-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
remaining	VBG	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
)	)	O	O
,	,	O	O
all	DT	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
adopted	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
subjects	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
median	JJ	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

MPO	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
at	IN	B-PP	O
intervals	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

Before	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
MPO	NN	I-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
titres	NNS	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
untreated	JJ	I-NP	O
Graves	NN	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patients	NNS	I-NP	O
were	VBD	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
reference	NN	I-NP	O
range	NN	I-NP	O
(	(	O	O
below	IN	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
for	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	I-NP	O
ANCA	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
PTU	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
,	,	O	O
the	DT	B-NP	O
MPO	NN	I-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
titres	NNS	I-NP	O
transiently	RB	B-ADVP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	O	O
ml	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
despite	IN	B-PP	O
continued	VBN	B-NP	O
PTU	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
but	CC	O	O
no	DT	B-NP	O
vasculitic	JJ	I-NP	B
disorders	NNS	I-NP	I
developed	VBD	B-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
patient	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
MPO	NN	I-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
titre	NN	I-NP	O
increased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
and	CC	O	O
she	PRP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
fever	NN	I-NP	B
,	,	O	O
oral	JJ	B-NP	B
ulcers	NNS	I-NP	I
and	CC	O	O
polyarthralgia	NN	B-NP	B
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
resolved	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
PTU	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
MPO	NN	I-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
titre	NN	I-NP	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
PTU	NN	B-NP	O
.	.	O	O

PTU	NN	B-NP	O
therapy	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
MPO	NN	B-NP	O
-	HYPH	B-NP	O
ANCA	NN	I-NP	O
,	,	O	O
but	CC	O	O
MPO	NN	B-NP	O
-	HYPH	O	O
ANCA	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
closely	RB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
vasculitis	NN	B-NP	B
.	.	O	O

Prevalence	NN	B-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
asymptomatic	JJ	B-NP	O
chronic	JJ	I-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	B
disease	NN	I-NP	I
in	IN	B-PP	O
outpatient	NN	B-NP	O
young	JJ	I-NP	O
asymptomatic	JJ	I-NP	O
chronic	JJ	I-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
age	NN	I-NP	O
-	HYPH	B-NP	O
matched	VBN	I-NP	O
controls	NNS	I-NP	O
underwent	VBD	B-VP	O
resting	VBG	I-VP	O
and	CC	O	O
exercise	NN	B-NP	O
electrocardiography	NN	I-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
and	CC	O	O
Doppler	NN	B-NP	O
echocardiography	NN	I-NP	O
.	.	O	O

Findings	NNS	B-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
were	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Decreased	VBN	B-VP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
systolic	JJ	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
demonstrated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Finally	RB	B-ADVP	O
,	,	O	O
resting	VBG	B-NP	O
and	CC	I-NP	O
peak	JJ	I-NP	O
exercise	NN	I-NP	O
abnormal	JJ	I-NP	B
left	JJ	I-NP	I
ventricular	JJ	I-NP	I
filling	NN	I-NP	I
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
or	CC	O	I
myocardial	JJ	B-NP	I
disease	NN	I-NP	I
is	VBZ	B-VP	O
common	JJ	B-ADJP	O
in	IN	B-PP	O
young	JJ	B-NP	O
asymptomatic	JJ	I-NP	O
chronic	JJ	I-NP	O
cocaine	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
screening	VBG	B-VP	O
ECG	NN	B-NP	O
and	CC	I-NP	O
echocardiography	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
warranted	VBN	I-VP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Cardioprotective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Picrorrhiza	NNP	B-NP	O
kurroa	NN	I-NP	O
against	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
cardioprotective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ethanol	NN	I-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
Picrorrhiza	NNP	B-NP	O
kurroa	NN	I-NP	O
rhizomes	NNS	I-NP	O
and	CC	I-NP	O
roots	NNS	I-NP	O
(	(	O	O
PK	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
isoproterenol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
lipid	NN	B-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
tissue	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Oral	JJ	O	O
pre	AFX	O	O
-	HYPH	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
PK	NN	B-NP	O
significantly	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
and	CC	O	O
maintained	VBD	B-VP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
at	IN	B-PP	O
near	IN	B-PP	O
normal	JJ	B-NP	O
status	NN	I-NP	O
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
early	JJ	I-NP	O
afterdepolarization	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
trigger	NN	I-NP	O
of	IN	B-PP	O
polymorphic	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
in	IN	B-PP	O
acquired	VBN	B-NP	O
long	JJ	I-NP	B
-	HYPH	I-NP	I
QT	NN	I-NP	I
syndrome	NN	I-NP	I
:	:	O	O
direct	JJ	B-NP	O
evidence	NN	I-NP	O
from	IN	B-PP	O
intracellular	JJ	B-NP	O
recordings	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
intact	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
phase	NN	B-NP	O
num	CD	I-NP	O
early	JJ	I-NP	O
afterdepolarization	NN	I-NP	O
(	(	O	O
EAD	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
producing	VBG	B-VP	O
a	DT	B-NP	O
trigger	NN	I-NP	O
to	TO	B-VP	O
initiate	VB	I-VP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
TdP	NN	B-NP	B
)	)	O	O
with	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
dl	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
and	CC	I-NP	O
azimilide	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
transmural	JJ	B-NP	O
dispersion	NN	I-NP	O
of	IN	B-PP	O
repolarization	NN	B-NP	O
(	(	O	O
TDR	NN	B-NP	O
)	)	O	O
to	TO	B-PP	O
transmural	JJ	B-NP	O
propagation	NN	I-NP	O
of	IN	B-PP	O
EAD	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
maintenance	NN	I-NP	O
of	IN	B-PP	O
TdP	NN	B-NP	B
was	VBD	B-VP	O
also	RB	I-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Transmembrane	NN	B-NP	O
action	NN	I-NP	O
potentials	NNS	I-NP	O
from	IN	B-PP	O
epicardium	NN	B-NP	O
,	,	O	O
midmyocardium	NN	B-NP	O
,	,	O	O
and	CC	O	O
endocardium	NN	B-NP	O
were	VBD	B-VP	O
recorded	VBN	I-VP	O
simultaneously	RB	B-ADVP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
transmural	JJ	I-NP	O
ECG	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
arterially	RB	B-NP	O
perfused	VBN	I-NP	O
canine	NN	I-NP	O
and	CC	I-NP	O
rabbit	NN	I-NP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
preparations.	JJ	I-NP	O
dl	NN	I-NP	O
-	HYPH	B-NP	O
Sotalol	NN	I-NP	O
preferentially	RB	B-ADVP	O
prolonged	VBD	B-VP	O
action	NN	B-NP	O
potential	NN	I-NP	O
duration	NN	I-NP	O
(	(	O	O
APD	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
M	NN	B-NP	O
cells	NNS	I-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
dependently	RB	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micromol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
TDR	NN	B-NP	O
.	.	O	O

Azimilide	NN	B-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
significantly	RB	B-VP	O
prolonged	VBD	I-VP	O
APD	NN	B-NP	O
and	CC	I-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
at	IN	B-PP	O
concentrations	NNS	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
but	CC	O	O
shortened	VBD	B-VP	O
them	PRP	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

Unlike	IN	B-PP	O
dl	NN	B-NP	O
-	HYPH	O	O
sotalol	NN	B-NP	O
,	,	O	O
azimilide	NN	B-NP	O
increased	VBD	B-VP	O
epicardial	JJ	B-NP	O
APD	NN	I-NP	O
markedly	RB	B-ADVP	O
,	,	O	O
causing	VBG	B-VP	O
a	DT	B-NP	O
diminished	JJ	I-NP	O
TDR	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
both	CC	O	O
dl	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
and	CC	I-NP	O
azimilide	NN	I-NP	O
rarely	RB	B-ADVP	O
induced	VBD	B-VP	O
EADs	NNS	B-NP	O
in	IN	B-PP	O
canine	JJ	B-NP	O
left	JJ	I-NP	O
ventricles	NNS	I-NP	O
,	,	O	O
they	PRP	B-NP	O
produced	VBD	B-VP	O
frequent	JJ	B-NP	O
EADs	NNS	I-NP	O
in	IN	B-PP	O
rabbits	NNS	B-NP	O
,	,	O	O
in	IN	B-PP	O
which	WDT	B-NP	O
more	RBR	B-NP	O
pronounced	JJ	I-NP	O
QT	NN	I-NP	B
prolongation	NN	I-NP	I
was	VBD	B-VP	O
seen	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
TDR	NN	B-NP	O
by	IN	B-PP	O
dl	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
facilitated	VBD	B-VP	O
transmural	JJ	B-NP	O
propagation	NN	I-NP	O
of	IN	B-PP	O
EADs	NNS	B-NP	O
that	WDT	B-NP	O
initiated	VBD	B-VP	O
multiple	JJ	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
TdP	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
rabbit	NN	I-NP	O
left	JJ	I-NP	O
ventricles	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
note	NN	B-NP	O
,	,	O	O
although	IN	B-SBAR	O
azimilide	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
micromol	NN	I-NP	O
/	SYM	I-NP	O
L	NN	I-NP	O
)	)	O	O
increased	VBD	B-VP	O
APD	NN	B-NP	O
more	JJR	B-ADJP	O
than	IN	B-PP	O
dl	NN	B-NP	O
-	HYPH	B-NP	O
sotalol	NN	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
EADs	NNS	I-NP	O
often	RB	B-ADVP	O
failed	VBD	B-VP	O
to	TO	I-VP	O
propagate	VB	I-VP	O
transmurally	RB	B-ADVP	O
,	,	O	O
probably	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
diminished	JJ	I-NP	O
TDR	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
provides	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
direct	JJ	I-NP	O
evidence	NN	I-NP	O
from	IN	B-PP	O
intracellular	JJ	B-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
recordings	NNS	I-NP	O
that	IN	B-SBAR	O
phase	NN	B-NP	O
num	CD	I-NP	O
EAD	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
generated	VBN	I-VP	O
from	IN	B-PP	O
intact	JJ	B-NP	O
ventricular	JJ	I-NP	O
wall	NN	I-NP	O
and	CC	O	O
produce	VBP	B-VP	O
a	DT	B-NP	O
trigger	NN	I-NP	O
to	TO	B-VP	O
initiate	VB	I-VP	O
the	DT	B-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
TdP	NN	B-NP	B
under	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
.	.	O	O

Prenatal	JJ	B-NP	O
cocaine	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
cranial	JJ	B-NP	O
sonographic	JJ	I-NP	O
findings	NNS	I-NP	O
in	IN	B-PP	O
preterm	JJ	B-NP	B
infants	NNS	I-NP	I
.	.	O	O

Prenatal	JJ	B-NP	O
cocaine	NN	I-NP	O
exposure	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
linked	VBN	I-VP	O
with	IN	B-PP	O
subependymal	JJ	B-NP	O
hemorrhage	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
cysts	NNS	B-NP	B
that	WDT	B-NP	O
are	VBP	B-VP	O
detectable	JJ	B-ADJP	O
on	IN	B-PP	O
cranial	JJ	B-NP	O
sonography	NN	I-NP	O
in	IN	B-PP	O
neonates	NNS	B-NP	O
born	VBN	B-VP	O
at	IN	B-PP	O
term	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
prenatal	JJ	B-NP	O
cocaine	NN	I-NP	O
exposure	NN	I-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
subependymal	JJ	B-NP	B
cysts	NNS	I-NP	I
in	IN	B-PP	O
preterm	JJ	B-NP	B
infants	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
retrospectively	RB	B-ADVP	O
reviewed	VBD	B-VP	O
the	DT	B-NP	O
medical	JJ	I-NP	O
records	NNS	I-NP	O
and	CC	O	O
cranial	JJ	B-NP	O
sonograms	NNS	I-NP	O
obtained	VBN	B-VP	O
during	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
on	IN	B-PP	O
num	CD	B-NP	O
premature	JJ	I-NP	B
infants	NNS	I-NP	I
.	.	O	O

Infants	NNS	B-NP	O
were	VBD	B-VP	O
categorized	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
those	DT	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
and	CC	O	O
those	DT	B-NP	O
not	RB	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

Infants	NNS	B-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
cocaine	NN	I-NP	O
-	HYPH	B-VP	O
exposed	VBN	B-NP	O
group	NN	I-NP	O
if	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
maternal	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	B
abuse	NN	I-NP	I
during	IN	B-PP	O
pregnancy	NN	B-NP	O
or	CC	O	O
if	IN	B-SBAR	O
maternal	JJ	B-NP	O
or	CC	I-NP	O
neonatal	JJ	I-NP	O
urine	NN	I-NP	O
toxicology	NN	I-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
delivery	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
infants	NNS	I-NP	O
were	VBD	B-VP	O
excluded	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
insufficient	JJ	B-NP	O
medical	JJ	I-NP	O
and	CC	I-NP	O
drug	NN	I-NP	O
histories	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
subependymal	JJ	B-NP	B
cysts	NNS	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
remaining	VBG	I-NP	O
infants	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
subependymal	JJ	B-NP	B
cysts	NNS	I-NP	I
in	IN	B-PP	O
infants	NNS	B-NP	O
exposed	VBN	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
prenatally	RB	B-ADVP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
unexposed	JJ	I-NP	O
group	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
subependymal	JJ	B-NP	B
cyst	NN	I-NP	I
formation	NN	I-NP	O
in	IN	B-PP	O
preterm	JJ	B-NP	B
infants	NNS	I-NP	I
who	WP	B-NP	O
were	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
prenatally	RB	B-ADVP	O
.	.	O	O

This	DT	B-NP	O
result	NN	I-NP	O
is	VBZ	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
results	NNS	B-NP	O
of	IN	B-PP	O
similar	JJ	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
term	NN	B-NP	O
infants	NNS	I-NP	O
.	.	O	O

Thalidomide	NN	B-NP	O
neuropathy	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
thalidomide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neuropathy	NN	I-NP	B
using	VBG	B-VP	O
electrodiagnostic	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
metastatic	JJ	B-NP	O
androgen	NN	I-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
in	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
thalidomide	NN	I-NP	O
underwent	VBD	B-VP	O
neurologic	JJ	B-NP	O
examinations	NNS	I-NP	O
and	CC	O	O
nerve	NN	B-NP	O
conduction	NN	I-NP	O
studies	NNS	I-NP	O
(	(	O	O
NCS	NNS	B-NP	O
)	)	O	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
and	CC	B-PP	O
at	IN	I-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
intervals	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

NCS	NN	B-NP	O
included	VBD	B-VP	O
recording	NN	B-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	O
nerve	NN	I-NP	O
action	NN	I-NP	O
potentials	NNS	I-NP	O
(	(	O	O
SNAPs	NNS	B-NP	O
)	)	O	O
from	IN	B-PP	O
median	JJ	B-NP	O
,	,	I-NP	O
radial	JJ	I-NP	O
,	,	I-NP	O
ulnar	JJ	I-NP	O
,	,	O	O
and	CC	O	O
sural	JJ	B-NP	O
nerves	NNS	I-NP	O
.	.	O	O

SNAP	NN	B-NP	O
amplitudes	NNS	I-NP	O
for	IN	B-PP	O
each	DT	B-NP	O
nerve	NN	I-NP	O
were	VBD	B-VP	O
expressed	VBN	I-VP	O
as	IN	B-PP	O
the	DT	B-NP	O
percentage	NN	I-NP	O
of	IN	B-PP	O
its	PRP$	B-NP	O
baseline	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
mean	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
termed	VBN	I-VP	O
the	DT	B-NP	O
SNAP	NN	I-NP	O
index	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SNAP	NN	I-NP	O
index	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
clinically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

Thalidomide	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
for	IN	B-PP	O
lack	NN	B-NP	O
of	IN	B-PP	O
therapeutic	JJ	B-NP	O
response	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
initially	RB	B-VP	O
enrolled	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
remained	VBD	B-VP	O
on	IN	B-PP	O
thalidomide	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
remained	VBD	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
remained	VBD	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
neuropathy	NN	B-NP	B
.	.	O	O

Clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
a	DT	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
SNAP	NN	I-NP	O
index	NN	I-NP	O
occurred	VBD	B-VP	O
concurrently	RB	B-ADVP	O
.	.	O	O

Older	JJR	B-NP	O
age	NN	I-NP	O
and	CC	O	O
cumulative	JJ	B-NP	O
dose	NN	I-NP	O
were	VBD	B-VP	O
possible	JJ	B-NP	O
contributing	VBG	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Neuropathy	NN	B-NP	B
may	MD	B-VP	O
thus	RB	I-VP	O
be	VB	I-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
SNAP	NN	I-NP	O
index	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
monitor	VB	I-VP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
,	,	O	O
but	CC	O	O
not	RB	B-PP	O
for	IN	I-PP	O
early	JJ	B-NP	O
detection	NN	I-NP	O
.	.	O	O

Overexpression	NN	B-NP	O
of	IN	B-PP	O
copper	NN	B-NP	O
/	SYM	B-NP	O
zinc	NN	I-NP	O
-	HYPH	B-NP	O
superoxide	NN	I-NP	O
dismutase	NN	I-NP	O
protects	VBZ	B-VP	O
from	IN	B-PP	O
kanamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hearing	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
participation	NN	I-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
in	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ototoxicity	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
deduced	VBN	I-VP	O
from	IN	B-PP	O
observations	NNS	B-NP	O
that	IN	B-SBAR	O
aminoglycoside	NN	B-NP	O
-	HYPH	O	O
iron	NN	B-NP	O
complexes	NNS	I-NP	O
catalyze	VBP	B-VP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
radicals	NNS	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
and	CC	O	O
that	IN	B-SBAR	O
antioxidants	NNS	B-NP	O
attenuate	VBP	B-VP	O
ototoxicity	NN	B-NP	B
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
overexpression	NN	B-NP	O
of	IN	B-PP	O
Cu	NN	B-NP	O
/	SYM	B-NP	O
Zn	NN	I-NP	O
-	HYPH	O	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
(	(	O	O
h	NN	B-NP	O
-	HYPH	B-NP	O
SOD1	NN	I-NP	O
)	)	O	O
should	MD	B-VP	O
protect	VB	I-VP	O
transgenic	JJ	B-NP	O
mice	NNS	I-NP	O
from	IN	B-PP	O
ototoxicity	NN	B-NP	B
.	.	O	O

Immunocytochemistry	NN	B-NP	O
confirmed	VBD	B-VP	O
expression	NN	B-NP	O
of	IN	B-PP	O
h	NN	B-NP	O
-	HYPH	B-NP	O
SOD1	NN	I-NP	O
in	IN	B-PP	O
inner	JJ	B-NP	O
ear	JJ	I-NP	O
tissues	NNS	I-NP	O
of	IN	B-PP	O
transgenic	JJ	B-NP	O
C57BL	NN	I-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
TgN	NN	I-NP	O
[	(	I-NP	O
SOD1	NN	I-NP	O
]	)	I-NP	O
3Cje	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Transgenic	JJ	B-NP	O
and	CC	I-NP	O
nontransgenic	JJ	I-NP	O
littermates	NNS	I-NP	O
received	VBD	B-VP	O
kanamycin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
beginning	VBG	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
birth	NN	B-NP	O
.	.	O	O

Auditory	JJ	B-NP	O
thresholds	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
by	IN	B-PP	O
evoked	VBN	B-NP	O
auditory	JJ	I-NP	O
brain	NN	I-NP	O
stem	NN	I-NP	O
responses	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
month	NN	I-NP	O
after	IN	B-PP	O
birth	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
nontransgenic	JJ	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
threshold	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kanamycin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
injected	VBN	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
transgenic	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
kanamycin	NN	B-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
threshold	NN	I-NP	O
by	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
dB	NN	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
respective	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
kHz	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
protection	NN	I-NP	O
by	IN	B-PP	O
overexpression	NN	B-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
supports	VBZ	B-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
oxidant	JJ	B-NP	O
stress	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
aminoglycoside	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ototoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
also	RB	B-ADVP	O
suggest	VBP	B-VP	O
transgenic	JJ	B-NP	O
animals	NNS	I-NP	O
as	IN	B-PP	O
suitable	JJ	B-NP	O
models	NNS	I-NP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
mechanisms	NNS	I-NP	O
and	CC	O	O
possible	JJ	B-NP	O
strategies	NNS	I-NP	O
for	IN	B-PP	O
prevention	NN	B-NP	O
.	.	O	O

Prednisone	NN	B-NP	O
induces	VBZ	B-VP	O
anxiety	NN	B-NP	B
and	CC	O	O
glial	JJ	B-NP	O
cerebral	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
whether	IN	B-SBAR	O
prednisone	NN	B-NP	O
(	(	O	O
PDN	NN	B-NP	O
)	)	O	O
produces	VBZ	B-VP	O
anxiety	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
cerebral	JJ	B-NP	O
glial	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
and	CC	O	O
num	CD	B-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
formed	VBN	I-VP	O
(	(	O	O
num	CD	B-NP	O
rats	NNS	I-NP	O
per	IN	B-PP	O
group	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
moderate	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
PDN	NN	I-NP	O
released	VBN	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
subcutaneous	JJ	I-NP	O
implant	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
implants	NNS	B-NP	O
containing	VBG	B-VP	O
PDN	NN	B-NP	O
equivalent	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
were	VBD	B-VP	O
applied	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
implants	NNS	I-NP	O
contained	VBD	B-VP	O
no	DT	B-NP	O
PDN	NN	I-NP	O
.	.	O	O

Anxiety	NN	B-NP	B
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	I-VP	O
an	DT	B-NP	O
open	JJ	I-NP	O
field	NN	I-NP	O
and	CC	O	O
elevated	VBN	B-VP	O
plus	CC	O	O
-	HYPH	B-NP	O
maze	NN	I-NP	O
devices	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
and	CC	O	O
cytoplasmic	JJ	B-NP	O
transformation	NN	I-NP	O
of	IN	B-PP	O
astrocytes	NNS	B-NP	O
and	CC	O	O
microglia	NN	B-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
immunohistochemical	JJ	B-NP	O
analyses	NNS	I-NP	O
.	.	O	O

Anxiety	NN	B-NP	B
was	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
PDN	NN	B-NP	O
treated	VBN	B-NP	O
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
magnitude	NN	I-NP	O
of	IN	B-PP	O
transformation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
microglia	NNS	I-NP	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
intersections	NNS	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
PDN	NN	I-NP	O
groups	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
and	CC	I-NP	O
striatum	NN	I-NP	O
,	,	B-PP	O
but	CC	I-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
hippocampus	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
stained	VBN	B-NP	O
microglia	NNS	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
PDN	NN	I-NP	O
treated	VBN	B-VP	O
groups	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Stained	VBN	B-NP	O
microglia	NN	I-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	B-NP	O
numerous	JJ	I-NP	O
striatum	NN	I-NP	O
and	CC	I-NP	O
hippocampus	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Subacute	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
PDN	NN	B-NP	O
induced	VBD	B-VP	O
anxiety	NN	B-NP	B
and	CC	I-NP	O
reactivity	NN	I-NP	O
of	IN	B-PP	O
microglia	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
relevance	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
features	NNS	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
using	VBG	B-VP	O
PDN	NN	B-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
elucidated	VBN	I-VP	O
.	.	O	O

Phase	NN	B-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
and	CC	O	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
squamous	JJ	I-NP	B
cell	NN	I-NP	I
carcinoma	NN	I-NP	I
of	IN	B-PP	I
the	DT	B-NP	I
cervix	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
and	CC	O	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
Phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
cervical	JJ	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
(	(	O	O
area	NN	B-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
concentration	NN	I-NP	O
curve	NN	I-NP	O
[	(	O	O
AUC	NN	B-NP	O
]	)	O	O
,	,	O	O
num	CD	B-NP	O
)	)	O	O
and	CC	O	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-NP	O
every	DT	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
squamous	JJ	I-NP	B
cell	NN	I-NP	I
cervical	JJ	I-NP	I
carcinoma	NN	I-NP	I
to	TO	B-VP	O
determine	VB	I-VP	O
antitumor	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
profile	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
assessable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
assessable	JJ	B-ADJP	O
for	IN	B-PP	O
toxicity	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
response	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
myelosuppression	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
Grade	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
neutropenia	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
anemia	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
thrombocytopenia	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
neutropenic	JJ	B-NP	B
fever	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
infusion	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
reactions	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
discontinuation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Grade	NN	B-NP	O
>	SYM	B-NP	O
or	CC	O	O
=	SYM	B-VP	O
num	CD	B-NP	O
nonhematologic	JJ	I-NP	O
toxicity	NN	I-NP	B
included	VBD	B-VP	O
nausea	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
emesis	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
fatigue	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
mucositis	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
stomatitis	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
constipation	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
weight	NN	B-NP	B
loss	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
hand	NN	B-NP	B
-	HYPH	I-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
skin	NN	B-NP	B
reactions	NNS	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
carboplatin	NN	B-NP	O
and	CC	O	O
liposomal	JJ	B-NP	O
doxorubicin	NN	I-NP	O
has	VBZ	B-VP	O
modest	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
recurrent	JJ	B-NP	O
cervical	JJ	I-NP	B
carcinoma	NN	I-NP	I
.	.	O	O

Antimicrobial	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
mania	NN	I-NP	B
(	(	O	O
antibiomania	NN	B-NP	B
)	)	O	O
:	:	O	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
spontaneous	JJ	B-NP	O
reports	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
reviewed	VBD	B-VP	O
reported	VBN	I-VP	O
cases	NNS	B-NP	O
of	IN	B-PP	O
antibiotic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
manic	JJ	I-NP	B
episodes	NNS	I-NP	O
by	IN	B-PP	O
means	NNS	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
MEDLINE	NNP	I-NP	O
and	CC	I-NP	O
PsychLit	NNP	I-NP	O
search	NN	I-NP	O
for	IN	B-PP	O
reports	NNS	B-NP	O
of	IN	B-PP	O
antibiotic	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
mania	NN	I-NP	B
.	.	O	O

Unpublished	JJ	B-NP	O
reports	NNS	I-NP	O
were	VBD	B-VP	O
requested	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
World	NNP	I-NP	O
Health	NNP	I-NP	O
Organization	NNP	I-NP	O
(	(	O	O
WHO	WP	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
Food	NNP	I-NP	O
and	CC	I-NP	O
Drug	NNP	I-NP	O
Administration	NNP	I-NP	O
(	(	O	O
FDA	NNP	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
antimicrobial	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
mania	NN	I-NP	B
were	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
implicating	VBG	B-VP	O
clarithromycin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
implicating	VBG	I-NP	O
isoniazid	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
case	NN	I-NP	O
each	DT	B-NP	O
implicating	VBG	I-NP	O
erythromycin	NN	I-NP	O
and	CC	I-NP	O
amoxicillin	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
WHO	NNP	I-NP	O
reported	VBD	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
clarithromycin	NN	B-NP	O
was	VBD	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
ciprofloxacin	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
and	CC	O	O
ofloxacin	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Cotrimoxazole	NN	B-NP	O
,	,	O	O
metronidazole	NN	B-NP	O
,	,	O	O
and	CC	O	O
erythromycin	NN	B-NP	O
were	VBD	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
reported	VBD	B-VP	O
manic	JJ	B-NP	B
episodes	NNS	I-NP	O
.	.	O	O

Cases	NNS	B-NP	O
reported	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
FDA	NNP	I-NP	O
showed	VBD	B-VP	O
clarithromycin	NN	B-NP	O
and	CC	I-NP	O
ciprofloxacin	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequently	RB	I-NP	O
associated	VBN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
mania	NN	B-NP	B
.	.	O	O

Statistical	JJ	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
data	NNS	I-NP	O
would	MD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
demonstrated	VBN	I-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
statistical	JJ	I-NP	O
correlative	JJ	I-NP	O
risk	NN	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
therefore	RB	I-VP	O
not	RB	I-VP	O
undertaken	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
mania	NN	B-NP	B
while	IN	B-SBAR	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
antimicrobials	NNS	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
this	DT	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
risk	NN	I-NP	O
,	,	O	O
physicians	NNS	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
and	CC	I-NP	O
reversibility	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
research	NN	I-NP	O
clearly	RB	B-ADVP	O
is	VBZ	B-VP	O
required	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
antimicrobial	JJ	B-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
mania	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
relative	JJ	I-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
an	DT	B-NP	O
antimicrobial	JJ	I-NP	O
-	HYPH	I-NP	O
induced	VBN	I-NP	O
manic	JJ	I-NP	B
episode	NN	I-NP	O
among	IN	B-PP	O
various	JJ	B-NP	O
demographic	JJ	I-NP	O
populations	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
continue	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
persistent	JJ	B-NP	O
affective	JJ	I-NP	O
disorders	NNS	I-NP	O
once	IN	B-SBAR	O
the	DT	B-NP	O
initial	JJ	I-NP	O
episode	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
occurs	VBZ	B-VP	O
while	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
is	VBZ	B-VP	O
taking	VBG	I-VP	O
antibiotics	NNS	B-NP	O
,	,	O	O
subsides	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
elected	VBD	B-VP	O
to	TO	I-VP	O
name	VB	I-VP	O
this	DT	B-NP	O
syndrome	NN	I-NP	O
antibiomania	NN	I-NP	B
.	.	O	O
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
dyskinesias	NNS	I-NP	I
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ocular	JJ	I-NP	B
dyskinesias	NNS	I-NP	I
are	VBP	B-VP	O
very	RB	B-ADJP	O
uncommon	JJ	I-ADJP	O
.	.	O	O

Usually	RB	B-ADVP	O
they	PRP	B-NP	O
occur	VBP	B-VP	O
simultaneously	RB	B-ADVP	O
with	IN	B-PP	O
limb	NN	B-NP	O
peak	NN	I-NP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
choreatic	JJ	I-NP	B
dyskinesias	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
leftward	JJ	B-NP	O
and	CC	I-NP	O
upward	JJ	I-NP	O
deviations	NNS	I-NP	O
of	IN	B-PP	O
gaze	NN	B-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
peak	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
,	,	O	O
and	CC	O	O
hypothesize	VBP	B-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
severe	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
denervation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
caudate	JJ	I-NP	O
nucleus	NN	I-NP	O
is	VBZ	B-VP	O
needed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
levodopa	NN	I-NP	O
-	HYPH	O	O
induce	VBP	B-VP	O
ocular	JJ	B-NP	B
dyskinesias	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
dysmenorrhea	NN	I-NP	B
:	:	O	O
an	DT	B-NP	O
open	JJ	I-NP	O
,	,	O	O
randomized	VBN	B-VP	O
,	,	O	O
cross	AFX	B-NP	O
-	HYPH	I-NP	O
over	IN	B-PP	O
trial	NN	B-NP	O
.	.	O	O

Primary	JJ	B-NP	O
dysmenorrhea	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
syndrome	NN	I-NP	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
painful	JJ	B-NP	O
uterine	JJ	I-NP	O
contractility	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
hypersecretion	NN	I-NP	O
of	IN	B-PP	O
endometrial	JJ	B-NP	O
prostaglandins	NNS	I-NP	O
;	:	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
steroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
choice	NN	I-NP	O
for	IN	B-PP	O
its	PRP$	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
and	CC	O	O
in	FW	B-NP	O
vitro	FW	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
myometrial	JJ	B-NP	O
cells	NNS	I-NP	O
are	VBP	B-VP	O
also	RB	B-ADVP	O
targets	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
relaxant	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
(	(	O	O
GTN	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
NO	NN	I-NP	O
donor	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
dysmenorrhea	NN	I-NP	B
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
diclofenac	NN	B-NP	O
(	(	O	O
DCF	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
primary	JJ	I-NP	O
dysmenorrhea	NN	I-NP	B
were	VBD	B-VP	O
studied	VBN	I-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
menstrual	JJ	I-NP	O
cycles	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
an	DT	B-NP	O
open	JJ	I-NP	O
,	,	O	O
cross	AFX	O	O
-	HYPH	B-VP	O
over	RP	B-PRT	O
,	,	O	O
controlled	VBN	B-VP	O
design	NN	B-NP	O
,	,	O	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-VP	O
receive	VB	I-VP	O
either	CC	O	O
DCF	NN	B-NP	O
per	IN	B-PP	O
os	NNS	B-NP	O
or	CC	O	O
GTN	NN	B-NP	O
patches	NNS	I-NP	O
the	DT	B-NP	O
first	JJ	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
menses	NNS	B-NP	O
,	,	O	O
when	WRB	B-ADVP	O
menstrual	JJ	B-NP	O
cramps	NNS	I-NP	O
became	VBD	B-VP	O
unendurable	JJ	B-ADJP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
subsequent	JJ	I-NP	O
cycle	NN	I-NP	O
the	DT	B-NP	O
other	JJ	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
received	VBD	B-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
doses	NNS	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
DCF	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
h	NN	I-NP	O
transdermal	JJ	I-NP	O
GTN	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cycle	NN	I-NP	O
,	,	O	O
according	VBG	B-PP	O
to	TO	B-PP	O
their	PRP$	B-NP	O
needs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
participants	NNS	I-NP	O
recorded	VBD	B-VP	O
menstrual	JJ	B-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
possible	JJ	B-NP	O
side	NN	I-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
at	IN	B-PP	O
different	JJ	B-NP	O
times	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
)	)	O	O
after	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
medication	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cycle	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
pain	NN	B-NP	B
intensity	NN	I-NP	O
score	NN	I-NP	O
(	(	O	O
DPI	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
outcome	NN	I-NP	O
variable	JJ	B-ADJP	O
.	.	O	O

Both	DT	B-NP	O
treatments	NNS	I-NP	O
significantly	RB	B-ADVP	O
reduced	VBD	B-VP	O
DPI	NN	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
30th	JJ	I-NP	O
minute	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
DCF	NN	B-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
reducing	VBG	B-VP	O
pelvic	JJ	B-NP	B
pain	NN	I-NP	I
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
GTN	NN	B-NP	O
scores	NNS	I-NP	O
remained	VBD	B-VP	O
more	RBR	B-ADVP	O
or	CC	I-ADVP	O
less	RBR	B-ADJP	O
stable	JJ	I-ADJP	O
after	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
and	CC	O	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
for	IN	B-PP	O
DFC	NN	B-NP	O
.	.	O	O

Low	JJ	B-NP	B
back	JJ	I-NP	I
pain	NN	I-NP	I
was	VBD	B-VP	O
also	RB	I-VP	O
relieved	VBN	I-VP	O
by	IN	B-PP	O
both	DT	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Headache	PRP	B-NP	B
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
GTN	NN	B-NP	O
but	CC	B-PP	O
not	RB	B-PP	O
by	IN	I-PP	O
DCF	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
stopped	VBD	B-VP	O
using	VBG	I-VP	O
GTN	NN	B-NP	O
because	IN	B-SBAR	O
headache	NN	B-NP	B
-	HYPH	B-NP	O
-	HYPH	I-NP	O
attributed	VBN	B-VP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
-	HYPH	O	O
-	SYM	B-NP	O
became	VBD	B-VP	O
intolerable	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
GTN	NN	B-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
reduced	VBN	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
by	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
DCF	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
dysmenorrhea	NN	I-NP	B
.	.	O	O

Temocapril	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
SH	NN	I-NP	O
group	NN	I-NP	O
angiotensin	NN	I-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
modulates	VBZ	B-VP	O
glomerular	JJ	B-NP	B
injury	NN	I-NP	I
in	IN	B-PP	O
chronic	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
nephrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
chronic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
temocapril	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
long	RB	I-NP	O
-	HYPH	I-NP	O
acting	VBG	B-VP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
SH	NN	I-NP	O
group	NN	I-NP	O
angiotensin	NN	I-NP	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
(	(	O	O
ACE	NN	B-NP	O
)	)	O	O
inhibitor	NN	B-NP	O
,	,	O	O
reduced	VBN	B-VP	O
proteinuria	NN	B-NP	B
,	,	O	O
inhibited	VBD	B-VP	O
glomerular	JJ	B-NP	O
hypertrophy	NN	I-NP	B
and	CC	O	O
prevented	VBD	B-VP	O
glomerulosclerosis	NN	B-NP	B
in	IN	B-PP	O
chronic	JJ	B-NP	O
puromycin	NN	I-NP	O
aminonucleoside	NN	I-NP	O
(	(	O	O
PAN	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
nephrotic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

Nephrosis	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
injection	NN	B-NP	O
of	IN	B-PP	O
PAN	NN	B-NP	O
in	IN	B-PP	O
male	JJ	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
,	,	O	O
i	LS	B-LST	O
)	)	O	O
the	DT	B-NP	O
PAN	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
ii	NN	B-NP	O
)	)	O	O
PAN	NN	B-NP	O
/	SYM	B-NP	O
temocapril	NN	I-NP	O
,	,	O	O
iii	NN	B-NP	O
)	)	O	O
temocapril	NN	B-NP	O
and	CC	I-NP	O
iv	NN	I-NP	O
)	)	I-NP	O
untreated	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

Temocapril	NNP	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
at	IN	B-PP	O
weeks	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

At	IN	B-PP	O
each	DT	B-NP	O
time	NN	I-NP	O
point	NN	I-NP	O
,	,	O	O
systolic	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
,	,	O	O
urinary	JJ	B-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	O
histopathological	JJ	I-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
morphometric	JJ	B-NP	O
image	NN	I-NP	O
analysis	NN	I-NP	O
was	VBD	B-VP	O
done	VBN	I-VP	O
.	.	O	O

Systolic	JJ	B-NP	O
BP	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
high	JJ	I-ADJP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
but	CC	O	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
/	SYM	B-NP	O
temocapril	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
group	NN	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
,	,	O	O
peaking	VBG	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
then	RB	B-ADVP	O
decreased	VBD	B-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
but	CC	O	O
rose	VBD	B-VP	O
again	RB	B-ADVP	O
significantly	RB	B-ADVP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Temocapril	NNP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
attenuate	VB	I-VP	O
proteinuria	NN	B-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
did	VBD	B-VP	O
markedly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
it	PRP	B-NP	O
from	IN	B-PP	O
weeks	NNS	B-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
glomerulosclerosis	NN	I-NP	B
index	NN	I-NP	O
(	(	O	O
GSI	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
respectively	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
between	IN	B-PP	O
urinary	JJ	B-NP	O
protein	NN	I-NP	O
excretion	NN	I-NP	O
and	CC	I-NP	O
GSI	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
glomerular	JJ	B-NP	O
tuft	NN	I-NP	O
area	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
area	NN	I-NP	O
of	IN	B-PP	O
Bowman	NNP	B-NP	O
s	NN	I-NP	O
capsules	NNS	I-NP	O
(	(	O	O
GT	NN	B-NP	O
/	SYM	B-NP	O
BC	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
,	,	O	O
but	CC	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
PAN	NN	I-NP	O
/	SYM	B-NP	O
temocapril	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
appears	VBZ	B-VP	O
that	IN	B-SBAR	O
temocapril	NN	B-NP	O
was	VBD	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
retarding	VBG	B-VP	O
renal	JJ	B-NP	O
progression	NN	I-NP	O
and	CC	O	O
protected	VBD	B-VP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
PAN	NN	B-NP	O
neprotic	JJ	I-NP	B
rats	NNS	I-NP	O
.	.	O	O

Pulmonary	JJ	B-NP	B
hypertension	NN	I-NP	I
after	IN	B-PP	O
ibuprofen	NN	B-NP	O
prophylaxis	NN	I-NP	O
in	IN	B-PP	O
very	RB	B-NP	O
preterm	JJ	I-NP	O
infants	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
hypoxaemia	NN	I-NP	B
after	IN	B-PP	O
ibuprofen	NN	B-NP	O
administration	NN	I-NP	O
during	IN	B-PP	O
a	DT	B-NP	O
randomised	VBN	I-NP	O
controlled	VBN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
prophylactic	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patent	NN	B-NP	B
ductus	NN	I-NP	I
arteriosus	NN	I-NP	I
with	IN	B-PP	O
ibuprofen	NN	B-NP	O
in	IN	B-PP	O
premature	JJ	B-NP	O
infants	NNS	I-NP	O
born	VBN	B-VP	O
at	IN	B-PP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
gestation	NN	B-NP	O
.	.	O	O

Echocardiography	NN	B-NP	O
showed	VBD	B-VP	O
severely	RB	B-NP	O
decreased	VBN	I-NP	O
pulmonary	JJ	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
.	.	O	O

Hypoxaemia	NN	B-NP	B
resolved	VBD	B-VP	O
quickly	RB	B-ADVP	O
on	IN	B-PP	O
inhaled	VBN	B-NP	O
nitric	JJ	I-NP	O
oxide	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
investigators	NNS	B-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
similar	JJ	B-NP	O
trials	NNS	I-NP	O
pay	VBP	B-VP	O
close	JJ	B-NP	O
attention	NN	I-NP	O
to	TO	B-PP	O
pulmonary	JJ	B-NP	O
pressure	NN	I-NP	O
if	IN	B-SBAR	O
hypoxaemia	NN	B-NP	B
occurs	VBZ	B-VP	O
after	IN	B-SBAR	O
prophylactic	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ibuprofen	NN	B-NP	O
.	.	O	O

Hyponatremia	NN	B-NP	B
and	CC	I-NP	O
syndrome	NN	I-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
anti	AFX	I-NP	I
-	HYPH	I-NP	I
diuretic	JJ	I-NP	I
hormone	NN	I-NP	I
reported	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
Vincristine	NN	B-NP	O
:	:	O	O
an	DT	B-NP	O
over	AFX	I-NP	O
-	HYPH	I-NP	O
representation	NN	I-NP	O
of	IN	B-PP	O
Asians	NNPS	B-NP	O
?	.	O	O
PURPOSE	NN	B-NP	O
:	:	O	O
This	DT	B-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
used	VBD	B-VP	O
a	DT	B-NP	O
pharmaceutical	JJ	I-NP	O
company	NN	I-NP	O
s	VBZ	B-VP	O
global	JJ	B-NP	O
safety	NN	I-NP	O
database	NN	I-NP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
reporting	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
hyponatremia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
syndrome	NN	B-NP	B
of	IN	B-PP	I
inappropriate	JJ	B-NP	I
secretion	NN	I-NP	I
of	IN	B-PP	I
anti	AFX	B-NP	I
-	HYPH	I-NP	I
diuretic	JJ	I-NP	I
hormone	NN	I-NP	I
(	(	O	O
SIADH	NN	B-NP	B
)	)	O	O
among	IN	B-PP	O
vincristine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
and	CC	O	O
to	TO	B-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
at	IN	B-PP	O
-	HYPH	B-NP	O
risk	NN	I-NP	O
population	NN	I-NP	O
subgroups	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
searched	VBD	B-VP	O
the	DT	B-NP	O
Eli	NNP	I-NP	O
Lilly	NNP	I-NP	O
and	CC	I-NP	O
Company	NNP	I-NP	O
s	NNS	I-NP	O
computerized	VBD	B-VP	O
adverse	JJ	B-NP	O
event	NN	I-NP	O
database	NN	I-NP	O
for	IN	B-PP	O
all	DT	B-NP	O
reported	VBN	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hyponatremia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
SIADH	NN	B-NP	B
as	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
November	NNP	I-NP	O
num	CD	I-NP	O
that	WDT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
vincristine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
hyponatremia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
SIADH	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
vincristine	NN	B-NP	O
use	NN	I-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
reporting	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
males	NNS	B-NP	O
.	.	O	O

Approximately	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
receiving	VBG	I-VP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
leukemia	NN	B-NP	B
or	CC	I-NP	O
lymphoma	NN	I-NP	B
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
reports	NNS	I-NP	O
that	WDT	B-NP	O
included	VBD	B-VP	O
information	NN	B-NP	O
on	IN	B-PP	O
race	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
racial	JJ	I-NP	O
distribution	NN	I-NP	O
was	VBD	B-VP	O
:	:	O	O
num	CD	B-NP	O
Black	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
Caucasian	NNP	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
Asian	JJ	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
Asian	JJ	B-NP	O
patients	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
at	IN	B-PP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
hyponatremia	NN	B-NP	B
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
SIADH	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
vincristine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
overall	JJ	I-NP	O
reported	VBN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
SIADH	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
vincristine	NN	B-NP	O
is	VBZ	B-VP	O
very	RB	B-ADJP	O
low	JJ	I-ADJP	O
,	,	O	O
physicians	NNS	B-NP	O
caring	VBG	B-VP	O
for	IN	B-PP	O
Asian	JJ	B-NP	O
oncology	NN	I-NP	O
patients	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
this	DT	B-NP	O
potential	JJ	I-NP	O
serious	JJ	I-NP	O
but	CC	I-NP	O
reversible	JJ	I-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
of	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
and	CC	O	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
female	JJ	I-NP	O
mouse	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
describes	VBZ	B-VP	O
the	DT	B-NP	O
delayed	VBN	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
severe	JJ	I-NP	O
bladder	NN	I-NP	O
pathology	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
susceptible	JJ	I-NP	O
strain	NN	I-NP	O
of	IN	B-PP	O
mice	NNS	B-NP	O
(	(	O	O
DBA	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
)	)	O	O
but	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
a	DT	B-NP	O
resistant	JJ	I-NP	O
strain	NN	I-NP	O
(	(	O	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
)	)	O	O
when	WRB	B-ADVP	O
both	DT	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CY	NN	B-NP	O
)	)	O	O
.	.	O	O

Inbred	VBN	B-NP	O
DBA	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
and	CC	O	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
female	JJ	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
CY	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
by	IN	B-PP	O
light	NN	B-NP	O
microscopy	NN	I-NP	O
using	VBG	B-VP	O
different	JJ	B-NP	O
staining	NN	I-NP	O
procedures	NNS	I-NP	O
,	,	O	O
and	CC	O	O
after	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
by	IN	B-PP	O
conventional	JJ	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
.	.	O	O

Early	JJ	B-NP	O
CY	NN	I-NP	O
toxicity	NN	I-NP	B
caused	VBD	B-VP	O
a	DT	B-NP	O
typical	JJ	I-NP	O
haemorrhagic	JJ	I-NP	B
cystitis	NN	I-NP	B
in	IN	B-PP	O
both	DT	B-NP	O
strains	NNS	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
completely	RB	I-VP	O
repaired	VBN	I-VP	O
in	IN	B-PP	O
about	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
CY	NN	B-NP	O
injection	NN	I-NP	O
ulcerous	JJ	B-ADJP	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
ulcerous	JJ	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
cystitis	NN	I-NP	B
appeared	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
but	CC	O	O
only	RB	B-PP	O
in	IN	I-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
cystitis	NN	I-NP	B
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
infiltration	NN	B-NP	O
and	CC	O	O
transepithelial	JJ	B-NP	O
passage	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
lumen	NN	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
cells	NNS	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
frequent	JJ	B-NP	O
exfoliation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
urothelium	NN	I-NP	O
.	.	O	O

Mast	NN	B-NP	O
cells	NNS	I-NP	O
appeared	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
connective	JJ	I-NP	O
and	CC	I-NP	O
muscular	JJ	I-NP	O
layers	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
bladder	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
much	RB	I-NP	O
higher	JJR	I-NP	O
number	NN	I-NP	O
in	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
or	CC	O	O
untreated	JJ	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Electron	NN	B-NP	O
microscopy	NN	I-NP	O
disclosed	VBD	B-VP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
typical	JJ	I-NP	O
discoidal	JJ	I-NP	O
vesicles	NNS	I-NP	O
normally	RB	B-ADJP	O
present	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
cytoplasm	NN	I-NP	O
of	IN	B-PP	O
surface	NN	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

Instead	RB	B-ADVP	O
,	,	O	O
numerous	JJ	B-NP	O
abnormal	JJ	I-NP	O
vesicles	NNS	I-NP	O
containing	VBG	B-VP	O
num	CD	B-NP	O
or	CC	O	O
several	JJ	B-NP	O
dark	JJ	I-NP	O
granules	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cytoplasm	NN	I-NP	O
of	IN	B-PP	O
cells	NNS	B-NP	O
from	IN	B-PP	O
all	PDT	B-NP	O
the	DT	I-NP	O
epithelial	JJ	I-NP	O
layers	NNS	I-NP	O
.	.	O	O

Delayed	VBN	B-NP	O
cystitis	NN	I-NP	B
still	RB	B-ADVP	O
persisted	VBD	B-VP	O
in	IN	B-PP	O
DBA	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
delayed	VBN	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
CY	NN	B-NP	O
in	IN	B-PP	O
female	JJ	B-NP	O
DBA	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
mice	NNS	I-NP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
bladder	NN	I-NP	O
pathology	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
C57BL	NN	B-NP	O
/	SYM	O	O
num	CD	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
pathology	NN	I-NP	O
resembles	VBZ	B-VP	O
interstitial	JJ	B-NP	B
cystitis	NN	I-NP	I
in	IN	B-PP	O
humans	NNS	B-NP	O
and	CC	O	O
could	MD	B-VP	O
perhaps	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
for	IN	B-PP	O
studies	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
/	SYM	B-NP	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
weekly	JJ	I-NP	O
mitomycin	NN	I-NP	O
C	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
advanced	VBN	B-NP	O
gastric	JJ	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
continuous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
and	CC	O	O
folinic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
FA	NN	B-NP	O
)	)	O	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
several	JJ	B-NP	O
new	JJ	I-NP	O
multidrug	JJ	I-NP	O
chemotherapy	NN	I-NP	O
regimens	NNS	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
gastric	JJ	I-NP	B
cancer	NN	I-NP	I
(	(	O	O
AGC	NN	B-NP	B
)	)	O	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
effective	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
low	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
weekly	JJ	I-NP	O
bolus	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
,	,	I-NP	O
FA	NN	I-NP	O
and	CC	I-NP	O
mitomycin	NN	I-NP	O
C	NN	I-NP	O
(	(	O	O
MMC	NN	B-NP	O
)	)	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
a	DT	B-NP	O
low	JJ	I-NP	O
toxicity	NN	I-NP	B
rate	NN	I-NP	O
and	CC	I-NP	O
response	NN	I-NP	O
rates	NNS	I-NP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
regimens	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
ELF	NN	B-NP	O
,	,	I-NP	O
FAM	NN	I-NP	O
or	CC	I-NP	O
FAMTX	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
promising	JJ	I-NP	O
median	JJ	I-NP	O
overall	JJ	I-NP	O
survival	NN	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
improve	VB	I-VP	O
this	DT	B-NP	O
MMC	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
schedule	NN	I-NP	O
we	PRP	B-NP	O
initiated	VBD	B-VP	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
/	SYM	B-NP	O
FA	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
weekly	JJ	I-NP	O
bolus	NN	I-NP	O
MMC	NN	I-NP	O
.	.	O	O

From	IN	B-PP	O
February	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
September	NNP	B-NP	O
,	,	O	O
num	CD	B-NP	O
we	PRP	B-NP	O
recruited	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
AGC	NN	B-NP	B
to	TO	B-VP	O
receive	VB	I-VP	O
weekly	RB	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
m	NN	I-NP	O
preceded	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hour	NN	I-NP	O
FA	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
rest	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

Bolus	NN	B-NP	O
MMC	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
m	NN	I-NP	O
was	VBD	B-VP	O
added	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
weekly	JJ	I-NP	O
intervals	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
given	VBN	B-PP	O
on	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
basis	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
portable	JJ	B-NP	O
pump	NN	I-NP	O
systems	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
repeated	VBN	I-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
s	NNS	I-NP	O
characteristics	NNS	I-NP	O
were	VBD	B-VP	O
:	:	O	O
male	JJ	B-NP	O
/	SYM	I-NP	O
female	JJ	I-NP	O
ratio	NN	I-NP	O
num	CD	I-NP	O
/	SYM	O	O
num	CD	B-NP	O
;	:	O	O
median	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
;	:	O	O
median	JJ	B-NP	O
WHO	NN	I-NP	O
status	NN	I-NP	O
num	CD	I-NP	O
.	.	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
primary	JJ	I-NP	O
AGC	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
relapsed	JJ	I-NP	O
AGC	NN	I-NP	B
.	.	O	O

Median	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
of	IN	B-PP	O
those	DT	B-NP	O
surviving	VBG	B-VP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
evaluable	JJ	B-ADJP	O
for	IN	B-PP	O
response	NN	B-NP	O
-	HYPH	B-NP	O
complete	JJ	I-NP	O
remission	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
partial	JJ	B-NP	O
remission	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
no	DT	B-NP	O
change	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
progressive	JJ	B-NP	O
disease	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
overall	JJ	I-NP	O
survival	NN	I-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
(	(	O	O
CI	NN	B-NP	O
)	)	O	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
]	)	O	O
,	,	O	O
and	CC	O	O
median	JJ	B-NP	O
progression	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survival	NN	I-NP	O
time	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
worst	JJS	I-NP	O
toxicities	NNS	I-NP	B
observed	VBN	B-VP	O
were	VBD	B-VP	O
(	(	O	O
CTC	NN	B-NP	O
-	HYPH	B-NP	O
NCI	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
)	)	O	O
:	:	O	O
leukopenia	SYM	B-NP	B
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	O	O
thrombocytopenia	NN	B-NP	B
num	CD	I-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	O	O
vomitus	NN	B-NP	B
num	CD	I-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
diarrhea	NN	I-NP	B
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	O	O
stomatitis	NN	B-NP	B
num	CD	I-NP	O
/	SYM	O	O
num	CD	O	O
/	SYM	O	O
num	CD	B-NP	O
hand	NN	I-NP	B
-	HYPH	B-NP	I
foot	NN	I-NP	I
syndrome	NN	I-NP	I
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
hemolytic	JJ	B-NP	B
-	HYPH	I-NP	I
uremic	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
HUS	NN	B-NP	B
)	)	O	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
/	SYM	I-NP	O
FA	NN	I-NP	O
/	SYM	B-NP	O
MMC	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
well	RB	I-NP	O
-	HYPH	B-VP	O
tolerated	VBN	B-NP	O
outpatient	NN	I-NP	O
regimen	NN	I-NP	O
for	IN	B-PP	O
AGC	NN	B-NP	B
(	(	O	O
objective	JJ	B-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

It	PRP	B-NP	O
may	MD	B-VP	O
serve	VB	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
alternative	NN	I-NP	O
to	TO	B-PP	O
cisplatin	NN	B-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
regimens	NNS	B-NP	O
;	:	O	O
however	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
has	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
that	IN	B-SBAR	O
possibly	RB	B-NP	O
HUS	NNS	I-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
.	.	O	O

Persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
impaired	JJ	B-NP	B
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
human	JJ	B-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
type	NN	I-NP	I
num	CD	I-NP	I
-	HYPH	B-NP	I
infected	VBN	I-NP	I
children	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
indinavir	NN	B-NP	O
.	.	O	O

Prolonged	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
indinavir	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
complications	NNS	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
documented	VBN	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
restricted	VBN	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
potent	JJ	I-NP	O
protease	NN	I-NP	O
inhibitor	NN	I-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
to	TO	B-VP	O
monitor	VB	I-VP	O
indinavir	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
nephrotoxicity	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
human	JJ	I-NP	B
immunodeficiency	NN	I-NP	I
virus	NN	I-NP	I
type	NN	I-NP	I
num	CD	I-NP	I
-	HYPH	B-NP	I
infected	VBN	I-NP	I
children	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
indinavir	NN	B-NP	O
.	.	O	O

Urinary	JJ	B-NP	O
pH	NN	I-NP	O
,	,	O	O
albumin	NN	B-NP	O
,	,	O	O
creatinine	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
erythrocytes	NNS	B-NP	O
,	,	I-NP	O
leukocytes	NNS	I-NP	O
,	,	I-NP	O
bacteria	NNS	I-NP	O
and	CC	I-NP	O
crystals	NNS	I-NP	O
,	,	O	O
and	CC	O	O
culture	NN	B-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
every	DT	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
routinely	RB	I-VP	O
determined	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
points	NNS	I-NP	O
.	.	O	O

Steady	JJ	B-NP	O
-	HYPH	I-NP	O
state	NN	I-NP	O
pharmacokinetics	NNS	I-NP	O
of	IN	B-PP	O
indinavir	NN	B-NP	O
were	VBD	B-VP	O
done	VBN	I-VP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
indinavir	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
was	VBD	B-VP	O
frequently	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
mild	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
urine	NN	I-NP	O
albumin	NN	I-NP	O
/	SYM	B-VP	O
creatinine	NN	B-NP	O
ratio	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
microscopic	JJ	B-NP	O
hematuria	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
cumulative	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
>	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
above	IN	B-PP	O
normal	JJ	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Children	NNS	B-NP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
had	VBD	B-VP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
above	IN	B-PP	O
normal	JJ	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
children	NNS	I-NP	O
without	IN	B-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
children	NNS	B-NP	O
younger	JJR	B-ADJP	O
than	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
frequent	JJ	I-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
older	JJR	B-NP	O
children	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
higher	JJR	I-NP	O
cumulative	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
leukocyturia	NN	I-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
curve	NN	I-NP	O
>	JJR	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
x	SYM	B-NP	O
h	NN	B-NP	O
or	CC	O	O
a	DT	B-NP	O
peak	JJ	I-NP	O
serum	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
indinavir	NN	B-NP	O
>	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
children	NNS	I-NP	O
,	,	O	O
indinavir	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
nephrotoxicity	NN	B-NP	B
.	.	O	O

Subsequently	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
serum	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
decreased	VBD	B-VP	O
,	,	O	O
the	DT	B-NP	O
urine	NN	I-NP	O
albumin	NN	I-NP	O
/	SYM	B-NP	O
creatinine	NN	I-NP	O
ratios	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
leukocyturia	NN	I-NP	B
disappeared	VBD	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

Children	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
indinavir	NN	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
cumulative	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
.	.	O	O

Children	NNS	B-NP	O
with	IN	B-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
had	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
above	IN	B-PP	O
normal	JJ	B-ADJP	O
.	.	O	O

Younger	NN	B-NP	O
children	NNS	I-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
additional	JJ	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
renal	JJ	B-NP	O
complications	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
impairment	NN	I-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
renal	JJ	I-NP	I
function	NN	I-NP	I
in	IN	B-PP	O
these	DT	B-NP	O
children	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
nephrolithiasis	NN	B-NP	B
.	.	O	O

Indinavir	NN	B-NP	O
-	HYPH	B-PP	O
associated	VBN	B-NP	O
nephrotoxicity	NN	I-NP	B
must	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
closely	RB	B-ADVP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
persistent	JJ	B-NP	O
sterile	JJ	I-NP	O
leukocyturia	NN	I-NP	B
,	,	O	O
age	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
,	,	O	O
an	DT	B-NP	O
area	NN	I-NP	O
under	IN	B-PP	O
the	DT	B-NP	O
curve	NN	I-NP	O
of	IN	B-PP	O
indinavir	NN	B-NP	O
>	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
x	SYM	O	O
h	NN	B-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
C	NN	I-NP	O
(	(	O	O
max	NN	B-NP	O
)	)	O	O
>	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

Utility	NN	B-NP	O
of	IN	B-PP	O
troponin	NN	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Baseline	NN	B-NP	O
electrocardiogram	NN	I-NP	O
abnormalities	NNS	I-NP	O
and	CC	O	O
market	NN	B-NP	O
elevations	NNS	I-NP	O
not	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
myocardial	JJ	B-NP	B
necrosis	NN	I-NP	I
make	VBP	B-VP	O
accurate	JJ	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
difficult	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Troponin	NN	B-NP	O
sampling	NN	I-NP	O
may	MD	B-VP	O
offer	VB	I-VP	O
greater	JJR	B-NP	O
diagnostic	JJ	I-NP	O
utility	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
outcomes	NNS	B-NP	O
based	VBN	B-PP	O
on	IN	B-PP	O
troponin	NN	B-NP	O
positivity	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
admitted	VBN	B-VP	O
for	IN	B-PP	O
exclusion	NN	B-NP	O
of	IN	B-PP	O
MI	NN	B-NP	B
.	.	O	O

Outcomes	NNS	B-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
admitted	VBN	B-VP	O
for	IN	B-PP	O
possible	JJ	B-NP	O
MI	NN	I-NP	B
after	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
underwent	VBD	B-VP	O
a	DT	B-NP	O
rapid	JJ	I-NP	O
rule	NN	I-NP	O
-	HYPH	B-ADJP	O
in	IN	B-PP	O
protocol	NN	B-NP	O
that	WDT	B-NP	O
included	VBD	B-VP	O
serial	JJ	B-NP	O
sampling	NN	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
kinase	NN	I-NP	O
(	(	O	O
CK	NN	B-NP	O
)	)	O	O
,	,	O	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
,	,	O	O
and	CC	O	O
cardiac	JJ	B-NP	O
troponin	NN	I-NP	O
num	CD	I-NP	O
(	(	O	O
cTnI	NN	B-NP	O
)	)	O	O
over	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Outcomes	NNS	B-NP	O
included	VBD	B-VP	O
CK	NN	B-NP	O
-	HYPH	O	O
MB	NN	B-NP	O
MI	NN	I-NP	B
(	(	O	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
>	SYM	B-NP	O
or=	SYM	B-VP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
relative	JJ	I-NP	O
index	NN	I-NP	O
[	(	O	O
(	(	O	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
x	SYM	I-NP	O
num	CD	I-NP	O
)	)	O	O
/	SYM	B-NP	O
total	JJ	B-NP	O
CK	NN	I-NP	O
]	)	O	O
>	SYM	B-NP	O
or=	SYM	B-VP	O
num	CD	B-NP	O
cardiac	JJ	I-NP	B
death	NN	I-NP	I
,	,	O	O
and	CC	O	O
significant	JJ	B-NP	O
coronary	JJ	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
admitted	VBN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
met	VBD	B-VP	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
MI	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
cTnI	NN	B-NP	O
elevations	NNS	I-NP	O
.	.	O	O

Angiography	NN	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
cTnI	NN	B-NP	O
-	HYPH	O	O
positive	JJ	B-ADJP	O
,	,	O	O
with	IN	B-PP	O
significant	JJ	B-NP	O
disease	NN	I-NP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
significant	JJ	B-NP	O
disease	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
cTnI	NN	B-NP	O
elevations	NNS	I-NP	O
met	VBD	B-VP	O
CK	NN	B-NP	O
-	HYPH	O	O
MB	NN	B-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
MI	NN	B-NP	B
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
other	JJ	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
peak	JJ	I-NP	O
CK	NN	I-NP	O
-	HYPH	I-NP	O
MB	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
.	.	O	O

Sensitivities	NNS	B-NP	O
,	,	O	O
specificities	NNS	B-NP	O
,	,	O	O
and	CC	O	O
positive	JJ	B-NP	O
and	CC	I-NP	O
negative	JJ	I-NP	O
likelihood	NN	I-NP	O
ratios	NNS	I-NP	O
for	IN	B-PP	O
predicting	VBG	B-VP	O
cardiac	JJ	B-NP	B
death	NN	I-NP	I
or	CC	O	O
significant	JJ	B-NP	O
disease	NN	I-NP	O
were	VBD	B-VP	O
high	JJ	B-ADJP	O
for	IN	B-PP	O
both	CC	O	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
MI	NN	I-NP	B
and	CC	I-NP	O
cTnI	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
not	RB	O	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cTnI	NN	B-NP	O
elevations	NNS	I-NP	O
meet	VBP	B-VP	O
CK	NN	B-NP	O
-	HYPH	I-NP	O
MB	NN	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
MI	NN	B-NP	B
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
have	VB	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
underlying	VBG	B-VP	O
significant	JJ	B-NP	O
disease	NN	I-NP	O
.	.	O	O

Troponin	NN	B-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
equivalent	JJ	I-NP	O
diagnostic	JJ	I-NP	O
accuracy	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
CK	NN	B-NP	O
-	HYPH	B-NP	O
MB	NN	I-NP	O
for	IN	B-PP	O
diagnosing	VBG	B-VP	O
necrosis	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
and	CC	O	O
suspected	VBN	B-NP	O
MI	NN	I-NP	B
.	.	O	O

Acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
nicergoline	NN	B-NP	O
(	(	O	O
Sermion	NN	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
(	(	O	O
AIN	NN	B-NP	B
)	)	O	O
due	IN	B-PP	O
to	TO	B-PP	O
nicergoline	NN	B-NP	O
(	(	O	O
Sermion	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
patient	NN	I-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
fever	NN	B-NP	B
and	CC	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Before	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
he	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
nicergoline	NN	B-NP	O
and	CC	I-NP	O
bendazac	NN	I-NP	O
lysine	NN	I-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
retinal	JJ	B-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
at	IN	B-PP	O
ophthalmologic	JJ	B-NP	O
department	NN	I-NP	O
.	.	O	O

Thereafter	RB	B-ADVP	O
,	,	O	O
he	PRP	B-NP	O
experienced	VBD	B-VP	O
intermittent	JJ	B-NP	O
fever	NN	I-NP	B
and	CC	I-NP	O
skin	NN	I-NP	B
rash	NN	I-NP	I
.	.	O	O

On	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
clinical	JJ	B-NP	O
symptoms	NNS	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
arthralgia	FW	I-NP	B
and	CC	O	O
fever	NN	B-NP	B
)	)	O	O
and	CC	O	O
laboratory	NN	B-NP	O
findings	NNS	I-NP	O
(	(	O	O
i.e.	FW	B-NP	O
eosinophilia	FW	I-NP	B
and	CC	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
)	)	O	O
suggested	VBD	B-VP	O
AIN	NN	B-NP	B
,	,	O	O
and	CC	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
pathologic	JJ	B-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
biopsy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
lymphocyte	NN	I-NP	O
transformation	NN	I-NP	O
test	NN	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
positive	JJ	I-NP	O
result	NN	I-NP	O
against	IN	B-PP	O
nicergoline	NN	B-NP	O
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
consisted	VBN	I-VP	O
of	IN	B-PP	O
withdrawal	NN	B-NP	O
of	IN	B-PP	O
nicergoline	NN	B-NP	O
and	CC	O	O
intravenous	JJ	B-NP	O
methylprednisolone	NN	I-NP	O
,	,	O	O
and	CC	O	O
his	PRP$	B-NP	O
renal	JJ	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
completely	RB	I-VP	O
recovered	VBN	I-VP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
nicergoline	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
AIN	NN	I-NP	B
.	.	O	O

Neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
complicated	VBN	B-VP	O
by	IN	B-PP	O
massive	JJ	B-NP	O
intestinal	JJ	I-NP	O
bleeding	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
CRF	NN	B-NP	B
)	)	O	O
developed	VBD	B-VP	O
neuroleptic	JJ	B-NP	B
malignant	JJ	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
NMS	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	I-NP	O
levomepromazine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
typical	JJ	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
NMS	NN	B-NP	B
,	,	O	O
massive	JJ	B-NP	O
intestinal	JJ	I-NP	O
bleeding	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
episode	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
report	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
NMS	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
CRF	NN	B-NP	B
may	MD	B-VP	O
be	VB	I-VP	O
complicated	VBN	I-VP	O
by	IN	B-PP	O
intestinal	JJ	B-NP	O
bleeding	NN	I-NP	B
and	CC	O	O
needs	VBZ	B-VP	O
special	JJ	B-NP	O
caution	NN	I-NP	O
for	IN	B-PP	O
this	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
in	IN	B-PP	O
right	JJ	B-NP	O
-	HYPH	I-NP	O
and	CC	O	O
left	VBN	B-VP	O
-	HYPH	O	O
pawed	VBN	B-VP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
staining	NN	I-NP	O
method	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
asymmetrical	JJ	I-NP	O
breakdown	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
(	(	O	O
BBB	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
female	JJ	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Paw	NN	B-NP	O
preference	NN	I-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
food	NN	I-NP	O
reaching	VBG	I-NP	O
test	NN	I-NP	O
.	.	O	O

Adrenaline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
destroy	VB	I-VP	O
the	DT	B-NP	O
BBB	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
using	VBG	I-VP	O
triphenyltetrazolium	NN	B-NP	O
(	(	O	O
TTC	NN	B-NP	O
)	)	O	O
staining	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
slices	NNS	I-NP	O
just	RB	B-ADVP	O
after	IN	B-PP	O
giving	VBG	B-VP	O
adrenaline	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
s	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
normal	JJ	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
whole	JJ	I-NP	O
brain	NN	I-NP	O
sections	NNS	I-NP	O
exhibited	VBD	B-VP	O
complete	JJ	B-NP	O
staining	NN	I-NP	O
with	IN	B-PP	O
TTC	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
adrenaline	NN	B-NP	O
infusion	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
s	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
large	JJ	B-NP	O
unstained	JJ	I-NP	O
areas	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
brain	NN	I-NP	O
in	IN	B-PP	O
right	JJ	B-NP	O
-	HYPH	I-NP	O
pawed	VBN	I-NP	O
animals	NNS	I-NP	O
,	,	O	O
and	CC	O	O
vice	NN	B-NP	O
versa	NN	I-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
-	HYPH	I-NP	O
pawed	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

Similar	JJ	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
obtained	VBN	I-VP	O
in	IN	B-PP	O
seizure	NN	B-NP	B
-	HYPH	B-NP	O
induced	VBN	I-NP	O
breakdown	NN	I-NP	O
of	IN	B-PP	O
BBB	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
explained	VBN	I-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
asymmetric	JJ	I-NP	O
cerebral	JJ	I-NP	O
blood	NN	I-NP	O
flow	NN	I-NP	O
depending	VBG	B-VP	O
upon	IN	B-PP	O
the	DT	B-NP	O
paw	NN	I-NP	O
preference	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
new	JJ	I-NP	O
method	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
contralateral	JJ	B-NP	O
motor	NN	I-NP	O
control	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
important	JJ	B-ADJP	O
in	IN	B-PP	O
determining	VBG	B-VP	O
the	DT	B-NP	O
dominant	JJ	I-NP	O
cerebral	JJ	I-NP	O
hemisphere	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Carvedilol	NN	B-NP	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
mitochondrial	JJ	I-NP	O
cardiomyopathy	NN	I-NP	B
.	.	O	O

Several	JJ	B-NP	O
cytopathic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
mediate	VB	I-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
cumulative	JJ	B-NP	O
and	CC	I-NP	O
irreversible	JJ	I-NP	O
cardiomyopathy	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Recent	JJ	B-NP	O
evidence	NN	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
are	VBP	B-VP	O
key	JJ	B-NP	O
factors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenic	JJ	I-NP	O
process	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
investigation	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-NP	O
carvedilol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
nonselective	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenergic	JJ	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
with	IN	B-PP	O
potent	JJ	B-NP	O
antioxidant	JJ	I-NP	O
properties	NNS	I-NP	O
,	,	O	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
and	CC	I-NP	O
hepatic	JJ	I-NP	O
mitochondrial	JJ	I-NP	O
bioenergetic	JJ	I-NP	O
dysfunction	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
subchronic	JJ	B-NP	O
doxorubicin	NN	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Heart	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
mitochondria	NNS	I-NP	O
were	VBD	B-VP	O
isolated	VBN	I-VP	O
from	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
with	IN	B-PP	O
doxorubicin	NN	B-NP	O
,	,	O	O
carvedilol	NN	B-NP	O
,	,	O	O
or	CC	O	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Heart	NN	B-NP	O
mitochondria	NNS	I-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
exhibited	VBD	B-VP	O
depressed	JJ	B-NP	O
rates	NNS	I-NP	O
for	IN	B-PP	O
state	NN	B-NP	O
num	CD	I-NP	O
respiration	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
lower	JJR	I-NP	O
respiratory	JJ	I-NP	O
control	NN	I-NP	O
ratio	NN	I-NP	O
(	(	O	O
RCR	NN	B-NP	O
)	)	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
cardiac	JJ	B-NP	O
mitochondria	NNS	I-NP	O
isolated	VBN	B-VP	O
from	IN	B-PP	O
saline	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Mitochondrial	JJ	B-NP	O
calcium	NN	I-NP	O
-	HYPH	O	O
loading	VBG	B-VP	O
capacity	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
NADH	NN	B-NP	O
-	HYPH	B-NP	O
dehydrogenase	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
suppressed	VBN	I-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
mitochondria	NNS	I-NP	O
from	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Doxorubicin	NN	B-NP	O
treatment	NN	I-NP	O
also	RB	B-ADVP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
RCR	NN	B-NP	O
for	IN	B-PP	O
liver	NN	B-NP	O
mitochondria	NNS	I-NP	O
and	CC	O	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
cytochrome	NN	I-NP	O
oxidase	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

Coadministration	NN	B-NP	O
of	IN	B-PP	O
carvedilol	NN	B-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
cellular	JJ	B-NP	O
vacuolization	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
myocytes	NNS	I-NP	O
and	CC	O	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
doxorubicin	NN	B-NP	O
on	IN	B-PP	O
mitochondrial	JJ	B-NP	O
respiration	NN	I-NP	O
in	IN	B-PP	O
both	CC	O	O
heart	NN	B-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
.	.	O	O

Carvedilol	NN	B-NP	O
also	RB	B-ADVP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
mitochondrial	JJ	B-NP	O
Ca	NN	I-NP	O
loading	NN	I-NP	O
capacity	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
complexes	NNS	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
mitochondria	NNS	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
doxorubicin	NN	B-NP	O
.	.	O	O

Carvedilol	NN	B-NP	O
by	IN	B-PP	O
itself	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
affect	VB	I-VP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
parameters	NNS	I-NP	O
measured	VBN	B-VP	O
for	IN	B-PP	O
heart	NN	B-NP	O
or	CC	I-NP	O
liver	NN	I-NP	O
mitochondria	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
this	DT	B-NP	O
protection	NN	I-NP	O
by	IN	B-PP	O
carvedilol	NN	B-NP	O
against	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
structural	JJ	I-NP	O
and	CC	I-NP	O
functional	JJ	I-NP	O
cardiac	JJ	I-NP	O
tissue	NN	I-NP	O
damage	NN	I-NP	O
may	MD	B-VP	O
afford	VB	I-VP	O
significant	JJ	B-NP	O
clinical	JJ	I-NP	O
advantage	NN	I-NP	O
in	IN	B-PP	O
minimizing	VBG	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	O	O
limiting	VBG	B-VP	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
and	CC	I-NP	O
cardiomyopathy	NN	I-NP	B
that	WDT	B-NP	O
accompanies	VBZ	B-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
doxorubicin	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
cancer	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
influenced	VBN	I-ADJP	O
by	IN	B-PP	O
adenosine	NN	B-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
than	IN	B-PP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
and	CC	I-NP	O
antagonists	NNS	I-NP	O
on	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

All	DT	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
significantly	RB	B-ADVP	O
decreased	VBD	B-VP	B
the	DT	B-NP	I
locomotor	NN	I-NP	I
activity	NN	I-NP	I
in	IN	B-PP	O
mice	NNS	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
dose	NN	B-NP	O
-	HYPH	B-VP	O
dependent	JJ	B-ADJP	O
.	.	O	O

It	PRP	B-NP	O
seems	VBZ	B-VP	O
that	IN	B-SBAR	O
adenosine	NN	B-NP	O
A1	NN	I-NP	O
and	CC	I-NP	O
A2	NN	I-NP	O
receptors	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
this	DT	B-NP	O
reaction	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
all	DT	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
p	NN	I-NP	O
-	HYPH	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
carboxyethyl	NN	I-NP	O
)	)	O	O
phenethylamino	AFX	O	O
-	HYPH	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
N	NN	I-NP	O
-	HYPH	O	O
ethylcarboxamidoadenosine	NN	B-NP	O
(	(	O	O
CGS	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
A2A	NN	B-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
N6	NN	B-NP	O
-	HYPH	O	O
cyclopentyladenosine	NN	B-NP	O
(	(	O	O
CPA	NN	B-NP	O
)	)	O	O
,	,	O	O
A1	NN	B-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
'	SYM	I-NP	O
-	HYPH	I-NP	O
N	NN	I-NP	O
-	HYPH	O	O
ethylcarboxamidoadenosine	NN	B-NP	O
(	(	O	O
NECA	NN	B-NP	O
)	)	O	O
,	,	O	O
A2	NN	B-NP	O
/	SYM	B-NP	O
A1	NN	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
significantly	RB	B-ADVP	O
and	CC	O	O
dose	NN	B-NP	O
-	HYPH	B-VP	O
dependently	RB	B-NP	O
decreased	VBN	I-NP	O
cocaine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

CPA	NN	B-NP	O
reduced	VBD	B-VP	O
cocaine	NN	B-NP	O
action	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
which	WDT	B-NP	O
,	,	O	O
given	VBN	B-PP	O
alone	RB	B-ADVP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
motility	NN	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
CGS	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
NECA	NNP	B-NP	O
decreased	VBD	B-VP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
which	WDT	B-NP	O
,	,	O	O
given	VBN	B-PP	O
alone	RB	B-ADVP	O
,	,	O	O
decreased	VBN	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
both	DT	B-NP	O
adenosine	NN	I-NP	O
receptors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
although	IN	B-SBAR	O
agonists	NNS	B-NP	O
of	IN	B-PP	O
A1	NN	B-NP	O
receptors	NNS	I-NP	O
seem	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
stronger	JJR	B-NP	O
influence	NN	I-NP	O
on	IN	B-PP	O
it	PRP	B-NP	O
.	.	O	O

The	DT	B-NP	O
selective	JJ	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
A2	NN	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
by	IN	B-PP	O
DMPX	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
dimethyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
propargylxanthine	NN	I-NP	O
)	)	O	O
significantly	RB	B-ADVP	O
enhanced	VBD	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
.	.	O	O

Caffeine	NN	B-NP	O
had	VBD	B-VP	O
similar	JJ	B-NP	O
action	NN	I-NP	O
but	CC	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
significant	JJ	B-ADJP	O
.	.	O	O

CPT	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
cyclopentyltheophylline	NN	I-NP	O
)	)	O	O
-	HYPH	O	O
-	HYPH	B-NP	O
A1	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
any	DT	B-NP	O
influence	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
test	NN	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
all	DT	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
decreased	VBD	B-VP	O
amphetamine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
,	,	O	O
but	CC	O	O
at	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
doses	NNS	I-NP	O
than	IN	B-PP	O
those	DT	B-NP	O
which	WDT	B-NP	O
were	VBD	B-VP	O
active	JJ	B-ADJP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
selective	JJ	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
A2	NN	B-NP	O
adenosine	NN	I-NP	O
receptors	NNS	I-NP	O
(	(	O	O
DMPX	NN	B-NP	O
)	)	O	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
adenosine	NN	B-NP	O
receptors	NNS	I-NP	O
(	(	O	O
caffeine	NN	B-NP	O
)	)	O	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
action	NN	I-NP	O
of	IN	B-PP	O
amphetamine	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
all	DT	B-NP	O
adenosine	NN	I-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
(	(	O	O
A1	NN	B-NP	O
and	CC	O	O
A2	NN	B-NP	O
)	)	O	O
reduce	VBP	B-VP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
amphetamine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
locomotor	NN	I-NP	O
activity	NN	I-NP	O
and	CC	O	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hyperactivity	NN	I-NP	B
is	VBZ	B-VP	O
more	RBR	B-ADJP	O
influenced	VBN	I-ADJP	O
by	IN	B-PP	O
adenosine	NN	B-NP	O
receptor	NN	I-NP	O
agonists	NNS	I-NP	O
(	(	O	O
particularly	RB	B-NP	O
A1	NN	I-NP	O
receptors	NNS	I-NP	O
)	)	O	O
than	IN	B-SBAR	O
amphetamine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hyperactivity	NN	I-NP	B
.	.	O	O

Amiodarone	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bradyarrhythmia	NN	B-NP	B
requiring	VBG	B-VP	O
permanent	JJ	B-NP	O
pacemaker	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
and	CC	O	O
prior	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
(	(	O	O
AF	NN	B-NP	B
)	)	O	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bradyarrhythmia	NN	B-NP	B
requiring	VBG	B-VP	O
a	DT	B-NP	O
permanent	JJ	I-NP	O
pacemaker	NN	I-NP	O
.	.	O	O

Reports	NNS	B-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	O
bradyarrhythmia	NN	I-NP	B
during	IN	B-PP	O
amiodarone	NN	B-NP	O
therapy	NN	I-NP	O
are	VBP	B-VP	O
infrequent	JJ	B-ADJP	O
and	CC	O	O
limited	JJ	B-ADJP	O
to	TO	B-PP	O
studies	NNS	B-NP	O
assessing	VBG	B-VP	O
the	DT	B-NP	O
therapy	NN	I-NP	O
s	VBZ	B-VP	O
use	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ventricular	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O

A	DT	B-NP	O
study	NN	I-NP	O
cohort	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
age	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
AF	NN	B-NP	B
was	VBD	B-VP	O
identified	VBN	I-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
provincewide	JJ	I-NP	O
database	NN	I-NP	O
of	IN	B-PP	O
Quebec	NNP	B-NP	O
residents	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
(	(	O	O
MI	NN	B-NP	B
)	)	O	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Using	VBG	B-VP	O
a	DT	B-NP	O
nested	VBN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
design	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
bradyarrhythmia	NN	B-NP	B
requiring	VBG	B-VP	O
a	DT	B-NP	O
permanent	JJ	I-NP	O
pacemaker	NN	I-NP	O
were	VBD	B-VP	O
matched	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Multivariable	JJ	B-NP	O
logistic	JJ	I-NP	O
regression	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
estimate	VB	I-VP	O
the	DT	B-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
(	(	O	O
OR	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
pacemaker	NN	B-NP	O
insertion	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
controlling	VBG	B-VP	O
for	IN	B-PP	O
baseline	NN	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
and	CC	O	O
exposure	NN	B-NP	O
to	TO	B-PP	O
sotalol	NN	B-NP	O
,	,	O	O
Class	NN	B-NP	O
num	CD	I-NP	O
antiarrhythmic	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
blockers	NNS	B-NP	O
,	,	O	O
calcium	NN	B-NP	O
channel	NN	I-NP	O
blockers	NNS	I-NP	O
,	,	O	O
and	CC	O	O
digoxin	NN	B-NP	O
.	.	O	O

amiodarone	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
pacemaker	NN	B-NP	O
insertion	NN	I-NP	O
(	(	O	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
modified	VBN	I-VP	O
by	IN	B-PP	O
gender	NN	B-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
risk	NN	I-NP	O
in	IN	B-PP	O
women	NNS	B-NP	O
versus	IN	B-PP	O
men	NNS	B-NP	O
(	(	O	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
vs.	IN	B-PP	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

Digoxin	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
only	RB	I-NP	O
other	JJ	I-NP	O
medication	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
pacemaker	NN	B-NP	O
insertion	NN	I-NP	O
(	(	O	O
OR	NN	B-NP	O
:	:	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
)	)	O	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
AF	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
previous	JJ	I-NP	O
MI	NN	I-NP	B
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
bradyarrhythmia	NN	B-NP	B
requiring	VBG	B-VP	O
a	DT	B-NP	O
permanent	JJ	I-NP	O
pacemaker	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
finding	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
augmented	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
pacemaker	NN	B-NP	O
insertion	NN	I-NP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
women	NNS	I-NP	O
receiving	VBG	B-VP	O
amiodarone	NN	B-NP	O
requires	VBZ	B-VP	O
further	JJ	B-NP	O
investigation	NN	I-NP	O
.	.	O	O

Indomethacin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
morphologic	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
epithelium	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
morphologic	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
urothelium	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
indomethacin	NN	B-NP	O
.	.	O	O

Nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
poorly	RB	I-NP	O
recognized	VBN	I-NP	O
and	CC	O	O
under	IN	B-PP	O
-	HYPH	B-NP	O
reported	VBN	I-NP	O
condition	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
tiaprofenic	JJ	B-NP	O
acid	NN	I-NP	O
,	,	O	O
indomethacin	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
established	VBN	I-VP	O
:	:	O	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
intraperitoneal	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
indomethacin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
therapeutic	JJ	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
oral	JJ	B-NP	O
indomethacin	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
body	NN	I-NP	O
weight	NN	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
then	RB	I-VP	O
killed	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
bladders	NNS	I-NP	O
removed	VBN	B-VP	O
for	IN	B-PP	O
light	NN	B-NP	O
and	CC	I-NP	O
electron	NN	I-NP	O
microscopic	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
light	JJ	I-NP	O
microscopic	JJ	I-NP	O
findings	NNS	I-NP	O
showed	VBD	B-VP	O
some	DT	B-NP	O
focal	JJ	I-NP	O
epithelial	JJ	I-NP	O
degeneration	NN	I-NP	O
that	WDT	B-NP	O
was	VBD	B-VP	O
more	RBR	B-ADJP	O
prominent	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
both	DT	B-NP	O
indomethacin	NN	I-NP	O
groups	NNS	I-NP	O
revealed	VBD	B-VP	O
statistically	RB	B-NP	O
increased	VBN	I-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
mast	NN	B-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
mucosa	NN	I-NP	O
and	CC	I-NP	O
penetration	NN	I-NP	O
of	IN	B-PP	O
lanthanum	NN	B-NP	O
nitrate	NN	I-NP	O
through	IN	B-PP	O
intercellular	JJ	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
epithelium	NN	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
mast	NN	B-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
and	CC	I-NP	O
therapeutic	JJ	I-NP	O
dose	NN	I-NP	O
groups	NNS	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
statistically	RB	B-ADJP	O
significant	JJ	I-ADJP	O
.	.	O	O

Indomethacin	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
histopathologic	JJ	B-NP	O
findings	NNS	I-NP	O
typical	JJ	B-ADJP	O
of	IN	B-PP	O
interstitial	JJ	B-NP	B
cystitis	NN	I-NP	I
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
leaky	JJ	B-NP	O
bladder	NN	I-NP	O
epithelium	NN	I-NP	O
and	CC	O	O
mucosal	JJ	B-NP	O
mastocytosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
true	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
nonsteroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	B-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
in	IN	B-PP	O
humans	NNS	B-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
clarified	VBN	I-VP	O
by	IN	B-PP	O
prospective	JJ	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
thalidomide	NN	I-NP	O
in	IN	B-PP	O
androgen	NN	B-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
antiangiogenic	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
assessed	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
various	JJ	B-NP	O
solid	JJ	I-NP	O
and	CC	I-NP	O
haematological	JJ	I-NP	B
malignancies	NNS	I-NP	I
.	.	O	O

Thalidomide	NN	B-NP	O
blocks	VBZ	B-VP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
angiogenic	JJ	B-NP	O
agents	NNS	I-NP	O
including	VBG	B-PP	O
bFGF	NN	B-NP	O
,	,	I-NP	O
VEGF	NN	I-NP	O
and	CC	I-NP	O
IL	NN	I-NP	O
-	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

We	PRP	B-NP	O
undertook	VBD	B-VP	O
an	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
study	NN	I-NP	O
using	VBG	B-VP	O
thalidomide	IN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
once	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
androgen	NN	B-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
study	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
(	(	O	O
median	NN	B-NP	O
num	CD	I-NP	O
range	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
)	)	O	O
.	.	O	O

Patients	NNS	B-NP	O
underwent	VBD	B-VP	O
regular	JJ	B-NP	O
measurement	NN	I-NP	O
of	IN	B-PP	O
prostate	NN	B-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
antigen	NN	I-NP	O
(	(	O	O
PSA	NN	B-NP	O
)	)	O	O
,	,	O	O
urea	NN	B-NP	O
and	CC	I-NP	O
electrolytes	NNS	I-NP	O
,	,	O	O
serum	NN	B-NP	O
bFGF	NN	I-NP	O
and	CC	I-NP	O
VEGF	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
men	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
PSA	NN	I-NP	O
of	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
sustained	VBN	B-VP	O
throughout	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
absolute	JJ	B-NP	O
PSA	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
median	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Increasing	VBG	B-VP	O
levels	NNS	B-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
bFGF	NN	I-NP	O
and	CC	I-NP	O
VEGF	NN	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
progressive	JJ	B-NP	O
disease	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
who	WP	B-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
PSA	NN	B-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
decline	NN	I-NP	O
in	IN	B-PP	O
bFGF	NN	B-NP	O
and	CC	I-NP	O
VEGF	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
of	IN	I-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
rising	VBG	I-NP	O
PSA	NN	I-NP	O
showed	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
growth	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
included	VBD	B-VP	O
constipation	NN	B-NP	B
,	,	O	O
morning	NN	B-NP	O
drowsiness	NN	I-NP	B
,	,	O	O
dizziness	NN	B-NP	B
and	CC	I-NP	O
rash	NN	I-NP	B
,	,	O	O
and	CC	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
withdrawal	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
.	.	O	O

Evidence	NN	B-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
sensory	JJ	I-NP	I
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
men	NNS	I-NP	O
before	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
men	NNS	I-NP	O
who	WP	B-NP	O
completed	VBD	B-VP	O
num	CD	B-NP	O
months	NNS	I-NP	O
on	IN	B-PP	O
thalidomide	NN	B-NP	O
,	,	O	O
subclinical	JJ	B-NP	O
evidence	NN	I-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
before	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
repeat	NN	B-NP	O
testing	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
findings	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
thalidomide	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
option	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
failed	VBN	I-VP	O
other	JJ	B-NP	O
forms	NNS	I-NP	O
of	IN	B-PP	O
therapy	NN	B-NP	O
,	,	O	O
provided	VBN	B-VP	O
close	RB	B-ADVP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
is	VBZ	B-VP	O
maintained	VBN	I-VP	O
for	IN	B-PP	O
development	NN	B-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
toxicity	NN	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
for	IN	B-PP	O
lumbar	NN	B-NP	O
plexus	NN	I-NP	O
block	NN	I-NP	O
:	:	O	O
A	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
.	.	O	O

Central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
and	CC	O	I
cardiac	JJ	B-NP	I
toxicity	NN	I-NP	I
following	VBG	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
recognized	VBN	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
regional	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Levobupivacaine	NNP	B-NP	O
,	,	O	O
the	DT	B-NP	O
pure	JJ	I-NP	O
S	NN	I-NP	O
enantiomer	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
developed	VBN	I-VP	O
to	TO	I-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
safety	NN	I-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
grand	JJ	B-NP	B
mal	JJ	I-NP	I
seizures	NNS	I-NP	I
following	VBG	B-PP	O
accidental	JJ	B-NP	O
intravascular	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
presenting	VBG	B-VP	O
for	IN	B-PP	O
elective	JJ	B-NP	O
orthopedic	JJ	I-NP	O
surgery	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lower	JJR	I-NP	O
limb	NN	I-NP	O
underwent	VBD	B-VP	O
blockade	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
lumbar	JJ	I-NP	O
plexus	NN	I-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
approach	NN	I-NP	O
.	.	O	O

Immediately	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
epinephrine	NN	B-NP	O
num	CD	I-NP	O
microgram	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
grand	JJ	B-NP	B
mal	JJ	I-NP	I
seizures	NNS	I-NP	I
,	,	O	O
despite	IN	B-PP	O
negative	JJ	B-NP	O
aspiration	NN	I-NP	O
for	IN	B-PP	O
blood	NN	B-NP	O
and	CC	O	O
no	DT	B-NP	O
clinical	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
intravenous	JJ	B-NP	O
epinephrine	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
seizures	NNS	I-NP	B
were	VBD	B-VP	O
successfully	RB	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
thiopental	NN	I-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
succinylcholine	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

Neither	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
signs	NNS	B-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

Both	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
preoperatively	RB	B-ADVP	O
with	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
adrenergic	JJ	I-NP	O
antagonist	NN	I-NP	O
medications	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
masked	VBN	I-VP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
unintentional	JJ	I-NP	O
intravascular	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
with	IN	B-PP	O
epinephrine	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
levobupivacaine	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
safer	JJR	I-NP	O
cardiac	JJ	I-NP	B
toxicity	NN	I-NP	I
profile	NN	I-NP	O
than	IN	B-PP	O
racemic	JJ	B-NP	O
bupivacaine	NN	I-NP	O
,	,	O	O
if	IN	B-SBAR	O
adequate	JJ	B-NP	O
amounts	NNS	I-NP	O
of	IN	B-PP	O
levobupivacaine	NN	B-NP	O
reach	VBP	B-VP	O
the	DT	B-NP	O
circulation	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
will	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
convulsions	NNS	B-NP	B
.	.	O	O

Plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
sufficient	JJ	B-ADJP	O
to	TO	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
central	JJ	B-NP	B
nervous	JJ	I-NP	I
system	NN	I-NP	I
toxicity	NN	I-NP	I
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
manifestations	NNS	B-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
in	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Anaesthetic	JJ	B-NP	O
complications	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
myotonia	NN	B-NP	B
congenita	NN	I-NP	I
:	:	O	O
case	NN	B-NP	O
study	NN	I-NP	O
and	CC	O	O
comparison	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
myotonic	JJ	I-NP	B
disorders	NNS	I-NP	I
.	.	O	O

Myotonia	NN	B-NP	B
congenita	NN	I-NP	I
(	(	O	O
MC	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
defect	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
skeletal	JJ	I-NP	O
muscle	NN	I-NP	O
chloride	NN	I-NP	O
channel	NN	I-NP	O
function	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
sustained	JJ	B-NP	B
membrane	NN	I-NP	I
depolarisation	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
previously	RB	I-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
life	NN	I-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
muscle	NN	B-NP	B
spasm	NN	I-NP	I
and	CC	O	O
secondary	JJ	B-NP	O
ventilation	NN	I-NP	O
difficulties	NNS	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
preoperative	JJ	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
suxamethonium	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
muscle	NN	I-NP	B
spasms	NNS	I-NP	I
disappeared	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
and	CC	O	O
the	DT	B-NP	O
surgery	NN	I-NP	O
proceeded	VBD	B-VP	O
without	IN	B-PP	O
further	JJ	B-NP	O
problems	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
subsequently	RB	B-VP	O
questioned	VBN	I-VP	O
,	,	O	O
she	PRP	B-NP	O
reported	VBD	B-VP	O
minor	JJ	B-NP	O
symptoms	NNS	I-NP	O
suggesting	VBG	B-VP	O
a	DT	B-NP	O
myotonic	JJ	I-NP	B
condition	NN	I-NP	I
.	.	O	O

Myotonia	NN	B-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
on	IN	B-PP	O
clinical	JJ	B-NP	O
examination	NN	I-NP	O
and	CC	I-NP	O
EMG	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
MC	NN	I-NP	B
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
genetically	RB	B-ADVP	O
.	.	O	O

Neither	CC	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
nor	CC	O	O
the	DT	B-NP	O
anaesthetist	NN	I-NP	O
were	VBD	B-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
before	IN	B-PP	O
this	DT	B-NP	O
potentially	RB	I-NP	O
lethal	JJ	I-NP	O
complication	NN	I-NP	O
occurred	VBD	B-VP	O
.	.	O	O

We	PRP	B-NP	O
give	VBP	B-VP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
overview	NN	I-NP	O
of	IN	B-PP	O
ion	NN	B-NP	B
channel	NN	I-NP	I
disorders	NNS	I-NP	I
including	VBG	B-PP	O
malignant	JJ	B-NP	B
hyperthermia	NN	I-NP	I
and	CC	O	O
their	PRP$	B-NP	O
anaesthetic	JJ	I-NP	O
considerations	NNS	I-NP	O
.	.	O	O

Respiratory	JJ	B-NP	O
pattern	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
.	.	O	O

Apnea	NNP	B-NP	B
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
occur	VB	I-VP	O
during	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
but	CC	O	O
systematic	JJ	B-NP	O
studies	NNS	I-NP	O
of	IN	B-PP	O
ictal	JJ	B-NP	O
respiratory	JJ	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
are	VBP	B-VP	O
few	JJ	B-ADJP	O
.	.	O	O

Data	NNS	B-NP	O
regarding	VBG	B-PP	O
respiratory	JJ	B-NP	O
pattern	NN	I-NP	O
defects	NNS	I-NP	O
during	IN	B-PP	O
interictal	JJ	B-NP	O
periods	NNS	I-NP	O
also	RB	B-ADVP	O
are	VBP	B-VP	O
scarce	JJ	B-ADJP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
generate	VB	I-VP	O
information	NN	B-NP	O
with	IN	B-PP	O
regard	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
interictal	JJ	I-NP	O
period	NN	I-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
with	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epilepsy	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
chronically	RB	I-NP	O
epileptic	JJ	I-NP	B
animals	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
anesthetized	VBN	I-VP	O
,	,	O	O
given	VBN	B-NP	O
tracheotomies	NNS	I-NP	O
,	,	O	O
and	CC	O	O
subjected	VBN	B-VP	O
to	TO	B-PP	O
hyperventilation	NN	B-NP	B
or	CC	I-NP	O
hypoventilation	NN	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Breathing	NN	B-NP	O
movements	NNS	I-NP	O
caused	VBD	B-VP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
thoracic	JJ	B-NP	O
volume	NN	I-NP	O
and	CC	O	O
forced	VBN	B-NP	O
air	NN	I-NP	O
to	TO	B-VP	O
flow	VB	I-VP	O
tidally	RB	B-ADVP	O
through	IN	B-PP	O
a	DT	B-NP	O
pneumotachograph	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
flow	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
using	VBG	B-VP	O
a	DT	B-NP	O
differential	JJ	I-NP	O
pressure	NN	I-NP	O
transducer	NN	I-NP	O
,	,	O	O
passed	VBN	B-VP	O
through	IN	B-PP	O
a	DT	B-NP	O
polygraph	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
from	IN	B-PP	O
this	DT	B-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
computer	NN	I-NP	O
with	IN	B-PP	O
custom	NN	B-NP	O
software	NN	I-NP	O
that	WDT	B-NP	O
derived	VBD	B-VP	O
ventilation	NN	B-NP	O
(	(	O	O
VE	NN	B-NP	O
)	)	O	O
,	,	O	O
tidal	JJ	B-NP	O
volume	NN	I-NP	O
(	(	O	O
VT	NN	B-NP	O
)	)	O	O
,	,	O	O
inspiratory	JJ	B-NP	O
time	NN	I-NP	O
(	(	O	O
TI	NN	B-NP	O
)	)	O	O
,	,	O	O
expiratory	JJ	B-NP	O
time	NN	I-NP	O
(	(	O	O
TE	NN	B-NP	O
)	)	O	O
,	,	O	O
breathing	NN	B-NP	O
frequency	NN	I-NP	O
(	(	O	O
f	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
mean	JJ	B-NP	O
inspiratory	JJ	I-NP	O
flow	NN	I-NP	O
(	(	O	O
VT	NN	B-NP	O
/	SYM	O	O
TI	NN	B-NP	O
)	)	O	O
on	IN	B-PP	O
a	DT	B-NP	O
breath	NN	I-NP	O
-	HYPH	B-ADJP	O
by	IN	B-PP	O
-	HYPH	B-NP	O
breath	NN	I-NP	O
basis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hyperventilation	NN	I-NP	B
maneuver	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
spontaneous	JJ	B-NP	O
ventilation	NN	I-NP	O
in	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
and	CC	O	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
VE	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
epileptic	JJ	I-NP	B
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
VE	NN	B-NP	O
was	VBD	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
TE	NN	B-NP	O
peak	NN	I-NP	O
in	IN	B-PP	O
relation	NN	B-NP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
hypoventilation	NN	I-NP	O
maneuver	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
arterial	JJ	I-NP	O
Paco2	NN	I-NP	O
,	,	O	O
followed	VBN	B-VP	O
by	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
VE	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
epileptic	JJ	I-NP	B
group	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
VE	NN	B-NP	O
was	VBD	B-VP	O
mediated	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
TE	NN	B-NP	O
peak	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
KCN	NN	B-NP	O
,	,	O	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
peripheral	JJ	B-NP	O
chemoreception	NN	I-NP	O
activation	NN	I-NP	O
on	IN	B-PP	O
ventilation	NN	B-NP	O
,	,	O	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
VE	NN	B-NP	O
for	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
altered	JJ	I-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
react	VB	I-VP	O
to	TO	B-PP	O
(	(	O	O
or	CC	O	O
compensate	VB	B-VP	O
for	IN	B-PP	O
)	)	O	O
blood	NN	B-NP	O
gas	NN	I-NP	O
changes	NNS	I-NP	O
with	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
ventilation	NN	B-NP	O
and	CC	O	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
centrally	RB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
speculate	VBP	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
relation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
treating	VBG	B-VP	O
different	JJ	B-NP	O
epilepsy	NN	I-NP	B
-	HYPH	B-NP	O
associated	VBN	I-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
serum	NN	I-NP	O
soluble	JJ	I-NP	O
Fas	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
paracetamol	NN	B-NP	O
overdose	NN	I-NP	B
.	.	O	O

Experimental	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
apoptosis	NN	B-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
Fas	NN	I-NP	O
/	SYM	B-NP	O
Fas	NN	I-NP	O
Ligand	NN	I-NP	O
signaling	NN	I-NP	O
system	NN	I-NP	O
may	MD	B-VP	O
play	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
soluble	JJ	I-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
Fas	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
sFas	NN	B-NP	O
(	(	O	O
soluble	JJ	B-NP	O
Fas	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
ELISA	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
and	CC	O	O
num	CD	B-NP	O
normal	JJ	I-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
necrosis	NN	I-NP	B
factor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
and	CC	O	O
interferon	NN	B-NP	O
-	HYPH	O	O
gamma	SYM	B-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
ELISA	NN	B-NP	O
.	.	O	O

Serum	NN	B-NP	O
sFas	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
median	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
;	:	O	O
range	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
U	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
)	)	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
normal	JJ	I-NP	O
controls	NNS	I-NP	O
.	.	O	O

Levels	NNS	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
due	IN	B-PP	O
to	TO	B-PP	O
paracetamol	NN	B-NP	O
overdose	NN	I-NP	B
than	IN	B-PP	O
those	DT	B-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
A	NN	I-NP	O
to	TO	B-PP	O
E	NN	B-NP	O
hepatitis	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
relationship	NN	I-NP	O
of	IN	B-PP	O
sFas	NN	B-NP	O
to	TO	B-PP	O
eventual	JJ	B-NP	O
outcome	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
correlation	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
serum	NN	B-NP	O
sFas	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
aspartate	NN	B-NP	O
aminotransferase	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
increased	VBN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
sFas	NN	B-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
may	MD	B-VP	O
reflect	VB	I-VP	O
activation	NN	B-NP	O
of	IN	B-PP	O
Fas	NN	B-NP	O
-	HYPH	O	O
mediated	VBN	B-NP	O
apoptosis	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	O	O
this	DT	B-NP	O
together	NN	I-NP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
tumor	NN	I-NP	B
necrosis	NN	I-NP	B
factor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
factor	NN	I-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
cell	NN	I-NP	O
loss	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
subthalamic	JJ	I-NP	O
nucleus	NN	I-NP	O
stimulation	NN	I-NP	O
for	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

High	JJ	B-NP	O
frequency	NN	I-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
subthalamic	JJ	I-NP	O
nucleus	NN	I-NP	O
(	(	O	O
STN	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
to	TO	I-VP	O
ameliorate	VB	I-VP	O
the	DT	B-NP	O
signs	NNS	I-NP	O
and	CC	I-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
advanced	VBN	B-NP	O
Parkinson	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
frequency	NN	I-NP	O
STN	NN	I-NP	O
stimulation	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
suffering	VBG	B-VP	O
from	IN	B-PP	O
severe	JJ	B-NP	O
Parkinson	NN	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
Stages	NNS	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
V	NN	I-NP	O
on	IN	B-PP	O
Hoehn	NNP	B-NP	O
and	CC	I-NP	O
Yahr	NNP	I-NP	O
scale	NN	I-NP	O
)	)	O	O
and	CC	O	O
,	,	O	O
particularly	RB	B-ADVP	O
bradykinesia	NN	B-NP	B
,	,	O	O
rigidity	NN	B-NP	B
,	,	O	O
and	CC	O	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
underwent	VBD	B-VP	O
bilateral	JJ	B-NP	O
implantation	NN	I-NP	O
of	IN	B-PP	O
electrodes	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
STN	NN	I-NP	O
.	.	O	O

Preoperative	JJ	B-NP	O
and	CC	I-NP	O
postoperative	JJ	I-NP	O
assessments	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
,	,	O	O
in	IN	B-PP	O
on	IN	B-PP	O
and	CC	I-PP	O
off	IN	I-PP	O
drug	NN	B-NP	O
conditions	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
using	VBG	B-VP	O
Unified	NNP	B-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
,	,	O	O
Hoehn	NNP	B-NP	O
and	CC	O	O
Yahr	NNP	B-NP	O
staging	NN	I-NP	O
,	,	O	O
England	NNP	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
living	NN	I-NP	O
score	NN	I-NP	O
and	CC	I-NP	O
video	NN	I-NP	O
recordings	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
electrical	JJ	B-NP	O
stimulation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
STN	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patients	NNS	I-NP	O
s	VBZ	B-VP	O
scores	NNS	B-NP	O
for	IN	B-PP	O
activities	NNS	B-NP	O
of	IN	B-PP	O
daily	JJ	B-NP	O
living	NN	I-NP	O
and	CC	I-NP	O
motor	NN	I-NP	O
examination	NN	I-NP	O
scores	NNS	I-NP	O
(	(	O	O
Unified	NNP	B-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
parts	NNS	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
)	)	O	O
off	IN	B-PP	O
medication	NN	B-NP	O
improved	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
subscores	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
akinesia	NN	I-NP	B
,	,	I-NP	O
rigidity	NN	I-NP	B
,	,	I-NP	O
tremor	NN	I-NP	B
and	CC	I-NP	O
gait	NN	I-NP	O
also	RB	B-ADVP	O
improved.	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
average	JJ	I-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
decreased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cognitive	JJ	I-NP	O
functions	NNS	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
developed	VBD	B-VP	O
device	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
complications	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
abnormal	JJ	B-NP	O
weight	NN	I-NP	O
gain	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
subthalamic	JJ	I-NP	O
nucleus	NN	I-NP	O
stimulation	NN	I-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
advanced	VBN	B-NP	O
Parkinson	NNP	I-NP	B
s	NNS	I-NP	I
disease	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
off	IN	B-PP	O
phase	NN	B-NP	O
symptoms	NNS	I-NP	O
,	,	O	O
improves	VBZ	B-VP	O
the	DT	B-NP	O
axial	JJ	I-NP	O
symptoms	NNS	I-NP	O
and	CC	O	O
reduces	VBZ	B-VP	O
levodopa	NN	B-NP	O
requirements	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
is	VBZ	B-VP	O
useful	JJ	B-ADJP	O
in	IN	B-PP	O
controlling	VBG	B-VP	O
drug	NN	B-NP	B
-	HYPH	B-NP	I
induced	VBN	I-NP	I
dyskinesias	NNS	I-NP	I
.	.	O	O

Ocular	JJ	B-NP	O
motility	NN	I-NP	O
changes	NNS	I-NP	O
after	IN	B-PP	O
subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
retinoblastoma	NN	B-NP	B
.	.	O	O

Focal	JJ	B-NP	O
subtenon	NN	I-NP	O
carboplatin	NN	I-NP	O
injections	NNS	I-NP	O
have	VBP	B-VP	O
recently	RB	I-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
presumably	RB	I-NP	O
toxicity	NN	I-NP	B
-	HYPH	O	O
free	JJ	B-NP	O
adjunct	NN	I-NP	O
to	TO	B-PP	O
systemic	JJ	B-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
intraocular	JJ	B-NP	O
retinoblastoma	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
our	PRP$	B-NP	O
clinical	JJ	I-NP	O
experience	NN	I-NP	O
with	IN	B-PP	O
abnormal	JJ	B-NP	B
ocular	JJ	I-NP	I
motility	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
noted	VBD	B-VP	O
abnormal	JJ	B-NP	B
ocular	JJ	I-NP	I
motility	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
retinoblastoma	NN	B-NP	B
who	WP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
ocular	JJ	B-NP	O
manipulation	NN	I-NP	O
under	IN	B-PP	O
general	JJ	B-NP	O
anesthesia	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
their	PRP$	B-NP	O
eyes	NNS	I-NP	O
by	IN	B-PP	O
forced	VBN	B-NP	O
duction	NN	I-NP	O
testing	NN	I-NP	O
,	,	O	O
comparing	VBG	B-VP	O
ocular	JJ	B-NP	O
motility	NN	I-NP	O
after	IN	B-PP	O
tumor	NN	B-NP	B
control	NN	I-NP	O
with	IN	B-PP	O
ocular	JJ	B-NP	O
motility	NN	I-NP	O
at	IN	B-PP	O
diagnosis	NN	B-NP	O
.	.	O	O

Eyes	NNS	B-NP	O
subsequently	RB	B-VP	O
enucleated	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
treatment	NN	B-NP	O
failure	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
histologically	RB	B-ADVP	O
.	.	O	O

Limitation	NN	B-NP	O
of	IN	B-PP	O
ocular	JJ	B-NP	O
motility	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
num	CD	I-NP	O
eyes	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
intraocular	JJ	B-NP	O
retinoblastoma	NN	I-NP	B
with	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
multimodality	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
revealed	VBD	B-VP	O
many	JJ	B-NP	O
lipophages	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
periorbital	JJ	I-NP	O
fat	NN	I-NP	O
surrounding	VBG	B-VP	O
the	DT	B-NP	O
optic	JJ	I-NP	O
nerve	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
eye	NN	I-NP	O
,	,	O	O
indicative	JJ	B-ADJP	O
of	IN	B-PP	O
phagocytosis	NN	B-NP	O
of	IN	B-PP	O
previously	RB	B-NP	O
existing	VBG	I-NP	O
fat	JJ	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
suggesting	VBG	B-VP	O
prior	JJ	B-NP	O
fat	NN	I-NP	O
necrosis	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
enucleations	NNS	I-NP	O
were	VBD	B-VP	O
technically	RB	B-ADJP	O
difficult	JJ	I-ADJP	O
and	CC	I-ADJP	O
hazardous	JJ	I-ADJP	O
for	IN	B-PP	O
globe	NN	B-NP	O
rupture	NN	I-NP	B
because	IN	B-PP	O
of	IN	I-PP	O
extensive	JJ	B-NP	O
orbital	JJ	I-NP	O
soft	JJ	I-NP	O
tissue	NN	I-NP	O
adhesions	NNS	I-NP	O
.	.	O	O

Subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
chemotherapy	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significant	JJ	B-NP	O
fibrosis	NN	I-NP	B
of	IN	B-PP	O
orbital	JJ	B-NP	O
soft	JJ	I-NP	O
tissues	NNS	I-NP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
mechanical	JJ	B-NP	O
restriction	NN	I-NP	O
of	IN	B-PP	O
eye	NN	B-NP	O
movements	NNS	I-NP	O
and	CC	O	O
making	VBG	B-VP	O
subsequent	JJ	B-NP	O
enucleation	NN	I-NP	O
difficult	JJ	B-ADJP	O
.	.	O	O

Subtenon	NN	B-NP	O
carboplatin	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
free	JJ	B-ADJP	O
of	IN	B-PP	O
toxicity	NN	B-NP	B
,	,	O	O
and	CC	O	O
its	PRP$	B-NP	O
use	NN	I-NP	O
is	VBZ	B-VP	O
best	RBS	B-ADJP	O
restricted	JJ	I-ADJP	O
to	TO	B-PP	O
specific	JJ	B-NP	O
indications	NNS	I-NP	O
.	.	O	O

Ethambutol	NN	B-NP	O
and	CC	I-NP	O
optic	JJ	I-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
demonstrate	VB	I-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
ethambutol	NN	B-NP	O
and	CC	O	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
after	IN	B-PP	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
ethambutol	NN	B-NP	O
for	IN	B-PP	O
tuberculosis	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
lung	NN	I-NP	I
or	CC	I-NP	I
lymph	NN	I-NP	I
node	NN	I-NP	I
at	IN	B-PP	O
Siriraj	NNP	B-NP	O
Hospital	NNP	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
retrospectively	RB	I-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
clinical	JJ	I-NP	O
characteristics	NNS	I-NP	O
and	CC	O	O
initial	JJ	B-NP	O
and	CC	I-NP	O
final	JJ	I-NP	O
visual	JJ	I-NP	O
acuity	NN	I-NP	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
visual	JJ	B-NP	O
outcome	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
between	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
starting	VBG	B-VP	O
ethambutol	NN	B-NP	O
therapy	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dosage	NN	I-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
experienced	VBD	B-VP	O
visual	JJ	B-NP	O
recovery	NN	I-NP	O
after	IN	B-PP	O
stopping	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
irreversible	JJ	B-NP	O
visual	JJ	I-NP	B
impairment	NN	I-NP	I
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
,	,	O	O
glaucoma	NN	B-NP	B
and	CC	O	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
heavy	JJ	B-NP	O
smoking	NN	I-NP	O
.	.	O	O

Early	RB	B-NP	O
recognition	NN	I-NP	O
of	IN	B-PP	O
optic	JJ	B-NP	B
neuropathy	NN	I-NP	I
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
ethambutol	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
low	JJ	I-NP	O
dose	NN	I-NP	O
and	CC	O	O
prompt	JJ	B-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
individuals	NNS	B-NP	O
with	IN	B-PP	O
diabetes	NN	B-NP	B
mellitus	NN	I-NP	I
,	,	O	O
glaucoma	NN	B-NP	B
or	CC	O	O
who	WP	B-NP	O
are	VBP	B-VP	O
heavy	JJ	B-NP	O
smokers	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
of	IN	B-PP	O
compensatory	JJ	B-NP	O
gustatory	JJ	I-NP	B
hyperhidrosis	NN	I-NP	I
with	IN	B-PP	O
topical	JJ	B-NP	O
glycopyrrolate	NN	I-NP	O
.	.	O	O

Gustatory	JJ	B-NP	B
hyperhidrosis	NN	I-NP	I
is	VBZ	B-VP	O
facial	JJ	B-NP	O
sweating	NN	I-NP	B
usually	RB	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
eating	NN	I-NP	O
of	IN	B-PP	O
hot	JJ	B-NP	O
spicy	NN	I-NP	O
food	NN	I-NP	O
or	CC	O	O
even	RB	B-ADVP	O
smelling	VBG	B-VP	O
this	DT	B-NP	O
food	NN	I-NP	O
.	.	O	O

Current	JJ	B-NP	O
options	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
include	VBP	B-VP	O
oral	JJ	B-NP	O
anticholinergic	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
topical	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
anticholinergics	NNS	B-NP	O
or	CC	O	O
aluminum	NN	B-NP	O
chloride	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
botulinum	NN	B-NP	O
toxin	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
to	TO	B-PP	O
date	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
topical	JJ	I-NP	O
glycopyrrolate	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
gustatory	JJ	B-NP	B
hyperhidrosis	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
interfered	VBD	B-VP	O
with	IN	B-PP	O
their	PRP$	B-NP	O
social	JJ	I-NP	O
activities	NNS	I-NP	O
,	,	O	O
after	IN	B-PP	O
transthroacic	JJ	B-NP	O
endoscopic	JJ	I-NP	O
sympathectomy	NN	I-NP	O
,	,	O	O
and	CC	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
compensatory	JJ	B-NP	O
focal	JJ	I-NP	O
hyperhidrosis	NN	I-NP	B
.	.	O	O

After	IN	B-PP	O
applying	VBG	B-VP	O
topical	JJ	B-NP	O
glycopyrrolate	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
subjective	JJ	I-NP	O
effect	NN	I-NP	O
was	VBD	B-VP	O
excellent	JJ	B-ADJP	O
(	(	O	O
no	DT	B-NP	O
sweating	NN	I-NP	B
after	IN	B-PP	O
eating	VBG	B-VP	O
hot	JJ	B-NP	O
spicy	NN	I-NP	O
food	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
fair	JJ	B-ADJP	O
(	(	O	O
clearly	RB	B-VP	O
reduced	VBN	I-VP	O
sweating	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
had	VBD	B-VP	O
reported	VBN	I-VP	O
incidents	NNS	B-NP	O
of	IN	B-PP	O
being	VBG	B-VP	O
very	RB	B-ADJP	O
embarrassed	JJ	I-ADJP	O
whilst	IN	B-PP	O
eating	VBG	B-VP	O
hot	JJ	B-NP	O
spicy	NN	I-NP	O
foods	NNS	I-NP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
included	VBD	B-VP	O
a	DT	B-NP	O
mildly	RB	I-NP	O
dry	JJ	I-NP	B
mouth	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
sore	JJ	I-NP	B
throat	NN	I-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
glycopyrrolate	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
light	JJ	I-NP	O
headache	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
glycopyrrolate	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
topical	JJ	I-NP	O
application	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
glycopyrrolate	NN	I-NP	O
pad	NN	I-NP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
safe	JJ	B-ADJP	O
,	,	O	O
efficacious	JJ	B-ADJP	O
,	,	O	O
well	RB	B-ADJP	O
tolerated	VBN	I-ADJP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
convenient	JJ	I-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
moderate	JJ	B-ADJP	O
to	TO	B-PP	O
severe	JJ	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
gustatory	JJ	B-NP	B
hyperhidrosis	NN	I-NP	I
in	IN	B-PP	O
post	NN	B-NP	O
transthoracic	JJ	I-NP	O
endoscopic	JJ	I-NP	O
sympathectomy	NN	I-NP	O
or	CC	I-NP	O
sympathicotomy	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
few	JJ	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Pharmacological	JJ	B-NP	O
characteristics	NNS	I-NP	O
and	CC	O	O
side	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
galenic	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
without	IN	B-PP	O
soyabean	JJ	B-NP	O
oil	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
pharmacokinetics	NNS	I-NP	O
,	,	O	O
pharmacodynamics	NNS	B-NP	O
and	CC	O	O
safety	NN	B-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
new	JJ	I-NP	O
galenic	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
(	(	O	O
AM149	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
contain	VB	I-VP	O
soyabean	JJ	B-NP	O
oil	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
standard	JJ	I-NP	O
formulation	NN	I-NP	O
of	IN	B-PP	O
propofol	NN	B-NP	O
(	(	O	O
Disoprivan	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
randomised	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	O	O
cross	AFX	O	O
-	HYPH	O	O
over	IN	B-PP	O
study	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
intravenous	JJ	I-NP	O
bolus	NN	I-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg.kg	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
propofol	NN	I-NP	O
.	.	O	O

Plasma	NN	B-NP	O
propofol	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
following	VBG	B-PP	O
drug	NN	B-NP	O
administration	NN	I-NP	O
and	CC	O	O
evaluated	VBD	B-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
compartment	NN	I-NP	O
model	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
pharmacodynamic	JJ	I-NP	O
parameters	NNS	I-NP	O
assessed	VBN	B-VP	O
included	VBD	B-VP	O
induction	NN	B-NP	O
and	CC	O	O
emergence	NN	B-NP	O
times	NNS	I-NP	O
,	,	O	O
respiratory	JJ	B-NP	O
and	CC	I-NP	O
cardiovascular	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
and	CC	O	O
pain	NN	B-NP	B
on	IN	B-PP	O
injection	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
for	IN	B-PP	O
side	NN	B-NP	O
effects	NNS	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Owing	VBG	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
thrombophlebitis	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
terminated	VBN	I-VP	O
prematurely	RB	B-ADVP	O
and	CC	O	O
only	RB	B-NP	O
the	DT	I-NP	O
data	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
parallel	JJ	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
.	.	O	O

Plasma	NN	B-NP	O
concentrations	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
significantly	RB	B-ADVP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
formulations	NNS	I-NP	O
.	.	O	O

Anaesthesia	NN	B-NP	O
induction	NN	I-NP	O
and	CC	O	O
emergence	NN	B-NP	O
times	NNS	I-NP	O
,	,	O	O
respiratory	JJ	B-NP	O
and	CC	I-NP	O
cardiovascular	JJ	I-NP	O
variables	NNS	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Pain	NN	B-NP	B
on	IN	B-PP	O
injection	NN	B-NP	O
and	CC	I-NP	O
thrombophlebitis	NN	I-NP	B
occurred	VBD	B-VP	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
with	IN	B-PP	O
AM149	NN	B-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
Disoprivan	NNP	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
both	DT	B-NP	O
formulations	NNS	I-NP	O
had	VBD	B-VP	O
similar	JJ	B-NP	O
pharmacokinetic	JJ	I-NP	O
and	CC	I-NP	O
pharmacodynamic	JJ	I-NP	O
profiles	NNS	I-NP	O
the	DT	B-NP	O
new	JJ	I-NP	O
formulation	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	O	O
suitable	JJ	B-ADJP	O
for	IN	B-PP	O
clinical	JJ	B-NP	O
use	NN	I-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
thrombophlebitis	NN	B-NP	B
produced	VBN	B-VP	O
.	.	O	O

Vinorelbine	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cardiac	JJ	I-NP	O
events	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
meta	JJ	I-NP	O
-	HYPH	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
randomized	VBN	B-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

Several	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
vinorelbine	NN	B-NP	O
(	(	O	O
VNR	NN	B-NP	O
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
quantify	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
cardiac	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
meta	JJ	I-NP	O
-	HYPH	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
comparing	VBG	B-VP	O
VNR	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
chemotherapeutic	JJ	I-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
various	JJ	B-NP	O
malignancies	NNS	I-NP	B
.	.	O	O

Randomized	VBN	B-VP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
comparing	VBG	B-VP	O
VNR	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
cancer	NN	B-NP	B
were	VBD	B-VP	O
searched	VBN	I-VP	O
in	IN	B-PP	O
Medline	NN	B-NP	O
,	,	O	O
Embase	NN	B-NP	O
,	,	O	O
Evidence	NN	B-NP	O
-	HYPH	B-VP	O
based	VBN	B-NP	O
Medicine	NN	I-NP	O
Reviews	NNP	I-NP	O
databases	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Cochrane	NN	I-NP	O
library	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

Outcomes	NNS	B-NP	O
of	IN	B-PP	O
interest	NN	B-NP	O
were	VBD	B-VP	O
severe	JJ	B-NP	O
cardiac	JJ	I-NP	O
events	NNS	I-NP	O
,	,	O	O
toxic	JJ	B-NP	O
deaths	NNS	I-NP	O
and	CC	O	O
cardiac	JJ	B-NP	O
event	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
deaths	NNS	I-NP	O
reported	VBN	B-VP	O
in	IN	B-PP	O
each	DT	B-NP	O
publication	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
found	VBD	B-VP	O
num	CD	B-NP	O
trials	NNS	I-NP	O
,	,	O	O
involving	VBG	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
treated	VBN	B-VP	O
by	IN	B-PP	O
VNR	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
control	NN	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
events	NNS	I-NP	O
with	IN	B-PP	O
VNR	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
[	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
(	(	O	O
CI	NN	B-NP	O
)	)	O	O
]	)	O	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
events	NNS	I-NP	O
between	IN	B-PP	O
VNR	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
drugs	NNS	I-NP	O
[	(	O	O
odds	NNS	B-NP	O
ratio	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
]	)	O	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
VNR	NN	B-NP	O
cardiac	JJ	I-NP	O
events	NNS	I-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
vindesine	NN	B-NP	O
(	(	O	O
VDS	NN	B-NP	O
)	)	O	O
and	CC	O	O
other	JJ	B-NP	O
cardiotoxic	JJ	I-NP	B
drugs	NNS	I-NP	O
[	(	O	O
fluorouracil	NN	B-NP	O
,	,	O	O
anthracyclines	NNS	B-NP	O
,	,	O	O
gemcitabine	NN	B-NP	O
(	(	O	O
GEM	NN	B-NP	O
)	)	O	O
em	NN	B-NP	O
leader	NN	I-NP	O
]	)	O	O
.	.	O	O

Even	RB	B-SBAR	O
if	IN	I-SBAR	O
it	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
few	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
cases	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
in	IN	B-PP	O
trials	NNS	B-NP	O
excluding	VBG	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cardiac	JJ	B-NP	O
history	NN	I-NP	O
,	,	O	O
and	CC	O	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
trials	NNS	B-NP	O
including	VBG	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	B-PP	O
existing	VBG	B-NP	O
cardiac	JJ	I-NP	B
diseases	NNS	I-NP	I
.	.	O	O

Vinorelbine	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cardiac	JJ	I-NP	O
events	NNS	I-NP	O
concern	NN	I-NP	O
about	RB	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
treated	VBN	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
trials	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
risk	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
VNR	NN	B-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
other	JJ	B-NP	O
chemotherapeutic	JJ	I-NP	O
agents	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
indications	NNS	I-NP	O
.	.	O	O

MRI	NN	B-NP	O
findings	NNS	I-NP	O
of	IN	B-PP	O
hypoxic	JJ	B-NP	O
cortical	JJ	I-NP	O
laminar	JJ	I-NP	O
necrosis	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
with	IN	B-PP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
crisis	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
present	VBP	B-VP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
findings	NNS	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
girl	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
rapidly	RB	I-NP	O
installing	VBG	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
crisis	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
trimethoprim	NN	B-NP	O
-	HYPH	B-NP	O
sulfomethoxazole	NN	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
cerebral	JJ	B-NP	B
anoxia	NN	I-NP	I
leading	VBG	B-VP	O
to	TO	B-PP	O
permanent	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

Magnetic	JJ	B-NP	O
Resonance	NN	I-NP	O
imaging	NN	I-NP	O
revealed	VBD	B-VP	O
cortical	JJ	B-NP	O
laminar	JJ	I-NP	O
necrosis	NN	I-NP	B
in	IN	B-PP	O
arterial	JJ	B-NP	O
border	NN	I-NP	O
zones	NNS	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
cerebral	JJ	I-NP	O
hemispheres	NNS	I-NP	O
,	,	O	O
ischemic	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
subcortical	JJ	B-NP	O
white	JJ	I-NP	O
matter	NN	I-NP	O
of	IN	B-PP	O
left	JJ	B-NP	O
cerebral	JJ	I-NP	O
hemisphere	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
putamen	NNS	I-NP	O
.	.	O	O

Although	IN	B-SBAR	O
cortical	JJ	B-NP	O
laminar	JJ	I-NP	O
necrosis	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
classic	JJ	I-NP	O
entity	NN	I-NP	O
in	IN	B-PP	O
adulthood	NN	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
conditions	NNS	B-NP	O
of	IN	B-PP	O
energy	NN	B-NP	O
depletions	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
are	VBP	B-VP	O
few	JJ	B-NP	O
reports	NNS	I-NP	O
available	JJ	B-ADJP	O
in	IN	B-PP	O
children	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
wide	JJ	I-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
is	VBZ	B-VP	O
also	RB	I-VP	O
presented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
natural	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
Vigabatrin	NN	B-NP	O
associated	JJ	I-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
electing	VBG	B-VP	O
to	TO	I-VP	O
continue	VB	I-VP	O
their	PRP$	B-NP	O
medication	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
natural	JJ	I-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
known	VBN	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
Vigabatrin	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
changes	NNS	I-NP	O
who	WP	B-NP	O
elected	VBD	B-VP	O
to	TO	I-VP	O
continue	VB	I-VP	O
the	DT	B-NP	O
medication	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
good	JJ	B-NP	O
seizure	NN	I-NP	B
control	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
taking	VBG	B-VP	O
Vigabatrin	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
other	JJ	B-NP	O
antiepileptic	JJ	I-NP	O
drugs	NNS	I-NP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
entered	VBN	I-VP	O
into	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
surveillance	NN	I-NP	O
programme	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
followed	VBN	I-VP	O
up	RP	B-PRT	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
monthly	JJ	I-NP	O
intervals	NNS	I-NP	O
for	IN	B-PP	O
not	RB	B-NP	O
less	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
all	DT	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
unequivocal	JJ	B-NP	O
defects	NNS	I-NP	O
continued	VBD	B-VP	O
the	DT	B-NP	O
medication	NN	I-NP	O
.	.	O	O

Following	VBG	B-VP	O
already	RB	I-VP	O
published	VBN	I-VP	O
methodology	NN	B-NP	O
(	(	O	O
Eye	NN	B-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
monocular	JJ	B-NP	O
mean	JJ	I-NP	O
radial	JJ	I-NP	O
degrees	NNS	I-NP	O
(	(	O	O
MRDs	NNS	B-NP	O
)	)	O	O
to	TO	B-PP	O
the	DT	B-NP	O
I	NN	I-NP	O
/	SYM	B-NP	O
4e	NN	I-NP	O
isopter	NN	I-NP	O
on	IN	B-PP	O
Goldmann	NNP	B-NP	O
perimetry	NN	I-NP	O
was	VBD	B-VP	O
calculated	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
right	JJ	I-NP	O
eye	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
discovery	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
defect	NN	I-NP	I
and	CC	O	O
again	RB	B-ADVP	O
after	IN	B-PP	O
not	RB	B-NP	O
less	JJR	I-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
.	.	O	O

Mean	JJ	B-NP	O
right	JJ	I-NP	O
eye	NN	I-NP	O
MRD	NN	I-NP	O
at	IN	B-PP	O
presentation	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
compared	VBN	B-PP	O
to	TO	B-PP	O
num	CD	B-NP	O
degrees	NNS	I-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
after	IN	B-SBAR	O
follow	VB	B-VP	O
-	HYPH	B-ADJP	O
up	RP	B-PRT	O
;	:	O	O
P=0.338	NN	B-NP	O
unpaired	JJ	I-NP	O
t	NN	I-NP	O
-	HYPH	I-NP	O
test	NN	I-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
demonstrated	VBD	B-VP	O
a	DT	B-NP	O
deterioration	NN	I-NP	B
in	IN	B-PP	I
visual	JJ	B-NP	I
field	NN	I-NP	I
during	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
period	NN	I-NP	O
and	CC	O	O
discontinued	VBN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Established	VBN	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
presumed	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
Vigabatrin	NN	B-NP	O
therapy	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
usually	RB	I-VP	O
progress	VBP	I-VP	O
in	IN	B-PP	O
spite	NN	B-NP	O
of	IN	B-PP	O
continuing	VBG	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
medication	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
give	VBP	B-VP	O
support	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
Vigabatrin	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
idiosyncratic	JJ	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
dose	NN	B-NP	O
-	HYPH	I-NP	O
dependent	JJ	I-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Induction	NN	B-NP	O
of	IN	B-PP	O
rosaceiform	JJ	B-NP	O
dermatitis	NN	I-NP	B
during	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
facial	JJ	B-NP	B
inflammatory	JJ	I-NP	I
dermatoses	NNS	I-NP	I
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
ointment	NN	I-NP	O
.	.	O	O

Tacrolimus	NN	B-NP	O
ointment	NN	I-NP	O
is	VBZ	B-VP	O
increasingly	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
sensitive	JJ	B-NP	O
areas	NNS	I-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
the	DT	B-NP	O
face	NN	I-NP	O
,	,	O	O
and	CC	O	O
recent	JJ	B-NP	O
observations	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
steroid	NN	B-NP	O
-	HYPH	B-NP	O
aggravated	VBN	I-NP	O
rosacea	NN	I-NP	B
and	CC	I-NP	O
perioral	JJ	I-NP	B
dermatitis	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
rosaceiform	NN	B-NP	O
dermatitis	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
ointment	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
inflammatory	JJ	B-NP	B
facial	JJ	I-NP	I
dermatoses	NNS	I-NP	I
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
ointment	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
ineffectiveness	NN	I-NP	O
of	IN	B-PP	O
standard	JJ	B-NP	O
treatments	NNS	I-NP	O
.	.	O	O

Within	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
initially	RB	B-NP	O
effective	JJ	I-NP	O
and	CC	O	O
well	RB	B-VP	O
-	HYPH	I-VP	O
tolerated	VBN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
rosacea	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
acne	NN	B-NP	B
experienced	VBD	B-VP	O
sudden	JJ	B-NP	O
worsening	VBG	I-NP	O
with	IN	B-PP	O
pustular	JJ	B-NP	O
rosaceiform	NN	I-NP	O
lesions	NNS	I-NP	O
.	.	O	O

Biopsy	NN	B-NP	O
revealed	VBD	B-VP	O
an	DT	B-NP	O
abundance	NN	I-NP	O
of	IN	B-PP	O
Demodex	NN	B-NP	O
mites	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
eyelid	JJ	B-NP	O
eczema	NN	I-NP	B
,	,	O	O
rosaceiform	VBP	B-VP	O
periocular	JJ	B-NP	B
dermatitis	NN	I-NP	I
gradually	RB	B-ADVP	O
appeared	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
atopic	JJ	B-NP	B
dermatitis	NN	I-NP	I
,	,	O	O
telangiectatic	JJ	B-NP	O
and	CC	I-NP	O
papular	JJ	I-NP	B
rosacea	NN	I-NP	I
insidiously	RB	B-ADVP	O
appeared	VBD	B-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Our	PRP$	B-NP	O
observations	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
spectrum	NN	I-NP	O
of	IN	B-PP	O
rosaceiform	JJ	B-NP	O
dermatitis	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
tacrolimus	NN	B-NP	O
ointment	NN	I-NP	O
is	VBZ	B-VP	O
heterogeneous	JJ	B-ADJP	O
.	.	O	O

A	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
factors	NNS	B-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
vasoactive	JJ	B-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
tacrolimus	NN	B-NP	O
,	,	O	O
proliferation	NN	B-NP	O
of	IN	B-PP	O
Demodex	NN	B-NP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
local	JJ	B-NP	O
immunosuppression	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
occlusive	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ointment	NN	I-NP	O
,	,	O	O
may	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
observed	VBN	I-NP	O
phenomena	NNS	I-NP	O
.	.	O	O

Future	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
individual	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Structural	JJ	B-NP	O
abnormalities	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brains	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
use	VBP	B-VP	O
methamphetamine	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
visualize	VBP	B-VP	O
,	,	O	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
profile	NN	I-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	B
deficits	NNS	I-NP	I
in	IN	B-PP	I
the	DT	B-NP	I
human	JJ	I-NP	I
brain	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
methamphetamine	NN	I-NP	O
(	(	O	O
MA	NN	B-NP	O
)	)	O	O
abuse	NN	B-NP	O
.	.	O	O

Studies	NNS	B-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
used	VBN	I-VP	O
MA	NN	B-NP	O
chronically	RB	B-ADVP	O
have	VBP	B-VP	O
revealed	VBN	I-VP	O
deficits	NNS	B-NP	O
in	IN	B-PP	O
dopaminergic	JJ	B-NP	O
and	CC	I-NP	O
serotonergic	JJ	I-NP	O
systems	NNS	I-NP	O
and	CC	O	O
cerebral	JJ	B-NP	O
metabolic	JJ	I-NP	B
abnormalities	NNS	I-NP	I
.	.	O	O

Using	VBG	B-VP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
(	(	O	O
MRI	NN	B-NP	O
)	)	O	O
and	CC	O	O
new	JJ	B-NP	O
computational	JJ	I-NP	O
brain	NN	I-NP	O
-	HYPH	O	O
mapping	VBG	B-VP	O
techniques	NNS	B-NP	O
,	,	O	O
we	PRP	B-NP	O
determined	VBD	B-VP	O
the	DT	B-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
structural	JJ	B-NP	O
brain	NN	I-NP	O
alterations	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
chronic	JJ	B-NP	O
MA	JJ	I-NP	O
abuse	NN	I-NP	O
in	IN	B-PP	O
human	JJ	B-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
related	VBN	B-VP	O
these	DT	B-NP	O
deficits	NNS	I-NP	O
to	TO	B-PP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
used	VBD	B-VP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
resolution	NN	I-NP	O
MRI	NN	I-NP	O
and	CC	I-NP	O
surface	NN	I-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
computational	JJ	B-NP	O
image	NN	I-NP	O
analyses	NNS	I-NP	O
to	TO	B-VP	O
map	VB	I-VP	O
regional	JJ	B-NP	O
abnormalities	NNS	I-NP	B
in	IN	B-PP	I
the	DT	B-NP	I
cortex	NN	I-NP	I
,	,	O	I
hippocampus	NN	B-NP	I
,	,	O	I
white	JJ	B-NP	I
matter	NN	I-NP	I
,	,	O	I
and	CC	O	I
ventricles	NNS	B-NP	I
in	IN	B-PP	O
num	CD	B-NP	O
human	JJ	I-NP	O
subjects	NNS	I-NP	O
who	WP	B-NP	O
used	VBD	B-VP	O
MA	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
age	NN	I-NP	O
-	HYPH	B-VP	O
matched	VBN	I-VP	O
,	,	O	O
healthy	JJ	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

Cortical	JJ	B-NP	O
maps	NNS	I-NP	O
revealed	VBD	B-VP	O
severe	JJ	B-NP	O
gray	JJ	I-NP	O
-	HYPH	I-NP	O
matter	NN	I-NP	O
deficits	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cingulate	NN	I-NP	O
,	,	O	O
limbic	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
paralimbic	JJ	B-NP	O
cortices	NNS	I-NP	O
of	IN	B-PP	O
MA	JJ	B-NP	O
abusers	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
average	NN	B-NP	O
,	,	O	O
MA	JJ	B-NP	O
abusers	NNS	I-NP	O
had	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
smaller	JJR	B-NP	O
hippocampal	JJ	I-NP	O
volumes	NNS	I-NP	O
than	IN	B-PP	O
control	JJ	B-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
significant	JJ	B-NP	O
white	JJ	I-NP	O
-	HYPH	I-NP	O
matter	NN	I-NP	O
hypertrophy	NN	I-NP	B
.	.	O	O

Hippocampal	JJ	B-NP	O
deficits	NNS	I-NP	O
were	VBD	B-VP	O
mapped	VBN	I-VP	O
and	CC	O	O
correlated	VBN	B-VP	O
with	IN	B-PP	O
memory	NN	B-NP	O
performance	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
word	NN	I-NP	O
-	HYPH	B-NP	O
recall	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

MRI	NN	B-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
maps	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
chronic	JJ	B-NP	O
methamphetamine	NN	I-NP	O
abuse	NN	I-NP	O
causes	VBZ	B-VP	O
a	DT	B-NP	O
selective	JJ	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
cerebral	JJ	B-NP	O
deterioration	NN	I-NP	O
that	WDT	B-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
impaired	JJ	B-NP	B
memory	NN	I-NP	I
performance	NN	I-NP	I
.	.	O	O

MA	NN	B-NP	O
may	MD	B-VP	O
selectively	RB	I-VP	O
damage	VB	I-VP	O
the	DT	B-NP	O
medial	JJ	I-NP	O
temporal	JJ	I-NP	O
lobe	NN	I-NP	O
and	CC	O	O
,	,	O	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
metabolic	JJ	B-NP	O
studies	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
cingulate	NN	I-NP	O
-	HYPH	B-NP	O
limbic	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	O	O
inducing	VBG	B-VP	O
neuroadaptation	NN	B-NP	O
,	,	O	O
neuropil	NN	B-NP	O
reduction	NN	I-NP	O
,	,	O	O
or	CC	O	O
cell	NN	B-NP	O
death	NN	I-NP	O
.	.	O	O

Prominent	JJ	B-NP	O
white	JJ	I-NP	O
-	HYPH	I-NP	O
matter	NN	I-NP	O
hypertrophy	NN	I-NP	B
may	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
altered	VBN	B-NP	O
myelination	NN	I-NP	O
and	CC	O	O
adaptive	JJ	B-NP	O
glial	JJ	I-NP	O
changes	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
gliosis	NN	B-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
neuronal	JJ	B-NP	B
damage	NN	I-NP	I
.	.	O	O

These	DT	B-NP	O
brain	NN	I-NP	O
substrates	NNS	I-NP	O
may	MD	B-VP	O
help	VB	I-VP	O
account	VB	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
MA	JJ	B-NP	O
abuse	NN	I-NP	O
,	,	O	O
providing	VBG	B-VP	O
therapeutic	JJ	B-NP	O
targets	NNS	I-NP	O
for	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
brain	NN	I-NP	B
injury	NN	I-NP	I
.	.	O	O

Disruption	NN	B-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
lipid	NN	I-NP	O
homeostasis	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
after	IN	B-PP	O
amiodarone	NN	B-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
peroxisome	NN	B-NP	O
proliferator	NN	I-NP	O
-	HYPH	B-VP	O
activated	VBN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	B-NP	O
alpha	SYM	I-NP	O
target	NN	I-NP	O
gene	NN	I-NP	O
activation	NN	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
efficacious	JJ	I-NP	O
and	CC	I-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
antiarrhythmic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
to	TO	I-VP	O
cause	VB	I-VP	O
hepatotoxicity	NN	B-NP	B
in	IN	B-PP	O
some	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
gain	VB	I-VP	O
insight	NN	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
unwanted	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
various	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
and	CC	O	O
examined	VBN	B-VP	O
for	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
hepatic	JJ	B-NP	O
histology	NN	I-NP	O
and	CC	I-NP	O
gene	NN	I-NP	O
regulation	NN	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
induced	VBD	B-VP	O
hepatomegaly	RB	B-ADVP	B
,	,	O	O
hepatocyte	NN	B-NP	O
microvesicular	JJ	I-NP	O
lipid	NN	I-NP	O
accumulation	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
triglycerides	NNS	I-NP	O
and	CC	O	O
glucose	NN	B-NP	O
.	.	O	O

Northern	NN	B-NP	O
blot	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
RNA	NN	I-NP	O
revealed	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
genes	NNS	B-NP	O
critical	JJ	B-ADJP	O
for	IN	B-PP	O
fatty	JJ	B-NP	O
acid	NN	I-NP	O
oxidation	NN	I-NP	O
,	,	O	O
lipoprotein	NN	B-NP	O
assembly	NN	I-NP	O
,	,	O	O
and	CC	O	O
lipid	NN	B-NP	O
transport	NN	I-NP	O
.	.	O	O

Many	JJ	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
genes	NNS	I-NP	O
are	VBP	B-VP	O
regulated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
peroxisome	NN	I-NP	O
proliferator	NN	I-NP	O
-	HYPH	B-VP	O
activated	VBN	B-NP	O
receptor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
(	(	O	O
PPARalpha	NN	B-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
ligand	NN	I-NP	O
-	HYPH	O	O
activated	VBN	B-VP	O
nuclear	JJ	B-NP	O
hormone	NN	I-NP	O
receptor	NN	I-NP	O
transcription	NN	I-NP	O
factor	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
genes	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
hepatomegaly	NN	B-NP	B
in	IN	B-PP	O
PPARalpha	NN	B-NP	O
knockout	NN	I-NP	O
[	(	O	O
PPARalpha	NN	B-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
]	)	I-NP	O
mice	NNS	I-NP	O
indicated	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
were	VBD	B-VP	O
dependent	JJ	B-ADJP	O
upon	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
functional	JJ	I-NP	O
PPARalpha	NN	I-NP	O
gene	NN	I-NP	O
.	.	O	O

Compared	VBN	B-PP	O
to	TO	B-PP	O
wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
treatment	NN	B-NP	O
of	IN	B-PP	O
PPARalpha	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
total	JJ	B-NP	O
body	NN	I-NP	O
weight	NN	I-NP	B
loss	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
inability	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
to	TO	B-VP	O
directly	RB	I-VP	O
activate	VB	I-VP	O
either	CC	O	O
human	JJ	O	O
or	CC	O	O
mouse	NN	B-NP	O
PPARalpha	NN	I-NP	O
transiently	RB	B-VP	O
expressed	VBN	I-VP	O
in	IN	B-PP	O
human	JJ	B-NP	O
HepG2	NN	I-NP	O
hepatoma	NN	I-NP	B
cells	NNS	I-NP	O
indicates	VBZ	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
receptor	NN	I-NP	O
were	VBD	B-VP	O
indirect	JJ	B-ADJP	O
.	.	O	O

Based	VBN	B-VP	O
upon	IN	B-PP	O
these	DT	B-NP	O
results	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
amiodarone	NN	B-NP	O
disrupts	VBZ	B-VP	O
hepatic	JJ	B-NP	O
lipid	NN	I-NP	O
homeostasis	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
the	DT	B-NP	O
increased	VBN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
PPARalpha	NN	B-NP	O
target	NN	I-NP	O
genes	NNS	I-NP	O
is	VBZ	B-VP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
this	DT	B-NP	O
toxic	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
important	JJ	B-NP	O
new	JJ	I-NP	O
mechanistic	JJ	I-NP	O
information	NN	I-NP	O
regarding	VBG	B-VP	O
the	DT	B-NP	O
hepatotoxic	JJ	I-NP	B
effects	NNS	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
and	CC	O	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
PPARalpha	NN	B-NP	O
protects	VBZ	B-VP	O
against	IN	B-PP	O
amiodarone	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
.	.	O	O

Safety	NN	B-NP	O
and	CC	I-NP	O
compliance	NN	I-NP	O
with	IN	B-PP	O
once	RB	B-ADVP	O
-	HYPH	I-ADVP	O
daily	JJ	B-NP	O
niacin	NN	I-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-NP	O
lovastatin	NN	I-NP	O
as	IN	B-PP	O
initial	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Impact	NNP	I-NP	O
of	IN	B-PP	O
Medical	NNP	B-NP	O
Subspecialty	NNP	I-NP	O
on	IN	B-PP	O
Patient	NNP	B-NP	O
Compliance	NN	I-NP	O
to	TO	B-PP	O
Treatment	NN	B-NP	O
(	(	O	O
IMPACT	NN	B-NP	O
)	)	O	O
study	NN	B-NP	O
.	.	O	O

Niacin	NN	B-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-NP	O
lovastatin	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
combination	NN	I-NP	O
product	NN	I-NP	O
approved	VBN	B-VP	O
for	IN	B-PP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
primary	JJ	B-NP	O
hypercholesterolemia	NN	I-NP	B
and	CC	O	O
mixed	JJ	B-NP	O
dyslipidemia	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
labeled	VBN	B-VP	O
,	,	O	O
multicenter	JJ	B-NP	O
study	NN	I-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
bedtime	NN	B-NP	O
niacin	NN	I-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-NP	O
lovastatin	NN	I-NP	O
when	WRB	B-ADVP	O
dosed	VBN	B-VP	O
as	IN	B-PP	O
initial	JJ	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
patient	NN	B-NP	O
compliance	NN	I-NP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
in	IN	B-PP	O
various	JJ	B-NP	O
clinical	JJ	I-NP	O
practice	NN	I-NP	O
settings	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
dyslipidemia	NN	B-NP	B
requiring	VBG	B-VP	O
drug	NN	B-NP	O
intervention	NN	I-NP	O
was	VBD	B-VP	O
enrolled	VBN	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
sites	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
tablet	NN	I-NP	O
once	RB	B-ADVP	O
nightly	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
then	RB	O	O
num	CD	B-NP	O
tablets	NNS	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
also	RB	B-ADVP	O
received	VBD	B-VP	O
dietary	JJ	B-NP	O
counseling	NN	I-NP	O
,	,	O	O
educational	JJ	B-NP	O
materials	NNS	I-NP	O
,	,	O	O
and	CC	O	O
reminders	VBZ	B-VP	O
to	TO	I-VP	O
call	VB	I-VP	O
a	DT	B-NP	O
toll	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
number	NN	I-NP	O
that	WDT	B-NP	O
provided	VBD	B-VP	O
further	JJ	B-NP	O
education	NN	I-NP	O
about	IN	B-PP	O
dyslipidemia	NN	B-NP	B
and	CC	I-NP	O
niacin	NN	I-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-NP	O
lovastatin	NN	I-NP	O
.	.	O	O

Primary	JJ	B-NP	O
end	NN	I-NP	O
points	NNS	I-NP	O
were	VBD	B-VP	O
study	NN	B-NP	O
compliance	NN	I-NP	O
,	,	O	O
increases	VBZ	B-VP	O
in	IN	B-PP	O
liver	NN	B-NP	O
transaminases	NNS	I-NP	O
to	TO	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
,	,	O	O
and	CC	O	O
clinical	JJ	B-NP	O
myopathy	NN	I-NP	B
.	.	O	O

Final	JJ	B-NP	O
study	NN	I-NP	O
status	NN	I-NP	O
was	VBD	B-VP	O
available	JJ	B-ADJP	O
for	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Compliance	NN	B-NP	O
to	TO	B-PP	O
niacin	NN	B-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-NP	O
lovastatin	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
completing	VBG	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
southeast	NN	I-NP	O
and	CC	O	O
those	DT	B-NP	O
enrolled	VBN	B-VP	O
by	IN	B-PP	O
endocrinologists	NNS	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
lowest	JJS	I-NP	O
compliance	NN	I-NP	O
and	CC	O	O
highest	JJS	B-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
rates	NNS	I-NP	O
.	.	O	O

Flushing	NN	B-NP	B
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
event	NN	I-NP	O
,	,	O	O
reported	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
and	CC	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
discontinuation	NN	B-NP	O
by	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Incidence	NN	B-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
aspartate	NN	I-NP	O
aminotransferase	NN	I-NP	O
and	CC	O	O
/	SYM	B-NP	O
or	CC	O	O
alanine	NN	B-NP	O
aminotransferase	NN	I-NP	O
>	SYM	B-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
was	VBD	B-VP	O
<	JJR	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
.	.	O	O

An	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
creatine	NN	B-NP	O
phosphokinase	NN	I-NP	O
to	TO	B-PP	O
>	SYM	B-NP	O
num	CD	B-NP	O
times	NNS	I-NP	O
the	DT	I-NP	O
upper	JJ	I-NP	O
limit	NN	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
and	CC	O	O
no	DT	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myopathy	NN	I-NP	B
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Niacin	NN	B-NP	O
extended	VBN	B-VP	O
-	HYPH	B-NP	O
release	NN	I-NP	O
/	SYM	B-VP	O
lovastatin	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
,	,	O	O
dosed	VBN	B-VP	O
as	IN	B-PP	O
initial	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
good	JJ	B-NP	O
compliance	NN	I-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
very	RB	B-NP	O
low	JJ	I-NP	O
incidences	NNS	I-NP	O
of	IN	B-PP	O
increased	VBN	B-NP	O
liver	NN	I-NP	O
and	CC	I-NP	O
muscle	NN	I-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

Protective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
Terminalia	NNP	B-NP	O
chebula	NN	I-NP	O
against	IN	B-PP	O
experimental	JJ	B-NP	O
myocardial	JJ	I-NP	B
injury	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
isoproterenol	NN	B-NP	O
.	.	O	O

Cardioprotective	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
ethanolic	JJ	B-NP	O
extract	NN	I-NP	O
of	IN	B-PP	O
Terminalia	NNP	B-NP	O
chebula	NN	I-NP	O
fruits	NNS	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
in	IN	B-PP	O
isoproterenol	NN	B-NP	O
induced	VBD	B-VP	O
myocardial	JJ	B-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

In	IN	B-PP	O
isoproterenol	NN	B-NP	O
administered	VBN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
peroxides	NNS	I-NP	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
and	CC	I-NP	O
heart	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
decrease	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
concomitant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
.	.	O	O

Histopathological	JJ	B-NP	O
examination	NN	I-NP	O
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
to	TO	B-VP	O
confirm	VB	I-VP	O
the	DT	B-NP	O
myocardial	JJ	I-NP	O
necrosis	NN	I-NP	B
.	.	O	O

T.	NN	B-NP	O
chebula	NN	I-NP	O
extract	NN	I-NP	O
pretreatment	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
ameliorate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
isoproterenol	NN	B-NP	O
on	IN	B-PP	O
lipid	NN	B-NP	O
peroxide	NN	I-NP	O
formation	NN	I-NP	O
and	CC	O	O
retained	VBD	B-VP	O
the	DT	B-NP	O
activities	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
diagnostic	JJ	I-NP	O
marker	NN	I-NP	O
enzymes	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
postoperative	JJ	B-NP	O
anxiety	NN	I-NP	B
due	JJ	B-PP	O
to	TO	B-PP	O
low	JJ	B-NP	O
dose	NN	I-NP	O
droperidol	NN	I-NP	O
used	VBN	B-VP	O
with	IN	B-PP	O
patient	NN	B-NP	O
-	HYPH	B-NP	O
controlled	VBN	I-NP	O
analgesia	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
multiparous	JJ	I-NP	O
woman	NN	I-NP	O
in	IN	B-PP	O
good	JJ	B-NP	O
psychological	JJ	I-NP	O
health	NN	I-NP	O
underwent	VBD	B-VP	O
urgent	JJ	B-NP	O
caesarean	JJ	I-NP	O
section	NN	I-NP	O
in	IN	B-PP	O
labour	NN	B-NP	O
.	.	O	O

Postoperatively	RB	B-ADVP	O
,	,	O	O
she	PRP	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
-	HYPH	O	O
controlled	VBN	B-NP	O
analgesia	NN	I-NP	O
device	NN	I-NP	O
delivering	VBG	B-VP	O
boluses	NNS	B-NP	O
of	IN	B-PP	O
diamorphine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
and	CC	I-NP	O
droperidol	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Whilst	IN	B-PP	O
using	VBG	B-VP	O
the	DT	B-NP	O
device	NN	I-NP	O
she	PRP	B-NP	O
gradually	RB	B-ADVP	O
became	VBD	B-VP	O
anxious	JJ	B-ADJP	O
,	,	O	O
the	DT	B-NP	O
feeling	NN	I-NP	O
worsening	VBG	B-VP	O
after	IN	B-SBAR	O
each	DT	B-NP	O
bolus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
droperidol	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
psychological	JJ	I-NP	B
disturbance	NN	I-NP	I
was	VBD	B-VP	O
not	RB	I-VP	O
made	VBN	I-VP	O
straight	RB	B-ADVP	O
away	RB	I-ADVP	O
although	IN	B-SBAR	O
on	IN	B-PP	O
subsequent	JJ	B-NP	O
close	NN	I-NP	O
questioning	VBG	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
gave	VBD	B-VP	O
a	DT	B-NP	O
very	RB	I-NP	O
clear	JJ	I-NP	O
history	NN	I-NP	O
.	.	O	O

After	IN	B-SBAR	O
she	PRP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
a	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
only	RB	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
droperidol	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
syringe	NN	I-NP	O
containing	VBG	B-VP	O
diamorphine	NN	B-NP	O
only	RB	B-ADVP	O
was	VBD	B-VP	O
substituted	VBN	I-VP	O
and	CC	O	O
her	PRP$	B-NP	O
unease	NN	I-NP	O
resolved	VBD	B-VP	O
completely	RB	B-ADVP	O
.	.	O	O

We	PRP	B-NP	O
feel	VBP	B-VP	O
that	IN	B-SBAR	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
dramatic	JJ	I-NP	O
extrapyramidal	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
dopaminergic	JJ	B-NP	O
antiemetics	NNS	I-NP	O
are	VBP	B-VP	O
well	RB	I-VP	O
known	VBN	I-VP	O
,	,	O	O
more	RBR	B-NP	O
subtle	JJ	I-NP	O
manifestations	NNS	I-NP	O
may	MD	B-VP	O
easily	RB	I-VP	O
be	VB	I-VP	O
overlooked	VBN	I-VP	O
.	.	O	O

Accurate	JJ	B-NP	O
patient	NN	I-NP	O
history	NN	I-NP	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
differentiating	VBG	B-VP	O
diabetes	NNS	B-NP	B
insipidus	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
study	NN	I-NP	O
highlights	VBZ	B-VP	O
the	DT	B-NP	O
important	JJ	I-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
nursing	NN	B-NP	O
in	IN	B-PP	O
obtaining	VBG	B-VP	O
an	DT	B-NP	O
accurate	JJ	I-NP	O
health	NN	I-NP	O
history	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
case	NN	I-NP	O
discussed	VBD	B-VP	O
herein	RB	B-ADVP	O
initially	RB	B-ADVP	O
appeared	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
neurogenic	JJ	B-NP	B
diabetes	NN	I-NP	I
insipidus	NN	I-NP	I
(	(	O	O
DI	NN	B-NP	B
)	)	O	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
traumatic	JJ	I-NP	B
brain	NN	I-NP	I
injury	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
nursing	NN	I-NP	O
staff	NN	I-NP	O
,	,	O	O
by	IN	B-PP	O
reviewing	VBG	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
health	NN	I-NP	O
history	NN	I-NP	O
with	IN	B-PP	O
his	PRP$	B-NP	O
family	NN	I-NP	O
,	,	O	O
discovered	VBD	B-VP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
polydipsia	NN	B-NP	B
and	CC	O	O
long	RB	B-ADVP	O
-	HYPH	O	O
standing	VBG	B-VP	O
lithium	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
is	VBZ	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrogenic	JJ	I-NP	B
DI	NN	I-NP	I
,	,	O	O
and	CC	O	O
because	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
not	RB	I-VP	O
received	VBN	I-VP	O
lithium	NN	B-NP	O
since	IN	B-PP	O
being	VBG	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
hospital	NN	I-NP	O
,	,	O	O
his	PRP$	B-NP	O
treatment	NN	I-NP	O
changed	VBD	B-VP	O
to	TO	I-VP	O
focus	VB	I-VP	O
on	IN	B-PP	O
nephrogenic	JJ	B-NP	B
DI	NNP	I-NP	I
.	.	O	O

By	IN	B-PP	O
combining	VBG	B-VP	O
information	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
history	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
physical	JJ	I-NP	O
examination	NN	I-NP	O
,	,	O	O
and	CC	O	O
radiologic	JJ	B-NP	O
and	CC	I-NP	O
laboratory	JJ	I-NP	O
studies	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
critical	JJ	I-NP	O
care	NN	I-NP	O
team	NN	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
self	AFX	B-ADJP	O
-	HYPH	O	O
treating	VBG	B-VP	O
his	PRP$	B-NP	O
lithium	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
nephrogenic	JJ	I-NP	B
DI	NN	I-NP	I
and	CC	O	O
developed	VBD	B-VP	O
neurogenic	JJ	B-NP	B
DI	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
brain	NN	B-NP	B
trauma	NN	I-NP	I
.	.	O	O

Thus	RB	B-NP	O
successful	JJ	I-NP	O
treatment	NN	I-NP	O
required	VBD	B-VP	O
that	IN	B-SBAR	O
nephrogenic	JJ	B-NP	O
and	CC	I-NP	O
neurogenic	JJ	I-NP	B
DI	NN	I-NP	I
be	VB	B-VP	O
treated	VBN	I-VP	O
concomitantly	RB	B-ADVP	O
.	.	O	O

Factors	NNS	B-NP	O
contributing	VBG	B-VP	O
to	TO	B-PP	O
ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

Interferon	NN	B-NP	O
and	CC	I-NP	O
ribavirin	NN	I-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
produces	VBZ	B-VP	O
hemolytic	JJ	B-NP	B
anemia	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
conducted	VBN	I-VP	O
to	TO	I-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
factors	NNS	I-NP	O
contributing	VBG	B-VP	O
to	TO	B-PP	O
ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
C	NN	I-NP	I
who	WP	B-NP	O
received	VBD	B-VP	O
interferon	NN	B-NP	O
-	HYPH	O	O
alpha	SYM	O	O
-	HYPH	O	O
2b	NN	B-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
MU	NN	I-NP	O
administered	VBN	B-VP	O
intramuscularly	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
ribavirin	NN	B-NP	O
administered	VBN	B-VP	O
orally	RB	B-ADVP	O
at	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
participated	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
hemoglobin	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
<	SYM	B-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

Ribavirin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
during	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	I-NP	O
dL	NN	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
concentrations	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
anemia	NN	B-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
hemoglobin	NN	I-NP	O
concentration	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
>	SYM	B-NP	O
or	CC	O	O
=2	SYM	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
decrease	NN	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
significantly	RB	B-ADJP	O
lower	JJR	I-ADJP	O
even	RB	B-ADVP	O
after	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
<	SYM	B-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
decrease	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
significant	JJ	I-NP	O
relationship	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
between	IN	B-PP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
hemoglobin	NN	B-NP	O
concentrations	NNS	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
.	.	O	O

Such	JJ	B-NP	O
factors	NNS	I-NP	O
as	IN	B-PP	O
sex	NN	B-NP	O
(	(	O	O
female	JJ	B-ADVP	O
)	)	O	O
,	,	O	O
age	NN	B-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
ribavirin	NN	I-NP	O
dose	NN	I-NP	O
by	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
were	VBD	B-VP	O
significant	JJ	B-ADJP	O
by	IN	B-PP	O
univariate	JJ	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Careful	JJ	B-NP	O
administration	NN	I-NP	O
is	VBZ	B-VP	O
necessary	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
>	SYM	B-VP	O
or	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
old	JJ	B-ADJP	O
,	,	O	O
in	IN	B-PP	O
female	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
a	DT	B-NP	O
ribavirin	NN	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
experience	VBP	B-VP	O
a	DT	B-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
hemoglobin	NN	B-NP	O
concentrations	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
at	IN	B-PP	O
week	NN	B-NP	O
num	CD	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
start	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
with	IN	B-PP	O
particular	JJ	B-NP	O
care	NN	I-NP	O
.	.	O	O

Oxidative	JJ	B-NP	O
damage	NN	I-NP	O
precedes	VBZ	B-VP	O
nitrative	JJ	B-NP	O
damage	NN	I-NP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	O
mitochondrial	JJ	I-NP	B
injury	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
if	IN	B-SBAR	O
elevated	JJ	B-NP	O
reactive	JJ	I-NP	O
oxygen	NN	I-NP	O
(	(	O	O
ROS	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
nitrogen	NN	I-NP	O
species	NNS	I-NP	O
(	(	O	O
RNS	NNS	B-NP	O
)	)	O	O
reported	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
adriamycin	NN	B-NP	O
(	(	O	O
ADR	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
actually	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
cardiomyocyte	NN	B-NP	O
oxidative	JJ	B-NP	O
/	SYM	I-NP	O
nitrative	JJ	I-NP	O
damage	NN	I-NP	O
,	,	O	O
and	CC	O	O
to	TO	B-VP	O
quantitatively	RB	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
and	CC	O	O
subcellular	JJ	B-NP	O
localization	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
postulated	VBN	I-NP	O
damage	NN	I-NP	O
products	NNS	I-NP	O
using	VBG	B-VP	O
an	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
approach	NN	I-NP	O
.	.	O	O

B6C3	NN	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
ADR	NN	I-NP	O
.	.	O	O

Ultrastructural	JJ	B-NP	O
damage	NN	I-NP	O
and	CC	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
nonenal	JJ	I-NP	O
(	(	O	O
4HNE	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
protein	NN	I-NP	O
adducts	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
nitrotyrosine	NN	I-NP	O
(	(	O	O
3NT	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
.	.	O	O

Quantitative	JJ	B-NP	O
ultrastructural	JJ	I-NP	O
damage	NN	I-NP	O
using	VBG	B-VP	O
computerized	JJ	B-NP	O
image	NN	I-NP	O
techniques	NNS	I-NP	O
showed	VBD	B-VP	O
cardiomyocyte	NN	B-NP	O
injury	NN	I-NP	O
as	RB	B-ADVP	O
early	RB	I-ADVP	O
as	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
mitochondria	NNS	B-NP	O
being	VBG	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
extensively	RB	I-NP	O
and	CC	O	O
progressively	RB	B-NP	O
injured	VBN	I-NP	O
subcellular	JJ	I-NP	O
organelle	NN	I-NP	O
.	.	O	O

Analysis	NN	B-NP	O
of	IN	B-PP	O
4HNE	NN	B-NP	O
protein	NN	I-NP	O
adducts	NNS	I-NP	O
by	IN	B-PP	O
immunogold	NN	B-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
showed	VBD	B-VP	O
appearance	NN	B-NP	O
of	IN	B-PP	O
4HNE	NN	B-NP	O
protein	NN	I-NP	O
adducts	NNS	I-NP	O
in	IN	B-PP	O
mitochondria	NNS	B-NP	O
as	RB	B-ADVP	O
early	RB	I-ADVP	O
as	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
peak	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
and	CC	O	O
subsequent	JJ	B-NP	O
decline	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours.	NN	I-NP	O
3NT	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
significantly	RB	I-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
subcellular	JJ	I-NP	O
compartments	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
and	CC	O	O
subsequently	RB	B-VP	O
declined	VBD	I-VP	O
at	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
showed	VBD	B-VP	O
ADR	NN	B-NP	O
induced	JJ	I-NP	O
4HNE	NN	I-NP	O
-	HYPH	B-NP	O
protein	NN	I-NP	O
adducts	NNS	I-NP	O
in	IN	B-PP	O
mitochondria	NNS	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
point	NN	I-NP	O
as	IN	B-PP	O
when	WRB	B-ADVP	O
mitochondrial	JJ	B-NP	B
injury	NN	I-NP	I
initially	RB	B-ADVP	O
appeared	VBD	B-VP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
document	VBP	B-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
time	NN	I-NP	O
in	FW	B-ADVP	O
vivo	FW	I-ADVP	O
that	IN	B-SBAR	O
mitochondrial	JJ	B-NP	B
oxidative	JJ	I-NP	I
damage	NN	I-NP	I
precedes	VBZ	B-VP	O
nitrative	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
progressive	JJ	I-NP	O
nature	NN	I-NP	O
of	IN	B-PP	O
mitochondrial	JJ	B-NP	B
injury	NN	I-NP	I
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
mitochondria	NNS	B-NP	O
,	,	B-NP	O
not	RB	I-NP	O
other	JJ	B-NP	O
subcellular	JJ	I-NP	O
organelles	NNS	I-NP	O
,	,	O	O
are	VBP	B-VP	O
the	DT	B-NP	O
major	JJ	I-NP	O
site	NN	I-NP	O
of	IN	B-PP	O
intracellular	JJ	B-NP	O
injury	NN	I-NP	O
.	.	O	O

Sotalol	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
coronary	JJ	I-NP	B
spasm	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
dilated	JJ	B-NP	B
cardiomyopathy	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
sustained	JJ	B-NP	O
ventricular	JJ	I-NP	B
tachycardia	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	B
dysfunction	NN	I-NP	I
due	JJ	B-PP	O
to	TO	B-PP	O
dilated	VBN	B-NP	B
cardiomyopathy	NN	I-NP	I
was	VBD	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
hospital	NN	I-NP	O
for	IN	B-PP	O
symptomatic	JJ	B-NP	O
incessant	NN	I-NP	O
sustained	VBD	B-VP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
(	(	O	O
VT	NN	B-NP	B
)	)	O	O
.	.	O	O

After	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
nifekalant	JJ	B-NP	O
hydrochloride	NN	I-NP	O
,	,	O	O
sustained	JJ	B-NP	O
VT	NN	I-NP	B
was	VBD	B-VP	O
terminated	VBN	I-VP	O
.	.	O	O

An	DT	B-NP	O
alternate	JJ	I-NP	O
class	NN	I-NP	O
num	CD	I-NP	O
agent	NN	I-NP	O
,	,	O	O
sotalol	NN	B-NP	O
,	,	O	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
effective	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
VT	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
month	NN	I-NP	O
after	IN	B-PP	O
switching	VBG	B-VP	O
over	IN	B-PP	O
nifekalant	NN	B-NP	O
to	TO	B-PP	O
sotalol	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
short	JJ	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
ST	JJ	B-NP	O
elevation	NN	I-NP	O
was	VBD	B-VP	O
documented	VBN	I-VP	O
in	IN	B-PP	O
ECG	NN	B-NP	O
monitoring	NN	I-NP	O
at	IN	B-PP	O
almost	RB	B-NP	O
the	DT	I-NP	O
same	JJ	I-NP	O
time	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

ST	JJ	B-NP	O
elevation	NN	I-NP	O
with	IN	B-PP	O
chest	NN	B-NP	O
discomfort	NN	I-NP	O
disappeared	VBD	B-VP	O
since	IN	B-SBAR	O
he	PRP	B-NP	O
began	VBD	B-VP	O
taking	VBG	I-VP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
acting	VBG	I-NP	O
diltiazem	NN	I-NP	O
.	.	O	O

Coronary	JJ	B-NP	B
vasospasm	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocking	VBG	B-VP	O
properties	NNS	B-NP	O
of	IN	B-PP	O
sotalol	NN	B-NP	O
.	.	O	O

Effects	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antidepressant	NN	I-NP	O
trazodone	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2A	NN	I-NP	O
/	SYM	B-NP	O
2C	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
dopamine	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
behaviors	NNS	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
Hydroxytryptamine	NN	I-NP	O
,	,	O	O
via	IN	B-PP	O
stimulation	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2C	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
exerts	VBZ	B-VP	O
a	DT	B-NP	O
tonic	JJ	I-NP	O
inhibitory	JJ	I-NP	O
influence	NN	I-NP	O
on	IN	B-PP	O
dopaminergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
activation	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2A	NN	I-NP	O
receptors	NNS	I-NP	O
enhances	VBZ	B-VP	O
stimulated	VBN	I-VP	O
DAergic	JJ	B-NP	O
neurotransmission	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
antidepressant	NN	I-NP	O
trazodone	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2A	NN	I-NP	O
/	SYM	B-NP	O
2C	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
trazodone	NN	B-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
behaviors	NNS	B-NP	O
dependent	JJ	B-ADJP	O
on	IN	B-PP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
status	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
nigrostriatal	JJ	I-NP	O
DAergic	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
trazodone	NN	B-NP	O
on	IN	B-PP	O
dexamphetamine	NN	B-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
apomorphine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
oral	JJ	I-NP	B
stereotypies	NNS	I-NP	I
,	,	O	O
on	IN	B-PP	O
catalepsy	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
haloperidol	NN	B-NP	O
and	CC	I-NP	O
apomorphine	NN	I-NP	O
,	,	O	O
on	IN	B-PP	O
ergometrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
wet	JJ	I-NP	O
dog	NN	I-NP	O
shake	NN	I-NP	O
(	(	O	O
WDS	NN	B-NP	O
)	)	O	O
behavior	NN	B-NP	O
and	CC	I-NP	O
fluoxetine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
penile	JJ	I-NP	O
erections	NNS	I-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
also	RB	B-ADVP	O
investigated	VBD	B-VP	O
whether	IN	B-SBAR	O
trazodone	NN	B-NP	O
induces	VBZ	B-VP	O
catalepsy	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Trazodone	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
i.p.	RB	B-ADVP	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
catalepsy	NN	B-NP	B
,	,	O	O
and	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
antagonize	VB	I-VP	O
apomorphine	NN	B-NP	O
stereotypy	NN	I-NP	O
and	CC	I-NP	O
apomorphine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
i.p.	JJ	I-NP	O
trazodone	NN	I-NP	O
enhanced	VBD	B-VP	O
dexamphetamine	NN	B-NP	O
stereotypy	NN	I-NP	O
,	,	O	O
and	CC	O	O
antagonized	VBD	B-VP	O
haloperidol	NN	B-NP	O
catalepsy	NN	I-NP	B
,	,	O	O
ergometrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
WDS	NN	I-NP	O
behavior	NN	I-NP	O
and	CC	I-NP	O
fluoxetine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
penile	JJ	I-NP	O
erections	NNS	I-NP	O
.	.	O	O

Trazodone	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
i.p.	RB	B-ADVP	O
induced	VBD	B-VP	O
catalepsy	NN	B-NP	B
and	CC	O	O
antagonized	VBD	B-VP	O
apomorphine	NN	B-NP	O
and	CC	I-NP	O
dexamphetamine	NN	I-NP	O
stereotypies	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
trazodone	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
block	VB	I-VP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
postsynaptic	JJ	I-NP	O
striatal	JJ	I-NP	O
D2	NN	I-NP	O
DA	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
it	PRP	B-NP	O
blocks	VBZ	B-VP	O
postsynaptic	JJ	B-NP	O
striatal	JJ	I-NP	O
D2	NN	I-NP	O
DA	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
,	,	O	O
trazodone	NN	B-NP	O
blocks	VBZ	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2A	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2C	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
trazodone	NN	B-NP	O
,	,	O	O
by	IN	B-PP	O
blocking	VBG	B-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
2C	NN	I-NP	O
receptors	NNS	I-NP	O
,	,	O	O
releases	VBZ	B-VP	O
the	DT	B-NP	O
nigrostriatal	JJ	I-NP	O
DAergic	JJ	I-NP	O
neurons	NNS	I-NP	O
from	IN	B-PP	O
tonic	JJ	B-NP	O
inhibition	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
HT	NN	I-NP	O
,	,	O	O
and	CC	O	O
thereby	RB	B-VP	O
potentiates	VBZ	I-VP	O
dexamphetamine	NN	B-NP	O
stereotypy	NN	I-NP	O
and	CC	O	O
antagonizes	VBZ	B-VP	O
haloperidol	NN	B-NP	O
catalepsy	NN	I-NP	B
.	.	O	O

Swallowing	VBG	B-NP	B
abnormalities	NNS	I-NP	I
and	CC	I-NP	O
dyskinesia	NN	I-NP	B
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Gastrointestinal	JJ	B-NP	B
abnormalities	NNS	I-NP	I
in	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
known	VBN	I-VP	O
for	IN	B-PP	O
almost	RB	B-NP	O
num	CD	I-NP	O
centuries	NNS	I-NP	O
,	,	O	O
but	CC	O	O
many	JJ	B-NP	O
aspects	NNS	I-NP	O
concerning	VBG	B-VP	O
their	PRP$	B-NP	O
pathophysiology	NN	I-NP	O
have	VBP	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
completely	RB	B-ADJP	O
clarified	VBN	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
characterize	VB	I-VP	O
the	DT	B-NP	O
oropharyngeal	JJ	I-NP	O
dynamics	NNS	I-NP	O
in	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
and	CC	I-PP	O
without	IN	I-PP	O
levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
dyskinesia	NN	I-NP	B
.	.	O	O

num	CD	B-NP	O
dyskinetic	JJ	I-NP	B
,	,	O	O
num	CD	B-NP	O
nondyskinetic	JJ	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
asked	VBN	I-VP	O
about	IN	B-PP	O
dysphagia	NN	B-NP	B
and	CC	O	O
evaluated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
Unified	NNP	I-NP	O
Parkinson	NNP	I-NP	B
s	VBZ	B-VP	I
Disease	NNP	B-NP	I
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
Parts	NNP	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Hoehn	NNP	I-NP	O
and	CC	O	O
Yahr	NN	B-NP	O
scale	NN	I-NP	O
.	.	O	O

Deglutition	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
using	VBG	B-VP	O
modified	VBN	B-NP	O
barium	NN	I-NP	O
swallow	NN	I-NP	O
with	IN	B-PP	O
videofluoroscopy	NN	B-NP	O
.	.	O	O

Nondyskinetic	JJ	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
the	DT	B-NP	O
dyskinetic	JJ	I-NP	B
ones	NNS	I-NP	O
,	,	O	O
showed	VBD	B-VP	O
less	RBR	B-NP	O
oropharyngeal	JJ	I-NP	O
swallowing	VBG	I-NP	O
efficiency	NN	I-NP	O
(	(	O	O
OPSE	NN	B-NP	O
)	)	O	O
for	IN	B-PP	O
liquid	JJ	B-NP	O
food	NN	I-NP	O
than	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

Dyskinetic	JJ	B-NP	B
patients	NNS	I-NP	O
tended	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
OPSE	NN	I-NP	O
than	IN	B-PP	O
nondyskinetic	JJ	B-ADJP	O
.	.	O	O

Patients	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
higher	JJR	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
OPSE	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
trend	NN	I-NP	O
toward	IN	B-PP	O
a	DT	B-NP	O
smaller	JJR	I-NP	O
oral	JJ	I-NP	O
transit	NN	I-NP	O
time	NN	I-NP	O
.	.	O	O

Neither	CC	O	O
the	DT	B-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
dysphagia	NN	B-NP	B
nor	CC	O	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
PD	NN	I-NP	B
severity	NN	I-NP	O
parameters	NNS	I-NP	O
correlated	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
videofluoroscopic	JJ	I-NP	O
variables	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
dyskinetic	JJ	B-NP	B
patients	NNS	I-NP	O
performed	VBN	B-VP	O
better	RBR	B-ADVP	O
in	IN	B-PP	O
swallowing	VBG	B-VP	O
function	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
explained	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
levodopa	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
levodopa	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
oral	JJ	I-NP	O
phase	NN	I-NP	O
of	IN	B-PP	O
deglutition	NN	B-NP	O
and	CC	O	O
confirm	VBP	B-VP	O
that	IN	B-SBAR	O
dysphagia	NN	B-NP	B
is	VBZ	B-VP	O
not	RB	O	O
a	DT	B-NP	O
good	JJ	I-NP	O
predictor	NN	I-NP	O
of	IN	B-PP	O
deglutition	NN	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
PD	NN	B-NP	B
.	.	O	O

Inhibition	NN	B-NP	O
of	IN	B-PP	O
nuclear	JJ	B-NP	O
factor	NN	I-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
activation	NN	I-NP	O
attenuates	VBZ	B-VP	O
tubulointerstitial	JJ	B-NP	B
nephritis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
can	MD	B-VP	O
show	VB	I-VP	O
residual	JJ	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
interstitial	JJ	B-NP	O
fibrosis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortex	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
nuclear	JJ	B-NP	O
factor	NN	I-NP	O
-	HYPH	O	O
kappaB	NN	B-NP	O
(	(	O	O
NF	NN	B-NP	O
-	HYPH	B-NP	O
kappaB	NN	I-NP	O
)	)	O	O
,	,	O	O
mitogen	NN	B-NP	O
-	HYPH	B-VP	O
activated	VBN	B-NP	O
protein	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
kinases	NNS	B-NP	O
and	CC	O	O
macrophages	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortex	NN	I-NP	O
and	CC	O	O
structural	JJ	B-NP	O
and	CC	I-NP	O
functional	JJ	I-NP	O
renal	JJ	I-NP	O
changes	NNS	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
or	CC	I-NP	O
gentamicin	NN	I-NP	O
+	SYM	O	O
pyrrolidine	NN	B-NP	O
dithiocarbamate	NN	I-NP	O
(	(	O	O
PDTC	NN	B-NP	O
)	)	O	O
,	,	O	O
an	DT	B-NP	O
NF	NN	I-NP	O
-	HYPH	I-NP	O
kappaB	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
female	JJ	I-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
twice	RB	B-NP	O
a	DT	I-NP	O
day	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
+	SYM	I-NP	O
PDTC	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
M	NN	I-NP	O
NaCl	NN	I-NP	O
solution	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
these	DT	B-NP	O
injections	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
were	VBD	B-VP	O
removed	VBN	I-VP	O
for	IN	B-PP	O
histological	JJ	B-NP	O
and	CC	I-NP	O
immunohistochemical	JJ	I-NP	O
studies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
immunohistochemical	JJ	I-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
scored	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
staining	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
fractional	JJ	I-NP	O
interstitial	JJ	I-NP	O
area	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
morphometry	NN	B-NP	O
.	.	O	O

Gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
presented	VBD	B-VP	O
a	DT	B-NP	O
transitory	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Increased	VBN	B-VP	O
ED	VBN	B-VP	O
-	HYPH	O	O
num	CD	B-NP	O
MAP	NN	I-NP	O
kinases	NNS	I-NP	O
and	CC	O	O
NF	NN	B-NP	O
-	HYPH	I-NP	O
kappaB	NN	I-NP	O
staining	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortex	NN	I-NP	O
from	IN	B-PP	O
all	DT	B-NP	O
gentamicin	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
control	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
animals	NNS	I-NP	O
killed	VBN	B-VP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
also	RB	B-NP	O
presented	VBN	I-NP	O
fibrosis	NN	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
renal	JJ	I-NP	O
cortex	NN	I-NP	O
despite	IN	B-PP	O
the	DT	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
PDTC	NN	B-NP	O
reduced	VBD	B-VP	O
the	DT	B-NP	O
functional	JJ	I-NP	O
and	CC	I-NP	O
structural	JJ	I-NP	O
changes	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
NF	NN	B-NP	O
-	HYPH	O	O
kappaB	NN	B-NP	O
activation	NN	I-NP	O
attenuates	VBZ	B-VP	O
tubulointerstitial	JJ	B-NP	B
nephritis	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
gentamicin	NN	B-NP	O
.	.	O	O

Glucose	NN	B-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
atypical	JJ	B-NP	O
antipsychotic	JJ	I-NP	O
agents	NNS	I-NP	O
:	:	O	O
a	DT	B-NP	O
frequently	RB	I-NP	O
sampled	VBN	I-NP	O
intravenous	JJ	I-NP	O
glucose	NN	I-NP	O
tolerance	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
minimal	JJ	B-NP	O
model	NN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

While	IN	B-SBAR	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
new	JJ	B-NP	O
-	HYPH	I-NP	O
onset	NN	I-NP	O
diabetes	NN	I-NP	B
mellitus	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
increasing	VBG	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
certain	JJ	B-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
agents	NNS	I-NP	O
,	,	O	O
it	PRP	B-NP	O
remains	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
atypical	JJ	B-NP	O
agents	NNS	I-NP	O
are	VBP	B-VP	O
directly	RB	I-VP	O
affecting	VBG	I-VP	O
glucose	NN	B-NP	O
metabolism	NN	I-NP	O
or	CC	O	O
simply	RB	B-VP	O
increasing	VBG	I-VP	O
known	VBN	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
diabetes	NNS	B-NP	B
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
drugs	NNS	I-NP	O
most	RBS	B-VP	O
clearly	RB	I-VP	O
implicated	VBN	I-VP	O
(	(	O	O
clozapine	NN	B-NP	O
and	CC	O	O
olanzapine	NN	B-NP	O
)	)	O	O
and	CC	O	O
risperidone	NN	B-NP	O
using	VBG	B-VP	O
a	DT	B-NP	O
frequently	RB	I-NP	O
sampled	VBN	I-NP	O
intravenous	JJ	I-NP	O
glucose	NN	I-NP	O
tolerance	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
cross	AFX	I-NP	O
-	HYPH	I-NP	O
sectional	JJ	I-NP	O
design	NN	I-NP	O
in	IN	B-PP	O
stable	JJ	B-NP	O
,	,	O	O
treated	VBN	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
evaluated	VBN	B-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
frequently	RB	I-NP	O
sampled	VBN	I-NP	O
intravenous	JJ	I-NP	O
glucose	NN	I-NP	O
tolerance	NN	I-NP	O
test	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Bergman	NNP	I-NP	O
minimal	JJ	I-NP	O
model	NN	I-NP	O
analysis	NN	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
were	VBD	B-VP	O
recruited	VBN	I-VP	O
from	IN	B-PP	O
an	DT	B-NP	O
urban	JJ	I-NP	O
community	NN	I-NP	O
mental	JJ	I-NP	O
health	NN	I-NP	O
clinic	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
studied	VBN	I-VP	O
at	IN	B-PP	O
a	DT	B-NP	O
general	JJ	I-NP	O
clinical	JJ	I-NP	O
research	NN	I-NP	O
center	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
Fifty	JJ	I-NP	O
subjects	NNS	I-NP	O
signed	VBD	B-VP	O
informed	VBN	B-NP	O
consent	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
underwent	VBD	B-VP	O
the	DT	B-NP	O
frequently	RB	I-NP	O
sampled	VBN	I-NP	O
intravenous	JJ	I-NP	O
glucose	NN	I-NP	O
tolerance	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
nonobese	JJ	I-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
or	CC	O	O
schizoaffective	JJ	B-NP	B
disorder	NN	I-NP	I
,	,	O	O
matched	VBN	B-VP	O
by	IN	B-PP	O
body	NN	B-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
and	CC	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
either	CC	O	O
clozapine	NN	B-NP	O
,	,	O	O
olanzapine	NN	B-NP	O
,	,	O	O
or	CC	O	O
risperidone	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Fasting	VBG	B-VP	O
plasma	NN	B-NP	O
glucose	NN	I-NP	O
and	CC	O	O
fasting	VBG	B-VP	O
serum	NN	B-NP	O
insulin	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
insulin	NN	B-NP	B
sensitivity	NN	I-NP	I
index	NN	I-NP	O
,	,	O	O
homeostasis	NN	B-NP	O
model	NN	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	B
resistance	NN	I-NP	I
,	,	O	O
and	CC	O	O
glucose	NN	B-NP	O
effectiveness	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	NN	I-NP	O
+	SYM	B-VP	O
/	SYM	B-NP	O
-	HYPH	B-NP	O
SD	NN	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
identified	VBN	I-NP	O
atypical	JJ	I-NP	O
antipsychotic	JJ	I-NP	O
agent	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
clozapine	NN	B-NP	O
)	)	O	O
,	,	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
olanzapine	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
(	(	O	O
risperidone	NN	B-NP	O
)	)	O	O
.	.	O	O

Fasting	VBG	B-VP	O
serum	NN	B-NP	O
insulin	NN	I-NP	O
concentrations	NNS	I-NP	O
differed	VBD	B-VP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
(	(	O	O
clozapine	NN	B-NP	O
>	SYM	I-NP	O
olanzapine	NN	I-NP	O
>	SYM	B-NP	O
risperidone	NN	I-NP	O
)	)	O	O
with	IN	B-PP	O
significant	JJ	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
clozapine	NN	B-NP	O
and	CC	I-NP	O
risperidone	NN	I-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
and	CC	I-NP	O
risperidone	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
in	IN	B-PP	O
insulin	NN	B-NP	B
sensitivity	NN	I-NP	I
index	NN	I-NP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
(	(	O	O
clozapine	NN	B-NP	O
<	SYM	I-NP	O
olanzapine	NN	I-NP	O
<	SYM	B-NP	O
risperidone	NN	I-NP	O
)	)	O	O
,	,	O	O
with	IN	B-PP	O
subjects	NNS	B-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
clozapine	NN	B-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
exhibiting	VBG	B-VP	O
significant	JJ	B-NP	O
insulin	NN	I-NP	B
resistance	NN	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
subjects	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
homeostasis	NN	I-NP	O
model	NN	I-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
insulin	NN	B-NP	B
resistance	NN	I-NP	I
also	RB	B-ADVP	O
differed	VBD	B-VP	O
significantly	RB	B-ADVP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
(	(	O	O
clozapine	NN	B-NP	O
>	SYM	I-NP	O
olanzapine	NN	I-NP	O
>	SYM	B-NP	O
risperidone	NN	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
among	IN	B-PP	O
groups	NNS	B-NP	O
in	IN	B-PP	O
glucose	NN	B-NP	O
effectiveness	NN	I-NP	O
(	(	O	O
clozapine	NN	B-NP	O
<	SYM	B-NP	O
olanzapine	NN	I-NP	O
<	SYM	I-NP	O
risperidone	NN	I-NP	O
)	)	O	O
with	IN	B-PP	O
significant	JJ	B-NP	O
differences	NNS	I-NP	O
between	IN	B-PP	O
clozapine	NN	B-NP	O
and	CC	I-NP	O
risperidone	NN	I-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
and	CC	I-NP	O
risperidone	NN	I-NP	O
.	.	O	O

Both	CC	O	O
nonobese	JJ	B-NP	O
clozapine	NN	I-NP	O
-	HYPH	B-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
-	HYPH	I-NP	O
treated	VBN	I-NP	O
groups	NNS	I-NP	O
displayed	VBD	B-VP	O
significant	JJ	B-NP	O
insulin	NN	I-NP	B
resistance	NN	I-NP	I
and	CC	I-NP	O
impairment	NN	I-NP	O
of	IN	B-PP	O
glucose	NN	B-NP	O
effectiveness	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
taking	VBG	B-VP	O
clozapine	NN	B-NP	O
and	CC	I-NP	O
olanzapine	NN	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
examined	VBN	I-VP	O
for	IN	B-PP	O
insulin	NN	B-NP	B
resistance	NN	I-NP	I
and	CC	O	O
its	PRP$	B-NP	O
consequences	NNS	I-NP	O
.	.	O	O

Focal	JJ	B-NP	O
cerebral	JJ	I-NP	B
ischemia	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
:	:	O	O
effect	NN	B-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
during	IN	B-PP	O
reperfusion	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
temporary	JJ	B-NP	O
middle	JJ	I-NP	B
cerebral	JJ	I-NP	I
artery	NN	I-NP	I
occlusion	NN	I-NP	I
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
phenylephrine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hypertension	NN	I-NP	B
on	IN	B-PP	O
ischemic	JJ	B-NP	B
brain	NN	I-NP	I
injury	NN	I-NP	I
and	CC	I-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
permeability	NN	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
manipulated	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
schedules	NNS	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
reperfusion	NN	B-NP	O
:	:	O	O
Control	NN	B-NP	O
,	,	O	O
normotensive	JJ	B-NP	O
reperfusion	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
hypertension	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
)	)	O	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
reperfusion	NN	B-NP	O
only	RB	B-ADVP	O
;	:	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
hypertension	NN	I-NP	B
(	(	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
)	)	O	O
,	,	O	O
normotensive	JJ	B-NP	O
reperfusion	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
min	NN	I-NP	O
of	IN	B-PP	O
normotension	NN	B-NP	O
.	.	O	O

Part	NNP	B-NP	O
A	NNP	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
brain	NN	I-NP	B
injury	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
staining	VBG	B-VP	O
tissue	NN	B-NP	O
using	VBG	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
triphenyltetrazolium	NN	I-NP	O
chloride	NN	I-NP	O
and	CC	I-NP	O
edema	NN	I-NP	B
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
microgravimetry	NN	B-NP	O
.	.	O	O

Part	NNP	B-NP	O
B	NNP	I-NP	O
,	,	O	O
for	IN	B-PP	O
num	CD	B-NP	O
different	JJ	I-NP	O
rats	NNS	I-NP	O
in	IN	B-PP	O
each	DT	B-NP	O
group	NN	I-NP	O
blood	NN	I-NP	O
-	HYPH	B-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
permeability	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
by	IN	B-PP	O
measuring	VBG	B-VP	O
the	DT	B-NP	O
amount	NN	I-NP	O
and	CC	I-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
extravasation	NN	B-NP	O
of	IN	B-PP	O
Evans	NNP	B-NP	O
Blue	NNP	I-NP	O
dye	NN	I-NP	O
.	.	O	O

Brain	NN	B-NP	B
injury	NN	I-NP	I
(	(	O	O
percentage	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemic	JJ	I-NP	B
hemisphere	NN	I-NP	I
)	)	O	O
was	VBD	B-VP	O
less	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
group	NN	I-NP	O
versus	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
group	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
turn	NN	B-NP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Specific	JJ	B-NP	O
gravity	NN	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
group	NN	I-NP	O
versus	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
and	CC	I-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Evans	NNP	B-NP	O
Blue	NNP	I-NP	O
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
group	NN	I-NP	O
versus	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
was	VBD	B-VP	O
in	IN	B-PP	O
turn	NN	B-NP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
HTN	NN	I-NP	B
group	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
supports	VBZ	B-VP	O
a	DT	B-NP	O
hypothesis	NN	I-NP	O
that	IN	B-NP	O
during	IN	B-PP	O
reperfusion	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
short	JJ	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
decreases	VBZ	B-VP	O
brain	NN	B-NP	B
injury	NN	I-NP	I
and	CC	I-NP	O
edema	NN	I-NP	B
;	:	O	O
and	CC	O	O
that	IN	B-SBAR	O
sustained	JJ	B-NP	O
hypertension	NN	I-NP	B
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
vasogenic	JJ	B-NP	B
edema	NN	I-NP	I
.	.	O	O

People	NNS	B-NP	O
aged	VBN	B-VP	O
over	IN	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
on	IN	B-PP	O
warfarin	NN	B-NP	O
:	:	O	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
major	JJ	B-NP	O
hemorrhage	NN	I-NP	B
and	CC	I-NP	O
stroke	NN	I-NP	B
in	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
major	JJ	B-NP	O
hemorrhage	NN	I-NP	B
and	CC	I-NP	O
stroke	NN	I-NP	B
in	IN	B-PP	O
people	NNS	B-NP	O
aged	VBN	B-VP	O
num	CD	B-NP	O
and	CC	O	O
older	JJR	B-ADJP	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
on	IN	B-PP	O
adjusted	VBN	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
warfarin	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
recently	RB	I-VP	O
been	VBN	I-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
hospital	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
retrospective	JJ	I-NP	O
observational	JJ	I-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
major	JJ	I-NP	O
healthcare	NN	I-NP	O
network	NN	I-NP	O
involving	VBG	B-VP	O
num	CD	B-NP	O
tertiary	JJ	I-NP	O
hospitals	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
aged	VBN	B-ADJP	O
num	CD	B-NP	O
and	CC	O	O
older	JJR	B-ADJP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
major	JJ	I-NP	O
healthcare	NN	I-NP	O
network	NN	I-NP	O
between	IN	B-PP	O
July	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
June	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
with	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
on	IN	B-PP	O
warfarin	NN	B-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
.	.	O	O

Information	NN	B-NP	O
regarding	VBG	B-PP	O
major	JJ	B-NP	O
bleeding	VBG	I-NP	B
episodes	NNS	I-NP	O
,	,	O	O
strokes	NNS	B-NP	B
,	,	O	O
and	CC	O	O
warfarin	NN	B-NP	O
use	NN	I-NP	O
was	VBD	B-VP	O
obtained	VBN	I-VP	O
from	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
relatives	NNS	B-NP	O
,	,	O	O
primary	JJ	B-NP	O
physicians	NNS	I-NP	O
,	,	O	O
and	CC	O	O
medical	JJ	B-NP	O
records	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
men	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
range	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Total	JJ	B-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
on	IN	B-PP	O
warfarin	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
(	(	O	O
mean	NN	B-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
)	)	O	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
major	JJ	I-NP	O
hemorrhages	NNS	I-NP	B
,	,	O	O
for	IN	B-PP	O
an	DT	B-NP	O
annual	JJ	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
num	CD	B-NP	O
life	NN	I-NP	O
-	HYPH	B-NP	O
threatening	VBG	B-VP	O
and	CC	O	O
num	CD	B-NP	O
fatal	JJ	I-NP	O
bleeds	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
annual	JJ	I-NP	O
stroke	NN	I-NP	B
rate	NN	I-NP	O
after	IN	B-PP	O
initiation	NN	B-NP	O
of	IN	B-PP	O
warfarin	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
major	JJ	B-NP	O
hemorrhage	NN	I-NP	B
was	VBD	B-VP	O
high	JJ	B-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
old	JJ	I-NP	O
,	,	I-NP	O
frail	NN	I-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
excluding	VBG	B-PP	O
fatalities	NNS	B-NP	O
,	,	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
no	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
sequelae	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
stroke	NN	I-NP	B
rate	NN	I-NP	O
on	IN	B-PP	O
warfarin	NN	B-NP	O
was	VBD	B-VP	O
low	JJ	B-ADJP	O
,	,	O	O
demonstrating	VBG	B-VP	O
how	WRB	B-ADVP	O
effective	JJ	B-NP	O
warfarin	NN	I-NP	O
treatment	NN	I-NP	O
is	VBZ	B-VP	O
.	.	O	O

Safety	NN	B-NP	O
of	IN	B-PP	O
celecoxib	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
adverse	JJ	B-NP	O
skin	NN	I-NP	B
reactions	NNS	I-NP	I
to	TO	B-PP	O
acetaminophen	NN	B-NP	O
(	(	O	O
paracetamol	NN	B-NP	O
)	)	O	O
and	CC	O	O
nimesulide	NN	B-NP	O
associated	VBN	B-VP	O
or	CC	O	O
not	RB	O	O
with	IN	B-PP	O
common	JJ	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Acetaminophen	NN	B-NP	O
(	(	O	O
paracetamol	NN	B-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
P	NN	I-NP	O
)	)	O	O
and	CC	O	O
Nimesulide	NN	B-NP	O
(	(	O	O
N	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
analgesic	JJ	B-NP	O
-	HYPH	I-NP	O
antipyretic	JJ	I-NP	O
/	SYM	O	O
anti	AFX	O	O
-	HYPH	B-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
hypersensitivity	NN	I-NP	B
reactions	NNS	I-NP	O
to	TO	B-PP	O
these	DT	B-NP	O
agents	NNS	I-NP	O
is	VBZ	B-VP	O
generally	RB	B-ADJP	O
low	JJ	I-ADJP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	JJ	I-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
are	VBP	B-VP	O
commonly	RB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
such	JJ	B-NP	O
reactions	NNS	I-NP	O
.	.	O	O

Celecoxib	NN	B-NP	O
(	(	O	O
CE	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
high	JJ	B-NP	O
selectivity	NN	I-NP	O
and	CC	O	O
affinity	NN	B-NP	O
for	IN	B-PP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
enzyme	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
CE	NN	B-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
documented	VBN	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
cutaneous	JJ	I-NP	B
reactions	NNS	I-NP	I
to	TO	B-PP	O
P	NN	B-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
associated	VBN	B-VP	O
or	CC	O	O
not	RB	O	O
to	TO	B-PP	O
classic	JJ	B-NP	O
NSAIDs	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
hypersensitivity	NN	B-NP	B
to	TO	B-PP	O
P	NN	B-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
associated	JJ	B-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
classic	JJ	B-NP	O
NSAIDs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
diagnosis	NN	I-NP	O
of	IN	B-PP	O
P	NN	B-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
skin	NN	I-NP	B
reactions	NNS	I-NP	I
was	VBD	B-VP	O
based	VBN	I-VP	O
in	FW	B-NP	O
vivo	FW	I-NP	O
challenge	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
placebo	NN	I-NP	O
was	VBD	B-VP	O
blindly	RB	I-VP	O
administered	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
beginning	NN	I-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
challenge	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
cumulative	JJ	I-NP	O
dosage	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
of	IN	B-PP	O
CE	NN	B-NP	O
in	IN	B-PP	O
refracted	JJ	B-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
,	,	O	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
after	IN	B-PP	O
each	DT	B-NP	O
challenge	NN	I-NP	O
,	,	O	O
and	CC	O	O
controlled	VBN	B-VP	O
again	RB	B-ADVP	O
after	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
to	TO	B-VP	O
exclude	VB	I-VP	O
delayed	JJ	B-NP	O
reactions	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
challenge	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
positive	JJ	B-ADJP	O
if	IN	B-SBAR	O
num	CD	B-NP	O
or	CC	I-NP	O
more	JJR	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
following	NN	I-NP	O
appeared	VBD	B-VP	O
:	:	O	O
erythema	NN	B-NP	B
,	,	I-NP	O
rush	NN	I-NP	O
or	CC	I-NP	O
urticaria	NN	I-NP	B
-	HYPH	B-NP	O
angioedema	NN	I-NP	B
.	.	O	O

No	DT	B-NP	O
reaction	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
tolerated	VBD	B-VP	O
CE	NN	B-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
moderate	JJ	I-NP	O
angioedema	NN	I-NP	B
of	IN	B-PP	O
the	DT	B-NP	O
lips	NNS	I-NP	O
.	.	O	O

Only	RB	B-NP	O
num	CD	I-NP	O
hypersensitivity	NN	I-NP	B
reaction	NN	I-NP	O
to	TO	B-PP	O
CE	NN	B-NP	O
was	VBD	B-VP	O
documented	VBN	I-VP	O
among	IN	B-PP	O
num	CD	B-NP	O
P	NN	I-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
-	HYPH	O	O
highly	RB	B-ADVP	O
NSAIDs	NNS	B-NP	O
intolerant	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
CE	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
reasonably	RB	I-NP	O
safe	JJ	I-NP	O
alternative	NN	I-NP	O
to	TO	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
subjects	NNS	B-NP	O
who	WP	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
P	NN	B-NP	O
and	CC	I-NP	O
N	NN	I-NP	O
.	.	O	O

Case	NN	B-NP	O
-	HYPH	I-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
of	IN	B-PP	O
regular	JJ	B-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
nonsteroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
use	NN	I-NP	O
and	CC	I-NP	O
end	NN	I-NP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Studies	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
analgesic	JJ	I-NP	O
and	CC	I-NP	O
nonsteroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
(	(	O	O
ESRD	NN	B-NP	B
)	)	O	O
have	VBP	B-VP	O
given	VBN	I-VP	O
conflicting	VBG	I-VP	O
results	NNS	B-NP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
examine	VB	I-VP	O
this	DT	B-NP	O
association	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
with	IN	B-PP	O
incident	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
was	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
.	.	O	O

The	DT	B-NP	O
cases	NNS	I-NP	O
were	VBD	B-VP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
entering	VBG	B-VP	O
the	DT	B-NP	O
local	JJ	I-NP	O
dialysis	NN	I-NP	O
program	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
ESRD	NNP	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
area	NN	I-NP	O
between	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
and	CC	O	O
November	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
.	.	O	O

They	PRP	B-NP	O
were	VBD	B-VP	O
classified	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
underlying	VBG	I-NP	O
disease	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
had	VBD	B-VP	O
presumably	RB	I-VP	O
led	VBN	I-VP	O
them	PRP	B-NP	O
to	TO	B-PP	O
ESRD	NNP	B-NP	B
.	.	O	O

Controls	NNS	B-NP	O
were	VBD	B-VP	O
patients	NNS	B-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
hospitals	NNS	I-NP	O
from	IN	B-PP	O
where	WRB	B-ADVP	O
the	DT	B-NP	O
cases	NNS	I-NP	O
arose	VBD	B-VP	O
,	,	O	O
also	RB	B-ADVP	O
matched	VBN	B-VP	O
by	IN	B-PP	O
age	NN	B-NP	O
and	CC	I-NP	O
sex	NN	I-NP	O
.	.	O	O

Odds	NNS	B-NP	O
ratios	NNS	I-NP	O
were	VBD	B-VP	O
calculated	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
conditional	JJ	I-NP	O
logistic	JJ	I-NP	O
model	NN	I-NP	O
,	,	O	O
including	VBG	B-PP	O
potential	JJ	B-NP	O
confounding	VBG	I-NP	O
factors	NNS	I-NP	O
,	,	O	O
both	DT	B-PP	O
for	IN	I-PP	O
the	DT	B-NP	O
whole	JJ	I-NP	O
study	NN	I-NP	O
population	NN	I-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
various	JJ	I-NP	O
underlying	VBG	I-NP	O
diseases	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
controls	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
analgesic	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
odds	NNS	I-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

For	IN	B-PP	O
specific	JJ	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
risks	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
for	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
for	IN	B-PP	O
pyrazolones	NNS	B-NP	O
,	,	O	O
num	CD	B-NP	O
for	IN	B-PP	O
paracetamol	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
for	IN	B-PP	O
nonaspirin	JJ	B-NP	O
NSAIDs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ESRD	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
aspirin	NN	B-NP	O
was	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
cumulated	VBN	I-NP	O
dose	NN	I-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
use	NN	B-NP	O
,	,	O	O
and	CC	O	O
it	PRP	B-NP	O
was	VBD	B-VP	O
particularly	RB	B-ADJP	O
high	JJ	I-ADJP	O
among	IN	B-PP	O
the	DT	B-NP	O
subset	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
vascular	JJ	B-NP	O
nephropathy	NN	I-NP	B
as	IN	B-PP	O
underlying	VBG	B-VP	O
disease	NN	B-NP	O
[	(	O	O
num	CD	B-NP	O
]	)	O	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
nonaspirin	JJ	B-NP	O
analgesic	JJ	I-NP	O
drugs	NNS	I-NP	O
and	CC	I-NP	O
NSAIDs	NNS	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ESRD	NNP	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
chronic	JJ	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
may	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
ESRD	NNP	B-NP	B
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
overdose	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
cause	NN	I-NP	O
for	IN	B-PP	O
prolonged	JJ	B-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
deliberate	JJ	B-NP	O
self	NN	I-NP	O
-	HYPH	O	O
poisoning	VBG	B-VP	B
with	IN	B-PP	O
num	CD	B-NP	O
g	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
g	NN	I-NP	O
of	IN	B-PP	O
amisulpride	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
are	VBP	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
cases	NNS	I-NP	O
,	,	O	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
and	CC	I-NP	O
hypocalcaemia	NN	I-NP	B
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
QT	NN	I-NP	B
prolongation	NN	I-NP	I
appeared	VBD	B-VP	O
to	TO	I-VP	O
respond	VB	I-VP	O
to	TO	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
i.v.	JJ	B-NP	O
calcium	NN	I-NP	O
gluconate	NN	I-NP	O
.	.	O	O

Growth	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
protein	NN	B-NP	O
num	CD	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
hippocampal	JJ	B-NP	O
molecular	JJ	I-NP	O
layer	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
epileptic	JJ	I-NP	B
rats	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
cycloheximide	NN	B-NP	O
.	.	O	O

GAP43	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
thought	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
linked	VBN	I-VP	O
with	IN	B-PP	O
mossy	NN	B-NP	O
fiber	NN	I-NP	O
sprouting	NN	I-NP	O
(	(	O	O
MFS	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
various	JJ	B-NP	O
experimental	JJ	I-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
.	.	O	O

To	TO	B-VP	O
investigate	VB	I-VP	O
how	WRB	B-ADVP	O
GAP43	NN	B-NP	O
expression	NN	I-NP	O
(	(	O	O
GAP43	NN	B-NP	O
-	HYPH	B-NP	O
ir	NN	I-NP	O
)	)	O	O
correlates	VBZ	B-VP	O
with	IN	B-PP	O
MFS	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
intensity	NN	I-NP	O
(	(	O	O
densitometry	NN	B-NP	O
)	)	O	O
and	CC	O	O
extension	NN	B-NP	O
(	(	O	O
width	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
GAP43	NN	B-NP	O
-	HYPH	B-NP	O
ir	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
inner	JJ	I-NP	O
molecular	JJ	I-NP	O
layer	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
(	(	O	O
IML	NN	B-NP	O
)	)	O	O
of	IN	B-PP	O
rats	NNS	B-NP	O
subject	JJ	B-ADJP	O
to	TO	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
(	(	O	O
Pilo	NN	B-NP	O
)	)	O	O
,	,	O	O
previously	RB	B-VP	O
injected	VBN	I-VP	O
or	CC	O	O
not	RB	O	O
with	IN	B-PP	O
cycloheximide	NN	B-NP	O
(	(	O	O
CHX	NN	B-NP	O
)	)	O	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
inhibit	VB	I-VP	O
MFS	NN	B-NP	O
.	.	O	O

CHX	NN	B-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
Pilo	NNP	I-NP	O
injection	NN	I-NP	O
in	IN	B-PP	O
adult	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
Pilo	NNP	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
same	JJ	I-NP	O
drugs	NNS	I-NP	O
,	,	O	O
except	IN	B-PP	O
for	IN	B-PP	O
CHX	NN	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
between	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
brain	NN	B-NP	O
sections	NNS	I-NP	O
were	VBD	B-VP	O
processed	VBN	I-VP	O
for	IN	B-PP	O
GAP43	NN	B-NP	O
immunohistochemistry	NN	I-NP	O
.	.	O	O

Densitometry	NN	B-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
difference	NN	I-NP	O
regarding	VBG	B-VP	O
GAP43	NN	B-NP	O
-	HYPH	O	O
ir	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
IML	NNP	I-NP	O
between	IN	B-PP	O
Pilo	NNP	B-NP	O
,	,	O	O
CHX+Pilo	NNP	B-NP	O
,	,	O	O
and	CC	O	O
control	NN	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
results	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
width	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
GAP43	NN	I-NP	O
-	HYPH	B-NP	O
ir	NN	I-NP	O
band	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
IML	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
CHX+Pilo	NN	B-NP	O
and	CC	I-NP	O
control	NN	I-NP	O
animals	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
larger	JJR	I-NP	O
band	NN	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-PP	O
with	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
Pilo	NNP	I-NP	O
group	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
current	JJ	I-NP	O
finding	NN	I-NP	O
that	IN	B-SBAR	O
animals	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CHX+Pilo	NNP	I-NP	O
group	NN	I-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
GAP43	NN	I-NP	O
-	HYPH	I-NP	O
ir	NN	I-NP	O
band	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
IML	NN	I-NP	O
,	,	O	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
controls	NNS	B-NP	O
,	,	O	O
reinforces	VBZ	B-VP	O
prior	JJ	B-NP	O
data	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
MFS	NN	B-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
animals	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
GAP43	NN	B-NP	O
-	HYPH	B-NP	O
ir	NN	I-NP	O
present	JJ	B-ADJP	O
in	IN	B-PP	O
Pilo	NNP	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
thinning	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
band	NN	I-NP	O
to	TO	B-PP	O
a	DT	B-NP	O
very	RB	I-NP	O
narrow	JJ	I-NP	O
layer	NN	I-NP	O
just	RB	B-PP	O
above	IN	I-PP	O
the	DT	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
layer	NN	I-NP	O
that	WDT	B-NP	O
is	VBZ	B-VP	O
likely	JJ	B-ADJP	O
to	TO	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
hilar	JJ	B-NP	O
cell	NN	I-NP	O
projections	NNS	I-NP	O
that	WDT	B-NP	O
express	VBP	B-VP	O
GAP	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
antagonizes	VBZ	B-VP	O
caffeine	NN	B-NP	O
-	HYPH	B-ADJP	O
but	CC	B-NP	O
not	RB	I-NP	O
pentylenetetrazole	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
anxiogenic	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
and	CC	I-NP	O
caffeine	NN	I-NP	O
are	VBP	B-VP	O
widely	RB	I-VP	O
consumed	VBN	I-VP	O
licit	NN	B-NP	O
psychoactive	JJ	I-NP	O
drugs	NNS	I-NP	O
worldwide	RB	B-ADVP	O
.	.	O	O

Epidemiological	JJ	B-NP	O
studies	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
they	PRP	B-NP	O
were	VBD	B-VP	O
generally	RB	I-VP	O
used	VBN	I-VP	O
concurrently	RB	B-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
some	DT	B-NP	O
studies	NNS	I-NP	O
in	IN	B-PP	O
experimental	JJ	B-NP	O
animals	NNS	I-NP	O
indicate	VBP	B-VP	O
clear	JJ	B-NP	O
pharmacological	JJ	I-NP	O
interactions	NNS	I-NP	O
between	IN	B-PP	O
them	PRP	B-NP	O
,	,	O	O
no	DT	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
a	DT	B-NP	O
specific	JJ	I-NP	O
interaction	NN	I-NP	O
on	IN	B-PP	O
anxiety	NN	B-NP	B
responses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
investigates	VBZ	B-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
on	IN	B-PP	O
anxiety	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
caffeine	NN	B-NP	O
and	CC	O	O
another	DT	B-NP	O
anxiogenic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
pentylenetetrazole	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
elevated	JJ	I-NP	O
plus	CC	I-NP	O
-	HYPH	I-NP	O
maze	NN	I-NP	O
(	(	O	O
EPM	NN	B-NP	O
)	)	O	O
test	NN	B-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
on	IN	B-PP	O
anxiety	NN	B-NP	B
.	.	O	O

Adult	JJ	B-NP	O
male	JJ	I-NP	O
Swiss	JJ	I-NP	O
Webster	NN	I-NP	O
mice	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
given	VBN	I-VP	O
nicotine	NN	B-NP	O
or	CC	I-NP	O
saline	NN	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
caffeine	NN	B-NP	O
or	CC	I-NP	O
pentylenetetrazole	NN	I-NP	O
injections	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
min	NN	I-NP	O
,	,	O	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
closed	VBN	I-NP	O
-	HYPH	I-NP	O
arm	NN	I-NP	O
time	NN	I-NP	O
and	CC	O	O
entries	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
EPM	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
min	NN	I-NP	O
session	NN	I-NP	O
.	.	O	O

Locomotor	NN	B-NP	O
activity	NN	I-NP	O
was	VBD	B-VP	O
recorded	VBN	I-VP	O
for	IN	B-PP	O
individual	JJ	B-NP	O
groups	NNS	I-NP	O
by	IN	B-PP	O
using	VBG	B-VP	O
the	DT	B-NP	O
same	JJ	I-NP	O
treatment	NN	I-NP	O
protocol	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
EPM	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
itself	PRP	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
significant	JJ	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
EPM	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
caffeine	NN	B-NP	O
and	CC	I-NP	O
pentylenetetrazole	NN	I-NP	O
produced	VBD	B-VP	O
an	DT	B-NP	O
anxiogenic	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
apparent	JJ	B-ADJP	O
with	IN	B-PP	O
decreases	NNS	B-NP	O
in	IN	B-PP	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
arm	NN	I-NP	O
time	NN	I-NP	O
and	CC	I-NP	O
entry	NN	I-NP	O
.	.	O	O

Nicotine	NN	B-NP	O
pretreatment	NN	I-NP	O
blocked	VBD	B-VP	O
the	DT	B-NP	O
caffeine	NN	I-NP	O
-	HYPH	B-VP	O
but	CC	B-NP	O
not	RB	I-NP	O
pentylenetetrazole	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
each	DT	B-NP	O
drug	NN	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
combinations	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
produce	VB	I-VP	O
any	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
locomotor	NN	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
antagonistic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
nicotine	NN	B-NP	O
on	IN	B-PP	O
caffeine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anxiety	NN	I-NP	B
is	VBZ	B-VP	O
specific	JJ	B-ADJP	O
to	TO	B-PP	O
caffeine	NN	B-NP	O
,	,	O	O
instead	RB	B-PP	O
of	IN	I-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
anxiolytic	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
it	PRP	B-NP	O
may	MD	B-VP	O
extend	VB	I-VP	O
the	DT	B-NP	O
current	JJ	I-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
nicotine	NN	B-NP	O
and	CC	I-NP	O
caffeine	NN	I-NP	O
.	.	O	O

Long	JJ	B-NP	O
term	NN	I-NP	O
hormone	NN	I-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
perimenopausal	JJ	B-NP	O
and	CC	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
.	.	O	O

Hormone	NN	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
HT	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
controlling	VBG	B-VP	O
menopausal	JJ	B-NP	B
symptoms	NNS	I-NP	I
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
also	RB	I-VP	O
been	VBN	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
osteoporosis	NN	B-NP	B
and	CC	I-NP	O
dementia	NN	I-NP	B
in	IN	B-PP	O
older	JJR	B-NP	O
women	NNS	I-NP	O
but	CC	O	O
the	DT	B-NP	O
evidence	NN	I-NP	O
supporting	VBG	B-VP	O
its	PRP$	B-NP	O
use	NN	I-NP	O
for	IN	B-PP	O
these	DT	B-NP	O
indications	NNS	I-NP	O
is	VBZ	B-VP	O
largely	RB	B-ADJP	O
observational	JJ	I-ADJP	O
.	.	O	O

To	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
HT	NN	I-NP	O
on	IN	B-PP	O
mortality	NN	B-NP	O
,	,	O	O
heart	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
,	,	O	O
stroke	NN	B-NP	B
,	,	O	O
transient	JJ	B-NP	B
ischaemic	JJ	I-NP	I
attacks	NNS	I-NP	I
,	,	O	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
colorectal	JJ	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
ovarian	JJ	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
endometrial	JJ	B-NP	B
cancer	NN	I-NP	I
,	,	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
,	,	O	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
,	,	O	O
dementia	NN	B-NP	B
,	,	O	O
fractures	NNS	B-NP	B
and	CC	O	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
searched	VBD	B-VP	O
the	DT	B-NP	O
following	VBG	I-NP	O
databases	NNS	I-NP	O
up	RB	B-PP	O
to	TO	B-PP	O
November	NNP	B-NP	O
num	CD	I-NP	O
:	:	O	O
the	DT	B-NP	O
Cochrane	NNP	I-NP	O
Menstrual	NNP	I-NP	O
Disorders	NNP	I-NP	O
and	CC	O	O
Subfertility	NNP	B-NP	O
Group	NNP	I-NP	O
Trials	NNP	I-NP	O
Register	NNP	I-NP	O
,	,	O	O
Cochrane	NNP	B-NP	O
Central	NNP	I-NP	O
Register	NNP	I-NP	O
of	IN	B-PP	O
Controlled	NNP	B-NP	O
Trials	NNP	I-NP	O
(	(	O	O
CENTRAL	NN	B-NP	O
)	)	O	O
,	,	O	O
MEDLINE	NNP	B-NP	O
,	,	O	O
EMBASE	NNP	B-NP	O
,	,	O	O
Biological	NNP	B-NP	O
Abstracts	NNPS	I-NP	O
.	.	O	O

Relevant	JJ	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
indexed	JJ	I-NP	O
journals	NNS	I-NP	O
and	CC	O	O
conference	NN	B-NP	O
abstracts	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
searched	VBN	I-VP	O
.	.	O	O

Randomised	VBN	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
trials	NNS	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
(	(	O	O
oestrogens	NNS	B-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
progestogens	NNS	B-NP	O
)	)	O	O
versus	IN	B-PP	O
placebo	NN	B-NP	O
,	,	O	O
taken	VBN	B-VP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
by	IN	B-PP	O
perimenopausal	JJ	B-NP	O
or	CC	I-NP	O
postmenopausal	JJ	I-NP	O
women	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
RCTs	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
.	.	O	O

Trials	NNS	B-NP	O
were	VBD	B-VP	O
assessed	VBN	I-VP	O
for	IN	B-PP	O
quality	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
review	NN	I-NP	O
authors	NNS	I-NP	O
extracted	VBD	B-VP	O
data	NNS	B-NP	O
independently	RB	B-ADVP	O
.	.	O	O

They	PRP	B-NP	O
calculated	VBD	B-VP	O
risk	NN	B-NP	O
ratios	NNS	I-NP	O
for	IN	B-PP	O
dichotomous	JJ	B-NP	O
outcomes	NNS	I-NP	O
and	CC	O	O
weighted	VBD	B-VP	O
mean	JJ	B-NP	O
differences	NNS	I-NP	O
for	IN	B-PP	O
continuous	JJ	B-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
heterogeneity	NN	I-NP	O
precluded	VBD	B-VP	O
meta	JJ	B-NP	O
-	HYPH	I-NP	O
analysis	NN	I-NP	O
for	IN	B-PP	O
most	JJS	B-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

All	PDT	B-NP	O
the	DT	I-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
derived	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
biggest	JJS	I-NP	O
trials	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
relatively	RB	B-NP	O
healthy	JJ	I-NP	O
women	NNS	I-NP	O
,	,	O	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
or	CC	O	O
coronary	JJ	B-NP	O
event	NN	I-NP	O
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
s	NNS	I-NP	O
use	NN	I-NP	O
)	)	O	O
,	,	O	O
stroke	NN	B-NP	B
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
,	,	O	O
breast	NN	B-NP	B
cancer	NN	I-NP	I
(	(	O	O
after	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
)	)	O	O
and	CC	O	O
gallbladder	NN	B-NP	B
disease	NN	I-NP	I
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
oestrogen	NN	I-NP	O
-	HYPH	B-VP	O
only	RB	B-NP	O
HT	NN	I-NP	O
also	RB	B-ADVP	O
significantly	RB	B-VP	O
increased	VBD	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
stroke	NN	B-NP	B
and	CC	I-NP	O
gallbladder	NN	I-NP	B
disease	NN	I-NP	I
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
only	RB	I-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
were	VBD	B-VP	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
fractures	NNS	B-NP	B
and	CC	O	O
colon	NN	B-NP	B
cancer	NN	I-NP	I
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
relatively	RB	B-NP	O
healthy	JJ	I-NP	O
women	NNS	I-NP	O
over	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
taking	VBG	B-VP	O
continuous	JJ	B-NP	O
combined	VBN	I-NP	O
HT	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
statistically	RB	I-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
dementia	NN	B-NP	B
.	.	O	O

Among	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
,	,	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
.	.	O	O

No	DT	B-NP	O
trials	NNS	I-NP	O
focussed	VBD	B-VP	O
specifically	RB	B-ADVP	O
on	IN	B-PP	O
younger	JJR	B-NP	O
women	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
trial	NN	I-NP	O
analysed	VBN	B-VP	O
subgroups	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
relatively	RB	I-NP	O
healthy	JJ	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
women	NNS	I-NP	O
taking	VBG	B-VP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
taking	VBG	I-NP	O
oestrogen	NN	I-NP	O
-	HYPH	B-VP	O
only	RB	B-NP	O
HT	NN	I-NP	O
,	,	O	O
versus	IN	B-PP	O
similar	JJ	B-NP	O
-	HYPH	I-NP	O
sized	JJ	I-NP	O
placebo	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
only	RB	I-NP	O
significantly	RB	I-ADVP	O
increased	VBD	B-VP	O
risk	NN	B-NP	O
reported	VBN	B-VP	O
was	VBD	B-VP	O
for	IN	B-PP	O
venous	JJ	B-NP	B
thromboembolism	NN	I-NP	I
in	IN	B-PP	O
women	NNS	B-NP	O
taking	VBG	B-VP	O
combined	JJ	B-NP	O
continuous	JJ	I-NP	O
HT	NN	I-NP	O
;	:	O	O
their	PRP$	B-NP	O
absolute	JJ	I-NP	O
risk	NN	I-NP	O
remained	VBD	B-VP	O
very	RB	B-ADJP	O
low	JJ	I-ADJP	O
.	.	O	O

AUTHORS	NN	B-NP	O
CONCLUSIONS	NNS	I-NP	O
:	:	O	O
HT	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
indicated	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
routine	JJ	I-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
disease	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
need	VBP	B-VP	O
more	JJR	B-NP	O
evidence	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
HT	NN	B-NP	O
for	IN	B-PP	O
menopausal	JJ	B-NP	O
symptom	NN	I-NP	O
control	NN	I-NP	O
,	,	O	O
though	IN	B-SBAR	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
use	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
relatively	RB	B-ADJP	O
safe	JJ	I-ADJP	O
for	IN	B-PP	O
healthy	JJ	B-NP	O
younger	JJR	I-NP	O
women	NNS	I-NP	O
.	.	O	O

Drug	NN	B-NP	B
-	HYPH	B-PP	I
induced	VBN	B-NP	I
liver	NN	I-NP	I
injury	NN	I-NP	I
:	:	O	O
an	DT	B-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
incidences	NNS	I-NP	O
submitted	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
Spanish	JJ	I-NP	O
registry	NN	I-NP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

BACKGROUND	NN	B-NP	O
&	CC	I-NP	O
AIMS	NNS	I-NP	O
:	:	O	O
Progress	NNP	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
understanding	NN	I-NP	O
of	IN	B-PP	O
susceptibility	NN	B-NP	O
factors	NNS	I-NP	O
to	TO	B-PP	O
drug	NN	B-NP	B
-	HYPH	O	I
induced	VBN	B-NP	I
liver	NN	I-NP	I
injury	NN	I-NP	I
(	(	O	O
DILI	NN	B-NP	B
)	)	O	O
and	CC	O	O
outcome	NN	B-NP	O
predictability	NN	I-NP	O
are	VBP	B-VP	O
hampered	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
systematic	JJ	B-NP	O
programs	NNS	I-NP	O
to	TO	B-VP	O
detect	VB	I-VP	O
bona	NN	B-NP	O
fide	NN	I-NP	O
cases	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
cooperative	JJ	I-NP	O
network	NN	I-NP	O
was	VBD	B-VP	O
created	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
in	IN	B-PP	O
Spain	NNP	B-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
all	DT	B-NP	O
suspicions	NNS	I-NP	O
of	IN	B-PP	O
DILI	NN	B-NP	B
following	VBG	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
structured	VBN	I-NP	O
report	NN	I-NP	O
form	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
liver	NN	I-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
characterized	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
hepatocellular	JJ	B-NP	O
,	,	I-NP	O
cholestatic	JJ	I-NP	B
,	,	O	O
and	CC	O	O
mixed	JJ	B-NP	O
laboratory	NN	I-NP	O
criteria	NNS	I-NP	O
and	CC	B-PP	O
to	TO	B-PP	O
histologic	JJ	B-NP	O
criteria	NNS	I-NP	O
when	WRB	B-ADVP	O
available	JJ	B-ADJP	O
.	.	O	O

Further	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
causality	NN	B-NP	O
assessment	NN	I-NP	O
was	VBD	B-VP	O
centrally	RB	I-VP	O
performed	VBN	I-VP	O
.	.	O	O

Since	IN	B-PP	O
April	NNP	B-NP	O
num	CD	I-NP	O
to	TO	B-PP	O
August	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
out	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
submitted	VBN	I-NP	O
cases	NNS	I-NP	O
,	,	O	O
involving	VBG	B-VP	O
num	CD	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
were	VBD	B-VP	O
deemed	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
DILI	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
antiinfective	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
was	VBD	B-VP	O
the	DT	O	O
more	RBR	B-ADVP	O
frequently	RB	I-ADVP	O
incriminated	VBN	B-VP	O
,	,	O	O
amoxicillin	NN	B-NP	O
-	HYPH	I-NP	O
clavulanate	NN	I-NP	O
accounting	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
whole	JJ	I-NP	O
series	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
hepatocellular	JJ	I-NP	O
pattern	NN	I-NP	O
of	IN	B-PP	O
damage	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
,	,	O	O
was	VBD	B-VP	O
inversely	RB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
age	NN	B-NP	O
,	,	O	O
and	CC	O	O
had	VBD	B-VP	O
the	DT	B-NP	O
worst	JJS	I-NP	O
outcome	NN	I-NP	O
.	.	O	O

Indeed	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
and	CC	I-NP	O
death	NN	I-NP	O
in	IN	B-PP	O
this	DT	B-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
if	IN	B-SBAR	O
patients	NNS	B-NP	O
had	VBD	B-VP	O
jaundice	NN	B-NP	B
at	IN	B-PP	O
presentation	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
corresponding	VBG	I-NP	O
figure	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
nonjaundiced	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Factors	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
were	VBD	B-VP	O
female	JJ	B-NP	O
sex	NN	I-NP	O
,	,	O	O
hepatocellular	JJ	B-NP	O
damage	NN	I-NP	O
,	,	O	O
and	CC	O	O
higher	JJR	B-NP	O
baseline	NN	I-NP	O
plasma	NN	I-NP	O
bilirubin	NN	I-NP	O
value	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatocellular	JJ	I-NP	O
jaundice	NNS	I-NP	B
have	VBP	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
chance	NN	I-NP	O
of	IN	B-PP	O
progressing	VBG	B-VP	O
to	TO	B-PP	O
death	NN	B-NP	O
or	CC	I-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Amoxicillin	NN	B-NP	O
-	HYPH	I-NP	O
clavulanate	NN	I-NP	O
stands	VBZ	B-VP	O
out	RP	B-PRT	O
as	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
drug	NN	I-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
DILI	NN	B-NP	B
.	.	O	O

Morphological	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	I-NP	O
ribose	NN	B-NP	O
on	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	O	O
evoked	VBN	B-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
ribose	NN	I-NP	O
on	IN	B-PP	O
adriamycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
myocardiopathy	NN	I-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
was	VBD	B-VP	O
studied	VBN	I-VP	O
.	.	O	O

Adriamycin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
evoked	VBD	B-VP	O
fully	RB	I-VP	O
developed	VBN	I-VP	O
cardiac	JJ	B-NP	B
toxicity	NN	I-NP	I
.	.	O	O

D	NN	B-NP	O
-	HYPH	I-NP	O
ribose	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
multiple	JJ	I-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	O	O
kg	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
influence	VB	I-VP	O
ADR	NN	B-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

In	FW	B-NP	O
vivo	FW	I-NP	O
evidences	NNS	I-NP	O
suggesting	VBG	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
pathogenesis	NN	B-NP	O
of	IN	B-PP	O
vancomycin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
:	:	O	O
protection	NN	B-NP	O
by	IN	B-PP	O
erdosteine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aims	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
vancomycin	NN	B-NP	O
(	(	O	O
VCM	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
that	WDT	B-NP	O
promotes	VBZ	B-VP	O
production	NN	B-NP	O
of	IN	B-PP	O
reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
(	(	O	O
ROS	NNS	B-NP	O
)	)	O	O
and	CC	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
erdosteine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
expectorant	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
also	RB	B-ADVP	O
antioxidant	JJ	B-NP	O
properties	NNS	I-NP	O
,	,	O	O
on	IN	B-PP	O
kidney	NN	B-NP	O
tissue	NN	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
VCM	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
renal	JJ	I-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
sham	NN	B-NP	O
,	,	I-NP	O
VCM	NN	I-NP	O
and	CC	I-NP	O
VCM	NN	I-NP	O
plus	CC	I-NP	O
erdosteine	NN	I-NP	O
.	.	O	O

VCM	NN	B-NP	O
was	VBD	B-VP	O
administrated	VBN	I-VP	O
intraperitoneally	RB	B-ADVP	O
(	(	O	O
i.p.	RB	B-ADVP	O
)	)	O	O
with	IN	B-PP	O
200mgkg	NN	B-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Erdosteine	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
orally	RB	B-ADVP	O
.	.	O	O

VCM	NN	B-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
renal	JJ	B-NP	O
malondialdehyde	NN	I-NP	O
(	(	O	O
MDA	NN	B-NP	O
)	)	O	O
and	CC	O	O
urinary	JJ	B-NP	O
N	NN	I-NP	O
-	HYPH	B-NP	O
acetyl	NN	I-NP	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
d	NN	I-NP	O
-	HYPH	O	O
glucosaminidase	NN	B-NP	O
(	(	O	O
NAG	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	B
tubular	JJ	I-NP	I
injury	NN	I-NP	I
)	)	O	O
excretion	NN	B-NP	O
but	CC	O	O
decreased	VBD	B-VP	O
superoxide	NN	B-NP	O
dismutase	NN	I-NP	O
(	(	O	O
SOD	NN	B-NP	O
)	)	O	O
and	CC	O	O
catalase	NN	B-NP	O
(	(	O	O
CAT	NN	B-NP	O
)	)	O	O
activities	NNS	B-NP	O
.	.	O	O

Erdosteine	NN	B-NP	O
administration	NN	I-NP	O
with	IN	B-PP	O
VCM	NN	B-NP	O
injections	NNS	I-NP	O
caused	VBD	B-VP	O
significantly	RB	B-NP	O
decreased	VBN	I-NP	O
renal	JJ	I-NP	O
MDA	NN	I-NP	O
and	CC	O	O
urinary	JJ	B-NP	O
NAG	NN	I-NP	O
excretion	NN	I-NP	O
,	,	O	O
and	CC	O	O
increased	VBD	B-VP	O
SOD	NN	B-NP	O
activity	NN	I-NP	O
,	,	O	O
but	CC	O	O
not	RB	O	O
CAT	NN	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
renal	JJ	B-NP	O
tissue	NN	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
VCM	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Erdosteine	NN	B-NP	O
showed	VBD	B-VP	O
histopathological	JJ	B-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
VCM	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephrotoxicity	NN	I-NP	B
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
dilatation	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
lumens	NNS	I-NP	O
,	,	O	O
extensive	JJ	B-NP	O
epithelial	JJ	I-NP	O
cell	NN	I-NP	O
vacuolization	NN	I-NP	O
,	,	O	O
atrophy	NN	B-NP	B
,	,	O	O
desquamation	NN	B-NP	B
,	,	O	O
and	CC	O	O
necrosis	NN	B-NP	B
in	IN	B-PP	O
VCM	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
more	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
erdosteine	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Erdosteine	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
damage	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
concluded	VBN	I-VP	O
that	IN	B-SBAR	O
oxidative	JJ	B-NP	O
tubular	JJ	I-NP	O
damage	NN	I-NP	O
plays	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
VCM	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
nephrotoxicity	NN	I-NP	B
and	CC	O	O
the	DT	B-NP	O
modulation	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
with	IN	B-PP	O
erdosteine	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
VCM	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
kidney	NN	I-NP	B
damage	NN	I-NP	I
both	CC	B-PP	O
at	IN	B-PP	O
the	DT	B-NP	O
biochemical	JJ	I-NP	O
and	CC	I-NP	O
histological	JJ	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Does	VBZ	O	O
domperidone	NN	B-NP	O
potentiate	NN	I-NP	O
mirtazapine	NN	I-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
restless	JJ	I-NP	B
legs	NNS	I-NP	I
syndrome	NN	I-NP	I
?	.	O	O
There	EX	B-NP	O
is	VBZ	B-VP	O
now	RB	B-ADVP	O
evidence	NN	B-NP	O
to	TO	B-VP	O
suggest	VB	I-VP	O
a	DT	B-NP	O
central	JJ	I-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
dopaminergic	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
restless	JJ	B-NP	B
legs	NNS	I-NP	I
syndrome	NN	I-NP	I
(	(	O	O
RLS	NN	B-NP	B
)	)	O	O
.	.	O	O

For	IN	B-PP	O
example	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
RLS	NN	B-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
dramatically	RB	I-VP	O
improved	VBN	I-VP	O
by	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	I-NP	O
dopamine	NN	I-NP	O
agonists	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
central	JJ	B-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
can	MD	B-VP	O
induce	VB	I-VP	O
or	CC	I-VP	O
aggravate	VB	I-VP	O
RLS	NN	B-NP	B
symptoms	NNS	I-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
no	DT	B-NP	O
previous	JJ	I-NP	O
report	NN	I-NP	O
regarding	VBG	B-VP	O
whether	IN	B-SBAR	O
domperidone	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
peripheral	JJ	I-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
can	MD	B-VP	O
also	RB	I-VP	O
induce	VB	I-VP	O
or	CC	I-VP	O
aggravate	VB	I-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
RLS	NN	B-NP	B
.	.	O	O

Mirtazapine	NNP	B-NP	O
,	,	O	O
the	DT	B-NP	O
first	JJ	I-NP	O
noradrenergic	JJ	I-NP	O
and	CC	I-NP	O
specific	JJ	I-NP	O
serotonergic	JJ	I-NP	O
antidepressant	NN	I-NP	O
(	(	O	O
NaSSA	NN	B-NP	O
)	)	O	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
RLS	NN	B-NP	B
in	IN	B-PP	O
several	JJ	B-NP	O
recent	JJ	I-NP	O
publications	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
report	VBP	B-VP	O
here	RB	B-ADVP	O
a	DT	B-NP	O
depressed	JJ	I-NP	O
patient	NN	I-NP	O
comorbid	NN	I-NP	O
with	IN	B-PP	O
postprandial	JJ	B-NP	B
dyspepsia	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
RLS	NN	B-NP	B
after	IN	B-SBAR	O
mirtazapine	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
added	VBN	I-VP	O
to	TO	B-PP	O
his	PRP$	B-NP	O
domperidone	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
patient	NN	I-NP	O
started	VBD	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
symptoms	NNS	B-NP	O
of	IN	B-PP	O
RLS	NN	B-NP	B
only	RB	B-ADVP	O
after	IN	B-SBAR	O
he	PRP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
mirtazapine	NN	B-NP	O
,	,	O	O
and	CC	O	O
his	PRP$	B-NP	O
RLS	NN	I-NP	B
symptoms	NNS	I-NP	O
resolved	VBD	B-VP	O
completely	RB	B-ADVP	O
upon	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
his	PRP$	B-NP	O
mirtazapine	NN	I-NP	O
.	.	O	O

Such	PDT	B-NP	O
a	DT	I-NP	O
temporal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
mirtazapine	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
RLS	NN	B-NP	B
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
support	VB	I-VP	O
a	DT	B-NP	O
potentiating	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
domperione	NN	B-NP	O
on	IN	B-PP	O
mirtazapine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
RLS	NN	I-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
physicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
mirtazapine	NN	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
RLS	NN	B-NP	B
in	IN	B-PP	O
some	DT	B-NP	O
individuals	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
those	DT	B-NP	O
receiving	VBG	I-NP	O
concomitant	JJ	I-NP	O
dopamine	NN	I-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
antagonists	NNS	I-NP	O
.	.	O	O

Antiandrogenic	JJ	B-NP	O
therapy	NN	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
coronary	JJ	B-NP	B
arterial	JJ	I-NP	I
disease	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
study	VB	I-VP	O
the	DT	B-NP	O
change	NN	I-NP	O
of	IN	B-PP	O
lipid	NN	B-NP	O
metabolism	NN	I-NP	O
by	IN	B-PP	O
antiandrogen	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
prostate	NN	B-NP	B
cancer	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
the	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
plasma	NN	B-NP	O
cholesterols	NNS	I-NP	O
(	(	O	O
C	NN	B-NP	O
)	)	O	O
,	,	O	O
triglycerides	NNS	B-NP	O
(	(	O	O
TG	NN	B-NP	O
)	)	O	O
,	,	O	O
lipoproteins	NNS	B-NP	O
(	(	O	O
LP	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
apolipoproteins	NNS	B-NP	O
(	(	O	O
Apo	NN	B-NP	O
)	)	O	O
B	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
A	NN	I-NP	O
-	HYPH	I-NP	O
I	NN	I-NP	O
,	,	O	O
and	CC	O	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
pro	JJ	I-NP	O
fi	NN	I-NP	O
les	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
of	IN	B-PP	O
mean	JJ	B-NP	O
age	NN	I-NP	O
num	CD	B-NP	O
years	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
risk	NN	I-NP	O
prostate	NN	I-NP	B
cancer	NN	I-NP	I
(	(	O	O
stage	NN	B-NP	O
:	:	O	O
T1cN0M0	NN	B-NP	O
,	,	O	O
Gleason	NNP	B-NP	O
score	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
cyproterone	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
CPA	NN	B-NP	O
)	)	O	O
without	IN	B-PP	O
surgical	JJ	B-NP	O
management	NN	I-NP	O
or	CC	I-NP	O
radiation	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Significant	JJ	B-NP	O
decreases	NNS	I-NP	O
of	IN	B-PP	O
HDL	NN	B-NP	O
-	HYPH	I-NP	O
C	NN	I-NP	O
,	,	O	O
Apo	IN	B-PP	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	O	O
Apo	NNP	B-NP	O
A	NNP	I-NP	O
-	:	O	O
num	CD	B-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
triglyceride	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
VLDL	NN	B-NP	O
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
CPA	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
on	IN	B-PP	O
CPA	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
out	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
coronary	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Ischaemic	JJ	B-NP	O
coronary	JJ	I-NP	B
arteriosclerosis	NN	I-NP	I
with	IN	B-PP	O
an	DT	B-NP	O
incidence	NN	I-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
as	IN	B-SBAR	O
caused	VBN	B-VP	O
by	IN	B-PP	O
prolonged	VBN	B-NP	O
CPA	NN	I-NP	O
therapy	NN	I-NP	O
is	VBZ	B-VP	O
mediated	VBN	I-VP	O
through	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
HDL	NN	B-NP	O
cholesterol	NN	I-NP	O
,	,	O	O
Apo	IN	B-PP	O
A	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
and	CC	O	O
Apo	NNP	B-NP	O
A	NNP	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
pro	JJ	I-NP	O
fi	NN	I-NP	O
les	NNS	I-NP	O
,	,	O	O
other	JJ	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
well	RB	I-NP	O
-	HYPH	I-NP	O
known	VBN	I-NP	O
hyperglyceridemic	JJ	I-NP	B
effect	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
estrogen	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
Fluorouracil	NN	I-NP	O
cardiotoxicity	NN	I-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
fluoro	SYM	O	O
-	HYPH	O	O
beta	SYM	B-NP	O
-	HYPH	B-VP	O
alanine	NN	B-NP	O
.	.	O	O

Cardiotoxicity	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
occurring	VBG	B-VP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
treatment	NN	B-NP	O
for	IN	B-PP	O
malignancies	NNS	B-NP	B
.	.	O	O

We	PRP	B-NP	O
herein	RB	B-ADVP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
,	,	O	O
in	IN	B-PP	O
whom	WP	B-NP	O
a	DT	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
alpha	SYM	B-NP	O
-	HYPH	O	O
fluoro	SYM	O	O
-	HYPH	O	O
beta	SYM	O	O
-	HYPH	O	O
alanine	NN	B-NP	O
(	(	O	O
FBAL	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
,	,	O	O
who	WP	B-NP	O
had	VBD	B-VP	O
unresectable	JJ	B-NP	O
colon	NN	I-NP	B
cancer	NN	I-NP	I
metastases	NNS	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	I-NP	O
lung	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
us	PRP	B-NP	O
for	IN	B-PP	O
chemotherapy	NN	B-NP	O
from	IN	B-PP	O
an	DT	B-NP	O
affiliated	JJ	I-NP	O
hospital	NN	I-NP	O
;	:	O	O
he	PRP	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
cardiac	JJ	I-NP	O
history	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
continuous	JJ	I-NP	O
intravenous	JJ	I-NP	O
infusion	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
,	,	O	O
during	IN	B-PP	O
which	WDT	B-NP	O
precordial	JJ	B-NP	B
pain	NN	I-NP	I
with	IN	B-PP	O
right	JJ	B-NP	B
bundle	NN	I-NP	I
branch	NN	I-NP	I
block	NN	I-NP	I
occurred	VBD	B-VP	O
concomitantly	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
serum	NN	I-NP	O
FBAL	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

Both	CC	O	O
the	DT	B-NP	O
precordial	JJ	I-NP	B
pain	NN	I-NP	I
and	CC	O	O
the	DT	B-NP	O
electrocardiographic	JJ	I-NP	O
changes	NNS	I-NP	O
disappeared	VBD	B-VP	O
spontaneously	RB	B-ADVP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
discontinuation	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
the	DT	B-NP	O
precordial	JJ	I-NP	B
pain	NN	I-NP	I
in	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
was	VBD	B-VP	O
abandoned	VBN	I-VP	O
.	.	O	O

Instead	RB	B-ADVP	O
,	,	O	O
oral	JJ	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
(	(	O	O
a	DT	B-NP	O
derivative	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
,	,	O	O
at	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
twice	RB	B-ADVP	O
a	DT	B-NP	O
week	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
instituted	VBN	I-VP	O
,	,	O	O
because	IN	B-SBAR	O
S	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
inhibitory	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
dihydropyrimidine	NN	B-NP	O
dehydrogenase	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
catalyzes	VBZ	B-VP	O
the	DT	B-NP	O
degradative	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
into	IN	B-PP	O
FBAL	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
serum	NN	I-NP	O
FBAL	NN	I-NP	O
concentration	NN	I-NP	O
subsequently	RB	B-ADVP	O
decreased	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
same	JJ	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
value	NN	I-NP	O
measured	VBN	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
day	NN	I-NP	O
of	IN	B-PP	O
S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
administration	NN	I-NP	O
.	.	O	O

Thereafter	RB	B-ADVP	O
,	,	O	O
no	DT	B-NP	O
cardiac	JJ	I-NP	B
symptoms	NNS	I-NP	I
were	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
achieved	VBD	B-VP	O
a	DT	B-NP	O
partial	JJ	I-NP	O
response	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
initiation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
S	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
experience	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
,	,	O	O
together	RB	B-ADVP	O
with	IN	B-PP	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
literature	NN	I-NP	O
,	,	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
FBAL	NN	B-NP	O
is	VBZ	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

S	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
safely	RB	B-ADVP	O
to	TO	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
influence	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
interval	NN	I-NP	O
between	IN	B-PP	O
monoHER	NN	B-NP	O
and	CC	I-NP	O
doxorubicin	NN	I-NP	O
administration	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
protection	NN	I-NP	O
against	IN	B-PP	O
doxorubicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
.	.	O	O

Despite	IN	B-PP	O
its	PRP$	B-NP	O
well	NN	I-NP	O
-	HYPH	B-VP	O
known	VBN	I-VP	O
cardiotoxicity	NN	B-NP	B
,	,	O	O
the	DT	B-NP	O
anthracyclin	NN	I-NP	O
doxorubicin	NN	I-NP	O
(	(	O	O
DOX	NN	B-NP	O
)	)	O	O
continues	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
and	CC	I-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
chemotherapeutic	JJ	I-NP	O
agent	NN	I-NP	O
.	.	O	O

DOX	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
damage	NN	I-NP	I
presumably	RB	B-ADVP	O
results	VBZ	B-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
free	JJ	B-NP	O
radicals	NNS	I-NP	O
by	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

Reactive	JJ	B-NP	O
oxygen	NN	I-NP	O
species	NNS	I-NP	O
particularly	RB	B-ADVP	O
affect	VBP	B-VP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
myocytes	NNS	I-NP	O
because	IN	B-SBAR	O
these	DT	B-NP	O
cells	NNS	I-NP	O
seem	VBP	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
relatively	RB	I-NP	O
poor	JJ	I-NP	O
antioxidant	JJ	I-NP	O
defense	NN	I-NP	O
system	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
semisynthetic	JJ	I-NP	O
flavonoid	NN	I-NP	O
monohydroxyethylrutoside	NN	I-NP	O
(	(	O	O
monoHER	NN	B-NP	O
)	)	O	O
showed	VBD	B-VP	O
cardioprotection	NN	B-NP	O
against	IN	B-PP	O
DOX	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiotoxicity	NN	I-NP	B
through	IN	B-PP	O
its	PRP$	B-NP	O
radical	JJ	I-NP	O
scavenging	NN	I-NP	O
and	CC	I-NP	O
iron	NN	I-NP	O
chelating	NN	I-NP	O
properties	NNS	I-NP	O
.	.	O	O

Because	IN	B-PP	O
of	IN	I-PP	O
the	DT	B-NP	O
relatively	RB	I-NP	O
short	JJ	I-NP	O
final	JJ	I-NP	O
half	JJ	I-NP	O
-	HYPH	I-NP	O
life	NN	I-NP	O
of	IN	B-PP	O
monoHER	NN	B-NP	O
(	(	O	O
about	RB	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
)	)	O	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
expected	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
time	NN	I-NP	O
interval	NN	I-NP	O
between	IN	B-PP	O
monoHER	NN	B-NP	O
and	CC	I-NP	O
DOX	NN	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
of	IN	B-PP	O
influence	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
cardioprotective	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
monoHER	NN	B-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
this	DT	B-NP	O
possible	JJ	I-NP	O
effect	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
groups	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
BALB	NN	I-NP	O
/	SYM	B-NP	O
c	NN	I-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
,	,	O	O
DOX	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
DOX	NN	B-NP	O
preceded	VBN	B-VP	O
by	IN	B-PP	O
monoHER	NN	B-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
treatment	NN	I-NP	O
period	NN	I-NP	O
and	CC	O	O
additional	JJ	B-NP	O
observation	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
mice	NNS	I-NP	O
were	VBD	B-VP	O
sacrificed	VBN	I-VP	O
.	.	O	O

Their	PRP$	B-NP	O
cardiac	JJ	I-NP	O
tissues	NNS	I-NP	O
were	VBD	B-VP	O
processed	VBN	I-VP	O
for	IN	B-PP	O
light	JJ	B-NP	O
microscopy	NN	I-NP	O
,	,	O	O
after	IN	B-PP	O
which	WDT	B-NP	O
cardiomyocyte	NN	B-NP	B
damage	NN	I-NP	I
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
Billingham	NNP	B-NP	O
(	(	O	O
in	IN	B-PP	O
Cancer	NNP	B-NP	B
Treat	NNP	I-NP	O
Rep	NNP	I-NP	O
num	CD	I-NP	O
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Microscopic	JJ	B-NP	O
evaluation	NN	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
treatment	NN	B-NP	O
with	IN	B-PP	O
DOX	NN	B-NP	O
alone	RB	B-ADVP	O
induced	VBD	B-VP	O
significant	JJ	B-NP	O
cardiac	JJ	I-NP	B
damage	NN	I-NP	I
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
saline	NN	I-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
damaged	VBN	B-NP	O
cardiomyocytes	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
higher	JJR	B-ADJP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DOX	NN	B-NP	O
alone	RB	B-ADVP	O
than	IN	B-PP	O
that	DT	B-NP	O
in	IN	B-PP	O
animals	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
ratio	NN	I-NP	O
of	IN	B-PP	O
aberrant	JJ	B-NP	O
cardiomyocytes	NNS	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
DOX	NN	B-NP	O
preceded	VBN	B-VP	O
by	IN	B-PP	O
monoHER	NN	B-NP	O
and	CC	O	O
those	DT	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
ranged	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
by	IN	B-PP	O
adding	VBG	B-VP	O
monoHER	NN	B-NP	O
before	IN	B-SBAR	O
DOX	NN	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fold	JJ	I-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
abnormal	JJ	B-NP	O
cardiomyocytes	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
protective	JJ	I-NP	O
effect	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
depend	VB	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
interval	NN	I-NP	O
between	IN	B-PP	O
monoHER	NN	B-NP	O
and	CC	I-NP	O
DOX	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
in	IN	B-PP	O
an	DT	B-NP	O
outpatient	NN	I-NP	O
clinical	JJ	I-NP	O
setting	VBG	I-NP	O
monoHER	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
administered	VBN	I-VP	O
shortly	RB	B-ADVP	O
before	IN	B-PP	O
DOX	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
bepridil	NN	B-NP	O
administration	NN	I-NP	O
for	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
and	CC	I-NP	I
flutter	NN	I-NP	I
.	.	O	O

Bepridil	NN	B-NP	O
hydrochloride	NN	I-NP	O
(	(	O	O
Bpd	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
attracted	VBN	I-VP	O
attention	NN	B-NP	O
as	IN	B-PP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
(	(	O	O
AF	NN	B-NP	B
)	)	O	O
and	CC	O	O
atrial	JJ	B-NP	B
flutter	NN	I-NP	I
(	(	O	O
AFL	NN	B-NP	B
)	)	O	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
serious	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
torsade	FW	B-NP	B
de	FW	I-NP	I
pointes	FW	I-NP	I
(	(	O	O
Tdp	NN	B-NP	B
)	)	O	O
,	,	O	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
Bpd	NN	B-NP	O
requiring	VBG	B-VP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Bpd	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
comprising	VBG	B-VP	O
num	CD	B-NP	O
AF	NN	I-NP	B
and	CC	I-NP	O
num	CD	I-NP	O
AFL	NN	I-NP	B
cases	NNS	I-NP	O
.	.	O	O

Mean	NNP	B-NP	O
left	VBD	B-VP	O
ventricular	JJ	B-NP	O
ejection	NN	I-NP	O
fraction	NN	I-NP	O
and	CC	O	O
atrial	JJ	B-NP	O
dimension	NN	I-NP	O
(	(	O	O
LAD	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mm	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Adverse	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
during	IN	B-PP	O
an	DT	B-NP	O
average	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
marked	JJ	B-NP	O
QT	NN	I-NP	B
prolongation	NN	I-NP	I
greater	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
s	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
bradycardia	NN	B-NP	B
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
beats	NNS	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
dizziness	NN	B-NP	B
and	CC	O	O
general	JJ	B-NP	O
fatigue	NN	I-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
each	DT	B-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
,	,	O	O
Tdp	NN	B-NP	B
occurred	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
major	JJ	I-NP	O
triggering	NN	I-NP	O
factors	NNS	I-NP	O
of	IN	B-PP	O
Tdp	NN	B-NP	B
were	VBD	B-VP	O
hypokalemia	NN	B-NP	B
and	CC	O	O
sudden	JJ	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
backgrounds	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
and	CC	B-PP	O
without	IN	B-PP	O
Tdp	NN	B-NP	B
other	JJ	B-ADJP	O
than	IN	B-PP	O
LAD	NN	B-NP	O
and	CC	I-NP	O
age	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
larger	JJR	B-ADJP	O
and	CC	I-ADJP	O
older	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
Tdp	NN	B-NP	B
.	.	O	O

Careful	JJ	B-NP	O
observation	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
potassium	NN	I-NP	O
concentration	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
ECG	NN	I-NP	O
should	MD	B-VP	O
always	RB	I-VP	O
be	VB	I-VP	O
done	VBN	I-VP	O
during	IN	B-PP	O
Bpd	NN	B-NP	O
administration	NN	I-NP	O
,	,	O	O
particularly	RB	B-ADVP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Enhanced	VBN	B-NP	O
isoproterenol	NN	I-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
hypertrophy	NN	I-NP	I
in	IN	B-PP	O
transgenic	JJ	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
brain	NN	I-NP	O
angiotensinogen	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
previously	RB	I-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
permanent	JJ	I-NP	O
deficiency	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
(	(	O	O
RAS	NN	B-NP	O
)	)	O	O
may	MD	B-VP	O
increase	VB	I-VP	O
the	DT	B-NP	O
sensitivity	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
baroreflex	NN	I-NP	O
control	NN	I-NP	O
of	IN	B-PP	O
heart	NN	B-NP	O
rate	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
at	IN	B-PP	O
studying	VBG	B-VP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
RAS	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
cardiac	JJ	I-NP	O
reactivity	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
adrenoceptor	NN	I-NP	O
(	(	O	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
AR	NN	I-NP	O
)	)	O	O
agonist	NN	B-NP	O
isoproterenol	NN	I-NP	O
(	(	O	O
Iso	NN	B-NP	O
)	)	O	O
.	.	O	O

Transgenic	JJ	B-NP	O
rats	NNS	I-NP	O
with	IN	B-PP	O
low	JJ	B-NP	O
brain	NN	I-NP	O
angiotensinogen	NN	I-NP	O
(	(	O	O
TGR	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
used	VBN	I-VP	O
.	.	O	O

In	IN	B-PP	O
isolated	VBN	B-NP	O
hearts	NNS	I-NP	O
,	,	O	O
Iso	NNP	B-NP	O
induced	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
greater	JJR	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
left	JJ	B-NP	O
ventricular	JJ	I-NP	O
(	(	O	O
LV	NN	B-NP	O
)	)	O	O
pressure	NN	B-NP	O
and	CC	O	O
maximal	JJ	B-NP	O
contraction	NN	I-NP	O
(	(	O	O
+dP	NN	B-NP	O
/	SYM	O	O
dt	NN	B-NP	O
(	(	O	O
max	NN	B-NP	O
)	)	O	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
TGR	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
Sprague	NNP	I-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
(	(	O	O
SD	NNP	B-NP	O
)	)	O	O
rats	NNS	B-NP	O
.	.	O	O

LV	NN	B-NP	B
hypertrophy	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
Iso	NN	B-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
TGR	NN	B-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
SD	NNP	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
greater	JJR	I-NP	O
LV	NN	I-NP	B
hypertrophy	NN	I-NP	I
in	IN	B-PP	O
TGR	NN	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
more	RBR	B-NP	O
pronounced	JJ	I-NP	O
downregulation	NN	I-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	I-NP	O
AR	NN	I-NP	O
and	CC	I-NP	O
upregulation	NN	I-NP	O
of	IN	B-PP	O
LV	NN	B-NP	O
beta	SYM	O	O
-	HYPH	O	O
AR	NN	B-NP	O
kinase	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
mRNA	NN	I-NP	O
levels	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
SD	NNP	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
HR	NN	B-NP	O
)	)	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
AR	NN	I-NP	O
antagonist	NN	I-NP	O
metoprolol	NN	I-NP	O
in	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
attenuated	VBN	I-VP	O
in	IN	B-PP	O
TGR	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
SD	NN	B-NP	O
rats	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
parasympathetic	JJ	B-NP	O
blockade	NN	I-NP	O
by	IN	B-PP	O
atropine	NN	B-NP	O
on	IN	B-PP	O
HR	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
in	IN	B-PP	O
both	DT	B-NP	O
strains	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
TGR	NN	B-NP	O
are	VBP	B-VP	O
more	RBR	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
beta	SYM	B-NP	O
-	HYPH	O	O
AR	NN	B-NP	O
agonist	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
inotropic	JJ	I-NP	I
response	NN	I-NP	O
and	CC	I-NP	O
hypertrophy	NN	I-NP	B
,	,	O	O
possibly	RB	B-ADJP	O
due	JJ	I-ADJP	O
to	TO	B-PP	O
chronically	RB	B-NP	O
low	JJ	I-NP	O
sympathetic	JJ	I-NP	O
outflow	NN	I-NP	O
directed	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
heart	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
long	JJ	I-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
in	IN	B-PP	O
injection	NN	B-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
receiving	VBG	B-VP	O
methadone	NN	B-NP	O
:	:	O	O
high	JJ	B-NP	O
frequency	NN	I-NP	O
in	IN	B-PP	O
hospitalized	VBN	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
risk	NN	B-NP	O
factors	NNS	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
long	JJ	I-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
drug	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

Methadone	NN	B-NP	O
prolongs	VBZ	B-VP	O
the	DT	B-NP	O
QT	NN	I-NP	O
interval	NN	I-NP	O
in	FW	B-ADVP	O
vitro	FW	I-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
inpatient	NN	I-NP	O
setting	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
QT	NN	B-NP	B
interval	NN	I-NP	I
prolongation	NN	I-NP	I
with	IN	B-PP	O
methadone	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
dose	NN	I-NP	O
dependence	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
importance	NN	I-NP	O
of	IN	B-PP	O
cofactors	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
remain	VBP	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
performed	VBD	B-VP	O
a	DT	B-NP	O
systematic	JJ	I-NP	O
,	,	I-NP	O
retrospective	JJ	I-NP	O
study	NN	I-NP	O
comparing	VBG	B-VP	O
active	JJ	B-NP	O
or	CC	I-NP	O
former	JJ	I-NP	O
intravenous	JJ	I-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
receiving	VBG	B-VP	O
methadone	NN	B-NP	O
and	CC	O	O
those	DT	B-NP	O
not	RB	B-VP	O
receiving	VBG	I-VP	O
methadone	NN	B-NP	O
among	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
hospitalized	VBD	B-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
period	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
tertiary	JJ	I-NP	O
care	NN	I-NP	O
hospital	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
methadone	NN	B-NP	O
fulfilled	VBD	B-VP	O
the	DT	B-NP	O
inclusion	NN	I-NP	O
criteria	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
injection	NN	I-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
not	RB	B-VP	O
receiving	VBG	I-VP	O
methadone	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
methadone	NN	B-NP	O
dose	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
demographic	JJ	I-NP	O
,	,	I-NP	O
biological	JJ	I-NP	O
,	,	O	O
and	CC	O	O
pharmacological	JJ	B-NP	O
variables	NNS	I-NP	O
were	VBD	B-VP	O
considered	VBN	I-VP	O
as	IN	B-PP	O
potential	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
for	IN	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
.	.	O	O

Among	IN	B-PP	O
num	CD	B-NP	O
methadone	NN	I-NP	O
maintenance	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
QTc	NN	B-NP	O
prolongation	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
second	JJ	I-NP	O
or	CC	I-NP	O
longer	JJR	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
control	NN	I-NP	O
subjects	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
methadone	NN	I-NP	O
group	NN	I-NP	O
presented	VBD	B-VP	O
torsades	NNS	B-NP	B
de	IN	B-PP	I
pointes	NNS	B-NP	I
.	.	O	O

QTc	NN	B-NP	O
length	NN	I-NP	O
was	VBD	B-VP	O
weakly	RB	B-VP	O
but	CC	I-VP	O
significantly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
methadone	NN	B-NP	O
daily	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Multivariate	JJ	B-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
allowed	VBD	B-VP	O
attribution	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
QTc	NN	B-NP	O
variability	NN	I-NP	O
to	TO	B-PP	O
methadone	NN	B-NP	O
dose	NN	I-NP	O
,	,	O	O
cytochrome	NN	B-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
3A4	NN	I-NP	O
drug	NN	I-NP	O
-	HYPH	B-NP	O
drug	NN	I-NP	O
interactions	NNS	I-NP	O
,	,	O	O
hypokalemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
altered	VBD	B-VP	O
liver	NN	B-NP	O
function	NN	I-NP	O
.	.	O	O

QT	NN	B-NP	B
interval	NN	I-NP	I
prolongation	NN	I-NP	I
in	IN	B-PP	O
methadone	NN	B-NP	O
maintenance	NN	I-NP	O
patients	NNS	I-NP	O
hospitalized	VBN	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
tertiary	JJ	I-NP	O
care	NN	I-NP	O
center	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
frequent	JJ	I-NP	O
finding	NN	I-NP	O
.	.	O	O

Methadone	NN	B-NP	O
dose	NN	I-NP	O
,	,	O	O
presence	NN	B-NP	O
of	IN	B-PP	O
cytochrome	NN	B-NP	O
P	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
3A4	NN	I-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
potassium	NN	B-NP	O
level	NN	I-NP	O
,	,	O	O
and	CC	O	O
liver	NN	B-NP	O
function	NN	I-NP	O
contribute	VBP	B-VP	O
to	TO	B-PP	O
QT	NN	B-NP	B
prolongation	NN	I-NP	I
.	.	O	O

Long	JJ	B-NP	B
QT	NN	I-NP	I
syndrome	NN	I-NP	I
can	MD	B-VP	O
occur	VB	I-VP	O
with	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
methadone	NN	B-NP	O
.	.	O	O

Mechanisms	NNS	B-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
deficiency	NN	B-NP	O
:	:	O	O
focus	NN	B-NP	O
on	IN	B-PP	O
venous	JJ	B-NP	O
function	NN	I-NP	O
.	.	O	O

Loss	NN	B-NP	O
of	IN	B-PP	O
endothelial	JJ	B-NP	O
cell	NN	I-NP	O
-	HYPH	O	O
derived	VBN	B-VP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
hypertension	NN	B-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
hallmark	NN	I-NP	O
of	IN	B-PP	O
arterial	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Experimental	JJ	B-NP	O
hypertension	NN	I-NP	B
created	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
removal	NN	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
involves	VBZ	B-VP	O
mechanisms	NNS	B-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
decreased	VBN	B-NP	O
arterial	JJ	I-NP	O
vasodilator	NN	I-NP	O
activity	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
include	VBP	B-VP	O
augmented	JJ	B-NP	O
endothelin	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
(	(	O	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	O	O
)	)	O	O
release	NN	B-NP	O
,	,	O	O
increased	VBD	B-VP	O
sympathetic	JJ	B-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
activity	NN	I-NP	O
,	,	O	O
and	CC	O	O
elevated	VBD	B-VP	O
tissue	NN	B-NP	O
oxidative	JJ	I-NP	O
stress	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
increased	VBN	B-NP	O
venous	JJ	I-NP	O
smooth	JJ	I-NP	O
muscle	NN	I-NP	O
(	(	O	O
venomotor	NN	B-NP	O
)	)	O	O
tone	NN	B-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
Nomega	NNP	B-NP	O
-	HYPH	O	O
nitro	AFX	O	O
-	HYPH	B-NP	O
L	NN	I-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
(	(	O	O
LNNA	NN	B-NP	O
)	)	O	O
hypertension	NN	B-NP	B
through	IN	B-PP	O
these	DT	B-NP	O
mechanisms	NNS	I-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
NO	NN	I-NP	O
synthase	NN	I-NP	O
inhibitor	NN	I-NP	O
LNNA	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
in	IN	B-PP	O
drinking	NN	B-NP	O
water	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Mean	JJ	B-NP	O
arterial	JJ	I-NP	O
pressure	NN	I-NP	O
of	IN	B-PP	O
conscious	JJ	B-NP	O
rats	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
in	IN	B-PP	O
LNNA	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Carotid	JJ	B-NP	O
arteries	NNS	I-NP	O
and	CC	O	O
vena	NN	B-NP	O
cava	NN	I-NP	O
were	VBD	B-VP	O
removed	VBN	I-VP	O
for	IN	B-PP	O
measurement	NN	B-NP	O
of	IN	B-PP	O
isometric	JJ	B-NP	O
contraction	NN	I-NP	O
.	.	O	O

Maximal	JJ	B-NP	O
contraction	NN	I-NP	O
to	TO	B-PP	O
norepinephrine	NN	B-NP	O
was	VBD	B-VP	O
modestly	RB	I-VP	O
reduced	VBN	I-VP	O
in	IN	B-PP	O
arteries	NNS	B-NP	O
from	IN	B-PP	O
LNNA	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
whereas	IN	B-PP	O
the	DT	B-NP	O
maximum	JJ	I-NP	O
contraction	NN	I-NP	O
to	TO	B-PP	O
ET	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
reduced	VBN	I-VP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
control	NN	I-NP	O
)	)	O	O
.	.	O	O

Maximum	JJ	B-NP	O
contraction	NN	I-NP	O
of	IN	B-PP	O
vena	NN	B-NP	O
cava	NN	I-NP	O
to	TO	B-PP	O
norepinephrine	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
control	NN	I-NP	O
)	)	O	O
also	RB	B-ADVP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
but	CC	O	O
no	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
response	NN	B-NP	O
to	TO	B-PP	O
ET	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
.	.	O	O

Mean	JJ	B-NP	O
circulatory	JJ	I-NP	O
filling	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
measure	NN	I-NP	O
of	IN	B-PP	O
venomotor	NN	B-NP	O
tone	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
not	RB	I-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
LNNA	NN	B-NP	O
hypertension	NN	I-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
LNNA	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
superoxide	NN	I-NP	O
scavenger	NN	I-NP	O
tempol	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
change	VB	I-VP	O
arterial	JJ	B-NP	O
pressure	NN	I-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
but	CC	O	O
caused	VBD	B-VP	O
a	DT	B-NP	O
dose	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
LNNA	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
ganglionic	JJ	B-NP	O
blockade	NN	I-NP	O
with	IN	B-PP	O
hexamethonium	NN	B-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significantly	RB	I-NP	O
greater	JJR	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
LNNA	NN	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Carotid	JJ	B-NP	O
arteries	NNS	I-NP	O
,	,	O	O
vena	NN	B-NP	O
cava	NN	I-NP	O
,	,	O	O
and	CC	O	O
sympathetic	JJ	B-NP	O
ganglia	NNS	I-NP	O
from	IN	B-PP	O
LNNA	NN	B-NP	O
rats	NNS	I-NP	O
had	VBD	B-VP	O
higher	JJR	B-NP	O
basal	JJ	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
superoxide	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
from	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
while	IN	B-SBAR	O
NO	NN	B-NP	O
deficiency	NN	I-NP	O
increases	VBZ	B-VP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
and	CC	O	O
sympathetic	JJ	B-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
arterial	JJ	I-NP	O
and	CC	I-NP	O
venous	JJ	I-NP	O
vessels	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
impact	NN	I-NP	O
on	IN	B-PP	O
veins	NNS	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
make	VB	I-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
contribution	NN	I-NP	O
to	TO	B-PP	O
this	DT	B-NP	O
form	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
.	.	O	O

Association	NN	B-NP	O
of	IN	B-PP	O
DRD2	NN	B-NP	O
polymorphisms	NNS	I-NP	O
and	CC	I-NP	O
chlorpromazine	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
extrapyramidal	JJ	I-NP	B
syndrome	NN	I-NP	I
in	IN	B-PP	O
Chinese	JJ	B-NP	O
schizophrenic	JJ	I-NP	B
patients	NNS	I-NP	O
.	.	O	O

Extrapyramidal	JJ	B-NP	B
syndrome	NN	I-NP	I
(	(	O	O
EPS	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
most	RBS	I-VP	O
commonly	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
typical	JJ	B-NP	O
antipsychotic	JJ	I-NP	O
drugs	NNS	I-NP	O
that	WDT	B-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
affinity	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
D2	NN	I-NP	O
receptor	NN	I-NP	O
.	.	O	O

Recently	RB	B-ADVP	O
,	,	O	O
many	JJ	B-NP	O
research	NN	I-NP	O
groups	NNS	I-NP	O
have	VBP	B-VP	O
reported	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
positive	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
genetic	JJ	I-NP	O
variations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
DRD2	NN	I-NP	O
gene	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
therapeutic	JJ	I-NP	O
response	NN	I-NP	O
in	IN	B-PP	O
schizophrenia	NN	B-NP	B
patients	NNS	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
variations	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
receptor	NN	I-NP	O
in	IN	B-PP	O
modulating	VBG	B-VP	O
receptor	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
evaluate	VBP	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
DRD2	NN	I-NP	O
plays	VBZ	B-VP	O
in	IN	B-PP	O
chlorpromazine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
EPS	NN	I-NP	B
in	IN	B-PP	O
schizophrenic	JJ	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
identified	VBD	B-VP	O
num	CD	B-NP	O
SNP	NN	I-NP	O
(	(	O	O
single	JJ	B-NP	O
nucleotide	NN	I-NP	O
polymorphism	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
DRD2	NN	I-NP	O
gene	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
schizophrenic	JJ	I-NP	B
inpatients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
with	IN	B-PP	O
EPS	NN	B-NP	B
and	CC	O	O
num	CD	B-NP	O
without	IN	B-PP	O
EPS	NN	B-NP	B
according	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
Simpson	NNP	I-NP	O
-	HYPH	I-NP	O
Angus	NNP	I-NP	O
Scale	NNP	I-NP	O
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
chlorpromazine	NN	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
alleles	NNS	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
loci	NNS	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
PCR	NN	B-NP	O
(	(	O	O
polymerase	NN	B-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
)	)	O	O
.	.	O	O

Polymorphisms	NNS	B-NP	O
TaqID	NN	I-NP	O
,	,	I-NP	O
Ser311Cys	NN	I-NP	O
and	CC	I-NP	O
rs6277	NN	I-NP	O
were	VBD	B-VP	O
not	RB	B-ADJP	O
polymorphic	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
population	NN	I-NP	O
recruited	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

No	DT	B-NP	O
statistical	JJ	I-NP	O
significance	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
allele	NN	I-NP	O
distribution	NN	I-NP	O
of	IN	B-PP	O
-	SYM	B-NP	O
141Cins	NN	I-NP	O
>	SYM	B-NP	O
del	NN	I-NP	O
,	,	I-NP	O
TaqIB	NN	I-NP	O
,	,	I-NP	O
rs6275	NN	I-NP	O
and	CC	I-NP	O
TaqIA	NN	I-NP	O
or	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
estimated	VBN	I-NP	O
haplotypes	NNS	I-NP	O
(	(	O	O
constituted	VBN	B-VP	O
by	IN	B-PP	O
TaqIB	NN	B-NP	O
,	,	O	O
rs6275	NN	B-NP	O
and	CC	O	O
TaqIA	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
linkage	NN	B-NP	O
disequilibrium	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
lend	VB	I-VP	O
strong	JJ	B-NP	O
support	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
view	NN	I-NP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
genetic	JJ	I-NP	O
variation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
DRD2	NN	I-NP	O
gene	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
major	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
individually	RB	I-NP	O
variable	JJ	I-NP	O
adverse	JJ	I-NP	O
effect	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
chlorpromazine	NN	B-NP	O
,	,	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
Chinese	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
schizophrenia	NN	B-NP	B
.	.	O	O

Our	PRP$	B-NP	O
results	NNS	I-NP	O
confirmed	VBD	B-VP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
DRD2	NN	B-NP	O
and	CC	I-NP	O
EPS	NN	I-NP	B
in	IN	B-PP	O
Caucasians	NNPS	B-NP	O
.	.	O	O

Physical	JJ	B-NP	O
training	NN	I-NP	O
decreases	VBZ	B-VP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
subsequent	JJ	B-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
.	.	O	O

Regular	JJ	B-NP	O
motor	NN	I-NP	O
activity	NN	I-NP	O
has	VBZ	B-VP	O
many	JJ	B-NP	O
benefits	NNS	I-NP	O
for	IN	B-PP	O
mental	JJ	B-NP	O
and	CC	I-NP	O
physical	JJ	I-NP	O
condition	NN	I-NP	O
but	CC	O	O
its	PRP$	B-NP	O
implications	NNS	I-NP	O
for	IN	B-PP	O
epilepsy	NN	B-NP	B
are	VBP	B-VP	O
still	RB	B-ADVP	O
controversial	JJ	B-ADJP	O
.	.	O	O

In	IN	B-SBAR	O
order	NN	O	O
to	TO	B-VP	O
elucidate	VB	I-VP	O
this	DT	B-NP	O
problem	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
have	VBP	B-VP	O
studied	VBN	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
physical	JJ	I-NP	O
activity	NN	I-NP	O
on	IN	B-PP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
subsequent	JJ	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
subjected	VBN	I-VP	O
to	TO	B-PP	O
repeated	VBN	B-NP	O
training	NN	I-NP	O
sessions	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
treadmill	NN	I-NP	O
and	CC	I-NP	O
swimming	NN	I-NP	O
pool	NN	I-NP	O
.	.	O	O

Thereafter	RB	B-ADVP	O
,	,	O	O
seizures	NNS	B-NP	B
were	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
injections	NNS	I-NP	O
in	IN	B-PP	O
trained	JJ	O	O
and	CC	O	O
non	AFX	O	O
-	HYPH	O	O
trained	VBN	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
,	,	O	O
we	PRP	B-NP	O
measured	VBD	B-VP	O
:	:	O	O
the	DT	B-NP	O
latency	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
motor	NN	I-NP	O
sign	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
intensity	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
,	,	O	O
the	DT	B-NP	O
time	NN	I-NP	O
when	WRB	B-ADVP	O
it	PRP	B-NP	O
occurred	VBD	B-VP	O
within	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
h	NN	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
time	NN	I-NP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
period	NN	I-NP	O
ended	VBN	B-VP	O
.	.	O	O

All	PDT	B-NP	O
these	DT	I-NP	O
behavioral	JJ	I-NP	O
parameters	NNS	I-NP	O
showed	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
changes	NNS	I-NP	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
regular	JJ	B-NP	O
physical	JJ	I-NP	O
exercises	NNS	I-NP	O
decrease	VBP	B-VP	O
susceptibility	NN	B-NP	O
to	TO	B-PP	O
subsequently	RB	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
and	CC	O	O
ameliorate	VB	B-VP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
experimentally	RB	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Tonic	JJ	B-NP	O
dopaminergic	JJ	I-NP	O
stimulation	NN	I-NP	O
impairs	VBZ	B-VP	B
associative	JJ	B-NP	I
learning	NN	I-NP	I
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Endogenous	JJ	B-NP	O
dopamine	NN	I-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
central	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
salience	NN	B-NP	O
coding	NN	I-NP	O
during	IN	B-PP	O
associative	JJ	B-NP	O
learning	NN	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dopamine	NN	I-NP	O
precursor	NN	I-NP	O
levodopa	NN	I-NP	O
enhances	VBZ	B-VP	O
learning	NN	B-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
stroke	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
levodopa	NN	B-NP	O
increases	VBZ	B-VP	O
both	CC	O	O
phasic	JJ	B-NP	O
and	CC	I-NP	O
tonic	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
neurotransmission	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
critical	JJ	I-NP	O
mechanism	NN	I-NP	O
mediating	VBG	B-VP	O
the	DT	B-NP	O
enhancement	NN	I-NP	O
of	IN	B-PP	O
learning	NN	B-NP	O
is	VBZ	B-VP	O
unresolved	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
here	RB	B-ADVP	O
probed	VBD	B-VP	O
how	WRB	B-ADVP	O
selective	JJ	B-NP	O
tonic	JJ	I-NP	O
dopaminergic	JJ	I-NP	O
stimulation	NN	I-NP	O
affects	VBZ	B-VP	O
associative	JJ	B-NP	O
learning	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
healthy	JJ	I-NP	O
subjects	NNS	I-NP	O
were	VBD	B-VP	O
trained	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
vocabulary	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
concrete	JJ	I-NP	O
nouns	NNS	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
training	NN	I-NP	O
days	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
randomized	VBN	I-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	B-NP	O
design	NN	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
received	VBD	B-VP	O
the	DT	B-NP	O
tonically	RB	I-NP	O
stimulating	VBG	I-NP	O
dopamine	NN	I-NP	O
-	HYPH	I-NP	O
receptor	NN	I-NP	O
agonist	NN	I-NP	O
pergolide	NN	I-NP	O
vs	IN	B-PP	O
placebo	NN	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
training	NN	B-NP	O
on	IN	B-PP	O
each	DT	B-NP	O
training	NN	I-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
dopamine	NN	I-NP	O
agonist	NN	I-NP	O
significantly	RB	B-ADVP	O
impaired	VBD	B-VP	B
novel	JJ	B-NP	I
word	NN	I-NP	I
learning	NN	I-NP	I
compared	VBN	B-VP	O
to	TO	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
learning	VBG	I-NP	O
decrement	NN	I-NP	O
persisted	VBD	B-VP	O
up	RB	B-ADVP	O
to	TO	B-PP	O
the	DT	B-NP	O
last	JJ	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
training	NN	B-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
restricted	JJ	B-NP	O
emotional	JJ	I-NP	O
responses	NNS	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
PLACEBO	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
extent	NN	I-NP	O
of	IN	B-PP	O
flattened	JJ	B-NP	O
affect	NN	I-NP	O
with	IN	B-PP	O
pergolide	NN	B-NP	O
was	VBD	B-VP	O
related	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
degree	NN	I-NP	O
of	IN	B-PP	O
learning	VBG	B-VP	O
inhibition	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
tonic	JJ	B-NP	O
occupation	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
receptors	NNS	I-NP	O
impairs	VBZ	B-VP	O
learning	NN	B-NP	O
by	IN	B-PP	O
competition	NN	B-NP	O
with	IN	B-PP	O
phasic	JJ	B-NP	O
dopamine	NN	I-NP	O
signals	NNS	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
phasic	JJ	B-NP	O
signaling	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
critical	JJ	I-NP	O
mechanism	NN	I-NP	O
by	IN	B-PP	O
which	WDT	B-NP	O
dopamine	NN	B-NP	O
enhances	VBZ	B-VP	O
associative	JJ	B-NP	O
learning	NN	I-NP	O
in	IN	B-PP	O
healthy	JJ	B-NP	O
subjects	NNS	I-NP	O
and	CC	O	O
stroke	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Minocycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasculitis	NN	I-NP	B
fulfilling	VBG	B-VP	O
the	DT	B-NP	O
criteria	NNS	I-NP	O
of	IN	B-PP	O
polyarteritis	NN	B-NP	B
nodosa	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
man	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
minocycline	NN	B-NP	O
for	IN	B-PP	O
palmoplantar	JJ	B-NP	B
pustulosis	NN	I-NP	I
developed	VBD	B-VP	O
fever	NN	B-NP	B
,	,	O	O
myalgias	NNS	B-NP	B
,	,	O	O
polyneuropathy	NN	B-NP	B
,	,	O	O
and	CC	O	O
testicular	JJ	B-NP	B
pain	NN	I-NP	I
,	,	O	O
with	IN	B-PP	O
elevated	VBN	B-NP	O
C	NN	I-NP	O
-	HYPH	O	O
reactive	JJ	B-NP	O
protein	NN	I-NP	O
(	(	O	O
CRP	NN	B-NP	O
)	)	O	O
.	.	O	O

Neither	CC	O	O
myeloperoxidase	NN	B-NP	O
-	HYPH	O	O
nor	CC	O	O
proteinase	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
antineutrophil	NN	I-NP	O
cytoplasmic	JJ	I-NP	O
antibody	NN	I-NP	O
was	VBD	B-VP	O
positive	JJ	B-ADJP	O
.	.	O	O

These	DT	B-NP	O
manifestations	NNS	I-NP	O
met	VBD	B-VP	O
the	DT	B-NP	O
American	NNP	I-NP	O
College	NNP	I-NP	O
of	IN	B-PP	O
Rheumatology	NNP	B-NP	O
num	CD	I-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
classification	NN	I-NP	O
of	IN	B-PP	O
polyarteritis	NN	B-NP	B
nodosa	NN	I-NP	I
.	.	O	O

Stopping	VBG	B-NP	O
minocycline	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
amelioration	NN	B-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
and	CC	O	O
normalization	NN	B-NP	O
of	IN	B-PP	O
CRP	NN	B-NP	O
level	NN	I-NP	O
.	.	O	O

To	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
second	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
minocycline	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
vasculitis	NN	I-NP	B
satisfying	VBG	B-VP	O
the	DT	B-NP	O
criteria	NNS	I-NP	O
.	.	O	O

Differential	JJ	B-NP	O
diagnosis	NN	I-NP	O
for	IN	B-PP	O
drug	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
disease	NN	I-NP	O
is	VBZ	B-VP	O
invaluable	JJ	B-ADJP	O
even	RB	B-ADVP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
classical	JJ	B-NP	O
polyarteritis	NN	I-NP	B
nodosa	NN	I-NP	I
.	.	O	O

Intramuscular	JJ	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
lamivudine	NN	B-NP	O
in	IN	B-PP	O
prevention	NN	B-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
recurrence	NN	I-NP	O
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Combined	VBN	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
immune	JJ	I-NP	O
globulin	NN	I-NP	O
(	(	O	O
HBIg	NN	B-NP	O
)	)	O	O
and	CC	O	O
lamivudine	NN	B-NP	O
in	IN	B-PP	O
prophylaxis	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
has	VBZ	B-VP	O
significantly	RB	I-VP	O
improved	VBN	I-VP	O
the	DT	B-NP	O
survival	NN	I-NP	O
of	IN	B-PP	O
HBsAg	NN	B-NP	O
positive	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
undertaken	VBN	I-VP	O
to	TO	I-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hepatitis	NN	B-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
(	(	O	O
HBV	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
retrospective	JJ	I-NP	O
chart	NN	I-NP	O
analysis	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
review	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
organ	NN	I-NP	O
transplant	NN	I-NP	O
database	NN	I-NP	O
identified	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
men	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
women	NNS	I-NP	O
)	)	O	O
transplanted	VBN	B-VP	O
for	IN	B-PP	O
benign	JJ	B-NP	O
HBV	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
cirrhotic	JJ	I-NP	B
diseases	NNS	I-NP	I
between	IN	B-PP	O
June	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
December	NNP	B-NP	O
num	CD	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
survived	VBN	I-VP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
.	.	O	O

HBIg	NN	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
intravenously	RB	B-ADVP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
week	NN	I-NP	O
and	CC	O	O
intramuscularly	RB	B-ADVP	O
thereafter	RB	I-ADVP	O
.	.	O	O

At	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
overall	JJ	I-NP	O
recurrence	NN	I-NP	O
rate	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
overall	JJ	I-NP	O
patient	NN	I-NP	O
survival	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

A	DT	B-NP	O
daily	JJ	I-NP	O
oral	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
lamivudine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
before	IN	B-PP	O
transplantation	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
enabled	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
-	HYPH	B-NP	O
DNA	NN	I-NP	O
and	CC	I-NP	O
HBeAg	NN	I-NP	O
positive	JJ	B-NP	O
patients	NNS	I-NP	O
respectively	RB	B-ADVP	O
to	TO	B-VP	O
convert	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
negative	JJ	B-ADJP	O
.	.	O	O

Intramuscular	JJ	B-NP	O
HBIg	NN	I-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Lamivudine	NN	B-NP	O
combined	VBN	B-VP	O
with	IN	B-PP	O
intramuscular	JJ	B-NP	O
HBIg	NN	I-NP	O
can	MD	B-VP	O
effectively	RB	I-VP	O
prevent	VB	I-VP	O
allograft	NN	B-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
recurrence	NN	I-NP	O
of	IN	B-PP	O
HBV	NN	B-NP	O
after	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
.	.	O	O

Anticonvulsant	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
eslicarbazepine	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
BIA	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
)	)	O	O
on	IN	B-PP	O
seizures	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
microperfusion	NN	B-NP	O
of	IN	B-PP	O
picrotoxin	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
of	IN	B-PP	O
freely	RB	B-ADVP	O
moving	VBG	B-VP	O
rats	NNS	B-NP	O
.	.	O	O

Eslicarbazepine	NN	B-NP	O
acetate	NN	I-NP	O
(	(	O	O
BIA	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
S	NN	I-NP	O
-	SYM	B-NP	O
-	SYM	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
acetoxy	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
dihydro	AFX	O	O
-	HYPH	B-NP	O
5H	NN	I-NP	O
-	HYPH	I-NP	O
dibenzo	NN	I-NP	O
/	SYM	I-NP	O
b	NN	I-NP	O
,	,	O	O
f	NN	B-NP	O
/	SYM	B-NP	O
azepine	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
carboxamide	NN	I-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
now	RB	B-ADVP	O
in	IN	B-PP	O
Phase	NN	B-NP	O
num	CD	I-NP	O
clinical	JJ	I-NP	O
trials	NNS	I-NP	O
,	,	O	O
designed	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
improving	VBG	B-VP	O
efficacy	NN	B-NP	O
and	CC	I-NP	O
safety	NN	I-NP	O
in	IN	B-PP	O
comparison	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
structurally	RB	I-NP	O
related	VBN	I-NP	O
drugs	NNS	I-NP	O
carbamazepine	NN	I-NP	O
(	(	O	O
CBZ	NN	B-NP	O
)	)	O	O
and	CC	O	O
oxcarbazepine	NN	B-NP	O
(	(	O	O
OXC	NN	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
studied	VBN	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
eslicarbazepine	NN	B-NP	O
acetate	NN	I-NP	O
on	IN	B-PP	O
a	DT	B-NP	O
whole	JJ	I-NP	O
-	HYPH	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
partial	JJ	B-NP	O
seizures	NNS	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
elicited	VBN	I-VP	O
repeatedly	RB	B-ADVP	O
on	IN	B-PP	O
different	JJ	B-NP	O
days	NNS	I-NP	O
without	IN	B-PP	O
changes	NNS	B-NP	O
in	IN	B-PP	O
threshold	NN	B-NP	O
or	CC	I-NP	O
seizure	NN	I-NP	B
patterns	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
animals	NNS	I-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
threshold	NN	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
picrotoxin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
average	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
,	,	O	O
and	CC	O	O
average	JJ	B-NP	O
seizure	NN	I-NP	B
duration	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	HYPH	O	O
8.4s	NNS	B-NP	O
.	.	O	O

Pre	AFX	B-NP	O
-	HYPH	I-NP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
2h	NN	I-NP	O
before	IN	B-PP	O
picrotoxin	NN	B-NP	O
microperfusion	NN	I-NP	O
prevented	VBD	B-VP	O
seizures	NNS	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Lower	JJR	B-NP	O
doses	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
suppress	VB	I-VP	O
seizures	NNS	B-NP	B
,	,	O	O
however	RB	B-ADVP	O
,	,	O	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
10mg	NN	B-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
significant	JJ	B-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
seizures	NNS	B-NP	B
duration	NN	I-NP	O
and	CC	I-NP	O
seizure	NN	I-NP	B
number	NN	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
.	.	O	O

No	DT	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
eslicarbazepine	NN	B-NP	O
acetate	NN	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
behavioral	NN	I-NP	O
/	SYM	B-VP	O
EEG	NN	B-NP	O
patterns	NNS	I-NP	O
studied	VBN	B-VP	O
,	,	O	O
including	VBG	B-PP	O
sleep	NN	B-NP	O
/	SYM	B-NP	O
wakefulness	NN	I-NP	O
cycle	NN	I-NP	O
,	,	O	O
at	IN	B-PP	O
the	DT	B-NP	O
doses	NNS	I-NP	O
studied	VBN	B-VP	O
.	.	O	O

Acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
prolonged	JJ	B-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
slimming	VBG	B-VP	O
pills	NNS	B-NP	O
containing	VBG	B-VP	O
anthraquinones	NNS	B-NP	O
.	.	O	O

Chinese	JJ	B-NP	O
herbal	JJ	I-NP	O
medicine	NN	I-NP	O
preparations	NNS	I-NP	O
are	VBP	B-VP	O
widely	RB	B-ADJP	O
available	JJ	I-ADJP	O
and	CC	O	O
often	RB	B-VP	O
regarded	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
public	NN	I-NP	O
as	IN	B-PP	O
natural	JJ	B-NP	O
and	CC	I-NP	O
safe	JJ	I-NP	O
remedies	NNS	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
medical	JJ	B-NP	O
conditions	NNS	I-NP	O
.	.	O	O

Nephropathy	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
Chinese	JJ	B-NP	O
herbs	NNS	I-NP	O
has	VBZ	B-VP	O
previously	RB	I-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
,	,	O	O
usually	RB	B-ADVP	O
involving	VBG	B-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
aristolochic	JJ	B-NP	O
acids	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
following	VBG	B-PP	O
prolonged	VBN	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
proprietary	JJ	I-NP	O
Chinese	JJ	I-NP	O
herbal	JJ	I-NP	O
slimming	JJ	I-NP	O
pill	NN	I-NP	O
that	WDT	B-NP	O
contained	VBD	B-VP	O
anthraquinone	NN	B-NP	O
derivatives	NNS	I-NP	O
,	,	O	O
extracted	VBN	B-VP	O
from	IN	B-PP	O
Rhizoma	NNP	B-NP	O
Rhei	NNP	I-NP	O
(	(	O	O
rhubarb	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
renal	JJ	I-NP	B
injury	NN	I-NP	I
was	VBD	B-VP	O
probably	RB	I-VP	O
aggravated	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
concomitant	JJ	I-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drug	NN	I-NP	O
,	,	O	O
diclofenac	NN	B-NP	O
.	.	O	O

Renal	JJ	B-NP	O
pathology	NN	I-NP	O
was	VBD	B-VP	O
that	IN	B-SBAR	O
of	IN	B-PP	O
hypocellular	JJ	B-NP	O
interstitial	JJ	I-NP	O
fibrosis	NN	I-NP	B
.	.	O	O

Spontaneous	JJ	B-NP	O
renal	JJ	I-NP	O
recovery	NN	I-NP	O
occurred	VBD	B-VP	O
upon	IN	B-PP	O
cessation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
slimming	JJ	I-NP	O
pills	NNS	I-NP	O
,	,	O	O
but	CC	O	O
mild	JJ	B-NP	O
interstitial	JJ	I-NP	O
fibrosis	NN	I-NP	B
and	CC	O	O
tubular	JJ	B-NP	O
atrophy	NN	I-NP	B
was	VBD	B-VP	O
still	RB	B-ADVP	O
evident	JJ	B-NP	O
histologically	RB	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Although	IN	B-SBAR	O
a	DT	B-NP	O
causal	JJ	I-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
anthraquinone	NN	I-NP	O
-	HYPH	O	O
containing	VBG	B-VP	O
herbal	JJ	B-NP	O
agent	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	B
injury	NN	I-NP	I
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
proven	VBN	I-VP	O
,	,	O	O
phytotherapy	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
interstitial	JJ	I-NP	O
nephropathy	NN	I-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
present	VBP	B-VP	O
with	IN	B-PP	O
unexplained	JJ	B-NP	O
renal	JJ	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Chloroacetaldehyde	NN	B-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
sulfhydryl	NN	I-NP	O
reagent	NN	I-NP	O
:	:	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
critical	JJ	B-NP	O
thiol	NN	I-NP	O
groups	NNS	I-NP	O
in	IN	B-PP	O
ifosfamide	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Chloroacetaldehyde	NN	B-NP	O
(	(	O	O
CAA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
metabolite	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
alkylating	VBG	I-NP	O
agent	NN	I-NP	O
ifosfamide	NN	I-NP	O
(	(	O	O
IFO	NN	B-NP	O
)	)	O	O
and	CC	O	O
putatively	RB	B-ADJP	O
responsible	JJ	I-ADJP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
following	VBG	B-PP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
tumor	NN	I-NP	B
therapy	NN	I-NP	O
with	IN	B-PP	O
IFO	NN	B-NP	O
.	.	O	O

Depletion	NN	B-NP	O
of	IN	B-PP	O
sulfhydryl	NN	B-NP	O
(	(	O	O
SH	NN	B-NP	O
)	)	O	O
groups	NNS	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
from	IN	B-PP	O
cell	NN	B-NP	O
culture	NN	I-NP	O
,	,	O	O
animal	NN	B-NP	O
and	CC	O	O
clinical	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
work	NN	I-NP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
CAA	NN	B-NP	O
on	IN	B-PP	O
human	JJ	B-NP	O
proximal	JJ	I-NP	O
tubule	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
primary	JJ	B-NP	O
culture	NN	I-NP	O
(	(	O	O
hRPTEC	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
investigated	VBN	I-VP	O
.	.	O	O

Toxicity	NN	B-NP	B
of	IN	B-PP	O
CAA	NN	B-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
protein	NN	B-NP	O
content	NN	I-NP	O
,	,	O	O
cell	NN	B-NP	O
number	NN	I-NP	O
,	,	O	O
LDH	NN	B-NP	O
release	NN	I-NP	O
,	,	O	O
trypan	NN	B-NP	O
blue	JJ	I-NP	O
exclusion	NN	I-NP	O
assay	NN	I-NP	O
and	CC	I-NP	O
caspase	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
activity	NN	I-NP	O
.	.	O	O

Free	JJ	B-NP	O
thiols	NNS	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
method	NN	I-NP	O
of	IN	B-PP	O
Ellman	NNP	B-NP	O
.	.	O	O

CAA	NN	B-NP	O
reduced	VBD	B-VP	O
hRPTEC	NN	B-NP	O
cell	NN	I-NP	O
number	NN	I-NP	O
and	CC	O	O
protein	NN	B-NP	O
,	,	O	O
induced	VBD	B-VP	O
a	DT	B-NP	O
loss	NN	I-NP	O
in	IN	B-PP	O
free	JJ	B-NP	O
intracellular	JJ	I-NP	O
thiols	NNS	I-NP	O
and	CC	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
necrosis	NN	B-NP	B
markers	NNS	I-NP	O
.	.	O	O

CAA	NN	B-NP	O
but	CC	B-NP	O
not	RB	I-NP	O
acrolein	NN	B-NP	O
inhibited	VBD	B-VP	O
the	DT	B-NP	O
cysteine	NN	I-NP	O
proteases	VBZ	B-VP	O
caspase	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
caspase	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
and	CC	O	O
cathepsin	NN	B-NP	O
B	NN	B-NP	O
.	.	O	O

Caspase	NN	B-NP	O
activation	NN	I-NP	O
by	IN	B-PP	O
cisplatin	NN	B-NP	O
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
CAA	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
cells	NNS	B-NP	O
stained	VBN	B-VP	O
with	IN	B-PP	O
fluorescent	JJ	B-NP	O
dyes	NNS	I-NP	O
targeting	VBG	B-VP	O
lysosomes	NNS	B-NP	O
,	,	O	O
CAA	NN	B-NP	O
induced	VBD	B-VP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
lysosomal	JJ	B-NP	O
size	NN	I-NP	O
and	CC	I-NP	O
lysosomal	JJ	I-NP	O
leakage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
CAA	NN	B-NP	O
on	IN	B-PP	O
cysteine	NN	B-NP	O
protease	NN	I-NP	O
activities	NNS	I-NP	O
and	CC	I-NP	O
thiols	NNS	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
reproduced	VBN	I-VP	O
in	IN	B-PP	O
cell	NN	B-NP	O
lysate	NN	I-NP	O
.	.	O	O

Acidification	NN	B-NP	O
,	,	O	O
which	WDT	B-NP	O
slowed	VBD	B-VP	O
the	DT	B-NP	O
reaction	NN	I-NP	O
of	IN	B-PP	O
CAA	NN	B-NP	O
with	IN	B-PP	O
thiol	NN	B-NP	O
donors	NNS	I-NP	O
,	,	O	O
could	MD	B-VP	O
also	RB	I-VP	O
attenuate	VB	I-VP	O
effects	NNS	B-NP	O
of	IN	B-PP	O
CAA	NN	B-NP	O
on	IN	B-PP	O
necrosis	NN	B-NP	B
markers	NNS	I-NP	O
,	,	O	O
thiol	NN	B-NP	O
depletion	NN	I-NP	O
and	CC	I-NP	O
cysteine	NN	I-NP	O
protease	NN	I-NP	O
inhibition	NN	I-NP	O
in	IN	B-PP	O
living	VBG	B-VP	O
cells	NNS	B-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
CAA	NN	B-NP	O
directly	RB	B-ADVP	O
reacts	VBZ	B-VP	O
with	IN	B-PP	O
cellular	JJ	B-NP	O
protein	NN	I-NP	O
and	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
protein	NN	I-NP	O
thiols	NNS	I-NP	O
,	,	O	O
mediating	VBG	B-VP	O
its	PRP$	B-NP	O
toxicity	NN	I-NP	B
on	IN	B-PP	O
hRPTEC	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
effect	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
reduced	VBN	I-VP	O
by	IN	B-PP	O
acidification	NN	B-NP	O
.	.	O	O

Therefore	RB	B-ADVP	O
,	,	O	O
urinary	JJ	B-NP	O
acidification	NN	I-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
option	NN	I-NP	O
to	TO	B-VP	O
prevent	VB	I-VP	O
IFO	NN	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
.	.	O	O

Stereological	JJ	B-NP	O
methods	NNS	I-NP	O
reveal	VBP	B-VP	O
the	DT	B-NP	O
robust	JJ	I-NP	O
size	NN	I-NP	O
and	CC	I-NP	O
stability	NN	I-NP	O
of	IN	B-PP	O
ectopic	JJ	B-NP	O
hilar	JJ	I-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
adult	JJ	I-NP	O
rat	NN	I-NP	O
.	.	O	O

Following	VBG	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
,	,	O	O
dentate	NN	B-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
neurogenesis	NN	I-NP	O
increases	VBZ	B-VP	O
greatly	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
many	JJ	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
new	JJ	I-NP	O
neurons	NNS	I-NP	O
appear	VBP	B-VP	O
to	TO	I-VP	O
develop	VB	I-VP	O
ectopically	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
hilar	JJ	I-NP	O
region	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hippocampal	JJ	I-NP	O
formation	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
ectopic	JJ	I-NP	O
hilar	JJ	I-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
could	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
spontaneous	JJ	I-NP	O
seizures	NNS	I-NP	B
that	WDT	B-NP	O
ultimately	RB	B-ADVP	O
develop	VBP	B-VP	O
after	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
population	NN	I-NP	O
has	VBZ	B-VP	O
never	RB	I-VP	O
been	VBN	I-VP	O
quantified	VBN	I-VP	O
,	,	O	O
so	IN	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
substantial	JJ	B-ADJP	O
enough	RB	I-ADJP	O
to	TO	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
strong	JJ	I-NP	O
influence	NN	I-NP	O
on	IN	B-PP	O
epileptogenesis	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
quantify	VB	I-VP	O
this	DT	B-NP	O
population	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
total	JJ	I-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
ectopic	JJ	B-NP	O
hilar	JJ	I-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
using	VBG	B-VP	O
unbiased	JJ	B-NP	O
stereology	NN	I-NP	O
at	IN	B-PP	O
different	JJ	B-NP	O
times	NNS	I-NP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
hilar	JJ	B-NP	O
neurons	NNS	I-NP	O
immunoreactive	JJ	B-ADJP	O
for	IN	B-PP	O
Prox	NNP	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
a	DT	B-NP	O
granule	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
marker	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
estimated	VBN	I-VP	O
using	VBG	I-VP	O
the	DT	B-NP	O
optical	JJ	I-NP	O
fractionator	NN	I-NP	O
method	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hilar	JJ	I-NP	O
ectopic	JJ	I-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
population	NN	I-NP	O
after	IN	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
is	VBZ	B-VP	O
substantial	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
stable	JJ	B-ADJP	O
over	IN	B-PP	O
time	NN	B-NP	O
.	.	O	O

Interestingly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
size	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
population	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
correlated	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
behavioral	JJ	B-NP	O
seizures	NNS	I-NP	B
,	,	O	O
because	IN	B-SBAR	O
animals	NNS	B-NP	O
with	IN	B-PP	O
more	RBR	B-NP	O
ectopic	JJ	I-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
have	VBP	B-VP	O
more	RBR	B-NP	O
frequent	JJ	I-NP	O
behavioral	JJ	I-NP	O
seizures	NNS	I-NP	B
.	.	O	O

The	DT	B-NP	O
hilar	JJ	I-NP	O
ectopic	JJ	I-NP	O
granule	NN	I-NP	O
cell	NN	I-NP	O
population	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
appear	VB	I-VP	O
to	TO	I-VP	O
vary	VB	I-VP	O
systematically	RB	B-ADVP	O
across	IN	B-PP	O
the	DT	B-NP	O
septotemporal	JJ	I-NP	O
axis	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
volume	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
hilus	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
provide	VBP	B-VP	O
new	JJ	B-NP	O
insight	NN	I-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
ectopic	JJ	B-NP	O
hilar	JJ	I-NP	O
granule	NN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pilocarpine	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
temporal	JJ	B-NP	B
lobe	NN	I-NP	I
epilepsy	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
prospective	JJ	I-NP	O
,	,	I-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
galantamine	NN	B-NP	O
in	IN	B-PP	O
autistic	JJ	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

Post	AFX	B-NP	O
-	HYPH	I-NP	O
mortem	NN	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
reported	VBN	I-VP	O
abnormalities	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
cholinergic	JJ	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
autism	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
galantamine	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
acetylcholinesterase	NN	I-NP	O
inhibitor	NN	I-NP	O
and	CC	O	O
nicotinic	JJ	B-NP	O
receptor	NN	I-NP	O
modulator	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
interfering	VBG	B-VP	O
behaviors	NNS	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
autism	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
medication	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
children	NNS	I-NP	O
with	IN	B-PP	O
autism	NN	B-NP	B
participated	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
galantamine	NN	B-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
rated	VBN	I-VP	O
monthly	JJ	B-ADJP	O
by	IN	B-PP	O
parents	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Aberrant	NNP	I-NP	O
Behavior	NNP	I-NP	O
Checklist	NNP	I-NP	O
(	(	O	O
ABC	NNP	B-NP	O
)	)	O	O
and	CC	O	O
the	DT	B-NP	O
Conners	NNPS	I-NP	O
s	VBZ	B-VP	O
Parent	NNP	B-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
-	HYPH	B-NP	O
Revised	NNP	I-NP	O
,	,	O	O
and	CC	B-PP	O
by	IN	B-PP	O
a	DT	B-NP	O
physician	NN	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Psychiatric	NNP	B-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
and	CC	O	O
the	DT	B-NP	O
Clinical	NNP	I-NP	O
Global	NNP	I-NP	O
Impressions	NNP	I-NP	O
scale	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
parent	NN	B-NP	O
-	HYPH	B-PP	O
rated	VBN	B-NP	O
irritability	NN	I-NP	B
and	CC	O	O
social	JJ	B-NP	O
withdrawal	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
ABC	NNP	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
significant	JJ	B-NP	O
improvements	NNS	I-NP	O
in	IN	B-PP	O
emotional	JJ	B-NP	O
lability	NN	I-NP	O
and	CC	I-NP	O
inattention	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Conners	NNP	I-NP	O
s	VBZ	B-VP	O
Parent	NNP	B-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
Revised	VBN	B-VP	O
.	.	O	O

Similarly	RB	B-ADVP	O
,	,	O	O
clinician	JJ	B-NP	O
ratings	NNS	I-NP	O
showed	VBD	B-VP	O
reductions	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
anger	NN	I-NP	O
subscale	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Children	NNP	I-NP	O
s	VBZ	B-VP	O
Psychiatric	NNP	B-NP	O
Rating	NNP	I-NP	O
Scale	NNP	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
participants	NNS	I-NP	O
were	VBD	B-VP	O
rated	VBN	I-VP	O
as	IN	B-PP	O
responders	NNS	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
their	PRP$	B-NP	O
improvement	NN	I-NP	O
scores	NNS	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
Clinical	NNP	I-NP	O
Global	NNP	I-NP	O
Impressions	NNP	I-NP	O
scale	NN	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
galantamine	NN	B-NP	O
was	VBD	B-VP	O
well	RB	B-VP	O
-	HYPH	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
apart	RB	B-ADVP	O
from	IN	B-PP	O
headaches	NNS	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
patient	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
open	JJ	I-NP	O
trial	NN	I-NP	O
,	,	O	O
galantamine	NN	B-NP	O
was	VBD	B-VP	O
well	RB	B-VP	O
-	HYPH	I-VP	O
tolerated	VBN	I-VP	O
and	CC	O	O
appeared	VBN	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
beneficial	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
interfering	VBG	B-VP	O
behaviors	NNS	B-NP	O
in	IN	B-PP	O
children	NNS	B-NP	O
with	IN	B-PP	O
autism	NN	B-NP	B
,	,	O	O
particularly	RB	B-NP	O
aggression	NN	I-NP	B
,	,	O	O
behavioral	JJ	B-NP	B
dyscontrol	NN	I-NP	I
,	,	O	O
and	CC	O	O
inattention	NN	B-NP	B
.	.	O	O

Further	JJ	B-NP	O
controlled	JJ	I-NP	O
trials	NNS	I-NP	O
are	VBP	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Randomized	VBN	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
olanzapine	NN	B-NP	O
versus	CC	I-NP	O
risperidone	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
episode	NN	I-NP	O
schizophrenia	NN	I-NP	B
:	:	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
authors	NNS	I-NP	O
compared	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
treatment	NN	I-NP	O
outcomes	VBZ	B-VP	O
for	IN	B-PP	O
olanzapine	NN	B-NP	O
versus	CC	O	O
risperidone	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
episode	NN	I-NP	O
schizophrenia	NN	I-NP	B
spectrum	NN	I-NP	O
disorders	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
subjects	NNS	I-NP	O
with	IN	B-PP	O
first	JJ	B-NP	O
-	HYPH	I-NP	O
episode	NN	I-NP	O
schizophrenia	NN	I-NP	B
,	,	O	O
schizophreniform	NN	B-NP	B
disorder	NN	I-NP	I
,	,	O	O
or	CC	O	O
schizoaffective	JJ	B-NP	B
disorder	NN	I-NP	I
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
or	CC	I-NP	O
risperidone	NN	I-NP	O
.	.	O	O

Response	NN	B-NP	O
rates	NNS	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
differ	VBP	I-VP	O
between	IN	B-PP	O
olanzapine	NN	B-NP	O
and	CC	I-NP	O
risperidone	NN	I-NP	O
.	.	O	O

Among	IN	B-PP	O
those	DT	B-NP	O
responding	VBG	B-VP	O
to	TO	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
more	JJR	B-NP	O
subjects	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
olanzapine	NN	I-NP	O
group	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
the	DT	B-NP	O
risperidone	NN	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
subsequent	JJ	B-NP	O
ratings	NNS	I-NP	O
not	RB	B-VP	O
meeting	VBG	I-VP	O
response	NN	B-NP	O
criteria	NNS	I-NP	O
.	.	O	O

Negative	JJ	B-NP	O
symptom	NN	I-NP	O
outcomes	NNS	I-NP	O
and	CC	I-NP	O
measures	NNS	I-NP	O
of	IN	B-PP	O
parkinsonism	NN	B-NP	B
and	CC	I-NP	O
akathisia	NN	I-NP	B
did	VBD	B-VP	O
not	RB	I-VP	O
differ	VB	I-VP	O
between	IN	B-PP	O
medications	NNS	B-NP	O
.	.	O	O

Extrapyramidal	JJ	B-NP	B
symptom	NN	I-NP	I
severity	NN	I-NP	O
scores	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
.	.	O	O

Significantly	RB	B-NP	O
more	JJR	I-NP	O
weight	NN	I-NP	B
gain	NN	I-NP	I
occurred	VBD	B-VP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
:	:	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
weight	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
relative	JJ	B-ADJP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
weight	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

Body	JJ	B-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
and	CC	O	O
at	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
versus	IN	B-PP	O
num	CD	B-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
outcomes	NNS	I-NP	O
with	IN	B-PP	O
risperidone	NN	B-NP	O
were	VBD	B-VP	O
equal	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
,	,	O	O
and	CC	O	O
response	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
more	RBR	B-ADJP	O
stable	JJ	I-ADJP	O
.	.	O	O

Olanzapine	NN	B-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
an	DT	B-NP	O
advantage	NN	I-NP	O
for	IN	B-PP	O
motor	NN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
medications	NNS	I-NP	O
caused	VBD	B-VP	O
substantial	JJ	B-NP	O
rapid	JJ	I-NP	O
weight	NN	I-NP	B
gain	NN	I-NP	I
,	,	O	O
but	CC	O	O
weight	NN	B-NP	B
gain	NN	I-NP	I
was	VBD	B-VP	O
greater	JJR	B-ADJP	O
with	IN	B-PP	O
olanzapine	NN	B-NP	O
.	.	O	O

Early	RB	B-NP	O
paracentral	JJ	I-NP	O
visual	JJ	I-NP	B
field	NN	I-NP	I
loss	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
hydroxychloroquine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
review	VB	I-VP	O
the	DT	B-NP	O
natural	JJ	I-NP	O
history	NN	I-NP	O
and	CC	O	O
ocular	JJ	B-NP	O
and	CC	I-NP	O
systemic	JJ	I-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
taking	VBG	B-VP	O
hydroxychloroquine	NN	B-NP	O
sulfate	NN	I-NP	O
who	WP	B-NP	O
attended	VBD	B-VP	O
an	DT	B-NP	O
ophthalmic	JJ	I-NP	O
screening	NN	I-NP	O
program	NN	I-NP	O
.	.	O	O

Retrospective	JJ	B-NP	O
study	NN	I-NP	O
.	.	O	O

Records	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
taking	VBG	I-VP	O
hydroxychloroquine	NN	B-NP	O
and	CC	O	O
screened	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Department	NNP	I-NP	O
of	IN	B-PP	O
Ophthalmology	NNP	B-NP	O
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
stopped	VBN	I-VP	O
treatment	NN	B-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
time	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
experienced	VBD	B-VP	O
documented	VBN	I-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
and	CC	O	O
ocular	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
visual	JJ	B-NP	B
field	NN	I-NP	I
abnormalities	NNS	I-NP	I
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
hydroxychloroquine	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
taking	VBG	I-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
per	IN	B-PP	O
day	NN	B-NP	O
and	CC	O	O
all	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
normal	JJ	B-NP	O
renal	JJ	I-NP	O
and	CC	I-NP	O
liver	NN	I-NP	O
function	NN	I-NP	O
test	NN	I-NP	O
results	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
used	VBD	B-VP	O
a	DT	B-NP	O
protocol	NN	I-NP	O
of	IN	B-PP	O
visual	JJ	B-NP	O
acuity	NN	I-NP	O
and	CC	I-NP	O
color	NN	I-NP	O
vision	NN	I-NP	O
assessment	NN	I-NP	O
,	,	O	O
funduscopy	NN	B-NP	O
,	,	O	O
and	CC	O	O
Humphrey	NNP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
testing	NN	I-NP	O
and	CC	O	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
visual	JJ	B-NP	B
field	NN	I-NP	I
defects	NNS	I-NP	I
appeared	VBD	B-VP	O
before	IN	B-SBAR	O
any	DT	B-NP	O
corresponding	VBG	I-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
any	DT	B-NP	O
other	JJ	I-NP	O
tested	VBN	I-NP	O
clinical	JJ	I-NP	O
parameters	NNS	I-NP	O
;	:	O	O
the	DT	B-NP	O
defects	NNS	I-NP	O
were	VBD	B-VP	O
reproducible	JJ	B-ADJP	O
and	CC	O	O
the	DT	B-NP	O
test	NN	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
reliable	JJ	B-ADJP	O
.	.	O	O

Patients	NNS	B-NP	O
taking	VBG	B-VP	O
hydroxychloroquine	NN	B-NP	O
can	MD	B-VP	O
demonstrate	VB	I-VP	O
a	DT	B-NP	O
toxic	JJ	I-NP	O
reaction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
retina	NN	I-NP	O
despite	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
known	JJ	B-NP	O
risk	NN	I-NP	O
factors	NNS	I-NP	O
.	.	O	O

Screening	NN	B-NP	O
,	,	O	O
including	VBG	B-PP	O
Humphrey	NNP	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
assessment	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
initial	JJ	I-NP	O
baseline	NN	I-NP	O
and	CC	O	O
yearly	RB	B-ADVP	O
thereafter	RB	I-ADVP	O
.	.	O	O

Peri	NNP	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
atrioventricular	JJ	I-NP	B
block	NN	I-NP	I
as	IN	B-PP	O
a	DT	B-NP	O
result	NN	I-NP	O
of	IN	B-PP	O
chemotherapy	NN	B-NP	O
with	IN	B-PP	O
epirubicin	NN	B-NP	O
and	CC	I-NP	O
paclitaxel	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
presented	VBN	B-VP	O
for	IN	B-PP	O
mastectomy	NN	B-NP	O
and	CC	O	O
immediate	JJ	B-NP	O
latissimus	JJ	I-NP	O
dorsi	NN	I-NP	O
flap	NN	I-NP	O
reconstruction	NN	I-NP	O
having	VBG	B-VP	O
been	VBN	I-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
carcinoma	NN	B-NP	B
of	IN	B-PP	I
the	DT	B-NP	I
breast	NN	I-NP	I
num	CD	B-NP	O
months	NNS	I-NP	O
previously	RB	B-ADVP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
preceding	VBG	I-NP	O
months	NNS	I-NP	O
she	PRP	B-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
neo	AFX	B-NP	O
-	HYPH	I-NP	O
adjuvant	JJ	B-NP	O
chemotherapy	NN	I-NP	O
with	IN	B-PP	O
epirubicin	NN	B-NP	O
,	,	O	O
paclitaxel	NN	B-NP	O
(	(	O	O
Taxol	NN	B-NP	O
)	)	O	O
and	CC	O	O
cyclophosphamide	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
apparently	RB	I-VP	O
uncomplicated	VBN	I-VP	O
and	CC	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
maintained	VBN	I-VP	O
a	DT	B-NP	O
remarkably	RB	I-NP	O
high	JJ	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
physical	JJ	B-NP	O
activity	NN	I-NP	O
.	.	O	O

She	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
bradycardic	JJ	B-ADJP	B
at	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
assessment	NN	I-NP	O
but	CC	O	O
had	VBD	B-VP	O
no	DT	B-NP	O
cardiac	JJ	I-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Second	NNP	B-NP	O
degree	VBP	B-VP	O
Mobitz	NNP	B-NP	O
type	NN	I-NP	O
num	CD	I-NP	O
atrioventricular	JJ	I-NP	B
block	NN	I-NP	I
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
on	IN	B-PP	O
electrocardiogram	NN	B-NP	O
,	,	O	O
and	CC	O	O
temporary	JJ	B-NP	O
transvenous	JJ	I-NP	O
ventricular	JJ	I-NP	O
pacing	NN	I-NP	O
instituted	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
peri	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
period	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
discuss	VBP	B-VP	O
how	WRB	B-ADVP	O
evidence	NN	B-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
guidelines	NNS	I-NP	O
would	MD	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
been	VBN	I-VP	O
helpful	JJ	B-ADJP	O
in	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
,	,	O	O
and	CC	O	O
how	WRB	B-ADVP	O
chemotherapy	NN	B-NP	O
can	MD	B-VP	O
exhibit	VB	I-VP	O
substantial	JJ	B-NP	O
cardiotoxicity	NN	I-NP	B
that	WDT	B-NP	O
may	MD	B-VP	O
develop	VB	I-VP	O
over	IN	B-PP	O
many	JJ	B-NP	O
years	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
received	VBN	I-VP	O
chemotherapy	NN	B-NP	O
at	IN	B-PP	O
any	DT	B-NP	O
time	NN	I-NP	O
should	MD	B-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
operative	JJ	I-NP	O
electrocardiogram	NN	I-NP	O
even	RB	B-SBAR	O
if	IN	I-SBAR	O
they	PRP	B-NP	O
are	VBP	B-VP	O
asymptomatic	JJ	B-ADJP	O
.	.	O	O

Risks	NNS	B-NP	O
and	CC	I-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
vs	CC	O	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	B-NP	O
NSAIDs	NNS	I-NP	O
:	:	O	O
does	VBZ	B-VP	O
their	PRP$	B-NP	O
cardiovascular	JJ	I-NP	O
risk	NN	I-NP	O
exceed	VBP	B-VP	O
their	PRP$	B-NP	O
gastrointestinal	JJ	I-NP	O
benefit	NN	I-NP	O
?	.	O	O
A	DT	B-NP	O
retrospective	JJ	I-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
myocardial	JJ	I-NP	I
infarction	NN	I-NP	I
(	(	O	O
AMI	NN	B-NP	B
)	)	O	O
with	IN	B-PP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
may	MD	B-VP	O
offset	VB	I-VP	O
their	PRP$	B-NP	O
gastrointestinal	JJ	I-NP	O
(	(	O	O
GI	NN	B-NP	O
)	)	O	O
benefit	NN	B-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
selective	JJ	I-NP	O
(	(	O	O
NS	NN	B-NP	O
)	)	O	O
non	AFX	O	O
-	HYPH	O	O
steroidal	JJ	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
hospitalization	NN	B-NP	O
for	IN	B-PP	O
AMI	NN	B-NP	B
and	CC	I-NP	O
GI	NN	I-NP	B
bleeding	NN	I-NP	I
among	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
using	VBG	B-VP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
NS	NN	B-NP	O
-	HYPH	I-NP	O
NSAIDs	NNS	I-NP	O
and	CC	I-NP	O
acetaminophen	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
conducted	VBD	B-VP	O
a	DT	B-NP	O
retrospective	JJ	I-NP	O
cohort	JJ	I-NP	O
study	NN	I-NP	O
using	VBG	B-VP	O
administrative	JJ	B-NP	O
data	NNS	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
>	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
age	NN	B-NP	O
who	WP	B-NP	O
filled	VBD	B-VP	O
a	DT	B-NP	O
prescription	NN	I-NP	O
for	IN	B-PP	O
NSAID	NN	B-NP	O
or	CC	I-NP	O
acetaminophen	NN	I-NP	O
during	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
.	.	O	O

Outcomes	NNS	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
using	VBG	B-VP	O
Cox	NNP	B-NP	O
regression	NN	I-NP	O
models	NNS	I-NP	O
with	IN	B-PP	O
time	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
exposures	NNS	I-NP	O
.	.	O	O

Person	NNP	B-NP	O
-	HYPH	B-NP	O
years	NNS	I-NP	O
of	IN	B-PP	O
exposure	NN	B-NP	O
among	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
were	VBD	B-VP	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
acetaminophen	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-VP	O
rofecoxib	VB	I-VP	O
num	CD	B-NP	O
to	TO	B-VP	O
celecoxib	VB	I-VP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
to	TO	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
NSAIDs	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
they	PRP	B-NP	O
were	VBD	B-VP	O
:	:	O	O
num	CD	B-NP	O
to	TO	B-PP	O
rofecoxib	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-VP	O
celecoxib	VB	I-VP	O
,	,	O	O
num	CD	B-NP	O
to	TO	B-PP	O
NS	NN	B-NP	O
-	HYPH	B-NP	O
NSAIDs	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
to	TO	B-PP	O
acetaminophen	NN	B-NP	O
.	.	O	O

Among	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
adjusted	VBN	I-NP	O
hazard	NN	I-NP	O
ratios	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
)	)	O	O
of	IN	B-PP	O
hospitalization	NN	B-NP	O
for	IN	B-PP	O
AMI	NN	B-NP	B
/	SYM	B-NP	O
GI	NN	I-NP	O
vs	IN	B-PP	O
the	DT	B-NP	O
acetaminophen	NN	I-NP	O
(	(	O	O
with	IN	B-PP	O
no	DT	B-NP	O
aspirin	NN	I-NP	O
)	)	O	O
group	NN	B-NP	O
were	VBD	B-VP	O
:	:	O	O
rofecoxib	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
celecoxib	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
naproxen	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
diclofenac	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
ibuprofen	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
they	PRP	B-NP	O
were	VBD	B-VP	O
:	:	O	O
rofecoxib	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
celecoxib	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
ibuprofen	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
diclofenac	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
naproxen	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
acetaminophen	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Among	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
users	NNS	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
naproxen	NN	B-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
carry	VB	I-VP	O
the	DT	B-NP	O
highest	JJS	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
AMI	NN	B-NP	B
/	SYM	B-NP	O
GI	NN	I-NP	B
bleeding	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
AMI	NN	I-NP	B
/	SYM	B-VP	O
GI	NN	B-NP	O
toxicity	NN	I-NP	B
of	IN	B-PP	O
celecoxib	NN	B-NP	O
was	VBD	B-VP	O
similar	JJ	B-ADJP	O
to	TO	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
acetaminophen	NN	B-NP	O
and	CC	O	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
better	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
of	IN	B-PP	O
rofecoxib	NN	B-NP	O
and	CC	I-NP	O
NS	NN	I-NP	O
-	HYPH	B-NP	O
NSAIDs	NNS	I-NP	O
.	.	O	O

Among	IN	B-PP	O
users	NNS	B-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
,	,	O	O
both	CC	O	O
celecoxib	NN	B-NP	O
and	CC	I-NP	O
naproxen	NN	I-NP	O
seemed	VBD	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
least	JJS	I-NP	O
toxic	JJ	I-NP	O
.	.	O	O

Quinine	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
arrhythmia	NN	I-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
severe	JJ	B-NP	B
malaria	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
was	VBD	B-VP	O
reported	VBN	I-VP	O
that	IN	B-SBAR	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
severe	JJ	B-NP	B
malaria	NN	I-NP	I
patient	NN	I-NP	O
with	IN	B-PP	O
jaundice	NN	B-NP	B
who	WP	B-NP	O
presented	VBD	B-VP	O
with	IN	B-PP	O
arrhythmia	NN	B-NP	B
(	(	O	O
premature	JJ	B-NP	B
ventricular	JJ	I-NP	I
contraction	NN	I-NP	I
)	)	O	O
while	IN	B-SBAR	O
getting	VBG	B-VP	O
quinine	NN	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
reported	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
man	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
years	NNS	I-NP	O
old	JJ	B-ADJP	O
,	,	O	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
hospital	NN	B-NP	O
with	IN	B-PP	O
high	JJ	B-NP	O
fever	NN	I-NP	B
,	,	O	O
chill	NN	B-NP	B
,	,	O	O
vomiting	NN	B-NP	B
,	,	O	O
jaundice	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
fully	RB	B-ADJP	O
conscious	JJ	I-ADJP	O
,	,	O	O
blood	NN	B-NP	O
pressure	NN	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mmHg	NN	I-NP	O
,	,	O	O
pulse	NN	B-NP	O
rate	NN	I-NP	O
num	CD	I-NP	O
x	NN	I-NP	O
/	SYM	B-NP	O
minute	NN	I-NP	O
,	,	O	O
regular	JJ	B-ADJP	O
.	.	O	O

On	IN	B-PP	O
admission	NN	B-NP	O
,	,	O	O
laboratory	NN	B-NP	O
examination	NN	I-NP	O
showed	VBD	B-VP	O
Plasmodium	NNP	B-NP	O
falciparum	NNP	I-NP	O
,	,	O	O
total	JJ	B-NP	O
bilirubin	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
,	,	O	O
conjugated	VBD	B-VP	O
bilirubin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dL	NN	I-NP	O
,	,	O	O
unconjugated	JJ	B-NP	O
bilirubin	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	O	O
dL	NN	B-NP	O
,	,	O	O
potassium	NN	B-NP	O
num	CD	I-NP	O
meq	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
Patient	NN	I-NP	O
was	VBD	B-VP	O
diagnosed	VBN	I-VP	O
as	IN	B-PP	O
severe	JJ	B-NP	B
malaria	NN	I-NP	I
with	IN	B-PP	O
jaundice	NN	B-NP	B
and	CC	O	O
got	VBD	B-VP	O
quinine	NN	B-NP	O
infusion	NN	I-NP	O
in	IN	B-PP	O
dextrose	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
hour	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
second	JJ	I-NP	O
day	NN	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
vomitus	NN	B-NP	B
,	,	O	O
diarrhea	NN	B-NP	B
,	,	O	O
tinnitus	NN	B-NP	B
,	,	O	O
loss	NN	B-NP	B
of	IN	B-PP	I
hearing	NN	B-NP	I
.	.	O	O

After	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
of	IN	B-PP	O
quinine	NN	B-NP	O
infusion	NN	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
felt	VBD	B-VP	O
palpitation	NN	B-NP	B
and	CC	O	O
electrocardiography	NN	B-NP	O
(	(	O	O
ECG	NN	B-NP	O
)	)	O	O
recording	NN	B-NP	O
showed	VBD	B-VP	O
premature	JJ	B-NP	B
ventricular	JJ	I-NP	I
contraction	NN	I-NP	I
(	(	O	O
PVC	NN	B-NP	B
)	)	O	O
>	SYM	B-NP	O
num	CD	I-NP	O
x	SYM	I-NP	O
/	SYM	I-NP	O
minute	NN	I-NP	O
,	,	O	O
trigemini	NN	B-NP	O
,	,	O	O
constant	JJ	B-NP	O
type	NN	I-NP	O
-	HYPH	O	O
-	HYPH	B-NP	O
sinoatrial	JJ	I-NP	B
block	NN	I-NP	I
,	,	O	O
positive	JJ	B-NP	O
U	NN	I-NP	O
wave	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lidocaine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
intravenously	RB	B-VP	O
followed	VBN	I-VP	O
by	IN	B-PP	O
infusion	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
in	IN	B-PP	O
dextrose	NN	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
and	CC	I-NP	O
potassium	NN	I-NP	O
aspartate	NN	I-NP	O
tablet	NN	I-NP	O
.	.	O	O

Quinine	NN	B-NP	O
infusion	NN	I-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
changed	VBN	B-VP	O
with	IN	B-PP	O
sulfate	NN	B-NP	O
quinine	NN	I-NP	O
tablets	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
hours	NNS	I-NP	O
later	RB	B-ADVP	O
the	DT	B-NP	O
patient	NN	I-NP	O
felt	VBD	B-VP	O
better	RBR	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
PVC	NN	B-NP	B
reduced	VBD	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
x	NN	I-NP	O
/	SYM	I-NP	O
minute	NN	I-NP	O
and	CC	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
day	NN	I-NP	O
ECG	NN	I-NP	O
was	VBD	B-VP	O
normal	JJ	B-ADJP	O
,	,	O	O
potassium	NN	B-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
meq	NN	I-NP	O
/	SYM	B-NP	O
L	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
discharged	VBN	I-VP	O
on	IN	B-PP	O
7th	JJ	B-NP	O
day	NN	I-NP	O
in	IN	B-PP	O
good	JJ	B-NP	O
condition	NN	I-NP	O
.	.	O	O

Quinine	NN	B-NP	O
,	,	O	O
like	IN	B-PP	O
quinidine	NN	B-NP	O
,	,	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
chincona	NN	I-NP	O
alkaloid	NN	I-NP	O
that	WDT	B-NP	O
has	VBZ	B-VP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
arrhythmic	JJ	I-NP	B
property	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
it	PRP	B-NP	O
also	RB	B-ADVP	O
pro	AFX	B-VP	O
-	HYPH	B-ADJP	O
arrhythmic	JJ	I-ADJP	B
that	WDT	B-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
various	JJ	B-NP	O
arrhythmias	NNS	I-NP	B
,	,	O	O
including	VBG	B-PP	O
severe	JJ	B-NP	O
arrhythmia	NN	I-NP	B
such	JJ	B-PP	O
as	IN	I-PP	O
multiple	JJ	B-NP	O
PVC	NN	I-NP	B
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
parenteral	JJ	B-NP	O
quinine	NN	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
done	VBN	I-VP	O
carefully	RB	B-ADVP	O
and	CC	O	O
with	IN	B-PP	O
good	JJ	B-NP	O
observation	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
its	PRP$	B-NP	O
pro	AFX	I-NP	O
-	HYPH	I-NP	O
arrhythmic	JJ	I-NP	B
effect	NN	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
older	JJR	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
heart	NN	B-NP	B
diseases	NNS	I-NP	I
or	CC	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
electrolyte	NN	B-NP	B
disorder	NN	I-NP	I
(	(	O	O
hypokalemia	NN	B-NP	B
)	)	O	O
which	WDT	B-NP	O
frequently	RB	B-ADVP	O
occurs	VBZ	B-VP	O
due	IN	B-PP	O
to	TO	B-PP	O
vomiting	NN	B-NP	B
and	CC	O	O
or	CC	O	O
diarrhea	NN	B-NP	B
in	IN	B-PP	O
malaria	NN	B-NP	B
cases	NNS	I-NP	O
.	.	O	O

Penicillamine	NN	B-NP	O
-	HYPH	B-PP	O
related	VBN	B-NP	O
lichenoid	NN	I-NP	B
dermatitis	NN	I-NP	I
and	CC	I-NP	O
utility	NN	I-NP	O
of	IN	B-PP	O
zinc	NN	B-NP	O
acetate	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
Wilson	NNP	I-NP	B
disease	NN	I-NP	I
patient	NN	I-NP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	O
presentation	NN	I-NP	O
,	,	O	O
anxiety	NN	B-NP	B
and	CC	I-NP	O
SPECT	NN	I-NP	O
abnormalities	NNS	I-NP	O
.	.	O	O

Wilson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
is	VBZ	B-VP	O
an	DT	B-NP	O
autosomal	JJ	I-NP	O
recessive	JJ	I-NP	O
disorder	NN	I-NP	O
of	IN	B-PP	O
hepatic	JJ	B-NP	O
copper	NN	I-NP	O
metabolism	NN	I-NP	O
with	IN	B-PP	O
consequent	JJ	B-NP	O
copper	NN	I-NP	O
accumulation	NN	I-NP	O
and	CC	I-NP	O
toxicity	NN	I-NP	B
in	IN	B-PP	O
many	JJ	B-NP	O
tissues	NNS	I-NP	O
and	CC	O	O
consequent	JJ	B-NP	O
hepatic	JJ	I-NP	B
,	,	I-NP	I
neurologic	JJ	I-NP	I
and	CC	I-NP	I
psychiatric	JJ	I-NP	I
disorders	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
Wilson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
with	IN	B-PP	O
chronic	JJ	B-NP	B
liver	NN	I-NP	I
disease	NN	I-NP	I
;	:	O	O
moreover	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
,	,	O	O
presenting	VBG	B-VP	O
also	RB	B-ADVP	O
with	IN	B-PP	O
high	JJ	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
state	NN	B-NP	O
anxiety	NN	I-NP	B
without	IN	B-PP	O
depression	NN	B-NP	B
,	,	O	O
99mTc	NN	B-NP	O
-	HYPH	B-NP	O
ECD	NN	I-NP	O
-	HYPH	O	O
SPECT	NN	B-NP	O
showed	VBD	B-VP	O
cortical	JJ	B-NP	O
hypoperfusion	NN	I-NP	O
in	IN	B-PP	O
frontal	JJ	B-NP	O
lobes	NNS	I-NP	O
,	,	O	O
more	JJR	B-NP	O
marked	JJ	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
frontal	JJ	I-NP	O
lobe	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
follow	VB	I-NP	O
-	HYPH	B-VP	O
up	RP	B-PRT	O
of	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
,	,	O	O
penicillamine	NN	B-NP	O
was	VBD	B-VP	O
interrupted	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
lichenoid	JJ	I-NP	B
dermatitis	NN	I-NP	I
,	,	O	O
and	CC	O	O
zinc	NN	B-NP	O
acetate	NN	I-NP	O
permitted	VBD	B-VP	O
to	TO	I-VP	O
continue	VB	I-VP	O
the	DT	B-NP	O
successful	JJ	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
without	IN	B-PP	O
side	NN	B-NP	O
-	HYPH	B-NP	O
effects	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
our	PRP$	B-NP	O
case	NN	I-NP	O
the	DT	B-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
zinc	NN	B-NP	O
acetate	NN	I-NP	O
represented	VBD	B-VP	O
an	DT	B-NP	O
effective	JJ	I-NP	O
treatment	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
Wilson	NNP	I-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
patient	NN	I-NP	O
in	IN	B-PP	O
which	WDT	B-NP	O
penicillamine	NN	B-NP	O
-	HYPH	I-NP	O
related	VBN	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
appeared	VBD	B-VP	O
.	.	O	O

The	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
zinc	NN	I-NP	O
acetate	NN	I-NP	O
allowed	VBD	B-VP	O
us	PRP	B-NP	O
to	TO	B-VP	O
avoid	VB	I-VP	O
other	JJ	B-NP	O
potentially	RB	I-NP	O
toxic	JJ	I-NP	O
chelating	VBG	I-NP	O
drugs	NNS	I-NP	O
;	:	O	O
this	DT	B-NP	O
observation	NN	I-NP	O
is	VBZ	B-VP	O
in	IN	B-PP	O
line	NN	B-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
growing	VBG	I-NP	O
evidence	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
drug	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Wilson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Since	IN	B-SBAR	O
most	JJS	B-NP	O
of	IN	B-PP	O
Wilson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
penicillamine	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
develop	VB	I-VP	O
this	DT	B-NP	O
skin	NN	I-NP	B
lesion	NN	I-NP	I
,	,	O	O
it	PRP	B-NP	O
could	MD	B-VP	O
be	VB	I-VP	O
conceivable	JJ	B-ADJP	O
that	IN	B-SBAR	O
a	DT	B-NP	O
specific	JJ	I-NP	O
genetic	JJ	I-NP	O
factor	NN	I-NP	O
is	VBZ	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
drug	NN	B-NP	O
response	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
studies	NNS	I-NP	O
are	VBP	B-VP	O
needed	VBN	I-VP	O
for	IN	B-PP	O
a	DT	B-NP	O
better	JJR	I-NP	O
clarification	NN	I-NP	O
of	IN	B-PP	O
Wilson	NNP	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
therapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
in	IN	B-PP	O
particular	JJ	B-ADJP	O
to	TO	B-VP	O
differentiate	VB	I-VP	O
specific	JJ	B-NP	O
therapies	NNS	I-NP	O
for	IN	B-PP	O
different	JJ	B-NP	O
Wilson	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
phenotypes	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
dramatic	JJ	I-NP	O
drop	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
following	VBG	B-PP	O
prehospital	NN	B-NP	O
GTN	NN	I-NP	O
administration	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
male	NN	I-NP	O
in	IN	B-PP	O
his	PRP$	B-NP	O
sixties	NNS	I-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
awoke	NN	I-NP	O
with	IN	B-PP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
following	VBG	B-PP	O
an	DT	B-NP	O
afternoon	NN	I-NP	O
sleep	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
self	VB	I-VP	O
medicate	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
observations	NNS	I-NP	O
were	VBD	B-VP	O
within	IN	B-PP	O
normal	JJ	B-NP	O
limits	NNS	I-NP	O
,	,	O	O
he	PRP	B-NP	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
oxygen	NN	B-NP	O
via	IN	B-PP	O
a	DT	B-NP	O
face	NN	I-NP	O
mask	NN	I-NP	O
and	CC	O	O
glyceryl	NN	B-NP	O
trinitrate	NN	I-NP	O
(	(	O	O
GTN	NN	B-NP	O
)	)	O	O
.	.	O	O

Several	JJ	B-NP	O
minutes	NNS	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
GTN	NN	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
a	DT	B-NP	O
sudden	JJ	I-NP	O
drop	NN	I-NP	B
in	IN	B-PP	I
blood	NN	B-NP	I
pressure	NN	I-NP	I
and	CC	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
,	,	O	O
this	DT	B-NP	O
was	VBD	B-VP	O
rectified	VBN	I-VP	O
by	IN	B-PP	O
atropine	NN	B-NP	O
sulphate	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
fluid	NN	I-NP	O
challenge	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
further	JJ	I-NP	O
deterioration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
condition	NN	B-NP	O
during	IN	B-PP	O
transport	NN	B-NP	O
to	TO	B-PP	O
hospital	NN	B-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
very	RB	B-NP	O
few	JJ	I-NP	O
documented	VBN	I-NP	O
case	NN	I-NP	O
like	IN	B-PP	O
this	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prehospital	NN	I-NP	O
scientific	JJ	I-NP	O
literature	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cause	NN	I-NP	O
appears	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
the	DT	B-NP	O
Bezold	NNP	I-NP	O
-	HYPH	I-NP	O
Jarish	JJ	I-NP	O
reflex	NN	I-NP	O
,	,	O	O
stimulation	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ventricular	JJ	I-NP	O
walls	NNS	I-NP	O
which	WDT	B-NP	O
in	IN	B-PP	O
turn	NN	B-NP	O
decreases	VBZ	B-VP	O
sympathetic	JJ	B-NP	O
outflow	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
vasomotor	NN	I-NP	O
centre	NN	I-NP	O
.	.	O	O

Prehospital	NN	B-NP	O
care	NN	I-NP	O
providers	NNS	I-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
managing	VBG	I-VP	O
any	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
syncopal	JJ	I-NP	B
episode	NN	I-NP	I
that	WDT	B-NP	O
fails	VBZ	B-VP	O
to	TO	I-VP	O
recover	VB	I-VP	O
within	IN	B-PP	O
a	DT	B-NP	O
reasonable	JJ	I-NP	O
time	NN	I-NP	O
frame	NN	I-NP	O
should	MD	B-VP	O
consider	VB	I-VP	O
the	DT	B-NP	O
Bezold	NNP	I-NP	O
-	HYPH	I-NP	O
Jarisch	NNP	I-NP	O
reflex	NN	I-NP	O
as	IN	B-PP	O
the	DT	B-NP	O
cause	NN	I-NP	O
and	CC	O	O
manage	VB	B-VP	O
the	DT	B-NP	O
patient	NN	I-NP	O
accordingly	RB	B-ADVP	O
.	.	O	O

Acute	JJ	B-NP	B
encephalopathy	NN	I-NP	I
and	CC	O	O
cerebral	JJ	B-NP	B
vasospasm	NN	I-NP	I
after	IN	B-PP	O
multiagent	JJ	B-NP	O
chemotherapy	NN	I-NP	O
including	VBG	B-PP	O
PEG	NN	B-NP	O
-	HYPH	B-NP	O
asparaginase	NN	I-NP	O
and	CC	O	O
intrathecal	JJ	B-NP	O
cytarabine	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
girl	NN	I-NP	O
with	IN	B-PP	O
an	DT	B-NP	O
unusual	JJ	I-NP	O
reaction	NN	I-NP	O
to	TO	B-PP	O
induction	NN	B-NP	O
chemotherapy	NN	I-NP	O
for	IN	B-PP	O
precursor	NN	B-NP	O
B	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
acute	JJ	I-NP	B
lymphoblastic	JJ	I-NP	I
leukemia	NN	I-NP	I
(	(	O	O
ALL	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
encephalopathy	NN	I-NP	I
evidenced	VBN	B-VP	O
by	IN	B-PP	O
behavioral	JJ	B-NP	O
changes	NNS	I-NP	O
,	,	O	O
aphasia	NN	B-NP	B
,	,	O	O
incontinence	NN	B-NP	B
,	,	O	O
visual	JJ	B-NP	B
hallucinations	NNS	I-NP	I
,	,	O	O
and	CC	O	O
right	JJ	B-NP	O
-	HYPH	I-NP	O
sided	JJ	I-NP	O
weakness	NN	I-NP	B
with	IN	B-PP	O
diffuse	JJ	B-NP	O
cerebral	JJ	I-NP	B
vasospasm	NN	I-NP	I
on	IN	B-PP	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
angiography	NN	I-NP	O
after	IN	B-SBAR	O
the	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
intrathecal	JJ	B-NP	O
cytarabine	NN	I-NP	O
.	.	O	O

Vincristine	NN	B-NP	O
,	,	O	O
dexamethasone	NN	B-NP	O
,	,	O	O
and	CC	O	O
polyethylene	NN	B-NP	O
glycol	NN	I-NP	O
-	HYPH	B-NP	O
asparaginase	NN	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
administered	VBN	I-VP	O
before	IN	B-PP	O
the	DT	B-NP	O
episode	NN	I-NP	O
as	IN	B-PP	O
part	NN	B-NP	O
of	IN	B-PP	O
induction	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Neurologic	JJ	B-NP	O
status	NN	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
acute	JJ	I-NP	O
event	NN	I-NP	O
,	,	O	O
and	CC	O	O
magnetic	JJ	B-NP	O
resonance	NN	I-NP	O
angiography	NN	I-NP	O
findings	NNS	I-NP	O
returned	VBD	B-VP	O
to	TO	B-PP	O
normal	JJ	B-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
valsartan	NN	B-NP	O
/	SYM	B-NP	O
hydrochlorothiazide	NN	I-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
at	IN	B-PP	O
doses	NNS	B-NP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
versus	IN	B-PP	O
monotherapy	NN	B-NP	O
:	:	O	O
a	DT	B-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
-	HYPH	I-NP	O
controlled	VBN	I-NP	O
study	NN	I-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
combination	NN	I-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
hypertensive	JJ	B-NP	B
adults	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
third	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
for	IN	B-PP	O
hypertension	NN	B-NP	B
attain	NN	I-NP	O
adequate	JJ	I-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
BP	NN	B-NP	O
)	)	O	O
control	NN	B-NP	O
,	,	O	O
and	CC	O	O
multidrug	JJ	B-NP	O
regimens	NNS	I-NP	O
are	VBP	B-VP	O
often	RB	I-VP	O
required	VBN	I-VP	O
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
lifelong	JJ	I-NP	O
nature	NN	I-NP	O
of	IN	B-PP	O
hypertension	NN	B-NP	B
,	,	O	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
need	NN	I-NP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
higher	JJR	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
hypertensive	JJ	I-NP	B
therapies	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
valsartan	NN	B-NP	O
(	(	O	O
VAL	NN	B-NP	O
)	)	O	O
or	CC	O	O
hydrochlorothiazide	NN	B-NP	O
(	(	O	O
HCTZ	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
monotherapy	NN	I-NP	O
and	CC	O	O
higher	JJR	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
combinations	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
essential	JJ	B-NP	B
hypertension	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
first	JJ	I-NP	O
part	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
multicenter	NN	B-NP	O
,	,	O	O
randomized	VBN	B-NP	O
,	,	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
,	,	I-NP	O
placebo	NN	I-NP	O
controlled	VBN	B-VP	O
,	,	O	O
parallel	JJ	B-NP	O
-	HYPH	I-NP	O
group	NN	I-NP	O
trial	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
essential	JJ	B-NP	B
hypertension	NN	I-NP	I
were	VBD	B-VP	O
randomized	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
:	:	O	O
VAL	NN	B-NP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
;	:	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
;	:	O	O
VAL	NN	B-NP	O
/	SYM	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
,	,	O	O
or	CC	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
;	:	O	O
or	CC	O	O
placebo	NN	B-NP	O
.	.	O	O

Mean	JJ	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
MSDBP	NN	B-NP	O
and	CC	I-NP	O
mean	NN	I-NP	O
sitting	VBG	B-VP	O
systolic	JJ	B-NP	O
BP	NN	I-NP	O
(	(	O	O
MSSBP	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
analyzed	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
core	NN	I-NP	O
study	NN	I-NP	O
end	NN	I-NP	O
point	NN	I-NP	O
.	.	O	O

VAL	NN	B-NP	O
/	SYM	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
were	VBD	B-VP	O
further	RB	I-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
,	,	O	O
open	JJ	B-NP	O
-	HYPH	I-NP	O
label	NN	I-NP	O
extension	NN	I-NP	O
.	.	O	O

Response	NN	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
MSDBP	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
>	JJR	I-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
decrease	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Control	NN	B-NP	O
was	VBD	B-VP	O
defined	VBN	I-VP	O
as	IN	B-PP	O
MSDBP	NN	B-NP	O
<	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
baseline	NN	B-NP	O
.	.	O	O

Tolerability	NN	B-NP	O
was	VBD	B-VP	O
assessed	VBN	I-VP	O
by	IN	B-PP	O
monitoring	VBG	B-VP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
at	IN	B-PP	O
randomization	NN	B-NP	O
and	CC	O	O
all	DT	B-NP	O
subsequent	JJ	I-NP	O
study	NN	I-NP	O
visits	NNS	I-NP	O
and	CC	O	O
regular	JJ	B-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
hematology	NN	B-NP	O
and	CC	I-NP	O
blood	NN	I-NP	O
chemistry	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
randomized	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
core	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
active	JJ	I-NP	O
treatments	NNS	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significantly	RB	B-NP	O
reduced	VBN	I-NP	O
MSSBP	NN	I-NP	O
and	CC	I-NP	O
MSDBP	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
core	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
study	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
each	DT	B-NP	O
monotherapy	NN	I-NP	O
significantly	RB	B-VP	O
contributing	VBG	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
overall	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
combination	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Each	DT	B-NP	O
combination	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significantly	RB	B-NP	O
greater	JJR	I-NP	O
reductions	NNS	I-NP	O
in	IN	B-PP	O
MSSBP	NN	B-NP	O
and	CC	I-NP	O
MSDBP	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
monotherapies	NNS	I-NP	O
and	CC	I-NP	O
placebo	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
MSSBP	NN	B-NP	O
/	SYM	B-NP	O
MSDBP	NN	I-NP	O
with	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
/	SYM	B-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
num	CD	B-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mm	NN	I-NP	O
Hg	NN	I-NP	O
with	IN	B-PP	O
placebo	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
MSSBP	NN	B-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
greater	JJR	I-ADJP	O
with	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	O	O
HCTZ	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
.	.	O	O

Rates	NNS	B-NP	O
of	IN	B-PP	O
response	NN	B-NP	O
and	CC	I-NP	O
BP	NN	I-NP	O
control	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
combination	NN	B-NP	O
treatment	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
monotherapy	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
hypokalemia	NN	B-NP	B
was	VBD	B-VP	O
lower	JJR	B-ADJP	O
with	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	B-VP	O
HCTZ	NN	B-NP	O
combinations	NNS	I-NP	O
than	IN	B-PP	O
with	IN	B-PP	O
HCTZ	NN	B-NP	O
monotherapies	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
majority	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
core	NN	I-NP	O
study	NN	I-NP	O
were	VBD	B-VP	O
of	IN	B-PP	O
mild	JJ	B-NP	O
to	TO	B-PP	O
moderate	JJ	B-NP	O
severity	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
efficacy	NN	I-NP	O
and	CC	I-NP	O
tolerability	NN	I-NP	O
of	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	B-NP	O
HCTZ	NN	I-NP	O
combinations	NNS	I-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
during	IN	B-PP	O
the	DT	B-NP	O
extension	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
population	NN	I-NP	O
,	,	O	O
combination	NN	B-NP	O
therapies	NNS	I-NP	O
with	IN	B-PP	O
VAL	NN	B-NP	O
/	SYM	B-NP	O
HCTZ	NN	I-NP	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
significantly	RB	B-NP	O
greater	JJR	I-NP	O
BP	NN	I-NP	O
reductions	NNS	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
either	CC	O	O
monotherapy	NN	B-NP	O
,	,	O	O
were	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
and	CC	O	O
were	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
less	JJR	B-NP	O
hypokalemia	NN	I-NP	B
than	IN	B-PP	O
HCTZ	NN	B-NP	O
alone	RB	B-ADVP	O
.	.	O	O

Succimer	NN	B-NP	O
chelation	NN	I-NP	O
improves	VBZ	B-VP	O
learning	NN	B-NP	O
,	,	O	O
attention	NN	B-NP	O
,	,	O	O
and	CC	O	O
arousal	JJ	B-NP	O
regulation	NN	I-NP	O
in	IN	B-PP	O
lead	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
rats	NNS	I-NP	O
but	CC	O	O
produces	VBZ	B-VP	O
lasting	VBG	I-VP	O
cognitive	JJ	B-NP	B
impairment	NN	I-NP	I
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
lead	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
is	VBZ	B-VP	O
growing	VBG	B-NP	O
pressure	NN	I-NP	O
for	IN	B-SBAR	O
clinicians	NNS	B-NP	O
to	TO	B-VP	O
prescribe	VB	I-VP	O
chelation	NN	B-NP	O
therapy	NN	I-NP	O
at	IN	B-PP	O
only	RB	B-NP	O
slightly	RB	I-NP	O
elevated	JJ	I-NP	O
blood	NN	I-NP	O
lead	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
very	RB	B-NP	O
few	JJ	I-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
evaluated	VBN	I-VP	O
whether	IN	B-SBAR	O
chelation	NN	B-NP	O
improves	VBZ	B-VP	O
cognitive	JJ	B-NP	O
outcomes	NNS	I-NP	O
in	IN	B-PP	O
Pb	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
children	NNS	I-NP	O
,	,	O	O
or	CC	O	O
whether	IN	B-SBAR	O
these	DT	B-NP	O
agents	NNS	I-NP	O
have	VBP	B-VP	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
affect	VB	I-VP	O
brain	NN	B-NP	O
development	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
Pb	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
answer	VB	I-VP	O
these	DT	B-NP	O
questions	NNS	I-NP	O
,	,	O	O
using	VBG	B-VP	O
a	DT	B-NP	O
rodent	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
childhood	NN	I-NP	O
Pb	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
succimer	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
chelating	VBG	I-NP	O
agent	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
Pb	NN	B-NP	B
poisoning	NN	I-NP	I
.	.	O	O

Pb	NN	B-NP	O
exposure	NN	I-NP	O
produced	VBD	B-VP	O
lasting	VBG	I-VP	O
impairments	NNS	B-NP	B
in	IN	B-PP	I
learning	NN	B-NP	I
,	,	O	I
attention	NN	B-NP	I
,	,	O	I
inhibitory	JJ	B-NP	I
control	NN	I-NP	I
,	,	O	I
and	CC	O	I
arousal	JJ	B-NP	I
regulation	NN	I-NP	I
,	,	O	O
paralleling	VBG	B-VP	O
the	DT	B-NP	O
areas	NNS	I-NP	O
of	IN	B-PP	O
dysfunction	NN	B-NP	O
seen	VBN	B-VP	O
in	IN	B-PP	O
Pb	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
children	NNS	I-NP	O
.	.	O	O

Succimer	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Pb	NN	I-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
rats	NNS	I-NP	O
significantly	RB	B-ADVP	O
improved	VBD	B-VP	O
learning	NN	B-NP	O
,	,	O	O
attention	NN	B-NP	O
,	,	O	O
and	CC	O	O
arousal	JJ	B-NP	O
regulation	NN	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
the	DT	B-NP	O
efficacy	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
varied	VBD	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
function	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
Pb	NN	I-NP	O
exposure	NN	I-NP	O
level	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
specific	JJ	I-NP	O
functional	JJ	I-NP	O
deficit	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
succimer	NN	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
not	RB	B-VP	O
previously	RB	I-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
Pb	NN	B-NP	O
produced	VBD	B-VP	O
lasting	JJ	B-NP	O
and	CC	I-NP	O
pervasive	JJ	I-NP	O
cognitive	JJ	I-NP	B
and	CC	I-NP	I
affective	JJ	I-NP	I
dysfunction	NN	I-NP	I
comparable	JJ	B-ADJP	O
in	IN	B-PP	O
magnitude	NN	B-NP	O
to	TO	B-PP	O
that	DT	B-NP	O
produced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
higher	JJR	I-NP	O
Pb	NN	I-NP	O
exposure	NN	I-NP	O
regimen	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
data	NNS	I-NP	O
,	,	O	O
to	TO	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
,	,	O	O
to	TO	B-VP	O
show	VB	I-VP	O
that	IN	B-SBAR	O
treatment	NN	B-NP	O
with	IN	B-PP	O
any	DT	B-NP	O
chelating	VBG	I-NP	O
agent	NN	I-NP	O
can	MD	B-VP	O
alleviate	VB	I-VP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
Pb	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
possible	JJ	B-ADJP	O
to	TO	B-VP	O
identify	VB	I-VP	O
a	DT	B-NP	O
succimer	NN	I-NP	O
treatment	NN	I-NP	O
protocol	NN	I-NP	O
that	WDT	B-NP	O
improves	VBZ	B-VP	O
cognitive	JJ	B-NP	O
outcomes	NNS	I-NP	O
in	IN	B-PP	O
Pb	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
children	NNS	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
they	PRP	B-NP	O
also	RB	B-ADVP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
succimer	NN	B-NP	O
treatment	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
strongly	RB	I-VP	O
discouraged	VBN	I-VP	O
for	IN	B-PP	O
children	NNS	B-NP	O
who	WP	B-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
have	VB	I-VP	O
elevated	VBN	I-VP	O
tissue	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
Pb	NN	B-NP	O
or	CC	O	O
other	JJ	B-NP	O
heavy	JJ	I-NP	O
metals	NNS	I-NP	O
.	.	O	O

Caffeine	NN	B-NP	O
challenge	NN	I-NP	O
test	NN	I-NP	O
in	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
and	CC	O	O
depression	NN	B-NP	B
with	IN	B-PP	O
panic	NN	B-NP	B
attacks	NNS	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
observe	VB	I-VP	O
if	IN	B-SBAR	O
patients	NNS	B-NP	O
with	IN	B-PP	O
panic	NN	B-NP	B
disorder	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
and	CC	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
major	JJ	B-NP	B
depression	NN	I-NP	I
with	IN	B-PP	O
panic	JJ	B-NP	B
attacks	NNS	I-NP	I
(	(	O	O
MDP	NN	B-NP	B
)	)	O	O
(	(	O	O
Diagnostic	NNP	B-NP	O
and	CC	O	O
Statistical	NNP	B-NP	O
Manual	NNP	I-NP	O
of	IN	B-PP	O
Mental	NNP	B-NP	B
Disorders	NNP	I-NP	I
,	,	O	O
Fourth	NNP	B-NP	O
Edition	NNP	I-NP	O
criteria	NNS	I-NP	O
)	)	O	O
respond	VBP	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
similar	JJ	I-NP	O
way	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
induction	NN	I-NP	O
of	IN	B-PP	O
panic	NN	B-NP	B
attacks	NNS	I-NP	I
by	IN	B-PP	O
an	DT	B-NP	O
oral	JJ	I-NP	O
caffeine	NN	I-NP	O
challenge	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
randomly	RB	B-ADVP	O
selected	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
MDP	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
with	IN	B-PP	O
major	JJ	B-NP	B
depression	NN	I-NP	I
without	IN	B-PP	O
panic	JJ	B-NP	B
attacks	NNS	I-NP	I
(	(	O	O
MD	NN	B-NP	B
)	)	O	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
healthy	JJ	I-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
psychotropic	JJ	I-NP	O
drug	NN	I-NP	O
for	IN	B-PP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
randomized	VBN	I-NP	O
double	JJ	I-NP	O
-	HYPH	I-NP	O
blind	JJ	I-NP	O
experiment	NN	I-NP	O
performed	VBN	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
occasions	NNS	I-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
apart	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
caffeine	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
caffeine	NN	I-NP	O
-	HYPH	O	O
free	JJ	O	O
(	(	O	O
placebo	NN	B-NP	O
)	)	O	O
solution	NN	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
coffee	NN	I-NP	O
form	NN	I-NP	O
and	CC	I-NP	O
anxiety	NN	I-NP	B
scales	NNS	I-NP	O
were	VBD	B-VP	O
applied	VBN	I-VP	O
before	IN	B-PP	O
and	CC	I-PP	O
after	IN	I-PP	O
each	DT	B-NP	O
test	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
MDP	NN	B-NP	B
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
MD	NN	B-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
control	NN	B-NP	O
subjects	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
panic	JJ	I-NP	B
attack	NN	I-NP	I
after	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
mg	NN	I-NP	O
caffeine	NN	I-NP	O
challenge	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
PD	NN	B-NP	B
and	CC	I-NP	O
MDP	NN	I-NP	B
were	VBD	B-VP	O
more	RBR	B-ADJP	O
sensitive	JJ	I-ADJP	O
to	TO	B-PP	O
caffeine	NN	B-NP	O
than	IN	B-SBAR	O
were	VBD	B-VP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
MD	NN	B-NP	B
and	CC	O	O
healthy	JJ	B-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

No	DT	B-NP	O
panic	NN	I-NP	B
attack	NN	I-NP	I
was	VBD	B-VP	O
observed	VBN	I-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
caffeine	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
solution	NN	I-NP	O
intake	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
MD	NN	B-NP	B
had	VBD	B-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
heart	NN	I-NP	O
rate	NN	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
test	NN	I-NP	O
than	IN	B-SBAR	O
all	PDT	B-NP	O
the	DT	I-NP	O
other	JJ	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
panic	JJ	B-NP	B
attacks	NNS	I-NP	I
,	,	O	O
no	DT	B-NP	O
matter	NN	I-NP	O
if	IN	B-SBAR	O
associated	VBN	B-VP	O
with	IN	B-PP	O
PD	NN	B-NP	B
or	CC	I-NP	O
MDP	NN	I-NP	B
,	,	O	O
and	CC	O	O
hyperreactivity	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
oral	JJ	I-NP	O
caffeine	NN	I-NP	O
challenge	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Mitral	JJ	B-NP	O
annuloplasty	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
ventricular	JJ	I-NP	O
restoration	NN	I-NP	O
method	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
failing	VBG	I-NP	B
left	JJ	I-NP	I
ventricle	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
pilot	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Undersized	JJ	B-NP	O
mitral	JJ	I-NP	O
annuloplasty	NN	I-NP	O
(	(	O	O
MAP	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
dilated	VBN	B-NP	B
cardiomyopathy	NN	I-NP	I
and	CC	O	O
functional	JJ	B-NP	O
mitral	JJ	I-NP	B
regurgitation	NN	I-NP	I
(	(	O	O
MR	NN	B-NP	B
)	)	O	O
since	IN	B-SBAR	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
addressing	VBG	B-VP	O
the	DT	B-NP	O
MR	NN	I-NP	B
,	,	O	O
the	DT	B-NP	O
MAP	NN	I-NP	O
may	MD	B-VP	O
also	RB	I-VP	O
reshape	VB	I-VP	O
the	DT	B-NP	O
dilated	JJ	I-NP	O
left	JJ	I-NP	O
ventricular	JJ	I-NP	O
(	(	O	O
LV	NN	B-NP	O
)	)	O	O
base	NN	B-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
direct	JJ	I-NP	O
benefits	NNS	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
possible	JJ	I-NP	O
reshaping	NN	I-NP	O
on	IN	B-PP	O
LV	NN	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
underlying	VBG	B-VP	O
MR	NN	B-NP	B
remain	VBP	B-VP	O
incompletely	RB	B-ADJP	O
understood	VBN	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
these	DT	B-NP	O
benefits	NNS	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
canine	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
dogs	NNS	I-NP	O
underwent	VBD	B-VP	O
MAP	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
prosthetic	JJ	I-NP	O
band	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
mitral	JJ	I-NP	O
annulus	NN	I-NP	O
,	,	O	O
using	VBG	B-VP	O
num	CD	B-NP	O
mattress	NN	I-NP	O
sutures	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
sutures	NNS	I-NP	O
were	VBD	B-VP	O
passed	VBN	I-VP	O
individually	RB	B-ADVP	O
through	IN	B-PP	O
num	CD	B-NP	O
tourniquets	NNS	I-NP	O
and	CC	O	O
exteriorized	VBN	B-VP	O
untied	JJ	B-ADJP	O
via	IN	B-PP	O
the	DT	B-NP	O
left	JJ	I-NP	O
atriotomy	NN	I-NP	O
.	.	O	O

Sonomicrometry	NN	B-NP	O
crystals	NNS	I-NP	O
were	VBD	B-VP	O
implanted	VBN	I-VP	O
around	IN	B-PP	O
the	DT	B-NP	O
mitral	JJ	I-NP	O
annulus	NN	I-NP	O
and	CC	O	O
left	VBD	B-VP	O
ventricle	NN	B-NP	O
to	TO	B-VP	O
measure	VB	I-VP	O
geometry	NN	B-NP	O
and	CC	I-NP	O
regional	JJ	I-NP	O
function	NN	I-NP	O
.	.	O	O

Acute	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	I-NP	O
volume	NN	I-NP	O
loading	NN	I-NP	O
after	IN	B-PP	O
weaning	VBG	B-VP	O
from	IN	B-PP	O
cardiopulmonary	JJ	B-NP	O
bypass	NN	I-NP	O
;	:	O	O
an	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
MR	NN	B-NP	B
was	VBD	B-VP	O
confirmed	VBN	I-VP	O
by	IN	B-PP	O
echocardiography	NN	B-NP	O
.	.	O	O

MAP	NN	B-NP	O
was	VBD	B-VP	O
accomplished	VBN	I-VP	O
by	IN	B-PP	O
cinching	VBG	B-VP	O
the	DT	B-NP	O
tourniquets	NNS	I-NP	O
.	.	O	O

Data	NNS	B-NP	O
were	VBD	B-VP	O
acquired	VBN	I-VP	O
at	IN	B-PP	O
baseline	NN	B-NP	O
,	,	O	O
after	IN	B-PP	O
induction	NN	B-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
,	,	B-PP	O
and	CC	I-PP	O
after	IN	B-PP	O
MAP	NN	B-NP	O
.	.	O	O

MAP	NN	B-NP	O
decreased	VBD	B-VP	O
mitral	JJ	B-NP	O
annular	JJ	I-NP	O
dimensions	NNS	I-NP	O
in	IN	B-PP	O
both	CC	B-NP	O
commissure	NN	I-NP	O
-	HYPH	I-NP	O
commissure	NN	B-NP	O
and	CC	O	O
septal	JJ	B-NP	O
-	HYPH	I-NP	O
lateral	JJ	I-NP	O
directions	NNS	I-NP	O
.	.	O	O

Concomitantly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
diastolic	JJ	I-NP	O
diameter	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
LV	NN	I-NP	O
base	NN	I-NP	O
and	CC	O	O
LV	NN	B-NP	O
sphericity	NN	I-NP	O
decreased	VBD	B-VP	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
improved	VBN	B-VP	O
)	)	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mm	NN	I-NP	O
,	,	B-PP	O
and	CC	I-PP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Decreases	NNS	B-NP	O
were	VBD	B-VP	O
evident	JJ	B-ADJP	O
in	IN	B-PP	O
both	CC	O	O
LV	NN	B-NP	O
end	NN	I-NP	O
-	HYPH	B-NP	O
diastolic	JJ	I-NP	O
pressure	NN	I-NP	O
(	(	O	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	B-NP	O
mmHg	NN	I-NP	O
,	,	O	O
p	NN	B-NP	O
=	SYM	B-VP	O
num	CD	B-NP	O
and	CC	O	O
Tau	NNP	B-NP	O
,	,	O	O
while	IN	B-SBAR	O
fractional	JJ	B-NP	O
shortening	NN	I-NP	O
at	IN	B-PP	O
the	DT	B-NP	O
LV	NN	I-NP	O
base	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
+	SYM	B-ADJP	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

After	IN	B-PP	O
MAP	NN	B-NP	O
,	,	O	O
increases	NNS	B-NP	O
were	VBD	B-VP	O
identified	VBN	I-VP	O
in	IN	B-PP	O
both	CC	B-NP	O
cardiac	JJ	I-NP	O
output	NN	I-NP	O
and	CC	I-NP	O
Emax	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
acquired	VBN	B-VP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
isolated	VBN	B-NP	O
MAP	NN	I-NP	O
may	MD	B-VP	O
have	VB	I-VP	O
certain	JJ	B-NP	O
benefits	NNS	I-NP	O
on	IN	B-PP	O
LV	NN	B-NP	O
dimension	NN	I-NP	O
/	SYM	B-NP	O
function	NN	I-NP	O
in	IN	B-PP	O
acute	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
,	,	O	O
even	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
MR	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
further	JJ	B-NP	O
investigations	NNS	I-NP	O
are	VBP	B-VP	O
warranted	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
heart	NN	I-NP	B
failure	NN	I-NP	I
.	.	O	O

Piperacillin	NN	B-NP	O
/	SYM	I-NP	O
tazobactam	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizure	NN	I-NP	B
rapidly	RB	B-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
high	JJ	B-NP	O
flux	NN	I-NP	O
hemodialysis	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
on	IN	B-PP	O
peritoneal	JJ	B-NP	O
dialysis	NN	I-NP	O
.	.	O	O

Despite	IN	B-PP	O
popular	JJ	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
piperacillin	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
dire	JJ	I-NP	O
neurotoxicity	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
piperacillin	NN	B-NP	O
still	RB	B-ADVP	O
goes	VBZ	B-VP	O
unrecognized	JJ	B-ADJP	O
,	,	O	O
leading	VBG	B-VP	O
to	TO	B-PP	O
a	DT	B-NP	O
delay	NN	I-NP	O
in	IN	B-PP	O
appropriate	JJ	B-NP	O
management	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
end	NN	B-NP	B
-	HYPH	I-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
receiving	VBG	B-VP	O
continuous	JJ	B-NP	O
ambulatory	JJ	I-NP	O
peritoneal	JJ	I-NP	O
dialysis	NN	I-NP	O
(	(	O	O
CAPD	NN	B-NP	O
)	)	O	O
,	,	O	O
who	WP	B-NP	O
developed	VBD	B-VP	O
slurred	VBN	I-VP	O
speech	NN	B-NP	O
,	,	O	O
tremor	NN	B-NP	B
,	,	O	O
bizarre	JJ	B-NP	O
behavior	NN	I-NP	O
,	,	O	O
progressive	JJ	B-NP	O
mental	JJ	I-NP	O
confusion	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
episodes	NNS	I-NP	O
of	IN	B-PP	O
generalized	VBN	B-NP	O
tonic	JJ	I-NP	B
-	HYPH	I-NP	I
clonic	JJ	I-NP	I
seizure	NN	I-NP	I
(	(	O	O
GTCS	NN	B-NP	B
)	)	O	O
after	IN	B-PP	O
num	CD	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
piperacillin	NN	B-NP	O
/	SYM	B-NP	O
tazobactam	NN	I-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
for	IN	B-PP	O
bronchiectasis	NN	B-NP	B
with	IN	B-PP	O
secondary	JJ	B-NP	B
infection	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
laboratory	NN	I-NP	O
data	NNS	I-NP	O
revealed	VBD	B-VP	O
normal	JJ	B-NP	O
plasma	NN	I-NP	O
electrolyte	NN	I-NP	O
and	CC	I-NP	O
ammonia	NN	I-NP	O
levels	NNS	I-NP	O
but	CC	O	O
leukocytosis	NN	B-NP	B
.	.	O	O

Neurologic	JJ	B-NP	O
examinations	NNS	I-NP	O
showed	VBD	B-VP	O
dysarthria	NN	B-NP	B
and	CC	I-NP	O
bilateral	JJ	I-NP	O
Babinski	NNP	I-NP	O
sign	NN	I-NP	O
.	.	O	O

Computed	VBN	B-NP	O
tomography	NN	I-NP	O
of	IN	B-PP	O
brain	NN	B-NP	O
and	CC	I-NP	O
electroencephalogram	NN	I-NP	O
were	VBD	B-VP	O
unremarkable	JJ	B-ADJP	O
.	.	O	O

Despite	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
antiepileptic	JJ	B-NP	O
agents	NNS	I-NP	O
,	,	O	O
another	DT	B-NP	O
GTCS	NN	I-NP	B
episode	NN	I-NP	O
recurred	VBD	B-VP	O
after	IN	B-PP	O
the	DT	B-NP	O
sixth	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
piperacillin	NN	B-NP	O
/	SYM	B-NP	O
tazobactam	NN	I-NP	O
.	.	O	O

Brain	NN	B-NP	O
magnetic	JJ	I-NP	O
resonance	NN	I-NP	O
imaging	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
demonstrate	VB	I-VP	O
acute	JJ	B-NP	O
infarction	NN	I-NP	B
and	CC	O	O
organic	JJ	B-NP	B
brain	NN	I-NP	I
lesions	NNS	I-NP	I
.	.	O	O

Initiation	NN	B-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
flux	NN	I-NP	O
hemodialysis	NN	I-NP	O
rapidly	RB	B-ADVP	O
reversed	VBD	B-VP	O
the	DT	B-NP	O
neurologic	JJ	I-NP	O
symptoms	NNS	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

Piperacillin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
encephalopathy	NN	I-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
uremic	JJ	I-NP	B
patients	NNS	I-NP	O
with	IN	B-PP	O
unexplained	JJ	B-NP	O
neurological	JJ	I-NP	O
manifestations	NNS	I-NP	O
.	.	O	O

CAPD	NN	B-NP	O
is	VBZ	B-VP	O
inefficient	JJ	B-ADJP	O
in	IN	B-PP	O
removing	VBG	B-VP	O
piperacillin	NN	B-NP	O
,	,	O	O
whereas	IN	O	O
hemodialysis	NN	B-NP	O
can	MD	B-VP	O
rapidly	RB	I-VP	O
terminate	VB	I-VP	O
the	DT	B-NP	O
piperacillin	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
encephalopathy	NN	I-NP	B
.	.	O	O

Frequency	NN	B-NP	O
of	IN	B-PP	O
transient	JJ	B-NP	O
ipsilateral	JJ	I-NP	O
vocal	JJ	I-NP	B
cord	NN	I-NP	I
paralysis	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
carotid	NN	B-NP	O
endarterectomy	NN	I-NP	O
under	IN	B-PP	O
local	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Especially	RB	B-ADVP	O
because	IN	B-PP	O
of	IN	I-PP	O
improvements	NNS	B-NP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
neurologic	JJ	I-NP	O
monitoring	NN	I-NP	O
,	,	O	O
carotid	NN	B-NP	O
endarterectomy	NN	I-NP	O
done	VBN	B-VP	O
under	IN	B-PP	O
local	JJ	B-NP	O
anesthesia	NN	I-NP	O
has	VBZ	B-VP	O
become	VBN	I-VP	O
the	DT	B-NP	O
technique	NN	I-NP	O
of	IN	B-PP	O
choice	NN	B-NP	O
in	IN	B-PP	O
several	JJ	B-NP	O
centers	NNS	I-NP	O
.	.	O	O

Temporary	JJ	B-NP	O
ipsilateral	JJ	I-NP	O
vocal	JJ	I-NP	B
nerve	NN	I-NP	I
palsies	NNS	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
described	VBN	I-VP	O
,	,	O	O
however	RB	B-ADVP	O
.	.	O	O

Such	JJ	B-NP	O
complications	NNS	I-NP	O
are	VBP	B-VP	O
most	RBS	B-ADJP	O
important	JJ	I-ADJP	O
in	IN	B-PP	O
situations	NNS	B-NP	O
where	WRB	B-ADVP	O
there	EX	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
existing	VBG	I-NP	O
contralateral	JJ	I-NP	O
paralysis	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
therefore	RB	B-ADVP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
local	JJ	B-NP	O
anesthesia	NN	I-NP	O
on	IN	B-PP	O
vocal	JJ	B-NP	O
cord	NN	I-NP	O
function	NN	I-NP	O
to	TO	B-VP	O
better	RBR	I-VP	O
understand	VB	I-VP	O
its	PRP$	B-NP	O
possible	JJ	I-NP	O
consequences	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
prospective	JJ	I-NP	O
study	NN	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
carotid	NN	B-NP	O
endarterectomy	NN	I-NP	O
under	IN	B-PP	O
local	JJ	B-NP	O
anesthesia	NN	I-NP	O
.	.	O	O

Vocal	JJ	B-NP	O
cord	NN	I-NP	O
function	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
before	IN	B-ADVP	O
,	,	O	O
during	IN	B-ADVP	O
,	,	O	O
and	CC	O	O
after	IN	B-PP	O
surgery	NN	B-NP	O
(	(	O	O
postoperative	JJ	B-NP	O
day	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
using	VBG	B-VP	O
flexible	JJ	B-NP	O
laryngoscopy	NN	I-NP	O
.	.	O	O

Anesthesia	NNP	B-NP	O
was	VBD	B-VP	O
performed	VBN	I-VP	O
by	IN	B-PP	O
injecting	VBG	B-VP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mL	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
mixture	NN	I-NP	O
of	IN	B-PP	O
long	JJ	O	O
-	HYPH	O	O
acting	VBG	B-VP	O
(	(	O	O
ropivacaine	NN	B-NP	O
)	)	O	O
and	CC	O	O
short	JJ	B-ADJP	O
-	HYPH	O	O
acting	VBG	B-VP	O
(	(	O	O
prilocaine	NN	B-NP	O
)	)	O	O
anesthetic	JJ	B-ADJP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
normal	JJ	B-NP	O
vocal	JJ	I-NP	O
cord	NN	I-NP	O
function	NN	I-NP	O
preoperatively	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
intraoperative	JJ	B-NP	O
ipsilateral	JJ	I-NP	O
vocal	JJ	I-NP	B
cord	NN	I-NP	I
paralysis	NN	I-NP	I
.	.	O	O

It	PRP	B-NP	O
resolved	VBD	B-VP	O
in	IN	B-PP	O
all	DT	B-NP	O
cases	NNS	I-NP	O
<	SYM	B-NP	O
or	CC	O	O
num	CD	B-NP	O
hours	NNS	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
operating	NN	B-NP	O
time	NN	I-NP	O
or	CC	O	O
volume	NN	B-NP	O
or	CC	I-NP	O
frequency	NN	I-NP	O
of	IN	B-PP	O
anesthetic	JJ	B-NP	O
administration	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
temporary	JJ	B-NP	O
vocal	JJ	I-NP	B
cord	NN	I-NP	I
paralysis	NN	I-NP	I
compared	VBN	B-PP	O
with	IN	B-PP	O
those	DT	B-NP	O
without	IN	B-PP	O
.	.	O	O

Local	JJ	B-NP	O
anesthesia	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
temporary	JJ	B-NP	O
ipsilateral	JJ	I-NP	O
vocal	JJ	I-NP	B
cord	NN	I-NP	I
paralysis	NN	I-NP	I
in	IN	B-PP	O
almost	RB	B-NP	O
half	NN	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Because	IN	B-SBAR	O
pre	AFX	B-NP	O
-	HYPH	B-PP	O
existing	VBG	B-NP	O
paralysis	NN	I-NP	B
is	VBZ	B-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
relevant	JJ	I-NP	O
frequency	NN	I-NP	O
(	(	O	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
,	,	O	O
a	DT	B-NP	O
preoperative	JJ	I-NP	O
evaluation	NN	I-NP	O
of	IN	B-PP	O
vocal	JJ	B-NP	O
cord	NN	I-NP	O
function	NN	I-NP	O
before	IN	B-PP	O
carotid	NN	B-NP	O
endarterectomy	NN	I-NP	O
under	IN	B-PP	O
local	JJ	B-NP	O
anesthesia	NN	I-NP	O
is	VBZ	B-VP	O
recommended	VBN	I-VP	O
to	TO	I-VP	O
avoid	VB	I-VP	O
intraoperative	JJ	B-NP	O
bilateral	JJ	I-NP	O
paralysis	NN	I-NP	B
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
preoperative	JJ	B-NP	O
contralateral	JJ	I-NP	O
vocal	JJ	I-NP	B
cord	NN	I-NP	I
paralysis	NN	I-NP	I
,	,	O	O
surgery	NN	B-NP	O
under	IN	B-PP	O
general	JJ	B-NP	O
anesthesia	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
.	.	O	O

Neuroprotective	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
melatonin	NN	B-NP	O
upon	IN	B-PP	O
the	DT	B-NP	O
offspring	NN	I-NP	O
cerebellar	JJ	I-NP	O
cortex	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
BCNU	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cortical	JJ	I-NP	B
dysplasia	NN	I-NP	I
.	.	O	O

Cortical	JJ	B-NP	B
dysplasia	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
malformation	NN	I-NP	O
characterized	VBN	B-VP	O
by	IN	B-PP	O
defects	NNS	B-NP	O
in	IN	B-PP	O
proliferation	NN	B-NP	O
,	,	I-NP	O
migration	NN	I-NP	O
and	CC	I-NP	O
maturation	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
designed	VBN	I-VP	O
to	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
alterations	NNS	I-NP	O
in	IN	B-PP	O
offspring	VBG	B-VP	O
rat	NN	B-NP	O
cerebellum	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
maternal	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
carmustine	NN	B-NP	O
-	HYPH	B-NP	O
[	(	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
bis	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
chloroethyl	NN	I-NP	O
)	)	O	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
nitrosoure	NN	I-NP	O
]	)	O	O
(	(	O	O
BCNU	NN	B-NP	O
)	)	O	O
and	CC	O	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
exogenous	JJ	B-NP	O
melatonin	NN	I-NP	O
upon	IN	B-PP	O
cerebellar	JJ	B-NP	O
BCNU	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cortical	JJ	I-NP	B
dysplasia	NN	I-NP	I
,	,	O	O
using	VBG	B-VP	O
histological	JJ	B-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
analyses	NNS	I-NP	O
.	.	O	O

Pregnant	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
assigned	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
intact	JJ	B-ADJP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
,	,	O	O
saline	NN	B-NP	O
-	HYPH	O	O
control	NN	B-NP	O
,	,	O	O
melatonin	NN	B-NP	O
-	HYPH	O	O
treated	VBN	B-VP	O
,	,	O	O
BCNU	NN	B-NP	O
-	HYPH	O	O
exposed	VBN	B-VP	O
and	CC	O	O
BCNU	NN	B-NP	O
-	HYPH	O	O
exposed	VBN	B-VP	O
plus	CC	O	O
melatonin	NN	B-NP	O
.	.	O	O

Rats	NNS	B-NP	O
were	VBD	B-VP	O
exposed	VBN	I-VP	O
to	TO	B-PP	O
BCNU	NN	B-NP	O
on	IN	B-PP	O
embryonic	JJ	B-NP	O
day	NN	I-NP	O
num	CD	I-NP	O
and	CC	O	O
melatonin	NN	B-NP	O
was	VBD	B-VP	O
given	VBN	I-VP	O
until	IN	B-PP	O
delivery	NN	B-NP	O
.	.	O	O

Immuno	NN	B-NP	O
/	SYM	I-NP	O
histochemistry	NN	I-NP	O
and	CC	I-NP	O
electron	NN	I-NP	O
microscopy	NN	I-NP	O
were	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
on	IN	B-PP	O
the	DT	B-NP	O
offspring	NN	I-NP	O
cerebellum	NN	I-NP	O
,	,	O	O
and	CC	O	O
levels	NNS	B-NP	O
of	IN	B-PP	O
malondialdehyde	NN	B-NP	O
and	CC	I-NP	O
superoxide	NN	I-NP	O
dismutase	NN	I-NP	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
.	.	O	O

Histopathologically	RB	B-ADVP	O
,	,	O	O
typical	JJ	B-NP	O
findings	NNS	I-NP	O
were	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
cerebella	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
findings	NNS	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
early	JJ	B-NP	O
embryonic	JJ	I-NP	O
development	NN	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
in	IN	B-PP	O
BCNU	NN	B-NP	O
-	HYPH	O	O
exposed	VBN	B-NP	O
cortical	JJ	I-NP	B
dysplasia	NN	I-NP	I
group	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
marked	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
TUNEL	NN	B-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
and	CC	O	O
nestin	NN	B-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
BCNU	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
group	NN	I-NP	O
,	,	O	O
but	CC	O	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
immunoreactivity	NN	I-NP	O
to	TO	B-PP	O
glial	JJ	B-NP	O
fibrillary	JJ	I-NP	O
acidic	JJ	I-NP	O
protein	NN	I-NP	O
,	,	O	O
synaptophysin	NN	B-NP	O
and	CC	O	O
transforming	VBG	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
beta1	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
,	,	O	O
indicating	VBG	B-VP	O
a	DT	B-NP	O
delayed	VBN	I-NP	O
maturation	NN	I-NP	O
,	,	O	O
and	CC	O	O
melatonin	NN	B-NP	O
significantly	RB	B-ADVP	O
reversed	VBD	B-VP	O
these	DT	B-NP	O
changes	NNS	I-NP	O
.	.	O	O

Malondialdehyde	NN	B-NP	O
level	NN	I-NP	O
in	IN	B-PP	O
BCNU	NN	B-NP	O
-	HYPH	B-NP	O
exposed	VBN	I-NP	O
group	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
those	DT	B-NP	O
in	IN	B-PP	O
control	NN	B-NP	O
groups	NNS	I-NP	O
and	CC	O	O
melatonin	NN	B-NP	O
decreased	VBD	B-VP	O
malondialdehyde	NN	B-NP	O
levels	NNS	I-NP	O
in	IN	B-PP	O
BCNU	NN	B-NP	O
group	NN	I-NP	O
,	,	O	O
while	IN	B-SBAR	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
superoxide	NN	I-NP	O
dismutase	NN	I-NP	O
levels	NNS	I-NP	O
between	IN	B-PP	O
these	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
exposure	NN	B-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
to	TO	B-PP	O
BCNU	NN	B-NP	O
during	IN	B-PP	O
pregnancy	NN	B-NP	O
leads	VBZ	B-VP	O
to	TO	B-PP	O
delayed	VBN	B-NP	O
maturation	NN	I-NP	O
of	IN	B-PP	O
offspring	NN	B-NP	O
cerebellum	NN	I-NP	O
and	CC	I-NP	O
melatonin	NN	I-NP	O
protects	VBZ	B-VP	O
the	DT	B-NP	O
cerebellum	NN	I-NP	O
against	IN	B-PP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
BCNU	NN	B-NP	O
.	.	O	O

Myo	AFX	B-NP	O
-	HYPH	I-NP	O
inositol	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
phosphate	NN	I-NP	O
(	(	O	O
MIP	NN	B-NP	O
)	)	O	O
synthase	NN	B-NP	O
inhibition	NN	I-NP	O
:	:	O	O
in	FW	B-PP	O
-	HYPH	B-NP	O
vivo	FW	I-NP	O
study	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Lithium	NN	B-NP	O
and	CC	I-NP	O
valproate	NN	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
prototypic	JJ	I-NP	O
mood	NN	I-NP	O
stabilizers	NNS	I-NP	O
and	CC	O	O
have	VBP	B-VP	O
diverse	JJ	B-NP	O
structures	NNS	I-NP	O
and	CC	I-NP	O
targets	NNS	I-NP	O
.	.	O	O

Both	DT	B-NP	O
drugs	NNS	I-NP	O
influence	VBP	B-VP	O
inositol	NN	B-NP	O
metabolism	NN	I-NP	O
.	.	O	O

Lithium	NN	B-NP	O
inhibits	VBZ	B-VP	O
IMPase	NN	B-NP	O
and	CC	I-NP	O
valproate	NN	I-NP	O
inhibits	VBZ	B-VP	O
MIP	NN	B-NP	O
synthase	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
shows	VBZ	B-VP	O
that	IN	B-SBAR	O
MIP	NN	B-NP	O
synthase	NN	I-NP	O
inhibition	NN	I-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
replicate	VB	I-VP	O
or	CC	I-VP	O
augment	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
inositol	NN	I-NP	O
sensitive	JJ	I-NP	O
pilocarpine	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
seizures	NNS	I-NP	B
model	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
effects	NNS	B-NP	O
may	MD	B-VP	O
stem	VB	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
low	JJ	I-NP	O
contribution	NN	I-NP	O
of	IN	B-PP	O
de	NN	B-NP	O
-	HYPH	I-NP	O
novo	NN	I-NP	O
synthesis	NN	I-NP	O
to	TO	B-PP	O
cellular	JJ	B-NP	O
inositol	NN	I-NP	O
supply	NN	I-NP	O
or	CC	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
de	NN	I-NP	O
-	HYPH	I-NP	O
novo	NN	I-NP	O
synthesis	NN	I-NP	O
by	IN	B-PP	O
lithium	NN	B-NP	O
itself	PRP	B-NP	O
.	.	O	O

Non	AFX	B-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	B-NP	O
drugs	NNS	I-NP	O
-	HYPH	O	O
associated	VBN	B-VP	O
acute	JJ	B-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
with	IN	B-PP	O
granular	JJ	B-NP	O
tubular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
deposits	NNS	I-NP	O
.	.	O	O

Acute	JJ	B-NP	B
tubulo	AFX	I-NP	I
-	HYPH	I-NP	I
interstitial	JJ	I-NP	I
nephritis	NN	I-NP	I
(	(	O	O
ATIN	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
resulting	VBG	B-VP	O
from	IN	B-PP	O
a	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
insults	NNS	B-NP	O
,	,	O	O
including	VBG	B-PP	O
immune	JJ	B-NP	O
complex	NN	I-NP	O
-	HYPH	O	O
mediated	VBN	B-VP	O
tubulo	AFX	B-NP	B
-	HYPH	I-NP	I
interstitial	JJ	B-NP	I
injury	NN	I-NP	I
,	,	O	O
but	CC	O	O
drugs	NNS	B-NP	O
such	JJ	B-PP	O
as	IN	I-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
steroidal	JJ	I-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
inflammatory	JJ	I-NP	O
drugs	NNS	I-NP	O
(	(	O	O
NSAIDs	NNS	B-NP	O
)	)	O	O
are	VBP	B-VP	O
a	DT	O	O
far	RB	B-ADVP	O
more	RBR	I-ADVP	O
frequent	JJ	B-NP	O
cause	NN	I-NP	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
as	IN	B-PP	O
an	DT	B-NP	O
entity	NN	I-NP	O
,	,	O	O
ATIN	NN	B-NP	B
remains	VBZ	B-VP	O
under	IN	B-PP	O
-	HYPH	B-NP	O
diagnosed	VBN	I-NP	O
,	,	O	O
as	IN	B-SBAR	O
symptoms	NNS	B-NP	O
resolve	VBP	B-VP	O
spontaneously	RB	B-ADVP	O
if	IN	B-SBAR	O
the	DT	B-NP	O
medication	NN	I-NP	O
is	VBZ	B-VP	O
stopped	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
on	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
boy	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
aortic	JJ	B-NP	O
valve	NN	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
put	VBN	I-VP	O
on	IN	B-PP	O
aspirin	NN	B-NP	O
following	VBG	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
took	VBD	B-VP	O
ibuprofen	NN	B-NP	O
for	IN	B-PP	O
fever	NN	B-NP	B
for	IN	B-PP	O
nearly	RB	B-NP	O
a	DT	I-NP	O
week	NN	I-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
presentation	NN	B-NP	O
.	.	O	O

He	PRP	B-NP	O
then	RB	B-ADVP	O
presented	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
feeling	VBG	B-VP	O
quite	RB	B-ADVP	O
ill	RB	I-ADVP	O
and	CC	O	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
blood	NN	I-NP	O
urea	NN	I-NP	O
nitrogen	NN	I-NP	O
(	(	O	O
BUN	NN	B-NP	O
)	)	O	O
concentration	NN	B-NP	O
of	IN	B-PP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
dl	NN	I-NP	O
,	,	O	O
creatinine	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
dl	NN	B-NP	O
and	CC	I-NP	O
serum	NN	I-NP	O
potassium	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mEq	NN	I-NP	O
/	SYM	B-NP	O
l	NN	I-NP	O
.	.	O	O

Dialysis	NN	B-NP	O
was	VBD	B-VP	O
immediately	RB	I-VP	O
initiated	VBN	I-VP	O
.	.	O	O

A	DT	B-NP	O
kidney	NN	I-NP	O
biopsy	NN	I-NP	O
showed	VBD	B-VP	O
inflammatory	JJ	B-NP	O
infiltrate	NN	I-NP	O
consistent	JJ	B-ADJP	O
with	IN	B-PP	O
ATIN	NN	B-NP	B
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
tubular	JJ	I-NP	O
basement	NN	I-NP	O
membrane	NN	I-NP	O
(	(	O	O
TBM	NN	B-NP	O
)	)	O	O
,	,	O	O
very	RB	B-NP	O
intense	JJ	I-NP	O
granular	JJ	I-NP	O
deposits	NNS	I-NP	O
of	IN	B-PP	O
polyclonal	JJ	B-NP	O
IgG	NN	I-NP	O
and	CC	I-NP	O
C3	NN	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

He	PRP	B-NP	O
needed	VBD	B-VP	O
dialysis	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	O	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
successfully	RB	B-ADVP	O
with	IN	B-PP	O
steroids	NNS	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

His	PRP$	B-NP	O
renal	JJ	I-NP	O
recovery	NN	I-NP	O
and	CC	I-NP	O
disappearance	NN	I-NP	O
of	IN	B-PP	O
proteinuria	NN	B-NP	B
took	VBD	B-VP	O
a	DT	B-NP	O
year	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
this	DT	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
first	JJ	I-NP	O
report	NN	I-NP	O
of	IN	B-PP	O
NSAIDs	NNS	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
ATIN	NN	I-NP	B
,	,	O	O
showing	VBG	B-VP	O
deposits	NNS	B-NP	O
of	IN	B-PP	O
granular	JJ	B-NP	O
immune	JJ	I-NP	O
complex	NN	I-NP	O
present	VBP	B-VP	O
only	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
TBM	NN	I-NP	O
and	CC	B-PP	O
not	RB	B-PP	O
in	IN	I-PP	O
the	DT	B-NP	O
glomeruli	NNS	I-NP	O
.	.	O	O

Rifampicin	NN	B-NP	O
-	HYPH	B-VP	O
associated	VBN	B-NP	O
segmental	JJ	I-NP	O
necrotizing	VBG	I-NP	O
glomerulonephritis	NN	I-NP	B
in	IN	B-PP	O
staphylococcal	JJ	B-NP	B
endocarditis	NN	I-NP	I
.	.	O	O

Segmental	JJ	B-NP	O
necrotising	NN	I-NP	O
glomerulonephritis	NN	I-NP	B
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
as	IN	B-PP	O
complication	NN	B-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
receiving	VBG	B-VP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
tuberculosis	NN	B-NP	B
.	.	O	O

Changing	VBG	B-VP	O
epidemiology	NN	B-NP	O
of	IN	B-PP	O
infections	NNS	B-NP	B
such	JJ	B-PP	O
as	IN	I-PP	O
infective	JJ	B-NP	B
endocarditis	NN	I-NP	I
(	(	O	O
IE	NN	B-NP	B
)	)	O	O
has	VBZ	B-VP	O
led	VBN	I-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
for	IN	B-PP	O
Staphylococcal	JJ	B-NP	B
infections	NNS	I-NP	I
.	.	O	O

We	PRP	B-NP	O
describe	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
Staphylococcal	JJ	B-NP	B
IE	NN	I-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
a	DT	B-NP	O
segmental	JJ	I-NP	O
necrotising	VBG	I-NP	O
glomerulonephritis	NN	I-NP	B
while	IN	B-SBAR	O
being	VBG	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
rifampicin	NN	B-NP	O
,	,	O	O
and	CC	O	O
review	VB	B-VP	O
the	DT	B-NP	O
literature	NN	I-NP	O
regarding	VBG	B-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
rifampicin	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Rate	NN	B-NP	O
of	IN	B-PP	O
YMDD	NN	B-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
in	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
Iranian	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
virus	NN	I-NP	I
infection	NN	I-NP	I
.	.	O	O

Lamivudine	NN	B-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
studies	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
YMDD	NN	I-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
(	(	O	O
resistant	JJ	B-NP	O
hepatitis	NN	I-NP	B
B	NN	I-NP	I
virus	NN	I-NP	O
)	)	O	O
occur	VBP	B-VP	O
as	IN	B-PP	O
natural	JJ	B-NP	O
genome	NN	I-NP	O
variability	NN	I-NP	O
in	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
chronic	JJ	I-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
we	PRP	B-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
YMDD	NN	B-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
in	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
chronic	JJ	I-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
patients	NNS	I-NP	O
in	IN	B-PP	O
Iran	NNP	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
chronic	JJ	I-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
lamivudine	NN	B-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
.	.	O	O

Serum	NN	B-NP	O
samples	NNS	I-NP	O
from	IN	B-PP	O
patients	NNS	B-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
by	IN	B-PP	O
polymerase	NN	B-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
-	HYPH	B-NP	O
restriction	NN	I-NP	O
fragment	NN	I-NP	O
length	NN	I-NP	O
polymorphism	NN	I-NP	O
(	(	O	O
PCR	NN	B-NP	O
-	HYPH	B-NP	O
RFLP	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
YMDD	NN	B-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
also	RB	I-VP	O
tested	VBN	I-VP	O
for	IN	B-PP	O
liver	NN	B-NP	O
enzymes	NNS	I-NP	O
,	,	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HCV	NN	B-NP	O
,	,	O	O
HBeAg	NN	B-NP	O
,	,	O	O
and	CC	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBe	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
enrolled	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
male	JJ	B-ADJP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
were	VBD	B-VP	O
female	JJ	B-ADJP	O
.	.	O	O

Mean	JJ	B-NP	O
ALT	NN	I-NP	O
and	CC	I-NP	O
AST	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
+	SYM	B-NP	O
/	SYM	I-NP	O
-	SYM	I-NP	O
num	CD	I-NP	O
IU	NN	I-NP	O
/	SYM	I-NP	O
l	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

HBeAg	NN	B-NP	O
was	VBD	B-VP	O
positive	JJ	B-ADJP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBe	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

Anti	AFX	B-NP	O
-	HYPH	I-NP	O
HCV	NN	B-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
in	IN	B-PP	O
all	DT	B-NP	O
of	IN	B-PP	O
them	PRP	B-NP	O
.	.	O	O

YMDD	NN	B-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
despite	IN	B-PP	O
the	DT	B-NP	O
liver	NN	I-NP	O
enzyme	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
HBeAg	NN	B-NP	O
or	CC	O	O
anti	AFX	B-NP	O
-	HYPH	I-NP	O
HBe	NN	B-NP	O
.	.	O	O

Although	IN	B-SBAR	O
the	DT	B-NP	O
natural	JJ	I-NP	O
occurrence	NN	I-NP	O
of	IN	B-PP	O
YMDD	NN	B-NP	O
motif	NN	I-NP	O
mutants	NNS	I-NP	O
in	IN	B-PP	O
lamivudine	NN	B-NP	O
-	HYPH	O	O
untreated	JJ	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
chronic	JJ	B-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
has	VBZ	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
,	,	O	O
these	DT	B-NP	O
mutants	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
detected	VBN	I-VP	O
in	IN	B-PP	O
Iranian	JJ	B-NP	O
lamivudine	NN	I-NP	O
-	HYPH	B-NP	O
untreated	JJ	I-NP	O
chronic	JJ	I-NP	B
hepatitis	NN	I-NP	I
B	NN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

Branch	NN	B-NP	O
retinal	JJ	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
and	CC	I-NP	O
fluoxetine	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
branch	NN	B-NP	O
retinal	NN	I-NP	B
vein	NN	I-NP	I
occlusion	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
fluoxetine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
secondary	JJ	I-NP	O
hypertension	NN	I-NP	B
is	VBZ	B-VP	O
described	VBN	I-VP	O
.	.	O	O

Although	IN	B-SBAR	O
an	DT	B-NP	O
infrequent	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
selective	JJ	B-NP	O
serotonin	NN	I-NP	O
reuptake	NN	I-NP	O
inhibitor	NN	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
it	PRP	B-NP	O
is	VBZ	B-VP	O
important	JJ	B-ADJP	O
that	IN	B-SBAR	O
ophthalmologists	NNS	B-NP	O
are	VBP	B-VP	O
aware	JJ	B-ADJP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
agents	NNS	I-NP	O
can	MD	B-VP	O
cause	VB	I-VP	O
hypertension	NN	B-NP	B
because	IN	B-SBAR	O
this	DT	B-NP	O
class	NN	I-NP	O
of	IN	B-PP	O
drugs	NNS	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
prescribed	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
differential	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
and	CC	I-NP	O
lidocaine	NN	I-NP	O
on	IN	B-PP	O
prostaglandin	NN	B-NP	O
E2	NN	I-NP	O
release	NN	I-NP	O
,	,	O	O
cyclooxygenase	NN	B-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
and	CC	O	O
pain	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
clinical	JJ	I-NP	O
pain	NN	I-NP	B
model	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
blocking	VBG	B-VP	O
nociceptive	JJ	B-NP	O
input	NN	I-NP	O
from	IN	B-PP	O
surgical	JJ	B-NP	O
sites	NNS	I-NP	O
,	,	O	O
long	RB	B-ADVP	O
-	HYPH	B-NP	O
acting	VBG	B-VP	O
local	JJ	B-NP	O
anesthetics	NNS	I-NP	O
might	MD	B-VP	O
directly	RB	I-VP	O
modulate	VB	I-VP	O
inflammation	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
describe	VBP	B-VP	O
the	DT	B-NP	O
proinflammatory	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
bupivacaine	NN	B-NP	O
on	IN	B-PP	O
local	JJ	B-NP	O
prostaglandin	NN	I-NP	O
E2	NN	I-NP	O
(	(	O	O
PGE2	NN	B-NP	O
)	)	O	O
production	NN	B-NP	O
and	CC	O	O
cyclooxygenase	NN	B-NP	O
(	(	O	O
COX	NN	B-NP	O
)	)	O	O
gene	NN	B-NP	O
expression	NN	I-NP	O
that	WDT	B-NP	O
increases	VBZ	B-VP	O
postoperative	JJ	B-NP	B
pain	NN	I-NP	I
in	IN	B-PP	O
human	JJ	B-NP	O
subjects	NNS	I-NP	O
.	.	O	O

Subjects	NNS	B-NP	O
undergoing	VBG	B-VP	O
extraction	NN	B-NP	O
of	IN	B-PP	O
impacted	JJ	B-NP	O
third	JJ	I-NP	O
molars	NNS	I-NP	O
received	VBD	B-VP	O
either	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
lidocaine	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
bupivacaine	NN	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
either	CC	O	O
rofecoxib	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
or	CC	I-NP	O
placebo	NN	I-NP	O
orally	RB	B-NP	O
num	CD	I-NP	O
min	NN	I-NP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	B-PP	O
for	IN	B-PP	O
the	DT	B-NP	O
following	VBG	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
.	.	O	O

Oral	JJ	B-NP	O
mucosal	JJ	I-NP	O
biopsies	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
before	IN	B-PP	O
surgery	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
surgery	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
extraction	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
microdialysis	NN	I-NP	O
probe	NN	I-NP	O
was	VBD	B-VP	O
placed	VBN	I-VP	O
at	IN	B-PP	O
the	DT	B-NP	O
surgical	JJ	I-NP	O
site	NN	I-NP	O
for	IN	B-PP	O
PGE2	NN	B-NP	O
and	CC	O	O
thromboxane	NN	B-NP	O
B2	NN	I-NP	O
(	(	O	O
TXB2	NN	B-NP	O
)	)	O	O
measurements	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
bupivacaine	NN	I-NP	O
/	SYM	I-NP	O
rofecoxib	NN	I-NP	O
group	NN	I-NP	O
reported	VBD	B-VP	O
significantly	RB	B-NP	O
less	JJR	I-NP	O
pain	NN	I-NP	B
,	,	O	O
as	IN	B-SBAR	O
assessed	VBN	B-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
visual	JJ	I-NP	O
analog	NN	I-NP	O
scale	NN	I-NP	O
,	,	O	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
bupivacaine	NN	I-NP	O
/	SYM	I-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
reported	VBD	B-VP	O
significantly	RB	B-NP	O
more	JJR	I-NP	O
pain	NN	I-NP	B
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
and	CC	I-NP	O
PGE2	NN	I-NP	O
levels	NNS	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
bupivacaine	NN	B-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
COX	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
lidocaine	NN	I-NP	O
/	SYM	I-NP	O
placebo	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Thromboxane	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
significantly	RB	I-VP	O
affected	VBN	I-VP	O
by	IN	B-PP	O
any	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
treatments	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
effects	NNS	I-NP	O
seen	VBN	B-VP	O
were	VBD	B-VP	O
attributable	JJ	B-ADJP	O
to	TO	B-PP	O
inhibition	NN	B-NP	O
of	IN	B-PP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
but	CC	I-NP	O
not	RB	I-NP	O
COX	NN	B-NP	O
-	HYPH	O	O
num	CD	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
bupivacaine	NN	B-NP	O
stimulates	VBZ	B-VP	O
COX	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
after	IN	B-PP	O
tissue	NN	B-NP	B
injury	NN	I-NP	I
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
higher	JJR	B-NP	O
PGE2	NN	I-NP	O
production	NN	I-NP	O
and	CC	I-NP	O
pain	NN	I-NP	B
after	IN	B-PP	O
the	DT	B-NP	O
local	JJ	I-NP	O
anesthetic	JJ	I-NP	O
effect	NN	I-NP	O
dissipates	NNS	I-NP	O
.	.	O	O

p75NTR	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
sensory	JJ	I-NP	O
neurons	NNS	I-NP	O
and	CC	O	O
spinal	JJ	B-NP	O
cord	NN	I-NP	O
with	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
.	.	O	O

A	DT	B-NP	O
role	NN	I-NP	O
for	IN	B-PP	O
nerve	NN	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
(	(	O	O
NGF	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
contributing	VBG	B-VP	O
to	TO	B-PP	O
increased	VBN	B-NP	O
voiding	VBG	I-NP	O
frequency	NN	I-NP	O
and	CC	O	O
altered	JJ	B-NP	O
sensation	NN	I-NP	O
from	IN	B-PP	O
the	DT	B-NP	O
urinary	JJ	I-NP	O
bladder	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
.	.	O	O

Previous	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
examined	VBN	I-VP	O
the	DT	B-NP	O
expression	NN	B-NP	O
and	CC	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
tyrosine	NN	B-NP	O
kinase	NN	I-NP	O
receptors	NNS	I-NP	O
(	(	O	O
Trks	NNS	B-NP	O
)	)	O	O
in	IN	B-PP	O
micturition	NN	B-NP	O
reflexes	NNS	I-NP	O
with	IN	B-PP	O
urinary	JJ	B-NP	B
bladder	NN	I-NP	I
inflammation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
studies	NNS	I-NP	O
examine	VBP	B-VP	O
the	DT	O	O
expression	NN	B-NP	O
and	CC	O	O
regulation	NN	B-NP	O
of	IN	B-PP	O
another	DT	B-NP	O
receptor	NN	I-NP	O
known	VBN	B-VP	O
to	TO	B-VP	O
bind	VB	I-VP	O
NGF	NN	B-NP	O
,	,	O	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
,	,	O	O
after	IN	B-PP	O
various	JJ	B-NP	O
durations	NNS	I-NP	O
of	IN	B-PP	O
bladder	NN	B-NP	B
inflammation	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
cyclophosphamide	NN	B-NP	O
(	(	O	O
CYP	NN	B-NP	O
)	)	O	O
.	.	O	O

CYP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
increased	VBD	B-VP	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
superficial	JJ	I-NP	O
lateral	JJ	I-NP	O
and	CC	I-NP	O
medial	JJ	I-NP	O
dorsal	JJ	I-NP	O
horn	NN	I-NP	O
in	IN	B-PP	O
L1	NN	B-NP	O
-	HYPH	B-NP	O
L2	NN	I-NP	O
and	CC	I-NP	O
L6	NN	I-NP	O
-	HYPH	B-NP	O
S1	NN	I-NP	O
spinal	JJ	I-NP	O
segments	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
immunoreactive	JJ	B-ADJP	O
(	(	O	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
)	)	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lumbosacral	JJ	I-NP	O
dorsal	JJ	I-NP	O
root	NN	I-NP	O
ganglia	NNS	I-NP	O
(	(	O	O
DRG	NN	B-NP	O
)	)	O	O
also	RB	B-ADVP	O
increased	VBD	B-VP	O
with	IN	B-PP	O
CYP	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
(	(	O	O
acute	JJ	B-ADJP	O
,	,	O	O
intermediate	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
chronic	JJ	B-ADJP	O
)	)	O	O
.	.	O	O

Quantitative	JJ	B-NP	O
,	,	I-NP	O
real	JJ	I-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
polymerase	NN	I-NP	O
chain	NN	I-NP	O
reaction	NN	I-NP	O
also	RB	B-ADVP	O
demonstrated	VBD	B-VP	O
significant	JJ	B-NP	O
increases	NNS	I-NP	O
in	IN	B-PP	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
mRNA	NN	B-NP	O
in	IN	B-PP	O
DRG	NN	B-NP	O
with	IN	B-PP	O
intermediate	JJ	B-NP	O
and	CC	I-NP	O
chronic	JJ	I-NP	O
CYP	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cystitis	NN	I-NP	B
.	.	O	O

Retrograde	NN	B-NP	O
dye	NN	I-NP	O
-	HYPH	O	O
tracing	VBG	B-VP	O
techniques	NNS	B-NP	O
with	IN	B-PP	O
Fastblue	NN	B-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
identify	VB	I-VP	O
presumptive	JJ	B-NP	O
bladder	NN	I-NP	O
afferent	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
lumbosacral	JJ	I-NP	O
DRG	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
bladder	NN	B-NP	O
afferent	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
DRG	NN	B-NP	O
,	,	O	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
increased	VBN	I-VP	O
with	IN	B-PP	O
cystitis	NN	B-NP	B
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
increases	NNS	B-NP	O
in	IN	B-PP	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
in	IN	B-PP	O
DRG	NN	B-NP	O
cell	NN	I-NP	O
bodies	NNS	I-NP	O
,	,	O	O
increases	NNS	B-NP	O
in	IN	B-PP	O
pericellular	JJ	B-NP	O
(	(	O	O
encircling	VBG	B-VP	O
DRG	NN	B-NP	O
cells	NNS	I-NP	O
)	)	O	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
in	IN	B-PP	O
DRG	NN	B-NP	O
also	RB	B-ADVP	O
increased	VBD	B-VP	O
.	.	O	O

Confocal	JJ	B-NP	O
analyses	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
pericellular	JJ	B-NP	O
p75	NN	I-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
IR	NN	I-NP	O
was	VBD	B-VP	O
not	RB	I-VP	O
colocalized	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
glial	JJ	I-NP	O
marker	NN	I-NP	O
,	,	O	O
glial	JJ	B-NP	O
fibrillary	JJ	I-NP	O
acidic	JJ	I-NP	O
protein	NN	I-NP	O
(	(	O	O
GFAP	NN	B-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
studies	NNS	I-NP	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
reflexes	NNS	I-NP	O
is	VBZ	B-VP	O
present	JJ	B-ADJP	O
constitutively	RB	B-ADVP	O
and	CC	O	O
modified	VBN	B-VP	O
by	IN	B-PP	O
bladder	NN	B-NP	B
inflammation	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
functional	JJ	I-NP	O
significance	NN	I-NP	O
of	IN	B-PP	O
p75	NN	B-NP	O
(	(	O	O
NTR	NN	B-NP	O
)	)	O	O
expression	NN	B-NP	O
in	IN	B-PP	O
micturition	NN	B-NP	O
reflexes	NNS	I-NP	O
remains	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

Azathioprine	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
suicidal	JJ	I-NP	O
erythrocyte	NN	I-NP	O
death	NN	I-NP	O
.	.	O	O

Azathioprine	NN	B-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
immunosuppressive	JJ	I-NP	O
drug	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
side	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
azathioprine	NN	B-NP	O
include	VBP	B-VP	O
anemia	NN	B-NP	B
,	,	O	O
which	WDT	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
attributed	VBN	I-VP	O
to	TO	B-PP	O
bone	NN	B-NP	O
marrow	NN	I-NP	O
suppression	NN	I-NP	O
.	.	O	O

Alternatively	RB	B-ADVP	O
,	,	O	O
anemia	NN	B-NP	B
could	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
accelerated	VBN	B-NP	O
suicidal	JJ	I-NP	O
erythrocyte	NN	I-NP	O
death	NN	I-NP	O
or	CC	I-NP	O
eryptosis	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
exposure	NN	B-NP	O
of	IN	B-PP	O
phosphatidylserine	NN	B-NP	O
(	(	O	O
PS	NN	B-NP	O
)	)	O	O
at	IN	B-PP	O
the	DT	B-NP	O
erythrocyte	NN	I-NP	O
surface	NN	I-NP	O
and	CC	B-PP	O
by	IN	B-PP	O
cell	NN	B-NP	O
shrinkage	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
experiments	NNS	I-NP	O
explored	VBD	B-VP	O
whether	IN	B-SBAR	O
azathioprine	NN	B-NP	O
influences	VBZ	B-VP	O
eryptosis	NN	B-NP	O
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
annexin	NN	B-NP	O
V	NN	I-NP	O
binding	NN	I-NP	O
,	,	O	O
erythrocytes	NNS	B-NP	O
from	IN	B-PP	O
patients	NNS	B-NP	O
indeed	RB	B-ADVP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
increase	NN	I-NP	O
of	IN	B-PP	O
PS	NN	B-NP	O
exposure	NN	I-NP	O
within	IN	B-PP	O
num	CD	B-NP	O
week	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
azathioprine	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
a	DT	B-NP	O
second	JJ	I-NP	O
series	NN	I-NP	O
,	,	O	O
cytosolic	JJ	B-NP	O
Ca2	NN	I-NP	O
+	SYM	O	O
activity	NN	B-NP	O
(	(	O	O
Fluo3	NN	B-NP	O
fluorescence	NN	I-NP	O
)	)	O	O
,	,	O	O
cell	NN	B-NP	O
volume	NN	I-NP	O
(	(	O	O
forward	JJ	B-NP	O
scatter	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
PS	NN	B-NP	O
-	HYPH	O	O
exposure	NN	B-NP	O
(	(	O	O
annexin	NN	B-NP	O
V	NN	I-NP	O
binding	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
FACS	NN	B-NP	O
analysis	NN	I-NP	O
in	IN	B-PP	O
erythrocytes	NNS	B-NP	O
from	IN	B-PP	O
healthy	JJ	B-NP	O
volunteers	NNS	I-NP	O
.	.	O	O

Exposure	NN	B-NP	O
to	TO	B-PP	O
azathioprine	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
increased	VBD	B-VP	O
cytosolic	JJ	B-NP	O
Ca2	NN	I-NP	O
+	SYM	B-NP	O
activity	NN	B-NP	O
and	CC	I-NP	O
annexin	NN	I-NP	O
V	NN	I-NP	O
binding	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
forward	RB	B-ADJP	O
scatter	JJR	I-ADJP	O
.	.	O	O

The	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
azathioprine	NN	B-NP	O
on	IN	B-PP	O
both	CC	O	O
annexin	NN	B-NP	O
V	NN	I-NP	O
binding	NN	I-NP	O
and	CC	O	O
forward	JJ	B-NP	O
scatter	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
blunted	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
nominal	JJ	I-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
extracellular	JJ	B-NP	O
Ca2	NN	I-NP	O
+	SYM	B-NP	O
.	.	O	O

Azathioprine	NN	B-NP	O
triggers	VBZ	B-VP	O
suicidal	JJ	B-NP	O
erythrocyte	NN	I-NP	O
death	NN	I-NP	O
,	,	O	O
an	DT	B-NP	O
effect	NN	I-NP	O
presumably	RB	B-VP	O
contributing	VBG	I-VP	O
to	TO	B-PP	O
azathioprine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

Clinical	JJ	B-NP	O
comparison	NN	I-NP	O
of	IN	B-PP	O
cardiorespiratory	JJ	B-NP	O
effects	NNS	I-NP	O
during	IN	B-PP	O
unilateral	JJ	B-NP	O
and	CC	I-NP	O
conventional	JJ	I-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

Spinal	JJ	B-NP	O
anaesthesia	NN	I-NP	O
is	VBZ	B-VP	O
widely	RB	I-VP	O
employed	VBN	I-VP	O
in	IN	B-PP	O
clinical	JJ	B-NP	O
practice	NN	I-NP	O
but	CC	O	O
has	VBZ	B-VP	O
the	DT	B-NP	O
main	JJ	I-NP	O
drawback	NN	I-NP	O
of	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
spinal	JJ	I-NP	O
block	NN	I-NP	O
hypotension	NN	I-NP	B
.	.	O	O

Efforts	NNS	B-NP	O
must	MD	B-VP	O
therefore	RB	I-VP	O
continue	VB	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
made	VBN	I-VP	O
to	TO	B-VP	O
obviate	VB	I-VP	O
this	DT	B-NP	O
setback	NN	I-NP	O
OBJECTIVE	NN	I-NP	O
:	:	O	O
To	TO	B-VP	O
evaluate	VB	I-VP	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
and	CC	I-NP	O
respiratory	JJ	I-NP	O
changes	NNS	I-NP	O
during	IN	B-PP	O
unilateral	JJ	B-NP	O
and	CC	I-NP	O
conventional	JJ	I-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
.	.	O	O

With	IN	B-PP	O
ethical	JJ	B-NP	O
approval	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
studied	VBD	B-VP	O
num	CD	B-NP	O
American	NNP	I-NP	O
Society	NNP	I-NP	O
of	IN	B-PP	O
Anesthesiologists	NNS	B-NP	O
(	(	O	O
ASA	NN	B-NP	O
)	)	O	O
,	,	O	O
physical	JJ	B-NP	O
status	NN	I-NP	O
class	NN	I-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
scheduled	VBN	B-VP	O
for	IN	B-PP	O
elective	JJ	B-NP	O
unilateral	JJ	I-NP	O
lower	JJR	I-NP	O
limb	NN	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
allocated	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
lateral	JJ	B-NP	O
and	CC	I-NP	O
conventional	JJ	I-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
position	NN	I-NP	O
with	IN	B-PP	O
operative	JJ	B-NP	O
side	NN	I-NP	O
down	RP	B-PRT	O
,	,	O	O
patients	NNS	B-NP	O
recived	VBD	B-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
(	(	O	O
2mls	NNS	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
hyperbaric	JJ	I-NP	O
bupivacaine	NN	I-NP	O
through	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
gauge	NN	I-NP	O
spinal	JJ	I-NP	O
needle	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
unilateral	JJ	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
maintained	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
lateral	JJ	I-NP	O
position	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
minutes	NNS	I-NP	O
following	VBG	B-PP	O
spinal	JJ	B-NP	O
injection	NN	I-NP	O
while	IN	B-SBAR	O
those	DT	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
group	NN	I-NP	O
were	VBD	B-VP	O
turned	VBN	I-VP	O
supine	NN	B-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
injection	NN	B-NP	O
.	.	O	O

Blood	NN	B-NP	O
pressure	NN	I-NP	O
,	,	O	O
heart	NN	B-NP	O
rate	NN	I-NP	O
,	,	O	O
respiratory	JJ	B-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
oxygen	NN	I-NP	O
saturation	NN	I-NP	O
were	VBD	B-VP	O
monitored	VBN	I-VP	O
over	IN	B-NP	O
num	CD	I-NP	O
hour	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
unilateral	JJ	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
group	NN	I-NP	O
developed	VBD	B-VP	O
hypotension	NN	B-NP	B
,	,	O	O
P=	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
group	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
unilateral	JJ	I-NP	O
group	NN	I-NP	O
,	,	O	O
P=	NN	B-NP	O
num	CD	I-NP	O
required	VBD	B-VP	O
epinephrine	NN	B-NP	O
infusion	NN	I-NP	O
to	TO	B-VP	O
treat	VB	I-VP	O
hypotension	NN	B-NP	B
.	.	O	O

Patients	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
conventional	JJ	I-NP	O
group	NN	I-NP	O
had	VBD	B-VP	O
statistically	RB	B-NP	O
significant	JJ	I-NP	O
greater	JJR	I-NP	O
fall	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
systolic	JJ	I-NP	O
blood	NN	I-NP	O
pressures	NNS	I-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
minutes	NNS	I-NP	O
when	WRB	B-ADVP	O
compared	VBN	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
baseline	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
respiratory	JJ	I-NP	O
rate	NN	I-NP	O
and	CC	I-NP	O
oxygen	NN	I-NP	O
saturations	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
were	VBD	B-VP	O
similar	JJ	B-ADJP	O
.	.	O	O

Compared	VBN	B-PP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
,	,	O	O
unilateral	JJ	B-NP	O
spinal	JJ	I-NP	O
anaesthesia	NN	I-NP	O
was	VBD	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
fewer	JJR	B-NP	O
cardiovascular	JJ	I-NP	O
perturbations	NNS	I-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
spinal	JJ	B-NP	O
block	NN	I-NP	O
instituted	VBN	B-VP	O
affected	VBD	B-VP	O
neither	CC	O	O
the	DT	B-NP	O
respiratory	JJ	I-NP	O
rate	NN	I-NP	O
nor	CC	O	O
the	DT	B-NP	O
arterial	JJ	I-NP	O
oxygen	NN	I-NP	O
saturation	NN	I-NP	O
.	.	O	O

Spectrum	NN	B-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
events	NNS	I-NP	O
after	IN	B-PP	O
generic	JJ	B-NP	O
HAART	NN	I-NP	O
in	IN	B-PP	O
southern	JJ	B-NP	O
Indian	JJ	I-NP	O
HIV	NN	I-NP	B
-	HYPH	B-NP	I
infected	VBN	I-NP	I
patients	NNS	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
clinically	RB	B-NP	O
significant	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
after	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
,	,	O	O
fixed	VBN	B-VP	O
-	HYPH	B-NP	O
dose	NN	I-NP	O
,	,	O	O
generic	JJ	B-NP	O
highly	RB	I-NP	O
active	JJ	I-NP	O
antiretroviral	JJ	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
HAART	NN	B-NP	O
)	)	O	O
use	NN	B-NP	O
among	IN	B-PP	O
HIV	NN	B-NP	B
-	HYPH	O	I
infected	VBN	B-VP	I
individuals	NNS	B-NP	O
in	IN	B-PP	O
South	NNP	B-NP	O
India	NNP	I-NP	O
,	,	O	O
we	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
experiences	NNS	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
HIV	NN	I-NP	B
-	HYPH	B-NP	I
infected	VBN	I-NP	I
individuals	NNS	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
minimum	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
of	IN	B-PP	O
generic	JJ	B-NP	O
HAART	NN	I-NP	O
between	IN	B-PP	O
February	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
December	NNP	B-NP	O
num	CD	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
tertiary	JJ	I-NP	O
HIV	NN	I-NP	O
care	NN	I-NP	O
referral	JJ	I-NP	O
center	NN	I-NP	O
in	IN	B-PP	O
South	NNP	B-NP	O
India	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
regimens	NNS	I-NP	O
were	VBD	B-VP	O
3TC	NN	B-NP	O
+	SYM	B-NP	O
d4T	NN	I-NP	O
+	SYM	O	O
nevirapine	NN	B-NP	O
(	(	O	O
NVP	NN	B-NP	O
)	)	O	O
,	,	O	O
zidovudine	NN	B-NP	O
(	(	O	O
AZT	NN	B-NP	O
)	)	O	O
+	SYM	B-NP	O
3TC	NN	I-NP	O
+	SYM	B-NP	O
NVP	NN	I-NP	O
,	,	O	O
3TC	NN	B-NP	O
+	SYM	I-NP	O
d4T	NN	I-NP	O
+	SYM	O	O
efavirenz	NN	B-NP	O
(	(	O	O
EFV	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
AZT	NN	B-NP	O
+	SYM	I-NP	O
3TC	NN	I-NP	O
+	SYM	B-NP	O
EFV	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
and	CC	O	O
median	JJ	B-NP	O
CD4	NN	I-NP	O
at	IN	B-PP	O
time	NN	B-NP	O
of	IN	B-PP	O
event	NN	B-NP	O
were	VBD	B-VP	O
rash	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
CD4	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
microL	NN	B-NP	O
)	)	O	O
and	CC	O	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
microL	NN	B-NP	O
)	)	O	O
.	.	O	O

Clinically	RB	B-NP	O
significant	JJ	I-NP	O
anemia	NN	I-NP	B
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
(	(	O	O
CD4	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
microL	NN	B-NP	O
)	)	O	O
and	CC	O	O
hepatitis	NN	B-NP	B
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
(	(	O	O
CD4	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
cells	NNS	I-NP	O
/	SYM	O	O
microL	NN	B-NP	O
)	)	O	O
.	.	O	O

Women	NNS	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
experience	VB	I-VP	O
lactic	JJ	B-NP	B
acidosis	NN	I-NP	I
,	,	O	O
while	IN	B-SBAR	O
men	NNS	B-NP	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
more	RBR	I-ADJP	O
likely	JJ	I-ADJP	O
to	TO	B-VP	O
experience	VB	I-VP	O
immune	JJ	B-NP	B
reconstitution	NN	I-NP	I
syndrome	NN	I-NP	I
.	.	O	O

Among	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
year	NN	I-NP	O
of	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
,	,	O	O
NVP	NN	B-NP	O
therapy	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
developing	VBG	B-VP	O
rash	NN	B-NP	B
and	CC	I-NP	O
d4T	NN	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
developing	VBG	B-VP	O
peripheral	JJ	B-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

Anemia	NN	B-NP	B
and	CC	I-NP	O
hepatitis	NN	I-NP	B
often	RB	B-ADVP	O
occur	VBP	B-VP	O
within	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
of	IN	B-PP	O
initiating	VBG	B-VP	O
generic	JJ	B-NP	O
HAART	NN	I-NP	O
.	.	O	O

Frequent	JJ	B-NP	O
and	CC	I-NP	O
early	JJ	I-NP	O
monitoring	NN	I-NP	O
for	IN	B-PP	O
these	DT	B-NP	O
toxicities	NNS	I-NP	B
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
in	IN	B-PP	O
developing	VBG	B-NP	O
countries	NNS	I-NP	O
where	WRB	B-ADVP	O
generic	JJ	B-NP	O
HAART	NN	I-NP	O
is	VBZ	B-VP	O
increasingly	RB	B-ADJP	O
available	JJ	I-ADJP	O
.	.	O	O

Thalidomide	NN	B-NP	O
and	CC	O	O
sensory	JJ	B-NP	B
neurotoxicity	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
neurophysiological	JJ	I-NP	O
study	NN	I-NP	O
.	.	O	O

Recent	JJ	B-NP	O
studies	NNS	I-NP	O
confirmed	VBD	B-VP	O
a	DT	B-NP	O
high	JJ	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	B
axonal	JJ	I-NP	I
neuropathy	NN	I-NP	I
in	IN	B-PP	O
patients	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
different	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
s	NN	I-NP	O
aims	NNS	I-NP	O
were	VBD	B-VP	O
to	TO	I-VP	O
measure	VB	I-VP	O
variations	NNS	B-NP	O
in	IN	B-PP	O
sural	JJ	B-NP	O
nerve	NN	I-NP	O
sensory	JJ	I-NP	O
action	NN	I-NP	O
potential	NN	I-NP	O
(	(	O	O
SAP	NN	B-NP	O
)	)	O	O
amplitude	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
refractory	JJ	B-NP	O
cutaneous	JJ	I-NP	B
lupus	NN	I-NP	I
erythematosus	NN	I-NP	I
(	(	O	O
CLE	NN	B-NP	B
)	)	O	O
treated	VBN	B-VP	O
with	IN	B-PP	O
thalidomide	NN	B-NP	O
and	CC	O	O
use	VB	B-VP	O
these	DT	B-NP	O
findings	NNS	I-NP	O
to	TO	B-VP	O
identify	VB	I-VP	O
the	DT	B-NP	O
neurotoxic	JJ	I-NP	B
potential	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
recovery	NN	I-NP	O
capacity	NN	I-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	O
fibres	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Clinical	JJ	B-NP	O
and	CC	I-NP	O
electrophysiological	JJ	I-NP	O
data	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
female	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
CLE	NN	B-NP	B
during	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
thalidomide	NN	B-NP	O
and	CC	O	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
months	NNS	I-NP	O
after	IN	B-PP	O
discontinuation	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
were	VBD	B-VP	O
analysed	VBN	I-VP	O
.	.	O	O

Sural	JJ	B-NP	O
nerve	NN	I-NP	O
SAP	NN	I-NP	O
amplitude	NN	I-NP	O
reduction	NN	I-NP	O
>	SYM	B-VP	O
or	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
criteria	NNS	I-NP	O
for	IN	B-PP	O
discontinuing	VBG	B-VP	O
therapy	NN	B-NP	O
.	.	O	O

During	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
sural	JJ	B-NP	O
nerve	NN	I-NP	O
SAP	NN	I-NP	O
amplitude	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
baseline	NN	B-NP	O
values	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
no	DT	B-NP	O
changes	NNS	I-NP	O
in	IN	B-PP	O
SAP	NN	B-NP	O
amplitude	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
complained	VBD	B-VP	O
of	IN	B-PP	O
paresthesias	NNS	B-NP	B
and	CC	O	O
leg	NN	B-NP	O
cramps	NNS	I-NP	B
.	.	O	O

After	IN	B-PP	O
thalidomide	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
sural	JJ	B-NP	O
SAP	NN	I-NP	O
amplitude	NN	I-NP	O
recovered	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
detection	NN	B-NP	O
of	IN	B-PP	O
reduction	NN	B-NP	O
in	IN	B-PP	O
sural	JJ	B-NP	O
nerve	NN	I-NP	O
SAP	NN	I-NP	O
amplitude	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
median	JJ	I-NP	O
thalidomide	NN	I-NP	O
cumulative	JJ	I-NP	O
dose	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
g	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
threshold	NN	I-NP	O
neurotoxic	JJ	I-NP	B
dosage	NN	I-NP	O
is	VBZ	B-VP	O
lower	JJR	B-ADJP	O
than	IN	B-SBAR	O
previously	RB	B-ADVP	O
reported	VBN	B-VP	O
.	.	O	O

Sural	JJ	B-NP	O
nerve	NN	I-NP	O
SAP	NN	I-NP	O
amplitude	NN	I-NP	O
reduction	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
reliable	JJ	I-NP	O
and	CC	I-NP	O
sensitive	JJ	I-NP	O
marker	NN	I-NP	O
of	IN	B-PP	O
degeneration	NN	B-NP	O
and	CC	I-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	O
fibres	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
electrophysiological	JJ	I-NP	O
parameter	NN	I-NP	O
provides	VBZ	B-VP	O
information	NN	B-NP	O
about	IN	B-PP	O
subclinical	JJ	B-NP	O
neurotoxic	JJ	I-NP	B
potential	NN	I-NP	O
of	IN	B-PP	O
thalidomide	NN	B-NP	O
but	CC	O	O
is	VBZ	B-VP	O
not	RB	O	O
helpful	JJ	B-ADJP	O
in	IN	B-PP	O
predicting	VBG	B-VP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
sensory	JJ	B-NP	O
symptoms	NNS	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-VP	O
pulmonary	JJ	B-NP	B
mass	NN	I-NP	I
and	CC	O	O
unique	JJ	B-NP	O
membranous	JJ	I-NP	B
glomerulonephritis	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
:	:	O	O
Diagnostic	JJ	B-NP	O
pitfall	NN	I-NP	O
and	CC	O	O
new	JJ	B-NP	O
findings	NNS	I-NP	O
.	.	O	O

Amiodarone	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
anti	AFX	I-NP	O
-	HYPH	I-NP	O
arrhythmic	JJ	I-NP	B
drug	NN	I-NP	O
for	IN	B-PP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
tachycardia	NN	B-NP	B
,	,	O	O
but	CC	O	O
various	JJ	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
reported	VBN	I-VP	O
.	.	O	O

Reported	VBN	B-VP	O
herein	RB	B-ADVP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
autopsy	NN	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
valvular	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
,	,	O	O
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
a	DT	B-NP	O
lung	NN	I-NP	B
mass	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
cm	NN	I-NP	O
in	IN	B-PP	O
diameter	NN	B-NP	O
)	)	O	O
and	CC	O	O
proteinuria	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
g	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
)	)	O	O
after	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
amiodarone	NN	B-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
long	JJ	I-NP	O
time	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
lung	NN	I-NP	B
mass	NN	I-NP	I
was	VBD	B-VP	O
highly	RB	I-VP	O
suspected	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
lung	NN	B-NP	B
cancer	NN	I-NP	I
on	IN	B-PP	O
CT	NN	B-NP	O
and	CC	I-NP	O
positron	NN	I-NP	O
emission	NN	I-NP	O
tomography	NN	I-NP	O
,	,	O	O
but	CC	O	O
histologically	RB	B-ADVP	O
the	DT	B-NP	O
lesion	NN	I-NP	O
was	VBD	B-VP	O
composed	VBN	I-VP	O
of	IN	B-PP	O
lymphoplasmacytic	JJ	B-NP	O
infiltrates	NNS	I-NP	O
in	IN	B-PP	O
alveolar	JJ	B-NP	O
walls	NNS	I-NP	O
and	CC	O	O
intra	AFX	B-NP	O
-	HYPH	I-NP	O
alveolar	JJ	I-NP	O
accumulation	NN	I-NP	O
of	IN	B-PP	O
foamy	JJ	B-NP	O
macrophages	NNS	I-NP	O
containing	VBG	B-VP	O
characteristic	JJ	B-NP	O
myelinoid	JJ	I-NP	O
bodies	NNS	I-NP	O
,	,	O	O
indicating	VBG	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
an	DT	B-NP	O
amiodarone	NN	I-NP	O
-	HYPH	B-VP	O
related	VBN	B-NP	O
lesion	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
lung	NN	I-NP	O
tissue	NN	I-NP	O
had	VBD	B-VP	O
unevenly	RB	I-VP	O
distributed	VBN	I-VP	O
hemosiderin	NN	B-NP	B
deposition	NN	I-NP	O
,	,	O	O
and	CC	O	O
abnormally	RB	B-NP	O
tortuous	JJ	I-NP	O
capillaries	NNS	I-NP	O
were	VBD	B-VP	O
seen	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
mass	NN	I-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
heavily	RB	B-NP	O
hemosiderotic	JJ	I-NP	B
lung	NN	I-NP	O
portions	NNS	I-NP	O
outside	IN	B-PP	O
the	DT	B-NP	O
mass	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
kidneys	NNS	I-NP	O
,	,	O	O
glomeruli	NNS	B-NP	O
had	VBD	B-VP	O
membrane	NN	B-NP	O
spikes	NNS	I-NP	O
,	,	O	O
prominent	JJ	B-NP	O
swelling	NN	I-NP	O
of	IN	B-PP	O
podocytes	NNS	B-NP	O
and	CC	O	O
subepithelial	JJ	B-NP	O
deposits	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
were	VBD	B-VP	O
sometimes	RB	B-ADJP	O
large	JJ	I-ADJP	O
and	CC	I-ADJP	O
hump	JJ	I-ADJP	O
-	HYPH	B-ADJP	O
like	JJ	I-ADJP	O
.	.	O	O

Autoimmune	JJ	B-NP	B
diseases	NNS	I-NP	I
,	,	O	O
viral	JJ	B-NP	B
hepatitis	NN	I-NP	I
,	,	O	O
malignant	JJ	B-NP	O
neoplasms	NNS	I-NP	B
or	CC	O	O
other	JJ	B-NP	O
diseases	NNS	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
known	VBN	I-NP	O
relationship	NN	I-NP	O
to	TO	B-PP	O
membranous	JJ	B-NP	B
glomerulonephritis	NN	I-NP	I
were	VBD	B-VP	O
not	RB	I-VP	O
found	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
highlights	VBZ	B-VP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
that	IN	B-SBAR	O
differential	JJ	B-NP	O
diagnosis	NN	I-NP	O
between	IN	B-PP	O
an	DT	B-NP	O
amiodarone	NN	I-NP	O
-	HYPH	O	O
related	VBN	B-VP	O
pulmonary	JJ	B-NP	B
lesion	NN	I-NP	I
and	CC	O	O
a	DT	B-NP	O
neoplasm	NN	I-NP	B
can	MD	B-VP	O
be	VB	I-VP	O
very	RB	B-ADJP	O
difficult	JJ	I-ADJP	O
radiologically	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
membranous	JJ	B-NP	B
glomerulonephritis	NN	I-NP	I
might	MD	B-VP	O
be	VB	I-VP	O
another	DT	B-NP	O
possible	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
amiodarone	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Risk	NN	B-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
initial	JJ	B-NP	O
sulphonylurea	NN	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
:	:	O	O
a	DT	B-NP	O
matched	VBN	I-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
assess	VB	I-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
coronary	JJ	B-NP	B
artery	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
CAD	NN	B-NP	B
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
initial	JJ	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
with	IN	B-PP	O
different	JJ	B-NP	O
sulphonylureas	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetic	JJ	I-NP	I
patients	NNS	I-NP	O
,	,	O	O
cases	NNS	B-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
CAD	NN	B-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
retrospectively	RB	B-ADVP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
that	WDT	B-NP	O
did	VBD	B-VP	O
not	RB	O	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
CAD	NN	B-NP	B
at	IN	B-PP	O
diagnosis	NN	B-NP	O
of	IN	B-PP	O
diabetes	NNS	B-NP	B
,	,	O	O
using	VBG	B-VP	O
the	DT	B-NP	O
UKPDS	NN	I-NP	O
risk	NN	I-NP	O
engine	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
match	VB	I-VP	O
cases	NNS	B-NP	O
with	IN	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
CAD	NN	B-NP	B
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
controls	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
hazard	NN	I-NP	O
of	IN	B-PP	O
developing	VBG	B-VP	O
CAD	NN	B-NP	B
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
)	)	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
initial	JJ	B-NP	O
treatment	NN	I-NP	O
increased	VBD	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
glibenclamide	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
glipizide	NN	B-NP	O
;	:	O	O
num	CD	B-NP	O
-	HYPH	B-ADJP	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
either	CC	O	O
,	,	O	O
and	CC	O	O
was	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
with	IN	B-PP	O
metformin	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
hazard	NN	I-NP	O
decreased	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
glimepiride	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
gliclazide	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
-	HYPH	O	O
fold	RB	B-ADVP	O
with	IN	B-PP	O
either	RB	B-NP	O
.	.	O	O

Initiating	VBG	B-VP	O
treatment	NN	B-NP	O
of	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
with	IN	B-PP	O
glibenclamide	NN	B-NP	O
or	CC	I-NP	O
glipizide	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
CAD	NN	B-NP	B
in	IN	B-PP	O
comparison	NN	B-NP	O
to	TO	B-PP	O
gliclazide	NN	B-NP	O
or	CC	I-NP	O
glimepiride	NN	I-NP	O
.	.	O	O

If	IN	B-SBAR	O
confirmed	VBN	B-VP	O
,	,	O	O
this	DT	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
important	JJ	B-ADJP	O
because	IN	B-SBAR	O
most	JJS	B-NP	O
Indian	JJ	I-NP	O
patients	NNS	I-NP	O
receive	VBP	B-VP	O
the	DT	B-NP	O
cheaper	JJR	I-NP	O
older	JJR	I-NP	O
sulphonylureas	NNS	I-NP	O
,	,	O	O
and	CC	O	O
present	JJ	B-NP	O
guidelines	NNS	I-NP	O
do	VBP	B-VP	O
not	RB	I-VP	O
distinguish	VB	I-VP	O
between	IN	B-PP	O
individual	JJ	B-NP	O
agents	NNS	I-NP	O
.	.	O	O

Reduced	VBN	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
adriamycin	NN	B-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
treated	VBN	B-VP	O
by	IN	B-PP	O
losartan	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
the	DT	B-NP	O
antihypertensive	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
angiotensin	NN	B-NP	O
num	CD	I-NP	O
type	NN	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
receptor	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
losartan	NN	B-NP	O
,	,	O	O
and	CC	O	O
its	PRP$	B-NP	O
potential	NN	I-NP	O
in	IN	B-PP	O
slowing	VBG	B-VP	O
down	RP	B-PRT	O
renal	JJ	B-NP	B
disease	NN	I-NP	I
progression	NN	I-NP	O
in	IN	B-PP	O
spontaneously	RB	B-NP	O
hypertensive	JJ	I-NP	B
rats	NNS	I-NP	O
(	(	O	O
SHR	NN	B-NP	O
)	)	O	O
with	IN	B-PP	O
adriamycin	NN	B-NP	O
(	(	O	O
ADR	NN	B-NP	O
)	)	O	O
nephropathy	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	JJ	I-NP	O
SHR	NN	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
selected	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
control	NN	I-NP	O
groups	NNS	I-NP	O
(	(	O	O
SH	NN	B-NP	O
,	,	I-NP	O
SH	NN	I-NP	O
)	)	O	O
received	VBD	B-VP	O
vehicle	NN	B-NP	O
.	.	O	O

Groups	NNS	B-NP	O
ADR	NN	I-NP	O
,	,	I-NP	O
ADR+LOS	NN	I-NP	O
and	CC	I-NP	O
ADR	NN	I-NP	O
,	,	O	O
and	CC	O	O
ADR+LOS	NN	B-NP	O
received	VBD	B-VP	O
ADR	NN	B-NP	O
twice	RB	B-ADVP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
week	NN	I-NP	O
interval	NN	I-NP	O
.	.	O	O

Group	NN	B-NP	O
ADR+LOS	NN	I-NP	O
received	VBD	B-VP	O
losartan	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
and	CC	I-NP	O
group	NN	I-NP	O
ADR+LOS	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
after	IN	B-PP	O
second	JJ	B-NP	O
injection	NN	I-NP	O
of	IN	B-PP	O
ADR	NN	B-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
killed	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
num	CD	I-NP	O
weeks	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

Haemodynamic	JJ	B-NP	O
measurements	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
on	IN	B-PP	O
anaesthetized	VBN	B-NP	O
animals	NNS	I-NP	O
,	,	O	O
blood	NN	B-NP	O
and	CC	I-NP	O
urine	NN	I-NP	O
samples	NNS	I-NP	O
were	VBD	B-VP	O
taken	VBN	I-VP	O
for	IN	B-PP	O
biochemical	JJ	B-NP	O
analysis	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
left	JJ	I-NP	O
kidney	NN	I-NP	O
was	VBD	B-VP	O
processed	VBN	I-VP	O
for	IN	B-PP	O
morphological	JJ	B-NP	O
studies	NNS	I-NP	O
.	.	O	O

Short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
losartan	NN	I-NP	O
treatment	NN	I-NP	O
,	,	O	O
besides	IN	B-PP	O
antihypertensive	JJ	B-NP	O
effect	NN	I-NP	O
,	,	O	O
improved	VBD	B-VP	O
glomerular	JJ	B-NP	O
filtration	NN	I-NP	O
rate	NN	I-NP	O
and	CC	O	O
ameliorated	VBN	B-NP	O
glomerulosclerosis	NN	I-NP	B
resulting	VBG	B-VP	O
in	IN	B-PP	O
decreased	VBN	B-NP	O
proteinuria	NN	I-NP	B
.	.	O	O

Prolonged	JJ	B-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
losartan	NN	B-NP	O
showed	VBD	B-VP	O
further	JJ	B-NP	O
reduction	NN	I-NP	O
of	IN	B-PP	O
glomerulosclerosis	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
reduced	VBN	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
atrophy	NN	I-NP	B
and	CC	O	O
interstitial	JJ	B-NP	B
fibrosis	NN	I-NP	I
,	,	O	O
thus	RB	B-ADVP	O
preventing	VBG	B-VP	O
heavy	JJ	B-NP	O
proteinuria	NN	I-NP	B
and	CC	O	O
chronic	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Losartan	NNP	B-NP	O
reduced	VBD	B-VP	O
uraemia	NN	B-NP	B
and	CC	O	O
increased	VBD	B-VP	O
urea	NN	B-NP	O
clearance	NN	I-NP	O
in	IN	B-PP	O
advanced	VBN	B-NP	O
ADR	NN	I-NP	O
nephropathy	NN	I-NP	B
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

Histological	JJ	B-NP	O
examination	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
losartan	NN	B-NP	O
could	MD	B-VP	O
prevent	VB	I-VP	O
tubular	JJ	B-NP	O
atrophy	NN	I-NP	B
,	,	O	O
interstitial	JJ	B-NP	O
infiltration	NN	I-NP	O
and	CC	I-NP	O
fibrosis	NN	I-NP	B
in	IN	B-PP	O
ADR	NN	B-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Losartan	NNP	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
rate	NN	I-NP	O
of	IN	B-PP	O
progression	NN	B-NP	O
of	IN	B-PP	O
ADR	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
focal	JJ	I-NP	B
segmental	JJ	I-NP	I
glomerulosclerosis	NN	I-NP	I
to	TO	B-VP	O
end	VB	I-VP	B
-	HYPH	B-NP	I
stage	NN	I-NP	I
renal	JJ	I-NP	I
disease	NN	I-NP	I
in	IN	B-PP	O
SHR	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
risks	NNS	I-NP	O
of	IN	B-PP	O
aprotinin	NN	B-NP	O
and	CC	O	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
:	:	O	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
of	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
patients	NNS	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
aim	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
investigate	VB	I-VP	O
postoperative	JJ	B-NP	O
complications	NNS	I-NP	O
and	CC	I-NP	O
mortality	NN	I-NP	O
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
aprotinin	NN	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
unselected	JJ	I-NP	O
,	,	I-NP	O
consecutive	JJ	I-NP	O
cohort	NN	I-NP	O
.	.	O	O

Perioperative	JJ	B-NP	O
data	NNS	I-NP	O
from	IN	B-PP	O
consecutive	JJ	B-NP	O
cardiac	JJ	I-NP	O
surgery	NN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
prospectively	RB	I-VP	O
collected	VBN	I-VP	O
between	IN	B-PP	O
September	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
June	NNP	B-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
university	NN	I-NP	O
-	HYPH	O	O
affiliated	VBN	B-NP	O
clinic	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
first	JJ	I-NP	O
num	CD	I-NP	O
mo	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
aprotinin	NN	B-NP	O
(	(	O	O
Group	NN	B-NP	O
A	NN	I-NP	O
)	)	O	O
;	:	O	O
in	IN	B-PP	O
the	DT	B-NP	O
next	JJ	I-NP	O
num	CD	I-NP	O
mo	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
Group	NN	B-NP	O
T	NN	I-NP	O
)	)	O	O
.	.	O	O

Except	IN	B-PP	O
for	IN	B-PP	O
antifibrinolytic	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
anesthetic	JJ	I-NP	O
and	CC	I-NP	O
surgical	JJ	I-NP	O
protocols	NNS	I-NP	O
remained	VBD	B-VP	O
unchanged	JJ	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
pre	AFX	I-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
intraoperative	JJ	I-NP	O
variables	NNS	I-NP	O
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

Postoperatively	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
significantly	RB	I-NP	O
higher	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
seizures	NNS	B-NP	B
was	VBD	B-VP	O
found	VBN	I-VP	O
in	IN	B-PP	O
Group	NNP	B-NP	O
T	NNP	I-NP	O
.	VBD	B-VP	O

This	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
also	RB	B-ADVP	O
significant	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
valve	NN	I-NP	O
surgery	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
high	JJ	I-NP	O
risk	NN	I-NP	O
surgery	NN	I-NP	O
subgroups	NNS	I-NP	O
.	.	O	O

Persistent	JJ	B-NP	O
atrial	JJ	I-NP	O
fibrillation	NN	I-NP	O
and	CC	O	O
renal	JJ	B-NP	B
failure	NN	I-NP	I
were	VBD	B-VP	O
also	RB	B-ADVP	O
more	RBR	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
Group	NNP	B-NP	O
T	NNP	I-NP	O
,	,	O	O
in	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
valve	NN	I-NP	O
surgery	NN	I-NP	O
subgroup	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
among	IN	B-PP	O
primary	JJ	B-NP	O
coronary	JJ	I-NP	O
artery	NN	I-NP	O
bypass	IN	B-PP	O
surgery	NN	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
more	RBR	B-NP	O
acute	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarctions	NNS	I-NP	I
and	CC	O	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
Group	NN	B-NP	O
A	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
yr	NN	I-NP	O
mortality	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
higher	JJR	I-ADJP	O
after	IN	B-PP	O
aprotinin	NN	B-NP	O
treatment	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
high	JJ	I-NP	O
risk	NN	I-NP	O
surgery	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
antifibrinolytic	JJ	I-NP	O
drugs	NNS	I-NP	O
bear	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
adverse	JJ	B-NP	O
outcome	NN	I-NP	O
depending	VBG	B-PP	O
on	IN	B-PP	O
the	DT	B-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

Administration	NN	B-NP	O
of	IN	B-PP	O
aprotinin	NN	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
avoided	VBN	I-VP	O
in	IN	B-PP	O
coronary	JJ	B-NP	O
artery	NN	I-NP	O
bypass	IN	B-PP	O
graft	NN	B-NP	O
and	CC	O	O
high	JJ	B-NP	O
risk	NN	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
whereas	IN	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
tranexamic	JJ	B-NP	O
acid	NN	I-NP	O
is	VBZ	B-VP	O
not	RB	I-VP	O
recommended	VBN	I-VP	O
in	IN	B-PP	O
valve	NN	B-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
biological	JJ	I-NP	O
properties	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
optical	JJ	I-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
and	CC	O	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
cardiac	JJ	B-NP	B
arrhythmias	NNS	I-NP	I
.	.	O	O
num	CD	B-NP	O
.	.	O	O

The	DT	B-NP	O
optical	JJ	I-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
compared	VBN	I-VP	O
for	IN	B-PP	O
their	PRP$	B-NP	O
beta	SYM	I-NP	O
-	HYPH	I-NP	O
blocking	VBG	I-NP	O
and	CC	I-NP	O
antiarrhythmic	JJ	I-NP	O
activities.2	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
blocking	VBG	B-VP	O
the	DT	B-NP	O
positive	JJ	I-NP	O
inotropic	JJ	I-NP	O
and	CC	I-NP	O
chronotropic	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoprenaline	NN	B-NP	O
,	,	O	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
had	VBD	B-VP	O
less	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
hundredth	NN	I-NP	O
the	DT	B-NP	O
potency	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
dose	NN	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
which	WDT	B-NP	O
attenuated	VBD	B-VP	O
the	DT	B-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoprenaline	NN	B-NP	O
,	,	O	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
prolongation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
PR	NN	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
electrocardiogram.3	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
metabolic	JJ	I-NP	O
responses	NNS	I-NP	O
to	TO	B-PP	O
isoprenaline	NN	B-NP	O
in	IN	B-PP	O
dogs	NNS	B-NP	O
(	(	O	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
circulating	VBG	B-VP	O
glucose	NN	B-NP	O
,	,	O	O
lactate	NN	B-NP	O
and	CC	O	O
free	JJ	B-NP	O
fatty	JJ	I-NP	O
acids	NNS	I-NP	O
)	)	O	O
were	VBD	B-VP	O
all	DT	O	O
blocked	VBN	B-VP	O
by	IN	B-PP	O
-	HYPH	B-NP	O
propranolol.	NN	I-NP	O
-	HYPH	O	O
Propranolol	NN	B-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
fatty	JJ	B-NP	O
acid	NN	I-NP	O
mobilization	NN	I-NP	O
but	CC	O	O
significantly	RB	B-VP	O
reduced	VBD	I-VP	O
the	DT	B-NP	O
increments	NNS	I-NP	O
in	IN	B-PP	O
both	CC	O	O
lactate	NN	B-NP	O
and	CC	I-NP	O
glucose.4	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
possessed	VBD	B-VP	O
similar	JJ	B-NP	O
depressant	NN	I-NP	O
potency	NN	I-NP	O
on	IN	B-PP	O
isolated	VBN	B-NP	O
atrial	JJ	I-NP	O
muscle	NN	I-NP	O
taken	VBN	B-VP	O
from	IN	B-PP	O
guinea	NN	B-NP	O
-	HYPH	B-NP	O
pigs.5	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
exhibited	VBD	B-VP	O
similar	JJ	B-NP	O
local	JJ	I-NP	O
anaesthetic	JJ	I-NP	O
potencies	NNS	I-NP	O
on	IN	B-PP	O
an	DT	B-NP	O
isolated	VBN	I-NP	O
frog	NN	I-NP	O
nerve	NN	I-NP	O
preparation	NN	I-NP	O
at	IN	B-PP	O
a	DT	B-NP	O
level	NN	I-NP	O
approximately	RB	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
that	DT	I-NP	O
of	IN	B-PP	O
procaine	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
racemic	JJ	I-NP	O
compound	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
less	RBR	I-ADJP	O
potent	JJ	I-ADJP	O
than	IN	B-PP	O
either	DT	B-NP	O
isomer.6	NN	I-NP	O
.	.	O	O

Both	DT	B-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
were	VBD	B-VP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
preventing	VBG	B-VP	O
adrenaline	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cardiac	JJ	I-NP	B
arrhythmias	NNS	I-NP	I
in	IN	B-PP	O
cats	NNS	B-NP	O
anaesthetized	VBN	B-VP	O
with	IN	B-PP	O
halothane	NN	B-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
mean	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
whereas	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
.	.	O	O

At	IN	B-PP	O
the	DT	B-NP	O
effective	JJ	I-NP	O
dose	NN	I-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
prolongation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
PR	NN	I-NP	O
interval	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
electrocardiogram	NN	I-NP	O
.	.	O	O

Blockade	NN	B-NP	O
of	IN	B-PP	O
arrhythmias	NNS	B-NP	B
with	IN	B-PP	O
both	DT	B-NP	O
isomers	NNS	I-NP	O
was	VBD	B-VP	O
surmountable	JJ	B-ADJP	O
by	IN	B-PP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
adrenaline.7	NN	B-NP	O
.	.	O	O

Both	DT	B-NP	O
isomers	NNS	I-NP	O
of	IN	B-PP	O
propranolol	NN	B-NP	O
were	VBD	B-VP	O
also	RB	B-ADVP	O
capable	JJ	B-ADJP	O
of	IN	B-PP	O
reversing	VBG	B-VP	O
ventricular	JJ	B-NP	B
tachycardia	NN	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
ouabain	NN	B-NP	O
in	IN	B-PP	O
anaesthetized	VBN	B-NP	O
cats	NNS	I-NP	O
and	CC	I-NP	O
dogs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
was	VBD	B-VP	O
significantly	RB	B-ADJP	O
smaller	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
-	HYPH	B-NP	O
propranolol	NN	I-NP	O
in	IN	B-PP	O
both	CC	O	O
species	NNS	B-NP	O
but	CC	O	O
much	RB	B-ADJP	O
higher	JJR	I-ADJP	O
than	IN	B-PP	O
that	DT	B-NP	O
required	VBN	B-VP	O
to	TO	B-VP	O
produce	VB	I-VP	O
evidence	NN	B-NP	O
of	IN	B-PP	O
beta	SYM	B-NP	O
-	HYPH	B-NP	O
blockade.8	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
implications	NNS	I-NP	O
of	IN	B-PP	O
these	DT	B-NP	O
results	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Topotecan	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
radiotherapy	NN	B-NP	O
in	IN	B-PP	O
unresectable	JJ	B-NP	O
glioblastoma	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
phase	NN	I-NP	O
num	CD	I-NP	O
study	NN	I-NP	O
.	.	O	O

Improving	VBG	B-VP	O
glioblastoma	NN	B-NP	B
multiforme	NN	I-NP	I
(	(	O	O
GBM	NN	B-NP	B
)	)	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
radio	AFX	B-NP	O
-	HYPH	I-NP	O
chemotherapy	NN	I-NP	O
remains	VBZ	B-VP	O
a	DT	B-NP	O
challenge	NN	I-NP	O
.	.	O	O

Topotecan	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
attractive	JJ	I-NP	O
option	NN	I-NP	O
as	IN	B-SBAR	O
it	PRP	B-NP	O
exhibits	VBZ	B-VP	O
growth	NN	B-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
glioma	NN	I-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
brain	NN	B-NP	O
penetration	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
assessed	VBD	B-VP	O
the	DT	B-NP	O
combination	NN	I-NP	O
of	IN	B-PP	O
radiotherapy	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
Gy	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
fractions	NNS	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
days	NNS	I-NP	O
)	)	O	O
and	CC	O	O
topotecan	NN	B-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
adults	NNS	I-NP	O
with	IN	B-PP	O
histologically	RB	B-NP	O
proven	JJ	I-NP	O
and	CC	I-NP	O
untreated	JJ	I-NP	O
GBM	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
hematological	JJ	I-NP	O
toxicities	NNS	I-NP	B
was	VBD	B-VP	O
low	JJ	B-ADJP	O
and	CC	O	O
grade	NN	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
hematological	JJ	I-NP	O
toxicities	NNS	I-NP	B
were	VBD	B-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
(	(	O	O
mainly	RB	B-NP	O
lymphopenia	NN	I-NP	B
and	CC	I-NP	O
neutropenia	NN	I-NP	B
)	)	O	O
.	.	O	O

Partial	JJ	B-NP	O
response	NN	I-NP	O
and	CC	I-NP	O
stabilization	NN	I-NP	O
rates	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
with	IN	B-PP	O
an	DT	B-NP	O
overall	JJ	I-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
progression	NN	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
overall	JJ	I-NP	O
survival	NN	I-NP	O
(	(	O	O
OS	NN	B-NP	O
)	)	O	O
rate	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
a	DT	B-NP	O
median	JJ	I-NP	O
OS	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
.	.	O	O

Topotecan	NN	B-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
radiotherapy	NN	B-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
while	IN	B-SBAR	O
response	NN	B-NP	O
and	CC	I-NP	O
stabilization	NN	I-NP	O
concerned	VBN	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
third	JJ	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
study	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
show	VB	I-VP	O
increased	VBN	B-NP	O
benefits	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
survival	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
unresectable	JJ	B-NP	O
GBM	NN	I-NP	B
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lithium	NN	I-NP	O
therapy	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
hyperparathyroidism	NN	B-NP	B
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
report	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
paper	NN	I-NP	O
reviews	VBZ	B-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
lithium	NN	I-NP	O
therapy	NN	I-NP	O
on	IN	B-PP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
level	NN	I-NP	O
and	CC	O	O
parathyroid	JJ	B-NP	O
glands	NNS	I-NP	O
,	,	O	O
its	PRP$	B-NP	O
pathogenesis	NN	I-NP	O
,	,	O	O
and	CC	O	O
treatment	NN	B-NP	O
options	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
examined	VBD	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
lithium	NN	I-NP	O
-	HYPH	O	O
treated	VBN	B-NP	O
patient	NN	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
recurrent	JJ	B-NP	O
hypercalcemia	NN	I-NP	B
to	TO	B-VP	O
better	RBR	I-VP	O
understand	VB	I-VP	O
the	DT	B-NP	O
disease	NN	I-NP	O
process	NN	I-NP	O
.	.	O	O

Primary	JJ	B-NP	B
hyperparathyroidism	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	O	O
potentially	RB	B-ADVP	O
life	NN	B-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
side	NN	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
lithium	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Careful	JJ	B-NP	O
patient	NN	I-NP	O
selection	NN	I-NP	O
and	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
can	MD	B-VP	O
reduce	VB	I-VP	O
morbidity	NN	B-NP	O
.	.	O	O

As	RB	B-NP	O
much	JJ	I-NP	O
as	IN	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
lithium	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
patients	NNS	I-NP	O
become	VBP	B-VP	O
hypercalcemic	JJ	B-ADJP	B
.	.	O	O

By	IN	B-PP	O
routinely	RB	B-ADVP	O
monitoring	VBG	B-VP	O
serum	NN	B-NP	O
calcium	NN	I-NP	O
levels	NNS	I-NP	O
,	,	O	O
healthcare	NN	B-NP	O
providers	NNS	I-NP	O
can	MD	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
quality	NN	I-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
patient	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
laryngeal	JJ	B-NP	O
mask	NN	I-NP	O
with	IN	B-PP	O
endotracheal	JJ	B-NP	O
tube	NN	I-NP	O
for	IN	B-PP	O
anesthesia	NN	B-NP	O
in	IN	B-PP	O
endoscopic	JJ	B-NP	O
sinus	NN	I-NP	O
surgery	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
purpose	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
compare	VB	I-VP	O
surgical	JJ	B-NP	O
conditions	NNS	I-NP	O
,	,	O	O
including	VBG	B-PP	O
the	DT	B-NP	O
amount	NN	I-NP	O
of	IN	B-PP	O
intraoperative	JJ	B-NP	O
bleeding	NN	I-NP	B
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
intraoperative	JJ	B-NP	O
blood	NN	I-NP	O
pressure	NN	I-NP	O
,	,	O	O
during	IN	B-PP	O
functional	JJ	B-NP	O
endoscopic	JJ	I-NP	O
sinus	NN	I-NP	O
surgery	NN	I-NP	O
(	(	O	O
FESS	NN	B-NP	O
)	)	O	O
using	VBG	B-VP	O
flexible	JJ	B-NP	O
reinforced	JJ	I-NP	O
laryngeal	JJ	I-NP	O
mask	NN	I-NP	O
airway	NN	I-NP	O
(	(	O	O
FRLMA	NN	B-NP	O
)	)	O	O
versus	IN	B-PP	O
endotracheal	JJ	B-NP	O
tube	NN	I-NP	O
(	(	O	O
ETT	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
maintaining	VBG	B-VP	O
controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
anesthesia	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
propofol	NN	B-NP	O
-	HYPH	B-NP	O
remifentanil	NN	I-NP	O
total	JJ	I-NP	O
i.v.	JJ	I-NP	O
anesthesia	NN	I-NP	O
(	(	O	O
TIVA	NN	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
normotensive	JJ	I-NP	O
American	JJ	I-NP	O
Society	NN	I-NP	O
of	IN	B-PP	O
Anesthesiologists	NNS	B-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
adult	JJ	I-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
FESS	NN	B-NP	O
under	IN	B-PP	O
controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
anesthesia	NN	I-NP	O
caused	VBN	B-VP	O
by	IN	B-PP	O
propofol	NN	B-NP	O
-	HYPH	B-NP	O
remifentanil	NN	I-NP	O
-	HYPH	B-NP	O
TIVA	NN	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
assigned	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
:	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
FRLMA	NNP	B-NP	O
;	:	O	O
group	NN	B-NP	O
num	CD	I-NP	O
,	,	O	O
ETT	NNP	B-NP	O
.	.	O	O

Hemorrhage	NN	B-NP	B
was	VBD	B-VP	O
measured	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
visibility	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
operative	JJ	I-NP	O
field	NN	I-NP	O
was	VBD	B-VP	O
evaluated	VBN	I-VP	O
according	VBG	B-PP	O
to	TO	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
point	NN	I-NP	O
scale	NN	I-NP	O
.	.	O	O

Controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
was	VBD	B-VP	O
achieved	VBN	I-VP	O
within	IN	B-PP	O
a	DT	B-NP	O
shorter	JJR	I-NP	O
period	NN	I-NP	O
using	VBG	B-VP	O
laryngeal	JJ	B-NP	O
mask	NN	I-NP	O
using	VBG	B-VP	O
lower	JJR	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
remifentanil	NN	B-NP	O
infusion	NN	I-NP	O
and	CC	O	O
lower	JJR	B-NP	O
total	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
remifentanil	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
our	PRP$	B-NP	O
results	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
airway	NN	B-NP	O
management	NN	I-NP	O
using	VBG	B-VP	O
FRLMA	NN	B-NP	O
during	IN	B-PP	O
controlled	VBN	B-NP	O
hypotension	NN	I-NP	B
anesthesia	NN	I-NP	O
provided	VBD	B-VP	O
better	JJR	B-NP	O
surgical	JJ	I-NP	O
conditions	NNS	I-NP	O
in	IN	B-PP	O
terms	NNS	B-NP	O
of	IN	B-PP	O
quality	NN	B-NP	O
of	IN	B-PP	O
operative	JJ	B-NP	O
field	NN	I-NP	O
and	CC	I-NP	O
blood	NN	I-NP	O
loss	NN	I-NP	O
and	CC	O	O
allowed	VBN	B-VP	O
for	IN	B-PP	O
convenient	NN	B-NP	O
induced	VBD	B-VP	O
hypotension	NN	B-NP	B
with	IN	B-PP	O
low	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
remifentanil	NN	B-NP	O
during	IN	B-PP	O
TIVA	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
FESS	NNS	B-NP	O
.	.	O	O

Nonalcoholic	JJ	B-NP	B
fatty	JJ	I-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
during	IN	B-PP	O
valproate	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Valproic	JJ	B-NP	O
acid	NN	I-NP	O
(	(	O	O
VPA	NN	B-NP	O
)	)	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
many	JJ	B-NP	O
types	NNS	I-NP	O
of	IN	B-PP	O
epilepsy	NN	B-NP	B
,	,	O	O
but	CC	O	O
its	PRP$	B-NP	O
use	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
an	DT	B-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
body	NN	B-NP	O
weight	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
nonalcoholic	JJ	B-NP	B
fatty	JJ	I-NP	I
liver	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
NAFLD	NN	B-NP	B
)	)	O	O
arising	VBG	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
child	NN	I-NP	O
who	WP	B-NP	O
developed	VBD	B-VP	O
obesity	NN	B-NP	B
during	IN	B-PP	O
VPA	NN	B-NP	O
treatment	NN	I-NP	O
.	.	O	O

Laboratory	NN	B-NP	O
data	NNS	I-NP	O
revealed	VBD	B-VP	O
hyperinsulinemia	NN	B-NP	B
with	IN	B-PP	O
insulin	NN	B-NP	B
resistance	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
the	DT	B-NP	O
withdrawal	NN	I-NP	O
of	IN	B-PP	O
VPA	NN	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
weight	NN	I-NP	B
loss	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
body	NN	B-NP	O
mass	NN	I-NP	O
index	NN	I-NP	O
,	,	O	O
and	CC	O	O
normalization	NN	B-NP	O
of	IN	B-PP	O
metabolic	JJ	B-NP	O
and	CC	I-NP	O
endocrine	JJ	I-NP	O
parameters	NNS	I-NP	O
;	:	O	O
moreover	RB	B-ADVP	O
,	,	O	O
ultrasound	JJ	B-NP	O
measurements	NNS	I-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
normalization	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
case	NN	I-NP	O
suggests	VBZ	B-VP	O
that	IN	B-SBAR	O
obesity	NN	B-NP	B
,	,	O	O
hyperinsulinemia	NN	B-NP	B
,	,	O	O
insulin	NN	B-NP	B
resistance	NN	I-NP	I
,	,	O	O
and	CC	O	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
treatment	NN	I-NP	O
with	IN	B-PP	O
VPA	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
all	DT	O	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
NAFLD	NN	B-NP	B
;	:	O	O
this	DT	B-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
is	VBZ	B-VP	O
reversible	JJ	B-ADJP	O
after	IN	B-PP	O
VPA	NN	B-NP	O
withdrawal	NN	I-NP	O
.	.	O	O

Carbimazole	NN	B-NP	O
induced	VBD	B-VP	O
ANCA	CC	B-NP	B
positive	JJ	I-NP	I
vasculitis	NN	I-NP	I
.	.	O	O

Anti	AFX	B-NP	O
-	HYPH	I-NP	O
thyroid	JJ	B-NP	O
drugs	NNS	I-NP	O
,	,	O	O
like	IN	B-PP	O
carbimazole	NN	B-NP	O
and	CC	O	O
propylthiouracil	NN	B-NP	O
(	(	O	O
PTU	NN	B-NP	O
)	)	O	O
are	VBP	B-VP	O
commonly	RB	I-VP	O
prescribed	VBN	I-VP	O
for	IN	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
hyperthyroidism	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
aware	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
antithyroid	JJ	B-NP	O
medications	NNS	I-NP	O
.	.	O	O

Antineutrophil	NN	B-NP	B
cytoplasmic	JJ	I-NP	I
antibody	NN	I-NP	I
(	(	O	I
ANCA	NN	B-NP	I
)	)	O	I
-	HYPH	O	I
-	HYPH	B-NP	I
associated	VBN	I-NP	I
vasculitis	NN	I-NP	I
is	VBZ	B-VP	O
a	DT	B-NP	O
potentially	RB	I-NP	O
life	NN	I-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
adverse	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
antithyroidmedications	NNS	B-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
Graves	NN	B-NP	B
s	VBZ	B-VP	I
disease	NN	B-NP	I
who	WP	B-NP	O
developed	VBD	B-VP	O
ANCA	NN	B-NP	O
positive	JJ	I-NP	O
carbimazole	NN	I-NP	O
induced	VBD	B-VP	O
vasculitis	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
episode	NN	I-NP	O
was	VBD	B-VP	O
characterized	VBN	I-VP	O
by	IN	B-PP	O
a	DT	B-NP	O
vasculitic	JJ	I-NP	B
skin	NN	I-NP	B
rash	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
large	JJ	B-NP	O
joint	JJ	I-NP	O
arthritis	NN	I-NP	B
,	,	O	O
pyrexia	NN	B-NP	B
and	CC	I-NP	O
parotiditis	NN	I-NP	B
but	CC	O	O
no	DT	B-NP	O
renal	JJ	I-NP	O
or	CC	I-NP	O
pulmonary	JJ	I-NP	O
involvement	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
referred	VBN	I-VP	O
to	TO	B-PP	O
us	PRP	B-NP	O
for	IN	B-PP	O
neurological	JJ	B-NP	O
evaluation	NN	I-NP	O
because	IN	B-SBAR	O
he	PRP	B-NP	O
had	VBD	B-VP	O
difficulty	NN	B-NP	O
in	IN	B-PP	O
getting	VBG	B-VP	O
up	RP	B-PRT	O
from	IN	B-PP	O
squatting	VBG	B-VP	O
position	NN	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
suspected	VBN	I-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
myositis	NN	B-NP	B
.	.	O	O

Carbimazole	NN	B-NP	O
and	CC	I-NP	O
methimazole	NN	I-NP	O
have	VBP	B-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
reported	VBN	B-NP	O
ANCA	NN	I-NP	O
positive	JJ	I-NP	O
side	NN	I-NP	O
effects	NNS	I-NP	O
than	IN	B-PP	O
PUT	NN	B-NP	O
.	.	O	O

To	TO	B-PP	O
the	DT	B-NP	O
best	JJS	I-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
first	JJ	I-NP	O
ANCA	NN	I-NP	O
positive	JJ	I-NP	O
carbimazole	NN	I-NP	O
induced	VBD	B-VP	O
vasculitis	NN	B-NP	B
case	NN	I-NP	O
reported	VBN	B-VP	O
from	IN	B-PP	O
India	NNP	B-NP	O
.	.	O	O

Aspirin	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	O
events	NNS	I-NP	O
:	:	O	O
an	DT	B-NP	O
update	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
evidence	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
U.S	NNP	I-NP	O
.	.	O	O

Preventive	JJ	B-NP	O
Services	NNP	I-NP	O
Task	NNP	I-NP	O
Force	NNP	I-NP	O
.	.	O	O

Coronary	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
and	CC	O	O
cerebrovascular	JJ	B-NP	B
disease	NN	I-NP	I
are	VBP	B-VP	O
leading	VBG	I-VP	O
causes	NNS	B-NP	O
of	IN	B-PP	O
death	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
United	NNP	I-NP	O
States	NNPS	I-NP	O
.	.	O	O

In	IN	B-PP	O
num	CD	B-NP	O
the	DT	B-NP	O
U.S	NNP	I-NP	O
.	.	O	O

Preventive	JJ	B-NP	O
Services	NNP	I-NP	O
Task	NNP	I-NP	O
Force	NNP	I-NP	O
(	(	O	O
USPSTF	NNP	B-NP	O
)	)	O	O
strongly	RB	B-VP	O
recommended	VBD	I-VP	O
that	IN	B-SBAR	O
clinicians	NNS	B-NP	O
discuss	VBP	B-VP	O
aspirin	NN	B-NP	O
with	IN	B-PP	O
adults	NNS	B-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
at	IN	B-PP	O
increased	VBN	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
coronary	JJ	B-NP	B
heart	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
benefits	NNS	I-NP	O
and	CC	I-NP	O
harms	NNS	I-NP	O
of	IN	B-PP	O
taking	VBG	B-VP	O
aspirin	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
myocardial	JJ	B-NP	B
infarctions	NNS	I-NP	I
,	,	O	O
strokes	NNS	B-NP	B
,	,	O	O
and	CC	O	O
death	NN	B-NP	O
.	.	O	O

MEDLINE	NNP	B-NP	O
and	CC	I-NP	O
Cochrane	NNP	I-NP	O
Library	NNP	I-NP	O
(	(	O	O
search	NN	B-NP	O
dates	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
January	NNP	I-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
August	NNP	I-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
recent	JJ	B-NP	O
systematic	JJ	I-NP	O
reviews	NNS	I-NP	O
,	,	O	O
reference	NN	B-NP	O
lists	NNS	I-NP	O
of	IN	B-PP	O
retrieved	JJ	B-NP	O
articles	NNS	I-NP	O
,	,	O	O
and	CC	O	O
suggestions	NNS	B-NP	O
from	IN	B-PP	O
experts	NNS	B-NP	O
.	.	O	O

English	JJ	B-NP	O
-	HYPH	I-NP	O
language	NN	I-NP	O
randomized	VBN	B-VP	O
,	,	O	O
controlled	VBN	B-NP	O
trials	NNS	I-NP	O
(	(	O	O
RCTs	NNS	B-NP	O
)	)	O	O
;	:	O	O
case	NN	O	O
-	HYPH	O	O
control	NN	B-NP	O
studies	NNS	I-NP	O
;	:	O	O
meta	SYM	O	O
-	HYPH	O	O
analyses	NNS	B-NP	O
;	:	O	O
and	CC	O	O
systematic	JJ	B-NP	O
reviews	NNS	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
versus	CC	I-NP	O
control	NN	I-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
cardiovascular	JJ	B-NP	B
disease	NN	I-NP	I
(	(	O	O
CVD	NN	B-NP	B
)	)	O	O
were	VBD	B-VP	O
selected	VBN	I-VP	O
to	TO	I-VP	O
answer	VB	I-VP	O
the	DT	B-NP	O
following	VBG	I-NP	O
questions	NNS	I-NP	O
:	:	O	O
Does	VBZ	B-VP	O
aspirin	NN	B-NP	O
decrease	NN	I-NP	O
coronary	JJ	I-NP	O
heart	NN	I-NP	O
events	NNS	I-NP	O
,	,	O	O
strokes	NNS	B-NP	B
,	,	O	O
death	NN	B-NP	O
from	IN	B-PP	O
coronary	JJ	B-NP	O
heart	NN	I-NP	O
events	NNS	I-NP	O
or	CC	O	O
stroke	VB	B-VP	B
,	,	O	O
or	CC	O	O
all	RB	B-NP	O
-	HYPH	I-NP	O
cause	NN	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
adults	NNS	B-NP	O
without	IN	B-PP	O
known	JJ	B-NP	O
CVD	NN	I-NP	B
?	.	O	O
Does	VBZ	B-VP	O
aspirin	NN	B-NP	O
increase	NN	I-NP	O
gastrointestinal	JJ	I-NP	B
bleeding	NN	I-NP	I
or	CC	O	O
hemorrhagic	JJ	B-NP	B
strokes	NNS	I-NP	I
?	.	O	O
DATA	NNP	B-NP	O
EXTRACTION	NNP	I-NP	O
:	:	O	O
All	DT	B-NP	O
studies	NNS	I-NP	O
were	VBD	B-VP	O
reviewed	VBN	I-VP	O
,	,	O	O
abstracted	VBN	B-VP	O
,	,	O	O
and	CC	O	O
rated	VBN	B-VP	O
for	IN	B-PP	O
quality	NN	B-NP	O
by	IN	B-PP	O
using	VBG	B-VP	O
predefined	JJ	B-NP	O
USPSTF	NN	I-NP	O
criteria	NNS	I-NP	O
.	.	O	O

New	JJ	B-NP	O
evidence	NN	I-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
good	JJ	I-NP	O
-	HYPH	I-NP	O
quality	NN	I-NP	O
RCT	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
good	JJ	I-NP	O
-	HYPH	I-NP	O
quality	NN	I-NP	O
meta	SYM	O	O
-	HYPH	O	O
analysis	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
fair	JJ	I-NP	O
-	HYPH	I-NP	O
quality	NN	I-NP	O
subanalyses	NNS	I-NP	O
of	IN	B-PP	O
RCTs	NNS	B-NP	O
demonstrates	VBZ	B-VP	O
that	IN	B-SBAR	O
aspirin	NN	B-NP	O
use	NN	I-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
CVD	NN	B-NP	B
events	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
known	JJ	B-NP	O
CVD	NN	I-NP	B
.	.	O	O

Men	NN	B-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
studies	NNS	I-NP	O
experienced	VBD	B-VP	O
fewer	JJR	B-NP	O
myocardial	JJ	I-NP	B
infarctions	NNS	I-NP	I
and	CC	I-NP	O
women	NNS	I-NP	O
experienced	VBD	B-VP	O
fewer	JJR	B-NP	O
ischemic	JJ	I-NP	O
strokes	NNS	I-NP	B
.	.	O	O

Aspirin	NN	B-NP	O
does	VBZ	B-VP	O
not	RB	I-VP	O
seem	VB	I-VP	O
to	TO	I-VP	O
affect	VB	I-VP	O
CVD	NN	B-NP	B
mortality	NN	I-NP	O
or	CC	O	O
all	RB	B-NP	O
-	HYPH	I-NP	O
cause	NN	I-NP	O
mortality	NN	I-NP	O
in	IN	B-PP	O
either	CC	O	O
men	NNS	B-NP	O
or	CC	I-NP	O
women	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
for	IN	B-PP	O
primary	JJ	B-NP	O
prevention	NN	I-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
major	JJ	B-NP	O
bleeding	VBG	I-NP	B
events	NNS	I-NP	O
,	,	O	O
primarily	RB	B-NP	O
gastrointestinal	JJ	I-NP	B
bleeding	VBG	I-NP	I
events	NNS	I-NP	O
,	,	O	O
in	IN	B-PP	O
both	CC	B-NP	O
men	NNS	I-NP	O
and	CC	I-NP	O
women	NNS	I-NP	O
.	.	O	O

Men	NN	B-NP	O
have	VBP	B-VP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
hemorrhagic	JJ	B-NP	B
strokes	NNS	I-NP	I
with	IN	B-PP	O
aspirin	NN	B-NP	O
use	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
new	JJ	I-NP	O
RCT	NN	I-NP	O
and	CC	I-NP	O
meta	NN	I-NP	O
-	HYPH	O	O
analysis	NN	B-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
hemorrhagic	JJ	B-NP	B
strokes	NNS	I-NP	I
in	IN	B-PP	O
women	NNS	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
statistically	RB	B-ADVP	O
significantly	RB	B-ADJP	O
increased	VBN	I-ADJP	O
.	.	O	O

New	JJ	B-NP	O
evidence	NN	I-NP	O
on	IN	B-PP	O
aspirin	NN	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
primary	JJ	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
CVD	NN	B-NP	B
is	VBZ	B-VP	O
limited	VBN	B-ADJP	O
.	.	O	O

The	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
aspirin	NN	B-NP	O
used	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
RCTs	NNS	I-NP	O
varied	VBD	B-VP	O
,	,	O	O
which	WDT	B-NP	O
prevented	VBD	B-VP	O
the	DT	B-NP	O
estimation	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
appropriate	JJ	I-NP	O
dose	NN	I-NP	O
for	IN	B-PP	O
primary	JJ	B-NP	O
prevention	NN	I-NP	O
.	.	O	O

Several	JJ	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
RCTs	NNS	I-NP	O
were	VBD	B-VP	O
conducted	VBN	I-VP	O
within	IN	B-PP	O
populations	NNS	B-NP	O
of	IN	B-PP	O
health	NN	B-NP	O
professionals	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
potentially	RB	B-ADVP	O
limits	VBZ	B-VP	O
generalizability	NN	B-NP	O
.	.	O	O

Aspirin	NN	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
in	IN	B-PP	O
men	NNS	B-NP	O
and	CC	I-NP	O
strokes	NNS	I-NP	B
in	IN	B-PP	O
women	NNS	B-NP	O
.	.	O	O

Aspirin	NN	B-NP	O
use	NN	I-NP	O
increases	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
serious	JJ	B-NP	O
bleeding	NN	I-NP	B
events	NNS	I-NP	O
.	.	O	O

Reducing	VBG	B-NP	O
harm	NN	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
anticoagulation	NN	B-NP	O
:	:	O	O
practical	JJ	B-NP	O
considerations	NNS	I-NP	O
of	IN	B-PP	O
argatroban	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
.	.	O	O

Argatroban	NNP	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
hepatically	RB	I-NP	O
metabolized	VBN	I-NP	O
,	,	I-NP	O
direct	JJ	I-NP	O
thrombin	NN	I-NP	O
inhibitor	NN	I-NP	O
used	VBN	B-VP	O
for	IN	B-PP	O
prophylaxis	NN	B-NP	O
or	CC	I-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
thrombosis	NN	B-NP	B
in	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
(	(	O	O
HIT	NN	B-NP	B
)	)	O	O
and	CC	O	O
for	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
or	CC	B-PP	O
at	IN	B-PP	O
risk	NN	B-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
undergoing	VBG	B-VP	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
intervention	NN	I-NP	O
(	(	O	O
PCI	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
objective	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
review	NN	I-NP	O
is	VBZ	B-VP	O
to	TO	B-VP	O
summarize	VB	I-VP	O
practical	JJ	B-NP	O
considerations	NNS	I-NP	O
of	IN	B-PP	O
argatroban	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
HIT	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
US	NNP	I-NP	O
FDA	NNP	I-NP	O
-	HYPH	B-NP	O
recommended	VBN	I-NP	O
argatroban	NN	I-NP	O
dose	NN	I-NP	O
in	IN	B-PP	O
HIT	NN	B-NP	B
is	VBZ	B-VP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
(	(	O	O
reduced	VBN	B-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	B
impairment	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
paediatric	JJ	B-NP	O
patients	NNS	I-NP	O
)	)	O	O
,	,	O	O
adjusted	VBN	B-VP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
activated	VBN	B-NP	O
partial	JJ	I-NP	O
thromboplastin	NN	I-NP	O
times	NNS	I-NP	O
(	(	O	O
aPTTs	NNS	B-NP	O
)	)	O	O
num	CD	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
times	NNS	I-NP	O
baseline	NN	I-NP	O
.	.	O	O

Contemporary	JJ	B-NP	O
experiences	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
reduced	VBN	B-NP	O
doses	NNS	I-NP	O
are	VBP	B-VP	O
also	RB	I-VP	O
needed	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
conditions	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
hepatic	JJ	B-NP	O
hypoperfusion	NN	I-NP	O
,	,	O	O
e.g	NN	B-NP	O
.	.	O	O

heart	NN	B-NP	B
failure	NN	I-NP	I
,	,	O	O
yet	CC	O	O
are	VBP	B-VP	O
unnecessary	JJ	B-ADJP	O
for	IN	B-PP	O
renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
,	,	O	O
adult	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
race	NN	B-NP	O
/	SYM	B-VP	O
ethnicity	NN	B-NP	O
or	CC	I-NP	O
obesity	NN	I-NP	B
.	.	O	O

Argatroban	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
min	NN	I-NP	O
typically	RB	B-VP	O
supports	VBZ	I-VP	O
therapeutic	JJ	B-NP	O
aPTTs	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
FDA	NNP	I-NP	O
-	HYPH	I-NP	O
recommended	VBN	I-NP	O
dose	NN	I-NP	O
during	IN	B-PP	O
PCI	NN	B-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
/	SYM	I-NP	O
min	NN	I-NP	O
,	,	O	O
adjusted	VBN	B-VP	O
to	TO	B-VP	O
achieve	VB	I-VP	O
activated	VBN	B-NP	O
clotting	NN	I-NP	O
times	NNS	I-NP	O
(	(	O	O
ACTs	NNS	B-NP	O
)	)	O	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
sec	NN	I-NP	O
.	.	O	O

For	IN	B-PP	O
PCI	NN	B-NP	O
,	,	O	O
argatroban	NN	B-NP	O
has	VBZ	B-VP	O
not	RB	I-VP	O
been	VBN	I-VP	O
investigated	VBN	I-VP	O
in	IN	B-PP	O
hepatically	RB	B-NP	O
impaired	JJ	I-NP	O
patients	NNS	I-NP	O
;	:	O	O
dose	NN	B-NP	O
adjustment	NN	I-NP	O
is	VBZ	B-VP	O
unnecessary	JJ	B-ADJP	O
for	IN	B-PP	O
adult	JJ	B-NP	O
age	NN	I-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
race	NN	B-NP	O
/	SYM	B-VP	O
ethnicity	NN	B-NP	O
or	CC	I-NP	O
obesity	NN	I-NP	B
,	,	O	O
and	CC	O	O
lesser	JJR	B-NP	O
doses	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
adequate	JJ	B-ADJP	O
with	IN	B-PP	O
concurrent	JJ	B-NP	O
glycoprotein	NN	I-NP	O
IIb	NN	I-NP	O
/	SYM	B-NP	O
IIIa	NN	I-NP	O
inhibition	NN	I-NP	O
.	.	O	O

Argatroban	NNP	B-NP	O
prolongs	VBZ	B-VP	O
the	DT	B-NP	O
International	NNP	I-NP	O
Normalized	NNP	I-NP	O
Ratio	NNP	I-NP	O
,	,	O	O
and	CC	O	O
published	VBN	B-NP	O
approaches	NNS	I-NP	O
for	IN	B-PP	O
monitoring	VBG	B-VP	O
the	DT	B-NP	O
argatroban	NN	I-NP	O
-	HYPH	B-ADJP	O
to	TO	B-PP	O
-	HYPH	B-NP	O
warfarin	NN	I-NP	O
transition	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
followed	VBN	I-VP	O
.	.	O	O

Major	JJ	B-NP	O
bleeding	NN	I-NP	B
with	IN	B-PP	O
argatroban	NN	B-NP	O
is	VBZ	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
interventional	JJ	I-NP	O
setting	NN	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
periprocedurally	RB	B-ADVP	O
.	.	O	O

Argatroban	NNP	B-NP	O
has	VBZ	B-VP	O
no	DT	B-NP	O
specific	JJ	I-NP	O
antidote	NN	I-NP	O
,	,	O	O
and	CC	O	O
if	IN	B-SBAR	O
excessive	JJ	B-NP	O
anticoagulation	NN	I-NP	O
occurs	VBZ	B-VP	O
,	,	O	O
argatroban	JJ	B-NP	O
infusion	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
stopped	VBN	I-VP	O
or	CC	I-VP	O
reduced	VBN	I-VP	O
.	.	O	O

Improved	VBN	B-NP	O
familiarity	NN	I-NP	O
of	IN	B-PP	O
healthcare	NN	B-NP	O
professionals	NNS	I-NP	O
with	IN	B-PP	O
argatroban	JJ	B-NP	O
therapy	NN	I-NP	O
in	IN	B-PP	O
HIT	NN	B-NP	B
,	,	O	O
including	VBG	B-PP	O
in	IN	B-PP	O
special	JJ	B-NP	O
populations	NNS	I-NP	O
and	CC	B-PP	O
during	IN	B-PP	O
PCI	NN	B-NP	O
,	,	O	O
may	MD	B-VP	O
facilitate	VB	I-VP	O
reduction	NN	B-NP	O
of	IN	B-PP	O
harm	NN	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
HIT	NN	B-NP	B
(	(	O	O
e.g.	FW	B-NP	O
fewer	JJR	I-NP	O
thromboses	NNS	I-NP	O
)	)	O	O
or	CC	O	O
its	PRP$	B-NP	O
treatment	NN	I-NP	O
(	(	O	O
e.g.	FW	B-NP	O
fewer	JJR	I-NP	O
argatroban	JJ	I-NP	O
medication	NN	I-NP	O
errors	NNS	I-NP	O
)	)	O	O
.	.	O	O

Rhabdomyolysis	NN	B-NP	B
and	CC	I-NP	O
brain	NN	I-NP	O
ischemic	JJ	I-NP	B
stroke	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
heroin	NN	I-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
male	NN	I-NP	O
under	IN	B-PP	O
methadone	NN	B-NP	O
maintenance	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
are	VBP	B-VP	O
several	JJ	B-NP	O
complications	NNS	I-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
heroin	NN	B-NP	B
abuse	NN	I-NP	I
,	,	O	O
some	DT	B-NP	O
of	IN	B-PP	O
which	WDT	B-NP	O
are	VBP	B-VP	O
life	NN	B-NP	O
-	HYPH	B-NP	O
threatening	NN	I-NP	O
.	.	O	O

Methadone	NN	B-NP	O
may	MD	B-VP	O
aggravate	VB	I-VP	O
this	DT	B-NP	O
problem	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
clinical	JJ	I-NP	O
case	NN	I-NP	O
description	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
man	NN	I-NP	O
presented	VBN	B-VP	O
with	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
and	CC	O	O
cerebral	JJ	B-NP	O
ischemic	JJ	I-NP	B
stroke	NN	I-NP	I
after	IN	B-PP	O
intravenous	JJ	B-NP	O
heroin	NN	I-NP	O
.	.	O	O

He	PRP	B-NP	O
had	VBD	B-VP	O
used	VBN	I-VP	O
heroin	NN	B-NP	O
since	IN	B-PP	O
age	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
had	VBD	B-VP	O
used	VBN	I-VP	O
num	CD	B-NP	O
mg	NN	I-NP	O
methadone	NN	I-NP	O
daily	RB	B-ADVP	O
for	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

He	PRP	B-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
unconsciousness	NN	B-NP	B
at	IN	B-PP	O
home	NN	B-NP	O
and	CC	O	O
was	VBD	B-VP	O
sent	VBN	I-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
hospital	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
ER	NN	I-NP	O
,	,	O	O
his	PRP$	B-NP	O
opiate	JJ	I-NP	O
level	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
ng	NN	I-NP	O
/	SYM	B-NP	O
ml	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
ICU	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
rhabdomyolysis	NN	B-NP	B
,	,	O	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
and	CC	O	O
acute	JJ	B-NP	O
respiratory	JJ	I-NP	B
failure	NN	I-NP	I
.	.	O	O

After	IN	B-PP	O
transfer	NN	B-NP	O
to	TO	B-PP	O
an	DT	B-NP	O
internal	JJ	I-NP	O
ward	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
noted	VBD	B-VP	O
aphasia	NN	B-NP	B
and	CC	I-NP	O
weakness	NN	I-NP	B
of	IN	B-PP	O
his	PRP$	B-NP	O
left	JJ	I-NP	O
limbs	NNS	I-NP	O
.	.	O	O

After	IN	B-PP	O
MRI	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
cerebral	JJ	B-NP	B
ischemic	JJ	I-NP	I
infarction	NN	I-NP	I
.	.	O	O

Those	DT	B-NP	O
using	VBG	I-NP	O
methadone	NN	I-NP	O
and	CC	I-NP	O
heroin	NN	I-NP	O
simultaneously	RB	B-ADVP	O
may	MD	B-VP	O
increase	VB	I-VP	O
risk	NN	B-NP	O
of	IN	B-PP	O
rhabdomyolysis	NN	B-NP	B
and	CC	O	O
ischemic	JJ	B-NP	B
stroke	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
under	IN	B-PP	O
methadone	NN	B-NP	O
maintenance	NN	I-NP	O
therapy	NN	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
warned	VBN	I-VP	O
regarding	VBG	B-PP	O
these	DT	B-NP	O
serious	JJ	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

Hypotheses	NNS	B-NP	O
of	IN	B-PP	O
heroin	NN	B-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
rhabdomyolysis	NN	I-NP	B
and	CC	I-NP	O
stroke	NN	I-NP	B
in	IN	B-PP	O
heroin	NN	B-NP	O
abusers	NNS	I-NP	O
are	VBP	B-VP	O
discussed	VBN	I-VP	O
.	.	O	O

Increased	VBN	B-NP	O
vulnerability	NN	I-NP	O
to	TO	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
hydroxydopamine	NN	I-NP	O
lesion	NN	I-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
dyskinesias	NNS	B-NP	B
in	IN	B-PP	O
mice	NNS	B-NP	O
lacking	VBG	B-VP	O
CB1	NN	B-NP	O
cannabinoid	NN	I-NP	O
receptors	NNS	I-NP	O
.	.	O	O

Motor	NNP	B-NP	O
impairment	NN	I-NP	O
,	,	O	O
dopamine	NN	B-NP	O
(	(	O	O
DA	NN	B-NP	O
)	)	O	O
neuronal	JJ	B-NP	O
activity	NN	I-NP	O
and	CC	O	O
proenkephalin	NN	B-NP	O
(	(	O	O
PENK	NN	B-NP	O
)	)	O	O
gene	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
caudate	NN	I-NP	O
-	HYPH	O	O
putamen	NNS	B-NP	O
(	(	O	O
CPu	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
-	HYPH	B-VP	O
lesioned	VBN	I-VP	O
and	CC	I-VP	O
treated	VBN	I-VP	O
(	(	O	O
L	NN	O	O
-	HYPH	O	O
DOPA+benserazide	NN	B-NP	O
)	)	O	O
CB1	NN	B-NP	O
KO	NN	I-NP	O
and	CC	O	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
lesion	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
OHDA	NN	I-NP	O
produced	VBD	B-VP	O
more	RBR	B-NP	O
severe	JJ	I-NP	O
motor	NN	I-NP	O
deterioration	NN	I-NP	O
in	IN	B-PP	O
CB1	NN	B-NP	O
KO	NN	I-NP	O
mice	NNS	I-NP	O
accompanied	VBN	B-VP	O
by	IN	B-PP	O
more	JJR	B-NP	O
loss	NN	I-NP	O
of	IN	B-PP	O
DA	NN	B-NP	O
neurons	NNS	I-NP	O
and	CC	O	O
increased	VBN	B-NP	O
PENK	NN	I-NP	O
gene	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CPu	NN	I-NP	O
.	.	O	O

Oxidative	JJ	B-NP	O
/	SYM	I-NP	O
nitrosative	JJ	I-NP	O
and	CC	I-NP	O
neuroinflammatory	JJ	I-NP	O
parameters	NNS	I-NP	O
were	VBD	B-VP	O
estimated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
CPu	NN	I-NP	O
and	CC	O	O
cingulate	VBP	B-VP	O
cortex	NN	B-NP	O
(	(	O	O
Cg	NN	B-NP	O
)	)	O	O
.	.	O	O

CB1	NN	B-NP	O
KO	NN	I-NP	O
mice	NNS	I-NP	O
exhibited	VBD	B-VP	O
higher	JJR	B-NP	O
MDA	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
iNOS	NN	B-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
CPu	NN	I-NP	O
and	CC	I-NP	O
Cg	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
DOPA+benserazide	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
less	RBR	B-NP	O
severe	JJ	I-NP	O
dyskinesias	NNS	I-NP	B
in	IN	B-PP	O
CB1	NN	B-NP	O
KO	NN	I-NP	O
than	IN	B-PP	O
in	IN	B-PP	O
WT	JJ	B-NP	O
mice	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
results	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
lack	NN	I-NP	O
of	IN	B-PP	O
cannabinoid	NN	B-NP	O
CB1	NN	I-NP	O
receptors	NNS	I-NP	O
increased	VBD	B-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
motor	NN	B-NP	O
impairment	NN	I-NP	O
and	CC	O	O
DA	NN	B-NP	O
lesion	NN	I-NP	O
,	,	O	O
and	CC	O	O
reduced	VBN	B-NP	O
L	NN	I-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
activation	NN	B-NP	O
of	IN	B-PP	O
CB1	NN	B-NP	O
receptors	NNS	I-NP	O
offers	VBZ	B-VP	O
neuroprotection	NN	B-NP	O
against	IN	B-PP	O
dopaminergic	JJ	B-NP	O
lesion	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	B-NP	O
DOPA	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
dyskinesias	NNS	I-NP	B
.	.	O	O

Animal	NN	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
mania	NN	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
ouabain	NN	B-NP	O
:	:	O	O
Evidence	NN	B-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
submitochondrial	JJ	B-NP	O
particles	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
brain	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
intracerebroventricular	JJ	I-NP	O
(	(	O	O
ICV	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
(	(	O	O
a	DT	B-NP	O
Na	NN	I-NP	O
/	SYM	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
inhibitor	NN	I-NP	O
)	)	O	O
in	IN	B-PP	O
rats	NNS	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
suggested	VBN	I-VP	O
to	TO	I-VP	O
mimic	VB	I-VP	O
some	DT	B-NP	O
symptoms	NNS	I-NP	O
of	IN	B-PP	O
human	JJ	B-NP	O
bipolar	JJ	I-NP	B
mania	NN	I-NP	I
.	.	O	O

Clinical	JJ	B-NP	O
studies	NNS	I-NP	O
have	VBP	B-VP	O
shown	VBN	I-VP	O
that	IN	B-SBAR	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
mitochondrial	JJ	B-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

Herein	RB	B-ADVP	O
,	,	O	O
we	PRP	B-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
behavioral	JJ	I-NP	O
and	CC	I-NP	O
biochemical	JJ	I-NP	O
effects	NNS	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
ICV	NN	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

To	TO	B-VP	O
achieve	VB	I-VP	O
this	DT	B-NP	O
aim	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
ouabain	NN	B-NP	O
injection	NN	I-NP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
ICV	NN	I-NP	O
administration	NN	I-NP	O
(	(	O	O
at	IN	B-PP	O
concentrations	NNS	B-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
)	)	O	O
on	IN	B-PP	O
locomotion	NN	B-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
using	VBG	B-VP	O
the	DT	B-NP	O
open	JJ	I-NP	O
-	HYPH	I-NP	O
field	NN	I-NP	O
test	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
thiobarbituric	JJ	B-NP	O
acid	NN	I-NP	O
reactive	JJ	I-NP	O
substances	NNS	I-NP	O
(	(	O	O
TBARSs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
superoxide	NN	B-NP	O
production	NN	I-NP	O
were	VBD	B-VP	O
measured	VBN	I-VP	O
in	IN	B-PP	O
submitochondrial	JJ	B-NP	O
particles	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	I-NP	O
hippocampus	NN	I-NP	O
,	,	I-NP	O
striatum	NN	I-NP	O
and	CC	I-NP	O
amygdala	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
ouabain	NN	B-NP	O
at	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
M	NN	I-NP	O
induced	VBD	B-VP	O
hyperlocomotion	NN	B-NP	B
in	IN	B-PP	O
rats	NNS	B-NP	O
,	,	O	O
and	CC	O	O
this	DT	B-NP	O
response	NN	I-NP	O
remained	VBD	B-VP	O
up	RB	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
days	NNS	I-NP	O
following	VBG	B-PP	O
a	DT	B-NP	O
single	JJ	I-NP	O
ICV	NN	I-NP	O
injection	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
observed	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
persistent	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
spontaneous	JJ	I-NP	O
locomotion	NN	I-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
TBARS	NN	I-NP	O
levels	NNS	I-NP	O
and	CC	O	O
superoxide	NN	B-NP	O
generation	NN	I-NP	O
in	IN	B-PP	O
submitochondrial	JJ	B-NP	O
particles	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
prefrontal	JJ	I-NP	O
cortex	NN	I-NP	O
,	,	I-NP	O
striatum	NN	I-NP	O
and	CC	I-NP	O
amygdala	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
ouabain	NN	B-NP	O
-	HYPH	B-VP	O
induced	VBN	B-NP	O
mania	NN	I-NP	B
-	HYPH	O	O
like	JJ	B-NP	O
behavior	NN	I-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
a	DT	B-NP	O
useful	JJ	I-NP	O
animal	NN	I-NP	O
model	NN	I-NP	O
to	TO	B-VP	O
test	VB	I-VP	O
the	DT	B-NP	O
hypothesis	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
involvement	NN	I-NP	O
of	IN	B-PP	O
oxidative	JJ	B-NP	O
stress	NN	I-NP	O
in	IN	B-PP	O
bipolar	JJ	B-NP	B
disorder	NN	I-NP	I
.	.	O	O

Intraoperative	JJ	B-NP	O
dialysis	NN	I-NP	O
during	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
with	IN	B-PP	O
citrate	NN	B-NP	O
dialysate	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
transplantation	NN	I-NP	O
for	IN	B-PP	O
acutely	RB	B-NP	O
ill	JJ	I-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
fulminant	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
carries	VBZ	B-VP	O
high	JJ	B-NP	O
intraoperative	JJ	I-NP	O
and	CC	I-NP	O
immediate	JJ	I-NP	O
postoperative	JJ	I-NP	O
risks	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
are	VBP	B-VP	O
increased	VBN	I-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
concomitant	JJ	B-NP	O
acute	JJ	I-NP	B
kidney	NN	I-NP	I
injury	NN	I-NP	I
(	(	O	O
AKI	NN	B-NP	B
)	)	O	O
and	CC	O	O
intraoperative	JJ	B-NP	O
dialysis	NN	I-NP	O
is	VBZ	B-VP	O
sometimes	RB	I-VP	O
required	VBN	I-VP	O
to	TO	B-VP	O
allow	VB	I-VP	O
the	DT	B-NP	O
transplant	NN	I-NP	O
to	TO	B-VP	O
proceed	VB	I-VP	O
.	.	O	O

The	DT	B-NP	O
derangements	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
procoagulant	NN	I-NP	O
and	CC	O	O
anticoagulant	JJ	B-NP	O
pathways	NNS	I-NP	O
during	IN	B-PP	O
fulminant	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
can	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
difficulties	NNS	B-NP	O
with	IN	B-PP	O
anticoagulation	NN	B-NP	O
during	IN	B-PP	O
dialysis	NN	B-NP	O
,	,	O	O
especially	RB	B-ADVP	O
when	WRB	B-ADVP	O
continued	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
operating	NN	I-NP	O
room	NN	I-NP	O
.	.	O	O

Systemic	JJ	B-NP	O
anticoagulation	NN	I-NP	O
is	VBZ	B-VP	O
unsafe	JJ	B-NP	O
and	CC	I-NP	O
regional	JJ	I-NP	O
citrate	NN	I-NP	O
anticoagulation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
absence	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
functional	JJ	I-NP	O
liver	NN	I-NP	O
carries	VBZ	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
citrate	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Citrate	JJ	B-NP	O
dialysate	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
new	JJ	I-NP	O
dialysate	NN	I-NP	O
with	IN	B-PP	O
citric	JJ	B-NP	O
acid	NN	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
for	IN	B-PP	O
anticoagulation	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
can	MD	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
heparin	NN	B-NP	O
or	CC	O	O
regional	JJ	B-NP	O
citrate	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	NN	I-NP	O
with	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
fulminant	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
with	IN	B-PP	O
associated	VBN	B-NP	O
AKI	NN	I-NP	B
who	WP	B-NP	O
underwent	VBD	B-VP	O
intraoperative	JJ	B-NP	O
dialytic	JJ	I-NP	O
support	NN	I-NP	O
during	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
anticoagulated	VBN	B-VP	O
with	IN	B-PP	O
citrate	NN	B-NP	O
dialysate	NN	I-NP	O
during	IN	B-PP	O
the	DT	B-NP	O
entire	JJ	I-NP	O
procedure	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
tolerated	VBD	B-VP	O
the	DT	B-NP	O
procedure	NN	I-NP	O
well	RB	B-ADVP	O
without	IN	B-PP	O
any	DT	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
citrate	NN	B-NP	O
toxicity	NN	I-NP	B
and	CC	O	O
maintained	VBD	B-VP	O
adequate	JJ	B-NP	O
anticoagulation	NN	I-NP	O
for	IN	B-PP	O
patency	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dialysis	NN	I-NP	O
circuit	NN	I-NP	O
.	.	O	O

Citrate	JJ	B-NP	O
dialysate	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
safe	JJ	I-NP	O
alternative	NN	I-NP	O
for	IN	B-PP	O
intradialytic	JJ	B-NP	O
support	NN	I-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
in	IN	B-PP	O
fulminant	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
.	.	O	O

Delirium	NN	B-NP	B
in	IN	B-PP	O
a	DT	B-NP	O
patient	NN	I-NP	O
with	IN	B-PP	O
toxic	JJ	B-NP	O
flecainide	NN	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
:	:	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
pharmacokinetic	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
with	IN	B-PP	O
paroxetine	NN	B-NP	O
.	.	O	O

To	TO	B-VP	O
describe	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
flecainide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
delirium	NN	I-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
pharmacokinetic	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
with	IN	B-PP	O
paroxetine	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
white	JJ	I-NP	O
female	JJ	I-NP	O
presented	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
confusion	NN	B-NP	B
and	CC	I-NP	O
paranoia	NN	I-NP	B
over	IN	B-PP	O
the	DT	B-NP	O
past	JJ	I-NP	O
several	JJ	I-NP	O
days	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
admission	NN	B-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
taking	VBG	I-VP	O
carvedilol	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
,	,	O	O
warfarin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
folic	JJ	B-NP	O
acid	NN	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
levothyroxine	NN	B-NP	O
num	CD	I-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
pantoprazole	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
paroxetine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
,	,	O	O
and	CC	O	O
flecainide	NN	B-NP	O
num	CD	B-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
.	.	O	O

Flecainide	NN	B-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
started	VBN	I-VP	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
prior	JJ	B-ADJP	O
for	IN	B-PP	O
atrial	JJ	B-NP	B
fibrillation	NN	I-NP	I
.	.	O	O

Laboratory	NN	B-NP	O
test	NN	I-NP	O
findings	NNS	I-NP	O
on	IN	B-PP	O
admission	NN	B-NP	O
were	VBD	B-VP	O
notable	JJ	B-ADJP	O
only	RB	B-ADVP	O
for	IN	B-PP	O
a	DT	B-NP	O
flecainide	NN	I-NP	O
plasma	NN	I-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
microg	NN	I-NP	O
/	SYM	B-NP	O
L	NN	B-NP	O
(	(	O	O
reference	NN	B-NP	O
range	NN	I-NP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
metabolic	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
flecainide	NN	B-NP	O
and	CC	I-NP	O
paroxetine	NN	I-NP	O
,	,	O	O
which	WDT	B-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
taking	VBG	I-VP	O
for	IN	B-PP	O
more	JJR	B-NP	O
than	IN	I-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
,	,	O	O
was	VBD	B-VP	O
considered	VBN	I-VP	O
.	.	O	O

Paroxetine	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
the	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
flecainide	NN	B-NP	O
was	VBD	B-VP	O
reduced	VBN	I-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
twice	RB	B-ADVP	O
daily	RB	I-ADVP	O
.	.	O	O

Her	PRP$	B-NP	O
delirium	NN	I-NP	B
resolved	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
later	RB	B-ADVP	O
.	.	O	O

Flecainide	NN	B-NP	O
and	CC	O	O
pharmacologically	RB	B-NP	O
similar	JJ	I-NP	O
agents	NNS	I-NP	O
that	WDT	B-NP	O
interact	VBP	B-VP	O
with	IN	B-PP	O
sodium	NN	B-NP	O
channels	NNS	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
delirium	NN	B-NP	B
in	IN	B-PP	O
susceptible	JJ	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

A	DT	B-NP	O
MEDLINE	NNP	I-NP	O
search	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
January	NNP	I-NP	O
num	CD	I-NP	O
)	)	O	O
revealed	VBD	B-VP	O
num	CD	B-NP	O
in	FW	I-NP	O
vivo	FW	I-NP	O
pharmacokinetic	JJ	I-NP	O
study	NN	I-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
flecainide	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
CYP2D6	NN	I-NP	O
substrate	NN	I-NP	O
,	,	O	O
and	CC	O	O
paroxetine	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
CYP2D6	NN	I-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
num	CD	B-NP	O
case	NN	I-NP	O
reports	NNS	I-NP	O
of	IN	B-PP	O
flecainide	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
delirium	NN	I-NP	B
.	.	O	O

According	VBG	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
Naranjo	NNP	I-NP	O
probability	NN	I-NP	O
scale	NN	I-NP	O
,	,	O	O
flecainide	NN	B-NP	O
was	VBD	B-VP	O
the	DT	B-NP	O
probable	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	NN	I-NP	O
delirium	NN	I-NP	B
;	:	O	O
the	DT	B-NP	O
Horn	NNP	I-NP	O
Drug	NNP	I-NP	O
Interaction	NNP	I-NP	O
Probability	NNP	I-NP	O
Scale	NNP	I-NP	O
indicates	VBZ	B-VP	O
a	DT	B-NP	O
possible	JJ	I-NP	O
pharmacokinetic	JJ	I-NP	O
drug	NN	I-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
flecainide	NN	B-NP	O
and	CC	I-NP	O
paroxetine	NN	I-NP	O
.	.	O	O

Supratherapeutic	JJ	B-NP	O
flecainide	NN	I-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
delirium	NN	B-NP	B
.	.	O	O

Because	IN	B-SBAR	O
toxicity	NN	B-NP	B
may	MD	B-VP	O
occur	VB	I-VP	O
when	WRB	B-ADVP	O
flecainide	NN	B-NP	O
is	VBZ	B-VP	O
prescribed	VBN	I-VP	O
with	IN	B-PP	O
paroxetine	NN	B-NP	O
and	CC	O	O
other	JJ	B-NP	O
potent	JJ	I-NP	O
CYP2D6	NN	I-NP	O
inhibitors	NNS	I-NP	O
,	,	O	O
flecainide	NN	B-NP	O
plasma	NN	I-NP	O
concentrations	NNS	I-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
monitored	VBN	I-VP	O
closely	RB	B-ADVP	O
with	IN	B-PP	O
commencement	NN	B-NP	O
of	IN	B-PP	O
CYP2D6	NN	B-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Efficacy	NN	B-NP	O
of	IN	B-PP	O
everolimus	NN	B-NP	O
(	(	O	O
RAD001	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
advanced	VBN	B-NP	O
NSCLC	NN	I-NP	B
previously	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
chemotherapy	NN	B-NP	O
alone	RB	B-ADVP	O
or	CC	O	O
with	IN	B-PP	O
chemotherapy	NN	B-NP	O
and	CC	I-NP	O
EGFR	NN	I-NP	O
inhibitors	NNS	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
options	NNS	I-NP	O
are	VBP	B-VP	O
scarce	JJ	B-ADJP	O
in	IN	B-PP	O
pretreated	VBN	B-VP	O
advanced	VBN	I-VP	O
non	AFX	O	B
-	HYPH	O	I
small	JJ	B-NP	I
-	HYPH	I-NP	I
cell	NN	I-NP	I
lung	NN	I-NP	I
cancer	NN	I-NP	I
(	(	O	O
NSCLC	NN	B-NP	B
)	)	O	O
patients	NNS	B-NP	O
.	.	O	O

RAD001	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
oral	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
mammalian	JJ	I-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
rapamycin	NN	B-NP	O
(	(	O	O
mTOR	NN	B-NP	O
)	)	O	O
,	,	O	O
has	VBZ	B-VP	O
shown	VBN	I-VP	O
phase	NN	B-NP	O
num	CD	I-NP	O
efficacy	NN	I-NP	O
in	IN	B-PP	O
NSCLC	NN	B-NP	B
.	.	O	O

Stage	NN	B-NP	O
IIIb	NN	I-NP	O
or	CC	O	O
num	CD	B-NP	O
NSCLC	NN	I-NP	B
patients	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
or	CC	I-NP	O
fewer	JJR	I-NP	O
prior	JJ	I-NP	O
chemotherapy	NN	I-NP	O
regimens	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
platinum	NN	I-NP	O
based	VBN	B-VP	O
(	(	O	O
stratum	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
or	CC	O	O
both	CC	O	O
chemotherapy	NN	B-NP	O
and	CC	O	O
epidermal	JJ	B-NP	O
growth	NN	I-NP	O
factor	NN	I-NP	O
receptor	NN	I-NP	O
tyrosine	NN	I-NP	O
kinase	NN	I-NP	O
inhibitors	NNS	I-NP	O
(	(	O	O
stratum	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
received	VBD	B-VP	O
RAD001	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
until	IN	B-PP	O
progression	NN	B-NP	O
or	CC	O	O
unacceptable	JJ	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Primary	JJ	B-NP	O
objective	NN	I-NP	O
was	VBD	B-VP	O
overall	JJ	B-NP	O
response	NN	I-NP	O
rate	NN	I-NP	O
(	(	O	O
ORR	NN	B-NP	O
)	)	O	O
.	.	O	O

Analyses	NNS	B-NP	O
of	IN	B-PP	O
markers	NNS	B-NP	O
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
mTOR	NN	I-NP	O
pathway	NN	I-NP	O
were	VBD	B-VP	O
carried	VBN	I-VP	O
out	RP	B-PRT	O
on	IN	B-PP	O
archival	JJ	B-NP	O
tumor	NN	I-NP	B
from	IN	B-PP	O
a	DT	B-NP	O
subgroup	NN	I-NP	O
using	VBG	B-VP	O
immunohistochemistry	NN	B-NP	O
(	(	O	O
IHC	NN	B-NP	O
)	)	O	O
and	CC	O	O
direct	JJ	B-NP	O
mutation	NN	I-NP	O
sequencing	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
enrolled	VBN	I-VP	O
,	,	O	O
num	CD	B-NP	O
in	IN	B-PP	O
stratum	NN	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
stratum	NN	B-NP	O
.	.	O	O

ORR	NN	B-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
stratum	NN	I-NP	O
num	CD	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
stratum	NN	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Overall	JJ	B-NP	O
disease	NN	I-NP	O
control	NN	I-NP	O
rate	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Median	JJ	B-NP	O
progression	NN	I-NP	O
-	HYPH	O	O
free	JJ	B-NP	O
survivals	NNS	I-NP	O
(	(	O	O
PFSs	NNS	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
(	(	O	O
stratum	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
(	(	O	O
stratum	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Common	JJ	B-ADJP	O
>	SYM	B-NP	O
or	CC	O	O
=grade	VB	B-VP	O
num	CD	B-NP	O
events	NNS	I-NP	O
were	VBD	B-VP	O
fatigue	NN	B-NP	B
,	,	O	O
dyspnea	NN	B-NP	B
,	,	O	O
stomatitis	NN	B-NP	B
,	,	O	O
anemia	NN	B-NP	B
,	,	O	O
and	CC	O	O
thrombocytopenia	NN	B-NP	B
.	.	O	O

Pneumonitis	NN	B-NP	B
,	,	O	O
probably	RB	B-ADVP	O
or	CC	I-ADVP	O
possibly	RB	B-ADJP	O
related	JJ	I-ADJP	O
,	,	O	O
mainly	RB	B-ADVP	O
grade	NN	B-NP	O
num	CD	I-NP	O
/	SYM	I-NP	O
num	CD	I-NP	O
occurred	VBD	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Cox	NNP	B-NP	O
regression	NN	I-NP	O
analysis	NN	I-NP	O
of	IN	B-PP	O
IHC	NN	B-NP	O
scores	NNS	I-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
only	RB	B-NP	O
phospho	JJ	I-NP	O
AKT	NN	I-NP	O
(	(	O	O
pAKT	NN	B-NP	O
)	)	O	O
was	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
independent	JJ	I-NP	O
predictor	NN	I-NP	O
of	IN	B-PP	O
worse	JJR	B-NP	O
PFS	NN	I-NP	O
.	.	O	O

RAD001	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
was	VBD	B-VP	O
well	RB	I-VP	O
tolerated	VBN	I-VP	O
,	,	O	O
showing	VBG	B-VP	O
modest	JJ	B-NP	O
clinical	JJ	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
pretreated	VBN	B-NP	O
NSCLC	NN	I-NP	B
.	.	O	O

Evaluation	NN	B-NP	O
of	IN	B-PP	O
RAD001	NN	B-NP	O
plus	CC	O	O
standard	JJ	B-NP	O
therapy	NN	I-NP	O
for	IN	B-PP	O
metastatic	JJ	B-NP	O
NSCLC	NN	I-NP	B
continues	VBZ	B-VP	O
.	.	O	O

Posttransplant	NN	B-NP	O
anemia	NN	I-NP	B
:	:	O	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
sirolimus	NN	B-NP	O
.	.	O	O

Posttransplant	NN	B-NP	O
anemia	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
common	JJ	I-NP	O
problem	NN	I-NP	O
that	WDT	B-NP	O
may	MD	B-VP	O
hinder	VB	I-VP	O
patients	NNS	B-NP	O
s	NNS	I-NP	O
quality	NN	B-NP	O
of	IN	B-PP	O
life	NN	B-NP	O
.	.	O	O

It	PRP	B-NP	O
occurs	VBZ	B-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
,	,	O	O
and	CC	O	O
is	VBZ	B-VP	O
most	RBS	B-ADJP	O
common	JJ	I-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
immediate	JJ	I-NP	O
posttransplant	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
variety	NN	I-NP	O
of	IN	B-PP	O
factors	NNS	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
identified	VBN	I-VP	O
that	WDT	B-NP	O
increase	VBP	B-VP	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
posttransplant	NN	B-NP	O
anemia	NN	I-NP	B
,	,	O	O
of	IN	B-PP	O
which	WDT	B-NP	O
the	DT	B-NP	O
level	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
is	VBZ	B-VP	O
most	RBS	B-ADJP	O
important	JJ	I-ADJP	O
.	.	O	O

Sirolimus	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
mammalian	JJ	I-NP	O
target	NN	I-NP	O
of	IN	B-PP	O
rapamycin	NN	B-NP	O
inhibitor	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
implicated	VBN	I-VP	O
as	IN	B-PP	O
playing	VBG	B-VP	O
a	DT	B-NP	O
special	JJ	I-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
posttransplant	NN	B-NP	O
anemia	NN	I-NP	B
.	.	O	O

This	DT	B-NP	O
review	NN	I-NP	O
considers	VBZ	B-VP	O
anemia	NN	B-NP	B
associated	VBN	B-VP	O
with	IN	B-PP	O
sirolimus	NN	B-NP	O
,	,	O	O
including	VBG	B-PP	O
its	PRP$	B-NP	O
presentation	NN	I-NP	O
,	,	O	O
mechanisms	NNS	B-NP	O
,	,	O	O
and	CC	O	O
management	NN	B-NP	O
.	.	O	O

Coronary	JJ	B-NP	O
computerized	JJ	I-NP	O
tomography	NN	I-NP	O
angiography	NN	I-NP	O
for	IN	B-PP	O
rapid	JJ	B-NP	O
discharge	NN	I-NP	O
of	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
presenting	VBG	B-VP	O
to	TO	B-PP	O
emergency	NN	B-NP	O
departments	NNS	I-NP	O
(	(	O	O
EDs	NNS	B-NP	O
)	)	O	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
are	VBP	B-VP	O
admitted	VBN	I-VP	O
for	IN	B-PP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
hours	NNS	I-NP	O
and	CC	O	O
receive	VB	B-VP	O
a	DT	B-NP	O
rule	NN	I-NP	O
out	RP	B-PRT	O
acute	JJ	B-NP	B
coronary	JJ	I-NP	I
syndrome	NN	I-NP	I
protocol	NN	I-NP	O
,	,	O	O
often	RB	B-ADVP	O
with	IN	B-PP	O
noninvasive	JJ	B-NP	O
testing	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-VP	O
discharge	VB	I-VP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
without	IN	B-PP	O
cocaine	NN	B-NP	O
use	NN	I-NP	O
,	,	O	O
coronary	JJ	B-NP	O
computerized	JJ	I-NP	O
tomography	NN	I-NP	O
angiography	NN	I-NP	O
(	(	O	O
CTA	NN	B-NP	O
)	)	O	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
useful	JJ	B-ADJP	O
for	IN	B-PP	O
identifying	VBG	B-VP	O
a	DT	B-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
at	IN	B-PP	O
low	JJ	B-NP	O
risk	NN	I-NP	O
for	IN	B-PP	O
cardiac	JJ	B-NP	O
events	NNS	I-NP	O
who	WP	B-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
safely	RB	I-VP	O
discharged	VBN	I-VP	O
.	.	O	O

It	PRP	B-NP	O
is	VBZ	B-VP	O
unclear	JJ	B-ADJP	O
whether	IN	B-SBAR	O
a	DT	B-NP	O
coronary	JJ	I-NP	O
CTA	NN	I-NP	O
strategy	NN	I-NP	O
would	MD	B-VP	O
be	VB	I-VP	O
efficacious	JJ	B-ADJP	O
in	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
,	,	O	O
as	IN	B-SBAR	O
coronary	JJ	B-NP	B
vasospasm	NN	I-NP	I
may	MD	B-VP	O
account	VB	I-VP	O
for	IN	B-PP	O
some	DT	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ischemia	NN	I-NP	B
.	.	O	O

We	PRP	B-NP	O
studied	VBD	B-VP	O
whether	IN	B-SBAR	O
a	DT	B-NP	O
negative	JJ	I-NP	O
coronary	JJ	I-NP	O
CTA	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
could	MD	B-VP	O
identify	VB	I-VP	O
a	DT	B-NP	O
subset	NN	I-NP	O
safe	JJ	B-ADJP	O
for	IN	B-PP	O
discharge	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
prospectively	RB	B-ADVP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
safety	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	O
CTA	NN	I-NP	O
for	IN	B-PP	O
low	JJ	B-NP	O
-	HYPH	I-NP	O
risk	NN	I-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
presented	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
ED	NN	I-NP	O
with	IN	B-PP	O
cocaineassociated	VBN	B-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
(	(	O	O
self	NN	B-NP	O
-	HYPH	B-VP	O
reported	VBN	I-VP	O
or	CC	O	O
positive	JJ	B-NP	O
urine	NN	I-NP	O
test	NN	I-NP	O
)	)	O	O
.	.	O	O

Consecutive	JJ	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
either	CC	O	O
immediate	JJ	B-NP	O
coronary	JJ	I-NP	O
CTA	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ED	NN	I-NP	O
(	(	O	O
without	IN	B-PP	O
serial	JJ	B-NP	O
markers	NNS	I-NP	O
)	)	O	O
or	CC	O	O
underwent	VBD	B-VP	O
coronary	JJ	B-NP	O
CTA	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
with	IN	B-PP	O
serial	JJ	B-NP	O
cardiac	JJ	I-NP	O
marker	NN	I-NP	O
measurements	NNS	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
negative	JJ	B-NP	O
coronary	JJ	I-NP	O
CTA	NN	I-NP	O
were	VBD	B-VP	O
discharged	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
main	JJ	I-NP	O
outcome	NN	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
cardiovascular	JJ	I-NP	O
death	NN	I-NP	O
or	CC	O	O
myocardial	JJ	B-NP	B
infarction	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
associated	VBN	I-NP	O
chest	NN	I-NP	B
pain	NN	I-NP	I
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
mean	JJ	I-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
+	SYM	O	O
/	SYM	O	O
-	SYM	B-NP	O
num	CD	B-NP	O
yrs	NNS	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
black	JJ	B-ADJP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
male	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
percent	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
normal	JJ	I-NP	O
or	CC	I-NP	O
nonspecific	JJ	I-NP	O
ECG	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
TIMI	NN	I-NP	O
score	NN	I-NP	O
<	SYM	B-NP	O
num	CD	B-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
received	VBD	B-VP	O
coronary	JJ	B-NP	O
CTA	NN	I-NP	O
immediately	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
ED	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
of	IN	B-PP	O
whom	WP	B-NP	O
were	VBD	B-VP	O
discharged	VBN	I-VP	O
following	VBG	B-PP	O
CTA	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
received	VBD	B-VP	O
coronary	JJ	B-NP	O
CTA	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
observation	NN	I-NP	O
period	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
num	CD	B-NP	O
discharged	VBN	I-NP	O
home	NN	I-NP	O
following	VBG	I-NP	O
CTA	NN	I-NP	O
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
coronary	JJ	B-NP	B
stenosis	NN	I-NP	I
>	SYM	B-NP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
period	NN	B-NP	O
,	,	O	O
no	DT	B-NP	O
patients	NNS	I-NP	O
died	VBD	B-VP	O
of	IN	B-PP	O
a	DT	B-NP	O
cardiovascular	JJ	I-NP	O
event	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
and	CC	O	O
no	DT	B-NP	O
patient	NN	I-NP	O
sustained	VBD	B-VP	O
a	DT	B-NP	O
nonfatal	JJ	I-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
)	)	O	O
.	.	O	O

Although	IN	B-SBAR	O
cocaine	NN	B-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
myocardial	JJ	I-NP	B
ischemia	NN	I-NP	I
can	MD	B-VP	O
result	VB	I-VP	O
from	IN	B-PP	O
coronary	JJ	B-NP	O
vasoconstriction	NN	I-NP	O
,	,	O	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cocaine	NN	B-NP	O
associated	VBN	B-VP	O
chest	NN	B-NP	B
pain	NN	I-NP	I
,	,	O	O
a	DT	B-NP	O
non	AFX	I-NP	O
-	HYPH	I-NP	O
ischemic	JJ	I-NP	B
ECG	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
TIMI	NN	I-NP	O
risk	NN	I-NP	O
score	NN	I-NP	O
<	SYM	B-NP	O
num	CD	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
safely	RB	I-VP	O
discharged	VBN	I-VP	O
from	IN	B-PP	O
the	DT	B-NP	O
ED	NN	I-NP	O
after	IN	B-PP	O
a	DT	B-NP	O
negative	JJ	I-NP	O
coronary	JJ	I-NP	O
CTA	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
low	JJ	I-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
adverse	JJ	I-NP	O
events	NNS	I-NP	O
.	.	O	O

Late	JJ	B-NP	O
fulminant	JJ	I-NP	O
posterior	JJ	I-NP	B
reversible	JJ	I-NP	I
encephalopathy	NN	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
.	.	O	O

Posterior	JJ	B-NP	B
leukoencephalopathy	NN	I-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
calcineurin	NN	B-NP	O
-	HYPH	I-NP	O
inhibitor	NN	I-NP	O
-	HYPH	B-NP	O
related	VBN	I-NP	O
neurotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
but	CC	I-NP	O
severe	JJ	I-NP	O
complication	NN	I-NP	O
that	WDT	B-NP	O
results	VBZ	B-VP	O
from	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
immunosuppressive	JJ	B-NP	O
agents	NNS	I-NP	O
(	(	O	O
primarily	RB	B-NP	O
those	DT	I-NP	O
administered	VBN	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
liver	NN	I-NP	O
or	CC	I-NP	O
kidney	NN	I-NP	O
transplant	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
pathophysiologic	JJ	I-NP	O
mechanisms	NNS	I-NP	O
of	IN	B-PP	O
that	DT	B-NP	O
disorder	NN	I-NP	O
remain	VBP	B-VP	O
unknown	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
the	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	B-NP	O
old	JJ	I-NP	O
woman	NN	I-NP	O
who	WP	B-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
liver	NN	I-NP	O
transplant	NN	I-NP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
center	NN	I-NP	O
as	IN	B-PP	O
treatment	NN	B-NP	O
for	IN	B-PP	O
alcoholic	JJ	B-NP	B
cirrhosis	NN	I-NP	I
and	CC	B-PP	O
in	IN	B-PP	O
whom	WP	B-NP	O
either	CC	O	O
a	DT	B-NP	O
fulminant	JJ	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
posterior	JJ	B-NP	B
leukoencephalopathy	NN	I-NP	I
or	CC	O	O
posterior	JJ	B-NP	B
reversible	JJ	I-NP	I
encephalopathy	NN	I-NP	I
syndrome	NN	I-NP	I
developed	VBD	B-VP	O
num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
transplant	NN	B-NP	O
.	.	O	O

After	IN	B-PP	O
an	DT	B-NP	O
initially	RB	I-NP	O
uneventful	JJ	I-NP	O
course	NN	I-NP	O
after	IN	B-PP	O
the	DT	B-NP	O
transplant	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
patient	NN	I-NP	O
rapidly	RB	B-ADVP	O
fell	VBD	B-VP	O
into	IN	B-PP	O
deep	JJ	B-NP	O
coma	NN	I-NP	O
.	.	O	O

Cerebral	JJ	B-NP	O
MRI	NN	I-NP	O
scan	NN	I-NP	O
showed	VBD	B-VP	O
typical	JJ	B-NP	O
signs	NNS	I-NP	O
of	IN	B-PP	O
enhancement	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pontine	NN	I-NP	O
and	CC	O	O
posterior	JJ	B-NP	O
regions	NNS	I-NP	O
.	.	O	O

Switching	VBG	B-VP	O
the	DT	B-NP	O
immunosuppressive	JJ	I-NP	O
regimen	NN	I-NP	O
from	IN	B-PP	O
tacrolimus	NN	B-NP	O
to	TO	B-PP	O
cyclosporine	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
situation	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
termination	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
with	IN	B-PP	O
any	DT	B-NP	O
calcineurin	NN	I-NP	O
inhibitor	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
resolution	NN	I-NP	O
of	IN	B-PP	O
that	DT	B-NP	O
complication	NN	I-NP	O
.	.	O	O

Posterior	JJ	B-NP	B
reversible	JJ	I-NP	I
encephalopathy	NN	I-NP	I
syndrome	NN	I-NP	I
after	IN	B-PP	O
liver	NN	B-NP	O
transplant	NN	I-NP	O
is	VBZ	B-VP	O
rare	JJ	B-ADJP	O
.	.	O	O

We	PRP	B-NP	O
recommend	VBP	B-VP	O
a	DT	B-NP	O
complete	JJ	I-NP	O
cessation	NN	I-NP	O
of	IN	B-PP	O
any	DT	B-NP	O
calcineurin	NN	I-NP	O
inhibitor	NN	I-NP	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
a	DT	B-NP	O
dose	NN	I-NP	O
reduction	NN	I-NP	O
.	.	O	O

Prolonged	JJ	B-NP	O
hypothermia	NN	I-NP	B
as	IN	B-PP	O
a	DT	B-NP	O
bridge	NN	I-NP	O
to	TO	B-PP	O
recovery	NN	B-NP	O
for	IN	B-PP	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
and	CC	O	O
intracranial	JJ	B-NP	B
hypertension	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

To	TO	B-VP	O
review	VB	I-VP	O
evidence	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-NP	O
treatment	NN	I-NP	O
options	NNS	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
complicating	VBG	B-VP	O
fulminant	JJ	B-NP	B
hepatic	JJ	I-NP	I
failure	NN	I-NP	I
(	(	O	O
FHF	NN	B-NP	B
)	)	O	O
and	CC	O	O
discuss	VBP	B-VP	O
the	DT	B-NP	O
potential	JJ	I-NP	O
applications	NNS	I-NP	O
of	IN	B-PP	O
hypothermia	NN	B-NP	B
.	.	O	O

Case	NN	B-NP	O
-	HYPH	B-NP	O
based	VBN	I-NP	O
observations	NNS	I-NP	O
from	IN	B-PP	O
a	DT	B-NP	O
medical	JJ	I-NP	O
intensive	JJ	I-NP	O
care	NN	I-NP	O
unit	NN	I-NP	O
(	(	O	O
MICU	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
a	DT	B-NP	O
tertiary	JJ	I-NP	O
care	NN	I-NP	O
facility	NN	I-NP	O
in	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
female	NN	I-NP	O
with	IN	B-PP	O
FHF	NN	B-NP	B
from	IN	B-PP	O
acetaminophen	NN	B-NP	O
and	CC	O	O
resultant	JJ	B-NP	O
cerebral	JJ	I-NP	B
edema	NN	I-NP	I
.	.	O	O

Our	PRP$	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
admitted	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
MICU	NN	I-NP	O
after	IN	B-PP	O
being	VBG	B-VP	O
found	VBN	I-VP	O
unresponsive	JJ	B-ADJP	O
with	IN	B-PP	O
presumed	VBN	B-NP	O
toxicity	NN	I-NP	B
from	IN	B-PP	O
acetaminophen	NN	B-NP	O
which	WDT	B-NP	O
was	VBD	B-VP	O
ingested	VBN	I-VP	O
over	IN	B-PP	O
a	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
day	NN	I-NP	O
period	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
had	VBD	B-VP	O
depressed	VBN	I-VP	O
of	IN	B-PP	O
mental	JJ	B-NP	O
status	NN	I-NP	O
lasting	VBG	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
admission	NN	B-NP	O
.	.	O	O

Initial	JJ	B-NP	O
evaluation	NN	I-NP	O
confirmed	VBD	B-VP	O
FHF	NN	B-NP	B
from	IN	B-PP	O
acetaminophen	NN	B-NP	O
and	CC	O	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
was	VBD	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
hyperosmolar	JJ	B-NP	O
therapy	NN	I-NP	O
,	,	O	O
hyperventilation	NN	B-NP	B
,	,	O	O
sedation	NN	B-NP	O
,	,	O	O
and	CC	O	O
chemical	NN	B-NP	O
paralysis	NN	I-NP	B
.	.	O	O

Her	PRP$	B-NP	O
intracranial	JJ	I-NP	O
pressure	NN	I-NP	O
remained	VBD	B-VP	O
elevated	JJ	B-ADJP	O
despite	IN	B-PP	O
maximal	JJ	B-NP	O
medical	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
then	RB	B-ADVP	O
initiated	VBD	B-VP	O
therapeutic	JJ	B-NP	O
hypothermia	NN	I-NP	B
which	WDT	B-NP	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

At	IN	B-PP	O
re	AFX	B-NP	O
-	HYPH	I-NP	O
warming	VBG	B-VP	O
,	,	O	O
patient	NN	B-NP	O
had	VBD	B-VP	O
resolution	NN	B-NP	O
of	IN	B-PP	O
her	PRP$	B-NP	O
cerebral	JJ	I-NP	B
edema	NN	I-NP	I
and	CC	O	O
intracranial	JJ	B-NP	B
hypertension	NN	I-NP	I
.	.	O	O

At	IN	B-PP	O
discharge	NN	B-NP	O
,	,	O	O
she	PRP	B-NP	O
had	VBD	B-VP	O
complete	JJ	B-NP	O
recovery	NN	I-NP	O
of	IN	B-PP	O
neurological	JJ	B-NP	O
and	CC	I-NP	O
hepatic	JJ	I-NP	O
functions	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
FHF	NN	B-NP	B
and	CC	O	O
cerebral	JJ	B-NP	B
edema	NN	I-NP	I
from	IN	B-PP	O
acetaminophen	NN	B-NP	O
overdose	NN	I-NP	B
,	,	O	O
prolonged	VBD	B-VP	O
therapeutic	JJ	B-NP	O
hypothermia	NN	I-NP	B
could	MD	B-VP	O
potentially	RB	I-VP	O
be	VB	I-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
life	NN	I-NP	O
saving	VBG	I-NP	O
therapy	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
bridge	NN	I-NP	O
to	TO	B-PP	O
hepatic	JJ	B-NP	O
and	CC	I-NP	O
neurological	JJ	I-NP	O
recovery	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
clinical	JJ	I-NP	O
trial	NN	I-NP	O
of	IN	B-PP	O
hypothermia	NN	B-NP	B
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
this	DT	B-NP	O
condition	NN	I-NP	O
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

Binasal	JJ	B-NP	B
visual	JJ	I-NP	I
field	NN	I-NP	I
defects	NNS	I-NP	I
are	VBP	B-VP	O
not	RB	O	O
specific	JJ	B-ADJP	O
to	TO	B-PP	O
vigabatrin	NN	B-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigated	VBD	B-VP	O
the	DT	B-NP	O
visual	JJ	I-NP	B
defects	NNS	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
antiepileptic	JJ	I-NP	O
drug	NN	I-NP	O
vigabatrin	NN	I-NP	O
(	(	O	O
VGB	NN	B-NP	O
)	)	O	O
.	.	O	O

num	CD	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
people	NNS	I-NP	O
with	IN	B-PP	O
epilepsy	NN	B-NP	B
were	VBD	B-VP	O
grouped	VBN	I-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
basis	NN	I-NP	O
of	IN	B-PP	O
antiepileptic	JJ	B-NP	O
drug	NN	I-NP	O
therapy	NN	I-NP	O
(	(	O	O
current	JJ	B-ADJP	O
,	,	O	O
previous	JJ	B-ADJP	O
,	,	O	O
or	CC	O	O
no	DT	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
VGB	NN	B-NP	O
)	)	O	O
.	.	O	O

Groups	NNS	B-NP	O
were	VBD	B-VP	O
matched	VBN	I-VP	O
with	IN	B-PP	O
respect	NN	B-NP	O
to	TO	B-PP	O
age	NN	B-NP	O
,	,	O	O
gender	NN	B-NP	O
,	,	O	O
and	CC	O	O
seizure	NN	B-NP	B
frequency	NN	I-NP	O
.	.	O	O

All	DT	B-NP	O
patients	NNS	I-NP	O
underwent	VBD	B-VP	O
objective	JJ	B-NP	O
assessment	NN	I-NP	O
of	IN	B-PP	O
electrophysiological	JJ	B-NP	O
function	NN	I-NP	O
(	(	O	O
wide	JJ	B-NP	O
-	HYPH	I-NP	O
field	NN	I-NP	O
multifocal	JJ	I-NP	O
electroretinography	NN	I-NP	O
)	)	O	O
and	CC	O	O
conventional	JJ	B-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
testing	NN	I-NP	O
(	(	O	O
static	JJ	B-NP	O
perimetry	NN	I-NP	O
)	)	O	O
.	.	O	O

Bilateral	JJ	B-NP	O
visual	JJ	I-NP	O
field	NN	I-NP	O
constriction	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
currently	RB	B-VP	O
taking	VBG	I-VP	O
VGB	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
previously	RB	B-ADVP	O
took	VBD	B-VP	O
VGB	NN	B-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
no	DT	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
VGB	NN	B-NP	O
.	.	O	O

Assessment	NN	B-NP	O
of	IN	B-PP	O
retinal	JJ	B-NP	O
function	NN	I-NP	O
revealed	VBD	B-VP	O
abnormal	JJ	B-NP	O
responses	NNS	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
current	JJ	B-NP	O
VGB	NN	I-NP	O
users	NNS	I-NP	O
and	CC	O	O
num	CD	B-NP	O
%	NN	I-NP	O
of	IN	B-PP	O
prior	JJ	B-NP	O
VGB	NN	I-NP	O
users	NNS	I-NP	O
,	,	O	O
but	CC	O	O
in	IN	B-PP	O
none	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
patients	NNS	I-NP	O
without	IN	B-PP	O
previous	JJ	B-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
VGB	NN	B-NP	O
.	.	O	O

Bilateral	JJ	B-NP	B
visual	JJ	I-NP	I
field	NN	I-NP	I
abnormalities	NNS	I-NP	I
are	VBP	B-VP	O
common	JJ	B-ADJP	O
in	IN	B-PP	O
the	DT	B-NP	O
treated	VBN	I-NP	O
epilepsy	NN	I-NP	B
population	NN	I-NP	O
,	,	O	O
irrespective	JJ	B-ADJP	O
of	IN	B-PP	O
drug	NN	B-NP	O
history	NN	I-NP	O
.	.	O	O

Assessment	NN	B-NP	O
by	IN	B-PP	O
conventional	JJ	B-NP	O
static	JJ	I-NP	O
perimetry	NN	I-NP	O
may	MD	B-VP	O
neither	CC	I-VP	O
be	VB	I-VP	O
sufficiently	RB	B-ADJP	O
sensitive	JJ	I-ADJP	O
nor	CC	I-ADJP	O
specific	JJ	I-ADJP	O
to	TO	B-VP	O
reliably	RB	I-VP	O
identify	VB	I-VP	O
retinal	JJ	B-NP	B
toxicity	NN	I-NP	I
associated	VBN	B-VP	O
with	IN	B-PP	O
VGB	NN	B-NP	O
.	.	O	O

Smoking	NN	B-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
as	IN	B-PP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
HIV	NN	B-NP	B
infection	NN	I-NP	I
among	IN	B-PP	O
people	NNS	B-NP	O
who	WP	B-NP	O
use	VBP	B-VP	O
injection	NN	B-NP	O
drugs	NNS	I-NP	O
.	.	O	O

Little	JJ	B-NP	O
is	VBZ	B-VP	O
known	VBN	I-VP	O
about	IN	B-PP	O
the	DT	B-NP	O
possible	JJ	I-NP	O
role	NN	I-NP	O
that	WDT	B-NP	O
smoking	VBG	B-VP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
has	VBZ	B-VP	O
on	IN	B-PP	O
the	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
HIV	NN	B-NP	B
infection	NN	I-NP	I
.	.	O	O

Given	VBN	B-PP	O
the	DT	B-NP	O
increasing	VBG	I-NP	O
use	NN	I-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
sought	VBD	B-VP	O
to	TO	I-VP	O
examine	VB	I-VP	O
whether	IN	B-SBAR	O
use	NN	B-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
illicit	JJ	I-NP	O
drug	NN	I-NP	O
has	VBZ	B-VP	O
become	VBN	I-VP	O
a	DT	B-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
HIV	NN	B-NP	B
infection	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
included	VBD	B-VP	O
data	NNS	B-NP	O
from	IN	B-PP	O
people	NNS	B-NP	O
participating	VBG	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
Vancouver	NNP	I-NP	O
Injection	NNP	I-NP	O
Drug	NNP	I-NP	O
Users	NNP	I-NP	O
Study	NNP	I-NP	O
who	WP	B-NP	O
reported	VBD	B-VP	O
injecting	VBG	I-VP	O
illicit	JJ	B-NP	O
drugs	NNS	I-NP	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
once	RB	I-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
month	NN	I-NP	O
before	IN	B-PP	O
enrolment	NN	B-NP	O
,	,	O	O
lived	VBD	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
greater	JJR	I-NP	O
Vancouver	NNP	I-NP	O
area	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
HIV	NN	B-NP	O
-	HYPH	O	O
negative	JJ	B-ADJP	O
at	IN	B-PP	O
enrolment	NN	B-NP	O
and	CC	O	O
completed	VBD	B-VP	O
at	IN	B-NP	O
least	JJS	I-NP	O
num	CD	I-NP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
study	NN	B-NP	O
visit	NN	I-NP	O
.	.	O	O

To	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
HIV	NN	B-NP	B
seroconversion	NN	I-NP	I
among	IN	B-PP	O
daily	JJ	B-NP	O
smokers	NNS	I-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
changed	VBD	B-VP	O
over	IN	B-PP	O
time	NN	B-NP	O
,	,	O	O
we	PRP	B-NP	O
used	VBD	B-VP	O
Cox	NNP	B-NP	O
proportional	JJ	I-NP	O
hazards	NNS	I-NP	O
regression	NN	I-NP	O
and	CC	O	O
divided	VBD	B-VP	O
the	DT	B-NP	O
study	NN	I-NP	O
into	IN	B-PP	O
num	CD	B-NP	O
periods	NNS	I-NP	O
:	:	O	O
May	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
Nov.	NNP	I-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
(	(	O	O
period	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
Dec.	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
Nov.	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
(	(	O	O
period	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
Dec.	NNP	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
-	HYPH	O	O
Dec.	NNP	B-NP	O
num	CD	I-NP	O
num	CD	I-NP	O
(	(	O	O
period	NN	B-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Overall	RB	B-ADVP	O
,	,	O	O
num	CD	B-NP	O
eligible	JJ	I-NP	O
injection	NN	I-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
were	VBD	B-VP	O
included	VBN	I-VP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
study	NN	I-NP	O
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
,	,	O	O
num	CD	B-NP	O
acquired	VBD	B-VP	O
HIV	NN	B-NP	B
infection	NN	I-NP	I
during	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
.	.	O	O

The	DT	B-NP	O
mean	JJ	I-NP	O
proportion	NN	I-NP	O
of	IN	B-PP	O
participants	NNS	B-NP	O
who	WP	B-NP	O
reported	VBD	B-VP	O
daily	JJ	B-NP	O
smoking	NN	I-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
increased	VBD	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
period	NN	B-NP	O
num	CD	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
period	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

After	IN	B-PP	O
adjusting	VBG	B-VP	O
for	IN	B-PP	O
potential	JJ	B-NP	O
confounders	NNS	I-NP	O
,	,	O	O
we	PRP	B-NP	O
found	VBD	B-VP	O
that	IN	B-SBAR	O
the	DT	B-NP	O
risk	NN	I-NP	O
of	IN	B-PP	O
HIV	NN	B-NP	B
seroconversion	NN	I-NP	I
among	IN	B-PP	O
participants	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
daily	JJ	B-NP	O
smokers	NNS	I-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
increased	VBD	B-VP	O
over	IN	B-PP	O
time	NN	B-NP	O
(	(	O	O
period	NN	B-NP	O
num	CD	I-NP	O
:	:	O	O
hazard	NN	B-NP	O
ratio	NN	I-NP	O
[	(	O	O
HR	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
,	,	O	O
num	CD	B-NP	O
%	NN	I-NP	O
confidence	NN	I-NP	O
interval	NN	I-NP	O
[	(	O	O
CI	NN	B-NP	O
]	)	O	O
num	CD	B-NP	O
-	:	O	O
num	CD	B-NP	O
;	:	O	O
period	NN	B-NP	O
num	CD	I-NP	O
:	:	O	O
HR	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
;	:	O	O
and	CC	O	O
period	NN	B-NP	O
num	CD	I-NP	O
:	:	O	O
HR	NN	B-NP	O
num	CD	I-NP	O
,	,	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
CI	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
)	)	O	O
.	.	O	O

Smoking	NN	B-NP	O
of	IN	B-PP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
was	VBD	B-VP	O
found	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
independent	JJ	I-NP	O
risk	NN	I-NP	O
factor	NN	I-NP	O
for	IN	B-PP	O
HIV	NN	B-NP	B
seroconversion	NN	I-NP	I
among	IN	B-PP	O
people	NNS	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
injection	NN	B-NP	O
drug	NN	I-NP	O
users	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
finding	NN	I-NP	O
points	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
urgent	JJ	I-NP	O
need	NN	I-NP	O
for	IN	B-PP	O
evidence	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
public	JJ	B-NP	O
health	NN	I-NP	O
initiatives	NNS	I-NP	O
targeted	VBN	B-VP	O
at	IN	B-PP	O
people	NNS	B-NP	O
who	WP	B-NP	O
smoke	VBP	B-VP	O
crack	NN	B-NP	O
cocaine	NN	I-NP	O
.	.	O	O

Fluoxetine	NN	B-NP	O
improves	VBZ	B-VP	O
the	DT	B-NP	O
memory	NN	I-NP	B
deficits	NNS	I-NP	I
caused	VBN	B-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
chemotherapy	NN	I-NP	O
agent	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
.	.	O	O

Cancer	NN	B-NP	B
patients	NNS	I-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
systemic	JJ	B-NP	O
adjuvant	JJ	I-NP	O
chemotherapy	NN	I-NP	O
have	VBP	B-VP	O
described	VBN	I-VP	O
experiencing	VBG	I-VP	O
deteriorations	NNS	B-NP	O
in	IN	B-PP	O
cognition	NN	B-NP	O
.	.	O	O

A	DT	B-NP	O
widely	RB	I-NP	O
used	VBN	I-NP	O
chemotherapeutic	JJ	I-NP	O
agent	NN	I-NP	O
,	,	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
fluorouracil	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
)	)	O	O
,	,	O	O
readily	RB	B-ADVP	O
crosses	VBZ	B-VP	O
the	DT	B-NP	O
blood	NN	I-NP	O
-	HYPH	I-NP	O
brain	NN	I-NP	O
barrier	NN	I-NP	O
and	CC	O	O
so	RB	B-VP	O
could	MD	I-VP	O
have	VB	I-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
brain	NN	B-NP	O
function	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
particular	JJ	B-ADJP	O
this	DT	B-NP	O
anti	JJ	I-NP	O
mitotic	JJ	I-NP	O
drug	NN	I-NP	O
could	MD	B-VP	O
reduce	VB	I-VP	O
cell	NN	B-NP	O
proliferation	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neurogenic	JJ	I-NP	O
regions	NNS	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
adult	JJ	I-NP	O
brain	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
reports	NNS	I-NP	O
indicate	VBP	B-VP	O
that	IN	B-SBAR	O
hippocampal	JJ	B-NP	O
dependent	JJ	I-NP	O
neurogenesis	NN	I-NP	O
and	CC	I-NP	O
cognition	NN	I-NP	O
are	VBP	B-VP	O
enhanced	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
SSRI	NN	I-NP	O
antidepressant	NN	I-NP	O
Fluoxetine	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
investigation	NN	I-NP	O
the	DT	B-NP	O
behavioural	JJ	I-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
chronic	JJ	B-NP	O
(	(	O	O
num	CD	B-NP	O
week	NN	I-NP	O
)	)	O	O
treatment	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
and	CC	O	O
(	(	O	O
num	CD	B-NP	O
weeks	NNS	I-NP	O
)	)	O	O
with	IN	B-PP	O
Fluoxetine	NN	B-NP	O
either	CC	O	O
separately	RB	B-ADVP	O
or	CC	O	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
on	IN	B-PP	O
adult	JJ	B-NP	O
Lister	NNP	I-NP	O
hooded	VBD	B-VP	O
rats	NNS	B-NP	O
.	.	O	O

Behavioural	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
tested	VBN	I-VP	O
using	VBG	B-VP	O
a	DT	B-NP	O
context	NN	I-NP	O
dependent	JJ	I-NP	O
conditioned	VBN	I-NP	O
emotional	JJ	I-NP	O
response	NN	I-NP	O
test	NN	I-NP	O
(	(	O	O
CER	NN	B-NP	O
)	)	O	O
which	WDT	B-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
animals	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
freezing	VBG	B-VP	O
time	NN	B-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
separate	JJ	I-NP	O
group	NN	I-NP	O
of	IN	B-PP	O
animals	NNS	B-NP	O
was	VBD	B-VP	O
tested	VBN	I-VP	O
using	VBG	I-VP	O
a	DT	B-NP	O
hippocampal	JJ	I-NP	O
dependent	JJ	I-NP	O
spatial	JJ	I-NP	O
working	NN	I-NP	O
memory	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
object	NN	I-NP	O
location	NN	I-NP	O
recognition	NN	I-NP	O
test	NN	I-NP	O
(	(	O	O
OLR	NN	B-NP	O
)	)	O	O
.	.	O	O

Animals	NNS	B-NP	O
treated	VBN	B-VP	O
only	RB	B-ADVP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
showed	VBD	B-VP	O
significant	JJ	B-NP	O
deficits	NNS	I-NP	O
in	IN	B-PP	O
their	PRP$	B-NP	O
ability	NN	I-NP	O
to	TO	B-VP	O
carry	VB	I-VP	O
out	RP	B-PRT	O
the	DT	B-NP	O
OLR	NN	I-NP	O
task	NN	I-NP	O
but	CC	O	O
co	NN	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
Fluoxetine	NN	B-NP	O
improved	VBD	B-VP	O
their	PRP$	B-NP	O
performance.	NN	I-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
chemotherapy	NN	I-NP	O
caused	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
proliferating	VBG	B-VP	O
cells	NNS	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
sub	NN	I-NP	O
granular	JJ	I-NP	O
zone	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
controls	NNS	B-NP	O
.	.	O	O

This	DT	B-NP	O
reduction	NN	I-NP	O
was	VBD	B-VP	O
eliminated	VBN	I-VP	O
when	WRB	B-ADVP	O
Fluoxetine	NN	B-NP	O
was	VBD	B-VP	O
co	NN	B-NP	O
administered	VBN	B-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
.	.	O	O

Fluoxetine	NN	B-NP	O
on	IN	B-PP	O
its	PRP$	B-NP	O
own	JJ	I-NP	O
had	VBD	B-VP	O
no	DT	B-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
proliferating	VBG	B-VP	O
cell	NN	B-NP	O
number	NN	I-NP	O
or	CC	O	O
behaviour	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
num	CD	B-NP	O
-	HYPH	I-NP	O
FU	NN	I-NP	O
can	MD	B-VP	O
negatively	RB	I-VP	O
affect	VB	I-VP	O
both	CC	O	O
cell	NN	B-NP	O
proliferation	NN	I-NP	O
and	CC	O	O
hippocampal	NN	B-NP	O
dependent	JJ	B-NP	O
working	VBG	I-NP	O
memory	NN	I-NP	O
and	CC	O	O
that	IN	B-SBAR	O
these	DT	B-NP	O
deficits	NNS	I-NP	O
can	MD	B-VP	O
be	VB	I-VP	O
reversed	VBN	I-VP	O
by	IN	B-PP	O
the	DT	B-NP	O
simultaneous	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
antidepressant	NN	I-NP	O
Fluoxetine	NN	I-NP	O
.	.	O	O

Liver	NN	B-NP	O
-	HYPH	I-NP	O
specific	JJ	I-NP	O
ablation	NN	I-NP	O
of	IN	B-PP	O
integrin	NN	B-NP	O
-	HYPH	O	O
linked	VBN	B-NP	O
kinase	NN	I-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
results	VBZ	B-VP	O
in	IN	B-PP	O
enhanced	VBN	B-NP	O
and	CC	I-NP	O
prolonged	VBN	I-NP	O
cell	NN	I-NP	O
proliferation	NN	I-NP	O
and	CC	O	O
hepatomegaly	RB	B-ADVP	B
after	IN	B-SBAR	O
phenobarbital	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
recently	RB	I-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
disruption	NN	B-NP	O
of	IN	B-PP	O
extracellular	JJ	B-NP	O
matrix	NN	I-NP	O
(	(	O	O
ECM	NN	B-NP	O
)	)	O	O
/	SYM	B-NP	O
integrin	NN	I-NP	O
signaling	NN	I-NP	O
via	IN	B-PP	O
elimination	NN	B-NP	O
of	IN	B-PP	O
integrin	NN	B-NP	O
-	HYPH	O	O
linked	VBN	B-NP	O
kinase	NN	I-NP	O
(	(	O	O
ILK	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
hepatocytes	NNS	B-NP	O
interferes	VBZ	B-VP	O
with	IN	B-PP	O
signals	NNS	B-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
termination	NN	B-NP	O
of	IN	B-PP	O
liver	NN	B-NP	O
regeneration	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
investigates	VBZ	B-VP	O
the	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
ILK	NN	B-NP	O
in	IN	B-PP	O
liver	NN	B-NP	O
enlargement	NN	I-NP	O
induced	VBN	B-VP	O
by	IN	B-PP	O
phenobarbital	NN	B-NP	O
(	(	O	O
PB	NN	B-NP	O
)	)	O	O
.	.	O	O

Wild	JJ	B-NP	O
-	HYPH	I-NP	O
type	NN	I-NP	O
(	(	O	O
WT	NN	B-NP	O
)	)	O	O
and	CC	O	O
ILK	NN	B-NP	O
:	:	O	O
liver	NN	B-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
were	VBD	B-VP	O
given	VBN	I-VP	O
PB	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
%	NN	I-NP	O
in	IN	B-PP	O
drinking	NN	B-NP	O
water	NN	I-NP	O
)	)	O	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Livers	NNS	B-NP	O
were	VBD	B-VP	O
harvested	VBN	I-VP	O
on	IN	B-PP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
days	NNS	I-NP	O
during	IN	B-PP	O
PB	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
hepatocyte	NN	I-NP	O
-	HYPH	B-NP	O
specific	JJ	I-NP	O
ILK	NN	I-NP	O
/	SYM	B-NP	O
liver	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
,	,	O	O
the	DT	B-NP	O
liver	NN	I-NP	O
:	:	O	O
body	NN	B-NP	O
weight	NN	I-NP	O
ratio	NN	I-NP	O
was	VBD	B-VP	O
more	JJR	B-ADVP	O
than	IN	I-ADVP	O
double	JJ	I-ADVP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
)	)	O	O
,	,	O	O
while	IN	B-SBAR	O
at	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
it	PRP	B-NP	O
was	VBD	B-VP	O
enlarged	VBN	I-VP	O
num	CD	B-NP	O
times	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
WT	JJ	I-NP	O
mice	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
increase	NN	I-NP	O
was	VBD	B-VP	O
as	RB	B-VP	O
expected	VBN	I-VP	O
from	IN	B-PP	O
previous	JJ	B-NP	O
literature	NN	I-NP	O
(	(	O	O
num	CD	B-NP	O
times	NNS	I-NP	O
)	)	O	O
and	CC	O	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
have	VB	I-VP	O
leveled	VBN	I-VP	O
off	RP	B-PRT	O
after	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

There	EX	B-NP	O
were	VBD	B-VP	O
slightly	RB	I-VP	O
increased	VBN	I-VP	O
proliferating	VBG	B-VP	O
cell	NN	B-NP	O
nuclear	JJ	I-NP	O
antigen	NN	I-NP	O
-	HYPH	I-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
ILK	NN	I-NP	O
/	SYM	B-NP	O
liver	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
animals	NNS	B-NP	O
at	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
as	IN	B-SBAR	O
compared	VBN	B-VP	O
to	TO	B-PP	O
WT	NN	B-NP	O
after	IN	B-PP	O
PB	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
WT	JJ	I-NP	O
animals	NNS	I-NP	O
,	,	O	O
the	DT	B-NP	O
proliferative	JJ	I-NP	O
response	NN	I-NP	O
had	VBD	B-VP	O
come	VBN	I-VP	O
back	RB	B-ADVP	O
to	TO	B-PP	O
normal	JJ	B-ADJP	O
by	IN	B-PP	O
days	NNS	B-NP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
.	.	O	O

Hepatocytes	NNS	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
ILK	NN	I-NP	O
/	SYM	B-NP	O
liver	NN	I-NP	O
-	HYPH	B-NP	O
/	SYM	I-NP	O
-	HYPH	I-NP	O
mice	NNS	I-NP	O
continued	VBD	B-VP	O
to	TO	I-VP	O
proliferate	VB	I-VP	O
up	RP	B-PRT	O
until	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

ILK	NN	B-NP	O
/	SYM	B-NP	O
liver	NN	I-NP	O
-	HYPH	O	O
/	SYM	O	O
-	HYPH	O	O
mice	NNS	B-NP	O
also	RB	B-ADVP	O
showed	VBD	B-VP	O
increased	VBN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
key	JJ	B-NP	O
genes	NNS	I-NP	O
involved	VBN	B-VP	O
in	IN	B-PP	O
hepatocyte	NN	B-NP	O
proliferation	NN	I-NP	O
at	IN	B-PP	O
different	JJ	B-NP	O
time	NN	I-NP	O
points	NNS	I-NP	O
during	IN	B-PP	O
PB	NN	B-NP	O
administration	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
summary	NN	B-NP	O
,	,	O	O
ECM	NN	B-NP	O
proteins	NNS	I-NP	O
communicate	VBP	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
signaling	NN	I-NP	O
machinery	NN	I-NP	O
of	IN	B-PP	O
dividing	VBG	B-VP	O
cells	NNS	B-NP	O
via	IN	B-PP	O
ILK	NN	B-NP	O
to	TO	B-VP	O
regulate	VB	I-VP	O
hepatocyte	NN	B-NP	O
proliferation	NN	I-NP	O
and	CC	I-NP	O
termination	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
proliferative	JJ	I-NP	O
response	NN	I-NP	O
.	.	O	O

Lack	NN	B-NP	O
of	IN	B-PP	O
ILK	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hepatocytes	NNS	I-NP	O
imparts	VBZ	B-VP	O
prolonged	JJ	B-NP	O
proliferative	JJ	I-NP	O
response	NN	I-NP	O
not	RB	B-CONJP	O
only	RB	I-CONJP	O
to	TO	B-PP	O
stimuli	NNS	B-NP	O
related	VBN	B-VP	O
to	TO	B-PP	O
liver	NN	B-NP	O
regeneration	NN	I-NP	O
but	CC	B-CONJP	O
also	RB	I-CONJP	O
to	TO	B-PP	O
xenobiotic	JJ	B-NP	O
chemical	JJ	I-NP	O
mitogens	NNS	I-NP	O
,	,	O	O
such	JJ	B-PP	O
as	IN	I-PP	O
PB	NN	B-NP	O
.	.	O	O

Decreased	VBN	B-NP	O
Expression	NN	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
/	SYM	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
,	,	O	O
NHE3	NN	B-NP	O
,	,	O	O
NBC1	NN	B-NP	O
,	,	O	O
AQP1	NN	B-NP	O
and	CC	I-NP	O
OAT	NN	I-NP	O
in	IN	B-PP	O
Gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
Nephropathy	NN	I-NP	B
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
aimed	VBN	I-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
whether	IN	B-SBAR	O
there	EX	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
altered	JJ	I-NP	O
regulation	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
transporters	NNS	I-NP	O
in	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
nephropathy	NN	I-NP	B
.	.	O	O

Sprague	NNP	B-NP	O
-	HYPH	I-NP	O
Dawley	NNP	I-NP	O
male	JJ	I-NP	O
rats	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
~	SYM	I-NP	O
num	CD	I-NP	O
g	NN	I-NP	O
)	)	O	O
were	VBD	B-VP	O
subcutaneously	RB	I-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
gentamicin	NN	B-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
tubular	JJ	B-NP	O
transporters	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
by	IN	B-PP	O
immunoblotting	NN	B-NP	O
and	CC	I-NP	O
immunohistochemistry	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
mRNA	NN	I-NP	O
and	CC	I-NP	O
protein	NN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
OAT	NN	B-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
determined	VBN	I-VP	O
.	.	O	O

Gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
exhibited	VBD	B-VP	O
significantly	RB	B-NP	O
decreased	VBN	I-NP	O
creatinine	NN	I-NP	O
clearance	NN	I-NP	O
along	IN	B-PP	O
with	IN	B-PP	O
increased	VBN	B-NP	O
plasma	NN	I-NP	O
creatinine	NN	I-NP	O
levels	NNS	I-NP	O
.	.	O	O

Accordingly	RB	B-ADVP	O
,	,	O	O
the	DT	B-NP	O
fractional	JJ	I-NP	O
excretion	NN	I-NP	O
of	IN	B-PP	O
sodium	NN	B-NP	O
increased	VBD	B-VP	O
.	.	O	O

Urine	NN	B-NP	O
volume	NN	I-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
while	IN	B-SBAR	O
urine	NN	B-NP	O
osmolality	NN	I-NP	O
and	CC	O	O
free	JJ	B-NP	O
water	NN	I-NP	O
reabsorption	NN	I-NP	O
were	VBD	B-VP	O
decreased	VBN	I-VP	O
.	.	O	O

Immunoblotting	NN	B-NP	O
and	CC	I-NP	O
immunohistochemistry	NN	I-NP	O
revealed	VBD	B-VP	O
decreased	VBN	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
/	SYM	B-NP	O
K	NN	I-NP	O
-	HYPH	O	O
ATPase	NN	B-NP	O
,	,	O	O
NHE3	NN	B-NP	O
,	,	O	O
NBC1	NN	B-NP	O
,	,	O	O
and	CC	O	O
AQP1	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
kidney	NN	I-NP	O
of	IN	B-PP	O
gentamicin	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
OAT1	NN	B-NP	O
and	CC	I-NP	O
OAT3	NN	I-NP	O
was	VBD	B-VP	O
also	RB	I-VP	O
decreased	VBN	I-VP	O
.	.	O	O

Gentamicin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
nephropathy	NN	I-NP	B
may	MD	O	O
at	IN	B-ADVP	O
least	JJS	I-ADVP	O
in	IN	B-PP	O
part	NN	B-NP	O
be	VB	B-VP	O
causally	RB	B-ADJP	O
related	JJ	I-ADJP	O
with	IN	B-PP	O
a	DT	B-NP	O
decreased	VBN	I-NP	O
expression	NN	I-NP	O
of	IN	B-PP	O
Na	NN	B-NP	O
/	SYM	B-NP	O
K	NN	I-NP	O
-	HYPH	B-NP	O
ATPase	NN	I-NP	O
,	,	O	O
NHE3	NN	B-NP	O
,	,	O	O
NBC1	NN	B-NP	O
,	,	O	O
AQP1	NN	B-NP	O
and	CC	I-NP	O
OAT	NN	I-NP	O
.	.	O	O

Longitudinal	JJ	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	B
disease	NN	I-NP	I
progression	NN	I-NP	O
and	CC	O	O
psychological	JJ	B-NP	O
health	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
evaluated	VBD	B-VP	O
the	DT	B-NP	O
association	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
and	CC	I-NP	O
depression	NN	I-NP	B
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
effects	NNS	I-NP	O
on	IN	B-PP	O
HIV	NN	B-NP	B
disease	NN	I-NP	I
progression	NN	I-NP	O
among	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
study	NN	I-NP	O
included	VBD	B-VP	O
num	CD	B-NP	O
women	NNS	I-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
who	WP	B-NP	O
were	VBD	B-VP	O
recruited	VBN	I-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
US	NNP	I-NP	O
cities	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
participants	NNS	I-NP	O
had	VBD	B-VP	O
physical	JJ	B-NP	O
examination	NN	I-NP	O
,	,	O	O
medical	JJ	B-NP	O
record	NN	I-NP	O
extraction	NN	I-NP	O
,	,	O	O
and	CC	O	O
venipuncture	NN	B-NP	O
,	,	O	O
CD4+T	NN	B-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
determination	NN	I-NP	O
,	,	O	O
measurement	NN	B-NP	O
of	IN	B-PP	O
depression	NN	B-NP	B
symptoms	NNS	I-NP	O
(	(	O	O
using	VBG	B-VP	O
the	DT	B-NP	O
self	AFX	I-NP	O
-	HYPH	I-NP	O
report	NN	I-NP	O
Center	NNP	I-NP	O
for	IN	B-PP	O
Epidemiological	NNP	B-NP	O
Studies	NNPS	I-NP	O
-	HYPH	I-NP	O
Depression	NN	I-NP	B
Scale	NN	I-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
alcohol	NN	B-NP	O
use	VBP	B-VP	O
assessment	NN	B-NP	O
at	IN	B-PP	O
enrollment	NN	B-NP	O
,	,	O	O
and	CC	O	O
semiannually	RB	B-ADVP	O
until	IN	B-PP	O
March	NNP	B-NP	O
num	CD	I-NP	O
.	.	O	O

Multilevel	JJ	B-NP	O
random	JJ	I-NP	O
coefficient	JJ	I-NP	O
ordinal	JJ	I-NP	O
models	NNS	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
multilevel	JJ	B-NP	O
models	NNS	I-NP	O
with	IN	B-PP	O
joint	JJ	B-NP	O
responses	NNS	I-NP	O
were	VBD	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
analysis	NN	I-NP	O
.	.	O	O

There	EX	B-NP	O
was	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
level	NN	B-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
and	CC	I-NP	O
CD4	NN	I-NP	O
+	SYM	I-NP	O
T	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
.	.	O	O

When	WRB	B-ADVP	O
participants	NNS	B-NP	O
were	VBD	B-VP	O
stratified	VBN	I-VP	O
by	IN	B-PP	O
antiretroviral	JJ	B-NP	O
therapy	NN	I-NP	O
(	(	O	O
ART	NN	B-NP	O
)	)	O	O
use	NN	B-NP	O
,	,	O	O
the	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
alcohol	NN	B-NP	O
and	CC	I-NP	O
CD4	NN	I-NP	O
+	SYM	B-NP	O
T	NN	I-NP	O
-	HYPH	O	O
cell	NN	B-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
reach	VB	I-VP	O
statistical	JJ	B-NP	O
significance	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
association	NN	I-NP	O
between	IN	B-PP	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
and	CC	O	O
depression	NN	B-NP	B
was	VBD	B-VP	O
significant	JJ	B-ADJP	O
.	.	O	O

Depression	NN	B-NP	B
had	VBD	B-VP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
negative	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
CD4	NN	B-NP	O
+	SYM	I-NP	O
T	NN	I-NP	O
-	HYPH	B-NP	O
cell	NN	I-NP	O
counts	NNS	I-NP	O
over	IN	B-PP	O
time	NN	B-NP	O
regardless	RB	B-ADVP	O
of	IN	B-PP	O
ART	NNP	B-NP	O
use	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
alcohol	NN	B-NP	O
consumption	NN	I-NP	O
has	VBZ	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
association	NN	I-NP	O
with	IN	B-PP	O
depression	NN	B-NP	B
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
depression	NN	B-NP	B
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
HIV	NN	B-NP	B
disease	NN	I-NP	I
progression	NN	I-NP	O
.	.	O	O

Our	PRP$	B-NP	O
findings	NNS	I-NP	O
have	VBP	B-VP	O
implications	NNS	B-NP	O
for	IN	B-PP	O
the	DT	B-NP	O
provision	NN	I-NP	O
of	IN	B-PP	O
alcohol	NN	B-NP	O
use	NN	I-NP	O
interventions	NNS	I-NP	O
and	CC	O	O
psychological	JJ	B-NP	O
resources	NNS	I-NP	O
to	TO	B-VP	O
improve	VB	I-VP	O
the	DT	B-NP	O
health	NN	I-NP	O
of	IN	B-PP	O
women	NNS	B-NP	O
with	IN	B-PP	O
HIV	NN	B-NP	O
.	.	O	O

Chemokine	NN	B-NP	O
CCL2	NN	I-NP	O
and	CC	O	O
its	PRP$	B-NP	O
receptor	NN	I-NP	O
CCR2	NN	I-NP	O
are	VBP	B-VP	O
increased	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
following	VBG	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
status	NN	I-NP	B
epilepticus	NN	I-NP	I
.	.	O	O

Neuroinflammation	NN	B-NP	B
occurs	VBZ	B-VP	O
after	IN	B-PP	O
seizures	NNS	B-NP	B
and	CC	O	O
is	VBZ	B-VP	O
implicated	VBN	I-VP	O
in	IN	B-PP	O
epileptogenesis	NN	B-NP	O
.	.	O	O

CCR2	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
chemokine	NN	I-NP	O
receptor	NN	I-NP	O
for	IN	B-PP	O
CCL2	NN	B-NP	O
and	CC	O	O
their	PRP$	B-NP	O
interaction	NN	I-NP	O
mediates	VBZ	B-VP	O
monocyte	NN	B-NP	O
infiltration	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neuroinflammatory	JJ	I-NP	B
cascade	NN	I-NP	O
triggered	VBN	B-VP	O
in	IN	B-PP	O
different	JJ	B-NP	O
brain	NN	I-NP	O
pathologies	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
work	NN	I-NP	O
CCR2	NN	I-NP	O
and	CC	O	O
CCL2	NN	B-NP	O
expression	NN	I-NP	O
were	VBD	B-VP	O
examined	VBN	I-VP	O
following	VBG	B-PP	O
status	NN	B-NP	B
epilepticus	NN	I-NP	I
(	(	O	O
SE	NN	B-NP	B
)	)	O	O
induced	VBN	B-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

SE	NN	B-NP	B
was	VBD	B-VP	O
induced	VBN	I-VP	O
by	IN	B-PP	O
pilocarpine	NN	B-NP	O
injection	NN	I-NP	O
.	.	O	O

Control	NN	B-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
injected	VBN	I-VP	O
with	IN	B-PP	O
saline	NN	B-NP	O
instead	RB	B-PP	O
of	IN	I-PP	O
pilocarpine	NN	B-NP	O
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
after	IN	B-PP	O
SE	NN	B-NP	B
,	,	O	O
CCR2	NN	B-NP	O
staining	NN	I-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
and	CC	O	O
glial	JJ	B-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
using	VBG	B-VP	O
imunohistochemical	JJ	B-NP	O
analyses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
CCR2	NN	B-NP	O
positive	JJ	I-NP	O
cells	NNS	I-NP	O
was	VBD	B-VP	O
determined	VBN	I-VP	O
using	VBG	B-VP	O
stereology	NN	B-NP	O
probes	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
.	.	O	O

CCL2	NN	B-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
was	VBD	B-VP	O
examined	VBN	I-VP	O
by	IN	B-PP	O
molecular	JJ	B-NP	O
assay	NN	I-NP	O
.	.	O	O

Increased	VBN	B-NP	O
CCR2	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
after	IN	B-PP	O
SE	NN	B-NP	B
.	.	O	O

Seizures	NNS	B-NP	B
also	RB	B-ADVP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
alterations	NNS	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
cell	NN	I-NP	O
types	NNS	I-NP	O
expressing	VBG	B-VP	O
CCR2	NN	B-NP	O
.	.	O	O

Increased	VBN	B-NP	O
numbers	NNS	I-NP	O
of	IN	B-PP	O
neurons	NNS	B-NP	O
that	WDT	B-NP	O
expressed	VBD	B-VP	O
CCR2	NN	B-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
following	VBG	B-PP	O
SE	NN	B-NP	B
.	.	O	O

Microglial	JJ	B-NP	O
cells	NNS	I-NP	O
were	VBD	B-VP	O
more	RBR	I-VP	O
closely	RB	I-VP	O
apposed	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
CCR2	NN	I-NP	O
-	HYPH	B-NP	O
labeled	VBN	I-NP	O
cells	NNS	I-NP	O
in	IN	B-PP	O
SE	NN	B-NP	B
rats	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
addition	NN	B-NP	O
,	,	O	O
rats	NNS	B-NP	O
that	WDT	B-NP	O
experienced	VBD	B-VP	O
SE	NN	B-NP	B
exhibited	VBD	B-VP	O
CCR2	NN	B-NP	O
-	HYPH	B-NP	O
labeling	NN	I-NP	O
in	IN	B-PP	O
populations	NNS	B-NP	O
of	IN	B-PP	O
hypertrophied	JJ	B-NP	B
astrocytes	NNS	I-NP	O
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
CA1	NN	B-NP	O
and	CC	I-NP	O
dentate	NN	I-NP	O
gyrus	NN	I-NP	O
.	.	O	O

These	DT	B-NP	O
CCR2	NN	I-NP	O
+	SYM	B-NP	O
astroctytes	NNS	I-NP	O
were	VBD	B-VP	O
not	RB	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
control	NN	B-NP	O
rats	NNS	I-NP	O
.	.	O	O

Examination	NN	B-NP	O
of	IN	B-PP	O
CCL2	NN	B-NP	O
expression	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
it	PRP	B-NP	O
was	VBD	B-VP	O
elevated	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
following	VBG	B-PP	O
SE	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
show	VBP	B-VP	O
that	IN	B-SBAR	O
CCR2	NN	B-NP	O
and	CC	I-NP	O
CCL2	NN	I-NP	O
are	VBP	B-VP	O
up	RB	B-ADVP	O
-	HYPH	B-NP	O
regulated	VBN	B-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
hippocampus	NN	I-NP	O
after	IN	B-PP	O
pilocarpine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
SE	NN	I-NP	B
.	.	O	O

Seizures	NNS	B-NP	B
also	RB	B-ADVP	O
result	VBP	B-VP	O
in	IN	B-PP	O
changes	NNS	B-NP	O
to	TO	B-PP	O
CCR2	NN	B-NP	O
receptor	NN	I-NP	O
expression	NN	I-NP	O
in	IN	B-PP	O
neurons	NNS	B-NP	O
and	CC	I-NP	O
astrocytes	NNS	I-NP	O
.	.	O	O

These	DT	B-NP	O
changes	NNS	I-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
detrimental	JJ	B-NP	O
neuroplasticity	NN	I-NP	O
and	CC	O	O
neuroinflammatory	JJ	B-NP	B
changes	NNS	I-NP	O
that	WDT	B-NP	O
occur	VBP	B-VP	O
following	VBG	B-PP	O
seizures	NNS	B-NP	B
.	.	O	O

Metallothionein	NN	B-NP	O
induction	NN	I-NP	O
reduces	VBZ	B-VP	O
caspase	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
activity	NN	I-NP	O
and	CC	I-NP	O
TNFalpha	NN	I-NP	O
levels	NNS	I-NP	O
with	IN	B-PP	O
preservation	NN	B-NP	O
of	IN	B-PP	O
cognitive	JJ	B-NP	O
function	NN	I-NP	O
and	CC	O	O
intact	JJ	B-NP	O
hippocampal	JJ	I-NP	O
neurons	NNS	I-NP	O
in	IN	B-PP	O
carmustine	NN	B-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

Hippocampal	JJ	B-NP	O
integrity	NN	I-NP	O
is	VBZ	B-VP	O
essential	JJ	B-ADJP	O
for	IN	B-PP	O
cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
hand	NN	I-NP	O
,	,	O	O
induction	NN	B-NP	O
of	IN	B-PP	O
metallothionein	NN	B-NP	O
(	(	O	O
MT	NN	B-NP	O
)	)	O	O
by	IN	B-PP	O
ZnSO	NN	B-NP	O
and	CC	O	O
its	PRP$	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
neuroprotection	NN	B-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
documented	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
aimed	VBD	B-VP	O
to	TO	I-VP	O
explore	VB	I-VP	O
the	DT	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
MT	NN	B-NP	O
induction	NN	I-NP	O
on	IN	B-PP	O
carmustine	NN	B-NP	O
(	(	O	O
BCNU	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
hippocampal	JJ	I-NP	O
cognitive	JJ	I-NP	B
dysfunction	NN	I-NP	I
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
male	JJ	I-NP	O
Wistar	NNP	I-NP	O
albino	NNP	I-NP	O
rats	NNS	I-NP	O
were	VBD	B-VP	O
randomly	RB	I-VP	O
divided	VBN	I-VP	O
into	IN	B-PP	O
num	CD	B-NP	O
groups	NNS	I-NP	O
(	(	O	O
num	CD	B-NP	O
/	SYM	I-NP	O
group	NN	I-NP	O
)	)	O	O
:	:	O	O
The	DT	B-NP	O
control	NN	I-NP	O
group	NN	I-NP	O
injected	VBN	B-VP	O
with	IN	B-PP	O
single	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
(	(	O	O
i.c.v	NN	B-NP	O
)	)	O	O
followed	VBD	B-VP	O
num	CD	B-NP	O
h	NN	I-NP	O
later	RB	B-ADVP	O
by	IN	B-PP	O
BCNU	NN	B-NP	O
solvent	NN	I-NP	O
(	(	O	O
i.v	NN	B-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
second	JJ	I-NP	O
group	NN	I-NP	O
administered	VBN	B-VP	O
ZnSO	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
microl	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
,	,	O	O
i.c.v	NN	B-NP	O
,	,	O	O
once	RB	B-ADVP	O
)	)	O	O
then	RB	B-ADVP	O
BCNU	NN	B-NP	O
solvent	NN	I-NP	O
(	(	O	O
i.v	NN	B-NP	O
)	)	O	O
after	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

Third	JJ	B-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
BCNU	NN	B-NP	O
num	CD	I-NP	O
h	NN	I-NP	O
after	IN	B-PP	O
injection	NN	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
saline	NN	I-NP	O
(	(	O	O
i.c.v	NN	B-NP	O
)	)	O	O
.	.	O	O

Fourth	JJ	B-NP	O
group	NN	I-NP	O
received	VBD	B-VP	O
a	DT	B-NP	O
single	JJ	I-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
ZnSO	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
micromol	NN	I-NP	O
/	SYM	B-NP	O
num	CD	B-NP	O
microl	NN	I-NP	O
normal	JJ	I-NP	O
saline	NN	I-NP	O
,	,	O	O
i.c.v	JJ	B-ADJP	O
)	)	O	O
then	RB	B-ADVP	O
BCNU	NN	B-NP	O
after	IN	B-PP	O
num	CD	B-NP	O
h	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
obtained	VBN	I-NP	O
data	NNS	I-NP	O
revealed	VBD	B-VP	O
that	IN	B-SBAR	O
BCNU	NN	B-NP	O
administration	NN	I-NP	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
deterioration	NN	B-NP	B
of	IN	B-PP	I
learning	NN	B-NP	I
and	CC	O	I
short	JJ	B-NP	I
-	HYPH	I-NP	I
term	NN	I-NP	I
memory	NN	I-NP	I
(	(	O	O
STM	NN	B-NP	O
)	)	O	O
,	,	O	O
as	IN	B-SBAR	O
measured	VBN	B-VP	O
by	IN	B-PP	O
using	VBG	B-VP	O
radial	JJ	B-NP	O
arm	NN	I-NP	O
water	NN	I-NP	O
maze	NN	I-NP	O
,	,	O	O
accompanied	VBN	B-VP	O
with	IN	B-PP	O
decreased	VBN	B-NP	O
hippocampal	JJ	I-NP	O
glutathione	NN	I-NP	O
reductase	NN	I-NP	O
(	(	O	O
GR	NN	B-NP	O
)	)	O	O
activity	NN	B-NP	O
and	CC	O	O
reduced	VBN	B-NP	O
glutathione	NN	I-NP	O
(	(	O	O
GSH	NN	B-NP	O
)	)	O	O
content	NN	B-NP	O
.	.	O	O

Also	RB	B-ADVP	O
,	,	O	O
BCNU	NN	B-NP	O
administration	NN	I-NP	O
increased	VBD	B-VP	O
serum	NN	B-NP	O
tumor	NN	I-NP	B
necrosis	NN	I-NP	B
factor	NN	I-NP	O
-	HYPH	O	O
alpha	SYM	B-NP	O
(	(	O	O
TNFalpha	NN	B-NP	O
)	)	O	O
,	,	O	O
hippocampal	JJ	B-NP	O
MT	NN	I-NP	O
and	CC	O	O
malondialdehyde	NN	B-NP	O
(	(	O	O
MDA	NN	B-NP	O
)	)	O	O
contents	NNS	B-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
caspase	NN	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
activity	NN	I-NP	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
histological	JJ	B-NP	O
alterations	NNS	I-NP	O
.	.	O	O

ZnSO	NN	B-NP	O
pretreatment	NN	I-NP	O
counteracted	VBD	B-VP	O
BCNU	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
inhibition	NN	I-NP	O
of	IN	B-PP	O
GR	NN	B-NP	O
and	CC	I-NP	O
depletion	NN	I-NP	O
of	IN	B-PP	O
GSH	NN	B-NP	O
and	CC	O	O
resulted	VBD	B-VP	O
in	IN	B-PP	O
significant	JJ	B-NP	O
reduction	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
MDA	NN	B-NP	O
and	CC	I-NP	O
TNFalpha	NN	I-NP	O
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
the	DT	B-NP	O
activity	NN	I-NP	O
of	IN	B-PP	O
caspase	NN	B-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
histological	JJ	I-NP	O
features	NNS	I-NP	O
were	VBD	B-VP	O
improved	VBN	I-VP	O
in	IN	B-PP	O
hippocampus	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
treated	VBN	B-VP	O
with	IN	B-PP	O
ZnSO	NN	B-NP	O
+	SYM	B-NP	O
BCNU	NN	I-NP	O
compared	VBN	B-VP	O
to	TO	B-PP	O
only	RB	B-NP	O
BCNU	NN	I-NP	O
-	HYPH	B-NP	O
treated	VBN	I-NP	O
animals	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
conclusion	NN	B-NP	O
,	,	O	O
MT	NN	B-NP	O
induction	NN	I-NP	O
halts	VBZ	B-VP	O
BCNU	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
hippocampal	JJ	I-NP	O
toxicity	NN	I-NP	B
as	IN	B-SBAR	O
it	PRP	B-NP	O
prevented	VBD	B-VP	O
GR	NN	B-NP	O
inhibition	NN	I-NP	O
and	CC	O	O
GSH	NN	B-NP	O
depletion	NN	I-NP	O
and	CC	O	O
counteracted	VBD	B-VP	O
the	DT	B-NP	O
increased	VBN	I-NP	O
levels	NNS	I-NP	O
of	IN	B-PP	O
TNFalpha	NN	B-NP	O
,	,	O	O
MDA	NN	B-NP	O
and	CC	I-NP	O
caspase	NN	I-NP	O
-	HYPH	O	O
num	CD	B-NP	O
activity	NN	I-NP	O
with	IN	B-PP	O
subsequent	JJ	B-NP	O
preservation	NN	I-NP	O
of	IN	B-PP	O
cognition	NN	B-NP	O
.	.	O	O

Fatal	JJ	B-NP	O
carbamazepine	NN	I-NP	O
induced	VBD	B-VP	O
fulminant	JJ	B-NP	B
eosinophilic	JJ	I-NP	I
(	(	O	O
hypersensitivity	NN	B-NP	B
)	)	O	O
myocarditis	NN	B-NP	B
:	:	O	O
emphasis	NN	B-NP	O
on	IN	B-PP	O
anatomical	JJ	B-NP	O
and	CC	I-NP	O
histological	JJ	I-NP	O
characteristics	NNS	I-NP	O
,	,	O	O
mechanisms	NNS	B-NP	O
and	CC	I-NP	O
genetics	NNS	I-NP	O
of	IN	B-PP	O
drug	NN	B-NP	B
hypersensitivity	NN	I-NP	I
and	CC	O	O
differential	JJ	B-NP	O
diagnosis	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
most	RBS	I-NP	O
severe	JJ	I-NP	O
adverse	JJ	I-NP	O
reactions	NNS	I-NP	O
to	TO	B-PP	O
carbamazepine	NN	B-NP	O
have	VBP	B-VP	O
been	VBN	I-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
haemopoietic	JJ	I-NP	O
system	NN	I-NP	O
,	,	O	O
the	DT	B-NP	O
liver	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
cardiovascular	JJ	I-NP	O
system	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
frequently	RB	I-NP	O
fatal	JJ	I-NP	O
,	,	O	O
although	IN	B-SBAR	O
exceptionally	RB	B-NP	O
rare	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
is	VBZ	B-VP	O
necrotizing	VBG	I-VP	O
eosinophilic	JJ	B-NP	O
(	(	O	O
hypersensitivity	NN	B-NP	B
)	)	O	O
myocarditis	NN	B-NP	B
.	.	O	O

We	PRP	B-NP	O
report	VBP	B-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
hypersensitivity	NN	B-NP	B
myocarditis	NN	I-NP	B
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
carbamazepine	NN	B-NP	O
.	.	O	O

Acute	JJ	B-NP	O
hypersensitivity	NN	I-NP	B
myocarditis	NN	I-NP	B
was	VBD	B-VP	O
not	RB	I-VP	O
suspected	VBN	I-VP	O
clinically	RB	B-ADVP	O
,	,	O	O
and	CC	O	O
the	DT	B-NP	O
diagnosis	NN	I-NP	O
was	VBD	B-VP	O
made	VBN	I-VP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
mortem	NN	B-NP	O
.	.	O	O

Histology	NNP	B-NP	O
revealed	VBD	B-VP	O
diffuse	JJ	B-NP	O
infiltration	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
myocardium	NN	I-NP	O
by	IN	B-PP	O
eosinophils	NNS	B-NP	O
and	CC	I-NP	O
lymphocytes	NNS	I-NP	O
with	IN	B-PP	O
myocyte	NN	B-NP	O
damage	NN	I-NP	O
.	.	O	O

Clinically	RB	B-ADVP	O
,	,	O	O
death	NN	B-NP	O
was	VBD	B-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
cardiogenic	JJ	B-NP	B
shock	NN	I-NP	I
.	.	O	O

To	TO	B-PP	O
best	JJS	B-NP	O
of	IN	B-PP	O
our	PRP$	B-NP	O
knowledge	NN	I-NP	O
this	DT	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
second	JJ	I-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
fatal	JJ	B-NP	O
carbamazepine	NN	I-NP	O
induced	VBD	B-VP	O
myocarditis	NN	B-NP	B
reported	VBN	B-VP	O
in	IN	B-PP	O
English	JJ	B-NP	O
literature	NN	I-NP	O
.	.	O	O

Neuropsychiatric	JJ	B-NP	O
behaviors	NNS	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
MPTP	NN	I-NP	O
marmoset	NN	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NNP	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Neuropsychiatric	JJ	B-NP	O
symptoms	NNS	I-NP	O
are	VBP	B-VP	O
increasingly	RB	I-VP	O
recognised	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
significant	JJ	I-NP	O
problem	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
Parkinson	NNP	B-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
PD	NN	B-NP	B
)	)	O	O
.	.	O	O

These	DT	B-NP	O
symptoms	NNS	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADJP	O
to	TO	B-PP	O
sensitisation	NN	B-NP	O
following	VBG	B-PP	O
repeated	VBN	B-NP	O
levodopa	NN	I-NP	O
treatment	NN	I-NP	O
or	CC	O	O
a	DT	B-NP	O
direct	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
dopamine	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
disease	NN	I-NP	O
state	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
levodopa	NN	I-NP	O
-	HYPH	B-VP	O
treated	VBN	B-NP	O
MPTP	NN	I-NP	O
-	HYPH	O	O
lesioned	VBN	B-NP	O
marmoset	NN	I-NP	O
was	VBD	B-VP	O
used	VBN	I-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
neuropsychiatric	JJ	B-NP	B
symptoms	NNS	I-NP	I
in	IN	B-PP	O
PD	NN	B-NP	B
patients	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
compare	VBP	B-VP	O
the	DT	B-NP	O
time	NN	I-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
motor	NN	I-NP	O
fluctuations	NNS	I-NP	O
and	CC	O	O
neuropsychiatric	JJ	B-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
behaviors	NNS	I-NP	I
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
relationship	NN	I-NP	O
between	IN	B-PP	O
duration	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
and	CC	I-NP	O
onset	NN	I-NP	O
of	IN	B-PP	O
symptoms	NNS	B-NP	O
.	.	O	O

Marmosets	NNS	B-NP	O
were	VBD	B-VP	O
administered	VBN	I-VP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
methyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
phenyl	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
tetrahydropyridine	NN	I-NP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
,	,	O	O
resulting	VBG	B-VP	O
in	IN	B-PP	O
stable	JJ	B-NP	O
parkinsonism	NN	I-NP	B
.	.	O	O

Levodopa	FW	B-NP	O
p.o.	FW	I-NP	O
b.i.d	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
administered	VBN	I-VP	O
for	IN	B-PP	O
num	CD	B-NP	O
days	NNS	I-NP	O
.	.	O	O

Animals	NNS	B-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
for	IN	B-PP	O
parkinsonian	JJ	B-NP	B
disability	NN	I-NP	I
,	,	O	O
dyskinesia	NN	B-NP	B
and	CC	B-PP	O
on	IN	B-PP	O
-	HYPH	B-NP	O
time	NN	I-NP	O
(	(	O	O
motor	NN	B-NP	O
fluctuations	NNS	I-NP	O
)	)	O	O
and	CC	O	O
neuropsychiatric	JJ	B-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
behaviors	NNS	I-NP	I
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
(	(	O	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
levodopa	NN	B-NP	O
)	)	O	O
and	CC	O	O
on	IN	B-PP	O
Days	NNS	B-NP	O
num	CD	B-NP	O
num	CD	I-NP	O
,	,	O	O
num	CD	B-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
using	VBG	B-VP	O
post	NN	B-NP	O
hoc	NN	I-NP	O
DVD	NN	I-NP	O
analysis	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
trained	JJ	I-NP	O
rater	NN	I-NP	O
,	,	O	O
blind	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
treatment	NN	I-NP	O
day	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
neuropsychiatric	JJ	I-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
behavior	NN	I-NP	I
rating	NN	I-NP	O
scale	NN	I-NP	O
demonstrated	VBD	B-VP	O
high	JJ	B-NP	O
interrater	NN	I-NP	O
reliability	NN	I-NP	O
between	IN	B-PP	O
num	CD	B-NP	O
trained	VBN	I-NP	O
raters	NNS	I-NP	O
of	IN	B-PP	O
differing	VBG	B-VP	O
professional	JJ	B-NP	O
backgrounds	NNS	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
anticipated	VBN	B-VP	O
,	,	O	O
animals	NNS	B-NP	O
exhibited	VBD	B-VP	O
a	DT	B-NP	O
progressive	JJ	I-NP	O
increase	NN	I-NP	O
in	IN	B-PP	O
levodopa	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
motor	NN	I-NP	O
fluctuations	NNS	I-NP	O
,	,	O	O
dyskinesia	NN	B-NP	B
and	CC	O	O
wearing	VB	B-VP	O
-	HYPH	B-ADJP	O
off	RP	B-PRT	O
,	,	O	O
that	WDT	B-NP	O
correlated	VBD	B-VP	O
with	IN	B-PP	O
the	DT	B-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

In	IN	B-PP	O
contrast	NN	B-NP	O
,	,	O	O
levodopa	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
neuropsychiatric	JJ	I-NP	B
-	HYPH	I-NP	I
like	JJ	I-NP	I
behaviors	NNS	I-NP	I
were	VBD	B-VP	O
present	JJ	B-ADJP	O
on	IN	B-PP	O
Day	NN	B-NP	O
num	CD	I-NP	O
of	IN	B-PP	O
levodopa	NN	B-NP	O
treatment	NN	I-NP	O
and	CC	O	O
their	PRP$	B-NP	O
severity	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
correlate	VB	I-VP	O
with	IN	B-PP	O
duration	NN	B-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
data	NNS	I-NP	O
suggest	VBP	B-VP	O
that	IN	B-SBAR	O
neuropsychiatric	JJ	B-NP	B
disorders	NNS	I-NP	I
in	IN	B-PP	O
PD	NN	B-NP	B
are	VBP	B-VP	O
more	RBR	B-ADVP	O
likely	RB	I-ADVP	O
an	DT	B-NP	O
interaction	NN	I-NP	O
between	IN	B-PP	O
levodopa	NN	B-NP	O
and	CC	O	O
the	DT	B-NP	O
disease	NN	I-NP	O
state	NN	I-NP	O
than	IN	B-PP	O
a	DT	B-NP	O
consequence	NN	I-NP	O
of	IN	B-PP	O
sensitisation	NN	B-NP	O
to	TO	B-PP	O
repeated	VBN	B-NP	O
dopaminergic	JJ	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Contrast	NN	B-NP	O
medium	NN	I-NP	O
nephrotoxicity	NN	I-NP	B
after	IN	B-PP	O
renal	JJ	B-NP	O
artery	NN	I-NP	O
and	CC	O	O
coronary	JJ	B-NP	O
angioplasty	NN	I-NP	O
.	.	O	O

Renal	JJ	B-NP	B
dysfunction	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
iodinated	VBN	B-NP	O
contrast	NN	I-NP	O
medium	NN	I-NP	O
(	(	O	O
CM	NN	B-NP	O
)	)	O	O
administration	NN	B-NP	O
can	MD	B-VP	O
minimize	VB	I-VP	O
the	DT	B-NP	O
benefit	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
interventional	JJ	I-NP	O
procedure	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
renal	JJ	B-NP	O
angioplasty	JJ	I-NP	O
(	(	O	O
PTRA	NN	B-NP	O
)	)	O	O
.	.	O	O

To	TO	B-VP	O
compare	VB	I-VP	O
the	DT	B-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
nephrotoxic	JJ	B-NP	B
effect	NN	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
PTRA	NN	B-NP	O
with	IN	B-PP	O
that	DT	B-NP	O
of	IN	B-PP	O
patients	NNS	B-NP	O
submitted	VBN	B-VP	O
to	TO	B-PP	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
intervention	NN	I-NP	O
(	(	O	O
PCI	NN	B-NP	O
)	)	O	O
.	.	O	O

A	DT	B-NP	O
total	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
successfully	RB	B-VP	O
treated	VBN	I-VP	O
with	IN	B-PP	O
PTRA	NN	B-NP	O
were	VBD	B-VP	O
compared	VBN	I-VP	O
with	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
successful	JJ	B-NP	O
PCI	NN	I-NP	O
(	(	O	O
PCI	NN	B-NP	O
group	NN	I-NP	O
)	)	O	O
,	,	O	O
matched	VBN	B-VP	O
for	IN	B-PP	O
basal	JJ	B-NP	O
creatinine	NN	I-NP	O
,	,	O	O
gender	NN	B-NP	O
,	,	O	O
and	CC	O	O
age	NN	B-NP	O
.	.	O	O

In	IN	B-PP	O
both	DT	B-NP	O
groups	NNS	I-NP	O
postprocedural	JJ	B-ADJP	O
(	(	O	O
num	CD	B-NP	O
h	NN	I-NP	O
)	)	O	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
was	VBD	B-VP	O
measured	VBN	I-VP	O
.	.	O	O

Postprocedural	JJ	B-NP	O
creatinine	NN	I-NP	O
level	NN	I-NP	O
decreased	VBD	B-VP	O
nonsignificantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
PTRA	NN	I-NP	O
group	NN	I-NP	O
and	CC	O	O
increased	VBD	B-VP	O
significantly	RB	B-ADVP	O
in	IN	B-PP	O
the	DT	B-NP	O
PCI	NN	I-NP	O
group	NN	I-NP	O
.	.	O	O

Changes	NNS	B-NP	O
in	IN	B-PP	O
serum	NN	B-NP	O
creatinine	NN	I-NP	O
after	IN	B-PP	O
intervention	NN	B-NP	O
(	(	O	O
after	IN	B-PP	O
-	HYPH	B-NP	O
before	IN	B-SBAR	O
)	)	O	O
were	VBD	B-VP	O
significantly	RB	B-ADJP	O
different	JJ	I-ADJP	O
between	IN	B-PP	O
the	DT	B-NP	O
PTRA	NN	I-NP	O
and	CC	I-NP	O
PCI	NN	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
related	JJ	B-ADJP	O
to	TO	B-PP	O
either	CC	O	O
a	DT	B-NP	O
different	JJ	I-NP	O
clinical	JJ	I-NP	O
risk	NN	I-NP	O
profile	NN	I-NP	O
or	CC	B-PP	O
to	TO	B-PP	O
the	DT	B-NP	O
volume	NN	I-NP	O
of	IN	B-PP	O
CM	NN	B-NP	O
administered	VBN	B-VP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
preliminary	JJ	I-NP	O
study	NN	I-NP	O
patients	NNS	I-NP	O
submitted	VBN	B-VP	O
to	TO	B-PP	O
PTRA	NN	B-NP	O
showed	VBD	B-VP	O
a	DT	B-NP	O
lower	JJR	I-NP	O
susceptibility	NN	I-NP	O
to	TO	B-PP	O
renal	JJ	B-NP	B
damage	NN	I-NP	I
induced	VBN	B-VP	O
by	IN	B-PP	O
CM	NN	B-NP	O
administration	NN	I-NP	O
than	IN	B-PP	O
PCI	NN	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
effectiveness	NN	I-NP	O
of	IN	B-PP	O
PTRA	NN	B-NP	O
on	IN	B-PP	O
renal	JJ	B-NP	O
function	NN	I-NP	O
seems	VBZ	B-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
barely	RB	I-VP	O
influenced	VBN	I-VP	O
by	IN	B-PP	O
CM	NN	B-NP	O
toxicity	NN	I-NP	B
.	.	O	O

Medical	JJ	B-NP	O
and	CC	I-NP	O
psychiatric	JJ	I-NP	O
outcomes	NNS	I-NP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
transplanted	VBN	B-VP	O
for	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
acute	JJ	I-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
:	:	O	O
a	DT	B-NP	O
case	NN	I-NP	O
-	HYPH	B-NP	O
control	NN	I-NP	O
study	NN	I-NP	O
.	.	O	O

Acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
hepatotoxicity	NN	I-NP	B
is	VBZ	B-VP	O
the	DT	B-NP	O
most	RBS	I-NP	O
common	JJ	I-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
acute	JJ	B-NP	B
liver	NN	I-NP	I
failure	NN	I-NP	I
(	(	O	O
ALF	NN	B-NP	B
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
UK	NNP	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
often	RB	B-ADVP	O
consume	VBP	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
with	IN	B-PP	O
suicidal	JJ	B-NP	O
intent	NN	I-NP	O
or	CC	B-PP	O
with	IN	B-PP	O
a	DT	B-NP	O
background	NN	I-NP	O
of	IN	B-PP	O
substance	NN	B-NP	O
dependence	NN	I-NP	O
.	.	O	O

We	PRP	B-NP	O
compared	VBD	B-VP	O
the	DT	B-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
pretransplant	NN	B-NP	O
illness	NN	I-NP	O
,	,	O	O
psychiatric	JJ	B-NP	O
co	AFX	I-NP	O
-	HYPH	I-NP	O
morbidity	NN	I-NP	O
,	,	O	O
medical	JJ	B-NP	O
and	CC	I-NP	O
psychosocial	JJ	I-NP	O
outcomes	NNS	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
had	VBD	B-VP	O
undergone	VBN	I-VP	O
liver	NN	B-NP	O
transplantation	NN	I-NP	O
(	(	O	O
LT	NN	B-NP	O
)	)	O	O
emergently	RB	B-ADVP	O
between	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
num	CD	I-NP	O
for	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
with	IN	B-PP	O
age	NN	B-NP	O
-	HYPH	O	O
and	CC	O	O
sex	NN	B-NP	O
-	HYPH	B-NP	O
matched	VBN	B-VP	O
patients	NNS	B-NP	O
undergoing	VBG	B-VP	O
emergent	JJ	B-NP	O
LT	NN	I-NP	O
for	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
acetaminophen	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
and	CC	I-NP	O
elective	JJ	I-NP	O
LT	NN	I-NP	O
for	IN	B-PP	O
chronic	JJ	B-NP	B
liver	NN	I-NP	I
disease	NN	I-NP	I
.	.	O	O

Acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
undergoing	VBG	B-VP	O
LT	NN	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
greater	JJR	I-NP	O
severity	NN	I-NP	O
of	IN	B-PP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
LT	NN	I-NP	O
illness	NN	I-NP	O
reflected	VBN	B-VP	O
by	IN	B-PP	O
higher	JJR	B-NP	O
Acute	NNP	I-NP	O
Physiology	NNP	I-NP	O
and	CC	O	O
Chronic	NNP	B-NP	O
Health	NNP	I-NP	O
Evaluation	NN	I-NP	O
num	CD	B-NP	O
scores	NNS	I-NP	O
and	CC	O	O
requirement	NN	B-NP	O
for	IN	B-PP	O
organ	NN	B-NP	O
support	NN	I-NP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
the	DT	B-NP	O
other	JJ	I-NP	O
num	CD	I-NP	O
groups	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
acetaminophen	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
formal	JJ	I-NP	O
psychiatric	JJ	I-NP	O
diagnosis	NN	I-NP	O
before	IN	B-PP	O
LT	NN	B-NP	O
and	CC	O	O
num	CD	B-NP	O
had	VBD	B-VP	O
a	DT	B-NP	O
previous	JJ	I-NP	O
suicide	NN	I-NP	O
attempt	NN	I-NP	O
.	.	O	O

During	IN	B-PP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
(	(	O	O
median	JJ	B-NP	O
num	CD	I-NP	O
years	NNS	I-NP	O
)	)	O	O
,	,	O	O
there	EX	B-NP	O
were	VBD	B-VP	O
no	DT	B-NP	O
significant	JJ	I-NP	O
differences	NNS	I-NP	O
in	IN	B-PP	O
rejection	NN	B-NP	O
(	(	O	O
acute	JJ	B-ADJP	O
and	CC	O	O
chronic	JJ	B-ADJP	O
)	)	O	O
,	,	O	O
graft	NN	B-NP	O
failure	NN	I-NP	O
or	CC	I-NP	O
survival	NN	I-NP	O
between	IN	B-PP	O
the	DT	B-NP	O
groups	NNS	I-NP	O
.	.	O	O

num	CD	B-NP	O
acetaminophen	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
patients	NNS	I-NP	O
reattempted	VBD	B-VP	O
suicide	NN	B-NP	O
post	AFX	O	O
-	HYPH	O	O
LT	NN	B-NP	O
(	(	O	O
num	CD	B-NP	O
died	VBD	B-VP	O
num	CD	B-NP	O
years	NNS	I-NP	O
post	AFX	O	O
-	HYPH	O	O
LT	NN	B-NP	O
)	)	O	O
.	.	O	O

Despite	IN	B-PP	O
a	DT	B-NP	O
high	JJ	I-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
psychiatric	JJ	B-NP	O
disturbance	NN	I-NP	O
,	,	O	O
outcomes	VBZ	B-VP	O
for	IN	B-PP	O
patients	NNS	B-NP	O
transplanted	VBN	B-VP	O
emergently	RB	B-ADVP	O
for	IN	B-PP	O
acetaminophen	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
ALF	NN	I-NP	B
were	VBD	B-VP	O
comparable	JJ	B-ADJP	O
to	TO	B-PP	O
those	DT	B-NP	O
transplanted	VBN	B-VP	O
for	IN	B-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
acetaminophen	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
ALF	NN	I-NP	B
and	CC	O	O
electively	RB	B-ADVP	O
for	IN	B-PP	O
CLD	NN	B-NP	B
.	.	O	O

Multidisciplinary	JJ	B-NP	O
approaches	NNS	I-NP	O
with	IN	B-PP	O
long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
psychiatric	JJ	B-ADJP	O
follow	VB	B-VP	O
-	HYPH	O	O
up	RP	B-PRT	O
may	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
low	JJ	B-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
transplant	NN	I-NP	O
suicide	NN	I-NP	O
rates	NNS	I-NP	O
seen	VBN	B-VP	O
and	CC	O	O
low	JJ	B-NP	O
rates	NNS	I-NP	O
of	IN	B-PP	O
graft	NN	B-NP	O
loss	NN	I-NP	O
because	IN	B-PP	O
of	IN	I-PP	O
non	AFX	B-NP	O
-	HYPH	I-NP	O
compliance	NN	I-NP	O
.	.	O	O

Studies	NNS	B-NP	O
of	IN	B-PP	O
synergy	NN	B-NP	O
between	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	O	O
a	DT	B-NP	O
novel	JJ	I-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
,	,	O	O
CNSB002	NN	B-NP	O
,	,	O	O
in	IN	B-PP	O
rat	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
and	CC	I-NP	O
neuropathic	JJ	I-NP	B
pain	NN	I-NP	I
.	.	O	O

This	DT	B-NP	O
study	NN	I-NP	O
determined	VBD	B-VP	O
the	DT	B-NP	O
antihyperalgesic	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
CNSB002	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
sodium	NN	I-NP	O
channel	NN	I-NP	O
blocker	NN	I-NP	O
with	IN	B-PP	O
antioxidant	JJ	B-NP	O
properties	NNS	I-NP	O
given	VBN	B-VP	O
alone	RB	B-ADVP	O
and	CC	O	O
in	IN	B-PP	O
combinations	NNS	B-NP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
models	NNS	I-NP	O
of	IN	B-PP	O
inflammatory	JJ	B-NP	O
and	CC	I-NP	O
neuropathic	JJ	I-NP	B
pain	NN	I-NP	I
.	.	O	O

Dose	NN	B-NP	O
response	NN	I-NP	O
curves	NNS	I-NP	O
for	IN	B-PP	O
nonsedating	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
and	CC	I-NP	O
CNSB002	NN	I-NP	O
given	VBN	B-VP	O
intraperitoneally	RB	B-ADVP	O
alone	RB	I-ADVP	O
and	CC	I-ADVP	O
together	RB	I-ADVP	O
in	IN	B-PP	O
combinations	NNS	B-NP	O
were	VBD	B-VP	O
constructed	VBN	I-VP	O
for	IN	B-PP	O
antihyperalgesic	JJ	B-NP	O
effect	NN	I-NP	O
using	VBG	B-VP	O
paw	NN	B-NP	O
withdrawal	NN	I-NP	O
from	IN	B-PP	O
noxious	JJ	B-NP	O
heat	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
rat	NN	I-NP	O
pain	NN	I-NP	B
models	NNS	I-NP	O
:	:	O	O
carrageenan	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
paw	NN	I-NP	O
inflammation	NN	I-NP	B
and	CC	O	O
streptozotocin	NN	B-NP	O
(	(	O	O
STZ	NN	B-NP	O
)	)	O	O
-	HYPH	O	O
induced	VBN	B-NP	O
diabetic	JJ	I-NP	B
neuropathy	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
nonsedating	JJ	I-NP	O
doses	NNS	I-NP	O
were	VBD	B-VP	O
:	:	O	O
morphine	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
CNSB002	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
;	:	O	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
CNSB002	NN	I-NP	O
with	IN	B-PP	O
morphine	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
doses	NNS	I-NP	O
calculated	VBN	B-VP	O
to	TO	B-VP	O
cause	VB	I-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
hyperalgesia	NN	B-NP	B
(	(	O	O
ED50	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
carrageenan	NN	I-NP	O
model	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
STZ	NN	I-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
neuropathy	NN	I-NP	B
model	NN	I-NP	O
for	IN	B-PP	O
CNSB002	NN	B-NP	O
and	CC	I-NP	O
morphine	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
(	(	O	O
mg	NN	B-NP	O
/	SYM	O	O
kg	NN	B-NP	O
;	:	O	O
mean	NN	B-NP	O
,	,	I-NP	O
SEM	NN	I-NP	O
)	)	O	O
.	.	O	O

These	DT	B-NP	O
values	NNS	I-NP	O
were	VBD	B-VP	O
greater	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
maximum	JJ	I-NP	O
nonsedating	JJ	I-NP	O
doses	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
ED50	NN	I-NP	O
values	NNS	I-NP	O
for	IN	B-PP	O
morphine	NN	B-NP	O
when	WRB	B-ADVP	O
given	VBN	B-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
CNSB002	NN	B-NP	O
were	VBD	B-VP	O
less	JJR	B-ADJP	O
than	IN	B-PP	O
the	DT	B-NP	O
maximum	NN	I-NP	O
nonsedating	JJ	I-NP	O
dose	NN	I-NP	O
:	:	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
carrageenan	NN	I-NP	O
model	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
neuropathy	NN	I-NP	B
model	NN	I-NP	O
(	(	O	O
mg	NN	B-NP	O
/	SYM	O	O
kg	NN	B-NP	O
;	:	O	O
mean	NN	B-NP	O
,	,	I-NP	O
SEM	NN	I-NP	O
)	)	O	O
.	.	O	O

The	DT	B-NP	O
antinociception	NN	I-NP	O
after	IN	B-PP	O
morphine	NN	B-NP	O
was	VBD	B-VP	O
increased	VBN	I-VP	O
by	IN	B-PP	O
co	AFX	B-NP	O
-	HYPH	I-NP	O
administration	NN	I-NP	O
with	IN	B-PP	O
CNSB002	NN	B-NP	O
from	IN	B-PP	O
num	CD	B-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
and	CC	I-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
reversal	NN	I-NP	O
of	IN	B-PP	O
hyperalgesia	NN	B-NP	B
in	IN	B-PP	O
the	DT	B-NP	O
inflammatory	JJ	I-NP	O
and	CC	I-NP	O
neuropathic	JJ	I-NP	B
models	NNS	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

The	DT	B-NP	O
maximum	JJ	I-NP	O
antihyperalgesic	JJ	I-NP	O
effect	NN	I-NP	O
achievable	JJ	B-ADJP	O
with	IN	B-PP	O
nonsedating	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
morphine	NN	B-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
increased	VBN	I-VP	O
significantly	RB	B-ADVP	O
when	WRB	B-ADVP	O
the	DT	B-NP	O
drug	NN	I-NP	O
is	VBZ	B-VP	O
used	VBN	I-VP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
CNSB002	NN	B-NP	O
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
thrombocytopenia	NN	I-NP	B
:	:	O	O
a	DT	B-NP	O
practical	JJ	I-NP	O
review	NN	I-NP	O
.	.	O	O

Heparin	NN	B-NP	O
-	HYPH	B-PP	O
induced	VBN	B-NP	O
thrombocytopenia	NN	I-NP	B
(	(	O	O
HIT	NN	B-NP	B
)	)	O	O
remains	VBZ	B-VP	O
under	IN	B-PP	O
-	HYPH	B-NP	O
recognized	VBN	B-VP	O
despite	IN	B-PP	O
its	PRP$	B-NP	O
potentially	RB	I-NP	O
devastating	VBG	I-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

It	PRP	B-NP	O
begins	VBZ	B-VP	O
when	WRB	B-ADVP	O
heparin	NN	B-NP	O
exposure	NN	I-NP	O
stimulates	VBZ	B-VP	O
the	DT	B-NP	O
formation	NN	I-NP	O
of	IN	B-PP	O
heparin	NN	B-NP	O
-	HYPH	B-NP	O
platelet	NN	I-NP	O
factor	NN	I-NP	O
num	CD	B-NP	O
antibodies	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
in	IN	B-PP	O
turn	NN	B-NP	O
triggers	VBZ	B-VP	O
the	DT	B-NP	O
release	NN	I-NP	O
of	IN	B-PP	O
procoagulant	JJ	B-NP	O
platelet	NN	I-NP	O
particles	NNS	I-NP	O
.	.	O	O

Thrombosis	NN	B-NP	B
and	CC	I-NP	O
thrombocytopenia	NN	I-NP	B
that	WDT	B-NP	O
follow	VBP	B-VP	O
comprise	VB	I-VP	O
the	DT	B-NP	O
num	CD	I-NP	O
hallmark	NN	I-NP	O
traits	NNS	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
,	,	O	O
with	IN	B-PP	O
the	DT	B-NP	O
former	JJ	I-NP	O
largely	RB	B-ADJP	O
responsible	JJ	I-ADJP	O
for	IN	B-PP	O
significant	JJ	B-NP	O
vascular	JJ	I-NP	O
complications	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
prevalence	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
varies	VBZ	B-VP	O
among	IN	B-PP	O
several	JJ	B-NP	O
subgroups	NNS	I-NP	O
,	,	O	O
with	IN	B-PP	O
greater	JJR	B-NP	O
incidence	NN	I-NP	O
in	IN	B-PP	O
surgical	JJ	B-NP	O
as	IN	B-PP	O
compared	VBN	B-PP	O
with	IN	B-PP	O
medical	JJ	B-NP	O
populations	NNS	I-NP	O
.	.	O	O

HIT	NN	B-NP	B
must	MD	B-VP	O
be	VB	I-VP	O
acknowledged	VBN	I-VP	O
for	IN	B-PP	O
its	PRP$	B-NP	O
intense	JJ	I-NP	O
predilection	NN	I-NP	O
for	IN	B-PP	O
thrombosis	NN	B-NP	B
and	CC	O	O
suspected	VBN	B-VP	O
whenever	WRB	B-ADVP	O
thrombosis	NN	B-NP	B
occurs	VBZ	B-VP	O
after	IN	B-PP	O
heparin	NN	B-NP	O
exposure	NN	I-NP	O
.	.	O	O

Early	JJ	B-NP	O
recognition	NN	I-NP	O
that	WDT	B-NP	O
incorporates	VBZ	B-VP	O
the	DT	B-NP	O
clinical	JJ	I-NP	O
and	CC	I-NP	O
serologic	JJ	I-NP	O
clues	NNS	I-NP	O
is	VBZ	B-VP	O
paramount	JJ	B-ADJP	O
to	TO	B-PP	O
timely	JJ	B-NP	O
institution	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
,	,	O	O
as	IN	B-SBAR	O
its	PRP$	B-NP	O
delay	NN	I-NP	O
may	MD	B-VP	O
result	VB	I-VP	O
in	IN	B-PP	O
catastrophic	JJ	B-NP	O
outcomes	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
treatment	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
mandates	VBZ	B-VP	O
an	DT	B-NP	O
immediate	JJ	I-NP	O
cessation	NN	I-NP	O
of	IN	B-PP	O
all	DT	B-NP	O
heparin	NN	I-NP	O
exposure	NN	I-NP	O
and	CC	O	O
the	DT	B-NP	O
institution	NN	I-NP	O
of	IN	B-PP	O
an	DT	B-NP	O
antithrombotic	JJ	I-NP	O
therapy	NN	I-NP	O
,	,	O	O
most	RBS	B-ADVP	O
commonly	RB	I-ADVP	O
using	VBG	B-VP	O
a	DT	B-NP	O
direct	JJ	I-NP	O
thrombin	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

Current	JJ	B-NP	O
diagnostic	JJ	I-NP	O
tests	NNS	I-NP	O
,	,	O	O
which	WDT	B-NP	O
primarily	RB	B-ADVP	O
include	VBP	B-VP	O
functional	JJ	B-NP	O
and	CC	I-NP	O
antigenic	JJ	I-NP	O
assays	NNS	I-NP	O
,	,	O	O
have	VBP	B-VP	O
more	JJR	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
confirmatory	JJ	I-NP	O
than	IN	B-PP	O
diagnostic	JJ	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
management	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
.	.	O	O

Special	JJ	B-NP	O
attention	NN	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
paid	VBN	I-VP	O
to	TO	B-PP	O
cardiac	JJ	B-NP	O
patients	NNS	I-NP	O
who	WP	B-NP	O
are	VBP	B-VP	O
often	RB	I-VP	O
exposed	VBN	I-VP	O
to	TO	B-VP	O
heparin	VB	I-VP	O
multiple	JJ	B-NP	O
times	NNS	I-NP	O
during	IN	B-PP	O
their	PRP$	B-NP	O
course	NN	I-NP	O
of	IN	B-PP	O
treatment	NN	B-NP	O
.	.	O	O

Direct	JJ	B-NP	O
thrombin	NN	I-NP	O
inhibitors	NNS	I-NP	O
are	VBP	B-VP	O
appropriate	JJ	B-ADJP	O
,	,	O	O
evidence	NN	B-NP	O
-	HYPH	O	O
based	VBN	B-VP	O
alternatives	NNS	B-NP	O
to	TO	B-PP	O
heparin	NN	B-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
HIT	NN	B-NP	B
,	,	O	O
who	WP	B-NP	O
need	VBP	B-VP	O
to	TO	I-VP	O
undergo	VB	I-VP	O
percutaneous	JJ	B-NP	O
coronary	JJ	I-NP	O
intervention	NN	I-NP	O
.	.	O	O

As	IN	B-SBAR	O
heparin	NN	B-NP	O
remains	VBZ	B-VP	O
num	CD	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
most	RBS	I-NP	O
frequently	RB	I-NP	O
used	VBN	I-NP	O
medications	NNS	I-NP	O
today	NN	B-NP	O
with	IN	B-PP	O
potential	NN	B-NP	O
for	IN	B-PP	O
HIT	NN	B-NP	B
with	IN	B-PP	O
every	DT	B-NP	O
heparin	NN	I-NP	O
exposure	NN	I-NP	O
,	,	O	O
a	DT	B-NP	O
close	JJ	I-NP	O
vigilance	NN	I-NP	O
of	IN	B-PP	O
platelet	NN	B-NP	O
counts	NNS	I-NP	O
must	MD	B-VP	O
be	VB	I-VP	O
practiced	VBN	I-VP	O
whenever	WRB	B-ADVP	O
heparin	NN	B-NP	O
is	VBZ	B-VP	O
initiated	VBN	I-VP	O
.	.	O	O

Abductor	NN	B-NP	O
paralysis	NN	I-NP	B
after	IN	B-PP	O
botox	NN	B-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
adductor	NN	B-NP	B
spasmodic	JJ	I-NP	I
dysphonia	NN	I-NP	I
.	.	O	O

Botulinum	NN	B-NP	O
toxin	NN	I-NP	O
(	(	O	O
Botox	NN	B-NP	O
)	)	O	O
injections	NNS	B-NP	O
into	IN	B-PP	O
the	DT	B-NP	O
thyroarytenoid	JJ	I-NP	O
muscles	NNS	I-NP	O
are	VBP	B-VP	O
the	DT	B-NP	O
current	JJ	I-NP	O
standard	NN	I-NP	O
of	IN	B-PP	O
care	NN	B-NP	O
for	IN	B-PP	O
adductor	NN	B-NP	B
spasmodic	JJ	I-NP	I
dysphonia	NN	I-NP	I
(	(	O	O
ADSD	NN	B-NP	B
)	)	O	O
.	.	O	O

Reported	VBN	B-NP	O
adverse	JJ	I-NP	O
effects	NNS	I-NP	O
include	VBP	B-VP	O
a	DT	B-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
breathiness	NN	B-NP	O
,	,	O	O
throat	DT	B-NP	B
pain	NN	I-NP	I
,	,	O	O
and	CC	O	O
difficulty	NN	B-NP	O
with	IN	B-PP	O
swallowing	VBG	B-NP	O
liquids	NNS	I-NP	O
.	.	O	O

Here	RB	B-ADVP	O
we	PRP	B-NP	O
report	VBP	B-VP	O
multiple	JJ	B-NP	O
cases	NNS	I-NP	O
of	IN	B-PP	O
bilateral	JJ	B-NP	O
abductor	NN	I-NP	O
paralysis	NN	I-NP	B
following	VBG	B-PP	O
Botox	NN	B-NP	O
injections	NNS	I-NP	O
for	IN	B-PP	O
ADSD	NN	B-NP	B
,	,	O	O
a	DT	B-NP	O
complication	NN	I-NP	O
previously	RB	B-ADJP	O
unreported	JJ	I-ADJP	O
.	.	O	O

Retrospective	JJ	B-NP	O
case	NN	I-NP	O
series	NN	I-NP	O
.	.	O	O

Patients	NNS	B-NP	O
that	WDT	B-NP	O
received	VBD	B-VP	O
Botox	NN	B-NP	O
injections	NNS	I-NP	O
for	IN	B-PP	O
spasmodic	JJ	B-NP	B
dysphonia	NN	I-NP	I
between	IN	B-PP	O
January	NNP	B-NP	O
num	CD	I-NP	O
and	CC	O	O
October	NNP	B-NP	O
num	CD	I-NP	O
were	VBD	B-VP	O
evaluated	VBN	I-VP	O
.	.	O	O

Patients	NNS	B-NP	O
with	IN	B-PP	O
ADSD	NN	B-NP	B
were	VBD	B-VP	O
identified	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
treatments	NNS	B-NP	O
received	VBN	B-VP	O
and	CC	O	O
adverse	JJ	B-NP	O
effects	NNS	I-NP	O
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

For	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
bilateral	JJ	B-NP	O
abductor	NN	I-NP	O
paralysis	NN	I-NP	B
,	,	O	O
age	NN	B-NP	O
,	,	O	O
sex	NN	B-NP	O
,	,	O	O
paralytic	JJ	B-NP	O
Botox	NN	I-NP	O
dose	NN	I-NP	O
,	,	O	O
prior	JJ	B-NP	O
Botox	NN	I-NP	O
dose	NN	I-NP	O
,	,	O	O
and	CC	O	O
course	NN	B-NP	O
following	VBG	B-PP	O
paralysis	NN	B-NP	B
were	VBD	B-VP	O
noted	VBN	I-VP	O
.	.	O	O

From	IN	B-PP	O
a	DT	B-NP	O
database	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
patients	NNS	I-NP	O
receiving	VBG	B-VP	O
Botox	NN	B-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
been	VBN	I-VP	O
diagnosed	VBN	I-VP	O
with	IN	B-PP	O
ADSD	NN	B-NP	B
.	.	O	O

Of	IN	B-PP	O
these	DT	B-NP	O
num	CD	I-NP	O
patients	NNS	I-NP	O
,	,	O	O
num	CD	B-NP	O
patients	NNS	I-NP	O
suffered	VBD	B-VP	O
bilateral	JJ	B-NP	O
abductor	NN	I-NP	O
paralysis	NN	I-NP	B
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
suffered	VBD	B-VP	O
this	DT	B-NP	O
complication	NN	I-NP	O
twice	RB	B-ADVP	O
.	.	O	O

All	DT	B-NP	O
affected	VBN	I-NP	O
patients	NNS	I-NP	O
were	VBD	B-VP	O
females	NNS	B-NP	O
over	IN	B-PP	O
the	DT	B-NP	O
age	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Most	JJS	B-NP	O
patients	NNS	I-NP	O
had	VBD	B-VP	O
received	VBN	I-VP	O
treatments	NNS	B-NP	O
prior	RB	B-ADVP	O
to	TO	B-PP	O
abductor	NN	B-NP	O
paralysis	NN	I-NP	B
and	CC	O	O
continued	VBD	B-VP	O
receiving	VBG	I-VP	O
after	IN	B-PP	O
paralysis	NN	B-NP	B
.	.	O	O

num	CD	B-NP	O
patients	NNS	I-NP	O
recovered	VBD	B-VP	O
after	IN	B-PP	O
a	DT	B-NP	O
brief	JJ	I-NP	O
period	NN	I-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
restrictions	NNS	I-NP	O
,	,	O	O
and	CC	O	O
num	CD	B-NP	O
underwent	VBD	B-VP	O
a	DT	B-NP	O
tracheotomy	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
incidence	NN	I-NP	O
of	IN	B-PP	O
abductor	NN	B-NP	O
paralysis	NN	I-NP	B
after	IN	B-PP	O
Botox	NN	B-NP	O
injection	NN	I-NP	O
for	IN	B-PP	O
ADSD	NN	B-NP	B
was	VBD	B-VP	O
num	CD	B-NP	O
%	NN	I-NP	O
.	.	O	O

Bilateral	JJ	B-NP	O
abductor	NN	I-NP	O
paralysis	NN	I-NP	B
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
complication	NN	I-NP	O
of	IN	B-PP	O
Botox	NN	B-NP	O
injections	NNS	I-NP	O
for	IN	B-PP	O
ADSD	NN	B-NP	B
,	,	O	O
causing	VBG	B-VP	O
difficulty	NN	B-NP	O
with	IN	B-PP	O
breathing	NN	B-NP	O
upon	IN	B-PP	O
exertion	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
likely	JJ	I-NP	O
mechanism	NN	I-NP	O
of	IN	B-PP	O
paralysis	NN	B-NP	B
is	VBZ	B-VP	O
diffusion	NN	B-NP	O
of	IN	B-PP	O
Botox	NNP	B-NP	O
around	IN	B-PP	O
the	DT	B-NP	O
muscular	JJ	I-NP	O
process	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
arytenoid	NN	I-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
posterior	JJ	I-NP	O
cricoarytenoid	JJ	I-NP	O
muscles	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
paralysis	NN	I-NP	B
is	VBZ	B-VP	O
temporary	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
watchful	JJ	B-NP	O
waiting	NN	I-NP	O
with	IN	B-PP	O
restriction	NN	B-NP	O
of	IN	B-PP	O
activity	NN	B-NP	O
is	VBZ	B-VP	O
the	DT	B-NP	O
recommended	VBN	I-NP	O
management	NN	I-NP	O
.	.	O	O

Mitochondrial	JJ	B-NP	B
impairment	NN	I-NP	I
contributes	VBZ	B-VP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
:	:	O	O
Prevention	NN	B-NP	O
by	IN	B-PP	O
the	DT	B-NP	O
targeted	VBN	I-NP	O
antioxidant	NN	I-NP	O
MitoQ	NNP	I-NP	O
.	.	O	O

The	DT	B-NP	O
goal	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
assess	VB	I-VP	O
mitochondrial	JJ	B-NP	O
function	NN	I-NP	O
and	CC	I-NP	O
ROS	NN	I-NP	O
production	NN	I-NP	O
in	IN	B-PP	O
an	DT	B-NP	O
experimental	JJ	I-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
.	.	O	O

We	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	B
abuse	NN	I-NP	I
may	MD	B-VP	O
lead	VB	I-VP	O
to	TO	B-PP	O
altered	JJ	B-NP	O
mitochondrial	JJ	I-NP	O
function	NN	I-NP	O
that	IN	B-NP	O
in	IN	B-PP	O
turn	NN	B-NP	O
may	MD	B-VP	O
cause	VB	I-VP	O
left	JJ	B-NP	B
ventricular	JJ	I-NP	I
dysfunction	NN	I-NP	I
.	.	O	O

num	CD	B-NP	O
days	NNS	I-NP	O
of	IN	B-PP	O
cocaine	NN	B-NP	O
administration	NN	I-NP	O
to	TO	B-PP	O
rats	NNS	B-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
an	DT	B-NP	O
increased	VBN	I-NP	O
oxygen	NN	I-NP	O
consumption	NN	I-NP	O
detected	VBN	B-VP	O
in	IN	B-PP	O
cardiac	JJ	B-NP	O
fibers	NNS	I-NP	O
,	,	O	O
specifically	RB	B-ADVP	O
through	IN	B-PP	O
complex	NN	B-NP	O
num	CD	I-NP	O
and	CC	O	O
complex	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

ROS	NN	B-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
increased	VBN	I-VP	O
,	,	O	O
specifically	RB	B-ADVP	O
in	IN	B-PP	O
interfibrillar	JJ	B-NP	O
mitochondria	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
parallel	NN	B-NP	O
there	EX	B-NP	O
was	VBD	B-VP	O
a	DT	B-NP	O
decrease	NN	I-NP	O
in	IN	B-PP	O
ATP	NN	B-NP	O
synthesis	NN	I-NP	O
,	,	O	O
whereas	IN	O	O
no	DT	B-NP	O
difference	NN	I-NP	O
was	VBD	B-VP	O
observed	VBN	I-VP	O
in	IN	B-PP	O
subsarcolemmal	JJ	B-NP	O
mitochondria	NNS	I-NP	O
.	.	O	O

This	DT	B-NP	O
uncoupling	JJ	I-NP	O
effect	NN	I-NP	O
on	IN	B-PP	O
oxidative	JJ	B-NP	O
phosphorylation	NN	I-NP	O
was	VBD	B-VP	O
not	RB	O	O
detectable	JJ	B-ADJP	O
after	IN	B-PP	O
short	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
exposure	NN	I-NP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
these	DT	B-NP	O
mitochondrial	JJ	I-NP	B
abnormalities	NNS	I-NP	I
were	VBD	B-VP	O
a	DT	O	O
late	JJ	O	O
rather	RB	B-CONJP	O
than	IN	I-CONJP	O
a	DT	B-NP	O
primary	JJ	I-NP	O
event	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathological	JJ	I-NP	O
response	NN	I-NP	O
to	TO	B-PP	O
cocaine	NN	B-NP	O
.	.	O	O

MitoQ	NNP	B-NP	O
,	,	O	O
a	DT	B-NP	O
mitochondrial	JJ	I-NP	O
-	HYPH	I-NP	O
targeted	VBN	I-NP	O
antioxidant	NN	I-NP	O
,	,	O	O
was	VBD	B-VP	O
shown	VBN	I-VP	O
to	TO	I-VP	O
completely	RB	I-VP	O
prevent	VB	I-VP	O
these	DT	B-NP	O
mitochondrial	JJ	I-NP	B
abnormalities	NNS	I-NP	I
as	RB	B-CONJP	O
well	RB	I-CONJP	O
as	IN	I-CONJP	O
cardiac	JJ	B-NP	B
dysfunction	NN	I-NP	I
characterized	VBN	B-VP	O
here	RB	B-ADVP	O
by	IN	B-PP	O
a	DT	B-NP	O
diastolic	JJ	I-NP	B
dysfunction	NN	I-NP	I
studied	VBN	B-VP	O
with	IN	B-PP	O
a	DT	B-NP	O
conductance	NN	I-NP	O
catheter	NN	I-NP	O
to	TO	B-VP	O
obtain	VB	I-VP	O
pressure	NN	B-NP	O
-	HYPH	B-NP	O
volume	NN	I-NP	O
data	NNS	I-NP	O
.	.	O	O

Taken	VBN	B-VP	O
together	RB	B-ADVP	O
,	,	O	O
these	DT	B-NP	O
results	NNS	I-NP	O
extend	VBP	B-VP	O
previous	JJ	B-NP	O
studies	NNS	I-NP	O
and	CC	O	O
demonstrate	VBP	B-VP	O
that	IN	B-SBAR	O
cocaine	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
cardiac	JJ	I-NP	B
dysfunction	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
due	JJ	B-ADVP	O
to	TO	B-PP	O
a	DT	B-NP	O
mitochondrial	JJ	I-NP	B
defect	NN	I-NP	I
.	.	O	O

Trimethoprim	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
in	IN	B-PP	O
a	DT	B-NP	O
pediatric	JJ	I-NP	O
oncology	NN	I-NP	O
patient	NN	I-NP	O
presenting	VBG	B-VP	O
as	IN	B-PP	O
an	DT	B-NP	O
acute	JJ	I-NP	O
hemolytic	JJ	I-NP	O
transfusion	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	NN	I-NP	O
with	IN	B-PP	O
acute	JJ	B-NP	B
leukemia	NN	I-NP	I
presented	VBD	B-VP	O
with	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
chemotherapy	NN	I-NP	O
anemia	NN	I-NP	B
.	.	O	O

During	IN	B-PP	O
red	JJ	B-NP	O
cell	NN	I-NP	O
transfusion	NN	I-NP	O
,	,	O	O
he	PRP	B-NP	O
developed	VBD	B-VP	O
hemoglobinuria	NN	B-NP	B
.	.	O	O

Transfusion	NN	B-NP	O
reaction	NN	I-NP	O
workup	NN	I-NP	O
was	VBD	B-VP	O
negative	JJ	B-ADJP	O
.	.	O	O

Drug	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
immune	JJ	I-NP	O
hemolytic	JJ	I-NP	B
anemia	NN	I-NP	I
was	VBD	B-VP	O
suspected	VBN	I-VP	O
because	IN	B-PP	O
of	IN	I-PP	O
positive	JJ	B-NP	O
direct	JJ	I-NP	O
antiglobulin	NN	I-NP	O
test	NN	I-NP	O
,	,	O	O
negative	JJ	B-NP	O
eluate	NN	I-NP	O
,	,	O	O
and	CC	O	O
microspherocytes	NNS	B-NP	O
on	IN	B-PP	O
smear	NN	B-NP	O
pre	AFX	B-NP	O
-	HYPH	I-NP	O
and	CC	I-NP	O
post	AFX	I-NP	O
-	HYPH	I-NP	O
transfusion	NN	I-NP	O
.	.	O	O

Drug	NN	B-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
the	DT	B-NP	O
indirect	JJ	I-NP	O
antiglobulin	NN	I-NP	O
test	NN	I-NP	O
were	VBD	B-VP	O
strongly	RB	B-ADJP	O
positive	JJ	I-ADJP	O
with	IN	B-PP	O
trimethoprim	NN	B-NP	O
and	CC	I-NP	O
trimethoprim	NN	I-NP	O
-	HYPH	O	O
sulfamethoxazole	NN	B-NP	O
but	CC	O	O
negative	JJ	B-ADJP	O
with	IN	B-PP	O
sulfamethoxazole	NN	B-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
recovered	VBD	B-VP	O
after	IN	B-PP	O
discontinuing	VBG	B-VP	O
the	DT	B-NP	O
drug	NN	I-NP	O
,	,	O	O
with	IN	B-PP	O
no	DT	B-NP	O
recurrence	NN	I-NP	O
in	IN	B-PP	O
num	CD	B-NP	O
years	NNS	I-NP	O
.	.	O	O

Other	JJ	B-NP	O
causes	NNS	I-NP	O
of	IN	B-PP	O
anemia	NN	B-NP	B
should	MD	B-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
worse	JJR	B-NP	O
-	HYPH	I-NP	O
than	IN	B-PP	O
-	HYPH	B-NP	O
expected	VBN	I-NP	O
anemia	NN	I-NP	B
after	IN	B-PP	O
chemotherapy	NN	B-NP	O
.	.	O	O

Furthermore	RB	B-ADVP	O
,	,	O	O
hemolysis	NN	B-NP	B
during	IN	B-PP	O
transfusion	NN	B-NP	O
is	VBZ	B-VP	O
not	RB	O	O
always	RB	B-ADVP	O
a	DT	B-NP	O
transfusion	NN	I-NP	O
reaction	NN	I-NP	O
.	.	O	O

Blockade	NN	B-NP	O
of	IN	B-PP	O
endothelial	JJ	B-NP	O
-	HYPH	I-NP	O
mesenchymal	JJ	I-NP	O
transition	NN	I-NP	O
by	IN	B-PP	O
a	DT	B-NP	O
Smad3	NN	I-NP	O
inhibitor	NN	I-NP	O
delays	VBZ	B-VP	O
the	DT	B-NP	O
early	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

A	DT	B-NP	O
multicenter	NN	I-NP	O
,	,	O	O
controlled	VBN	B-NP	O
trial	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
early	JJ	B-NP	O
blockade	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
renin	NN	I-NP	O
-	HYPH	I-NP	O
angiotensin	NN	I-NP	O
system	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
type	NN	B-NP	B
num	CD	I-NP	I
diabetes	NNS	I-NP	I
and	CC	I-NP	O
normoalbuminuria	NN	I-NP	O
did	VBD	B-VP	O
not	RB	I-VP	O
retard	VB	I-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
nephropathy	NN	B-NP	B
,	,	O	O
suggesting	VBG	B-VP	O
that	IN	B-SBAR	O
other	JJ	B-NP	O
mechanism	NN	I-NP	O
(	(	I-NP	O
s	NNS	I-NP	O
)	)	O	O
are	VBP	B-VP	O
involved	VBN	I-VP	O
in	IN	B-PP	O
the	DT	B-NP	O
pathogenesis	NN	I-NP	O
of	IN	B-PP	O
early	JJ	B-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
(	(	O	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
)	)	O	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
previously	RB	I-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
endothelial	JJ	B-NP	O
-	HYPH	I-NP	O
mesenchymal	JJ	I-NP	O
-	HYPH	I-NP	O
transition	NN	I-NP	O
(	(	O	O
EndoMT	NN	B-NP	O
)	)	O	O
contributes	VBZ	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
early	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
renal	JJ	B-NP	O
interstitial	JJ	I-NP	O
fibrosis	NN	I-NP	B
independently	RB	B-ADVP	O
of	IN	B-PP	O
microalbuminuria	NN	B-NP	O
in	IN	B-PP	O
mice	NNS	B-NP	O
with	IN	B-PP	O
streptozotocin	NN	B-NP	O
(	(	O	O
STZ	NN	B-NP	O
)	)	O	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetes	NNS	I-NP	B
.	.	O	O

In	IN	B-PP	O
the	DT	B-NP	O
present	JJ	I-NP	O
study	NN	I-NP	O
,	,	O	O
we	PRP	B-NP	O
hypothesized	VBD	B-VP	O
that	IN	B-SBAR	O
blocking	VBG	B-VP	O
EndoMT	NNP	B-NP	O
reduces	VBZ	B-VP	O
the	DT	B-NP	O
early	JJ	I-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

EndoMT	NN	B-NP	O
was	VBD	B-VP	O
induced	VBN	I-VP	O
in	IN	B-PP	O
a	DT	B-NP	O
mouse	NN	I-NP	O
pancreatic	JJ	I-NP	O
microvascular	JJ	I-NP	O
endothelial	JJ	I-NP	O
cell	NN	I-NP	O
line	NN	I-NP	O
(	(	O	O
MMEC	NN	B-NP	O
)	)	O	O
in	IN	B-PP	O
the	DT	B-NP	O
presence	NN	I-NP	O
of	IN	B-PP	O
advanced	VBN	B-NP	O
glycation	NN	I-NP	O
end	NN	I-NP	O
products	NNS	I-NP	O
(	(	O	O
AGEs	NNS	B-NP	O
)	)	O	O
and	CC	O	O
in	IN	B-PP	O
the	DT	B-NP	O
endothelial	JJ	I-NP	O
lineage	NN	I-NP	O
-	HYPH	B-NP	O
traceble	JJ	I-NP	O
mouse	NN	I-NP	O
line	NN	I-NP	O
Tie2	NN	I-NP	O
-	HYPH	B-NP	O
Cre	NN	I-NP	O
;	:	O	O
Loxp	NN	B-NP	O
-	HYPH	O	O
EGFP	NN	B-NP	O
by	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
AGEs	NNS	B-NP	O
,	,	O	O
with	IN	B-PP	O
nonglycated	JJ	B-NP	O
mouse	NN	I-NP	O
albumin	NN	I-NP	O
serving	VBG	B-VP	O
as	IN	B-PP	O
a	DT	B-NP	O
control	NN	I-NP	O
.	.	O	O

Phosphorylated	VBN	B-NP	O
Smad3	NN	I-NP	O
was	VBD	B-VP	O
detected	VBN	I-VP	O
by	IN	B-PP	O
immunoprecipitation	NN	B-NP	O
/	SYM	O	O
Western	NN	B-NP	O
blotting	NN	I-NP	O
and	CC	O	O
confocal	JJ	B-NP	O
microscopy	NN	I-NP	O
.	.	O	O

Blocking	NN	B-NP	O
studies	NNS	I-NP	O
using	VBG	B-VP	O
receptor	NN	B-NP	O
for	IN	B-PP	O
AGE	NN	B-NP	O
siRNA	NN	I-NP	O
and	CC	O	O
a	DT	B-NP	O
specific	JJ	I-NP	O
inhibitor	NN	I-NP	O
of	IN	B-PP	O
Smad3	NN	B-NP	O
(	(	O	O
SIS3	NN	B-NP	O
)	)	O	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
in	IN	B-PP	O
MMECs	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
in	IN	B-PP	O
Tie2	NN	B-NP	O
-	HYPH	B-NP	O
Cre	NN	I-NP	O
;	:	O	O
Loxp	NN	B-NP	O
-	HYPH	I-NP	O
EGFP	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Confocal	JJ	B-NP	O
microscopy	NN	I-NP	O
and	CC	O	O
real	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
PCR	NN	I-NP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
AGEs	NNS	B-NP	O
induced	VBD	B-VP	O
EndoMT	NN	B-NP	O
in	IN	B-PP	O
MMECs	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
Tie2	NN	B-NP	O
-	HYPH	B-NP	O
Cre	NN	I-NP	O
;	:	O	O
Loxp	NN	B-NP	O
-	HYPH	I-NP	O
EGFP	NN	I-NP	O
mice	NNS	I-NP	O
.	.	O	O

Immunoprecipitation	NN	B-NP	O
/	SYM	I-NP	O
Western	NN	I-NP	O
blotting	NN	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
Smad3	NN	B-NP	O
was	VBD	B-VP	O
activated	VBN	I-VP	O
by	IN	B-PP	O
AGEs	NNS	B-NP	O
but	CC	O	O
was	VBD	B-VP	O
inhibited	VBN	I-VP	O
by	IN	B-PP	O
SIS3	NN	B-NP	O
in	IN	B-PP	O
MMECs	NNS	B-NP	O
and	CC	B-PP	O
in	IN	B-PP	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
diabetic	JJ	I-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

Confocal	JJ	B-NP	O
microscopy	NN	I-NP	O
and	CC	O	O
real	JJ	B-NP	O
-	HYPH	I-NP	O
time	NN	I-NP	O
PCR	NN	I-NP	O
further	RBR	B-ADVP	O
demonstrated	VBD	B-VP	O
that	IN	B-SBAR	O
SIS3	NN	B-NP	O
abrogated	VBD	B-VP	O
EndoMT	NNP	B-NP	O
,	,	O	O
reduced	VBD	B-VP	O
renal	JJ	B-NP	O
fibrosis	NN	I-NP	B
,	,	O	O
and	CC	O	O
retarded	VBN	B-VP	O
progression	NN	B-NP	O
of	IN	B-PP	O
nephropathy	NN	B-NP	B
.	.	O	O

EndoMT	NN	B-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
novel	JJ	I-NP	O
pathway	NN	I-NP	O
leading	VBG	B-VP	O
to	TO	B-PP	O
early	JJ	B-NP	O
development	NN	I-NP	O
of	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
.	.	O	O

Blockade	NN	B-NP	O
of	IN	B-PP	O
EndoMT	NN	B-NP	O
by	IN	B-PP	O
SIS3	NN	B-NP	O
may	MD	B-VP	O
provide	VB	I-VP	O
a	DT	B-NP	O
new	JJ	I-NP	O
strategy	NN	I-NP	O
to	TO	B-VP	O
retard	VB	I-VP	O
the	DT	B-NP	O
progression	NN	I-NP	O
of	IN	B-PP	O
diabetic	JJ	B-NP	B
nephropathy	NN	I-NP	I
and	CC	O	O
other	JJ	B-NP	O
diabetes	NN	I-NP	B
complications	NNS	I-NP	I
.	.	O	O

Cytostatic	JJ	B-ADJP	O
and	CC	O	O
anti	AFX	O	O
-	HYPH	O	O
angiogenic	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
temsirolimus	NN	B-NP	O
in	IN	B-PP	O
refractory	JJ	B-NP	O
mantle	NN	I-NP	B
cell	NN	I-NP	I
lymphoma	NN	I-NP	I
.	.	O	O

Mantle	NN	B-NP	B
cell	NN	I-NP	I
lymphoma	NN	I-NP	I
(	(	O	O
MCL	NN	B-NP	B
)	)	O	O
is	VBZ	B-VP	O
a	DT	B-NP	O
rare	JJ	I-NP	O
and	CC	I-NP	O
aggressive	JJ	I-NP	O
type	NN	I-NP	O
of	IN	B-PP	O
B	NN	B-NP	B
-	HYPH	B-NP	I
cell	NN	I-NP	I
non	AFX	I-NP	I
-	HYPH	I-NP	I
Hodgkin	NNP	I-NP	I
s	NN	I-NP	I
lymphoma	NN	I-NP	I
.	.	O	O

Patients	NNS	B-NP	O
become	VBP	B-VP	O
progressively	RB	B-ADJP	O
refractory	JJ	I-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
chemotherapy	NN	I-NP	O
,	,	O	O
and	CC	O	O
their	PRP$	B-NP	O
prognosis	NN	I-NP	O
is	VBZ	B-VP	O
poor	JJ	B-ADJP	O
.	.	O	O

However	RB	B-ADVP	O
,	,	O	O
a	DT	B-NP	O
num	CD	I-NP	O
%	NN	I-NP	O
remission	NN	I-NP	O
rate	NN	I-NP	O
has	VBZ	B-VP	O
been	VBN	I-VP	O
recently	RB	I-VP	O
reported	VBN	I-VP	O
in	IN	B-PP	O
refractory	JJ	B-NP	O
MCL	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
temsirolimus	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
mTOR	NN	I-NP	O
inhibitor.Here	NN	I-NP	O
we	PRP	B-NP	O
had	VBD	B-VP	O
the	DT	B-NP	O
opportunity	NN	I-NP	O
to	TO	B-VP	O
study	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
refractory	JJ	B-NP	O
MCL	NN	I-NP	B
who	WP	B-NP	O
had	VBD	B-VP	O
tumor	NN	B-NP	B
regression	NN	I-NP	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
temsirolimus	NN	B-NP	O
treatment	NN	I-NP	O
,	,	O	O
and	CC	O	O
a	DT	B-NP	O
progression	NN	I-NP	O
-	HYPH	B-NP	O
free	JJ	I-NP	O
survival	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
months	NNS	I-NP	O
.	.	O	O

In	IN	B-PP	O
this	DT	B-NP	O
case	NN	I-NP	O
,	,	O	O
lymph	NN	B-NP	O
node	NN	I-NP	O
biopsies	NNS	I-NP	O
were	VBD	B-VP	O
performed	VBN	I-VP	O
before	IN	B-PP	O
and	CC	O	O
num	CD	B-NP	O
months	NNS	I-NP	O
after	IN	B-SBAR	O
temsirolimus	NN	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Comparison	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
num	CD	I-NP	O
biopsies	NNS	I-NP	O
showed	VBD	B-VP	O
that	IN	B-SBAR	O
temsirolimus	NN	B-NP	O
inhibited	VBD	B-VP	O
tumor	NN	B-NP	B
cell	NN	I-NP	O
proliferation	NN	I-NP	O
through	IN	B-PP	O
cell	NN	B-NP	O
cycle	NN	I-NP	O
arrest	NN	I-NP	O
,	,	O	O
but	CC	O	O
did	VBD	B-VP	O
not	RB	I-VP	O
induce	VB	I-VP	O
any	DT	B-NP	O
change	NN	I-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
number	NN	I-NP	O
of	IN	B-PP	O
apoptotic	JJ	B-NP	O
tumor	NN	I-NP	B
cells	NNS	I-NP	O
.	.	O	O

Apart	RB	B-ADVP	O
from	IN	B-PP	O
this	DT	B-NP	O
cytostatic	JJ	I-NP	O
effect	NN	I-NP	O
,	,	O	O
temsirolimus	NN	B-NP	O
had	VBD	B-VP	O
an	DT	B-NP	O
antiangiogenic	JJ	I-NP	O
effect	NN	I-NP	O
with	IN	B-PP	O
decrease	NN	B-NP	O
of	IN	B-PP	O
tumor	NN	B-NP	B
microvessel	NN	I-NP	O
density	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
VEGF	NN	B-NP	O
expression	NN	I-NP	O
.	.	O	O

Moreover	RB	B-ADVP	O
,	,	O	O
numerous	JJ	B-NP	O
patchy	NN	I-NP	O
,	,	O	O
well	RB	B-NP	O
-	HYPH	I-NP	O
limited	JJ	I-NP	O
fibrotic	JJ	I-NP	O
areas	NNS	I-NP	O
,	,	O	O
compatible	JJ	B-ADJP	O
with	IN	B-PP	O
post	AFX	B-NP	O
-	HYPH	I-NP	O
necrotic	JJ	I-NP	B
tissue	NN	I-NP	O
repair	NN	I-NP	O
,	,	O	O
were	VBD	B-VP	O
found	VBN	I-VP	O
after	IN	B-PP	O
num	CD	B-NP	O
-	HYPH	I-NP	O
month	NN	I-NP	O
temsirolimus	NN	I-NP	O
therapy	NN	I-NP	O
.	.	O	O

Thus	RB	B-ADVP	O
,	,	O	O
temsirolimus	NN	B-NP	O
reduced	VBD	B-VP	O
tumor	NN	B-NP	B
burden	NN	I-NP	O
through	IN	B-PP	O
associated	VBN	B-NP	O
cytostatic	JJ	I-NP	O
and	CC	O	O
anti	AFX	O	O
-	HYPH	B-NP	O
angiogenic	JJ	I-NP	O
effects.This	NN	I-NP	O
dual	JJ	I-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
temsirolimus	NN	B-NP	O
on	IN	B-PP	O
tumor	NN	B-NP	B
tissue	NN	I-NP	O
could	MD	B-VP	O
contribute	VB	I-VP	O
to	TO	B-PP	O
its	PRP$	B-NP	O
recently	RB	I-NP	O
reported	VBN	I-NP	O
efficiency	NN	I-NP	O
in	IN	B-PP	O
refractory	JJ	B-NP	O
MCL	NN	I-NP	B
resistant	JJ	B-ADJP	O
to	TO	B-PP	O
conventional	JJ	B-NP	O
chemotherapy	NN	I-NP	O
.	.	O	O

Syncope	NN	B-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
hyperkalemia	NN	B-NP	B
during	IN	B-PP	O
use	NN	B-NP	O
of	IN	B-PP	O
a	DT	B-NP	O
combined	JJ	I-NP	O
therapy	NN	I-NP	O
with	IN	B-PP	O
the	DT	B-NP	O
angiotensin	NN	I-NP	O
-	HYPH	O	O
converting	VBG	B-VP	O
enzyme	NN	B-NP	O
inhibitor	NN	I-NP	O
and	CC	I-NP	O
spironolactone	NN	I-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
woman	NN	I-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
history	NN	I-NP	O
of	IN	B-PP	O
coronary	JJ	B-NP	O
artery	NN	I-NP	O
bypass	IN	B-PP	O
grafting	VBG	B-VP	O
and	CC	O	O
prior	JJ	B-NP	O
myocardial	JJ	I-NP	B
infarction	NN	I-NP	I
was	VBD	B-VP	O
transferred	VBN	I-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
room	NN	I-NP	O
with	IN	B-PP	O
loss	NN	B-NP	B
of	IN	B-PP	I
consciousness	NN	B-NP	I
due	JJ	B-ADJP	O
to	TO	B-PP	O
marked	JJ	B-NP	O
bradycardia	NN	I-NP	B
caused	VBN	B-VP	O
by	IN	B-PP	O
hyperkalemia	NN	B-NP	B
.	.	O	O

The	DT	B-NP	O
concentration	NN	I-NP	O
of	IN	B-PP	O
serum	NN	B-NP	O
potassium	NN	I-NP	O
was	VBD	B-VP	O
high	JJ	B-ADJP	O
,	,	O	O
and	CC	O	O
normal	JJ	B-NP	O
sinus	NN	I-NP	O
rhythm	NN	I-NP	O
was	VBD	B-VP	O
restored	VBN	I-VP	O
after	IN	B-PP	O
correction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
serum	NN	I-NP	O
potassium	NN	I-NP	O
level	NN	I-NP	O
.	.	O	O

The	DT	B-NP	O
cause	NN	I-NP	O
of	IN	B-PP	O
hyperkalemia	NN	B-NP	B
was	VBD	B-VP	O
considered	VBN	I-VP	O
to	TO	I-VP	O
be	VB	I-VP	O
several	JJ	B-NP	O
doses	NNS	I-NP	O
of	IN	B-PP	O
spiranolactone	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
aldosterone	NN	I-NP	O
antagonist	NN	I-NP	O
,	,	O	O
in	IN	B-PP	O
addition	NN	B-NP	O
to	TO	B-PP	O
the	DT	B-NP	O
long	JJ	I-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
intake	NN	I-NP	O
of	IN	B-PP	O
ramipril	NN	B-NP	O
,	,	O	O
an	DT	B-NP	O
ACE	NN	I-NP	O
inhibitor	NN	I-NP	O
.	.	O	O

This	DT	B-NP	O
case	NN	I-NP	O
is	VBZ	B-VP	O
a	DT	B-NP	O
good	JJ	I-NP	O
example	NN	I-NP	O
of	IN	B-PP	O
electrolyte	NN	B-NP	O
imbalance	NN	I-NP	O
causing	VBG	B-VP	O
acute	JJ	B-NP	O
life	NN	I-NP	O
-	HYPH	O	O
threatening	VBG	B-VP	O
cardiac	JJ	B-NP	O
events	NNS	I-NP	O
.	.	O	O

Clinicians	NNS	B-NP	O
should	MD	B-VP	O
be	VB	I-VP	O
alert	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
possibility	NN	I-NP	O
of	IN	B-PP	O
hyperkalemia	NN	B-NP	B
,	,	O	O
especially	RB	B-ADVP	O
in	IN	B-PP	O
elderly	JJ	B-NP	O
patients	NNS	I-NP	O
using	VBG	B-VP	O
ACE	NN	B-NP	O
/	SYM	B-NP	O
ARB	NN	I-NP	O
in	IN	B-PP	O
combination	NN	B-NP	O
with	IN	B-PP	O
potassium	NN	B-NP	O
sparing	VBG	I-NP	O
agents	NNS	I-NP	O
and	CC	O	O
who	WP	B-NP	O
have	VBP	B-VP	O
mild	JJ	B-NP	O
renal	JJ	I-NP	B
disturbance	NN	I-NP	I
.	.	O	O

Diffuse	NN	B-NP	O
skeletal	JJ	I-NP	O
pain	NN	I-NP	B
after	IN	B-PP	O
administration	NN	B-NP	O
of	IN	B-PP	O
alendronate	NN	B-NP	O
.	.	O	O

Osteoporosis	NN	B-NP	B
is	VBZ	B-VP	O
caused	VBN	I-VP	O
by	IN	B-PP	O
bone	NN	B-NP	O
resorption	NN	I-NP	O
in	IN	B-PP	O
excess	NN	B-NP	O
of	IN	B-PP	O
bone	NN	B-NP	O
formation	NN	I-NP	O
,	,	O	O
and	CC	O	O
bisphosphonates	NNS	B-NP	O
,	,	O	O
are	VBP	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
inhibit	VB	I-VP	O
bone	NN	B-NP	O
resorption	NN	I-NP	O
.	.	O	O

Alendronate	NN	B-NP	O
,	,	O	O
a	DT	B-NP	O
biphosphonate	NN	I-NP	O
,	,	O	O
is	VBZ	B-VP	O
effective	JJ	B-ADJP	O
for	IN	B-PP	O
both	CC	O	O
the	DT	B-NP	O
treatment	NN	I-NP	O
and	CC	I-NP	O
prevention	NN	I-NP	O
of	IN	B-PP	O
osteoporosis	NN	B-NP	B
in	IN	B-PP	O
postmenopausal	JJ	B-NP	O
women	NNS	I-NP	O
.	.	O	O

Side	NN	B-NP	O
effects	NNS	I-NP	O
are	VBP	B-VP	O
relatively	RB	B-ADJP	O
few	JJ	I-ADJP	O
and	CC	O	O
prominently	RB	B-ADJP	O
gastrointestinal	JJ	I-ADJP	O
.	.	O	O

Musculoskeletal	JJ	B-NP	B
pain	NN	I-NP	I
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
important	JJ	I-NP	O
side	NN	I-NP	O
effect	NN	I-NP	O
in	IN	B-PP	O
these	DT	B-NP	O
patients	NNS	I-NP	O
.	.	O	O

We	PRP	B-NP	O
presented	VBD	B-VP	O
a	DT	B-NP	O
patient	NN	I-NP	O
admitted	VBN	B-VP	O
to	TO	B-PP	O
our	PRP$	B-NP	O
out	RP	I-NP	O
-	HYPH	I-NP	O
patient	NN	I-NP	O
clinic	NN	I-NP	O
with	IN	B-PP	O
diffuse	JJ	B-NP	O
skeletal	JJ	I-NP	O
pain	NN	I-NP	B
after	IN	B-PP	O
num	CD	B-NP	O
consecutive	JJ	I-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
alendronate	NN	B-NP	O
.	.	O	O

We	PRP	B-NP	O
conclude	VBP	B-VP	O
that	IN	B-SBAR	O
patients	NNS	B-NP	O
with	IN	B-PP	O
osteoporosis	NN	B-NP	B
can	MD	B-VP	O
report	VB	I-VP	O
pain	NN	B-NP	B
,	,	O	O
and	CC	O	O
bisphosphonate	NN	B-NP	O
-	HYPH	O	O
related	VBN	B-NP	O
pain	NN	I-NP	B
should	MD	B-VP	O
also	RB	I-VP	O
be	VB	I-VP	O
considered	VBN	I-VP	O
before	IN	B-PP	O
ascribing	VBG	B-VP	O
this	DT	B-NP	O
complaint	NN	I-NP	O
to	TO	B-PP	O
osteoporosis	NN	B-NP	B
.	.	O	O

Cerebrospinal	JJ	B-NP	O
fluid	NN	I-NP	O
penetration	NN	I-NP	O
of	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
daptomycin	NN	I-NP	O
in	IN	B-PP	O
suspected	VBN	B-NP	O
Staphylococcus	FW	I-NP	O
aureus	FW	I-NP	O
meningitis	NN	I-NP	B
.	.	O	O

To	TO	B-VP	O
report	VB	I-VP	O
a	DT	B-NP	O
case	NN	I-NP	O
of	IN	B-PP	O
methicillin	NN	B-NP	O
-	HYPH	O	O
sensitive	JJ	B-NP	O
Staphylococcus	FW	I-NP	O
aureus	FW	I-NP	O
(	(	O	O
MSSA	NN	B-NP	O
)	)	O	O
bacteremia	NN	B-NP	B
with	IN	B-PP	O
suspected	VBN	B-NP	O
MSSA	NN	I-NP	O
meningitis	NN	I-NP	B
treated	VBN	B-VP	O
with	IN	B-PP	O
high	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
daptomycin	NN	I-NP	O
assessed	VBN	B-VP	O
with	IN	B-PP	O
concurrent	JJ	B-NP	O
serum	NN	I-NP	O
and	CC	O	O
cerebrospinal	JJ	B-NP	O
fluid	NN	I-NP	O
(	(	O	O
CSF	NN	B-NP	O
)	)	O	O
concentrations	NNS	B-NP	O
.	.	O	O

A	DT	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
year	NN	I-NP	O
-	HYPH	O	O
old	JJ	B-NP	O
male	JJ	I-NP	O
presented	VBN	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
emergency	NN	I-NP	O
department	NN	I-NP	O
with	IN	B-PP	O
generalized	VBN	B-NP	O
weakness	NN	I-NP	B
and	CC	O	O
presumed	VBN	B-NP	O
health	NN	I-NP	O
-	HYPH	B-NP	O
care	NN	I-NP	O
-	HYPH	O	O
associated	VBN	B-NP	O
pneumonia	NN	I-NP	B
shown	VBN	B-VP	O
on	IN	B-PP	O
chest	NN	B-NP	O
radiograph	NN	I-NP	O
.	.	O	O

Treatment	NN	B-NP	O
was	VBD	B-VP	O
empirically	RB	I-VP	O
initiated	VBN	I-VP	O
with	IN	B-PP	O
vancomycin	NN	B-NP	O
,	,	O	O
levofloxacin	NN	B-NP	O
,	,	O	O
and	CC	O	O
piperacillin	NN	B-NP	O
/	SYM	B-NP	O
tazobactam	NN	I-NP	O
.	.	O	O

Blood	NN	B-NP	O
cultures	NNS	I-NP	O
revealed	VBD	B-VP	O
S.	NNP	B-NP	O
aureus	NN	I-NP	O
susceptible	JJ	B-ADJP	O
to	TO	B-PP	O
oxacillin	NN	B-NP	O
.	.	O	O

Empiric	JJ	B-NP	O
antibiotic	JJ	I-NP	O
treatment	NN	I-NP	O
was	VBD	B-VP	O
narrowed	VBN	I-VP	O
to	TO	B-PP	O
nafcillin	NN	B-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

On	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
the	DT	B-NP	O
patient	NN	I-NP	O
developed	VBD	B-VP	O
acute	JJ	B-NP	B
renal	JJ	I-NP	I
failure	NN	I-NP	I
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
Glasgow	NNP	B-NP	O
Coma	NNP	I-NP	O
Score	NNP	I-NP	O
was	VBD	B-VP	O
num	CD	B-NP	O
with	IN	B-PP	O
normal	JJ	B-NP	O
findings	NNS	I-NP	O
shown	VBN	B-VP	O
on	IN	B-PP	O
computed	VBN	B-NP	O
tomography	NN	I-NP	O
scan	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
head	NN	I-NP	O
num	CD	B-NP	O
hours	NNS	I-NP	O
following	VBG	B-PP	O
an	DT	B-NP	O
episode	NN	I-NP	O
of	IN	B-PP	O
cardiac	JJ	B-NP	B
arrest	NN	I-NP	I
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

The	DT	B-NP	O
patient	NN	I-NP	O
experienced	VBD	B-VP	O
relapsing	VBG	I-VP	O
MSSA	NN	B-NP	O
bacteremia	NN	I-NP	B
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
increasing	VBG	B-VP	O
the	DT	B-NP	O
suspicion	NN	I-NP	O
for	IN	B-PP	O
a	DT	B-NP	O
central	JJ	I-NP	O
nervous	JJ	I-NP	O
system	NN	I-NP	O
(	(	O	O
CNS	NN	B-NP	O
)	)	O	O
infection	NN	B-NP	B
.	.	O	O

Nafcillin	NN	B-NP	O
was	VBD	B-VP	O
discontinued	VBN	I-VP	O
and	CC	O	O
daptomycin	NN	B-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
daily	RB	B-ADVP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
for	IN	B-PP	O
suspected	VBN	B-NP	O
meningitis	NN	I-NP	B
and	CC	O	O
was	VBD	B-VP	O
continued	VBN	I-VP	O
until	IN	B-SBAR	O
the	DT	B-NP	O
patient	NN	I-NP	O
s	VBZ	B-VP	O
death	NN	B-NP	O
on	IN	B-PP	O
day	NN	B-NP	O
num	CD	I-NP	O
.	.	O	O

Daptomycin	NN	B-NP	O
serum	NN	I-NP	O
and	CC	O	O
CSF	NN	B-NP	O
trough	NN	I-NP	O
concentrations	NNS	I-NP	O
were	VBD	B-VP	O
num	CD	B-NP	O
ug	NN	I-NP	O
/	SYM	B-NP	O
mL	NN	I-NP	O
and	CC	O	O
num	CD	B-NP	O
ug	NN	I-NP	O
/	SYM	O	O
mL	NN	B-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
,	,	O	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
the	DT	B-NP	O
third	JJ	I-NP	O
dose	NN	I-NP	O
.	.	O	O

Lumbar	JJ	B-NP	O
puncture	NN	I-NP	O
results	NNS	I-NP	O
were	VBD	B-VP	O
inconclusive	JJ	B-ADJP	O
and	CC	O	O
no	DT	B-NP	O
further	JJ	I-NP	O
blood	NN	I-NP	O
cultures	NNS	I-NP	O
were	VBD	B-VP	O
positive	JJ	B-ADJP	O
for	IN	B-PP	O
MSSA	NN	B-NP	O
.	.	O	O

Creatine	NN	B-NP	O
kinase	NN	I-NP	O
levels	NNS	I-NP	O
were	VBD	B-VP	O
normal	JJ	B-ADJP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
daptomycin	NN	B-NP	O
therapy	NN	I-NP	O
and	CC	O	O
were	VBD	B-VP	O
not	RB	I-VP	O
reassessed	VBN	I-VP	O
.	.	O	O

Daptomycin	NN	B-NP	O
was	VBD	B-VP	O
initiated	VBN	I-VP	O
in	IN	B-PP	O
our	PRP$	B-NP	O
patient	NN	I-NP	O
secondary	JJ	B-ADJP	O
to	TO	B-PP	O
possible	JJ	B-NP	O
nafcillin	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
acute	JJ	I-NP	O
interstitial	JJ	I-NP	B
nephritis	NN	I-NP	I
and	CC	O	O
relapsing	VBG	B-VP	O
bacteremia	NN	B-NP	B
.	.	O	O

At	IN	B-PP	O
a	DT	B-NP	O
dose	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
mg	NN	I-NP	O
/	SYM	B-NP	O
kg	NN	I-NP	O
,	,	O	O
resultant	JJ	B-NP	O
penetration	NN	I-NP	O
of	IN	B-PP	O
num	CD	B-NP	O
%	NN	I-NP	O
was	VBD	B-VP	O
higher	JJR	B-ADJP	O
than	IN	B-PP	O
in	IN	B-PP	O
previous	JJ	B-NP	O
reports	NNS	I-NP	O
,	,	O	O
more	RBR	B-ADJP	O
consistent	JJ	I-ADJP	O
with	IN	B-PP	O
inflamed	JJ	B-NP	O
meninges	NNS	I-NP	O
.	.	O	O

High	JJ	B-NP	O
-	HYPH	I-NP	O
dose	NN	I-NP	O
daptomycin	NN	I-NP	O
may	MD	B-VP	O
be	VB	I-VP	O
an	DT	B-NP	O
alternative	JJ	I-NP	O
option	NN	I-NP	O
for	IN	B-PP	O
MSSA	NN	B-NP	O
bacteremia	NN	I-NP	B
with	IN	B-PP	O
or	CC	B-PP	O
without	IN	B-PP	O
a	DT	B-NP	O
CNS	NN	I-NP	O
source	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
who	WP	B-NP	O
have	VBP	B-VP	O
failed	VBN	I-VP	O
or	CC	O	O
can	MD	B-VP	O
not	RB	I-VP	O
tolerate	VB	I-VP	O
standard	JJ	B-NP	O
therapy	NN	I-NP	O
.	.	O	O

Further	JJ	B-NP	O
clinical	JJ	I-NP	O
evaluation	NN	I-NP	O
in	IN	B-PP	O
patients	NNS	B-NP	O
with	IN	B-PP	O
confirmed	VBN	B-NP	O
meningitis	NN	I-NP	B
is	VBZ	B-VP	O
warranted	VBN	I-VP	O
.	.	O	O

The	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
nitric	JJ	B-NP	O
oxide	NN	I-NP	O
in	IN	B-PP	O
convulsions	NNS	B-NP	B
induced	VBN	B-VP	O
by	IN	B-PP	O
lindane	NN	B-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
.	.	O	O

Lindane	NN	B-NP	O
is	VBZ	B-VP	O
an	DT	B-NP	O
organochloride	NN	I-NP	O
pesticide	NN	I-NP	O
and	CC	I-NP	O
scabicide	NN	I-NP	O
.	.	O	O

It	PRP	B-NP	O
evokes	VBZ	B-VP	O
convulsions	NNS	B-NP	B
mainly	RB	B-ADVP	O
trough	IN	B-PP	O
the	DT	B-NP	O
blockage	NN	I-NP	O
of	IN	B-PP	O
GABA	NN	B-NP	O
(	(	O	O
A	NN	B-NP	O
)	)	O	O
receptors	NNS	B-NP	O
.	.	O	O

Nitric	JJ	B-NP	O
oxide	NN	I-NP	O
(	(	O	O
NO	NN	B-NP	O
)	)	O	O
,	,	O	O
gaseous	JJ	B-NP	O
neurotransmitter	NN	I-NP	O
,	,	O	O
has	VBZ	B-VP	O
contradictor	NN	B-NP	O
role	NN	I-NP	O
in	IN	B-PP	O
epileptogenesis	NN	B-NP	O
due	JJ	B-PP	O
to	TO	B-PP	O
opposite	JJ	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
,	,	O	O
precursor	NN	B-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
syntheses	NNS	I-NP	O
(	(	O	O
NOS	NN	B-NP	O
)	)	O	O
,	,	O	O
and	CC	O	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
(	(	O	O
NOS	NN	B-NP	O
inhibitor	NN	I-NP	O
)	)	O	O
observed	VBN	B-VP	O
in	IN	B-PP	O
different	JJ	B-NP	O
epilepsy	NN	I-NP	B
models	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
aim	NN	I-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
current	JJ	I-NP	O
study	NN	I-NP	O
was	VBD	B-VP	O
to	TO	B-VP	O
determine	VB	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
NO	NN	B-NP	O
on	IN	B-PP	O
the	DT	B-NP	O
behavioral	NN	I-NP	O
and	CC	I-NP	O
EEG	NN	I-NP	O
characteristics	NNS	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
-	HYPH	B-NP	O
induced	VBN	I-NP	O
epilepsy	NN	I-NP	B
in	IN	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
albino	NNP	I-NP	O
rats	NNS	I-NP	O
.	.	O	O

The	DT	B-NP	O
administration	NN	I-NP	O
of	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
arginine	NN	B-NP	O
in	IN	B-PP	O
dose	NN	B-NP	O
-	HYPH	B-NP	O
dependent	JJ	I-NP	O
manner	NN	I-NP	O
significantly	RB	B-ADVP	O
increased	VBD	B-VP	O
convulsion	NN	B-NP	B
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
and	CC	O	O
shortened	VBD	B-VP	O
latency	NN	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
first	JJ	B-NP	O
convulsion	NN	I-NP	B
elicited	VBN	B-VP	O
by	IN	B-PP	O
lower	JJR	B-NP	O
lindane	NN	I-NP	O
dose	NN	I-NP	O
.	.	O	O

On	IN	B-PP	O
the	DT	B-NP	O
contrary	NN	I-NP	O
,	,	O	O
pretreatment	NN	B-NP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
decreased	VBD	B-VP	O
convulsion	NN	B-NP	B
incidence	NN	I-NP	O
and	CC	I-NP	O
severity	NN	I-NP	O
and	CC	O	O
prolonged	VBD	B-VP	O
latency	NN	B-NP	O
time	NN	I-NP	O
to	TO	B-PP	O
convulsion	NN	B-NP	B
following	VBG	B-PP	O
injection	NN	B-NP	O
with	IN	B-PP	O
a	DT	B-NP	O
convulsive	JJ	I-NP	B
dose	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
.	.	O	O

EEG	NN	B-NP	O
analyses	NNS	I-NP	O
showed	VBD	B-VP	O
increase	NN	B-NP	O
of	IN	B-PP	O
number	NN	B-NP	O
and	CC	I-NP	O
duration	NN	I-NP	O
of	IN	B-PP	O
ictal	JJ	B-NP	O
periods	NNS	I-NP	O
in	IN	B-PP	O
EEG	NN	B-NP	O
of	IN	B-PP	O
rats	NNS	B-NP	O
receiving	VBG	B-VP	O
l	NN	B-NP	O
-	HYPH	B-NP	O
arginine	NN	I-NP	O
prior	JJ	B-ADJP	O
to	TO	B-PP	O
lindane	NN	B-NP	O
and	CC	I-NP	O
decrease	NN	I-NP	O
of	IN	B-PP	O
this	DT	B-NP	O
number	NN	I-NP	O
in	IN	B-PP	O
rats	NNS	B-NP	O
pretreated	VBN	B-VP	O
with	IN	B-PP	O
L	NN	B-NP	O
-	HYPH	O	O
NAME	NN	B-NP	O
.	.	O	O

These	DT	B-NP	O
results	NNS	I-NP	O
support	VBP	B-VP	O
the	DT	B-NP	O
conclusion	NN	I-NP	O
that	IN	B-SBAR	O
NO	NN	B-NP	O
plays	VBZ	B-VP	O
a	DT	B-NP	O
role	NN	I-NP	O
of	IN	B-PP	O
endogenous	JJ	B-NP	O
convulsant	NN	I-NP	O
in	IN	B-PP	O
rat	NN	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
lindane	NN	B-NP	O
seizures	NNS	I-NP	B
.	.	O	O

Long	JJ	B-NP	O
-	HYPH	I-NP	O
term	NN	I-NP	O
oral	JJ	I-NP	O
galactose	NN	I-NP	O
treatment	NN	I-NP	O
prevents	VBZ	B-VP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
in	IN	B-PP	O
male	JJ	B-NP	O
Wistar	NNP	I-NP	O
rats	NNS	I-NP	O
treated	VBN	B-VP	O
intracerebroventricularly	RB	B-ADVP	O
with	IN	B-PP	O
streptozotocin	NN	B-NP	O
.	.	O	O

Basic	JJ	B-NP	O
and	CC	I-NP	O
clinical	JJ	I-NP	O
research	NN	I-NP	O
has	VBZ	B-VP	O
demonstrated	VBN	I-VP	O
that	IN	B-SBAR	O
dementia	NN	B-NP	B
of	IN	B-PP	O
sporadic	JJ	B-NP	O
Alzheimer	NNP	I-NP	B
s	NN	I-NP	I
disease	NN	I-NP	I
(	(	O	O
sAD	NN	B-NP	O
)	)	O	O
type	NN	B-NP	O
is	VBZ	B-VP	O
associated	VBN	I-VP	O
with	IN	B-PP	O
dysfunction	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
insulin	NN	I-NP	O
-	HYPH	O	O
receptor	NN	B-NP	O
(	(	O	O
IR	NN	B-NP	O
)	)	O	O
system	NN	B-NP	O
followed	VBN	B-VP	O
by	IN	B-PP	O
decreased	VBN	B-NP	O
glucose	NN	I-NP	O
transport	NN	I-NP	O
via	IN	B-PP	O
glucose	NN	B-NP	O
transporter	NN	I-NP	O
GLUT4	NN	I-NP	O
and	CC	O	O
decreased	VBD	B-VP	O
glucose	NN	B-NP	O
metabolism	NN	I-NP	O
in	IN	B-PP	O
brain	NN	B-NP	O
cells	NNS	I-NP	O
.	.	O	O

An	DT	B-NP	O
alternative	JJ	I-NP	O
source	NN	I-NP	O
of	IN	B-PP	O
energy	NN	B-NP	O
is	VBZ	B-VP	O
d	VBN	I-VP	O
-	:	O	O
galactose	NN	B-NP	O
(	(	O	O
the	DT	B-NP	O
C	NN	I-NP	O
-	HYPH	B-NP	O
num	CD	I-NP	O
-	HYPH	I-NP	O
epimer	NN	I-NP	O
of	IN	B-PP	O
d	NN	B-NP	O
-	HYPH	B-NP	O
glucose	NN	I-NP	O
)	)	O	O
which	WDT	B-NP	O
is	VBZ	B-VP	O
transported	VBN	I-VP	O
into	IN	B-PP	O
the	DT	B-NP	O
brain	NN	I-NP	O
by	IN	B-PP	O
insulin	NN	B-NP	O
-	HYPH	B-NP	O
independent	JJ	I-NP	O
GLUT3	NN	I-NP	O
transporter	NN	I-NP	O
where	WRB	B-ADVP	O
it	PRP	B-NP	O
might	MD	B-VP	O
be	VB	I-VP	O
metabolized	VBN	I-VP	O
to	TO	B-PP	O
glucose	NN	B-NP	O
via	IN	B-PP	O
the	DT	B-NP	O
Leloir	NNP	I-NP	O
pathway	NN	I-NP	O
.	.	O	O

Exclusively	RB	B-NP	O
parenteral	JJ	I-NP	O
daily	JJ	I-NP	O
injections	NNS	I-NP	O
of	IN	B-PP	O
galactose	NN	B-NP	O
induce	VBP	B-VP	O
memory	NN	B-NP	B
deterioration	NN	I-NP	I
in	IN	B-PP	O
rodents	NNS	B-NP	O
and	CC	O	O
are	VBP	B-VP	O
used	VBN	I-VP	O
to	TO	B-VP	O
generate	VB	I-VP	O
animal	NN	B-NP	O
aging	NN	I-NP	O
model	NN	I-NP	O
,	,	O	O
but	CC	O	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
galactose	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	O
functions	NNS	I-NP	O
have	VBP	B-VP	O
never	RB	I-VP	O
been	VBN	I-VP	O
tested	VBN	I-VP	O
.	.	O	O

We	PRP	B-NP	O
have	VBP	B-VP	O
investigated	VBN	I-VP	O
the	DT	B-NP	O
effects	NNS	I-NP	O
of	IN	B-PP	O
continuous	JJ	B-NP	O
daily	JJ	I-NP	O
oral	JJ	I-NP	O
galactose	NN	I-NP	O
treatment	NN	I-NP	O
on	IN	B-PP	O
cognitive	JJ	B-NP	B
deficits	NNS	I-NP	I
in	IN	B-PP	O
streptozotocin	NN	B-NP	O
-	HYPH	O	O
induced	VBN	B-VP	O
(	(	O	O
STZ	NN	B-NP	O
-	HYPH	B-NP	O
icv	NN	I-NP	O
)	)	O	O
rat	NN	B-NP	O
model	NN	I-NP	O
of	IN	B-PP	O
sAD	NN	B-NP	O
,	,	O	O
tested	VBN	B-VP	O
by	IN	B-PP	O
Morris	NNP	B-NP	O
Water	NNP	I-NP	O
Maze	NNP	I-NP	O
and	CC	O	O
Passive	NNP	B-NP	O
Avoidance	NNP	I-NP	O
test	NN	I-NP	O
,	,	O	O
respectively	RB	B-ADVP	O
.	.	O	O

num	CD	B-NP	O
month	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
galactose	NN	I-NP	O
treatment	NN	I-NP	O
initiated	VBN	B-VP	O
immediately	RB	B-ADVP	O
after	IN	B-PP	O
the	DT	B-NP	O
STZ	NN	I-NP	O
-	HYPH	B-NP	O
icv	NN	I-NP	O
administration	NN	I-NP	O
,	,	O	O
successfully	RB	B-VP	O
prevented	VBD	I-VP	O
development	NN	B-NP	O
of	IN	B-PP	O
the	DT	B-NP	O
STZ	NN	I-NP	O
-	HYPH	B-NP	O
icv	NN	I-NP	O
-	HYPH	O	O
induced	VBN	B-NP	O
cognitive	JJ	I-NP	B
deficits	NNS	I-NP	I
.	.	O	O

Beneficial	JJ	B-NP	O
effect	NN	I-NP	O
of	IN	B-PP	O
oral	JJ	B-NP	O
galactose	NN	I-NP	O
was	VBD	B-VP	O
independent	JJ	B-ADJP	O
of	IN	B-PP	O
the	DT	B-NP	O
rat	NN	I-NP	O
age	NN	I-NP	O
and	CC	B-PP	O
of	IN	B-PP	O
the	DT	B-NP	O
galactose	NN	I-NP	O
dose	NN	I-NP	O
ranging	VBG	B-VP	O
from	IN	B-PP	O
num	CD	B-NP	O
to	TO	I-NP	O
num	CD	I-NP	O
mg	NN	I-NP	O
/	SYM	I-NP	O
kg	NN	I-NP	O
/	SYM	B-NP	O
day	NN	I-NP	O
.	.	O	O

Additionally	RB	B-ADVP	O
,	,	O	O
oral	JJ	B-NP	O
galactose	NN	I-NP	O
administration	NN	I-NP	O
led	VBD	B-VP	O
to	TO	B-PP	O
the	DT	B-NP	O
appearance	NN	I-NP	O
of	IN	B-PP	O
galactose	NN	B-NP	O
in	IN	B-PP	O
the	DT	B-NP	O
blood	NN	I-NP	O
.	.	O	O
